<SEC-DOCUMENT>0001159036-22-000050.txt : 20220809
<SEC-HEADER>0001159036-22-000050.hdr.sgml : 20220809
<ACCEPTANCE-DATETIME>20220809161200
ACCESSION NUMBER:		0001159036-22-000050
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		85
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220809
DATE AS OF CHANGE:		20220809

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HALOZYME THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001159036
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				880488686
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32335
		FILM NUMBER:		221148423

	BUSINESS ADDRESS:	
		STREET 1:		11388 SORRENTO VALLEY ROAD
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121-1345
		BUSINESS PHONE:		(858) 794-8889

	MAIL ADDRESS:	
		STREET 1:		11388 SORRENTO VALLEY ROAD
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121-1345

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HALOZYME THERAPEUTICS INC
		DATE OF NAME CHANGE:	20040312

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GLOBAL YACHT SERVICES INC
		DATE OF NAME CHANGE:	20010912
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>halo-20220630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:73069a0e-fffd-482c-8df8-d4ff810732e3,g:be228a77-9c6c-4f8e-9f2c-fe0d390b647c,d:bd09c52bdc03451493df7fb7077280c7--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:halo="http://www.halozyme.com/20220630" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>halo-20220630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180L2ZyYWc6YTgwOWFiNmNiNTY3NDI1NTk2ZDdjOTgxMzFjYjEyMzAvdGFibGU6M2Y0Yjk0Zjk5YzgwNGZjMjhiYzAwNDNjN2U3NjM2ZDUvdGFibGVyYW5nZTozZjRiOTRmOTljODA0ZmMyOGJjMDA0M2M3ZTc2MzZkNV8xLTEtMS0xLTQ3ODAx_fc33a280-c0dc-448c-8f0a-58aad57a998a">0001159036</ix:nonNumeric><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180L2ZyYWc6YTgwOWFiNmNiNTY3NDI1NTk2ZDdjOTgxMzFjYjEyMzAvdGFibGU6M2Y0Yjk0Zjk5YzgwNGZjMjhiYzAwNDNjN2U3NjM2ZDUvdGFibGVyYW5nZTozZjRiOTRmOTljODA0ZmMyOGJjMDA0M2M3ZTc2MzZkNV8yLTEtMS0xLTQ3ODAx_218ed7ec-e5a3-45fa-8cfe-de7fa9b66473">false</ix:nonNumeric><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180L2ZyYWc6YTgwOWFiNmNiNTY3NDI1NTk2ZDdjOTgxMzFjYjEyMzAvdGFibGU6M2Y0Yjk0Zjk5YzgwNGZjMjhiYzAwNDNjN2U3NjM2ZDUvdGFibGVyYW5nZTozZjRiOTRmOTljODA0ZmMyOGJjMDA0M2M3ZTc2MzZkNV8zLTEtMS0xLTQ3ODAx_c15c1158-47d6-4fb3-99e5-6a4e6e9d6b51">2022</ix:nonNumeric><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180L2ZyYWc6YTgwOWFiNmNiNTY3NDI1NTk2ZDdjOTgxMzFjYjEyMzAvdGFibGU6M2Y0Yjk0Zjk5YzgwNGZjMjhiYzAwNDNjN2U3NjM2ZDUvdGFibGVyYW5nZTozZjRiOTRmOTljODA0ZmMyOGJjMDA0M2M3ZTc2MzZkNV80LTEtMS0xLTQ3ODAx_9b3579af-cd1f-49f9-9466-e9f5a4188501">Q2</ix:nonNumeric><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180L2ZyYWc6YTgwOWFiNmNiNTY3NDI1NTk2ZDdjOTgxMzFjYjEyMzAvdGFibGU6M2Y0Yjk0Zjk5YzgwNGZjMjhiYzAwNDNjN2U3NjM2ZDUvdGFibGVyYW5nZTozZjRiOTRmOTljODA0ZmMyOGJjMDA0M2M3ZTc2MzZkNV81LTEtMS0xLTQ3ODAx_73a865cb-f8b5-4e81-9ec2-e962d0175ccc">6/30</ix:nonNumeric><ix:nonNumeric contextRef="i70ed32619a3c450b95acdcb7833975bf_I20220630" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181OC9mcmFnOmRiMTk5MTNjMzE2YjRlMzE4YzRhOTdlOGEyMDE5MjlhL3RhYmxlOjc3ODljNDgzY2IzZjQ5MzZhZTlkYTg3ZmNjNjE0MzUxL3RhYmxlcmFuZ2U6Nzc4OWM0ODNjYjNmNDkzNmFlOWRhODdmY2M2MTQzNTFfMS0xLTEtMS00NzgwMQ_a958d286-9d61-4224-ad66-7007d509228e">12</ix:nonNumeric><ix:nonNumeric contextRef="i02c1d101b0e4433cb0667cb17eedd9ca_D20211201-20211231" name="us-gaap:StockRepurchaseProgramPeriodInForce1" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMTUzMw_f787b3d2-f4a4-40e0-98f4-002839096391">P3Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="halo-20220630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73af0220bff74c0b84c26e30e7814735_I20220802"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-08-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ia8f041b537984ded88384fd5745e75e2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ibbcde496e999416f83088ace845dbf65_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2302c2baba3a4084b1cd7169564a4517_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifecd7d767a3c48d6a094b68ee21e3340_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i488611ceda1e4bf3a1df6ada966c72ff_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie448ea4ebc7a4047b9528cc3d06dac35_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefbbc65edf2e4319adad4df5fa76e1f3_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9220796b173a4a9298008c86f02bacf1_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5cfeb9eb65745ed9779cd8409a1de20_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d0fdcb3db8c45fdb97bc693b3691d65_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5331ecfa85164578966f7ba36c8377ac_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:CollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88e4277b0c454a79a9c899981c6d0ade_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:CollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if13d9aa4327240bcaf9417558eeae8c3_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:CollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic72a2d641a084db2bfd8a448fdafa5bb_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:CollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07515ff25e39495196802eb714e47e89_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3b15a6a41d2423d9142e3d2a1b50b32_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaed74cb4c1b045a48ff8547f85ae3d8e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia62abf9a289242aaacca39406bc0f1e4_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9f7dc1cc92f4c1690a144db55ad717c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5e07277da1a43438f0f8d84d2f7bc96_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c9b3b22251847568c83ac3f79ea4436_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i678f6fef80154c5b8c01dadcd09593ac_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b633a2efd834d73bd14291c139ac728_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64fb6378ac874aa599802032078bb7e5_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a959347106f415cb34e9be834baba86_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c00abe406104a5fa545c8d934524371_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09401d5b007348c08fa5bd1cce5097ce_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id807b2395d514e89a6ed524bc67e0ed3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01b7804e8c8443c18f2bf4001bc7328d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2a2ebb74994496290986a6cbda39dc8_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57063aa70d174824a4db07d8773b05bf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39034bfa63bd4a90ac54d7016591ef9d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac6ced6cc2b3433c8b37d84dc56b068e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a77403a19ee410d81160e0a394e0979_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic61e51e1f5f94cd39c6967eae2703020_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb6ff5498b9346a8b865a91ca3bb935c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37c4cbbc8ea6440cb197130f93f66a30_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c794de6a0af4c0a9af7f772745e791c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6b066604d9e4d658947efe4930f28f6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie27fff43f3db4d7d8d49ecaaf23b1d61_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e4238b1c16a4fd28a06ed5e284bb84a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i727d5a62b3f847b797bca56701f39cf9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if67373bdd7be4012b17710d463c192a1_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i380920b6a9284e80ae55f918a1ae24cb_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12326da779a8483f93c5e05dd4d6d7c4_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f15b7f19dfa4b62bc91d2ad4477ae61_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c838a1fe9a644b6956ff4487ba688eb_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14d6ff976f1c46d0bae0a1ff38eae093_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac7f0b69fa364a3e83aa58d5f386c6ca_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26444fd86b024585b6b74771eb48128a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7985573ca9a44f7ea10f5ecb82f97c91_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2bb1215be014cfeae503eb2306453b0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6ca52ba2c1e43a7b6a8fd1d47849366_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ca0a460bc7a457a905e2205ba207797_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i256c983ac3a44d07b5c0bbac2a5206ef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if563dcd8d731444e986d351aa923f779_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3449ce3d1a2440f9631288531d75f21_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i715d67b1e934443c87c14fc6a9baf147_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b21a0a518454ebb9f2099e2057850ed_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dbcbf35901d41ee95e2479d1b0cc0e8_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i322f16862e9a44f9ad3ca6a551d79a4f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="collaborator"><xbrli:measure>halo:collaborator</xbrli:measure></xbrli:unit><xbrli:context id="i8939fd0a8f934008b17b41bf8467d682_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">halo:BaxaltaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>halo:product</xbrli:measure></xbrli:unit><xbrli:context id="ie69bf9190a574ccbbe399d8da056c46e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">halo:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6aeb602d0b6f4c559f18892fc21aa407_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">halo:JanssenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03b0b3511b2544be8e14af45977bfbce_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecce61f93caa4b668869678174aa5845_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>halo:segment</xbrli:measure></xbrli:unit><xbrli:context id="i4bc0e55590f348ac92553d587cadfd3d_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i475bb2a82ae54a4286363422e755c916_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86ae6c3b418d4a88aa081e1790735e1b_I20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c984de515d647a5b30035159dcaec53_I20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00acc9b249264652bb496012352851f4_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if15049277def4dcdb9cbdffbe5d753f1_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i615a905f496c4c0d9f797e929cacf41f_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">halo:ShareBasedCompensationAwardsVestedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82c9562114b64891bb65718130793579_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">halo:ShareBasedCompensationAwardUnvestedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e07b7230a7b4293910918c1158913a7_I20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77c93c8b4e414609a78dfb4f6f64ed57_I20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36b527310aeb4abebd94653011e3f9db_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:AutoInjectorTechnologyPlatformMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i079a89cb03c6429c974b822df12e4303_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:XYOSTEDProprietaryProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i827e16b84dc24a16a310f235506fdd09_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:TLANDOProductRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89ede30c1fb341e6b5c377169cbac030_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a3a21a6a5d44d869b7b90d70c8531c7_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9372d0e89f64744be923e43620998cc_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fc34bcf05bf42a1ad015e84425c8d0d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i919614e2dc9744fea40ea36e3bad8795_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02b96f8f266746e5bef1a7a56d0020d7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c5035736b1a4598ae99008fbf3463ef_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i729eff0e2b1b45abacd1da9f077ac641_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3327c7ae03814e5b98e511ab356d1e06_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6a49dbb96ea4e068ffae31a73e0450d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbbf1f4395c847e88fbb88a23315b862_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibadaba53276e46a791964bbdd74a640d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4820381fb1924e4b8f10130527b2a041_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="security"><xbrli:measure>halo:security</xbrli:measure></xbrli:unit><xbrli:context id="i7582cec4a13c42d3948f9997e4a05ea2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i524d67132d7a47e18cfb74ff6a106bd6_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d8fc069e3434518b16ab9ff92f7ac83_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib35f4ff4fd844014ad607bcd93940767_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08ee73d0afc54dd4af894979a2e3d955_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70626fa06a394bfb9bd482b2edc20c84_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i394b8f9cfd4246c9ad0423ab43c011ee_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b150997591648f4bb1e80dcf1a1016c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b00c3afda9e45bb8cd0405f8b5f14a0_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib42d2c1ec2894fec8370868a75e097f5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b3fe709b3f74022a916820d6a66f819_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30d3e114033048b4bf56fe57daa86654_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaff254b4c0d8405ba942acab54575f2f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8485788d2894891ac3dbdffaa1a04f6_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35bedd3b896a45e6bef76a745aea55b8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6f16378a34f47e5bc64f9f37e501985_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8679bef0769643ff80b9deb03b454f3e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf47bb6ce3e3440e8d32edd5fa5d2a77_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ce27062172c4df39f203c5fbbcda25d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0355f361557b4963951d67530b3f33a4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0a3288eab784be19fb61c3da624b2ce_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46f6abf3fb844711ba56aa80aa191fde_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fb4248efc9c4394903dd84bafe5032c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf3f9180d2d54718b7d17a4b462cd60f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i797d735ce11e40a3a597d7b067205876_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c825fe74c2e4db9a79927b3f36b3b4b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3ddca14e94e4ee7bc84deba437d724a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied28f46dba994350bcda53f1634bf3dd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1965c9e97674996b395dc7e83265e6e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41ce1d46c93d4d23a5dcc7490d03b394_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d7cfdf4a9444c87946ea6f8f8104d55_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbee317a1c93450289e3face1229333c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35a6d850025546848755145a7abf15b7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8114c060d9e745e0ad9ea5a8ccb12e9b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73361786868247609ad6e713642b4441_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18df9e45de3648af8edb0ce21a72898c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6fcbc87cdee4fccae17a9f9a6e02d05_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41ae64b0863d43efb250b560920603c1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic37ed5614087440da569f079f0f651bd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia715fa809717495ca3ea42208886f693_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30cb808ae8294ad2963b8d25bd8ddd70_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:BulkrHuPH20Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5ac7dbc74fd416bba2eecdc24f27658_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:BulkrHuPH20Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61902b5268704612925502d224a5f0dc_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:BulkrHuPH20Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1581eb1b56a4683bd3a80a5ce16e03c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:BulkrHuPH20Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5576b7ccca364865ba7aae184bb4cf37_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:ProprietaryProductsSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b180128f3634ec092ab2d598df56185_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:ProprietaryProductsSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i727ff9da39cc4faab1ee412cb6667251_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:ProprietaryProductsSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c83d19f90094700a1790868f713787d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:ProprietaryProductsSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b1f6429290349caa513971198a9d7f3_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DevicePartneredProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccc79e0e6fcd45f7baf4dc4675fdb639_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DevicePartneredProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic38072713d2a499bb6a5b530797ec390_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DevicePartneredProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idff30f1d38214c3cbaa6aa448432d11c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DevicePartneredProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c4e1c2852834e3db83be2ab724c4ec7_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:UpfrontfeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b169ddfeec745d1be5c150f76f1b9ce_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:UpfrontfeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id99a3d7ca0084d3c8ad32c30e53803ca_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:UpfrontfeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29bf66c271ba4ae7987ec7bd8ff4520f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:UpfrontfeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68f176f459d54d48893f0655ba31ec14_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DevelopmentFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i044be8133aeb4fe6a48b3663a56504bc_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DevelopmentFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i120c080d9b5a4f57b9e656994552257c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DevelopmentFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifaf7a7f2b9314cabb0bba3ca0238fc37_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DevelopmentFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i667bd7d9d0494b2f898d65a0be893385_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:SalesbasedmilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4f91bfe396b4e2fabebbdcc9ab97e9a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:SalesbasedmilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0177b2094d7a422a923115b1b3b4755d_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:SalesbasedmilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b98cb4091434500999a3bd53a43e318_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:SalesbasedmilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id036393f1ef94ab59c494be346f81453_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DeviceLicensingAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2c6a315d3c94850a81a0adb2158a25b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DeviceLicensingAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i889d129efa02476986931ae8af732baa_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DeviceLicensingAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8770b425828c4e6cadb0c28e912fc453_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DeviceLicensingAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffcd168ae7a94e5db1b32f7feb3a8b62_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:LicenseFeesAndEventBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice04128a0ca3439cae58ae72f295f29f_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:LicenseFeesAndEventBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ce4ecc3d70b49ab961fee2475a6ee4e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">halo:OthercollaboratorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i065c6dc939e647029141b2829def68d5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70ed32619a3c450b95acdcb7833975bf_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9bf3392f031425891062f5e0f545ba6_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ResearchEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91ce62cbf8364228b4b121202d34470e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ResearchEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51bfe79b4f7f4ddea8ca6aecd47c6748_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e78480ba6bd4f1d9d17749c899a126b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8be187f821b4c40912a67590b98722f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if48f37b3f1b94e6bb28d9642c03cb051_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifef082b6dbf1487f9b03c2077818edec_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia927806080fd413c87442beab744f69b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb0dbd53c41e477d9ab6a6f8b2df947a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:AutoInjectorTechnologyPlatformMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e8b070a3aa646febf62fbbd0ae3ce5e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:AutoInjectorTechnologyPlatformMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6cf0130a2b443be99ea94b47e536125_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:XYOSTEDProprietaryProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd6500afde964db6843f15bf9ff223c9_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:XYOSTEDProprietaryProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idab608f91ce0499fb31e66934a3d01cd_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:TLANDOProductRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9cf38a8f67047f4b770a4b2f6f4c0c4_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:TLANDOProductRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i930ea774bf7d4904b46c5d6ce72d032d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0d782f4478a4d7ea80f060e128b6b7a_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd66a9946d9840eba7c66b86f6e2fe5a_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd4cd55303894cb1aa89a03028006576_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="trading_day"><xbrli:measure>halo:trading_day</xbrli:measure></xbrli:unit><xbrli:context id="i9bc3be2ae627408894cf317b830d625e_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79862e9f8f4240af943f624cdae37039_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92d9886e9d374222a3d3959bf913fd55_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae83682afbfd42498583c6364b173a85_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dffca0ebc3943fe8411a72b02312868_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i564c0f73ae6841618d8d0305f3c128f2_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc9e7ea69dc54bc580f0327b080e6620_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i522b480a4e0c413cbd63f8e8b3903d03_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7db32790c0274f1b85142a533eef25ea_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4bc8fa5f8b24012aff99c9e405c3c38_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia71fa90d90d249b2826bd60cb35507b5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb771b640f1343b39c99c088eeaa56cc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b4b3f5b65f748fea9d3a16a4370a81e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dac37b234cb4e39aa59635df2320abd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f9a5cd5449946e383c3e70f8ef08350_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac94068bcee94ca094f560cb73997234_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50e1360e4c7b4de39282c845c5d73c43_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i765e5eeb91e54b43b5f00f6ebddec276_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i421730450b74464b90e09befbd503cfc_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9858e2352550465683b249270d6735a6_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5021845805034e388a208b835a6c92c0_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ec81c8774a34665930c2c67a277cbbf_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00e19a2b430241ed99f4d4d16ef7f9d0_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd0b274a39124464a2f81ffe163b7216_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib06303cf7360468aad8efb6d193ac2e0_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf400d7ec4c1409c979f5a18ed50eed6_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c76ed9108314a75b3e7842e7f8460ec_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d86d5b0f18546fa82fc1f13b48c7daa_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78253359e5ad475094259801bb6c9cca_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87582d2ecc124f6db85794fe5ea82eb5_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i904690f836a44521b7c1da764f701566_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia588495e94d64915826033625b6cae2d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09b74f6ef1644d8e930a5c4759e82823_I20220531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A2021CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib607a4df5a844d5ebe887a6e5e01a915_I20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bbab44d4d5c4f71b7e66b61049265a3_I20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie899756b47294e60987e6e1a4eefdc3e_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb0fc522997c467cbcef1d255211f031_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02f9ba7cd53c4aa2923afca3b66da448_I20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="halo:AnnualInterestPaymentPeriodAxis">halo:DebtInstrumentInterestPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib893c55155b64b2d9ba4c8642f2c3120_I20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="halo:AnnualInterestPaymentPeriodAxis">halo:DebtInstrumentInterestPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d84d81913354102bacd27bce79cae8a_I20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="halo:AnnualInterestPaymentPeriodAxis">halo:DebtInstrumentInterestPeriodThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5959be9d203461f9800ee2d21d52824_I20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="halo:AnnualInterestPaymentPeriodAxis">halo:DebtInstrumentInterestPeriodFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd07e3cd9dc54a55ac0339e3aa933aa6_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="halo:VariableRateComponentAxis">halo:VariableRateComponentOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39c021912c0a4737966b6fc9307a0131_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b5fd9edb8e049a19ff19cafcd90c13b_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia986ec6d3c6d41d2a6808a4f5cfcff5c_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dce68f7e11a4d3a8fa7baa2b614c2aa_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3809e60efe0d46cab0ef2132238b94c8_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64eaeaec62e1494894adad24d117aef9_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="halo:VariableRateComponentAxis">halo:VariableRateComponentTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71fba559ee5e40e6895e295b7e58d09a_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="halo:VariableRateComponentAxis">halo:VariableRateComponentTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10a6ebe671434acfac51d92f04f6b880_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1a876b10c4244179ee15979f3e64628_D20220524-20220524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79fb023f35cc4ee996ea4cb525c92c5f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icac5073a8dfa4150a03fa81e7c9db6f9_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b599c875f4f40e294c8d28f8eb1e582_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cfceed396a74b66a22f992517fbad65_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59eefa49da754fc4a678bcfece8e4fa5_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b377684337249a79d005226a445c9d3_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie13a988e22704be5a5271b3555ac5742_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc0b6f8877784e66b28f844b0f81f44c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbf1cd99aace4cbfa194e2f7dedc5157_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57f7d92fa5174c7a9550dfc6b218d957_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c0e86c5373e4602b110c2747e91ff9a_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb8fed0bdf764dd2bd8a75a83eba117c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46d36ab336df48ad98a01cfdfc1a2696_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8257a7f99e248c4b487a6942b94aec0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03beebbe6fad4ae4a59c0a56d53de652_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:RSURSAandPRSUawardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa122ca61ec54b1c824632d4d8f8bd63_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:RSURSAandPRSUawardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8786b34524304c2c89d022706441552b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:RSURSAandPRSUawardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3dfae04892c4acfbec9d00a8bc5641d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:RSURSAandPRSUawardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b9b85bf65324a6796a32c109822a4ae_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7177752d30b457e85b8d0e18806711a_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia075a8f22ebb4c19bcb72e7ad3ead56a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia02f509257fd46da8f0a5f3e5e678761_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i132fba3a55ea459d84aa0bb90100bdd7_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa39c538bf934a02b5928070f514abbb_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i543c949f5482411dabdc5d1d89631950_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0f607a6eb8841f78c2d102cf0eab6aa_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21d64138ff854e21be215de2a288c045_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">halo:A2021ESPPPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96a1543f8d6e4bfbb485a55166a6038c_I20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">halo:A2021ESPPPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49fcdbfe0faf49d1a3e26def4e7b572f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">halo:A2021ESPPPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6ded8ac2e08484aa08a3116e39e8ed6_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">halo:A2021ESPPPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i039a8cae3d874e6fb7155efc49a70811_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90338c7e90e04fbb88f9eaebe6f9c0a4_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i846c45d299c548bd93d9ca4e31ef2c27_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd47428a7d224a1cb5358f0397539915_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife8e3a854f8d4e9a9d92bcbe808224ee_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d6e73a624be47fea5d20e683c6bea8e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc726257139b49b6a58fe70d504a57d9_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68a4a2f139194eaf961414023ef77512_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea8e1a13442143e58800a7fa395d7502_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c6331a6ec0e49a3ba11830898b654f5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida58a610325c429a94dfe3fb62450540_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2cda56e59c543bdb0c8c9ac8c626f34_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6eddd51f62374e059ee58a39542c4f58_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if429dbd362794e36ab10ac51992df878_D20191101-20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02c1d101b0e4433cb0667cb17eedd9ca_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic73a9ae57f1f4045a6e76817123e3ac0_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">halo:AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia44d229bf8fa4a2cbef0e366dafed174_D20220601-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">halo:AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie55dcf742b2e4dffa0c703e02b2973d4_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i589ea088db504147b0ffc55414faf533_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a8ca59aa7d8490c970c1e0dae5c4eae_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i472657a1189640ed803ebfce1b25d59f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fd2c85ec0bb4267bea086d8a0cd4161_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7f900d934cc4dfca248ded4a6faaf36_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24cfdda4dd3d45168530f3505f70dc4d_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfecde32e655413b98a5b79476a9c15f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001159036</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ibd09c52bdc03451493df7fb7077280c7_1"></div><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGV4dHJlZ2lvbjoxOTVlODlhNTRlYmQ0NjUzODdiOGYxNDk5Njg5OWJmOV8xODA0_3c294a08-26c0-4afb-a8d5-a965f01943ec">10-Q</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Mark One)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.861%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGFibGU6ZTE2OTA0ODFlOTliNGRiY2JmZjRkYjU4NzRmZThlOTIvdGFibGVyYW5nZTplMTY5MDQ4MWU5OWI0ZGJjYmZmNGRiNTg3NGZlOGU5Ml8wLTAtMS0xLTQ3ODAx_b9320bd8-d064-4221-bb05-df1cdc5c4bd3">&#9746;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGV4dHJlZ2lvbjoxOTVlODlhNTRlYmQ0NjUzODdiOGYxNDk5Njg5OWJmOV8xMzQ_9b9b3d80-3220-4f18-81d5-49604edcecb9">June&#160;30, 2022</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.861%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGFibGU6YzQ0MjJmYmRjMDc5NGFjZmIyMGY3NTcxMzlkMmQyNzQvdGFibGVyYW5nZTpjNDQyMmZiZGMwNzk0YWNmYjIwZjc1NzEzOWQyZDI3NF8wLTAtMS0xLTQ3ODAx_7259ae3e-2b4f-4b9b-9fd0-2b8e76bf2d23">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number <ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGV4dHJlZ2lvbjoxOTVlODlhNTRlYmQ0NjUzODdiOGYxNDk5Njg5OWJmOV8xODAx_e02706c4-1ed2-4cda-ab78-96a3c6ef0f4f">001-32335</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">___________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGV4dHJlZ2lvbjoxOTVlODlhNTRlYmQ0NjUzODdiOGYxNDk5Njg5OWJmOV8xNzk3_3a6fcb1b-9ba2-4833-81a7-700e7d709e35">HALOZYME THERAPEUTICS, INC.</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Exact name of registrant as specified in its charter</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">___________________________</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.861%"><tr><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.486%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGFibGU6OTYxOGZhYzU4OTA3NGZkYTlmNDNhY2YzNDQzNGMyMjUvdGFibGVyYW5nZTo5NjE4ZmFjNTg5MDc0ZmRhOWY0M2FjZjM0NDM0YzIyNV8wLTAtMS0xLTQ3ODAx_6cfcdd40-2028-4276-a491-f08b90ca6243">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGFibGU6OTYxOGZhYzU4OTA3NGZkYTlmNDNhY2YzNDQzNGMyMjUvdGFibGVyYW5nZTo5NjE4ZmFjNTg5MDc0ZmRhOWY0M2FjZjM0NDM0YzIyNV8wLTItMS0xLTQ3ODAx_ac295ef2-d5df-43f9-a91a-01bde10255fb">88-0488686</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGFibGU6OTYxOGZhYzU4OTA3NGZkYTlmNDNhY2YzNDQzNGMyMjUvdGFibGVyYW5nZTo5NjE4ZmFjNTg5MDc0ZmRhOWY0M2FjZjM0NDM0YzIyNV8zLTAtMS0xLTQ3ODAx_a7ae3d3a-b659-4cf6-a722-833e86f187c4">11388 Sorrento Valley Road</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGFibGU6OTYxOGZhYzU4OTA3NGZkYTlmNDNhY2YzNDQzNGMyMjUvdGFibGVyYW5nZTo5NjE4ZmFjNTg5MDc0ZmRhOWY0M2FjZjM0NDM0YzIyNV8zLTItMS0xLTQ3ODAx_91a5b43d-7ee4-4a28-b89c-64a6197e3d9f">92121</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGFibGU6OTYxOGZhYzU4OTA3NGZkYTlmNDNhY2YzNDQzNGMyMjUvdGFibGVyYW5nZTo5NjE4ZmFjNTg5MDc0ZmRhOWY0M2FjZjM0NDM0YzIyNV80LTAtMS0xLTQ3ODAx_5fb7f4c6-0138-4ad6-8e37-df6d20973d1f">San Diego</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Zip Code)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGFibGU6OTYxOGZhYzU4OTA3NGZkYTlmNDNhY2YzNDQzNGMyMjUvdGFibGVyYW5nZTo5NjE4ZmFjNTg5MDc0ZmRhOWY0M2FjZjM0NDM0YzIyNV81LTAtMS0xLTQ3ODAx_ec60de9d-ab4f-4f4a-b029-f8635545a392">California</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGV4dHJlZ2lvbjoxOTVlODlhNTRlYmQ0NjUzODdiOGYxNDk5Njg5OWJmOV8xNzk4_206fe21a-7adb-4dfc-b198-e0b574573489">858</ix:nonNumeric>) <ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGV4dHJlZ2lvbjoxOTVlODlhNTRlYmQ0NjUzODdiOGYxNDk5Njg5OWJmOV8xODAy_5f642421-6248-4c71-a739-90681c4c889d">794-8889</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.277%"><tr><td style="width:1.0%"></td><td style="width:33.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.010%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.104%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGFibGU6NmQyNmRiOTU2NjAyNDljYzlkN2RkYjEwZTMzMGNjZGQvdGFibGVyYW5nZTo2ZDI2ZGI5NTY2MDI0OWNjOWQ3ZGRiMTBlMzMwY2NkZF8xLTAtMS0xLTQ3ODAx_17ce1eea-18bd-42a3-a4b4-a90b97a409a2">Common Stock, $0.001 par value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGFibGU6NmQyNmRiOTU2NjAyNDljYzlkN2RkYjEwZTMzMGNjZGQvdGFibGVyYW5nZTo2ZDI2ZGI5NTY2MDI0OWNjOWQ3ZGRiMTBlMzMwY2NkZF8xLTEtMS0xLTQ3ODAx_d7efc617-bdb5-4eaa-b144-f6a3e7efd7fc">HALO</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGFibGU6NmQyNmRiOTU2NjAyNDljYzlkN2RkYjEwZTMzMGNjZGQvdGFibGVyYW5nZTo2ZDI2ZGI5NTY2MDI0OWNjOWQ3ZGRiMTBlMzMwY2NkZF8xLTItMS0xLTQ3ODAx_ae3b6731-00c2-4837-9de2-0b312a8cbe83">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGV4dHJlZ2lvbjoxOTVlODlhNTRlYmQ0NjUzODdiOGYxNDk5Njg5OWJmOV8xODAz_aa725dcb-3676-4651-96b7-7e71b0df2735">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGV4dHJlZ2lvbjoxOTVlODlhNTRlYmQ0NjUzODdiOGYxNDk5Njg5OWJmOV8xNzk5_2a939cc9-f8c3-4fd9-b2d1-987b41896c2a">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221;, and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.:</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.277%"><tr><td style="width:1.0%"></td><td style="width:31.925%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.213%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGFibGU6ZjMzNzBiYTkxODA3NDllNzk5Mjk1MWUwZWE1ZTliOTkvdGFibGVyYW5nZTpmMzM3MGJhOTE4MDc0OWU3OTkyOTUxZTBlYTVlOWI5OV8wLTAtMS0xLTQ3ODAx_9cf3d7c5-058d-4317-a1c6-f39aaa08f61b">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer&#160;&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGFibGU6ZjMzNzBiYTkxODA3NDllNzk5Mjk1MWUwZWE1ZTliOTkvdGFibGVyYW5nZTpmMzM3MGJhOTE4MDc0OWU3OTkyOTUxZTBlYTVlOWI5OV8xLTMtMS0xLTQ3ODAx_dd63f45c-5a40-47d5-b863-0e6e7b35a4a6">&#9744;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGFibGU6ZjMzNzBiYTkxODA3NDllNzk5Mjk1MWUwZWE1ZTliOTkvdGFibGVyYW5nZTpmMzM3MGJhOTE4MDc0OWU3OTkyOTUxZTBlYTVlOWI5OV8yLTMtMS0xLTQ3ODAx_c6d2bf7f-2abb-4b5f-a124-d0b606f5d411">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.472%"><tr><td style="width:1.0%"></td><td style="width:17.517%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.696%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.658%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.894%"></td><td style="width:0.1%"></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#168;</span></div></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGV4dHJlZ2lvbjoxOTVlODlhNTRlYmQ0NjUzODdiOGYxNDk5Njg5OWJmOV8xODAw_4200c5a9-93d8-456d-b1db-0196f1e1ba0c">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of outstanding shares of the registrant&#8217;s common stock, par value $0.001 per share, was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i73af0220bff74c0b84c26e30e7814735_I20220802" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGV4dHJlZ2lvbjoxOTVlODlhNTRlYmQ0NjUzODdiOGYxNDk5Njg5OWJmOV8xNzgy_fd525d12-c39a-4747-8db1-da798cffb6c9">137,779,370</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> as of August&#160;2, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ibd09c52bdc03451493df7fb7077280c7_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HALOZYME THERAPEUTICS, INC.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160; </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"></td><td style="width:9.036%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.542%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.161%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.102%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.559%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd09c52bdc03451493df7fb7077280c7_10">Summary of Risk Factors</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd09c52bdc03451493df7fb7077280c7_10">3</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibd09c52bdc03451493df7fb7077280c7_13">PART&#160;I &#8212; FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd09c52bdc03451493df7fb7077280c7_16">Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd09c52bdc03451493df7fb7077280c7_19">Condensed Consolidated Balance Sheets (Unaudited) - June 30, 2022 and December 31, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd09c52bdc03451493df7fb7077280c7_19">6</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd09c52bdc03451493df7fb7077280c7_25">Condensed Consolidated Statements of Income (Unaudited) - Three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd09c52bdc03451493df7fb7077280c7_25">and Six Months Ended June 30, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd09c52bdc03451493df7fb7077280c7_25">6</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd09c52bdc03451493df7fb7077280c7_28">Condensed Consolidated Statements of Comprehensive Income (Unaudited) - Three and Six Months Ended June 30, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd09c52bdc03451493df7fb7077280c7_28">7</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd09c52bdc03451493df7fb7077280c7_31">Condensed Consolidated Statements of Cash Flows (Unaudited) - Six Months Ended June 30, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd09c52bdc03451493df7fb7077280c7_31">8</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd09c52bdc03451493df7fb7077280c7_34">Condensed Consolidated Statements of Stockholders&#8217; Equity (Unaudited) - Three and Six Months Ended June 30, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd09c52bdc03451493df7fb7077280c7_34">9</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd09c52bdc03451493df7fb7077280c7_37">Notes to Condensed Consolidated Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd09c52bdc03451493df7fb7077280c7_40">10</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd09c52bdc03451493df7fb7077280c7_85">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd09c52bdc03451493df7fb7077280c7_85">39</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd09c52bdc03451493df7fb7077280c7_103">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd09c52bdc03451493df7fb7077280c7_103">78</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd09c52bdc03451493df7fb7077280c7_106">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd09c52bdc03451493df7fb7077280c7_106">78</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ibd09c52bdc03451493df7fb7077280c7_109">PART&#160;II &#8212; OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd09c52bdc03451493df7fb7077280c7_112">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd09c52bdc03451493df7fb7077280c7_112">79</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd09c52bdc03451493df7fb7077280c7_115">Risk Factors</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd09c52bdc03451493df7fb7077280c7_115">79</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd09c52bdc03451493df7fb7077280c7_118">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd09c52bdc03451493df7fb7077280c7_118">79</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd09c52bdc03451493df7fb7077280c7_121">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd09c52bdc03451493df7fb7077280c7_121">79</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd09c52bdc03451493df7fb7077280c7_124">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd09c52bdc03451493df7fb7077280c7_124">79</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd09c52bdc03451493df7fb7077280c7_127">Other Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd09c52bdc03451493df7fb7077280c7_127">79</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd09c52bdc03451493df7fb7077280c7_130">Exhibits</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd09c52bdc03451493df7fb7077280c7_130">80</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd09c52bdc03451493df7fb7077280c7_133">SIGNATURES</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ibd09c52bdc03451493df7fb7077280c7_133">81</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ibd09c52bdc03451493df7fb7077280c7_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Risk Factors</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to a number of risks and uncertainties, including those described in the section labeled &#8220;Risk Factors&#8221; in &#8220;Part I, Item 2, Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; of this Quarterly Report. These risks include the following:</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related To Our Business</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Business interruptions resulting from the COVID-19 outbreak or similar public health crises could cause a disruption of the development of our and our partnered product candidates and commercialization of our approved and our partnered products, impede our ability to supply bulk rHuPH20 to our ENHANZE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> partners or procure and sell our proprietary products and otherwise adversely impact our business and results of operations.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">If our partnered or proprietary product candidates do not receive and maintain regulatory approvals, or if approvals are not obtained in a timely manner, such failure or delay would substantially impair our ability to generate revenues.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Use of our partnered or proprietary products and product candidates could be associated with side effects or adverse events or product recalls.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">If our contract manufacturers or vendors are unable or elect not  to manufacture and supply to us bulk rHuPH20 or other raw materials, reagents, components or devices in the quantity and quality required by us or our partners for use in the production of Hylenex or other proprietary or partnered products and product candidates, our and our partners&#8217; product development or commercialization efforts could be delayed or suspended and our business results of operations and our collaborations could be harmed.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on third parties to perform many necessary services for our products including services related to the distribution, invoicing, rebates and contract administration, co-pay program administration, sample distribution and administration, storage and transportation of our products. If anything should impede their ability to meet their commitments this could impact our business performance.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">If we or any party to a key collaboration agreement fail to perform material obligations under such agreement, or if a key collaboration agreement, is terminated for any reason, our business could significantly suffer.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Hylenex and our partners&#8217; ENHANZE products and product candidates rely on the rHuPH20 enzyme, and any adverse development regarding rHuPH20 could substantially impact multiple areas of our business, including current and potential ENHANZE collaborations, as well as any proprietary programs.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our business strategy and our strategic focus is currently limited to only a few fields or applications of our technology which may increase the risk for potential negative impact from adverse developments. Future expansion of our strategic focus to additional applications of our technology may require the use of additional resources, result in increased expense and ultimately may not be successful.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our partnered or proprietary product candidates may not receive regulatory approvals or their development may be delayed for a variety of reasons, including delayed or unsuccessful clinical trials, regulatory requirements or safety concerns. If we or our partners fail to obtain, or have delays in obtaining, regulatory approvals for any product candidates, our business, financial condition and results of operations may be materially adversely affected.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our third party partners are responsible for providing certain proprietary materials that are essential components of our partnered products and product candidates, and any failure to supply these materials could delay the development and commercialization efforts for these partnered products and product candidates and/or damage our collaborations. Our partners are also responsible for distributing and commercializing their products, and any failure to successfully commercialize their products could materially adversely affect our revenues.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">If we or our partners fail to comply with regulatory requirements applicable to promotion, sale and manufacturing of approved products, regulatory agencies may take action against us or them, which could significantly harm our business.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Failure to successfully integrate the Antares business, or failure of the Antares business to perform could adversely impact our stock price and future business and operations.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We may need to raise additional capital in the future and there can be no assurance that we will be able to obtain such funds.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We currently have significant debt and expect to incur additional debt. Failure by us to fulfill our obligations under the applicable debt agreements may cause the repayment obligations to accelerate.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The conditional conversion feature of the Convertible Notes, if triggered, may adversely affect our financial condition and operating results.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Conversion of our Convertible Notes may dilute the ownership interest of existing stockholders or may otherwise depress the price of our common stock.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If proprietary or partnered product candidates are approved for marketing but do not gain market acceptance resulting in commercial performance below that which was expected or projected, our business may suffer.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our ability to license our ENHANZE and device technologies to our partners depends on the validity of our patents and other proprietary rights.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Developing, manufacturing and marketing pharmaceutical products for human use involves significant product liability risks for which we may have insufficient insurance coverage.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">If our partners do not achieve projected development, clinical, or regulatory goals in the timeframes publicly announced or otherwise expected, the commercialization of our partnered products may be delayed and, as a result, our stock price may decline, and we may face lawsuits relating to such declines.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Future acquisitions could disrupt our business and harm our financial condition.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related To Ownership of Our Common Stock</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our stock price is subject to significant volatility.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Future transactions where we raise capital may negatively affect our stock price.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Anti-takeover provisions in our charter documents, the Indentures and Delaware law may make an acquisition of us more difficult.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Our Industry</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our or our partnered products must receive regulatory approval before they can be sold, and compliance with the extensive government regulations is expensive and time consuming and may result in the delay or cancellation of our or our partnered product sales, introductions or modifications.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Because some of our and our partners&#8217; products and product candidates are considered to be drug/device combination products, the approval and post-approval requirements that we and they are required to comply with can be more complex.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We may be subject, directly or indirectly, to various broad federal and state healthcare laws. If we are unable to comply, or have not fully complied, with such laws, we could face civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We may be required to initiate or defend against legal proceedings related to intellectual property rights, which may result in substantial expense, delay and/or cessation of the development and commercialization of our products.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may incur significant liability if it is determined that we are promoting or have in the past promoted the &#8220;off-label&#8221; use of drugs or medical devices, or otherwise promoted or marketed approved products in a manner inconsistent with the FDA&#8217;s requirements.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For certain of our products, we and our independent contractors, distributors, prescribers, and dispensers are required to comply with regulatory requirements related to controlled substances, which will require the expenditure of additional time and will incur additional expenses to maintain compliance and may subject us to additional penalties for noncompliance, which could inhibit successful commercialization.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Patent protection for protein-based therapeutic products and other biotechnology inventions is subject to a great deal of uncertainty, and if patent laws or the interpretation of patent laws change, our competitors may be able to develop and commercialize products based on our discoveries.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">If third party reimbursement and customer contracts are not available, our proprietary and our partnered products may not be accepted in the market resulting in commercial performance below that which was expected or projected.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The rising cost of healthcare and related pharmaceutical product pricing has led to cost containment pressures from third-party payers as well as changes in federal coverage and reimbursement policies and practices that could cause us and our partners to sell our products at lower prices, and impact access to our and our partners&#8217; products, resulting in less revenue to us.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We face intense competition and rapid technological change that could result in the development of products by others that are competitive with or superior to our proprietary and partnered products, including those under development.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risks</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Our inability to attract, hire and retain key management and scientific personnel could negatively affect our business.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our operations might be interrupted by the occurrence of a natural disaster or other catastrophic event.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Cyberattacks, security breaches or system breakdowns may disrupt our operations and harm our operating results and reputation.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ibd09c52bdc03451493df7fb7077280c7_13"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I &#8212; FINANCIAL INFORMATION</span></div><div id="ibd09c52bdc03451493df7fb7077280c7_16"></div><div style="padding-left:54pt;text-indent:-49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. &#160;&#160;&#160;&#160;Financial Statements</span></div><div id="ibd09c52bdc03451493df7fb7077280c7_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HALOZYME THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.162%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.604%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMy0yLTEtMS00NzgwMQ_ad3c84b6-4b33-4d44-91bd-4952795f3e37">90,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMy00LTEtMS00NzgwMQ_02a03b13-585d-4977-991d-005e4adcff99">118,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities, available-for-sale</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfNC0yLTEtMS00NzgwMQ_0aa28eda-6ab2-4349-b184-242b559d78cc">118,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfNC00LTEtMS00NzgwMQ_5cf2c69f-d01c-412f-adf4-31bae1b745ec">622,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net and contract assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfNS0yLTEtMS00NzgwMQ_e7aca5e2-35c8-4e1a-8406-33b8612e43c6">189,368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfNS00LTEtMS00NzgwMQ_c17c6176-a72d-4e18-bd76-fc7cb8b0d5a5">90,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfNi0yLTEtMS00NzgwMQ_a8929514-b043-4c6d-a50f-8bc174365051">97,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfNi00LTEtMS00NzgwMQ_83dd31a4-da74-4c4c-b169-bb497ecd0f3c">53,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfNy0yLTEtMS00NzgwMQ_0071273d-7d87-4fcb-8ca1-dfccbf2b2635">45,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfNy00LTEtMS00NzgwMQ_a9710c0b-369c-4623-834d-bfaf9fe12a63">40,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfOC0yLTEtMS00NzgwMQ_a7c3d446-5dab-4b3b-a883-85c34ede2045">541,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfOC00LTEtMS00NzgwMQ_f03fd4eb-199e-41d1-960c-ad1ac5b05f96">926,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfOS0yLTEtMS00NzgwMQ_5c1d2be8-d56c-4146-90d2-1f4a46a74078">37,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfOS00LTEtMS00NzgwMQ_c88397a7-21e6-4f72-bda8-15df3e7f5618">8,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMTAtMi0xLTEtNDc4MDE_354035b5-8c41-4032-b1cb-99b0b2ce5019">26,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMTAtNC0xLTEtNDc4MDE_c502011c-57cd-4885-b612-63bc87339af2">13,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMTEtMi0xLTEtNTAxMjA_1e8a0ec9-d736-4a17-9f7d-958942a80e86">199,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMTEtNC0xLTEtNTAxMjc_0c1aa864-22ad-4c49-aecc-1d734beb9ce9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMTItMi0xLTEtNTAxMjA_add42e21-b609-4af3-9267-61d8992497d1">976,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMTItNC0xLTEtNTAxMjc_aa76334a-acfb-4441-8b7b-94b6c879d96d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMTEtMi0xLTEtNDc4MDE_4a191d78-dc64-4719-b1a4-dc8cfb278fa8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMTEtNC0xLTEtNDc4MDE_125f81a9-ec20-45f0-bd7f-8080fa10d3f5">155,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMTItMi0xLTEtNDc4MDE_c47694da-816f-4a29-b2fc-8af45f3a5d29">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMTItNC0xLTEtNDc4MDE_55084aa2-405f-44e1-b068-7c1766cc5a62">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMTMtMi0xLTEtNDc4MDE_cad02db4-0658-478c-a7d1-48ecd9f670f6">1,781,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMTMtNC0xLTEtNDc4MDE_f8efb009-b7be-4cf2-b9c4-72149f256ec0">1,104,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMTctMi0xLTEtNDc4MDE_a8c358e4-0fa4-4496-ac86-2a5c62de6d76">12,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMTctNC0xLTEtNDc4MDE_4b348b15-576f-4aa8-baf0-82b0143a0de5">1,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMTgtMi0xLTEtNDc4MDE_61d40961-d433-4c46-b30e-2baff0140e58">84,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMTgtNC0xLTEtNDc4MDE_809e3d7e-eb64-479c-bd8d-16b961b0c8ef">24,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:DeferredRevenueCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMTktMi0xLTEtNDc4MDE_9f9ae700-8b19-4059-ba73-ae19379ca721">4,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:DeferredRevenueCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMTktNC0xLTEtNDc4MDE_25a3b981-e140-4697-a787-1d5fef7cbc61">1,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjAtMi0xLTEtNDc4MDE_82e006a9-47ff-4051-a6fa-06fe7b1fd0d6">99,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjAtNC0xLTEtNDc4MDE_14afe1dc-b4ae-4184-899e-e0182fdd50e4">89,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjEtMi0xLTEtNDc4MDE_a89e2a61-6e59-4801-8932-a2eae8abcb5a">199,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjEtNC0xLTEtNDc4MDE_1c9a00fa-f375-4e21-9a54-8c8923c5f594">117,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:DeferredRevenueNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjItMi0xLTEtNDc4MDE_23c79696-f31e-4ab2-8729-5dafcdf0bf75">2,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:DeferredRevenueNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjItNC0xLTEtNDc4MDE_fc2a3485-46ce-482b-a7c0-8e1090f2baad">2,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjMtMi0xLTEtNDc4MDE_5e4c09cf-5b3d-450d-bd03-0da484893045">1,147,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjMtNC0xLTEtNDc4MDE_3c276ce1-f719-4639-a48a-9483d78e7a31">787,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjQtMi0xLTEtNDc4MDE_0a63b4d4-6a48-4d4d-9361-3b130bdc019c">5,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjQtNC0xLTEtNDc4MDE_334f83b7-82eb-4e89-ad9d-d7d0698a6cbe">544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjctMi0xLTEtNjEyMTA_294c269e-95f0-475b-a236-053dfda1a767">3,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjctNC0xLTEtNjEyMjQ_201dbe58-11c8-4d0b-a33e-b1e76aa69f03">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjctMi0xLTEtNTQ4ODU_a8dae0bd-f427-4836-8f1a-378a5f4dc00d">130,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjctNC0xLTEtNTQ4OTM_f3cab9fa-6a66-4df6-b6ed-f077671721f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 12)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjUtMi0xLTEtNDc4MDE_d2c5e1c6-eb9e-4b58-9b93-513f9d15288b"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjUtNC0xLTEtNDc4MDE_303e4ccb-7af4-4a89-b69f-ab73fdfa8bc4"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock - $<ix:nonFraction unitRef="usdPerShare" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjctMC0xLTEtNDc4MDEvdGV4dHJlZ2lvbjo2NzZhM2VhNDk4MzE0ZTY3ODkxNmU4ZTkwYWRmMDhjNl8yMg_e07f430c-9df7-46aa-b0f3-3b9ddddcaed2"><ix:nonFraction unitRef="usdPerShare" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjctMC0xLTEtNDc4MDEvdGV4dHJlZ2lvbjo2NzZhM2VhNDk4MzE0ZTY3ODkxNmU4ZTkwYWRmMDhjNl8yMg_fd66dfaf-ce20-489e-aeed-7cb195dfe1c0">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjctMC0xLTEtNDc4MDEvdGV4dHJlZ2lvbjo2NzZhM2VhNDk4MzE0ZTY3ODkxNmU4ZTkwYWRmMDhjNl8zNg_9966d590-95fe-4c43-b83c-eb9795985f53"><ix:nonFraction unitRef="shares" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjctMC0xLTEtNDc4MDEvdGV4dHJlZ2lvbjo2NzZhM2VhNDk4MzE0ZTY3ODkxNmU4ZTkwYWRmMDhjNl8zNg_ab47fd08-6912-40a8-b419-052a95965df2">20,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjctMC0xLTEtNDc4MDEvdGV4dHJlZ2lvbjo2NzZhM2VhNDk4MzE0ZTY3ODkxNmU4ZTkwYWRmMDhjNl81OA_1e5c20b1-a161-46b9-aeea-5eb445f14ce0"><ix:nonFraction unitRef="shares" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjctMC0xLTEtNDc4MDEvdGV4dHJlZ2lvbjo2NzZhM2VhNDk4MzE0ZTY3ODkxNmU4ZTkwYWRmMDhjNl81OA_572cc325-a4ee-45ad-856e-2f81bbac5adc"><ix:nonFraction unitRef="shares" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjctMC0xLTEtNDc4MDEvdGV4dHJlZ2lvbjo2NzZhM2VhNDk4MzE0ZTY3ODkxNmU4ZTkwYWRmMDhjNl81OA_7a2db87b-537f-49ed-a2f8-29e39b3b5f49"><ix:nonFraction unitRef="shares" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjctMC0xLTEtNDc4MDEvdGV4dHJlZ2lvbjo2NzZhM2VhNDk4MzE0ZTY3ODkxNmU4ZTkwYWRmMDhjNl81OA_e9696133-15df-47bd-9224-35f2935263c5">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares </span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;issued and outstanding</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjctMi0xLTEtNDc4MDE_efca8b59-47a7-4020-a096-83dc6b1f6b36">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjctNC0xLTEtNDc4MDE_8673db7b-9bd6-4953-85f7-4a8a6b261836">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock - $<ix:nonFraction unitRef="usdPerShare" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjgtMC0xLTEtNDc4MDEvdGV4dHJlZ2lvbjo2ZWNjNTFjMjFmMjQ0YjBkODE2OTk1MmE2ZDcxMjkwYl8xOQ_1e505b16-98b8-4e26-b126-d3cbb5c827a7"><ix:nonFraction unitRef="usdPerShare" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjgtMC0xLTEtNDc4MDEvdGV4dHJlZ2lvbjo2ZWNjNTFjMjFmMjQ0YjBkODE2OTk1MmE2ZDcxMjkwYl8xOQ_a50c7eec-930e-4f80-9bf9-57b10e2f92be">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjgtMC0xLTEtNDc4MDEvdGV4dHJlZ2lvbjo2ZWNjNTFjMjFmMjQ0YjBkODE2OTk1MmE2ZDcxMjkwYl8zMw_4e585c26-e225-423b-bb68-94ec6d694ddc"><ix:nonFraction unitRef="shares" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjgtMC0xLTEtNDc4MDEvdGV4dHJlZ2lvbjo2ZWNjNTFjMjFmMjQ0YjBkODE2OTk1MmE2ZDcxMjkwYl8zMw_dd4e6a3e-adc7-4e60-9b48-74c24904a55e">300,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjgtMC0xLTEtNDc4MDEvdGV4dHJlZ2lvbjo2ZWNjNTFjMjFmMjQ0YjBkODE2OTk1MmE2ZDcxMjkwYl81NQ_0c18b088-b750-430e-ab83-709b398eb577"><ix:nonFraction unitRef="shares" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjgtMC0xLTEtNDc4MDEvdGV4dHJlZ2lvbjo2ZWNjNTFjMjFmMjQ0YjBkODE2OTk1MmE2ZDcxMjkwYl81NQ_153aa585-5bbc-4bef-b39b-d803feac14d2">137,681</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ibbcde496e999416f83088ace845dbf65_I20211231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjgtMC0xLTEtNDc4MDEvdGV4dHJlZ2lvbjo2ZWNjNTFjMjFmMjQ0YjBkODE2OTk1MmE2ZDcxMjkwYl82Mg_ba9a13cd-2260-4684-ab8a-174fd7304c72">137,498</ix:nonFraction> shares issued and outstanding at June&#160;30, 2022 and December&#160;31, 2021, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjgtMi0xLTEtNDc4MDE_50f33a50-76a9-4309-91ad-7cfeafae458a">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjgtNC0xLTEtNDc4MDE_39024a37-2671-439c-abb1-b07f4c9639af">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjktMi0xLTEtNDc4MDE_4095f9df-d6bc-471e-8f1d-a7df140d75e3">271,169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjktNC0xLTEtNDc4MDE_3fff563b-a53f-4f07-bb3c-d7e17ed9857d">256,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMzAtMi0xLTEtNDc4MDE_6f219974-683a-4775-acb2-daaf873facf5">2,017</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMzAtNC0xLTEtNDc4MDE_20c3583f-e510-4998-9975-14dd247042aa">620</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings (accumulated deficit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMzEtMi0xLTEtNDc4MDE_b73119dd-be7b-4687-b387-70d112dabfff">23,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMzEtNC0xLTEtNDc4MDE_5aee779a-021a-4946-99cb-a9b2ed2d3f1f">58,912</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMzItMi0xLTEtNDc4MDE_00cbbdef-1378-48fe-b8fd-0d31247f19b0">293,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMzItNC0xLTEtNDc4MDE_5e9cf375-38b6-4604-b5a0-9de75e78fc2c">196,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMzMtMi0xLTEtNDc4MDE_c98f5c41-8bf0-40a7-8260-5fedd36374af">1,781,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMzMtNC0xLTEtNDc4MDE_3f6a4744-b4a3-4c94-874e-2e4def9372f7">1,104,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="ibd09c52bdc03451493df7fb7077280c7_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HALOZYME THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.802%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.012%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.961%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.127%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.967%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2302c2baba3a4084b1cd7169564a4517_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMy0yLTEtMS00NzgwMQ_c2f396aa-bdcd-4e53-9649-3a6a710b2773">85,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifecd7d767a3c48d6a094b68ee21e3340_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMy00LTEtMS00NzgwMQ_71b7807b-b1af-4548-bd89-e059d6e3e2eb">45,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i488611ceda1e4bf3a1df6ada966c72ff_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMy02LTEtMS00NzgwMQ_7888c8c4-0ef0-4624-baf7-05b5e6e78c1d">154,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie448ea4ebc7a4047b9528cc3d06dac35_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMy04LTEtMS00NzgwMQ_4f48cdd4-b6e7-48ce-bfdf-3ed4049c5e71">82,701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefbbc65edf2e4319adad4df5fa76e1f3_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfNC0yLTEtMS00NzgwMQ_a826e5dd-a4f2-4395-bd6b-59a3b293243b">46,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9220796b173a4a9298008c86f02bacf1_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfNC00LTEtMS00NzgwMQ_76729442-4a74-46ac-ad81-ee0af370af6e">30,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5cfeb9eb65745ed9779cd8409a1de20_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfNC02LTEtMS00NzgwMQ_389384c6-1224-4708-b5e6-0362089eb059">68,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d0fdcb3db8c45fdb97bc693b3691d65_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfNC04LTEtMS00NzgwMQ_da092fce-2379-49cb-ae55-49c88eec6ded">52,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues under collaborative agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5331ecfa85164578966f7ba36c8377ac_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfNS0yLTEtMS00NzgwMQ_0a974d9c-302c-499d-860e-32ab262f8def">20,725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88e4277b0c454a79a9c899981c6d0ade_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfNS00LTEtMS00NzgwMQ_7aa646fa-6be8-4474-aecc-5ff86be08e4a">60,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if13d9aa4327240bcaf9417558eeae8c3_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfNS02LTEtMS00NzgwMQ_d0d4d3ed-0578-407f-b65b-0d5c3c99fd60">46,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic72a2d641a084db2bfd8a448fdafa5bb_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfNS04LTEtMS00NzgwMQ_87f7687c-51ae-4c4b-a971-c76a07dc0950">90,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfNi0yLTEtMS00NzgwMQ_5001e0b7-578c-4358-a707-db5986f44847">152,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfNi00LTEtMS00NzgwMQ_bfe89e09-7222-478c-8eab-cb0c569c691d">136,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfNi02LTEtMS00NzgwMQ_8c43bbed-c334-4d79-b27e-a9d021dd79aa">269,644</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfNi04LTEtMS00NzgwMQ_7712a555-19a8-4d6a-bcf6-ae5ee4b6a41a">225,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfOC0yLTEtMS00NzgwMQ_e3c59560-5f13-42ce-b1f3-7352ccab8ce0">33,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfOC00LTEtMS00NzgwMQ_f85b1a7e-c042-43df-a6a8-ba17130436e3">23,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfOC02LTEtMS00NzgwMQ_9bd694db-4a23-432e-93c4-7807099e0d9b">49,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfOC04LTEtMS00NzgwMQ_0951ea85-de43-4614-af1c-4bd5b00fce5f">41,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfOS0yLTEtMS01ODcyNQ_67a6926d-b60a-4784-a1ac-4cc78d5e0ef7">11,403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfOS00LTEtMS01ODczMg_55df2673-7d44-42b0-911b-e904076776c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfOS02LTEtMS01ODczOQ_5cc4db4e-dbdd-4b63-986f-b08e43bec53b">11,403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfOS04LTEtMS01ODc0Ng_29daae19-74ad-46d6-bf0a-6e38c750fad1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfOS0yLTEtMS00NzgwMQ_39076623-9065-4b02-8897-f76f3176bf11">15,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfOS00LTEtMS00NzgwMQ_43f9dc87-7d55-4730-b094-9385653ebcf0">8,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfOS02LTEtMS00NzgwMQ_2f99143f-a388-4e57-b840-b9c2d9994da8">27,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfOS04LTEtMS00NzgwMQ_ac384f87-f318-4e5b-8862-419e024c48d1">17,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTAtMi0xLTEtNDc4MDE_ca504eb2-47e7-4937-9d1a-d7816dd09c58">57,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTAtNC0xLTEtNDc4MDE_cb931620-7b12-40c0-9e8d-1ec1c98f5780">12,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTAtNi0xLTEtNDc4MDE_95d9749c-82cc-49f7-b2b6-30e3894feec7">71,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTAtOC0xLTEtNDc4MDE_c9346d05-6281-41d0-a855-8b59be8445b2">23,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTEtMi0xLTEtNDc4MDE_3aec1171-1cca-45ca-91e9-d26597d6af05">118,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTEtNC0xLTEtNDc4MDE_6269cda7-9bbd-4af9-bbc4-af944563577c">43,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTEtNi0xLTEtNDc4MDE_f6911c7b-52e9-4447-a95e-9ef441c228de">159,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTEtOC0xLTEtNDc4MDE_033cd66f-26e4-484f-8d80-7b6a3cae50f5">81,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTItMi0xLTEtNDc4MDE_49c27242-2312-471c-b381-f0d1e2625282">34,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTItNC0xLTEtNDc4MDE_ed485071-0e6d-4945-9f0a-7c2896af91cb">93,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTItNi0xLTEtNDc4MDE_b86aee11-7740-4c94-bb3c-4b345ed83f82">109,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTItOC0xLTEtNDc4MDE_f74872a4-f2f7-4a0c-bcdd-5b9154470023">143,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment and other (expense) income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTQtMi0xLTEtNDc4MDE_d8a8fd67-c063-480f-a326-3b06bb3cbd4b">945</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTQtNC0xLTEtNDc4MDE_541e44f7-53fe-4e77-95b6-b7ae8a768f19">221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTQtNi0xLTEtNDc4MDE_8ac3ec6b-3c0b-4b73-a69f-5e34f57c88e1">447</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTQtOC0xLTEtNDc4MDE_000ae063-2a5c-4f73-b837-dbcecb539955">497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inducement expense related to convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="-3" name="us-gaap:InducedConversionOfConvertibleDebtExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTUtMi0xLTEtNDc4MDE_d852fb40-626f-4f7d-bf77-063a5db575d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="-3" name="us-gaap:InducedConversionOfConvertibleDebtExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTUtNC0xLTEtNDc4MDE_7ba65d53-695c-4f9e-ae26-f219df868043">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:InducedConversionOfConvertibleDebtExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTUtNi0xLTEtNDc4MDE_942331eb-bcf8-4802-9649-9cef298d2d17">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:InducedConversionOfConvertibleDebtExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTUtOC0xLTEtNDc4MDE_9b451ca6-df15-40eb-a070-d8bec119d070">20,960</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTYtMi0xLTEtNDc4MDE_30ae56ec-3ba9-41bb-99b4-7fe76d8a0e7d">3,104</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTYtNC0xLTEtNDc4MDE_0a64a006-33ac-401e-be59-f45b8964248a">1,752</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTYtNi0xLTEtNDc4MDE_0a47a69e-bbd6-4353-8d07-7edca669af4a">4,863</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTYtOC0xLTEtNDc4MDE_25b35e4d-ee9f-4f5e-a7a6-2060847c1ce1">3,717</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTctMi0xLTEtNDc4MDE_4721deb4-fe4e-47ad-9d73-c23eecb7f0ae">30,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTctNC0xLTEtNDc4MDE_24a4bf4e-d508-4d31-b240-efb559493ae9">91,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTctNi0xLTEtNDc4MDE_9a3d46b6-a230-4031-8901-1c3880df16dd">104,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTctOC0xLTEtNDc4MDE_8c3e5f8c-568e-4eb4-85fb-00b026877fd5">119,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTgtMi0xLTEtNDc4MDE_ba48ff0c-95d8-4747-b836-534f3ab47456">7,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTgtNC0xLTEtNDc4MDE_eb5da88a-5ab1-4dca-8efd-2ddb4603ede6">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTgtNi0xLTEtNDc4MDE_9a6a9410-62e0-411a-95a9-22a3f8e1a473">21,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTgtOC0xLTEtNDc4MDE_103c59db-3f2e-411f-83f5-7ca2703deedf">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTktMi0xLTEtNDc4MDE_b854388d-e3fd-4fa3-8855-20458af28a5b">22,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTktNC0xLTEtNDc4MDE_176fce60-02a9-4dee-a93b-41d148685c09">91,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTktNi0xLTEtNDc4MDE_a0754598-91f1-4937-8bb8-d82427c9b01c">82,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTktOC0xLTEtNDc4MDE_786b2ab9-7142-411f-83c4-d7eb6d91474d">119,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMjItMi0xLTEtNDc4MDE_1d2092c9-27ac-4a6f-8b38-09f855b78a38">0.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMjItNC0xLTEtNDc4MDE_7552e1b1-c3ee-47ef-89dc-4c0246a1290f">0.64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMjItNi0xLTEtNDc4MDE_523b7e11-a8e2-409e-aedc-aa4e8791e748">0.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMjItOC0xLTEtNDc4MDE_9f546968-24d4-4837-bde9-41718f13d2b8">0.85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMjMtMi0xLTEtNDc4MDE_8995a73b-5ccb-4438-a3c6-eff5ea978e53">0.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMjMtNC0xLTEtNDc4MDE_aee1a367-b89e-4924-8293-c2bd74fca42b">0.62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMjMtNi0xLTEtNDc4MDE_bf0eb8de-d3f7-431d-b291-a424d5f94f1b">0.58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMjMtOC0xLTEtNDc4MDE_e93a9c21-20fc-45f2-8de4-1115bfea56fe">0.81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net income per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMjYtMi0xLTEtNDc4MDE_cff2ced6-d891-420c-8900-b6d609a9b7ef">137,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMjYtNC0xLTEtNDc4MDE_ee6523cf-b967-4eb8-adeb-fa4211cd1a61">142,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMjYtNi0xLTEtNDc4MDE_36eebfc3-0083-49ce-9127-3bda4721a6fc">137,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMjYtOC0xLTEtNDc4MDE_89e6a812-a2d3-4534-93c2-9653f10161c6">140,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMjctMi0xLTEtNDc4MDE_22cd4c1b-79bc-4da8-976c-d4a8d8094bf7">142,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMjctNC0xLTEtNDc4MDE_25f7537f-48e6-40f9-9b09-a8242b15f633">147,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMjctNi0xLTEtNDc4MDE_bca66a71-04cb-4465-8896-c65ab56a3800">141,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMjctOC0xLTEtNDc4MDE_4d518a34-00c9-4da5-a89c-e1969cdb4823">148,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="ibd09c52bdc03451493df7fb7077280c7_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HALOZYME THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"></td><td style="width:46.100%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.080%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.620%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.080%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yOC9mcmFnOmRkNGQ3ZTA1NGZkZDQzYWE5MWIyOWY1OGRlNTk5NTc2L3RhYmxlOjhhOWI1M2Y4ZDhjODQzNWNhMTBjZTVkN2NmZTY4ZGFlL3RhYmxlcmFuZ2U6OGE5YjUzZjhkOGM4NDM1Y2ExMGNlNWQ3Y2ZlNjhkYWVfMi0yLTEtMS00NzgwMQ_85b363d4-a679-442b-baa8-ad436f7b43ee">22,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yOC9mcmFnOmRkNGQ3ZTA1NGZkZDQzYWE5MWIyOWY1OGRlNTk5NTc2L3RhYmxlOjhhOWI1M2Y4ZDhjODQzNWNhMTBjZTVkN2NmZTY4ZGFlL3RhYmxlcmFuZ2U6OGE5YjUzZjhkOGM4NDM1Y2ExMGNlNWQ3Y2ZlNjhkYWVfMi00LTEtMS00NzgwMQ_c154d82d-6939-45b0-940a-bc0ef625135c">91,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yOC9mcmFnOmRkNGQ3ZTA1NGZkZDQzYWE5MWIyOWY1OGRlNTk5NTc2L3RhYmxlOjhhOWI1M2Y4ZDhjODQzNWNhMTBjZTVkN2NmZTY4ZGFlL3RhYmxlcmFuZ2U6OGE5YjUzZjhkOGM4NDM1Y2ExMGNlNWQ3Y2ZlNjhkYWVfMi02LTEtMS00NzgwMQ_a0754598-91f1-4937-8bb8-d82427c9b01c">82,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yOC9mcmFnOmRkNGQ3ZTA1NGZkZDQzYWE5MWIyOWY1OGRlNTk5NTc2L3RhYmxlOjhhOWI1M2Y4ZDhjODQzNWNhMTBjZTVkN2NmZTY4ZGFlL3RhYmxlcmFuZ2U6OGE5YjUzZjhkOGM4NDM1Y2ExMGNlNWQ3Y2ZlNjhkYWVfMi04LTEtMS00NzgwMQ_786b2ab9-7142-411f-83c4-d7eb6d91474d">119,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yOC9mcmFnOmRkNGQ3ZTA1NGZkZDQzYWE5MWIyOWY1OGRlNTk5NTc2L3RhYmxlOjhhOWI1M2Y4ZDhjODQzNWNhMTBjZTVkN2NmZTY4ZGFlL3RhYmxlcmFuZ2U6OGE5YjUzZjhkOGM4NDM1Y2ExMGNlNWQ3Y2ZlNjhkYWVfNC0yLTEtMS00NzgwMQ_31c3175d-30d5-4fa8-a1f7-f2ecf84fccdc">732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yOC9mcmFnOmRkNGQ3ZTA1NGZkZDQzYWE5MWIyOWY1OGRlNTk5NTc2L3RhYmxlOjhhOWI1M2Y4ZDhjODQzNWNhMTBjZTVkN2NmZTY4ZGFlL3RhYmxlcmFuZ2U6OGE5YjUzZjhkOGM4NDM1Y2ExMGNlNWQ3Y2ZlNjhkYWVfNC00LTEtMS00NzgwMQ_170e2384-ac7d-4ad0-991b-27da34771a55">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yOC9mcmFnOmRkNGQ3ZTA1NGZkZDQzYWE5MWIyOWY1OGRlNTk5NTc2L3RhYmxlOjhhOWI1M2Y4ZDhjODQzNWNhMTBjZTVkN2NmZTY4ZGFlL3RhYmxlcmFuZ2U6OGE5YjUzZjhkOGM4NDM1Y2ExMGNlNWQ3Y2ZlNjhkYWVfNC02LTEtMS00NzgwMQ_d1fab9fd-1a94-4fdb-a5ca-d82e97ce56a7">1,439</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yOC9mcmFnOmRkNGQ3ZTA1NGZkZDQzYWE5MWIyOWY1OGRlNTk5NTc2L3RhYmxlOjhhOWI1M2Y4ZDhjODQzNWNhMTBjZTVkN2NmZTY4ZGFlL3RhYmxlcmFuZ2U6OGE5YjUzZjhkOGM4NDM1Y2ExMGNlNWQ3Y2ZlNjhkYWVfNC04LTEtMS00NzgwMQ_9bf040b3-d5b9-449e-8aab-89f645ad47ac">84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yOC9mcmFnOmRkNGQ3ZTA1NGZkZDQzYWE5MWIyOWY1OGRlNTk5NTc2L3RhYmxlOjhhOWI1M2Y4ZDhjODQzNWNhMTBjZTVkN2NmZTY4ZGFlL3RhYmxlcmFuZ2U6OGE5YjUzZjhkOGM4NDM1Y2ExMGNlNWQ3Y2ZlNjhkYWVfNS0yLTEtMS00NzgwMQ_aef0f93e-14bb-4c50-bf49-2e6b56bd5a76">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yOC9mcmFnOmRkNGQ3ZTA1NGZkZDQzYWE5MWIyOWY1OGRlNTk5NTc2L3RhYmxlOjhhOWI1M2Y4ZDhjODQzNWNhMTBjZTVkN2NmZTY4ZGFlL3RhYmxlcmFuZ2U6OGE5YjUzZjhkOGM4NDM1Y2ExMGNlNWQ3Y2ZlNjhkYWVfNS00LTEtMS00NzgwMQ_137ce8be-ac48-468a-a4be-7a6aa89db555">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yOC9mcmFnOmRkNGQ3ZTA1NGZkZDQzYWE5MWIyOWY1OGRlNTk5NTc2L3RhYmxlOjhhOWI1M2Y4ZDhjODQzNWNhMTBjZTVkN2NmZTY4ZGFlL3RhYmxlcmFuZ2U6OGE5YjUzZjhkOGM4NDM1Y2ExMGNlNWQ3Y2ZlNjhkYWVfNS02LTEtMS00NzgwMQ_6946d03a-e15c-419d-b2de-54bc6f9ac363">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yOC9mcmFnOmRkNGQ3ZTA1NGZkZDQzYWE5MWIyOWY1OGRlNTk5NTc2L3RhYmxlOjhhOWI1M2Y4ZDhjODQzNWNhMTBjZTVkN2NmZTY4ZGFlL3RhYmxlcmFuZ2U6OGE5YjUzZjhkOGM4NDM1Y2ExMGNlNWQ3Y2ZlNjhkYWVfNS04LTEtMS00NzgwMQ_d065bf49-7ca3-4a58-9e63-e7f2ac5420d9">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on foreign currency</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yOC9mcmFnOmRkNGQ3ZTA1NGZkZDQzYWE5MWIyOWY1OGRlNTk5NTc2L3RhYmxlOjhhOWI1M2Y4ZDhjODQzNWNhMTBjZTVkN2NmZTY4ZGFlL3RhYmxlcmFuZ2U6OGE5YjUzZjhkOGM4NDM1Y2ExMGNlNWQ3Y2ZlNjhkYWVfNi0yLTEtMS00NzgwMQ_3c53ed3c-330d-4269-a9dd-376dc8038e60">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yOC9mcmFnOmRkNGQ3ZTA1NGZkZDQzYWE5MWIyOWY1OGRlNTk5NTc2L3RhYmxlOjhhOWI1M2Y4ZDhjODQzNWNhMTBjZTVkN2NmZTY4ZGFlL3RhYmxlcmFuZ2U6OGE5YjUzZjhkOGM4NDM1Y2ExMGNlNWQ3Y2ZlNjhkYWVfNi00LTEtMS00NzgwMQ_26891dc0-1c14-41c6-bccd-bdf4e2b9ec6d">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yOC9mcmFnOmRkNGQ3ZTA1NGZkZDQzYWE5MWIyOWY1OGRlNTk5NTc2L3RhYmxlOjhhOWI1M2Y4ZDhjODQzNWNhMTBjZTVkN2NmZTY4ZGFlL3RhYmxlcmFuZ2U6OGE5YjUzZjhkOGM4NDM1Y2ExMGNlNWQ3Y2ZlNjhkYWVfNi02LTEtMS00NzgwMQ_abd83111-dc00-4c56-bda3-7c5ef0a658cd">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yOC9mcmFnOmRkNGQ3ZTA1NGZkZDQzYWE5MWIyOWY1OGRlNTk5NTc2L3RhYmxlOjhhOWI1M2Y4ZDhjODQzNWNhMTBjZTVkN2NmZTY4ZGFlL3RhYmxlcmFuZ2U6OGE5YjUzZjhkOGM4NDM1Y2ExMGNlNWQ3Y2ZlNjhkYWVfNi04LTEtMS00NzgwMQ_08500d53-254b-4726-8cf5-d314f833cfaa">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yOC9mcmFnOmRkNGQ3ZTA1NGZkZDQzYWE5MWIyOWY1OGRlNTk5NTc2L3RhYmxlOjhhOWI1M2Y4ZDhjODQzNWNhMTBjZTVkN2NmZTY4ZGFlL3RhYmxlcmFuZ2U6OGE5YjUzZjhkOGM4NDM1Y2ExMGNlNWQ3Y2ZlNjhkYWVfNy0yLTEtMS00NzgwMQ_39b18530-89d2-4ab1-bcc3-86745caab9a5">23,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yOC9mcmFnOmRkNGQ3ZTA1NGZkZDQzYWE5MWIyOWY1OGRlNTk5NTc2L3RhYmxlOjhhOWI1M2Y4ZDhjODQzNWNhMTBjZTVkN2NmZTY4ZGFlL3RhYmxlcmFuZ2U6OGE5YjUzZjhkOGM4NDM1Y2ExMGNlNWQ3Y2ZlNjhkYWVfNy00LTEtMS00NzgwMQ_ddbd5cdd-d036-4fba-9a1a-a5789693d798">91,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yOC9mcmFnOmRkNGQ3ZTA1NGZkZDQzYWE5MWIyOWY1OGRlNTk5NTc2L3RhYmxlOjhhOWI1M2Y4ZDhjODQzNWNhMTBjZTVkN2NmZTY4ZGFlL3RhYmxlcmFuZ2U6OGE5YjUzZjhkOGM4NDM1Y2ExMGNlNWQ3Y2ZlNjhkYWVfNy02LTEtMS00NzgwMQ_4bdc0de4-ea64-4716-9cf0-1f6de8186518">81,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yOC9mcmFnOmRkNGQ3ZTA1NGZkZDQzYWE5MWIyOWY1OGRlNTk5NTc2L3RhYmxlOjhhOWI1M2Y4ZDhjODQzNWNhMTBjZTVkN2NmZTY4ZGFlL3RhYmxlcmFuZ2U6OGE5YjUzZjhkOGM4NDM1Y2ExMGNlNWQ3Y2ZlNjhkYWVfNy04LTEtMS00NzgwMQ_5e140ab4-ddb0-40e2-83f5-cbbbc849a5ea">119,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="ibd09c52bdc03451493df7fb7077280c7_31"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HALOZYME THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:77.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.328%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfNC0yLTEtMS00NzgwMQ_4d4fb5e7-4a25-43af-bbf2-5e67ac5b4555">82,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfNC00LTEtMS00NzgwMQ_286b5831-7102-4eeb-b73f-b2d7be78ede4">119,353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfNi0yLTEtMS00NzgwMQ_6d174f9b-31e1-4b47-9aa2-eaae2eee588a">10,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfNi00LTEtMS00NzgwMQ_735a0e9f-763c-41dc-b6de-1c6b3036f57e">10,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfNy0yLTEtMS00NzgwMQ_8a4c8e6b-50dd-4f2c-9b8d-4612e6c753bb">1,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfNy00LTEtMS00NzgwMQ_69282028-24c8-4e3d-aabb-7c78618f696c">1,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfOC0yLTEtMS01NjMwNg_90071ad2-84b9-400c-abb2-a6a2595a874c">11,403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfOC00LTEtMS01NjMxNQ_86d6769e-4f7c-4d95-9d80-33bfef7c60c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfOC0yLTEtMS00NzgwMQ_4478e3ac-f315-4164-ab61-563112339a21">2,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfOC00LTEtMS00NzgwMQ_d23ece6f-7a64-492e-8437-022dae907feb">1,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of discounts on marketable securities, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMTAtMi0xLTEtNDc4MDE_489c8eaa-bb61-4c09-9d96-dce49e5acb1c">800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMTAtNC0xLTEtNDc4MDE_7d6af0c6-0fea-4390-ae10-501db6227110">945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized  loss on marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMTEtMi0xLTEtNDc4MDE_3cfcf1db-af00-4a74-b070-66f4ebfea841">1,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMTEtNC0xLTEtNDc4MDE_9109d0d6-861f-435f-b22f-e2148b49f9da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal of equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMTItMi0xLTEtNDc4MDE_0b51d171-25b9-4f28-9507-f73f7d066eed">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMTItNC0xLTEtNDc4MDE_232c16a1-ba6c-4970-9e60-7c67678b4cef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of deferred revenue </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMTQtMi0xLTEtNDc4MDE_10d6bebc-a05e-4ddf-af15-1975593c76e7">1,122</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMTQtNC0xLTEtNDc4MDE_0c889080-862f-4cc7-ab7d-56a2e3559849">499</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease payments deferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="halo:DeferredRentPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMTUtMi0xLTEtNDc4MDE_1eb74232-851a-43ae-af4c-a6432f80ffc6">394</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="halo:DeferredRentPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMTUtNC0xLTEtNDc4MDE_dd1bf5ee-d2b1-4d12-b426-20838ec2901a">385</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Induced conversion expense related to convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:InducedConversionOfConvertibleDebtExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMTgtMi0xLTEtNDc4MDE_7e1eff4c-d20d-4d0e-8247-f4c059e7eca5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:InducedConversionOfConvertibleDebtExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMTgtNC0xLTEtNDc4MDE_83b7ac1a-de37-44f6-91f7-4ab16b1edc7a">20,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMTktMi0xLTEtNDc4MDE_f8bca400-9b51-48b1-b463-b21c92f2ede0">372</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMTktNC0xLTEtNDc4MDE_95df51ba-b9af-4a0f-aa49-56229b9edca3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net and other contract assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMjItMi0xLTEtNDc4MDE_ffb7417b-7f9c-4719-b80f-7d3c6c9592f4">32,252</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMjItNC0xLTEtNDc4MDE_54a4da76-14e4-4363-8d1c-e05882a451a8">55,466</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMjMtMi0xLTEtNDc4MDE_d434ae42-27de-4f21-bf85-a1105c2962bd">9,025</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMjMtNC0xLTEtNDc4MDE_47355bf9-8bbd-4277-81a5-2087d6d5e457">2,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMjQtMi0xLTEtNDc4MDE_482ffbf6-3617-4a39-b099-57a25af68a3a">9,319</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMjQtNC0xLTEtNDc4MDE_043811d0-6bb7-4f4d-862b-99ff3e8de76e">5,831</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMjUtMi0xLTEtNDc4MDE_119a5821-bb01-4395-a672-587e120db470">29,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMjUtNC0xLTEtNDc4MDE_fcf0bc60-33af-4170-be6c-734d44811b4b">207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMjYtMi0xLTEtNDc4MDE_d7bca708-5c73-4291-970c-16928ebc587b">88,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMjYtNC0xLTEtNDc4MDE_5e33ec54-b74b-4bbb-b4dd-667618e5e171">95,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMjgtMi0xLTEtNDc4MDE_57ee1d09-f6e2-4b17-919e-c2c281ca4157">225,689</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMjgtNC0xLTEtNDc4MDE_0a23b9bd-f041-46fe-b729-5022d78b85a1">241,926</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMjktMi0xLTEtNDc4MDE_a2bc11d3-bd83-41ce-b44e-e6c58be25ad4">725,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMjktNC0xLTEtNDc4MDE_29cbc73d-72f1-43b1-810d-6a54ae5a7924">152,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions of business, net of cash acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMzAtMi0xLTEtNTAxNDA_586bc0a5-03cb-4f43-94c8-b9c0c1720797">999,120</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMzAtNC0xLTEtNTAxNTY_7065eb27-ac55-47e6-b082-ddbab050209e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMzAtMi0xLTEtNDc4MDE_857aae5e-4ad9-4614-9df5-f33ab9b893b7">1,458</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMzAtNC0xLTEtNDc4MDE_16fc35fb-5589-4c82-b15e-f2d960061a9c">803</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the sale of assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMzEtMi0xLTEtNDc4MDE_bfcf2047-fc52-4bc8-b1d4-4ece99b0a77f">16,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMzEtNC0xLTEtNDc4MDE_1d7f5a97-4e3a-4c75-b83d-7fc1da40e75c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMzItMi0xLTEtNDc4MDE_866e3151-62c5-40aa-82e7-6f839c09e93a">484,251</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMzItNC0xLTEtNDc4MDE_cea4df63-37b6-48be-b895-dd7534991c7f">89,866</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from term loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMzYtMi0xLTEtNTAxNzM_c7cfa007-6dbd-465c-8a91-3f7606f4a1d1">250,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMzYtNC0xLTEtNTAxODU_fbc96c53-c3b3-474b-885f-348845a7bf16">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from revolving credit facilities </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMzctMi0xLTEtNTAxNzM_33a078c0-62cf-4ee0-9487-29ac1c2eded2">120,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMzctNC0xLTEtNTAxODU_6a523714-79a6-4be9-af85-31bc0cdc3aa3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of 2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMzUtMi0xLTEtNDc4MDE_afe2dc99-fee7-44a4-9e59-98b704a6f25c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMzUtNC0xLTEtNDc4MDE_90b0d147-e82c-409d-b911-b593f173136b">784,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of 2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:RepaymentsOfSecuredDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMzYtMi0xLTEtNDc4MDE_ce726d27-10ac-4ab5-9672-a086ab455f78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:RepaymentsOfSecuredDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMzYtNC0xLTEtNDc4MDE_83d99f7a-7b06-4167-a123-f12e373616e2">369,064</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of debt issuance cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMzctMi0xLTEtNDc4MDE_3d0df2f4-812c-4ed6-b355-b7cdedc20e93">6,003</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMzctNC0xLTEtNDc4MDE_94cbf44a-9ba9-4de6-b69b-1cf3885ce5e3">424</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMzgtMi0xLTEtNDc4MDE_763ec87b-e75f-461a-9eaa-3fce7a523d4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMzgtNC0xLTEtNDc4MDE_850aab96-30a0-4023-9528-45cd1f1417a9">125,021</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under equity incentive plans, net of taxes paid related to net share settlement</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="halo:ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMzktMi0xLTEtNDc4MDE_bcb56f61-8a80-433a-9ebe-74cad5d69845">4,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="halo:ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMzktNC0xLTEtNDc4MDE_7eb79d1b-2bb2-42db-9ec9-2e95123c5089">3,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfNDAtMi0xLTEtNDc4MDE_e2fe13cd-f001-43a7-b36f-ab6301a361b0">368,442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfNDAtNC0xLTEtNDc4MDE_cc129ab8-ef29-4bf8-8564-d0470e61c3c9">293,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (decrease) increase in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfNDEtMi0xLTEtNDc4MDE_45b57cee-d444-4cc2-86df-129b7e8b3c19">27,787</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfNDEtNC0xLTEtNDc4MDE_d59e4535-8f51-40e9-81b7-181e23cf9849">299,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfNDItMi0xLTEtNDc4MDE_7d9c4056-4b55-4a55-aa6b-fb5c0bbf548a">119,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3b15a6a41d2423d9142e3d2a1b50b32_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfNDItNC0xLTEtNDc4MDE_772c08d9-1fa4-4a90-99d3-3a3a5fafad11">148,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfNDMtMi0xLTEtNDc4MDE_9a676689-8ce8-4878-9f94-f1659efde375">91,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaed74cb4c1b045a48ff8547f85ae3d8e_I20210630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfNDMtNC0xLTEtNDc4MDE_6309e9c1-7e5a-49ed-a2ed-bda10ff3ea8c">447,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental disclosure of non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts accrued for purchases of property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfNDYtMi0xLTEtNDc4MDE_d0ae9a17-05a6-473f-992a-8f090813b56d">336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfNDYtNC0xLTEtNDc4MDE_18fc141e-dd63-4c65-84fb-0167e404b7e5">242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfNDctMi0xLTEtNDc4MDE_c6d745f5-ea88-455b-9314-05c8c4adeb65">217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfNDctNC0xLTEtNDc4MDE_e084bb03-a7f0-4455-afb1-7f820738304a">318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock issued for induced conversion related to convertible notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfNTAtMi0xLTEtNDc4MDE_109b6ea6-ee57-4639-8e2e-557ecff71cdf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfNTAtNC0xLTEtNDc4MDE_ac565517-23a7-4e5b-a6c5-72b78a8e3123">7,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:22.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="ibd09c52bdc03451493df7fb7077280c7_34"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HALOZYME THERAPEUTICS, INC.</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited) (in thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.749%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Income/(Loss)</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Retained Earnings (Accumulated<br/>Deficit)</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">BALANCE AS OF MARCH 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia62abf9a289242aaacca39406bc0f1e4_I20220331" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMy0yLTEtMS00NzgwMQ_1d46b0ea-a8c4-46b0-ae37-dac71e822396">137,888</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia62abf9a289242aaacca39406bc0f1e4_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMy00LTEtMS00NzgwMQ_da9ebcf3-45df-401c-981b-9cdc6789f457">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9f7dc1cc92f4c1690a144db55ad717c_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMy02LTEtMS00NzgwMQ_fde2c027-64c7-426f-b1be-66b0479c695d">261,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5e07277da1a43438f0f8d84d2f7bc96_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMy04LTEtMS00NzgwMQ_88076fe4-7d60-442a-97af-8a20d20a5e82">2,791</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c9b3b22251847568c83ac3f79ea4436_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMy0xMC0xLTEtNDc4MDE_7259b076-d74e-48a7-8eb0-9255a024bc82">1,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i678f6fef80154c5b8c01dadcd09593ac_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMy0xMi0xLTEtNDc4MDE_c6bffbfc-810f-49c1-aa32-ea7da4f111ca">260,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b633a2efd834d73bd14291c139ac728_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNS02LTEtMS00NzgwMQ_ac6065fa-fd73-417d-b1ee-b72c8d63f727">5,635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNS0xMi0xLTEtNDc4MDE_77412365-5bca-490a-af88-0e79cccff3ff">5,635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units, net and shares issued under the ESPP plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i64fb6378ac874aa599802032078bb7e5_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNy0yLTEtMS00NzgwMQ_065d804d-5ddb-4d3e-82d8-7e0b110b491e">226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64fb6378ac874aa599802032078bb7e5_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNy00LTEtMS00NzgwMQ_0d551fd6-008b-4285-960b-4b538518f5b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b633a2efd834d73bd14291c139ac728_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNy02LTEtMS00NzgwMQ_8ae70ad9-c3ed-412a-8861-3f35e20b14f9">3,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNy0xMi0xLTEtNDc4MDE_667d7249-9ac0-4b85-9050-18413955d7a1">3,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Repurchase of  common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i64fb6378ac874aa599802032078bb7e5_D20220401-20220630" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfOS0yLTEtMS00NzgwMQ_ed6ebbac-31fb-483a-9415-3d4c53ee1825">433</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64fb6378ac874aa599802032078bb7e5_D20220401-20220630" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfOS00LTEtMS00NzgwMQ_6c1308c2-611c-4a50-81b4-a3767e7a86f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b633a2efd834d73bd14291c139ac728_D20220401-20220630" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfOS02LTEtMS00NzgwMQ_c95cd40b-dd62-4707-9f4c-f431a359708c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfOS0xMi0xLTEtNDc4MDE_c713bdf0-d348-4cf4-a6a6-9af77a21c505">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a959347106f415cb34e9be834baba86_D20220401-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMTAtOC0xLTEtNDc4MDE_5c35db40-c1a4-428e-ba43-1b7c2468cb9d">774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMTAtMTItMS0xLTQ3ODAx_6ce3a70c-d082-401d-8cf9-5c9b7d84ccb0">774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c00abe406104a5fa545c8d934524371_D20220401-20220630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMTEtMTAtMS0xLTQ3ODAx_28496c7a-3c8c-4cda-87ba-89d99fa358f9">22,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMTEtMTItMS0xLTQ3ODAx_796c988a-28bf-4da2-b499-3fdb52bc7fff">22,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">BALANCE AS OF JUNE 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i09401d5b007348c08fa5bd1cce5097ce_I20220630" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMTItMi0xLTEtNDc4MDE_98c3ee96-d73e-404a-a730-adec243175c4">137,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09401d5b007348c08fa5bd1cce5097ce_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMTItNC0xLTEtNDc4MDE_6905059c-cc53-4bdd-a8db-bff39bb88374">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id807b2395d514e89a6ed524bc67e0ed3_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMTItNi0xLTEtNDc4MDE_489b2230-3dfe-4ea0-af1c-eaf4ae09d24b">271,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01b7804e8c8443c18f2bf4001bc7328d_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMTItOC0xLTEtNDc4MDE_0c2cdf87-4f26-4cb4-bd5c-2b96960131b9">2,017</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2a2ebb74994496290986a6cbda39dc8_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMTItMTAtMS0xLTQ3ODAx_a31570b5-b241-403e-8908-e5d90955cf22">23,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMTItMTItMS0xLTQ3ODAx_17f42f89-3876-4df7-a951-1b08eea53897">293,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Income/(Loss)</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Retained Earnings (Accumulated<br/>Deficit)</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">BALANCE AS OF DECEMBER 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibbcde496e999416f83088ace845dbf65_I20211231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMTctMi0xLTEtNDc4MDE_ba9a13cd-2260-4684-ab8a-174fd7304c72">137,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbcde496e999416f83088ace845dbf65_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMTctNC0xLTEtNDc4MDE_9ea23412-bf0c-4df6-a1c9-2bebeccf8145">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57063aa70d174824a4db07d8773b05bf_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMTctNi0xLTEtNDc4MDE_15154dba-214a-4ac7-a692-9808e4b174b7">256,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39034bfa63bd4a90ac54d7016591ef9d_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMTctOC0xLTEtNDc4MDE_eca830a8-7ae5-413a-bea3-6a31ccb9808b">620</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac6ced6cc2b3433c8b37d84dc56b068e_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMTctMTAtMS0xLTQ3ODAx_95dd9269-077d-4c5f-afd8-709d72843d1c">58,912</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMTctMTItMS0xLTQ3ODAx_b2568fa7-c9c5-45ea-ad94-5bf9daaa01d7">196,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a77403a19ee410d81160e0a394e0979_D20220101-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMTktNi0xLTEtNDc4MDE_b3cbb0b2-7f2d-4635-9fd0-41feb1fac69b">10,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMTktMTItMS0xLTQ3ODAx_ef32dec2-8c68-4f6a-b4c9-067ff6aa6e2d">10,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units, net and shares issued under the ESPP plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic61e51e1f5f94cd39c6967eae2703020_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMjEtMi0xLTEtNDc4MDE_66c744b1-2fa6-4349-992d-0e4d3f1e5a7e">616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic61e51e1f5f94cd39c6967eae2703020_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMjEtNC0xLTEtNDc4MDE_28b28b68-2c6f-49ab-b870-3515fe0558ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a77403a19ee410d81160e0a394e0979_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMjEtNi0xLTEtNDc4MDE_7fd2e74f-ff4c-4c5d-a4d4-0ec456facb72">4,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMjEtMTItMS0xLTQ3ODAx_84eabb14-c644-485d-8ab9-b051d988fc26">4,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic61e51e1f5f94cd39c6967eae2703020_D20220101-20220630" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMjMtMi0xLTEtNDc4MDE_273fe946-d8aa-48b8-ad58-3c216618c91b">433</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic61e51e1f5f94cd39c6967eae2703020_D20220101-20220630" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMjMtNC0xLTEtNDc4MDE_ee6879f5-c5fb-4e03-8fc4-399f4be0575b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a77403a19ee410d81160e0a394e0979_D20220101-20220630" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMjMtNi0xLTEtNDc4MDE_5ef96f60-c707-4844-bf28-0a252202cf82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMjMtMTItMS0xLTQ3ODAx_1eac0dae-fb1e-4f1e-8b9d-3a267a03e376">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb6ff5498b9346a8b865a91ca3bb935c_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMjUtOC0xLTEtNDc4MDE_37b61223-f547-454a-ba28-6da04f5c460a">1,397</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMjUtMTItMS0xLTQ3ODAx_d93eb640-aa2d-4a75-8a89-d8d4718d4469">1,397</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37c4cbbc8ea6440cb197130f93f66a30_D20220101-20220630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMjYtMTAtMS0xLTQ3ODAx_b357c4e9-630c-47b0-94a8-f7de715e2690">82,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMjYtMTItMS0xLTQ3ODAx_59851858-975f-4004-8aea-0709e214d398">82,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">BALANCE AS OF JUNE 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i09401d5b007348c08fa5bd1cce5097ce_I20220630" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMjctMi0xLTEtNDc4MDE_fb12a84c-84a0-4add-bc02-0b1e267a9b80">137,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09401d5b007348c08fa5bd1cce5097ce_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMjctNC0xLTEtNDc4MDE_60f2b6d1-8135-49de-bf9d-d6b9f05e3c1a">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id807b2395d514e89a6ed524bc67e0ed3_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMjctNi0xLTEtNDc4MDE_4766f106-f275-4fed-bff3-e7c93ef1c61f">271,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01b7804e8c8443c18f2bf4001bc7328d_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMjctOC0xLTEtNDc4MDE_ea1dc012-bdab-4ea2-bfc0-abb5e9821acb">2,017</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2a2ebb74994496290986a6cbda39dc8_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMjctMTAtMS0xLTQ3ODAx_db2d9317-94be-4afc-bbcf-64cc304aa271">23,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMjctMTItMS0xLTQ3ODAx_43028c73-23b6-48c9-9e44-fe7650ace428">293,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Income/(Loss)</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Retained Earnings (Accumulated<br/>Deficit)</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">BALANCE AS OF MARCH 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c794de6a0af4c0a9af7f772745e791c_I20210331" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMzItMi0xLTEtNDc4MDE_a9eefdd2-194b-410d-a33c-df6713e0de42">143,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c794de6a0af4c0a9af7f772745e791c_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMzItNC0xLTEtNDc4MDE_d7bfd71a-419f-48ec-975e-37e116caa48a">143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6b066604d9e4d658947efe4930f28f6_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMzItNi0xLTEtNDc4MDE_bc3ce288-e147-4824-8b69-28217991ed27">501,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie27fff43f3db4d7d8d49ecaaf23b1d61_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMzItOC0xLTEtNDc4MDE_bb69e29b-0dce-47f7-a047-c15a306b0928">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e4238b1c16a4fd28a06ed5e284bb84a_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMzItMTAtMS0xLTQ3ODAx_409855c1-ad3e-4f69-8011-54e89011efba">433,725</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727d5a62b3f847b797bca56701f39cf9_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMzItMTItMS0xLTQ3ODAx_7d21b333-c0e2-4611-ac23-b26340a060b7">67,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if67373bdd7be4012b17710d463c192a1_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMzQtNi0xLTEtNDc4MDE_868235c4-89ce-4665-80f4-f110fd0ca753">5,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMzQtMTItMS0xLTQ3ODAx_ff0b9602-73b1-45d5-af70-b43c0f3d8fe9">5,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i380920b6a9284e80ae55f918a1ae24cb_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMzYtMi0xLTEtNDc4MDE_2259db90-ae9d-447b-a167-a4198dabf025">318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i380920b6a9284e80ae55f918a1ae24cb_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMzYtNC0xLTEtNDc4MDE_8c3dbdb1-93b5-4b0a-b071-7dafb68360ae">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if67373bdd7be4012b17710d463c192a1_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMzYtNi0xLTEtNDc4MDE_4a02b012-7e9f-4baf-92a4-cc4dfe8ff60c">4,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMzYtMTItMS0xLTQ3ODAx_d13bfc67-075f-4f4b-a80e-7e0ec55962b0">4,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i380920b6a9284e80ae55f918a1ae24cb_D20210401-20210630" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMzgtMi0xLTEtNDc4MDE_63c0f7a7-37bc-4bf3-a82a-2fa3dd37e38c">1,517</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i380920b6a9284e80ae55f918a1ae24cb_D20210401-20210630" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMzgtNC0xLTEtNDc4MDE_c983962b-2c9a-40db-b6f6-cb3075ae666d">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if67373bdd7be4012b17710d463c192a1_D20210401-20210630" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMzgtNi0xLTEtNDc4MDE_10ffe1e5-8551-4a05-b3ce-f8fee4ba7c8b">48,840</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMzgtMTItMS0xLTQ3ODAx_a7c99358-9050-41cb-b497-775c6fa1c4bc">48,842</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12326da779a8483f93c5e05dd4d6d7c4_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNDAtOC0xLTEtNDc4MDE_28a36620-1ccb-47e4-8dfb-4859fe7c59ed">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNDAtMTItMS0xLTQ3ODAx_c83c579b-cd90-404e-8480-4f7839cb7fce">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15b7f19dfa4b62bc91d2ad4477ae61_D20210401-20210630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNDEtMTAtMS0xLTQ3ODAx_e9cd62e4-c780-474a-8236-8cffe9aef199">91,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNDEtMTItMS0xLTQ3ODAx_cf3f3c47-0218-48b1-a77e-e2393d232b65">91,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">BALANCE AS OF JUNE 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c838a1fe9a644b6956ff4487ba688eb_I20210630" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNDItMi0xLTEtNDc4MDE_24f6a8c4-91ac-45bd-8353-48ce4062bce6">142,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c838a1fe9a644b6956ff4487ba688eb_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNDItNC0xLTEtNDc4MDE_7f9cf7c6-ee0b-4302-ac12-77010fcb0a82">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d6ff976f1c46d0bae0a1ff38eae093_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNDItNi0xLTEtNDc4MDE_5c24511c-2b23-4e3a-83e5-cb6aa0d3e667">461,897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac7f0b69fa364a3e83aa58d5f386c6ca_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNDItOC0xLTEtNDc4MDE_985a1132-4ac6-4e49-b620-0709827f4133">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26444fd86b024585b6b74771eb48128a_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNDItMTAtMS0xLTQ3ODAx_6c2cbe41-c9e1-44f2-bc99-5e5b5c48a8fa">342,267</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaed74cb4c1b045a48ff8547f85ae3d8e_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNDItMTItMS0xLTQ3ODAx_94c1dd31-af1e-4b84-9dbb-0c673f87c897">119,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Income (Loss)</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Retained Earnings (Accumulated<br/>Deficit)</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">BALANCE AS OF DECEMBER 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7985573ca9a44f7ea10f5ecb82f97c91_I20201231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNDctMi0xLTEtNDc4MDE_800b220b-2820-4047-8ee1-ac1a031644cd">135,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7985573ca9a44f7ea10f5ecb82f97c91_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNDctNC0xLTEtNDc4MDE_3d148657-528c-4993-bb2a-623330f62cc5">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2bb1215be014cfeae503eb2306453b0_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNDctNi0xLTEtNDc4MDE_2e340f88-1f0c-44a8-afe7-b63d893fb10a">625,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ca52ba2c1e43a7b6a8fd1d47849366_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNDctOC0xLTEtNDc4MDE_2a6cc8e3-f9af-49e5-aedd-6167d359dead">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ca0a460bc7a457a905e2205ba207797_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNDctMTAtMS0xLTQ3ODAx_8d8f975b-b22a-4c02-b494-f1fb792ea132">474,593</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3b15a6a41d2423d9142e3d2a1b50b32_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNDctMTItMS0xLTQ3ODAx_a857057c-c98b-45ff-8fb9-00b73aa053bb">151,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Adjustment to beginning accumulated deficit </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i256c983ac3a44d07b5c0bbac2a5206ef_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNDgtNi0xLTEtNDk0OTE_d741dd1f-f0eb-4b90-bf11-1be2a2da9ae3">65,535</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if563dcd8d731444e986d351aa923f779_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNDgtMTAtMS0xLTQ3ODAx_1d068ef2-66f9-464c-8195-701da3423019">12,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3449ce3d1a2440f9631288531d75f21_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNDgtMTItMS0xLTYwMjY2_0d24b7b5-290d-4eb3-8b59-cc6e931da043">52,562</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i715d67b1e934443c87c14fc6a9baf147_D20210101-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNDktNi0xLTEtNDc4MDE_6ac3fa98-6a25-4609-8ba7-87a1f2e0a0cb">10,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNDktMTItMS0xLTQ3ODAx_0cc3c85c-fbda-4038-9368-2934c53523b1">10,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Issuance of common stock for the induced conversion related to convertible notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b21a0a518454ebb9f2099e2057850ed_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNTAtMi0xLTEtNDk0Njc_2fb54e7b-aeff-4443-bb2f-da3e6bb02b6a">9,083</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b21a0a518454ebb9f2099e2057850ed_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNTAtNC0xLTEtNDk0NzQ_1cd7237b-c4f6-4924-9196-14f62edb995d">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i715d67b1e934443c87c14fc6a9baf147_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNTAtNi0xLTEtNDk0ODE_4f66e3b8-879f-4846-a3aa-fbfb2eacdabd">13,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNTAtMTItMS0xLTYwMjYx_d23da5ad-86ac-4f89-b906-0a8651905030">13,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b21a0a518454ebb9f2099e2057850ed_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNTAtMi0xLTEtNDc4MDE_c849b193-5334-430f-9ecf-d1699f6419fa">881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b21a0a518454ebb9f2099e2057850ed_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNTAtNC0xLTEtNDc4MDE_c9cdb605-2cea-4e75-a38e-dce55c4b769f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i715d67b1e934443c87c14fc6a9baf147_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNTAtNi0xLTEtNDc4MDE_9bb7f63f-a061-40e9-8ef0-71127568d116">3,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNTAtMTItMS0xLTQ3ODAx_1c8dc64c-2d04-4bc0-b3a8-e9e47244c5f7">3,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3b21a0a518454ebb9f2099e2057850ed_D20210101-20210630" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNTItMi0xLTEtNDc4MDE_dfc9ac15-04b2-487b-9fe7-f774b4cdec41">2,813</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b21a0a518454ebb9f2099e2057850ed_D20210101-20210630" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNTItNC0xLTEtNDc4MDE_dbbcfa93-1519-427a-a1bf-8a9351efea8f">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i715d67b1e934443c87c14fc6a9baf147_D20210101-20210630" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNTItNi0xLTEtNDc4MDE_3bc783ce-c800-4a0e-a6c6-3647386f49d3">125,018</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNTItMTItMS0xLTQ3ODAx_21215848-723e-48d0-95f9-040047fdda0a">125,021</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6dbcbf35901d41ee95e2479d1b0cc0e8_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNTQtOC0xLTEtNDc4MDE_e83105cf-3dea-453f-b2f1-338b4ebbc43e">46</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNTQtMTItMS0xLTQ3ODAx_93b83c1f-f789-45e3-85f2-315dc9ba04da">46</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i322f16862e9a44f9ad3ca6a551d79a4f_D20210101-20210630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNTUtMTAtMS0xLTQ3ODAx_054b224e-bb18-49a6-9e07-318868b89c1c">119,353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNTUtMTItMS0xLTQ3ODAx_cfc316bf-1a92-45f2-8ae7-52bbb8d5ed53">119,353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">BALANCE AS OF JUNE 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c838a1fe9a644b6956ff4487ba688eb_I20210630" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNTYtMi0xLTEtNDc4MDE_54bf529a-158a-4325-adfb-1a9e307d2dfd">142,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c838a1fe9a644b6956ff4487ba688eb_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNTYtNC0xLTEtNDc4MDE_86c75e27-ff0b-436f-a754-df2d19cc71b8">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d6ff976f1c46d0bae0a1ff38eae093_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNTYtNi0xLTEtNDc4MDE_f92a4213-1964-4f6f-b414-b1673a200ef2">461,897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac7f0b69fa364a3e83aa58d5f386c6ca_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNTYtOC0xLTEtNDc4MDE_71fa99aa-8a49-4676-8ad9-3992bd01df28">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26444fd86b024585b6b74771eb48128a_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNTYtMTAtMS0xLTQ3ODAx_256293e4-8ade-40e6-8632-2436e8997b8d">342,267</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaed74cb4c1b045a48ff8547f85ae3d8e_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNTYtMTItMS0xLTQ3ODAx_b4a241ff-6333-4b61-8933-41917d58e468">119,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to condensed consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="ibd09c52bdc03451493df7fb7077280c7_37"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div id="ibd09c52bdc03451493df7fb7077280c7_40"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HALOZYME THERAPEUTICS, INC.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180MC9mcmFnOjgzZjVhMzdlNDE3NTQ3ZmViNjcxZWRlMjA5YjQxYTA4L3RleHRyZWdpb246ODNmNWEzN2U0MTc1NDdmZWI2NzFlZGUyMDliNDFhMDhfNDA0NA_dffd928e-abea-489b-a7ae-4276c2ba0d20" continuedAt="i68c01657e49b48d2a1928fb5c8b7d1a4" escape="true">Organization and Business </ix:nonNumeric></span></div><ix:continuation id="i68c01657e49b48d2a1928fb5c8b7d1a4"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Halozyme Therapeutics, Inc. is a biopharma technology platform company that provides innovative and disruptive solutions with the goal of improving patient experience and outcomes. Our proprietary enzyme, rHuPH20, is used to facilitate the delivery of injected drugs and fluids. We license our technology to biopharmaceutical companies to collaboratively develop products that combine our ENHANZE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> drug delivery</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">technology with the partners&#8217; proprietary compounds.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our first commercially approved product, Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> recombinant, (&#8220;Hylenex&#8221;), and our partners&#8217; approved products and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 is the active ingredient in Hylenex and it works by breaking down hyaluronan (or &#8220;HA&#8221;), a naturally occurring carbohydrate that is a major component of the extracellular matrix of the subcutaneous (SC) space. This temporarily increases dispersion and absorption allowing for improved SC delivery of injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as our ENHANZE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> drug delivery technology (&#8220;ENHANZE&#8221;). We license the ENHANZE technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the SC route of administration. In the development of proprietary intravenous (IV) drugs combined with our ENHANZE technology, data have been generated supporting the potential for ENHANZE to reduce patient treatment burden, as a result of shorter duration of SC administration. ENHANZE may enable fixed-dose SC dosing compared to weight-based dosing required for IV administration, and potentially allow for lower rates of infusion related reactions.&#160;ENHANZE may enable more flexible treatment options such as home administration by a healthcare professional or potentially the patient. Lastly, certain proprietary drugs co-formulated with ENHANZE have been granted additional exclusivity, extending the patent life of the product beyond the patent expiry of the proprietary IV drug.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have ENHANZE collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (&#8220;Roche&#8221;), Baxalta US Inc. and Baxalta GmbH (members of the Takeda group of companies) (&#8220;Baxalta&#8221;), Pfizer Inc. (&#8220;Pfizer&#8221;), Janssen Biotech, Inc. (&#8220;Janssen&#8221;), AbbVie, Inc. (&#8220;AbbVie&#8221;), Eli Lilly and Company (&#8220;Lilly&#8221;), Bristol-Myers Squibb Company (&#8220;BMS&#8221;), Alexion Pharma International Operations Unlimited Company (an indirect wholly owned subsidiary of AstraZeneca PLC (&#8220;Alexion&#8221;), argenx BVBA (&#8220;argenx&#8221;), Horizon Therapeutics plc. (&#8220;Horizon&#8221;), ViiV Healthcare (the global specialist HIV Company majority owned by GlaxoSmithKline) (&#8220;ViiV&#8221;) and Chugai Pharmaceutical Co., Ltd (&#8220;Chugai&#8221;). In addition to receiving upfront licensing fees from our ENHANZE collaborations, we are entitled to receive event and sales attainment milestone payments, revenues from the sale of bulk rHuPH20 and royalties from commercial sales of approved partner products co-formulated with ENHANZE.  We currently receive royalties from <ix:nonFraction unitRef="collaborator" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="INF" name="halo:RoyaltiesReceivedNumberOfCollaborators" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180MC9mcmFnOjgzZjVhMzdlNDE3NTQ3ZmViNjcxZWRlMjA5YjQxYTA4L3RleHRyZWdpb246ODNmNWEzN2U0MTc1NDdmZWI2NzFlZGUyMDliNDFhMDhfMzExMQ_7d232ba7-12e9-4b5b-b77a-6bba07afb509">three</ix:nonFraction> of these collaborations, including royalties from sales of <ix:nonFraction unitRef="product" contextRef="i8939fd0a8f934008b17b41bf8467d682_D20220101-20220630" decimals="INF" name="halo:RoyaltiesReceivedNumberOfProductsSold" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180MC9mcmFnOjgzZjVhMzdlNDE3NTQ3ZmViNjcxZWRlMjA5YjQxYTA4L3RleHRyZWdpb246ODNmNWEzN2U0MTc1NDdmZWI2NzFlZGUyMDliNDFhMDhfMzE3Mw_8829b4ab-a021-433f-a531-e8b0ce57a300">one</ix:nonFraction> product from the Baxalta collaboration, <ix:nonFraction unitRef="product" contextRef="ie69bf9190a574ccbbe399d8da056c46e_D20220101-20220630" decimals="INF" name="halo:RoyaltiesReceivedNumberOfProductsSold" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180MC9mcmFnOjgzZjVhMzdlNDE3NTQ3ZmViNjcxZWRlMjA5YjQxYTA4L3RleHRyZWdpb246ODNmNWEzN2U0MTc1NDdmZWI2NzFlZGUyMDliNDFhMDhfMzIxNg_94a7420e-dff9-4475-a1c0-ccd1432c09a5">three</ix:nonFraction> products from the Roche collaboration and <ix:nonFraction unitRef="product" contextRef="i6aeb602d0b6f4c559f18892fc21aa407_D20220101-20220630" decimals="INF" name="halo:RoyaltiesReceivedNumberOfProductsSold" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180MC9mcmFnOjgzZjVhMzdlNDE3NTQ3ZmViNjcxZWRlMjA5YjQxYTA4L3RleHRyZWdpb246ODNmNWEzN2U0MTc1NDdmZWI2NzFlZGUyMDliNDFhMDhfMzI2MQ_6a8f535e-a562-42b5-8de7-350af7cceebe">one</ix:nonFraction> product from the Janssen collaboration. Future potential revenues from ENHANZE collaborations and from the sales and/or royalties of our approved products will depend on the ability of Halozyme and our partners to develop, manufacture, secure and maintain regulatory approvals for approved products and product candidates and commercialize product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our recent acquisition of Antares Pharma, Inc. (&#8220;Antares&#8221;), we also develop, manufacture and commercialize, for ourselves or with our partners, drug-device combination products using our advanced auto-injector technologies that are designed to provide commercial or functional advantages such as convenience, improved tolerability, and enhanced patient comfort and adherence. Also, as a result of our acquisition of Antares, our commercial portfolio of proprietary products includes XYOSTED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, TLANDO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and NOCDURNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and partnered commercial products and ongoing product development programs with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (&#8220;Teva&#8221;), Covis Group S.a.r.l. (&#8220;Covis&#8221;), Pfizer and Idorsia Pharmaceuticals Ltd. (&#8220;Idorsia&#8221;).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except where specifically noted or the context otherwise requires, references to &#8220;Halozyme,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; and &#8220;us&#8221; in these notes to the condensed consolidated financial statements refer to Halozyme Therapeutics, Inc. and its wholly owned subsidiaries, Halozyme, Inc. and Antares Pharma, Inc., Halozyme, Inc.&#8217;s wholly owned subsidiary, Halozyme Switzerland Holdings GmbH and Antares Pharma, Inc.&#8217;s wholly owned subsidiaries Antares Pharma IPL AG and Antares Pharma AG.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="ibd09c52bdc03451493df7fb7077280c7_43"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMzI3ODc_40e21d5f-af3b-45b4-b4e5-f70077e43996" continuedAt="i832042f782d64227b93ca159227831d4" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i832042f782d64227b93ca159227831d4" continuedAt="i0edc4cdd6d45468e9786c8fc14e2b830"><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMzI5MjI_92a1fab3-eff3-40ab-bcb7-2d4a4658f6eb" escape="true"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and with the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) related to a quarterly report on Form 10-Q. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for a complete set of financial statements. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC on February&#160;22, 2022. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operations for the periods presented, with such adjustments consisting only of normal recurring adjustments. Operating results for interim periods are not necessarily indicative of the operating results for an entire fiscal year.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMzI4NTY_1caf1409-4e99-407f-99a2-928b0fc98910" escape="true">The accompanying interim unaudited condensed consolidated financial statements include the accounts of Halozyme Therapeutics, Inc. and our wholly owned subsidiaries, Halozyme, Inc. and Antares Pharma, Inc., Halozyme, Inc.&#8217;s wholly owned subsidiary Halozyme Switzerland Holdings GmbH and Antares Pharma, Inc.&#8217;s wholly-owned Swiss subsidiaries, Antares Pharma IPL AG and Antares Pharma AG. All intercompany accounts and transactions have been eliminated.</ix:nonNumeric> </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMzI4ODI_caff0e20-69ab-4473-9be1-ee1bd81b52fc" continuedAt="i50dd124045694ebea2a15c638598b0a7" escape="true">Use of Estimates</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i50dd124045694ebea2a15c638598b0a7">The preparation of interim unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our interim unaudited condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management&#8217;s estimates</ix:continuation>.</span></div><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMzI4MDA_1de9c2e1-c428-4b4d-ae08-cec16050bd23" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents and Marketable Securities </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of highly liquid investments, readily convertible to cash, that mature within ninety days or less from the date of purchase. As of June&#160;30, 2022, our cash and cash equivalents consisted of money market funds, bank certificate of deposits and demands deposits at commercial banks.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities are investments with original maturities of more than ninety days from the date of purchase that are specifically identified to fund current operations. Marketable securities are considered available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management&#8217;s intention to use the proceeds from the sale of these investments to fund our operations, as necessary. Such available-for-sale investments are carried at fair value with unrealized gains and losses recorded in other comprehensive income (loss) and included as a separate component of stockholders&#8217; equity. The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in the interim unaudited condensed consolidated statements of income. We use the specific identification method for calculating realized gains and losses on marketable securities sold. None of the realized gains and losses and declines in value that were judged to be as a result of credit loss on marketable securities, if any, are included in investment and other income, net in the interim unaudited condensed consolidated statements of operations.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the leases of our facilities, we are required to maintain letters of credit as security deposits during the terms of such leases. As of June&#160;30, 2022 and December&#160;31, 2021, restricted cash of $<ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfNDE4MQ_c47694da-816f-4a29-b2fc-8af45f3a5d29">0.5</ix:nonFraction> million was pledged as collateral for the letters of credit.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMzI4NDQ_5ff96427-3c3f-4ee3-a941-276a70792805" continuedAt="i733fe21484464b4ea50cda4226a59c9d" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authoritative guidance for fair value measurements establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i0edc4cdd6d45468e9786c8fc14e2b830" continuedAt="i6ceffe7964fb4b978a49d517cf7d59e0"><ix:continuation id="i733fe21484464b4ea50cda4226a59c9d"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments include cash equivalents, available-for-sale marketable securities, accounts receivable, prepaid expenses and other assets, accounts payable, accrued expenses, long-term debt and contingent liability. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities consist of asset-backed securities, corporate debt securities, U.S. Treasury securities and commercial paper, and are measured at fair value using Level 1 and Level 2 inputs. Level 2 financial instruments are valued using market prices on less active markets and proprietary pricing valuation models with observable inputs, including interest rates, yield curves, maturity dates, issue dates, settlement dates, reported trades, broker-dealer quotes, issue spreads, benchmark securities or other market related data. We obtain the fair value of Level 2 investments from our investment manager, who obtains these fair values from a third-party pricing source. We validate the fair values of Level 2 financial instruments provided by our investment manager by comparing these fair values to a third-party pricing source.</span></div></ix:continuation><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMzI3Njg_a94f1344-5de2-4936-8147-0a4c30a39659" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Inventories are reviewed periodically for potential excess, dated or obsolete status. We evaluate the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price we expect to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMzI4MDI_2feda62f-e147-427f-ba31-5e3fbbc75b02" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into operating leases primarily for real estate and automobiles. These leases have contractual terms which range from <ix:nonNumeric contextRef="i03b0b3511b2544be8e14af45977bfbce_I20220630" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfNzM5Mw_fb6c6124-0da4-4f58-95a9-dbfff0ea66a0">3</ix:nonNumeric> years to <ix:nonNumeric contextRef="iecce61f93caa4b668869678174aa5845_I20220630" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfNzM5OQ_ba8999e5-08c5-45c6-8d0e-0a36f6aaf917">12</ix:nonNumeric> years. We determine if an arrangement contains a lease at inception. Right of use (&#8220;ROU&#8221;) assets and liabilities resulting from operating leases are included in property and equipment, accrued expenses and other long-term liabilities on our condensed consolidated balance sheets. Operating lease ROU assets and liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the discount rate to calculate the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Our leases often include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that we will exercise that option. Short-term leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as automobiles, we account for the lease and non-lease components as a single lease component.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, we entered into an agreement for assignment and assumption of lease with Seismic Software, Inc. pursuant to which effective January 1, 2023, we will assume Seismic&#8217;s office lease, as amended with Kilroy Realty L.P. for approximately 72,534 square feet of space in office and research facilities which is expected to commence on January 1, 2023. The premises are intended to serve as our new headquarters.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMTkyNDE0NTM1NjQ1NzU_af1dd1bb-1dad-49f2-b127-c92cc5ab5824" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. Costs that we incur to complete the business combination, such as legal and other professional fees, are expensed as they are incurred.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the initial accounting for a business combination is incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date. We record these adjustments to the provisional amounts with a corresponding offset to goodwill. Any adjustments identified after the measurement period are recorded in the consolidated statements of income.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i6ceffe7964fb4b978a49d517cf7d59e0" continuedAt="iebceeafabdc047758522e18e13b90468"><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="halo:GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMTkyNDE0NTM1NjQ1NzY_ef15ce84-3552-4a12-8530-ecf5f7ceffad" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill, Intangible Assets and Other Long-Lived Asset</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets acquired, including intangible assets and in-process research and development (IPR&amp;D), and liabilities assumed are measured at fair value as of the acquisition date. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of the net assets acquired. Intangible assets acquired in a business combination that are used for IPR&amp;D activities are considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon reaching the end of the relevant research and development project (i.e., upon commercialization), the IPR&amp;D asset is amortized over its estimated useful life. If the relevant research and development project is abandoned, the IPR&amp;D asset is expensed in the period of abandonment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and IPR&amp;D are not amortized; however, they are reviewed for impairment at least annually during the second quarter, or more frequently if an event occurs indicating the potential for impairment. Goodwill and IPR&amp;D are considered to be impaired if the carrying value of the reporting unit or IPR&amp;D asset exceeds its respective fair value.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform our goodwill impairment analysis at the reporting unit level, which aligns with our reporting structure and availability of discrete financial information. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair values of our reporting units are less than the carrying amounts, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and our overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair values of our reporting units are less than the carrying amounts, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair values of the reporting units with the carrying values, including goodwill. If the carrying amounts of the reporting units exceed the fair values, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill impairment test.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our identifiable intangible assets with a finite life are typically comprised of acquired device technologies and product rights. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#8217; respective estimated useful lives.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform regular reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant changes in the ability of a particular asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMzI4MTI_f098c36d-e795-44d2-a8e0-4604abc9ab10" continuedAt="i38d80cce6b5a4690923608545810f0f4" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate revenues from payments received (i) as royalties from licensing our ENHANZE technology and other royalty arrangements, (ii) under collaborative agreements and (iii) from sales of our proprietary and partnered products. We recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers we perform the following five steps: (i) identify the promised goods or services in the contract; (ii) identify the performance obligations in the contract, including whether they are distinct in the context of the contract; (iii) determine the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligations.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iebceeafabdc047758522e18e13b90468" continuedAt="ic75f6694ecdb42fca59fd384afcbc219"><ix:continuation id="i38d80cce6b5a4690923608545810f0f4" continuedAt="i46b9708a8fac4b30817020f6b790088d"><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ENHANZE and Device Royalties</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our ENHANZE collaboration and license agreements, our partners will pay us royalties at an on average mid-single digit percent rate of their sales if products under the collaboration are commercialized. All amounts owed to us are noncancelable after the underlying triggering event occurs, and nonrefundable once paid. Unless terminated earlier in accordance with its terms, collaborations generally continue in effect until the last to expire royalty payment term, as determined on a product by product and on a country by country basis, with each royalty term starting on the first commercial sale of that product and ending the later of: (i) a specified period or term set forth in the agreement or (ii) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration. When there are no valid claims during the applicable royalty term in a given country, the royalty rate is reduced for those sales. Partners may terminate the agreement prior to expiration for any reason in its entirety or on a target-by-target basis generally upon <ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="halo:RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMTI3ODU_b5ced0df-453b-43f0-a9fc-39ab90cc3892">90</ix:nonNumeric> days prior written notice to us.&#160;Upon any such termination, the license granted to partners (in total or with respect to the terminated target, as applicable) will terminate provided, however, that in the event of expiration of the agreement (as opposed to a termination), the on-going licenses granted will become perpetual, non-exclusive and fully paid. Sales-based milestones and royalties are recognized in the period the underlying sales or milestones occur. We do not receive final royalty reports from our ENHANZE partners until after we complete our financial statements for a prior quarter. Therefore, we recognize revenue based on estimates of the royalty earned, which are based on internal estimates and available preliminary reports provided by our partners. We will record adjustments in the following quarter, if necessary, when final royalty reports are received. To date, we have not recorded any material adjustments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the royalties received from licensing our ENHANZE technology, we also earn royalties in connection with licenses granted under license and development arrangements with our device partners as a result of our acquisition of Antares. These royalties are based upon a percentage of commercial sales of partnered products with rates ranging from mid-single digits to low double digits and are tiered based on levels of net sales. These sales-based royalties, for which the license was deemed the predominant element to which the royalties relate, are estimated and recognized in the period in which the partners&#8217; commercial sales occur. The royalties are generally reported and payable to us within 45 to 60 days of the end of the period in which the commercial sales are made. We base our estimates of royalties earned on actual sales information from our partners when available or estimated, prescription sales from external sources and estimated net selling price. We will record adjustments in the following quarter, if necessary, when final royalty reports are received. To date, we have not recorded any material adjustments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue under ENHANZE and Device Collaborative Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ENHANZE Collaboration and License Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our ENHANZE collaboration agreements, we grant the partner a worldwide license to develop and commercialize products using our ENHANZE technology to combine our patented rHuPH20 enzyme with their proprietary biologics directed at up to a specified number of targets. Targets are usually licensed on an exclusive, global basis. Targets selected subsequent to inception of the arrangement generally require payment of an additional license fee. The partner is responsible for all development, manufacturing, clinical, regulatory, sales and marketing costs for any products developed under the agreement. We are responsible for supply of bulk rHuPH20 based on the partner&#8217;s purchase orders and may also be separately engaged to perform research and development services. While these collaboration agreements are similar in that they originate from the same framework, each one is the result of an arms-length negotiation and thus may vary from one to the other.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, in general, collect an upfront license payment from partners and are also entitled to receive event-based payments subject to partners&#8217; achievement of specified development, regulatory and sales-based milestones. In several agreements, partners pay us annual fees to maintain their exclusive license rights if they are unable to advance product development to specified stages. We earn separate fees for bulk rHuPH20 supplies and research and development services. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although these agreements are in form identified as collaborative agreements, we concluded for accounting purposes they represent contracts with customers and are not subject to accounting literature on collaborative arrangements. This is because we grant to partners licenses to our intellectual property and provide supply of bulk rHuPH20 and research and development services which are all outputs of our ongoing activities, in exchange for consideration. Under these collaborative agreements, we do not develop assets jointly with partners, and do not share in significant risks of their development or commercialization activities. Accordingly, we concluded our collaborative agreements are appropriately accounted for pursuant to ASC Topic 606, Revenue from Contracts with Customers. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under all of our collaborative agreements, we have identified licenses to use functional intellectual property as the only performance obligation. The intellectual property underlying the license is our proprietary ENHANZE technology which represents application of rHuPH20 to facilitate delivery of drugs or fluids. Each of the licenses grants the partners rights to use </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic75f6694ecdb42fca59fd384afcbc219" continuedAt="i7b9b1ca029b6448299c21382c8e80bd4"><ix:continuation id="i46b9708a8fac4b30817020f6b790088d" continuedAt="i823c5be73f404e97bb1f36aeefe1286e"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our intellectual property as it exists and is identified on the effective date of the license, because there is no ongoing development of the ENHANZE technology required. Therefore, we recognize revenue from licenses at the point when the license becomes effective and the partner has received access to our intellectual property, usually at the inception of the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When partners can select additional targets to add to the licenses granted, we consider these rights to be options. We evaluate whether such options contain material rights, i.e. have exercise prices that are discounted compared to what we would charge for a similar license to a new partner. The exercise price of these options includes a combination of the target selection fees, event-based milestone payments and royalties. When these amounts in aggregate are not offered at a discount that exceeds discounts available to other customers, we conclude the option does not contain a material right, and we consider grants of additional licensing rights upon option exercises to be separate contracts (target selection contracts).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide customary indemnification and protection of licensed intellectual property for our customers. These provisions are part of assurance that the licenses meet the agreements&#8217; representations and are not obligations to provide goods or services.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also fulfill purchase orders for supply of bulk rHuPH20 and perform research and development services pursuant to projects authorization forms for our partners, which represent separate contracts. Additionally, we price our supply of bulk rHuPH20 and research and development services at our regular selling prices, called standalone selling price or (&#8220;SSP&#8221;). Therefore, our partners do not have material rights to order these items at prices not reflective of SSP. Refer to the discussion below regarding recognition of revenue for these separate contracts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction price for a contract represents the amount to which we are entitled in exchange for providing goods and services to the customer. Transaction price does not include amounts subject to uncertainties unless it is probable that there will be no significant reversal of revenue when the uncertainty is resolved. Apart from the upfront license payment (or target selection fees in the target selection contracts), all other fees we may earn under our collaborative agreements are subject to significant uncertainties of product development. Achievement of many of the event-based development and regulatory milestones may not be probable until such milestones are actually achieved. This generally relates to milestones such as obtaining marketing authorization approvals. With respect to other development milestones, e.g. dosing of a first patient in a clinical trial, achievement could be considered probable prior to its actual occurrence, based on the progress towards commencement of the trial. In order to evaluate progress towards commencement of a trial, we assess the status of activities leading up to our partner&#8217;s initiation of a trial such as feedback received from the applicable regulatory authorities, completion of IND or equivalent filings, readiness and availability of drug, readiness of study sites and our partner&#8217;s commitment of resources to the program. We do not include any amounts subject to uncertainties into the transaction price until it is probable that the amount will not result in a significant reversal of revenue in the future. At the end of each reporting period, we re-evaluate the probability of achievement of such milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When target exchange rights are held by partners, and the amounts attributed to these rights are not refundable, they are included in the transaction price. However, they are recorded as deferred revenues because we have a potential performance obligation to provide a new target upon an exchange right being exercised. These amounts are recognized in revenue when the right of exchange expires or is exercised.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our agreements have one type of performance obligation (licenses) which are typically all transferred at the same time at agreement inception, allocation of transaction price often is not required. However, allocation is required when licenses for some of the individual targets are subject to rights of exchange, because revenue associated with these targets cannot be recognized. When allocation is needed, we perform an allocation of the upfront amount based on relative SSP of licenses for individual targets. We determine license SSP using income-based valuation approach utilizing risk-adjusted discounted cash flow projections of the estimated return a licensor would receive. When amounts subject to uncertainties, such as milestones and royalties, are included in the transaction price, we attribute them to the specific individual target licenses which generate such milestone or royalty amounts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also estimate SSP of bulk rHuPH20 and research and development services, to determine that our partners do not have material rights to order them at discounted prices. For supplies of bulk rHuPH20, because we effectively act as a contract manufacturer to our partners, we estimate and charge SSP based on the typical contract manufacturer margins consistently with all of our partners. We determine SSP of research and development services based on a fully-burdened labor rate. Our rates are comparable to those we observe in other collaborative agreements. We also have a history of charging similar rates to all of our partners. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront amounts allocated to licenses to individual targets are recognized as revenue when the license is transferred to the partner, as discussed above, if the license is not subject to exchange rights, or when the exchange right expires or is exercised. </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7b9b1ca029b6448299c21382c8e80bd4" continuedAt="ibfe3d0b9348541698626c4a102fcfd30"><ix:continuation id="i823c5be73f404e97bb1f36aeefe1286e" continuedAt="i98a03b3327a549e1931a226ce3d247e4"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development milestones and other fees are recognized in revenue when they are included in the transaction price, because by that time we have already transferred the related license to the partner. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In contracts to provide research and development services, such services represent the only performance obligation. The fees are charged based on hours worked by our employees and the fixed contractual rate per hour, plus third-party pass-through costs, on a monthly basis. We recognize revenues as the related services are performed based on the amounts billed, as the partner consumes the benefit of research and development work simultaneously as we perform these services, and the amounts billed reflect the value of these services to the customer. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Device License, Development and Supply Arrangements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have several license, development and supply arrangements with pharmaceutical partners as a result of our acquisition of Antares, under which we grant a license to our device technology and know-how and provide research and development services that often involve multiple performance obligations and highly customized deliverables. For such arrangements, we identify each of the promised goods and services within the contract and the distinct performance obligations at inception and allocate consideration to each performance obligation based on relative standalone selling price, which is generally determined based on the expected cost plus mark-up. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the contract includes an enforceable right to payment for performance completed to date and performance obligations are satisfied over time, we recognize revenue over the development period using either the input or output method depending on which is most appropriate given the nature of the distinct deliverable. For other contracts that do not contain an enforceable right to payment for performance completed to date, revenue is recognized when control of the product is transferred to the customer. Factors that may indicate that the transfer of control has occurred include the transfer of legal title, transfer of physical possession, the customer has obtained the significant risks and rewards of ownership of the assets and we have a present right to payment. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our typical payment terms for development contracts may include an upfront payment equal to a percentage of the total contract value with the remaining portion to be billed upon completion and transfer of the individual deliverables or satisfaction of the individual performance obligations. We record a contract liability for cash received in advance of performance, which is presented within deferred revenue and deferred revenue, long-term in the Condensed Consolidated Balance Sheets and recognized as revenue in the Consolidated Statements of income when the associated performance obligations have been satisfied. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License fees and milestones received in exchange for the grant of a license to our functional intellectual property such as patented technology and know-how in connection with a partnered development arrangement are generally recognized at inception of the arrangement, or over the development period depending on the facts and circumstances, as the license is generally not distinct from the non-licensed goods or services to be provided under the contract. Milestone payments that are contingent upon the occurrence of future events are evaluated and recorded at the most likely amount, and to the extent that it is probable that a significant reversal will not occur when the associated uncertainty is resolved.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion on our collaborative arrangements.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Proprietary Product Sales</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recombinant</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell Hylenex recombinant in the U.S. to wholesale pharmaceutical distributors, who sell the product to hospitals and other end-user customers. Sales to wholesalers are made pursuant to purchase orders subject to the terms of a master agreement, and delivery of individual packages of Hylenex recombinant represent performance obligations under each purchase order. We use a contract manufacturer to produce Hylenex recombinant and a third-party logistics (3PL) vendor to process and fulfill orders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We concluded we are the principal in the sales to wholesalers because we control access to services rendered by both vendors and direct their activities. We have no significant obligations to wholesalers to generate pull-through sales.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling prices initially billed to wholesalers are subject to discounts for prompt payment and subsequent chargebacks when wholesalers sell Hylenex recombinant at negotiated discounted prices to members of certain group purchasing organizations (&#8220;GPOs&#8221;) and government programs. We also pay quarterly distribution fees to certain wholesalers for inventory reporting and chargeback processing, and to GPOs as administrative fees for services and for access to GPO members. We concluded the benefits received in exchange for these fees are not distinct from our sales of Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recombinant, and accordingly we apply these amounts to reduce revenues. Wholesalers also have rights to return unsold product nearing or past the expiration date. Because of the shelf life of Hylenex recombinant and our lengthy return period, there may be a significant period of time between when the product is shipped and when we issue credits on returned product. </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ibfe3d0b9348541698626c4a102fcfd30" continuedAt="ib897d412d3fd4585a7e1d1ee852e41cf"><ix:continuation id="i98a03b3327a549e1931a226ce3d247e4" continuedAt="i7248552538bc4ca8aba8be3ad0445b0d"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the transaction price when we receive each purchase order taking into account the expected reductions of the selling price initially billed to the wholesaler arising from all of the above factors. We have compiled historical experience and data to estimate future returns and chargebacks of Hylenex recombinant and the impact of the other discounts and fees we pay. When estimating these adjustments to the transaction price, we reduce it sufficiently to be able to assert that it is probable that there will be no significant reversal of revenue when the ultimate adjustment amounts are known.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each purchase order contains only one type of product, and is usually shipped to the wholesaler in a single shipment. Therefore, allocation of the transaction price to individual packages is not required.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue from Hylenex recombinant product sales and related cost of sales upon product delivery to the wholesaler location. At that time, the wholesalers take control of the product as they take title, bear the risk of loss of ownership, and have an enforceable obligation to pay us. They also have the ability to direct sales of product to their customers on terms and at prices they negotiate. Although wholesalers have product return rights, we do not believe they have a significant incentive to return the product to us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon recognition of revenue from product sales of Hylenex recombinant, the estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, and GPO fees are included in accrued liabilities and net of accounts receivable. We monitor actual product returns, chargebacks, discounts and fees subsequent to the sale. If these amounts differ from our estimates, we make adjustments to these allowances, which are applied to increase or reduce product sales revenue and earnings in the period of adjustment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the orders placed by wholesalers, we incur costs such as commissions to our sales representatives. However, as revenue from product sales is recognized upon delivery to the wholesaler, which occurs shortly after we receive a purchase order, we do not capitalize these commissions and other costs, based on application of the practical expedient allowed within the applicable guidance. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Proprietary Product Sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Antares, our commercial portfolio of proprietary products includes XYOSTED, TLANDO and NOCDURNA, which we sell primarily to wholesale and specialty distributors. Revenue is recognized when control has transferred to the customer, which is typically upon delivery, at the net selling price, which reflects the variable consideration for which reserves and sales allowances are established for estimated returns, wholesale distribution fees, prompt payment discounts, government rebates and chargebacks, plan rebate arrangements and patient discount and support programs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of certain reserves and sales allowances requires us to make a number of judgements and estimates to reflect our best estimate of the transaction price and the amount of consideration to which we believe we would be ultimately entitled to receive. The expected value is determined based on unit sales data, contractual terms with customers and third-party payers, historical and estimated future percentage of rebates incurred on sales, historical and future insurance plan billings, any new or anticipated changes in programs or regulations that would impact the amount of the actual rebates, customer purchasing patterns, product expiration dates and levels of inventory in the distribution channel. The estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, rebates and customer co-pay support programs are included in accrued liabilities and net of accounts receivable.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Partnered Product Sales</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bulk rHuPH20</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell bulk rHuPH20 to partners for use in research and development and, subsequent to receiving marketing approval, we sell it for use in collaboration commercial products. Sales are made pursuant to purchase orders subject to the terms of the collaborative agreement or a supply agreement, and delivery of units of bulk rHuPH20 represent performance obligations under each purchase order. We provide a standard warranty that the product conforms to specifications. We use contract manufacturers to produce bulk rHuPH20 and have concluded we are the principal in the sales to partners. The transaction price for each purchase order of bulk rHuPH20 is fixed based on the cost of production plus a contractual markup, and is not subject to adjustments. Allocation of the transaction price to individual quantities of the product is usually not required because each order contains only one type of product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue from the sale of bulk rHuPH20 as product sales and related cost of sales upon transfer of title to our partners. At that time, the partners take control of the product, bear the risk of loss of ownership, and have an enforceable obligation to pay us. </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib897d412d3fd4585a7e1d1ee852e41cf" continuedAt="icc93a6cb95d245bc9707483c19323308"><ix:continuation id="i7248552538bc4ca8aba8be3ad0445b0d"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Devices</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Antares, we are party to several license, development, supply and distribution arrangements with pharmaceutical partners, under which we produce and are the exclusive supplier of certain products, devices and/or components. Revenue is recognized when or as control of the goods transfers to the customer as discussed below.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the exclusive supplier of the Makena</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> subcutaneous auto-injector product to Covis and the exclusive supplier of OTREXUP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to Otter Pharmaceuticals, LLC (&#8220;Otter&#8221;). Because these products are custom manufactured for each customer with no alternative use and we have a contractual right to payment for performance completed to date, control is continuously transferred to the customer as the product is produced pursuant to firm purchase orders. Revenue is recognized over time using the output method based on the contractual selling price and number of units produced. The amount of revenue recognized in excess of the amount shipped/billed to the customer, if any, is recorded as contract assets in the Condensed Consolidated Balance Sheets due to the short-term nature in which the amount is ultimately expected to be billed and collected from the customer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other device partnered product sales are recognized at the point in time in which control is transferred to the customer, which is typically upon shipment. Sales terms and pricing are governed by the respective supply and distribution agreements, and there is generally no right of return. Revenue is recognized at the transaction price, which includes the contractual per unit selling price and estimated variable consideration, such as volume-based pricing arrangements or profit sharing arrangements, if any. We recognize revenue, including the estimated variable consideration we expect to receive for contract margin on future commercial sales, upon shipment of the goods to our partner. The estimated variable consideration is recognized at an amount we believe is not subject to significant reversal based on historical experience and is adjusted at each reporting period if the most likely amount of expected consideration changes or becomes fixed.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our statements of income, we report as revenues under collaborative agreements the upfront payments, event-based development and regulatory milestones and sales milestones. We also include in this category revenues from separate research and development contracts pursuant to project authorization forms. We report royalties received from partners as a separate line in our statements of income.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from sales of our proprietary and partnered products are included in product sales, net.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the footnotes to our condensed consolidated financial statements, we provide disaggregated revenue information by type of arrangement (product sales, net, collaborative agreements and research and device licensing and development revenues), and additionally, by type of payment stream received under collaborative agreements (upfront license and target nomination fees, event-based development and regulatory milestones and other fees, sales milestones and royalties).</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal costs and manufacturing overhead associated with the production of proprietary and partnered products. Cost of sales also consists of the write-down of excess, dated and obsolete inventories and the write-off of inventories that do not meet certain product specifications, if any.</span></div></ix:continuation><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMzI4OTI_1e9b5196-c4b5-4e0a-ad2a-24342c75fd61" escape="true"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include salaries and benefits, facilities and other overhead expenses, research related manufacturing services, contract services and other outside expenses. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to our research and development efforts and have no alternative future uses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed or such time when we do not expect the goods to be delivered or services to be performed.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="icc93a6cb95d245bc9707483c19323308" continuedAt="i5640d9d02b324044bd58c4bcdd9c2aeb"><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMzI4NDg_75083d03-412d-4e7d-8d0e-00691b6e8535" escape="true"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record compensation expense associated with stock options, restricted stock awards (&#8220;RSAs&#8221;), restricted stock units (&#8220;RSUs&#8221;), performance stock units (&#8220;PSUs&#8221;) and shares issued under our employee stock purchase plan (&#8220;ESPP&#8221;) in accordance with the authoritative guidance for stock-based compensation. The cost of employee services received in exchange for an award of an equity instrument is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period of the award. Share-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed. Forfeitures are recognized as a reduction of share-based compensation expense as they occur.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMzI4NzA_860a8e51-c163-40da-b6dc-707c32420460" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases at each reporting period. We measure deferred tax assets and liabilities using enacted tax rates for the year in which the differences are expected to reverse. Significant judgment is required by management to determine our provision for income taxes, our deferred tax assets and liabilities, and any associated valuation allowances recorded against our net deferred tax assets, which are based on complex and evolving tax regulations. Deferred tax assets (&#8220;DTA&#8221;) and other tax benefits are recorded when they are more likely than not to be realized. On a quarterly basis, we assess the need for valuation allowance on our DTAs, weighing all positive and negative evidence, to assess if it is more-likely-than-not that some or all of our DTAs will be realized. We recorded a provision for income taxes of $<ix:nonFraction unitRef="usd" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMTkyNDE0NTM1ODY0NzA_3f3b1f8e-7e4a-4edd-aeeb-7e0dbd4256e6">7.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMTkyNDE0NTM1ODY1MjY_2a8196ef-c7a4-4664-a85d-3f728600a2a1">21.6</ix:nonFraction>&#160;million using an effective tax rate of <ix:nonFraction unitRef="number" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMzE2ODY_935bfac5-32c0-4828-8a00-704f8164a9b4">8.1</ix:nonFraction>% and  <ix:nonFraction unitRef="number" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMTA5OTUxMTY2MDc2Nw_5e99b9c3-29f0-4146-96af-453c6c644f8f">20.7</ix:nonFraction>% the three and six months ended June&#160;30, 2022 respectively. The difference between our effective tax rate and the U.S. federal statutory rate of 21% is primarily due to tax benefits on Foreign Derived Intangible Income Deduction (FDII), and tax detriments on 162(m), other share-based compensation and non-deductible transaction costs related to Antares acquisition.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMzI3NjA_5c673233-4558-438a-9a65-90b9f2991cb7" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:3pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the acquisition of Antares, we assessed the organization of our business and concluded that we continue to operate our business in <ix:nonFraction unitRef="segment" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMzIwMDM_e76f0d31-1b9a-49aa-8f2c-c673f153d1ca">one</ix:nonFraction> segment, which includes all activities related to the research, development and commercialization of our proprietary enzymes and devices. This segment also includes revenues and expenses related to (i)&#160;research and development and manufacturing activities conducted under our collaborative agreements with third parties (ii)&#160;product sales of proprietary and partnered  products. The chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations as a single operating segment.</span></div></ix:nonNumeric></ix:continuation><div style="text-indent:24.75pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:24.75pt"><span><br/></span></div><ix:continuation id="i5640d9d02b324044bd58c4bcdd9c2aeb"><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMzI3OTA_60b2a329-dd18-45e8-b00c-6324b516330d" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adoption and Pending Adoption of Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a brief description of recently issued accounting standards, those adopted in the current period and those not yet adopted:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.046%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.647%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect on the Financial <br/>Statements or Other Significant Matters</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from contracts with customers</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The new guidance requires an acquirer to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with topic 606 as if it had originated the contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2023</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Early adoption is permitted, including adoption in an interim period)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We early adopted ASU 2021-08 on April 1, 2022. The adoption did not have a material impact on our condensed consolidated financial position or results of operations.</span></div></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" xsi:nil="true" name="us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMzI5MjE_7c059d42-8dca-4546-a45a-e0783f1ca8da" escape="true"></ix:nonNumeric>  </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="ibd09c52bdc03451493df7fb7077280c7_1114"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGV4dHJlZ2lvbjo2NTU5OTViOThjYTk0NThkYmM3NTFmODA1N2FlNDliM18xOTI0MTQ1MzUyNjA1Mg_5392483c-db92-4fb8-8303-2de2e6a6e54e" continuedAt="ia799939c2b304cf48877d18b7fc3c6bd" escape="true">Business Combination</ix:nonNumeric></span></div><ix:continuation id="ia799939c2b304cf48877d18b7fc3c6bd" continuedAt="i6de64fd89d6849adbf073e5a11d371ad"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 24, 2022, we acquired all outstanding equity interests of Antares Pharma, Inc. ("Antares") according to the terms and conditions of the Agreement and Plan of Merger, dated as of April 12, 2022 (the &#8220;Merger Agreement&#8221;). Antares is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. We acquired Antares as a part of our strategy to expand as a drug delivery company and include specialty products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total purchase consideration of Antares was $<ix:nonFraction unitRef="usd" contextRef="i4bc0e55590f348ac92553d587cadfd3d_D20220524-20220524" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGV4dHJlZ2lvbjo2NTU5OTViOThjYTk0NThkYmM3NTFmODA1N2FlNDliM18xOTI0MTQ1MzUyNjEzNw_140b1ff0-5b3c-4655-99b7-19bd78efbc5f">1,045.7</ix:nonFraction>&#160;million. Each share of Antares common stock issued and outstanding was converted into the right to receive $<ix:nonFraction unitRef="usdPerShare" contextRef="i4bc0e55590f348ac92553d587cadfd3d_D20220524-20220524" decimals="2" name="halo:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGV4dHJlZ2lvbjo2NTU5OTViOThjYTk0NThkYmM3NTFmODA1N2FlNDliM18xOTI0MTQ1MzUyNjE1Nw_b9dd2e5a-827e-453d-b1fb-7999f4806341">5.60</ix:nonFraction> in cash without interest, less any applicable withholding taxes (&#8220;Merger Consideration&#8221;). Additionally, in connection with the transaction, each Antares equity award granted and outstanding as of May 24, 2022 under the Antares&#8217; equity compensation plans was converted into the right to receive Merger Consideration. Other components of purchase consideration include cash paid at closing to settle Antares existing debt of $<ix:nonFraction unitRef="usd" contextRef="i475bb2a82ae54a4286363422e755c916_D20220524-20220524" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGV4dHJlZ2lvbjo2NTU5OTViOThjYTk0NThkYmM3NTFmODA1N2FlNDliM18xOTI0MTQ1MzUyNjA5MA_313be68c-5251-4cc5-94d9-48ac1776e240">19.7</ix:nonFraction>&#160;million and seller transaction costs paid by us on behalf of Antares of $<ix:nonFraction unitRef="usd" contextRef="i4bc0e55590f348ac92553d587cadfd3d_D20220524-20220524" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredOther1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGV4dHJlZ2lvbjo2NTU5OTViOThjYTk0NThkYmM3NTFmODA1N2FlNDliM18xOTI0MTQ1MzUyNjE2NQ_2fbd2e5c-c0d8-4437-84a6-ffea0463abcd">22.9</ix:nonFraction>&#160;million. </span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of Antares was funded by cash on hand and borrowings under the new credit agreement with Bank of America, N.A. (&#8220;BofA&#8221;) and other lenders that provides for (i) a $<ix:nonFraction unitRef="usd" contextRef="i86ae6c3b418d4a88aa081e1790735e1b_I20220524" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGV4dHJlZ2lvbjo2NTU5OTViOThjYTk0NThkYmM3NTFmODA1N2FlNDliM18xOTI0MTQ1MzUyNjE5NA_a7e578d4-8934-46ac-8d41-e3825e80062e">350</ix:nonFraction>&#160;million revolving credit facility (the &#8220;Revolving Credit Facility&#8221;) and (ii) a $<ix:nonFraction unitRef="usd" contextRef="i5c984de515d647a5b30035159dcaec53_I20220524" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGV4dHJlZ2lvbjo2NTU5OTViOThjYTk0NThkYmM3NTFmODA1N2FlNDliM18xOTI0MTQ1MzUyNjE4MA_6f46283c-212f-4e31-bb75-68d57e94938e">250</ix:nonFraction>&#160;million term loan facility (the &#8220;Term Facility&#8221;, collectively with the Revolving Credit Facility, the &#8220;2022 Facility&#8221;) as described in Note 8. We recognized transaction costs of $<ix:nonFraction unitRef="usd" contextRef="i00acc9b249264652bb496012352851f4_D20220401-20220630" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGV4dHJlZ2lvbjo2NTU5OTViOThjYTk0NThkYmM3NTFmODA1N2FlNDliM18xOTI0MTQ1MzUyNjEwNg_4b7b5cb1-bfea-486e-a012-faf1da508c5a">18.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if15049277def4dcdb9cbdffbe5d753f1_D20220101-20220630" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGV4dHJlZ2lvbjo2NTU5OTViOThjYTk0NThkYmM3NTFmODA1N2FlNDliM18xOTI0MTQ1MzUyNjEyMQ_daaea80a-3849-4b8b-90bf-8dfb561b7d27">20.1</ix:nonFraction>&#160;million in the three and six months ended June 30, 2022, respectively. These costs are reported in the selling, general and administrative expenses line of our consolidated statements of income. Transaction costs include, but are not limited to, investment banker, advisory, legal, and other professional fees.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Consideration</span></div><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGV4dHJlZ2lvbjo2NTU5OTViOThjYTk0NThkYmM3NTFmODA1N2FlNDliM18xOTI0MTQ1MzUyNjA1Mw_59ff7158-6626-4b04-92aa-fe6d858a9a2f" escape="true"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total purchase consideration was comprised of the following (in thousands):</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"></td><td style="width:87.539%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.514%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash consideration for Antares shares outstanding as of May 24, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bc0e55590f348ac92553d587cadfd3d_D20220524-20220524" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6ZjRiZDU1ZTlkMGQ2NGY4ZWJkZjg0NzM4NDIxMjRkYzEvdGFibGVyYW5nZTpmNGJkNTVlOWQwZDY0ZjhlYmRmODQ3Mzg0MjEyNGRjMV8wLTItMS0xLTYwMjk0_9023feee-6eeb-4174-9905-8a7915a74045">956,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration for Antares equity compensation awards </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bc0e55590f348ac92553d587cadfd3d_D20220524-20220524" decimals="-3" name="halo:BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6ZjRiZDU1ZTlkMGQ2NGY4ZWJkZjg0NzM4NDIxMjRkYzEvdGFibGVyYW5nZTpmNGJkNTVlOWQwZDY0ZjhlYmRmODQ3Mzg0MjEyNGRjMV8xLTItMS0xLTYwMjk0_e840ab42-8a49-44de-a579-9976f018ac45">45,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration for seller transaction costs paid by Halozyme</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bc0e55590f348ac92553d587cadfd3d_D20220524-20220524" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredOther1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6ZjRiZDU1ZTlkMGQ2NGY4ZWJkZjg0NzM4NDIxMjRkYzEvdGFibGVyYW5nZTpmNGJkNTVlOWQwZDY0ZjhlYmRmODQ3Mzg0MjEyNGRjMV8yLTItMS0xLTYwMjk0_e380158e-208d-478f-bf42-a2eb7fe783ef">22,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration related to Antares closing indebtedness settled by Halozyme</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bc0e55590f348ac92553d587cadfd3d_D20220524-20220524" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6ZjRiZDU1ZTlkMGQ2NGY4ZWJkZjg0NzM4NDIxMjRkYzEvdGFibGVyYW5nZTpmNGJkNTVlOWQwZDY0ZjhlYmRmODQ3Mzg0MjEyNGRjMV8zLTItMS0xLTYwMjk0_e3b3f421-1053-47c3-98de-77185dc40248">19,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash consideration related to cash bonus awards paid by Halozyme</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bc0e55590f348ac92553d587cadfd3d_D20220524-20220524" decimals="-3" name="halo:BusinessCombinationConsiderationTransferredBonusAwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6ZjRiZDU1ZTlkMGQ2NGY4ZWJkZjg0NzM4NDIxMjRkYzEvdGFibGVyYW5nZTpmNGJkNTVlOWQwZDY0ZjhlYmRmODQ3Mzg0MjEyNGRjMV80LTItMS0xLTU3Mjg5_bc9212a1-b34d-49a4-8bc9-d123aca4f17f">365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total purchase consideration</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bc0e55590f348ac92553d587cadfd3d_D20220524-20220524" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6ZjRiZDU1ZTlkMGQ2NGY4ZWJkZjg0NzM4NDIxMjRkYzEvdGFibGVyYW5nZTpmNGJkNTVlOWQwZDY0ZjhlYmRmODQ3Mzg0MjEyNGRjMV81LTItMS0xLTYwMjk0_185888ba-924b-4267-a40d-79e81ce4fdcb">1,045,668</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%">(a) Consideration for Antares equity compensation awards consists of $<ix:nonFraction unitRef="usd" contextRef="i615a905f496c4c0d9f797e929cacf41f_D20220524-20220524" decimals="-3" name="halo:BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGV4dHJlZ2lvbjo2NTU5OTViOThjYTk0NThkYmM3NTFmODA1N2FlNDliM18xOTI0MTQ1MzUyNjA3NA_db6da482-f657-43c9-8bbf-81c0f35d6976">32.2</ix:nonFraction>&#160;million paid for vested equity awards as well as $<ix:nonFraction unitRef="usd" contextRef="i82c9562114b64891bb65718130793579_D20220524-20220524" decimals="-3" name="halo:BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGV4dHJlZ2lvbjo2NTU5OTViOThjYTk0NThkYmM3NTFmODA1N2FlNDliM18xOTI0MTQ1MzUyNjA1OQ_cff0da33-27c7-4486-9e8f-991ee6a4f1d0">13.6</ix:nonFraction>&#160;million paid for the pre-combination portion of unvested equity awards that were accelerated as part of the Merger Agreement. The fair value of the unvested equity awards attributable to the post-combination period of $<ix:nonFraction unitRef="usd" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="-5" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGV4dHJlZ2lvbjo2NTU5OTViOThjYTk0NThkYmM3NTFmODA1N2FlNDliM18xOTI0MTQ1MzUyNjIwOQ_54eef4ec-e40c-470b-836b-14ef8216c361">8.7</ix:nonFraction>&#160;million is included in Statement of Income in Q2 2022.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Fair Value of Assets Acquired and Liabilities Assumed</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of Antares has been accounted for using the acquisition method of accounting in accordance with ASC 805, Business Combinations, with Halozyme treated as the accounting acquirer, which requires, among other things, that the assets acquired and liabilities assumed be recognized at their fair value on the acquisition date. Acquisition accounting is dependent upon certain valuations and other studies that have yet to commence or progress to a stage where there is sufficient information for a definitive measurement. The process for estimating the fair values of identifiable intangible assets and certain tangible assets and assumed liabilities requires the use of judgment in determining the appropriate assumptions and estimates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the preliminary estimated fair values of assets acquired and liabilities assumed on the acquisition date based on preliminary valuations and management estimates that are subject to change when formal valuations and other studies are finalized. Fair value estimates are based on a complex series of judgments about future events and uncertainties and rely heavily on estimates and assumptions. The judgments used to determine the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact our results of operations. <ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGV4dHJlZ2lvbjo2NTU5OTViOThjYTk0NThkYmM3NTFmODA1N2FlNDliM18xOTI0MTQ1MzUyNjA1NA_928ff590-0029-4cd0-81ef-753f06cb30ff" continuedAt="id351ee58a8984d19b9a2b91a94856c9f" escape="true">These preliminary estimates may be revised during the measurement period as third-party valuations are finalized, additional information becomes available, and as additional analyses are performed, and these differences could change the value of the intangible assets acquired, the contingent liability assumed, and the tax impacts related to the acquisition and could have a material impact on our results of operations and financial position.</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i6de64fd89d6849adbf073e5a11d371ad" continuedAt="i29284513a1394b228afe122b8f76f12b"><div><ix:continuation id="id351ee58a8984d19b9a2b91a94856c9f"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:84.593%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.618%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Total purchase consideration, net of $<ix:nonFraction unitRef="usd" contextRef="i4bc0e55590f348ac92553d587cadfd3d_D20220524-20220524" decimals="0" name="us-gaap:CashAcquiredFromAcquisition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NzA5NGVkY2MyOTRiNDA2ZDk5ZTA0NTk0YmYwZWY0OTQvdGFibGVyYW5nZTo3MDk0ZWRjYzI5NGI0MDZkOTllMDQ1OTRiZjBlZjQ5NF8xLTAtMS0xLTU4MjIzL3RleHRyZWdpb246MjNhZTIyNTBhMGI2NGMwY2FjOTIzNWYwZDc3MmM5YWJfMTA5OTUxMTYyNzk4MA_29ac8fd0-3e42-4433-a3e7-8d9b39123f0a">46,548</ix:nonFraction> cash acquired</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bc0e55590f348ac92553d587cadfd3d_D20220524-20220524" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NzA5NGVkY2MyOTRiNDA2ZDk5ZTA0NTk0YmYwZWY0OTQvdGFibGVyYW5nZTo3MDk0ZWRjYzI5NGI0MDZkOTllMDQ1OTRiZjBlZjQ5NF8xLTItMS0xLTYwMzQx_c35bbe12-f213-40df-99ee-ee2a59c7b52c">999,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e07b7230a7b4293910918c1158913a7_I20220524" decimals="-3" name="halo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NzA5NGVkY2MyOTRiNDA2ZDk5ZTA0NTk0YmYwZWY0OTQvdGFibGVyYW5nZTo3MDk0ZWRjYzI5NGI0MDZkOTllMDQ1OTRiZjBlZjQ5NF8zLTItMS0xLTYwMzUw_29ac4565-cd9a-4b4f-a0da-7ff3a6bc629c">498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e07b7230a7b4293910918c1158913a7_I20220524" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NzA5NGVkY2MyOTRiNDA2ZDk5ZTA0NTk0YmYwZWY0OTQvdGFibGVyYW5nZTo3MDk0ZWRjYzI5NGI0MDZkOTllMDQ1OTRiZjBlZjQ5NF80LTItMS0xLTYwMzUw_e88d75a4-bca5-48d2-970b-133f0363c920">82,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e07b7230a7b4293910918c1158913a7_I20220524" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NzA5NGVkY2MyOTRiNDA2ZDk5ZTA0NTk0YmYwZWY0OTQvdGFibGVyYW5nZTo3MDk0ZWRjYzI5NGI0MDZkOTllMDQ1OTRiZjBlZjQ5NF81LTItMS0xLTYwMzUw_0270e239-109d-4f14-9bca-ff480260dac8">34,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e07b7230a7b4293910918c1158913a7_I20220524" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NzA5NGVkY2MyOTRiNDA2ZDk5ZTA0NTk0YmYwZWY0OTQvdGFibGVyYW5nZTo3MDk0ZWRjYzI5NGI0MDZkOTllMDQ1OTRiZjBlZjQ5NF82LTItMS0xLTYwMzUw_f4778dba-f985-4f97-a7bc-db362c054e93">5,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e07b7230a7b4293910918c1158913a7_I20220524" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NzA5NGVkY2MyOTRiNDA2ZDk5ZTA0NTk0YmYwZWY0OTQvdGFibGVyYW5nZTo3MDk0ZWRjYzI5NGI0MDZkOTllMDQ1OTRiZjBlZjQ5NF83LTItMS0xLTYwMzQz_540ab2da-b0c1-4761-ada8-cad443a195e5">28,661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e07b7230a7b4293910918c1158913a7_I20220524" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NzA5NGVkY2MyOTRiNDA2ZDk5ZTA0NTk0YmYwZWY0OTQvdGFibGVyYW5nZTo3MDk0ZWRjYzI5NGI0MDZkOTllMDQ1OTRiZjBlZjQ5NF84LTItMS0xLTYwMzQ1_5d23ad3f-6236-47d0-9e82-5a5dfb6ba5ee">987,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts Payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e07b7230a7b4293910918c1158913a7_I20220524" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NzA5NGVkY2MyOTRiNDA2ZDk5ZTA0NTk0YmYwZWY0OTQvdGFibGVyYW5nZTo3MDk0ZWRjYzI5NGI0MDZkOTllMDQ1OTRiZjBlZjQ5NF8xMC0yLTEtMS02MDM0Nw_fdc542a3-5311-4332-b2dd-fd28a10c90a8">7,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e07b7230a7b4293910918c1158913a7_I20220524" decimals="-3" name="halo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NzA5NGVkY2MyOTRiNDA2ZDk5ZTA0NTk0YmYwZWY0OTQvdGFibGVyYW5nZTo3MDk0ZWRjYzI5NGI0MDZkOTllMDQ1OTRiZjBlZjQ5NF8xMS0yLTEtMS02MDM0Nw_2a83257c-7a44-4f9b-b9c2-fb7be3e72c1a">33,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e07b7230a7b4293910918c1158913a7_I20220524" decimals="-3" name="halo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NzA5NGVkY2MyOTRiNDA2ZDk5ZTA0NTk0YmYwZWY0OTQvdGFibGVyYW5nZTo3MDk0ZWRjYzI5NGI0MDZkOTllMDQ1OTRiZjBlZjQ5NF8xMi0yLTEtMS02MDM0Nw_e4abb3c5-9e92-4a38-b767-27043e38cd51">2,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e07b7230a7b4293910918c1158913a7_I20220524" decimals="-3" name="halo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NzA5NGVkY2MyOTRiNDA2ZDk5ZTA0NTk0YmYwZWY0OTQvdGFibGVyYW5nZTo3MDk0ZWRjYzI5NGI0MDZkOTllMDQ1OTRiZjBlZjQ5NF8xMy0yLTEtMS02MDM0Nw_9901993d-2a34-4ba5-8897-ac2e03610df3">1,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e07b7230a7b4293910918c1158913a7_I20220524" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NzA5NGVkY2MyOTRiNDA2ZDk5ZTA0NTk0YmYwZWY0OTQvdGFibGVyYW5nZTo3MDk0ZWRjYzI5NGI0MDZkOTllMDQ1OTRiZjBlZjQ5NF8xNC0yLTEtMS02MDM0Nw_64a705e3-8f83-41db-a8c4-93d6d22d2153">159,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e07b7230a7b4293910918c1158913a7_I20220524" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NzA5NGVkY2MyOTRiNDA2ZDk5ZTA0NTk0YmYwZWY0OTQvdGFibGVyYW5nZTo3MDk0ZWRjYzI5NGI0MDZkOTllMDQ1OTRiZjBlZjQ5NF8xNS0yLTEtMS02MDM0Nw_e35ee853-7545-4e11-ac18-e8cc712a9d5e">135,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net assets acquired, excluding goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e07b7230a7b4293910918c1158913a7_I20220524" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NzA5NGVkY2MyOTRiNDA2ZDk5ZTA0NTk0YmYwZWY0OTQvdGFibGVyYW5nZTo3MDk0ZWRjYzI5NGI0MDZkOTllMDQ1OTRiZjBlZjQ5NF8xNi0yLTEtMS02MDM0Nw_3767c71d-fb72-4fa0-962a-7fc130c75297">799,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77c93c8b4e414609a78dfb4f6f64ed57_I20220524" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NzA5NGVkY2MyOTRiNDA2ZDk5ZTA0NTk0YmYwZWY0OTQvdGFibGVyYW5nZTo3MDk0ZWRjYzI5NGI0MDZkOTllMDQ1OTRiZjBlZjQ5NF8xNy0yLTEtMS01Njk2NA_1d648f11-0977-4b60-82da-61988288f894">199,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is the excess of the consideration transferred over the net assets recognized and represents the expected revenue and cost synergies of the combined company and assembled workforce. Goodwill will be allocated entirely to the single reportable segment. Goodwill recognized as a result of the acquisition is not deductible for tax purposes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Identifiable Intangible Assets</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The estimated fair values of identifiable intangible assets were prepared using the excess earnings method which calculates the present value of the incremental after-tax cash flows attributable solely to each intangible asset. The estimated useful lives are based on forecasted periods of benefit for each intangible asset which consider commercialization dates, the estimated revenue cycle based on the products&#8217; competitiveness in the market, and the loss of exclusivity timing with subsequent trending down of revenue. For the ATRS-1902 IPR&amp;D, the useful life is considered indefinite as the asset has not been placed into service. As such, the ATRS-1902 IPR&amp;D will be tested annually for impairment and will not be amortized. Useful lives and <ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGV4dHJlZ2lvbjo2NTU5OTViOThjYTk0NThkYmM3NTFmODA1N2FlNDliM18xOTI0MTQ1MzUyNjA1NQ_271c7a75-c1f4-429b-8be1-fb8d9d067941" continuedAt="i8add5bf3c5f94b2397e7b14a467a3277" escape="true"><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGV4dHJlZ2lvbjo2NTU5OTViOThjYTk0NThkYmM3NTFmODA1N2FlNDliM18xOTI0MTQ1MzUyNjA1NQ_c4d8f763-d96c-431f-850e-1685aa363363" continuedAt="i33195201b17f4348b3a3d0763d266976" escape="true">preliminary values are presented in the table below.</ix:nonNumeric></ix:nonNumeric></span></div><div><ix:continuation id="i8add5bf3c5f94b2397e7b14a467a3277"><ix:continuation id="i33195201b17f4348b3a3d0763d266976"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:76.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.421%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount (in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful life (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auto Injector technology platform</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36b527310aeb4abebd94653011e3f9db_D20220524-20220524" decimals="-3" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6ZTc3YzAzYWUzZTYyNDE3MWFkYmE1N2ZjYmQzOGUyMDAvdGFibGVyYW5nZTplNzdjMDNhZTNlNjI0MTcxYWRiYTU3ZmNiZDM4ZTIwMF8xLTItMS0xLTYwNDIw_855554c2-7061-4429-b7f5-65b39076d11e">372,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i36b527310aeb4abebd94653011e3f9db_D20220524-20220524" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6ZTc3YzAzYWUzZTYyNDE3MWFkYmE1N2ZjYmQzOGUyMDAvdGFibGVyYW5nZTplNzdjMDNhZTNlNjI0MTcxYWRiYTU3ZmNiZDM4ZTIwMF8xLTQtMS0xLTYwNDI4_24f9e192-5932-4e84-bdf3-41e659e6b9fd">7</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XYOSTED proprietary product</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i079a89cb03c6429c974b822df12e4303_D20220524-20220524" decimals="-3" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6ZTc3YzAzYWUzZTYyNDE3MWFkYmE1N2ZjYmQzOGUyMDAvdGFibGVyYW5nZTplNzdjMDNhZTNlNjI0MTcxYWRiYTU3ZmNiZDM4ZTIwMF8yLTItMS0xLTYwNDIw_9b35b12a-6c41-4650-8f00-f26794a957f7">277,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i079a89cb03c6429c974b822df12e4303_D20220524-20220524" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6ZTc3YzAzYWUzZTYyNDE3MWFkYmE1N2ZjYmQzOGUyMDAvdGFibGVyYW5nZTplNzdjMDNhZTNlNjI0MTcxYWRiYTU3ZmNiZDM4ZTIwMF8yLTQtMS0xLTYwNDI4_cb526134-a555-4e31-93fd-7d447c67d840">10</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TLANDO product rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i827e16b84dc24a16a310f235506fdd09_D20220524-20220524" decimals="-3" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6ZTc3YzAzYWUzZTYyNDE3MWFkYmE1N2ZjYmQzOGUyMDAvdGFibGVyYW5nZTplNzdjMDNhZTNlNjI0MTcxYWRiYTU3ZmNiZDM4ZTIwMF8zLTItMS0xLTYwNDIw_cd975507-aaba-4425-adfe-b729fe2bf328">277,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i827e16b84dc24a16a310f235506fdd09_D20220524-20220524" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6ZTc3YzAzYWUzZTYyNDE3MWFkYmE1N2ZjYmQzOGUyMDAvdGFibGVyYW5nZTplNzdjMDNhZTNlNjI0MTcxYWRiYTU3ZmNiZDM4ZTIwMF8zLTQtMS0xLTYwNDI4_102887a3-0903-47ba-be76-e376a9feb05e">10</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ATRS-1902 (IPR&amp;D)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89ede30c1fb341e6b5c377169cbac030_D20220524-20220524" decimals="-3" name="us-gaap:IndefinitelivedIntangibleAssetsAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6ZTc3YzAzYWUzZTYyNDE3MWFkYmE1N2ZjYmQzOGUyMDAvdGFibGVyYW5nZTplNzdjMDNhZTNlNjI0MTcxYWRiYTU3ZmNiZDM4ZTIwMF80LTItMS0xLTYwNDIw_a6fb999f-3c9f-4600-b0ef-dccc5f42913e">59,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated fair value of intangible assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e07b7230a7b4293910918c1158913a7_I20220524" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6ZTc3YzAzYWUzZTYyNDE3MWFkYmE1N2ZjYmQzOGUyMDAvdGFibGVyYW5nZTplNzdjMDNhZTNlNjI0MTcxYWRiYTU3ZmNiZDM4ZTIwMF81LTItMS0xLTYwNDIw_1e0cf02f-6d27-4820-81f2-f5258da407ba">987,500</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></ix:continuation></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A contingent liability with a preliminary value of $<ix:nonFraction unitRef="usd" contextRef="i1e07b7230a7b4293910918c1158913a7_I20220524" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGV4dHJlZ2lvbjo2NTU5OTViOThjYTk0NThkYmM3NTFmODA1N2FlNDliM18xOTI0MTQ1MzUzNDU5Mg_5d0d1c3c-ecb5-47d2-ab1d-e277d0218235">130.0</ix:nonFraction>&#160;million was assumed related to TLANDO. We assumed an obligation to pay development milestone payments as well as commercial milestone payments and minimum tiered royalty payments based on TLANDO net sales which are contingent upon future events. The acquisition date fair value was measured using the income approach, specifically the probability weighted expected return method for the development milestone payments and the option pricing methodology using the Monte Carlo simulation for commercial milestone payments and royalty payments. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Pro Forma Results</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements include Antares' results of operations from the date of acquisition on May 24, 2022 through June 30, 2022. Total revenues and net loss before taxes attributable to Antares during this period and included in our consolidated financial statements for both the three and six months ended June 30, 2022 total $<ix:nonFraction unitRef="usd" contextRef="if15049277def4dcdb9cbdffbe5d753f1_D20220101-20220630" decimals="-5" name="us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGV4dHJlZ2lvbjo2NTU5OTViOThjYTk0NThkYmM3NTFmODA1N2FlNDliM18xOTI0MTQ1MzUyNjIyMw_6c4ab53d-c413-4998-8312-9fab94c506e0"><ix:nonFraction unitRef="usd" contextRef="i00acc9b249264652bb496012352851f4_D20220401-20220630" decimals="-5" name="us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGV4dHJlZ2lvbjo2NTU5OTViOThjYTk0NThkYmM3NTFmODA1N2FlNDliM18xOTI0MTQ1MzUyNjIyMw_c516787b-4b87-4a3e-8cb0-81315a408841">18.7</ix:nonFraction></ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if15049277def4dcdb9cbdffbe5d753f1_D20220101-20220630" decimals="-5" name="us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGV4dHJlZ2lvbjo2NTU5OTViOThjYTk0NThkYmM3NTFmODA1N2FlNDliM18xOTI0MTQ1MzUyNjI0MQ_91fd9aeb-8d55-4564-a81b-c9fe9cac1019"><ix:nonFraction unitRef="usd" contextRef="i00acc9b249264652bb496012352851f4_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGV4dHJlZ2lvbjo2NTU5OTViOThjYTk0NThkYmM3NTFmODA1N2FlNDliM18xOTI0MTQ1MzUyNjI0MQ_ab146ce7-6cc7-4046-ae12-82a0b1460ac6">39.8</ix:nonFraction></ix:nonFraction>&#160;million, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i29284513a1394b228afe122b8f76f12b"><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGV4dHJlZ2lvbjo2NTU5OTViOThjYTk0NThkYmM3NTFmODA1N2FlNDliM18xOTI0MTQ1MzUyNjA1Ng_deb7006a-e604-4d64-b861-d6c16613eac8" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma financial information summarizes combined results of operations of Halozyme and Antares as if the companies had been combined as of the beginning of our fiscal year 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"><tr><td style="width:1.0%"></td><td style="width:58.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.179%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a3a21a6a5d44d869b7b90d70c8531c7_D20210401-20210630" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NjBjZGU0OTAwNzhlNGUwMGI2ZjAxOTBjZGFhYjViZGMvdGFibGVyYW5nZTo2MGNkZTQ5MDA3OGU0ZTAwYjZmMDE5MGNkYWFiNWJkY18yLTItMS0xLTYwNDk2_8a9f49d6-0189-468f-a409-a592aa559aa1">163,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00acc9b249264652bb496012352851f4_D20220401-20220630" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NjBjZGU0OTAwNzhlNGUwMGI2ZjAxOTBjZGFhYjViZGMvdGFibGVyYW5nZTo2MGNkZTQ5MDA3OGU0ZTAwYjZmMDE5MGNkYWFiNWJkY18yLTQtMS0xLTYwNDk4_dbdfa059-7cc7-4a4e-b300-4f39f075dafc">168,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9372d0e89f64744be923e43620998cc_D20210101-20210630" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NjBjZGU0OTAwNzhlNGUwMGI2ZjAxOTBjZGFhYjViZGMvdGFibGVyYW5nZTo2MGNkZTQ5MDA3OGU0ZTAwYjZmMDE5MGNkYWFiNWJkY18yLTYtMS0xLTYwNTAw_9c2e95ac-284e-4c76-bd95-968fcff94b7c">322,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if15049277def4dcdb9cbdffbe5d753f1_D20220101-20220630" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NjBjZGU0OTAwNzhlNGUwMGI2ZjAxOTBjZGFhYjViZGMvdGFibGVyYW5nZTo2MGNkZTQ5MDA3OGU0ZTAwYjZmMDE5MGNkYWFiNWJkY18yLTgtMS0xLTYwNTAy_7d82d80f-87f6-4a83-9835-00c35bb97b63">312,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a3a21a6a5d44d869b7b90d70c8531c7_D20210401-20210630" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NjBjZGU0OTAwNzhlNGUwMGI2ZjAxOTBjZGFhYjViZGMvdGFibGVyYW5nZTo2MGNkZTQ5MDA3OGU0ZTAwYjZmMDE5MGNkYWFiNWJkY18zLTItMS0xLTYwNDk2_2ff33072-17df-4cde-83df-12b09e38e960">60,461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00acc9b249264652bb496012352851f4_D20220401-20220630" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NjBjZGU0OTAwNzhlNGUwMGI2ZjAxOTBjZGFhYjViZGMvdGFibGVyYW5nZTo2MGNkZTQ5MDA3OGU0ZTAwYjZmMDE5MGNkYWFiNWJkY18zLTQtMS0xLTYwNDk4_7a84eac8-9c6f-4ad0-aae9-e35a54d44b59">70,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9372d0e89f64744be923e43620998cc_D20210101-20210630" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NjBjZGU0OTAwNzhlNGUwMGI2ZjAxOTBjZGFhYjViZGMvdGFibGVyYW5nZTo2MGNkZTQ5MDA3OGU0ZTAwYjZmMDE5MGNkYWFiNWJkY18zLTYtMS0xLTYwNTAw_5ec3ad48-284d-4d94-b33b-6a8217deb35e">96,752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if15049277def4dcdb9cbdffbe5d753f1_D20220101-20220630" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NjBjZGU0OTAwNzhlNGUwMGI2ZjAxOTBjZGFhYjViZGMvdGFibGVyYW5nZTo2MGNkZTQ5MDA3OGU0ZTAwYjZmMDE5MGNkYWFiNWJkY18zLTgtMS0xLTYwNTAy_cb852c7e-e3ce-4969-b1e5-4b6edcd90373">18,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The unaudited pro forma financial information for all periods presented includes the business combination accounting effects resulting from this acquisition. The unaudited pro forma results include adjustments to reflect the amortization of the inventory step-up and the incremental intangible asset amortization to be incurred based on preliminary valuations of assets as well as certain material non-recurring transaction adjustments related to the acquisition. Adjustments to interest expense, financing costs and investment income were made to reflect the capital structure of the combined entity. Adjustments to income tax expense also were made to reflect the anticipated effective tax rate of the combined entity. The unaudited pro forma financial information as presented is for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved if the acquisition had taken place at the beginning of fiscal 2021, nor is it necessarily an indication of trends in future results for a number of reasons, including, but not limited to, differences between the assumptions used to prepare the pro forma information, cost savings from operating efficiencies, potential synergies, and the impact of incremental costs incurred in integrating the businesses.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="ibd09c52bdc03451493df7fb7077280c7_49"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RleHRyZWdpb246MmY1MTI5Mjc5OGYzNGYzNzhmZGQ5NjI5NTBiMDIyMTVfMTAyOQ_2519ca22-2dc6-47c1-9add-7eb95781bbef" continuedAt="ic01d5b5f34104071b1dbb25dc2c9bee6" escape="true">Fair Value Measurement</ix:nonNumeric></span></div><ix:continuation id="ic01d5b5f34104071b1dbb25dc2c9bee6" continuedAt="i1797cdae13554ebab8d0b858e0424522"><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RleHRyZWdpb246MmY1MTI5Mjc5OGYzNGYzNzhmZGQ5NjI5NTBiMDIyMTVfMTAyMg_6412e797-2b51-4669-94ad-5aa1b0a99f48" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities consisted of the following (in thousands):</span></div><div style="margin-top:11pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:52.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.779%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fc34bcf05bf42a1ad015e84425c8d0d_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfMi0yLTEtMS00NzgwMQ_5c9c44bf-4d8f-4fca-a6d1-1342bae7bf22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fc34bcf05bf42a1ad015e84425c8d0d_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfMi00LTEtMS00NzgwMQ_ea69c792-d02f-4c51-99e8-cf59737505aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fc34bcf05bf42a1ad015e84425c8d0d_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfMi02LTEtMS00NzgwMQ_05f445d7-c1d6-4d33-bca7-9862113b2aef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fc34bcf05bf42a1ad015e84425c8d0d_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfMi04LTEtMS00NzgwMQ_05fba5a4-d6f0-4ebe-8a42-cab9dff402d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i919614e2dc9744fea40ea36e3bad8795_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfMy0yLTEtMS00NzgwMQ_d745ddcf-3f16-4647-9be9-a5745d1759ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i919614e2dc9744fea40ea36e3bad8795_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfMy00LTEtMS00NzgwMQ_27a4d922-a3c5-4e19-becb-b9ef37222e53">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i919614e2dc9744fea40ea36e3bad8795_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfMy02LTEtMS00NzgwMQ_1f6ff51b-67da-47fa-841b-8f1fe341018e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i919614e2dc9744fea40ea36e3bad8795_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfMy04LTEtMS00NzgwMQ_e5e59471-c05d-4be2-916c-94c578300e13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02b96f8f266746e5bef1a7a56d0020d7_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfNC0yLTEtMS00NzgwMQ_50427455-e5fd-4d62-88d6-d1d06f4a4aa9">120,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02b96f8f266746e5bef1a7a56d0020d7_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfNC00LTEtMS00NzgwMQ_55afe951-bb12-402e-a63d-26f395abc4ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02b96f8f266746e5bef1a7a56d0020d7_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfNC02LTEtMS00NzgwMQ_e2b5ab2a-d77f-4fb0-b116-55aa7a17baaa">2,032</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02b96f8f266746e5bef1a7a56d0020d7_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfNC04LTEtMS00NzgwMQ_0e0878ff-de01-4208-ba2b-70967df4fd45">118,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-US Government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c5035736b1a4598ae99008fbf3463ef_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfNS0yLTEtMS00NzgwMQ_abdd6344-a555-4532-9eed-377d73c6bac3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c5035736b1a4598ae99008fbf3463ef_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfNS00LTEtMS00NzgwMQ_d95dba17-5447-47f1-a90a-0fa42155e7a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c5035736b1a4598ae99008fbf3463ef_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfNS02LTEtMS00NzgwMQ_73933991-779d-4114-99ec-110bbd591f85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c5035736b1a4598ae99008fbf3463ef_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfNS04LTEtMS00NzgwMQ_c691d6a2-29a3-4bdb-b421-e12e1e51591c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i729eff0e2b1b45abacd1da9f077ac641_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfNi0yLTEtMS00NzgwMQ_0afb7b10-bcb0-4cd5-b2e7-fcde0d72ecc6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i729eff0e2b1b45abacd1da9f077ac641_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfNi00LTEtMS00NzgwMQ_73698b16-dc10-466d-a0f8-c33ea4ce2810">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i729eff0e2b1b45abacd1da9f077ac641_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfNi02LTEtMS00NzgwMQ_d73b7a03-7fde-44db-beb3-66315ac50506">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i729eff0e2b1b45abacd1da9f077ac641_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfNi04LTEtMS00NzgwMQ_7b837b03-02b2-4fdb-a2b8-4e309b271420">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfNy0yLTEtMS00NzgwMQ_d6445524-a668-4d06-85d9-92cdd17dd163">120,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfNy00LTEtMS00NzgwMQ_0642aa78-5cc3-4738-8fe0-53d64d3c567d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfNy02LTEtMS00NzgwMQ_392b0d67-cd5a-436c-b18f-fb48702d1e53">2,032</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfNy04LTEtMS00NzgwMQ_253c3caa-7c09-459e-b3f8-1e9645dfc704">118,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:52.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.779%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3327c7ae03814e5b98e511ab356d1e06_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfMi0yLTEtMS00NzgwMQ_e23d0cb5-8306-465b-9cbb-5b0e7b04f1e1">32,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3327c7ae03814e5b98e511ab356d1e06_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfMi00LTEtMS00NzgwMQ_f530ce7a-9546-4f94-9233-1a6fb48bf008">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3327c7ae03814e5b98e511ab356d1e06_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfMi02LTEtMS00NzgwMQ_ee9412c1-8b7c-479b-93d8-54bfd8684267">53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3327c7ae03814e5b98e511ab356d1e06_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfMi04LTEtMS00NzgwMQ_2df4d7f1-4365-4b01-8f70-5025f056bcd6">32,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6a49dbb96ea4e068ffae31a73e0450d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfMy0yLTEtMS00NzgwMQ_d136a713-d561-4fa1-94a9-8c486ec34bb2">58,885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6a49dbb96ea4e068ffae31a73e0450d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfMy00LTEtMS00NzgwMQ_eb1eecc4-751e-4b15-b367-46fad0a6703e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6a49dbb96ea4e068ffae31a73e0450d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfMy02LTEtMS00NzgwMQ_b7b90c57-6cfc-4cab-9a97-85da85945384">86</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6a49dbb96ea4e068ffae31a73e0450d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfMy04LTEtMS00NzgwMQ_4b7b49d8-ad40-44a8-869b-bb86ce2ddac3">58,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbbf1f4395c847e88fbb88a23315b862_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfNC0yLTEtMS00NzgwMQ_3c9b22a4-2d49-4d57-b112-ab477e59b61d">231,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbbf1f4395c847e88fbb88a23315b862_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfNC00LTEtMS00NzgwMQ_f3942ca8-d991-40a4-a950-6692ff753dcd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifbbf1f4395c847e88fbb88a23315b862_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfNC02LTEtMS00NzgwMQ_dcd87cff-e9ba-4bd3-8824-2d2bea7d4724">469</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbbf1f4395c847e88fbb88a23315b862_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfNC04LTEtMS00NzgwMQ_66f58a5a-9054-4dc5-bda1-904130147eb8">230,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non- U.S Government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibadaba53276e46a791964bbdd74a640d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfNS0yLTEtMS00NzgwMQ_02515649-3cf0-4bcb-b1ac-10b2c00b6781">17,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibadaba53276e46a791964bbdd74a640d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfNS00LTEtMS00NzgwMQ_589e5a9d-0640-49c7-a78b-16ef89062185">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibadaba53276e46a791964bbdd74a640d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfNS02LTEtMS00NzgwMQ_28c46523-2bd5-4cc6-98bd-683f9a215ab1">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibadaba53276e46a791964bbdd74a640d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfNS04LTEtMS00NzgwMQ_86ea875e-a8f5-48e4-9ebf-693ac30299d2">17,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4820381fb1924e4b8f10130527b2a041_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfNi0yLTEtMS00NzgwMQ_e6c8db08-683e-4eff-9849-7781519ca0ff">282,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4820381fb1924e4b8f10130527b2a041_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfNi00LTEtMS00NzgwMQ_708489d0-7f39-48c6-86db-0ad1598e457b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4820381fb1924e4b8f10130527b2a041_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfNi02LTEtMS00NzgwMQ_e207ed1e-bea6-428d-a345-22114f7d428f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4820381fb1924e4b8f10130527b2a041_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfNi04LTEtMS00NzgwMQ_568d146a-1575-4eec-be7c-f7b5f40e8ab7">282,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfNy0yLTEtMS00NzgwMQ_f418baec-9612-4188-be1d-40f351b99517">622,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfNy00LTEtMS00NzgwMQ_c38e0246-9a8b-4c88-88cc-f4194c44c2d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfNy02LTEtMS00NzgwMQ_c937fdc3-9bb7-4e68-8db1-c8a3f780dc04">620</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfNy04LTEtMS00NzgwMQ_4b81bff2-1e69-4cd1-9c9d-f851da9ad0bd">622,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, <ix:nonFraction unitRef="security" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RleHRyZWdpb246MmY1MTI5Mjc5OGYzNGYzNzhmZGQ5NjI5NTBiMDIyMTVfMTI5_90e50ecc-3762-490b-a018-030b742e6927">6</ix:nonFraction> available-for-sale marketable securities with a fair market value of $<ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RleHRyZWdpb246MmY1MTI5Mjc5OGYzNGYzNzhmZGQ5NjI5NTBiMDIyMTVfMjAx_2be437e3-8246-4a00-b4d4-e6aa8ab7adf1">118.4</ix:nonFraction> million were in a gross unrealized loss position of $<ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RleHRyZWdpb246MmY1MTI5Mjc5OGYzNGYzNzhmZGQ5NjI5NTBiMDIyMTVfMjQ4_78861cce-7d03-40d4-b060-c59f1a3bbd64">2.0</ix:nonFraction> million. Based on our review of these marketable securities, we believe <ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RleHRyZWdpb246MmY1MTI5Mjc5OGYzNGYzNzhmZGQ5NjI5NTBiMDIyMTVfMzE1_e1a16560-c982-4920-ae3d-e3fb5a54924a">none</ix:nonFraction> of the unrealized loss is as a result of a credit loss as of&#160;June&#160;30, 2022, because we do not intend to sell these securities and it is not more-likely-than-not that we will be required to sell these securities before the recovery of their amortized cost basis.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of our c<ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RleHRyZWdpb246MmY1MTI5Mjc5OGYzNGYzNzhmZGQ5NjI5NTBiMDIyMTVfMTAyNw_0617675f-c1d5-423c-8464-6ffaa9c61b1f" continuedAt="i48633fd0b3e34a659490529ef94b8502" escape="true">ontractual maturities of available-for-sale debt securities are as follows (in thousands):</ix:nonNumeric></span></div><div style="margin-top:11pt;text-align:center;text-indent:22.5pt"><ix:continuation id="i48633fd0b3e34a659490529ef94b8502"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:67.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.063%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjkxZTEwNThiNGIwMDRiNzY5MDJmMGI4NDM2OTY3ZjIxL3RhYmxlcmFuZ2U6OTFlMTA1OGI0YjAwNGI3NjkwMmYwYjg0MzY5NjdmMjFfMi0yLTEtMS00NzgwMQ_1ebddc84-9026-4287-8101-f0ef3941b268">118,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjkxZTEwNThiNGIwMDRiNzY5MDJmMGI4NDM2OTY3ZjIxL3RhYmxlcmFuZ2U6OTFlMTA1OGI0YjAwNGI3NjkwMmYwYjg0MzY5NjdmMjFfMi00LTEtMS00NzgwMQ_ccc74c9e-6142-4a71-a1e0-b9e80fafaa8e">500,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one but within five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjkxZTEwNThiNGIwMDRiNzY5MDJmMGI4NDM2OTY3ZjIxL3RhYmxlcmFuZ2U6OTFlMTA1OGI0YjAwNGI3NjkwMmYwYjg0MzY5NjdmMjFfMy0yLTEtMS00NzgwMQ_5a24aecb-7593-4af9-929e-0c0ef309aab4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjkxZTEwNThiNGIwMDRiNzY5MDJmMGI4NDM2OTY3ZjIxL3RhYmxlcmFuZ2U6OTFlMTA1OGI0YjAwNGI3NjkwMmYwYjg0MzY5NjdmMjFfMy00LTEtMS00NzgwMQ_4bdfcecc-f345-45f5-9a0e-6832c4cc1d9e">121,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjkxZTEwNThiNGIwMDRiNzY5MDJmMGI4NDM2OTY3ZjIxL3RhYmxlcmFuZ2U6OTFlMTA1OGI0YjAwNGI3NjkwMmYwYjg0MzY5NjdmMjFfNC0yLTEtMS00NzgwMQ_961b6e4e-ca40-4ccd-9298-90362ce66a0a">118,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjkxZTEwNThiNGIwMDRiNzY5MDJmMGI4NDM2OTY3ZjIxL3RhYmxlcmFuZ2U6OTFlMTA1OGI0YjAwNGI3NjkwMmYwYjg0MzY5NjdmMjFfNC00LTEtMS00NzgwMQ_c359452f-c277-465f-b806-064afea99a7f">622,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1797cdae13554ebab8d0b858e0424522"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RleHRyZWdpb246MmY1MTI5Mjc5OGYzNGYzNzhmZGQ5NjI5NTBiMDIyMTVfMTA0NQ_f3ae2225-2767-4faa-8e2c-7b727da54b32" continuedAt="i4cd68ae5f1744237beb39db00a459f4e" escape="true">The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:4.5pt"><ix:continuation id="i4cd68ae5f1744237beb39db00a459f4e"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"></td><td style="width:29.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.329%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.329%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.967%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.329%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.329%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.337%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total estimated fair value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total estimated fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7582cec4a13c42d3948f9997e4a05ea2_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMy0yLTEtMS00NzgwMQ_4d5eb49c-f5e6-4001-87c8-aadc9c2a42c8">70,843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524d67132d7a47e18cfb74ff6a106bd6_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMy00LTEtMS00NzgwMQ_daa98bd3-0d10-4156-95e1-1258fbc6c03c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d8fc069e3434518b16ab9ff92f7ac83_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMy02LTEtMS00NzgwMQ_56c59dd8-3aa0-4393-a85d-5f9e12e19867">70,843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib35f4ff4fd844014ad607bcd93940767_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMy04LTEtMS00NzgwMQ_7f1ae9b9-d3d6-4f60-b314-5e9a75d59fe1">118,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ee73d0afc54dd4af894979a2e3d955_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMy0xMC0xLTEtNDc4MDE_3896b370-239c-4943-af95-2612dae4ab37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70626fa06a394bfb9bd482b2edc20c84_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMy0xMi0xLTEtNDc4MDE_2dfb58de-a769-4603-96f3-05c99dd1758c">118,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i394b8f9cfd4246c9ad0423ab43c011ee_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfNC0yLTEtMS00NzgwMQ_52fd60eb-0c60-492f-ab42-8d6584f8512a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b150997591648f4bb1e80dcf1a1016c_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfNC00LTEtMS00NzgwMQ_f6c53fbe-90ff-4945-805e-7e8606dee674">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b00c3afda9e45bb8cd0405f8b5f14a0_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfNC02LTEtMS00NzgwMQ_94ab7971-d6ab-4409-acdd-7820ce464156">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib42d2c1ec2894fec8370868a75e097f5_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfNC04LTEtMS00NzgwMQ_c7db4b04-bb2b-402d-bc0c-597ce41a7dcd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b3fe709b3f74022a916820d6a66f819_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfNC0xMC0xLTEtNDc4MDE_5a473f42-005d-48d0-8e26-f8f20c9688a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30d3e114033048b4bf56fe57daa86654_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfNC0xMi0xLTEtNDc4MDE_e5868000-e66a-4cac-b031-48c6c665393a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:20pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale marketable <br/>&#160;&#160;&#160;securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaff254b4c0d8405ba942acab54575f2f_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfNy0yLTEtMS00NzgwMQ_f1b80947-de07-4d30-9bae-fff86b63b35e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8485788d2894891ac3dbdffaa1a04f6_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfNy00LTEtMS00NzgwMQ_693a00a2-9c60-4063-bf82-42a1f8d2d6c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fc34bcf05bf42a1ad015e84425c8d0d_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfNy02LTEtMS00NzgwMQ_22a3b83b-b923-49cd-b00f-a3a623543ac6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35bedd3b896a45e6bef76a745aea55b8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfNy04LTEtMS00NzgwMQ_74fc0c85-9dfc-4025-ba19-e92670cab1bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6f16378a34f47e5bc64f9f37e501985_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfNy0xMC0xLTEtNDc4MDE_73a16cd4-ed3a-4820-aa12-5d70bc6cd4da">32,692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3327c7ae03814e5b98e511ab356d1e06_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfNy0xMi0xLTEtNDc4MDE_db6047f4-27e6-4acd-8109-be7a411cdae2">32,692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8679bef0769643ff80b9deb03b454f3e_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfOC0yLTEtMS00NzgwMQ_ddb9546a-1c6e-432c-b08f-78f2681d570c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf47bb6ce3e3440e8d32edd5fa5d2a77_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfOC00LTEtMS00NzgwMQ_e918c689-27fc-43ed-acc8-871ac92a9ac0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i919614e2dc9744fea40ea36e3bad8795_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfOC02LTEtMS00NzgwMQ_a738eba0-7b5d-41dc-8d51-d1ca02863d0f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce27062172c4df39f203c5fbbcda25d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfOC04LTEtMS00NzgwMQ_e028cefe-1372-4c32-b884-98cf2987d5f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0355f361557b4963951d67530b3f33a4_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfOC0xMC0xLTEtNDc4MDE_b06636f4-11e6-4837-b7f1-d2f747687e87">58,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6a49dbb96ea4e068ffae31a73e0450d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfOC0xMi0xLTEtNDc4MDE_03a28906-2f52-494c-ba21-913a6c86336e">58,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0a3288eab784be19fb61c3da624b2ce_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfOS0yLTEtMS00NzgwMQ_6f2eb51b-3930-4f54-bfe1-61bc04d6e510">118,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f6abf3fb844711ba56aa80aa191fde_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfOS00LTEtMS00NzgwMQ_d85571db-0795-49aa-9b87-e9024bc7703a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02b96f8f266746e5bef1a7a56d0020d7_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfOS02LTEtMS00NzgwMQ_dd686fec-e548-494d-8449-903e7c85755e">118,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fb4248efc9c4394903dd84bafe5032c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfOS04LTEtMS00NzgwMQ_d1d2bd28-cf19-4e15-9186-f653bb3158ae">230,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf3f9180d2d54718b7d17a4b462cd60f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfOS0xMC0xLTEtNDc4MDE_1c2b7073-083c-4dc3-bc4a-776d97e4d909">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbbf1f4395c847e88fbb88a23315b862_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfOS0xMi0xLTEtNDc4MDE_dcab0701-ada6-4aeb-842c-09cd63b101e4">230,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-US Government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i797d735ce11e40a3a597d7b067205876_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMTAtMi0xLTEtNDc4MDE_e3956dcc-82f2-44c1-a784-3584be54751f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c825fe74c2e4db9a79927b3f36b3b4b_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMTAtNC0xLTEtNDc4MDE_52939578-5c1b-4850-a6f4-98047ab26d46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3ddca14e94e4ee7bc84deba437d724a_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMTAtNi0xLTEtNDc4MDE_e4bd090d-3c67-400d-a078-f31c490a15bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied28f46dba994350bcda53f1634bf3dd_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMTAtOC0xLTEtNDc4MDE_188d16a6-105f-49b0-a88c-a76b8fd44870">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1965c9e97674996b395dc7e83265e6e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMTAtMTAtMS0xLTQ3ODAx_1f31c94a-8098-4ae6-af78-cc7ff00b18e2">17,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41ce1d46c93d4d23a5dcc7490d03b394_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMTAtMTItMS0xLTQ3ODAx_276e9cc2-1bec-4659-9355-a38c137f58b6">17,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d7cfdf4a9444c87946ea6f8f8104d55_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMTEtMi0xLTEtNDc4MDE_7f09869e-6592-4712-890d-414c347974f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbee317a1c93450289e3face1229333c_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMTEtNC0xLTEtNDc4MDE_9e0b8525-5ed0-407c-bf8f-02ec3b94a6d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i729eff0e2b1b45abacd1da9f077ac641_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMTEtNi0xLTEtNDc4MDE_45e47f50-6710-4d1c-bf7b-bc1c418de7ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35a6d850025546848755145a7abf15b7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMTEtOC0xLTEtNDc4MDE_bd9d4ae0-1c51-49d4-befc-a11d44e22aba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8114c060d9e745e0ad9ea5a8ccb12e9b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMTEtMTAtMS0xLTQ3ODAx_dac8b604-ae03-4382-929f-8331123cd0ca">282,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4820381fb1924e4b8f10130527b2a041_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMTEtMTItMS0xLTQ3ODAx_b0c9d618-73da-40da-a464-76d44018f02f">282,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73361786868247609ad6e713642b4441_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMTItMi0xLTEtNDc4MDE_c5450450-68b8-4a6e-a5a3-185aa8383a80">189,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18df9e45de3648af8edb0ce21a72898c_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMTItNC0xLTEtNDc4MDE_06a45108-fb42-40dd-a0c2-baa93fd1713c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMTItNi0xLTEtNDc4MDE_f668b883-88d1-4249-81e4-4a0cf995f738">189,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6fcbc87cdee4fccae17a9f9a6e02d05_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMTItOC0xLTEtNDc4MDE_6f10b4ab-3d2c-4d93-8f55-687797063337">349,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41ae64b0863d43efb250b560920603c1_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMTItMTAtMS0xLTQ3ODAx_80bede3d-0af6-4907-9563-3fca89e1bdcf">391,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMTItMTItMS0xLTQ3ODAx_3e6d29dc-6c73-4ed5-b477-5d9173cdcb30">740,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had <ix:nonFraction unitRef="usd" contextRef="ic37ed5614087440da569f079f0f651bd_I20211231" decimals="INF" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RleHRyZWdpb246MmY1MTI5Mjc5OGYzNGYzNzhmZGQ5NjI5NTBiMDIyMTVfOTQ5_8f9b3722-99a7-4d8f-99ba-eb1051f835f5"><ix:nonFraction unitRef="usd" contextRef="ia715fa809717495ca3ea42208886f693_I20220630" decimals="INF" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RleHRyZWdpb246MmY1MTI5Mjc5OGYzNGYzNzhmZGQ5NjI5NTBiMDIyMTVfOTQ5_aa29295a-fb8a-4030-9fc8-684a44b316d1">no</ix:nonFraction></ix:nonFraction> available for sale securities that were classified within Level 3 as of June&#160;30, 2022 and December&#160;31, 2021.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A contingent liability with a preliminary value of $<ix:nonFraction unitRef="usd" contextRef="i1e07b7230a7b4293910918c1158913a7_I20220524" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RleHRyZWdpb246MmY1MTI5Mjc5OGYzNGYzNzhmZGQ5NjI5NTBiMDIyMTVfMTkyNDE0NTM0OTM3OTY_3147a3b8-d61d-48f2-ba95-ba0c35bd5a5e">130.0</ix:nonFraction>&#160;million was assumed related to TLANDO. The acquisition date fair value was measured using the income approach, specifically the probability weighted expected return method for the development milestone payments and the option pricing methodology using the Monte Carlo simulation for commercial milestone payments and royalty payments. We will remeasure the fair value of  the contingent liability on a quarterly basis. Estimates and assumptions used in the Monte Carlo simulation include forecasted revenues, cost of debt, risk free rate, weighted average cost of capital, revenue market price risk and revenue volatility. Estimates and assumptions used in the income approach include the probability of achieving certain milestones and a discount rate. These unobservable inputs represent a Level 3 measurement because they are supported by little or no market activity and reflect our own assumptions in measuring fair value. Changes in the fair value subsequent to the acquisition date will be recognized in our consolidated statements of income.</span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="ibd09c52bdc03451493df7fb7077280c7_55"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RleHRyZWdpb246OTQzNTc4NTJkNzlkNGViYTg5YTU4YjM2Y2MyMWJhZjZfMTY1Mw_3f4e9a67-3f08-4f5f-9a2b-6632e7e4fdb8" continuedAt="ib910f0edf8e94376a433b7943907081c" escape="true">Revenue</ix:nonNumeric></span></div><ix:continuation id="ib910f0edf8e94376a433b7943907081c" continuedAt="i8e66cde9fce5464c89bf0a283a0384fb"><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RleHRyZWdpb246OTQzNTc4NTJkNzlkNGViYTg5YTU4YjM2Y2MyMWJhZjZfMTYzNg_12d6913b-f22d-4e19-acb0-07a634bd7333" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our disaggregated revenues were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"><tr><td style="width:1.0%"></td><td style="width:58.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.179%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2302c2baba3a4084b1cd7169564a4517_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMi0yLTEtMS00NzgwMQ_6b6d87a8-114d-4579-b9a5-bf4dead29f84">85,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifecd7d767a3c48d6a094b68ee21e3340_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMi00LTEtMS00NzgwMQ_c4a726bc-5b94-4901-9ea1-089fae425b9e">45,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i488611ceda1e4bf3a1df6ada966c72ff_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMi02LTEtMS00NzgwMQ_e1be3e19-2395-4fef-bf1b-a438e198fac0">154,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie448ea4ebc7a4047b9528cc3d06dac35_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMi04LTEtMS00NzgwMQ_9ee2d6bc-59cc-4143-b19c-6b55af7abd5d">82,701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Sales of bulk rHuPH20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30cb808ae8294ad2963b8d25bd8ddd70_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfNS0yLTEtMS00NzgwMQ_9c44a031-e9c2-4ff4-a997-c83cad11cccb">25,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5ac7dbc74fd416bba2eecdc24f27658_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfNS00LTEtMS00NzgwMQ_9c3b4371-275e-411a-a007-7280f483f51f">24,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61902b5268704612925502d224a5f0dc_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfNS02LTEtMS00NzgwMQ_e3f0b061-ccf5-44c3-9f90-30c024270b16">41,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1581eb1b56a4683bd3a80a5ce16e03c_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfNS04LTEtMS00NzgwMQ_9c52c362-23ae-4eab-bfaf-2314c2b890d1">40,857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of proprietary products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5576b7ccca364865ba7aae184bb4cf37_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfNy0yLTEtMS01MDQwMQ_f9693459-85db-46d0-9107-1667e66cc330">14,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b180128f3634ec092ab2d598df56185_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfNy00LTEtMS01MDQxMA_17b737bf-c5a4-4569-9451-8b96721477ba">6,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727ff9da39cc4faab1ee412cb6667251_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfNy02LTEtMS01MDQxNw_b17c9e38-7a41-457e-9431-dd8edf542cf5">20,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c83d19f90094700a1790868f713787d_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfNy04LTEtMS01MDQyNA_c8e917d8-c2e2-4e92-b549-0b2fff9e8bf2">11,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of device partnered products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b1f6429290349caa513971198a9d7f3_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfOC0yLTEtMS01MDQwMQ_04ed64f6-46ab-4ce6-9eb8-d420c261f9fb">6,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc79e0e6fcd45f7baf4dc4675fdb639_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfOC00LTEtMS01MDQxMA_95052b07-f219-4aff-8a5d-56f7481ad2f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic38072713d2a499bb6a5b530797ec390_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfOC02LTEtMS01MDQxNw_6812a8b1-c73d-4cfd-acda-9d1562b9bf8d">6,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idff30f1d38214c3cbaa6aa448432d11c_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfOC04LTEtMS01MDQyNA_b80761bd-fca9-402c-ae5b-1d99461ff5a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefbbc65edf2e4319adad4df5fa76e1f3_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfOC0yLTEtMS00NzgwMQ_3b06f73c-e305-46e6-ab36-c01ec6c0e968">46,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9220796b173a4a9298008c86f02bacf1_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfOC00LTEtMS00NzgwMQ_91c8bede-e58d-4a23-84c6-b8d85969ceeb">30,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5cfeb9eb65745ed9779cd8409a1de20_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfOC02LTEtMS00NzgwMQ_6747d499-7b27-493b-9302-806f039a1e1c">68,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d0fdcb3db8c45fdb97bc693b3691d65_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfOC04LTEtMS00NzgwMQ_4b89caf7-98b0-4673-b4bf-678c563e9890">52,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues under collaborative agreements:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Upfront license and target nomination fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c4e1c2852834e3db83be2ab724c4ec7_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTEtMi0xLTEtNDc4MDE_f9fbb4a9-3533-4810-9076-83c25807d2fb">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b169ddfeec745d1be5c150f76f1b9ce_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTEtNC0xLTEtNDc4MDE_c9c679de-0023-40aa-a3e4-b1ca97897b52">40,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99a3d7ca0084d3c8ad32c30e53803ca_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTEtNi0xLTEtNDc4MDE_2ce4f1c3-7adf-4408-ba59-cfbcdf95361e">30,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29bf66c271ba4ae7987ec7bd8ff4520f_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTEtOC0xLTEtNDc4MDE_69d5fa85-b1c9-4919-83df-5f55dff88dde">40,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Event-based development and regulatory milestones and other fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68f176f459d54d48893f0655ba31ec14_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTItMi0xLTEtNDc4MDE_6ebd0a4c-8f2c-4a9c-a060-852aa3d091c8">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i044be8133aeb4fe6a48b3663a56504bc_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTItNC0xLTEtNDc4MDE_2676ee92-d7b0-47d2-9c99-bcef5c705df8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i120c080d9b5a4f57b9e656994552257c_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTItNi0xLTEtNDc4MDE_b84f1571-af10-4409-a5ec-5dd2eeb37c8a">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaf7a7f2b9314cabb0bba3ca0238fc37_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTItOC0xLTEtNDc4MDE_2aaeb3f2-db34-44ee-bbc0-57066dfb5ef5">30,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Sales-based milestones</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667bd7d9d0494b2f898d65a0be893385_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTMtMi0xLTEtNDc4MDE_dc193bce-edd9-4984-b7f4-590b8ae7b317">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4f91bfe396b4e2fabebbdcc9ab97e9a_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTMtNC0xLTEtNDc4MDE_aabd0cbc-b993-4dbf-98ac-78705dcc00e5">20,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0177b2094d7a422a923115b1b3b4755d_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTMtNi0xLTEtNDc4MDE_dadb2e6e-cee8-4e23-b98f-b9506214a220">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b98cb4091434500999a3bd53a43e318_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTMtOC0xLTEtNDc4MDE_27ab215c-10e7-4ba1-ad5a-6baf4150e735">20,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Device Licensing and development revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id036393f1ef94ab59c494be346f81453_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTQtMi0xLTEtNDc4MDE_89778ddb-0ba5-4e57-ad1b-75018e2b9e14">725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2c6a315d3c94850a81a0adb2158a25b_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTQtNC0xLTEtNDc4MDE_453ce1f9-d79a-47a1-9823-f846ecab2204">317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i889d129efa02476986931ae8af732baa_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTQtNi0xLTEtNDc4MDE_5b1820cb-3d80-4d3b-be14-63e7c4a60557">1,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8770b425828c4e6cadb0c28e912fc453_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTQtOC0xLTEtNDc4MDE_20bca2fb-630a-494f-8ac7-72811ba85227">650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues under collaborative agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5331ecfa85164578966f7ba36c8377ac_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTUtMi0xLTEtNDc4MDE_c943e45b-811a-4688-9daa-c2826c0c6a22">20,725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88e4277b0c454a79a9c899981c6d0ade_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTUtNC0xLTEtNDc4MDE_9517dc92-197a-44d3-ada5-1a2fdbfeda62">60,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if13d9aa4327240bcaf9417558eeae8c3_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTUtNi0xLTEtNDc4MDE_3b98206c-8bf8-4231-82f6-d57283650ccc">46,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic72a2d641a084db2bfd8a448fdafa5bb_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTUtOC0xLTEtNDc4MDE_c983fe36-355a-42aa-a64b-33c64fc573ab">90,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTctMi0xLTEtNDc4MDE_c1741f49-12e0-4adf-a9f4-6c9440fff173">152,365</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTctNC0xLTEtNDc4MDE_fddcd0a2-a55f-4169-9cde-cbc72d4835d7">136,455</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTctNi0xLTEtNDc4MDE_e1be95a9-e03b-4168-9189-13a8751a3555">269,644</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTctOC0xLTEtNDc4MDE_170941de-996b-4dec-bf99-c1020128131a">225,477</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June&#160;30, 2022 we recognized revenue related to licenses granted to partners in prior periods in the amount of $<ix:nonFraction unitRef="usd" contextRef="iffcd168ae7a94e5db1b32f7feb3a8b62_D20220401-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RleHRyZWdpb246OTQzNTc4NTJkNzlkNGViYTg5YTU4YjM2Y2MyMWJhZjZfMjE3_957cfccc-3f15-4022-bd76-89628a748aa4">100.3</ix:nonFraction> million. This amount represents royalties earned in the current period in addition to $<ix:nonFraction unitRef="usd" contextRef="i68f176f459d54d48893f0655ba31ec14_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RleHRyZWdpb246OTQzNTc4NTJkNzlkNGViYTg5YTU4YjM2Y2MyMWJhZjZfMTA5OTUxMTYyOTk0Ng_6ebd0a4c-8f2c-4a9c-a060-852aa3d091c8">15.0</ix:nonFraction> million of variable consideration in the contracts where uncertainties have been resolved and the development milestones were expected to be achieved or were achieved. We also recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RleHRyZWdpb246OTQzNTc4NTJkNzlkNGViYTg5YTU4YjM2Y2MyMWJhZjZfMzE0_2a8be76b-3164-40d4-be1e-d06a9b1b7294">0.5</ix:nonFraction> million during the three months ended June&#160;30, 2022 that had been included in deferred revenues at December&#160;31, 2021. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2022 we recognized revenue related to licenses granted to partners in prior periods in the amount of $<ix:nonFraction unitRef="usd" contextRef="ice04128a0ca3439cae58ae72f295f29f_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RleHRyZWdpb246OTQzNTc4NTJkNzlkNGViYTg5YTU4YjM2Y2MyMWJhZjZfMTA5OTUxMTYyOTkxMA_7438bf71-b4eb-4b45-86c3-df05739fda18">169.9</ix:nonFraction> million. This amount represents royalties earned in the current period in addition to $<ix:nonFraction unitRef="usd" contextRef="i120c080d9b5a4f57b9e656994552257c_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RleHRyZWdpb246OTQzNTc4NTJkNzlkNGViYTg5YTU4YjM2Y2MyMWJhZjZfMTA5OTUxMTYzMTg0OA_b84f1571-af10-4409-a5ec-5dd2eeb37c8a">15.0</ix:nonFraction> million of variable consideration.in the contracts where uncertainties have been resolved and the development milestones were expected to be achieved or were achieved. We also recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RleHRyZWdpb246OTQzNTc4NTJkNzlkNGViYTg5YTU4YjM2Y2MyMWJhZjZfMTA5OTUxMTYzMTg1Ng_7c445da8-1357-49bc-b925-7b510e04b352">1.0</ix:nonFraction> million during the six months ended June&#160;30, 2022 that had been included in deferred revenues at December&#160;31, 2021. We did not recognize any adjustments to reduce sales reserves and allowances liability related to Hylenex recombinant sales in prior periods</span></div><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RleHRyZWdpb246OTQzNTc4NTJkNzlkNGViYTg5YTU4YjM2Y2MyMWJhZjZfMTY0Mw_44d3c292-0764-4998-a15b-0a5a0d5c336c" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net, and deferred revenues (contract liabilities) from contracts with customers, including partners, consisted of the following (in thousands): </span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"></td><td style="width:76.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.176%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.065%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="halo:AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOmFjZTc1MGQ4NDI2MjQyY2ZiNDA0ZWJmODIzNTA5M2NmL3RhYmxlcmFuZ2U6YWNlNzUwZDg0MjYyNDJjZmI0MDRlYmY4MjM1MDkzY2ZfMS0yLTEtMS00NzgwMQ_9d775e62-0303-4a27-8129-097f4ed01800">169,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="halo:AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOmFjZTc1MGQ4NDI2MjQyY2ZiNDA0ZWJmODIzNTA5M2NmL3RhYmxlcmFuZ2U6YWNlNzUwZDg0MjYyNDJjZmI0MDRlYmY4MjM1MDkzY2ZfMS00LTEtMS00NzgwMQ_cdc20857-4c70-4315-9d3e-0abcf6f04fa3">90,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOmFjZTc1MGQ4NDI2MjQyY2ZiNDA0ZWJmODIzNTA5M2NmL3RhYmxlcmFuZ2U6YWNlNzUwZDg0MjYyNDJjZmI0MDRlYmY4MjM1MDkzY2ZfMi0yLTEtMS00NzgwMQ_ce3388fd-ae8f-41e3-8821-2e4a33671586">19,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOmFjZTc1MGQ4NDI2MjQyY2ZiNDA0ZWJmODIzNTA5M2NmL3RhYmxlcmFuZ2U6YWNlNzUwZDg0MjYyNDJjZmI0MDRlYmY4MjM1MDkzY2ZfMi00LTEtMS00NzgwMQ_32a0ba7c-6b25-4d85-81c9-7c41202f90f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:DeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOmFjZTc1MGQ4NDI2MjQyY2ZiNDA0ZWJmODIzNTA5M2NmL3RhYmxlcmFuZ2U6YWNlNzUwZDg0MjYyNDJjZmI0MDRlYmY4MjM1MDkzY2ZfMy0yLTEtMS00NzgwMQ_68f17dda-3d26-4a93-80e7-387d9912acff">6,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:DeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOmFjZTc1MGQ4NDI2MjQyY2ZiNDA0ZWJmODIzNTA5M2NmL3RhYmxlcmFuZ2U6YWNlNzUwZDg0MjYyNDJjZmI0MDRlYmY4MjM1MDkzY2ZfMy00LTEtMS00NzgwMQ_50a40147-33e8-4f38-a400-d352f311d528">4,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the amounts included in the transaction price of our contracts with customers and allocated to goods and services not yet provided were $<ix:nonFraction unitRef="usd" contextRef="i1ce4ecc3d70b49ab961fee2475a6ee4e_I20220630" decimals="-5" name="us-gaap:DeferredRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RleHRyZWdpb246OTQzNTc4NTJkNzlkNGViYTg5YTU4YjM2Y2MyMWJhZjZfOTAz_ba5f40fd-c602-473a-82d1-4be9e2b6187f">68.1</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="i065c6dc939e647029141b2829def68d5_I20220630" decimals="-5" name="us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RleHRyZWdpb246OTQzNTc4NTJkNzlkNGViYTg5YTU4YjM2Y2MyMWJhZjZfOTE2_83e19b2f-77ed-4a79-8cc0-852dabcbbe70">61.2</ix:nonFraction> million relates to unfulfilled purchase commitments and $<ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-5" name="us-gaap:DeferredCreditsAndOtherLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RleHRyZWdpb246OTQzNTc4NTJkNzlkNGViYTg5YTU4YjM2Y2MyMWJhZjZfOTY3_a0f2291f-b344-4526-bdac-a8e4ed22105f">6.9</ix:nonFraction> million has been collected and is reported as deferred revenues. The unfulfilled purchase commitments are estimated to be delivered by the end of 2023. Of the total deferred revenues of $<ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-5" name="us-gaap:DeferredCreditsAndOtherLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RleHRyZWdpb246OTQzNTc4NTJkNzlkNGViYTg5YTU4YjM2Y2MyMWJhZjZfMTE0OA_a0f2291f-b344-4526-bdac-a8e4ed22105f">6.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i70ed32619a3c450b95acdcb7833975bf_I20220630" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RleHRyZWdpb246OTQzNTc4NTJkNzlkNGViYTg5YTU4YjM2Y2MyMWJhZjZfMTE1Mg_27b897ad-cc21-41d8-ae16-ae253972ac7c">4.1</ix:nonFraction> million is expected to be used by our customers within the next 12 months. </span></div></ix:continuation><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8e66cde9fce5464c89bf0a283a0384fb">We recognized contract assets of $<ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RleHRyZWdpb246OTQzNTc4NTJkNzlkNGViYTg5YTU4YjM2Y2MyMWJhZjZfMTIzNA_f6359586-0d70-4799-8efd-3fd940b55d18">19.8</ix:nonFraction>&#160;million at June&#160;30, 2022, which related to development milestones deemed probable of receipt for intellectual property licenses granted to partners in prior periods</ix:continuation> and for goods or services when control has transferred to the customer, and corresponding revenue is recognized on an over time basis but is not yet billable to the customer in accordance with the terms of the contract.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="ibd09c52bdc03451493df7fb7077280c7_61"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfMTE4Nw_846d0b9a-07cb-4a08-859d-e5dff5acf84c" continuedAt="i688738dc74fe4f3d8902ebbe5bbf42ed" escape="true">Certain Balance Sheet Items</ix:nonNumeric></span></div><ix:continuation id="i688738dc74fe4f3d8902ebbe5bbf42ed" continuedAt="if720e1c14d4142d99ede6691ff10e5aa"><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfMTIwOQ_fb37e134-15fb-4c02-952f-c83ba2390a80" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:68.485%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from product sales to partners</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="halo:Accountsreceivablefromproductsalestocollaborators" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjVlODhmZGFiOTdiNjQ0Y2E4ZTk4OTc2OGNjNTRjMGRkL3RhYmxlcmFuZ2U6NWU4OGZkYWI5N2I2NDRjYThlOTg5NzY4Y2M1NGMwZGRfMS0yLTEtMS00NzgwMQ_3af4c21b-0543-4b80-a6f3-c078d36b50d9">56,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="halo:Accountsreceivablefromproductsalestocollaborators" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjVlODhmZGFiOTdiNjQ0Y2E4ZTk4OTc2OGNjNTRjMGRkL3RhYmxlcmFuZ2U6NWU4OGZkYWI5N2I2NDRjYThlOTg5NzY4Y2M1NGMwZGRfMS00LTEtMS00NzgwMQ_97fa564f-c953-4201-ab75-7035076fd092">18,504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from revenues under collaborative agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="halo:Accountsreceivablefromcollaborators" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjVlODhmZGFiOTdiNjQ0Y2E4ZTk4OTc2OGNjNTRjMGRkL3RhYmxlcmFuZ2U6NWU4OGZkYWI5N2I2NDRjYThlOTg5NzY4Y2M1NGMwZGRfMi0yLTEtMS00NzgwMQ_f091618d-9a40-4f38-940c-9cc1c96cb141">11,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="halo:Accountsreceivablefromcollaborators" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjVlODhmZGFiOTdiNjQ0Y2E4ZTk4OTc2OGNjNTRjMGRkL3RhYmxlcmFuZ2U6NWU4OGZkYWI5N2I2NDRjYThlOTg5NzY4Y2M1NGMwZGRfMi00LTEtMS00NzgwMQ_afdedcdd-18d9-4021-b751-5efbd91bfeb9">5,422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from royalty payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="halo:Accountsreceivablefromroyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjVlODhmZGFiOTdiNjQ0Y2E4ZTk4OTc2OGNjNTRjMGRkL3RhYmxlcmFuZ2U6NWU4OGZkYWI5N2I2NDRjYThlOTg5NzY4Y2M1NGMwZGRfMy0yLTEtMS00NzgwMQ_2e7ad72b-4e0b-4c2d-9ea9-ac4cb4c8506f">87,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="halo:Accountsreceivablefromroyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjVlODhmZGFiOTdiNjQ0Y2E4ZTk4OTc2OGNjNTRjMGRkL3RhYmxlcmFuZ2U6NWU4OGZkYWI5N2I2NDRjYThlOTg5NzY4Y2M1NGMwZGRfMy00LTEtMS00NzgwMQ_eb4b7405-5499-4c0c-9e43-bbbb100b2da4">63,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from other product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="halo:Accountsreceivablefromproductsales" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjVlODhmZGFiOTdiNjQ0Y2E4ZTk4OTc2OGNjNTRjMGRkL3RhYmxlcmFuZ2U6NWU4OGZkYWI5N2I2NDRjYThlOTg5NzY4Y2M1NGMwZGRfNC0yLTEtMS00NzgwMQ_bb303a1f-7630-4923-a6f8-a1e43d54bb47">6,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="halo:Accountsreceivablefromproductsales" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjVlODhmZGFiOTdiNjQ0Y2E4ZTk4OTc2OGNjNTRjMGRkL3RhYmxlcmFuZ2U6NWU4OGZkYWI5N2I2NDRjYThlOTg5NzY4Y2M1NGMwZGRfNC00LTEtMS00NzgwMQ_bdbf7aac-65a4-49f8-9ae3-9e2bb8b5dea4">4,634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:OtherReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjVlODhmZGFiOTdiNjQ0Y2E4ZTk4OTc2OGNjNTRjMGRkL3RhYmxlcmFuZ2U6NWU4OGZkYWI5N2I2NDRjYThlOTg5NzY4Y2M1NGMwZGRfNS0yLTEtMS01ODY4Mw_05e7a4ba-bedc-464b-8c5e-5903c48fc735">9,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:OtherReceivables" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjVlODhmZGFiOTdiNjQ0Y2E4ZTk4OTc2OGNjNTRjMGRkL3RhYmxlcmFuZ2U6NWU4OGZkYWI5N2I2NDRjYThlOTg5NzY4Y2M1NGMwZGRfNS00LTEtMS01ODY5MA_7df1c677-68c5-4c33-a7a8-e75bcdbd2f80">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjVlODhmZGFiOTdiNjQ0Y2E4ZTk4OTc2OGNjNTRjMGRkL3RhYmxlcmFuZ2U6NWU4OGZkYWI5N2I2NDRjYThlOTg5NzY4Y2M1NGMwZGRfNS0yLTEtMS00NzgwMQ_ce3388fd-ae8f-41e3-8821-2e4a33671586">19,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjVlODhmZGFiOTdiNjQ0Y2E4ZTk4OTc2OGNjNTRjMGRkL3RhYmxlcmFuZ2U6NWU4OGZkYWI5N2I2NDRjYThlOTg5NzY4Y2M1NGMwZGRfNS00LTEtMS00NzgwMQ_32a0ba7c-6b25-4d85-81c9-7c41202f90f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:AccountsReceivableGrossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjVlODhmZGFiOTdiNjQ0Y2E4ZTk4OTc2OGNjNTRjMGRkL3RhYmxlcmFuZ2U6NWU4OGZkYWI5N2I2NDRjYThlOTg5NzY4Y2M1NGMwZGRfNi0yLTEtMS00NzgwMQ_a44d7637-4da0-498c-b218-17a06e48457a">191,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:AccountsReceivableGrossCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjVlODhmZGFiOTdiNjQ0Y2E4ZTk4OTc2OGNjNTRjMGRkL3RhYmxlcmFuZ2U6NWU4OGZkYWI5N2I2NDRjYThlOTg5NzY4Y2M1NGMwZGRfNi00LTEtMS00NzgwMQ_952df24b-bc5f-4ee4-a27b-ec2ace313829">92,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for distribution fees and discounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="halo:AllowanceforDistributionFeesandDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjVlODhmZGFiOTdiNjQ0Y2E4ZTk4OTc2OGNjNTRjMGRkL3RhYmxlcmFuZ2U6NWU4OGZkYWI5N2I2NDRjYThlOTg5NzY4Y2M1NGMwZGRfNy0yLTEtMS00NzgwMQ_c1ec1d16-fdaa-49f0-b99f-8221c5c0782f">2,400</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="halo:AllowanceforDistributionFeesandDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjVlODhmZGFiOTdiNjQ0Y2E4ZTk4OTc2OGNjNTRjMGRkL3RhYmxlcmFuZ2U6NWU4OGZkYWI5N2I2NDRjYThlOTg5NzY4Y2M1NGMwZGRfNy00LTEtMS00NzgwMQ_d86ec0e6-1b20-439b-a816-91bc34ee0f9b">1,140</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjVlODhmZGFiOTdiNjQ0Y2E4ZTk4OTc2OGNjNTRjMGRkL3RhYmxlcmFuZ2U6NWU4OGZkYWI5N2I2NDRjYThlOTg5NzY4Y2M1NGMwZGRfOC0yLTEtMS00NzgwMQ_129e0234-fa6d-40e9-9eaa-ee9cc4ea7902">189,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjVlODhmZGFiOTdiNjQ0Y2E4ZTk4OTc2OGNjNTRjMGRkL3RhYmxlcmFuZ2U6NWU4OGZkYWI5N2I2NDRjYThlOTg5NzY4Y2M1NGMwZGRfOC00LTEtMS00NzgwMQ_3a826a02-5b95-4208-834d-9cd18eb07d7f">90,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfMTE5MA_2b258bf0-1100-4bab-99d9-f1e6ab565200" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:68.485%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmM4YzFlYzhmNDVkNjQ2NTQ4ZDE4ZTM1ZGJlMTQxM2I0L3RhYmxlcmFuZ2U6YzhjMWVjOGY0NWQ2NDY1NDhkMThlMzVkYmUxNDEzYjRfMS0yLTEtMS00NzgwMQ_f9027114-f5db-478d-a341-9f29cb745caf">10,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmM4YzFlYzhmNDVkNjQ2NTQ4ZDE4ZTM1ZGJlMTQxM2I0L3RhYmxlcmFuZ2U6YzhjMWVjOGY0NWQ2NDY1NDhkMThlMzVkYmUxNDEzYjRfMS00LTEtMS00NzgwMQ_bec0ee16-22cd-464f-b4df-0a8f90bee447">10,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmM4YzFlYzhmNDVkNjQ2NTQ4ZDE4ZTM1ZGJlMTQxM2I0L3RhYmxlcmFuZ2U6YzhjMWVjOGY0NWQ2NDY1NDhkMThlMzVkYmUxNDEzYjRfMi0yLTEtMS00NzgwMQ_6a5755db-e3d1-4039-b3b0-8085673506ee">44,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmM4YzFlYzhmNDVkNjQ2NTQ4ZDE4ZTM1ZGJlMTQxM2I0L3RhYmxlcmFuZ2U6YzhjMWVjOGY0NWQ2NDY1NDhkMThlMzVkYmUxNDEzYjRfMi00LTEtMS00NzgwMQ_d37dad60-7ed5-48d6-bced-200e4e68b928">17,451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmM4YzFlYzhmNDVkNjQ2NTQ4ZDE4ZTM1ZGJlMTQxM2I0L3RhYmxlcmFuZ2U6YzhjMWVjOGY0NWQ2NDY1NDhkMThlMzVkYmUxNDEzYjRfMy0yLTEtMS00NzgwMQ_71823a67-4632-4bda-9ccc-ca11d0dd90d5">43,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmM4YzFlYzhmNDVkNjQ2NTQ4ZDE4ZTM1ZGJlMTQxM2I0L3RhYmxlcmFuZ2U6YzhjMWVjOGY0NWQ2NDY1NDhkMThlMzVkYmUxNDEzYjRfMy00LTEtMS00NzgwMQ_a7aa23af-dac5-457a-9161-68b71f344f0f">25,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmM4YzFlYzhmNDVkNjQ2NTQ4ZDE4ZTM1ZGJlMTQxM2I0L3RhYmxlcmFuZ2U6YzhjMWVjOGY0NWQ2NDY1NDhkMThlMzVkYmUxNDEzYjRfNC0yLTEtMS00NzgwMQ_aaba38a7-ee56-420c-8bfc-280c27698ffa">97,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmM4YzFlYzhmNDVkNjQ2NTQ4ZDE4ZTM1ZGJlMTQxM2I0L3RhYmxlcmFuZ2U6YzhjMWVjOGY0NWQ2NDY1NDhkMThlMzVkYmUxNDEzYjRfNC00LTEtMS00NzgwMQ_b89ef4d8-509e-43cd-a8fa-2a7deb819612">53,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:ScheduleOfOtherAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfMTIyMQ_ad03e946-08d0-4a9c-b016-c16d1c544099" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:68.485%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid manufacturing expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjBjNzE3MDFlYTllZDQ2M2RiMmMyNjcxNWQxOWM5ODY4L3RhYmxlcmFuZ2U6MGM3MTcwMWVhOWVkNDYzZGIyYzI2NzE1ZDE5Yzk4NjhfMS0yLTEtMS00NzgwMQ_e0bd5b68-d14a-4b19-973f-da8283f6a105">50,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjBjNzE3MDFlYTllZDQ2M2RiMmMyNjcxNWQxOWM5ODY4L3RhYmxlcmFuZ2U6MGM3MTcwMWVhOWVkNDYzZGIyYzI2NzE1ZDE5Yzk4NjhfMS00LTEtMS00NzgwMQ_80f8f307-cfcf-4a70-8b72-a70762228e43">47,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjBjNzE3MDFlYTllZDQ2M2RiMmMyNjcxNWQxOWM5ODY4L3RhYmxlcmFuZ2U6MGM3MTcwMWVhOWVkNDYzZGIyYzI2NzE1ZDE5Yzk4NjhfMy0yLTEtMS00NzgwMQ_141d6b9f-237d-42fc-ad2d-539cb8b51085">14,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjBjNzE3MDFlYTllZDQ2M2RiMmMyNjcxNWQxOWM5ODY4L3RhYmxlcmFuZ2U6MGM3MTcwMWVhOWVkNDYzZGIyYzI2NzE1ZDE5Yzk4NjhfMy00LTEtMS00NzgwMQ_c3d97db6-17c4-4648-a6f2-e411c335a15d">3,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:OtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjBjNzE3MDFlYTllZDQ2M2RiMmMyNjcxNWQxOWM5ODY4L3RhYmxlcmFuZ2U6MGM3MTcwMWVhOWVkNDYzZGIyYzI2NzE1ZDE5Yzk4NjhfNC0yLTEtMS00NzgwMQ_aae3a854-4902-4362-94f3-2eddf93c50a8">6,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:OtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjBjNzE3MDFlYTllZDQ2M2RiMmMyNjcxNWQxOWM5ODY4L3RhYmxlcmFuZ2U6MGM3MTcwMWVhOWVkNDYzZGIyYzI2NzE1ZDE5Yzk4NjhfNC00LTEtMS00NzgwMQ_43e48f08-3d98-49d6-ad55-f4f2e3533296">2,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjBjNzE3MDFlYTllZDQ2M2RiMmMyNjcxNWQxOWM5ODY4L3RhYmxlcmFuZ2U6MGM3MTcwMWVhOWVkNDYzZGIyYzI2NzE1ZDE5Yzk4NjhfNS0yLTEtMS00NzgwMQ_325a8318-4850-4f5f-a1e1-ef45c47467c1">71,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjBjNzE3MDFlYTllZDQ2M2RiMmMyNjcxNWQxOWM5ODY4L3RhYmxlcmFuZ2U6MGM3MTcwMWVhOWVkNDYzZGIyYzI2NzE1ZDE5Yzk4NjhfNS00LTEtMS00NzgwMQ_d08bbdd9-f040-4930-b4f9-c4efa601000a">53,896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less long-term portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjBjNzE3MDFlYTllZDQ2M2RiMmMyNjcxNWQxOWM5ODY4L3RhYmxlcmFuZ2U6MGM3MTcwMWVhOWVkNDYzZGIyYzI2NzE1ZDE5Yzk4NjhfNi0yLTEtMS00NzgwMQ_0f5b3c47-0a18-442f-b8fc-ad7c3073d4d3">26,283</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjBjNzE3MDFlYTllZDQ2M2RiMmMyNjcxNWQxOWM5ODY4L3RhYmxlcmFuZ2U6MGM3MTcwMWVhOWVkNDYzZGIyYzI2NzE1ZDE5Yzk4NjhfNi00LTEtMS00NzgwMQ_3ae77e25-8609-4a5d-8f4c-9a177bed6bf8">13,414</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total prepaid expenses and other assets, current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjBjNzE3MDFlYTllZDQ2M2RiMmMyNjcxNWQxOWM5ODY4L3RhYmxlcmFuZ2U6MGM3MTcwMWVhOWVkNDYzZGIyYzI2NzE1ZDE5Yzk4NjhfNy0yLTEtMS00NzgwMQ_d884f219-c4a3-4ba3-bb89-835c7c03d586">45,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjBjNzE3MDFlYTllZDQ2M2RiMmMyNjcxNWQxOWM5ODY4L3RhYmxlcmFuZ2U6MGM3MTcwMWVhOWVkNDYzZGIyYzI2NzE1ZDE5Yzk4NjhfNy00LTEtMS00NzgwMQ_76fbc849-c149-4124-a482-7d6583f04214">40,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid manufacturing expenses include raw materials, slot reservation fees and other amounts paid to contract manufacturing organizations.&#160;Such amounts are reclassified to work-in-process inventory as materials are used or the contract manufacturing organization services are complete.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfMTIzNA_84265cb1-bbf1-413f-ac36-c2627b3c2027" continuedAt="ia890001fc9184f398561440ef962a3fe" escape="true">Property and equipment, net consisted of the following (in thousands):</ix:nonNumeric></span></div><div style="text-align:center;text-indent:22.5pt"><ix:continuation id="ia890001fc9184f398561440ef962a3fe"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:68.485%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9bf3392f031425891062f5e0f545ba6_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjNjN2I3MWJjM2U2ODQ0ZTdhOTFjZjUwOGQ0YjFhOWEzL3RhYmxlcmFuZ2U6M2M3YjcxYmMzZTY4NDRlN2E5MWNmNTA4ZDRiMWE5YTNfMS0yLTEtMS00NzgwMQ_08e6b377-480b-4529-8dbb-5b230870cee7">7,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ce62cbf8364228b4b121202d34470e_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjNjN2I3MWJjM2U2ODQ0ZTdhOTFjZjUwOGQ0YjFhOWEzL3RhYmxlcmFuZ2U6M2M3YjcxYmMzZTY4NDRlN2E5MWNmNTA4ZDRiMWE5YTNfMS00LTEtMS00NzgwMQ_30643fa0-307c-4ce2-bd2f-3c68b75f2814">7,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51bfe79b4f7f4ddea8ca6aecd47c6748_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjNjN2I3MWJjM2U2ODQ0ZTdhOTFjZjUwOGQ0YjFhOWEzL3RhYmxlcmFuZ2U6M2M3YjcxYmMzZTY4NDRlN2E5MWNmNTA4ZDRiMWE5YTNfMi0yLTEtMS00NzgwMQ_9e5cd419-e847-4762-9e9f-093501b24e4b">22,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e78480ba6bd4f1d9d17749c899a126b_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjNjN2I3MWJjM2U2ODQ0ZTdhOTFjZjUwOGQ0YjFhOWEzL3RhYmxlcmFuZ2U6M2M3YjcxYmMzZTY4NDRlN2E5MWNmNTA4ZDRiMWE5YTNfMi00LTEtMS00NzgwMQ_cc7d6e4f-b97b-4e63-b1c9-b536c6990e81">5,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer and office equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8be187f821b4c40912a67590b98722f_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjNjN2I3MWJjM2U2ODQ0ZTdhOTFjZjUwOGQ0YjFhOWEzL3RhYmxlcmFuZ2U6M2M3YjcxYmMzZTY4NDRlN2E5MWNmNTA4ZDRiMWE5YTNfMy0yLTEtMS00NzgwMQ_4394b75e-8ee1-4032-ac4e-27df6ac33da7">6,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if48f37b3f1b94e6bb28d9642c03cb051_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjNjN2I3MWJjM2U2ODQ0ZTdhOTFjZjUwOGQ0YjFhOWEzL3RhYmxlcmFuZ2U6M2M3YjcxYmMzZTY4NDRlN2E5MWNmNTA4ZDRiMWE5YTNfMy00LTEtMS00NzgwMQ_3e5ba674-4d05-428a-a3f8-36903cbdcc0d">5,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifef082b6dbf1487f9b03c2077818edec_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjNjN2I3MWJjM2U2ODQ0ZTdhOTFjZjUwOGQ0YjFhOWEzL3RhYmxlcmFuZ2U6M2M3YjcxYmMzZTY4NDRlN2E5MWNmNTA4ZDRiMWE5YTNfNC0yLTEtMS00NzgwMQ_a5ef604e-1098-4cf6-9165-02e0ecb2310a">8,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia927806080fd413c87442beab744f69b_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjNjN2I3MWJjM2U2ODQ0ZTdhOTFjZjUwOGQ0YjFhOWEzL3RhYmxlcmFuZ2U6M2M3YjcxYmMzZTY4NDRlN2E5MWNmNTA4ZDRiMWE5YTNfNC00LTEtMS00NzgwMQ_14202db2-4005-4325-9da2-dcb62790549e">1,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjNjN2I3MWJjM2U2ODQ0ZTdhOTFjZjUwOGQ0YjFhOWEzL3RhYmxlcmFuZ2U6M2M3YjcxYmMzZTY4NDRlN2E5MWNmNTA4ZDRiMWE5YTNfNS0yLTEtMS00NzgwMQ_b4b8e3ce-c23f-4d91-b0a3-1116333c67a3">45,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjNjN2I3MWJjM2U2ODQ0ZTdhOTFjZjUwOGQ0YjFhOWEzL3RhYmxlcmFuZ2U6M2M3YjcxYmMzZTY4NDRlN2E5MWNmNTA4ZDRiMWE5YTNfNS00LTEtMS00NzgwMQ_cb7db1db-b454-4c32-8c9b-8dd97bbae858">19,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjNjN2I3MWJjM2U2ODQ0ZTdhOTFjZjUwOGQ0YjFhOWEzL3RhYmxlcmFuZ2U6M2M3YjcxYmMzZTY4NDRlN2E5MWNmNTA4ZDRiMWE5YTNfNi0yLTEtMS00NzgwMQ_01ff37d4-e9a7-4910-9e7d-95bb3bccc2f4">13,749</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjNjN2I3MWJjM2U2ODQ0ZTdhOTFjZjUwOGQ0YjFhOWEzL3RhYmxlcmFuZ2U6M2M3YjcxYmMzZTY4NDRlN2E5MWNmNTA4ZDRiMWE5YTNfNi00LTEtMS00NzgwMQ_69b80f3a-9b26-4eb3-a55d-f93b821981c9">13,100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjNjN2I3MWJjM2U2ODQ0ZTdhOTFjZjUwOGQ0YjFhOWEzL3RhYmxlcmFuZ2U6M2M3YjcxYmMzZTY4NDRlN2E5MWNmNTA4ZDRiMWE5YTNfNy0yLTEtMS00NzgwMQ_54b3558e-3823-47bd-bed8-927a5ae4be1d">31,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjNjN2I3MWJjM2U2ODQ0ZTdhOTFjZjUwOGQ0YjFhOWEzL3RhYmxlcmFuZ2U6M2M3YjcxYmMzZTY4NDRlN2E5MWNmNTA4ZDRiMWE5YTNfNy00LTEtMS00NzgwMQ_54c751d9-429b-4d54-9f6b-790b8706bc4e">6,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use of assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjNjN2I3MWJjM2U2ODQ0ZTdhOTFjZjUwOGQ0YjFhOWEzL3RhYmxlcmFuZ2U6M2M3YjcxYmMzZTY4NDRlN2E5MWNmNTA4ZDRiMWE5YTNfOC0yLTEtMS00NzgwMQ_51c0f714-2122-4504-b670-fa72857f7d86">5,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjNjN2I3MWJjM2U2ODQ0ZTdhOTFjZjUwOGQ0YjFhOWEzL3RhYmxlcmFuZ2U6M2M3YjcxYmMzZTY4NDRlN2E5MWNmNTA4ZDRiMWE5YTNfOC00LTEtMS00NzgwMQ_6c2789b4-8783-461b-9fef-130ce55bbe7e">2,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjNjN2I3MWJjM2U2ODQ0ZTdhOTFjZjUwOGQ0YjFhOWEzL3RhYmxlcmFuZ2U6M2M3YjcxYmMzZTY4NDRlN2E5MWNmNTA4ZDRiMWE5YTNfOS0yLTEtMS00NzgwMQ_b7c43fe0-b894-401c-b2f1-5074b761685a">37,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjNjN2I3MWJjM2U2ODQ0ZTdhOTFjZjUwOGQ0YjFhOWEzL3RhYmxlcmFuZ2U6M2M3YjcxYmMzZTY4NDRlN2E5MWNmNTA4ZDRiMWE5YTNfOS00LTEtMS00NzgwMQ_5cb3f2c2-db87-46aa-9549-b89ce3799da5">8,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">                            </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense was approximately $<ix:nonFraction unitRef="usd" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfNjg2_3d49ae50-fa6f-458a-b4cf-fef27536e1a2">1.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfNjkz_1077b454-3e39-487f-bb93-9552766f069f">0.8</ix:nonFraction> million, inclusive of ROU asset amortization of $<ix:nonFraction unitRef="usd" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfNzM2_8730b509-c4ba-472b-83bf-cbc13dffa6fb">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfNzQz_6ef3b479-ef5c-4f23-a8b3-ebfcb6f05b9a">0.4</ix:nonFraction> million for the three months ended June&#160;30, 2022 and 2021 respectively. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if720e1c14d4142d99ede6691ff10e5aa" continuedAt="if093e11c03c34fd8a0ac4d2515f88ad4"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense was approximately $<ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfMTA5OTUxMTYyOTIwMw_a7616433-bd08-4022-b508-be1d8193e71f">1.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfMTA5OTUxMTYyOTIxMQ_d8fc2c46-95a5-448f-a75e-3bec3b0a5293">1.5</ix:nonFraction> million, inclusive of ROU asset amortization of $<ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfMTA5OTUxMTYyOTIxOQ_ac5b6132-12f2-44c8-a548-2315751146d7">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfMTA5OTUxMTYyOTIyNw_791ba9a3-08f1-41f6-b4d7-6426b5a90d8a">0.8</ix:nonFraction> million for the six months ended June&#160;30, 2022 and 2021 respectively.</span></div><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfMTIwMQ_4bc8c31f-c6d0-43f4-835a-282bad9c815e" escape="true"><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:68.485%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and payroll taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmE5MjEwMTIxM2U2NjRjOTZiNTRhYWE3OTZiZGFhMjIzL3RhYmxlcmFuZ2U6YTkyMTAxMjEzZTY2NGM5NmI1NGFhYTc5NmJkYWEyMjNfMi0yLTEtMS00NzgwMQ_1951e6f5-7e08-4f1f-a011-11baec51b5b2">15,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmE5MjEwMTIxM2U2NjRjOTZiNTRhYWE3OTZiZGFhMjIzL3RhYmxlcmFuZ2U6YTkyMTAxMjEzZTY2NGM5NmI1NGFhYTc5NmJkYWEyMjNfMi00LTEtMS00NzgwMQ_fc9ee8f6-4d1e-41b2-ac2e-24474dd2ffdd">9,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued outsourced manufacturing expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="halo:Accruedmanufacturingexpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmE5MjEwMTIxM2U2NjRjOTZiNTRhYWE3OTZiZGFhMjIzL3RhYmxlcmFuZ2U6YTkyMTAxMjEzZTY2NGM5NmI1NGFhYTc5NmJkYWEyMjNfMy0yLTEtMS00NzgwMQ_e067e4b8-f56b-4541-beab-904e8a5a268f">6,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="halo:Accruedmanufacturingexpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmE5MjEwMTIxM2U2NjRjOTZiNTRhYWE3OTZiZGFhMjIzL3RhYmxlcmFuZ2U6YTkyMTAxMjEzZTY2NGM5NmI1NGFhYTc5NmJkYWEyMjNfMy00LTEtMS00NzgwMQ_04a63b30-e3fb-4015-9df7-e4d6688eeaad">6,514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:TaxesPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmE5MjEwMTIxM2U2NjRjOTZiNTRhYWE3OTZiZGFhMjIzL3RhYmxlcmFuZ2U6YTkyMTAxMjEzZTY2NGM5NmI1NGFhYTc5NmJkYWEyMjNfNC0yLTEtMS01ODM4Mg_061668e1-8519-4720-9eb2-f6dcb9e8ad89">23,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:TaxesPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmE5MjEwMTIxM2U2NjRjOTZiNTRhYWE3OTZiZGFhMjIzL3RhYmxlcmFuZ2U6YTkyMTAxMjEzZTY2NGM5NmI1NGFhYTc5NmJkYWEyMjNfNC00LTEtMS01ODM4OQ_60d0128c-b9e9-470c-a805-b007fa0ee97d">1,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product returns and sales allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:ContractWithCustomerRefundLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmE5MjEwMTIxM2U2NjRjOTZiNTRhYWE3OTZiZGFhMjIzL3RhYmxlcmFuZ2U6YTkyMTAxMjEzZTY2NGM5NmI1NGFhYTc5NmJkYWEyMjNfNS0yLTEtMS01ODM4Mg_d56564c2-e932-4bbe-98dd-325b3f5e4b9d">21,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerRefundLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmE5MjEwMTIxM2U2NjRjOTZiNTRhYWE3OTZiZGFhMjIzL3RhYmxlcmFuZ2U6YTkyMTAxMjEzZTY2NGM5NmI1NGFhYTc5NmJkYWEyMjNfNS00LTEtMS01ODM4OQ_f7b1db0e-9337-4488-bcf6-8dbc5b1f0079">706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmE5MjEwMTIxM2U2NjRjOTZiNTRhYWE3OTZiZGFhMjIzL3RhYmxlcmFuZ2U6YTkyMTAxMjEzZTY2NGM5NmI1NGFhYTc5NmJkYWEyMjNfNC0yLTEtMS00NzgwMQ_634d1026-80d8-4178-b1ad-a57a6ec1568e">15,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmE5MjEwMTIxM2U2NjRjOTZiNTRhYWE3OTZiZGFhMjIzL3RhYmxlcmFuZ2U6YTkyMTAxMjEzZTY2NGM5NmI1NGFhYTc5NmJkYWEyMjNfNC00LTEtMS00NzgwMQ_22aa9213-eb47-4721-b45c-d2299354dbd8">3,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmE5MjEwMTIxM2U2NjRjOTZiNTRhYWE3OTZiZGFhMjIzL3RhYmxlcmFuZ2U6YTkyMTAxMjEzZTY2NGM5NmI1NGFhYTc5NmJkYWEyMjNfNS0yLTEtMS00NzgwMQ_f17554fc-2fd9-4136-a8f0-d8b196a3f184">7,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmE5MjEwMTIxM2U2NjRjOTZiNTRhYWE3OTZiZGFhMjIzL3RhYmxlcmFuZ2U6YTkyMTAxMjEzZTY2NGM5NmI1NGFhYTc5NmJkYWEyMjNfNS00LTEtMS00NzgwMQ_8df2d951-46d3-47f0-b8d4-c65007896e70">2,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmE5MjEwMTIxM2U2NjRjOTZiNTRhYWE3OTZiZGFhMjIzL3RhYmxlcmFuZ2U6YTkyMTAxMjEzZTY2NGM5NmI1NGFhYTc5NmJkYWEyMjNfNi0yLTEtMS00NzgwMQ_9f5ee6c9-f9d9-41ee-b329-61c5e1b2efda">89,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmE5MjEwMTIxM2U2NjRjOTZiNTRhYWE3OTZiZGFhMjIzL3RhYmxlcmFuZ2U6YTkyMTAxMjEzZTY2NGM5NmI1NGFhYTc5NmJkYWEyMjNfNi00LTEtMS00NzgwMQ_5148193a-b8b1-473e-a1f3-3fd402b6974d">24,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less long-term portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="halo:AccruedLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmE5MjEwMTIxM2U2NjRjOTZiNTRhYWE3OTZiZGFhMjIzL3RhYmxlcmFuZ2U6YTkyMTAxMjEzZTY2NGM5NmI1NGFhYTc5NmJkYWEyMjNfNy0yLTEtMS00NzgwMQ_013081f9-e35a-413a-aaba-78570fba3e63">5,551</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="halo:AccruedLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmE5MjEwMTIxM2U2NjRjOTZiNTRhYWE3OTZiZGFhMjIzL3RhYmxlcmFuZ2U6YTkyMTAxMjEzZTY2NGM5NmI1NGFhYTc5NmJkYWEyMjNfNy00LTEtMS00NzgwMQ_f84d0996-3e7e-4461-9b13-32c9b2b09676">544</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total accrued expenses, current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmE5MjEwMTIxM2U2NjRjOTZiNTRhYWE3OTZiZGFhMjIzL3RhYmxlcmFuZ2U6YTkyMTAxMjEzZTY2NGM5NmI1NGFhYTc5NmJkYWEyMjNfOC0yLTEtMS00NzgwMQ_ab555280-f128-4a2e-a2a9-bd0a9767a9f7">84,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmE5MjEwMTIxM2U2NjRjOTZiNTRhYWE3OTZiZGFhMjIzL3RhYmxlcmFuZ2U6YTkyMTAxMjEzZTY2NGM5NmI1NGFhYTc5NmJkYWEyMjNfOC00LTEtMS00NzgwMQ_aa17db5a-08bd-482b-8a48-873f8ef070be">24,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense associated with the accretion of the lease liabilities was approximately $<ix:nonFraction unitRef="usd" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="-5" name="halo:OperatingLeaseAccretionOfLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfOTM4_c74e36bd-7a3a-4ed8-bc7b-653e8ab94595">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="-5" name="halo:OperatingLeaseAccretionOfLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfOTQ1_ef514d56-9c06-4c3b-add6-02014294d9c2">0.1</ix:nonFraction> million for the three months ended June&#160;30, 2022 and 2021 respectively and $<ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-5" name="halo:OperatingLeaseAccretionOfLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfMTY0OTI2NzQ0MzUxOQ_0ec52906-9f23-4950-b8a1-1cf8ab13e0e3">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-5" name="halo:OperatingLeaseAccretionOfLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfMTY0OTI2NzQ0MzUyNw_827d9ed3-7721-46c5-9123-08e7b10b42f6">0.2</ix:nonFraction> million for the six months ended June&#160;30, 2022 and 2021 respectively. Total lease expense for the three months ended June&#160;30, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfMTA1NA_b4e8cdad-b3bc-4aad-aeea-561a4a57b51a">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfMTA2MQ_923b6f81-649e-46e5-9de3-4499b71a6aad">0.5</ix:nonFraction> million respectively and  $<ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfMTY0OTI2NzQ0MzU5NA_f9061add-81b3-4e7d-bfac-24f886cccf33">1.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfMTY0OTI2NzQ0MzYwMg_164a7524-c612-4486-be50-526bcbf307bb">1.0</ix:nonFraction> million for the six months ended June&#160;30, 2022 and 2021, respectively. .  </span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if093e11c03c34fd8a0ac4d2515f88ad4">Cash paid for amounts related to leases for the three months ended June&#160;30, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfMTE1OA_b19d1d5f-290a-42d2-a5e5-5f2417d23746">0.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfMTE2NQ_ae5988a7-a412-4be4-bc20-3020dc1d07fe">0.7</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfMTA5OTUxMTYyOTUxNA_8df62f8e-1403-44fc-bff7-7aecfc7c986b">1.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfMTA5OTUxMTYyOTUyNg_cf6fcaa6-b74c-4a96-8e37-6ccc112c07a4">1.4</ix:nonFraction> million for the six months ended June&#160;30, 2022 and 2021 respectively.</ix:continuation> </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div style="text-align:center;text-indent:22.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="ibd09c52bdc03451493df7fb7077280c7_1181"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGV4dHJlZ2lvbjpmNGE2NmUyYTFjMTM0ODRkYWZiMjY1ZjFmODg5NWRiN18xOTI0MTQ1MzQ4NzcyMQ_7c8b0599-f6d7-4204-b36b-d543bdcea7c0" continuedAt="ib883859fee8546d7ba4d3bbb114a4f5e" escape="true">Goodwill and Intangible Assets</ix:nonNumeric></span></div><ix:continuation id="ib883859fee8546d7ba4d3bbb114a4f5e"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 24, 2022, we acquired all outstanding equity interests of Antares Pharma, Inc. A Goodwill balance of $<ix:nonFraction unitRef="usd" contextRef="i1e07b7230a7b4293910918c1158913a7_I20220524" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGV4dHJlZ2lvbjpmNGE2NmUyYTFjMTM0ODRkYWZiMjY1ZjFmODg5NWRiN18xOTI0MTQ1MzQ4ODc4NA_db6a7b9a-250f-46d3-8977-7c5943a81c2f">199.5</ix:nonFraction>&#160;million is recognized for the the excess of the consideration transferred over the net assets acquired and represents the expected revenue and cost synergies of the combined company and assembled workforce.</span></div><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGV4dHJlZ2lvbjpmNGE2NmUyYTFjMTM0ODRkYWZiMjY1ZjFmODg5NWRiN18xOTI0MTQ1MzQ4ODc5OQ_523e7c1d-584f-4d63-bba5-fc6dbb7e9dc3" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the activity impacting goodwill is presented below (in thousands):</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"><tr><td style="width:1.0%"></td><td style="width:84.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-5" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6YjNiZTM4Y2E5ZTBmNDNiODliYjExNjJhOGIxMDc2NWMvdGFibGVyYW5nZTpiM2JlMzhjYTllMGY0M2I4OWJiMTE2MmE4YjEwNzY1Y18wLTItMS0xLTYwNTUy_9438fee0-6bdb-49e0-9065-e66208bac497">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6YjNiZTM4Y2E5ZTBmNDNiODliYjExNjJhOGIxMDc2NWMvdGFibGVyYW5nZTpiM2JlMzhjYTllMGY0M2I4OWJiMTE2MmE4YjEwNzY1Y18xLTItMS0xLTU2OTgz_c21b7a4b-d517-4f26-a8f6-1433e5409cb2">199,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6YjNiZTM4Y2E5ZTBmNDNiODliYjExNjJhOGIxMDc2NWMvdGFibGVyYW5nZTpiM2JlMzhjYTllMGY0M2I4OWJiMTE2MmE4YjEwNzY1Y18yLTItMS0xLTYwNTU2_9e873ba6-14e8-49d6-a7ca-b1123f6eda3f">199,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our acquired intangible assets are amortized using the straight-line method over their estimated useful lives of seven to ten years. <ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGV4dHJlZ2lvbjpmNGE2NmUyYTFjMTM0ODRkYWZiMjY1ZjFmODg5NWRiN18xOTI0MTQ1MzQ4NzczMw_becd017a-04ff-4dac-98ef-8b16c2638504" continuedAt="i4d7180fe987f49e89b733d848856b64f" escape="true">The following table shows the cost, accumulated amortization and weighted average life in years for our acquired intangible assets at June&#160;30, 2022 (in thousands).</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><ix:continuation id="i4d7180fe987f49e89b733d848856b64f"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"></td><td style="width:47.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.993%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.993%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average remaining life (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auto Injector technology platform</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifb0dbd53c41e477d9ab6a6f8b2df947a_D20220101-20220630" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6OTJhZmRlNzJjMDMyNDJiZGJmYzIxNjJiNjhmMjZmMWEvdGFibGVyYW5nZTo5MmFmZGU3MmMwMzI0MmJkYmZjMjE2MmI2OGYyNmYxYV8xLTItMS0xLTYwNjAy_afb7d490-f97a-4a9d-b183-903cb26f8bba">7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e8b070a3aa646febf62fbbd0ae3ce5e_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6OTJhZmRlNzJjMDMyNDJiZGJmYzIxNjJiNjhmMjZmMWEvdGFibGVyYW5nZTo5MmFmZGU3MmMwMzI0MmJkYmZjMjE2MmI2OGYyNmYxYV8xLTQtMS0xLTYwNTU5_5f4c4e96-ed18-4195-932c-19e361c68e43">372,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e8b070a3aa646febf62fbbd0ae3ce5e_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6OTJhZmRlNzJjMDMyNDJiZGJmYzIxNjJiNjhmMjZmMWEvdGFibGVyYW5nZTo5MmFmZGU3MmMwMzI0MmJkYmZjMjE2MmI2OGYyNmYxYV8xLTYtMS0xLTYwNTYw_6ea618d7-e2ef-40b8-8178-9d58009c6da1">5,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e8b070a3aa646febf62fbbd0ae3ce5e_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6OTJhZmRlNzJjMDMyNDJiZGJmYzIxNjJiNjhmMjZmMWEvdGFibGVyYW5nZTo5MmFmZGU3MmMwMzI0MmJkYmZjMjE2MmI2OGYyNmYxYV8xLTgtMS0xLTYwNTc3_599c5fab-4a25-4b33-8ec3-e3d23dfa16f8">367,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XYOSTED proprietary product</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie6cf0130a2b443be99ea94b47e536125_D20220101-20220630" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6OTJhZmRlNzJjMDMyNDJiZGJmYzIxNjJiNjhmMjZmMWEvdGFibGVyYW5nZTo5MmFmZGU3MmMwMzI0MmJkYmZjMjE2MmI2OGYyNmYxYV8yLTItMS0xLTYwNjAy_223292b7-2100-4213-8932-fb4b0e7d88ae">10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6500afde964db6843f15bf9ff223c9_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6OTJhZmRlNzJjMDMyNDJiZGJmYzIxNjJiNjhmMjZmMWEvdGFibGVyYW5nZTo5MmFmZGU3MmMwMzI0MmJkYmZjMjE2MmI2OGYyNmYxYV8yLTQtMS0xLTYwNTU5_ea84ddc2-9536-4570-94f8-b4f4f6028307">277,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6500afde964db6843f15bf9ff223c9_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6OTJhZmRlNzJjMDMyNDJiZGJmYzIxNjJiNjhmMjZmMWEvdGFibGVyYW5nZTo5MmFmZGU3MmMwMzI0MmJkYmZjMjE2MmI2OGYyNmYxYV8yLTYtMS0xLTYwNTYw_e266fc7d-3776-4299-b4ae-969f8871e5b7">2,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd6500afde964db6843f15bf9ff223c9_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6OTJhZmRlNzJjMDMyNDJiZGJmYzIxNjJiNjhmMjZmMWEvdGFibGVyYW5nZTo5MmFmZGU3MmMwMzI0MmJkYmZjMjE2MmI2OGYyNmYxYV8yLTgtMS0xLTYwNTc3_ab703757-b0f3-4acc-88db-f1eb264f4bb0">274,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TLANDO product rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idab608f91ce0499fb31e66934a3d01cd_D20220101-20220630" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6OTJhZmRlNzJjMDMyNDJiZGJmYzIxNjJiNjhmMjZmMWEvdGFibGVyYW5nZTo5MmFmZGU3MmMwMzI0MmJkYmZjMjE2MmI2OGYyNmYxYV8zLTItMS0xLTYwNjAy_85227d31-03c8-4edc-b315-a886b968c5d8">10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9cf38a8f67047f4b770a4b2f6f4c0c4_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6OTJhZmRlNzJjMDMyNDJiZGJmYzIxNjJiNjhmMjZmMWEvdGFibGVyYW5nZTo5MmFmZGU3MmMwMzI0MmJkYmZjMjE2MmI2OGYyNmYxYV8zLTQtMS0xLTYwNTU5_a83ab2fc-f058-4db8-a20d-e773c8fbb4c5">277,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9cf38a8f67047f4b770a4b2f6f4c0c4_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6OTJhZmRlNzJjMDMyNDJiZGJmYzIxNjJiNjhmMjZmMWEvdGFibGVyYW5nZTo5MmFmZGU3MmMwMzI0MmJkYmZjMjE2MmI2OGYyNmYxYV8zLTYtMS0xLTYwNTYw_ea562b2d-68af-4aa7-83f3-be780bc00417">2,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9cf38a8f67047f4b770a4b2f6f4c0c4_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6OTJhZmRlNzJjMDMyNDJiZGJmYzIxNjJiNjhmMjZmMWEvdGFibGVyYW5nZTo5MmFmZGU3MmMwMzI0MmJkYmZjMjE2MmI2OGYyNmYxYV8zLTgtMS0xLTYwNTc3_afcbc8bd-8e4a-4136-afb9-cd5b0e694f7b">274,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total definite-lived intangibles, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6OTJhZmRlNzJjMDMyNDJiZGJmYzIxNjJiNjhmMjZmMWEvdGFibGVyYW5nZTo5MmFmZGU3MmMwMzI0MmJkYmZjMjE2MmI2OGYyNmYxYV80LTQtMS0xLTYwNTU5_883d4461-af46-42b2-9514-f27caac08b32">927,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6OTJhZmRlNzJjMDMyNDJiZGJmYzIxNjJiNjhmMjZmMWEvdGFibGVyYW5nZTo5MmFmZGU3MmMwMzI0MmJkYmZjMjE2MmI2OGYyNmYxYV80LTYtMS0xLTYwNTYw_316a0e5a-0861-4aba-bd84-1aded77beb28">11,403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6OTJhZmRlNzJjMDMyNDJiZGJmYzIxNjJiNjhmMjZmMWEvdGFibGVyYW5nZTo5MmFmZGU3MmMwMzI0MmJkYmZjMjE2MmI2OGYyNmYxYV80LTgtMS0xLTYwNTc3_3fe4f3e6-a030-4035-8bcd-220b7f37a383">916,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ATRS-1902 (IPR&amp;D)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6OTJhZmRlNzJjMDMyNDJiZGJmYzIxNjJiNjhmMjZmMWEvdGFibGVyYW5nZTo5MmFmZGU3MmMwMzI0MmJkYmZjMjE2MmI2OGYyNmYxYV81LTgtMS0xLTYwNTgy_e85fb20c-9899-4a05-886e-d42a9dd82aa3">59,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Intangibles, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6OTJhZmRlNzJjMDMyNDJiZGJmYzIxNjJiNjhmMjZmMWEvdGFibGVyYW5nZTo5MmFmZGU3MmMwMzI0MmJkYmZjMjE2MmI2OGYyNmYxYV82LTgtMS0xLTYwNTgy_bbb9e3a5-3bd8-45d9-b016-36b06f4b51d3">976,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGV4dHJlZ2lvbjpmNGE2NmUyYTFjMTM0ODRkYWZiMjY1ZjFmODg5NWRiN18xOTI0MTQ1MzQ4NzczNA_e5db5c22-64db-422b-9100-dfbd926c3d8b" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future annual amortization of finite-lived intangible assets is shown in the following table. Actual amortization expense to be reported in future periods could differ from these estimates as a result of acquisitions, divestitures, and asset impairments, among other factors.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"></td><td style="width:82.561%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.010%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Year:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6MDlmNjQ0ODk1MDEwNGY4NDk1MTgzMTNhNTNiYWE0YjEvdGFibGVyYW5nZTowOWY2NDQ4OTUwMTA0Zjg0OTUxODMxM2E1M2JhYTRiMV8xLTItMS0xLTYwNjA4_b2e626de-f58f-45ff-84c7-fe44cd7e81a1">54,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6MDlmNjQ0ODk1MDEwNGY4NDk1MTgzMTNhNTNiYWE0YjEvdGFibGVyYW5nZTowOWY2NDQ4OTUwMTA0Zjg0OTUxODMxM2E1M2JhYTRiMV8yLTItMS0xLTYwNjA4_d8d3bd49-0aa5-4209-9069-24f3f6b8d3e0">108,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6MDlmNjQ0ODk1MDEwNGY4NDk1MTgzMTNhNTNiYWE0YjEvdGFibGVyYW5nZTowOWY2NDQ4OTUwMTA0Zjg0OTUxODMxM2E1M2JhYTRiMV8zLTItMS0xLTYwNjA4_5dce2fda-fab4-449f-b8cd-7381272ce9db">108,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6MDlmNjQ0ODk1MDEwNGY4NDk1MTgzMTNhNTNiYWE0YjEvdGFibGVyYW5nZTowOWY2NDQ4OTUwMTA0Zjg0OTUxODMxM2E1M2JhYTRiMV80LTItMS0xLTYwNjA4_7f456d6d-f53b-41d4-a9be-b6e7b109e803">108,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6MDlmNjQ0ODk1MDEwNGY4NDk1MTgzMTNhNTNiYWE0YjEvdGFibGVyYW5nZTowOWY2NDQ4OTUwMTA0Zjg0OTUxODMxM2E1M2JhYTRiMV81LTItMS0xLTYwNjA4_4d5672e9-8799-404d-85d5-575eb2c6f2c9">108,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="halo:FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6MDlmNjQ0ODk1MDEwNGY4NDk1MTgzMTNhNTNiYWE0YjEvdGFibGVyYW5nZTowOWY2NDQ4OTUwMTA0Zjg0OTUxODMxM2E1M2JhYTRiMV82LTItMS0xLTYwNjA4_9c9f8d08-ab82-4759-a44b-9776d6e3b671">427,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6MDlmNjQ0ODk1MDEwNGY4NDk1MTgzMTNhNTNiYWE0YjEvdGFibGVyYW5nZTowOWY2NDQ4OTUwMTA0Zjg0OTUxODMxM2E1M2JhYTRiMV83LTItMS0xLTYwNjA4_d0b16955-94a7-4bea-975b-0911e171db8a">916,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="ibd09c52bdc03451493df7fb7077280c7_64"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:LongTermDebtTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTkyNDE0NTM1MjE2MDU_9a87d1f3-dd35-49a4-8937-913d1ebaf3a6" continuedAt="i763d2937bfed46d6a34ad2c660f509b9" escape="true">Long-Term Debt, Net</ix:nonNumeric></span></div><ix:continuation id="i763d2937bfed46d6a34ad2c660f509b9" continuedAt="i9c316cb119114f9aa8932d47fa9aa715"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i930ea774bf7d4904b46c5d6ce72d032d_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMjg_ebad1dd9-c335-4820-8647-83e56a1a14f0">0.25</ix:nonFraction>% Convertible Notes due 2027</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we completed the sale of $<ix:nonFraction unitRef="usd" contextRef="i930ea774bf7d4904b46c5d6ce72d032d_I20210331" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfOTg_96b96655-0626-47c6-9309-81baa531945e">805.0</ix:nonFraction>&#160;million in aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i930ea774bf7d4904b46c5d6ce72d032d_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTM0_4c4e627a-9d51-4ed6-98da-7d98d2680561">0.25</ix:nonFraction>% Convertible Senior Notes due 2027 (the &#8220;2027 Convertible Notes&#8221; and collectively with the 2024 Convertible Notes the &#8220;Convertible Notes&#8221;). The net proceeds in connection with the issuance of the 2027 Convertible Notes, after deducting the initial purchasers&#8217; fee of $<ix:nonFraction unitRef="usd" contextRef="i930ea774bf7d4904b46c5d6ce72d032d_I20210331" decimals="-5" name="us-gaap:DebtInstrumentFeeAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfNDAz_383c3094-ac67-4a8f-81b6-6cbfc5d15e9d">20.1</ix:nonFraction>&#160;million, was approximately $<ix:nonFraction unitRef="usd" contextRef="ic0d782f4478a4d7ea80f060e128b6b7a_D20210301-20210331" decimals="-5" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfNDI1_c5448208-2738-44cd-beac-c226dd161863">784.9</ix:nonFraction>&#160;million. We also incurred additional debt issuance costs totaling $<ix:nonFraction unitRef="usd" contextRef="idd66a9946d9840eba7c66b86f6e2fe5a_D20210301-20210331" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfNDg2_6a14f941-f4f7-461b-ae6c-7351d4b63db8">0.4</ix:nonFraction>&#160;million. Debt issuance costs and the initial purchasers&#8217; fee are presented as a debt discount.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2027 Convertible Notes pay interest semi-annually in arrears on March 1st and September 1st of each year at an annual rate of <ix:nonFraction unitRef="number" contextRef="i930ea774bf7d4904b46c5d6ce72d032d_I20210331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfNzA2_d3b719c5-5090-4bb0-a960-77dd1d7169bd">0.25</ix:nonFraction>%. The 2027 Convertible Notes are general unsecured obligations and will rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the 2027 Convertible Notes, will rank equally in right of payment with all existing and future liabilities that are not so subordinated, will be effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness and will be structurally subordinated to all indebtedness and other liabilities (including trade payables) of our current or future subsidiaries. The 2027 Convertible Notes have a maturity date of March 1, 2027.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their 2027 Convertible Notes at their option only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on June 30, 2021, if the last reported sale price per share of  common stock exceeds <ix:nonFraction unitRef="number" contextRef="ifd4cd55303894cb1aa89a03028006576_D20210301-20210331" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTYyMg_11e6129f-c649-46da-bdb6-0ce0cf69d87c">130</ix:nonFraction>% of the conversion price for each of at least <ix:nonFraction unitRef="trading_day" contextRef="ifd4cd55303894cb1aa89a03028006576_D20210301-20210331" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTY3MA_32f55a85-d76e-45c8-9b25-dc51d0613c06">20</ix:nonFraction> trading days during the <ix:nonFraction unitRef="trading_day" contextRef="ifd4cd55303894cb1aa89a03028006576_D20210301-20210331" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTY5Nw_0de4e68b-d0b3-4d66-a306-b47d8d289374">30</ix:nonFraction> consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the <ix:nonFraction unitRef="trading_day" contextRef="i9bc3be2ae627408894cf317b830d625e_D20210301-20210331" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTgzNA_040e5b7a-b0f2-41bf-a1d9-3350e9cb0a4d">five</ix:nonFraction> consecutive business days immediately after any <ix:nonFraction unitRef="trading_day" contextRef="i9bc3be2ae627408894cf317b830d625e_D20210301-20210331" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTg4NQ_90983067-b5aa-4181-8ab8-ad67dbb7e2da">five</ix:nonFraction> consecutive trading day period (such <ix:nonFraction unitRef="trading_day" contextRef="i9bc3be2ae627408894cf317b830d625e_D20210301-20210331" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTkyNQ_9c2b510c-8fe7-42de-9320-cc616ecf8066">five</ix:nonFraction> consecutive trading day period, the &#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than <ix:nonFraction unitRef="number" contextRef="i9bc3be2ae627408894cf317b830d625e_D20210301-20210331" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMjExMQ_7976c97a-3068-4bfd-afd6-49db6768a633">98</ix:nonFraction>% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on our common stock, as described in the offering memorandum for the 2027 Convertible Notes; (4) if we call such notes for redemption; and (5) at any time from, and including, September 1, 2026 until the close of business on the scheduled trading day immediately before the maturity date. The Notes will be convertible, regardless of the foregoing circumstances, at any time from, and including, September 1, 2026 until the close of business on the scheduled trading day immediately preceding the maturity date. As of June&#160;30, 2022, the 2027 Convertible Notes are not convertible.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, we will pay cash for the settlement of principal and for the premium, if applicable, we will pay cash, deliver shares of common stock or a combination of cash and shares of common stock, at our election. The initial conversion rate for the 2027 Convertible Notes will be <ix:nonFraction unitRef="number" contextRef="idd66a9946d9840eba7c66b86f6e2fe5a_D20210301-20210331" decimals="4" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMzE4Mw_1882bdbf-ca81-4ca8-8db0-0ec0070cc517">12.9576</ix:nonFraction> shares of common stock per $1,000 in principal amount of 2027 Convertible Notes, equivalent to a conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i930ea774bf7d4904b46c5d6ce72d032d_I20210331" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMzMxNw_de6da82c-ebaa-4343-ae04-b633572d84ec">77.17</ix:nonFraction> per share of our common stock. The conversion rate is subject to adjustment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, we were <ix:nonNumeric contextRef="i79862e9f8f4240af943f624cdae37039_D20220101-20220630" name="us-gaap:DebtInstrumentCovenantCompliance" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMzQxNQ_4e8ccb92-810a-4ebc-8b04-6b3ef0356bfe">in compliance</ix:nonNumeric> with all covenants and there was no material adverse change in our business, operations or financial condition. </span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i92d9886e9d374222a3d3959bf913fd55_I20191130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMzUzMQ_2833304e-0406-424b-9685-63f5c995b43c">1.25</ix:nonFraction>% Convertible Notes due 2024</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we completed the sale of $<ix:nonFraction unitRef="usd" contextRef="i92d9886e9d374222a3d3959bf913fd55_I20191130" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMzYwNA_4f45f50b-dd11-48bd-aae8-752bf2229a32">460.0</ix:nonFraction> million in aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i92d9886e9d374222a3d3959bf913fd55_I20191130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMzY0MA_e624539a-9553-40b4-8cb1-33e0bc564f2d">1.25</ix:nonFraction>% Convertible Senior Notes due 2024 (&#8220;2024 Convertible Notes&#8221;). The net proceeds in connection with the 2024 Convertible Notes, after deducting  the initial purchasers&#8217; fee of $<ix:nonFraction unitRef="usd" contextRef="i92d9886e9d374222a3d3959bf913fd55_I20191130" decimals="-5" name="us-gaap:DebtInstrumentFeeAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMzgxNw_691e920c-d886-439a-b519-f2882fa0763e">12.7</ix:nonFraction>&#160;million, was approximately $<ix:nonFraction unitRef="usd" contextRef="iae83682afbfd42498583c6364b173a85_D20191101-20191130" decimals="-5" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMzgzOQ_ed256c8f-5399-4820-a965-735fda2ac31a">447.3</ix:nonFraction> million. We also incurred debt issuance cost totaling $<ix:nonFraction unitRef="usd" contextRef="i9dffca0ebc3943fe8411a72b02312868_D20191101-20191130" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMzg4OA_13858194-e305-4620-8c0e-52f97809b6b6">0.3</ix:nonFraction>&#160;million. Debt issuance costs and the initial purchasers&#8217; fee are presented as a debt discount.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Convertible Notes pay interest semi-annually in arrears on June 1st and December 1st of each year, beginning on June 1, 2020, at an annual rate of <ix:nonFraction unitRef="number" contextRef="i92d9886e9d374222a3d3959bf913fd55_I20191130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfNDEzNA_75c6aa7d-e6cf-44de-941e-6768079753dd">1.25</ix:nonFraction>%. The 2024 Convertible Notes are general unsecured obligations and will rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the 2024 Convertible Notes, will rank equally in right of payment with all existing and future liabilities that are not so subordinated, will be effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness and will be structurally subordinated to all indebtedness and other liabilities (including trade payables) of the our current or future subsidiaries. The 2024 Convertible Notes have a maturity date of December 1, 2024.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their 2024 Convertible Notes at their option only in the following circumstances: (1)&#160;during any calendar quarter commencing after the calendar quarter ending on March&#160;31, 2020, if the last reported sale price per share of common stock exceeds <ix:nonFraction unitRef="number" contextRef="i564c0f73ae6841618d8d0305f3c128f2_D20191101-20191130" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfNTA1Nw_cde2ee08-f101-4b41-bc9f-5e987aec8d11">130</ix:nonFraction>% of the conversion price for each of at least <ix:nonFraction unitRef="trading_day" contextRef="i564c0f73ae6841618d8d0305f3c128f2_D20191101-20191130" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfNTEwNQ_4be6c316-520d-4854-bc9a-20fd4027a88d">20</ix:nonFraction> trading days during the <ix:nonFraction unitRef="trading_day" contextRef="i564c0f73ae6841618d8d0305f3c128f2_D20191101-20191130" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfNTEzMg_ac022122-205a-4098-bc02-228f07b04255">30</ix:nonFraction> consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2)&#160;during the <ix:nonFraction unitRef="trading_day" contextRef="ibc9e7ea69dc54bc580f0327b080e6620_D20191101-20191130" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfNTI2OQ_a46ea2df-d8f8-46e9-abea-a5d81d8db758">five</ix:nonFraction> consecutive business days immediately after any <ix:nonFraction unitRef="trading_day" contextRef="ibc9e7ea69dc54bc580f0327b080e6620_D20191101-20191130" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfNTMyMA_beb75265-b7ab-4df5-84d0-d00416ca9a66">five</ix:nonFraction> consecutive trading day period (such <ix:nonFraction unitRef="trading_day" contextRef="ibc9e7ea69dc54bc580f0327b080e6620_D20191101-20191130" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfNTM2MA_7fcd8cdd-b780-4119-be35-d0aa159747d5">five</ix:nonFraction> consecutive trading day period, the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i9c316cb119114f9aa8932d47fa9aa715" continuedAt="if5150fc530cd4c208a2a1095f1d74317"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than <ix:nonFraction unitRef="number" contextRef="ibc9e7ea69dc54bc580f0327b080e6620_D20191101-20191130" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfNTU0Ng_34ebb931-d8e8-4ca2-afe8-952b3ac18fec">98</ix:nonFraction>% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day; (3)&#160;upon the occurrence of certain corporate events or distributions on our common stock, as described in the offering memorandum for the 2024 Convertible Notes; (4)&#160;if we call such notes for redemption; and (5)&#160;at any time from, and including, June&#160;1, 2024 until the close of business on the scheduled trading day immediately before the maturity date. As of June&#160;30, 2022, the 2024 Convertible Notes are convertible and are classified as a current liability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021 we notified the note holders of our irrevocable election to settle the principal of the 2024 Convertible Notes in cash and for the premium, if applicable, to deliver shares of common stock. The conversion rate for the 2024 Convertible Notes will be <ix:nonFraction unitRef="number" contextRef="i9dffca0ebc3943fe8411a72b02312868_D20191101-20191130" decimals="4" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfNjQwNQ_285e2111-cef2-44e7-8f09-79133dc1ef9c">41.9208</ix:nonFraction> shares of common stock per $1,000 in principal amount of 2024 Convertible Notes, equivalent to a conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i92d9886e9d374222a3d3959bf913fd55_I20191130" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfNjUzOQ_fb49103c-ada5-43d8-9bf7-b2ecf81033b0">23.85</ix:nonFraction> per share of our common stock. The conversion rate is subject to adjustment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we completed a privately negotiated induced conversion of $<ix:nonFraction unitRef="usd" contextRef="i522b480a4e0c413cbd63f8e8b3903d03_D20210301-20210331" decimals="-5" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfNjY5Mg_208da09e-9bde-4206-8635-5b763ed839d8">369.1</ix:nonFraction>&#160;million principal amount of the 2024 Convertible Notes (&#8220;Note Repurchases&#8221; or the &#8220;Induced Conversion&#8221;). In connection with the Induced Conversion, we paid approximately $<ix:nonFraction unitRef="usd" contextRef="i522b480a4e0c413cbd63f8e8b3903d03_D20210301-20210331" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfNjg1Nw_9a18b78c-2dcb-4e71-a72b-ec498b03387a">370.2</ix:nonFraction>&#160;million in cash, which includes principal and accrued interest, and issued approximately <ix:nonFraction unitRef="shares" contextRef="i522b480a4e0c413cbd63f8e8b3903d03_D20210301-20210331" decimals="-4" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfNjk0MQ_eae5039b-354e-4b02-bca4-a240bd5efcf5">9.08</ix:nonFraction>&#160;million shares of our common stock representing the intrinsic value based on the contractual conversion rate and incremental shares as an inducement for conversion. As a result of the Induced Conversion, we recorded $<ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-5" name="us-gaap:InducedConversionOfConvertibleDebtExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfNzE1Mg_d78736b9-9362-4b9c-804e-22718cee8f73"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-5" name="us-gaap:InducedConversionOfConvertibleDebtExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfNzE1Mg_dc8c860a-b215-41bd-9cbf-e42959636509">21.0</ix:nonFraction></ix:nonFraction> million in induced conversion expense which is included in Other income (expense) of the Condensed Consolidated Statements of Income in 2021. The induced conversion expense represents the fair value of the common stock issued upon conversion in excess of the common stock issuable under the original terms of the 2024 Convertible Notes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, we were <ix:nonNumeric contextRef="i79862e9f8f4240af943f624cdae37039_D20220101-20220630" name="us-gaap:DebtInstrumentCovenantCompliance" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfOTY5Mg_4e8ccb92-810a-4ebc-8b04-6b3ef0356bfe">in compliance</ix:nonNumeric> with all covenants and there was no material adverse change in our business, operations or financial condition. </span></div><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfOTY5OQ_a491ce9a-65c8-49c2-a731-af9db19325b7" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Carrying Amounts of the Convertible Notes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount and fair value of our Convertible Notes were as follows as of the dates indicated (in thousands). </span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"><tr><td style="width:1.0%"></td><td style="width:69.570%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.474%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7db32790c0274f1b85142a533eef25ea_I20220630" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfMi0yLTEtMS00NzgwMQ_f954abf4-c775-461b-adee-eb3003e8ad1d">90,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4bc8fa5f8b24012aff99c9e405c3c38_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfMi00LTEtMS00NzgwMQ_90206761-6e26-4a42-a4fc-5bc39615ecbb">90,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71fa90d90d249b2826bd60cb35507b5_I20220630" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfMy0yLTEtMS00NzgwMQ_4e6d3060-846a-48a7-b3ad-81d9e879b45f">805,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb771b640f1343b39c99c088eeaa56cc_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfMy00LTEtMS00NzgwMQ_f09ba1bd-1477-4104-8348-d66ffb329f45">805,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Principal Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfNC0yLTEtMS00NzgwMQ_c932a86c-ec32-4c7a-bbff-dcfd48ab9faf">895,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfNC00LTEtMS00NzgwMQ_ba532d80-464f-4c67-8960-77c5c83ad095">895,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7db32790c0274f1b85142a533eef25ea_I20220630" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfNy0yLTEtMS00NzgwMQ_1758ca9d-3b7d-4696-a8f3-74fd445ff33e">1,263</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4bc8fa5f8b24012aff99c9e405c3c38_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfNy00LTEtMS00NzgwMQ_af014d4b-72c2-4e5e-b811-b1a3baf3f187">1,517</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia71fa90d90d249b2826bd60cb35507b5_I20220630" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfOC0yLTEtMS00NzgwMQ_02880d70-55f2-4017-8e08-1c4676024bd4">16,055</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb771b640f1343b39c99c088eeaa56cc_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfOC00LTEtMS00NzgwMQ_4147560b-dcc5-4450-b0d2-28a77c1a887c">17,745</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total unamortized debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfOS0yLTEtMS00NzgwMQ_6d1e1edf-ac80-43ac-a79f-abeed7f04c8d">17,318</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfOS00LTEtMS00NzgwMQ_ec8ce63d-40f1-442c-807b-1251733ad072">19,262</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amount:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7db32790c0274f1b85142a533eef25ea_I20220630" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfMTItMi0xLTEtNDc4MDE_99c29c6b-1302-4725-b02f-df71e74c18ee">89,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4bc8fa5f8b24012aff99c9e405c3c38_I20211231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfMTItNC0xLTEtNDc4MDE_cd0c7e9e-f7f7-4dc1-8c22-18df519208fe">89,419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71fa90d90d249b2826bd60cb35507b5_I20220630" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfMTMtMi0xLTEtNDc4MDE_e46ccf8c-2b42-4786-8e59-530c4ee0d296">788,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb771b640f1343b39c99c088eeaa56cc_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfMTMtNC0xLTEtNDc4MDE_6f35b905-bb6a-48d0-9617-ae3887efdcdc">787,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:ConvertibleNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfMTQtMi0xLTEtNDc4MDE_89aabfa8-72e6-468c-ab70-261937fa5268">878,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:ConvertibleNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfMTQtNC0xLTEtNDc4MDE_2674653a-d215-41ed-9f7d-46f49d5ffcea">876,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value based on trading levels (Level 2):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7db32790c0274f1b85142a533eef25ea_I20220630" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfMTctMi0xLTEtNDc4MDE_2f982da6-6fbe-4f10-8e95-9b9a8d69458a">172,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4bc8fa5f8b24012aff99c9e405c3c38_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfMTctNC0xLTEtNDc4MDE_7a471da7-1921-4cb0-8241-3a150339ef7e">159,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia71fa90d90d249b2826bd60cb35507b5_I20220630" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfMTgtMi0xLTEtNDc4MDE_badae77e-abdd-4e0e-a258-5e3d6c30e7e3">711,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb771b640f1343b39c99c088eeaa56cc_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfMTgtNC0xLTEtNDc4MDE_55426922-88ea-458a-8b03-f3d8fa3fc10d">718,889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of outstanding notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfMTktMi0xLTEtNDc4MDE_bd5343ff-61d8-475d-8423-d5d4677e4718">884,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfMTktNC0xLTEtNDc4MDE_787617e3-434b-4f19-9e82-cc7c78f446af">878,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization per period of debt discount (in years):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0b4b3f5b65f748fea9d3a16a4370a81e_D20220101-20220630" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfMjItMi0xLTEtNDc4MDE_9deb6103-c923-404c-ad5b-1edd532359fb">2.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9dac37b234cb4e39aa59635df2320abd_D20220101-20220331" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfMjItNC0xLTEtNDc4MDE_edc7fef6-998e-4d3c-b39d-be71e49fe0fb">2.9</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3f9a5cd5449946e383c3e70f8ef08350_D20220101-20220630" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfMjMtMi0xLTEtNDc4MDE_132d61e1-04a5-46f6-a5a6-f3d599ee384f">4.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iac94068bcee94ca094f560cb73997234_D20220101-20220331" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfMjMtNC0xLTEtNDc4MDE_e3a2cc0a-9e3a-4691-af4c-877d7ee384aa">5.2</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><ix:continuation id="if5150fc530cd4c208a2a1095f1d74317" continuedAt="ie968d19e384a46c99064613c4a9f4a57"><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfOTcwMA_83be3301-bb5d-402b-b26d-aebf8ab41563" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of interest expense and the effective interest rates for each of our Convertible Notes for the periods shown (in thousands).</span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.058%"><tr><td style="width:1.0%"></td><td style="width:38.997%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.023%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.023%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.261%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.023%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.026%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coupon Interest:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50e1360e4c7b4de39282c845c5d73c43_D20220401-20220630" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMy0yLTEtMS00NzgwMQ_d9cc934b-a828-4704-925a-e336e92b004f">284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i765e5eeb91e54b43b5f00f6ebddec276_D20210401-20210630" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMy00LTEtMS00NzgwMQ_c09d3d23-df8f-42cf-a28e-df0e07cfa44c">284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i421730450b74464b90e09befbd503cfc_D20220101-20220630" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMy02LTEtMS00NzgwMQ_45e64819-71f6-4c82-94b9-5d78e11e2ffd">568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9858e2352550465683b249270d6735a6_D20210101-20210630" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMy04LTEtMS00NzgwMQ_54c5490e-ccca-4c78-9895-a9c81b85cf45">1,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5021845805034e388a208b835a6c92c0_D20220401-20220630" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfNC0yLTEtMS00NzgwMQ_22e13ad6-42e8-49df-8449-fea3ec2dc0c2">503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ec81c8774a34665930c2c67a277cbbf_D20210401-20210630" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfNC00LTEtMS00NzgwMQ_228d8fc8-23c6-4877-ace6-668b738251b3">503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00e19a2b430241ed99f4d4d16ef7f9d0_D20220101-20220630" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfNC02LTEtMS00NzgwMQ_4f095f85-8d0c-4e72-acaa-ddbe0c159ca9">1,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0b274a39124464a2f81ffe163b7216_D20210101-20210630" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfNC04LTEtMS00NzgwMQ_e7670bf6-223d-42f4-b555-4b7b9cdcc85d">671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Coupon Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib06303cf7360468aad8efb6d193ac2e0_D20220401-20220630" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfNS0yLTEtMS00NzgwMQ_d68fee5d-3d9f-4223-9cfd-ccb9cdb12d72">787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf400d7ec4c1409c979f5a18ed50eed6_D20210401-20210630" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfNS00LTEtMS00NzgwMQ_ee78461c-de74-4023-8334-8d9fca792528">787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c76ed9108314a75b3e7842e7f8460ec_D20220101-20220630" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfNS02LTEtMS00NzgwMQ_8d7a1c53-97ba-4926-98fe-f011096c2a56">1,574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d86d5b0f18546fa82fc1f13b48c7daa_D20210101-20210630" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfNS04LTEtMS00NzgwMQ_c7462e19-25be-42b7-96f3-e9bae86aa477">2,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt discount:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50e1360e4c7b4de39282c845c5d73c43_D20220401-20220630" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfOC0yLTEtMS00NzgwMQ_8b5f7cb8-13a3-4b8a-8516-c5dddc9762fa">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i765e5eeb91e54b43b5f00f6ebddec276_D20210401-20210630" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfOC00LTEtMS00NzgwMQ_ca06170a-1863-4f68-ba4b-03c1dc5529aa">125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i421730450b74464b90e09befbd503cfc_D20220101-20220630" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfOC02LTEtMS00NzgwMQ_c4e79744-4afe-4598-8439-170c5b9a91a1">254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9858e2352550465683b249270d6735a6_D20210101-20210630" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfOC04LTEtMS00NzgwMQ_8f3dec83-edd7-496d-8b6b-9e80c22cf191">586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5021845805034e388a208b835a6c92c0_D20220401-20220630" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfOS0yLTEtMS00NzgwMQ_b2461e60-934d-47ce-ac51-f97e878aa5b7">846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ec81c8774a34665930c2c67a277cbbf_D20210401-20210630" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfOS00LTEtMS00NzgwMQ_0cd2278c-7141-4190-96bd-74adda88d90d">840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00e19a2b430241ed99f4d4d16ef7f9d0_D20220101-20220630" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfOS02LTEtMS00NzgwMQ_4c634fb2-20e6-422c-924e-fdc5f721570e">1,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0b274a39124464a2f81ffe163b7216_D20210101-20210630" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfOS04LTEtMS00NzgwMQ_8b25fcc7-9dcc-4f92-92bf-e8bdb3c1f865">1,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortization of debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib06303cf7360468aad8efb6d193ac2e0_D20220401-20220630" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTAtMi0xLTEtNDc4MDE_cce10154-cf2c-42ef-9c75-eea5531edfbc">973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf400d7ec4c1409c979f5a18ed50eed6_D20210401-20210630" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTAtNC0xLTEtNDc4MDE_e428c37d-53a1-4c09-86f4-5c3582443d2b">965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c76ed9108314a75b3e7842e7f8460ec_D20220101-20220630" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTAtNi0xLTEtNDc4MDE_48b6b49f-1a66-4b94-8e31-b47f0f9a41b4">1,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d86d5b0f18546fa82fc1f13b48c7daa_D20210101-20210630" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTAtOC0xLTEtNDc4MDE_836e9144-e16b-47f9-9dba-ffd93d115e58">1,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50e1360e4c7b4de39282c845c5d73c43_D20220401-20220630" decimals="-3" name="us-gaap:InterestExpenseDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTMtMi0xLTEtNDc4MDE_38578a75-1525-40f3-a5a1-50aa66e6afeb">411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i765e5eeb91e54b43b5f00f6ebddec276_D20210401-20210630" decimals="-3" name="us-gaap:InterestExpenseDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTMtNC0xLTEtNDc4MDE_98003f57-7440-4456-9665-37c782909cfc">409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i421730450b74464b90e09befbd503cfc_D20220101-20220630" decimals="-3" name="us-gaap:InterestExpenseDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTMtNi0xLTEtNDc4MDE_d4ffce28-1b71-4fc2-a483-e7c439b8a40b">822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9858e2352550465683b249270d6735a6_D20210101-20210630" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTMtOC0xLTEtNDc4MDE_4eba4186-a9ce-4485-a71e-7e2babcfcc83">1,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5021845805034e388a208b835a6c92c0_D20220401-20220630" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTQtMi0xLTEtNDc4MDE_4cef0b1e-5d46-4cf7-82fc-bda55260fc82">1,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ec81c8774a34665930c2c67a277cbbf_D20210401-20210630" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTQtNC0xLTEtNDc4MDE_b018843f-a36d-4f31-b9b6-efbd07a84ca9">1,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00e19a2b430241ed99f4d4d16ef7f9d0_D20220101-20220630" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTQtNi0xLTEtNDc4MDE_653dc124-ee63-4920-bf1c-ad7a170fe421">2,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0b274a39124464a2f81ffe163b7216_D20210101-20210630" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTQtOC0xLTEtNDc4MDE_1cb68d67-07c4-4475-9800-e7b1182a721a">1,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib06303cf7360468aad8efb6d193ac2e0_D20220401-20220630" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTUtMi0xLTEtNDc4MDE_feb3f70c-790d-45c1-ad25-c205884d81c2">1,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf400d7ec4c1409c979f5a18ed50eed6_D20210401-20210630" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTUtNC0xLTEtNDc4MDE_f9ff79a5-4222-4bd7-ab66-2eca66c2a897">1,752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c76ed9108314a75b3e7842e7f8460ec_D20220101-20220630" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTUtNi0xLTEtNDc4MDE_3c008a13-e2ed-44f6-a864-9195eff2fec2">3,518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d86d5b0f18546fa82fc1f13b48c7daa_D20210101-20210630" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTUtOC0xLTEtNDc4MDE_2916924b-8fb0-4f84-b353-03723397afe7">3,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective interest rates:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i78253359e5ad475094259801bb6c9cca_I20220630" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTgtMi0xLTEtNDc4MDE_db68cccb-f132-4cc2-b6ba-016382382f81">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i87582d2ecc124f6db85794fe5ea82eb5_I20210630" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTgtNC0xLTEtNDc4MDE_84ffcb5a-8319-4cdb-bf54-f7b89a386139">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i78253359e5ad475094259801bb6c9cca_I20220630" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTgtNi0xLTEtNDc4MDE_b0d0cad6-6285-4ade-99a9-cbb7e95c0533">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i87582d2ecc124f6db85794fe5ea82eb5_I20210630" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTgtOC0xLTEtNDc4MDE_f42a66ef-d3f1-4ab6-97dc-6c08431615be">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i904690f836a44521b7c1da764f701566_I20220630" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTktMi0xLTEtNDc4MDE_089aab27-026d-412e-bb50-2939c0725f81">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia588495e94d64915826033625b6cae2d_I20210630" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTktNC0xLTEtNDc4MDE_5d7923ed-ea9c-4f4e-9ceb-f14b6221b2b7">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i904690f836a44521b7c1da764f701566_I20220630" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTktNi0xLTEtNDc4MDE_3f4963f3-f5ca-4e1d-98f7-d98e1e8f5be4">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia588495e94d64915826033625b6cae2d_I20210630" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTktOC0xLTEtNjI1NjI_1808250e-9014-4f61-9cb1-0fda51e43d1d">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revolving Credit Facility (December 2021)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, we terminated that certain credit agreement entered into on December 23, 2021 with Bank of America and the other lenders party thereto (the &#8220;2021 Credit Agreement&#8221;) evidencing a revolving credit facility (the &#8220;2021 Facility&#8221;) that provided for secured revolving loans and letters of credit in an aggregate amount of up to $<ix:nonFraction unitRef="usd" contextRef="i09b74f6ef1644d8e930a5c4759e82823_I20220531" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1Nzc4Mw_8f80be4d-b5b8-414f-a0bd-1156ffff7fdd">75.0</ix:nonFraction>&#160;million.  No proceeds from the 2021 Facility were drawn down as of the date the 2021 Credit Agreement was terminated.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revolving Credit and Term Loan Facilities (May 2022)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, in connection with the closing of Antares acquisition, we entered into a credit agreement with Bank of America, N.A., as Administrative Agent, Swing Line Lender and an L/C Issuer, and the other lenders and L/C Issuers party thereto (the &#8220;2022 Credit Agreement), evidencing a credit facility (the &#8220;2022 Facility&#8221;) that provides for (i) a $<ix:nonFraction unitRef="usd" contextRef="ib607a4df5a844d5ebe887a6e5e01a915_I20220524" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1Nzc5OA_68427f7e-decd-4a1d-a39c-036190203c71">350</ix:nonFraction>&#160;million revolving credit facility (the &#8220;Revolving Credit Facility&#8221;) and (ii) a $<ix:nonFraction unitRef="usd" contextRef="i5bbab44d4d5c4f71b7e66b61049265a3_I20220524" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1NzgxMg_4975ae03-3c21-4ed6-857b-d093d797b5c1">250</ix:nonFraction>&#160;million term loan facility (the &#8220;Term Facility&#8221;). The proceeds from a $<ix:nonFraction unitRef="usd" contextRef="ie899756b47294e60987e6e1a4eefdc3e_D20220524-20220524" decimals="-6" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1NzgyNg_8667bf6b-955e-427f-a369-9cf3899d0541">120</ix:nonFraction>&#160;million draw on the Revolving Credit Facility and the $<ix:nonFraction unitRef="usd" contextRef="ibb0fc522997c467cbcef1d255211f031_D20220524-20220524" decimals="-6" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1Nzg0MA_1bda7534-84e7-471a-bcbb-5f3d65765c4c">250</ix:nonFraction>&#160;million Term Facility were used to fund a portion of the Antares acquisition, pay off Antares&#8217; existing debt and pay fees and expenses in connection with the acquisition. The 2022 Credit Agreement contains an expansion feature, which allows us, subject to certain conditions, to increase the aggregate principal amount of the 2022 Facility, provided we remain in compliance with underlying financial covenants on a pro forma basis including the consolidated interest coverage ratio and the consolidated net leverage ratio covenants set forth in the 2022 Credit Agreement. The 2022 Facility will mature on November 30, 2026 unless either the Revolving Credit Facility or the Term Facility is extended prior to such date in accordance with the 2022 Credit Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Facility requires quarterly scheduled repayments of the term loans in each of the first, second, third and fourth years following the Closing in annual amounts equal to <ix:nonFraction unitRef="number" contextRef="i02f9ba7cd53c4aa2923afca3b66da448_I20220524" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1Nzg1NA_d0ef17e7-bda9-4a71-9e82-3622ddc1b474">2.50</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="ib893c55155b64b2d9ba4c8642f2c3120_I20220524" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1Nzg2MQ_4969d246-d589-4c57-9aaf-0829bd46e4a8">5.00</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i2d84d81913354102bacd27bce79cae8a_I20220524" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1Nzg2OA_c30fcc06-9df0-41c6-bcbd-3ef37c116614">7.50</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ib5959be9d203461f9800ee2d21d52824_I20220524" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1Nzg3NQ_116c2953-dcec-4798-94f1-8a543f46df37">10.00</ix:nonFraction>% of the initial principal amount of the term loans, respectively. The term loans are also subject to mandatory prepayments from the proceeds of certain asset sales, subject to our right to reinvest the proceeds thereof.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2022 Facility bear interest, at our option, at a rate equal to an applicable margin plus: (a) the applicable Term Secured Overnight Financing Rate (SOFR) (which includes a SOFR adjustment of <ix:nonFraction unitRef="number" contextRef="icd07e3cd9dc54a55ac0339e3aa933aa6_D20220524-20220524" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1Nzg4Mw_5352f057-50a7-4486-92c4-ef0716f029be">0.10</ix:nonFraction>%), or (b) a base rate determined by reference to the highest of (1) the federal funds effective rate plus <ix:nonFraction unitRef="number" contextRef="i39c021912c0a4737966b6fc9307a0131_D20220524-20220524" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1Nzg5Nw_d1a820e3-e49c-444c-a49f-0c1c2f0cf69b">0.50</ix:nonFraction>%, (2) the Bank of America prime rate, (3) the Term SOFR rate for an interest period of one month plus <ix:nonFraction unitRef="number" contextRef="i3b5fd9edb8e049a19ff19cafcd90c13b_D20220524-20220524" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1Nzg5MA_d368326b-ae53-496a-ac0d-4650f7c214e6">1.10</ix:nonFraction>%, and (4) <ix:nonFraction unitRef="number" contextRef="ia986ec6d3c6d41d2a6808a4f5cfcff5c_D20220524-20220524" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1NzkwNA_3517e304-8c55-4d2d-b781-d0957d61abf0">1.00</ix:nonFraction>%. The margin for the 2022 Facility ranges, based on our consolidated total net leverage ratio, from <ix:nonFraction unitRef="number" contextRef="i1dce68f7e11a4d3a8fa7baa2b614c2aa_D20220524-20220524" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1NzkxMQ_48141653-bfbc-4232-a66f-a782acd5093c">0.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i3809e60efe0d46cab0ef2132238b94c8_D20220524-20220524" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1NzkxOA_826751a4-3cd1-402b-b1e5-905e76858a0d">1.25</ix:nonFraction>% in the case of base rate loans and from <ix:nonFraction unitRef="number" contextRef="i64eaeaec62e1494894adad24d117aef9_D20220524-20220524" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1NzkyNQ_0b1361aa-55b1-405d-a8d1-b4a8b580d1c4">1.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i71fba559ee5e40e6895e295b7e58d09a_D20220524-20220524" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1NzkzMg_5dd21d7c-daab-4e05-9e27-db807892295c">2.25</ix:nonFraction>% </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie968d19e384a46c99064613c4a9f4a57">in the case of Term SOFR rate loans. In addition to paying interest on the outstanding principal under the Facility, we will pay (i) a commitment fee in respect of the unutilized commitments thereunder and (ii) customary letter of credit fees and agency fees. The commitment fees range from <ix:nonFraction unitRef="number" contextRef="i10a6ebe671434acfac51d92f04f6b880_D20220524-20220524" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1NzkzOQ_46cd527d-9d03-4840-accf-d934e50b8e0b">0.15</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ia1a876b10c4244179ee15979f3e64628_D20220524-20220524" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1Nzk0Ng_083a1de4-12d4-4b09-b804-a351fe3a733f">0.35</ix:nonFraction>% per annum based on our consolidated net leverage ratio. As of June&#160;30, 2022, we had $<ix:nonFraction unitRef="usd" contextRef="i79fb023f35cc4ee996ea4cb525c92c5f_I20220630" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1NzEyNw_92cfb4de-21b0-424e-b51a-b111dbb469c1">120.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="icac5073a8dfa4150a03fa81e7c9db6f9_I20220630" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1NzE0Mw_1e542eda-54bd-42a4-9a32-a9c31e8d60af">250</ix:nonFraction>&#160;million in principal amount of outstanding borrowings under the 2022 Revolving Credit Facility and the 2022 Term Facility, respectively. We incurred a total of $<ix:nonFraction unitRef="usd" contextRef="i475bb2a82ae54a4286363422e755c916_D20220524-20220524" decimals="-5" name="halo:DebtInstrumentThirdPartyCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1NzYzMA_ddd7c029-25d5-424c-b307-3c904b2c4dc3">6.0</ix:nonFraction>&#160;million in third party costs related to the 2022 credit agreement and recorded $<ix:nonFraction unitRef="usd" contextRef="ib607a4df5a844d5ebe887a6e5e01a915_I20220524" decimals="-5" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1NzY1MQ_432f10af-2d31-4646-9a5c-6a3f9428bf88">3.5</ix:nonFraction>&#160;million as the revolving credit facility debt issuance cost and $<ix:nonFraction unitRef="usd" contextRef="i5bbab44d4d5c4f71b7e66b61049265a3_I20220524" decimals="-5" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1NzY2OQ_3038becc-251d-4ae4-abe3-4ddd84752ff8">2.5</ix:nonFraction>&#160;million as the term loan debt issuance cost.  As of June&#160;30, 2022, the unamortized debt issuance cost related to the revolving credit facility and the term loan is $<ix:nonFraction unitRef="usd" contextRef="i79fb023f35cc4ee996ea4cb525c92c5f_I20220630" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1NzY4Nw_29f0c9f3-e29b-4312-a79a-1f861ea30416">3.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icac5073a8dfa4150a03fa81e7c9db6f9_I20220630" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1NzcwMg_59757ebc-a9a3-4fd6-aae4-53877008c00f">2.4</ix:nonFraction> million, respectively.</ix:continuation></span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="ibd09c52bdc03451493df7fb7077280c7_67"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RleHRyZWdpb246YTk0M2RlMDBjM2NhNDYzNGJmNGNkYTc3YjUyMzkzZThfMjM5MA_fa301b3a-733c-4da6-b3ed-7a72eb251d25" continuedAt="id4f47fcdb87b44ba91f9f3f1cc352a7a" escape="true">Share-based Compensation</ix:nonNumeric></span></div><ix:continuation id="id4f47fcdb87b44ba91f9f3f1cc352a7a" continuedAt="icf205f64ef6e40cfa496cea5de1f8469"><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RleHRyZWdpb246YTk0M2RlMDBjM2NhNDYzNGJmNGNkYTc3YjUyMzkzZThfMjQwMQ_334abf7a-3f58-40a2-976e-80e833f8e55c" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense related to share-based awards excluding the acceleration of Antares unvested equity awards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was comprised of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.959%"><tr><td style="width:1.0%"></td><td style="width:57.246%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b599c875f4f40e294c8d28f8eb1e582_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjQyNDY3NDM2NTI0ZTQ1MTg4NzFiMzAzNjY3ZTIyMjZmL3RhYmxlcmFuZ2U6NDI0Njc0MzY1MjRlNDUxODg3MWIzMDM2NjdlMjIyNmZfMi0yLTEtMS00NzgwMQ_0b79707f-2bba-4d3a-863c-139e3a163433">2,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cfceed396a74b66a22f992517fbad65_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjQyNDY3NDM2NTI0ZTQ1MTg4NzFiMzAzNjY3ZTIyMjZmL3RhYmxlcmFuZ2U6NDI0Njc0MzY1MjRlNDUxODg3MWIzMDM2NjdlMjIyNmZfMi00LTEtMS00NzgwMQ_9185d10b-03fb-4a08-965a-c32f56c8f22b">1,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59eefa49da754fc4a678bcfece8e4fa5_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjQyNDY3NDM2NTI0ZTQ1MTg4NzFiMzAzNjY3ZTIyMjZmL3RhYmxlcmFuZ2U6NDI0Njc0MzY1MjRlNDUxODg3MWIzMDM2NjdlMjIyNmZfMi02LTEtMS00NzgwMQ_b5c222a4-1c04-4e5a-9268-89c6402d3def">4,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b377684337249a79d005226a445c9d3_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjQyNDY3NDM2NTI0ZTQ1MTg4NzFiMzAzNjY3ZTIyMjZmL3RhYmxlcmFuZ2U6NDI0Njc0MzY1MjRlNDUxODg3MWIzMDM2NjdlMjIyNmZfMi04LTEtMS00NzgwMQ_6309ea46-7362-437b-acf5-fe8c9526de7d">3,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie13a988e22704be5a5271b3555ac5742_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjQyNDY3NDM2NTI0ZTQ1MTg4NzFiMzAzNjY3ZTIyMjZmL3RhYmxlcmFuZ2U6NDI0Njc0MzY1MjRlNDUxODg3MWIzMDM2NjdlMjIyNmZfMy0yLTEtMS00NzgwMQ_7e01b0de-1e77-464d-b9ea-46d0c6c39b74">3,179</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0b6f8877784e66b28f844b0f81f44c_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjQyNDY3NDM2NTI0ZTQ1MTg4NzFiMzAzNjY3ZTIyMjZmL3RhYmxlcmFuZ2U6NDI0Njc0MzY1MjRlNDUxODg3MWIzMDM2NjdlMjIyNmZfMy00LTEtMS00NzgwMQ_4b355e4f-e269-4532-84f1-8ee4ed2b3338">3,608</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbf1cd99aace4cbfa194e2f7dedc5157_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjQyNDY3NDM2NTI0ZTQ1MTg4NzFiMzAzNjY3ZTIyMjZmL3RhYmxlcmFuZ2U6NDI0Njc0MzY1MjRlNDUxODg3MWIzMDM2NjdlMjIyNmZfMy02LTEtMS00NzgwMQ_ac19370b-2e35-4efa-a412-ea0d22a77e91">5,904</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57f7d92fa5174c7a9550dfc6b218d957_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjQyNDY3NDM2NTI0ZTQ1MTg4NzFiMzAzNjY3ZTIyMjZmL3RhYmxlcmFuZ2U6NDI0Njc0MzY1MjRlNDUxODg3MWIzMDM2NjdlMjIyNmZfMy04LTEtMS00NzgwMQ_508ecba5-4536-4c39-a114-3a612a2250d0">6,883</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjQyNDY3NDM2NTI0ZTQ1MTg4NzFiMzAzNjY3ZTIyMjZmL3RhYmxlcmFuZ2U6NDI0Njc0MzY1MjRlNDUxODg3MWIzMDM2NjdlMjIyNmZfNC0yLTEtMS00NzgwMQ_fbbfeac0-f578-4991-aed8-c353fa31a3ee">5,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjQyNDY3NDM2NTI0ZTQ1MTg4NzFiMzAzNjY3ZTIyMjZmL3RhYmxlcmFuZ2U6NDI0Njc0MzY1MjRlNDUxODg3MWIzMDM2NjdlMjIyNmZfNC00LTEtMS00NzgwMQ_828854db-6884-4970-9561-2ea2efdd2f6c">5,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjQyNDY3NDM2NTI0ZTQ1MTg4NzFiMzAzNjY3ZTIyMjZmL3RhYmxlcmFuZ2U6NDI0Njc0MzY1MjRlNDUxODg3MWIzMDM2NjdlMjIyNmZfNC02LTEtMS00NzgwMQ_362d1624-bfbf-4398-a60c-ddd31a75976f">10,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjQyNDY3NDM2NTI0ZTQ1MTg4NzFiMzAzNjY3ZTIyMjZmL3RhYmxlcmFuZ2U6NDI0Njc0MzY1MjRlNDUxODg3MWIzMDM2NjdlMjIyNmZfNC04LTEtMS00NzgwMQ_b42c45da-70ca-42f1-9905-f81e13e0ce74">10,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RleHRyZWdpb246YTk0M2RlMDBjM2NhNDYzNGJmNGNkYTc3YjUyMzkzZThfMjQwOQ_90131b2c-3fa1-48be-9bfc-7d51d1d8fc91" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense by type of share-based award (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:57.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.469%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.469%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.469%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.473%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c0e86c5373e4602b110c2747e91ff9a_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjgzZTIyNTM0YTEzZDRmN2RiZTdlYTAyZDk2ZWJhOGU0L3RhYmxlcmFuZ2U6ODNlMjI1MzRhMTNkNGY3ZGJlN2VhMDJkOTZlYmE4ZTRfMi0yLTEtMS00NzgwMQ_3511b9a0-f661-4cba-aeab-473785328e83">2,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb8fed0bdf764dd2bd8a75a83eba117c_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjgzZTIyNTM0YTEzZDRmN2RiZTdlYTAyZDk2ZWJhOGU0L3RhYmxlcmFuZ2U6ODNlMjI1MzRhMTNkNGY3ZGJlN2VhMDJkOTZlYmE4ZTRfMi00LTEtMS00NzgwMQ_0de3312f-9547-48c1-8709-4c7af069fb5d">2,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46d36ab336df48ad98a01cfdfc1a2696_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjgzZTIyNTM0YTEzZDRmN2RiZTdlYTAyZDk2ZWJhOGU0L3RhYmxlcmFuZ2U6ODNlMjI1MzRhMTNkNGY3ZGJlN2VhMDJkOTZlYmE4ZTRfMi02LTEtMS00NzgwMQ_3feab985-9392-467b-8436-c5121140a162">5,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8257a7f99e248c4b487a6942b94aec0_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjgzZTIyNTM0YTEzZDRmN2RiZTdlYTAyZDk2ZWJhOGU0L3RhYmxlcmFuZ2U6ODNlMjI1MzRhMTNkNGY3ZGJlN2VhMDJkOTZlYmE4ZTRfMi04LTEtMS00NzgwMQ_bd0a94fe-7e21-4750-99e9-d054764718dd">5,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSAs, RSUs, PSUs and ESPP</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03beebbe6fad4ae4a59c0a56d53de652_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjgzZTIyNTM0YTEzZDRmN2RiZTdlYTAyZDk2ZWJhOGU0L3RhYmxlcmFuZ2U6ODNlMjI1MzRhMTNkNGY3ZGJlN2VhMDJkOTZlYmE4ZTRfMy0yLTEtMS00NzgwMQ_92398c8a-4051-47de-a1bc-c873051b4343">3,132</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa122ca61ec54b1c824632d4d8f8bd63_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjgzZTIyNTM0YTEzZDRmN2RiZTdlYTAyZDk2ZWJhOGU0L3RhYmxlcmFuZ2U6ODNlMjI1MzRhMTNkNGY3ZGJlN2VhMDJkOTZlYmE4ZTRfMy00LTEtMS00NzgwMQ_562b7ac6-a9c2-48c4-a435-260c95e3ea27">2,735</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8786b34524304c2c89d022706441552b_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjgzZTIyNTM0YTEzZDRmN2RiZTdlYTAyZDk2ZWJhOGU0L3RhYmxlcmFuZ2U6ODNlMjI1MzRhMTNkNGY3ZGJlN2VhMDJkOTZlYmE4ZTRfMy02LTEtMS00NzgwMQ_ba6fc98c-0104-4cf6-9b57-a5e209ce3a45">5,254</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3dfae04892c4acfbec9d00a8bc5641d_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjgzZTIyNTM0YTEzZDRmN2RiZTdlYTAyZDk2ZWJhOGU0L3RhYmxlcmFuZ2U6ODNlMjI1MzRhMTNkNGY3ZGJlN2VhMDJkOTZlYmE4ZTRfMy04LTEtMS00NzgwMQ_d6ea8808-d084-47df-857a-883be7be8230">5,176</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjgzZTIyNTM0YTEzZDRmN2RiZTdlYTAyZDk2ZWJhOGU0L3RhYmxlcmFuZ2U6ODNlMjI1MzRhMTNkNGY3ZGJlN2VhMDJkOTZlYmE4ZTRfNC0yLTEtMS00NzgwMQ_9b33e0b3-5de5-43aa-8074-6d23bd2e7359">5,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjgzZTIyNTM0YTEzZDRmN2RiZTdlYTAyZDk2ZWJhOGU0L3RhYmxlcmFuZ2U6ODNlMjI1MzRhMTNkNGY3ZGJlN2VhMDJkOTZlYmE4ZTRfNC00LTEtMS00NzgwMQ_cebc9fc0-4196-41f3-bf84-921586bf483b">5,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjgzZTIyNTM0YTEzZDRmN2RiZTdlYTAyZDk2ZWJhOGU0L3RhYmxlcmFuZ2U6ODNlMjI1MzRhMTNkNGY3ZGJlN2VhMDJkOTZlYmE4ZTRfNC02LTEtMS00NzgwMQ_23a2a184-fb49-46f8-8f38-331f853da236">10,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjgzZTIyNTM0YTEzZDRmN2RiZTdlYTAyZDk2ZWJhOGU0L3RhYmxlcmFuZ2U6ODNlMjI1MzRhMTNkNGY3ZGJlN2VhMDJkOTZlYmE4ZTRfNC04LTEtMS00NzgwMQ_7e993628-2ba6-45c5-bc9c-e3dfad267497">10,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We granted stock options to purchase approximately <ix:nonFraction unitRef="shares" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RleHRyZWdpb246YTk0M2RlMDBjM2NhNDYzNGJmNGNkYTc3YjUyMzkzZThfMjgy_d3adf6eb-6129-4694-aa82-5b7eb7f3afd0">0.2</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="-2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RleHRyZWdpb246YTk0M2RlMDBjM2NhNDYzNGJmNGNkYTc3YjUyMzkzZThfMjg5_1d950f5d-293a-473a-8f47-c774e9e38f0d">36.3</ix:nonFraction> thousand shares of common stock during the three months ended June&#160;30, 2022 and 2021, respectively and <ix:nonFraction unitRef="shares" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RleHRyZWdpb246YTk0M2RlMDBjM2NhNDYzNGJmNGNkYTc3YjUyMzkzZThfMTA5OTUxMTYzMDMzMQ_518c8c1b-e298-4b64-a820-9d9d2a7f260e">1.5</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RleHRyZWdpb246YTk0M2RlMDBjM2NhNDYzNGJmNGNkYTc3YjUyMzkzZThfMTA5OTUxMTYzMDM0OQ_1493b505-6c5c-4e24-9f06-fcfe4524cbe9">0.7</ix:nonFraction> million shares of common stock during the six months ended June&#160;30, 2022 and 2021, respectively. The exercise price of stock options granted is equal to the closing price of the common stock on the date of grant. The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model (&#8220;Black-Scholes model&#8221;). Expected volatility is based on historical volatility of our common stock. The expected term of options granted is based on analyses of historical employee termination rates and option exercises. The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The dividend yield assumption is based on the expectation of no future dividend payments. <ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RleHRyZWdpb246YTk0M2RlMDBjM2NhNDYzNGJmNGNkYTc3YjUyMzkzZThfMjM4MA_f8839f39-5dc0-4d75-ba05-88d5050efd36" continuedAt="i6a3f92576e6a43c0b02726653e3dd6e3" escape="true">The assumptions used in the Black-Scholes model were as follows:</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center;text-indent:24.75pt"><ix:continuation id="i6a3f92576e6a43c0b02726653e3dd6e3"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:42.517%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.817%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.665%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.665%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.952%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2b9b85bf65324a6796a32c109822a4ae_D20220401-20220630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfMi0yLTEtMS00NzgwMS90ZXh0cmVnaW9uOmZiYmE1MDNmMmUxZTQ3ZWNiMTcyMTlkYjEyNDZlNjYwXzQ_8f132a95-5a14-4517-a8de-c79ba2c1976d">41.05</ix:nonFraction>-<ix:nonFraction unitRef="number" contextRef="ic7177752d30b457e85b8d0e18806711a_D20220401-20220630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfMi0yLTEtMS00NzgwMS90ZXh0cmVnaW9uOmZiYmE1MDNmMmUxZTQ3ZWNiMTcyMTlkYjEyNDZlNjYwXzc_08fad020-7665-464b-b6ca-b8af6efab09e">41.29</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia075a8f22ebb4c19bcb72e7ad3ead56a_D20210401-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfMi00LTEtMS00NzgwMS90ZXh0cmVnaW9uOjI5ZjJlMjRlM2UxMTQwNTY5OTY0Mjg2NWZjMzdmZjMyXzQ_b1984ea3-1dbd-41eb-9950-69c361cf1b44">44.91</ix:nonFraction>-<ix:nonFraction unitRef="number" contextRef="ia02f509257fd46da8f0a5f3e5e678761_D20210401-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfMi00LTEtMS00NzgwMS90ZXh0cmVnaW9uOjI5ZjJlMjRlM2UxMTQwNTY5OTY0Mjg2NWZjMzdmZjMyXzc_44793256-5fbc-468f-9533-5bc89a0bbc9a">44.91</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i132fba3a55ea459d84aa0bb90100bdd7_D20220101-20220630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfMi02LTEtMS00NzgwMS90ZXh0cmVnaW9uOmNkZDgwMTA3NjNkYzQwOTdiYmRhNTMzZWRhZWVkN2U5XzQ_97744a84-e104-46c0-a8bf-9770fdbb730d">41.05</ix:nonFraction>-<ix:nonFraction unitRef="number" contextRef="ifa39c538bf934a02b5928070f514abbb_D20220101-20220630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfMi02LTEtMS00NzgwMS90ZXh0cmVnaW9uOmNkZDgwMTA3NjNkYzQwOTdiYmRhNTMzZWRhZWVkN2U5Xzc_59b8a9a9-e680-4719-bce7-28fe047a3d0c">41.29</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i543c949f5482411dabdc5d1d89631950_D20210101-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfMi04LTEtMS00NzgwMS90ZXh0cmVnaW9uOmRiODMzOWY4ZWNkYzQzNDliYmI1NjZjMjRhNTk4NzY0XzQ_a2c09628-196d-4335-bb17-2f0c0f98feb8">44.91</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="ib0f607a6eb8841f78c2d102cf0eab6aa_D20210101-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfMi04LTEtMS00NzgwMS90ZXh0cmVnaW9uOmRiODMzOWY4ZWNkYzQzNDliYmI1NjZjMjRhNTk4NzY0Xzc_33ff6722-45a2-45f5-9f66-f29fb64a92d6">46.45</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfMy0yLTEtMS00NzgwMQ_e46657a1-5831-470f-bb48-a37640e55cfd">4.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfMy00LTEtMS00NzgwMQ_7b8f8637-8da6-42e5-8da0-291109dcd620">4.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfMy02LTEtMS00NzgwMQ_04430e64-bf98-408e-8c00-1f15a48a499c">4.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfMy04LTEtMS00NzgwMQ_6c7cb493-f85b-4ce0-b307-d2d457cd3dcb">4.7</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfNC0yLTEtMS00NzgwMS90ZXh0cmVnaW9uOjNmNTY2YWYyMzdhZTQ5MTI5MzNmOTJiNzc0MGZmOTdmXzQ_19867fda-9fc2-46d6-bb65-10a3c397e273">2.56</ix:nonFraction>-<ix:nonFraction unitRef="number" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfNC0yLTEtMS00NzgwMS90ZXh0cmVnaW9uOjNmNTY2YWYyMzdhZTQ5MTI5MzNmOTJiNzc0MGZmOTdmXzc_08698426-01c6-4dc0-aa44-0a5887174ace">3.01</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfNC00LTEtMS00NzgwMS90ZXh0cmVnaW9uOjkyMTQ3MjU2MDI1NjQyMTlhYmZiMjk0NDhmOTc3NjZiXzQ_d5517230-31ad-4fd5-9856-537bae283384">0.81</ix:nonFraction>-<ix:nonFraction unitRef="number" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfNC00LTEtMS00NzgwMS90ZXh0cmVnaW9uOjkyMTQ3MjU2MDI1NjQyMTlhYmZiMjk0NDhmOTc3NjZiXzc_3f8f6b19-94f8-48d0-96f8-0491420281f2">0.81</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfNC02LTEtMS00NzgwMS90ZXh0cmVnaW9uOjQ4MTQ1MWM0MDVjNjQ3MjNhYjgyYzQ5MDRiNDAzZDdlXzQ_79bffbf2-aad4-4e06-b0cf-384d02df8a6d">1.37</ix:nonFraction>-<ix:nonFraction unitRef="number" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfNC02LTEtMS00NzgwMS90ZXh0cmVnaW9uOjQ4MTQ1MWM0MDVjNjQ3MjNhYjgyYzQ5MDRiNDAzZDdlXzc_81d77bad-f231-4934-a58f-312454f9780e">3.01</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfNC04LTEtMS00NzgwMS90ZXh0cmVnaW9uOjkyNDk0YzBmN2ViNjRhNTg4MGEzYzEzYzMxZmY5OTI3XzQ_04fa95b6-84ff-41bb-86e0-1b73ecef65b6">0.36</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfNC04LTEtMS00NzgwMS90ZXh0cmVnaW9uOjkyNDk0YzBmN2ViNjRhNTg4MGEzYzEzYzMxZmY5OTI3Xzc_828ebf6a-a6bf-4068-a0f0-f106e39fa538">0.81</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfNS0yLTEtMS00NzgwMQ_c8e0814e-a339-4fc8-9ad6-61c7686b6d4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfNS00LTEtMS00NzgwMQ_40ee8f9b-1ec3-49c0-85b1-bbe9ac48a78a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfNS02LTEtMS00NzgwMQ_0ade22db-6e12-4766-a4a7-1f74ff1c00c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfNS04LTEtMS00NzgwMQ_044a9d37-57e1-4881-a71c-43663842c02a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, our Board of Directors approved our 2021 ESPP and our stockholders approved the plan in May 2021. The ESPP enables eligible employees to purchase shares of our common stock at the end of each offering period at a price equal to <ix:nonFraction unitRef="number" contextRef="i21d64138ff854e21be215de2a288c045_D20210201-20210228" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RleHRyZWdpb246YTk0M2RlMDBjM2NhNDYzNGJmNGNkYTc3YjUyMzkzZThfMTM5MA_cfd34c30-f3b4-40cf-96fc-148a7e34f59b">85</ix:nonFraction>% of the fair market value of the shares on the first business day or the last business day of the offering period, whichever is lower. Share purchases are funded through payroll deduction of at least <ix:nonFraction unitRef="number" contextRef="i96a1543f8d6e4bfbb485a55166a6038c_I20210228" decimals="INF" name="halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RleHRyZWdpb246YTk0M2RlMDBjM2NhNDYzNGJmNGNkYTc3YjUyMzkzZThfMTU5Mg_3a1564d9-ecc5-46c0-afae-a1ba4b31d95f">1</ix:nonFraction>% and up to <ix:nonFraction unitRef="number" contextRef="i96a1543f8d6e4bfbb485a55166a6038c_I20210228" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RleHRyZWdpb246YTk0M2RlMDBjM2NhNDYzNGJmNGNkYTc3YjUyMzkzZThfMTYwNQ_902c1da3-4a12-4983-ba79-8a0376bdaf76">15</ix:nonFraction>% of an employee&#8217;s compensation for each payroll period, and no employee may purchase shares under the ESPP that exceeds $<ix:nonFraction unitRef="usd" contextRef="i21d64138ff854e21be215de2a288c045_D20210201-20210228" decimals="-3" name="halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RleHRyZWdpb246YTk0M2RlMDBjM2NhNDYzNGJmNGNkYTc3YjUyMzkzZThfMTcyNw_93062d15-1df4-4ad3-a3a5-df93b4d1f466">25,000</ix:nonFraction> worth of our common stock for a calendar year. As of June&#160;30, 2022, <ix:nonFraction unitRef="shares" contextRef="i49fcdbfe0faf49d1a3e26def4e7b572f_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RleHRyZWdpb246YTk0M2RlMDBjM2NhNDYzNGJmNGNkYTc3YjUyMzkzZThfMTA5OTUxMTYzMDQyNw_4f6ad5cf-bdca-4beb-8b6a-f4462da829b3">2,665,369</ix:nonFraction> shares were available for future purchase. The offering period is generally for a <ix:nonNumeric contextRef="i21d64138ff854e21be215de2a288c045_D20210201-20210228" name="halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RleHRyZWdpb246YTk0M2RlMDBjM2NhNDYzNGJmNGNkYTc3YjUyMzkzZThfMjM4OA_164f171d-7cfa-4039-8560-c4d3202ee334">six-months</ix:nonNumeric> period and the first offering period commenced on June 16, 2021. Offering periods shall commence on or about the sixteenth day of June and December of each year and end on or about the fifteenth day of the next December and June respectively, occurring thereafter. During the three months ended June&#160;30, 2022, <ix:nonFraction unitRef="shares" contextRef="ib6ded8ac2e08484aa08a3116e39e8ed6_D20220401-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RleHRyZWdpb246YTk0M2RlMDBjM2NhNDYzNGJmNGNkYTc3YjUyMzkzZThfMTkyNDE0NTM0ODk1MTY_97324c15-9443-4997-983b-0abb8a3a95bb">16,858</ix:nonFraction>  shares were issued pursuant to the ESPP.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="icf205f64ef6e40cfa496cea5de1f8469"><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RleHRyZWdpb246YTk0M2RlMDBjM2NhNDYzNGJmNGNkYTc3YjUyMzkzZThfMjM3NA_b82bbff2-ca1b-4690-94ef-1383bcca2dd9" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unrecognized estimated compensation cost by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):</span></div><div style="margin-top:5pt;text-align:center;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"></td><td style="width:70.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.243%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.246%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrecognized<br/>Expense</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining<br/>Weighted-Average<br/>Recognition Period<br/>(years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i039a8cae3d874e6fb7155efc49a70811_I20220630" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjk2MDdiZThjMWI4YzRkMDNhYWZhZTVlNWVhOGJiNGMxL3RhYmxlcmFuZ2U6OTYwN2JlOGMxYjhjNGQwM2FhZmFlNWU1ZWE4YmI0YzFfMi0yLTEtMS00NzgwMQ_05f922e5-9250-4283-b639-3536bb010e79">28,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i46d36ab336df48ad98a01cfdfc1a2696_D20220101-20220630" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjk2MDdiZThjMWI4YzRkMDNhYWZhZTVlNWVhOGJiNGMxL3RhYmxlcmFuZ2U6OTYwN2JlOGMxYjhjNGQwM2FhZmFlNWU1ZWE4YmI0YzFfMi00LTEtMS00NzgwMQ_f6d9e301-123b-4840-949a-df6c6120431f">2.81</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90338c7e90e04fbb88f9eaebe6f9c0a4_I20220630" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjk2MDdiZThjMWI4YzRkMDNhYWZhZTVlNWVhOGJiNGMxL3RhYmxlcmFuZ2U6OTYwN2JlOGMxYjhjNGQwM2FhZmFlNWU1ZWE4YmI0YzFfNC0yLTEtMS00NzgwMQ_0472af45-b40a-428d-a976-4ce6aab7c6ed">33,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i846c45d299c548bd93d9ca4e31ef2c27_D20220101-20220630" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjk2MDdiZThjMWI4YzRkMDNhYWZhZTVlNWVhOGJiNGMxL3RhYmxlcmFuZ2U6OTYwN2JlOGMxYjhjNGQwM2FhZmFlNWU1ZWE4YmI0YzFfNC00LTEtMS00NzgwMQ_c498d661-c997-4c59-9b9b-48f26abb5065">2.82</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd47428a7d224a1cb5358f0397539915_I20220630" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjk2MDdiZThjMWI4YzRkMDNhYWZhZTVlNWVhOGJiNGMxL3RhYmxlcmFuZ2U6OTYwN2JlOGMxYjhjNGQwM2FhZmFlNWU1ZWE4YmI0YzFfNS0yLTEtMS00NzgwMQ_67a08adc-0ed7-4761-ae87-dbb393cda3a2">5,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ife8e3a854f8d4e9a9d92bcbe808224ee_D20220101-20220630" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjk2MDdiZThjMWI4YzRkMDNhYWZhZTVlNWVhOGJiNGMxL3RhYmxlcmFuZ2U6OTYwN2JlOGMxYjhjNGQwM2FhZmFlNWU1ZWE4YmI0YzFfNS00LTEtMS00NzgwMQ_57ecfd56-52cf-45b1-a7e0-411553b48db5">2.41</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6e73a624be47fea5d20e683c6bea8e_I20220630" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjk2MDdiZThjMWI4YzRkMDNhYWZhZTVlNWVhOGJiNGMxL3RhYmxlcmFuZ2U6OTYwN2JlOGMxYjhjNGQwM2FhZmFlNWU1ZWE4YmI0YzFfNi0yLTEtMS00NzgwMQ_86fe1f41-d32c-4d0d-83a8-0e29dc59ef1a">172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idc726257139b49b6a58fe70d504a57d9_D20220101-20220630" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjk2MDdiZThjMWI4YzRkMDNhYWZhZTVlNWVhOGJiNGMxL3RhYmxlcmFuZ2U6OTYwN2JlOGMxYjhjNGQwM2FhZmFlNWU1ZWE4YmI0YzFfNi00LTEtMS00NzgwMQ_89d5bd6b-bb37-4ef9-8e1d-a73c534a5a6e">0.46</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:center;text-indent:24.75pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="ibd09c52bdc03451493df7fb7077280c7_73"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMjAwMw_e520d78d-c9bd-457b-83ca-857b155c8dd5" continuedAt="i44dba27b872e47e4a76ef7646763c75b" escape="true">Stockholders&#8217; Equity </ix:nonNumeric></span></div><ix:continuation id="i44dba27b872e47e4a76ef7646763c75b"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2022 and 2021, we issued an aggregate of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i46d36ab336df48ad98a01cfdfc1a2696_D20220101-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfOTQ_c09eb107-cf71-4760-a550-c52354f20e99">350,216</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and <ix:nonFraction unitRef="shares" contextRef="if8257a7f99e248c4b487a6942b94aec0_D20210101-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMTAx_d7cc20d1-4b44-43e0-858f-88f12b1f9c7f">591,891</ix:nonFraction> shares of common stock, respectively, in connection with the exercises of stock options at a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i46d36ab336df48ad98a01cfdfc1a2696_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMjMy_b3ae20fb-061a-4c97-bea1-4968cefc2b49">17.94</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="if8257a7f99e248c4b487a6942b94aec0_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMjM5_d919bbc2-e68b-4fed-ba32-b62a7ea4033d">13.64</ix:nonFraction> per share, respectively, for net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i46d36ab336df48ad98a01cfdfc1a2696_D20220101-20220630" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMzAx_1ae88145-ef59-4a16-aec1-e35af5c5d636">6.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if8257a7f99e248c4b487a6942b94aec0_D20210101-20210630" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMzA4_f872a8fd-2344-4a0d-ad6d-406306559c1c">8.1</ix:nonFraction> million, respectively. For the six months ended June&#160;30, 2022 and 2021, we issued <ix:nonFraction unitRef="shares" contextRef="i846c45d299c548bd93d9ca4e31ef2c27_D20220101-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMzcx_3d30d8e9-ef97-482b-92e4-a868b16ec540">248,343</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i68a4a2f139194eaf961414023ef77512_D20210101-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMzc4_3b1582a8-0950-40f0-9a72-3f94b69e9bfe">290,149</ix:nonFraction> shares of common stock, respectively, upon vesting of certain RSUs and PSUs for which <ix:nonFraction unitRef="shares" contextRef="i846c45d299c548bd93d9ca4e31ef2c27_D20220101-20220630" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfNDY3_18176739-b2b7-4f1a-ac89-82b390f278ca">68,425</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i68a4a2f139194eaf961414023ef77512_D20210101-20210630" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfNDc0_8b1ad177-0d66-4598-88dc-cf1ec58d5fee">91,383</ix:nonFraction> RSUs were withheld from the RSU holders, respectively, to pay for minimum withholding taxes totaling approximately $<ix:nonFraction unitRef="usd" contextRef="i846c45d299c548bd93d9ca4e31ef2c27_D20220101-20220630" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfNTky_5d286895-390f-4164-8d3d-8317aa6a2f25">4.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i68a4a2f139194eaf961414023ef77512_D20210101-20210630" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfNTk5_8bf81e7e-a7fb-405a-9a85-16d26ae5397e">8.0</ix:nonFraction> million, respectively. Stock options and unvested restricted units totaling approximately <ix:nonFraction unitRef="shares" contextRef="iea8e1a13442143e58800a7fa395d7502_I20220630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfNjg0_0e3a24dd-07be-46fc-a34e-2c88a71d6e01">6.8</ix:nonFraction> million shares and <ix:nonFraction unitRef="shares" contextRef="i0c6331a6ec0e49a3ba11830898b654f5_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfNjk4_e637adf6-5f74-48fc-a6af-37219f18f45c">5.9</ix:nonFraction> million shares of our common stock were outstanding as of June&#160;30, 2022 and December&#160;31, 2021, respectively. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we announced that the Board of Directors has authorized the initiation of a capital return program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="ida58a610325c429a94dfe3fb62450540_I20191130" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfOTMy_ece30798-fd6e-471c-ac24-27230b51a970">550.0</ix:nonFraction> million of outstanding common stock over a <ix:nonNumeric contextRef="iae83682afbfd42498583c6364b173a85_D20191101-20191130" name="us-gaap:StockRepurchaseProgramPeriodInForce1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMjAwOQ_a69b7a69-ec0d-427a-a392-6a23d197a24c">three-year</ix:nonNumeric> period. During 2020, we repurchased <ix:nonFraction unitRef="shares" contextRef="if2cda56e59c543bdb0c8c9ac8c626f34_D20210101-20210331" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMTAxNA_79cec606-d504-43f8-af0e-fa4580090856">6.5</ix:nonFraction>&#160;million shares of common stock for $<ix:nonFraction unitRef="usd" contextRef="if2cda56e59c543bdb0c8c9ac8c626f34_D20210101-20210331" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMTA0NA_b0bfcd08-b4c1-4da9-aa75-2cf6ff1465fb">150.0</ix:nonFraction>&#160;million at an average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="if2cda56e59c543bdb0c8c9ac8c626f34_D20210101-20210331" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMTA3MA_5ebc14a5-0106-436c-bde0-7203b0338b6d">23.05</ix:nonFraction>. During 2021, we repurchased <ix:nonFraction unitRef="shares" contextRef="i6eddd51f62374e059ee58a39542c4f58_D20220101-20220331" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMTEwMg_205ffbfb-c0e3-4bd7-a6ed-2ad8d0990a81">4.6</ix:nonFraction>&#160;million shares of common stock for $<ix:nonFraction unitRef="usd" contextRef="i6eddd51f62374e059ee58a39542c4f58_D20220101-20220331" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMTEzMg_4002ae35-5321-4b0e-ba45-8ba9f09fd9db">200.0</ix:nonFraction>&#160;million at an average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i6eddd51f62374e059ee58a39542c4f58_D20220101-20220331" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMTE1OA_b02256f3-fdc3-4f0c-bd8c-330e4995508b">43.02</ix:nonFraction> under the program. The shares were purchased through open market transactions and through an ASR agreement. The $<ix:nonFraction unitRef="usd" contextRef="ida58a610325c429a94dfe3fb62450540_I20191130" decimals="-5" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMTI3Mw_40ebf162-d4d1-4732-a25d-ed7e0f0c4ca8">550.0</ix:nonFraction>&#160;million share repurchase program was completed in October 2021 having repurchased a total of <ix:nonFraction unitRef="shares" contextRef="if429dbd362794e36ab10ac51992df878_D20191101-20211031" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMTM2MQ_1a7dcada-fef0-4220-a631-9025253d94d0">22.3</ix:nonFraction>&#160;million shares at an average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="if429dbd362794e36ab10ac51992df878_D20191101-20211031" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMTM5NA_48885ada-2cb0-4202-b602-647facdb19b5">24.72</ix:nonFraction>.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2021, the Board of Directors authorized a second capital return program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231" decimals="-5" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMTUwMg_845f7f1d-174e-4462-ac71-236302b2ce23">750.0</ix:nonFraction>&#160;million of outstanding stock over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMTUzMw_f787b3d2-f4a4-40e0-98f4-002839096391">three</span>-year period. Also in December 2021, as part of the second capital return program, we entered into an ASR agreement to repurchase $<ix:nonFraction unitRef="usd" contextRef="ic73a9ae57f1f4045a6e76817123e3ac0_D20211201-20211231" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMTY2NQ_b9efd4f1-606d-4af7-90e5-028a2bb7c263">150.0</ix:nonFraction>&#160;million of common stock. At inception pursuant to the agreement, we paid $<ix:nonFraction unitRef="usd" contextRef="ic73a9ae57f1f4045a6e76817123e3ac0_D20211201-20211231" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMTczMw_2339e7ac-11b5-4497-80aa-a2d6db8b97e9">150.0</ix:nonFraction>&#160;million to Bank of America and took initial delivery of <ix:nonFraction unitRef="shares" contextRef="ic73a9ae57f1f4045a6e76817123e3ac0_D20211201-20211231" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMTc4NA_7cc15244-c42f-41ff-998e-3c4525335187">3.5</ix:nonFraction>&#160;million shares. In June 2022, we finalized the transaction and received an additional <ix:nonFraction unitRef="shares" contextRef="ia44d229bf8fa4a2cbef0e366dafed174_D20220601-20220630" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMTY0OTI2NzQ0Mzk3OA_6a8adbc4-b826-4a07-a26b-532fad34fbb1">0.4</ix:nonFraction>&#160;million shares. We retired the repurchased shares and they resumed the status of authorized and unissued shares.</span></div></ix:continuation><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="ibd09c52bdc03451493df7fb7077280c7_76"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RleHRyZWdpb246NmExZDEyMzNiODQ2NDdiODkzN2IyMTdiNjczODczMTNfMTY0OQ_1976105a-ecb9-4a64-ab02-ecc8319d9de2" continuedAt="i8c5736112ccb467f87ace0624e92380a" escape="true">Net Income per share</ix:nonNumeric></span></div><ix:continuation id="i8c5736112ccb467f87ace0624e92380a" continuedAt="i97cc9b779fbb407b876b3e9ceefb46c3"><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income per common share is computed by dividing net income for the period by the weighted average number of common shares outstanding during the period, without consideration for common stock equivalents. Outstanding stock options, unvested RSAs, unvested RSUs, unvested PSUs, common shares expected to be issued under our ESPP and the Convertible Notes are considered common stock equivalents and are only included in the calculation of diluted earnings per common share when net income is reported and their effect is dilutive. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive common shares issuable upon vesting of stock options, RSAs, RSUs and PSUs are determined using the average share price for each period under the treasury stock method. Potentially dilutive common shares issuable upon conversion of our Convertible Notes are determined using the if-converted method. Since we have committed to settle the principal amount of the Convertible Notes in cash upon conversion only, the number of shares for the conversion spread will be included as a dilutive common stock equivalent. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RleHRyZWdpb246NmExZDEyMzNiODQ2NDdiODkzN2IyMTdiNjczODczMTNfMTY1MA_943f473f-d87e-45f4-98d0-d20056574bb2" continuedAt="i80e80915046a421fa0fe3213d954da92" escape="true">A reconciliation of the numerators and the denominators of the basic and diluted net income per common share computations is as follows (in thousands, except per share amounts):</ix:nonNumeric></span></div><div style="margin-top:11pt;text-align:center;text-indent:24.75pt"><ix:continuation id="i80e80915046a421fa0fe3213d954da92"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:58.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.266%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfMy0yLTEtMS00NzgwMQ_85b363d4-a679-442b-baa8-ad436f7b43ee">22,685</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfMy00LTEtMS00NzgwMQ_c154d82d-6939-45b0-940a-bc0ef625135c">91,458</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfMy02LTEtMS00NzgwMQ_a0754598-91f1-4937-8bb8-d82427c9b01c">82,793</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfMy04LTEtMS00NzgwMQ_786b2ab9-7142-411f-83c4-d7eb6d91474d">119,353</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding for basic net income per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfNS0yLTEtMS00NzgwMQ_57c25836-e644-4680-8ecf-c09236d1ad16">137,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfNS00LTEtMS00NzgwMQ_e77992b0-4c38-4982-878f-bd76da612939">142,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfNS02LTEtMS00NzgwMQ_73afdbac-a78c-436a-b096-80925455eb32">137,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfNS04LTEtMS00NzgwMQ_9f7773b0-107d-45fc-92ef-5c53ffd2d040">140,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive potential common stock outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c0e86c5373e4602b110c2747e91ff9a_D20220401-20220630" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfNy0yLTEtMS00NzgwMQ_c9797492-3966-400a-9d3f-6445b2d74a91">2,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibb8fed0bdf764dd2bd8a75a83eba117c_D20210401-20210630" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfNy00LTEtMS00NzgwMQ_4f339c0c-532e-4c5a-b60a-70fadb1b7e87">2,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i46d36ab336df48ad98a01cfdfc1a2696_D20220101-20220630" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfNy02LTEtMS00NzgwMQ_9fd9d92f-becb-48c2-b772-734503090711">2,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if8257a7f99e248c4b487a6942b94aec0_D20210101-20210630" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfNy04LTEtMS00NzgwMQ_cde04780-ae88-4237-9287-3c2768e07493">3,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSAs, RSUs, PSUs and ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie55dcf742b2e4dffa0c703e02b2973d4_D20220401-20220630" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfOC0yLTEtMS00NzgwMQ_5391f07b-36e6-4ea9-b9e9-cae1ea2dd4e8">296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i589ea088db504147b0ffc55414faf533_D20210401-20210630" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfOC00LTEtMS00NzgwMQ_31bb633f-87e3-40db-a4f2-935283fcefce">447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1a8ca59aa7d8490c970c1e0dae5c4eae_D20220101-20220630" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfOC02LTEtMS00NzgwMQ_1d96642d-ce9b-4485-923f-98470766f304">331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i472657a1189640ed803ebfce1b25d59f_D20210101-20210630" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfOC04LTEtMS00NzgwMQ_67131c3e-2a40-46d3-a2a1-eefb1e11926b">609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7fd2c85ec0bb4267bea086d8a0cd4161_D20220401-20220630" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfOS0yLTEtMS00NzgwMQ_03c50635-2d56-4e3d-9c2a-1cc25413a274">1,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic7f900d934cc4dfca248ded4a6faaf36_D20210401-20210630" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfOS00LTEtMS00NzgwMQ_1e78adaa-7dc8-4ad8-9d11-c36ec7b550d3">1,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i24cfdda4dd3d45168530f3505f70dc4d_D20220101-20220630" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfOS02LTEtMS00NzgwMQ_ef32702e-4017-4f31-8306-36e2c6f8bc80">1,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibfecde32e655413b98a5b79476a9c15f_D20210101-20210630" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfOS04LTEtMS00NzgwMQ_c6568f58-c2e1-4a04-b12f-526aa7cd0680">4,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding for diluted net income per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfMTAtMi0xLTEtNDc4MDE_294c63cf-01a2-4b06-8dce-72e72a3f6ba2">142,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfMTAtNC0xLTEtNDc4MDE_ffac6d27-c7d1-49f9-975e-5068b575f794">147,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfMTAtNi0xLTEtNDc4MDE_78bf488c-215a-456e-b3e2-cbc101d3d1ae">141,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfMTAtOC0xLTEtNDc4MDE_84eea921-ff9a-4548-9212-0363fe46ea58">148,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfMTItMi0xLTEtNDc4MDE_1d2092c9-27ac-4a6f-8b38-09f855b78a38">0.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfMTItNC0xLTEtNDc4MDE_7552e1b1-c3ee-47ef-89dc-4c0246a1290f">0.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfMTItNi0xLTEtNDc4MDE_523b7e11-a8e2-409e-aedc-aa4e8791e748">0.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfMTItOC0xLTEtNDc4MDE_9f546968-24d4-4837-bde9-41718f13d2b8">0.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfMTMtMi0xLTEtNDc4MDE_8995a73b-5ccb-4438-a3c6-eff5ea978e53">0.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfMTMtNC0xLTEtNDc4MDE_aee1a367-b89e-4924-8293-c2bd74fca42b">0.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfMTMtNi0xLTEtNDc4MDE_bf0eb8de-d3f7-431d-b291-a424d5f94f1b">0.58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfMTMtOC0xLTEtNDc4MDE_e93a9c21-20fc-45f2-8de4-1115bfea56fe">0.81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RleHRyZWdpb246NmExZDEyMzNiODQ2NDdiODkzN2IyMTdiNjczODczMTNfMTY1MQ_8933b7cb-0556-4349-8500-ce858e4134fd" continuedAt="i9962dee1cabf47d7a5cef4f63c79dbaf" escape="true"><div style="margin-top:11pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares which have been excluded from the calculation of diluted net income per common share because their effect was anti-dilutive, include the following (shares in millions):</span></div><div style="margin-top:11pt;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"><tr><td style="width:1.0%"></td><td style="width:57.531%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.702%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;June 30,</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOjk1OTZkZDdkODdkYTQ4NDhhYzRlZDA2NmJlNzVlNjExL3RhYmxlcmFuZ2U6OTU5NmRkN2Q4N2RhNDg0OGFjNGVkMDY2YmU3NWU2MTFfMi0yLTEtMS00NzgwMQ_24ecae5b-90c4-48b5-880d-bd8146596eef">15.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOjk1OTZkZDdkODdkYTQ4NDhhYzRlZDA2NmJlNzVlNjExL3RhYmxlcmFuZ2U6OTU5NmRkN2Q4N2RhNDg0OGFjNGVkMDY2YmU3NWU2MTFfMi0zLTEtMS00NzgwMQ_a3bfa5f6-3c90-43c5-8329-3c56536ae0e6">13.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOjk1OTZkZDdkODdkYTQ4NDhhYzRlZDA2NmJlNzVlNjExL3RhYmxlcmFuZ2U6OTU5NmRkN2Q4N2RhNDg0OGFjNGVkMDY2YmU3NWU2MTFfMi01LTEtMS00NzgwMQ_1f59b2c5-6437-4b41-92f2-fee4366b1517">15.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOjk1OTZkZDdkODdkYTQ4NDhhYzRlZDA2NmJlNzVlNjExL3RhYmxlcmFuZ2U6OTU5NmRkN2Q4N2RhNDg0OGFjNGVkMDY2YmU3NWU2MTFfMi03LTEtMS00NzgwMQ_a63e7fd1-7cac-44e4-ad46-932222de1329">13.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:11pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i97cc9b779fbb407b876b3e9ceefb46c3"><ix:continuation id="i9962dee1cabf47d7a5cef4f63c79dbaf">(1). The anti-dilutive securities include outstanding stock options, unvested RSAs, unvested RSUs, unvested PSUs, common shares expected to be issued under our ESPP and Convertible Notes</ix:continuation></ix:continuation>.</span></div><div style="height:90pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="ibd09c52bdc03451493df7fb7077280c7_79"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183OS9mcmFnOjMxOGQ3ODVmM2ZkNDRmN2U4MzA4NDk5NmVmN2U1ZWZjL3RleHRyZWdpb246MzE4ZDc4NWYzZmQ0NGY3ZTgzMDg0OTk2ZWY3ZTVlZmNfMTAwNg_5d35b51f-45bc-423b-980d-58a15917e754" continuedAt="iacdf0302cede42f3bbf79dcad2adb5bf" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iacdf0302cede42f3bbf79dcad2adb5bf">From time to time, we may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of our business. Any of these claims could subject us to costly legal expenses and, while we generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on our consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage our reputation and business. We currently are not a party to any legal proceedings, the adverse outcome of which, in management&#8217;s opinion, individually or in the aggregate, would have a material adverse effect on our consolidated results of operations or financial position.</ix:continuation></span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="ibd09c52bdc03451493df7fb7077280c7_85"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. &#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div id="ibd09c52bdc03451493df7fb7077280c7_88"></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> used in this report, unless the context suggests otherwise, references to &#8220;Halozyme,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;ours,&#8221; and &#8220;us&#8221; refer to Halozyme Therapeutics, Inc., its wholly owned subsidiaries, Halozyme, Inc. Antares Pharma Inc., Halozyme Inc.&#8217;s wholly-owned subsidiary Halozyme Switzerland Holdings GmbH. and Antares Pharma Inc.s&#8217; wholly-owned subsidiaries, Antares Pharma IPL AG and Antares Pharma AG. References to &#8220;Notes&#8221; refer to the Notes to Condensed Consolidated Financial Statements included herein (refer to Item 1 of Part I).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following information should be read in conjunction with the interim unaudited condensed consolidated financial statements and Notes thereto included in Item&#160;1 of this Quarterly Report on Form 10-Q, as well as the audited financial statements and notes thereto and Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations for the fiscal year ended December&#160;31, 2021, included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021. Past financial or operating performance is not necessarily a reliable indicator of future performance, and our historical performance should not be used to anticipate results or future period trends.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This report contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this report other than statements of historical fact are, or may be deemed to be, forward-looking statements. Words such as &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;seek,&#8221; &#8220;estimate,&#8221; &#8220;think,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;continue,&#8221; &#8220;potential,&#8221; &#8220;likely,&#8221; &#8220;opportunity,&#8221; &#8220;project&#8221; and similar expressions or variations of such words are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements in this report. Additionally, statements concerning future matters such as the development or regulatory approval of new partner products, enhancements of existing products or technologies, timing and success of the launch of new products by our partners, third party performance under key collaboration agreements, the ability to successfully integrate Antares Pharma, Inc, into our business, the ability of our bulk drug manufacturers to provide adequate supply for our partners, revenue, expense, cash burn levels and our ability to make timely repayments of debt, anticipated amounts and timing of share repurchases, anticipated profitability and expected trends, the potential impact of the COVID-19 global pandemic on our business and trends and other statements regarding matters that are not historical are forward-looking statements. Such statements reflect management&#8217;s current forecast of certain aspects of our future, are based on currently available operating, financial and competitive information and are subject to various risks, uncertainties and assumptions that could cause actual results to differ materially from those anticipated or implied in our forward-looking statements due to a number of factors including, but not limited to, those set forth below under the section entitled &#8220;Risks Factors&#8221; and elsewhere in this Quarterly Report on Form 10-Q and our most recent Annual Report on Form 10-K. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this Quarterly Report. We undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this Quarterly Report.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Halozyme Therapeutics, Inc. is a biopharma technology platform company that provides innovative and disruptive solutions with the goal of improving patient experience and outcomes. Our proprietary enzyme, rHuPH20, is used to facilitate the delivery of injected drugs and fluids. We license our technology to biopharmaceutical companies to collaboratively develop products that combine our ENHANZE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> drug delivery technology (ENHANZE) with the partners&#8217; proprietary compounds.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our first commercially approved product, Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> recombinant, (&#8220;Hylenex&#8221;), and our partners&#8217; approved products and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 is the active ingredient in Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and it works by breaking down hyaluronan (or HA), a naturally occurring carbohydrate that is a major component of the extracellular matrix of the subcutaneous (SC) space. This temporarily increases dispersion and absorption allowing for improved SC delivery of injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as ENHANZE. We license the ENHANZE technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the subcutaneous route of administration. In the development of proprietary intravenous (IV) drugs combined with our ENHANZE technology, data have been generated supporting the potential for ENHANZE to reduce patient treatment burden, as a result of shorter duration of SC administration. ENHANZE may enable fixed-dose SC dosing compared to weight-based dosing required for IV administration, and potentially allow for lower rates of infusion-related reactions. ENHANZE may enable more flexible treatment options such as home administration by a healthcare professional or potentially the patient. Lastly, certain proprietary drugs co-formulated with ENHANZE have been granted additional exclusivity, extending the patent life of the product beyond the patent expiry of  of the proprietary IV drug.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have ENHANZE collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (Roche), Baxalta US Inc. and Baxalta GmbH (members of the Takeda group of companies) (Baxalta), Pfizer Inc. (Pfizer), Janssen Biotech, Inc. (Janssen), AbbVie, Inc. (AbbVie), Eli Lilly and Company (Lilly), Bristol Myers Squibb Company (BMS), Alexion Pharma International Operations Unlimited Company (an indirect wholly owned subsidiary of AstraZeneca PLC) (Alexion), argenx BVBA (argenx), Horizon Therapeutics plc. (Horizon), ViiV Healthcare (the global specialist HIV company majority owned by GlaxoSmithKline) (ViiV) and Chugai Pharmaceutical Co., Ltd (Chugai). In addition to receiving upfront licensing fees from our ENHANZE collaborations, we are entitled to receive event and sales attainment  milestone payments, revenues from the sale of bulk rHuPH20 and royalties from commercial sales of approved partner products co-formulated with ENHANZE. We currently receive royalties from three of these collaborations, including royalties from sales of one product from the Baxalta collaboration, three products from the Roche collaboration and one product from the Janssen collaboration. Future potential revenues from from ENHANZE collaborations and from the sales and/or royalties of our approved products will depend on the ability of Halozyme and our partners to develop, manufacture, secure and maintain regulatory approvals for approved products and product candidates and commercialize product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our recent acquisition of Antares Pharma, Inc. (&#8220;Antares&#8221;), we also develop, manufacture and commercialize, for ourselves or with our partners, drug-device combination products using our advanced auto-injector technologies that are designed to seek to provide commercial or functional advantages such as convenience, improved tolerability, and enhanced patient comfort and adherence. Also as a result of our acquisition of Antares, our commercial portfolio of proprietary products includes XYOSTED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, TLANDO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and NOCDURNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and partnered commercial products and ongoing product development programs with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (&#8220;Teva&#8221;), Covis Group S.a.r.l. (&#8220;Covis&#8221;), Pfizer and Idorsia Pharmaceuticals Ltd. (&#8220;Indorsia&#8221;).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our second quarter of 2022 and recent key events are as follows:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Partners</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In August 2022, Roche  announced that the Phase III IMscin001 study evaluating a subcutaneous (SC) formulation of Tecentriq&#174; (atezolizumab) with ENHANZE met its co-primary endpoints. The study showed non-inferior levels of Tecentriq  in the blood (pharmacokinetics), when injected subcutaneously, compared with intravenous (IV) infusion, in cancer immunotherapy-na&#239;ve patients with advanced or metastatic non-small cell lung cancer for whom prior platinum therapy has failed. The safety profile of the SC formulation was consistent with that of IV Tecentriq.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">In July 2022, Baxalta US Inc., a Takeda company, announced positive topline results from pivotal Phase 3 trial evaluating HYQVIA&#174; (Immunoglobulin infusion 10% (Human) with rHuPH20), for maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In June 2022, we recognized $15 million in milestone revenues related to variable consideration in the contracts where uncertainties have been resolved and the development milestones were expected to be achieved.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In June 2022, BMS nominated an undisclosed target resulting in a $5 million payment.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In June 2022, ViiV initiated enrollment of a Phase 1 single dose escalation study in subjects with HIV to evaluate pharmacokinetics, safety and tolerability of long-acting cabotegravir administered subcutaneously with ENHANZE.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In June 2022, argenx initiated a phase 2 study evaluating efgartigimod with ENHANZE in subjects with bullous pemphigoid.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In May 2022, Chugai initiated a Phase 1 study to evaluate the pharmacokinetics, pharmacodynamics, and safety of targeted antibody administered subcutaneously with ENHANZE.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In April 2022, Roche initiated a phase 3 study evaluating OCREVUS (ocrelizumab) with ENHANZE in subjects with multiple sclerosis.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Corporate</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In June 2022, we announced the commercial launch of TLANDO&#8482; (testosterone undecanoate), an oral treatment indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (primary or hypogonadotropic hypogonadism). TLANDO&#8482; was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2022.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In June 2022, we completed the $150 million ASR that was initiated in December of 2021, resulting in the total repurchase of 3.9 million shares at a price of $38.51 per share.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In May 2022, we completed the acquisition of Antares resulting in an expansion of our commercial portfolio of proprietary and partnered products and the potential for future growth through new agreements </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In May 2022, in connection with the closing of Antares acquisition, we entered into a credit agreement with Bank of America, N.A., as Administrative Agent, Swing Line Lender and an L/C Issuer, and the other lenders and L/C Issuers party thereto (the &#8220;2022 Credit Agreement), evidencing a credit facility (the &#8220;2022 Facility&#8221;) that provides for (i) a $350 million revolving credit facility (the &#8220;Revolving Credit Facility&#8221;) and (ii) a $250 million term loan facility (the &#8220;Term Facility&#8221;). The proceeds from a $120 million draw on the Revolving Credit Facility and the $250 million Term Facility were used to fund a portion of the Antares acquisition, refinance Antares&#8217; existing debt and pay fees and expenses in connection with the acquisition. </span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product and Product Candidates</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The following table summarizes our marketed proprietary products and product candidates under development and our marketed partnered products and product candidates under development with our partners:</span></div><div style="margin-top:9pt;text-align:center;text-indent:18pt"><img src="halo-20220630_g1.jpg" alt="halo-20220630_g1.jpg" style="height:875px;margin-bottom:5pt;vertical-align:text-bottom;width:675px"/></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:center"><img src="halo-20220630_g2.jpg" alt="halo-20220630_g2.jpg" style="height:942px;margin-bottom:5pt;vertical-align:text-bottom;width:678px"/></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-top:9pt;text-align:center;text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Proprietary Products and Product Candidates</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hylenex Recombinant (hyaluronidase human injection)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market and sell Hylenex recombinant which is a formulation of rHuPH20 that facilitates subcutaneous fluid administration for achieving hydration, increases the dispersion and absorption of other injected drugs and, in subcutaneous urography, to improve resorption of radiopaque agents. Hylenex recombinant is currently the number one prescribed branded hyaluronidase. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">XYOSTED&#174; (testosterone enanthate) Injection</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market and sell in the U.S. our proprietary product XYOSTED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> injection for subcutaneous administration of testosterone replacement therapy (&#8220;TRT&#8221;) in adult males for conditions associated with a deficiency or absence of endogenous testosterone (primary or hypogonadism). Safety and efficacy of XYOSTED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in males less than 18 years old have not been established. XYOSTED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is the only FDA approved subcutaneous testosterone enanthate product for once-weekly, at-home self-administration and is approved and marketed in three dosage strengths, 50 mg, 75 mg and 100 mg. XYOSTED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> provides an easy and virtually pain-free administration and the ability to achieve and maintain steady target  levels of testosterone.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NOCDURNA&#174; (desmopressin acetate) Sublingual Tablets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market and sell NOCDURNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S., which is the first and only sublingual tablet indicated for the treatment of nocturia due to nocturnal polyuria (&#8220;NP&#8221;) in adults who awaken at least two times per night to urinate. In the NOCDURNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical trials, NP was defined as night-time urine production exceeding one-third of the 24-hour urine production.  NOCDURNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a sublingual tablet, marketed in two dosage strengths, that dissolves quickly under the tongue without water and has been shown in clinical studies to reduce nighttime urination by nearly one-half (in patients who average three nighttime bathroom visits.) We license NOCDURNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from Ferring. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TLANDO&#174; (testosterone undecanoate) Oral Formulation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TLANDO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a twice daily oral formulation of testosterone  indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (primary or hypogonadotropic hypogonadism). Safety and efficacy of TLANDO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in males less than 18 years old have not been established. TLANDO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was granted FDA approval on March 28, 2022. In June 2022, we announced the commercial launch of TLANDO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ATRS - 1902</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an ongoing  program to develop a proprietary drug device combination product for the endocrinology market, a pen for patients who require additional supplemental hydrocortisone, identified as ATRS-1902. The development program uses a novel proprietary auto-injector platform to deliver a liquid stable formulation of hydrocortisone. We have conducted initial formulation work and developed a working prototype of a new device to support this program.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, we submitted an IND application with the FDA for the initiation of a Phase 1 clinical study of ATRS-1902 for adrenal crisis rescue. The IND application includes the protocol for an initial clinical study to compare the pharmacokinetic profile of our novel formulation of hydrocortisone versus Solu-Cortef</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is an anti-inflammatory glucocorticoid and is the current standard of care for the management of acute adrenal crises.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the FDA accepted our IND for ATRS-1902 enabling us to initiate our Phase 1 clinical study. The Phase 1 clinical study, designed to evaluate the safety, tolerability and pharmacokinetics (&#8220;PK&#8221;) of a liquid stable formulation of hydrocortisone, was initiated in September 2021. The study was a cross-over design to establish the PK profile of ATRS-1902 (100 mg) compared to Solu-Cortef</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (100 mg), the reference-listed drug, in 32 healthy adults. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, we announced the positive results from the Phase 1 clinical study and were granted Fast Track designation by the FDA. The positive results support the advancement of our ATRS-1902 development program to a pivotal study for the treatment of acute adrenal insufficiency, known as adrenal crisis, using our Vai&#8482; novel proprietary rescue pen platform to deliver a liquid stable formulation of hydrocortisone. The pivotal study in adults is on target to start in the third quarter of 2022 and we expect to submit a 505(b)(2) NDA with the FDA by the end of 2022 pending the success of the study, the completion of a summative human factors study and confirmation of the product stability from our ongoing stability program.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Partnered Products</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ENHANZE Collaborations</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Roche Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2006, we and Roche entered into a collaboration and license agreement under which Roche obtained a worldwide license to develop and commercialize product combinations of rHuPH20 and up to twelve Roche target compounds (the Roche Collaboration). Under this agreement, Roche elected a total of eight targets, two of which are exclusive. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2013, Roche launched a subcutaneous (SC) formulation of Herceptin (trastuzumab) (Herceptin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SC) in Europe for the treatment of patients with HER2-positive breast cancer followed by launches in additional countries. This formulation utilizes our ENHANZE technology and is administered in two to five minutes, compared to 30 to 90 minutes with the standard intravenous form. In September 2018, we announced that Roche received approval from Health Canada for Herceptin SC for the treatment of patients with HER2-positive breast cancer. In February 2019, we announced that Roche received approval from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for Herceptin SC under the brand name Herceptin Hylecta&#8482; (trastuzumab and hyaluronidase-oysk). In April 2019, Roche made Herceptin Hylecta available in the U.S. In June 2020, the FDA approved the fixed-dose combination of Perjeta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pertuzumab) and Herceptin for subcutaneous injection (Phesgo&#8482;) utilizing ENHANZE technology for the treatment of patients with HER2-positive breast cancer. In December 2020, the European Commission (EC) also approved Phesgo for the treatment of patients with early and metastatic HER2-positive breast cancer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2014, Roche launched MabThera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SC in Europe for the treatment of patients with common forms of non-Hodgkin lymphoma (NHL) followed by launches in additional countries. This formulation utilizes our ENHANZE technology and is administered in approximately five minutes compared to the approximately 1.5 to 4 hour intravenous infusion. In May 2016, Roche announced that the European Medicines Agency (EMA) approved Mabthera SC to treat patients with chronic lymphocytic leukemia (CLL). In June 2017, the FDA approved Genentech&#8217;s RITUXAN HYCELA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a combination of rituximab using ENHANZE technology (approved and marketed under the MabThera SC brand in countries outside the U.S. and Canada), for CLL and two types of NHL, follicular lymphoma and diffuse large B-cell lymphoma. In March 2018, Health Canada approved a combination of rituximab and rHuPH20 (approved and marketed under the brand name RITUXAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SC) for patients with CLL.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, we and Roche entered into an agreement providing Roche the right to develop and commercialize one additional exclusive target using ENHANZE technology. The upfront license payment may be followed by event-based payments subject to Roche&#8217;s achievement of specified development, regulatory and sales-based milestones. In addition, Roche will pay royalties to us if products under the collaboration are commercialized.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we entered into an agreement with Roche for the right to develop and commercialize one additional exclusive target and an option to select two additional targets within four years using ENHANZE technology. The upfront license payment may be followed by event-based payments subject to Roche&#8217;s achievement of specified development, regulatory and sales-based milestones. In addition, Roche will pay royalties to us if products under the collaboration are commercialized. Roche subsequently returned the rights for the first exclusive target.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, Roche initiated a Phase 1b/2 study in patients with non-small cell lung cancer for TECENTRIQ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  (atezolizumab) using ENHANZE technology. In September 2020, Roche presented a poster with data from Part 1 of its Phase 1b study (IMscin001) evaluating TECENTRIQ for subcutaneous administration utilizing ENHANZE technology in patients with locally advanced or metastatic non-small cell lung cancer at the ESMO Virtual Congress 2020. The poster concluded that atezolizumab utilizing ENHANZE technology provided similar exposure as atezolizumab IV and that results support further development of subcutaneous atezolizumab in IMscin001 Part 2, a confirmatory Phase 3 study. In December 2020, Roche initiated a Phase 3 study in patients with non-small cell lung cancer for TECENTRIQ using ENHANZE technology. In August 2022, Roche announced that the Phase III IMscin001 study evaluating a subcutaneous (SC) formulation of Tecentriq (atezolizumab) met its co-primary endpoints. The study showed non-inferior levels of Tecentriq  in the blood (pharmacokinetics), when injected subcutaneously, compared with intravenous (IV) infusion, in cancer immunotherapy-na&#239;ve patients with advanced or metastatic non-small cell lung cancer (NSCLC) for whom prior platinum therapy has failed. The safety profile of the SC formulation was consistent with that of IV Tecentriq.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, Roche initiated a Phase 1 study evaluating OCREVUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ocrelizumab) with ENHANZE technology in subjects with multiple sclerosis. In April 2022, Roche initiated a phase 3 study evaluating OCREVUS with ENHANZE technology in subjects with multiple sclerosis.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, Roche nominated a new undisclosed exclusive target to be studied using ENHANZE technology. In November 2021, Roche initiated a Phase 1 study with the undisclosed target and ENHANZE.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Baxalta Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2007, we and Baxalta entered into a collaboration and license agreement under which Baxalta obtained a worldwide, exclusive license to develop and commercialize product combinations of rHuPH20 with GAMMAGARD LIQUID (HYQVIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) (the Baxalta Collaboration). HYQVIA is indicated for the treatment of primary immunodeficiency disorders associated with defects in the immune system.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2013, the EC granted Baxalta marketing authorization in all EU Member States for the use of HYQVIA (solution for subcutaneous use) as replacement therapy for adult patients with primary and secondary immunodeficiencies. Baxalta launched HYQVIA in the first EU country in July 2013 and has continued to launch in additional countries.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2014, HYQVIA was approved by the FDA for treatment of adult patients with primary immunodeficiency in the U.S. HYQVIA is the first subcutaneous immune globulin (IG) treatment approved for adult primary immunodeficiency patients with a dosing regimen requiring only one infusion up to once per month (every three to four weeks) and one injection site per infusion in most patients, to deliver a full therapeutic dose of IG.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2016, Baxalta announced that HYQVIA received a marketing authorization from the EC for a pediatric indication, which was launched in Europe to treat primary and certain secondary immunodeficiencies. In September 2020, Takeda announced that the EMA approved a label update for HYQVIA broadening its use and making it the first and only facilitated subcutaneous immunoglobulin replacement therapy in adults, adolescents and children with an expanded range of secondary immunodeficiencies (SID).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Baxalta initiated a Phase 1 single-dose, single-center, open-label, three-arm study to assess the tolerability and safety of immune globulin subcutaneous (human), 20% solution with ENHANZE (TAK-881) at various infusion rates in healthy adult subjects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, Baxalta announced positive topline results from pivotal Phase 3 trial evaluating HYQVIA, for maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfizer Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2012, we and Pfizer entered into a collaboration and license agreement, under which Pfizer has the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with Pfizer proprietary biologics in primary care and specialty care indications. Pfizer has elected five targets and has returned two targets. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Janssen Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2014, we and Janssen entered into a collaboration and license agreement, under which Janssen has the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with Janssen proprietary biologics directed to up to five targets. Targets may be selected on an exclusive basis. Janssen has elected CD38 as the first target on an exclusive basis. Janssen has initiated several Phase 3 studies, Phase 2 studies and Phase 1 studies of DARZALEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(daratumumab), directed at CD38, using ENHANZE technology in patients with amyloidosis, smoldering myeloma and multiple myeloma.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, Janssen&#8217;s development partner, Genmab, announced positive Phase 3 trial results from the COLUMBA study evaluating subcutaneous DARZALEX in comparison to intravenous DARZALEX in patients with relapsed or refractory multiple myeloma. DARZALEX SC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (utilizing ENHANZE technology) was found to be non-inferior to DARZALEX IV with regard the co-primary endpoints of Overall Response Rate and Maximum Trough concentration. In May 2020, we announced that Janssen received US FDA approval and launched the commercial sale of DARZALEX FASPRO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in four regimens across five indications in multiple myeloma patients, including newly diagnosed, transplant-ineligible patients as well as relapsed or refractory patients. As a fixed-dose formulation, DARZALEX FASPRO can be administered over three to five minutes, significantly less time than DARZALEX IV which requires multi-hour infusions. In June 2020, we announced that Janssen received European marketing authorization and launched the commercial sale of DARZALEX SC utilizing ENHANZE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the European Union. Subsequent to these approvals, Janssen received several additional regulatory approvals for additional indications and patient populations in US, EU, Japan and China. Beginning with the US, in January 2021, Janssen received FDA approval for DARZALEX FASPRO in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplant. In January 2021, Janssen received accelerated approval from the FDA for DARZALEX FASPRO in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adult patients with newly diagnosed AL amyloidosis (not recommended for the treatment of patients with AL amyloidosis who have NYHA Class IIIB or Class IV cardiac disease or Mayo Stage IIIB outside of controlled clinical trials). In July 2021, Janssen received FDA approval for DARZALEX FASPRO in combination with pomalidomide and dexamethasone (D-Pd) for patients with multiple myeloma after first or subsequent relapse. In July 2021, Janssen received FDA approval for DARZALEX FASPRO in combination with D-Pd for patients with multiple myeloma after first or subsequent relapse. In December 2021, Janssen received FDA approval for DARZALEX FASPRO in combination with </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kyprolis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (carfilzomib) and dexamethasone for patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy. In the EU, in June 2021, we announced that Janssen received marketing authorization from the EC for DARZALEX SC in two new indications, in combination with D-VCd in newly diagnosed adult patients with AL amyloidosis and in combination with D-Pd in adult patients with relapsed or refractory multiple myeloma. In Japan in March 2021, Janssen announced approval from Japan&#8217;s Ministry of Health, Labour and Welfare (MHLW) for subcutaneous formulation of DARZALEX (known as DARZQURO in Japan) for the treatment of multiple myeloma, and in May 2021 Janssen commenced commercial sale in Japan. In August 2021, Janssen received approval of DARZQURO (Daratumumab SC) for systemic AL amyloidosis in Japan. In China in October 2021, Janssen&#8217;s DARZALEX FASPRO was approved by the China National Medical Products Administration (NMPA) for the treatment of primary light chain amyloidosis, in combination with D-VCd in newly diagnosed patients.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, Janssen elected EGFR and cMET as a bispecific antibody (amivantamab) target on an exclusive basis, which is being studied in solid tumors. In November 2020, Janssen initiated a Phase 1 study of amivantamab and ENHANZE. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, Janssen elected the target HIV reverse transcriptase limited to non-nucleoside reverse transcriptase inhibitors. In December 2021, Janssen initiated a Phase 1 clinical trial combining rilpivirine and ENHANZE. Janssen and ViiV are exploring the possibility of an ultra-long acting version of CABENUVA using ENHANZE</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AbbVie Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2015, we and AbbVie entered into a collaboration and license agreement, under which AbbVie has the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with AbbVie proprietary biologics directed to up to nine targets. Targets may be selected on an exclusive basis. AbbVie elected one target on an exclusive basis, TNF alpha, for which it has discontinued development and returned the target.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lilly Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2015, we and Lilly entered into a collaboration and license agreement, under which Lilly has the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with Lilly proprietary biologics directed to up to five targets. Targets may be selected on an exclusive basis. Lilly has elected two targets on an exclusive basis and one target on a semi-exclusive basis. In August 2017, Lilly initiated a Phase 1 study of an investigational therapy in combination with rHuPH20.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BMS Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, we and BMS entered into a collaboration and license agreement, which became effective in November 2017, under which BMS had the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with BMS products directed at up to eleven targets. Targets may be selected on an exclusive or non-exclusive basis. BMS has designated multiple immuno-oncology targets including programmed death 1 (PD-1) and has an option to select 3 additional targets by November 2024.  In October 2019, BMS initiated a Phase 1 study of relatlimab, an anti-LAG-3 antibody, in combination with nivolumab using ENHANZE technology. In June 2021, BMS initiated a Phase 3 study of nivolumab using ENHANZE technology for patients with advanced or metastatic clear cell renal cell carcinoma, leveraging data and insights from Phase 1/2 CA209-8KX study in patients with solid tumors.  In June 2022, BMS nominated a new undisclosed target.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Alexion Collaboration </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, we and Alexion entered into a collaboration and license agreement, under which Alexion has the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with Alexion&#8217;s portfolio of products directed at up to four targets and has access to three targets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">argenx Collaboration </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we and argenx entered into an agreement for the right to develop and commercialize one exclusive target, the human neonatal Fc receptor FcRn, which includes argenx's lead asset efgartigimod (ARGX-113), and an option to select two additional targets using ENHANZE technology. In May 2019, argenx nominated a second target to be studied using ENHANZE technology, a human complement factor C2 associated with the product candidate ARGX-117, which is being developed to treat severe autoimmune diseases in Multifocal Motor Neuropathy (MMN).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, argenx dosed the first subject in a phase 1 clinical trial evaluating the safety, pharmacokinetics and pharmacodynamics of efgartigimod (ARGX-113), using ENHANZE technology. In December 2019, argenx reported that based on data from the phase 1 study and internal company analysis, a one minute injection administered every 2 weeks may be possible. In December 2020, argenx initiated a Phase 3 study of ARGX-113 using ENHANZE technology for patients with immune thrombocytopenia (ITP), an immune disorder in which the blood does not  clot normally. In January 2021, argenx initiated a Phase 3 study of ARGX-113 using ENHANZE technology in pemphigus vulgaris and foliaceus (PV), a rare autoimmune disease that causes painful blisters on the skin and mucous membranes.  In February 2021, argenx initiated a Phase </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 study of ARGX-113 using ENHANZE technology for patients with chronic inflammatory demyelinating polyneuropathy (CIDP) and initiated a Phase 3 study of ARGX-113 using ENHANZE technology in myasthenia gravis (MG), an autoimmune disorder of the musculoskeletal system caused by IgG autoantibodies. In December 2021, argenx announced the FDA approval of efgartigimod (VYVGART</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for the treatment of generalized myasthenia gravis for the IV dosing regimen. In March 2022, argenx announced that data from argenx&#8217;s phase 3 ADAPT-SC study evaluating SC efgartigimod (1000mg efgartigimod-PH20) for the treatment of generalized myasthenia gravis (gMG) achieved the primary endpoint of total IgG reduction from baseline at day 29, demonstrating statistical non-inferiority to VYVGART (efgartigimod alfa-fcab) IV formulation in gMG patients. In June 2022, argenx initiated a study, ADDRESS, evaluating Efgartigimod with ENHANZE in bullous pemphigoid.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, we and argenx entered into agreement to expand the collaboration relationship. Under the newly announced expansion, argenx gained the ability to exclusively access our ENHANZE technology for three additional targets  for a total of up to six targets under the existing and newly expanded collaboration. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Horizon Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, we and Horizon entered into a global collaboration and license agreement that gives Horizon exclusive access to ENHANZE technology for subcutaneous formulation of medicines targeting IGF-1R. Horizon intends to use ENHANZE to develop a SC formulation of TEPEZZA&#174; (teprotumumab-trbw), indicated for the treatment of thyroid eye disease, a serious, progressive and vision-threatening rare autoimmune disease, potentially shortening drug administration time, reducing healthcare practitioner time and offering additional flexibility and convenience for patients. In March 2021, Horizon completed dosing in a Phase 1 study exploring the SC formulation of TEPEZZA. The trial was a small, single-dose Phase 1 pharmacokinetic trial which included evaluation of ENHANZE technology for a SC formulation. In March 2022, Horizon announced the completion of a Phase 1 trial for the TEPEZZA subcutaneous program.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ViiV Healthcare Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, we entered into a global collaboration and license agreement with ViiV. The license gives ViiV exclusive access to our ENHANZE technology for four specific small and large molecule targets for the treatment and prevention of HIV. These targets are integrase inhibitors, reverse transcriptase inhibitors limited to nucleoside reverse transcriptase inhibitors (NRTI) and nucleoside reverse transcriptase translocation inhibitors (NRTTIs), capsid inhibitors and broadly neutralising monoclonal antibodies (bNAbs), that bind to the gp120 CD4 binding site. In December 2021, ViiV initiated enrollment of a Phase 1 study to evaluate cabotegravir administered subcutaneously with ENHANZE. In March 2022, ViiV initiated enrollment of a Phase 1 study to evaluate the safety and pharmacokinetics of N6LS, a broadly neutralizing antibody, administered subcutaneously with ENHANZE technology. In June 2022, ViiV initiated enrollment of a Phase 1 single dose escalation study to evaluate pharmacokinetics, safety and tolerability of long-acting cabotegravir administered subcutaneously with ENHANZE technology.    </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Chugai Collaboration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2022, we entered into a global collaboration and license agreement with Chugai Pharmaceutical Co., Ltd.  The license gives Chugai exclusive access to ENHANZE drug delivery technology for an undisclosed target. Chugai intends to explore the potential use of ENHANZE for a Chugai drug candidate. In May 2022, Chugai initiated a Phase 1 study to evaluate the pharmacokinetics, pharmacodynamics, and safety of targeted antibody administered subcutaneously with ENHANZE.</span></div><div><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NIH CRADA</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, we announced a Cooperative Research and Development Agreement (CRADA) with the National Institute of Allergy and Infectious Diseases&#8217; Vaccine Research Center (VRC), part of National Institute of Health (NIH), enabling the VRC&#8217;s use of ENHANZE technology to develop subcutaneous formulations of VRC07-523LS and N6LS broadly neutralizing antibodies (bnAbs) against HIV for HIV treatment. In March 2021, we were notified that the first patient was dosed with N6LS and rHuPH20 in VRC 609 Phase 1 dose-escalation study to evaluate safety, tolerability, and pharmacokinetics of N6LS using ENHANZE technology.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CAPRISA</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into a collaboration with the Centre for the AIDS Programme of Research in South Africa (CAPRISA), a non-profit company, to evaluate safety, tolerability and pharmacokinetics of a human monoclonal antibody (CAP256V2LS) in HIV-negative and HIV-positive women in South Africa. In October 2020, we were notified that the first patient was dosed with CAP256V2LS and rHuPH20 in CAPRISA 012B Phase 1 dose-escalation study to evaluate safety, tolerability, and pharmacokinetics of CAPR256V2LS alone and in combination with VRC07-523LS using ENHANZE technology. In January 2021, we were notified the first patient was dosed with CAP256V2LS and rHuPH20 in combination with VRC07-523LS and rHuPH20 in CAPRISA 012B Phase 1 study. VRC07-523LS broadly neutralizing antibody was supplied by the NIH/VRC under a research collaboration with CAPRISA.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Device Collaborations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Teva License, Development and Supply Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2006, we entered into an exclusive license, development and supply agreement with Teva for an epinephrine auto- injector product to be marketed in the U.S. and Canada. Pursuant to the agreement, Teva is obligated to purchase all of its delivery device requirements from us. We received an upfront cash payment and a milestone payment upon FDA product approval. We also receive a negotiated purchase price for each device sold, as well as royalties on Teva&#8217;s commercial sales of the product. This agreement has been amended to provide for payment of capital equipment and other ongoing development work that was outside the scope of the original agreement. The agreement will continue until the expiration of the last to expire patent that is filed no later than 12 months after FDA approval. We have multiple patents that have been granted by the United States Patent and Trademark Office (&#8220;USPTO&#8221;) that cover this product, the latest of which will expire in 2033. We have and plan to continue to file patent applications covering this product. We are the exclusive supplier of the device, which we developed, for Teva&#8217;s generic Epinephrine Injection USP products, indicated for emergency treatment of severe allergic reactions including those that are life threatening (anaphylaxis) in adults and certain pediatric patients. Teva&#8217;s Epinephrine Injection, utilizing our patented VIBEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> injection technology, was approved by the FDA as a generic drug product with an AB rating, meaning that it is therapeutically equivalent to the branded products EpiPen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and EpiPen Jr</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and therefore, subject to state law, substitutable at the pharmacy. We supply the device and Teva is responsible for the drug, assembly and packaging, distribution and commercialization of the finished product, for which we also receive royalties on Teva&#8217;s net sales.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2007, we entered into a license, development and supply agreement with Teva under which we developed and will supply a disposable pen injector for two therapeutic products: exenatide and teriparatide. Under the agreement, we received an upfront payment and development milestones, and may receive royalties on future product sales. This agreement has been amended numerous times and provides for payment of capital equipment and other development work that was outside the scope of the original agreement. This agreement will continue until the expiration date of the last to expire patent covering the device or product that is filed no later than 12 months after FDA approval and will be automatically renewed for successive periods of two years each. Currently, the expiration date of the last to expire patent is 2035. On February 25, 2022, Teva notified us that it was terminating the exenatide program and related agreement due to a lack of commercial viability. The termination is effective August 23, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the exclusive supplier of the multi-dose pen, which we developed, used in Teva&#8217;s generic teriparatide injection product. In 2020, our partner Teva launched Teriparatide Injection, the generic version of Eli Lilly&#8217;s branded product Forsteo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> featuring the Antares multi-dose pen platform, for commercial sale in several countries outside of the U.S. Under an exclusive development, license and supply agreement with Teva, we are responsible for the manufacturing and supply of the multi-dose pen used in Teva&#8217;s generic teriparatide product and Teva is responsible for the sale and distribution of the product. We are compensated for devices sold to Teva and we are entitled to receive royalties on net product sales by Teva in the territories.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2012, we entered into a license, supply and distribution agreement with Teva for an auto-injector product containing sumatriptan for the treatment of migraines. Under the agreement, we received an upfront payment and a milestone payment upon commercial launch. Teva is responsible for the manufacture and supply of the drug, and we are responsible for the manufacture and supply of the device and assembly and packaging of the finished product. We are compensated at cost for product shipment to Teva and Teva distributes the product in the U.S. Teva also received an option for distribution rights in other territories. In addition, net profits are split 50/50 between us and Teva. The term of the agreement continues seven years from commercial launch, which was in June 2016, with automatic one-year renewals unless terminated sooner by either party in accordance with the terms of the agreement. We, through our partner Teva, sell Sumatriptan Injection USP, indicated in the U.S. for the acute treatment of migraine headaches and cluster headache in adults. Sumatriptan Injection USP is a generic equivalent to Imitrex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> STATdose Pen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and available in the 4 mg/0.5 mL and 6 mg/0.5 mL single-dose pre-filled syringe auto-injectors. We have a license, supply and distribution agreement with Teva, under which Teva is responsible for the manufacture and supply of the drug, and we manufacture the device and complete assembly and packaging of the finished product. Teva is responsible for commercialization and distribution.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Covis Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2014, we entered into a development and license agreement with Lumara Health, Inc., which was subsequently acquired by AMAG, which was subsequently acquired by Covis, to develop and supply an auto-injector system for use with Makena</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a progestin drug (hydroxyprogesterone caproate) indicated to reduce the risk of preterm birth. Under the agreement, we granted an exclusive, worldwide, royalty-bearing license, with the right to sublicense, to certain intellectual property rights, including know-how, patents and trademarks, and received an upfront payment for our license and development activities. We are also entitled to milestone payments upon the achievement of pre-determined amounts of net sales of the product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Covis was responsible for the clinical development and preparation, submission and maintenance of all regulatory applications, and is responsible for the manufacture and supply of the drug to be used in the product, and to market, distribute </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and sell the product. We are the exclusive supplier of the auto injection system devices for the product and are responsible for the manufacture and supply of the devices and final assembly and packaging of the finished product. Under the arrangement, we receive payment for each device, and royalties based on net sales of products commencing on product launch in a particular country until the product is no longer developed, marketed, sold or offered for sale in such country. The royalty rates range from high single digit to low double digits and are tiered based on levels of net sales of products and decrease after the expiration of licensed patents or where there are generic equivalents to the auto-injector product being sold in a particular country.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, we entered into a manufacturing agreement with Covis for the exclusive supply of the devices and fully assembled and packaged final finished product of the Makena</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> subcutaneous auto-injector. The term of the agreement is concurrent with the term of the development and license agreement and will continue until such time as commercialization of the product is halted. We receive a contracted price per unit on each product manufactured. We are the exclusive supplier of the device, a variation of our VIBEX&#174; QuickShot</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> subcutaneous auto injector developed by us, for the progestin hormone drug Makena&#174; (hydroxyprogesterone caproate injection). The Makena</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> subcutaneous auto injector drug-device combination product is a ready-to-administer treatment indicated to reduce the risk of preterm birth in women pregnant with one baby and who spontaneously delivered one preterm baby in the past. The product was approved by the FDA under the accelerated approval pathway. We are the exclusive supplier of the devices and the final assembled and packaged commercial product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, Covis announced that the FDA&#8217;s Bone, Reproductive and Urologic Drugs Advisory Committee met to better understand and interpret the PROLONG (Progestin&#8217;s Role in Optimizing Neonatal Gestation) confirmatory clinical trial for Makena</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (hydroxyprogesterone caproate) injection. Nine advisory committee members voted to recommend that the FDA pursue withdrawal of approval for Makena</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and seven committee members voted to leave the product on the market under accelerated approval and require a new confirmatory trial. In October 2020, Covis received notice that the FDA is proposing to withdraw approval of Makena</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (hydroxyprogesterone caproate injection). Covis then formally requested a public hearing in response to the FDA&#8217;s proposal to withdraw its approval and has stated that it remains committed to working with the FDA to maintain patient access to Makena</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a treatment option to reduce pre-term birth. In August 2021, Covis announced the FDA had granted the request for a public hearing. In June 2022, Covis announced that the FDA anticipates holding the public meeting in October 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfizer Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, we entered into a development agreement with Pfizer to jointly develop a combination drug device rescue pen. This rescue pen will use the Antares QuickShot&#174; auto-injector and an undisclosed Pfizer drug. In 2022, we continued to work on this development program, and we expect to continue development of this product candidate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Idorsia Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we entered into a new global agreement with Idorsia to develop a novel, drug-device product containing selatogrel. A new chemical entity selatogrel is being developed for the treatment of a suspected acute myocardial infarction (AMI) in adult patients with a history of AMI. Idorsia will pay for the development of the combination product and will be responsible for applying for and obtaining global regulatory approvals for the product. The parties intend to enter into a separate commercial license and supply agreement pursuant to which Antares will provide fully assembled and labelled product to Idorsia at cost plus mark-up. Idorsia will then be responsible for global commercialization of the product, pending FDA or foreign approval we will be entitled to receive royalties on net sales of the commercial product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ferring Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, we entered into an exclusive license and commercial supply agreement with Ferring for the marketed product NOCDURNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (desmopressin acetate) in the U.S., Under the terms of the license agreement, we paid Ferring an upfront payment of $5.0 million upon execution and paid an additional $2.5 million on October 1, 2021. Ferring is eligible for tiered royalties and additional commercial milestone payments potentially totaling up to $17.5 million based on our net sales of NOCDURNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lipocine Agreement</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2021, we entered into an exclusive license agreement with Lipocine for the product TLANDO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (testosterone undecanoate) in the U.S. TLANDO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> was granted tentative approval from the FDA in December 2020. On February 3, 2022, we announced the FDA&#8217;s acceptance of our NDA resubmission for TLANDO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> with a target action date set for March 28, 2022. In June 2022, we announced the commercial launch of TLANDO. Under the terms of the license agreement, we paid Lipocine an upfront payment of $11.0 million. Lipocine is eligible for additional milestone payments up to $10.0 million and tiered royalty and commercial milestones based on net sales of TLANDO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in the U.S. We will be responsible for the manufacturing and commercialization of TLANDO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. The license agreement also granted us the option to license and develop LPCN 1111 (TLANDO XR) in the U.S., a potential once daily oral testosterone product containing testosterone tridecanoate in development </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">for the treatment of hypogonadism in adult males. Following a review of our product portfolio, we decided not to exercise the option which expired on June 30, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Otter Agreement</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we entered into an Asset Purchase Agreement with Otter to sell certain worldwide assets used in the operation of the OTREXUP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line for $44.0 million, subject to finalization of changes in closing inventory to be transferred, and a license agreement for rights to commercialize OTREXUP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Simultaneously, we entered into a supply agreement with Otter to manufacture the VIBEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> auto-injection system device, designed and developed to incorporate a pre-filled syringe for delivery of methotrexate, assemble, package, label and supply the final OTREXUP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product and related samples to Otter at cost plus mark-up. Otter is responsible for manufacturing, formulation and testing of methotrexate and the corresponding pre-filled syringe for assembly with the device manufactured by us, along with the commercialization and distribution of OTREXUP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. OTREXUP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a subcutaneous methotrexate injection for once weekly self-administration with an easy-to-use, single dose, disposable auto injector, indicated for adults with severe active rheumatoid arthritis (&#8220;RA&#8221;), children with active polyarticular juvenile idiopathic arthritis and adults with severe recalcitrant psoriasis. Further, we entered into a license agreement with Otter in which we granted Otter a worldwide, exclusive, fully paid-up license to certain patents relating to OTREXUP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that may also relate to our other products for Otter to commercialize and otherwise exploit OTREXUP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the field as defined in the license agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a further discussion of the collaboration agreements, refer to Note 5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of COVID-19 to our Business</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the World Health Organization declared a disease caused by a strain of novel coronavirus (&#8220;COVID-19&#8221;) to be a pandemic. In an effort to contain COVID-19 or slow its spread, governments around the world have enacted various measures, including orders to close all businesses not deemed &#8220;essential,&#8221; isolate residents to their homes or places of residence, and practice social distancing when engaging in essential activities. In an effort to protect the health and safety of our employees and in compliance with state regulations, we instituted working from home, limited the number of people that work on site at any one time, and suspended employee travel. As an organization we have returned to the office and continue to effectively operate with a combination of remote and office work utilizing a hybrid model. Importantly, our suppliers continue to operate without interruption related to COVID-19. We recognize that the duration of the pandemic and its continued impact on the global economy as a whole remains unknown at this time. We are not clear the extent to which long term operational and economic impacts of COVID-19, if any, will have on our business, including the effects on our suppliers, partners, proprietary product sales. customers, employees, and prospects. We will continue to monitor the&#160;COVID-19&#160;situation closely.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="ibd09c52bdc03451493df7fb7077280c7_91"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Three Months Ended June&#160;30, 2022 Compared to Three Months Ended June&#160;30, 2021 </span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Royalty revenue was $85.3 million for the three months ended June&#160;30, 2022 compared to $45.8 million for the three months ended June&#160;30, 2021. The increase was mainly driven by continued sales uptake of DARZALEX FASPRO by Janssen and Phesgo by Roche in all geographies, partially offset by slightly lower sales of Herceptin SC and MabThera SC by Roche. We expect royalty revenue to continue to grow as a result of our 2020 ENHANZE partner product launches, offsetting the ongoing impact from biosimilars related to our mature ENHANZE partner products.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Sales, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Product sales, net were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:55.255%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of bulk rHuPH20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,057&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,087&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of proprietary products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of device partnered product</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,300&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,360&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,940&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales, net increased by $15.9 million in the three months ended June&#160;30, 2022 compared to the same period in 2021, primarily due to contribution from our proprietary and device partnered products as the result of the Antares acquisition. We expect that sales of proprietary products will grow in future years as we work to expand market share in the TRT market. We expect that product sales of bulk rHuPH20 and device partnered products will fluctuate in future periods based on the needs of our partners.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues Under Collaborative Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Revenues under collaborative agreements were as follows (in thousands): </span></div><div style="margin-top:5pt;text-align:center;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"></td><td style="width:55.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.100%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.323%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.487%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.323%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.487%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.325%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ENHANZE licensing and development revenue:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BMS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ViiV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,000)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Device licensing and development revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues under collaborative agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,725&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,317&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,592)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from license fees decreased $39.6 million for the three months ended June&#160;30, 2022, compared to the same period in 2021, primarily due to the upfront payment associated with entering into the ViiV collaborations in the prior year period. Revenue from upfront licenses fees, license fees for the election of additional targets, license maintenance fees and other license fees and event-based payments vary from period to period based on our collaboration activity. We expect these revenues to continue to fluctuate in future periods based on our partners&#8217; ability to meet various clinical and regulatory milestones set forth in such agreements and our ability to obtain new collaborative agreements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of Antares is expected to be accretive to revenue in 2022, supported by Antares' proprietary product revenues and royalty revenues. The addition of Antares is also expected to accelerate top- and bottom-line growth and enhance cash flow generation through 2027 and beyond.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Cost of sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal costs and manufacturing overhead associated with the production of our proprietary and device partnered products and bulk rHuPH20. Cost of sales were $33.9 million for the three months ended June&#160;30, 2022 compared to $23.0 million for the three months ended June&#160;30, 2021. The increase of $10.9 million in cost of  sales was mainly due to an increase in sales in our proprietary and partnered products as a result of Antares acquisition.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Amortization of intangibles</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Amortization of intangibles expense were $11.4 million for the  three months ended June&#160;30, 2022. The increase in amortization of intangibles expense is due to the acquisition of Antares in May 2022, in which we acquired intangible assets that are amortized over their useful lives.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Research and Development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Research and development expenses consist of external costs, salaries and benefits and allocation of facilities and other overhead expenses related to research manufacturing, preclinical and regulatory activities related to our collaborations, our development platforms. Research and development expenses were $15.5 million for the three months ended June&#160;30, 2022 compared to $8.1 million for the three months ended June&#160;30, 2021. The increase of $7.4 million is primarily due to planned investments in ENHANZE and one-time compensation cost related to the Antares acquisition.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Selling, General and Administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Selling, general and administrative (SG&amp;A) expenses consist primarily of salaries and related costs for personnel in executive, selling and administrative functions as well as professional fees for legal and accounting, business development, commercial operations support for proprietary products and alliance management and marketing support for our collaborations. SG&amp;A expenses were $57.5 million for the three months ended June&#160;30, 2022 compared to $12.3 million for the three months ended June&#160;30, 2021. The increase of $45.2 million, was primarily due to one-time transaction and compensation costs related to the Antares Pharma acquisition and an increase in compensation expense related to the ongoing combined workforce.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Interest expense was $3.1 million for the three months ended June&#160;30, 2022 compared to $1.8 million for the three months ended June&#160;30, 2021. The increase of $1.3 million was primarily due to an  increase in interest expense related to the 2022 term loans and revolving credit facility. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Income tax expense was $7.3 million for the three months ended June&#160;30, 2022, compared to income tax expense of  $0.1 million for the three months ended June&#160;30, 2021. The increase in income tax expense is due to the recording of a full quarter income tax expense in the current year whereas in the prior year period there was minimal income tax expense due to a full valuation allowance in place.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Six Months Ended June&#160;30, 2022 Compared to Six Months Ended June&#160;30, 2021 </span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Royalty revenue was $154.9 million for the six months ended June&#160;30, 2022 compared to $82.7 million for the six months ended June&#160;30, 2021. The increase was mainly driven by continued sales uptake of DARZALEX FASPRO by Janssen and Phesgo by Roche in all geographies and contribution from Antares royalty revenue, partially offset by slightly lower sales of Herceptin SC and MabThera SC by Roche. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Sales, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Product sales, net were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:55.255%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of bulk rHuPH20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,505&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,857&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of proprietary products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of device partnered products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,440&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,126&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,314&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales, net increased by $16.3 million in the six months ended June&#160;30, 2022 compared to the same period in 2021, primarily due to a contribution from our proprietary and device partnered products driven by the acquisition of Antares. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues Under Collaborative Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Revenues under collaborative agreements were as follows (in thousands): </span></div><div style="margin-top:5pt;text-align:center;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"></td><td style="width:55.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.100%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.323%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.487%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.323%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.487%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.325%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ENHANZE licensing and development revenue:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chugai</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BMS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ViiV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Device licensing and development revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues under collaborative agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,259&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,650&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,391)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from license fees decreased $45.0 million in the six months ended June&#160;30, 2022, compared to the same period in 2021 primarily due to the upfront payment associated with entering into the ViiV collaborations in the prior year period, as well as the timing of other milestones driven by partner activities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Cost of sales were $49.9 million for the six months ended June&#160;30, 2022 compared to $41.2 million for the six months ended June&#160;30, 2021. The increase of $8.7 million in cost of sales was mainly due to an increase in sales in our proprietary and partnered products as a result of the Antares acquisition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Amortization of intangibles</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Amortization of intangibles expense were $11.4 million for the  six months ended June&#160;30, 2022. The increase in amortization of intangibles expense is due to the acquisition of Antares in May 2022.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development expenses were $27.3 million for the  six months ended June&#160;30, 2022 compared to $17.1 million for the six months ended June&#160;30, 2021. The increase of $10.2 million is primarily due to planned investments in ENHANZE and one-time compensation cost related to the Antares acquisition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SG&amp;A expenses were $71.3 million for the six months ended June&#160;30, 2022 compared to $23.4 million for the six months ended June&#160;30, 2021. The increase of $47.9 million  was primarily due to  one-time transaction and compensation costs related to the Antares Pharma acquisition and an increase in compensation expense related to the ongoing combined workforce.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Interest expense was $4.9 million for the six months ended June&#160;30, 2022 compared to $3.7 million for the six months ended June&#160;30, 2021. The increase of $1.2 million was primarily due to an  increase in interest expense related to the 2022 term loans and revolving credit facility. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Income tax benefit was $21.6 million for the six months ended June&#160;30, 2022, compared to income tax expense of $0.2 million for the six months ended June&#160;30, 2021. The increase in income tax expense is due to the recording of a </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">full six months of income tax expense in the current year whereas in the prior year period there was minimal income tax expense due to a full valuation allowance in place.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="ibd09c52bdc03451493df7fb7077280c7_97"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal sources of liquidity are our existing cash, cash equivalents and available-for-sale marketable securities. As of June&#160;30, 2022, we had cash, cash equivalents and marketable securities of $209.4 million. We believe that our current cash, cash equivalents and marketable securities will be sufficient to fund our operations for at least the next twelve months. We expect to fund our operations going forward with existing cash resources, anticipated revenues from our existing collaborations and cash that we may raise through future transactions. We may raise cash through any one of the following financing vehicles: (i) new collaborative agreements; (ii) expansions or revisions to existing collaborative relationships; (iii) private financings; (iv) other equity or debt financings; (v) monetizing assets; and/or (vi) the public offering of securities;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may, in the future, draw on our existing line of credit, offer and sell additional equity, debt securities and warrants to purchase any of such securities, either individually or in units to raise capital to raise funds for additional working capital, capital expenditures, share repurchases, acquisitions or for other general corporate purposes. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operations was $88.0 million for the six months ended June&#160;30, 2022 compared to $95.2 million cash provided in the six months ended June&#160;30, 2021. The $7.2 million decrease in cash provided by operations was mainly due to an increase in transaction expenses associated with Antares acquisition, partially offset by a decrease in working capital spend and an increase in royalties revenue during the six months ended June&#160;30, 2022 compared to the corresponding period in the prior year. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $484.3 million for the six months ended June&#160;30, 2022 compared to $89.9 million cash used in investing activities for the six months ended June&#160;30, 2021. The increase in cash used in investing activities was primarily due to the acquisition of Antares, partially offset by an increase in cash from the sale of marketable securities and the sale of assets for the six months ended June&#160;30, 2022. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $368.4 million for the six months ended June&#160;30, 2022, compared to $293.9 million cash provided by financing activities for the six months ended June&#160;30, 2021, mainly due to $370.0 million cash received from the term loan and the revolving credit facility during the current year, prior year $125.0 million in repurchase of common stock, $369.1 million related to the Induced Conversion of the 2024 Convertible Notes and a $0.9 million increase in net proceeds during the current year from the issuance of common stock under equity incentive plans, partially offset by  $784.9 million cash received from the 2027 Convertible Notes offering in the prior year. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, our Board of Directors approved a share repurchase program, pursuant to which we may repurchase our issued and outstanding shares of common stock from time to time. We completed the share repurchase program in October 2021 and retired the repurchased shares. In December 2021, we announced our second share repurchase program to repurchase up to $750.0 million of our outstanding common stock over a three-year period. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 10. Stockholders&#8217; Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, within the notes to the consolidated financial statements for additional information regarding our share repurchases.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Term Debt</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">0.25% Convertible Notes due 2027</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we completed the sale of $805.0&#160;million in aggregate principal amount of 0.25% Convertible Senior Notes due 2027 (the &#8220;2027 Convertible Notes&#8221; and collectively with the 2024 Convertible Notes the &#8220;Convertible Notes&#8221;). The net proceeds in connection with the 2027 Convertible Notes, after deducting the initial purchasers&#8217; fee of $20.1&#160;million, was approximately $784.9&#160;million. We also incurred additional debt issuance costs totaling $0.4&#160;million. Debt issuance costs and the initial purchasers&#8217; fee are presented as a debt discount.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2027 Convertible Notes pay interest semi-annually in arrears on March 1st and September 1st of each year at an annual rate of 0.25%. The 2027 Convertible Notes are general unsecured obligations and will rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the 2027 Convertible Notes, will rank equally in right of payment with all existing and future liabilities that are not so subordinated, will be effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness and will be structurally subordinated to all </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">indebtedness and other liabilities (including trade payables) of our current or future subsidiaries. The 2027 Convertible Notes have a maturity date of March 1, 2027.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their 2027 Convertible Notes at their option only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on June 30, 2021, if the last reported sale price per share of  common stock exceeds 130% of the conversion price for each of at least 20 trading days during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the five consecutive business days immediately after any 5 consecutive trading day period (such 5 consecutive trading day period, the &#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on our common stock, as described in the offering memorandum for the 2027 Convertible Notes; (4) if we call such notes for redemption; and (5) at any time from, and including, September 1, 2026 until the close of business on the scheduled trading day immediately before the maturity date. The Notes will be convertible, regardless of the foregoing circumstances, at any time from, and including, September 1, 2026 until the close of business on the scheduled trading day immediately preceding the maturity date. As of June&#160;30, 2022, the 2027 Convertible Notes are not convertible.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, we will pay cash for the settlement of principal and for the premium, if applicable, we will pay cash, deliver shares of common stock or a combination of cash and shares of common stock, at our election. The initial conversion rate for the 2027 Convertible Notes is 12.9576 shares of common stock per $1,000 in principal amount of 2027 Convertible Notes, equivalent to a conversion price of approximately $77.17 per share of our common stock. The conversion rate is subject to adjustment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">1.25% Convertible Notes due 2024</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we completed the sale of $460.0 million in aggregate principal amount of 1.25% Convertible Senior Notes due 2024 (&#8220;2024 Convertible Notes&#8221;). The net proceeds in connection with the issuance of the 2024 Convertible Notes, after deducting the initial purchasers&#8217; fee of $12.7&#160;million, was approximately $447.3 million. We also incurred debt issuance cost totaling $0.3&#160;million. Debt issuance costs and the initial purchasers&#8217; fee are presented as a debt discount.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Convertible Notes pay interest semi-annually in arrears on June 1st and December 1st of each year, beginning on June 1, 2020, at an annual rate of 1.25%. The 2024 Convertible Notes are general unsecured obligations and will rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the 2024 Convertible Notes, will rank equally in right of payment with all existing and future liabilities that are not so subordinated, will be effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness and will be structurally subordinated to all indebtedness and other liabilities (including trade payables) of the our current or future subsidiaries. The 2024 Convertible Notes have a maturity date of December 1, 2024.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their 2024 Convertible Notes at their option only in the following circumstances: (1)&#160;during any calendar quarter commencing after the calendar quarter ending on March&#160;31, 2020, if the last reported sale price per share of common stock exceeds 130% of the conversion price for each of at least 20 trading days during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2)&#160;during the five consecutive business days immediately after any five consecutive trading day period (such five consecutive trading day period, the &#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day; (3)&#160;upon the occurrence of certain corporate events or distributions on our common stock, as described in the offering memorandum for the 2024 Convertible Notes; (4)&#160;if we call such notes for redemption; and (5)&#160;at any time from, and including, June&#160;1, 2024 until the close of business on the scheduled trading day immediately before the maturity date. As of June&#160;30, 2022, the 2024 Convertible Notes are convertible.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021 we notified the note holders our irrevocable election to settle the principal of the 2024 Convertible Notes in cash and for the premium, if applicable, deliver shares of common stock. The conversion rate for the 2024 Convertible Notes is 41.9208 shares of common stock per $1,000 in principal amount of 2024 Convertible Notes, equivalent to a conversion price of approximately $23.85 per share of our common stock. The conversion rate is subject to adjustment. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we completed a privately negotiated and induced conversion of $369.1 million principal amount of the 2024 Convertibles (&#8220;Note Repurchases&#8221; or the &#8220;Induced Conversion&#8221;). In connection with the Induced Conversion, we paid approximately $370.2&#160;million in cash, which includes principal and accrued interest, and issued approximately 9.08&#160;million shares of our common stock representing the intrinsic value based on the contractual conversion rate and incremental shares as an inducement for conversion. As a result of the Induced Conversion, we recorded $21.0 million in induced conversion expense which is included in Other income (expense) of the Condensed Consolidated Statements of Income in 2021. The induced </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conversion expense represents the fair value of the common stock issued upon conversion in excess of the common stock issuable under the original terms of the 2024 Convertible Notes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revolving Credit Facility (December 2021)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, we terminated that certain credit agreement entered into on December 23, 2021 with Bank of America and the other lenders party thereto (the &#8220;2021 Credit Agreement&#8221;) evidencing a revolving credit facility (the &#8220;2021 Facility&#8221;) that provided for secured revolving loans and letters of credit in an aggregate amount of up to $75.0 million.  No proceeds from the 2021 Facility were drawn down as of the date the 2021 Credit Agreement was terminated.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revolving Credit and Term Loan Facilities (May 2022)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, in connection with the closing of Antares acquisition, we entered into a credit agreement with Bank of America, N.A., as Administrative Agent, Swing Line Lender and an L/C Issuer, and the other lenders and L/C Issuers party thereto (the &#8220;2022 Credit Agreement), evidencing a credit facility (the &#8220;2022 Facility&#8221;) that provides for (i) a $350 million revolving credit facility (the &#8220;Revolving Credit Facility&#8221;) and (ii) a $250 million term loan facility (the &#8220;Term Facility&#8221;). The proceeds from a $120 million draw on the Revolving Credit Facility and the $250 million Term Facility were used to fund a portion of the Antares acquisition, refinance Antares&#8217; existing debt and pay fees and expenses in connection with the acquisition. The 2022 Credit Agreement contains an expansion feature, which allows us, subject to certain conditions, to increase the aggregate principal amount of the 2022 Facility, provided we remain in compliance with underlying financial covenants on a pro forma basis including the consolidated interest coverage ratio and the consolidated net leverage ratio covenants set forth in the 2022 Credit Agreement. The 2022 Facility will mature on November 30, 2026 unless either the Revolving Credit Facility or the Term Facility is extended prior to such date in accordance with the 2022 Credit Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Facility requires quarterly scheduled repayments of the term loans in each of the first, second, third and fourth years following the Closing in annual amounts equal to 2.50%, 5.00%, 7.50% and 10.00% of the initial principal amount of the term loans, respectively. The term loans are also subject to mandatory prepayments from the proceeds of certain asset sales, subject to our right to reinvest the proceeds thereof.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2022 Facility bear interest, at our option, at a rate equal to an applicable margin plus: (a) the applicable Term Secured Overnight Financing Rate (SOFR) (which includes a SOFR adjustment of 0.10%), or (b) a base rate determined by reference to the highest of (1) the federal funds effective rate plus 0.50%, (2) the Bank of America prime rate, (3) the Term SOFR rate for an interest period of one month plus 1.10%, and (4) 1.00%. The margin for the 2022 Facility ranges, based on our consolidated total net leverage ratio, from 0.25% to 1.25% in the case of base rate loans and from 1.25% to 2.25% in the case of Term SOFR rate loans. In addition to paying interest on the outstanding principal under the Facility, we will pay (i) a commitment fee in respect of the unutilized commitments thereunder and (ii) customary letter of credit fees and agency fees. The commitment fees range from 0.15% to 0.35% per annum based on our consolidated net leverage ratio. As of June&#160;30, 2022, we had $120.0&#160;million and $250&#160;million in principal amount of outstanding borrowings under the 2022 Revolving Credit Facility and the 2022 Term Facility, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional Capital Requirements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our expected working and other capital requirements are described in our 2021 Annual Report on Form 10-K in &#8220;Part II, Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; At June&#160;30, 2022, other than the additional financing obtained to complete the Antares acquisition, which was completed on May 24, 2022 and the changes disclosed in the &#8220;Notes to Condensed Consolidated Financial Statements&#8221; and &#8220;Liquidity and Capital Resources&#8221; in this Quarterly Report, there have been no other material changes to our expected working and other capital requirements described in our 2021 Annual Report on Form 10-K.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion and analysis of our financial condition and results of operations are based on our condensed consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP. The preparation of our condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant accounting policies are described in Note 2 to the consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021. The accounting policies and estimates that are most critical to a full understanding and evaluation of our reported financial results are described in Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations in Item 7 of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021. There were no material changes to our critical accounting policies or estimates during the six months ended June&#160;30, 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of our condensed consolidated financial statements for a discussion of recent accounting pronouncements and their effect, if any.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><div id="ibd09c52bdc03451493df7fb7077280c7_100"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factors </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related To Our Business</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business interruptions resulting from the COVID-19 outbreak or similar public health crises could cause a disruption of the development of our and partnered product candidates and commercialization of our approved and our partnered products, impede our ability to supply bulk rHuPH20 to our ENHANZE partners or procure and sell our proprietary products and otherwise adversely impact our business and results of operations.*</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public health crises such as pandemics or similar outbreaks could adversely impact our business and results of operations by, among other things, disrupting the development of our and our  partnered product candidates and commercialization of our  approved partnered products, disrupting our ability to enter into new ENHANZE and other collaborations with potential partners in a timely manner, causing disruptions in the operations of our third party contract manufacturing organizations upon whom we rely for the production and supply of our proprietary products, including Hylenex and the bulk rHuPH20 we supply to our partners, and causing other disruptions to our operations.&#160;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has led to the implementation of various responses, including government-imposed quarantines, travel restrictions and other public health safety measures. The extent to which COVID-19 and its variants impacts our operations and/or those of our partners will depend on future developments, which are highly uncertain and unpredictable, including the duration or recurrence of the outbreak, additional or modified government actions, new information that will emerge concerning the severity and impact of COVID-19 and the actions to contain COVID-19 or address its impact in the short and long term, among others.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of COVID-19 restrictions and closures, our sales force has been subject to varying limitations on its ability to visit physicians and patient&#8217;s access to physicians has been negatively impacted.  As a result, we have experienced, and may continue to experience, a decrease in new prescriptions for our proprietary products.  Our partners may also experience a decrease in demand for our partnered products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The business disruptions associated with a global pandemic could impact the business, product development priorities and operations of our partners, including potential delays in manufacturing their product candidates or approved products. For example, some of our partners are conducting or are planning to conduct clinical trials in geographies affected by the COVID-19 pandemic. The progress or completion of these clinical trials could be adversely impacted by the pandemic. Additionally, interruption or delays in the operations of the FDA, the EMA and other similar foreign regulatory agencies, or changes in regulatory priorities to focus on the COVID-19 pandemic, may affect required regulatory review, inspection, clearance and approval timelines. Disruptions such as these could result in delays in the development programs of our partnered products or impede the commercial efforts for approved products, resulting in potential reductions or delays in our revenues from partner royalty or milestone payments. We do not know the extent to which our partners&#8217; development programs or product commercialization efforts will be impacted or delayed.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on many third parties to source active pharmaceutical ingredient and drug products, manufacture and assemble our devices, distribute finished products and provide various logistics activities in order to manufacture and sell our partnered and proprietary products.  For example, we rely on third party manufacturers to manufacture the bulk rHuPH20 that we supply to our partners for their commercial products and product candidates, as well as our commercial product Hylenex. If any such third party manufacturer is adversely impacted by the COVID-19 pandemic and related consequences, including staffing shortages, production slowdowns and disruptions in delivery systems, availability of raw materials, reagents or components or if they divert resources or manufacturing capacity to accommodate the development of coronavirus treatments or vaccines, our supply chain may be disrupted, limiting our ability to sell Hylenex or supply bulk rHuPH20 to our partners. Any such disruptions to the operations of the third parties upon whom we rely to manufacture and sell our partnered and proprietary products could result in reductions or delays in our revenues.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of COVID-19 could worsen in countries that are already afflicted with the coronavirus which could further adversely impact our ability to conduct our business and could have a material adverse impact on our operations, financial condition and results.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the&#160;trading&#160;prices for our common shares and other biopharmaceutical companies have been highly volatile as a result of market and investor reactions to the COVID-19 pandemic and its potential consequences. As a result, access to sources of financing, should those be needed, may be more difficult and/or expensive. In addition, a recession, depression or other sustained adverse market event resulting from the spread of the coronavirus could materially and adversely affect our business and the value of our common shares.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our partnered or proprietary product candidates do not receive and maintain regulatory approvals, or if approvals are not obtained in a timely manner, such failure or delay would substantially impair our ability to generate revenues.*</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approval from the FDA or equivalent health authorities is necessary to design, develop, test, manufacture and market pharmaceutical products and medical devices in the U.S. and the other countries in which we anticipate doing business have similar requirements. The process for obtaining FDA and other regulatory approvals is extensive, time-consuming, risky and costly, and there is no guarantee that the FDA or other regulatory bodies will approve any applications that may be filed with respect to any of our partnered or proprietary product candidates, or that the timing of any such approval will be appropriate for the desired product launch schedule for a product candidate. We and our partners attempt to provide guidance as to the timing for the filing and acceptance of such regulatory approvals, but such filings and approvals may not occur when we or our partners expect, or at all. The FDA or other foreign regulatory agency may refuse or delay approval of our partnered or proprietary product candidates for failure to collect sufficient clinical or animal safety data and require additional clinical or animal safety studies which may cause lengthy delays and increased costs to ours or our partners&#8217; development programs. Any such issues associated with rHuPH20 could have an adverse impact on future development of our partners&#8217; products which include rHuPH20, future sales of Hylenex recombinant, or our ability to maintain our existing ENHANZE collaborations or enter into new ENHANZE collaborations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our partners may not be successful in obtaining approvals for any additional potential products in a timely manner, or at all. Refer to the risk factor titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our partnered or proprietary product candidates may not receive regulatory approvals or their development may be delayed for a variety of reasons, including delayed or unsuccessful clinical trials, regulatory requirements or safety concerns</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for additional information relating to the approval of product candidates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, even with respect to products which have been approved for commercialization, in order to continue to manufacture and market pharmaceutical products, we or our partners must maintain our regulatory approvals. If we or any of our partners are unsuccessful in maintaining the required regulatory approvals, our  revenues would be adversely affected.</span></div><div style="margin-top:6pt;padding-left:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of our partnered or proprietary products and product candidates could be associated with side effects or adverse events or product recalls.*</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As with most pharmaceutical products, use of our partnered or proprietary products and product candidates could be associated with side effects or adverse events which can vary in severity (from minor reactions to death) and frequency (infrequent or prevalent) and product recalls. Side effects or adverse events associated with the use of our partnered or proprietary products or product candidates of our partners may be observed at any time, including in clinical trials or when a product is commercialized, and any such side effects or adverse events may negatively affect our or our partners&#8217; ability to obtain or maintain regulatory approval or market such products and product candidates. Side effects such as toxicity or other safety issues associated with the use of our partnered or proprietary products and product candidates could require us or our partners to perform additional studies or halt development or commercialization of these products and product candidates or expose us to product liability lawsuits which will harm our business. For example, we experienced a clinical hold on patient enrollment and dosing in our phase 2 study of PEGPH20 in patients with PDA (a discontinued program), which was not resolved until we implemented steps to address an observed possible difference in TE event rates between the arms of the study. We or our partners may be required by regulatory agencies to conduct additional animal or human studies regarding the safety and efficacy of our pharmaceutical products or product candidates which we have not planned or anticipated. There can be no assurance that we or our partners will resolve any issues related to any product or product candidate side effects or adverse events to the satisfaction of the FDA or any regulatory agency in a timely manner or ever, which could harm our business, prospects and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that a product fails to conform to its specifications or comply with the applicable laws or regulations, we or our partners may be required to or may decide to voluntarily recall the product or regulatory authorities may request or require that we recall a product even if there is no immediate potential harm to a patient. Any recall of our products or their components that we supply to our partners could materially adversely affect our business by rendering us unable to sell those products or components for some time and by adversely affecting our reputation. Recalls are costly and take time and effort to administer. Even if a recall only initially relates to a single product, product batch, or a portion of a batch, recalls may later be expanded to additional products or batches or we or our partners may incur additional costs and need to dedicate additional efforts to investigate and rule out the potential for additional impacted products or batches. Moreover, if any of our partners recall a product due to an issue with a product or component that we supplied, they may claim that we are responsible for such issue and may seek to recover the costs related to such recall or be entitled to certain contractual remedies from us. Recalls may further result in decreased demand for our partnered or proprietary products, could cause our partners or distributors to return products to us for which we may be required to provide refunds or replacement products, or could result in product shortages. Recalls may also require regulatory reporting and prompt regulators to conduct additional inspections of our or our partners&#8217; or contractors&#8217; facilities, which could result in findings of noncompliance and regulatory enforcement actions. A recall could also result in product liability claims by individuals and third-party payers. In addition, product liability claims or other safety issues </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">could result in an investigation of the safety or efficacy of our products, our manufacturing processes and facilities, or our marketing programs conducted by the FDA or the authorities of the EU member states and other jurisdictions. Such investigations could also potentially lead to a recall of our products or more serious enforcement actions, limitations on the indications for which they may be used, or suspension, variation, or withdrawal of approval. Any such regulatory action by the FDA, the EMA or the competent authorities of the EU member states could lead to product liability lawsuits as well.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our contract manufacturers or vendors are unable or elect not  to manufacture and supply to us bulk rHuPH20 or other raw materials, reagents, components or devices in the quantity and quality required by us or our partners for use in the production of Hylenex or our other proprietary or partnered products and product candidates, our and our partners&#8217; product development or commercialization efforts could be delayed or stopped and our business results of operations and our collaborations could be harmed.*</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a number of third parties in our supply chain for the supply and manufacture of our partnered and proprietary products and the availability of such products depends upon our ability to procure the raw materials, components, packaging materials and finished products from these third parties, many of which are currently our single source for the materials necessary for certain of our products.  We have entered into supply agreements with numerous third-party suppliers.  For example, we have existing supply agreements with contract manufacturing organizations Avid Bioservices, Inc. (Avid) and Catalent  Indiana LLC (Catalent) to produce bulk rHuPH20.&#160;These manufacturers each produce bulk rHuPH20 under cGMP for use in Hylenex recombinant, and for use in partnered products and product candidates. We rely on their ability to successfully manufacture bulk rHuPH20 according to product specifications. In addition to supply obligations, our contract manufacturers will also provide support for the chemistry, manufacturing and controls sections for FDA and other regulatory filings. We also rely on vendors to supply us with raw materials to produce reagents and other materials for bioanalytical assays used to support our partners&#8217; clinical trials. We also have a commercial manufacturing and supply agreement with Patheon under which Patheon provides the final fill and finishing steps in the production process of Hylenex recombinant. If any of our contract manufacturers or vendors: (i) is unable to retain its status as an FDA approved manufacturing facility; (ii) is unable to otherwise successfully scale up production to meet corporate or regulatory authority quality standards;  (iii) is unable to procure the labor, raw materials, reagents or components necessary to produce our proprietary products, including bulk rHuPH20 and  Hylenex recombinant our bioanalytical assays or our partnered products or (iv) fails to manufacture and supply our partnered and proprietary products, including bulk rHuPH20 in the quantity and quality required by us or our partners for use in Hylenex and partnered products and product candidates for any other reason, our business will be adversely affected. In addition, a significant change in such parties&#8217; or other third party manufacturers&#8217; business or financial condition could adversely affect their abilities or willingness to fulfill their contractual obligations to us. We have not established, and may not be able to establish, favorable arrangements with additional bulk rHuPH20 manufacturers and suppliers of the ingredients necessary to manufacture bulk rHuPH20 should the existing manufacturers and suppliers become unavailable or in the event that our existing manufacturers and suppliers are unable or unwilling to adequately perform their responsibilities. We have attempted to mitigate the impact of a potential supply interruption through the establishment of excess bulk rHuPH20 inventory where possible, but there can be no assurances that this safety stock will be maintained or that it will be sufficient to address any delays, interruptions or other problems experienced by any of our contract manufacturers. Any delays, interruptions or other problems regarding the ability or willingness of our contract manufacturers to supply bulk rHuPH20 or the ability or willingness of other third party manufacturers, to supply other raw materials or ingredients necessary to produce our other proprietary or partnered products on a timely basis could: (i) cause the delay of our partners&#8217; clinical trials or otherwise delay or prevent the regulatory approval of our partners&#8217; product candidates; (ii) delay or prevent the effective commercialization of our proprietary or partnered products and product candidates; and/or (iii) cause us to breach contractual obligations to deliver bulk rHuPH20 to our partners. Such delays would likely damage our relationship with our partners, and they would have a material adverse effect on royalties and thus our business and financial condition. Additionally, we rely on third parties to manufacture, prepare, fill, finish, package, store and ship our proprietary and partnered products and product candidates on our behalf. If the third parties we identify fail to perform their obligations, the progress of partners&#8217; clinical trials could be delayed or even suspended and the commercialization of our partnered or proprietary products could be delayed or prevented.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our Minnetonka, Minnesota facility supports our administrative functions, product development and quality operations and is intended to eventually provide additional manufacturing and warehousing capabilities in the future.  If we begin manufacturing and producing commercial products in the future, we will be subject to the same risks as our third-party manufacturers.  For example, we may not be able to begin product manufacturing and production due to a number of different reasons including, but not limited to, an ability to obtain necessary supplies and materials, labor and expertise.  To the extent we rely on our ability to manufacture any of our proprietary and partnered products, our inability to do so could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to perform many necessary services for our products including services related to the distribution, invoicing, rebates and contract administration, co-pay program administration, sample distribution and administration, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">storage and transportation of our products. If anything should impede their ability to meet their commitments this could impact our business performance.*</span></div><div><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on the product, we have retained third-party service providers to perform a variety of functions related to the distribution, invoicing, rebates and contract administration, co-pay program administration, sample distribution and administration, storage and transportation of our products, key aspects of which are out of our direct control. We place substantial reliance on these providers as well as other third-party providers that perform services for us, including, depending on the product, entrusting our inventories of products to their care and handling. We also may rely on third parties to administer our drug price reporting and rebate payments and contracting obligations under federal programs. Despite our reliance on third parties, we are responsible for compliance with the applicable legal and program requirements. By example, in certain states, we are required to hold licenses to distribute our products in these states and must comply with the associated state laws. Moreover, if these third-party service providers fail to meet expected deadlines, or otherwise do not carry out their contractual duties to us or encounter physical damage or a natural disaster at their facilities, our ability to deliver products to meet commercial demand would be significantly impaired. In addition, we may use third parties to perform various other services for us relating to regulatory monitoring, including adverse event reporting, safety database management and other product maintenance services. If our employees or any third-party service providers fail to comply with applicable laws and regulations, we and/or they may face regulatory or False Claims Act enforcement actions. Moreover, if the quality or accuracy of the data maintained by these service providers is insufficient, our ability to continue to market our products could be jeopardized or we and/or they could be subject to regulatory sanctions. We do not currently have the internal capacity to perform these important commercial functions, and we may not be able to maintain commercial arrangements for these services on reasonable terms.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or any party to a key collaboration agreement fail to perform material obligations under such agreement, or if&#160;a key collaboration agreement, is terminated for any reason, our business could significantly suffer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into multiple collaboration agreements under which we may receive significant future payments in the form of milestone payments, target designation fees, maintenance fees and royalties. We are heavily dependent on our partners to develop and commercialize product candidates subject to our collaborations in order for us to realize any financial benefits, including revenues from milestones, royalties and product sales from these collaborations. Our partners may not devote the attention and resources to such efforts that we would ourselves, change their clinical development plans, promotional efforts or simultaneously develop and commercialize products in competition to those products we have licensed to them. Any of these actions could not be visible to us immediately and could negatively impact our ability to forecast and our ability to achieve the benefits and revenue we receive from such collaboration. In addition, in the event that a party fails to perform under a key collaboration agreement, or if a key collaboration agreement is terminated, the reduction in anticipated revenues could negatively impact our operations. In addition, the termination of a key collaboration agreement by one or more of our partners could have a material adverse impact on our ability to enter into additional collaboration agreements with new partners on favorable terms, if at all. In certain circumstances, the termination of a key collaboration agreement would require us to revise our corporate strategy going forward and reevaluate the applications and value of our technology.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hylenex and our partners&#8217; ENHANZE products and product candidates rely on the rHuPH20 enzyme, and any adverse development regarding rHuPH20 could substantially impact multiple areas of our business, including current and potential ENHANZE collaborations, as well as any proprietary programs.*</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rHuPH20 is a key technological component of Hylenex and our ENHANZE technology and most of our ENHANZE partnered products and product candidates, including the current and future products and product candidates under our ENHANZE collaborations. We drive substantial portion of our revenues from our ENHANZE collaborations. Therefore, if there is an adverse development for rHuPH20 (e.g., an adverse regulatory determination relating to rHuPH20, if we are unable to obtain sufficient quantities of rHuPH20, if we are unable to obtain or maintain material proprietary rights to rHuPH20 or if we discover negative characteristics of rHuPH20), multiple areas of our business, including current and potential collaborations, as well as proprietary programs would be substantially impacted. For example, elevated anti-rHuPH20 antibody titers were detected in the registration trial for Baxalta&#8217;s HYQVIA product as well as in a former partner&#8217;s product in a Phase 2 clinical trial with rHuPH20, but have not been associated, in either case, with any adverse events. We monitor for antibodies to rHuPH20 in our collaboration and proprietary programs, and although we do not believe at this time that the incidence of non-neutralizing anti-rHuPH20 antibodies in either the HYQVIA program or the former partner&#8217;s program will have a significant impact on our proprietary product and our partners&#8217; product and product candidates, there can be no assurance that there will not be other such occurrences in the foregoing programs or that concerns regarding these antibodies will not also be raised by the FDA or other health authorities in the future, which could result in delays or discontinuations of our Hylenex commercialization activities, the development or commercialization activities of our ENHANZE partners, or deter our entry into additional ENHANZE collaborations with third parties. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business strategy and our strategic focus is currently limited to only a few fields or applications of our technology which may increase the risk for potential negative impact from adverse developments. Future expansion of our strategic focus to additional applications of our technology may require the use of additional resources, result in increased expense and ultimately may not be successful.*</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We routinely evaluate our business strategy, and may modify this strategy in the future in light of our assessment of unmet medical needs, growth potential, resource requirements, regulatory issues, competition, risks and other factors. As a result of these strategic evaluations, we may focus our resources and efforts on one or a few programs or fields and may suspend or reduce our efforts on other programs and fields. For example, in the fourth quarter of 2019, we decided to focus our resources on our ENHANZE technology and our commercial product, Hylenex. By focusing on these areas, we increase the potential impact on us if one of those partner programs does not successfully complete clinical trials, achieve commercial acceptance or meet expectations regarding sales and revenue. We may also expand our strategic focus by seeking new therapeutics applications of our technology or by acquiring new technologies which may require the use of additional resources, increased expense and would require the attention of senior management. For example, in May 2022, we acquired Antares as a means to expand our strategic focus into new therapeutic applications with a goal of diversifying the sources of our revenues. There can be no assurance that our investment in Antares or any such future investment of resources in new technologies will ultimately result in additional approved proprietary or partnered products or commercial success of new therapeutic applications of our technology.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our  partnered or proprietary product candidates may not receive regulatory approvals or their development may be delayed for a variety of reasons, including delayed or unsuccessful clinical trials, regulatory requirements or safety concerns. If we or our partners fail to obtain, or have delays in obtaining, regulatory approvals for any product candidates, our business, financial condition and results of operations may be materially adversely affected.*</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing of pharmaceutical products is a long, expensive and uncertain process, and the failure or delay of a clinical trial can occur at any stage, including the patient enrollment stage. Even if initial results of preclinical and nonclinical studies or clinical trial results are promising, our partners may obtain different results in subsequent trials or studies that fail to show the desired levels of dose safety and efficacy, we or our partners may not obtain applicable regulatory approval for our products for a variety of other reasons. Preclinical, nonclinical, and clinical trials for proprietary and partnered product candidates could be unsuccessful, which would delay or preclude regulatory approval and commercialization of the product candidates. In the U.S. and other jurisdictions, regulatory approval can be delayed, limited or not granted for many reasons, including, among others:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">during the course of clinical studies, the final data may differ from initial reported data, and clinical results may not meet prescribed endpoints for the studies or otherwise provide sufficient data to support the efficacy of our partners&#8217; product candidates;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical and nonclinical test results may reveal inferior pharmacokinetics, side effects, adverse events or unexpected safety issues associated with the use of our partners&#8217; product candidates;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory review may not find that the data from preclinical testing and clinical trials justifies approval;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require that we or our partners change their studies or conduct additional studies which may significantly delay or make continued pursuit of approval commercially unattractive; </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a regulatory agency may reject our and our partners&#8217; trial data or disagree with their interpretations of either clinical trial data or applicable regulations;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a regulatory agency may require additional safety monitoring and reporting through Risk Evaluation and Mitigation Strategies or conditions to assure safe use programs;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or a partner may decide to not pursue regulatory approval for such a product;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a regulatory agency may not approve our manufacturing processes or facilities, or the processes or facilities of our partners, our contract manufacturers or our raw material suppliers;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of our or our partners&#8217; contract research organization, or CRO, to properly perform the clinical trial in accordance with the written protocol, our contractual obligations with them or applicable regulatory requirements; </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a regulatory agency may identify problems or other deficiencies in our existing manufacturing processes or facilities, or the existing processes or facilities of our partners, our contract manufacturers or our raw material suppliers; </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a regulatory agency may change its formal or informal approval requirements and policies, act contrary to previous guidance, adopt new regulations or raise new issues or concerns late in the approval process; or</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a proprietary or partnered product candidate may be approved only for indications that are narrow or under conditions that place the product at a competitive disadvantage, which may limit the sales and marketing activities for such product candidate or otherwise adversely impact the commercial potential of a product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a proprietary or partnered product candidate is not approved in a timely fashion or obtained on commercially viable terms, or if development of any product candidate is terminated due to difficulties or delays encountered in the regulatory approval process, it could have a material adverse impact on our business, financial condition and results of operation and we </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">would become more dependent on the development of other proprietary or partnered product candidates and/or our ability to successfully acquire other technologies. There can be no assurances that we or our any partnered product candidate will receive regulatory approval in a timely manner, or at all. There can be no assurance that partners will be able to gain clarity as to the FDA&#8217;s requirements or that the requirements may be satisfied in a commercially feasible way, in which case our ability to enter into collaborations with third parties or explore other strategic alternatives to exploit an opportunity will be limited or may not be possible.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that certain proprietary or partnered products will be marketed, and perhaps manufactured, in foreign countries. The process of obtaining regulatory approvals in foreign countries is subject to delay and failure for the reasons set forth above, as well as for reasons that vary from jurisdiction to jurisdiction. The approval process varies among countries and jurisdictions and can involve additional testing. The time required to obtain approval may differ from that required to obtain FDA approval. Foreign regulatory agencies may not provide approvals on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or jurisdictions or by the FDA.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our third party partners are responsible for providing certain proprietary materials that are essential components of our partnered products and product candidates, and any failure to supply these materials could delay the development and commercialization efforts for these partnered products and product candidates and/or damage our collaborations. Our partners are also responsible for distributing and commercializing their products, and any failure to successfully commercialize their products could materially adversely affect our revenues.*</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our development and commercialization partners are responsible for providing certain proprietary materials that are essential components of our partnered products and product candidates. For example, Roche is responsible for producing the Herceptin and MabThera required for its subcutaneous products and Baxalta is responsible for producing the GAMMAGARD LIQUID for its product HYQVIA. If a partner, or any applicable third party service provider of a partner, encounters difficulties in the manufacture, storage, delivery, fill, finish or packaging of the partnered product or product candidate or component of such product or product candidate, such difficulties could (i) cause the delay of clinical trials or otherwise delay or prevent the regulatory approval of partnered product candidates; and/or (ii) delay or prevent the effective commercialization of partnered products. Such delays could have a material adverse effect on our business and financial condition. We also rely on our partners to commercialize and distribute their products and if they are unsuccessful in commercializing their products, the resulting royalty revenue we would receive may be lower than expected.  </span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our partners fail to comply with regulatory requirements applicable to promotion, sale and manufacturing of approved products, regulatory agencies may take action against us or them, which could significantly harm our business.*</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any approved products, along with the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for these products, are subject to continual requirements and review by the FDA, state and foreign regulatory bodies. Regulatory authorities subject a marketed product, its manufacturer and the manufacturing facilities to continual review and periodic inspections. We, our partners and our respective contractors, suppliers and vendors, will be subject to ongoing regulatory requirements, including complying with regulations and laws regarding advertising, promotion and sales of drug products, required submissions of safety and other post-market information and reports, registration requirements, cGMP regulations (including requirements relating to quality control and quality assurance, as well as the corresponding maintenance of records and documentation), and the requirements regarding the distribution of samples to physicians and recordkeeping requirements. Further, because some of our proprietary and partnered products and product candidates are drug/device combination products, we and our partners will have to comply with extensive regulatory requirements than would otherwise be required for products that are not combination products.  Regulatory agencies may change existing requirements or adopt new requirements or policies. We, our partners and our respective contractors, suppliers and vendors, may be slow to adapt or may not be able to adapt to these changes or new requirements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, regulatory requirements applicable to pharmaceutical products make the substitution of suppliers and manufacturers costly and time consuming. We have minimal internal manufacturing capabilities and are, and expect to be in the future, substantially dependent on contract manufacturers and suppliers for the manufacture of our products and for their active and other ingredients. The disqualification of these manufacturers and suppliers through their failure to comply with regulatory requirements could negatively impact our business because the delays and costs in obtaining and qualifying alternate suppliers (if such alternative suppliers are available, which we cannot assure) could delay our or our partners&#8217; clinical trials or otherwise inhibit our or  partners&#8217; ability to bring approved products to market, which would have a material adverse effect on our business and financial condition. Likewise, if we, our partners and our respective contractors, suppliers and vendors involved in sales and promotion of our products do not comply with applicable laws and regulations, for example off-label or false or misleading promotion, this could materially harm our business and financial condition.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with regulatory requirements may result in adverse regulatory actions including but not limited to, any of the following:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on our or our partners&#8217; products or manufacturing processes;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">warning letters;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of our or our partners&#8217; products from the market;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">voluntary or mandatory recall;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension or withdrawal of regulatory approvals;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension or termination of any of our partners&#8217; ongoing clinical trials;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal to permit the import or export of our or our partners&#8217; products;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal to approve pending applications or supplements to approved applications that we submit;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure; </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions; or</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">imposition of civil or criminal penalties. </span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to successfully integrate the Antares business, or failure of the Antares business to perform could adversely impact our stock price and future business and operations.*</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, we completed the acquisition of Antares. Our integration of the Antares business into our operations will be a complex and time-consuming process that may not be successful. The primary areas of focus for successfully combining the business of Antares with our operations may include, among others: retaining and integrating management and other key employees; aligning and prioritizing product development initiatives, integrating information, communications and other systems; and managing the growth of the combined company.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we successfully integrate the business of Antares into our operations, we may not realize the anticipated benefits. We acquired Antares with the expectation that the acquisition will result in various benefits for the combined company, including providing an opportunity for increased revenues, expansion into additional market segments and the ability to leverage existing U.S. commercial infrastructure to promote the companies' proprietary products. Increased competition and/or deterioration in business conditions may limit our ability to expand this business. As such, we may not be able to realize the benefits anticipated in connection with the acquisition.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to raise additional capital in the future and there can be no assurance that we will be able to obtain such funds.*</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may need to raise additional capital in the future to fund our operations for general corporate purposes if we do not achieve the level of revenues we expected. Our current cash reserves and expected revenues may not be sufficient for us to fund general operations and conduct our business at the level desired. In addition, if we engage in acquisitions of companies, products or technologies in order to execute our business strategy, we may need to raise additional capital. We may raise additional capital in the future through one or more financing vehicles that may be available to us including (i)&#160;new collaborative agreements;  (ii)&#160;expansions or revisions to existing collaborative relationships; (iii) private financings; (iv) other equity or debt financings; (v)&#160;monetizing assets; and/or (vi) the public offering of securities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are required to raise additional capital in the future, it may not be available on favorable financing terms within the time required, or at all. If additional capital is not available on favorable terms when needed, we will be required to raise capital on adverse terms or significantly reduce operating expenses through the restructuring of our operations or deferral of strategic business initiatives. If we raise additional capital through a public offering of securities or equity, a substantial number of additional shares may be issued, which will dilute the ownership interest of our current investors and may negatively affect our stock price.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have significant debt and expect to incur additional debt. Failure by us to fulfill our obligations under the applicable debt agreements may cause the repayment obligations to accelerate.*</span></div><div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of our consolidated indebtedness, net of debt discount, as of&#160;June&#160;30, 2022&#160;was $1,246.2 million, which includes $250.0 million under our 2022 term facility, $120.0 million under our 2022 Revolving facility,  $90.9 million in aggregate principal amount of the 2024 Convertible Notes and $805.0 million in aggregate principal amount of the 2027 Convertible Notes, net of unamortized debt discount of $1.3 million,  $16.1 million and $2.4 million for 2024 Convertible Notes, 2027 Convertible Notes and 2022 term facility, respectively. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our indebtedness may:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make it difficult for us to satisfy our financial obligations, including making scheduled principal and interest payments on our indebtedness;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit our ability to borrow additional funds for working capital, capital expenditures, acquisitions or other general corporate purposes;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit our ability to use our cash flow or obtain additional financing for future working capital, capital expenditures, acquisitions, share repurchases or other general business purposes;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require us to use a portion of our cash flow from operations to make debt service payments;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit our flexibility to plan for, or react to, changes in our business and industry;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">place us at a competitive disadvantage compared to our less leveraged competitors; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increase our vulnerability to the impact of adverse economic and industry conditions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our 2022 Credit Agreement includes certain affirmative and negative covenants, that, among other things, may restrict our ability to: create liens on assets; incur additional indebtedness; make investments; make acquisitions and other fundamental changes; and sell and dispose of property or assets. The 2022 Credit Agreement also includes financial covenants requiring us to maintain, measured as of the end of each fiscal quarter, a maximum consolidated net leverage ratio of 4.75 to 1.00 initially, which declines to 4.00 to 1.00 over the term of the loan facility, and a minimum consolidated interest coverage ratio of 3.00 to 1.00. The 2022 Credit Agreement also contains customary representations and warranties and events of default.  Complying with the covenants contained in the 2022 Credit Agreement could make it more difficult for us to execute our business strategy.  Further, in the event of default by us under the 2022 Credit Agreement, the lenders would be entitled to exercise their remedies thereunder, including the right to accelerate the debt, upon which we may be required to repay all amounts then outstanding under the 2022 Credit Agreement which would harm our financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to make payments on our existing or any future debt will depend on our future operating performance and ability to generate cash and may also depend on our ability to obtain additional debt or equity financing. It will also depend on financial, business or other factors affecting our operations, many of which are beyond our control. We will need to use cash to pay principal and interest on our debt, thereby reducing the funds available to fund operations, strategic initiatives and working capital requirements. If we are unable to generate sufficient cash to service our debt obligations, an event of default may occur under any of our debt instruments which could result in an acceleration of such debt upon which we may be required to repay all the amounts outstanding under some or all of our debt instruments.  Such an acceleration of our debt obligations could harm our financial condition. From time to time, we may seek to retire or repurchase our outstanding debt through cash purchases and/or exchanges for equity or debt, in open-market purchases, privately negotiated transactions or otherwise. Any such repurchases or exchanges would be on such terms and at such prices as we determine, and will depend on current market conditions, our liquidity needs, any restrictions in our contracts and other factors. The amounts involved in such transactions could be material.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The conditional conversion feature of the Convertible Notes, if triggered, may adversely affect our financial condition and operating results.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event the conditional conversion feature of the Convertible Notes is triggered, holders of the Convertible Notes will be entitled to convert the notes at any time during specified periods at their option. If one or more holders elect to convert their notes, we would be required to settle a portion or all of our conversion obligation in cash, which could adversely affect our liquidity. Even if holders of the Convertible Notes do not elect to convert their notes, we are required under applicable accounting rules to reclassify all or a portion of the outstanding principal of the notes as a current rather than long-term liability when the conditional conversion feature is triggered, which results in a material reduction of our net working capital. For example, as of June&#160;30, 2022, the conditional conversion feature was triggered and our 2024 Convertible Notes are classified as a current liability. </span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conversion of our Convertible Notes may dilute the ownership interest of existing stockholders or may otherwise depress the price of our common stock.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conversion of some or all of our Convertible Notes, to the extent we deliver shares upon conversion, will dilute the ownership interests of existing stockholders. Any sales in the public market of the Convertible Notes or our common stock issuable upon conversion of the Convertible Notes could adversely affect prevailing market prices of our common stock. In addition, the existence of the Convertible Notes may encourage short selling by market participants because the conversion of the Convertible Notes could be used to satisfy short positions, or anticipated conversion of the Convertible Notes into shares of our common stock could depress the price of our common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If proprietary or partnered product candidates are approved for marketing but do not gain market acceptance resulting in commercial performance below that which was expected or projected, our business may suffer.*</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming that existing or future proprietary or partnered product candidates obtain the necessary regulatory approvals for commercial sale, a number of factors may affect the market acceptance of these newly-approved products, including, among others:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the degree to which the use of these products is restricted by the approved product label;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the price of these products relative to other therapies for the same or similar treatments;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which reimbursement for these products and related treatments will be available from third party payors including government insurance programs and private insurers;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the introduction of generic or biosimilar competitors to these products; </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the perception by patients, physicians and other members of the health care community of the effectiveness and safety of these products for their prescribed treatments relative to other therapies for the same or similar treatments;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability and willingness of our partners to fund sales and marketing efforts; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of the sales and marketing efforts of our partners.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If these proprietary or partnered products do not gain or maintain market acceptance or experience reduced sales resulting in commercial performance below that which was expected or projected, the revenues we expect to receive from these products will be diminished which could harm our ability to fund future operations, including conduct acquisitions, execute our planned share repurchases, or affect our ability to use funds for other general corporate purposes and cause our business to suffer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our proprietary or partnered product candidates will be restricted to the labels approved by FDA and applicable regulatory bodies, and these restrictions may limit the marketing and promotion of the ultimate products. If the approved labels are restrictive, the sales and marketing efforts for these products may be negatively affected.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to license our ENHANZE and device technologies to our partners depends on the validity of our patents and other proprietary rights.*&#160;&#160; </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents and other proprietary rights are essential to our business. Our success will depend in part on our ability to obtain and maintain patent protection for our inventions, to preserve our trade secrets and to operate without infringing the proprietary rights of third parties.&#160;We have multiple patents and patent applications throughout the world pertaining to our recombinant human hyaluronidase and methods of use and manufacture, including an issued U.S. patent which expires in 2027 and an issued European patent which expires in 2024, which we believe cover the products and product candidates under our existing collaborations, and Hylenex.&#160;Although we believe our patent filings represent a barrier to entry for potential competitors looking to utilize these hyaluronidases, upon expiration of our patents other pharmaceutical companies may (if they do not infringe our other patents) seek to compete with us by developing, manufacturing and selling biosimilars to the active drug ingredient in our ENHANZE technology used by our partners in combination with their products.&#160;Any such loss of patent protection or proprietary rights could lead to a reduction or loss of revenues, incentivize one or more of our key ENHANZE partners to terminate their relationship with us and impact our ability to enter into new collaboration and license agreements.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Developing, manufacturing and marketing pharmaceutical products for human use involves significant product liability risks for which we may have insufficient insurance coverage.*</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development, manufacture, testing, marketing and sale of pharmaceutical products and medical devices involves the risk of product liability claims by consumers and other third parties. Product liability claims may be brought by individuals seeking relief for themselves, or by groups seeking to represent a class of injured patients.  Further, third party payers, either individually or as a putative class, may bring actions seeking to recover monies spent on one of our products.  Although we maintain product liability insurance coverage, product liability claims can be high in the pharmaceutical industry, and our insurance may not sufficiently cover our actual liabilities. If product liability claims were to be made against us, it is possible that the liabilities may exceed the limits of our insurance policy, or our insurance carriers may deny, or attempt to deny, coverage in certain instances. If a lawsuit against us is successful, then the insurance coverage may not be sufficient and could materially and adversely affect our business and financial condition. Furthermore, various distributors of pharmaceutical products require minimum product liability insurance coverage before purchase or acceptance of products for distribution. Failure to satisfy these insurance requirements could impede our ability to achieve broad distribution of our proposed products, and higher insurance requirements could impose additional costs on us. In addition, since many of our partnered product candidates include the pharmaceutical products of a third party, we run the risk that problems with the third party pharmaceutical product will give rise to liability claims against us. Product liability claims can also result in additional regulatory consequences including, but not limited to, investigations and regulatory enforcement actions, as well as recalls, revocation or approvals, or labeling, marketing or promotional restrictions or changes.  Product liability claims could also harm our reputation and the reputation of our products, adversely affecting our ability to market our products successfully.  In addition, defending a product liability lawsuit is expensive and can divert the attention of our key employees from operating our business.  Such claims can also impact our ability to initiate or complete clinical trials.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our partners do not achieve projected development, clinical, or regulatory goals in the timeframes publicly announced or otherwise expected, the commercialization of our partnered products may be delayed and, as a result, our stock price may decline, and we may face lawsuits relating to such declines.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, our partners may publicly articulate the estimated timing for the accomplishment of certain scientific, clinical, regulatory and other product development goals. The accomplishment of any goal is typically based on numerous assumptions, and the achievement of a particular goal may be delayed for any number of reasons both within and outside of our and our partners&#8217; control. If scientific, regulatory, strategic or other factors cause a partner to not meet a goal, regardless of whether that goal has been publicly articulated or not, our stock price may decline rapidly. Stock price declines may also trigger direct or derivative shareholder lawsuits. As with any litigation proceeding, the eventual outcome of any legal action is difficult to predict. If any such lawsuits occur, we will incur expenses in connection with the defense of these lawsuits, and we may have to pay substantial damages or settlement costs in connection with any resolution thereof. Although we have insurance coverage against which we may claim recovery against some of these expenses and costs, the amount of coverage may not be adequate to cover the full amount or certain expenses and costs may be outside the scope of the policies we maintain. In the event of an adverse outcome or outcomes, our business could be materially harmed from depletion of cash resources, negative impact on our reputation, or restrictions or changes to our governance or other processes that may result from any final disposition of the lawsuit. Moreover, responding to and defending pending litigation significantly diverts management&#8217;s attention from our operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the consistent failure to meet publicly announced milestones may erode the credibility of our management team with respect to future milestone estimates. </span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future acquisitions could disrupt our business and harm our financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to augment our product pipeline or otherwise strengthen our business, we acquired Antares in May 2022 and we may decide to acquire additional businesses, products and technologies. As we have limited experience in evaluating and completing acquisitions, our ability as an organization to make such acquisitions is unproven. Acquisitions could require significant capital infusions and could involve many risks, including, but not limited to, the following:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may have to issue additional convertible debt or equity securities to complete an acquisition, which would dilute our stockholders and could adversely affect the market price of our common stock;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an acquisition may negatively impact our results of operations because it may require us to amortize or write down amounts related to goodwill and other intangible assets, or incur or assume substantial debt or liabilities, or it may cause adverse tax consequences, substantial depreciation or deferred compensation charges;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may encounter difficulties in assimilating and integrating the business, products, technologies, personnel or operations of companies that we acquire;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">certain acquisitions may impact our relationship with existing or potential partners who are competitive with the acquired business, products or technologies;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquisitions may require significant capital infusions and the acquired businesses, products or technologies may not generate sufficient value to justify acquisition costs;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may take on liabilities from the acquired company such as debt, legal liabilities or business risk which could be significant;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an acquisition may disrupt our ongoing business, divert resources, increase our expenses and distract our management;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquisitions may involve the entry into a geographic or business market in which we have little or no prior experience; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">key personnel of an acquired company may decide not to work for us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these risks occurred, it could adversely affect our business, financial condition and operating results. There is no assurance that we will be able to identify or consummate any future acquisitions on acceptable terms, or at all. If we do pursue any future acquisitions, it is possible that we may not realize the anticipated benefits from such acquisitions or that the market will not view such acquisitions positively.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Nevertheless, our effective tax rate may be different than experienced in the past due to numerous factors, including changes in the mix of our profitability between different tax jurisdictions, the results of examinations and audits of our tax filings, our inability to secure or sustain acceptable agreements with tax authorities, changes in accounting for income taxes and changes in tax laws. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations and may result in tax obligations in excess of amounts accrued in our financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, on September 30, 2021, we determined, based on our facts and circumstances, that it was more likely than not that a substantial portion of our deferred tax assets would be realized and, as a result, substantially all of our valuation allowance against our deferred tax assets was released. This resulted in substantially and disproportionately increasing our reported net income and our earnings per share compared to our operating results for 2021. Historical and future comparisons to these amounts are not, and will not be, indicative of actual profitability trends for our business. Beginning in 2022, we expect to commence recording income tax expense at an estimated tax rate that will likely approximate statutory tax rates, which would result in a significant reduction in our net income and net income per share.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related To Ownership of Our Common Stock</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price is subject to significant volatility.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in a highly dynamic industry which often results in significant volatility in the market price of common stock irrespective of company performance. The high and low sales prices of our common stock during the twelve months ended June&#160;30, 2022 were $48.58 and $31.36, respectively. In addition to the other risks and uncertainties described elsewhere in this Quarterly Report on Form 10-Q and all other risks and uncertainties that are either not known to us at this time or which we deem to be immaterial, any of the following factors may lead to a significant drop in our stock price:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the presence of competitive products to those being developed by our partners;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure (actual or perceived) of our partners to devote attention or resources to the development or commercialization of partnered products or product candidates licensed to such partner;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a dispute regarding our failure, or the failure of one of our partners, to comply with the terms of a collaboration agreement; </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the termination, for any reason, of any of our collaboration agreements;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sale of common stock by any significant stockholder, including, but not limited to, direct or indirect sales by members of management or our Board of Directors;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the resignation, or other departure, of members of management or our Board of Directors;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general negative conditions in the healthcare industry;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pandemics or other global crises;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general negative conditions in the financial markets;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost associated with obtaining regulatory approval for any of our proprietary or partnered product candidates;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the failure, for any reason, to secure or defend our intellectual property position;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the failure or delay of applicable regulatory bodies to approve our proprietary partnered product candidates;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identification of safety or tolerability issues;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of our our or our partners&#8217; clinical trials to meet efficacy endpoints;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspensions or delays in the conduct of our or our partners&#8217; clinical trials or securing of regulatory approvals;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse regulatory action with respect to our proprietary or partnered products and product candidates such as loss of regulatory approval to commercialize such products, clinical holds, imposition of onerous requirements for approval or product recalls;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our failure, or the failure of our partners, to successfully commercialize products approved by applicable regulatory bodies such as the FDA;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our failure, or the failure of our partners, to generate product revenues anticipated by investors;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruptions in our clinical or commercial supply chains, including disruptions caused by problems with a bulk rHuPH20 contract manufacturer or a fill and finish manufacturer for any product or product collaboration candidate; </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sale of additional debt and/or equity securities by us;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our failure to obtain financing on acceptable terms or at all; </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a restructuring of our operations;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an inability to execute our share repurchase program in the time and manner we expect due to market, business, legal or other considerations; or </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a conversion of the Convertible Notes into shares of our common stock.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future transactions where we raise capital may negatively affect our stock price.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently a &#8220;Well-Known Seasoned Issuer&#8221; and may file automatic shelf registration statements at any time with the SEC. Sales of substantial amounts of shares of our common stock or other securities under any future shelf registration statements could lower the market price of our common stock and impair our ability to raise capital through the sale of equity securities. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our charter documents, the Indentures and Delaware law may make an acquisition of us more difficult.*</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-takeover provisions in our charter documents, the Indentures and Delaware law may make an acquisition of us more difficult. First, our Board of Directors is classified into three classes of directors. Under Delaware law, directors of a corporation with a classified board may be removed only for cause unless the corporation&#8217;s certificate of incorporation provides otherwise. Our amended and restated certificate of incorporation does not provide otherwise. In addition, our bylaws limit who may call special meetings of stockholders, permitting only stockholders holding at least 50% of our outstanding shares to call a special meeting of stockholders. Our amended and restated certificate of incorporation does not include a provision for cumulative voting for directors. Under cumulative voting, a minority stockholder holding a sufficient percentage of a class of shares may be able to ensure the election of one or more directors. Finally, our bylaws establish procedures, including advance notice procedures, with regard to the nomination of candidates for election as directors and stockholder proposals.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions in our charter documents may discourage potential takeover attempts, discourage bids for our common stock at a premium over market price or adversely affect the market price of, and the voting and other rights of the holders of, our common stock. These provisions could also discourage proxy contests and make it more difficult for stockholders to elect directors other than the candidates nominated by our board of directors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, in connection with our Convertible Notes issuances, we entered into an indenture dated as of November&#160;18, 2019 and an indenture dated as of March 1, 2021 (the &#8220;Indentures&#8221;), with The Bank of New York Mellon Trust Company, N.A., as trustee. Certain provisions in the Indenture could make it more difficult or more expensive for a third party to acquire us.  For example, if a takeover would constitute a fundamental change, holders of the Convertible Notes will have the right to require us to repurchase their Convertible Notes in cash.  In addition, if a takeover constitutes a make-whole fundamental change, we may be required to increase the conversion rate for holders who convert their Convertible Notes in connection with such takeover. .  In addition, a change of control constitutes an event of default under our 2022 Credit Agreement.  Such event of default could result in the administrative agent or the lender parties thereto declaring the unpaid principal, all accrued and unpaid interest, and all other amounts owing or payable under the 2022 Credit Agreement to be immediately due and payable.   In either case, and in other cases, our obligations under the Convertible Notes,  the Indentures and the 2022 Credit Agreement could increase the cost of acquiring us or otherwise discourage a third party from acquiring us or removing incumbent management.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which may prohibit large stockholders from consummating a merger with, or acquisition of, us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions may deter an acquisition of us that might otherwise be attractive to stockholders.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Industry</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our or our partnered products must receive regulatory approval before they can be sold, and compliance with the extensive government regulations is expensive and time consuming and may result in the delay or cancellation of our or our partnered product sales, introductions or modifications.*</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Extensive industry regulation has had, and will continue to have, a significant impact on our business. All pharmaceutical and medical device companies, including ours, are subject to extensive, complex, costly and evolving regulation by the health regulatory agencies including the FDA (and with respect to controlled drug substances, the U.S. Drug Enforcement Administration (DEA)) and equivalent foreign regulatory agencies and state and local/regional government agencies. The Federal Food, Drug and Cosmetic Act, the Controlled Substances Act and other domestic and foreign statutes and regulations govern or influence the testing, manufacturing, packaging, labeling, storing, recordkeeping, safety, approval, advertising, promotion, sale and distribution of our product and our partners&#8217; products and product candidates. We are dependent on receiving FDA and other governmental approvals, including regulatory approvals in jurisdictions outside the United States, prior to manufacturing, marketing and shipping our products. Consequently, there is always a risk that the FDA or other applicable governmental authorities, including those outside the United States, will not approve our partners&#8217; products or may impose onerous, costly and time-consuming requirements such as additional clinical or animal testing. Regulatory authorities may require that our partners&#8217; change our studies or conduct additional studies, which may significantly delay or make continued pursuit of approval commercially unattractive to our partners. For example, the approval of Baxalta&#8217;s HYQVIA BLA was delayed by the FDA until we and Baxalta provided additional preclinical data sufficient to address concerns regarding non-neutralizing antibodies to rHuPH20 that were detected in the registration trial. Although these antibodies have not been associated with any known adverse clinical effects, and the HYQVIA BLA was ultimately approved by the FDA, the FDA or other foreign regulatory agency may, at any time, halt our and our partners&#8217; development and commercialization activities due to safety concerns. In addition, even if our proprietary or or partnered products are approved, regulatory agencies may also take post-approval action limiting or revoking our or our partners&#8217; ability to sell these products. Any of these regulatory actions may adversely affect the economic benefit we may derive from our proprietary or our partnered products and therefore harm our financial condition.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under certain of these regulations, in addition to our partners, we and our contract suppliers and manufacturers are subject to periodic inspection of our or their respective facilities, procedures and operations and/or the testing of products by the FDA, the DEA and other authorities, which conduct periodic inspections to confirm that we and our contract suppliers and manufacturers are in compliance with all applicable regulations. The FDA also conducts pre-approval and post-approval reviews and plant inspections to determine whether our systems, or our contract suppliers&#8217; and manufacturers&#8217; processes, are in compliance with cGMP and other FDA regulations. If our partners, we, or our contract suppliers, fail these inspections, our partners may not be able to commercialize their products in a timely manner without incurring significant additional costs, or at all.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the FDA imposes a number of complex regulatory requirements on entities that advertise and promote pharmaceuticals including, but not limited to, standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities, and promotional activities involving the Internet.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because some of our and our partners&#8217; products and product candidates are considered to be drug/device combination products, the approval and post-approval requirements that we and they are required to comply with can be more complex.*</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our and our partners&#8217; products and product candidates are considered to be drug/device combination products by the FDA, consisting of a drug product and a drug delivery device. If marketed individually, each component would be subject to different regulatory pathways and reviewed by different centers within the FDA. A combination product, however, is assigned to a center that will have primary jurisdiction over its pre-market review and regulation based on a determination of the product&#8217;s primary mode of action, which is the single mode of action that provides the most important therapeutic action. In the case of our and our partners&#8217; products and product candidates, the primary mode of action is typically attributable to the drug component of the products, which means that the Center of Drug Evaluation and Research has primary jurisdiction over the products&#8217; premarket development and review. These products and product candidates will be and have been subject to the FDA drug approval process and will not require a separate FDA clearance or approval for the device component. Even though these products and product candidates will not require a separate FDA clearance or approval, both the drug and device centers within the FDA will review the marketing application for safety, the efficacy of both the drug and device component, including the design and reliability of the injector, and a number of other different areas, such as to ensure that the drug labeling adequately discloses all relevant information and risks, and to confirm that the instructions for use are accurate and easy to use. These reviews could increase the time needed for review completion of a successful application and may require additional studies, such as usage studies, to establish the validity of the instructions. Such reviews and requirements may extend the time necessary for the approval of drug-device combinations. In the case of combination product candidates for which we or our partners are seeking approval via the ANDA pathway, it is also possible that the agency may decide that the unique nature of combination products leads it to question the claims of bioequivalence and/or same labeling, resulting in the need to refile the application under Section 505(b)(2). This may result in delays in product approval and may cause us or our partners to incur additional costs associated with testing, including clinical trials. Approval via the 505(b)(2) pathway may also result in additional selling expenses and a decrease in market acceptance due to the lack of substitutability by pharmacies or formularies. In addition, approval under the 505(b)(2) or ANDA regulatory pathway is not a guarantee of an exclusive position for the approved product in the marketplace.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, although precedent and guidance exist for the approval of such combination products,  FDA could change what it requires or how it reviews submissions. Changes in review processes or the requirement for the study of combination products could delay anticipated launch dates or be cost prohibitive. Such delay or failure to launch these products or devices could adversely affect our revenues and future profitability. If our or our partners&#8217; combination product candidates are approved, we, our partners, and any of our respective contractors will be required to comply with FDA regulatory requirements related to both drugs and devices. For instance, drug/device combination products must comply with both the drug cGMPs and device QSRs. Depending on whether the drug and device components are at the same facility, however, the FDA regulations provide a streamlined method to comply with both sets of requirements. The FDA has specifically promulgated guidance on injectors, which discuss FDA&#8217;s requirements with respect to marketing application and post-market injector design controls and reliability analyses. Additionally, drug/device combination products will be subject to additional FDA and constituent part reporting requirements. Compliance with these requirements will require additional effort and monetary expenditure.</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject, directly or indirectly, to various broad federal and state healthcare laws. If we are unable to comply, or have not fully complied, with such laws, we could face civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business operations and activities may be directly, or indirectly, subject to various broad federal and state healthcare laws, including without limitation, anti-kickback laws, the Foreign Corrupt Practices Act (FCPA), false claims laws, civil </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">monetary penalty laws, data privacy and security laws, tracing and tracking laws, as well as transparency (or &#8220;sunshine&#8221;) laws regarding payments or other items of value provided to healthcare providers. These laws may restrict or prohibit a wide range of business activities, including, but not limited to, research, manufacturing, distribution, pricing, discounting, marketing and promotion and other business arrangements. These laws may impact, among other things, our current activities with principal investigators and research subjects, as well as sales, marketing and education programs. Many states have similar healthcare fraud and abuse laws, some of which may be broader in scope and may not be limited to items or services for which payment is made by a government health care program.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. While we have adopted a healthcare corporate compliance program, it is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws. If our operations or activities are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to, without limitation, civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, any sales of products outside the U.S. will also likely subject us to the FCPA and foreign equivalents of the healthcare laws mentioned above, among other foreign laws.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be required to initiate or defend against legal proceedings related to intellectual property rights, which may result in substantial expense, delay and/or cessation of the development and commercialization of our products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We primarily rely on patents to protect our intellectual property rights. The strength of this protection, however, is uncertain. For example, it is not certain that:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we will be able to obtain patent protection for our products and technologies;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of any of our issued patents will be sufficient to provide commercially significant exclusivity for our products and technologies;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others will not independently develop similar or alternative technologies or duplicate our technologies and obtain patent protection before we do; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any of our issued patents, or patent pending applications that result in issued patents, will be held valid, enforceable and infringed in the event the patents are asserted against others.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently own or license several patents and also have pending patent applications applicable to rHuPH20 and other proprietary materials. There can be no assurance that our existing patents, or any patents issued to us as a result of our pending patent applications, will provide a basis for commercially viable products, will provide us with any competitive advantages, or will not face third party challenges or be the subject of further proceedings limiting their scope or enforceability. Any weaknesses or limitations in our patent portfolio could have a material adverse effect on our business and financial condition. In addition, if any of our pending patent applications do not result in issued patents, or result in issued patents with narrow or limited claims, this could result in us having no or limited protection against generic or biosimilar competition against our product candidates which would have a material adverse effect on our business and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may become involved in interference proceedings in the U.S. Patent and Trademark Office, or other proceedings in other jurisdictions, to determine the priority, validity or enforceability of our patents. In addition, costly litigation could be necessary to protect our patent position.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on trademarks to protect the names of our products (e.g. Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recombinant). We may not be able to obtain trademark protection for any proposed product names we select. In addition, product names for pharmaceutical products must be approved by health regulatory authorities such as the FDA in addition to meeting the legal standards required for trademark protection and product names we propose may not be timely approved by regulatory agencies which may delay product launch. In addition, our trademarks may be challenged by others. If we enforce our trademarks against third parties, such enforcement proceedings may be expensive.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on trade secrets, unpatented proprietary know-how and continuing technological innovation that we seek to protect with confidentiality agreements with employees, consultants and others with whom we discuss our business. Disputes may arise concerning the ownership of intellectual property or the applicability or enforceability of these agreements, and we might not be able to resolve these disputes in our favor.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to protecting our own intellectual property rights, third parties may assert patent, trademark or copyright infringement or other intellectual property claims against us. If we become involved in any intellectual property litigation, we may be required to pay substantial damages, including but not limited to treble damages, attorneys&#8217; fees and costs, for past infringement if it is ultimately determined that our products infringe a third party&#8217;s intellectual property rights. Even if infringement claims against us are without merit, defending a lawsuit takes significant time, may be expensive and may divert management&#8217;s attention from other business concerns. Further, we may be stopped from developing, manufacturing or selling our products until we obtain a license from the owner of the relevant technology or other intellectual property rights. If such a license is available at all, it may require us to pay substantial royalties or other fees.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may incur significant liability if it is determined that we are promoting or have in the past promoted the &#8220;off-label&#8221; use of drugs or medical devices, or otherwise promoted or marketed approved products in a manner inconsistent with the FDA&#8217;s requirements.*</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. and certain other jurisdictions, companies may not promote drugs or medical devices for &#8220;off-label&#8221; uses, that is, uses that are not described in the product&#8217;s labeling and that differ from those that were approved or cleared by the FDA or other foreign regulatory agencies. However, physicians and other healthcare practitioners may prescribe drug products and use medical devices for off-label or unapproved uses, and such uses are common across some medical specialties. Although the FDA does not regulate a physician&#8217;s choice of medications, treatments or product uses, the Federal Food, Drug and Cosmetic Act and FDA regulations significantly restrict permissible communications on the subject of off-label uses of drug products and medical devices by pharmaceutical and medical device companies. As the sponsors of FDA approved products, we and our partners will not only be responsible for the actions of the companies but also can be held liable for the actions of employees and contractors, requiring that all employees and contractors engaging in regulated functions, such as product promotion, be adequately trained and monitored, which requires time and monetary expenditures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA determines that a company has improperly promoted a product &#8220;off label&#8221; or otherwise not in accordance with the agency&#8217;s promotional requirements, the FDA may issue a warning letter or seek other enforcement action to limit or restrict certain promotional activities or materials or seek to have product withdrawn from the market or seize product, among other enforcement requirements. In addition, a company that is found to have improperly promoted off-label uses may be subject to significant liability, including civil fines, criminal fines and penalties, civil damages and exclusion from federal funded healthcare programs such as Medicare and Medicaid and/or government contracting, consent decrees and corporate integrity agreements, as well as potential liability under the federal FCA and applicable state false claims acts. Conduct giving rise to such liability could also form the basis for private civil litigation by third-party payers or other persons allegedly harmed by such conduct.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, in addition to the regulatory restrictions on off-label promotion, there are other FDA restrictions on and requirements concerning product promotion and advertising, such as requirements that such communications be truthful and non-misleading and adequately supported. The FDA also has requirements concerning the distribution of drug samples. The FDA and other authorities may take the position that we are not in compliance with promotional, advertising, and marketing requirements, and, if such non-compliance is proven, we may be subject to significant liability, including but not limited to administrative, civil and criminal penalties and fines, in addition to regulatory enforcement actions.  </span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">For certain of our products, we and our independent contractors, distributors, prescribers, and dispensers are required to comply with regulatory requirements related to controlled substances, which will require the expenditure of additional time and will incur additional expenses to maintain compliance and may subject us to additional penalties for noncompliance, which could inhibit successful commercialization.*</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our products are controlled substances and accordingly, we, and our contractors, distributors, prescribers, and dispensers must comply with Federal controlled substances laws and regulations, enforced by the U.S. Drug Enforcement Administration (&#8220;DEA&#8221;), as well as state-controlled substances laws and regulations enforced by state authorities. These requirements include, but are not limited to, registration, security, recordkeeping, reporting, storage, distribution, importation, exportation, inventory, and other requirements. These requirements are enforced by the DEA through periodic inspections. Not only must continuous controlled substance registration be maintained, but compliance with the applicable controlled substance requirements will require significant efforts and expenditures, which could also inhibit the successful commercialization. If we and our contractors, distributors, prescribers, and dispensers do not comply with the applicable controlled substance requirements, we or they may be subject to administrative, civil or criminal enforcement, including civil penalties, refusals to renew necessary registrations, revocation of registrations, criminal proceedings, or consent decrees.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent protection for protein-based therapeutic products and other biotechnology inventions is subject to a great deal of uncertainty, and if patent laws or the interpretation of patent laws change, our competitors may be able to develop and commercialize products based on our discoveries.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent protection for protein-based therapeutic products is highly uncertain and involves complex legal and factual questions. In recent years, there have been significant changes in patent law, including the legal standards that govern the scope of protein and biotechnology patents. Standards for patentability of full-length and partial genes, and their corresponding proteins, are changing. Recent court decisions have made it more difficult to obtain patents, by making it more difficult to satisfy the patentable subject matter requirement and the requirement of non-obviousness, have decreased the availability of injunctions against infringers, and have increased the likelihood of challenging the validity of a patent through a declaratory judgment action. Taken together, these decisions could make it more difficult and costly for us to obtain, license and enforce our patents. In addition, the Leahy-Smith America Invents Act (HR 1249) was signed into law in September 2011, which among other changes to the U.S. patent laws, changes patent priority from &#8220;first to invent&#8221; to &#8220;first to file,&#8221; implements a post-grant opposition system for patents and provides for a prior user defense to infringement. These judicial and legislative changes have introduced significant uncertainty in the patent law landscape and may potentially negatively impact our ability to procure, maintain and enforce patents to provide exclusivity for our products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There also have been, and continue to be, policy discussions concerning the scope of patent protection awarded to biotechnology inventions. Social and political opposition to biotechnology patents may lead to narrower patent protection within the biotechnology industry. Social and political opposition to patents on genes and proteins and recent court decisions concerning patentability of isolated genes may lead to narrower patent protection, or narrower claim interpretation, for isolated genes, their corresponding proteins and inventions related to their use, formulation and manufacture. Patent protection relating to biotechnology products is also subject to a great deal of uncertainty outside the U.S., and patent laws are evolving and undergoing revision in many countries. Changes in, or different interpretations of, patent laws worldwide may result in our inability to obtain or enforce patents, and may allow others to use our discoveries to develop and commercialize competitive products, which would impair our business.</span></div><div style="margin-top:6pt;padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If third party reimbursement and customer contracts are not available, our proprietary and  partnered products may not be accepted in the market resulting in commercial performance below that which was expected or projected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our and our partners&#8217; ability to earn sufficient returns on proprietary and partnered products will depend in part on the extent to which reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers, managed care organizations and other healthcare providers.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payors are increasingly attempting to limit both the coverage and the level of reimbursement of new drug products to contain costs. Consequently, significant uncertainty exists as to the reimbursement status of newly approved healthcare products. Third party payors may not establish adequate levels of reimbursement for the products that we and our partners commercialize, which could limit their market acceptance and result in a material adverse effect on our revenues and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer contracts, such as with group purchasing organizations and hospital formularies, will often not offer contract or formulary status without either the lowest price or substantial proven clinical differentiation. If, for example, Hylenex is compared to animal-derived hyaluronidases by these entities, it is possible that neither of these conditions will be met, which could limit market acceptance and result in a material adverse effect on our revenues and financial condition.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The rising cost of healthcare and related pharmaceutical product pricing has led to cost containment pressures from third-party payers as well as changes in federal coverage and reimbursement policies and practices that could cause us and our partners to sell our products at lower prices, and impact access to our and our partners&#8217; products, resulting in less revenue to us.*</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of our proprietary or partnered products that have been, or in the future are, approved by the FDA may be purchased or reimbursed by state and federal government authorities, private health insurers and other organizations, such as health maintenance organizations and managed care organizations. Such third party payors increasingly challenge pharmaceutical product pricing. The trend toward managed healthcare in the U.S., the growth of such organizations, and various legislative proposals and enactments to reform healthcare and government insurance programs, including the Medicare Prescription Drug Modernization Act of 2003 and the Affordable Care Act of 2010 (ACA), could significantly influence the manner in which pharmaceutical products are prescribed and purchased, resulting in lower prices and/or a reduction in demand. Such cost containment measures and healthcare reforms could adversely affect our ability to sell our product and our partners&#8217; ability to sell their products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., our business may be impacted by changes in federal reimbursement policy resulting from executive actions, federal regulations, or federal demonstration projects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal administration and/or agencies, such as the Centers for Medicare &amp; Medicaid Services, or CMS, have announced a number of demonstration projects, recommendations and proposals to implement various elements described in the drug pricing blueprint. CMS, the federal agency responsible for administering Medicare and overseeing state Medicaid programs and Health Insurance Marketplaces, has substantial power to implement policy changes or demonstration projects that can quickly and significantly affect how drugs, including our products, are covered and reimbursed. For example, in November 2020, former President Trump announced the interim final rule to implement the Most Favored Nations drug pricing model seeking to tie Medicare payment rates to an international index price. This final rule was subsequently rescinded by CMS. Additionally, a number of Congressional committees have also held hearings and evaluated proposed legislation on drug pricing and payment policy which may affect our business. For example, in July 2019, the Senate Finance Committee advanced a bill that in part would penalize pharmaceutical manufacturers for increasing drug list prices covered by Medicare Part B and Part D, faster than the rate of inflation, and cap out-of-pocket expenses for Medicare Part D beneficiaries.  Several other proposals have been introduced that, if enacted and implemented, could affect access to and sales of our and our partners&#8217; products, allow the federal government to engage in price negotiations on certain drugs, and allow importation of prescription medication from Canada or other countries.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this dynamic environment, we are unable to predict which or how many federal policy, legislative or regulatory changes may ultimately be enacted. To the extent federal government initiatives decrease or modify the coverage or reimbursement available for our or our partners&#8217; products, limit or impact our decisions regarding the pricing of biopharmaceutical products or otherwise reduce the use of our or our partners&#8217; U.S. products, such actions could have a material adverse effect on our business and results of operations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, individual states are considering proposed legislation and have become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third party payors or other restrictions could negatively and materially impact our revenues and financial condition. We anticipate that we will encounter similar regulatory and legislative issues in most other countries outside the U.S.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, private payers in the US, including insurers, pharmacy benefit managers (PBMs), integrated healthcare delivery systems, and group purchasing organizations, are continuously seeking ways to reduce drug costs.  Many payers have developed and continue to develop ways to shift a greater portion of drug costs to patients through, for example, limited benefit plan designs, high deductible plans and higher co-pay or coinsurance obligations. Consolidation in the payer space has also resulted in a few large PBMs and insurers which place greater pressure on pricing and utilization negotiations for our and our partners&#8217; products in the U.S., increasing the need for higher discounts and rebates and limiting patient access and utilization.  Ultimately, additional discounts, rebates and other price reductions, fees, coverage and plan changes, or exclusions imposed by these private payers on our and our partners&#8217; products could have an adverse event on product sales, our business and results of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To help patients afford certain of our products, we offer discount, rebate, and co-pay coupon programs. Co-pay coupon programs have received some negative publicity related to their use to promote branded pharmaceutical products over other less costly alternatives. CMS recently has issued a regulation imposing additional obligations on manufacturers in order to continue excluding such programs from government pricing calculations to avoid payment of increased Medicaid rebates. In recent years, other pharmaceutical manufacturers have been named in class action lawsuits challenging the legality of their co-pay programs under a variety of federal and state laws. Our co-pay coupon programs could become the target of similar lawsuits or insurer actions. It is possible that the outcome of litigation against other manufacturers, changes in insurer policies regarding co-pay coupons, and/or the introduction and enactment of new legislation or regulatory action could restrict or otherwise negatively affect these programs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also face risks relating to the reporting of pricing data that affects the reimbursement of and discounts provided for our products. Government price reporting regulations are complex and may require a manufacturer to update certain previously submitted data. If our submitted pricing data are incorrect, we may become subject to substantial fines and penalties or other government enforcement actions, which could have a material adverse effect on our business and results of operations. In addition, as a result of restating previously reported price data, we also may be required to pay additional rebates and provide additional discounts.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face intense competition and rapid technological change that could result in the development of products by others that are competitive with or superior to our proprietary and partnered products, including those under development.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary and partnered products have numerous competitors in the U.S. and abroad including, among others, major pharmaceutical and specialized biotechnology firms, universities and other research institutions that have developed competing products. Many of these competitors have substantially more resources and product development, manufacturing and marketing experience and capabilities than we do. The competitors for Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recombinant include, but are not limited to, Bausch Health </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companies, Inc.&#8217;s FDA-approved product, Vitrase</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an ovine (ram) hyaluronidase, and Amphastar Pharmaceuticals, Inc.&#8217;s product, Amphadase</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a bovine (bull) hyaluronidase. For our ENHANZE technology, such competitors may include major pharmaceutical and specialized biotechnology firms. These competitors may develop technologies and products that are more effective, safer, or less costly than our current or future proprietary and partnered products and product candidates or that could render our and our partners&#8217; products, technologies and product candidates obsolete or noncompetitive.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risks</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our inability to attract, hire and retain key management and scientific personnel could negatively affect our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends on the performance of key management and scientific employees with relevant experience. We depend substantially on our ability to hire, train, motivate and retain high quality personnel, especially our scientists and management team. If we are unable to identify, hire and retain qualified personnel, our ability to support current and future alliances with strategic partners could be adversely impacted. Our use of domestic and international third-party contractors, consultants and staffing agencies also subjects us to potential co-employment liability claims.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, if we were to lose key management personnel, we may lose some portion of our institutional knowledge and technical know-how, potentially causing a disruption or delay in one or more of our partnered development programs until adequate replacement personnel could be hired and trained. In addition, we do not have key person life insurance policies on the lives of any of our employees which would help cover the cost of associated with the loss of key employees.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations might be interrupted by the occurrence of a natural disaster or other catastrophic event.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations, including laboratories, offices and other research facilities, are located in multiple buildings in San Diego, California. We depend on our facilities and on our partners, contractors and vendors for the continued operation of our business. Natural disasters or other catastrophic events, pandemics, interruptions in the supply of natural resources, political and governmental changes, wildfires and other fires, floods, explosions, actions of animal rights activists, earthquakes and civil unrest could disrupt our operations or those of our partners, contractors and vendors. Even though we believe we carry commercially reasonable business interruption and liability insurance, and our contractors may carry liability insurance that protect us in certain events, we may suffer losses as a result of business interruptions that exceed the coverage available under our and our contractors&#8217; insurance policies or for which we or our contractors do not have coverage. Any natural disaster or catastrophic event could have a significant negative impact on our operations and financial results. Moreover, any such event could delay our partners&#8217; research and development programs.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cyberattacks, security breaches or system breakdowns may disrupt our operations and harm our operating results and reputation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our partners are subject to increasingly sophisticated attempts to gain unauthorized access to our information technology storage and access systems and are devoting resources to protect against such intrusion. Cyberattacks could render us or our partners unable to utilize key systems or access important data needed to operate our business.&#160;The wrongful use, theft, deliberate sabotage or any other type of security breach with respect to any of our or any of our vendors and partners&#8217; information technology storage and access systems could result in the breakdown or other service interruption, or the disruption of our ability to use such systems or disclosure or dissemination of  proprietary and confidential information that is electronically stored, including intellectual property, trade secrets, financial information, regulatory information, strategic plans, sales trends and forecasts, litigation materials or personal information belonging to us, our staff, our patients, customers and/or other business partners which could result in a material adverse impact on our business, operating results and financial condition. We continue to invest in monitoring, and other security and data recovery measures to protect our critical and sensitive data and systems. However, these may not be adequate to prevent or fully recover systems or data from all breakdowns, service interruptions, attacks or breaches of our systems. In addition, our cybersecurity insurance may not be sufficient to cover us against liability related to any such breaches. Furthermore, any physical break-in or trespass of our facilities could result in the misappropriation, theft, sabotage or any other type of security breach with respect to our proprietary and confidential information, including research or clinical data or damage to our research and development equipment and assets. Such adverse effects could be material and irrevocable to our business, operating results, financial condition and reputation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><div id="ibd09c52bdc03451493df7fb7077280c7_103"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.52pt">Quantitative and Qualitative Disclosures About Market Risk </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in our market risks during the quarter ended June&#160;30, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, our cash equivalents and marketable securities consisted of investments in money market funds, U.S. Treasury securities, asset-backed securities, corporate debt obligations and commercial paper. These investments were made in accordance with our investment policy which specifies the categories, allocations, and ratings of securities we may consider for investment. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive without significantly increasing risk. Some of the financial instruments that we invest in could be subject to market risk. This means that a change in prevailing interest rates may cause the value of the instruments to fluctuate. For example, if we purchase a security that was issued with a fixed interest rate and the prevailing interest rate later rises, the value of that security will probably decline. Based on our current investment portfolio as of June&#160;30, 2022, we do not believe that our results of operations would be materially impacted by an immediate change of 10% in interest rates. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not hold or issue derivatives, derivative commodity instruments or other financial instruments for speculative trading purposes. Further, we do not believe our cash, cash equivalents and marketable securities have significant risk of default or illiquidity. We made this determination based on discussions with our investment advisors and a review of our holdings. While we believe our cash, cash equivalents and marketable securities do not contain excessive risk, we cannot provide absolute assurance that in the future our investments will not be subject to adverse changes in market value. All of our cash equivalents and marketable securities are recorded at fair market value.</span></div><div id="ibd09c52bdc03451493df7fb7077280c7_106"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.52pt">Controls and Procedures</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the timelines specified in the Securities and Exchange Commission&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decision regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended. Based on this evaluation, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 24, 2022, we completed the acquisition of Antares. Under guidelines established by the SEC, companies are permitted to exclude acquisitions from their assessment of internal control over financial reporting during the first year of an acquisition while integrating the acquired company. In conducting our evaluation of the effectiveness of our internal control over financial reporting, we excluded Antares from our evaluation for the period ended June&#160;30, 2022. We are in the process of integrating Antares into our system of internal control over financial reporting.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as noted above. there have been no significant changes in our internal control over financial reporting that occurred during the quarter ended June&#160;30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><div id="ibd09c52bdc03451493df7fb7077280c7_109"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II &#8211; OTHER INFORMATION</span></div><div id="ibd09c52bdc03451493df7fb7077280c7_112"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.52pt">Legal Proceedings</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of our business. Any of these claims could subject us to costly legal expenses and, while we generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on our consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage our reputation and business. We currently are not a party to any legal proceedings, the adverse outcome of which, in management&#8217;s opinion, individually or in the aggregate, would have a material adverse effect on our consolidated results of operations or financial position.</span></div><div id="ibd09c52bdc03451493df7fb7077280c7_115"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12.3pt">Risk Factors </span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Reflecting our recent acquisition of Antares Pharma, Inc., we have provided some new and updated Risk Factors in the section labeled &#8220;Risk Factors&#8221; in Part&#160;I, Item&#160;2, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;. We believe these new and updated Risk Factors provide important disclosures regarding additional risks we face. The heading of each new and significantly updated Risk Factor is marked with an &#8220;*&#8221;. Other than the additions reflecting the acquisition of Antares, there have been no updates that have materially changed the type or magnitude of risks we face in comparison to the disclosure provided in our most recent Annual Report on form 10-K.  </span></div><div id="ibd09c52bdc03451493df7fb7077280c7_118"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.52pt">Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below sets forth information regarding repurchases of our common stock during the three months ended June&#160;30, 2022:</span></div><div style="margin-top:11pt;text-align:center;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"></td><td style="width:41.129%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.557%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.557%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.557%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares Purchased</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Price paid per share</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Programs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate Dollar Value of Shares That May Yet  Be Purchased under the Programs (thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 1, 2022 through April 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 1, 2022 through May 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 1, 2022 through June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-indent:38.25pt"><span><br/></span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November, 2019, we announced that our Board of Directors authorized a capital return program to repurchase up to $550.0 million of outstanding common stock during a three-year period. The $550.0 million share repurchase program was completed in October 2021. In December 2021, the Board of Directors authorized a second capital return program to repurchase up to $750.0 million of outstanding stock over a three-year period. Also in December 2021, as part of the second capital return program, we entered into an ASR agreement to repurchase $150.0 million of common stock. At inception pursuant to the agreement, we paid $150.0 million to Bank of America and took initial delivery of 3.5 million shares. In June 2022, we finalized the transaction and received an additional 0.4&#160;million shares.</span></div><div id="ibd09c52bdc03451493df7fb7077280c7_121"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.52pt">Defaults Upon Senior Securities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ibd09c52bdc03451493df7fb7077280c7_124"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.52pt">Mine Safety Disclosures</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ibd09c52bdc03451493df7fb7077280c7_127"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.52pt">Other Information</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><div id="ibd09c52bdc03451493df7fb7077280c7_130"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:12pt;padding-left:54pt;text-indent:-49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.52pt">Exhibits</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.375%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000119312522104452/d259127dex21.htm">Agreement and Plan Merger among Halozyme Therapeutics, Inc., Atlas Merger Sub, Inc. and Antares Pharma, Inc. dated as of April 12, 2022 (1)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903619000019/exhibit31.htm">Amended and Restated Certificate of Incorporation (2)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000115903621000056/ex31-amendedandrestatedbyl.htm">Bylaws, as amended (3)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000119312519294791/d826183dex41.htm">Indenture, dated November 18, 2019, between Halozyme Therapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee, and the Registrant (4)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000119312519294791/d826183dex42.htm">Form of Note, dated November 18, 2019, between Halozyme Therapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee, and the Registrant (4)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000119312521063401/d587130dex41.htm">Indenture, dated March 1, 2021, between Halozyme Therapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee, and the Registrant (5)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000119312521063401/d587130dex42.htm">Form of Note, dated March 1, 2021, between Halozyme Therapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee, and the Registrant (5)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000119312522158531/d326486dex101.htm">Credit Agreement, dated as of May 24, 2022, by and among Halozyme Therapeutics, Inc., the Guarantors, Bank of America N.A. and each of those additional Lenders that are a party to such agreement. (6)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1159036/000119312522158531/d326486dex102.htm">Security Agreement, dated as of May 24, 2022, by and among Halozyme Therapeutics, Inc., the Guarantors and Bank of America N.A (6).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1016169/000156459019024598/atrs-ex101_6.htm">Lease Agreement, dated July 1, 2019, by and between Antares Pharma, Inc. and Whitewater Properties I, LLC.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1016169/000156459019024598/atrs-ex101_6.htm"> (7)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex31110qq22022.htm">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex31210qq22022.htm">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex3210qq22022.htm">Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instance Document - the instance document does not appear in the interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline Taxonomy Extension Schema Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline Taxonomy Extension Label Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:2.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.478%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"># Indicates management contract or compensatory plan or arrangement</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K, filed April 13, 2022.</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K, filed May 3, 2019.</span></div><div style="padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K, filed December 10, 2021.</span></div><div style="padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K, filed November 18, 2019.</span></div><div style="padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K, filed March 1, 2021.</span></div><div style="padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K, filed May 24, 2022.</span></div><div style="padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Incorporated by reference to Antares Pharma, Inc.&#8217;s Current Report on Form 8-K, filed July 5, 2019.</span></div><div style="text-align:justify;text-indent:-4.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:-4.5pt"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><div id="ibd09c52bdc03451493df7fb7077280c7_133"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:6.084%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.210%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Halozyme Therapeutics, Inc.,<br/>a Delaware corporation</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 9, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;Helen I. Torley, M.B. Ch.B., M.R.C.P.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Helen I. Torley, M.B. Ch.B., M.R.C.P.<br/>President and Chief Executive Officer<br/>(Principal Executive Officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 9, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Nicole LaBrosse</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nicole LaBrosse<br/>Senior Vice President and Chief Financial Officer<br/>(Principal Financial and Accounting Officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex31110qq22022.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i233cfef1204f4496a5190cb9dae24044_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Helen I. Torley, M.B. Ch.B., M.R.C.P., Chief Executive Officer of Halozyme Therapeutics, Inc. certify that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">I have reviewed this Quarterly Report on Form 10-Q of Halozyme Therapeutics, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">The Registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.74pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.17pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.74pt">evaluated the effectiveness of the Registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.17pt">disclosed in this report any change in the Registrant&#8217;s internal control over financial reporting that occurred during the Registrant&#8217;s most recent fiscal quarter (the Registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">The Registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant&#8217;s auditors and the audit committee of the Registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.74pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.17pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:7.099%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.768%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.773%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 9, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Helen I. Torley, M.B. Ch.B., M.R.C.P.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Helen I. Torley, M.B. Ch.B., M.R.C.P</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex31210qq22022.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i0f209172ac604dc59b02323a7e40d50b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Nicole LaBrosse, Chief Financial Officer of Halozyme Therapeutics, Inc. certify that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">I have reviewed this Quarterly Report on Form 10-Q of Halozyme Therapeutics, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">The Registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.74pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.17pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.74pt">evaluated the effectiveness of the Registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.17pt">disclosed in this report any change in the Registrant&#8217;s internal control over financial reporting that occurred during the Registrant&#8217;s most recent fiscal quarter (the Registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24pt">The Registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant&#8217;s auditors and the audit committee of the Registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.74pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.17pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:6.074%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.922%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 9, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Nicole LaBrosse</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nicole LaBrosse</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>4
<FILENAME>ex3210qq22022.htm
<DESCRIPTION>EX-32
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i5b303eb584c54ddab4e318aa250770aa_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Halozyme Therapeutics, Inc. (the &#8220;Registrant&#8221;) on Form 10-Q for the quarter ended June&#160;30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Helen I. Torley, M.B. Ch.B., M.R.C.P., Chief Executive Officer of the Registrant, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge&#58;</font></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m)&#59; and</font></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.773%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 9, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Helen I. Torley, M.B. Ch.B., M.R.C.P.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Helen I. Torley, M.B. Ch.B., M.R.C.P.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Halozyme Therapeutics, Inc. (the &#8220;Registrant&#8221;) on Form 10-Q for the quarter ended June&#160;30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Nicole LaBrosse, Chief Financial Officer of the Registrant, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge&#58;</font></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m)&#59; and</font></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.774%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 9, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Nicole LaBrosse</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nicole LaBrosse</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>halo-20220630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:73069a0e-fffd-482c-8df8-d4ff810732e3,g:be228a77-9c6c-4f8e-9f2c-fe0d390b647c-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:halo="http://www.halozyme.com/20220630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.halozyme.com/20220630">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="halo-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="halo-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="halo-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="halo-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.halozyme.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsUnaudited" roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited" roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquityUnaudited" roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBusiness" roleURI="http://www.halozyme.com/role/OrganizationandBusiness">
        <link:definition>2101101 - Disclosure - Organization and Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBusinessDetails" roleURI="http://www.halozyme.com/role/OrganizationandBusinessDetails">
        <link:definition>2402401 - Disclosure - Organization and Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesRestrictedCashDetails" roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies - Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesLeasesDetails" roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesRevenueandCostofProductSalesDetails" roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesRevenueandCostofProductSalesDetails">
        <link:definition>2408404 - Disclosure - Summary of Significant Accounting Policies - Revenue and Cost of Product Sales (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesIncomeTaxesDetails" roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails">
        <link:definition>2409405 - Disclosure - Summary of Significant Accounting Policies - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSegmentInformationDetails" roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails">
        <link:definition>2410406 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombination" roleURI="http://www.halozyme.com/role/BusinessCombination">
        <link:definition>2111103 - Disclosure - Business Combination</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationTables" roleURI="http://www.halozyme.com/role/BusinessCombinationTables">
        <link:definition>2312302 - Disclosure - Business Combination (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationNarrativeDetails" roleURI="http://www.halozyme.com/role/BusinessCombinationNarrativeDetails">
        <link:definition>2413407 - Disclosure - Business Combination - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationPurchaseConsiderationDetails" roleURI="http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails">
        <link:definition>2414408 - Disclosure - Business Combination -Purchase Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails">
        <link:definition>2415409 - Disclosure - Business Combination - Schedule of Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationIntangibleAssetsAcquiredDetails" roleURI="http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails">
        <link:definition>2416410 - Disclosure - Business Combination - Intangible Assets Acquired (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationSummaryofProformaFinancialInformationDetails" roleURI="http://www.halozyme.com/role/BusinessCombinationSummaryofProformaFinancialInformationDetails">
        <link:definition>2417411 - Disclosure - Business Combination - Summary of Proforma Financial Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurement" roleURI="http://www.halozyme.com/role/FairValueMeasurement">
        <link:definition>2118104 - Disclosure - Fair Value Measurement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementTables" roleURI="http://www.halozyme.com/role/FairValueMeasurementTables">
        <link:definition>2319303 - Disclosure - Fair Value Measurement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails" roleURI="http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails">
        <link:definition>2420412 - Disclosure - Fair Value Measurement - Components of Available-for-sale Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementNarrativeDetails" roleURI="http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails">
        <link:definition>2421413 - Disclosure - Fair Value Measurement - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementContractualMaturitiesofAvailableforSaleDebtSecuritiesDetails" roleURI="http://www.halozyme.com/role/FairValueMeasurementContractualMaturitiesofAvailableforSaleDebtSecuritiesDetails">
        <link:definition>2422414 - Disclosure - Fair Value Measurement - Contractual Maturities of Available for Sale Debt Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>2423415 - Disclosure - Fair Value Measurement - Assets Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://www.halozyme.com/role/Revenue">
        <link:definition>2124105 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueTables" roleURI="http://www.halozyme.com/role/RevenueTables">
        <link:definition>2325304 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueDisaggregatedRevenuesDetails" roleURI="http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails">
        <link:definition>2426416 - Disclosure - Revenue - Disaggregated Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueNarrativeDetails" roleURI="http://www.halozyme.com/role/RevenueNarrativeDetails">
        <link:definition>2427417 - Disclosure - Revenue - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueAccountsReceivablenetandDeferredRevenuesfromContractsDetails" roleURI="http://www.halozyme.com/role/RevenueAccountsReceivablenetandDeferredRevenuesfromContractsDetails">
        <link:definition>2428418 - Disclosure - Revenue - Accounts Receivable, net and Deferred Revenues from Contracts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueAdditionalRevenueInformationDetails" roleURI="http://www.halozyme.com/role/RevenueAdditionalRevenueInformationDetails">
        <link:definition>2429419 - Disclosure - Revenue - Additional Revenue Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueAdditionalRevenueInformationDetails_1" roleURI="http://www.halozyme.com/role/RevenueAdditionalRevenueInformationDetails_1">
        <link:definition>2429419 - Disclosure - Revenue - Additional Revenue Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItems" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItems">
        <link:definition>2130106 - Disclosure - Certain Balance Sheet Items</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsTables" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsTables">
        <link:definition>2331305 - Disclosure - Certain Balance Sheet Items (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsAccountsReceivablenetDetails" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails">
        <link:definition>2432420 - Disclosure - Certain Balance Sheet Items - Accounts Receivable, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsInventoriesDetails" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails">
        <link:definition>2433421 - Disclosure - Certain Balance Sheet Items - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails">
        <link:definition>2434422 - Disclosure - Certain Balance Sheet Items - Prepaid Expenses and Other Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails_1" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails_1">
        <link:definition>2434422 - Disclosure - Certain Balance Sheet Items - Prepaid Expenses and Other Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsPropertyandEquipmentnetDetails" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails">
        <link:definition>2435423 - Disclosure - Certain Balance Sheet Items - Property and Equipment, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsAccruedExpensesDetails" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails">
        <link:definition>2436424 - Disclosure - Certain Balance Sheet Items - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsAccruedExpensesDetails_1" roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails_1">
        <link:definition>2436424 - Disclosure - Certain Balance Sheet Items - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssets" roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssets">
        <link:definition>2137107 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsTables" roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsTables">
        <link:definition>2338306 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsAdditionalDetails" roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalDetails">
        <link:definition>2439425 - Disclosure - Goodwill and Intangible Assets - Additional (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsGoodwillandOtherGoodwillRollforwardDetails" roleURI="http://www.halozyme.com/role/IntangibleAssetsGoodwillandOtherGoodwillRollforwardDetails">
        <link:definition>2440426 - Disclosure - Intangible Assets, Goodwill and Other -Goodwill Rollforward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsIntangibleAssetsDetails" roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails">
        <link:definition>2441427 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsFutureAmortizationDetails" roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails">
        <link:definition>2442428 - Disclosure - Goodwill and Intangible Assets -Future Amortization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtNet" roleURI="http://www.halozyme.com/role/LongTermDebtNet">
        <link:definition>2143108 - Disclosure - Long-Term Debt, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtNetTables" roleURI="http://www.halozyme.com/role/LongTermDebtNetTables">
        <link:definition>2344307 - Disclosure - Long-Term Debt, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtNetNarrativeDetails" roleURI="http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails">
        <link:definition>2445429 - Disclosure - Long-Term Debt, Net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtNetCarryingAmountofConvertibleNotesDetails" roleURI="http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails">
        <link:definition>2446430 - Disclosure - Long-Term Debt, Net - Carrying Amount of Convertible Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtNetComponentsofInterestExpenseDetails" roleURI="http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails">
        <link:definition>2447431 - Disclosure - Long-Term Debt, Net - Components of Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensation" roleURI="http://www.halozyme.com/role/SharebasedCompensation">
        <link:definition>2148109 - Disclosure - Share-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationTables" roleURI="http://www.halozyme.com/role/SharebasedCompensationTables">
        <link:definition>2349308 - Disclosure - Share-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationSharebasedCompensationExpenseDetails" roleURI="http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails">
        <link:definition>2450432 - Disclosure - Share-based Compensation - Share-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationNarrativeDetails" roleURI="http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails">
        <link:definition>2451433 - Disclosure - Share-based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails" roleURI="http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails">
        <link:definition>2452434 - Disclosure - Share-based Compensation - Assumptions Used in the Black-Scholes Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails" roleURI="http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails">
        <link:definition>2453435 - Disclosure - Share-based Compensation - Unrecognized Estimated Compensation Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.halozyme.com/role/StockholdersEquity">
        <link:definition>2154110 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.halozyme.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>2455436 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomelosspershare" roleURI="http://www.halozyme.com/role/NetIncomelosspershare">
        <link:definition>2156111 - Disclosure - Net Income (loss) per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomelosspershareTables" roleURI="http://www.halozyme.com/role/NetIncomelosspershareTables">
        <link:definition>2357309 - Disclosure - Net Income (loss) per share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomelosspershareSummaryDetails" roleURI="http://www.halozyme.com/role/NetIncomelosspershareSummaryDetails">
        <link:definition>2458437 - Disclosure - Net Income (loss) per share - Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomelosspershareAntidilutiveSecuritiesDetails" roleURI="http://www.halozyme.com/role/NetIncomelosspershareAntidilutiveSecuritiesDetails">
        <link:definition>2459438 - Disclosure - Net Income (loss) per share - Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.halozyme.com/role/CommitmentsandContingencies">
        <link:definition>2160112 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" abstract="false" name="PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_DebtInstrumentInterestPeriodTwoMember" abstract="true" name="DebtInstrumentInterestPeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_AntaresPharmaIncMember" abstract="true" name="AntaresPharmaIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_AnnualInterestPaymentPeriodDomain" abstract="true" name="AnnualInterestPaymentPeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_CollaborativeAgreementsMember" abstract="true" name="CollaborativeAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_DebtInstrumentInterestPeriodFourMember" abstract="true" name="DebtInstrumentInterestPeriodFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_DevelopmentFeesMember" abstract="true" name="DevelopmentFeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="halo_A2021ESPPPlanMember" abstract="true" name="A2021ESPPPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_CreditAgreementMember" abstract="true" name="CreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare" abstract="false" name="BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="halo_GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock" abstract="false" name="GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="halo_DeviceLicensingAndDevelopmentMember" abstract="true" name="DeviceLicensingAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_AnnualInterestPaymentPeriodAxis" abstract="true" name="AnnualInterestPaymentPeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="halo_RoyaltiesReceivedNumberOfProductsSold" abstract="false" name="RoyaltiesReceivedNumberOfProductsSold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="halo_AcceleratedShareRepurchaseAgreementMember" abstract="true" name="AcceleratedShareRepurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_DebtInstrumentThirdPartyCosts" abstract="false" name="DebtInstrumentThirdPartyCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_VariableRateComponentDomain" abstract="true" name="VariableRateComponentDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_LicenseFeesAndEventBasedMember" abstract="true" name="LicenseFeesAndEventBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_XYOSTEDProprietaryProductMember" abstract="true" name="XYOSTEDProprietaryProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_StockOptionsAndRestrictedStockUnitsMember" abstract="true" name="StockOptionsAndRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_A1.25ConvertibleSeniorNotesdue2024Member" abstract="true" name="A1.25ConvertibleSeniorNotesdue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_OthercollaboratorsMember" abstract="true" name="OthercollaboratorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_ProprietaryProductsSalesMember" abstract="true" name="ProprietaryProductsSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_OperatingLeaseAccretionOfLiability" abstract="false" name="OperatingLeaseAccretionOfLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_Accountsreceivablefromproductsalestocollaborators" abstract="false" name="Accountsreceivablefromproductsalestocollaborators" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised" abstract="false" name="ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_A2021CreditAgreementMember" abstract="true" name="A2021CreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_Accountsreceivablefromroyalties" abstract="false" name="Accountsreceivablefromroyalties" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_JanssenMember" abstract="true" name="JanssenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_Accountsreceivablefromproductsales" abstract="false" name="Accountsreceivablefromproductsales" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_DevicePartneredProductsMember" abstract="true" name="DevicePartneredProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_RocheMember" abstract="true" name="RocheMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_ManufacturingEquipmentMember" abstract="true" name="ManufacturingEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_DebtInstrumentInterestPeriodOneMember" abstract="true" name="DebtInstrumentInterestPeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets" abstract="false" name="AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_BusinessCombinationConsiderationTransferredBonusAwards" abstract="false" name="BusinessCombinationConsiderationTransferredBonusAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_VariableRateComponentAxis" abstract="true" name="VariableRateComponentAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="halo_AutoInjectorTechnologyPlatformMember" abstract="true" name="AutoInjectorTechnologyPlatformMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_TLANDOProductRightsMember" abstract="true" name="TLANDOProductRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_ShareBasedCompensationAwardsVestedMember" abstract="true" name="ShareBasedCompensationAwardsVestedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_ResearchEquipmentMember" abstract="true" name="ResearchEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_VariableRateComponentOneMember" abstract="true" name="VariableRateComponentOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_BaxaltaMember" abstract="true" name="BaxaltaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems" abstract="true" name="ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice" abstract="false" name="RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="halo_SalesbasedmilestoneMember" abstract="true" name="SalesbasedmilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_DeferredRentPayments" abstract="false" name="DeferredRentPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_A025ConvertibleSeniorNotesDue2027Member" abstract="true" name="A025ConvertibleSeniorNotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_TermLoanFacilityMember" abstract="true" name="TermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_Accruedmanufacturingexpenses" abstract="false" name="Accruedmanufacturingexpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_DebtInstrumentInterestPeriodThreeMember" abstract="true" name="DebtInstrumentInterestPeriodThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_VariableRateComponentTwoMember" abstract="true" name="VariableRateComponentTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable" abstract="true" name="ScheduleofSharebasedCompensationArrangementsValuationInputsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="halo_RSURSAandPRSUawardsMember" abstract="true" name="RSURSAandPRSUawardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards" abstract="false" name="BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_BulkrHuPH20Member" abstract="true" name="BulkrHuPH20Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_ShareBasedCompensationAwardUnvestedMember" abstract="true" name="ShareBasedCompensationAwardUnvestedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_AccruedLiabilitiesNoncurrent" abstract="false" name="AccruedLiabilitiesNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="halo_ComputerAndOfficeEquipmentMember" abstract="true" name="ComputerAndOfficeEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_RoyaltiesReceivedNumberOfCollaborators" abstract="false" name="RoyaltiesReceivedNumberOfCollaborators" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="halo_UpfrontfeesMember" abstract="true" name="UpfrontfeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="halo_Accountsreceivablefromcollaborators" abstract="false" name="Accountsreceivablefromcollaborators" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="halo_AllowanceforDistributionFeesandDiscounts" abstract="false" name="AllowanceforDistributionFeesandDiscounts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>halo-20220630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:73069a0e-fffd-482c-8df8-d4ff810732e3,g:be228a77-9c6c-4f8e-9f2c-fe0d390b647c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="halo-20220630.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_055d1aab-f678-4e0c-8e93-042987e917ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_0bc8b55a-0ab7-40ba-8310-896bbffcbabd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_055d1aab-f678-4e0c-8e93-042987e917ae" xlink:to="loc_us-gaap_LiabilitiesCurrent_0bc8b55a-0ab7-40ba-8310-896bbffcbabd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_9a53bb35-46fc-4430-a0a5-b6938a685a42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_055d1aab-f678-4e0c-8e93-042987e917ae" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_9a53bb35-46fc-4430-a0a5-b6938a685a42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_e507a3a2-d8d1-4ef7-b164-6692fca37ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_055d1aab-f678-4e0c-8e93-042987e917ae" xlink:to="loc_us-gaap_LongTermDebt_e507a3a2-d8d1-4ef7-b164-6692fca37ca8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_9f0e160a-38a2-43c8-b10c-bdff11a4fcfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_055d1aab-f678-4e0c-8e93-042987e917ae" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_9f0e160a-38a2-43c8-b10c-bdff11a4fcfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_c46ea50b-dc2b-4b8f-8de4-d5b85f5619d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_055d1aab-f678-4e0c-8e93-042987e917ae" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_c46ea50b-dc2b-4b8f-8de4-d5b85f5619d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_cfd728cf-b2f9-4d8d-8529-b919ad22e961" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_055d1aab-f678-4e0c-8e93-042987e917ae" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_cfd728cf-b2f9-4d8d-8529-b919ad22e961" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7b901ead-2352-4a9c-8aff-132ee8f69a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_055d1aab-f678-4e0c-8e93-042987e917ae" xlink:to="loc_us-gaap_StockholdersEquity_7b901ead-2352-4a9c-8aff-132ee8f69a9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_e5a4bec0-c007-4fb7-8e63-0b00fff37547" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_055d1aab-f678-4e0c-8e93-042987e917ae" xlink:to="loc_us-gaap_CommitmentsAndContingencies_e5a4bec0-c007-4fb7-8e63-0b00fff37547" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5227a2da-8091-416a-b371-88eadf14afb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cf679063-dc32-4fef-a592-a960cd0a9e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5227a2da-8091-416a-b371-88eadf14afb9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cf679063-dc32-4fef-a592-a960cd0a9e2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_1187fdf3-ffe0-44c8-99f6-2060aa53a8ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5227a2da-8091-416a-b371-88eadf14afb9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_1187fdf3-ffe0-44c8-99f6-2060aa53a8ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9f356e57-033d-4643-ac4b-18afe6274c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5227a2da-8091-416a-b371-88eadf14afb9" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_9f356e57-033d-4643-ac4b-18afe6274c4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_7b0dd701-f005-42fe-a458-1686072a0ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5227a2da-8091-416a-b371-88eadf14afb9" xlink:to="loc_us-gaap_InventoryNet_7b0dd701-f005-42fe-a458-1686072a0ec2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7103d7e3-a592-4979-b3c4-300d5a46f72a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5227a2da-8091-416a-b371-88eadf14afb9" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7103d7e3-a592-4979-b3c4-300d5a46f72a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_faa66bb2-2a43-4992-afd4-f6c52d02662e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_6b26c237-62f6-4ce9-b6df-72584e7aea2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_faa66bb2-2a43-4992-afd4-f6c52d02662e" xlink:to="loc_us-gaap_AccountsPayableCurrent_6b26c237-62f6-4ce9-b6df-72584e7aea2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c9106f6e-dc7d-4ae9-abe9-501edfe51265" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_faa66bb2-2a43-4992-afd4-f6c52d02662e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c9106f6e-dc7d-4ae9-abe9-501edfe51265" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_1a9264bb-de85-4569-bd6f-847a248e235c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_faa66bb2-2a43-4992-afd4-f6c52d02662e" xlink:to="loc_us-gaap_DeferredRevenueCurrent_1a9264bb-de85-4569-bd6f-847a248e235c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_123999c5-b189-45b7-9f9a-923348c58f91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_faa66bb2-2a43-4992-afd4-f6c52d02662e" xlink:to="loc_us-gaap_LongTermDebtCurrent_123999c5-b189-45b7-9f9a-923348c58f91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e1d8b9ec-d4c8-4b1f-83b3-af13c4160dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_ebf9e8ae-b455-43ba-847b-c4ad18c978a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e1d8b9ec-d4c8-4b1f-83b3-af13c4160dbd" xlink:to="loc_us-gaap_CommonStockValue_ebf9e8ae-b455-43ba-847b-c4ad18c978a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_6a3b3cfd-6750-4f86-b811-bcffc2b20f61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e1d8b9ec-d4c8-4b1f-83b3-af13c4160dbd" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_6a3b3cfd-6750-4f86-b811-bcffc2b20f61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fe91ec71-4b62-4a52-a5c7-1187c941e95e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e1d8b9ec-d4c8-4b1f-83b3-af13c4160dbd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fe91ec71-4b62-4a52-a5c7-1187c941e95e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c5f3c8f8-30ba-4581-8cd6-7facf4c07956" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e1d8b9ec-d4c8-4b1f-83b3-af13c4160dbd" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c5f3c8f8-30ba-4581-8cd6-7facf4c07956" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_743a156e-65c0-4719-9274-f7fd4502cef2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e1d8b9ec-d4c8-4b1f-83b3-af13c4160dbd" xlink:to="loc_us-gaap_PreferredStockValue_743a156e-65c0-4719-9274-f7fd4502cef2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_3a01fc0d-e22f-40cf-8bb3-4071fd720bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4e901226-3dd0-4bbb-aa24-bcbc44aaf887" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3a01fc0d-e22f-40cf-8bb3-4071fd720bd8" xlink:to="loc_us-gaap_AssetsCurrent_4e901226-3dd0-4bbb-aa24-bcbc44aaf887" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_d30b58c7-a926-423f-8fc4-6e32ff9c2078" xlink:href="halo-20220630.xsd#halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3a01fc0d-e22f-40cf-8bb3-4071fd720bd8" xlink:to="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_d30b58c7-a926-423f-8fc4-6e32ff9c2078" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_e1f6ee07-6614-4f5a-ae2a-281dd3b78240" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3a01fc0d-e22f-40cf-8bb3-4071fd720bd8" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_e1f6ee07-6614-4f5a-ae2a-281dd3b78240" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9a902100-1637-4395-bacc-63ad3ca7876f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3a01fc0d-e22f-40cf-8bb3-4071fd720bd8" xlink:to="loc_us-gaap_Goodwill_9a902100-1637-4395-bacc-63ad3ca7876f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_55530987-a417-4b18-8703-b9288bc3269b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3a01fc0d-e22f-40cf-8bb3-4071fd720bd8" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_55530987-a417-4b18-8703-b9288bc3269b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_05c1a8e9-fd20-48ea-95b0-30b43d0df2af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3a01fc0d-e22f-40cf-8bb3-4071fd720bd8" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_05c1a8e9-fd20-48ea-95b0-30b43d0df2af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_f9bb7478-c09c-41cd-8def-31dffbde21ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3a01fc0d-e22f-40cf-8bb3-4071fd720bd8" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_f9bb7478-c09c-41cd-8def-31dffbde21ad" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="halo-20220630.xsd#CondensedConsolidatedStatementsofOperationsUnaudited"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_8b21e96f-f2bb-402b-bb12-82708d8d590f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_6015a3d0-073f-4daf-855e-2295ca42ee9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8b21e96f-f2bb-402b-bb12-82708d8d590f" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_6015a3d0-073f-4daf-855e-2295ca42ee9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9d286c5d-5077-43b3-914b-5544ed03e00b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8b21e96f-f2bb-402b-bb12-82708d8d590f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9d286c5d-5077-43b3-914b-5544ed03e00b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_09308c4e-6422-49b4-aced-6c164aa8d8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8b21e96f-f2bb-402b-bb12-82708d8d590f" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_09308c4e-6422-49b4-aced-6c164aa8d8a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_51de04ef-b520-46a8-9947-679fe92b4fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8b21e96f-f2bb-402b-bb12-82708d8d590f" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_51de04ef-b520-46a8-9947-679fe92b4fcc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0fa36d02-127c-46f8-9b1f-57da56730324" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ddf14db0-cd51-432a-aa69-030891a20261" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0fa36d02-127c-46f8-9b1f-57da56730324" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ddf14db0-cd51-432a-aa69-030891a20261" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_227426a8-7699-42d1-beac-acf3d62fa3d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0fa36d02-127c-46f8-9b1f-57da56730324" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_227426a8-7699-42d1-beac-acf3d62fa3d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0bec5f9e-7180-4a59-bbc8-282f18913d75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_17d86863-e3ea-4ba1-ba35-0d88b1c5c9c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0bec5f9e-7180-4a59-bbc8-282f18913d75" xlink:to="loc_us-gaap_CostsAndExpenses_17d86863-e3ea-4ba1-ba35-0d88b1c5c9c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0d423b8e-2194-42ac-917b-43db8662664f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0bec5f9e-7180-4a59-bbc8-282f18913d75" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0d423b8e-2194-42ac-917b-43db8662664f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9d7a3e96-563f-4e82-b457-068215aeb293" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_bdab749f-f1a9-4733-8179-4656e19ab12d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9d7a3e96-563f-4e82-b457-068215aeb293" xlink:to="loc_us-gaap_OperatingIncomeLoss_bdab749f-f1a9-4733-8179-4656e19ab12d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1cdcb56e-b8f3-4e16-ae97-a8d43427f2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9d7a3e96-563f-4e82-b457-068215aeb293" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1cdcb56e-b8f3-4e16-ae97-a8d43427f2b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_89e31079-a5e2-4815-925a-86350a788f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9d7a3e96-563f-4e82-b457-068215aeb293" xlink:to="loc_us-gaap_InterestExpense_89e31079-a5e2-4815-925a-86350a788f9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_4ba8a3f2-7a10-48f7-8148-fb56656fd65a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9d7a3e96-563f-4e82-b457-068215aeb293" xlink:to="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_4ba8a3f2-7a10-48f7-8148-fb56656fd65a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited" xlink:type="simple" xlink:href="halo-20220630.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_d55bb3fc-12b2-4c20-b0c7-277649cca28c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_deb3ee50-1a13-40e0-8f33-82e888dc4fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d55bb3fc-12b2-4c20-b0c7-277649cca28c" xlink:to="loc_us-gaap_NetIncomeLoss_deb3ee50-1a13-40e0-8f33-82e888dc4fa4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_6c14f22f-a46f-4caa-9974-bf35deaea08d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d55bb3fc-12b2-4c20-b0c7-277649cca28c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_6c14f22f-a46f-4caa-9974-bf35deaea08d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_af903143-df21-4884-ba82-4fb854a0bfca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d55bb3fc-12b2-4c20-b0c7-277649cca28c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_af903143-df21-4884-ba82-4fb854a0bfca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_a10b0bf7-f751-442c-9d7e-c2e60f11d513" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d55bb3fc-12b2-4c20-b0c7-277649cca28c" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_a10b0bf7-f751-442c-9d7e-c2e60f11d513" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="halo-20220630.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f0139946-2967-453e-9c1b-e7589d2bab4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_13df0b17-065c-4a86-85e4-318b5916a3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f0139946-2967-453e-9c1b-e7589d2bab4c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_13df0b17-065c-4a86-85e4-318b5916a3ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_1fd26379-eefb-4139-9f62-de3c0ce001df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f0139946-2967-453e-9c1b-e7589d2bab4c" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_1fd26379-eefb-4139-9f62-de3c0ce001df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_277b5eae-8324-44a5-a13a-2700fdeee124" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f0139946-2967-453e-9c1b-e7589d2bab4c" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_277b5eae-8324-44a5-a13a-2700fdeee124" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt_ba2bb107-dc72-466e-bd56-20ef980716f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f0139946-2967-453e-9c1b-e7589d2bab4c" xlink:to="loc_us-gaap_RepaymentsOfSecuredDebt_ba2bb107-dc72-466e-bd56-20ef980716f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_0ea2ff30-6408-4bdf-b3db-afdb51c1bc8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f0139946-2967-453e-9c1b-e7589d2bab4c" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_0ea2ff30-6408-4bdf-b3db-afdb51c1bc8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_04f062b3-fb00-4fd9-9f2c-bce434f0f734" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f0139946-2967-453e-9c1b-e7589d2bab4c" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_04f062b3-fb00-4fd9-9f2c-bce434f0f734" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised_e4804589-3f67-4d1c-a9c6-21463d879d93" xlink:href="halo-20220630.xsd#halo_ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f0139946-2967-453e-9c1b-e7589d2bab4c" xlink:to="loc_halo_ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised_e4804589-3f67-4d1c-a9c6-21463d879d93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_820ac567-5bc1-4661-b5ab-f37d759b3419" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4b8331d5-4d1a-4c2a-b7ed-63a4acb568f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_820ac567-5bc1-4661-b5ab-f37d759b3419" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4b8331d5-4d1a-4c2a-b7ed-63a4acb568f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_5cc600b2-4118-4d72-b748-d1fc1837585e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_820ac567-5bc1-4661-b5ab-f37d759b3419" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_5cc600b2-4118-4d72-b748-d1fc1837585e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_3f6b0392-6586-4bab-bc72-28c26962dbae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_820ac567-5bc1-4661-b5ab-f37d759b3419" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_3f6b0392-6586-4bab-bc72-28c26962dbae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_79807c7f-2719-4a3b-bb68-66ce0e079139" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_820ac567-5bc1-4661-b5ab-f37d759b3419" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_79807c7f-2719-4a3b-bb68-66ce0e079139" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_0f5b8448-7bea-4341-a186-9ac798f61e49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_820ac567-5bc1-4661-b5ab-f37d759b3419" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_0f5b8448-7bea-4341-a186-9ac798f61e49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_81e77243-9e4a-4b20-ae1d-07b16b2164e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_43f51f0d-130f-451d-a6b9-a542121a9608" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_81e77243-9e4a-4b20-ae1d-07b16b2164e8" xlink:to="loc_us-gaap_NetIncomeLoss_43f51f0d-130f-451d-a6b9-a542121a9608" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_78d09b7b-6357-4952-8a80-1e184c2cb8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_81e77243-9e4a-4b20-ae1d-07b16b2164e8" xlink:to="loc_us-gaap_ShareBasedCompensation_78d09b7b-6357-4952-8a80-1e184c2cb8d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_961daf35-a1ab-4128-8c69-431c675deb4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_81e77243-9e4a-4b20-ae1d-07b16b2164e8" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_961daf35-a1ab-4128-8c69-431c675deb4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_5b714264-e1a4-4dbe-b2f6-ae3868a1fa15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_81e77243-9e4a-4b20-ae1d-07b16b2164e8" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_5b714264-e1a4-4dbe-b2f6-ae3868a1fa15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_f46ea8f1-c1a3-4208-abbf-7bf27def750a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_81e77243-9e4a-4b20-ae1d-07b16b2164e8" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_f46ea8f1-c1a3-4208-abbf-7bf27def750a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_b125a64e-8dea-4dd6-9565-ad64b734cbbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_81e77243-9e4a-4b20-ae1d-07b16b2164e8" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_b125a64e-8dea-4dd6-9565-ad64b734cbbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_0e39c9ec-e76f-44f7-b14e-d8a2e4cfa838" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_81e77243-9e4a-4b20-ae1d-07b16b2164e8" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_0e39c9ec-e76f-44f7-b14e-d8a2e4cfa838" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DeferredRentPayments_befb073b-08f1-4f9c-a43c-7aa7a4640c33" xlink:href="halo-20220630.xsd#halo_DeferredRentPayments"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_81e77243-9e4a-4b20-ae1d-07b16b2164e8" xlink:to="loc_halo_DeferredRentPayments_befb073b-08f1-4f9c-a43c-7aa7a4640c33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_d7202eb4-08ff-4b6e-a5d0-e6ce9bc11120" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_81e77243-9e4a-4b20-ae1d-07b16b2164e8" xlink:to="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_d7202eb4-08ff-4b6e-a5d0-e6ce9bc11120" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ab083dab-5f1e-4a10-a994-b054a3ebef9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_81e77243-9e4a-4b20-ae1d-07b16b2164e8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ab083dab-5f1e-4a10-a994-b054a3ebef9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_6592c3ab-4c72-46a4-ba4c-0ac88de7d5b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_81e77243-9e4a-4b20-ae1d-07b16b2164e8" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_6592c3ab-4c72-46a4-ba4c-0ac88de7d5b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2b6ce5af-603c-4e7e-a35c-427f18f8e0a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_81e77243-9e4a-4b20-ae1d-07b16b2164e8" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2b6ce5af-603c-4e7e-a35c-427f18f8e0a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_b29f0105-1e40-4433-a1b7-e3e17376f007" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_81e77243-9e4a-4b20-ae1d-07b16b2164e8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_b29f0105-1e40-4433-a1b7-e3e17376f007" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_1d35d4de-a239-4bc6-802a-ec6730a8f8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_81e77243-9e4a-4b20-ae1d-07b16b2164e8" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_1d35d4de-a239-4bc6-802a-ec6730a8f8d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_b20fe437-a170-4809-bd70-0adcbed87548" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_81e77243-9e4a-4b20-ae1d-07b16b2164e8" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_b20fe437-a170-4809-bd70-0adcbed87548" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_6cbe307a-dabf-42a1-99fd-9b129663aba6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_81e77243-9e4a-4b20-ae1d-07b16b2164e8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_6cbe307a-dabf-42a1-99fd-9b129663aba6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_076c42fc-0d29-47d8-9c08-4eb2396036ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a39dc095-1423-46d6-ad83-932cda2f18cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_076c42fc-0d29-47d8-9c08-4eb2396036ab" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a39dc095-1423-46d6-ad83-932cda2f18cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6e9f30d2-5486-48f5-9e1e-31da57317f43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_076c42fc-0d29-47d8-9c08-4eb2396036ab" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6e9f30d2-5486-48f5-9e1e-31da57317f43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_79d5e451-1ca0-4fdd-9014-06857959c5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_076c42fc-0d29-47d8-9c08-4eb2396036ab" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_79d5e451-1ca0-4fdd-9014-06857959c5cc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#BusinessCombinationPurchaseConsiderationDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_af23a891-c733-49f0-8d1c-53152be99550" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_08e227fc-34cf-447b-8405-117eb0c418ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_af23a891-c733-49f0-8d1c-53152be99550" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_08e227fc-34cf-447b-8405-117eb0c418ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards_748dfe57-75b7-415e-838c-2c857f0f3113" xlink:href="halo-20220630.xsd#halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_af23a891-c733-49f0-8d1c-53152be99550" xlink:to="loc_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards_748dfe57-75b7-415e-838c-2c857f0f3113" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_2f7d14ba-daa5-4d22-b6d1-995a6827fd6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_af23a891-c733-49f0-8d1c-53152be99550" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_2f7d14ba-daa5-4d22-b6d1-995a6827fd6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_0a0ac9f1-48f8-4888-9b19-08b5dc2d5099" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_af23a891-c733-49f0-8d1c-53152be99550" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_0a0ac9f1-48f8-4888-9b19-08b5dc2d5099" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationConsiderationTransferredBonusAwards_8e9d8d56-6b19-478b-be0f-baf145eafa88" xlink:href="halo-20220630.xsd#halo_BusinessCombinationConsiderationTransferredBonusAwards"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_af23a891-c733-49f0-8d1c-53152be99550" xlink:to="loc_halo_BusinessCombinationConsiderationTransferredBonusAwards_8e9d8d56-6b19-478b-be0f-baf145eafa88" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_bb28ed00-b9b4-4134-a0bc-495749439b09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_7b088d60-e21a-44c7-8d32-e1932fb5f730" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_bb28ed00-b9b4-4134-a0bc-495749439b09" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_7b088d60-e21a-44c7-8d32-e1932fb5f730" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_320bd6b1-75c5-4509-ae6c-e1195d903e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_bb28ed00-b9b4-4134-a0bc-495749439b09" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_320bd6b1-75c5-4509-ae6c-e1195d903e9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_44dade1c-adff-46f3-91c9-fb5c978cd580" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_bb28ed00-b9b4-4134-a0bc-495749439b09" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_44dade1c-adff-46f3-91c9-fb5c978cd580" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_4b03c53a-585a-4770-88f6-39a8dba70053" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_bb28ed00-b9b4-4134-a0bc-495749439b09" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_4b03c53a-585a-4770-88f6-39a8dba70053" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments_b9c1adb6-a744-412d-8e12-b4b1b3a133e7" xlink:href="halo-20220630.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_bb28ed00-b9b4-4134-a0bc-495749439b09" xlink:to="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments_b9c1adb6-a744-412d-8e12-b4b1b3a133e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_68ddbd9e-1c9a-425e-aba8-89b450f0111b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_bb28ed00-b9b4-4134-a0bc-495749439b09" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_68ddbd9e-1c9a-425e-aba8-89b450f0111b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability_e9f639eb-51e9-4148-891f-0854d0e6e961" xlink:href="halo-20220630.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_bb28ed00-b9b4-4134-a0bc-495749439b09" xlink:to="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability_e9f639eb-51e9-4148-891f-0854d0e6e961" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_e5f27d15-6934-4830-99e3-a9a966e2fda7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_bb28ed00-b9b4-4134-a0bc-495749439b09" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_e5f27d15-6934-4830-99e3-a9a966e2fda7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_84fb36cf-e197-4254-b111-71961707a7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_bb28ed00-b9b4-4134-a0bc-495749439b09" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_84fb36cf-e197-4254-b111-71961707a7c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability_4fd5800b-21df-4eb2-b52a-e3a81cb143c0" xlink:href="halo-20220630.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_bb28ed00-b9b4-4134-a0bc-495749439b09" xlink:to="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability_4fd5800b-21df-4eb2-b52a-e3a81cb143c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b772b768-d155-4372-a897-4b8910fe945d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_bb28ed00-b9b4-4134-a0bc-495749439b09" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b772b768-d155-4372-a897-4b8910fe945d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses_8efa690b-e409-43fd-a0fe-044168bcbc79" xlink:href="halo-20220630.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_bb28ed00-b9b4-4134-a0bc-495749439b09" xlink:to="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses_8efa690b-e409-43fd-a0fe-044168bcbc79" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_217ace9d-1709-4f32-ab1b-cc73a026abc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f24e6946-9dfd-4639-93c2-b1481d3b11c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_217ace9d-1709-4f32-ab1b-cc73a026abc6" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f24e6946-9dfd-4639-93c2-b1481d3b11c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_506081f3-1e34-4297-b97c-f76cc9ddd388" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_217ace9d-1709-4f32-ab1b-cc73a026abc6" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_506081f3-1e34-4297-b97c-f76cc9ddd388" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_669a317d-bf20-48db-9db1-d1a981e8e531" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_217ace9d-1709-4f32-ab1b-cc73a026abc6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_669a317d-bf20-48db-9db1-d1a981e8e531" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurementContractualMaturitiesofAvailableforSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#FairValueMeasurementContractualMaturitiesofAvailableforSaleDebtSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/FairValueMeasurementContractualMaturitiesofAvailableforSaleDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9abc465c-253d-4655-8a3e-36b1592ba1fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_7d5ac3a0-6d88-47fa-b2a1-98ce4b3dc5df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9abc465c-253d-4655-8a3e-36b1592ba1fe" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_7d5ac3a0-6d88-47fa-b2a1-98ce4b3dc5df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_450bf587-0e9c-4ca5-930b-cf98cff12217" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9abc465c-253d-4655-8a3e-36b1592ba1fe" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_450bf587-0e9c-4ca5-930b-cf98cff12217" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_3b8a4c09-1724-4674-a873-f27a64cc431b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a645628d-2cbb-4521-bdca-72c27ca3d99b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_3b8a4c09-1724-4674-a873-f27a64cc431b" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a645628d-2cbb-4521-bdca-72c27ca3d99b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8feb3e83-85ac-4fe7-a7a5-1f238f2feb58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_3b8a4c09-1724-4674-a873-f27a64cc431b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8feb3e83-85ac-4fe7-a7a5-1f238f2feb58" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#CertainBalanceSheetItemsAccountsReceivablenetDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_4e62d1e3-013d-45ca-b04d-4d0f2bddaf90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accountsreceivablefromproductsalestocollaborators_32c77ceb-52cd-4baa-8198-848255771298" xlink:href="halo-20220630.xsd#halo_Accountsreceivablefromproductsalestocollaborators"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableGrossCurrent_4e62d1e3-013d-45ca-b04d-4d0f2bddaf90" xlink:to="loc_halo_Accountsreceivablefromproductsalestocollaborators_32c77ceb-52cd-4baa-8198-848255771298" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accountsreceivablefromcollaborators_0096ffbc-701f-4a9b-8ec4-edbd11ab4c4d" xlink:href="halo-20220630.xsd#halo_Accountsreceivablefromcollaborators"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableGrossCurrent_4e62d1e3-013d-45ca-b04d-4d0f2bddaf90" xlink:to="loc_halo_Accountsreceivablefromcollaborators_0096ffbc-701f-4a9b-8ec4-edbd11ab4c4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accountsreceivablefromroyalties_4115f764-5f33-4a4a-ae84-f4fe7e561200" xlink:href="halo-20220630.xsd#halo_Accountsreceivablefromroyalties"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableGrossCurrent_4e62d1e3-013d-45ca-b04d-4d0f2bddaf90" xlink:to="loc_halo_Accountsreceivablefromroyalties_4115f764-5f33-4a4a-ae84-f4fe7e561200" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accountsreceivablefromproductsales_00afabd7-2e3e-4175-980f-940a21a48fe7" xlink:href="halo-20220630.xsd#halo_Accountsreceivablefromproductsales"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableGrossCurrent_4e62d1e3-013d-45ca-b04d-4d0f2bddaf90" xlink:to="loc_halo_Accountsreceivablefromproductsales_00afabd7-2e3e-4175-980f-940a21a48fe7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_5bfb2f1e-7ea5-48b3-bce8-9e1dcb6fab13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableGrossCurrent_4e62d1e3-013d-45ca-b04d-4d0f2bddaf90" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_5bfb2f1e-7ea5-48b3-bce8-9e1dcb6fab13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivables_5320bfa9-b00c-46b8-a716-72275a5c0449" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivables"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableGrossCurrent_4e62d1e3-013d-45ca-b04d-4d0f2bddaf90" xlink:to="loc_us-gaap_OtherReceivables_5320bfa9-b00c-46b8-a716-72275a5c0449" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_c21d1297-4aea-4183-b4af-e1c0fc151605" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_d19fa530-ac61-41de-941a-c23842c0a866" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_c21d1297-4aea-4183-b4af-e1c0fc151605" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_d19fa530-ac61-41de-941a-c23842c0a866" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AllowanceforDistributionFeesandDiscounts_c5e1e6fb-07c7-4d8a-ac96-8fb325032254" xlink:href="halo-20220630.xsd#halo_AllowanceforDistributionFeesandDiscounts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_c21d1297-4aea-4183-b4af-e1c0fc151605" xlink:to="loc_halo_AllowanceforDistributionFeesandDiscounts_c5e1e6fb-07c7-4d8a-ac96-8fb325032254" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#CertainBalanceSheetItemsInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_091ba890-ebc5-468f-af61-b1829a0d29f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_054bb5aa-5bd4-4f38-84c9-09f5135d8b17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_091ba890-ebc5-468f-af61-b1829a0d29f6" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_054bb5aa-5bd4-4f38-84c9-09f5135d8b17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_1f743ce1-8c53-461a-8625-1001eb850a48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_091ba890-ebc5-468f-af61-b1829a0d29f6" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_1f743ce1-8c53-461a-8625-1001eb850a48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_367785ea-bd0d-4b15-a321-66edb92451ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_091ba890-ebc5-468f-af61-b1829a0d29f6" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_367785ea-bd0d-4b15-a321-66edb92451ea" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_3372f09a-88e9-4bf3-8653-d4d74c123dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_c4e1913c-ec08-4ef8-8dd2-9b7b53e478ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_3372f09a-88e9-4bf3-8653-d4d74c123dd4" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_c4e1913c-ec08-4ef8-8dd2-9b7b53e478ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_666466e4-0eb5-477c-b4af-2fbabddd3b13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_3372f09a-88e9-4bf3-8653-d4d74c123dd4" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_666466e4-0eb5-477c-b4af-2fbabddd3b13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_62fb37f9-297c-44dc-b162-94bca84254a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_3372f09a-88e9-4bf3-8653-d4d74c123dd4" xlink:to="loc_us-gaap_OtherAssets_62fb37f9-297c-44dc-b162-94bca84254a6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails_1" xlink:type="simple" xlink:href="halo-20220630.xsd#CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails_1"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_c332a32c-9184-445d-a10a-fa6ebe9ed6de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_1cb4050c-408d-4271-847f-65f274f556d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_c332a32c-9184-445d-a10a-fa6ebe9ed6de" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_1cb4050c-408d-4271-847f-65f274f556d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7cfbe6bb-c1c7-42f6-9adf-45b294dc4b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_c332a32c-9184-445d-a10a-fa6ebe9ed6de" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7cfbe6bb-c1c7-42f6-9adf-45b294dc4b1e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#CertainBalanceSheetItemsPropertyandEquipmentnetDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7ee94a28-d642-4409-841a-6528f0eea451" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f2b17eb4-1028-4d21-aea0-15cca5d09072" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_7ee94a28-d642-4409-841a-6528f0eea451" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f2b17eb4-1028-4d21-aea0-15cca5d09072" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_ceddd9e8-bf9b-4484-ade5-832481c29956" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_7ee94a28-d642-4409-841a-6528f0eea451" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_ceddd9e8-bf9b-4484-ade5-832481c29956" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_d9ec3e1b-10fe-48b9-b1f0-f0300c942ee0" xlink:href="halo-20220630.xsd#halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_799ad0f9-5785-436c-adc9-58f8aab17895" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_d9ec3e1b-10fe-48b9-b1f0-f0300c942ee0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_799ad0f9-5785-436c-adc9-58f8aab17895" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c018dff9-3e52-4786-9439-921df942f886" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_d9ec3e1b-10fe-48b9-b1f0-f0300c942ee0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c018dff9-3e52-4786-9439-921df942f886" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#CertainBalanceSheetItemsAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_db9c25e7-c48d-4280-91b5-269561d7b0ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AccruedLiabilitiesNoncurrent_d4e6eb2e-e9eb-445a-80b5-63ffcac482e5" xlink:href="halo-20220630.xsd#halo_AccruedLiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_db9c25e7-c48d-4280-91b5-269561d7b0ee" xlink:to="loc_halo_AccruedLiabilitiesNoncurrent_d4e6eb2e-e9eb-445a-80b5-63ffcac482e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7c35b287-344d-492d-bb8b-b0836d805a35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_db9c25e7-c48d-4280-91b5-269561d7b0ee" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7c35b287-344d-492d-bb8b-b0836d805a35" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails_1" xlink:type="simple" xlink:href="halo-20220630.xsd#CertainBalanceSheetItemsAccruedExpensesDetails_1"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_a6ad6f1e-763c-40e3-ba66-4e3508c2ff58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_bb2db77b-2dbb-4bd5-9f58-b13f15c5bdf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_a6ad6f1e-763c-40e3-ba66-4e3508c2ff58" xlink:to="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_bb2db77b-2dbb-4bd5-9f58-b13f15c5bdf5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f99e16db-e8d4-48a4-a97b-99f6d015eca1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_a6ad6f1e-763c-40e3-ba66-4e3508c2ff58" xlink:to="loc_us-gaap_OperatingLeaseLiability_f99e16db-e8d4-48a4-a97b-99f6d015eca1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accruedmanufacturingexpenses_1f6b53d2-0212-4fb4-a060-a4e46c6c4394" xlink:href="halo-20220630.xsd#halo_Accruedmanufacturingexpenses"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_a6ad6f1e-763c-40e3-ba66-4e3508c2ff58" xlink:to="loc_halo_Accruedmanufacturingexpenses_1f6b53d2-0212-4fb4-a060-a4e46c6c4394" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_42080452-7987-4a0a-99fb-a481988d13c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_a6ad6f1e-763c-40e3-ba66-4e3508c2ff58" xlink:to="loc_us-gaap_TaxesPayableCurrent_42080452-7987-4a0a-99fb-a481988d13c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4c716050-430c-427b-be66-82ea433cd06c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_a6ad6f1e-763c-40e3-ba66-4e3508c2ff58" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4c716050-430c-427b-be66-82ea433cd06c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_614bbb28-de5f-43a7-97bd-12e3923727a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_a6ad6f1e-763c-40e3-ba66-4e3508c2ff58" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_614bbb28-de5f-43a7-97bd-12e3923727a1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#GoodwillandIntangibleAssetsIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d30de69b-53de-4092-87de-b5b39003e253" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_da41a44c-1804-4b00-8868-0c0f7106802f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d30de69b-53de-4092-87de-b5b39003e253" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_da41a44c-1804-4b00-8868-0c0f7106802f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_7e85950c-8366-4b55-ae3e-7f435e20cbf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d30de69b-53de-4092-87de-b5b39003e253" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_7e85950c-8366-4b55-ae3e-7f435e20cbf4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#GoodwillandIntangibleAssetsFutureAmortizationDetails"/>
  <link:calculationLink xlink:role="http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_787a75ad-ab30-46eb-8438-05296038b3f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_15741486-22f9-45a3-87b8-d19ef0a86f88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_787a75ad-ab30-46eb-8438-05296038b3f6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_15741486-22f9-45a3-87b8-d19ef0a86f88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_95bad7e5-95f9-49d8-bc33-dba5b8ec03c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_787a75ad-ab30-46eb-8438-05296038b3f6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_95bad7e5-95f9-49d8-bc33-dba5b8ec03c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ac3e7e7d-6b87-40b8-87dc-497f0cec2b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_787a75ad-ab30-46eb-8438-05296038b3f6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ac3e7e7d-6b87-40b8-87dc-497f0cec2b9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_3e0c8823-9368-47eb-b482-e2d7b6759d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_787a75ad-ab30-46eb-8438-05296038b3f6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_3e0c8823-9368-47eb-b482-e2d7b6759d7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour_66986b86-6a47-4724-8fb9-0ede4e2a1654" xlink:href="halo-20220630.xsd#halo_FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_787a75ad-ab30-46eb-8438-05296038b3f6" xlink:to="loc_halo_FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour_66986b86-6a47-4724-8fb9-0ede4e2a1654" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_e32f117e-206f-448f-9686-1ffbaf0de07b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_787a75ad-ab30-46eb-8438-05296038b3f6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_e32f117e-206f-448f-9686-1ffbaf0de07b" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>halo-20220630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:73069a0e-fffd-482c-8df8-d4ff810732e3,g:be228a77-9c6c-4f8e-9f2c-fe0d390b647c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="halo-20220630.xsd#CondensedConsolidatedStatementsofOperationsUnaudited"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="extended" id="ibe971e0cbd1a4163b9a4a4c36c36391c_CondensedConsolidatedStatementsofOperationsUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_09bd6f62-7bec-4be1-9827-f6f139f27f13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_6239fe96-a56f-4544-8985-9e032f4b2114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_09bd6f62-7bec-4be1-9827-f6f139f27f13" xlink:to="loc_us-gaap_RevenuesAbstract_6239fe96-a56f-4544-8985-9e032f4b2114" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5dbc62bb-6ca5-493f-aae2-d9f1f2646257" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_6239fe96-a56f-4544-8985-9e032f4b2114" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5dbc62bb-6ca5-493f-aae2-d9f1f2646257" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_c53c441a-dbe5-4736-8ce9-007168c659a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_09bd6f62-7bec-4be1-9827-f6f139f27f13" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_c53c441a-dbe5-4736-8ce9-007168c659a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_fbef14a3-46c2-47ba-b219-9936b5b81eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c53c441a-dbe5-4736-8ce9-007168c659a2" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_fbef14a3-46c2-47ba-b219-9936b5b81eb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_316b730e-237c-4f94-86d4-aa99fae958d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c53c441a-dbe5-4736-8ce9-007168c659a2" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_316b730e-237c-4f94-86d4-aa99fae958d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_46ead0db-473d-43e9-b67a-fd22aa61728d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c53c441a-dbe5-4736-8ce9-007168c659a2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_46ead0db-473d-43e9-b67a-fd22aa61728d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_db6a1799-88ac-4bc8-b1c7-1840419b4ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c53c441a-dbe5-4736-8ce9-007168c659a2" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_db6a1799-88ac-4bc8-b1c7-1840419b4ebe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_d70baac7-da01-4f2d-897c-2a71c63d7ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c53c441a-dbe5-4736-8ce9-007168c659a2" xlink:to="loc_us-gaap_CostsAndExpenses_d70baac7-da01-4f2d-897c-2a71c63d7ec8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b55ad54b-d034-4135-bafe-8b021196cfa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_09bd6f62-7bec-4be1-9827-f6f139f27f13" xlink:to="loc_us-gaap_OperatingIncomeLoss_b55ad54b-d034-4135-bafe-8b021196cfa8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_e9d489fc-c763-474a-a940-d62ae0c50bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_09bd6f62-7bec-4be1-9827-f6f139f27f13" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_e9d489fc-c763-474a-a940-d62ae0c50bcb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_039d3ea2-96c1-466e-a670-43037d747f87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_e9d489fc-c763-474a-a940-d62ae0c50bcb" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_039d3ea2-96c1-466e-a670-43037d747f87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_73ad6d44-fc72-47cb-9db2-71b1ff61e35d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_e9d489fc-c763-474a-a940-d62ae0c50bcb" xlink:to="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_73ad6d44-fc72-47cb-9db2-71b1ff61e35d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_265fcf20-454a-42db-9249-18fa18345713" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_e9d489fc-c763-474a-a940-d62ae0c50bcb" xlink:to="loc_us-gaap_InterestExpense_265fcf20-454a-42db-9249-18fa18345713" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3c581a94-aa9d-4482-bb27-a4cfc4801dab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_09bd6f62-7bec-4be1-9827-f6f139f27f13" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3c581a94-aa9d-4482-bb27-a4cfc4801dab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_66b78d07-a50c-4e6a-b8a7-17f9703e45a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_09bd6f62-7bec-4be1-9827-f6f139f27f13" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_66b78d07-a50c-4e6a-b8a7-17f9703e45a1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bd4960fc-f277-4516-a7ef-493d814e24f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_09bd6f62-7bec-4be1-9827-f6f139f27f13" xlink:to="loc_us-gaap_NetIncomeLoss_bd4960fc-f277-4516-a7ef-493d814e24f6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a42a6681-75f7-444d-8cb7-5ea77b9ded1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_09bd6f62-7bec-4be1-9827-f6f139f27f13" xlink:to="loc_us-gaap_EarningsPerShareAbstract_a42a6681-75f7-444d-8cb7-5ea77b9ded1b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6e00d106-44f6-45df-9d4a-6a33aa52b5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a42a6681-75f7-444d-8cb7-5ea77b9ded1b" xlink:to="loc_us-gaap_EarningsPerShareBasic_6e00d106-44f6-45df-9d4a-6a33aa52b5f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2718c953-f53a-4d63-aafc-6dc308fc9b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a42a6681-75f7-444d-8cb7-5ea77b9ded1b" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2718c953-f53a-4d63-aafc-6dc308fc9b2f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_b90cd4db-9458-4843-b178-626fe718f9d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_09bd6f62-7bec-4be1-9827-f6f139f27f13" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_b90cd4db-9458-4843-b178-626fe718f9d9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bfcc23b7-a6a4-4c9a-9a3f-a70f94d7cd17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_b90cd4db-9458-4843-b178-626fe718f9d9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bfcc23b7-a6a4-4c9a-9a3f-a70f94d7cd17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_49d20a95-d97a-4697-994b-c5fa5925cf21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_b90cd4db-9458-4843-b178-626fe718f9d9" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_49d20a95-d97a-4697-994b-c5fa5925cf21" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_869f9d6b-1e3d-4b87-89cc-168d63b59074" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_09bd6f62-7bec-4be1-9827-f6f139f27f13" xlink:to="loc_us-gaap_StatementTable_869f9d6b-1e3d-4b87-89cc-168d63b59074" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fe1c6e3b-f4e3-4aaa-8f88-434d41225f5e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_869f9d6b-1e3d-4b87-89cc-168d63b59074" xlink:to="loc_srt_ProductOrServiceAxis_fe1c6e3b-f4e3-4aaa-8f88-434d41225f5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fe1c6e3b-f4e3-4aaa-8f88-434d41225f5e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_fe1c6e3b-f4e3-4aaa-8f88-434d41225f5e" xlink:to="loc_srt_ProductsAndServicesDomain_fe1c6e3b-f4e3-4aaa-8f88-434d41225f5e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c1afea99-1e37-45db-a58b-016f793f8df6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_fe1c6e3b-f4e3-4aaa-8f88-434d41225f5e" xlink:to="loc_srt_ProductsAndServicesDomain_c1afea99-1e37-45db-a58b-016f793f8df6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_65c06d07-6347-4917-bb0c-9b0d7edcd72d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c1afea99-1e37-45db-a58b-016f793f8df6" xlink:to="loc_us-gaap_RoyaltyMember_65c06d07-6347-4917-bb0c-9b0d7edcd72d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_275d57f9-ef5a-4698-983d-a54376b81c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c1afea99-1e37-45db-a58b-016f793f8df6" xlink:to="loc_us-gaap_ProductMember_275d57f9-ef5a-4698-983d-a54376b81c4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_CollaborativeAgreementsMember_a7b687b6-c923-4569-94a1-e7c711782a09" xlink:href="halo-20220630.xsd#halo_CollaborativeAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c1afea99-1e37-45db-a58b-016f793f8df6" xlink:to="loc_halo_CollaborativeAgreementsMember_a7b687b6-c923-4569-94a1-e7c711782a09" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="simple" xlink:href="halo-20220630.xsd#CondensedConsolidatedStatementsofStockholdersEquityUnaudited"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="extended" id="iff558616d89a49ea850bebced60e98c9_CondensedConsolidatedStatementsofStockholdersEquityUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e0bc396c-6a1e-4db6-b699-b75aae7ba81b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d70cafd-3513-4d3d-a6c0-79d5fbc84b18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e0bc396c-6a1e-4db6-b699-b75aae7ba81b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d70cafd-3513-4d3d-a6c0-79d5fbc84b18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_03a7f0c9-0300-4ca6-858a-ffb2f2b9eb89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d70cafd-3513-4d3d-a6c0-79d5fbc84b18" xlink:to="loc_us-gaap_SharesOutstanding_03a7f0c9-0300-4ca6-858a-ffb2f2b9eb89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2cff3767-79e8-4fec-b058-a16d19bf74d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d70cafd-3513-4d3d-a6c0-79d5fbc84b18" xlink:to="loc_us-gaap_StockholdersEquity_2cff3767-79e8-4fec-b058-a16d19bf74d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2b463a8b-26ae-4c15-80bc-24ab41538250" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d70cafd-3513-4d3d-a6c0-79d5fbc84b18" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2b463a8b-26ae-4c15-80bc-24ab41538250" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_3cf8331b-3562-4792-8b37-1a16da96e203" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d70cafd-3513-4d3d-a6c0-79d5fbc84b18" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_3cf8331b-3562-4792-8b37-1a16da96e203" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_f0e7865d-0e12-4034-b131-4dcdb7b1ca43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d70cafd-3513-4d3d-a6c0-79d5fbc84b18" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_f0e7865d-0e12-4034-b131-4dcdb7b1ca43" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1033cb5f-1ed2-4227-804b-a018b5406aff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d70cafd-3513-4d3d-a6c0-79d5fbc84b18" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1033cb5f-1ed2-4227-804b-a018b5406aff" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f40736b0-8fba-4628-801c-80b982221cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d70cafd-3513-4d3d-a6c0-79d5fbc84b18" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f40736b0-8fba-4628-801c-80b982221cbb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_3b35ed63-b40b-4cde-81c7-21c1551b1cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d70cafd-3513-4d3d-a6c0-79d5fbc84b18" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_3b35ed63-b40b-4cde-81c7-21c1551b1cf0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_f3f3f9ce-0cac-4dd1-9bf5-304ad4664c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d70cafd-3513-4d3d-a6c0-79d5fbc84b18" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_f3f3f9ce-0cac-4dd1-9bf5-304ad4664c7b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_654d6a79-332b-416a-81d1-5d5dcaccd521" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d70cafd-3513-4d3d-a6c0-79d5fbc84b18" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_654d6a79-332b-416a-81d1-5d5dcaccd521" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f1ae5bbd-4b44-4434-922b-38ef41e2a6e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d70cafd-3513-4d3d-a6c0-79d5fbc84b18" xlink:to="loc_us-gaap_NetIncomeLoss_f1ae5bbd-4b44-4434-922b-38ef41e2a6e3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_886334f6-bc0a-421b-84f3-6e8fd470c343" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4dda46bf-ec1f-4ec1-ab89-305b61ae59a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_94f2d97b-87a1-45cf-984d-0c0159530784" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e0bc396c-6a1e-4db6-b699-b75aae7ba81b" xlink:to="loc_us-gaap_StatementTable_94f2d97b-87a1-45cf-984d-0c0159530784" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_66741488-d1d8-4851-b819-219b4b746d34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_94f2d97b-87a1-45cf-984d-0c0159530784" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_66741488-d1d8-4851-b819-219b4b746d34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_66741488-d1d8-4851-b819-219b4b746d34_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_66741488-d1d8-4851-b819-219b4b746d34" xlink:to="loc_us-gaap_EquityComponentDomain_66741488-d1d8-4851-b819-219b4b746d34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e1425889-b6d4-4945-a09e-4bd733916cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_66741488-d1d8-4851-b819-219b4b746d34" xlink:to="loc_us-gaap_EquityComponentDomain_e1425889-b6d4-4945-a09e-4bd733916cd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c2923359-3e06-4acf-b679-6710bb71863b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e1425889-b6d4-4945-a09e-4bd733916cd0" xlink:to="loc_us-gaap_CommonStockMember_c2923359-3e06-4acf-b679-6710bb71863b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4ecf8cee-1386-4765-85dc-9bea665ce4bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e1425889-b6d4-4945-a09e-4bd733916cd0" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_4ecf8cee-1386-4765-85dc-9bea665ce4bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_efaa44f4-d34b-454c-9d52-a4cdeb2ed1e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e1425889-b6d4-4945-a09e-4bd733916cd0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_efaa44f4-d34b-454c-9d52-a4cdeb2ed1e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_bf9928cc-9397-4016-9d08-efdb0cc0b89f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e1425889-b6d4-4945-a09e-4bd733916cd0" xlink:to="loc_us-gaap_RetainedEarningsMember_bf9928cc-9397-4016-9d08-efdb0cc0b89f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c6b7d1d4-ecd5-4d0a-98cd-b8009be1a01c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_94f2d97b-87a1-45cf-984d-0c0159530784" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c6b7d1d4-ecd5-4d0a-98cd-b8009be1a01c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c6b7d1d4-ecd5-4d0a-98cd-b8009be1a01c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c6b7d1d4-ecd5-4d0a-98cd-b8009be1a01c" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c6b7d1d4-ecd5-4d0a-98cd-b8009be1a01c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_744a58a8-48ba-45d4-9efa-e109fc0a30e3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c6b7d1d4-ecd5-4d0a-98cd-b8009be1a01c" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_744a58a8-48ba-45d4-9efa-e109fc0a30e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_ce6d5d3b-7a2f-4628-958c-4a7ac15c824a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_744a58a8-48ba-45d4-9efa-e109fc0a30e3" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_ce6d5d3b-7a2f-4628-958c-4a7ac15c824a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/OrganizationandBusinessDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#OrganizationandBusinessDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/OrganizationandBusinessDetails" xlink:type="extended" id="iaf657a40de664463b9c65a06b985d460_OrganizationandBusinessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d4b421f-b4ec-4868-8750-3b871e6131bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RoyaltiesReceivedNumberOfCollaborators_bd7594b2-c68d-4103-ac1d-f18612c2fbd3" xlink:href="halo-20220630.xsd#halo_RoyaltiesReceivedNumberOfCollaborators"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d4b421f-b4ec-4868-8750-3b871e6131bd" xlink:to="loc_halo_RoyaltiesReceivedNumberOfCollaborators_bd7594b2-c68d-4103-ac1d-f18612c2fbd3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RoyaltiesReceivedNumberOfProductsSold_7afa727e-cece-4534-bf56-cd66721481e7" xlink:href="halo-20220630.xsd#halo_RoyaltiesReceivedNumberOfProductsSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d4b421f-b4ec-4868-8750-3b871e6131bd" xlink:to="loc_halo_RoyaltiesReceivedNumberOfProductsSold_7afa727e-cece-4534-bf56-cd66721481e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ff58162-245e-46ef-9ddd-6261ca6dfe91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d4b421f-b4ec-4868-8750-3b871e6131bd" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ff58162-245e-46ef-9ddd-6261ca6dfe91" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2a894c19-1cf4-4067-8282-51853fea8dd3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ff58162-245e-46ef-9ddd-6261ca6dfe91" xlink:to="loc_srt_CounterpartyNameAxis_2a894c19-1cf4-4067-8282-51853fea8dd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2a894c19-1cf4-4067-8282-51853fea8dd3_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_2a894c19-1cf4-4067-8282-51853fea8dd3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2a894c19-1cf4-4067-8282-51853fea8dd3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c0065692-9fa9-4684-9d64-68e2320461b4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_2a894c19-1cf4-4067-8282-51853fea8dd3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c0065692-9fa9-4684-9d64-68e2320461b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BaxaltaMember_46095df9-424c-4c05-b7a8-6d342007a1d1" xlink:href="halo-20220630.xsd#halo_BaxaltaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c0065692-9fa9-4684-9d64-68e2320461b4" xlink:to="loc_halo_BaxaltaMember_46095df9-424c-4c05-b7a8-6d342007a1d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RocheMember_1c2e94cb-c274-4ef9-8852-8b6966fe4ff3" xlink:href="halo-20220630.xsd#halo_RocheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c0065692-9fa9-4684-9d64-68e2320461b4" xlink:to="loc_halo_RocheMember_1c2e94cb-c274-4ef9-8852-8b6966fe4ff3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_JanssenMember_93454dc7-52f3-44cc-bb92-d3406d508120" xlink:href="halo-20220630.xsd#halo_JanssenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c0065692-9fa9-4684-9d64-68e2320461b4" xlink:to="loc_halo_JanssenMember_93454dc7-52f3-44cc-bb92-d3406d508120" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#SummaryofSignificantAccountingPoliciesLeasesDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails" xlink:type="extended" id="i81976fdd3ae34d2ea081f106e47612c8_SummaryofSignificantAccountingPoliciesLeasesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_b7d8b5e8-267b-4a1c-b40e-e7713c6f53fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_689bb9d7-7bd2-4e91-a962-48e7177a30d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b7d8b5e8-267b-4a1c-b40e-e7713c6f53fb" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_689bb9d7-7bd2-4e91-a962-48e7177a30d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_7ce5d71e-0665-4400-9ca1-c95a481f0c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b7d8b5e8-267b-4a1c-b40e-e7713c6f53fb" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_7ce5d71e-0665-4400-9ca1-c95a481f0c4a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7f82a685-cdfa-4483-8a65-e1c39e79536a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_7ce5d71e-0665-4400-9ca1-c95a481f0c4a" xlink:to="loc_srt_RangeAxis_7f82a685-cdfa-4483-8a65-e1c39e79536a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7f82a685-cdfa-4483-8a65-e1c39e79536a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7f82a685-cdfa-4483-8a65-e1c39e79536a" xlink:to="loc_srt_RangeMember_7f82a685-cdfa-4483-8a65-e1c39e79536a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_43a63c8d-7d63-45d5-b372-8813b2b6484b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7f82a685-cdfa-4483-8a65-e1c39e79536a" xlink:to="loc_srt_RangeMember_43a63c8d-7d63-45d5-b372-8813b2b6484b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_636a1442-5ebe-42dd-bf82-2798fa796593" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_43a63c8d-7d63-45d5-b372-8813b2b6484b" xlink:to="loc_srt_MinimumMember_636a1442-5ebe-42dd-bf82-2798fa796593" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2c6ceeb1-8656-4971-8e33-4d084d319829" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_43a63c8d-7d63-45d5-b372-8813b2b6484b" xlink:to="loc_srt_MaximumMember_2c6ceeb1-8656-4971-8e33-4d084d319829" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/BusinessCombinationNarrativeDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#BusinessCombinationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/BusinessCombinationNarrativeDetails" xlink:type="extended" id="i52b9f9b354f04a72a2dfdab6d4893f61_BusinessCombinationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_9c282120-a7db-4f55-be26-186d58b74932" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_9f1c25b7-91c4-42aa-9114-2b49649b1d14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9c282120-a7db-4f55-be26-186d58b74932" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_9f1c25b7-91c4-42aa-9114-2b49649b1d14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare_d4995424-199d-46c5-9288-1b2ade24dcf0" xlink:href="halo-20220630.xsd#halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9c282120-a7db-4f55-be26-186d58b74932" xlink:to="loc_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare_d4995424-199d-46c5-9288-1b2ade24dcf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_445d1413-df48-4ad4-ab87-9628751b6cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9c282120-a7db-4f55-be26-186d58b74932" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_445d1413-df48-4ad4-ab87-9628751b6cc0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_4197aaaa-3810-4632-8eda-278e240c2152" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9c282120-a7db-4f55-be26-186d58b74932" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_4197aaaa-3810-4632-8eda-278e240c2152" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7557f128-e079-4e1a-b7a3-5d824c959444" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9c282120-a7db-4f55-be26-186d58b74932" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7557f128-e079-4e1a-b7a3-5d824c959444" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_1519a3e9-d0fc-447d-a93e-6db2db3cfac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9c282120-a7db-4f55-be26-186d58b74932" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_1519a3e9-d0fc-447d-a93e-6db2db3cfac9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b179df2a-98db-438e-9a48-7bb379d7e611" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9c282120-a7db-4f55-be26-186d58b74932" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b179df2a-98db-438e-9a48-7bb379d7e611" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_5ca38b91-b070-468b-b5be-14f9234f3184" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9c282120-a7db-4f55-be26-186d58b74932" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_5ca38b91-b070-468b-b5be-14f9234f3184" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_60440a6a-d3b4-489e-9829-41e7e01d2393" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9c282120-a7db-4f55-be26-186d58b74932" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_60440a6a-d3b4-489e-9829-41e7e01d2393" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6d94f55f-cc17-4aa2-bd22-24a847c546b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9c282120-a7db-4f55-be26-186d58b74932" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6d94f55f-cc17-4aa2-bd22-24a847c546b9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a75eef50-3bda-4b8b-beed-732337746452" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6d94f55f-cc17-4aa2-bd22-24a847c546b9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a75eef50-3bda-4b8b-beed-732337746452" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a75eef50-3bda-4b8b-beed-732337746452_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a75eef50-3bda-4b8b-beed-732337746452" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a75eef50-3bda-4b8b-beed-732337746452_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88a96e11-18be-4763-b4d5-17fb7627bdb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a75eef50-3bda-4b8b-beed-732337746452" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88a96e11-18be-4763-b4d5-17fb7627bdb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember_991fb474-2541-4a6f-b02d-68c8e597da8f" xlink:href="halo-20220630.xsd#halo_AntaresPharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88a96e11-18be-4763-b4d5-17fb7627bdb2" xlink:to="loc_halo_AntaresPharmaIncMember_991fb474-2541-4a6f-b02d-68c8e597da8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_60e2ae1b-8b01-4523-8f38-42df818cc5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6d94f55f-cc17-4aa2-bd22-24a847c546b9" xlink:to="loc_us-gaap_DebtInstrumentAxis_60e2ae1b-8b01-4523-8f38-42df818cc5c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_60e2ae1b-8b01-4523-8f38-42df818cc5c6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_60e2ae1b-8b01-4523-8f38-42df818cc5c6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_60e2ae1b-8b01-4523-8f38-42df818cc5c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e80f9629-5dac-41a1-8fda-9fad7bb13160" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_60e2ae1b-8b01-4523-8f38-42df818cc5c6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e80f9629-5dac-41a1-8fda-9fad7bb13160" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_TermLoanFacilityMember_9b2bf9eb-0cc1-4cc8-a4fd-d3070be55770" xlink:href="halo-20220630.xsd#halo_TermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e80f9629-5dac-41a1-8fda-9fad7bb13160" xlink:to="loc_halo_TermLoanFacilityMember_9b2bf9eb-0cc1-4cc8-a4fd-d3070be55770" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_d8728e4e-d36a-4fd1-aa58-09e95651ad01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6d94f55f-cc17-4aa2-bd22-24a847c546b9" xlink:to="loc_us-gaap_CreditFacilityAxis_d8728e4e-d36a-4fd1-aa58-09e95651ad01" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_d8728e4e-d36a-4fd1-aa58-09e95651ad01_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_d8728e4e-d36a-4fd1-aa58-09e95651ad01" xlink:to="loc_us-gaap_CreditFacilityDomain_d8728e4e-d36a-4fd1-aa58-09e95651ad01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_55c644b4-792a-4a92-9b91-0b8faa061e05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_d8728e4e-d36a-4fd1-aa58-09e95651ad01" xlink:to="loc_us-gaap_CreditFacilityDomain_55c644b4-792a-4a92-9b91-0b8faa061e05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_095debe2-b334-450a-9647-4e42bf77e6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_55c644b4-792a-4a92-9b91-0b8faa061e05" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_095debe2-b334-450a-9647-4e42bf77e6e2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#BusinessCombinationPurchaseConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails" xlink:type="extended" id="if3e1f29706d74b4a892a97e73664bc36_BusinessCombinationPurchaseConsiderationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_76f22748-d419-4148-b6ba-b74dc34af475" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_d9e2722e-f754-4fbb-8777-3ae55d8ed482" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_76f22748-d419-4148-b6ba-b74dc34af475" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_d9e2722e-f754-4fbb-8777-3ae55d8ed482" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards_bf9ffb60-0036-400b-90ee-15a2a973970b" xlink:href="halo-20220630.xsd#halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_76f22748-d419-4148-b6ba-b74dc34af475" xlink:to="loc_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards_bf9ffb60-0036-400b-90ee-15a2a973970b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_966c798b-5ece-4943-9b30-a8dc7d6a145a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_76f22748-d419-4148-b6ba-b74dc34af475" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_966c798b-5ece-4943-9b30-a8dc7d6a145a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_3ab33331-ee29-418b-91bc-107d4b52cfb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_76f22748-d419-4148-b6ba-b74dc34af475" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_3ab33331-ee29-418b-91bc-107d4b52cfb9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationConsiderationTransferredBonusAwards_ba8362bd-f45b-41e4-a06d-46bfe8f1a20b" xlink:href="halo-20220630.xsd#halo_BusinessCombinationConsiderationTransferredBonusAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_76f22748-d419-4148-b6ba-b74dc34af475" xlink:to="loc_halo_BusinessCombinationConsiderationTransferredBonusAwards_ba8362bd-f45b-41e4-a06d-46bfe8f1a20b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_fbebf852-cde2-4edb-8915-6ed1baa12b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_76f22748-d419-4148-b6ba-b74dc34af475" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_fbebf852-cde2-4edb-8915-6ed1baa12b8e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_1ea306e8-7641-4ea3-b524-d9204f8e4337" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_76f22748-d419-4148-b6ba-b74dc34af475" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_1ea306e8-7641-4ea3-b524-d9204f8e4337" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9d242c57-47cd-4252-b914-83526a5d8608" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_76f22748-d419-4148-b6ba-b74dc34af475" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9d242c57-47cd-4252-b914-83526a5d8608" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_43ea197f-79e2-45b8-a27c-06123e1fd94f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9d242c57-47cd-4252-b914-83526a5d8608" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_43ea197f-79e2-45b8-a27c-06123e1fd94f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_43ea197f-79e2-45b8-a27c-06123e1fd94f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_43ea197f-79e2-45b8-a27c-06123e1fd94f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_43ea197f-79e2-45b8-a27c-06123e1fd94f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_78c0ee35-c187-4dbe-8269-3381e7a985df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_43ea197f-79e2-45b8-a27c-06123e1fd94f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_78c0ee35-c187-4dbe-8269-3381e7a985df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember_922c4a9b-1526-4891-a09d-14d068a44a84" xlink:href="halo-20220630.xsd#halo_AntaresPharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_78c0ee35-c187-4dbe-8269-3381e7a985df" xlink:to="loc_halo_AntaresPharmaIncMember_922c4a9b-1526-4891-a09d-14d068a44a84" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_ee28d0f3-8386-4b03-8c4b-18828cd40163" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9d242c57-47cd-4252-b914-83526a5d8608" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_ee28d0f3-8386-4b03-8c4b-18828cd40163" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_ee28d0f3-8386-4b03-8c4b-18828cd40163_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_ee28d0f3-8386-4b03-8c4b-18828cd40163" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_ee28d0f3-8386-4b03-8c4b-18828cd40163_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_7dd7fe29-b841-490e-8aeb-bdb0ac87c441" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_ee28d0f3-8386-4b03-8c4b-18828cd40163" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_7dd7fe29-b841-490e-8aeb-bdb0ac87c441" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationAwardsVestedMember_12e62983-f184-4765-9aca-4afe95e12fdc" xlink:href="halo-20220630.xsd#halo_ShareBasedCompensationAwardsVestedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_7dd7fe29-b841-490e-8aeb-bdb0ac87c441" xlink:to="loc_halo_ShareBasedCompensationAwardsVestedMember_12e62983-f184-4765-9aca-4afe95e12fdc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationAwardUnvestedMember_4f5de63f-0f32-4485-87e5-2841a6db5176" xlink:href="halo-20220630.xsd#halo_ShareBasedCompensationAwardUnvestedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_7dd7fe29-b841-490e-8aeb-bdb0ac87c441" xlink:to="loc_halo_ShareBasedCompensationAwardUnvestedMember_4f5de63f-0f32-4485-87e5-2841a6db5176" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended" id="ib2ce3a28379743bb8efd6eb13263fa24_BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_8e2cd6f3-9152-4c09-976e-74f0f9859c55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c996ca79-3415-4164-8902-b56ffd13097d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8e2cd6f3-9152-4c09-976e-74f0f9859c55" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c996ca79-3415-4164-8902-b56ffd13097d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_c8cb14e8-1ea0-4dca-a92d-692d043c438b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8e2cd6f3-9152-4c09-976e-74f0f9859c55" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_c8cb14e8-1ea0-4dca-a92d-692d043c438b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_3c19b226-20e2-415d-861f-326dfd4d8cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8e2cd6f3-9152-4c09-976e-74f0f9859c55" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_3c19b226-20e2-415d-861f-326dfd4d8cc0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments_abe18d6e-7b99-4a1a-8a54-d29029586d62" xlink:href="halo-20220630.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_3c19b226-20e2-415d-861f-326dfd4d8cc0" xlink:to="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments_abe18d6e-7b99-4a1a-8a54-d29029586d62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_3ba6f616-7790-4e66-acd8-915ff5fc7fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_3c19b226-20e2-415d-861f-326dfd4d8cc0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_3ba6f616-7790-4e66-acd8-915ff5fc7fdb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_89f6b6aa-8386-43c3-ade1-bdd649b42387" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_3c19b226-20e2-415d-861f-326dfd4d8cc0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_89f6b6aa-8386-43c3-ade1-bdd649b42387" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_adbb9396-0ea0-4777-b3ef-738dbdbc62d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_3c19b226-20e2-415d-861f-326dfd4d8cc0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_adbb9396-0ea0-4777-b3ef-738dbdbc62d9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_5bb5a541-5b6f-490a-b058-b93cf7d54fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_3c19b226-20e2-415d-861f-326dfd4d8cc0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_5bb5a541-5b6f-490a-b058-b93cf7d54fb3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9a725d40-65da-4f7e-ba80-141b4528d0f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_3c19b226-20e2-415d-861f-326dfd4d8cc0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9a725d40-65da-4f7e-ba80-141b4528d0f4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_d829d299-d89e-4311-8cbe-e60a8c6e8639" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8e2cd6f3-9152-4c09-976e-74f0f9859c55" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_d829d299-d89e-4311-8cbe-e60a8c6e8639" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_abd617d0-78c5-483c-aa0e-61d1f4186be2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_d829d299-d89e-4311-8cbe-e60a8c6e8639" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_abd617d0-78c5-483c-aa0e-61d1f4186be2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses_8e4ce377-56fc-4db4-972c-faedc80c968c" xlink:href="halo-20220630.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_d829d299-d89e-4311-8cbe-e60a8c6e8639" xlink:to="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses_8e4ce377-56fc-4db4-972c-faedc80c968c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability_b96071d5-7f11-4f41-8e28-f249390e0ea2" xlink:href="halo-20220630.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_d829d299-d89e-4311-8cbe-e60a8c6e8639" xlink:to="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability_b96071d5-7f11-4f41-8e28-f249390e0ea2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability_9154cb9b-1f2e-4faa-bcf3-586dfc0fd729" xlink:href="halo-20220630.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_d829d299-d89e-4311-8cbe-e60a8c6e8639" xlink:to="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability_9154cb9b-1f2e-4faa-bcf3-586dfc0fd729" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_18c574f6-b082-4664-a658-b578ae74685d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_d829d299-d89e-4311-8cbe-e60a8c6e8639" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_18c574f6-b082-4664-a658-b578ae74685d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_1ec4e9cf-6649-45ef-addc-8a7cfeb2909f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_d829d299-d89e-4311-8cbe-e60a8c6e8639" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_1ec4e9cf-6649-45ef-addc-8a7cfeb2909f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1625713f-5a33-4d24-b2e1-a54988c93ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8e2cd6f3-9152-4c09-976e-74f0f9859c55" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1625713f-5a33-4d24-b2e1-a54988c93ccc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e6fc4b8d-f38b-410a-be4f-6f09e27826d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8e2cd6f3-9152-4c09-976e-74f0f9859c55" xlink:to="loc_us-gaap_Goodwill_e6fc4b8d-f38b-410a-be4f-6f09e27826d5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3207b0db-c64b-43cf-9573-b330ee5623d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8e2cd6f3-9152-4c09-976e-74f0f9859c55" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3207b0db-c64b-43cf-9573-b330ee5623d0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e442a303-da7b-4f8d-b4c7-33768033ad1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3207b0db-c64b-43cf-9573-b330ee5623d0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e442a303-da7b-4f8d-b4c7-33768033ad1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e442a303-da7b-4f8d-b4c7-33768033ad1a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e442a303-da7b-4f8d-b4c7-33768033ad1a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e442a303-da7b-4f8d-b4c7-33768033ad1a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c4f96cdb-21cb-41f9-9117-e3ca1760c496" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e442a303-da7b-4f8d-b4c7-33768033ad1a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c4f96cdb-21cb-41f9-9117-e3ca1760c496" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember_98f06041-3d23-4bdc-bb35-726b8ebd881b" xlink:href="halo-20220630.xsd#halo_AntaresPharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c4f96cdb-21cb-41f9-9117-e3ca1760c496" xlink:to="loc_halo_AntaresPharmaIncMember_98f06041-3d23-4bdc-bb35-726b8ebd881b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#BusinessCombinationIntangibleAssetsAcquiredDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails" xlink:type="extended" id="ic4dc9e0a7136411aae757685323eab82_BusinessCombinationIntangibleAssetsAcquiredDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_73397cef-0dec-429e-a257-c550857c9492" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_03d55002-dac5-44ed-a361-ec5a7613fbe8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_73397cef-0dec-429e-a257-c550857c9492" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_03d55002-dac5-44ed-a361-ec5a7613fbe8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6c171425-ed3f-4631-a537-f76b393bfa08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_73397cef-0dec-429e-a257-c550857c9492" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6c171425-ed3f-4631-a537-f76b393bfa08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_b6c85671-3101-4f4e-a953-6dd41d414bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_73397cef-0dec-429e-a257-c550857c9492" xlink:to="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_b6c85671-3101-4f4e-a953-6dd41d414bbe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_8be81136-a7e6-4c2f-a233-6b156e533cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_73397cef-0dec-429e-a257-c550857c9492" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_8be81136-a7e6-4c2f-a233-6b156e533cd5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6cde9861-7fc1-4bca-b1e6-f8a5dc9505a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_73397cef-0dec-429e-a257-c550857c9492" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6cde9861-7fc1-4bca-b1e6-f8a5dc9505a5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8775ecae-775a-4b46-aadc-6d1d847f6a90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6cde9861-7fc1-4bca-b1e6-f8a5dc9505a5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8775ecae-775a-4b46-aadc-6d1d847f6a90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8775ecae-775a-4b46-aadc-6d1d847f6a90_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8775ecae-775a-4b46-aadc-6d1d847f6a90" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8775ecae-775a-4b46-aadc-6d1d847f6a90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_999d2f74-f04e-4976-803a-31b7e2328aed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8775ecae-775a-4b46-aadc-6d1d847f6a90" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_999d2f74-f04e-4976-803a-31b7e2328aed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember_b72c62b1-f702-421d-bae4-34aabc55524a" xlink:href="halo-20220630.xsd#halo_AntaresPharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_999d2f74-f04e-4976-803a-31b7e2328aed" xlink:to="loc_halo_AntaresPharmaIncMember_b72c62b1-f702-421d-bae4-34aabc55524a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_01fe5658-d3ad-4c9c-b3dd-3da66798d05d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6cde9861-7fc1-4bca-b1e6-f8a5dc9505a5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_01fe5658-d3ad-4c9c-b3dd-3da66798d05d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_01fe5658-d3ad-4c9c-b3dd-3da66798d05d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_01fe5658-d3ad-4c9c-b3dd-3da66798d05d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_01fe5658-d3ad-4c9c-b3dd-3da66798d05d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0ac10d5d-4df9-4285-98aa-6aa066d98500" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_01fe5658-d3ad-4c9c-b3dd-3da66798d05d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0ac10d5d-4df9-4285-98aa-6aa066d98500" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AutoInjectorTechnologyPlatformMember_86e40b5e-be1a-4bfb-85bc-9691a1d09ccd" xlink:href="halo-20220630.xsd#halo_AutoInjectorTechnologyPlatformMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0ac10d5d-4df9-4285-98aa-6aa066d98500" xlink:to="loc_halo_AutoInjectorTechnologyPlatformMember_86e40b5e-be1a-4bfb-85bc-9691a1d09ccd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_XYOSTEDProprietaryProductMember_b1b3802f-c05b-4e4c-a789-558bcd4c4130" xlink:href="halo-20220630.xsd#halo_XYOSTEDProprietaryProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0ac10d5d-4df9-4285-98aa-6aa066d98500" xlink:to="loc_halo_XYOSTEDProprietaryProductMember_b1b3802f-c05b-4e4c-a789-558bcd4c4130" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_TLANDOProductRightsMember_f5881d0f-2442-4521-b9e2-e18c76dceae8" xlink:href="halo-20220630.xsd#halo_TLANDOProductRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0ac10d5d-4df9-4285-98aa-6aa066d98500" xlink:to="loc_halo_TLANDOProductRightsMember_f5881d0f-2442-4521-b9e2-e18c76dceae8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_367a4ea4-6f02-4f56-9d4f-bd1b4b2250e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6cde9861-7fc1-4bca-b1e6-f8a5dc9505a5" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_367a4ea4-6f02-4f56-9d4f-bd1b4b2250e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_367a4ea4-6f02-4f56-9d4f-bd1b4b2250e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_367a4ea4-6f02-4f56-9d4f-bd1b4b2250e5" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_367a4ea4-6f02-4f56-9d4f-bd1b4b2250e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_fe61e712-b551-4c72-a01b-687151f4baf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_367a4ea4-6f02-4f56-9d4f-bd1b4b2250e5" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_fe61e712-b551-4c72-a01b-687151f4baf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_85351189-31c1-489b-a865-1be469e248fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_fe61e712-b551-4c72-a01b-687151f4baf8" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_85351189-31c1-489b-a865-1be469e248fe" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/BusinessCombinationSummaryofProformaFinancialInformationDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#BusinessCombinationSummaryofProformaFinancialInformationDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/BusinessCombinationSummaryofProformaFinancialInformationDetails" xlink:type="extended" id="id06835acf9694ac0b27eaeeb2e5609ab_BusinessCombinationSummaryofProformaFinancialInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_74ea348c-9bd8-41f7-9708-c2b7ab678548" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_09950e9c-fa48-4e02-8218-f2965616609d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_74ea348c-9bd8-41f7-9708-c2b7ab678548" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_09950e9c-fa48-4e02-8218-f2965616609d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_655ed113-9b07-483a-abe7-9db401d06df9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_74ea348c-9bd8-41f7-9708-c2b7ab678548" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_655ed113-9b07-483a-abe7-9db401d06df9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d60e5972-c7b7-4de9-b406-92077e3df8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_74ea348c-9bd8-41f7-9708-c2b7ab678548" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d60e5972-c7b7-4de9-b406-92077e3df8d6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_334b25d6-3815-4480-a2ec-9d37885f707d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d60e5972-c7b7-4de9-b406-92077e3df8d6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_334b25d6-3815-4480-a2ec-9d37885f707d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_334b25d6-3815-4480-a2ec-9d37885f707d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_334b25d6-3815-4480-a2ec-9d37885f707d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_334b25d6-3815-4480-a2ec-9d37885f707d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dd5732c3-76a6-4920-9978-1f7b90434c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_334b25d6-3815-4480-a2ec-9d37885f707d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dd5732c3-76a6-4920-9978-1f7b90434c9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember_8a2a77ac-a83a-4d6e-a7d8-20f994029c5b" xlink:href="halo-20220630.xsd#halo_AntaresPharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dd5732c3-76a6-4920-9978-1f7b90434c9d" xlink:to="loc_halo_AntaresPharmaIncMember_8a2a77ac-a83a-4d6e-a7d8-20f994029c5b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails" xlink:type="extended" id="id7fa3bda2d854805857a926f07f77e3e_FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_55fee5df-b645-4c28-9d90-cd7cc9a3f20d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d731cd1a-9452-46cb-9b9c-141374e5c709" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_55fee5df-b645-4c28-9d90-cd7cc9a3f20d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d731cd1a-9452-46cb-9b9c-141374e5c709" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7b1fb50a-3b28-4014-99c7-40d3388d9bac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_55fee5df-b645-4c28-9d90-cd7cc9a3f20d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7b1fb50a-3b28-4014-99c7-40d3388d9bac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4aff93f5-637a-4cc7-8793-935f031b9c68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_55fee5df-b645-4c28-9d90-cd7cc9a3f20d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4aff93f5-637a-4cc7-8793-935f031b9c68" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e9f55fd3-7c33-4ee0-b721-702ac56bebd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_55fee5df-b645-4c28-9d90-cd7cc9a3f20d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e9f55fd3-7c33-4ee0-b721-702ac56bebd8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_e61347d7-d1ce-450f-8adc-0e8c5ec42b62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_55fee5df-b645-4c28-9d90-cd7cc9a3f20d" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_e61347d7-d1ce-450f-8adc-0e8c5ec42b62" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_eaa33995-3b88-479a-b2fb-e0378c85012c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_e61347d7-d1ce-450f-8adc-0e8c5ec42b62" xlink:to="loc_us-gaap_FinancialInstrumentAxis_eaa33995-3b88-479a-b2fb-e0378c85012c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eaa33995-3b88-479a-b2fb-e0378c85012c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_eaa33995-3b88-479a-b2fb-e0378c85012c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eaa33995-3b88-479a-b2fb-e0378c85012c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_69859cef-9fb7-4c28-8c3d-4143c1f20ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_eaa33995-3b88-479a-b2fb-e0378c85012c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_69859cef-9fb7-4c28-8c3d-4143c1f20ea4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_c6f12d7e-6730-4206-aaec-7284a8bd1a70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_69859cef-9fb7-4c28-8c3d-4143c1f20ea4" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_c6f12d7e-6730-4206-aaec-7284a8bd1a70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_a6286173-60fc-401d-ad17-f05cd7fe8461" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_69859cef-9fb7-4c28-8c3d-4143c1f20ea4" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_a6286173-60fc-401d-ad17-f05cd7fe8461" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_07052081-0dad-411b-b951-7196c4c6ca5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_69859cef-9fb7-4c28-8c3d-4143c1f20ea4" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_07052081-0dad-411b-b951-7196c4c6ca5d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_a2d41aa6-a372-458b-920e-bd39510a1d48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_69859cef-9fb7-4c28-8c3d-4143c1f20ea4" xlink:to="loc_us-gaap_NonUsMember_a2d41aa6-a372-458b-920e-bd39510a1d48" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_35497901-e3c7-4884-b38c-d30747f1176c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_69859cef-9fb7-4c28-8c3d-4143c1f20ea4" xlink:to="loc_us-gaap_CommercialPaperMember_35497901-e3c7-4884-b38c-d30747f1176c" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#FairValueMeasurementNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails" xlink:type="extended" id="i3106425cb74741faaaedfb20f7ea65bc_FairValueMeasurementNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_503a786f-6e96-45e5-86d0-ddf9617cb108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_b534f086-1277-4c81-af51-dfe7d9e71819" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_503a786f-6e96-45e5-86d0-ddf9617cb108" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_b534f086-1277-4c81-af51-dfe7d9e71819" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_642c7305-1b01-4a2d-9500-706aa196b3fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_503a786f-6e96-45e5-86d0-ddf9617cb108" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_642c7305-1b01-4a2d-9500-706aa196b3fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5d1a5bdc-4ad1-4b0d-abe5-24e1fb70e24b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_503a786f-6e96-45e5-86d0-ddf9617cb108" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5d1a5bdc-4ad1-4b0d-abe5-24e1fb70e24b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_99ad98c3-d42e-4d75-a01b-520ae6d9d799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_503a786f-6e96-45e5-86d0-ddf9617cb108" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_99ad98c3-d42e-4d75-a01b-520ae6d9d799" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8a56fe21-37bd-4015-b163-b10694578069" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_503a786f-6e96-45e5-86d0-ddf9617cb108" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8a56fe21-37bd-4015-b163-b10694578069" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_572a57c3-544a-4c9e-b94a-989bf159d082" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_503a786f-6e96-45e5-86d0-ddf9617cb108" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_572a57c3-544a-4c9e-b94a-989bf159d082" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_c51e44f3-03c3-4b72-ac4f-164339eb8208" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_503a786f-6e96-45e5-86d0-ddf9617cb108" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_c51e44f3-03c3-4b72-ac4f-164339eb8208" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e0c27876-1a77-4040-9c14-335662869ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_c51e44f3-03c3-4b72-ac4f-164339eb8208" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e0c27876-1a77-4040-9c14-335662869ef5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0c27876-1a77-4040-9c14-335662869ef5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e0c27876-1a77-4040-9c14-335662869ef5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0c27876-1a77-4040-9c14-335662869ef5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b79f01df-09ba-4f58-ab03-e3607e47f642" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e0c27876-1a77-4040-9c14-335662869ef5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b79f01df-09ba-4f58-ab03-e3607e47f642" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_349288c6-64ea-4944-8db1-bb3fc42d38d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b79f01df-09ba-4f58-ab03-e3607e47f642" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_349288c6-64ea-4944-8db1-bb3fc42d38d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_39d459e8-43f1-499b-b72e-0f7d09480a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_c51e44f3-03c3-4b72-ac4f-164339eb8208" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_39d459e8-43f1-499b-b72e-0f7d09480a5d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_39d459e8-43f1-499b-b72e-0f7d09480a5d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_39d459e8-43f1-499b-b72e-0f7d09480a5d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_39d459e8-43f1-499b-b72e-0f7d09480a5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3e9b9f7a-52d0-471e-8c0f-9d41324b3f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_39d459e8-43f1-499b-b72e-0f7d09480a5d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3e9b9f7a-52d0-471e-8c0f-9d41324b3f5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember_9fd7d358-47b3-4d92-82c6-8d4b027a6c92" xlink:href="halo-20220630.xsd#halo_AntaresPharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3e9b9f7a-52d0-471e-8c0f-9d41324b3f5f" xlink:to="loc_halo_AntaresPharmaIncMember_9fd7d358-47b3-4d92-82c6-8d4b027a6c92" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended" id="i6190cf80ced34c3192ae65c4b2a6324e_FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ce31343a-d3c7-4558-9ece-817a9b579a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7563f4a3-4528-4b25-9fdd-69e13c62b11e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ce31343a-d3c7-4558-9ece-817a9b579a9c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7563f4a3-4528-4b25-9fdd-69e13c62b11e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_421d552d-dd38-4b67-a748-0cdb3b1623b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ce31343a-d3c7-4558-9ece-817a9b579a9c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_421d552d-dd38-4b67-a748-0cdb3b1623b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_2559d2d6-1f1c-4480-9f78-960fb925ba39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ce31343a-d3c7-4558-9ece-817a9b579a9c" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_2559d2d6-1f1c-4480-9f78-960fb925ba39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_debfef8a-576a-43dd-8966-7f91de9a3316" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ce31343a-d3c7-4558-9ece-817a9b579a9c" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_debfef8a-576a-43dd-8966-7f91de9a3316" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a1da7886-219e-48f0-884a-063cc29612f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_debfef8a-576a-43dd-8966-7f91de9a3316" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a1da7886-219e-48f0-884a-063cc29612f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a1da7886-219e-48f0-884a-063cc29612f0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a1da7886-219e-48f0-884a-063cc29612f0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a1da7886-219e-48f0-884a-063cc29612f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_71297f9f-6dfd-4913-9f66-e4aa8e31d887" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a1da7886-219e-48f0-884a-063cc29612f0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_71297f9f-6dfd-4913-9f66-e4aa8e31d887" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_9e58810d-acdb-4013-be75-4f15fed239dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_71297f9f-6dfd-4913-9f66-e4aa8e31d887" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_9e58810d-acdb-4013-be75-4f15fed239dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e8c1c3c5-a1d5-4eaf-b49f-746710f4c150" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_71297f9f-6dfd-4913-9f66-e4aa8e31d887" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e8c1c3c5-a1d5-4eaf-b49f-746710f4c150" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4b4b8bd5-7d15-457d-9c9c-b06182758f33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_71297f9f-6dfd-4913-9f66-e4aa8e31d887" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_4b4b8bd5-7d15-457d-9c9c-b06182758f33" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_40d88978-916f-492d-8873-482d71a494da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_debfef8a-576a-43dd-8966-7f91de9a3316" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_40d88978-916f-492d-8873-482d71a494da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_40d88978-916f-492d-8873-482d71a494da_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_40d88978-916f-492d-8873-482d71a494da" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_40d88978-916f-492d-8873-482d71a494da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_7c49f59b-c87f-48be-bb60-811f694836cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_40d88978-916f-492d-8873-482d71a494da" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_7c49f59b-c87f-48be-bb60-811f694836cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_010adf41-37df-4a6f-9436-860c05640f81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_7c49f59b-c87f-48be-bb60-811f694836cc" xlink:to="loc_us-gaap_MoneyMarketFundsMember_010adf41-37df-4a6f-9436-860c05640f81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_c6821d19-9463-418f-94e2-01208a6ecc45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_7c49f59b-c87f-48be-bb60-811f694836cc" xlink:to="loc_us-gaap_CommercialPaperMember_c6821d19-9463-418f-94e2-01208a6ecc45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b2dfa752-f325-4d2b-9658-510258e63555" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_debfef8a-576a-43dd-8966-7f91de9a3316" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b2dfa752-f325-4d2b-9658-510258e63555" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b2dfa752-f325-4d2b-9658-510258e63555_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b2dfa752-f325-4d2b-9658-510258e63555" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b2dfa752-f325-4d2b-9658-510258e63555_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e91a14ea-6f70-4867-845b-e8c90c3a86e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b2dfa752-f325-4d2b-9658-510258e63555" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e91a14ea-6f70-4867-845b-e8c90c3a86e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_e25cb2e3-c503-4a83-ae0b-dea2c240d545" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e91a14ea-6f70-4867-845b-e8c90c3a86e2" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_e25cb2e3-c503-4a83-ae0b-dea2c240d545" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_d3ab6d7e-e1fb-481b-a5b6-8ab53c67e17e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e91a14ea-6f70-4867-845b-e8c90c3a86e2" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_d3ab6d7e-e1fb-481b-a5b6-8ab53c67e17e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_1fcd5863-a75b-497c-ae6f-7fc0fcf98c35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e91a14ea-6f70-4867-845b-e8c90c3a86e2" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_1fcd5863-a75b-497c-ae6f-7fc0fcf98c35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_eef1580a-d4d2-4287-9d36-6b4d7c52653e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e91a14ea-6f70-4867-845b-e8c90c3a86e2" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_eef1580a-d4d2-4287-9d36-6b4d7c52653e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_a0fbcb23-7c97-46fb-9f63-c99126775262" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e91a14ea-6f70-4867-845b-e8c90c3a86e2" xlink:to="loc_us-gaap_CommercialPaperMember_a0fbcb23-7c97-46fb-9f63-c99126775262" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#RevenueDisaggregatedRevenuesDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails" xlink:type="extended" id="i743fac03fe8d41caa42217a0581659b7_RevenueDisaggregatedRevenuesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_0d569be8-656e-40d9-950c-f28dfebc6a77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8c9d9f02-1a2b-45db-97c1-ab08e2a1b1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0d569be8-656e-40d9-950c-f28dfebc6a77" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8c9d9f02-1a2b-45db-97c1-ab08e2a1b1fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_5bb5d1ab-f04d-4f12-ad46-cc1eab9575ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0d569be8-656e-40d9-950c-f28dfebc6a77" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_5bb5d1ab-f04d-4f12-ad46-cc1eab9575ce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4a326d8d-e973-4872-9a7b-317085171398" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5bb5d1ab-f04d-4f12-ad46-cc1eab9575ce" xlink:to="loc_srt_ProductOrServiceAxis_4a326d8d-e973-4872-9a7b-317085171398" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4a326d8d-e973-4872-9a7b-317085171398_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4a326d8d-e973-4872-9a7b-317085171398" xlink:to="loc_srt_ProductsAndServicesDomain_4a326d8d-e973-4872-9a7b-317085171398_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6fbf36f0-45c1-4e28-96c8-825dcfc20087" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4a326d8d-e973-4872-9a7b-317085171398" xlink:to="loc_srt_ProductsAndServicesDomain_6fbf36f0-45c1-4e28-96c8-825dcfc20087" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_4cb809bf-bdeb-4771-b503-4f3b10eecccb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6fbf36f0-45c1-4e28-96c8-825dcfc20087" xlink:to="loc_us-gaap_RoyaltyMember_4cb809bf-bdeb-4771-b503-4f3b10eecccb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_786342cc-c3ea-4b75-be1a-0a53193be971" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6fbf36f0-45c1-4e28-96c8-825dcfc20087" xlink:to="loc_us-gaap_ProductMember_786342cc-c3ea-4b75-be1a-0a53193be971" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BulkrHuPH20Member_b9e07c2a-b20b-40f3-8918-3eb06af57fb3" xlink:href="halo-20220630.xsd#halo_BulkrHuPH20Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_786342cc-c3ea-4b75-be1a-0a53193be971" xlink:to="loc_halo_BulkrHuPH20Member_b9e07c2a-b20b-40f3-8918-3eb06af57fb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ProprietaryProductsSalesMember_0b04a7fe-2a39-48b6-9c2d-ea8041de24e2" xlink:href="halo-20220630.xsd#halo_ProprietaryProductsSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_786342cc-c3ea-4b75-be1a-0a53193be971" xlink:to="loc_halo_ProprietaryProductsSalesMember_0b04a7fe-2a39-48b6-9c2d-ea8041de24e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DevicePartneredProductsMember_4f5f54d0-ac27-4e38-a0cd-f83880629c3f" xlink:href="halo-20220630.xsd#halo_DevicePartneredProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_786342cc-c3ea-4b75-be1a-0a53193be971" xlink:to="loc_halo_DevicePartneredProductsMember_4f5f54d0-ac27-4e38-a0cd-f83880629c3f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_CollaborativeAgreementsMember_2896a367-ec46-4c68-bcfc-cd7c0242d081" xlink:href="halo-20220630.xsd#halo_CollaborativeAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6fbf36f0-45c1-4e28-96c8-825dcfc20087" xlink:to="loc_halo_CollaborativeAgreementsMember_2896a367-ec46-4c68-bcfc-cd7c0242d081" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_UpfrontfeesMember_9ce79ccc-79c3-49a8-bc5a-1367d7af8413" xlink:href="halo-20220630.xsd#halo_UpfrontfeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_CollaborativeAgreementsMember_2896a367-ec46-4c68-bcfc-cd7c0242d081" xlink:to="loc_halo_UpfrontfeesMember_9ce79ccc-79c3-49a8-bc5a-1367d7af8413" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DevelopmentFeesMember_0b6d71b9-b72c-45b7-b86e-7d0ff2b0f25f" xlink:href="halo-20220630.xsd#halo_DevelopmentFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_CollaborativeAgreementsMember_2896a367-ec46-4c68-bcfc-cd7c0242d081" xlink:to="loc_halo_DevelopmentFeesMember_0b6d71b9-b72c-45b7-b86e-7d0ff2b0f25f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_SalesbasedmilestoneMember_084f3b76-f75b-4491-b513-7eb1fa0b890a" xlink:href="halo-20220630.xsd#halo_SalesbasedmilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_CollaborativeAgreementsMember_2896a367-ec46-4c68-bcfc-cd7c0242d081" xlink:to="loc_halo_SalesbasedmilestoneMember_084f3b76-f75b-4491-b513-7eb1fa0b890a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DeviceLicensingAndDevelopmentMember_8b47b33b-e60b-4d7d-8931-3c5117088691" xlink:href="halo-20220630.xsd#halo_DeviceLicensingAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_CollaborativeAgreementsMember_2896a367-ec46-4c68-bcfc-cd7c0242d081" xlink:to="loc_halo_DeviceLicensingAndDevelopmentMember_8b47b33b-e60b-4d7d-8931-3c5117088691" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/RevenueNarrativeDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#RevenueNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/RevenueNarrativeDetails" xlink:type="extended" id="i1acd0468361a491db7eb54076bdf7f46_RevenueNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_98bced52-c732-4e09-9e20-921147af75a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1b466864-7ced-4236-ac09-e43f4b75fa62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_98bced52-c732-4e09-9e20-921147af75a3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1b466864-7ced-4236-ac09-e43f4b75fa62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7ec4def6-565f-4798-a06e-80d8c375148e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_98bced52-c732-4e09-9e20-921147af75a3" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7ec4def6-565f-4798-a06e-80d8c375148e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue_2ec3293a-d968-4072-9092-73137fab0004" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_98bced52-c732-4e09-9e20-921147af75a3" xlink:to="loc_us-gaap_DeferredRevenue_2ec3293a-d968-4072-9092-73137fab0004" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_0d1e7905-d2a3-47e9-8332-d590ddefefb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_98bced52-c732-4e09-9e20-921147af75a3" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_0d1e7905-d2a3-47e9-8332-d590ddefefb8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilities_6cb98236-1439-4206-8dbf-1cdfb4947132" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_98bced52-c732-4e09-9e20-921147af75a3" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilities_6cb98236-1439-4206-8dbf-1cdfb4947132" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_b5e8dacc-7ea4-4e08-844b-fc1bc5bcb36a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_98bced52-c732-4e09-9e20-921147af75a3" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_b5e8dacc-7ea4-4e08-844b-fc1bc5bcb36a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_2b863d6c-7566-4807-85a9-ea64324fc62f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_98bced52-c732-4e09-9e20-921147af75a3" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_2b863d6c-7566-4807-85a9-ea64324fc62f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6e92a428-9b5f-4504-b924-7e427944dc50" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2b863d6c-7566-4807-85a9-ea64324fc62f" xlink:to="loc_srt_ProductOrServiceAxis_6e92a428-9b5f-4504-b924-7e427944dc50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6e92a428-9b5f-4504-b924-7e427944dc50_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_6e92a428-9b5f-4504-b924-7e427944dc50" xlink:to="loc_srt_ProductsAndServicesDomain_6e92a428-9b5f-4504-b924-7e427944dc50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ed51c424-95ac-4fc3-9d2c-47dff0422259" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_6e92a428-9b5f-4504-b924-7e427944dc50" xlink:to="loc_srt_ProductsAndServicesDomain_ed51c424-95ac-4fc3-9d2c-47dff0422259" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_LicenseFeesAndEventBasedMember_ddc023ef-555e-4092-bc46-46bec498ed41" xlink:href="halo-20220630.xsd#halo_LicenseFeesAndEventBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ed51c424-95ac-4fc3-9d2c-47dff0422259" xlink:to="loc_halo_LicenseFeesAndEventBasedMember_ddc023ef-555e-4092-bc46-46bec498ed41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_59cc074e-9be4-4977-ac59-2d95a1382572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ed51c424-95ac-4fc3-9d2c-47dff0422259" xlink:to="loc_us-gaap_ProductMember_59cc074e-9be4-4977-ac59-2d95a1382572" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a6bdf9a3-245f-47a8-8dca-9b05f695280d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2b863d6c-7566-4807-85a9-ea64324fc62f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a6bdf9a3-245f-47a8-8dca-9b05f695280d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a6bdf9a3-245f-47a8-8dca-9b05f695280d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a6bdf9a3-245f-47a8-8dca-9b05f695280d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a6bdf9a3-245f-47a8-8dca-9b05f695280d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d144efeb-5481-417c-bf21-eff16df2b0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a6bdf9a3-245f-47a8-8dca-9b05f695280d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d144efeb-5481-417c-bf21-eff16df2b0ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_OthercollaboratorsMember_e826852c-24a9-48cd-8300-a544248f33d7" xlink:href="halo-20220630.xsd#halo_OthercollaboratorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d144efeb-5481-417c-bf21-eff16df2b0ce" xlink:to="loc_halo_OthercollaboratorsMember_e826852c-24a9-48cd-8300-a544248f33d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_07fce759-6886-49fd-9864-9c32ee809028" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2b863d6c-7566-4807-85a9-ea64324fc62f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_07fce759-6886-49fd-9864-9c32ee809028" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_07fce759-6886-49fd-9864-9c32ee809028_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_07fce759-6886-49fd-9864-9c32ee809028" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_07fce759-6886-49fd-9864-9c32ee809028_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_70518384-c728-4414-8af3-ae27a29250c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_07fce759-6886-49fd-9864-9c32ee809028" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_70518384-c728-4414-8af3-ae27a29250c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember_8f85d8d3-c133-465d-bbe6-ae4bfec4fc3f" xlink:href="halo-20220630.xsd#halo_AntaresPharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_70518384-c728-4414-8af3-ae27a29250c7" xlink:to="loc_halo_AntaresPharmaIncMember_8f85d8d3-c133-465d-bbe6-ae4bfec4fc3f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/RevenueAdditionalRevenueInformationDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#RevenueAdditionalRevenueInformationDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/RevenueAdditionalRevenueInformationDetails" xlink:type="extended" id="iaee1e12e699644b98b75ef5445412b01_RevenueAdditionalRevenueInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_3c905694-290f-46dd-b5cf-a3ec1c079848" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_d0a29818-980f-41fc-a97d-b47da6e6f7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_3c905694-290f-46dd-b5cf-a3ec1c079848" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_d0a29818-980f-41fc-a97d-b47da6e6f7c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_ff1c9386-1ad6-4c61-aa28-1400b1e70e75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_3c905694-290f-46dd-b5cf-a3ec1c079848" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_ff1c9386-1ad6-4c61-aa28-1400b1e70e75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2ac093e7-e68e-429c-b409-706b1ffb71cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_3c905694-290f-46dd-b5cf-a3ec1c079848" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2ac093e7-e68e-429c-b409-706b1ffb71cf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_54b2e682-8033-4b26-ab3e-72c99f75cfb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2ac093e7-e68e-429c-b409-706b1ffb71cf" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_54b2e682-8033-4b26-ab3e-72c99f75cfb1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/RevenueAdditionalRevenueInformationDetails_1" xlink:type="simple" xlink:href="halo-20220630.xsd#RevenueAdditionalRevenueInformationDetails_1"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/RevenueAdditionalRevenueInformationDetails_1" xlink:type="extended" id="i242d27668c664791b99bb5efbb3cab98_RevenueAdditionalRevenueInformationDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_3c905694-290f-46dd-b5cf-a3ec1c079848" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_d0a29818-980f-41fc-a97d-b47da6e6f7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_3c905694-290f-46dd-b5cf-a3ec1c079848" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_d0a29818-980f-41fc-a97d-b47da6e6f7c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_ff1c9386-1ad6-4c61-aa28-1400b1e70e75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_3c905694-290f-46dd-b5cf-a3ec1c079848" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_ff1c9386-1ad6-4c61-aa28-1400b1e70e75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2ac093e7-e68e-429c-b409-706b1ffb71cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_3c905694-290f-46dd-b5cf-a3ec1c079848" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2ac093e7-e68e-429c-b409-706b1ffb71cf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails" xlink:type="extended" id="ieebcc3597df241309c9a1aa226a8bf6f_CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5c614532-d8eb-47a7-b0a9-2abf86ffca80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_8fec9943-546d-4e7c-b4c3-fcb2f1703f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5c614532-d8eb-47a7-b0a9-2abf86ffca80" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_8fec9943-546d-4e7c-b4c3-fcb2f1703f7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_ca5e7dfb-1104-449b-a34d-ea74423b070c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5c614532-d8eb-47a7-b0a9-2abf86ffca80" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_ca5e7dfb-1104-449b-a34d-ea74423b070c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_293cfc6d-fbd5-425c-98eb-aacae3003eb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5c614532-d8eb-47a7-b0a9-2abf86ffca80" xlink:to="loc_us-gaap_OtherAssets_293cfc6d-fbd5-425c-98eb-aacae3003eb6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_b318afc0-be2d-43d2-8402-d3076abfd1ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5c614532-d8eb-47a7-b0a9-2abf86ffca80" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_b318afc0-be2d-43d2-8402-d3076abfd1ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_cfa4f31d-02be-4fae-819e-8ad2e21b5511" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5c614532-d8eb-47a7-b0a9-2abf86ffca80" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_cfa4f31d-02be-4fae-819e-8ad2e21b5511" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_554e85cb-f8f9-40e7-9e54-5b57db168357" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5c614532-d8eb-47a7-b0a9-2abf86ffca80" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_554e85cb-f8f9-40e7-9e54-5b57db168357" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2631b308-dfff-425b-af48-1dc8901db597" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_5c614532-d8eb-47a7-b0a9-2abf86ffca80" xlink:to="loc_us-gaap_StatementTable_2631b308-dfff-425b-af48-1dc8901db597" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_861b6bed-02df-4897-ab12-d07be809a027" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2631b308-dfff-425b-af48-1dc8901db597" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_861b6bed-02df-4897-ab12-d07be809a027" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_861b6bed-02df-4897-ab12-d07be809a027_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_861b6bed-02df-4897-ab12-d07be809a027" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_861b6bed-02df-4897-ab12-d07be809a027_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c920dfc7-55c9-4586-b874-b4e4526a943a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_861b6bed-02df-4897-ab12-d07be809a027" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c920dfc7-55c9-4586-b874-b4e4526a943a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ComputerAndOfficeEquipmentMember_cbc39630-cc7f-43b2-88cb-0e808656e438" xlink:href="halo-20220630.xsd#halo_ComputerAndOfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c920dfc7-55c9-4586-b874-b4e4526a943a" xlink:to="loc_halo_ComputerAndOfficeEquipmentMember_cbc39630-cc7f-43b2-88cb-0e808656e438" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#CertainBalanceSheetItemsPropertyandEquipmentnetDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails" xlink:type="extended" id="i374bc4b7eac7400083372862058f2fd8_CertainBalanceSheetItemsPropertyandEquipmentnetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_02420da8-a284-4e1c-8616-12606cd22a93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_853a43e2-b01f-41e2-be30-27a70943163c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_02420da8-a284-4e1c-8616-12606cd22a93" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_853a43e2-b01f-41e2-be30-27a70943163c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3cb0ce28-520b-4113-a779-fd5d7368dd15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_02420da8-a284-4e1c-8616-12606cd22a93" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3cb0ce28-520b-4113-a779-fd5d7368dd15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e943bfd7-bcc3-48f2-9a95-b3d859b7dafa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_02420da8-a284-4e1c-8616-12606cd22a93" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e943bfd7-bcc3-48f2-9a95-b3d859b7dafa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_181afd77-465f-4773-b830-91d332f1a9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_02420da8-a284-4e1c-8616-12606cd22a93" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_181afd77-465f-4773-b830-91d332f1a9f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_b101e660-8ba7-4247-97ff-ee3136bc0cfb" xlink:href="halo-20220630.xsd#halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_02420da8-a284-4e1c-8616-12606cd22a93" xlink:to="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_b101e660-8ba7-4247-97ff-ee3136bc0cfb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_fd8444ea-7aa3-480d-93e8-d73d88e6612f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_02420da8-a284-4e1c-8616-12606cd22a93" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_fd8444ea-7aa3-480d-93e8-d73d88e6612f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_619eb44b-55dc-4992-b874-2ffb17f72844" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_02420da8-a284-4e1c-8616-12606cd22a93" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_619eb44b-55dc-4992-b874-2ffb17f72844" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_62805228-2f6a-4514-876c-9c44eaf84667" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_02420da8-a284-4e1c-8616-12606cd22a93" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_62805228-2f6a-4514-876c-9c44eaf84667" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_693ddce9-185b-43f2-b175-f00b8fae5312" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_62805228-2f6a-4514-876c-9c44eaf84667" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_693ddce9-185b-43f2-b175-f00b8fae5312" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_693ddce9-185b-43f2-b175-f00b8fae5312_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_693ddce9-185b-43f2-b175-f00b8fae5312" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_693ddce9-185b-43f2-b175-f00b8fae5312_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5867c862-bac4-402f-b806-148d887feb01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_693ddce9-185b-43f2-b175-f00b8fae5312" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5867c862-bac4-402f-b806-148d887feb01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ResearchEquipmentMember_b48f6282-da2b-4f5b-b111-c68ec72f6e4f" xlink:href="halo-20220630.xsd#halo_ResearchEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5867c862-bac4-402f-b806-148d887feb01" xlink:to="loc_halo_ResearchEquipmentMember_b48f6282-da2b-4f5b-b111-c68ec72f6e4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ManufacturingEquipmentMember_e8f02c03-2137-4392-9cd4-118bce0e4a19" xlink:href="halo-20220630.xsd#halo_ManufacturingEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5867c862-bac4-402f-b806-148d887feb01" xlink:to="loc_halo_ManufacturingEquipmentMember_e8f02c03-2137-4392-9cd4-118bce0e4a19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ComputerAndOfficeEquipmentMember_ed5f0f57-8824-4c87-ae54-f8ba1a21a2c3" xlink:href="halo-20220630.xsd#halo_ComputerAndOfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5867c862-bac4-402f-b806-148d887feb01" xlink:to="loc_halo_ComputerAndOfficeEquipmentMember_ed5f0f57-8824-4c87-ae54-f8ba1a21a2c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_e5eed901-91f7-49cc-bc01-74e899a614c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5867c862-bac4-402f-b806-148d887feb01" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_e5eed901-91f7-49cc-bc01-74e899a614c7" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#GoodwillandIntangibleAssetsIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="extended" id="id956b6abddfd45ec9268db77dc6309df_GoodwillandIntangibleAssetsIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_84b78e71-8ce0-4649-a0d7-7b42371880a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_d45894dd-3f3e-42f0-9a3f-2bc36174efbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_84b78e71-8ce0-4649-a0d7-7b42371880a5" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_d45894dd-3f3e-42f0-9a3f-2bc36174efbc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b7a4f4c6-7717-4d9f-8da0-7d35bde5e9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_84b78e71-8ce0-4649-a0d7-7b42371880a5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b7a4f4c6-7717-4d9f-8da0-7d35bde5e9d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e2df0495-914e-4ae7-89e6-5382724ecad7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_84b78e71-8ce0-4649-a0d7-7b42371880a5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e2df0495-914e-4ae7-89e6-5382724ecad7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9b7b4b50-8b2a-4bb9-a55c-41f54e5b2897" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_84b78e71-8ce0-4649-a0d7-7b42371880a5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9b7b4b50-8b2a-4bb9-a55c-41f54e5b2897" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_d909b086-43aa-4152-91df-e8900aa7f215" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_84b78e71-8ce0-4649-a0d7-7b42371880a5" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_d909b086-43aa-4152-91df-e8900aa7f215" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3df157f0-0b07-4d64-81ce-afb037c6cea8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_84b78e71-8ce0-4649-a0d7-7b42371880a5" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3df157f0-0b07-4d64-81ce-afb037c6cea8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_68b09fc9-b028-447b-83c8-cbb4a1dfe801" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_84b78e71-8ce0-4649-a0d7-7b42371880a5" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_68b09fc9-b028-447b-83c8-cbb4a1dfe801" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_95884da8-b66e-4be5-bfc9-4da8e49eb596" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_68b09fc9-b028-447b-83c8-cbb4a1dfe801" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_95884da8-b66e-4be5-bfc9-4da8e49eb596" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_95884da8-b66e-4be5-bfc9-4da8e49eb596_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_95884da8-b66e-4be5-bfc9-4da8e49eb596" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_95884da8-b66e-4be5-bfc9-4da8e49eb596_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_16969e78-e329-4d10-8617-10c6fd5dbf76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_95884da8-b66e-4be5-bfc9-4da8e49eb596" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_16969e78-e329-4d10-8617-10c6fd5dbf76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AutoInjectorTechnologyPlatformMember_4aa06dd2-8857-4eff-a71b-0fe5da09f152" xlink:href="halo-20220630.xsd#halo_AutoInjectorTechnologyPlatformMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_16969e78-e329-4d10-8617-10c6fd5dbf76" xlink:to="loc_halo_AutoInjectorTechnologyPlatformMember_4aa06dd2-8857-4eff-a71b-0fe5da09f152" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_XYOSTEDProprietaryProductMember_ab9f96c7-c79d-4385-9508-ac8bb83eac36" xlink:href="halo-20220630.xsd#halo_XYOSTEDProprietaryProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_16969e78-e329-4d10-8617-10c6fd5dbf76" xlink:to="loc_halo_XYOSTEDProprietaryProductMember_ab9f96c7-c79d-4385-9508-ac8bb83eac36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_TLANDOProductRightsMember_b819e917-c55d-4e4d-86fc-508f2b9525a9" xlink:href="halo-20220630.xsd#halo_TLANDOProductRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_16969e78-e329-4d10-8617-10c6fd5dbf76" xlink:to="loc_halo_TLANDOProductRightsMember_b819e917-c55d-4e4d-86fc-508f2b9525a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3c9ca0d2-64a4-4079-8be3-821d3abe930d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_68b09fc9-b028-447b-83c8-cbb4a1dfe801" xlink:to="loc_srt_RangeAxis_3c9ca0d2-64a4-4079-8be3-821d3abe930d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3c9ca0d2-64a4-4079-8be3-821d3abe930d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3c9ca0d2-64a4-4079-8be3-821d3abe930d" xlink:to="loc_srt_RangeMember_3c9ca0d2-64a4-4079-8be3-821d3abe930d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_11e0c155-92fd-40a0-8905-b690f5bcca79" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3c9ca0d2-64a4-4079-8be3-821d3abe930d" xlink:to="loc_srt_RangeMember_11e0c155-92fd-40a0-8905-b690f5bcca79" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#LongTermDebtNetNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails" xlink:type="extended" id="ib5d3ac8e76dd416ab3bad4c944fe1b85_LongTermDebtNetNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_300ae9bf-7998-4419-848c-1fc14dc614a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_300ae9bf-7998-4419-848c-1fc14dc614a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_20372975-ee32-45f0-b1fe-1e96793944f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_20372975-ee32-45f0-b1fe-1e96793944f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_7d3f69f2-9cf2-410c-9bb3-8e1dc7f803d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_7d3f69f2-9cf2-410c-9bb3-8e1dc7f803d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_6729b0bd-e14f-414a-8a5a-a7f4184e0530" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_6729b0bd-e14f-414a-8a5a-a7f4184e0530" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_6e2be920-9743-4728-a7db-1bd76c6edf71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_6e2be920-9743-4728-a7db-1bd76c6edf71" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_f4205193-9a9c-4d74-87aa-0e0087bdab99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_f4205193-9a9c-4d74-87aa-0e0087bdab99" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_ac9de440-f4f7-4520-9637-e355a5760fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_ac9de440-f4f7-4520-9637-e355a5760fb9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_0ca6b9f5-478b-4533-90fe-534432090062" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_0ca6b9f5-478b-4533-90fe-534432090062" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_9722c911-facb-4104-a947-5a319c34311b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_9722c911-facb-4104-a947-5a319c34311b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_6b70247d-1b6d-4b54-b744-5b0642dff44e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_6b70247d-1b6d-4b54-b744-5b0642dff44e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_eebb94af-3933-4460-855d-f69ac35c9c07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_eebb94af-3933-4460-855d-f69ac35c9c07" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_f7c14dc6-bc75-4a70-b57b-601c832c4d18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_f7c14dc6-bc75-4a70-b57b-601c832c4d18" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_f5bc4e0d-dae5-43ff-b8a0-a2b0c9dd9518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_f5bc4e0d-dae5-43ff-b8a0-a2b0c9dd9518" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_da58ee4d-8548-4f70-b937-215daf44e270" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_da58ee4d-8548-4f70-b937-215daf44e270" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCovenantCompliance_0f93bcaf-c1d8-4df4-92c2-e384b42ad6b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCovenantCompliance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_DebtInstrumentCovenantCompliance_0f93bcaf-c1d8-4df4-92c2-e384b42ad6b8" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_61db881c-53fd-4ef1-bc48-0d74f8dcb698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_61db881c-53fd-4ef1-bc48-0d74f8dcb698" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_1fdeb199-23de-48d3-8d91-b972d0b0f625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_1fdeb199-23de-48d3-8d91-b972d0b0f625" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a8888e51-a501-4185-a337-34fe59ee9ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a8888e51-a501-4185-a337-34fe59ee9ee2" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_c04e83ba-c6b7-491d-a721-f1866b83b234" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_c04e83ba-c6b7-491d-a721-f1866b83b234" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_d7acdb72-0bbd-4ec3-b4b7-ca464fb8af47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_d7acdb72-0bbd-4ec3-b4b7-ca464fb8af47" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentThirdPartyCosts_12ee2c6d-80f5-43be-956d-648bd2e5ec47" xlink:href="halo-20220630.xsd#halo_DebtInstrumentThirdPartyCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_halo_DebtInstrumentThirdPartyCosts_12ee2c6d-80f5-43be-956d-648bd2e5ec47" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_afc1928a-6dd9-416b-a970-aaaa1f7e77ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_afc1928a-6dd9-416b-a970-aaaa1f7e77ba" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_e5d73063-7d79-4fec-93fb-5e3c42e44f99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_e5d73063-7d79-4fec-93fb-5e3c42e44f99" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_bc67cd5c-a104-4a11-a60d-39e039ea3c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_DebtInstrumentTable_bc67cd5c-a104-4a11-a60d-39e039ea3c3c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_a270ec0a-4dd9-4f68-a413-a0915ff2157d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_bc67cd5c-a104-4a11-a60d-39e039ea3c3c" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_a270ec0a-4dd9-4f68-a413-a0915ff2157d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_a270ec0a-4dd9-4f68-a413-a0915ff2157d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_a270ec0a-4dd9-4f68-a413-a0915ff2157d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_a270ec0a-4dd9-4f68-a413-a0915ff2157d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_7e9bccde-26c0-4e9f-b4d0-efb5aa328c57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_a270ec0a-4dd9-4f68-a413-a0915ff2157d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_7e9bccde-26c0-4e9f-b4d0-efb5aa328c57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_62086766-5937-4489-95b3-d3a81f4b462d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_7e9bccde-26c0-4e9f-b4d0-efb5aa328c57" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_62086766-5937-4489-95b3-d3a81f4b462d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_2d553f9c-7495-4f71-96cb-af13da5d06f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_7e9bccde-26c0-4e9f-b4d0-efb5aa328c57" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_2d553f9c-7495-4f71-96cb-af13da5d06f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_daabc065-a206-419a-9a0e-4c63005fe9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_bc67cd5c-a104-4a11-a60d-39e039ea3c3c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_daabc065-a206-419a-9a0e-4c63005fe9bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_daabc065-a206-419a-9a0e-4c63005fe9bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_daabc065-a206-419a-9a0e-4c63005fe9bb" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_daabc065-a206-419a-9a0e-4c63005fe9bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_57f18d12-1842-4f2d-b5ba-11ebe162e7e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_daabc065-a206-419a-9a0e-4c63005fe9bb" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_57f18d12-1842-4f2d-b5ba-11ebe162e7e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_7ad1e654-96ea-4af4-8ed3-d64a8c990ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_57f18d12-1842-4f2d-b5ba-11ebe162e7e9" xlink:to="loc_us-gaap_ConvertibleDebtMember_7ad1e654-96ea-4af4-8ed3-d64a8c990ab5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A025ConvertibleSeniorNotesDue2027Member_7fc64248-1fd8-4d16-9842-c136c06b7a9c" xlink:href="halo-20220630.xsd#halo_A025ConvertibleSeniorNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_57f18d12-1842-4f2d-b5ba-11ebe162e7e9" xlink:to="loc_halo_A025ConvertibleSeniorNotesDue2027Member_7fc64248-1fd8-4d16-9842-c136c06b7a9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_TermLoanFacilityMember_07880bda-e5b5-4956-80b8-899f2642d847" xlink:href="halo-20220630.xsd#halo_TermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_57f18d12-1842-4f2d-b5ba-11ebe162e7e9" xlink:to="loc_halo_TermLoanFacilityMember_07880bda-e5b5-4956-80b8-899f2642d847" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c515e500-278e-48c8-af68-59c8737555d1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_bc67cd5c-a104-4a11-a60d-39e039ea3c3c" xlink:to="loc_srt_RangeAxis_c515e500-278e-48c8-af68-59c8737555d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c515e500-278e-48c8-af68-59c8737555d1_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c515e500-278e-48c8-af68-59c8737555d1" xlink:to="loc_srt_RangeMember_c515e500-278e-48c8-af68-59c8737555d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_73058b6f-f8e2-4a6f-83e0-ded1f5cdbbf0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c515e500-278e-48c8-af68-59c8737555d1" xlink:to="loc_srt_RangeMember_73058b6f-f8e2-4a6f-83e0-ded1f5cdbbf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_462c27d9-44ce-4b55-9ebe-38ddfb71891d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_73058b6f-f8e2-4a6f-83e0-ded1f5cdbbf0" xlink:to="loc_srt_MinimumMember_462c27d9-44ce-4b55-9ebe-38ddfb71891d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_241e6f6d-dbe0-42d8-b807-c2e362abdc30" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_73058b6f-f8e2-4a6f-83e0-ded1f5cdbbf0" xlink:to="loc_srt_MaximumMember_241e6f6d-dbe0-42d8-b807-c2e362abdc30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_440d123c-f292-4854-a3e5-ff641e123cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_bc67cd5c-a104-4a11-a60d-39e039ea3c3c" xlink:to="loc_us-gaap_VariableRateAxis_440d123c-f292-4854-a3e5-ff641e123cc9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_440d123c-f292-4854-a3e5-ff641e123cc9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_440d123c-f292-4854-a3e5-ff641e123cc9" xlink:to="loc_us-gaap_VariableRateDomain_440d123c-f292-4854-a3e5-ff641e123cc9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_4b0a7f86-2b3d-4b6b-8a31-79dfdfa8d505" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_440d123c-f292-4854-a3e5-ff641e123cc9" xlink:to="loc_us-gaap_VariableRateDomain_4b0a7f86-2b3d-4b6b-8a31-79dfdfa8d505" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_ce1b6462-3f30-4318-9c64-6b4b4ac45cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_4b0a7f86-2b3d-4b6b-8a31-79dfdfa8d505" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_ce1b6462-3f30-4318-9c64-6b4b4ac45cd4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_9482e0d7-f330-43eb-ab6b-3d57ed9473c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_4b0a7f86-2b3d-4b6b-8a31-79dfdfa8d505" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_9482e0d7-f330-43eb-ab6b-3d57ed9473c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_d5ff0334-a8ac-4e48-8e64-2d12a3eabcce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_4b0a7f86-2b3d-4b6b-8a31-79dfdfa8d505" xlink:to="loc_us-gaap_BaseRateMember_d5ff0334-a8ac-4e48-8e64-2d12a3eabcce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5b418a8a-7245-49e4-a2b7-567ea54a05eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_bc67cd5c-a104-4a11-a60d-39e039ea3c3c" xlink:to="loc_us-gaap_DebtInstrumentAxis_5b418a8a-7245-49e4-a2b7-567ea54a05eb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5b418a8a-7245-49e4-a2b7-567ea54a05eb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_5b418a8a-7245-49e4-a2b7-567ea54a05eb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5b418a8a-7245-49e4-a2b7-567ea54a05eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_680b9b51-8dc9-4052-b1fa-8d4d5221a9c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_5b418a8a-7245-49e4-a2b7-567ea54a05eb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_680b9b51-8dc9-4052-b1fa-8d4d5221a9c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member_645e265f-b312-4f59-b1df-abea0a460013" xlink:href="halo-20220630.xsd#halo_A1.25ConvertibleSeniorNotesdue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_680b9b51-8dc9-4052-b1fa-8d4d5221a9c1" xlink:to="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member_645e265f-b312-4f59-b1df-abea0a460013" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A025ConvertibleSeniorNotesDue2027Member_39d6283a-4194-4e54-9904-21be6ad2ac5f" xlink:href="halo-20220630.xsd#halo_A025ConvertibleSeniorNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_680b9b51-8dc9-4052-b1fa-8d4d5221a9c1" xlink:to="loc_halo_A025ConvertibleSeniorNotesDue2027Member_39d6283a-4194-4e54-9904-21be6ad2ac5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A2021CreditAgreementMember_b5e7a298-403e-4a1e-b28e-436c5a8d6a77" xlink:href="halo-20220630.xsd#halo_A2021CreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_680b9b51-8dc9-4052-b1fa-8d4d5221a9c1" xlink:to="loc_halo_A2021CreditAgreementMember_b5e7a298-403e-4a1e-b28e-436c5a8d6a77" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_CreditAgreementMember_7336b443-a6ec-46aa-ada9-623da369245c" xlink:href="halo-20220630.xsd#halo_CreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_680b9b51-8dc9-4052-b1fa-8d4d5221a9c1" xlink:to="loc_halo_CreditAgreementMember_7336b443-a6ec-46aa-ada9-623da369245c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_69dab89a-b23d-4deb-bcfa-b9ca05a59966" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_bc67cd5c-a104-4a11-a60d-39e039ea3c3c" xlink:to="loc_us-gaap_CreditFacilityAxis_69dab89a-b23d-4deb-bcfa-b9ca05a59966" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_69dab89a-b23d-4deb-bcfa-b9ca05a59966_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_69dab89a-b23d-4deb-bcfa-b9ca05a59966" xlink:to="loc_us-gaap_CreditFacilityDomain_69dab89a-b23d-4deb-bcfa-b9ca05a59966_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2ed57352-0124-465c-b1ee-081c7e6e7c37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_69dab89a-b23d-4deb-bcfa-b9ca05a59966" xlink:to="loc_us-gaap_CreditFacilityDomain_2ed57352-0124-465c-b1ee-081c7e6e7c37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_949e2c88-123b-48cf-ad6d-6935643591e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_2ed57352-0124-465c-b1ee-081c7e6e7c37" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_949e2c88-123b-48cf-ad6d-6935643591e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AnnualInterestPaymentPeriodAxis_c83dddc0-6426-444c-8203-5aec821f636f" xlink:href="halo-20220630.xsd#halo_AnnualInterestPaymentPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_bc67cd5c-a104-4a11-a60d-39e039ea3c3c" xlink:to="loc_halo_AnnualInterestPaymentPeriodAxis_c83dddc0-6426-444c-8203-5aec821f636f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AnnualInterestPaymentPeriodDomain_c83dddc0-6426-444c-8203-5aec821f636f_default" xlink:href="halo-20220630.xsd#halo_AnnualInterestPaymentPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_halo_AnnualInterestPaymentPeriodAxis_c83dddc0-6426-444c-8203-5aec821f636f" xlink:to="loc_halo_AnnualInterestPaymentPeriodDomain_c83dddc0-6426-444c-8203-5aec821f636f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AnnualInterestPaymentPeriodDomain_a3822ac9-e7f8-4c6c-93c5-90042e306c4b" xlink:href="halo-20220630.xsd#halo_AnnualInterestPaymentPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_halo_AnnualInterestPaymentPeriodAxis_c83dddc0-6426-444c-8203-5aec821f636f" xlink:to="loc_halo_AnnualInterestPaymentPeriodDomain_a3822ac9-e7f8-4c6c-93c5-90042e306c4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodOneMember_98be7dae-f43d-4e5b-bd76-55b2d9a879f7" xlink:href="halo-20220630.xsd#halo_DebtInstrumentInterestPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_AnnualInterestPaymentPeriodDomain_a3822ac9-e7f8-4c6c-93c5-90042e306c4b" xlink:to="loc_halo_DebtInstrumentInterestPeriodOneMember_98be7dae-f43d-4e5b-bd76-55b2d9a879f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodTwoMember_67df17b8-20ed-413c-9a2e-c691fbe13f96" xlink:href="halo-20220630.xsd#halo_DebtInstrumentInterestPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_AnnualInterestPaymentPeriodDomain_a3822ac9-e7f8-4c6c-93c5-90042e306c4b" xlink:to="loc_halo_DebtInstrumentInterestPeriodTwoMember_67df17b8-20ed-413c-9a2e-c691fbe13f96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodThreeMember_42d2582e-8014-4501-ba2a-eae604066022" xlink:href="halo-20220630.xsd#halo_DebtInstrumentInterestPeriodThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_AnnualInterestPaymentPeriodDomain_a3822ac9-e7f8-4c6c-93c5-90042e306c4b" xlink:to="loc_halo_DebtInstrumentInterestPeriodThreeMember_42d2582e-8014-4501-ba2a-eae604066022" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodFourMember_01dfce30-53bc-4d04-a2b5-086ccb06f88a" xlink:href="halo-20220630.xsd#halo_DebtInstrumentInterestPeriodFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_AnnualInterestPaymentPeriodDomain_a3822ac9-e7f8-4c6c-93c5-90042e306c4b" xlink:to="loc_halo_DebtInstrumentInterestPeriodFourMember_01dfce30-53bc-4d04-a2b5-086ccb06f88a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentAxis_033b7449-366b-492a-b833-cee51f4b8d25" xlink:href="halo-20220630.xsd#halo_VariableRateComponentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_bc67cd5c-a104-4a11-a60d-39e039ea3c3c" xlink:to="loc_halo_VariableRateComponentAxis_033b7449-366b-492a-b833-cee51f4b8d25" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentDomain_033b7449-366b-492a-b833-cee51f4b8d25_default" xlink:href="halo-20220630.xsd#halo_VariableRateComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_halo_VariableRateComponentAxis_033b7449-366b-492a-b833-cee51f4b8d25" xlink:to="loc_halo_VariableRateComponentDomain_033b7449-366b-492a-b833-cee51f4b8d25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentDomain_471c0340-149b-4a06-98b4-9e33d0dfe67d" xlink:href="halo-20220630.xsd#halo_VariableRateComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_halo_VariableRateComponentAxis_033b7449-366b-492a-b833-cee51f4b8d25" xlink:to="loc_halo_VariableRateComponentDomain_471c0340-149b-4a06-98b4-9e33d0dfe67d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentOneMember_6cd50452-0838-48a3-9df3-b5174e3fb2a2" xlink:href="halo-20220630.xsd#halo_VariableRateComponentOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_VariableRateComponentDomain_471c0340-149b-4a06-98b4-9e33d0dfe67d" xlink:to="loc_halo_VariableRateComponentOneMember_6cd50452-0838-48a3-9df3-b5174e3fb2a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentTwoMember_f09e1ffe-8a83-44f9-9d39-5fcac973fe7a" xlink:href="halo-20220630.xsd#halo_VariableRateComponentTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_VariableRateComponentDomain_471c0340-149b-4a06-98b4-9e33d0dfe67d" xlink:to="loc_halo_VariableRateComponentTwoMember_f09e1ffe-8a83-44f9-9d39-5fcac973fe7a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#LongTermDebtNetCarryingAmountofConvertibleNotesDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails" xlink:type="extended" id="i4a1b9ffe332b440d9ca886dc10aff9fa_LongTermDebtNetCarryingAmountofConvertibleNotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_40885a20-578a-49a8-b7b1-3f614ac719bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_a392d679-ebb1-42ae-b68c-646e4b9e1b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40885a20-578a-49a8-b7b1-3f614ac719bc" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_a392d679-ebb1-42ae-b68c-646e4b9e1b8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_c21648c3-a4b2-44a3-b72f-a9e1faa8c20d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40885a20-578a-49a8-b7b1-3f614ac719bc" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_c21648c3-a4b2-44a3-b72f-a9e1faa8c20d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_3896a74d-33c1-4915-84a5-20d84bbb42ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40885a20-578a-49a8-b7b1-3f614ac719bc" xlink:to="loc_us-gaap_LongTermDebtCurrent_3896a74d-33c1-4915-84a5-20d84bbb42ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_47193bc9-6390-46c7-8dbd-0bbe7b5c032a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40885a20-578a-49a8-b7b1-3f614ac719bc" xlink:to="loc_us-gaap_LongTermDebt_47193bc9-6390-46c7-8dbd-0bbe7b5c032a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayable_982b6ba9-65ac-4ed6-91cb-6cc13badcb2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40885a20-578a-49a8-b7b1-3f614ac719bc" xlink:to="loc_us-gaap_ConvertibleNotesPayable_982b6ba9-65ac-4ed6-91cb-6cc13badcb2a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_eb5373bd-371f-41ad-a4af-111f5186e233" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40885a20-578a-49a8-b7b1-3f614ac719bc" xlink:to="loc_us-gaap_DebtInstrumentFairValue_eb5373bd-371f-41ad-a4af-111f5186e233" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_4cb51e5d-8b38-4af1-af9e-fd40529c213d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40885a20-578a-49a8-b7b1-3f614ac719bc" xlink:to="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_4cb51e5d-8b38-4af1-af9e-fd40529c213d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0259f0f1-c3d6-4477-922f-ed408c27084a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40885a20-578a-49a8-b7b1-3f614ac719bc" xlink:to="loc_us-gaap_DebtInstrumentTable_0259f0f1-c3d6-4477-922f-ed408c27084a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e2989909-b0fc-4c58-95a4-e17e2032404c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0259f0f1-c3d6-4477-922f-ed408c27084a" xlink:to="loc_us-gaap_DebtInstrumentAxis_e2989909-b0fc-4c58-95a4-e17e2032404c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e2989909-b0fc-4c58-95a4-e17e2032404c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_e2989909-b0fc-4c58-95a4-e17e2032404c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e2989909-b0fc-4c58-95a4-e17e2032404c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6913ccf1-5d56-48b8-b966-c6381d4c1bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_e2989909-b0fc-4c58-95a4-e17e2032404c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6913ccf1-5d56-48b8-b966-c6381d4c1bc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member_bced7893-e006-4294-b751-5ce2b6dab868" xlink:href="halo-20220630.xsd#halo_A1.25ConvertibleSeniorNotesdue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6913ccf1-5d56-48b8-b966-c6381d4c1bc7" xlink:to="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member_bced7893-e006-4294-b751-5ce2b6dab868" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A025ConvertibleSeniorNotesDue2027Member_815980eb-b261-4815-a30f-5423f485a623" xlink:href="halo-20220630.xsd#halo_A025ConvertibleSeniorNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6913ccf1-5d56-48b8-b966-c6381d4c1bc7" xlink:to="loc_halo_A025ConvertibleSeniorNotesDue2027Member_815980eb-b261-4815-a30f-5423f485a623" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#LongTermDebtNetComponentsofInterestExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails" xlink:type="extended" id="i8ef4c84a8d4f4d00877f9d37d6a39428_LongTermDebtNetComponentsofInterestExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6856580f-18e2-48b2-ac37-93a17595fff7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_85fa8301-446a-479e-9602-858c632a3441" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6856580f-18e2-48b2-ac37-93a17595fff7" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_85fa8301-446a-479e-9602-858c632a3441" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_c59c1904-ce46-4127-8cea-d4e5c8c6d821" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6856580f-18e2-48b2-ac37-93a17595fff7" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_c59c1904-ce46-4127-8cea-d4e5c8c6d821" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_088db1d2-78ad-488f-915f-06f9c61fad68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6856580f-18e2-48b2-ac37-93a17595fff7" xlink:to="loc_us-gaap_InterestExpenseDebt_088db1d2-78ad-488f-915f-06f9c61fad68" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_50aa931a-6b89-4bb4-863d-579b701b445c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6856580f-18e2-48b2-ac37-93a17595fff7" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_50aa931a-6b89-4bb4-863d-579b701b445c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a6ec531c-00f3-437e-b074-42181600781a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6856580f-18e2-48b2-ac37-93a17595fff7" xlink:to="loc_us-gaap_DebtInstrumentTable_a6ec531c-00f3-437e-b074-42181600781a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_629ed244-aed5-46ae-904e-bfb95b11ac8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a6ec531c-00f3-437e-b074-42181600781a" xlink:to="loc_us-gaap_DebtInstrumentAxis_629ed244-aed5-46ae-904e-bfb95b11ac8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_629ed244-aed5-46ae-904e-bfb95b11ac8e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_629ed244-aed5-46ae-904e-bfb95b11ac8e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_629ed244-aed5-46ae-904e-bfb95b11ac8e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2665b90d-da12-4580-b7ea-c7c9839d88b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_629ed244-aed5-46ae-904e-bfb95b11ac8e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2665b90d-da12-4580-b7ea-c7c9839d88b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member_b88bb343-cfd7-4e78-9a29-57019426a39c" xlink:href="halo-20220630.xsd#halo_A1.25ConvertibleSeniorNotesdue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2665b90d-da12-4580-b7ea-c7c9839d88b9" xlink:to="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member_b88bb343-cfd7-4e78-9a29-57019426a39c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A025ConvertibleSeniorNotesDue2027Member_f37fcd7b-f432-4814-b57b-dce7c4b41e4a" xlink:href="halo-20220630.xsd#halo_A025ConvertibleSeniorNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2665b90d-da12-4580-b7ea-c7c9839d88b9" xlink:to="loc_halo_A025ConvertibleSeniorNotesDue2027Member_f37fcd7b-f432-4814-b57b-dce7c4b41e4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7d6b136a-864b-40b3-894e-7831f13ec93b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a6ec531c-00f3-437e-b074-42181600781a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7d6b136a-864b-40b3-894e-7831f13ec93b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7d6b136a-864b-40b3-894e-7831f13ec93b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7d6b136a-864b-40b3-894e-7831f13ec93b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7d6b136a-864b-40b3-894e-7831f13ec93b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9048e39d-da98-432a-b6df-239fb29a2146" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7d6b136a-864b-40b3-894e-7831f13ec93b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9048e39d-da98-432a-b6df-239fb29a2146" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_b7e197d1-7853-4905-a004-471d10b0aab8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9048e39d-da98-432a-b6df-239fb29a2146" xlink:to="loc_us-gaap_ConvertibleDebtMember_b7e197d1-7853-4905-a004-471d10b0aab8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#SharebasedCompensationSharebasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails" xlink:type="extended" id="i9ff731f1609545359848e6a8f84c6161_SharebasedCompensationSharebasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_12a6873b-ec67-4940-922d-af5918686afd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0d86a708-f073-4c8a-b14b-1316dd4219e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_12a6873b-ec67-4940-922d-af5918686afd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0d86a708-f073-4c8a-b14b-1316dd4219e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_13fae61d-e124-4726-a9df-cb0b849febaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_12a6873b-ec67-4940-922d-af5918686afd" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_13fae61d-e124-4726-a9df-cb0b849febaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2c37f12a-6c12-4823-846b-863774493a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_12a6873b-ec67-4940-922d-af5918686afd" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2c37f12a-6c12-4823-846b-863774493a3e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d9273204-234d-4fd9-bd0a-2ae6d9b247e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2c37f12a-6c12-4823-846b-863774493a3e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d9273204-234d-4fd9-bd0a-2ae6d9b247e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d9273204-234d-4fd9-bd0a-2ae6d9b247e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d9273204-234d-4fd9-bd0a-2ae6d9b247e4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d9273204-234d-4fd9-bd0a-2ae6d9b247e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0859e25f-1608-47fc-a596-e56403c3b02c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d9273204-234d-4fd9-bd0a-2ae6d9b247e4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0859e25f-1608-47fc-a596-e56403c3b02c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f85f9f64-3b1d-4405-877c-aececbf8f037" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0859e25f-1608-47fc-a596-e56403c3b02c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f85f9f64-3b1d-4405-877c-aececbf8f037" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_c9cc15d3-2871-4a0b-b3d3-b110c1452515" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0859e25f-1608-47fc-a596-e56403c3b02c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_c9cc15d3-2871-4a0b-b3d3-b110c1452515" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_dfd55fe7-e15a-4594-ac65-91b76af5f1ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2c37f12a-6c12-4823-846b-863774493a3e" xlink:to="loc_us-gaap_AwardTypeAxis_dfd55fe7-e15a-4594-ac65-91b76af5f1ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dfd55fe7-e15a-4594-ac65-91b76af5f1ae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_dfd55fe7-e15a-4594-ac65-91b76af5f1ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dfd55fe7-e15a-4594-ac65-91b76af5f1ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21035167-bdf4-41bd-a839-f6d2fd983d39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_dfd55fe7-e15a-4594-ac65-91b76af5f1ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21035167-bdf4-41bd-a839-f6d2fd983d39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ab3a39a6-6b0d-4cde-9d62-3a5517b4f5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21035167-bdf4-41bd-a839-f6d2fd983d39" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ab3a39a6-6b0d-4cde-9d62-3a5517b4f5c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RSURSAandPRSUawardsMember_90202469-1822-4f96-b426-81e25173a789" xlink:href="halo-20220630.xsd#halo_RSURSAandPRSUawardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21035167-bdf4-41bd-a839-f6d2fd983d39" xlink:to="loc_halo_RSURSAandPRSUawardsMember_90202469-1822-4f96-b426-81e25173a789" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#SharebasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails" xlink:type="extended" id="iee78c590115d4215b47ffc4c9a3f27c4_SharebasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85c493b8-5d1a-4376-a0ca-a15bc878620d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_c2f0334e-f639-4b81-8945-d6c4e4459fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85c493b8-5d1a-4376-a0ca-a15bc878620d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_c2f0334e-f639-4b81-8945-d6c4e4459fc2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_fbc120b9-7b7a-4461-bb34-2cf811596832" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85c493b8-5d1a-4376-a0ca-a15bc878620d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_fbc120b9-7b7a-4461-bb34-2cf811596832" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_33b9c76c-6f2b-4127-8c70-e3319cf6b330" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85c493b8-5d1a-4376-a0ca-a15bc878620d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_33b9c76c-6f2b-4127-8c70-e3319cf6b330" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_9314c7b1-536b-4259-9afe-b7684f75b279" xlink:href="halo-20220630.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85c493b8-5d1a-4376-a0ca-a15bc878620d" xlink:to="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_9314c7b1-536b-4259-9afe-b7684f75b279" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d66bd9ca-fc1c-48e6-9d0e-21a333e79c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85c493b8-5d1a-4376-a0ca-a15bc878620d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d66bd9ca-fc1c-48e6-9d0e-21a333e79c0f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate_87b71745-c08a-4ae2-a0ac-644b342a727f" xlink:href="halo-20220630.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85c493b8-5d1a-4376-a0ca-a15bc878620d" xlink:to="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate_87b71745-c08a-4ae2-a0ac-644b342a727f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_e08dd3be-a8fb-480c-a53a-83871c8a37d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85c493b8-5d1a-4376-a0ca-a15bc878620d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_e08dd3be-a8fb-480c-a53a-83871c8a37d8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_c3ad2f57-c86a-4010-9597-f82843535c0d" xlink:href="halo-20220630.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85c493b8-5d1a-4376-a0ca-a15bc878620d" xlink:to="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_c3ad2f57-c86a-4010-9597-f82843535c0d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_7af9208c-504b-4366-a3de-6c41118de1f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85c493b8-5d1a-4376-a0ca-a15bc878620d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_7af9208c-504b-4366-a3de-6c41118de1f8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f3502d85-a02b-4235-9782-82fe8be30a76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85c493b8-5d1a-4376-a0ca-a15bc878620d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f3502d85-a02b-4235-9782-82fe8be30a76" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a432e52e-de99-4439-badc-1235c164b3c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f3502d85-a02b-4235-9782-82fe8be30a76" xlink:to="loc_us-gaap_AwardTypeAxis_a432e52e-de99-4439-badc-1235c164b3c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a432e52e-de99-4439-badc-1235c164b3c2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a432e52e-de99-4439-badc-1235c164b3c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a432e52e-de99-4439-badc-1235c164b3c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35133cf0-fd50-428d-91c4-adb94c70ecfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a432e52e-de99-4439-badc-1235c164b3c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35133cf0-fd50-428d-91c4-adb94c70ecfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_98fdf6e3-565c-42e0-89c1-84682e801506" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35133cf0-fd50-428d-91c4-adb94c70ecfb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_98fdf6e3-565c-42e0-89c1-84682e801506" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RSURSAandPRSUawardsMember_cace193d-0614-4cdd-8d5b-6f73b3c09ea4" xlink:href="halo-20220630.xsd#halo_RSURSAandPRSUawardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35133cf0-fd50-428d-91c4-adb94c70ecfb" xlink:to="loc_halo_RSURSAandPRSUawardsMember_cace193d-0614-4cdd-8d5b-6f73b3c09ea4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_6858e4a6-ef53-4228-92a8-4a610626e916" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35133cf0-fd50-428d-91c4-adb94c70ecfb" xlink:to="loc_us-gaap_EmployeeStockMember_6858e4a6-ef53-4228-92a8-4a610626e916" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_1197be69-f4fb-4c0f-bd9e-9fbe817551a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f3502d85-a02b-4235-9782-82fe8be30a76" xlink:to="loc_us-gaap_PlanNameAxis_1197be69-f4fb-4c0f-bd9e-9fbe817551a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_1197be69-f4fb-4c0f-bd9e-9fbe817551a6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1197be69-f4fb-4c0f-bd9e-9fbe817551a6" xlink:to="loc_us-gaap_PlanNameDomain_1197be69-f4fb-4c0f-bd9e-9fbe817551a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_682d46d4-27b2-473d-8ce3-1d69892f1180" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1197be69-f4fb-4c0f-bd9e-9fbe817551a6" xlink:to="loc_us-gaap_PlanNameDomain_682d46d4-27b2-473d-8ce3-1d69892f1180" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A2021ESPPPlanMember_60ca49a7-cfc6-4d1c-a179-483fb9d4eb2e" xlink:href="halo-20220630.xsd#halo_A2021ESPPPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_682d46d4-27b2-473d-8ce3-1d69892f1180" xlink:to="loc_halo_A2021ESPPPlanMember_60ca49a7-cfc6-4d1c-a179-483fb9d4eb2e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails" xlink:type="extended" id="ieccfdbc206e7401084eaba652e0dc7a8_SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails">
    <link:loc xlink:type="locator" xlink:label="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_cf94f81d-6246-4570-95e9-d16015d2c706" xlink:href="halo-20220630.xsd#halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_472f2652-b11d-4392-982b-6ea53c89b468" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_cf94f81d-6246-4570-95e9-d16015d2c706" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_472f2652-b11d-4392-982b-6ea53c89b468" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_945ea8ba-daed-4517-a78d-acd82cc93d32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_cf94f81d-6246-4570-95e9-d16015d2c706" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_945ea8ba-daed-4517-a78d-acd82cc93d32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_54be620e-380f-4fd0-94dc-b764400938f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_cf94f81d-6246-4570-95e9-d16015d2c706" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_54be620e-380f-4fd0-94dc-b764400938f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_f98a5cfe-c9f5-444a-a767-9d37ab7511be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_cf94f81d-6246-4570-95e9-d16015d2c706" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_f98a5cfe-c9f5-444a-a767-9d37ab7511be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2c030f9a-fccf-448f-ad07-16eb7435b3a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_cf94f81d-6246-4570-95e9-d16015d2c706" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2c030f9a-fccf-448f-ad07-16eb7435b3a6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable_05a5c4ca-8cd5-44f8-aeb5-abab13bef96e" xlink:href="halo-20220630.xsd#halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_cf94f81d-6246-4570-95e9-d16015d2c706" xlink:to="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable_05a5c4ca-8cd5-44f8-aeb5-abab13bef96e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7fbda548-f97c-4fd0-866f-c53065aa6981" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable_05a5c4ca-8cd5-44f8-aeb5-abab13bef96e" xlink:to="loc_srt_RangeAxis_7fbda548-f97c-4fd0-866f-c53065aa6981" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7fbda548-f97c-4fd0-866f-c53065aa6981_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7fbda548-f97c-4fd0-866f-c53065aa6981" xlink:to="loc_srt_RangeMember_7fbda548-f97c-4fd0-866f-c53065aa6981_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_958f87ad-1dda-4c77-a69c-de9e44231f67" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7fbda548-f97c-4fd0-866f-c53065aa6981" xlink:to="loc_srt_RangeMember_958f87ad-1dda-4c77-a69c-de9e44231f67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8ce2a814-9280-472a-b81f-bd9b0e3d6ece" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_958f87ad-1dda-4c77-a69c-de9e44231f67" xlink:to="loc_srt_MinimumMember_8ce2a814-9280-472a-b81f-bd9b0e3d6ece" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_acad3b7d-8012-468d-a40a-5134ed9c76ad" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_958f87ad-1dda-4c77-a69c-de9e44231f67" xlink:to="loc_srt_MaximumMember_acad3b7d-8012-468d-a40a-5134ed9c76ad" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails" xlink:type="extended" id="icaf9b9660442407184dfd71a7b33568e_SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80f58d29-dc61-4a58-b767-0e1c11697d63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_a30fa59f-b76a-4809-94c5-1f61ce1187d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80f58d29-dc61-4a58-b767-0e1c11697d63" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_a30fa59f-b76a-4809-94c5-1f61ce1187d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_584fdee2-419f-4bc1-99cb-a2e9af272b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80f58d29-dc61-4a58-b767-0e1c11697d63" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_584fdee2-419f-4bc1-99cb-a2e9af272b7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cea991eb-854e-4275-afd5-ab6f42c31370" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80f58d29-dc61-4a58-b767-0e1c11697d63" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cea991eb-854e-4275-afd5-ab6f42c31370" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4d1ed2b7-a0ce-4332-9de2-b9d202a4d0db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cea991eb-854e-4275-afd5-ab6f42c31370" xlink:to="loc_us-gaap_AwardTypeAxis_4d1ed2b7-a0ce-4332-9de2-b9d202a4d0db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4d1ed2b7-a0ce-4332-9de2-b9d202a4d0db_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4d1ed2b7-a0ce-4332-9de2-b9d202a4d0db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4d1ed2b7-a0ce-4332-9de2-b9d202a4d0db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd7e808a-243f-490d-8e02-ec129a2c574b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4d1ed2b7-a0ce-4332-9de2-b9d202a4d0db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd7e808a-243f-490d-8e02-ec129a2c574b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c4fdf444-699b-4b52-ae46-038aeaf7c715" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd7e808a-243f-490d-8e02-ec129a2c574b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c4fdf444-699b-4b52-ae46-038aeaf7c715" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_09a4e325-fccb-4d25-b553-423203d2ff1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd7e808a-243f-490d-8e02-ec129a2c574b" xlink:to="loc_us-gaap_RestrictedStockMember_09a4e325-fccb-4d25-b553-423203d2ff1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_32f37518-1f48-4203-9c12-520f52e7f695" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd7e808a-243f-490d-8e02-ec129a2c574b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_32f37518-1f48-4203-9c12-520f52e7f695" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_9bd85be6-8725-4694-9a04-9ff838d82aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd7e808a-243f-490d-8e02-ec129a2c574b" xlink:to="loc_us-gaap_PerformanceSharesMember_9bd85be6-8725-4694-9a04-9ff838d82aa8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_0f768a0d-51ae-4309-b32b-d0228c89037b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd7e808a-243f-490d-8e02-ec129a2c574b" xlink:to="loc_us-gaap_EmployeeStockMember_0f768a0d-51ae-4309-b32b-d0228c89037b" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" id="i3cb4d73e44c247fda8952c4a84bbd7d7_StockholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5ada5f1-4746-446f-bc31-8ae7dbfd0f08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_6ba19e6b-1e38-4036-b3ae-9393360b11f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5ada5f1-4746-446f-bc31-8ae7dbfd0f08" xlink:to="loc_us-gaap_StockholdersEquityAbstract_6ba19e6b-1e38-4036-b3ae-9393360b11f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2f937788-8589-438e-bb99-ec9a03e19b25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6ba19e6b-1e38-4036-b3ae-9393360b11f9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2f937788-8589-438e-bb99-ec9a03e19b25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_cb9aea08-0a0e-49a1-a52a-3f63b930206d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6ba19e6b-1e38-4036-b3ae-9393360b11f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_cb9aea08-0a0e-49a1-a52a-3f63b930206d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_78cfcf2f-7c5f-48bc-b116-c60fd92c4800" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6ba19e6b-1e38-4036-b3ae-9393360b11f9" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_78cfcf2f-7c5f-48bc-b116-c60fd92c4800" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_500a82c5-74df-410e-932f-b6a708b31d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6ba19e6b-1e38-4036-b3ae-9393360b11f9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_500a82c5-74df-410e-932f-b6a708b31d6c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_e772ff6f-bd70-4cc8-9a60-de59ed515357" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6ba19e6b-1e38-4036-b3ae-9393360b11f9" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_e772ff6f-bd70-4cc8-9a60-de59ed515357" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_436c7278-cd16-4a86-8eab-fb7e3aef39cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6ba19e6b-1e38-4036-b3ae-9393360b11f9" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_436c7278-cd16-4a86-8eab-fb7e3aef39cc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6caa2ebb-2efa-4caf-85e4-cabd6b74bf0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6ba19e6b-1e38-4036-b3ae-9393360b11f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6caa2ebb-2efa-4caf-85e4-cabd6b74bf0f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_2cf29cd9-3897-4e54-bf6e-888daa627cde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6ba19e6b-1e38-4036-b3ae-9393360b11f9" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_2cf29cd9-3897-4e54-bf6e-888daa627cde" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramPeriodInForce1_75f99f75-2387-45ab-a3a0-8e7c797eb0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramPeriodInForce1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6ba19e6b-1e38-4036-b3ae-9393360b11f9" xlink:to="loc_us-gaap_StockRepurchaseProgramPeriodInForce1_75f99f75-2387-45ab-a3a0-8e7c797eb0aa" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_09bf15c1-2d4e-4ecb-84f1-9a88ab0bfe97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6ba19e6b-1e38-4036-b3ae-9393360b11f9" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_09bf15c1-2d4e-4ecb-84f1-9a88ab0bfe97" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_82ba8d32-2da6-4d41-bd4f-c298c009fe6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6ba19e6b-1e38-4036-b3ae-9393360b11f9" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_82ba8d32-2da6-4d41-bd4f-c298c009fe6e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_2e57ab53-282e-4a58-a747-f625f9b0df83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6ba19e6b-1e38-4036-b3ae-9393360b11f9" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_2e57ab53-282e-4a58-a747-f625f9b0df83" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_e8e0be08-7158-4ea5-85fd-4198636b88db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6ba19e6b-1e38-4036-b3ae-9393360b11f9" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_e8e0be08-7158-4ea5-85fd-4198636b88db" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_847c8a69-b863-4e04-962a-8a9e123f3534" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5ada5f1-4746-446f-bc31-8ae7dbfd0f08" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_847c8a69-b863-4e04-962a-8a9e123f3534" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c04829cc-e0df-4d83-8912-a8d952a1e562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_847c8a69-b863-4e04-962a-8a9e123f3534" xlink:to="loc_us-gaap_AwardTypeAxis_c04829cc-e0df-4d83-8912-a8d952a1e562" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c04829cc-e0df-4d83-8912-a8d952a1e562_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c04829cc-e0df-4d83-8912-a8d952a1e562" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c04829cc-e0df-4d83-8912-a8d952a1e562_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_34b0cc28-79ca-4daa-8cc5-c6d2710b34d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c04829cc-e0df-4d83-8912-a8d952a1e562" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_34b0cc28-79ca-4daa-8cc5-c6d2710b34d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_084ded39-4602-4dd7-9e0d-0ae81051d5e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_34b0cc28-79ca-4daa-8cc5-c6d2710b34d8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_084ded39-4602-4dd7-9e0d-0ae81051d5e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6bb61d36-6fd6-4668-9edc-a2c00a70d677" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_34b0cc28-79ca-4daa-8cc5-c6d2710b34d8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6bb61d36-6fd6-4668-9edc-a2c00a70d677" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_StockOptionsAndRestrictedStockUnitsMember_617540b3-40ac-47b5-a67e-2e31626359ba" xlink:href="halo-20220630.xsd#halo_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_34b0cc28-79ca-4daa-8cc5-c6d2710b34d8" xlink:to="loc_halo_StockOptionsAndRestrictedStockUnitsMember_617540b3-40ac-47b5-a67e-2e31626359ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_78ad3157-9f39-4faa-9407-4c2acb59f7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_847c8a69-b863-4e04-962a-8a9e123f3534" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_78ad3157-9f39-4faa-9407-4c2acb59f7a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_78ad3157-9f39-4faa-9407-4c2acb59f7a4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_78ad3157-9f39-4faa-9407-4c2acb59f7a4" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_78ad3157-9f39-4faa-9407-4c2acb59f7a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_50d23fe5-3d99-4ac6-a82f-d36c14a3b6d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_78ad3157-9f39-4faa-9407-4c2acb59f7a4" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_50d23fe5-3d99-4ac6-a82f-d36c14a3b6d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AcceleratedShareRepurchaseAgreementMember_e9a28929-f7ae-4740-a722-5962dd4b3705" xlink:href="halo-20220630.xsd#halo_AcceleratedShareRepurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_50d23fe5-3d99-4ac6-a82f-d36c14a3b6d3" xlink:to="loc_halo_AcceleratedShareRepurchaseAgreementMember_e9a28929-f7ae-4740-a722-5962dd4b3705" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/NetIncomelosspershareSummaryDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#NetIncomelosspershareSummaryDetails"/>
  <link:definitionLink xlink:role="http://www.halozyme.com/role/NetIncomelosspershareSummaryDetails" xlink:type="extended" id="i3d9e085f00844b5393bbe0f8feecc51c_NetIncomelosspershareSummaryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_8832c113-2e5c-4ff2-946b-65dae88ea7d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bd7db1dd-8ce0-4015-aabf-3259021fa614" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_8832c113-2e5c-4ff2-946b-65dae88ea7d1" xlink:to="loc_us-gaap_NetIncomeLoss_bd7db1dd-8ce0-4015-aabf-3259021fa614" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fa748220-1145-4211-86f6-0b3ea3f31cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_8832c113-2e5c-4ff2-946b-65dae88ea7d1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fa748220-1145-4211-86f6-0b3ea3f31cc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_cf9c3fa2-178f-4a6a-9b43-664672be225c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_8832c113-2e5c-4ff2-946b-65dae88ea7d1" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_cf9c3fa2-178f-4a6a-9b43-664672be225c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_89a06b50-4f01-4eff-ad7e-f2e3813d942d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_8832c113-2e5c-4ff2-946b-65dae88ea7d1" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_89a06b50-4f01-4eff-ad7e-f2e3813d942d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_1acde423-5a44-49ac-a0de-8b79c6670f66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_8832c113-2e5c-4ff2-946b-65dae88ea7d1" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_1acde423-5a44-49ac-a0de-8b79c6670f66" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_b52bf557-a253-4ae4-88ed-67eb63251f78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_1acde423-5a44-49ac-a0de-8b79c6670f66" xlink:to="loc_us-gaap_EarningsPerShareBasic_b52bf557-a253-4ae4-88ed-67eb63251f78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_7bc3ba1c-9e30-4024-80c0-76157c246241" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_1acde423-5a44-49ac-a0de-8b79c6670f66" xlink:to="loc_us-gaap_EarningsPerShareDiluted_7bc3ba1c-9e30-4024-80c0-76157c246241" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_924445c9-c129-41c9-a182-b56401e2b877" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_8832c113-2e5c-4ff2-946b-65dae88ea7d1" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_924445c9-c129-41c9-a182-b56401e2b877" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ea11ff1f-4414-45d1-aaac-44d0e904bf05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_924445c9-c129-41c9-a182-b56401e2b877" xlink:to="loc_us-gaap_AwardTypeAxis_ea11ff1f-4414-45d1-aaac-44d0e904bf05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ea11ff1f-4414-45d1-aaac-44d0e904bf05_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ea11ff1f-4414-45d1-aaac-44d0e904bf05" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ea11ff1f-4414-45d1-aaac-44d0e904bf05_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4fbad283-8faa-4608-a2d1-1d3fd238570c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ea11ff1f-4414-45d1-aaac-44d0e904bf05" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4fbad283-8faa-4608-a2d1-1d3fd238570c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c4f1caaa-0d62-410a-ab49-99f9321a23e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4fbad283-8faa-4608-a2d1-1d3fd238570c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c4f1caaa-0d62-410a-ab49-99f9321a23e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_44893f6c-c9a6-4d88-a68b-e4d94303d9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4fbad283-8faa-4608-a2d1-1d3fd238570c" xlink:to="loc_us-gaap_RestrictedStockMember_44893f6c-c9a6-4d88-a68b-e4d94303d9b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c5ef76c9-a65b-4ced-8ec7-76bc6cc8343b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_924445c9-c129-41c9-a182-b56401e2b877" xlink:to="loc_us-gaap_DebtInstrumentAxis_c5ef76c9-a65b-4ced-8ec7-76bc6cc8343b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c5ef76c9-a65b-4ced-8ec7-76bc6cc8343b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_c5ef76c9-a65b-4ced-8ec7-76bc6cc8343b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c5ef76c9-a65b-4ced-8ec7-76bc6cc8343b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bec256c1-f3f6-4e06-9f0d-c964d6803129" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_c5ef76c9-a65b-4ced-8ec7-76bc6cc8343b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bec256c1-f3f6-4e06-9f0d-c964d6803129" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_a891332d-239a-48b5-a39a-a817b187a8df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bec256c1-f3f6-4e06-9f0d-c964d6803129" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_a891332d-239a-48b5-a39a-a817b187a8df" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>halo-20220630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:73069a0e-fffd-482c-8df8-d4ff810732e3,g:be228a77-9c6c-4f8e-9f2c-fe0d390b647c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_halo_DeferredRentPayments_4cf3ae99-e62c-4dd0-a252-c382420b2d16_negatedTerseLabel_en-US" xlink:label="lab_halo_DeferredRentPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease payments deferred</link:label>
    <link:label id="lab_halo_DeferredRentPayments_label_en-US" xlink:label="lab_halo_DeferredRentPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Rent Payments</link:label>
    <link:label id="lab_halo_DeferredRentPayments_documentation_en-US" xlink:label="lab_halo_DeferredRentPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Rent Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DeferredRentPayments" xlink:href="halo-20220630.xsd#halo_DeferredRentPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DeferredRentPayments" xlink:to="lab_halo_DeferredRentPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_ad3fe921-d73f-44de-815b-2f6880733f85_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount (shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability_0ad4f886-0746-44a6-b7b8-9bd7e87bcd88_terseLabel_en-US" xlink:label="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability_label_en-US" xlink:label="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Contract with Customer Liability</link:label>
    <link:label id="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability_documentation_en-US" xlink:label="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Contract with Customer Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability" xlink:href="halo-20220630.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability" xlink:to="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_69ecf61e-5529-46b6-a021-fc99758a8d14_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_0231ea25-71b3-4340-8bde-c31d5eb28f64_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Integration Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_cb06a133-797f-4741-a04b-96fc08941239_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bfc49eab-0347-407f-bd85-1a2555a768a0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_5c8f0f45-d749-464a-8ac2-33454552939d_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_b70805f2-746d-4731-82ac-2f43b20f2456_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_bf964c52-8e5c-4867-afce-aac1f93d27b5_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_0bad2292-ace5-40bd-a44a-77aeba839fa7_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use of assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_57b333b5-eff5-4b34-8889-0afb8170a310_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_cf677cfd-2e4b-44cc-ad6c-d696d9c0e941_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities, available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_331a670b-bcdc-486e-aa54-fd5fd1c2e399_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_3a9bee39-283e-48ac-9975-c73a9d31bf85_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and payroll taxes</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_4ede54bd-2678-4034-9f62-2d132ff026e0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_bb3cacf6-6fc0-447a-901b-a5eb7d9e4e11_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_62fb4ed5-5f53-40b6-9b8d-810ca17bb3cf_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_0f29a76d-3284-46b8-96df-852986d32239_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_cf7c925a-1774-48b1-bc13-f1c91de27862_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_9d3154fa-13ee-416d-8a38-5374d02fff08_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ComputerAndOfficeEquipmentMember_fa42dc52-1cab-4d78-b77e-cff1a4cfb19a_terseLabel_en-US" xlink:label="lab_halo_ComputerAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer and office equipment</link:label>
    <link:label id="lab_halo_ComputerAndOfficeEquipmentMember_label_en-US" xlink:label="lab_halo_ComputerAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer and Office Equipment [Member]</link:label>
    <link:label id="lab_halo_ComputerAndOfficeEquipmentMember_documentation_en-US" xlink:label="lab_halo_ComputerAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer and office equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ComputerAndOfficeEquipmentMember" xlink:href="halo-20220630.xsd#halo_ComputerAndOfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ComputerAndOfficeEquipmentMember" xlink:to="lab_halo_ComputerAndOfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_16209f8e-9fb7-4497-a58b-c90861d019ea_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, convertible, conversion price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_99844a99-af3d-4e65-a47c-41037b57a9c1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the sale of assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_343bf3c0-ae16-4f86-9292-2f289779a50f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_de679b63-f615-4889-8189-172b92f2076d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_4b6445ff-4303-471f-ba63-c5223e84076a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accounts receivable, deferred revenues from contracts with customers, and amounts under collaborative agreements included in transaction price</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_2c0a4622-6889-43c2-bac0-b5c9909b855a_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_49f61e7b-ded4-419d-86d9-fb3c2c55c47f_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_08f9082c-7df3-4dd1-bd81-1124e51bf224_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fb99c5b1-2e8e-47b7-9cab-5f75da8696c7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_153f478c-baaf-478f-8170-318865d644a2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ebf689c2-aafd-4a5f-bdcb-52f43d990d66_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_06734230-521b-4d55-855e-705253cb6c19_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATRS-1902 (IPR&amp;D)</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_52d97644-0e98-47d5-80fc-807347002534_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (decrease) increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_8cd3d3d4-1893-4443-b00c-6be543ad23cc_terseLabel_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum contribution amount</link:label>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_label_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount</link:label>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_documentation_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:href="halo-20220630.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:to="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9964f401-c6e1-4bae-a124-9953157af248_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_252be3f8-aadd-4a58-9380-c7641e5b9881_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of available-for-sale marketable securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_StockOptionsAndRestrictedStockUnitsMember_f01734ac-cf17-47d6-abc1-0c790bfc8381_terseLabel_en-US" xlink:label="lab_halo_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options and restricted units</link:label>
    <link:label id="lab_halo_StockOptionsAndRestrictedStockUnitsMember_label_en-US" xlink:label="lab_halo_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options And Restricted Stock Units [Member]</link:label>
    <link:label id="lab_halo_StockOptionsAndRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_halo_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options And Restricted Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_StockOptionsAndRestrictedStockUnitsMember" xlink:href="halo-20220630.xsd#halo_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_StockOptionsAndRestrictedStockUnitsMember" xlink:to="lab_halo_StockOptionsAndRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_4f4f980c-5bd9-4c38-8862-6e3d14052001_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_651180bd-5628-41c7-9f4d-5ebef4399b34_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_925fe4ad-9f48-48e3-95b8-1e4c4829303f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e729ee6e-665b-4bcc-9408-c0b801c7bb7f_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_e07886d7-71b4-4c68-810b-a2b957accbdf_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangibles</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9c6eb8f8-5ce7-4720-86d1-72cfcdf48c29_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9ae84cac-c440-419a-a5e5-552f54fae649_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value of intangible assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_98b60047-c5c4-4759-b9e9-b9b455985b40_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining life (in years)</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1dc45665-21c7-4523-93b5-6229e95d7dce_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive shares excluded from per share calculation (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_OperatingLeaseAccretionOfLiability_380c7121-d3aa-4f37-9f87-a1617f3196e3_terseLabel_en-US" xlink:label="lab_halo_OperatingLeaseAccretionOfLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense associated with accretion of lease liabilities</link:label>
    <link:label id="lab_halo_OperatingLeaseAccretionOfLiability_label_en-US" xlink:label="lab_halo_OperatingLeaseAccretionOfLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Accretion Of Liability</link:label>
    <link:label id="lab_halo_OperatingLeaseAccretionOfLiability_documentation_en-US" xlink:label="lab_halo_OperatingLeaseAccretionOfLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Accretion Of Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_OperatingLeaseAccretionOfLiability" xlink:href="halo-20220630.xsd#halo_OperatingLeaseAccretionOfLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_OperatingLeaseAccretionOfLiability" xlink:to="lab_halo_OperatingLeaseAccretionOfLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_50d77fc0-5e7e-441a-b6ec-32115f5cec6a_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_3b02f884-a2e8-4809-a181-d685c5489ab6_negatedLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_9df593d1-5303-4c99-87cc-dc72d48c5f0c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_5def62ec-6de0-4c03-970b-ed3b61ea21b7_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proforma earnings loss of acquiree since acquisition date</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_343aaa7e-5eb8-4082-a7ee-25296520f606_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents and Marketable Securities and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_545a2d12-c57c-474e-ae44-5a3507a46578_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_DevicePartneredProductsMember_ff63995a-4b9d-4596-aa28-277a7c7c0bc5_terseLabel_en-US" xlink:label="lab_halo_DevicePartneredProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Device Partnered Products</link:label>
    <link:label id="lab_halo_DevicePartneredProductsMember_label_en-US" xlink:label="lab_halo_DevicePartneredProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Device Partnered Products [Member]</link:label>
    <link:label id="lab_halo_DevicePartneredProductsMember_documentation_en-US" xlink:label="lab_halo_DevicePartneredProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Device Partnered Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DevicePartneredProductsMember" xlink:href="halo-20220630.xsd#halo_DevicePartneredProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DevicePartneredProductsMember" xlink:to="lab_halo_DevicePartneredProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_e67651d5-5c9e-45a1-9353-337c0db67f6b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_1a54a489-9899-45e4-8ae5-5010c4e5fcac_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR</link:label>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_label_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:to="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_fae1b5bb-b35a-469b-a542-3560e9a6d8a7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_CreditAgreementMember_b00f1f16-05cb-45ad-897c-beb558ef7d7b_terseLabel_en-US" xlink:label="lab_halo_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement</link:label>
    <link:label id="lab_halo_CreditAgreementMember_label_en-US" xlink:label="lab_halo_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:label id="lab_halo_CreditAgreementMember_documentation_en-US" xlink:label="lab_halo_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_CreditAgreementMember" xlink:href="halo-20220630.xsd#halo_CreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_CreditAgreementMember" xlink:to="lab_halo_CreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_a2f69f26-6541-4ae0-a608-23075e756378_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued for conversion of debt instrument (shares)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_898073b3-d9e7-405e-a091-40be1017ab17_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_f783d254-f7d2-4ec2-a90f-8108147c67cb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_AnnualInterestPaymentPeriodAxis_732cfc00-f8ae-4c15-aeee-679d025c7ed7_terseLabel_en-US" xlink:label="lab_halo_AnnualInterestPaymentPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Interest Payment Period [Axis]</link:label>
    <link:label id="lab_halo_AnnualInterestPaymentPeriodAxis_label_en-US" xlink:label="lab_halo_AnnualInterestPaymentPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Interest Payment Period [Axis]</link:label>
    <link:label id="lab_halo_AnnualInterestPaymentPeriodAxis_documentation_en-US" xlink:label="lab_halo_AnnualInterestPaymentPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Interest Payment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AnnualInterestPaymentPeriodAxis" xlink:href="halo-20220630.xsd#halo_AnnualInterestPaymentPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_AnnualInterestPaymentPeriodAxis" xlink:to="lab_halo_AnnualInterestPaymentPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_041df0f0-41b9-45e3-9cdd-ee5c16e9c305_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_51dbebec-0e36-468c-bb08-a7a5eecac114_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_8b7b8fc3-4720-48ec-8c20-d1f938940af3_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of contractual maturities of available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ResearchEquipmentMember_ff685f70-4f77-41cb-85a0-8835c238efe6_terseLabel_en-US" xlink:label="lab_halo_ResearchEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research equipment</link:label>
    <link:label id="lab_halo_ResearchEquipmentMember_label_en-US" xlink:label="lab_halo_ResearchEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Equipment [Member]</link:label>
    <link:label id="lab_halo_ResearchEquipmentMember_documentation_en-US" xlink:label="lab_halo_ResearchEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ResearchEquipmentMember" xlink:href="halo-20220630.xsd#halo_ResearchEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ResearchEquipmentMember" xlink:to="lab_halo_ResearchEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_e01168fe-4f13-4700-934c-13c8f6133335_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_00d111be-c04a-4be0-95cf-8095c24c3031_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock - $0.001 par value; 20,000 shares authorized; no shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_499d8566-437c-4ec1-b814-60ac5dc80114_terseLabel_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets acquired</link:label>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_TLANDOProductRightsMember_af21fc55-2d1f-4fd2-884f-a332ad4584ec_terseLabel_en-US" xlink:label="lab_halo_TLANDOProductRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TLANDO product rights</link:label>
    <link:label id="lab_halo_TLANDOProductRightsMember_label_en-US" xlink:label="lab_halo_TLANDOProductRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TLANDO, Product Rights [Member]</link:label>
    <link:label id="lab_halo_TLANDOProductRightsMember_documentation_en-US" xlink:label="lab_halo_TLANDOProductRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TLANDO, Product Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_TLANDOProductRightsMember" xlink:href="halo-20220630.xsd#halo_TLANDOProductRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_TLANDOProductRightsMember" xlink:to="lab_halo_TLANDOProductRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8ca54242-3f85-4d2a-b6c2-59ed3c79337d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding stock options and restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_dfe6e5fe-df91-47fb-af77-326c60b2331a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_31e66d9f-626a-42b3-9888-4e70b7e78ff5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_65d7c817-6299-46e9-a08c-ac8f9853a935_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_a4692def-2105-4eef-a5ca-e63aedd07723_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c602a156-61df-40c3-8ff2-39441744c747_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_b3cad667-e5ad-4714-a245-bb9ed18f989a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ManufacturingEquipmentMember_379d5db4-350c-48f4-846b-c4c1fcd90a3c_terseLabel_en-US" xlink:label="lab_halo_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing equipment</link:label>
    <link:label id="lab_halo_ManufacturingEquipmentMember_label_en-US" xlink:label="lab_halo_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Equipment [Member]</link:label>
    <link:label id="lab_halo_ManufacturingEquipmentMember_documentation_en-US" xlink:label="lab_halo_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ManufacturingEquipmentMember" xlink:href="halo-20220630.xsd#halo_ManufacturingEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ManufacturingEquipmentMember" xlink:to="lab_halo_ManufacturingEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e2b13243-a454-4015-9224-8f1eed1cd8e9_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_203dad85-2bbf-47f0-9909-d08731a507f6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for the induced conversion related to convertible notes</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_35569abd-051e-4e15-8d22-015f810e5fd2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_e085f9f1-4792-475d-965e-cd53843e26b7_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net and other contract assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_f54a3553-9c25-4fab-9ced-4e662275e1cb_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts accrued for purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_4c07ddc6-81d4-41f5-9f95-b27ea421bdf8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_fe614590-22e3-4ec1-bc28-98e6884ea72a_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligation</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_bbb77abc-d486-458b-b9c8-788501c4c456_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_d54ba4fc-c71b-491b-a2c2-7cd3f0c27dbf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum employee subscription rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice_34b42ad9-675c-4a61-bfc4-4ef036ee580d_terseLabel_en-US" xlink:label="lab_halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of contract termination by written notice</link:label>
    <link:label id="lab_halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice_label_en-US" xlink:label="lab_halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Period Of Termination By Written Notice</link:label>
    <link:label id="lab_halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice_documentation_en-US" xlink:label="lab_halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Period Of Termination By Written Notice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice" xlink:href="halo-20220630.xsd#halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice" xlink:to="lab_halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_cfc2b52a-0b77-46ea-a6cb-ee5720d3dbd1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_1be60250-5575-42fd-9240-34fa72c87ee9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_f8d9ef6a-8cd9-4cad-8853-ea21b1e1dd14_verboseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of RSUs withheld to pay for minimum withholding taxes (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d2be70ef-71ff-4dfb-a974-f4efc25ad735_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_7e62b74e-63ad-4c7f-a05d-160dd7bf7873_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_VariableRateComponentTwoMember_9b3d44e8-0b81-4a74-9370-2796f15abe4c_terseLabel_en-US" xlink:label="lab_halo_VariableRateComponentTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component Two</link:label>
    <link:label id="lab_halo_VariableRateComponentTwoMember_label_en-US" xlink:label="lab_halo_VariableRateComponentTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component Two [Member]</link:label>
    <link:label id="lab_halo_VariableRateComponentTwoMember_documentation_en-US" xlink:label="lab_halo_VariableRateComponentTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentTwoMember" xlink:href="halo-20220630.xsd#halo_VariableRateComponentTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_VariableRateComponentTwoMember" xlink:to="lab_halo_VariableRateComponentTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax_6aaea605-d89b-42de-8397-29204c6ab999_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_3088669e-14db-471b-9678-f39d4e40367c_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_RoyaltiesReceivedNumberOfCollaborators_dfb6468f-5796-41da-bee7-09bdc3bb0e89_terseLabel_en-US" xlink:label="lab_halo_RoyaltiesReceivedNumberOfCollaborators" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties Received, Number of Collaborators</link:label>
    <link:label id="lab_halo_RoyaltiesReceivedNumberOfCollaborators_label_en-US" xlink:label="lab_halo_RoyaltiesReceivedNumberOfCollaborators" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties Received, Number of Collaborators</link:label>
    <link:label id="lab_halo_RoyaltiesReceivedNumberOfCollaborators_documentation_en-US" xlink:label="lab_halo_RoyaltiesReceivedNumberOfCollaborators" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties Received, Number of Collaborators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RoyaltiesReceivedNumberOfCollaborators" xlink:href="halo-20220630.xsd#halo_RoyaltiesReceivedNumberOfCollaborators"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_RoyaltiesReceivedNumberOfCollaborators" xlink:to="lab_halo_RoyaltiesReceivedNumberOfCollaborators" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f67b4b8a-73d9-4cd3-a36e-07cec164d7bb_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_05d3ca20-783f-4122-97fc-f8996e4b0b4a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8277dd67-f226-4a8f-96ec-0fdb82291273_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_67fbf0ba-8c9b-4e0c-aadc-2fba8726acf0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodFourMember_1f96f109-8259-4fa9-bf81-1488922f72f0_terseLabel_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year four</link:label>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodFourMember_label_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest, Period Four [Member]</link:label>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodFourMember_documentation_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest, Period Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodFourMember" xlink:href="halo-20220630.xsd#halo_DebtInstrumentInterestPeriodFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DebtInstrumentInterestPeriodFourMember" xlink:to="lab_halo_DebtInstrumentInterestPeriodFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_a1c3ba65-0ebd-4f91-90e5-1cbc00343d16_terseLabel_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash acquired</link:label>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_label_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Acquired from Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAcquiredFromAcquisition" xlink:to="lab_us-gaap_CashAcquiredFromAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_78aafe01-2b51-4c12-941b-551b1ab943ba_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_65484617-e252-4b7c-b594-f1379785fc54_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net assets acquired, excluding goodwill</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_18cf0d84-f733-43c1-aed8-b604e65bffdb_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense recognized</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_31d6dcc9-b134-4b0e-9319-89840c7685dd_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid manufacturing expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_f0847719-4d44-424e-91a8-c94d1b28fa1a_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of disaggregation of revenues</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_36d9fbe1-67dd-47b8-8260-7db4c609dd18_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_fdbd6d40-145f-46b5-a231-fff9c19806ed_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_57dfc60a-fb40-4705-9edc-8f1103be627c_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of convertible debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_4a8e0e9c-c240-4e02-bf92-70b9436d4df2_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_187d848e-0336-4b23-a6f9-add93f95eb9c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts related to leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_Accountsreceivablefromcollaborators_a8ed4c16-6874-4666-82d0-458bb9382427_terseLabel_en-US" xlink:label="lab_halo_Accountsreceivablefromcollaborators" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable from revenues under collaborative agreements</link:label>
    <link:label id="lab_halo_Accountsreceivablefromcollaborators_label_en-US" xlink:label="lab_halo_Accountsreceivablefromcollaborators" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable from collaborators</link:label>
    <link:label id="lab_halo_Accountsreceivablefromcollaborators_documentation_en-US" xlink:label="lab_halo_Accountsreceivablefromcollaborators" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts due from collaborators, within one year of the balance sheet date (or the normal operating cycle, whichever is longer) for goods or services (including trade receivables) that have been delivered or sold in the normal course of business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accountsreceivablefromcollaborators" xlink:href="halo-20220630.xsd#halo_Accountsreceivablefromcollaborators"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_Accountsreceivablefromcollaborators" xlink:to="lab_halo_Accountsreceivablefromcollaborators" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_1f320c07-1d23-4482-b22d-a97824f8ea68_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_0ff37739-58cc-4f54-a2b8-1e828275c294_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_cd3a2c78-4eb9-42ef-b543-46df792393af_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_34e35682-95a9-4946-8b49-ef08ba0a78fa_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_111941ef-85ec-4780-bed1-e2620ec9ce11_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_e9d627ea-a5c8-4eed-b55b-a61608b49466_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_117c7a46-60c6-441f-92fb-06d3e6585f3f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Two</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_f42f41c9-178d-4b51-b8cc-0de6beee413f_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_UpfrontfeesMember_182ed14e-1c73-4e54-9bdc-0cbab45958d2_terseLabel_en-US" xlink:label="lab_halo_UpfrontfeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront License Fees</link:label>
    <link:label id="lab_halo_UpfrontfeesMember_label_en-US" xlink:label="lab_halo_UpfrontfeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront fees [Member]</link:label>
    <link:label id="lab_halo_UpfrontfeesMember_documentation_en-US" xlink:label="lab_halo_UpfrontfeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront fees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_UpfrontfeesMember" xlink:href="halo-20220630.xsd#halo_UpfrontfeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_UpfrontfeesMember" xlink:to="lab_halo_UpfrontfeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_355e5cc3-0e8f-4560-a357-8ceae0627746_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_b56f4104-932b-47c4-9965-cadd7421dd9c_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets measured on a recurring basis</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_e2c17f07-3e5e-42d7-8a2c-dc26a0c994f7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_09e15057-ebaf-4c58-9175-73020a0a1801_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_a8a9bc1b-f9d5-40b9-a27d-51aa4b8c6356_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain on foreign currency</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability_1d84be21-66d6-4bfd-9cc3-d22b028f1d92_terseLabel_en-US" xlink:label="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, current portion</link:label>
    <link:label id="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability_label_en-US" xlink:label="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Contract with Customer Liability</link:label>
    <link:label id="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability_documentation_en-US" xlink:label="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Contract with Customer Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability" xlink:href="halo-20220630.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability" xlink:to="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_ec4c8049-a886-4cfe-8eb9-bf6d5dfdbb44_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_708f00ca-b88c-46fd-a56e-e7610df6c9f7_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_A2021CreditAgreementMember_cdedab09-337e-497d-8b7f-3b7c44b87428_terseLabel_en-US" xlink:label="lab_halo_A2021CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Credit Agreement</link:label>
    <link:label id="lab_halo_A2021CreditAgreementMember_label_en-US" xlink:label="lab_halo_A2021CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Credit Agreement [Member]</link:label>
    <link:label id="lab_halo_A2021CreditAgreementMember_documentation_en-US" xlink:label="lab_halo_A2021CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A2021CreditAgreementMember" xlink:href="halo-20220630.xsd#halo_A2021CreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_A2021CreditAgreementMember" xlink:to="lab_halo_A2021CreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_eda9cf1a-9d57-40fe-ac0a-906b26b44287_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_64557a45-b77c-46ee-8c64-4556fdd26799_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_7d3da6b7-7925-4ab8-9e03-266c5c57273b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_BaxaltaMember_db5eed6c-77c2-4c32-96d8-58a7beca28f3_terseLabel_en-US" xlink:label="lab_halo_BaxaltaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baxalta</link:label>
    <link:label id="lab_halo_BaxaltaMember_label_en-US" xlink:label="lab_halo_BaxaltaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baxalta [Member]</link:label>
    <link:label id="lab_halo_BaxaltaMember_documentation_en-US" xlink:label="lab_halo_BaxaltaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baxalta [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BaxaltaMember" xlink:href="halo-20220630.xsd#halo_BaxaltaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_BaxaltaMember" xlink:to="lab_halo_BaxaltaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_5704f7d8-66dd-4b0e-929c-7d5f14b8a8c0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_401b7f0b-9003-4f61-97d7-1df8936fae34_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options weighted average exercise price (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised_a270212d-5ecc-43a0-ab49-a9b636d69729_terseLabel_en-US" xlink:label="lab_halo_ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under equity incentive plans, net of taxes paid related to net share settlement</link:label>
    <link:label id="lab_halo_ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised_label_en-US" xlink:label="lab_halo_ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From (Payments) for Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</link:label>
    <link:label id="lab_halo_ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised_documentation_en-US" xlink:label="lab_halo_ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From (Payments) for Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised" xlink:href="halo-20220630.xsd#halo_ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised" xlink:to="lab_halo_ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_9dd83d43-3e86-4b95-a959-f44b844f60fa_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4ca0af8b-8c3e-4b93-8e92-8257d9cc325b_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_2e477381-ef68-4806-a506-a9c52ae101d4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (loss) per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_a89ad102-ea87-4c70-b891-95d0e27c6ef6_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchased</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_3d955800-62a2-46ae-a0bd-e6d42767ba08_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average price paid per share (USD per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_LicenseFeesAndEventBasedMember_ab8d6389-9471-4131-95fa-055015ac3893_terseLabel_en-US" xlink:label="lab_halo_LicenseFeesAndEventBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fees And Event-Based</link:label>
    <link:label id="lab_halo_LicenseFeesAndEventBasedMember_label_en-US" xlink:label="lab_halo_LicenseFeesAndEventBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fees And Event-Based [Member]</link:label>
    <link:label id="lab_halo_LicenseFeesAndEventBasedMember_documentation_en-US" xlink:label="lab_halo_LicenseFeesAndEventBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fees And Event-Based [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_LicenseFeesAndEventBasedMember" xlink:href="halo-20220630.xsd#halo_LicenseFeesAndEventBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_LicenseFeesAndEventBasedMember" xlink:to="lab_halo_LicenseFeesAndEventBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_bb0557c1-e421-46f1-b495-7ee74625327e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c9492d01-8236-47e5-a708-0a0f38acc77c_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5d81d17a-175d-46a5-ba90-521cc228f631_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units, net and shares issued under the ESPP plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_37beaad3-d38f-4a8f-9e36-85bfd58930ec_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, current portion</link:label>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Credits and Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:to="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_d3bde72d-d175-4e3f-8e39-0dc58ca50b44_verboseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_48ec47fb-8c1d-439c-a21f-66ffdabf0d98_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_5f895e51-7457-4e22-9e67-94bf896794aa_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_763f8fe4-ab7d-4abc-aa6d-08ff97debdab_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9a1412c1-737a-4e92-af65-899226d81151_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_6ec279d6-fecd-4816-be65-3b922dd7bff4_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_0e36cfad-1cef-40de-af1b-a853ae584f29_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_13b96e87-c90a-4ec4-bfbf-bfba9cdd9ee1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_9560df56-0740-4801-a0cf-4d20c25af28f_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_59109d58-d55a-40b6-9a0f-cf2e62f2de63_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_a3b8265d-6965-4567-931a-65b2fa05fff9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_cb548448-7193-41a3-aff4-5d305bd1e9af_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_597e79e2-f65b-4a4d-b320-e548698f1f4b_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable_df6cc515-ffb3-4d94-a40f-03bc68ebcc17_terseLabel_en-US" xlink:label="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements Valuation Inputs [Table]</link:label>
    <link:label id="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable_label_en-US" xlink:label="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements Valuation Inputs [Table]</link:label>
    <link:label id="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable_documentation_en-US" xlink:label="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements Valuation Inputs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable" xlink:href="halo-20220630.xsd#halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable" xlink:to="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_69a2559d-e98d-479c-8502-1869ff722570_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions of business, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_e1e9efbd-606c-4397-a9cf-a3d913360988_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total purchase consideration, net of $46,548 cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_a293f9e8-906e-496a-b71f-e1e9465ade5b_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_9c109643-702c-4ab0-bce0-e18d882f07b9_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3efbbc55-e717-4578-bc33-bb3214645d7f_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_bd0df54e-a9c5-4bc1-9822-75f4fa943f5f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_023f0918-fc02-49ae-ada8-d205abdb031d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_57af06ef-b3d9-4236-a0cb-e673490da274_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_9133e692-813d-49be-ac5a-357288aeeb53_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US Government securities</link:label>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security, Government, Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1_71c2c8a6-7d07-449e-88ab-d110efcbd899_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration for seller transaction costs paid by Halozyme</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_bdb02c26-c85a-466c-aeb2-77e08439554a_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_04bdb431-1b18-46dc-8caa-cdf98ac5fd9c_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income and Interest Expense Disclosure</link:label>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income and Interest Expense Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_03ba3162-3e2d-4142-a432-7839bcb3934a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_a37295cc-6f07-4da5-b2db-69dc2cae0f7a_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_82898a20-d1da-409e-83e6-e357a51b87bf_terseLabel_en-US" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Interest Issued or Issuable, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_label_en-US" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Interest Issued or Issuable, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c324e0aa-be72-4b2b-b1af-2147384a9d3f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining Weighted-Average Recognition Period (years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_bb957caf-e4ff-45e5-a036-d4d5057210ee_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill acquired</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c875dc73-17f7-4bee-9974-6addeddc4ba5_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_b2cabe47-dd0d-4414-a6ce-7ebf97270edb_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_d164bc29-dba1-4a12-8549-9c4839a689fd_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 12)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodTwoMember_fd3bfc72-4236-44c1-9225-28ff8de82b63_terseLabel_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year two</link:label>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodTwoMember_label_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest, Period two [Member]</link:label>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodTwoMember_documentation_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest, Period two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodTwoMember" xlink:href="halo-20220630.xsd#halo_DebtInstrumentInterestPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DebtInstrumentInterestPeriodTwoMember" xlink:to="lab_halo_DebtInstrumentInterestPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2bfab152-6e5f-4464-bfbe-ebb35d5d88c3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_c81d6a5c-a398-4c6a-9535-def48960a53f_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset amortization</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_488a0158-8b1f-4f9d-b4c9-02b7fc3efbb0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of 2027 Convertible Notes</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_87642a9a-ccad-4896-8fa3-f946abd9030d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_538bc08e-2cbc-4d99-b02d-8906dc1d340c_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSAs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_8ebe86ac-3adf-490a-9480-3803fa93bb83_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_0bf94cb4-2beb-4de1-b863-c9b0820df571_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of debt issuance cost</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_bd4ae611-f85f-4fe5-ab47-2a4e059c8d56_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0cb56fea-5c1e-44cb-9e50-9c86533780d9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of assumptions used in Black-Scholes model</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_abce93e7-a617-4270-8c6a-f062c93f8e90_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from term loan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_f0b35210-ae55-4064-a754-4b48d1b4bffd_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_JanssenMember_1e5e4951-bed6-48c5-a323-02bd88c577b1_terseLabel_en-US" xlink:label="lab_halo_JanssenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen</link:label>
    <link:label id="lab_halo_JanssenMember_label_en-US" xlink:label="lab_halo_JanssenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen [Member]</link:label>
    <link:label id="lab_halo_JanssenMember_documentation_en-US" xlink:label="lab_halo_JanssenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Collaboration [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_JanssenMember" xlink:href="halo-20220630.xsd#halo_JanssenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_JanssenMember" xlink:to="lab_halo_JanssenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_7dfd0cf1-4b7b-4e9c-8645-9d2e8f494864_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive potential common stock outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_307ee4ab-7617-4f3c-a443-cd1b5467b257_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_5a5c0be5-6112-43b7-81a2-f431e08cce12_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_39ad517a-3117-4171-8854-7c51c5927f25_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_VariableRateComponentAxis_f73dfc2e-80a3-41e6-88a4-f8058184851c_terseLabel_en-US" xlink:label="lab_halo_VariableRateComponentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component [Axis]</link:label>
    <link:label id="lab_halo_VariableRateComponentAxis_label_en-US" xlink:label="lab_halo_VariableRateComponentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component [Axis]</link:label>
    <link:label id="lab_halo_VariableRateComponentAxis_documentation_en-US" xlink:label="lab_halo_VariableRateComponentAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentAxis" xlink:href="halo-20220630.xsd#halo_VariableRateComponentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_VariableRateComponentAxis" xlink:to="lab_halo_VariableRateComponentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_f7efcd5a-8f46-47e7-bdd5-12de92cf7eee_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_01bcf29e-313a-4e91-8793-afd69d29523a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_RocheMember_2bcc9959-e2c8-43b7-bbcc-dde2dee2bbf7_terseLabel_en-US" xlink:label="lab_halo_RocheMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche</link:label>
    <link:label id="lab_halo_RocheMember_label_en-US" xlink:label="lab_halo_RocheMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche [Member]</link:label>
    <link:label id="lab_halo_RocheMember_documentation_en-US" xlink:label="lab_halo_RocheMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RocheMember" xlink:href="halo-20220630.xsd#halo_RocheMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_RocheMember" xlink:to="lab_halo_RocheMember" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments_4f57590e-8064-4c88-b44a-d230315ccae7_terseLabel_en-US" xlink:label="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments_label_en-US" xlink:label="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Short-Term Investments</link:label>
    <link:label id="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments_documentation_en-US" xlink:label="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments" xlink:href="halo-20220630.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments" xlink:to="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1703978d-94d6-497c-8916-ba5922534f6a_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e97b7d6e-9d5a-478c-93d7-b5b8d935d4dc_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total prepaid expenses and other assets, current</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_c324e13b-b19c-4293-8e52-f176b1d0dd20_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4d8fe9f2-fdf9-4466-991d-a9b98d6ac66e_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_ce633b69-58b8-4a48-bf45-1a66800913ec_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_a67c8c79-1f3d-4bfa-b96a-99899e22ce93_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses, current</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3187a7bb-17e0-4b9f-a7fb-416f4c320e88_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_dc6b7e49-a3d7-4ccf-a9b8-e6834c12a9ea_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_94f2591c-1809-4577-8bf1-4b456ec1fc89_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_7fd309cb-cdef-48fc-8cbe-41768ab639c2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_60847df2-2055-4ab0-ab73-c788ce9f5d13_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_c6244542-75d7-487d-a284-ec595601b06c_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_e2452301-5855-46b2-a3b1-d7f19e3aad71_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_OthercollaboratorsMember_d95f98a3-f1be-4c07-a622-810477dde793_terseLabel_en-US" xlink:label="lab_halo_OthercollaboratorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other collaborators</link:label>
    <link:label id="lab_halo_OthercollaboratorsMember_label_en-US" xlink:label="lab_halo_OthercollaboratorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other collaborators [Member]</link:label>
    <link:label id="lab_halo_OthercollaboratorsMember_documentation_en-US" xlink:label="lab_halo_OthercollaboratorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other collaborators [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_OthercollaboratorsMember" xlink:href="halo-20220630.xsd#halo_OthercollaboratorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_OthercollaboratorsMember" xlink:to="lab_halo_OthercollaboratorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_954dfb57-9635-4960-97ca-a62049ee76cb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleNotesPayable_9101ce99-1334-42a6-8c3f-5b917cbd40b9_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayable_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayable" xlink:to="lab_us-gaap_ConvertibleNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_e91524fc-f480-487b-a448-06758693f79f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_ab9dcdf7-3302-453c-9db7-b50041f50e8f_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_5151799d-74bf-41d7-bf73-2e67e2cc0623_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_05aa2f5c-82e7-48e2-b5c8-50bfb0775087_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramPeriodInForce1_921c8868-b3ff-4833-9f4b-2f70fe4cc947_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, period</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramPeriodInForce1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Period in Force</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramPeriodInForce1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:to="lab_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b8561dac-fd03-4112-99d9-11c9d234ef87_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_394e2428-de78-43e9-80fd-ef4645c659e2_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After one but within five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_240b0244-39bf-4e43-8c16-b1fab97a74ee_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0058eb1f-a0b4-4499-94f6-eeec36dfb7c7_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss position of debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_a58223da-9acb-4078-902e-ba50ad6c3c91_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_97d77134-a0c8-41b2-8ae4-3a654b98a882_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_1a0ef304-4d98-400c-97d3-d43c2c6f7cdb_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized loss on marketable securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour_ef03219f-e713-4f37-a313-a79b9768c646_terseLabel_en-US" xlink:label="lab_halo_FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_halo_FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour_label_en-US" xlink:label="lab_halo_FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Yea, After Year Four</link:label>
    <link:label id="lab_halo_FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour_documentation_en-US" xlink:label="lab_halo_FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Yea, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour" xlink:href="halo-20220630.xsd#halo_FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour" xlink:to="lab_halo_FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_49fc5589-67a0-4b26-8c3f-a3c4e39e0f88_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodOneMember_81e706f5-c60a-4dbb-96a7-7729ec99a5b8_terseLabel_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year one</link:label>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodOneMember_label_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest, Period One [Member]</link:label>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodOneMember_documentation_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest, Period One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodOneMember" xlink:href="halo-20220630.xsd#halo_DebtInstrumentInterestPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DebtInstrumentInterestPeriodOneMember" xlink:to="lab_halo_DebtInstrumentInterestPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_9fb8db76-ae39-49d5-9ab5-cd2f1f3b9594_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_7c88db8e-19ee-4a81-a50f-07ab78273671_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_41afcb95-6171-497c-86c0-167e918d8130_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_17f05981-e762-494d-970c-a85e917e187f_verboseLabel_en-US" xlink:label="lab_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_d5cc68f0-c7f4-492e-97e7-1b1889b9fd75_totalLabel_en-US" xlink:label="lab_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Operating Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:label id="lab_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_documentation_en-US" xlink:label="lab_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Operating Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="halo-20220630.xsd#halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_05a87725-0bad-4b90-ae63-25769f2ca9c2_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_659f9bb8-5571-4f64-ae75-866428ab3e9c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_36f94cb1-d4dd-4021-bae6-d2b7aec1813a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pro forma revenue of acquiree since acquisition date</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_8db1a6d1-f4f8-4f19-8a8e-4991c839fd78_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_A025ConvertibleSeniorNotesDue2027Member_635e2e5c-4b0f-4988-89e6-1b853cec5711_terseLabel_en-US" xlink:label="lab_halo_A025ConvertibleSeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.25% Convertible Senior Notes due 2027</link:label>
    <link:label id="lab_halo_A025ConvertibleSeniorNotesDue2027Member_label_en-US" xlink:label="lab_halo_A025ConvertibleSeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.25% Convertible Senior Notes due 2027 [Member]</link:label>
    <link:label id="lab_halo_A025ConvertibleSeniorNotesDue2027Member_documentation_en-US" xlink:label="lab_halo_A025ConvertibleSeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.25% Convertible Senior Notes due 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A025ConvertibleSeniorNotesDue2027Member" xlink:href="halo-20220630.xsd#halo_A025ConvertibleSeniorNotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_A025ConvertibleSeniorNotesDue2027Member" xlink:to="lab_halo_A025ConvertibleSeniorNotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock_9303e358-40c8-4100-a924-c2f3b71d9695_terseLabel_en-US" xlink:label="lab_halo_GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets and Other Long-Lived Assets</link:label>
    <link:label id="lab_halo_GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_halo_GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets and Other Long-Lived Assets Policy [Policy Text Block]</link:label>
    <link:label id="lab_halo_GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_halo_GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets and Other Long-Lived Assets Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock" xlink:href="halo-20220630.xsd#halo_GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock" xlink:to="lab_halo_GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_ecb8c0b6-150d-444f-b527-1c594399c87b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b439cc18-f0c2-4a22-b474-6c7764ccf842_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_db4c9491-6e34-41eb-900f-b28a795d2159_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of adoption and pending adoption of recent accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_64c444b7-ed4a-404e-ab06-ea42d6282d5f_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment and other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCovenantCompliance_56b0d439-04b6-41b6-8716-6348a2072e79_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCovenantCompliance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCovenantCompliance_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCovenantCompliance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCovenantCompliance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCovenantCompliance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCovenantCompliance" xlink:to="lab_us-gaap_DebtInstrumentCovenantCompliance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_b5e12b56-ce65-4c8e-b6e4-01c6cbf18035_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock (shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_fcad2960-4886-43bf-b3a2-21053e4698f9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued for induced conversion related to convertible notes</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d43970df-d881-4b4c-8e04-2a2420020394_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards_2a991401-f990-46db-b841-a6acef542383_terseLabel_en-US" xlink:label="lab_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration for Antares equity compensation awards</link:label>
    <link:label id="lab_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards_label_en-US" xlink:label="lab_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issuable, Equity Compensation Awards</link:label>
    <link:label id="lab_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards_documentation_en-US" xlink:label="lab_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issuable, Equity Compensation Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards" xlink:href="halo-20220630.xsd#halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards" xlink:to="lab_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_7f1cde81-e847-4727-8bc0-10b30cea3af8_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_9f0c0c2a-49e6-4706-b21b-57ed49350916_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InducedConversionOfConvertibleDebtExpense_2f7cf90c-15fe-46ee-a930-b236018a24a4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement expense related to convertible notes</link:label>
    <link:label id="lab_us-gaap_InducedConversionOfConvertibleDebtExpense_9777bcd4-abfd-4340-8461-4fad9afc6427_terseLabel_en-US" xlink:label="lab_us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Induced conversion expense related to convertible notes</link:label>
    <link:label id="lab_us-gaap_InducedConversionOfConvertibleDebtExpense_label_en-US" xlink:label="lab_us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Induced Conversion of Convertible Debt Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:to="lab_us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_610be034-a38e-4b57-82b6-289f74b9d22d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accrued expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_4bc2eb0a-1c74-4fcb-9747-a3c9c07c7b9a_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodThreeMember_9cd61140-94a0-4d59-849d-f0c69bd00a26_terseLabel_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year three</link:label>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodThreeMember_label_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest, Period Three [Member]</link:label>
    <link:label id="lab_halo_DebtInstrumentInterestPeriodThreeMember_documentation_en-US" xlink:label="lab_halo_DebtInstrumentInterestPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest, Period Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodThreeMember" xlink:href="halo-20220630.xsd#halo_DebtInstrumentInterestPeriodThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DebtInstrumentInterestPeriodThreeMember" xlink:to="lab_halo_DebtInstrumentInterestPeriodThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_28137c77-4102-4f1a-9bc5-a354ff4548dc_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2f19acc3-57bb-411d-adfc-c23d4142b0b2_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_3c534ab6-0960-4a21-8d8b-9e45e44b17e8_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_92b86bfa-23b7-401b-a527-effe1736e4e0_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_10fe407b-b3db-4269-9131-7e665739fc4b_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_cdb33329-9ee6-416b-b5f9-3c4520e1217a_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_43ddb81c-55ad-4e13-8d9b-e2329e27dde8_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_997388a9-6ad5-4e2e-a5eb-c0f43f546ab5_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_d9b17d4c-1319-4ff9-8c1a-1cd7dab27fcd_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_70068757-2e29-4e72-81f3-f28359fe7725_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ShareBasedCompensationAwardsVestedMember_b3949689-4174-4ea2-aad5-a5948e1b30e2_terseLabel_en-US" xlink:label="lab_halo_ShareBasedCompensationAwardsVestedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Compensation Awards, Vested</link:label>
    <link:label id="lab_halo_ShareBasedCompensationAwardsVestedMember_label_en-US" xlink:label="lab_halo_ShareBasedCompensationAwardsVestedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Awards, Vested [Member]</link:label>
    <link:label id="lab_halo_ShareBasedCompensationAwardsVestedMember_documentation_en-US" xlink:label="lab_halo_ShareBasedCompensationAwardsVestedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Awards, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationAwardsVestedMember" xlink:href="halo-20220630.xsd#halo_ShareBasedCompensationAwardsVestedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ShareBasedCompensationAwardsVestedMember" xlink:to="lab_halo_ShareBasedCompensationAwardsVestedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_f367262f-a3e6-4bf1-91b1-6c7d88daec7f_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount paid for conversion of debt instrument</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_AutoInjectorTechnologyPlatformMember_6c97fdd8-1ab8-4d70-8cc1-19ee4c180cec_terseLabel_en-US" xlink:label="lab_halo_AutoInjectorTechnologyPlatformMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auto Injector technology platform</link:label>
    <link:label id="lab_halo_AutoInjectorTechnologyPlatformMember_label_en-US" xlink:label="lab_halo_AutoInjectorTechnologyPlatformMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auto Injector Technology Platform [Member]</link:label>
    <link:label id="lab_halo_AutoInjectorTechnologyPlatformMember_documentation_en-US" xlink:label="lab_halo_AutoInjectorTechnologyPlatformMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auto Injector Technology Platform</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AutoInjectorTechnologyPlatformMember" xlink:href="halo-20220630.xsd#halo_AutoInjectorTechnologyPlatformMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_AutoInjectorTechnologyPlatformMember" xlink:to="lab_halo_AutoInjectorTechnologyPlatformMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_786f3b2d-f580-4d93-a767-dbd9ef5f3ee8_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_b7f9c24d-1bd5-4382-94fe-1a4f4c1cc664_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilities_82450d02-9785-4e20-94dd-0563cc35a4ae_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues</link:label>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Credits and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:to="lab_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_74398ca5-9b03-4a97-9a28-f8a044d6e3b8_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_f6609174-edb9-4ae0-b58d-a8619cbbc37b_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity (deficit) (textual)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAbstract_0afb6f38-2207-4a02-bc26-5488177ef7b5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_a546a535-5f6c-4246-a5fd-9e6a40c8487f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_f18b8d31-daaa-468c-836e-2c8a26e2a92d_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_db31222f-e424-4115-a682-25aaa7978950_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total loan balance</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_9bb35be3-6877-4dc5-ad57-15cf2036644c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_fd7850f2-1b3d-4446-b9d5-2c119dc9981f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective rate at end of period</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_SalesbasedmilestoneMember_48b01858-40a5-4f2a-8f79-ccae1cdf4717_terseLabel_en-US" xlink:label="lab_halo_SalesbasedmilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-based milestone</link:label>
    <link:label id="lab_halo_SalesbasedmilestoneMember_label_en-US" xlink:label="lab_halo_SalesbasedmilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-based milestone [Member]</link:label>
    <link:label id="lab_halo_SalesbasedmilestoneMember_documentation_en-US" xlink:label="lab_halo_SalesbasedmilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-based milestone [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_SalesbasedmilestoneMember" xlink:href="halo-20220630.xsd#halo_SalesbasedmilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_SalesbasedmilestoneMember" xlink:to="lab_halo_SalesbasedmilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_119e84dc-1a83-4ae7-9b1b-2253ab51cd93_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_5fe1731b-e177-4134-a8aa-19a4d8e98983_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings (accumulated deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_BusinessCombinationConsiderationTransferredBonusAwards_da0cbc02-31cf-4d23-914d-d7b53c98d923_terseLabel_en-US" xlink:label="lab_halo_BusinessCombinationConsiderationTransferredBonusAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash consideration related to cash bonus awards paid by Halozyme</link:label>
    <link:label id="lab_halo_BusinessCombinationConsiderationTransferredBonusAwards_label_en-US" xlink:label="lab_halo_BusinessCombinationConsiderationTransferredBonusAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Bonus Awards</link:label>
    <link:label id="lab_halo_BusinessCombinationConsiderationTransferredBonusAwards_documentation_en-US" xlink:label="lab_halo_BusinessCombinationConsiderationTransferredBonusAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Bonus Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationConsiderationTransferredBonusAwards" xlink:href="halo-20220630.xsd#halo_BusinessCombinationConsiderationTransferredBonusAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_BusinessCombinationConsiderationTransferredBonusAwards" xlink:to="lab_halo_BusinessCombinationConsiderationTransferredBonusAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_7ccd8ce7-42e1-4ab9-9326-1f3075744b5f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_TermLoanFacilityMember_9fc9eb7b-9492-4668-b565-7850ff55b4fc_terseLabel_en-US" xlink:label="lab_halo_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility</link:label>
    <link:label id="lab_halo_TermLoanFacilityMember_label_en-US" xlink:label="lab_halo_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility [Member]</link:label>
    <link:label id="lab_halo_TermLoanFacilityMember_documentation_en-US" xlink:label="lab_halo_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_TermLoanFacilityMember" xlink:href="halo-20220630.xsd#halo_TermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_TermLoanFacilityMember" xlink:to="lab_halo_TermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_b08a0206-6f05-48d3-8470-5327972dd96e_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_8417567e-5129-4333-9cd0-84d84dc2c5e6_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_bc2ea4ed-6b6f-4653-82ee-f317feff1094_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_4af85863-ccba-4413-9578-faf9c0bd436e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_696829b4-9d9e-457a-bb15-1874197fc4e6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_acbbfb02-bff6-4752-adf2-1b6513a42fc3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_d7193eb9-fdc1-4b53-9e57-df7db4285ec8_terseLabel_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase period (in months)</link:label>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_label_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period</link:label>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_documentation_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:href="halo-20220630.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:to="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_010acabf-7421-4a81-b7a0-2387b4374b10_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_c0faf10d-cb57-4db4-89fa-3e963d6959f4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_4d0ed3a5-30a4-49d4-803a-b2b9835ad53b_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_4f97ef60-bcb4-4adf-aa35-346284c2c638_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_026e6032-1682-48a2-aad6-a1d566df9bd6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_AcceleratedShareRepurchaseAgreementMember_2730a00f-0333-48a6-81f8-5196a60dd2d3_terseLabel_en-US" xlink:label="lab_halo_AcceleratedShareRepurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated share repurchase agreement</link:label>
    <link:label id="lab_halo_AcceleratedShareRepurchaseAgreementMember_label_en-US" xlink:label="lab_halo_AcceleratedShareRepurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated share repurchase agreement [Member]</link:label>
    <link:label id="lab_halo_AcceleratedShareRepurchaseAgreementMember_documentation_en-US" xlink:label="lab_halo_AcceleratedShareRepurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated share repurchase agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AcceleratedShareRepurchaseAgreementMember" xlink:href="halo-20220630.xsd#halo_AcceleratedShareRepurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_AcceleratedShareRepurchaseAgreementMember" xlink:to="lab_halo_AcceleratedShareRepurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_44785b6f-fefe-4c87-abbf-5112c3f0ba49_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Remaining Discount Amortization Period</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Remaining Discount Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_eab74348-8c78-490c-b8f6-78ecaa42f3ab_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from stock options exercised</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_1903ed03-9f72-4d5f-8051-fce16908de43_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATRS-1902 (IPR&amp;D)</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6de3f0eb-8041-478e-a55a-81fd665a689d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_c96b1fa0-a17a-41dd-8166-d0abfa74adba_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_35d9b963-d3db-41d4-9d7f-daffaa8fa2cf_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net and contract assets</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_038b65b1-0c25-496e-9395-3647b53193e9_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_b03fd308-8596-4b5a-8bf9-0d1dfb9f2341_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_f59a4f20-063d-45c0-aaf2-911fbbdd2ef9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_585b41e7-9eb5-4610-b99d-1a2097e8677d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_64c46023-4394-48da-9d28-9113bb1e64ea_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_068d7e30-a855-4f75-bf90-f8ae3c3d04e9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in computing net income per share:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_09be848b-2d96-426f-a486-a1dd3215362f_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_4d5bc72b-2aef-45e8-a89c-5967704b4c58_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_3e31f8e5-6785-4770-9b60-8319743ac7ff_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_6e90b60e-d4ef-4dbd-b962-e3a041013b61_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_93b4afd1-aef4-4795-8510-577fef133f43_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_e39b0b28-bbef-4e07-a6e0-e045a13b5397_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_3b5901f6-7ddb-4398-b665-c83ae29ee61d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_6b7fcbc4-6803-49bd-b6d4-2e6f9a39faa4_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_9a88450c-bb79-4a32-8de5-d727b7dc2d41_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_6f71a074-5d02-4709-acd8-8d53d7a3f8e0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_523d8098-ff05-48a2-9aad-a8a58ff5b8b4_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_fe8bd1da-b796-48e0-98be-08ac0f5f39bd_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock_f8d3c6bb-1d29-41c7-acf5-f9120be14807_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Indefinite-lived Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Indefinite-lived Intangible Assets by Major Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_fd4ce3c6-a861-48b7-a0d2-5c78b531f64b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_CollaborativeAgreementsMember_a206d1f7-3631-497b-96e1-268cd909a2d6_terseLabel_en-US" xlink:label="lab_halo_CollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues under collaborative agreements</link:label>
    <link:label id="lab_halo_CollaborativeAgreementsMember_7b271d7c-564e-428e-ba82-2dea626c312c_verboseLabel_en-US" xlink:label="lab_halo_CollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements</link:label>
    <link:label id="lab_halo_CollaborativeAgreementsMember_label_en-US" xlink:label="lab_halo_CollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements [Member]</link:label>
    <link:label id="lab_halo_CollaborativeAgreementsMember_documentation_en-US" xlink:label="lab_halo_CollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_CollaborativeAgreementsMember" xlink:href="halo-20220630.xsd#halo_CollaborativeAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_CollaborativeAgreementsMember" xlink:to="lab_halo_CollaborativeAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_0f6e08b6-47e9-480f-90a9-8c7b030f9ae7_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivables_c0d42d8e-4a96-4a97-a30a-5a321a64655a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivable</link:label>
    <link:label id="lab_us-gaap_OtherReceivables_label_en-US" xlink:label="lab_us-gaap_OtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivables" xlink:to="lab_us-gaap_OtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_00106182-f3d2-4e72-ac8b-d47ee29ef782_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_1dba0f49-9f38-4edc-b14b-ea42b7cf9473_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_e446eb99-5a69-49fa-a2ac-a368003d8346_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_cce0e8e0-11fb-4f1b-b688-102e9d0a77b7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash consideration for Antares shares outstanding as of May 24, 2022</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_0317b1e2-7fa4-428f-a73e-ed92a3639259_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_821d2abe-d15a-445b-b342-64401987bc20_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_94096a09-9de0-40a2-99cd-9ed7bbf31c38_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_910e9f5e-ec11-427e-9f11-a86fd9ac6942_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_1c8ac76f-3ab6-447b-81db-c5277becd41b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_0a4d1e4d-39af-4d7c-b450-cf682d35deba_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, remaining performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_6a52be23-166f-4a39-b440-79e69ffea280_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of share-based compensation expense by type</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b5d12103-0f07-4da1-be11-64bb8f6fabd4_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_461e5eaf-b787-42fd-ab65-fe210c1e7bda_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f1477723-2d2a-42e0-a4e3-1257e8699ccb_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_e881f4b6-c7b9-4a56-8c36-7d07a554a98f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_eaeec689-55a9-46e2-9005-c92f24a8973d_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_d18b9623-ed59-4044-bc1a-4e84caba2997_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_VariableRateComponentOneMember_4ccbbad1-e196-4f1b-8a9c-e02189baec96_terseLabel_en-US" xlink:label="lab_halo_VariableRateComponentOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component One</link:label>
    <link:label id="lab_halo_VariableRateComponentOneMember_label_en-US" xlink:label="lab_halo_VariableRateComponentOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component One [Member]</link:label>
    <link:label id="lab_halo_VariableRateComponentOneMember_documentation_en-US" xlink:label="lab_halo_VariableRateComponentOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentOneMember" xlink:href="halo-20220630.xsd#halo_VariableRateComponentOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_VariableRateComponentOneMember" xlink:to="lab_halo_VariableRateComponentOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_a99dd676-1b67-4211-92b0-f93910ae1b0b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_14c5cfe4-533e-4e1b-84bc-c969b5dd0f27_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP purchase price of common stock, percent of market price</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_789c9664-7069-4d4b-bd75-3d090c7bd0f5_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_eb5b075f-784e-4bce-90c5-bdce44a186fb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5db73305-a10e-4492-86c5-f1e0fead43fc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_409a5c16-535a-41f5-8e49-c227376b9ead_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair market value of gross unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c423e83f-99b8-4298-9723-78dabfaec3f0_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_fe308d83-3008-43ba-9670-bca13d9cf51f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life (years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_49be35e6-a179-4e31-a94a-4f4161fbd01b_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a1cda4ec-158a-4b3c-9311-4f14f2c6bc78_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_263a7ac4-8c24-49e8-ac13-1323a038354a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of reconciliation of numerators and denominators of basic and diluted computations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_d4f970e2-d61a-453e-a2a9-2d311cea9811_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_7c66e185-2001-4beb-9c1f-a82187a42ee5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8ee57389-3125-49a6-8fe9-1262b3456700_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_cb3e9ed1-e1b2-45a2-8262-504ee6fb0324_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_19e0a200-d409-4183-9f3b-32b926667c26_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_8614ee2c-7569-4937-bef5-c16e8d486672_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_f159b273-6e00-4566-af14-0f2e347f46e4_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_7ec830f1-8421-476c-a0b4-1a92a0cfa88b_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_3df3d358-026f-458f-b4fe-8ee9cf50b61b_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSecuredDebt_3b491503-a087-498b-aaf3-c59a631861f0_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of 2024 Convertible Notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSecuredDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSecuredDebt" xlink:to="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_43d40bbe-20cc-4bc6-b798-2bf619b8e049_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_22bdd5ce-718b-46e5-abaf-196dff7d81d0_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_37d8e786-a35b-4e95-87cd-064a7409b2c4_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain Balance Sheet Items</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_15a79ef8-c208-4344-bb0e-79977c41d1ec_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate, stated percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_8de2940f-e9d9-4574-a297-9c13a97da00e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accounts receivable</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_45e80a05-ff45-41a5-bd79-c3072acb9ec5_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_e83841e9-54ec-4b19-b41e-a79ad5fd46e6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less long-term portion</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_a64a5185-28d7-4539-879f-452775dec48d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77920239-7e94-441c-afcd-91d1fa104573_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_185fbefe-ad95-4378-a0b3-291cd252f1e7_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent_2e4cc76d-7fc8-4993-9647-aeda122380fc_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product returns and sales allowance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Refund Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_2b2bf8ef-9d97-4579-8cbb-f6fb36aac0c8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of unrecognized estimated compensation cost by type</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_4dfb2765-a1a8-479e-acb2-39cc11f68245_verboseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_adb270b4-7145-4e1c-ad6d-a591374c00a6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, remaining performance obligation, expected timing</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_491e505d-7dc8-4e8f-89c4-2e758093eda6_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_ad91a1e5-d787-4cf2-8431-d94c308d1340_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedLineItems_3face290-ece4-4978-820e-f3822883db42_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedLineItems_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems" xlink:to="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_4426f2e3-0d65-435b-af29-ce4f46bde164_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_7267eed7-719a-47b1-a737-5e36fef64792_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_727e137e-bb47-4c59-bac6-3caf2985871b_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_b4de5139-1c6c-4801-b934-d0b51d753a82_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lenders fee</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_30719fcc-33b4-4b9a-81c1-afedde1eeedc_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7d6f5926-6cfb-43a9-92cc-b8cea255c0de_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding for basic net income (loss) per share (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_55fae798-abf7-404e-af26-a273a21d70e7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_91a3dfc4-fec2-4470-8c66-1e72e345f347_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate_22654f26-9120-4096-a67f-e86f0149830e_terseLabel_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum employee subscription rate</link:label>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Minimum Employee Subscription Rate</link:label>
    <link:label id="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate_documentation_en-US" xlink:label="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Minimum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:href="halo-20220630.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:to="lab_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_43866c12-a271-4029-b53c-f80237de449f_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired_8ed59a79-ac44-4fdf-b30a-6673fd3e9825_terseLabel_en-US" xlink:label="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived intangible assets acquired</link:label>
    <link:label id="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired_label_en-US" xlink:label="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:to="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_f12d3bcc-0742-49fb-a0f0-1703582394d9_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_64f1a05e-41bd-4d62-991b-bab2a4c3b397_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_cc564693-0af8-4220-9707-c249b9ba9654_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_94d1d22e-f5cb-4c55-8a33-98b8ef13a228_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Intangibles, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses_f20783a9-3ce1-4401-95bb-f5d090901f98_terseLabel_en-US" xlink:label="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses_label_en-US" xlink:label="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Accrued Expenses</link:label>
    <link:label id="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses_documentation_en-US" xlink:label="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses" xlink:href="halo-20220630.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses" xlink:to="lab_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_35630170-75e2-48b0-99d8-afac14a12552_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_cb30d555-d5d0-456f-94ec-bf103a4a258a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_ebce25b0-c6f6-4faf-9bfe-0bfe5bc19e83_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_ab19a023-fe82-4f48-a164-f0787e5c7a2e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for the induced conversion related to convertible notes (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_fcdaa0b0-858c-487f-b236-7f2a9dc28976_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_64045e00-40b3-4bcb-bf03-3cb7d079af28_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_188a1faf-8dc4-426d-96a4-9f50ff8616b6_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_c07eea2c-4e55-46b0-8b7e-f3dc5fe6fb4e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_5523dc82-eb76-4597-9f6a-a29698f76f71_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_ab9c38b1-aab8-4cd5-b2a8-27ef69020ec6_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_4d50e08d-fdbc-4321-8429-50ab15d92aab_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_cd593139-f0a5-44df-92de-76b5593b703f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_3c2e965e-7cc7-43f5-afec-daf31c560c20_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of assets measured at fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_4fd1e05d-3da4-43fe-bc9b-26066b05ad80_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from revolving credit facilities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Long-term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_e0fa477a-7228-49e7-935e-5aacce429f5c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_3a7a63cc-9d89-461e-a3df-5fea0672e149_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e997bc8c-f2db-468f-8973-da73332b2b90_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income/(Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_976cf419-70b4-4d11-a4e4-943cbb9d0347_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_e52b49ea-f4f8-4185-8373-98abf1266259_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssets_a4a22219-95de-4b0f-ada3-0c64aff2feec_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssets_label_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssets" xlink:to="lab_us-gaap_OtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_DevelopmentFeesMember_ff15be68-07cd-4429-946d-e7ce44c098c5_terseLabel_en-US" xlink:label="lab_halo_DevelopmentFeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Event-Based Development Fees</link:label>
    <link:label id="lab_halo_DevelopmentFeesMember_label_en-US" xlink:label="lab_halo_DevelopmentFeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Fees [Member]</link:label>
    <link:label id="lab_halo_DevelopmentFeesMember_documentation_en-US" xlink:label="lab_halo_DevelopmentFeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Fees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DevelopmentFeesMember" xlink:href="halo-20220630.xsd#halo_DevelopmentFeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DevelopmentFeesMember" xlink:to="lab_halo_DevelopmentFeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_a8aab47c-61ad-4cf4-b564-f07bde19d4fc_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5efde0ac-4f55-43d6-bf50-f0967c706911_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_4caf1100-777b-4d56-889f-d758210cd7a5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_cee74f2a-4642-44bd-b0ce-37c9d1456c76_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_072390d9-4e1f-41b8-a681-7d664b1e0a34_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales previously expensed as R&amp;D</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_ad6d5474-ee00-4a5f-a9a9-a5f7d9363593_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest_2bffc65a-3131-40bf-8102-145e18c6e4e6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Interest</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c5d77975-dd3a-4b78-9216-4586f3a83e46_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during period, shares, restricted stock award, net of forfeitures (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_Accountsreceivablefromroyalties_db9fc975-eee7-4a6c-8f0d-bcf3591c8345_terseLabel_en-US" xlink:label="lab_halo_Accountsreceivablefromroyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable from royalty payments</link:label>
    <link:label id="lab_halo_Accountsreceivablefromroyalties_label_en-US" xlink:label="lab_halo_Accountsreceivablefromroyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable from royalties</link:label>
    <link:label id="lab_halo_Accountsreceivablefromroyalties_documentation_en-US" xlink:label="lab_halo_Accountsreceivablefromroyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts due from royalties, within one year of the balance sheet date (or the normal operating cycle, whichever is longer) for goods or services (including trade receivables) that have been delivered or sold in the normal course of business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accountsreceivablefromroyalties" xlink:href="halo-20220630.xsd#halo_Accountsreceivablefromroyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_Accountsreceivablefromroyalties" xlink:to="lab_halo_Accountsreceivablefromroyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_87fb3a50-f690-4d39-a6e6-34b63ce9da91_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_9feb6b57-a691-4fcb-a67b-c96e10eb19ae_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_13c29146-1387-4d1f-b424-ec497a58bc82_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a5397831-4c60-4a53-a388-e9eee8c1006a_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_28b8fbc1-c634-42fa-9c9c-d6f1d2a4ce51_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_91c7bc39-1383-400f-9148-123734a61f08_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other prepaid expenses</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ShareBasedCompensationAwardUnvestedMember_68d24135-1c35-4ab1-a69e-eec73cf687b9_terseLabel_en-US" xlink:label="lab_halo_ShareBasedCompensationAwardUnvestedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Compensation Award, Unvested</link:label>
    <link:label id="lab_halo_ShareBasedCompensationAwardUnvestedMember_label_en-US" xlink:label="lab_halo_ShareBasedCompensationAwardUnvestedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Award, Unvested [Member]</link:label>
    <link:label id="lab_halo_ShareBasedCompensationAwardUnvestedMember_documentation_en-US" xlink:label="lab_halo_ShareBasedCompensationAwardUnvestedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Award, Unvested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationAwardUnvestedMember" xlink:href="halo-20220630.xsd#halo_ShareBasedCompensationAwardUnvestedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ShareBasedCompensationAwardUnvestedMember" xlink:to="lab_halo_ShareBasedCompensationAwardUnvestedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_e1af7048-2d9d-40fb-bf5e-1012dd93f870_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_DebtInstrumentThirdPartyCosts_1b441e22-5773-459f-81f0-f3352d6e1a76_terseLabel_en-US" xlink:label="lab_halo_DebtInstrumentThirdPartyCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third-party costs</link:label>
    <link:label id="lab_halo_DebtInstrumentThirdPartyCosts_label_en-US" xlink:label="lab_halo_DebtInstrumentThirdPartyCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Third-Party Costs</link:label>
    <link:label id="lab_halo_DebtInstrumentThirdPartyCosts_documentation_en-US" xlink:label="lab_halo_DebtInstrumentThirdPartyCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Third-Party Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentThirdPartyCosts" xlink:href="halo-20220630.xsd#halo_DebtInstrumentThirdPartyCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DebtInstrumentThirdPartyCosts" xlink:to="lab_halo_DebtInstrumentThirdPartyCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_Accountsreceivablefromproductsalestocollaborators_4592acd9-f662-4c6a-8716-05ff9ea86511_terseLabel_en-US" xlink:label="lab_halo_Accountsreceivablefromproductsalestocollaborators" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable from product sales to partners</link:label>
    <link:label id="lab_halo_Accountsreceivablefromproductsalestocollaborators_label_en-US" xlink:label="lab_halo_Accountsreceivablefromproductsalestocollaborators" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable from product sales to collaborators</link:label>
    <link:label id="lab_halo_Accountsreceivablefromproductsalestocollaborators_documentation_en-US" xlink:label="lab_halo_Accountsreceivablefromproductsalestocollaborators" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable from product sales to collaborators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accountsreceivablefromproductsalestocollaborators" xlink:href="halo-20220630.xsd#halo_Accountsreceivablefromproductsalestocollaborators"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_Accountsreceivablefromproductsalestocollaborators" xlink:to="lab_halo_Accountsreceivablefromproductsalestocollaborators" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_146553c6-d6f4-44b8-881b-49e3276cf352_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchased (shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_c3ccb707-b8b9-469a-b04b-5cf17ee5b6cc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_111b7865-f79c-4123-9baa-46c505c01e6a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_65030d46-6114-4987-bfd7-7bfc3ae2374c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_af71a7e6-28f6-4487-8ff1-1ba9fcbb9d86_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_DeviceLicensingAndDevelopmentMember_bfec8cc4-b8ad-4b83-a65e-82bf49536c52_terseLabel_en-US" xlink:label="lab_halo_DeviceLicensingAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Device Licensing and development revenue</link:label>
    <link:label id="lab_halo_DeviceLicensingAndDevelopmentMember_label_en-US" xlink:label="lab_halo_DeviceLicensingAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Device Licensing and Development [Member]</link:label>
    <link:label id="lab_halo_DeviceLicensingAndDevelopmentMember_documentation_en-US" xlink:label="lab_halo_DeviceLicensingAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Device Licensing and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DeviceLicensingAndDevelopmentMember" xlink:href="halo-20220630.xsd#halo_DeviceLicensingAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_DeviceLicensingAndDevelopmentMember" xlink:to="lab_halo_DeviceLicensingAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_e1bae71c-dd97-4159-a902-8609ee17b92a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Revenues</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_76acc66e-9c15-4eaf-bac6-97222503bd8c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ProprietaryProductsSalesMember_edf2de1c-1e51-4367-9f2f-54fb2c560daf_terseLabel_en-US" xlink:label="lab_halo_ProprietaryProductsSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proprietary Products Sales</link:label>
    <link:label id="lab_halo_ProprietaryProductsSalesMember_label_en-US" xlink:label="lab_halo_ProprietaryProductsSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proprietary Products Sales [Member]</link:label>
    <link:label id="lab_halo_ProprietaryProductsSalesMember_documentation_en-US" xlink:label="lab_halo_ProprietaryProductsSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proprietary Products Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ProprietaryProductsSalesMember" xlink:href="halo-20220630.xsd#halo_ProprietaryProductsSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ProprietaryProductsSalesMember" xlink:to="lab_halo_ProprietaryProductsSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_e1832f6c-737a-4ae9-b98a-c146af46c2bc_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_786197ac-d02c-4118-ae04-05e607486ba1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_af1c6651-e4fc-47e6-b0c6-eeb7737602a3_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_a76c6e3f-abad-4312-9921-2898f9c29a7b_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_XYOSTEDProprietaryProductMember_39c5a259-4438-4404-a957-7d438f9fa41f_terseLabel_en-US" xlink:label="lab_halo_XYOSTEDProprietaryProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XYOSTED proprietary product</link:label>
    <link:label id="lab_halo_XYOSTEDProprietaryProductMember_label_en-US" xlink:label="lab_halo_XYOSTEDProprietaryProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XYOSTED Proprietary Product [Member]</link:label>
    <link:label id="lab_halo_XYOSTEDProprietaryProductMember_documentation_en-US" xlink:label="lab_halo_XYOSTEDProprietaryProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XYOSTED Proprietary Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_XYOSTEDProprietaryProductMember" xlink:href="halo-20220630.xsd#halo_XYOSTEDProprietaryProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_XYOSTEDProprietaryProductMember" xlink:to="lab_halo_XYOSTEDProprietaryProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_a36516c7-e295-46cb-8126-0613d03ec6a8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of loss positions</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_e7e70a09-b100-4758-91ec-ac94d8241022_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_a190409c-9ec3-4842-baf0-466e70c1ef1b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration related to Antares closing indebtedness settled by Halozyme</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare_1f7fc79e-dcf0-4095-84c5-5c3954f62ebb_terseLabel_en-US" xlink:label="lab_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred, cash paid per acquiree share (in usd per share)</link:label>
    <link:label id="lab_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare_label_en-US" xlink:label="lab_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Cash Paid Per Acquiree Share</link:label>
    <link:label id="lab_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare_documentation_en-US" xlink:label="lab_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Cash Paid Per Acquiree Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare" xlink:href="halo-20220630.xsd#halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare" xlink:to="lab_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_RoyaltiesReceivedNumberOfProductsSold_a334aed1-8b46-4537-b2b4-f778aeeac887_terseLabel_en-US" xlink:label="lab_halo_RoyaltiesReceivedNumberOfProductsSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties Received, Number of Products Sold</link:label>
    <link:label id="lab_halo_RoyaltiesReceivedNumberOfProductsSold_label_en-US" xlink:label="lab_halo_RoyaltiesReceivedNumberOfProductsSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties Received, Number of Products Sold</link:label>
    <link:label id="lab_halo_RoyaltiesReceivedNumberOfProductsSold_documentation_en-US" xlink:label="lab_halo_RoyaltiesReceivedNumberOfProductsSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties Received, Number of Products Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RoyaltiesReceivedNumberOfProductsSold" xlink:href="halo-20220630.xsd#halo_RoyaltiesReceivedNumberOfProductsSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_RoyaltiesReceivedNumberOfProductsSold" xlink:to="lab_halo_RoyaltiesReceivedNumberOfProductsSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_28bf9241-6eb6-4f0e-a62f-144affeab444_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Securities</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_7042c679-2518-452e-8d3e-60125228687e_terseLabel_en-US" xlink:label="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements Valuation Inputs [Line Items]</link:label>
    <link:label id="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_label_en-US" xlink:label="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements Valuation Inputs [Line Items]</link:label>
    <link:label id="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_documentation_en-US" xlink:label="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Schedule of Share-based Compensation Arrangements Valuation Inputs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems" xlink:href="halo-20220630.xsd#halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems" xlink:to="lab_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_4510b34f-62df-4b82-8954-f8446faee7e8_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_RSURSAandPRSUawardsMember_0b6bef42-871c-4a4b-a5ad-b8caf5acc4e8_verboseLabel_en-US" xlink:label="lab_halo_RSURSAandPRSUawardsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSAs, RSUs, PSUs and ESPP</link:label>
    <link:label id="lab_halo_RSURSAandPRSUawardsMember_label_en-US" xlink:label="lab_halo_RSURSAandPRSUawardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSU, RSA, and PRSU awards [Member]</link:label>
    <link:label id="lab_halo_RSURSAandPRSUawardsMember_documentation_en-US" xlink:label="lab_halo_RSURSAandPRSUawardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Unit, Restricted Stock Awards, and Performance Restricted Stock Unit awards [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RSURSAandPRSUawardsMember" xlink:href="halo-20220630.xsd#halo_RSURSAandPRSUawardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_RSURSAandPRSUawardsMember" xlink:to="lab_halo_RSURSAandPRSUawardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3902c34b-1cc4-443a-9650-9546d8ff6030_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate, percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableGrossCurrent_21a1cb9a-5aa9-4188-9423-f3370763b676_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableGrossCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, before Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:to="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_1e921795-7dcc-4716-94eb-25fd08560206_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of discounts on marketable securities, net</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_fc362f59-ed69-4905-96f8-419e6ed9041d_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_AntaresPharmaIncMember_f42cdcb9-b33d-4134-9cec-73db0f66f5bf_terseLabel_en-US" xlink:label="lab_halo_AntaresPharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antares Pharma, Inc</link:label>
    <link:label id="lab_halo_AntaresPharmaIncMember_label_en-US" xlink:label="lab_halo_AntaresPharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antares Pharma, Inc [Member]</link:label>
    <link:label id="lab_halo_AntaresPharmaIncMember_documentation_en-US" xlink:label="lab_halo_AntaresPharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antares Pharma, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember" xlink:href="halo-20220630.xsd#halo_AntaresPharmaIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_AntaresPharmaIncMember" xlink:to="lab_halo_AntaresPharmaIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1f4f9b05-7e21-4f77-ae27-fe2c0cfc8e74_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_d89f5d0d-fd16-4d52-b65e-468acf5d9374_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_b6aa43da-125a-4639-9366-460b44fcf3fd_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_43a21752-335a-45df-85c2-26d5e5315a74_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_88dd4f4a-0f46-4d35-8da3-e2e0b6f86308_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_beebba93-f82d-4e83-93b4-7c1850fa9f12_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets_eaec594f-b2b4-49b9-b7a1-7e3cedcbd8f9_terseLabel_en-US" xlink:label="lab_halo_AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_halo_AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets_label_en-US" xlink:label="lab_halo_AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current, excluding Other Contract Assets</link:label>
    <link:label id="lab_halo_AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets_documentation_en-US" xlink:label="lab_halo_AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current, excluding Other Contract Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets" xlink:href="halo-20220630.xsd#halo_AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets" xlink:to="lab_halo_AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_ba93cbc0-13a1-426d-b3ec-4e689ca89f21_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_5d7a4e71-cf65-4d77-87ec-6238a00101bf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_266e0729-cd64-4596-b7b7-2abb7e5028e9_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f5c41f22-4df9-4635-bc2d-1d33ef0de04b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_f734ab79-4960-4087-8f9a-65a66fca821c_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_34dad9ad-2c49-4e98-9ffe-066e233038ce_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period One</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_92bae3f2-dc89-46ef-bf2e-2f708106a9bf_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Value</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_c1f5f9a6-8bec-44cd-a546-51bc905ef9d2_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_51979dbb-85e5-4510-bae8-0f796903a454_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_ec6d4eca-7dce-4f77-9f0d-78b473c47d70_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_b73e19da-11af-4530-b63c-ad4bddc2d53d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, current portion</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent" xlink:to="lab_us-gaap_DeferredRevenueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_5d9383c2-d541-4a9e-8a24-372d3e193dbf_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9a761a0e-53b1-4ec3-a391-eb8ce1bcc806_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_860400b5-5ba1-4808-8ec7-f08365ab6a45_terseLabel_en-US" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Interest Type [Axis]</link:label>
    <link:label id="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_label_en-US" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Interest Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_86c34436-282e-43d6-b86e-176ee6376528_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares of common stock issued as a result of stock option exercises (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_4daef6e7-90f4-4215-a4fc-8a37c796f6fa_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue and Cost of Product Sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9fd5eab0-5919-48ff-b4ef-40642ac9a14d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9e2bef39-647b-4b56-b50c-746728d1be2e_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding for diluted net income (loss) per share (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_a112afc6-4757-466c-a018-e6eefb8b426a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_AccruedLiabilitiesNoncurrent_480f2785-e641-4020-b0f2-973f630327ae_negatedTerseLabel_en-US" xlink:label="lab_halo_AccruedLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less long-term portion</link:label>
    <link:label id="lab_halo_AccruedLiabilitiesNoncurrent_label_en-US" xlink:label="lab_halo_AccruedLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Noncurrent</link:label>
    <link:label id="lab_halo_AccruedLiabilitiesNoncurrent_documentation_en-US" xlink:label="lab_halo_AccruedLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AccruedLiabilitiesNoncurrent" xlink:href="halo-20220630.xsd#halo_AccruedLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_AccruedLiabilitiesNoncurrent" xlink:to="lab_halo_AccruedLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_458fbe7e-68b2-4451-b73e-4a07b350d34d_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_57e671a5-554a-4e9c-a8c0-cb1fcfd1dcb0_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_6306c14f-cb93-474c-a616-ec90c08da376_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_40bccbfb-f38e-459b-bce4-859e46324537_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_dae6a4e7-a559-4d1d-a65c-d7d2a3ed07dd_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_82eb18d8-afa1-47ad-a732-d7ffae269504_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_9de11948-25da-4d92-a36c-fe9f04c96fb3_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_cfe1d822-be5a-4f38-b7d4-84b418d48db2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_AllowanceforDistributionFeesandDiscounts_d7ad202f-216b-4a82-8d6e-07fafc22496c_negatedTerseLabel_en-US" xlink:label="lab_halo_AllowanceforDistributionFeesandDiscounts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for distribution fees and discounts</link:label>
    <link:label id="lab_halo_AllowanceforDistributionFeesandDiscounts_label_en-US" xlink:label="lab_halo_AllowanceforDistributionFeesandDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for Distribution Fees and Discounts</link:label>
    <link:label id="lab_halo_AllowanceforDistributionFeesandDiscounts_documentation_en-US" xlink:label="lab_halo_AllowanceforDistributionFeesandDiscounts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for Discount and Distribution Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AllowanceforDistributionFeesandDiscounts" xlink:href="halo-20220630.xsd#halo_AllowanceforDistributionFeesandDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_AllowanceforDistributionFeesandDiscounts" xlink:to="lab_halo_AllowanceforDistributionFeesandDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_43230712-c955-4050-8ec0-8fc6f0157726_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_104a6fa3-e02e-4f09-a3b7-0b1e7778d42f_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_410d3085-698e-447f-81a7-fb6c165625bc_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_5dfbce0d-b908-42df-907f-5468fe68c890_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8540916a-1195-443c-8219-2710680c9aaa_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_fac4b9e4-177c-466e-882c-aea79417379f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a7aede7e-160d-41d4-8463-8a586470318a_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_573c201a-67fc-4386-bc24-a749b97d8ad8_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_60106139-8eef-4bc7-9931-e4130f94e44a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_f3ff8e7b-b476-4edf-9764-28e6e7595796_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_ed19c1ff-9e68-4fe3-87f8-b10ab354e448_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for tax withholding for restricted stock units vested, net</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_f1849390-9050-4837-b7ce-f52d49a7f733_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_A2021ESPPPlanMember_8754a6f4-65ad-4308-a370-31937f68a709_terseLabel_en-US" xlink:label="lab_halo_A2021ESPPPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 ESPP Plan</link:label>
    <link:label id="lab_halo_A2021ESPPPlanMember_label_en-US" xlink:label="lab_halo_A2021ESPPPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 ESPP Plan [Member]</link:label>
    <link:label id="lab_halo_A2021ESPPPlanMember_documentation_en-US" xlink:label="lab_halo_A2021ESPPPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 ESPP Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A2021ESPPPlanMember" xlink:href="halo-20220630.xsd#halo_A2021ESPPPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_A2021ESPPPlanMember" xlink:to="lab_halo_A2021ESPPPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_VariableRateComponentDomain_8ac37945-1ea3-457a-875a-40e0839bb274_terseLabel_en-US" xlink:label="lab_halo_VariableRateComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component [Domain]</link:label>
    <link:label id="lab_halo_VariableRateComponentDomain_label_en-US" xlink:label="lab_halo_VariableRateComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component [Domain]</link:label>
    <link:label id="lab_halo_VariableRateComponentDomain_documentation_en-US" xlink:label="lab_halo_VariableRateComponentDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentDomain" xlink:href="halo-20220630.xsd#halo_VariableRateComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_VariableRateComponentDomain" xlink:to="lab_halo_VariableRateComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_BulkrHuPH20Member_f8a32a5b-749d-4d12-8d4e-2379b2f01542_terseLabel_en-US" xlink:label="lab_halo_BulkrHuPH20Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">bulk rHuPH20</link:label>
    <link:label id="lab_halo_BulkrHuPH20Member_label_en-US" xlink:label="lab_halo_BulkrHuPH20Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">bulk rHuPH20 [Member]</link:label>
    <link:label id="lab_halo_BulkrHuPH20Member_documentation_en-US" xlink:label="lab_halo_BulkrHuPH20Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">bulk rHuPH20 for use in collaboration products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BulkrHuPH20Member" xlink:href="halo-20220630.xsd#halo_BulkrHuPH20Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_BulkrHuPH20Member" xlink:to="lab_halo_BulkrHuPH20Member" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_Accruedmanufacturingexpenses_36915701-d1f2-45c5-b77a-1c32e3315f2d_terseLabel_en-US" xlink:label="lab_halo_Accruedmanufacturingexpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued outsourced manufacturing expenses</link:label>
    <link:label id="lab_halo_Accruedmanufacturingexpenses_label_en-US" xlink:label="lab_halo_Accruedmanufacturingexpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued manufacturing expenses</link:label>
    <link:label id="lab_halo_Accruedmanufacturingexpenses_documentation_en-US" xlink:label="lab_halo_Accruedmanufacturingexpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued manufacturing expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accruedmanufacturingexpenses" xlink:href="halo-20220630.xsd#halo_Accruedmanufacturingexpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_Accruedmanufacturingexpenses" xlink:to="lab_halo_Accruedmanufacturingexpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ea9ca99e-c8d2-43cd-b6c2-98fe25a39836_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_7329c7e0-18ec-4e1e-bd2a-44dc5d43dd18_verboseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_f1d39acb-da69-4efb-9006-14093719394e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_837b79f8-3be3-4a7b-b8d3-f806b833fb79_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance cost</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_AnnualInterestPaymentPeriodDomain_76b24067-cd79-4f02-b113-e7ce328d04cd_terseLabel_en-US" xlink:label="lab_halo_AnnualInterestPaymentPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Interest Payment Period [Domain]</link:label>
    <link:label id="lab_halo_AnnualInterestPaymentPeriodDomain_label_en-US" xlink:label="lab_halo_AnnualInterestPaymentPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Interest Payment Period [Domain]</link:label>
    <link:label id="lab_halo_AnnualInterestPaymentPeriodDomain_documentation_en-US" xlink:label="lab_halo_AnnualInterestPaymentPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Interest Payment Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AnnualInterestPaymentPeriodDomain" xlink:href="halo-20220630.xsd#halo_AnnualInterestPaymentPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_AnnualInterestPaymentPeriodDomain" xlink:to="lab_halo_AnnualInterestPaymentPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_46b0b84e-3e6f-4f13-959f-b24cbf89a7c7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_7aa12755-0ee4-4729-9927-af5141ceaf6a_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_d3a94a63-2a96-4993-955b-e98febc9fdd1_terseLabel_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fed Funds Rate</link:label>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_label_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fed Funds Effective Rate Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:to="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_987db197-3f65-42bb-bc4e-12f73d71a2fa_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fa5d17f4-6f46-4f25-b364-3101fedbca24_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_26e3b79d-80bc-46ca-9411-1e1dd94f199a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d0c0287a-d07d-4e35-b117-cee80ae294b0_verboseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adoption and Pending Adoption of Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_A1.25ConvertibleSeniorNotesdue2024Member_af0bff8e-d4c3-4947-b8f5-e68acfa39fbe_terseLabel_en-US" xlink:label="lab_halo_A1.25ConvertibleSeniorNotesdue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.25% Convertible Senior Notes due 2024</link:label>
    <link:label id="lab_halo_A1.25ConvertibleSeniorNotesdue2024Member_label_en-US" xlink:label="lab_halo_A1.25ConvertibleSeniorNotesdue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.25% Convertible Senior Notes due 2024 [Member]</link:label>
    <link:label id="lab_halo_A1.25ConvertibleSeniorNotesdue2024Member_documentation_en-US" xlink:label="lab_halo_A1.25ConvertibleSeniorNotesdue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.25% Convertible Senior Notes due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member" xlink:href="halo-20220630.xsd#halo_A1.25ConvertibleSeniorNotesdue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member" xlink:to="lab_halo_A1.25ConvertibleSeniorNotesdue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_88f6b2f4-c6df-4216-b0dc-2e73d20d485e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_6608f6ed-6196-4259-a2b9-b73ce08e1fc5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_cfb97262-ad64-44d6-b43f-7948c1589eda_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_0565e4a4-ebdc-4c37-9f28-95abf22d3262_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock_29f893ec-c012-4de1-9e65-1736b362dbab_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_51cfe6f0-a5e4-42b0-8f4e-dec43737b05d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Value</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_b1a2141f-9ffb-4e88-99ae-1efd03a8d367_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_e674e4e5-1e53-4c9e-acb5-9ccef952a088_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_231904d4-fb09-4d4d-96f8-7d0f6e9b396f_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Beginning Balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_8cb5d2c6-f42c-410a-acf1-07b1a360b0bb_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Ending Balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenue_b01ccf28-1134-4663-b485-80312f361140_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues</link:label>
    <link:label id="lab_us-gaap_DeferredRevenue_label_en-US" xlink:label="lab_us-gaap_DeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenue" xlink:to="lab_us-gaap_DeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_da3fdfe1-73f3-467c-84be-6b9cb77d0cf5_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_halo_Accountsreceivablefromproductsales_d8de358b-00c0-4df4-987b-bcf14a213d6f_terseLabel_en-US" xlink:label="lab_halo_Accountsreceivablefromproductsales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable from other product sales</link:label>
    <link:label id="lab_halo_Accountsreceivablefromproductsales_label_en-US" xlink:label="lab_halo_Accountsreceivablefromproductsales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable from product sales</link:label>
    <link:label id="lab_halo_Accountsreceivablefromproductsales_documentation_en-US" xlink:label="lab_halo_Accountsreceivablefromproductsales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable from product sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accountsreceivablefromproductsales" xlink:href="halo-20220630.xsd#halo_Accountsreceivablefromproductsales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_halo_Accountsreceivablefromproductsales" xlink:to="lab_halo_Accountsreceivablefromproductsales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_3ba60c31-432a-46bb-8356-61f7a436b591_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_1106e006-9b8a-497a-942c-59dcfe8a3027_verboseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6b44514c-1d74-4de3-89df-c9e7897a8815_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_51887898-e8f7-441b-adcc-b07ccd16ed48_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_bce64492-2674-448c-849c-5cca2ce354ea_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_2bc62b48-1865-45f5-a8be-a212697da8a6_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_9319925e-1c0a-4fc1-8f3d-6d6432d67336_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_96f45557-7c05-459c-9200-b17d6a438227_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_43b1dc08-05b5-4120-ab79-1f6ccb2ca936_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_5365a99e-e169-4e3f-ae86-792a9066016a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock" xlink:to="lab_us-gaap_LongTermDebtTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9dc1c9b8-f6ca-4166-b43f-f1ba9e2b2ddc_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>halo-20220630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:73069a0e-fffd-482c-8df8-d4ff810732e3,g:be228a77-9c6c-4f8e-9f2c-fe0d390b647c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.halozyme.com/role/CoverPage" xlink:type="simple" xlink:href="halo-20220630.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_57cc60c8-e6ae-43ea-8c79-aef6f749a4f3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_5d1aa9de-2f5a-4527-a9c8-dba245f931d9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57cc60c8-e6ae-43ea-8c79-aef6f749a4f3" xlink:to="loc_dei_DocumentType_5d1aa9de-2f5a-4527-a9c8-dba245f931d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_6be7a84d-8fec-4472-8946-6eeee20e489f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57cc60c8-e6ae-43ea-8c79-aef6f749a4f3" xlink:to="loc_dei_DocumentQuarterlyReport_6be7a84d-8fec-4472-8946-6eeee20e489f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_15db77a5-4b6a-49c5-9fb2-804ea5478a99" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57cc60c8-e6ae-43ea-8c79-aef6f749a4f3" xlink:to="loc_dei_DocumentPeriodEndDate_15db77a5-4b6a-49c5-9fb2-804ea5478a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_1725b822-0a5b-47f7-9352-00acc719c452" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57cc60c8-e6ae-43ea-8c79-aef6f749a4f3" xlink:to="loc_dei_DocumentTransitionReport_1725b822-0a5b-47f7-9352-00acc719c452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_4826a145-520c-4027-b2c8-b5914a18a03f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57cc60c8-e6ae-43ea-8c79-aef6f749a4f3" xlink:to="loc_dei_EntityFileNumber_4826a145-520c-4027-b2c8-b5914a18a03f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_b78e0fc8-7408-4e9e-85a5-394634b1661f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57cc60c8-e6ae-43ea-8c79-aef6f749a4f3" xlink:to="loc_dei_EntityRegistrantName_b78e0fc8-7408-4e9e-85a5-394634b1661f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_7e73871b-a8ca-4fd1-9547-b801b6ce6428" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57cc60c8-e6ae-43ea-8c79-aef6f749a4f3" xlink:to="loc_dei_EntityIncorporationStateCountryCode_7e73871b-a8ca-4fd1-9547-b801b6ce6428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_778b2515-76ce-40f6-ac40-a3c8f6e5dcf8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57cc60c8-e6ae-43ea-8c79-aef6f749a4f3" xlink:to="loc_dei_EntityTaxIdentificationNumber_778b2515-76ce-40f6-ac40-a3c8f6e5dcf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_d48d84cb-75e6-4290-9272-0311bac17fad" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57cc60c8-e6ae-43ea-8c79-aef6f749a4f3" xlink:to="loc_dei_EntityAddressAddressLine1_d48d84cb-75e6-4290-9272-0311bac17fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_8062001e-0b9d-468f-a849-65221b16ec5f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57cc60c8-e6ae-43ea-8c79-aef6f749a4f3" xlink:to="loc_dei_EntityAddressCityOrTown_8062001e-0b9d-468f-a849-65221b16ec5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_78b9e219-c94d-4641-a6f0-74ce9fd61cf2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57cc60c8-e6ae-43ea-8c79-aef6f749a4f3" xlink:to="loc_dei_EntityAddressStateOrProvince_78b9e219-c94d-4641-a6f0-74ce9fd61cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_e59cb959-c07c-4098-9bb3-57e842aaf388" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57cc60c8-e6ae-43ea-8c79-aef6f749a4f3" xlink:to="loc_dei_EntityAddressPostalZipCode_e59cb959-c07c-4098-9bb3-57e842aaf388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_04c04d33-3ba1-478f-8a07-87c3756cd8c6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57cc60c8-e6ae-43ea-8c79-aef6f749a4f3" xlink:to="loc_dei_CityAreaCode_04c04d33-3ba1-478f-8a07-87c3756cd8c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_d9bbf3db-fe80-4abc-8833-7b03f6c75f33" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57cc60c8-e6ae-43ea-8c79-aef6f749a4f3" xlink:to="loc_dei_LocalPhoneNumber_d9bbf3db-fe80-4abc-8833-7b03f6c75f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_40622115-d5f9-4bf3-80e3-9e5725cd9ef3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57cc60c8-e6ae-43ea-8c79-aef6f749a4f3" xlink:to="loc_dei_Security12bTitle_40622115-d5f9-4bf3-80e3-9e5725cd9ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_752ae75c-f030-477c-8f14-454c09170420" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57cc60c8-e6ae-43ea-8c79-aef6f749a4f3" xlink:to="loc_dei_TradingSymbol_752ae75c-f030-477c-8f14-454c09170420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_cf7b45ef-101c-482c-b4f9-a9991d1dbd92" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57cc60c8-e6ae-43ea-8c79-aef6f749a4f3" xlink:to="loc_dei_SecurityExchangeName_cf7b45ef-101c-482c-b4f9-a9991d1dbd92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_ad8b8f7b-69e9-4829-b4ee-e558b1108f4c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57cc60c8-e6ae-43ea-8c79-aef6f749a4f3" xlink:to="loc_dei_EntityCurrentReportingStatus_ad8b8f7b-69e9-4829-b4ee-e558b1108f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_a94c243e-be30-47bc-93e5-5136de6c5d22" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57cc60c8-e6ae-43ea-8c79-aef6f749a4f3" xlink:to="loc_dei_EntityInteractiveDataCurrent_a94c243e-be30-47bc-93e5-5136de6c5d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_5a0b9208-a486-434d-b312-57c52c049af1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57cc60c8-e6ae-43ea-8c79-aef6f749a4f3" xlink:to="loc_dei_EntitySmallBusiness_5a0b9208-a486-434d-b312-57c52c049af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_db2a02f5-279c-4420-8687-bf989e67cdac" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57cc60c8-e6ae-43ea-8c79-aef6f749a4f3" xlink:to="loc_dei_EntityEmergingGrowthCompany_db2a02f5-279c-4420-8687-bf989e67cdac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_b6763cbf-1681-42d6-ad51-e3bc7636f349" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57cc60c8-e6ae-43ea-8c79-aef6f749a4f3" xlink:to="loc_dei_EntityShellCompany_b6763cbf-1681-42d6-ad51-e3bc7636f349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_92632d2d-00cf-4bf5-a2ab-14af471696a1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57cc60c8-e6ae-43ea-8c79-aef6f749a4f3" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_92632d2d-00cf-4bf5-a2ab-14af471696a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_379bf848-1b2e-4781-92e9-f1c61aa98268" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57cc60c8-e6ae-43ea-8c79-aef6f749a4f3" xlink:to="loc_dei_EntityCentralIndexKey_379bf848-1b2e-4781-92e9-f1c61aa98268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_81dba9d4-cb06-4a91-8243-405fdae9923c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57cc60c8-e6ae-43ea-8c79-aef6f749a4f3" xlink:to="loc_dei_AmendmentFlag_81dba9d4-cb06-4a91-8243-405fdae9923c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_a6f6d32e-8ab0-4cc4-b171-2ef0fc6d07f4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57cc60c8-e6ae-43ea-8c79-aef6f749a4f3" xlink:to="loc_dei_DocumentFiscalYearFocus_a6f6d32e-8ab0-4cc4-b171-2ef0fc6d07f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_38da845f-bc51-4149-a19b-6f79846a68d1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57cc60c8-e6ae-43ea-8c79-aef6f749a4f3" xlink:to="loc_dei_DocumentFiscalPeriodFocus_38da845f-bc51-4149-a19b-6f79846a68d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_bf11940c-6cbe-49d1-be38-164e7610c3c8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57cc60c8-e6ae-43ea-8c79-aef6f749a4f3" xlink:to="loc_dei_CurrentFiscalYearEndDate_bf11940c-6cbe-49d1-be38-164e7610c3c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_477c47e0-d91f-442e-8419-a8d53c0e4d82" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57cc60c8-e6ae-43ea-8c79-aef6f749a4f3" xlink:to="loc_dei_EntityFilerCategory_477c47e0-d91f-442e-8419-a8d53c0e4d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="halo-20220630.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_b594f92d-5a12-49b0-8462-7d290b359020" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_70ca952c-840a-404c-a2f8-d27ecf08331c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b594f92d-5a12-49b0-8462-7d290b359020" xlink:to="loc_us-gaap_AssetsAbstract_70ca952c-840a-404c-a2f8-d27ecf08331c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_adcdf2bd-286f-48bb-ab5e-feba9231d8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_70ca952c-840a-404c-a2f8-d27ecf08331c" xlink:to="loc_us-gaap_AssetsCurrentAbstract_adcdf2bd-286f-48bb-ab5e-feba9231d8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e307b41e-66e2-47a7-8f5d-441b6f06d3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_adcdf2bd-286f-48bb-ab5e-feba9231d8a7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e307b41e-66e2-47a7-8f5d-441b6f06d3d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f8ccac54-05af-4b48-a8a9-969bf33abd5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_adcdf2bd-286f-48bb-ab5e-feba9231d8a7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f8ccac54-05af-4b48-a8a9-969bf33abd5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_835381ba-5816-4257-9f44-69f56b496885" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_adcdf2bd-286f-48bb-ab5e-feba9231d8a7" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_835381ba-5816-4257-9f44-69f56b496885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_2001925f-12ea-48ca-9cf5-a0a1577da739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_adcdf2bd-286f-48bb-ab5e-feba9231d8a7" xlink:to="loc_us-gaap_InventoryNet_2001925f-12ea-48ca-9cf5-a0a1577da739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_72c04ea3-78fa-4775-8d6d-e5130e8f91c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_adcdf2bd-286f-48bb-ab5e-feba9231d8a7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_72c04ea3-78fa-4775-8d6d-e5130e8f91c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2ba26bc0-f64a-46a7-8179-2c2b5e034f41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_adcdf2bd-286f-48bb-ab5e-feba9231d8a7" xlink:to="loc_us-gaap_AssetsCurrent_2ba26bc0-f64a-46a7-8179-2c2b5e034f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_a076b398-392c-4acb-92df-e59f60af5c69" xlink:href="halo-20220630.xsd#halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_70ca952c-840a-404c-a2f8-d27ecf08331c" xlink:to="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_a076b398-392c-4acb-92df-e59f60af5c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_1fddddb2-6850-409f-ad32-4dea48900150" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_70ca952c-840a-404c-a2f8-d27ecf08331c" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_1fddddb2-6850-409f-ad32-4dea48900150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a61aa237-f601-442e-9892-954fdf8ef2b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_70ca952c-840a-404c-a2f8-d27ecf08331c" xlink:to="loc_us-gaap_Goodwill_a61aa237-f601-442e-9892-954fdf8ef2b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_21bb9fc7-07ae-4fac-a8ae-773e8dfc7889" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_70ca952c-840a-404c-a2f8-d27ecf08331c" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_21bb9fc7-07ae-4fac-a8ae-773e8dfc7889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_061c46bc-2336-4430-8e31-50be1a40af3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_70ca952c-840a-404c-a2f8-d27ecf08331c" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_061c46bc-2336-4430-8e31-50be1a40af3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_125512ae-7c78-411e-9d23-46bb8cfa7a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_70ca952c-840a-404c-a2f8-d27ecf08331c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_125512ae-7c78-411e-9d23-46bb8cfa7a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_84e73c1c-44b0-43a2-b020-fdb88e7ef2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_70ca952c-840a-404c-a2f8-d27ecf08331c" xlink:to="loc_us-gaap_Assets_84e73c1c-44b0-43a2-b020-fdb88e7ef2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8ccd83c1-2401-4917-8951-9be78a16f144" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b594f92d-5a12-49b0-8462-7d290b359020" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8ccd83c1-2401-4917-8951-9be78a16f144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_5a024733-5c88-4e2a-8544-484f8d632925" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8ccd83c1-2401-4917-8951-9be78a16f144" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_5a024733-5c88-4e2a-8544-484f8d632925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a65c02b0-cb88-45e7-97fb-e03064327390" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5a024733-5c88-4e2a-8544-484f8d632925" xlink:to="loc_us-gaap_AccountsPayableCurrent_a65c02b0-cb88-45e7-97fb-e03064327390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_66321750-fe80-4a45-92dd-8430b72b1da3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5a024733-5c88-4e2a-8544-484f8d632925" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_66321750-fe80-4a45-92dd-8430b72b1da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_aa2034c2-d237-4924-b9ff-d7a6769372c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5a024733-5c88-4e2a-8544-484f8d632925" xlink:to="loc_us-gaap_DeferredRevenueCurrent_aa2034c2-d237-4924-b9ff-d7a6769372c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_045d1489-1c95-423c-9eeb-1563c084111a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5a024733-5c88-4e2a-8544-484f8d632925" xlink:to="loc_us-gaap_LongTermDebtCurrent_045d1489-1c95-423c-9eeb-1563c084111a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_bd54eb56-ee95-43f9-8fa1-65954c1f52d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5a024733-5c88-4e2a-8544-484f8d632925" xlink:to="loc_us-gaap_LiabilitiesCurrent_bd54eb56-ee95-43f9-8fa1-65954c1f52d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_995dfd1d-567c-4735-bf2b-4c84ebc194ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8ccd83c1-2401-4917-8951-9be78a16f144" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_995dfd1d-567c-4735-bf2b-4c84ebc194ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_7f8a88aa-77b3-4228-a07e-3ced9bed34a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8ccd83c1-2401-4917-8951-9be78a16f144" xlink:to="loc_us-gaap_LongTermDebt_7f8a88aa-77b3-4228-a07e-3ced9bed34a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_a653a8f7-6f26-4163-b477-3a6c53f974dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8ccd83c1-2401-4917-8951-9be78a16f144" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_a653a8f7-6f26-4163-b477-3a6c53f974dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_c02b8b3b-9da3-43dd-81ef-620bb83b7c53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8ccd83c1-2401-4917-8951-9be78a16f144" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_c02b8b3b-9da3-43dd-81ef-620bb83b7c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_a31cec3c-dff6-4f93-8299-551f86ef1993" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8ccd83c1-2401-4917-8951-9be78a16f144" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_a31cec3c-dff6-4f93-8299-551f86ef1993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_c8355ed6-ef89-458a-b325-76141292a358" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8ccd83c1-2401-4917-8951-9be78a16f144" xlink:to="loc_us-gaap_CommitmentsAndContingencies_c8355ed6-ef89-458a-b325-76141292a358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_9f595794-7332-478e-8afe-074fd3e53470" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8ccd83c1-2401-4917-8951-9be78a16f144" xlink:to="loc_us-gaap_StockholdersEquityAbstract_9f595794-7332-478e-8afe-074fd3e53470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_359f9568-7c6a-4168-b5dd-8621034cb513" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9f595794-7332-478e-8afe-074fd3e53470" xlink:to="loc_us-gaap_PreferredStockValue_359f9568-7c6a-4168-b5dd-8621034cb513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_6401014c-0bd7-4195-8278-c36f29f0c352" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9f595794-7332-478e-8afe-074fd3e53470" xlink:to="loc_us-gaap_CommonStockValue_6401014c-0bd7-4195-8278-c36f29f0c352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_89603157-3bee-418e-a472-894e04aa49bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9f595794-7332-478e-8afe-074fd3e53470" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_89603157-3bee-418e-a472-894e04aa49bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_bb1bf3e4-e69c-48f3-9d17-a5884fd90592" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9f595794-7332-478e-8afe-074fd3e53470" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_bb1bf3e4-e69c-48f3-9d17-a5884fd90592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ac3a418e-b596-4c6b-a3db-d5a891061a33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9f595794-7332-478e-8afe-074fd3e53470" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ac3a418e-b596-4c6b-a3db-d5a891061a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4aef61bd-4d06-4451-8799-7ef492a29925" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9f595794-7332-478e-8afe-074fd3e53470" xlink:to="loc_us-gaap_StockholdersEquity_4aef61bd-4d06-4451-8799-7ef492a29925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_10c572ab-53e3-4d35-8cb4-cb66869acd22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8ccd83c1-2401-4917-8951-9be78a16f144" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_10c572ab-53e3-4d35-8cb4-cb66869acd22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="halo-20220630.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2592c9fb-4388-4f08-854a-60358c2e1185" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_12b60e2a-4ce5-475e-a7a1-7641baf3cfac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2592c9fb-4388-4f08-854a-60358c2e1185" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_12b60e2a-4ce5-475e-a7a1-7641baf3cfac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_e6aa66ee-8575-4a54-9784-8a66a00b9d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2592c9fb-4388-4f08-854a-60358c2e1185" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_e6aa66ee-8575-4a54-9784-8a66a00b9d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_2a66df40-2f1e-45d7-8d66-6ddc1a16f032" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2592c9fb-4388-4f08-854a-60358c2e1185" xlink:to="loc_us-gaap_PreferredStockSharesIssued_2a66df40-2f1e-45d7-8d66-6ddc1a16f032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_c8bb213c-0106-4afb-864d-eb303e48cabd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2592c9fb-4388-4f08-854a-60358c2e1185" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_c8bb213c-0106-4afb-864d-eb303e48cabd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9b3c071e-d931-460c-a522-27ebc9e192ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2592c9fb-4388-4f08-854a-60358c2e1185" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9b3c071e-d931-460c-a522-27ebc9e192ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0dfdcf48-e13c-4325-8f24-38549d5b2e12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2592c9fb-4388-4f08-854a-60358c2e1185" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_0dfdcf48-e13c-4325-8f24-38549d5b2e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_1049c679-f033-46ad-be4e-6492c9da72d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2592c9fb-4388-4f08-854a-60358c2e1185" xlink:to="loc_us-gaap_CommonStockSharesIssued_1049c679-f033-46ad-be4e-6492c9da72d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_64fd73f3-6268-45ab-ab68-248f35e2c1df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2592c9fb-4388-4f08-854a-60358c2e1185" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_64fd73f3-6268-45ab-ab68-248f35e2c1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="halo-20220630.xsd#CondensedConsolidatedStatementsofOperationsUnaudited"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_69205764-100e-4cd7-a03d-0552d975e27c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_869f9d6b-1e3d-4b87-89cc-168d63b59074" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_69205764-100e-4cd7-a03d-0552d975e27c" xlink:to="loc_us-gaap_StatementTable_869f9d6b-1e3d-4b87-89cc-168d63b59074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fe1c6e3b-f4e3-4aaa-8f88-434d41225f5e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_869f9d6b-1e3d-4b87-89cc-168d63b59074" xlink:to="loc_srt_ProductOrServiceAxis_fe1c6e3b-f4e3-4aaa-8f88-434d41225f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c1afea99-1e37-45db-a58b-016f793f8df6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_fe1c6e3b-f4e3-4aaa-8f88-434d41225f5e" xlink:to="loc_srt_ProductsAndServicesDomain_c1afea99-1e37-45db-a58b-016f793f8df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_65c06d07-6347-4917-bb0c-9b0d7edcd72d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c1afea99-1e37-45db-a58b-016f793f8df6" xlink:to="loc_us-gaap_RoyaltyMember_65c06d07-6347-4917-bb0c-9b0d7edcd72d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_275d57f9-ef5a-4698-983d-a54376b81c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c1afea99-1e37-45db-a58b-016f793f8df6" xlink:to="loc_us-gaap_ProductMember_275d57f9-ef5a-4698-983d-a54376b81c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_CollaborativeAgreementsMember_a7b687b6-c923-4569-94a1-e7c711782a09" xlink:href="halo-20220630.xsd#halo_CollaborativeAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c1afea99-1e37-45db-a58b-016f793f8df6" xlink:to="loc_halo_CollaborativeAgreementsMember_a7b687b6-c923-4569-94a1-e7c711782a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_09bd6f62-7bec-4be1-9827-f6f139f27f13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_869f9d6b-1e3d-4b87-89cc-168d63b59074" xlink:to="loc_us-gaap_StatementLineItems_09bd6f62-7bec-4be1-9827-f6f139f27f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_6239fe96-a56f-4544-8985-9e032f4b2114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_09bd6f62-7bec-4be1-9827-f6f139f27f13" xlink:to="loc_us-gaap_RevenuesAbstract_6239fe96-a56f-4544-8985-9e032f4b2114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5dbc62bb-6ca5-493f-aae2-d9f1f2646257" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_6239fe96-a56f-4544-8985-9e032f4b2114" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5dbc62bb-6ca5-493f-aae2-d9f1f2646257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_c53c441a-dbe5-4736-8ce9-007168c659a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_09bd6f62-7bec-4be1-9827-f6f139f27f13" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_c53c441a-dbe5-4736-8ce9-007168c659a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_fbef14a3-46c2-47ba-b219-9936b5b81eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c53c441a-dbe5-4736-8ce9-007168c659a2" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_fbef14a3-46c2-47ba-b219-9936b5b81eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_316b730e-237c-4f94-86d4-aa99fae958d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c53c441a-dbe5-4736-8ce9-007168c659a2" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_316b730e-237c-4f94-86d4-aa99fae958d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_46ead0db-473d-43e9-b67a-fd22aa61728d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c53c441a-dbe5-4736-8ce9-007168c659a2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_46ead0db-473d-43e9-b67a-fd22aa61728d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_db6a1799-88ac-4bc8-b1c7-1840419b4ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c53c441a-dbe5-4736-8ce9-007168c659a2" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_db6a1799-88ac-4bc8-b1c7-1840419b4ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_d70baac7-da01-4f2d-897c-2a71c63d7ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c53c441a-dbe5-4736-8ce9-007168c659a2" xlink:to="loc_us-gaap_CostsAndExpenses_d70baac7-da01-4f2d-897c-2a71c63d7ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b55ad54b-d034-4135-bafe-8b021196cfa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_09bd6f62-7bec-4be1-9827-f6f139f27f13" xlink:to="loc_us-gaap_OperatingIncomeLoss_b55ad54b-d034-4135-bafe-8b021196cfa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_e9d489fc-c763-474a-a940-d62ae0c50bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_09bd6f62-7bec-4be1-9827-f6f139f27f13" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_e9d489fc-c763-474a-a940-d62ae0c50bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_039d3ea2-96c1-466e-a670-43037d747f87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_e9d489fc-c763-474a-a940-d62ae0c50bcb" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_039d3ea2-96c1-466e-a670-43037d747f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_73ad6d44-fc72-47cb-9db2-71b1ff61e35d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_e9d489fc-c763-474a-a940-d62ae0c50bcb" xlink:to="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_73ad6d44-fc72-47cb-9db2-71b1ff61e35d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_265fcf20-454a-42db-9249-18fa18345713" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_e9d489fc-c763-474a-a940-d62ae0c50bcb" xlink:to="loc_us-gaap_InterestExpense_265fcf20-454a-42db-9249-18fa18345713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3c581a94-aa9d-4482-bb27-a4cfc4801dab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_09bd6f62-7bec-4be1-9827-f6f139f27f13" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3c581a94-aa9d-4482-bb27-a4cfc4801dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_66b78d07-a50c-4e6a-b8a7-17f9703e45a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_09bd6f62-7bec-4be1-9827-f6f139f27f13" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_66b78d07-a50c-4e6a-b8a7-17f9703e45a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bd4960fc-f277-4516-a7ef-493d814e24f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_09bd6f62-7bec-4be1-9827-f6f139f27f13" xlink:to="loc_us-gaap_NetIncomeLoss_bd4960fc-f277-4516-a7ef-493d814e24f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a42a6681-75f7-444d-8cb7-5ea77b9ded1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_09bd6f62-7bec-4be1-9827-f6f139f27f13" xlink:to="loc_us-gaap_EarningsPerShareAbstract_a42a6681-75f7-444d-8cb7-5ea77b9ded1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6e00d106-44f6-45df-9d4a-6a33aa52b5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a42a6681-75f7-444d-8cb7-5ea77b9ded1b" xlink:to="loc_us-gaap_EarningsPerShareBasic_6e00d106-44f6-45df-9d4a-6a33aa52b5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2718c953-f53a-4d63-aafc-6dc308fc9b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a42a6681-75f7-444d-8cb7-5ea77b9ded1b" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2718c953-f53a-4d63-aafc-6dc308fc9b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_b90cd4db-9458-4843-b178-626fe718f9d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_09bd6f62-7bec-4be1-9827-f6f139f27f13" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_b90cd4db-9458-4843-b178-626fe718f9d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bfcc23b7-a6a4-4c9a-9a3f-a70f94d7cd17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_b90cd4db-9458-4843-b178-626fe718f9d9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bfcc23b7-a6a4-4c9a-9a3f-a70f94d7cd17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_49d20a95-d97a-4697-994b-c5fa5925cf21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_b90cd4db-9458-4843-b178-626fe718f9d9" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_49d20a95-d97a-4697-994b-c5fa5925cf21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited" xlink:type="simple" xlink:href="halo-20220630.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_200828e3-ac74-47e6-b45d-5f192b525383" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e58ed87f-17c9-45c1-b695-b38b7a4c5a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_200828e3-ac74-47e6-b45d-5f192b525383" xlink:to="loc_us-gaap_NetIncomeLoss_e58ed87f-17c9-45c1-b695-b38b7a4c5a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_85aebcf2-b57f-4dc3-895d-d2b974093dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_200828e3-ac74-47e6-b45d-5f192b525383" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_85aebcf2-b57f-4dc3-895d-d2b974093dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_9469080b-72cd-471f-9237-6afb37a0b0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_85aebcf2-b57f-4dc3-895d-d2b974093dd0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_9469080b-72cd-471f-9237-6afb37a0b0a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_8f2973d9-1d98-43ff-94a4-64d1209a51dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_85aebcf2-b57f-4dc3-895d-d2b974093dd0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_8f2973d9-1d98-43ff-94a4-64d1209a51dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_dedd23e6-a943-4b69-9ace-55053a3ddbe6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_85aebcf2-b57f-4dc3-895d-d2b974093dd0" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_dedd23e6-a943-4b69-9ace-55053a3ddbe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_59d657c2-60bf-4a3d-a8bb-5d048dcd7382" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_200828e3-ac74-47e6-b45d-5f192b525383" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_59d657c2-60bf-4a3d-a8bb-5d048dcd7382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="halo-20220630.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_c187ce74-5045-4ce9-ab9e-b8d6fe64cddc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4e9d805f-d5aa-4f64-a162-92c34c263643" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c187ce74-5045-4ce9-ab9e-b8d6fe64cddc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4e9d805f-d5aa-4f64-a162-92c34c263643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c026f9a8-33ea-4af4-ab2d-d0e5ec400b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4e9d805f-d5aa-4f64-a162-92c34c263643" xlink:to="loc_us-gaap_NetIncomeLoss_c026f9a8-33ea-4af4-ab2d-d0e5ec400b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8b6ad66e-2d28-4a8e-aa56-742d9a861acb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4e9d805f-d5aa-4f64-a162-92c34c263643" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8b6ad66e-2d28-4a8e-aa56-742d9a861acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_901a9cc0-8a9e-4fe7-a28e-ee19c2490732" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8b6ad66e-2d28-4a8e-aa56-742d9a861acb" xlink:to="loc_us-gaap_ShareBasedCompensation_901a9cc0-8a9e-4fe7-a28e-ee19c2490732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_43b76d68-d11e-4308-b1d3-958da102c592" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8b6ad66e-2d28-4a8e-aa56-742d9a861acb" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_43b76d68-d11e-4308-b1d3-958da102c592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_db98af96-580a-494e-ab5c-552ac54bd8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8b6ad66e-2d28-4a8e-aa56-742d9a861acb" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_db98af96-580a-494e-ab5c-552ac54bd8ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_4b3e9f91-4200-431d-9681-52f9b11b9807" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8b6ad66e-2d28-4a8e-aa56-742d9a861acb" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_4b3e9f91-4200-431d-9681-52f9b11b9807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_47dbfcc8-a381-4238-9b57-847d3e67e0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8b6ad66e-2d28-4a8e-aa56-742d9a861acb" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_47dbfcc8-a381-4238-9b57-847d3e67e0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_e3a371e8-8ca4-4e6f-bebf-9c52e628ddd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8b6ad66e-2d28-4a8e-aa56-742d9a861acb" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_e3a371e8-8ca4-4e6f-bebf-9c52e628ddd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_4fa29f83-92e5-4944-89a0-5c6fa3dc56a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8b6ad66e-2d28-4a8e-aa56-742d9a861acb" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_4fa29f83-92e5-4944-89a0-5c6fa3dc56a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a692e6a8-3104-4634-ac5e-acf55f4f5f27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8b6ad66e-2d28-4a8e-aa56-742d9a861acb" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a692e6a8-3104-4634-ac5e-acf55f4f5f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DeferredRentPayments_028c6a11-0ab7-4e47-a3fc-d0d261459748" xlink:href="halo-20220630.xsd#halo_DeferredRentPayments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8b6ad66e-2d28-4a8e-aa56-742d9a861acb" xlink:to="loc_halo_DeferredRentPayments_028c6a11-0ab7-4e47-a3fc-d0d261459748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_5b811f83-6ec4-4d89-b155-c953739b7e47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8b6ad66e-2d28-4a8e-aa56-742d9a861acb" xlink:to="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_5b811f83-6ec4-4d89-b155-c953739b7e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_6e14be26-fb59-4aee-9f52-5d445c7ab482" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8b6ad66e-2d28-4a8e-aa56-742d9a861acb" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_6e14be26-fb59-4aee-9f52-5d445c7ab482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7d94e6bd-381c-483b-b6b4-0d0514e7b95f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8b6ad66e-2d28-4a8e-aa56-742d9a861acb" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7d94e6bd-381c-483b-b6b4-0d0514e7b95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f7fb0c4c-54ce-41f0-abe7-3e1e105dfec2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7d94e6bd-381c-483b-b6b4-0d0514e7b95f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f7fb0c4c-54ce-41f0-abe7-3e1e105dfec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_2be702f0-9397-4126-943f-26abe04ccfd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7d94e6bd-381c-483b-b6b4-0d0514e7b95f" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_2be702f0-9397-4126-943f-26abe04ccfd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_841de1ef-12d7-4b92-8785-02f34199457d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7d94e6bd-381c-483b-b6b4-0d0514e7b95f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_841de1ef-12d7-4b92-8785-02f34199457d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_14e26e8f-a1cf-4966-a53c-63c8d6b75de8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7d94e6bd-381c-483b-b6b4-0d0514e7b95f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_14e26e8f-a1cf-4966-a53c-63c8d6b75de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8807506b-4c95-49c2-bd56-78ff9da96bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4e9d805f-d5aa-4f64-a162-92c34c263643" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8807506b-4c95-49c2-bd56-78ff9da96bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bd1107d6-6174-4f7a-9b87-4477d1fd3075" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c187ce74-5045-4ce9-ab9e-b8d6fe64cddc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bd1107d6-6174-4f7a-9b87-4477d1fd3075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_db5d6f31-be33-48af-a10c-2ec5f62d2571" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bd1107d6-6174-4f7a-9b87-4477d1fd3075" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_db5d6f31-be33-48af-a10c-2ec5f62d2571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_57deaa7a-713e-4e8f-8640-848a27d41edd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bd1107d6-6174-4f7a-9b87-4477d1fd3075" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_57deaa7a-713e-4e8f-8640-848a27d41edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_fd164989-516a-42a7-99e7-c3cda01d8c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bd1107d6-6174-4f7a-9b87-4477d1fd3075" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_fd164989-516a-42a7-99e7-c3cda01d8c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9c767cb5-9669-4d2c-8347-ef47ade90310" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bd1107d6-6174-4f7a-9b87-4477d1fd3075" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9c767cb5-9669-4d2c-8347-ef47ade90310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_c67d9635-3a28-4894-a514-899d0a936eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bd1107d6-6174-4f7a-9b87-4477d1fd3075" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_c67d9635-3a28-4894-a514-899d0a936eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_40265ec4-6eb7-4f8c-a981-6628be295c40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bd1107d6-6174-4f7a-9b87-4477d1fd3075" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_40265ec4-6eb7-4f8c-a981-6628be295c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9fb7b2c6-230d-4b78-8adb-5d6a71ba15cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c187ce74-5045-4ce9-ab9e-b8d6fe64cddc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9fb7b2c6-230d-4b78-8adb-5d6a71ba15cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_1af45f4c-63c9-447e-9ff5-9f7deca9182e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9fb7b2c6-230d-4b78-8adb-5d6a71ba15cd" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_1af45f4c-63c9-447e-9ff5-9f7deca9182e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_3d486399-5f24-4127-8a1d-5086ec0362a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9fb7b2c6-230d-4b78-8adb-5d6a71ba15cd" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_3d486399-5f24-4127-8a1d-5086ec0362a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_469b2f20-542b-470a-b6c6-c4de2898fc3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9fb7b2c6-230d-4b78-8adb-5d6a71ba15cd" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_469b2f20-542b-470a-b6c6-c4de2898fc3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt_20a8f125-5627-42c9-8f81-243044d74e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9fb7b2c6-230d-4b78-8adb-5d6a71ba15cd" xlink:to="loc_us-gaap_RepaymentsOfSecuredDebt_20a8f125-5627-42c9-8f81-243044d74e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_fcf3054f-4b7c-47d2-a79b-53c2d021cc4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9fb7b2c6-230d-4b78-8adb-5d6a71ba15cd" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_fcf3054f-4b7c-47d2-a79b-53c2d021cc4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_cb114861-7c0b-4e5b-95aa-4a53a99ce1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9fb7b2c6-230d-4b78-8adb-5d6a71ba15cd" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_cb114861-7c0b-4e5b-95aa-4a53a99ce1b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised_a08ea540-8acd-4dcb-b4ff-1e78d26f5520" xlink:href="halo-20220630.xsd#halo_ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9fb7b2c6-230d-4b78-8adb-5d6a71ba15cd" xlink:to="loc_halo_ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised_a08ea540-8acd-4dcb-b4ff-1e78d26f5520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a30bbada-a3aa-45db-82a1-0f00b6f8f6ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9fb7b2c6-230d-4b78-8adb-5d6a71ba15cd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a30bbada-a3aa-45db-82a1-0f00b6f8f6ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a62259b6-70f0-4fd0-b774-8034135c1b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c187ce74-5045-4ce9-ab9e-b8d6fe64cddc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a62259b6-70f0-4fd0-b774-8034135c1b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_287203ff-dda1-4c31-8355-d2505438344f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c187ce74-5045-4ce9-ab9e-b8d6fe64cddc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_287203ff-dda1-4c31-8355-d2505438344f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dfb90db2-0c95-4b94-a23d-726fb8d1ba9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c187ce74-5045-4ce9-ab9e-b8d6fe64cddc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dfb90db2-0c95-4b94-a23d-726fb8d1ba9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_f30ee59a-f291-4391-b63a-de6fce93344e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c187ce74-5045-4ce9-ab9e-b8d6fe64cddc" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_f30ee59a-f291-4391-b63a-de6fce93344e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_a4ef89de-ec8c-4090-9a60-0458eb710d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_f30ee59a-f291-4391-b63a-de6fce93344e" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_a4ef89de-ec8c-4090-9a60-0458eb710d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_20d6df75-d77e-423b-9564-bbf0b551afae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_f30ee59a-f291-4391-b63a-de6fce93344e" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_20d6df75-d77e-423b-9564-bbf0b551afae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_0cd37782-8e9a-486a-8ae7-385ea03784f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_f30ee59a-f291-4391-b63a-de6fce93344e" xlink:to="loc_us-gaap_StockIssued1_0cd37782-8e9a-486a-8ae7-385ea03784f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="simple" xlink:href="halo-20220630.xsd#CondensedConsolidatedStatementsofStockholdersEquityUnaudited"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_511f5f17-1c63-4eb4-be20-01f8fc22c4d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_94f2d97b-87a1-45cf-984d-0c0159530784" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_511f5f17-1c63-4eb4-be20-01f8fc22c4d0" xlink:to="loc_us-gaap_StatementTable_94f2d97b-87a1-45cf-984d-0c0159530784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_66741488-d1d8-4851-b819-219b4b746d34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_94f2d97b-87a1-45cf-984d-0c0159530784" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_66741488-d1d8-4851-b819-219b4b746d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e1425889-b6d4-4945-a09e-4bd733916cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_66741488-d1d8-4851-b819-219b4b746d34" xlink:to="loc_us-gaap_EquityComponentDomain_e1425889-b6d4-4945-a09e-4bd733916cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c2923359-3e06-4acf-b679-6710bb71863b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e1425889-b6d4-4945-a09e-4bd733916cd0" xlink:to="loc_us-gaap_CommonStockMember_c2923359-3e06-4acf-b679-6710bb71863b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4ecf8cee-1386-4765-85dc-9bea665ce4bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e1425889-b6d4-4945-a09e-4bd733916cd0" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_4ecf8cee-1386-4765-85dc-9bea665ce4bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_efaa44f4-d34b-454c-9d52-a4cdeb2ed1e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e1425889-b6d4-4945-a09e-4bd733916cd0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_efaa44f4-d34b-454c-9d52-a4cdeb2ed1e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_bf9928cc-9397-4016-9d08-efdb0cc0b89f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e1425889-b6d4-4945-a09e-4bd733916cd0" xlink:to="loc_us-gaap_RetainedEarningsMember_bf9928cc-9397-4016-9d08-efdb0cc0b89f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c6b7d1d4-ecd5-4d0a-98cd-b8009be1a01c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_94f2d97b-87a1-45cf-984d-0c0159530784" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c6b7d1d4-ecd5-4d0a-98cd-b8009be1a01c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_744a58a8-48ba-45d4-9efa-e109fc0a30e3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c6b7d1d4-ecd5-4d0a-98cd-b8009be1a01c" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_744a58a8-48ba-45d4-9efa-e109fc0a30e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_ce6d5d3b-7a2f-4628-958c-4a7ac15c824a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_744a58a8-48ba-45d4-9efa-e109fc0a30e3" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_ce6d5d3b-7a2f-4628-958c-4a7ac15c824a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e0bc396c-6a1e-4db6-b699-b75aae7ba81b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_94f2d97b-87a1-45cf-984d-0c0159530784" xlink:to="loc_us-gaap_StatementLineItems_e0bc396c-6a1e-4db6-b699-b75aae7ba81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d70cafd-3513-4d3d-a6c0-79d5fbc84b18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e0bc396c-6a1e-4db6-b699-b75aae7ba81b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d70cafd-3513-4d3d-a6c0-79d5fbc84b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_03a7f0c9-0300-4ca6-858a-ffb2f2b9eb89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d70cafd-3513-4d3d-a6c0-79d5fbc84b18" xlink:to="loc_us-gaap_SharesOutstanding_03a7f0c9-0300-4ca6-858a-ffb2f2b9eb89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2cff3767-79e8-4fec-b058-a16d19bf74d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d70cafd-3513-4d3d-a6c0-79d5fbc84b18" xlink:to="loc_us-gaap_StockholdersEquity_2cff3767-79e8-4fec-b058-a16d19bf74d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2b463a8b-26ae-4c15-80bc-24ab41538250" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d70cafd-3513-4d3d-a6c0-79d5fbc84b18" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2b463a8b-26ae-4c15-80bc-24ab41538250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_3cf8331b-3562-4792-8b37-1a16da96e203" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d70cafd-3513-4d3d-a6c0-79d5fbc84b18" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_3cf8331b-3562-4792-8b37-1a16da96e203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_f0e7865d-0e12-4034-b131-4dcdb7b1ca43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d70cafd-3513-4d3d-a6c0-79d5fbc84b18" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_f0e7865d-0e12-4034-b131-4dcdb7b1ca43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1033cb5f-1ed2-4227-804b-a018b5406aff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d70cafd-3513-4d3d-a6c0-79d5fbc84b18" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1033cb5f-1ed2-4227-804b-a018b5406aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f40736b0-8fba-4628-801c-80b982221cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d70cafd-3513-4d3d-a6c0-79d5fbc84b18" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f40736b0-8fba-4628-801c-80b982221cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_3b35ed63-b40b-4cde-81c7-21c1551b1cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d70cafd-3513-4d3d-a6c0-79d5fbc84b18" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_3b35ed63-b40b-4cde-81c7-21c1551b1cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_f3f3f9ce-0cac-4dd1-9bf5-304ad4664c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d70cafd-3513-4d3d-a6c0-79d5fbc84b18" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_f3f3f9ce-0cac-4dd1-9bf5-304ad4664c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_654d6a79-332b-416a-81d1-5d5dcaccd521" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d70cafd-3513-4d3d-a6c0-79d5fbc84b18" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_654d6a79-332b-416a-81d1-5d5dcaccd521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f1ae5bbd-4b44-4434-922b-38ef41e2a6e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d70cafd-3513-4d3d-a6c0-79d5fbc84b18" xlink:to="loc_us-gaap_NetIncomeLoss_f1ae5bbd-4b44-4434-922b-38ef41e2a6e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_886334f6-bc0a-421b-84f3-6e8fd470c343" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d70cafd-3513-4d3d-a6c0-79d5fbc84b18" xlink:to="loc_us-gaap_SharesOutstanding_886334f6-bc0a-421b-84f3-6e8fd470c343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4dda46bf-ec1f-4ec1-ab89-305b61ae59a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d70cafd-3513-4d3d-a6c0-79d5fbc84b18" xlink:to="loc_us-gaap_StockholdersEquity_4dda46bf-ec1f-4ec1-ab89-305b61ae59a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/OrganizationandBusiness" xlink:type="simple" xlink:href="halo-20220630.xsd#OrganizationandBusiness"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/OrganizationandBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_76f6c0a5-cbd5-4de4-b2d1-f825d8b9c02f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_aaf02bf6-8346-4a84-906a-6ded050e937f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_76f6c0a5-cbd5-4de4-b2d1-f825d8b9c02f" xlink:to="loc_us-gaap_NatureOfOperations_aaf02bf6-8346-4a84-906a-6ded050e937f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/OrganizationandBusinessDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#OrganizationandBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/OrganizationandBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f5a031e0-b9ae-46f5-8ea0-6c8d39e573bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ff58162-245e-46ef-9ddd-6261ca6dfe91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f5a031e0-b9ae-46f5-8ea0-6c8d39e573bc" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ff58162-245e-46ef-9ddd-6261ca6dfe91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2a894c19-1cf4-4067-8282-51853fea8dd3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ff58162-245e-46ef-9ddd-6261ca6dfe91" xlink:to="loc_srt_CounterpartyNameAxis_2a894c19-1cf4-4067-8282-51853fea8dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c0065692-9fa9-4684-9d64-68e2320461b4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_2a894c19-1cf4-4067-8282-51853fea8dd3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c0065692-9fa9-4684-9d64-68e2320461b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BaxaltaMember_46095df9-424c-4c05-b7a8-6d342007a1d1" xlink:href="halo-20220630.xsd#halo_BaxaltaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c0065692-9fa9-4684-9d64-68e2320461b4" xlink:to="loc_halo_BaxaltaMember_46095df9-424c-4c05-b7a8-6d342007a1d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RocheMember_1c2e94cb-c274-4ef9-8852-8b6966fe4ff3" xlink:href="halo-20220630.xsd#halo_RocheMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c0065692-9fa9-4684-9d64-68e2320461b4" xlink:to="loc_halo_RocheMember_1c2e94cb-c274-4ef9-8852-8b6966fe4ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_JanssenMember_93454dc7-52f3-44cc-bb92-d3406d508120" xlink:href="halo-20220630.xsd#halo_JanssenMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c0065692-9fa9-4684-9d64-68e2320461b4" xlink:to="loc_halo_JanssenMember_93454dc7-52f3-44cc-bb92-d3406d508120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d4b421f-b4ec-4868-8750-3b871e6131bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ff58162-245e-46ef-9ddd-6261ca6dfe91" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d4b421f-b4ec-4868-8750-3b871e6131bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RoyaltiesReceivedNumberOfCollaborators_bd7594b2-c68d-4103-ac1d-f18612c2fbd3" xlink:href="halo-20220630.xsd#halo_RoyaltiesReceivedNumberOfCollaborators"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d4b421f-b4ec-4868-8750-3b871e6131bd" xlink:to="loc_halo_RoyaltiesReceivedNumberOfCollaborators_bd7594b2-c68d-4103-ac1d-f18612c2fbd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RoyaltiesReceivedNumberOfProductsSold_7afa727e-cece-4534-bf56-cd66721481e7" xlink:href="halo-20220630.xsd#halo_RoyaltiesReceivedNumberOfProductsSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1d4b421f-b4ec-4868-8750-3b871e6131bd" xlink:to="loc_halo_RoyaltiesReceivedNumberOfProductsSold_7afa727e-cece-4534-bf56-cd66721481e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="halo-20220630.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_fd1fee77-4be4-404e-ba99-aeaf7267b3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_79080d12-2f15-4689-94c0-3fd7ce730ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fd1fee77-4be4-404e-ba99-aeaf7267b3ad" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_79080d12-2f15-4689-94c0-3fd7ce730ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="halo-20220630.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_64993721-84fb-4d90-af04-837776e7682c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_33c82b7b-3af0-4bcc-a22a-347ee5bd4036" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_64993721-84fb-4d90-af04-837776e7682c" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_33c82b7b-3af0-4bcc-a22a-347ee5bd4036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_a8625ddc-d6b4-4399-a4c9-b451bf1bd745" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_64993721-84fb-4d90-af04-837776e7682c" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_a8625ddc-d6b4-4399-a4c9-b451bf1bd745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_576fe57c-c2ca-404b-a34c-8230e82a4d65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_64993721-84fb-4d90-af04-837776e7682c" xlink:to="loc_us-gaap_UseOfEstimates_576fe57c-c2ca-404b-a34c-8230e82a4d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0fba314c-69e8-4e15-a48c-27cb6e27c122" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_64993721-84fb-4d90-af04-837776e7682c" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0fba314c-69e8-4e15-a48c-27cb6e27c122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_342bca51-d40f-40b5-9537-bdaf2092a210" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_64993721-84fb-4d90-af04-837776e7682c" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_342bca51-d40f-40b5-9537-bdaf2092a210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_8a583858-0b1f-4b6c-bb3f-e7dd517c668a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_64993721-84fb-4d90-af04-837776e7682c" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_8a583858-0b1f-4b6c-bb3f-e7dd517c668a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_3baaf707-d365-4b71-83e2-48591d4c4850" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_64993721-84fb-4d90-af04-837776e7682c" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_3baaf707-d365-4b71-83e2-48591d4c4850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_1ca8db91-636f-4e3d-bcd8-0018e3378c21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_64993721-84fb-4d90-af04-837776e7682c" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_1ca8db91-636f-4e3d-bcd8-0018e3378c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock_9276b1b5-3f63-48e7-8e8c-701ddef08030" xlink:href="halo-20220630.xsd#halo_GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_64993721-84fb-4d90-af04-837776e7682c" xlink:to="loc_halo_GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock_9276b1b5-3f63-48e7-8e8c-701ddef08030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_617c57a6-a441-430b-bbe5-784983a229ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_64993721-84fb-4d90-af04-837776e7682c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_617c57a6-a441-430b-bbe5-784983a229ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_535faa1b-3527-4fdc-a593-a54587da04d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_64993721-84fb-4d90-af04-837776e7682c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_535faa1b-3527-4fdc-a593-a54587da04d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_d680280b-a6e5-477b-8539-f23bd9e5d749" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_64993721-84fb-4d90-af04-837776e7682c" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_d680280b-a6e5-477b-8539-f23bd9e5d749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_5ef51899-1e24-48f1-b8ad-41e8c28e9c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_64993721-84fb-4d90-af04-837776e7682c" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_5ef51899-1e24-48f1-b8ad-41e8c28e9c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_47a0c402-18c7-4252-8252-15a2d51e41dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_64993721-84fb-4d90-af04-837776e7682c" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_47a0c402-18c7-4252-8252-15a2d51e41dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0a4fd510-55d3-40e4-a0b8-20236d203ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_64993721-84fb-4d90-af04-837776e7682c" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0a4fd510-55d3-40e4-a0b8-20236d203ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="halo-20220630.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_cd1907be-9ab8-4c78-931b-a148817a96e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2408edef-d04c-46fa-ada5-152ea3ec05eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cd1907be-9ab8-4c78-931b-a148817a96e6" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2408edef-d04c-46fa-ada5-152ea3ec05eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_31c7f83f-d762-4d83-bad2-ef8f5600dc36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cd1907be-9ab8-4c78-931b-a148817a96e6" xlink:to="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_31c7f83f-d762-4d83-bad2-ef8f5600dc36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#SummaryofSignificantAccountingPoliciesRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_88c7a844-93be-4683-b6dd-fab300017f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_fcfca47d-0770-4e77-8c20-cbb9fd760db3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_88c7a844-93be-4683-b6dd-fab300017f5e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_fcfca47d-0770-4e77-8c20-cbb9fd760db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#SummaryofSignificantAccountingPoliciesLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_12a73166-113e-471b-8113-8f14fbda90a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_7ce5d71e-0665-4400-9ca1-c95a481f0c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12a73166-113e-471b-8113-8f14fbda90a8" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_7ce5d71e-0665-4400-9ca1-c95a481f0c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7f82a685-cdfa-4483-8a65-e1c39e79536a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_7ce5d71e-0665-4400-9ca1-c95a481f0c4a" xlink:to="loc_srt_RangeAxis_7f82a685-cdfa-4483-8a65-e1c39e79536a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_43a63c8d-7d63-45d5-b372-8813b2b6484b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7f82a685-cdfa-4483-8a65-e1c39e79536a" xlink:to="loc_srt_RangeMember_43a63c8d-7d63-45d5-b372-8813b2b6484b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_636a1442-5ebe-42dd-bf82-2798fa796593" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_43a63c8d-7d63-45d5-b372-8813b2b6484b" xlink:to="loc_srt_MinimumMember_636a1442-5ebe-42dd-bf82-2798fa796593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2c6ceeb1-8656-4971-8e33-4d084d319829" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_43a63c8d-7d63-45d5-b372-8813b2b6484b" xlink:to="loc_srt_MaximumMember_2c6ceeb1-8656-4971-8e33-4d084d319829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_b7d8b5e8-267b-4a1c-b40e-e7713c6f53fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_7ce5d71e-0665-4400-9ca1-c95a481f0c4a" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_b7d8b5e8-267b-4a1c-b40e-e7713c6f53fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_689bb9d7-7bd2-4e91-a962-48e7177a30d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b7d8b5e8-267b-4a1c-b40e-e7713c6f53fb" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_689bb9d7-7bd2-4e91-a962-48e7177a30d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesRevenueandCostofProductSalesDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#SummaryofSignificantAccountingPoliciesRevenueandCostofProductSalesDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesRevenueandCostofProductSalesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_91a58fe4-a95d-4d33-ada1-e2f4478ff373" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice_9f54300a-e647-4a6c-ad95-87541e1f67dd" xlink:href="halo-20220630.xsd#halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91a58fe4-a95d-4d33-ada1-e2f4478ff373" xlink:to="loc_halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice_9f54300a-e647-4a6c-ad95-87541e1f67dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_1225aff9-6240-4d3e-84f8-5c187a182628" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91a58fe4-a95d-4d33-ada1-e2f4478ff373" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_1225aff9-6240-4d3e-84f8-5c187a182628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#SummaryofSignificantAccountingPoliciesIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5d3d58da-a3d3-457e-b76b-d1e1db2453a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e488bf35-4eb5-41fe-ab4d-a943390a3277" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5d3d58da-a3d3-457e-b76b-d1e1db2453a9" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e488bf35-4eb5-41fe-ab4d-a943390a3277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5142badc-3f87-482b-8164-c39f0843cef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5d3d58da-a3d3-457e-b76b-d1e1db2453a9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5142badc-3f87-482b-8164-c39f0843cef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#SummaryofSignificantAccountingPoliciesSegmentInformationDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_27b69b8d-8ea9-49ba-afb8-2e5a1eca5a29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_aafa9fed-cdce-4b3d-8ad8-7e881ec2e553" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_27b69b8d-8ea9-49ba-afb8-2e5a1eca5a29" xlink:to="loc_us-gaap_NumberOfOperatingSegments_aafa9fed-cdce-4b3d-8ad8-7e881ec2e553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/BusinessCombination" xlink:type="simple" xlink:href="halo-20220630.xsd#BusinessCombination"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/BusinessCombination" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_64129544-678a-483a-9f26-8b0a0aa9c883" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_5ac341e0-f054-4088-bc3f-dfc0c386af67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_64129544-678a-483a-9f26-8b0a0aa9c883" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_5ac341e0-f054-4088-bc3f-dfc0c386af67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/BusinessCombinationTables" xlink:type="simple" xlink:href="halo-20220630.xsd#BusinessCombinationTables"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/BusinessCombinationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_16d36c19-35d7-46da-aafa-ae2edefc9c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_0331e6b8-3a71-442c-a45c-d3685f201ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_16d36c19-35d7-46da-aafa-ae2edefc9c8d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_0331e6b8-3a71-442c-a45c-d3685f201ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_7df87864-4355-4836-b499-aa669ccf4066" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_16d36c19-35d7-46da-aafa-ae2edefc9c8d" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_7df87864-4355-4836-b499-aa669ccf4066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_5fffcf96-46bc-47e7-a6b2-ad5ec396fd3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_16d36c19-35d7-46da-aafa-ae2edefc9c8d" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_5fffcf96-46bc-47e7-a6b2-ad5ec396fd3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock_b48e8aeb-f53a-4cba-a973-605df2e37e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_16d36c19-35d7-46da-aafa-ae2edefc9c8d" xlink:to="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock_b48e8aeb-f53a-4cba-a973-605df2e37e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_9e09104a-96c7-4d57-9fd5-6e32be6ea149" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_16d36c19-35d7-46da-aafa-ae2edefc9c8d" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_9e09104a-96c7-4d57-9fd5-6e32be6ea149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/BusinessCombinationNarrativeDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#BusinessCombinationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/BusinessCombinationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_bf8a1527-02fb-4069-b84a-476ba8cd41d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6d94f55f-cc17-4aa2-bd22-24a847c546b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_bf8a1527-02fb-4069-b84a-476ba8cd41d8" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6d94f55f-cc17-4aa2-bd22-24a847c546b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a75eef50-3bda-4b8b-beed-732337746452" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6d94f55f-cc17-4aa2-bd22-24a847c546b9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a75eef50-3bda-4b8b-beed-732337746452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88a96e11-18be-4763-b4d5-17fb7627bdb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a75eef50-3bda-4b8b-beed-732337746452" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88a96e11-18be-4763-b4d5-17fb7627bdb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember_991fb474-2541-4a6f-b02d-68c8e597da8f" xlink:href="halo-20220630.xsd#halo_AntaresPharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88a96e11-18be-4763-b4d5-17fb7627bdb2" xlink:to="loc_halo_AntaresPharmaIncMember_991fb474-2541-4a6f-b02d-68c8e597da8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_60e2ae1b-8b01-4523-8f38-42df818cc5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6d94f55f-cc17-4aa2-bd22-24a847c546b9" xlink:to="loc_us-gaap_DebtInstrumentAxis_60e2ae1b-8b01-4523-8f38-42df818cc5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e80f9629-5dac-41a1-8fda-9fad7bb13160" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_60e2ae1b-8b01-4523-8f38-42df818cc5c6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e80f9629-5dac-41a1-8fda-9fad7bb13160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_TermLoanFacilityMember_9b2bf9eb-0cc1-4cc8-a4fd-d3070be55770" xlink:href="halo-20220630.xsd#halo_TermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e80f9629-5dac-41a1-8fda-9fad7bb13160" xlink:to="loc_halo_TermLoanFacilityMember_9b2bf9eb-0cc1-4cc8-a4fd-d3070be55770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_d8728e4e-d36a-4fd1-aa58-09e95651ad01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6d94f55f-cc17-4aa2-bd22-24a847c546b9" xlink:to="loc_us-gaap_CreditFacilityAxis_d8728e4e-d36a-4fd1-aa58-09e95651ad01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_55c644b4-792a-4a92-9b91-0b8faa061e05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_d8728e4e-d36a-4fd1-aa58-09e95651ad01" xlink:to="loc_us-gaap_CreditFacilityDomain_55c644b4-792a-4a92-9b91-0b8faa061e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_095debe2-b334-450a-9647-4e42bf77e6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_55c644b4-792a-4a92-9b91-0b8faa061e05" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_095debe2-b334-450a-9647-4e42bf77e6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_9c282120-a7db-4f55-be26-186d58b74932" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6d94f55f-cc17-4aa2-bd22-24a847c546b9" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_9c282120-a7db-4f55-be26-186d58b74932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_9f1c25b7-91c4-42aa-9114-2b49649b1d14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9c282120-a7db-4f55-be26-186d58b74932" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_9f1c25b7-91c4-42aa-9114-2b49649b1d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare_d4995424-199d-46c5-9288-1b2ade24dcf0" xlink:href="halo-20220630.xsd#halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9c282120-a7db-4f55-be26-186d58b74932" xlink:to="loc_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare_d4995424-199d-46c5-9288-1b2ade24dcf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_445d1413-df48-4ad4-ab87-9628751b6cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9c282120-a7db-4f55-be26-186d58b74932" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_445d1413-df48-4ad4-ab87-9628751b6cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_4197aaaa-3810-4632-8eda-278e240c2152" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9c282120-a7db-4f55-be26-186d58b74932" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_4197aaaa-3810-4632-8eda-278e240c2152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7557f128-e079-4e1a-b7a3-5d824c959444" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9c282120-a7db-4f55-be26-186d58b74932" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7557f128-e079-4e1a-b7a3-5d824c959444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_1519a3e9-d0fc-447d-a93e-6db2db3cfac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9c282120-a7db-4f55-be26-186d58b74932" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_1519a3e9-d0fc-447d-a93e-6db2db3cfac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b179df2a-98db-438e-9a48-7bb379d7e611" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9c282120-a7db-4f55-be26-186d58b74932" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b179df2a-98db-438e-9a48-7bb379d7e611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_5ca38b91-b070-468b-b5be-14f9234f3184" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9c282120-a7db-4f55-be26-186d58b74932" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_5ca38b91-b070-468b-b5be-14f9234f3184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_60440a6a-d3b4-489e-9829-41e7e01d2393" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9c282120-a7db-4f55-be26-186d58b74932" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_60440a6a-d3b4-489e-9829-41e7e01d2393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#BusinessCombinationPurchaseConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_f8f62421-5941-47e2-9a94-d2050360b97e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9d242c57-47cd-4252-b914-83526a5d8608" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_f8f62421-5941-47e2-9a94-d2050360b97e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9d242c57-47cd-4252-b914-83526a5d8608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_43ea197f-79e2-45b8-a27c-06123e1fd94f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9d242c57-47cd-4252-b914-83526a5d8608" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_43ea197f-79e2-45b8-a27c-06123e1fd94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_78c0ee35-c187-4dbe-8269-3381e7a985df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_43ea197f-79e2-45b8-a27c-06123e1fd94f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_78c0ee35-c187-4dbe-8269-3381e7a985df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember_922c4a9b-1526-4891-a09d-14d068a44a84" xlink:href="halo-20220630.xsd#halo_AntaresPharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_78c0ee35-c187-4dbe-8269-3381e7a985df" xlink:to="loc_halo_AntaresPharmaIncMember_922c4a9b-1526-4891-a09d-14d068a44a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_ee28d0f3-8386-4b03-8c4b-18828cd40163" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9d242c57-47cd-4252-b914-83526a5d8608" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_ee28d0f3-8386-4b03-8c4b-18828cd40163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_7dd7fe29-b841-490e-8aeb-bdb0ac87c441" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_ee28d0f3-8386-4b03-8c4b-18828cd40163" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_7dd7fe29-b841-490e-8aeb-bdb0ac87c441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationAwardsVestedMember_12e62983-f184-4765-9aca-4afe95e12fdc" xlink:href="halo-20220630.xsd#halo_ShareBasedCompensationAwardsVestedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_7dd7fe29-b841-490e-8aeb-bdb0ac87c441" xlink:to="loc_halo_ShareBasedCompensationAwardsVestedMember_12e62983-f184-4765-9aca-4afe95e12fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationAwardUnvestedMember_4f5de63f-0f32-4485-87e5-2841a6db5176" xlink:href="halo-20220630.xsd#halo_ShareBasedCompensationAwardUnvestedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_7dd7fe29-b841-490e-8aeb-bdb0ac87c441" xlink:to="loc_halo_ShareBasedCompensationAwardUnvestedMember_4f5de63f-0f32-4485-87e5-2841a6db5176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_76f22748-d419-4148-b6ba-b74dc34af475" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9d242c57-47cd-4252-b914-83526a5d8608" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_76f22748-d419-4148-b6ba-b74dc34af475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_d9e2722e-f754-4fbb-8777-3ae55d8ed482" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_76f22748-d419-4148-b6ba-b74dc34af475" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_d9e2722e-f754-4fbb-8777-3ae55d8ed482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards_bf9ffb60-0036-400b-90ee-15a2a973970b" xlink:href="halo-20220630.xsd#halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_76f22748-d419-4148-b6ba-b74dc34af475" xlink:to="loc_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards_bf9ffb60-0036-400b-90ee-15a2a973970b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_966c798b-5ece-4943-9b30-a8dc7d6a145a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_76f22748-d419-4148-b6ba-b74dc34af475" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredOther1_966c798b-5ece-4943-9b30-a8dc7d6a145a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_3ab33331-ee29-418b-91bc-107d4b52cfb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_76f22748-d419-4148-b6ba-b74dc34af475" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_3ab33331-ee29-418b-91bc-107d4b52cfb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationConsiderationTransferredBonusAwards_ba8362bd-f45b-41e4-a06d-46bfe8f1a20b" xlink:href="halo-20220630.xsd#halo_BusinessCombinationConsiderationTransferredBonusAwards"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_76f22748-d419-4148-b6ba-b74dc34af475" xlink:to="loc_halo_BusinessCombinationConsiderationTransferredBonusAwards_ba8362bd-f45b-41e4-a06d-46bfe8f1a20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_fbebf852-cde2-4edb-8915-6ed1baa12b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_76f22748-d419-4148-b6ba-b74dc34af475" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_fbebf852-cde2-4edb-8915-6ed1baa12b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_1ea306e8-7641-4ea3-b524-d9204f8e4337" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_76f22748-d419-4148-b6ba-b74dc34af475" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_1ea306e8-7641-4ea3-b524-d9204f8e4337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_3fdd6cec-f40e-403d-9561-550929096cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3207b0db-c64b-43cf-9573-b330ee5623d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_3fdd6cec-f40e-403d-9561-550929096cf3" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3207b0db-c64b-43cf-9573-b330ee5623d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e442a303-da7b-4f8d-b4c7-33768033ad1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3207b0db-c64b-43cf-9573-b330ee5623d0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e442a303-da7b-4f8d-b4c7-33768033ad1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c4f96cdb-21cb-41f9-9117-e3ca1760c496" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e442a303-da7b-4f8d-b4c7-33768033ad1a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c4f96cdb-21cb-41f9-9117-e3ca1760c496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember_98f06041-3d23-4bdc-bb35-726b8ebd881b" xlink:href="halo-20220630.xsd#halo_AntaresPharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c4f96cdb-21cb-41f9-9117-e3ca1760c496" xlink:to="loc_halo_AntaresPharmaIncMember_98f06041-3d23-4bdc-bb35-726b8ebd881b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_8e2cd6f3-9152-4c09-976e-74f0f9859c55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3207b0db-c64b-43cf-9573-b330ee5623d0" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_8e2cd6f3-9152-4c09-976e-74f0f9859c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c996ca79-3415-4164-8902-b56ffd13097d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8e2cd6f3-9152-4c09-976e-74f0f9859c55" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c996ca79-3415-4164-8902-b56ffd13097d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_c8cb14e8-1ea0-4dca-a92d-692d043c438b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8e2cd6f3-9152-4c09-976e-74f0f9859c55" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_c8cb14e8-1ea0-4dca-a92d-692d043c438b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_3c19b226-20e2-415d-861f-326dfd4d8cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8e2cd6f3-9152-4c09-976e-74f0f9859c55" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_3c19b226-20e2-415d-861f-326dfd4d8cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments_abe18d6e-7b99-4a1a-8a54-d29029586d62" xlink:href="halo-20220630.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_3c19b226-20e2-415d-861f-326dfd4d8cc0" xlink:to="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments_abe18d6e-7b99-4a1a-8a54-d29029586d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_3ba6f616-7790-4e66-acd8-915ff5fc7fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_3c19b226-20e2-415d-861f-326dfd4d8cc0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_3ba6f616-7790-4e66-acd8-915ff5fc7fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_89f6b6aa-8386-43c3-ade1-bdd649b42387" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_3c19b226-20e2-415d-861f-326dfd4d8cc0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_89f6b6aa-8386-43c3-ade1-bdd649b42387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_adbb9396-0ea0-4777-b3ef-738dbdbc62d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_3c19b226-20e2-415d-861f-326dfd4d8cc0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_adbb9396-0ea0-4777-b3ef-738dbdbc62d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_5bb5a541-5b6f-490a-b058-b93cf7d54fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_3c19b226-20e2-415d-861f-326dfd4d8cc0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_5bb5a541-5b6f-490a-b058-b93cf7d54fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9a725d40-65da-4f7e-ba80-141b4528d0f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_3c19b226-20e2-415d-861f-326dfd4d8cc0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9a725d40-65da-4f7e-ba80-141b4528d0f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_d829d299-d89e-4311-8cbe-e60a8c6e8639" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8e2cd6f3-9152-4c09-976e-74f0f9859c55" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_d829d299-d89e-4311-8cbe-e60a8c6e8639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_abd617d0-78c5-483c-aa0e-61d1f4186be2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_d829d299-d89e-4311-8cbe-e60a8c6e8639" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_abd617d0-78c5-483c-aa0e-61d1f4186be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses_8e4ce377-56fc-4db4-972c-faedc80c968c" xlink:href="halo-20220630.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_d829d299-d89e-4311-8cbe-e60a8c6e8639" xlink:to="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses_8e4ce377-56fc-4db4-972c-faedc80c968c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability_b96071d5-7f11-4f41-8e28-f249390e0ea2" xlink:href="halo-20220630.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_d829d299-d89e-4311-8cbe-e60a8c6e8639" xlink:to="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability_b96071d5-7f11-4f41-8e28-f249390e0ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability_9154cb9b-1f2e-4faa-bcf3-586dfc0fd729" xlink:href="halo-20220630.xsd#halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_d829d299-d89e-4311-8cbe-e60a8c6e8639" xlink:to="loc_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability_9154cb9b-1f2e-4faa-bcf3-586dfc0fd729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_18c574f6-b082-4664-a658-b578ae74685d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_d829d299-d89e-4311-8cbe-e60a8c6e8639" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_18c574f6-b082-4664-a658-b578ae74685d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_1ec4e9cf-6649-45ef-addc-8a7cfeb2909f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_d829d299-d89e-4311-8cbe-e60a8c6e8639" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_1ec4e9cf-6649-45ef-addc-8a7cfeb2909f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1625713f-5a33-4d24-b2e1-a54988c93ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8e2cd6f3-9152-4c09-976e-74f0f9859c55" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_1625713f-5a33-4d24-b2e1-a54988c93ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e6fc4b8d-f38b-410a-be4f-6f09e27826d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8e2cd6f3-9152-4c09-976e-74f0f9859c55" xlink:to="loc_us-gaap_Goodwill_e6fc4b8d-f38b-410a-be4f-6f09e27826d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#BusinessCombinationIntangibleAssetsAcquiredDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_6bdf46a1-d951-4e13-bf46-46bae01d5cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6cde9861-7fc1-4bca-b1e6-f8a5dc9505a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_6bdf46a1-d951-4e13-bf46-46bae01d5cd5" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6cde9861-7fc1-4bca-b1e6-f8a5dc9505a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8775ecae-775a-4b46-aadc-6d1d847f6a90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6cde9861-7fc1-4bca-b1e6-f8a5dc9505a5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8775ecae-775a-4b46-aadc-6d1d847f6a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_999d2f74-f04e-4976-803a-31b7e2328aed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8775ecae-775a-4b46-aadc-6d1d847f6a90" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_999d2f74-f04e-4976-803a-31b7e2328aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember_b72c62b1-f702-421d-bae4-34aabc55524a" xlink:href="halo-20220630.xsd#halo_AntaresPharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_999d2f74-f04e-4976-803a-31b7e2328aed" xlink:to="loc_halo_AntaresPharmaIncMember_b72c62b1-f702-421d-bae4-34aabc55524a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_01fe5658-d3ad-4c9c-b3dd-3da66798d05d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6cde9861-7fc1-4bca-b1e6-f8a5dc9505a5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_01fe5658-d3ad-4c9c-b3dd-3da66798d05d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0ac10d5d-4df9-4285-98aa-6aa066d98500" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_01fe5658-d3ad-4c9c-b3dd-3da66798d05d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0ac10d5d-4df9-4285-98aa-6aa066d98500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AutoInjectorTechnologyPlatformMember_86e40b5e-be1a-4bfb-85bc-9691a1d09ccd" xlink:href="halo-20220630.xsd#halo_AutoInjectorTechnologyPlatformMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0ac10d5d-4df9-4285-98aa-6aa066d98500" xlink:to="loc_halo_AutoInjectorTechnologyPlatformMember_86e40b5e-be1a-4bfb-85bc-9691a1d09ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_XYOSTEDProprietaryProductMember_b1b3802f-c05b-4e4c-a789-558bcd4c4130" xlink:href="halo-20220630.xsd#halo_XYOSTEDProprietaryProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0ac10d5d-4df9-4285-98aa-6aa066d98500" xlink:to="loc_halo_XYOSTEDProprietaryProductMember_b1b3802f-c05b-4e4c-a789-558bcd4c4130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_TLANDOProductRightsMember_f5881d0f-2442-4521-b9e2-e18c76dceae8" xlink:href="halo-20220630.xsd#halo_TLANDOProductRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0ac10d5d-4df9-4285-98aa-6aa066d98500" xlink:to="loc_halo_TLANDOProductRightsMember_f5881d0f-2442-4521-b9e2-e18c76dceae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_367a4ea4-6f02-4f56-9d4f-bd1b4b2250e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6cde9861-7fc1-4bca-b1e6-f8a5dc9505a5" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_367a4ea4-6f02-4f56-9d4f-bd1b4b2250e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_fe61e712-b551-4c72-a01b-687151f4baf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_367a4ea4-6f02-4f56-9d4f-bd1b4b2250e5" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_fe61e712-b551-4c72-a01b-687151f4baf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_85351189-31c1-489b-a865-1be469e248fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_fe61e712-b551-4c72-a01b-687151f4baf8" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_85351189-31c1-489b-a865-1be469e248fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_73397cef-0dec-429e-a257-c550857c9492" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6cde9861-7fc1-4bca-b1e6-f8a5dc9505a5" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_73397cef-0dec-429e-a257-c550857c9492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_03d55002-dac5-44ed-a361-ec5a7613fbe8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_73397cef-0dec-429e-a257-c550857c9492" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_03d55002-dac5-44ed-a361-ec5a7613fbe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6c171425-ed3f-4631-a537-f76b393bfa08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_73397cef-0dec-429e-a257-c550857c9492" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6c171425-ed3f-4631-a537-f76b393bfa08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_b6c85671-3101-4f4e-a953-6dd41d414bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_73397cef-0dec-429e-a257-c550857c9492" xlink:to="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_b6c85671-3101-4f4e-a953-6dd41d414bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_8be81136-a7e6-4c2f-a233-6b156e533cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_73397cef-0dec-429e-a257-c550857c9492" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_8be81136-a7e6-4c2f-a233-6b156e533cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/BusinessCombinationSummaryofProformaFinancialInformationDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#BusinessCombinationSummaryofProformaFinancialInformationDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/BusinessCombinationSummaryofProformaFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_592cdeff-c74b-4c74-8ab3-cc00dc713ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d60e5972-c7b7-4de9-b406-92077e3df8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_592cdeff-c74b-4c74-8ab3-cc00dc713ed2" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d60e5972-c7b7-4de9-b406-92077e3df8d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_334b25d6-3815-4480-a2ec-9d37885f707d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d60e5972-c7b7-4de9-b406-92077e3df8d6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_334b25d6-3815-4480-a2ec-9d37885f707d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dd5732c3-76a6-4920-9978-1f7b90434c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_334b25d6-3815-4480-a2ec-9d37885f707d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dd5732c3-76a6-4920-9978-1f7b90434c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember_8a2a77ac-a83a-4d6e-a7d8-20f994029c5b" xlink:href="halo-20220630.xsd#halo_AntaresPharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dd5732c3-76a6-4920-9978-1f7b90434c9d" xlink:to="loc_halo_AntaresPharmaIncMember_8a2a77ac-a83a-4d6e-a7d8-20f994029c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_74ea348c-9bd8-41f7-9708-c2b7ab678548" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d60e5972-c7b7-4de9-b406-92077e3df8d6" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_74ea348c-9bd8-41f7-9708-c2b7ab678548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_09950e9c-fa48-4e02-8218-f2965616609d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_74ea348c-9bd8-41f7-9708-c2b7ab678548" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_09950e9c-fa48-4e02-8218-f2965616609d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_655ed113-9b07-483a-abe7-9db401d06df9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_74ea348c-9bd8-41f7-9708-c2b7ab678548" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_655ed113-9b07-483a-abe7-9db401d06df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurement" xlink:type="simple" xlink:href="halo-20220630.xsd#FairValueMeasurement"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/FairValueMeasurement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_025ceaca-7165-4fd2-8306-7283ab2cb6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_11d6ec12-3d3c-4d5d-8541-beb841805667" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_025ceaca-7165-4fd2-8306-7283ab2cb6cf" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_11d6ec12-3d3c-4d5d-8541-beb841805667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurementTables" xlink:type="simple" xlink:href="halo-20220630.xsd#FairValueMeasurementTables"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/FairValueMeasurementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_411c2c17-8923-433d-b64c-cbb36c908915" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_e7e2d04e-7a36-44a3-9fbf-c1cd13835278" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_411c2c17-8923-433d-b64c-cbb36c908915" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_e7e2d04e-7a36-44a3-9fbf-c1cd13835278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_3f3bf5f2-4105-4332-8c9b-300bf39ea33c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_411c2c17-8923-433d-b64c-cbb36c908915" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_3f3bf5f2-4105-4332-8c9b-300bf39ea33c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_ab7d0d4c-47e1-4fc5-9d32-64961be4e9d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_411c2c17-8923-433d-b64c-cbb36c908915" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_ab7d0d4c-47e1-4fc5-9d32-64961be4e9d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d023c389-2b56-4096-a12d-f4aba6af6bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_e61347d7-d1ce-450f-8adc-0e8c5ec42b62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d023c389-2b56-4096-a12d-f4aba6af6bfb" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_e61347d7-d1ce-450f-8adc-0e8c5ec42b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_eaa33995-3b88-479a-b2fb-e0378c85012c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_e61347d7-d1ce-450f-8adc-0e8c5ec42b62" xlink:to="loc_us-gaap_FinancialInstrumentAxis_eaa33995-3b88-479a-b2fb-e0378c85012c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_69859cef-9fb7-4c28-8c3d-4143c1f20ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_eaa33995-3b88-479a-b2fb-e0378c85012c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_69859cef-9fb7-4c28-8c3d-4143c1f20ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_c6f12d7e-6730-4206-aaec-7284a8bd1a70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_69859cef-9fb7-4c28-8c3d-4143c1f20ea4" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_c6f12d7e-6730-4206-aaec-7284a8bd1a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_a6286173-60fc-401d-ad17-f05cd7fe8461" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_69859cef-9fb7-4c28-8c3d-4143c1f20ea4" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_a6286173-60fc-401d-ad17-f05cd7fe8461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_07052081-0dad-411b-b951-7196c4c6ca5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_69859cef-9fb7-4c28-8c3d-4143c1f20ea4" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_07052081-0dad-411b-b951-7196c4c6ca5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_a2d41aa6-a372-458b-920e-bd39510a1d48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_69859cef-9fb7-4c28-8c3d-4143c1f20ea4" xlink:to="loc_us-gaap_NonUsMember_a2d41aa6-a372-458b-920e-bd39510a1d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_35497901-e3c7-4884-b38c-d30747f1176c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_69859cef-9fb7-4c28-8c3d-4143c1f20ea4" xlink:to="loc_us-gaap_CommercialPaperMember_35497901-e3c7-4884-b38c-d30747f1176c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_55fee5df-b645-4c28-9d90-cd7cc9a3f20d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_e61347d7-d1ce-450f-8adc-0e8c5ec42b62" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_55fee5df-b645-4c28-9d90-cd7cc9a3f20d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d731cd1a-9452-46cb-9b9c-141374e5c709" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_55fee5df-b645-4c28-9d90-cd7cc9a3f20d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d731cd1a-9452-46cb-9b9c-141374e5c709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7b1fb50a-3b28-4014-99c7-40d3388d9bac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_55fee5df-b645-4c28-9d90-cd7cc9a3f20d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7b1fb50a-3b28-4014-99c7-40d3388d9bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4aff93f5-637a-4cc7-8793-935f031b9c68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_55fee5df-b645-4c28-9d90-cd7cc9a3f20d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4aff93f5-637a-4cc7-8793-935f031b9c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e9f55fd3-7c33-4ee0-b721-702ac56bebd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_55fee5df-b645-4c28-9d90-cd7cc9a3f20d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e9f55fd3-7c33-4ee0-b721-702ac56bebd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#FairValueMeasurementNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_305066f9-7f4c-4cb0-852d-bbc202c7a91a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_c51e44f3-03c3-4b72-ac4f-164339eb8208" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_305066f9-7f4c-4cb0-852d-bbc202c7a91a" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_c51e44f3-03c3-4b72-ac4f-164339eb8208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e0c27876-1a77-4040-9c14-335662869ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_c51e44f3-03c3-4b72-ac4f-164339eb8208" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e0c27876-1a77-4040-9c14-335662869ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b79f01df-09ba-4f58-ab03-e3607e47f642" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e0c27876-1a77-4040-9c14-335662869ef5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b79f01df-09ba-4f58-ab03-e3607e47f642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_349288c6-64ea-4944-8db1-bb3fc42d38d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b79f01df-09ba-4f58-ab03-e3607e47f642" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_349288c6-64ea-4944-8db1-bb3fc42d38d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_39d459e8-43f1-499b-b72e-0f7d09480a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_c51e44f3-03c3-4b72-ac4f-164339eb8208" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_39d459e8-43f1-499b-b72e-0f7d09480a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3e9b9f7a-52d0-471e-8c0f-9d41324b3f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_39d459e8-43f1-499b-b72e-0f7d09480a5d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3e9b9f7a-52d0-471e-8c0f-9d41324b3f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember_9fd7d358-47b3-4d92-82c6-8d4b027a6c92" xlink:href="halo-20220630.xsd#halo_AntaresPharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3e9b9f7a-52d0-471e-8c0f-9d41324b3f5f" xlink:to="loc_halo_AntaresPharmaIncMember_9fd7d358-47b3-4d92-82c6-8d4b027a6c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_503a786f-6e96-45e5-86d0-ddf9617cb108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_c51e44f3-03c3-4b72-ac4f-164339eb8208" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_503a786f-6e96-45e5-86d0-ddf9617cb108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_b534f086-1277-4c81-af51-dfe7d9e71819" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_503a786f-6e96-45e5-86d0-ddf9617cb108" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_b534f086-1277-4c81-af51-dfe7d9e71819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_642c7305-1b01-4a2d-9500-706aa196b3fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_503a786f-6e96-45e5-86d0-ddf9617cb108" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_642c7305-1b01-4a2d-9500-706aa196b3fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5d1a5bdc-4ad1-4b0d-abe5-24e1fb70e24b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_503a786f-6e96-45e5-86d0-ddf9617cb108" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5d1a5bdc-4ad1-4b0d-abe5-24e1fb70e24b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_99ad98c3-d42e-4d75-a01b-520ae6d9d799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_503a786f-6e96-45e5-86d0-ddf9617cb108" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_99ad98c3-d42e-4d75-a01b-520ae6d9d799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8a56fe21-37bd-4015-b163-b10694578069" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_503a786f-6e96-45e5-86d0-ddf9617cb108" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8a56fe21-37bd-4015-b163-b10694578069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_572a57c3-544a-4c9e-b94a-989bf159d082" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_503a786f-6e96-45e5-86d0-ddf9617cb108" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_572a57c3-544a-4c9e-b94a-989bf159d082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurementContractualMaturitiesofAvailableforSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#FairValueMeasurementContractualMaturitiesofAvailableforSaleDebtSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/FairValueMeasurementContractualMaturitiesofAvailableforSaleDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_03dd9960-5119-4989-a3c6-23c89b4a67dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_66de514a-2230-46e5-9b27-6a534ceecbca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_03dd9960-5119-4989-a3c6-23c89b4a67dc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_66de514a-2230-46e5-9b27-6a534ceecbca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_00997f5e-55ea-4756-a14b-e28bef41cc71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_03dd9960-5119-4989-a3c6-23c89b4a67dc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_00997f5e-55ea-4756-a14b-e28bef41cc71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6a406012-cef5-4791-bd5e-c0595060888c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_03dd9960-5119-4989-a3c6-23c89b4a67dc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6a406012-cef5-4791-bd5e-c0595060888c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4b36ef69-9ae9-4c2f-a9b6-e93d1521894d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_debfef8a-576a-43dd-8966-7f91de9a3316" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4b36ef69-9ae9-4c2f-a9b6-e93d1521894d" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_debfef8a-576a-43dd-8966-7f91de9a3316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a1da7886-219e-48f0-884a-063cc29612f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_debfef8a-576a-43dd-8966-7f91de9a3316" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a1da7886-219e-48f0-884a-063cc29612f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_71297f9f-6dfd-4913-9f66-e4aa8e31d887" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a1da7886-219e-48f0-884a-063cc29612f0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_71297f9f-6dfd-4913-9f66-e4aa8e31d887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_9e58810d-acdb-4013-be75-4f15fed239dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_71297f9f-6dfd-4913-9f66-e4aa8e31d887" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_9e58810d-acdb-4013-be75-4f15fed239dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e8c1c3c5-a1d5-4eaf-b49f-746710f4c150" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_71297f9f-6dfd-4913-9f66-e4aa8e31d887" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e8c1c3c5-a1d5-4eaf-b49f-746710f4c150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4b4b8bd5-7d15-457d-9c9c-b06182758f33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_71297f9f-6dfd-4913-9f66-e4aa8e31d887" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_4b4b8bd5-7d15-457d-9c9c-b06182758f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_40d88978-916f-492d-8873-482d71a494da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_debfef8a-576a-43dd-8966-7f91de9a3316" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_40d88978-916f-492d-8873-482d71a494da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_7c49f59b-c87f-48be-bb60-811f694836cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_40d88978-916f-492d-8873-482d71a494da" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_7c49f59b-c87f-48be-bb60-811f694836cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_010adf41-37df-4a6f-9436-860c05640f81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_7c49f59b-c87f-48be-bb60-811f694836cc" xlink:to="loc_us-gaap_MoneyMarketFundsMember_010adf41-37df-4a6f-9436-860c05640f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_c6821d19-9463-418f-94e2-01208a6ecc45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_7c49f59b-c87f-48be-bb60-811f694836cc" xlink:to="loc_us-gaap_CommercialPaperMember_c6821d19-9463-418f-94e2-01208a6ecc45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b2dfa752-f325-4d2b-9658-510258e63555" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_debfef8a-576a-43dd-8966-7f91de9a3316" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b2dfa752-f325-4d2b-9658-510258e63555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e91a14ea-6f70-4867-845b-e8c90c3a86e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b2dfa752-f325-4d2b-9658-510258e63555" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e91a14ea-6f70-4867-845b-e8c90c3a86e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_e25cb2e3-c503-4a83-ae0b-dea2c240d545" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e91a14ea-6f70-4867-845b-e8c90c3a86e2" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_e25cb2e3-c503-4a83-ae0b-dea2c240d545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_d3ab6d7e-e1fb-481b-a5b6-8ab53c67e17e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e91a14ea-6f70-4867-845b-e8c90c3a86e2" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_d3ab6d7e-e1fb-481b-a5b6-8ab53c67e17e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_1fcd5863-a75b-497c-ae6f-7fc0fcf98c35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e91a14ea-6f70-4867-845b-e8c90c3a86e2" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_1fcd5863-a75b-497c-ae6f-7fc0fcf98c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_eef1580a-d4d2-4287-9d36-6b4d7c52653e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e91a14ea-6f70-4867-845b-e8c90c3a86e2" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_eef1580a-d4d2-4287-9d36-6b4d7c52653e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_a0fbcb23-7c97-46fb-9f63-c99126775262" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e91a14ea-6f70-4867-845b-e8c90c3a86e2" xlink:to="loc_us-gaap_CommercialPaperMember_a0fbcb23-7c97-46fb-9f63-c99126775262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ce31343a-d3c7-4558-9ece-817a9b579a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_debfef8a-576a-43dd-8966-7f91de9a3316" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ce31343a-d3c7-4558-9ece-817a9b579a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7563f4a3-4528-4b25-9fdd-69e13c62b11e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ce31343a-d3c7-4558-9ece-817a9b579a9c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7563f4a3-4528-4b25-9fdd-69e13c62b11e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_421d552d-dd38-4b67-a748-0cdb3b1623b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ce31343a-d3c7-4558-9ece-817a9b579a9c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_421d552d-dd38-4b67-a748-0cdb3b1623b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_2559d2d6-1f1c-4480-9f78-960fb925ba39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ce31343a-d3c7-4558-9ece-817a9b579a9c" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_2559d2d6-1f1c-4480-9f78-960fb925ba39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/Revenue" xlink:type="simple" xlink:href="halo-20220630.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1ef22d37-59aa-40a6-9bc0-a4b49b5beca5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_bc323296-ad78-4c87-acd1-a5a945efcbf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1ef22d37-59aa-40a6-9bc0-a4b49b5beca5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_bc323296-ad78-4c87-acd1-a5a945efcbf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/RevenueTables" xlink:type="simple" xlink:href="halo-20220630.xsd#RevenueTables"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/RevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a6e373f1-7c1c-4994-914e-7a47246e0abf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_f636b96d-bbae-459f-90b4-96fbe9279f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a6e373f1-7c1c-4994-914e-7a47246e0abf" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_f636b96d-bbae-459f-90b4-96fbe9279f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_9c418e59-0e62-4e02-b61d-fbc6e7e9a2cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a6e373f1-7c1c-4994-914e-7a47246e0abf" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_9c418e59-0e62-4e02-b61d-fbc6e7e9a2cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#RevenueDisaggregatedRevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_61651561-0edf-458f-91c7-077d720cfc3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_5bb5d1ab-f04d-4f12-ad46-cc1eab9575ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_61651561-0edf-458f-91c7-077d720cfc3f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_5bb5d1ab-f04d-4f12-ad46-cc1eab9575ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4a326d8d-e973-4872-9a7b-317085171398" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5bb5d1ab-f04d-4f12-ad46-cc1eab9575ce" xlink:to="loc_srt_ProductOrServiceAxis_4a326d8d-e973-4872-9a7b-317085171398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6fbf36f0-45c1-4e28-96c8-825dcfc20087" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4a326d8d-e973-4872-9a7b-317085171398" xlink:to="loc_srt_ProductsAndServicesDomain_6fbf36f0-45c1-4e28-96c8-825dcfc20087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_4cb809bf-bdeb-4771-b503-4f3b10eecccb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6fbf36f0-45c1-4e28-96c8-825dcfc20087" xlink:to="loc_us-gaap_RoyaltyMember_4cb809bf-bdeb-4771-b503-4f3b10eecccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_786342cc-c3ea-4b75-be1a-0a53193be971" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6fbf36f0-45c1-4e28-96c8-825dcfc20087" xlink:to="loc_us-gaap_ProductMember_786342cc-c3ea-4b75-be1a-0a53193be971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_BulkrHuPH20Member_b9e07c2a-b20b-40f3-8918-3eb06af57fb3" xlink:href="halo-20220630.xsd#halo_BulkrHuPH20Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_786342cc-c3ea-4b75-be1a-0a53193be971" xlink:to="loc_halo_BulkrHuPH20Member_b9e07c2a-b20b-40f3-8918-3eb06af57fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ProprietaryProductsSalesMember_0b04a7fe-2a39-48b6-9c2d-ea8041de24e2" xlink:href="halo-20220630.xsd#halo_ProprietaryProductsSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_786342cc-c3ea-4b75-be1a-0a53193be971" xlink:to="loc_halo_ProprietaryProductsSalesMember_0b04a7fe-2a39-48b6-9c2d-ea8041de24e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DevicePartneredProductsMember_4f5f54d0-ac27-4e38-a0cd-f83880629c3f" xlink:href="halo-20220630.xsd#halo_DevicePartneredProductsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_786342cc-c3ea-4b75-be1a-0a53193be971" xlink:to="loc_halo_DevicePartneredProductsMember_4f5f54d0-ac27-4e38-a0cd-f83880629c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_CollaborativeAgreementsMember_2896a367-ec46-4c68-bcfc-cd7c0242d081" xlink:href="halo-20220630.xsd#halo_CollaborativeAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6fbf36f0-45c1-4e28-96c8-825dcfc20087" xlink:to="loc_halo_CollaborativeAgreementsMember_2896a367-ec46-4c68-bcfc-cd7c0242d081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_UpfrontfeesMember_9ce79ccc-79c3-49a8-bc5a-1367d7af8413" xlink:href="halo-20220630.xsd#halo_UpfrontfeesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_CollaborativeAgreementsMember_2896a367-ec46-4c68-bcfc-cd7c0242d081" xlink:to="loc_halo_UpfrontfeesMember_9ce79ccc-79c3-49a8-bc5a-1367d7af8413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DevelopmentFeesMember_0b6d71b9-b72c-45b7-b86e-7d0ff2b0f25f" xlink:href="halo-20220630.xsd#halo_DevelopmentFeesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_CollaborativeAgreementsMember_2896a367-ec46-4c68-bcfc-cd7c0242d081" xlink:to="loc_halo_DevelopmentFeesMember_0b6d71b9-b72c-45b7-b86e-7d0ff2b0f25f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_SalesbasedmilestoneMember_084f3b76-f75b-4491-b513-7eb1fa0b890a" xlink:href="halo-20220630.xsd#halo_SalesbasedmilestoneMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_CollaborativeAgreementsMember_2896a367-ec46-4c68-bcfc-cd7c0242d081" xlink:to="loc_halo_SalesbasedmilestoneMember_084f3b76-f75b-4491-b513-7eb1fa0b890a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DeviceLicensingAndDevelopmentMember_8b47b33b-e60b-4d7d-8931-3c5117088691" xlink:href="halo-20220630.xsd#halo_DeviceLicensingAndDevelopmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_CollaborativeAgreementsMember_2896a367-ec46-4c68-bcfc-cd7c0242d081" xlink:to="loc_halo_DeviceLicensingAndDevelopmentMember_8b47b33b-e60b-4d7d-8931-3c5117088691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_0d569be8-656e-40d9-950c-f28dfebc6a77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5bb5d1ab-f04d-4f12-ad46-cc1eab9575ce" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_0d569be8-656e-40d9-950c-f28dfebc6a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8c9d9f02-1a2b-45db-97c1-ab08e2a1b1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0d569be8-656e-40d9-950c-f28dfebc6a77" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8c9d9f02-1a2b-45db-97c1-ab08e2a1b1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/RevenueNarrativeDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#RevenueNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/RevenueNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_794cbb41-9183-4cf5-89b6-553d25b342f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_2b863d6c-7566-4807-85a9-ea64324fc62f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_794cbb41-9183-4cf5-89b6-553d25b342f3" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_2b863d6c-7566-4807-85a9-ea64324fc62f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6e92a428-9b5f-4504-b924-7e427944dc50" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2b863d6c-7566-4807-85a9-ea64324fc62f" xlink:to="loc_srt_ProductOrServiceAxis_6e92a428-9b5f-4504-b924-7e427944dc50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ed51c424-95ac-4fc3-9d2c-47dff0422259" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_6e92a428-9b5f-4504-b924-7e427944dc50" xlink:to="loc_srt_ProductsAndServicesDomain_ed51c424-95ac-4fc3-9d2c-47dff0422259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_LicenseFeesAndEventBasedMember_ddc023ef-555e-4092-bc46-46bec498ed41" xlink:href="halo-20220630.xsd#halo_LicenseFeesAndEventBasedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ed51c424-95ac-4fc3-9d2c-47dff0422259" xlink:to="loc_halo_LicenseFeesAndEventBasedMember_ddc023ef-555e-4092-bc46-46bec498ed41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_59cc074e-9be4-4977-ac59-2d95a1382572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ed51c424-95ac-4fc3-9d2c-47dff0422259" xlink:to="loc_us-gaap_ProductMember_59cc074e-9be4-4977-ac59-2d95a1382572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a6bdf9a3-245f-47a8-8dca-9b05f695280d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2b863d6c-7566-4807-85a9-ea64324fc62f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a6bdf9a3-245f-47a8-8dca-9b05f695280d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d144efeb-5481-417c-bf21-eff16df2b0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a6bdf9a3-245f-47a8-8dca-9b05f695280d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d144efeb-5481-417c-bf21-eff16df2b0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_OthercollaboratorsMember_e826852c-24a9-48cd-8300-a544248f33d7" xlink:href="halo-20220630.xsd#halo_OthercollaboratorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d144efeb-5481-417c-bf21-eff16df2b0ce" xlink:to="loc_halo_OthercollaboratorsMember_e826852c-24a9-48cd-8300-a544248f33d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_07fce759-6886-49fd-9864-9c32ee809028" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2b863d6c-7566-4807-85a9-ea64324fc62f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_07fce759-6886-49fd-9864-9c32ee809028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_70518384-c728-4414-8af3-ae27a29250c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_07fce759-6886-49fd-9864-9c32ee809028" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_70518384-c728-4414-8af3-ae27a29250c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AntaresPharmaIncMember_8f85d8d3-c133-465d-bbe6-ae4bfec4fc3f" xlink:href="halo-20220630.xsd#halo_AntaresPharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_70518384-c728-4414-8af3-ae27a29250c7" xlink:to="loc_halo_AntaresPharmaIncMember_8f85d8d3-c133-465d-bbe6-ae4bfec4fc3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_98bced52-c732-4e09-9e20-921147af75a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2b863d6c-7566-4807-85a9-ea64324fc62f" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_98bced52-c732-4e09-9e20-921147af75a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1b466864-7ced-4236-ac09-e43f4b75fa62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_98bced52-c732-4e09-9e20-921147af75a3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1b466864-7ced-4236-ac09-e43f4b75fa62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7ec4def6-565f-4798-a06e-80d8c375148e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_98bced52-c732-4e09-9e20-921147af75a3" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7ec4def6-565f-4798-a06e-80d8c375148e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue_2ec3293a-d968-4072-9092-73137fab0004" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_98bced52-c732-4e09-9e20-921147af75a3" xlink:to="loc_us-gaap_DeferredRevenue_2ec3293a-d968-4072-9092-73137fab0004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_0d1e7905-d2a3-47e9-8332-d590ddefefb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_98bced52-c732-4e09-9e20-921147af75a3" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_0d1e7905-d2a3-47e9-8332-d590ddefefb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilities_6cb98236-1439-4206-8dbf-1cdfb4947132" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_98bced52-c732-4e09-9e20-921147af75a3" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilities_6cb98236-1439-4206-8dbf-1cdfb4947132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_b5e8dacc-7ea4-4e08-844b-fc1bc5bcb36a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_98bced52-c732-4e09-9e20-921147af75a3" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_b5e8dacc-7ea4-4e08-844b-fc1bc5bcb36a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/RevenueAccountsReceivablenetandDeferredRevenuesfromContractsDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#RevenueAccountsReceivablenetandDeferredRevenuesfromContractsDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/RevenueAccountsReceivablenetandDeferredRevenuesfromContractsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f8a0d0e2-8f9e-4968-8e72-65b07096da42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets_a7485442-6900-41b8-8484-7c38173f8f8e" xlink:href="halo-20220630.xsd#halo_AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f8a0d0e2-8f9e-4968-8e72-65b07096da42" xlink:to="loc_halo_AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets_a7485442-6900-41b8-8484-7c38173f8f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue_f230be07-421a-412e-a091-374f96f5c2f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f8a0d0e2-8f9e-4968-8e72-65b07096da42" xlink:to="loc_us-gaap_DeferredRevenue_f230be07-421a-412e-a091-374f96f5c2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/RevenueAdditionalRevenueInformationDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#RevenueAdditionalRevenueInformationDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/RevenueAdditionalRevenueInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f9824c8f-bd67-4175-86a9-02b1112456f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2ac093e7-e68e-429c-b409-706b1ffb71cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f9824c8f-bd67-4175-86a9-02b1112456f7" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2ac093e7-e68e-429c-b409-706b1ffb71cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_54b2e682-8033-4b26-ab3e-72c99f75cfb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2ac093e7-e68e-429c-b409-706b1ffb71cf" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_54b2e682-8033-4b26-ab3e-72c99f75cfb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_3c905694-290f-46dd-b5cf-a3ec1c079848" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2ac093e7-e68e-429c-b409-706b1ffb71cf" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_3c905694-290f-46dd-b5cf-a3ec1c079848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_d0a29818-980f-41fc-a97d-b47da6e6f7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_3c905694-290f-46dd-b5cf-a3ec1c079848" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_d0a29818-980f-41fc-a97d-b47da6e6f7c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_ff1c9386-1ad6-4c61-aa28-1400b1e70e75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_3c905694-290f-46dd-b5cf-a3ec1c079848" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_ff1c9386-1ad6-4c61-aa28-1400b1e70e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/RevenueAdditionalRevenueInformationDetails_1" xlink:type="simple" xlink:href="halo-20220630.xsd#RevenueAdditionalRevenueInformationDetails_1"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/RevenueAdditionalRevenueInformationDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItems" xlink:type="simple" xlink:href="halo-20220630.xsd#CertainBalanceSheetItems"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItems" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_c9b9451e-959e-43ca-a199-6ce680e8fa2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_b2a08b99-f667-4c66-8f27-cc9c921d45fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_c9b9451e-959e-43ca-a199-6ce680e8fa2d" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_b2a08b99-f667-4c66-8f27-cc9c921d45fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsTables" xlink:type="simple" xlink:href="halo-20220630.xsd#CertainBalanceSheetItemsTables"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_28ff0d9f-3f5f-4ae5-addb-1523dbda2f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_6f951505-da30-44bc-8680-aedf50682ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_28ff0d9f-3f5f-4ae5-addb-1523dbda2f6c" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_6f951505-da30-44bc-8680-aedf50682ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_37278474-7aa2-4307-8351-d7539873c5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_28ff0d9f-3f5f-4ae5-addb-1523dbda2f6c" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_37278474-7aa2-4307-8351-d7539873c5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_7e610dbc-6c36-4f87-ba6f-ba45c3200f87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_28ff0d9f-3f5f-4ae5-addb-1523dbda2f6c" xlink:to="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_7e610dbc-6c36-4f87-ba6f-ba45c3200f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_823bbce0-063c-4236-9a04-1464e76df75a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_28ff0d9f-3f5f-4ae5-addb-1523dbda2f6c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_823bbce0-063c-4236-9a04-1464e76df75a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_eedc0d62-593d-479b-905d-4bc47d3bb97f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_28ff0d9f-3f5f-4ae5-addb-1523dbda2f6c" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_eedc0d62-593d-479b-905d-4bc47d3bb97f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#CertainBalanceSheetItemsAccountsReceivablenetDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_c72b8e6e-ea93-4755-b17e-1197e70555e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accountsreceivablefromproductsalestocollaborators_18fdcd3f-bd6a-4dab-b420-44a4cc44df40" xlink:href="halo-20220630.xsd#halo_Accountsreceivablefromproductsalestocollaborators"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_c72b8e6e-ea93-4755-b17e-1197e70555e6" xlink:to="loc_halo_Accountsreceivablefromproductsalestocollaborators_18fdcd3f-bd6a-4dab-b420-44a4cc44df40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accountsreceivablefromcollaborators_63918517-5584-458a-8081-089001221419" xlink:href="halo-20220630.xsd#halo_Accountsreceivablefromcollaborators"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_c72b8e6e-ea93-4755-b17e-1197e70555e6" xlink:to="loc_halo_Accountsreceivablefromcollaborators_63918517-5584-458a-8081-089001221419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accountsreceivablefromroyalties_d11d1161-6520-4b58-b5dc-9296e2a83a7a" xlink:href="halo-20220630.xsd#halo_Accountsreceivablefromroyalties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_c72b8e6e-ea93-4755-b17e-1197e70555e6" xlink:to="loc_halo_Accountsreceivablefromroyalties_d11d1161-6520-4b58-b5dc-9296e2a83a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accountsreceivablefromproductsales_efdc69ae-51a2-48b5-8490-c68d4b0b877f" xlink:href="halo-20220630.xsd#halo_Accountsreceivablefromproductsales"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_c72b8e6e-ea93-4755-b17e-1197e70555e6" xlink:to="loc_halo_Accountsreceivablefromproductsales_efdc69ae-51a2-48b5-8490-c68d4b0b877f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivables_cddc2f66-3b83-4d40-bef4-bcf35ff58dca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivables"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_c72b8e6e-ea93-4755-b17e-1197e70555e6" xlink:to="loc_us-gaap_OtherReceivables_cddc2f66-3b83-4d40-bef4-bcf35ff58dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_a7342d47-8e21-4127-8981-4a28883e51e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_c72b8e6e-ea93-4755-b17e-1197e70555e6" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_a7342d47-8e21-4127-8981-4a28883e51e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_e269779a-c014-446e-aec6-e87c8b95dbfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_c72b8e6e-ea93-4755-b17e-1197e70555e6" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_e269779a-c014-446e-aec6-e87c8b95dbfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AllowanceforDistributionFeesandDiscounts_26b12a1c-7399-4ec3-8026-6413b298f3f9" xlink:href="halo-20220630.xsd#halo_AllowanceforDistributionFeesandDiscounts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_c72b8e6e-ea93-4755-b17e-1197e70555e6" xlink:to="loc_halo_AllowanceforDistributionFeesandDiscounts_26b12a1c-7399-4ec3-8026-6413b298f3f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_2342c454-04a6-4e5b-a165-0d8d5609875c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_c72b8e6e-ea93-4755-b17e-1197e70555e6" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_2342c454-04a6-4e5b-a165-0d8d5609875c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#CertainBalanceSheetItemsInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_a9f1a3e7-e0b5-4a06-862e-0a26088e9309" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_4ba1d26e-b8b6-4729-a7d3-c49e206471f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_a9f1a3e7-e0b5-4a06-862e-0a26088e9309" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_4ba1d26e-b8b6-4729-a7d3-c49e206471f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_c7abb1ac-9967-4aba-98e7-eae09c1d3188" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_a9f1a3e7-e0b5-4a06-862e-0a26088e9309" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_c7abb1ac-9967-4aba-98e7-eae09c1d3188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_5937463a-22d0-4530-9618-19cdeaf9d87c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_a9f1a3e7-e0b5-4a06-862e-0a26088e9309" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_5937463a-22d0-4530-9618-19cdeaf9d87c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e43bef40-6bc9-4ae1-ae91-7c294cf59ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_a9f1a3e7-e0b5-4a06-862e-0a26088e9309" xlink:to="loc_us-gaap_InventoryNet_e43bef40-6bc9-4ae1-ae91-7c294cf59ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_560c182e-db39-47a6-baeb-4536b9924a28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2631b308-dfff-425b-af48-1dc8901db597" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_560c182e-db39-47a6-baeb-4536b9924a28" xlink:to="loc_us-gaap_StatementTable_2631b308-dfff-425b-af48-1dc8901db597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_861b6bed-02df-4897-ab12-d07be809a027" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2631b308-dfff-425b-af48-1dc8901db597" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_861b6bed-02df-4897-ab12-d07be809a027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c920dfc7-55c9-4586-b874-b4e4526a943a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_861b6bed-02df-4897-ab12-d07be809a027" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c920dfc7-55c9-4586-b874-b4e4526a943a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ComputerAndOfficeEquipmentMember_cbc39630-cc7f-43b2-88cb-0e808656e438" xlink:href="halo-20220630.xsd#halo_ComputerAndOfficeEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c920dfc7-55c9-4586-b874-b4e4526a943a" xlink:to="loc_halo_ComputerAndOfficeEquipmentMember_cbc39630-cc7f-43b2-88cb-0e808656e438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5c614532-d8eb-47a7-b0a9-2abf86ffca80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2631b308-dfff-425b-af48-1dc8901db597" xlink:to="loc_us-gaap_StatementLineItems_5c614532-d8eb-47a7-b0a9-2abf86ffca80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_8fec9943-546d-4e7c-b4c3-fcb2f1703f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5c614532-d8eb-47a7-b0a9-2abf86ffca80" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_8fec9943-546d-4e7c-b4c3-fcb2f1703f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_ca5e7dfb-1104-449b-a34d-ea74423b070c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5c614532-d8eb-47a7-b0a9-2abf86ffca80" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_ca5e7dfb-1104-449b-a34d-ea74423b070c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_293cfc6d-fbd5-425c-98eb-aacae3003eb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5c614532-d8eb-47a7-b0a9-2abf86ffca80" xlink:to="loc_us-gaap_OtherAssets_293cfc6d-fbd5-425c-98eb-aacae3003eb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_b318afc0-be2d-43d2-8402-d3076abfd1ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5c614532-d8eb-47a7-b0a9-2abf86ffca80" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_b318afc0-be2d-43d2-8402-d3076abfd1ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_cfa4f31d-02be-4fae-819e-8ad2e21b5511" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5c614532-d8eb-47a7-b0a9-2abf86ffca80" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_cfa4f31d-02be-4fae-819e-8ad2e21b5511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_554e85cb-f8f9-40e7-9e54-5b57db168357" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5c614532-d8eb-47a7-b0a9-2abf86ffca80" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_554e85cb-f8f9-40e7-9e54-5b57db168357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails_1" xlink:type="simple" xlink:href="halo-20220630.xsd#CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails_1"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#CertainBalanceSheetItemsPropertyandEquipmentnetDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_1c444b93-abde-4ff3-a9ca-21a2867cd551" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_62805228-2f6a-4514-876c-9c44eaf84667" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_1c444b93-abde-4ff3-a9ca-21a2867cd551" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_62805228-2f6a-4514-876c-9c44eaf84667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_693ddce9-185b-43f2-b175-f00b8fae5312" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_62805228-2f6a-4514-876c-9c44eaf84667" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_693ddce9-185b-43f2-b175-f00b8fae5312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5867c862-bac4-402f-b806-148d887feb01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_693ddce9-185b-43f2-b175-f00b8fae5312" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5867c862-bac4-402f-b806-148d887feb01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ResearchEquipmentMember_b48f6282-da2b-4f5b-b111-c68ec72f6e4f" xlink:href="halo-20220630.xsd#halo_ResearchEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5867c862-bac4-402f-b806-148d887feb01" xlink:to="loc_halo_ResearchEquipmentMember_b48f6282-da2b-4f5b-b111-c68ec72f6e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ManufacturingEquipmentMember_e8f02c03-2137-4392-9cd4-118bce0e4a19" xlink:href="halo-20220630.xsd#halo_ManufacturingEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5867c862-bac4-402f-b806-148d887feb01" xlink:to="loc_halo_ManufacturingEquipmentMember_e8f02c03-2137-4392-9cd4-118bce0e4a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ComputerAndOfficeEquipmentMember_ed5f0f57-8824-4c87-ae54-f8ba1a21a2c3" xlink:href="halo-20220630.xsd#halo_ComputerAndOfficeEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5867c862-bac4-402f-b806-148d887feb01" xlink:to="loc_halo_ComputerAndOfficeEquipmentMember_ed5f0f57-8824-4c87-ae54-f8ba1a21a2c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_e5eed901-91f7-49cc-bc01-74e899a614c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5867c862-bac4-402f-b806-148d887feb01" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_e5eed901-91f7-49cc-bc01-74e899a614c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_02420da8-a284-4e1c-8616-12606cd22a93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_62805228-2f6a-4514-876c-9c44eaf84667" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_02420da8-a284-4e1c-8616-12606cd22a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_853a43e2-b01f-41e2-be30-27a70943163c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_02420da8-a284-4e1c-8616-12606cd22a93" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_853a43e2-b01f-41e2-be30-27a70943163c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3cb0ce28-520b-4113-a779-fd5d7368dd15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_02420da8-a284-4e1c-8616-12606cd22a93" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3cb0ce28-520b-4113-a779-fd5d7368dd15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e943bfd7-bcc3-48f2-9a95-b3d859b7dafa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_02420da8-a284-4e1c-8616-12606cd22a93" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e943bfd7-bcc3-48f2-9a95-b3d859b7dafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_181afd77-465f-4773-b830-91d332f1a9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_02420da8-a284-4e1c-8616-12606cd22a93" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_181afd77-465f-4773-b830-91d332f1a9f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_b101e660-8ba7-4247-97ff-ee3136bc0cfb" xlink:href="halo-20220630.xsd#halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_02420da8-a284-4e1c-8616-12606cd22a93" xlink:to="loc_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_b101e660-8ba7-4247-97ff-ee3136bc0cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_fd8444ea-7aa3-480d-93e8-d73d88e6612f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_02420da8-a284-4e1c-8616-12606cd22a93" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_fd8444ea-7aa3-480d-93e8-d73d88e6612f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_619eb44b-55dc-4992-b874-2ffb17f72844" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_02420da8-a284-4e1c-8616-12606cd22a93" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_619eb44b-55dc-4992-b874-2ffb17f72844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#CertainBalanceSheetItemsAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_da7b01ac-9ce6-44b5-80f0-d0c13db1fc9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_84da7286-fcdf-4e94-9a15-e3127525b43a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_da7b01ac-9ce6-44b5-80f0-d0c13db1fc9f" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_84da7286-fcdf-4e94-9a15-e3127525b43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_Accruedmanufacturingexpenses_ce9a8246-1fdf-45eb-99a6-2ba8ab41429e" xlink:href="halo-20220630.xsd#halo_Accruedmanufacturingexpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_da7b01ac-9ce6-44b5-80f0-d0c13db1fc9f" xlink:to="loc_halo_Accruedmanufacturingexpenses_ce9a8246-1fdf-45eb-99a6-2ba8ab41429e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_c947bbf1-65f6-410b-b0dd-de91aacc0ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_da7b01ac-9ce6-44b5-80f0-d0c13db1fc9f" xlink:to="loc_us-gaap_TaxesPayableCurrent_c947bbf1-65f6-410b-b0dd-de91aacc0ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_02f37bc7-ed3f-4694-ac63-95cd98dbc851" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_da7b01ac-9ce6-44b5-80f0-d0c13db1fc9f" xlink:to="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_02f37bc7-ed3f-4694-ac63-95cd98dbc851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ef0d84a3-239a-4444-849f-c1026fdd877c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_da7b01ac-9ce6-44b5-80f0-d0c13db1fc9f" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ef0d84a3-239a-4444-849f-c1026fdd877c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_41581923-838c-42f7-9762-5a3060a77b35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_da7b01ac-9ce6-44b5-80f0-d0c13db1fc9f" xlink:to="loc_us-gaap_OperatingLeaseLiability_41581923-838c-42f7-9762-5a3060a77b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_8e8e3181-fa12-42a5-83ff-8a67f148af02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_da7b01ac-9ce6-44b5-80f0-d0c13db1fc9f" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_8e8e3181-fa12-42a5-83ff-8a67f148af02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AccruedLiabilitiesNoncurrent_e95c1e8b-ddcd-4cd3-b78f-1b632dfb9676" xlink:href="halo-20220630.xsd#halo_AccruedLiabilitiesNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_da7b01ac-9ce6-44b5-80f0-d0c13db1fc9f" xlink:to="loc_halo_AccruedLiabilitiesNoncurrent_e95c1e8b-ddcd-4cd3-b78f-1b632dfb9676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_af1c7366-ae8a-4b48-a518-541f923194bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_da7b01ac-9ce6-44b5-80f0-d0c13db1fc9f" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_af1c7366-ae8a-4b48-a518-541f923194bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_OperatingLeaseAccretionOfLiability_c3521c3e-d9e6-4e9b-9363-bf9ceb8d3cf1" xlink:href="halo-20220630.xsd#halo_OperatingLeaseAccretionOfLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_da7b01ac-9ce6-44b5-80f0-d0c13db1fc9f" xlink:to="loc_halo_OperatingLeaseAccretionOfLiability_c3521c3e-d9e6-4e9b-9363-bf9ceb8d3cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_0232db55-114c-4071-a286-2667cd34321e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_da7b01ac-9ce6-44b5-80f0-d0c13db1fc9f" xlink:to="loc_us-gaap_OperatingLeaseCost_0232db55-114c-4071-a286-2667cd34321e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_f78199de-eff5-4a07-9485-9bb1379effcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_da7b01ac-9ce6-44b5-80f0-d0c13db1fc9f" xlink:to="loc_us-gaap_OperatingLeasePayments_f78199de-eff5-4a07-9485-9bb1379effcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails_1" xlink:type="simple" xlink:href="halo-20220630.xsd#CertainBalanceSheetItemsAccruedExpensesDetails_1"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="halo-20220630.xsd#GoodwillandIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/GoodwillandIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6d2d0d9b-0112-484d-948a-5d0df450d0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_32124085-d629-4e4a-af9d-998011c3af81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6d2d0d9b-0112-484d-948a-5d0df450d0b6" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_32124085-d629-4e4a-af9d-998011c3af81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="halo-20220630.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0bbfded4-5e60-490b-b03f-a1a359a2faa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_f15c99fb-f84b-4972-967a-e939f9984f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0bbfded4-5e60-490b-b03f-a1a359a2faa4" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_f15c99fb-f84b-4972-967a-e939f9984f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_4d72e647-b23a-4305-81f3-657b9a1aa9b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0bbfded4-5e60-490b-b03f-a1a359a2faa4" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_4d72e647-b23a-4305-81f3-657b9a1aa9b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_bfc8c140-35a3-4fa3-b777-73fd2e9b873b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0bbfded4-5e60-490b-b03f-a1a359a2faa4" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_bfc8c140-35a3-4fa3-b777-73fd2e9b873b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#GoodwillandIntangibleAssetsAdditionalDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_09da451d-69a8-4c1a-8fb4-ec89de801910" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d36c0ed0-ff30-443c-b0b2-96145ee2e668" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_09da451d-69a8-4c1a-8fb4-ec89de801910" xlink:to="loc_us-gaap_Goodwill_d36c0ed0-ff30-443c-b0b2-96145ee2e668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/IntangibleAssetsGoodwillandOtherGoodwillRollforwardDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#IntangibleAssetsGoodwillandOtherGoodwillRollforwardDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/IntangibleAssetsGoodwillandOtherGoodwillRollforwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_073c3044-b17a-411c-8bc8-5b396456ff9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_337d120f-276a-4d9c-9b46-b21545f677d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_073c3044-b17a-411c-8bc8-5b396456ff9c" xlink:to="loc_us-gaap_GoodwillRollForward_337d120f-276a-4d9c-9b46-b21545f677d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_029aaf49-14a4-43e8-93e2-5946c70620a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_337d120f-276a-4d9c-9b46-b21545f677d8" xlink:to="loc_us-gaap_Goodwill_029aaf49-14a4-43e8-93e2-5946c70620a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_eea882be-02c6-4441-8e6e-e3cf4ac2fc3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_337d120f-276a-4d9c-9b46-b21545f677d8" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_eea882be-02c6-4441-8e6e-e3cf4ac2fc3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_6c76fda4-fe98-48a2-845e-730b33ca89d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_337d120f-276a-4d9c-9b46-b21545f677d8" xlink:to="loc_us-gaap_Goodwill_6c76fda4-fe98-48a2-845e-730b33ca89d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#GoodwillandIntangibleAssetsIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ce76229b-cadd-4a46-b622-db85b0074425" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_68b09fc9-b028-447b-83c8-cbb4a1dfe801" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ce76229b-cadd-4a46-b622-db85b0074425" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_68b09fc9-b028-447b-83c8-cbb4a1dfe801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_95884da8-b66e-4be5-bfc9-4da8e49eb596" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_68b09fc9-b028-447b-83c8-cbb4a1dfe801" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_95884da8-b66e-4be5-bfc9-4da8e49eb596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_16969e78-e329-4d10-8617-10c6fd5dbf76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_95884da8-b66e-4be5-bfc9-4da8e49eb596" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_16969e78-e329-4d10-8617-10c6fd5dbf76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AutoInjectorTechnologyPlatformMember_4aa06dd2-8857-4eff-a71b-0fe5da09f152" xlink:href="halo-20220630.xsd#halo_AutoInjectorTechnologyPlatformMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_16969e78-e329-4d10-8617-10c6fd5dbf76" xlink:to="loc_halo_AutoInjectorTechnologyPlatformMember_4aa06dd2-8857-4eff-a71b-0fe5da09f152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_XYOSTEDProprietaryProductMember_ab9f96c7-c79d-4385-9508-ac8bb83eac36" xlink:href="halo-20220630.xsd#halo_XYOSTEDProprietaryProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_16969e78-e329-4d10-8617-10c6fd5dbf76" xlink:to="loc_halo_XYOSTEDProprietaryProductMember_ab9f96c7-c79d-4385-9508-ac8bb83eac36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_TLANDOProductRightsMember_b819e917-c55d-4e4d-86fc-508f2b9525a9" xlink:href="halo-20220630.xsd#halo_TLANDOProductRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_16969e78-e329-4d10-8617-10c6fd5dbf76" xlink:to="loc_halo_TLANDOProductRightsMember_b819e917-c55d-4e4d-86fc-508f2b9525a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3c9ca0d2-64a4-4079-8be3-821d3abe930d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_68b09fc9-b028-447b-83c8-cbb4a1dfe801" xlink:to="loc_srt_RangeAxis_3c9ca0d2-64a4-4079-8be3-821d3abe930d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_11e0c155-92fd-40a0-8905-b690f5bcca79" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3c9ca0d2-64a4-4079-8be3-821d3abe930d" xlink:to="loc_srt_RangeMember_11e0c155-92fd-40a0-8905-b690f5bcca79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_84b78e71-8ce0-4649-a0d7-7b42371880a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_68b09fc9-b028-447b-83c8-cbb4a1dfe801" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_84b78e71-8ce0-4649-a0d7-7b42371880a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_d45894dd-3f3e-42f0-9a3f-2bc36174efbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_84b78e71-8ce0-4649-a0d7-7b42371880a5" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_d45894dd-3f3e-42f0-9a3f-2bc36174efbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b7a4f4c6-7717-4d9f-8da0-7d35bde5e9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_84b78e71-8ce0-4649-a0d7-7b42371880a5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b7a4f4c6-7717-4d9f-8da0-7d35bde5e9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e2df0495-914e-4ae7-89e6-5382724ecad7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_84b78e71-8ce0-4649-a0d7-7b42371880a5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e2df0495-914e-4ae7-89e6-5382724ecad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9b7b4b50-8b2a-4bb9-a55c-41f54e5b2897" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_84b78e71-8ce0-4649-a0d7-7b42371880a5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9b7b4b50-8b2a-4bb9-a55c-41f54e5b2897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_d909b086-43aa-4152-91df-e8900aa7f215" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_84b78e71-8ce0-4649-a0d7-7b42371880a5" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_d909b086-43aa-4152-91df-e8900aa7f215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3df157f0-0b07-4d64-81ce-afb037c6cea8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_84b78e71-8ce0-4649-a0d7-7b42371880a5" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3df157f0-0b07-4d64-81ce-afb037c6cea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#GoodwillandIntangibleAssetsFutureAmortizationDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_488b57ad-20c6-455d-aec4-5fad57a536bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_ee1198c6-b2e3-4efc-9d26-b6fdfcf37d50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_488b57ad-20c6-455d-aec4-5fad57a536bf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_ee1198c6-b2e3-4efc-9d26-b6fdfcf37d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_3fb64668-d06e-4590-b361-14556f385d17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_488b57ad-20c6-455d-aec4-5fad57a536bf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_3fb64668-d06e-4590-b361-14556f385d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_062b683c-23c8-4452-b30f-79dec6049e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_488b57ad-20c6-455d-aec4-5fad57a536bf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_062b683c-23c8-4452-b30f-79dec6049e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_f454a198-fa08-4389-8fe3-0ef40261f94d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_488b57ad-20c6-455d-aec4-5fad57a536bf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_f454a198-fa08-4389-8fe3-0ef40261f94d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_04831075-468c-44f3-b893-999fa6c79109" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_488b57ad-20c6-455d-aec4-5fad57a536bf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_04831075-468c-44f3-b893-999fa6c79109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour_e89bf6a2-e885-47e9-b1df-9595aa77518f" xlink:href="halo-20220630.xsd#halo_FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_488b57ad-20c6-455d-aec4-5fad57a536bf" xlink:to="loc_halo_FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour_e89bf6a2-e885-47e9-b1df-9595aa77518f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ec328f4b-3bb5-48d8-8663-48e9cc3f65e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_488b57ad-20c6-455d-aec4-5fad57a536bf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ec328f4b-3bb5-48d8-8663-48e9cc3f65e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/LongTermDebtNet" xlink:type="simple" xlink:href="halo-20220630.xsd#LongTermDebtNet"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/LongTermDebtNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_15d0d999-344b-4629-99f3-f051e2a3520c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock_b1630b77-e9f2-4ed4-9dbe-2d9149c8e672" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_15d0d999-344b-4629-99f3-f051e2a3520c" xlink:to="loc_us-gaap_LongTermDebtTextBlock_b1630b77-e9f2-4ed4-9dbe-2d9149c8e672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/LongTermDebtNetTables" xlink:type="simple" xlink:href="halo-20220630.xsd#LongTermDebtNetTables"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/LongTermDebtNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_406a74c1-2686-4dd0-9230-08063667cf2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_feaff74b-8b11-409a-ab13-dfa1d9f1ecc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_406a74c1-2686-4dd0-9230-08063667cf2d" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_feaff74b-8b11-409a-ab13-dfa1d9f1ecc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_86dbd889-82a0-4039-bbe2-649db4247e97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_406a74c1-2686-4dd0-9230-08063667cf2d" xlink:to="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_86dbd889-82a0-4039-bbe2-649db4247e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#LongTermDebtNetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_80141820-8ada-42c8-8827-a9fef93abf16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_bc67cd5c-a104-4a11-a60d-39e039ea3c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_80141820-8ada-42c8-8827-a9fef93abf16" xlink:to="loc_us-gaap_DebtInstrumentTable_bc67cd5c-a104-4a11-a60d-39e039ea3c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_a270ec0a-4dd9-4f68-a413-a0915ff2157d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bc67cd5c-a104-4a11-a60d-39e039ea3c3c" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_a270ec0a-4dd9-4f68-a413-a0915ff2157d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_7e9bccde-26c0-4e9f-b4d0-efb5aa328c57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_a270ec0a-4dd9-4f68-a413-a0915ff2157d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_7e9bccde-26c0-4e9f-b4d0-efb5aa328c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_62086766-5937-4489-95b3-d3a81f4b462d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_7e9bccde-26c0-4e9f-b4d0-efb5aa328c57" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_62086766-5937-4489-95b3-d3a81f4b462d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_2d553f9c-7495-4f71-96cb-af13da5d06f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_7e9bccde-26c0-4e9f-b4d0-efb5aa328c57" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_2d553f9c-7495-4f71-96cb-af13da5d06f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_daabc065-a206-419a-9a0e-4c63005fe9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bc67cd5c-a104-4a11-a60d-39e039ea3c3c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_daabc065-a206-419a-9a0e-4c63005fe9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_57f18d12-1842-4f2d-b5ba-11ebe162e7e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_daabc065-a206-419a-9a0e-4c63005fe9bb" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_57f18d12-1842-4f2d-b5ba-11ebe162e7e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_7ad1e654-96ea-4af4-8ed3-d64a8c990ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_57f18d12-1842-4f2d-b5ba-11ebe162e7e9" xlink:to="loc_us-gaap_ConvertibleDebtMember_7ad1e654-96ea-4af4-8ed3-d64a8c990ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A025ConvertibleSeniorNotesDue2027Member_7fc64248-1fd8-4d16-9842-c136c06b7a9c" xlink:href="halo-20220630.xsd#halo_A025ConvertibleSeniorNotesDue2027Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_57f18d12-1842-4f2d-b5ba-11ebe162e7e9" xlink:to="loc_halo_A025ConvertibleSeniorNotesDue2027Member_7fc64248-1fd8-4d16-9842-c136c06b7a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_TermLoanFacilityMember_07880bda-e5b5-4956-80b8-899f2642d847" xlink:href="halo-20220630.xsd#halo_TermLoanFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_57f18d12-1842-4f2d-b5ba-11ebe162e7e9" xlink:to="loc_halo_TermLoanFacilityMember_07880bda-e5b5-4956-80b8-899f2642d847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c515e500-278e-48c8-af68-59c8737555d1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bc67cd5c-a104-4a11-a60d-39e039ea3c3c" xlink:to="loc_srt_RangeAxis_c515e500-278e-48c8-af68-59c8737555d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_73058b6f-f8e2-4a6f-83e0-ded1f5cdbbf0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c515e500-278e-48c8-af68-59c8737555d1" xlink:to="loc_srt_RangeMember_73058b6f-f8e2-4a6f-83e0-ded1f5cdbbf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_462c27d9-44ce-4b55-9ebe-38ddfb71891d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_73058b6f-f8e2-4a6f-83e0-ded1f5cdbbf0" xlink:to="loc_srt_MinimumMember_462c27d9-44ce-4b55-9ebe-38ddfb71891d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_241e6f6d-dbe0-42d8-b807-c2e362abdc30" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_73058b6f-f8e2-4a6f-83e0-ded1f5cdbbf0" xlink:to="loc_srt_MaximumMember_241e6f6d-dbe0-42d8-b807-c2e362abdc30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_440d123c-f292-4854-a3e5-ff641e123cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bc67cd5c-a104-4a11-a60d-39e039ea3c3c" xlink:to="loc_us-gaap_VariableRateAxis_440d123c-f292-4854-a3e5-ff641e123cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_4b0a7f86-2b3d-4b6b-8a31-79dfdfa8d505" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_440d123c-f292-4854-a3e5-ff641e123cc9" xlink:to="loc_us-gaap_VariableRateDomain_4b0a7f86-2b3d-4b6b-8a31-79dfdfa8d505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_ce1b6462-3f30-4318-9c64-6b4b4ac45cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_4b0a7f86-2b3d-4b6b-8a31-79dfdfa8d505" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_ce1b6462-3f30-4318-9c64-6b4b4ac45cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_9482e0d7-f330-43eb-ab6b-3d57ed9473c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_4b0a7f86-2b3d-4b6b-8a31-79dfdfa8d505" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_9482e0d7-f330-43eb-ab6b-3d57ed9473c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_d5ff0334-a8ac-4e48-8e64-2d12a3eabcce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_4b0a7f86-2b3d-4b6b-8a31-79dfdfa8d505" xlink:to="loc_us-gaap_BaseRateMember_d5ff0334-a8ac-4e48-8e64-2d12a3eabcce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5b418a8a-7245-49e4-a2b7-567ea54a05eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bc67cd5c-a104-4a11-a60d-39e039ea3c3c" xlink:to="loc_us-gaap_DebtInstrumentAxis_5b418a8a-7245-49e4-a2b7-567ea54a05eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_680b9b51-8dc9-4052-b1fa-8d4d5221a9c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_5b418a8a-7245-49e4-a2b7-567ea54a05eb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_680b9b51-8dc9-4052-b1fa-8d4d5221a9c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member_645e265f-b312-4f59-b1df-abea0a460013" xlink:href="halo-20220630.xsd#halo_A1.25ConvertibleSeniorNotesdue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_680b9b51-8dc9-4052-b1fa-8d4d5221a9c1" xlink:to="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member_645e265f-b312-4f59-b1df-abea0a460013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A025ConvertibleSeniorNotesDue2027Member_39d6283a-4194-4e54-9904-21be6ad2ac5f" xlink:href="halo-20220630.xsd#halo_A025ConvertibleSeniorNotesDue2027Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_680b9b51-8dc9-4052-b1fa-8d4d5221a9c1" xlink:to="loc_halo_A025ConvertibleSeniorNotesDue2027Member_39d6283a-4194-4e54-9904-21be6ad2ac5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A2021CreditAgreementMember_b5e7a298-403e-4a1e-b28e-436c5a8d6a77" xlink:href="halo-20220630.xsd#halo_A2021CreditAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_680b9b51-8dc9-4052-b1fa-8d4d5221a9c1" xlink:to="loc_halo_A2021CreditAgreementMember_b5e7a298-403e-4a1e-b28e-436c5a8d6a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_CreditAgreementMember_7336b443-a6ec-46aa-ada9-623da369245c" xlink:href="halo-20220630.xsd#halo_CreditAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_680b9b51-8dc9-4052-b1fa-8d4d5221a9c1" xlink:to="loc_halo_CreditAgreementMember_7336b443-a6ec-46aa-ada9-623da369245c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_69dab89a-b23d-4deb-bcfa-b9ca05a59966" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bc67cd5c-a104-4a11-a60d-39e039ea3c3c" xlink:to="loc_us-gaap_CreditFacilityAxis_69dab89a-b23d-4deb-bcfa-b9ca05a59966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2ed57352-0124-465c-b1ee-081c7e6e7c37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_69dab89a-b23d-4deb-bcfa-b9ca05a59966" xlink:to="loc_us-gaap_CreditFacilityDomain_2ed57352-0124-465c-b1ee-081c7e6e7c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_949e2c88-123b-48cf-ad6d-6935643591e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_2ed57352-0124-465c-b1ee-081c7e6e7c37" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_949e2c88-123b-48cf-ad6d-6935643591e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AnnualInterestPaymentPeriodAxis_c83dddc0-6426-444c-8203-5aec821f636f" xlink:href="halo-20220630.xsd#halo_AnnualInterestPaymentPeriodAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bc67cd5c-a104-4a11-a60d-39e039ea3c3c" xlink:to="loc_halo_AnnualInterestPaymentPeriodAxis_c83dddc0-6426-444c-8203-5aec821f636f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AnnualInterestPaymentPeriodDomain_a3822ac9-e7f8-4c6c-93c5-90042e306c4b" xlink:href="halo-20220630.xsd#halo_AnnualInterestPaymentPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_AnnualInterestPaymentPeriodAxis_c83dddc0-6426-444c-8203-5aec821f636f" xlink:to="loc_halo_AnnualInterestPaymentPeriodDomain_a3822ac9-e7f8-4c6c-93c5-90042e306c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodOneMember_98be7dae-f43d-4e5b-bd76-55b2d9a879f7" xlink:href="halo-20220630.xsd#halo_DebtInstrumentInterestPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_AnnualInterestPaymentPeriodDomain_a3822ac9-e7f8-4c6c-93c5-90042e306c4b" xlink:to="loc_halo_DebtInstrumentInterestPeriodOneMember_98be7dae-f43d-4e5b-bd76-55b2d9a879f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodTwoMember_67df17b8-20ed-413c-9a2e-c691fbe13f96" xlink:href="halo-20220630.xsd#halo_DebtInstrumentInterestPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_AnnualInterestPaymentPeriodDomain_a3822ac9-e7f8-4c6c-93c5-90042e306c4b" xlink:to="loc_halo_DebtInstrumentInterestPeriodTwoMember_67df17b8-20ed-413c-9a2e-c691fbe13f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodThreeMember_42d2582e-8014-4501-ba2a-eae604066022" xlink:href="halo-20220630.xsd#halo_DebtInstrumentInterestPeriodThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_AnnualInterestPaymentPeriodDomain_a3822ac9-e7f8-4c6c-93c5-90042e306c4b" xlink:to="loc_halo_DebtInstrumentInterestPeriodThreeMember_42d2582e-8014-4501-ba2a-eae604066022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentInterestPeriodFourMember_01dfce30-53bc-4d04-a2b5-086ccb06f88a" xlink:href="halo-20220630.xsd#halo_DebtInstrumentInterestPeriodFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_AnnualInterestPaymentPeriodDomain_a3822ac9-e7f8-4c6c-93c5-90042e306c4b" xlink:to="loc_halo_DebtInstrumentInterestPeriodFourMember_01dfce30-53bc-4d04-a2b5-086ccb06f88a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentAxis_033b7449-366b-492a-b833-cee51f4b8d25" xlink:href="halo-20220630.xsd#halo_VariableRateComponentAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bc67cd5c-a104-4a11-a60d-39e039ea3c3c" xlink:to="loc_halo_VariableRateComponentAxis_033b7449-366b-492a-b833-cee51f4b8d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentDomain_471c0340-149b-4a06-98b4-9e33d0dfe67d" xlink:href="halo-20220630.xsd#halo_VariableRateComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_VariableRateComponentAxis_033b7449-366b-492a-b833-cee51f4b8d25" xlink:to="loc_halo_VariableRateComponentDomain_471c0340-149b-4a06-98b4-9e33d0dfe67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentOneMember_6cd50452-0838-48a3-9df3-b5174e3fb2a2" xlink:href="halo-20220630.xsd#halo_VariableRateComponentOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_VariableRateComponentDomain_471c0340-149b-4a06-98b4-9e33d0dfe67d" xlink:to="loc_halo_VariableRateComponentOneMember_6cd50452-0838-48a3-9df3-b5174e3fb2a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_VariableRateComponentTwoMember_f09e1ffe-8a83-44f9-9d39-5fcac973fe7a" xlink:href="halo-20220630.xsd#halo_VariableRateComponentTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_VariableRateComponentDomain_471c0340-149b-4a06-98b4-9e33d0dfe67d" xlink:to="loc_halo_VariableRateComponentTwoMember_f09e1ffe-8a83-44f9-9d39-5fcac973fe7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_bc67cd5c-a104-4a11-a60d-39e039ea3c3c" xlink:to="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_300ae9bf-7998-4419-848c-1fc14dc614a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_300ae9bf-7998-4419-848c-1fc14dc614a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_20372975-ee32-45f0-b1fe-1e96793944f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_20372975-ee32-45f0-b1fe-1e96793944f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_7d3f69f2-9cf2-410c-9bb3-8e1dc7f803d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_7d3f69f2-9cf2-410c-9bb3-8e1dc7f803d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_6729b0bd-e14f-414a-8a5a-a7f4184e0530" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_6729b0bd-e14f-414a-8a5a-a7f4184e0530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_6e2be920-9743-4728-a7db-1bd76c6edf71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_6e2be920-9743-4728-a7db-1bd76c6edf71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_f4205193-9a9c-4d74-87aa-0e0087bdab99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_f4205193-9a9c-4d74-87aa-0e0087bdab99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_ac9de440-f4f7-4520-9637-e355a5760fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_ac9de440-f4f7-4520-9637-e355a5760fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_0ca6b9f5-478b-4533-90fe-534432090062" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_0ca6b9f5-478b-4533-90fe-534432090062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_9722c911-facb-4104-a947-5a319c34311b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_9722c911-facb-4104-a947-5a319c34311b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_6b70247d-1b6d-4b54-b744-5b0642dff44e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_6b70247d-1b6d-4b54-b744-5b0642dff44e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_eebb94af-3933-4460-855d-f69ac35c9c07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_eebb94af-3933-4460-855d-f69ac35c9c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_f7c14dc6-bc75-4a70-b57b-601c832c4d18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_f7c14dc6-bc75-4a70-b57b-601c832c4d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_f5bc4e0d-dae5-43ff-b8a0-a2b0c9dd9518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_f5bc4e0d-dae5-43ff-b8a0-a2b0c9dd9518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_da58ee4d-8548-4f70-b937-215daf44e270" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_da58ee4d-8548-4f70-b937-215daf44e270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCovenantCompliance_0f93bcaf-c1d8-4df4-92c2-e384b42ad6b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCovenantCompliance"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_DebtInstrumentCovenantCompliance_0f93bcaf-c1d8-4df4-92c2-e384b42ad6b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_61db881c-53fd-4ef1-bc48-0d74f8dcb698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_61db881c-53fd-4ef1-bc48-0d74f8dcb698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_1fdeb199-23de-48d3-8d91-b972d0b0f625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_1fdeb199-23de-48d3-8d91-b972d0b0f625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a8888e51-a501-4185-a337-34fe59ee9ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a8888e51-a501-4185-a337-34fe59ee9ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_c04e83ba-c6b7-491d-a721-f1866b83b234" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_c04e83ba-c6b7-491d-a721-f1866b83b234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_d7acdb72-0bbd-4ec3-b4b7-ca464fb8af47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_d7acdb72-0bbd-4ec3-b4b7-ca464fb8af47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_DebtInstrumentThirdPartyCosts_12ee2c6d-80f5-43be-956d-648bd2e5ec47" xlink:href="halo-20220630.xsd#halo_DebtInstrumentThirdPartyCosts"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_halo_DebtInstrumentThirdPartyCosts_12ee2c6d-80f5-43be-956d-648bd2e5ec47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_afc1928a-6dd9-416b-a970-aaaa1f7e77ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_afc1928a-6dd9-416b-a970-aaaa1f7e77ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_e5d73063-7d79-4fec-93fb-5e3c42e44f99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9e103d3e-a17f-44ab-8922-40058d3a6dc6" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_e5d73063-7d79-4fec-93fb-5e3c42e44f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#LongTermDebtNetCarryingAmountofConvertibleNotesDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f0283b69-8ba9-4544-9c92-ea1868a3d3ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0259f0f1-c3d6-4477-922f-ed408c27084a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f0283b69-8ba9-4544-9c92-ea1868a3d3ff" xlink:to="loc_us-gaap_DebtInstrumentTable_0259f0f1-c3d6-4477-922f-ed408c27084a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e2989909-b0fc-4c58-95a4-e17e2032404c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0259f0f1-c3d6-4477-922f-ed408c27084a" xlink:to="loc_us-gaap_DebtInstrumentAxis_e2989909-b0fc-4c58-95a4-e17e2032404c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6913ccf1-5d56-48b8-b966-c6381d4c1bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_e2989909-b0fc-4c58-95a4-e17e2032404c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6913ccf1-5d56-48b8-b966-c6381d4c1bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member_bced7893-e006-4294-b751-5ce2b6dab868" xlink:href="halo-20220630.xsd#halo_A1.25ConvertibleSeniorNotesdue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6913ccf1-5d56-48b8-b966-c6381d4c1bc7" xlink:to="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member_bced7893-e006-4294-b751-5ce2b6dab868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A025ConvertibleSeniorNotesDue2027Member_815980eb-b261-4815-a30f-5423f485a623" xlink:href="halo-20220630.xsd#halo_A025ConvertibleSeniorNotesDue2027Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6913ccf1-5d56-48b8-b966-c6381d4c1bc7" xlink:to="loc_halo_A025ConvertibleSeniorNotesDue2027Member_815980eb-b261-4815-a30f-5423f485a623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_40885a20-578a-49a8-b7b1-3f614ac719bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0259f0f1-c3d6-4477-922f-ed408c27084a" xlink:to="loc_us-gaap_DebtInstrumentLineItems_40885a20-578a-49a8-b7b1-3f614ac719bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_a392d679-ebb1-42ae-b68c-646e4b9e1b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40885a20-578a-49a8-b7b1-3f614ac719bc" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_a392d679-ebb1-42ae-b68c-646e4b9e1b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_c21648c3-a4b2-44a3-b72f-a9e1faa8c20d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40885a20-578a-49a8-b7b1-3f614ac719bc" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_c21648c3-a4b2-44a3-b72f-a9e1faa8c20d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_3896a74d-33c1-4915-84a5-20d84bbb42ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40885a20-578a-49a8-b7b1-3f614ac719bc" xlink:to="loc_us-gaap_LongTermDebtCurrent_3896a74d-33c1-4915-84a5-20d84bbb42ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_47193bc9-6390-46c7-8dbd-0bbe7b5c032a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40885a20-578a-49a8-b7b1-3f614ac719bc" xlink:to="loc_us-gaap_LongTermDebt_47193bc9-6390-46c7-8dbd-0bbe7b5c032a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayable_982b6ba9-65ac-4ed6-91cb-6cc13badcb2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40885a20-578a-49a8-b7b1-3f614ac719bc" xlink:to="loc_us-gaap_ConvertibleNotesPayable_982b6ba9-65ac-4ed6-91cb-6cc13badcb2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_eb5373bd-371f-41ad-a4af-111f5186e233" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40885a20-578a-49a8-b7b1-3f614ac719bc" xlink:to="loc_us-gaap_DebtInstrumentFairValue_eb5373bd-371f-41ad-a4af-111f5186e233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_4cb51e5d-8b38-4af1-af9e-fd40529c213d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40885a20-578a-49a8-b7b1-3f614ac719bc" xlink:to="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_4cb51e5d-8b38-4af1-af9e-fd40529c213d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#LongTermDebtNetComponentsofInterestExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5d3b2355-9640-457b-8d39-6fe88bea2b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a6ec531c-00f3-437e-b074-42181600781a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5d3b2355-9640-457b-8d39-6fe88bea2b3a" xlink:to="loc_us-gaap_DebtInstrumentTable_a6ec531c-00f3-437e-b074-42181600781a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_629ed244-aed5-46ae-904e-bfb95b11ac8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a6ec531c-00f3-437e-b074-42181600781a" xlink:to="loc_us-gaap_DebtInstrumentAxis_629ed244-aed5-46ae-904e-bfb95b11ac8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2665b90d-da12-4580-b7ea-c7c9839d88b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_629ed244-aed5-46ae-904e-bfb95b11ac8e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2665b90d-da12-4580-b7ea-c7c9839d88b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member_b88bb343-cfd7-4e78-9a29-57019426a39c" xlink:href="halo-20220630.xsd#halo_A1.25ConvertibleSeniorNotesdue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2665b90d-da12-4580-b7ea-c7c9839d88b9" xlink:to="loc_halo_A1.25ConvertibleSeniorNotesdue2024Member_b88bb343-cfd7-4e78-9a29-57019426a39c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A025ConvertibleSeniorNotesDue2027Member_f37fcd7b-f432-4814-b57b-dce7c4b41e4a" xlink:href="halo-20220630.xsd#halo_A025ConvertibleSeniorNotesDue2027Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2665b90d-da12-4580-b7ea-c7c9839d88b9" xlink:to="loc_halo_A025ConvertibleSeniorNotesDue2027Member_f37fcd7b-f432-4814-b57b-dce7c4b41e4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7d6b136a-864b-40b3-894e-7831f13ec93b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a6ec531c-00f3-437e-b074-42181600781a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7d6b136a-864b-40b3-894e-7831f13ec93b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9048e39d-da98-432a-b6df-239fb29a2146" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7d6b136a-864b-40b3-894e-7831f13ec93b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9048e39d-da98-432a-b6df-239fb29a2146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_b7e197d1-7853-4905-a004-471d10b0aab8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9048e39d-da98-432a-b6df-239fb29a2146" xlink:to="loc_us-gaap_ConvertibleDebtMember_b7e197d1-7853-4905-a004-471d10b0aab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6856580f-18e2-48b2-ac37-93a17595fff7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a6ec531c-00f3-437e-b074-42181600781a" xlink:to="loc_us-gaap_DebtInstrumentLineItems_6856580f-18e2-48b2-ac37-93a17595fff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_85fa8301-446a-479e-9602-858c632a3441" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6856580f-18e2-48b2-ac37-93a17595fff7" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_85fa8301-446a-479e-9602-858c632a3441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_c59c1904-ce46-4127-8cea-d4e5c8c6d821" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6856580f-18e2-48b2-ac37-93a17595fff7" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_c59c1904-ce46-4127-8cea-d4e5c8c6d821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_088db1d2-78ad-488f-915f-06f9c61fad68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6856580f-18e2-48b2-ac37-93a17595fff7" xlink:to="loc_us-gaap_InterestExpenseDebt_088db1d2-78ad-488f-915f-06f9c61fad68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_50aa931a-6b89-4bb4-863d-579b701b445c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6856580f-18e2-48b2-ac37-93a17595fff7" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_50aa931a-6b89-4bb4-863d-579b701b445c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensation" xlink:type="simple" xlink:href="halo-20220630.xsd#SharebasedCompensation"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SharebasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_479fbf9c-7f3e-4c49-a6a2-60c059a3bee0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ba88d869-a9cb-4938-9e92-384644a05e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_479fbf9c-7f3e-4c49-a6a2-60c059a3bee0" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ba88d869-a9cb-4938-9e92-384644a05e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensationTables" xlink:type="simple" xlink:href="halo-20220630.xsd#SharebasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SharebasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_b18cf27c-6291-45a5-bec3-54f63d1abda6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_cc2626ad-e051-461e-9a6f-f6351888b025" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_b18cf27c-6291-45a5-bec3-54f63d1abda6" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_cc2626ad-e051-461e-9a6f-f6351888b025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1c84cc23-9dd9-4162-b4f7-a0128aa37dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_b18cf27c-6291-45a5-bec3-54f63d1abda6" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1c84cc23-9dd9-4162-b4f7-a0128aa37dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_46f94ee9-686a-496c-a34a-988673b71565" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_b18cf27c-6291-45a5-bec3-54f63d1abda6" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_46f94ee9-686a-496c-a34a-988673b71565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_7948a89b-72b3-46dd-8d66-a7d891af1222" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_b18cf27c-6291-45a5-bec3-54f63d1abda6" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_7948a89b-72b3-46dd-8d66-a7d891af1222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#SharebasedCompensationSharebasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_aa0908c4-4dc9-4e17-a02a-d88bbd584e07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2c37f12a-6c12-4823-846b-863774493a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_aa0908c4-4dc9-4e17-a02a-d88bbd584e07" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2c37f12a-6c12-4823-846b-863774493a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d9273204-234d-4fd9-bd0a-2ae6d9b247e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2c37f12a-6c12-4823-846b-863774493a3e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d9273204-234d-4fd9-bd0a-2ae6d9b247e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0859e25f-1608-47fc-a596-e56403c3b02c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d9273204-234d-4fd9-bd0a-2ae6d9b247e4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0859e25f-1608-47fc-a596-e56403c3b02c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f85f9f64-3b1d-4405-877c-aececbf8f037" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0859e25f-1608-47fc-a596-e56403c3b02c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f85f9f64-3b1d-4405-877c-aececbf8f037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_c9cc15d3-2871-4a0b-b3d3-b110c1452515" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0859e25f-1608-47fc-a596-e56403c3b02c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_c9cc15d3-2871-4a0b-b3d3-b110c1452515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_dfd55fe7-e15a-4594-ac65-91b76af5f1ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2c37f12a-6c12-4823-846b-863774493a3e" xlink:to="loc_us-gaap_AwardTypeAxis_dfd55fe7-e15a-4594-ac65-91b76af5f1ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21035167-bdf4-41bd-a839-f6d2fd983d39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_dfd55fe7-e15a-4594-ac65-91b76af5f1ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21035167-bdf4-41bd-a839-f6d2fd983d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ab3a39a6-6b0d-4cde-9d62-3a5517b4f5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21035167-bdf4-41bd-a839-f6d2fd983d39" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ab3a39a6-6b0d-4cde-9d62-3a5517b4f5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RSURSAandPRSUawardsMember_90202469-1822-4f96-b426-81e25173a789" xlink:href="halo-20220630.xsd#halo_RSURSAandPRSUawardsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21035167-bdf4-41bd-a839-f6d2fd983d39" xlink:to="loc_halo_RSURSAandPRSUawardsMember_90202469-1822-4f96-b426-81e25173a789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_12a6873b-ec67-4940-922d-af5918686afd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2c37f12a-6c12-4823-846b-863774493a3e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_12a6873b-ec67-4940-922d-af5918686afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0d86a708-f073-4c8a-b14b-1316dd4219e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_12a6873b-ec67-4940-922d-af5918686afd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0d86a708-f073-4c8a-b14b-1316dd4219e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_13fae61d-e124-4726-a9df-cb0b849febaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_12a6873b-ec67-4940-922d-af5918686afd" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_13fae61d-e124-4726-a9df-cb0b849febaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#SharebasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_9391cbaa-0404-48fc-9c4b-530fcad217a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f3502d85-a02b-4235-9782-82fe8be30a76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_9391cbaa-0404-48fc-9c4b-530fcad217a2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f3502d85-a02b-4235-9782-82fe8be30a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a432e52e-de99-4439-badc-1235c164b3c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f3502d85-a02b-4235-9782-82fe8be30a76" xlink:to="loc_us-gaap_AwardTypeAxis_a432e52e-de99-4439-badc-1235c164b3c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35133cf0-fd50-428d-91c4-adb94c70ecfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a432e52e-de99-4439-badc-1235c164b3c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35133cf0-fd50-428d-91c4-adb94c70ecfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_98fdf6e3-565c-42e0-89c1-84682e801506" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35133cf0-fd50-428d-91c4-adb94c70ecfb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_98fdf6e3-565c-42e0-89c1-84682e801506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_RSURSAandPRSUawardsMember_cace193d-0614-4cdd-8d5b-6f73b3c09ea4" xlink:href="halo-20220630.xsd#halo_RSURSAandPRSUawardsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35133cf0-fd50-428d-91c4-adb94c70ecfb" xlink:to="loc_halo_RSURSAandPRSUawardsMember_cace193d-0614-4cdd-8d5b-6f73b3c09ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_6858e4a6-ef53-4228-92a8-4a610626e916" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35133cf0-fd50-428d-91c4-adb94c70ecfb" xlink:to="loc_us-gaap_EmployeeStockMember_6858e4a6-ef53-4228-92a8-4a610626e916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_1197be69-f4fb-4c0f-bd9e-9fbe817551a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f3502d85-a02b-4235-9782-82fe8be30a76" xlink:to="loc_us-gaap_PlanNameAxis_1197be69-f4fb-4c0f-bd9e-9fbe817551a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_682d46d4-27b2-473d-8ce3-1d69892f1180" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1197be69-f4fb-4c0f-bd9e-9fbe817551a6" xlink:to="loc_us-gaap_PlanNameDomain_682d46d4-27b2-473d-8ce3-1d69892f1180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_A2021ESPPPlanMember_60ca49a7-cfc6-4d1c-a179-483fb9d4eb2e" xlink:href="halo-20220630.xsd#halo_A2021ESPPPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_682d46d4-27b2-473d-8ce3-1d69892f1180" xlink:to="loc_halo_A2021ESPPPlanMember_60ca49a7-cfc6-4d1c-a179-483fb9d4eb2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85c493b8-5d1a-4376-a0ca-a15bc878620d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f3502d85-a02b-4235-9782-82fe8be30a76" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85c493b8-5d1a-4376-a0ca-a15bc878620d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_c2f0334e-f639-4b81-8945-d6c4e4459fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85c493b8-5d1a-4376-a0ca-a15bc878620d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_c2f0334e-f639-4b81-8945-d6c4e4459fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_fbc120b9-7b7a-4461-bb34-2cf811596832" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85c493b8-5d1a-4376-a0ca-a15bc878620d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_fbc120b9-7b7a-4461-bb34-2cf811596832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_33b9c76c-6f2b-4127-8c70-e3319cf6b330" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85c493b8-5d1a-4376-a0ca-a15bc878620d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_33b9c76c-6f2b-4127-8c70-e3319cf6b330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_9314c7b1-536b-4259-9afe-b7684f75b279" xlink:href="halo-20220630.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85c493b8-5d1a-4376-a0ca-a15bc878620d" xlink:to="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_9314c7b1-536b-4259-9afe-b7684f75b279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d66bd9ca-fc1c-48e6-9d0e-21a333e79c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85c493b8-5d1a-4376-a0ca-a15bc878620d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d66bd9ca-fc1c-48e6-9d0e-21a333e79c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate_87b71745-c08a-4ae2-a0ac-644b342a727f" xlink:href="halo-20220630.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85c493b8-5d1a-4376-a0ca-a15bc878620d" xlink:to="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate_87b71745-c08a-4ae2-a0ac-644b342a727f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_e08dd3be-a8fb-480c-a53a-83871c8a37d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85c493b8-5d1a-4376-a0ca-a15bc878620d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_e08dd3be-a8fb-480c-a53a-83871c8a37d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_c3ad2f57-c86a-4010-9597-f82843535c0d" xlink:href="halo-20220630.xsd#halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85c493b8-5d1a-4376-a0ca-a15bc878620d" xlink:to="loc_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_c3ad2f57-c86a-4010-9597-f82843535c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_7af9208c-504b-4366-a3de-6c41118de1f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85c493b8-5d1a-4376-a0ca-a15bc878620d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_7af9208c-504b-4366-a3de-6c41118de1f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_a3453c4d-8294-44c3-997a-bc2e761323e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable_05a5c4ca-8cd5-44f8-aeb5-abab13bef96e" xlink:href="halo-20220630.xsd#halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_a3453c4d-8294-44c3-997a-bc2e761323e4" xlink:to="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable_05a5c4ca-8cd5-44f8-aeb5-abab13bef96e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7fbda548-f97c-4fd0-866f-c53065aa6981" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable_05a5c4ca-8cd5-44f8-aeb5-abab13bef96e" xlink:to="loc_srt_RangeAxis_7fbda548-f97c-4fd0-866f-c53065aa6981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_958f87ad-1dda-4c77-a69c-de9e44231f67" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7fbda548-f97c-4fd0-866f-c53065aa6981" xlink:to="loc_srt_RangeMember_958f87ad-1dda-4c77-a69c-de9e44231f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8ce2a814-9280-472a-b81f-bd9b0e3d6ece" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_958f87ad-1dda-4c77-a69c-de9e44231f67" xlink:to="loc_srt_MinimumMember_8ce2a814-9280-472a-b81f-bd9b0e3d6ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_acad3b7d-8012-468d-a40a-5134ed9c76ad" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_958f87ad-1dda-4c77-a69c-de9e44231f67" xlink:to="loc_srt_MaximumMember_acad3b7d-8012-468d-a40a-5134ed9c76ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_cf94f81d-6246-4570-95e9-d16015d2c706" xlink:href="halo-20220630.xsd#halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable_05a5c4ca-8cd5-44f8-aeb5-abab13bef96e" xlink:to="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_cf94f81d-6246-4570-95e9-d16015d2c706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_472f2652-b11d-4392-982b-6ea53c89b468" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_cf94f81d-6246-4570-95e9-d16015d2c706" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_472f2652-b11d-4392-982b-6ea53c89b468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_945ea8ba-daed-4517-a78d-acd82cc93d32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_cf94f81d-6246-4570-95e9-d16015d2c706" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_945ea8ba-daed-4517-a78d-acd82cc93d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_54be620e-380f-4fd0-94dc-b764400938f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_cf94f81d-6246-4570-95e9-d16015d2c706" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_54be620e-380f-4fd0-94dc-b764400938f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_f98a5cfe-c9f5-444a-a767-9d37ab7511be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_cf94f81d-6246-4570-95e9-d16015d2c706" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_f98a5cfe-c9f5-444a-a767-9d37ab7511be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2c030f9a-fccf-448f-ad07-16eb7435b3a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems_cf94f81d-6246-4570-95e9-d16015d2c706" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2c030f9a-fccf-448f-ad07-16eb7435b3a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_2735c3c8-dade-41aa-a790-39f78286f457" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cea991eb-854e-4275-afd5-ab6f42c31370" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_2735c3c8-dade-41aa-a790-39f78286f457" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cea991eb-854e-4275-afd5-ab6f42c31370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4d1ed2b7-a0ce-4332-9de2-b9d202a4d0db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cea991eb-854e-4275-afd5-ab6f42c31370" xlink:to="loc_us-gaap_AwardTypeAxis_4d1ed2b7-a0ce-4332-9de2-b9d202a4d0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd7e808a-243f-490d-8e02-ec129a2c574b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4d1ed2b7-a0ce-4332-9de2-b9d202a4d0db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd7e808a-243f-490d-8e02-ec129a2c574b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c4fdf444-699b-4b52-ae46-038aeaf7c715" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd7e808a-243f-490d-8e02-ec129a2c574b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c4fdf444-699b-4b52-ae46-038aeaf7c715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_09a4e325-fccb-4d25-b553-423203d2ff1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd7e808a-243f-490d-8e02-ec129a2c574b" xlink:to="loc_us-gaap_RestrictedStockMember_09a4e325-fccb-4d25-b553-423203d2ff1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_32f37518-1f48-4203-9c12-520f52e7f695" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd7e808a-243f-490d-8e02-ec129a2c574b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_32f37518-1f48-4203-9c12-520f52e7f695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_9bd85be6-8725-4694-9a04-9ff838d82aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd7e808a-243f-490d-8e02-ec129a2c574b" xlink:to="loc_us-gaap_PerformanceSharesMember_9bd85be6-8725-4694-9a04-9ff838d82aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_0f768a0d-51ae-4309-b32b-d0228c89037b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd7e808a-243f-490d-8e02-ec129a2c574b" xlink:to="loc_us-gaap_EmployeeStockMember_0f768a0d-51ae-4309-b32b-d0228c89037b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80f58d29-dc61-4a58-b767-0e1c11697d63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cea991eb-854e-4275-afd5-ab6f42c31370" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80f58d29-dc61-4a58-b767-0e1c11697d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_a30fa59f-b76a-4809-94c5-1f61ce1187d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80f58d29-dc61-4a58-b767-0e1c11697d63" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_a30fa59f-b76a-4809-94c5-1f61ce1187d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_584fdee2-419f-4bc1-99cb-a2e9af272b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80f58d29-dc61-4a58-b767-0e1c11697d63" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_584fdee2-419f-4bc1-99cb-a2e9af272b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/StockholdersEquity" xlink:type="simple" xlink:href="halo-20220630.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_7eb05f81-e9dc-49ae-864e-4cc52a834314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_c4118991-9588-4f98-a1b1-6daa0b3a0a22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7eb05f81-e9dc-49ae-864e-4cc52a834314" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_c4118991-9588-4f98-a1b1-6daa0b3a0a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c417d471-2f54-4041-9361-11eee78fbd0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_847c8a69-b863-4e04-962a-8a9e123f3534" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c417d471-2f54-4041-9361-11eee78fbd0c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_847c8a69-b863-4e04-962a-8a9e123f3534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c04829cc-e0df-4d83-8912-a8d952a1e562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_847c8a69-b863-4e04-962a-8a9e123f3534" xlink:to="loc_us-gaap_AwardTypeAxis_c04829cc-e0df-4d83-8912-a8d952a1e562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_34b0cc28-79ca-4daa-8cc5-c6d2710b34d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c04829cc-e0df-4d83-8912-a8d952a1e562" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_34b0cc28-79ca-4daa-8cc5-c6d2710b34d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_084ded39-4602-4dd7-9e0d-0ae81051d5e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_34b0cc28-79ca-4daa-8cc5-c6d2710b34d8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_084ded39-4602-4dd7-9e0d-0ae81051d5e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6bb61d36-6fd6-4668-9edc-a2c00a70d677" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_34b0cc28-79ca-4daa-8cc5-c6d2710b34d8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6bb61d36-6fd6-4668-9edc-a2c00a70d677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_StockOptionsAndRestrictedStockUnitsMember_617540b3-40ac-47b5-a67e-2e31626359ba" xlink:href="halo-20220630.xsd#halo_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_34b0cc28-79ca-4daa-8cc5-c6d2710b34d8" xlink:to="loc_halo_StockOptionsAndRestrictedStockUnitsMember_617540b3-40ac-47b5-a67e-2e31626359ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_78ad3157-9f39-4faa-9407-4c2acb59f7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_847c8a69-b863-4e04-962a-8a9e123f3534" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_78ad3157-9f39-4faa-9407-4c2acb59f7a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_50d23fe5-3d99-4ac6-a82f-d36c14a3b6d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_78ad3157-9f39-4faa-9407-4c2acb59f7a4" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_50d23fe5-3d99-4ac6-a82f-d36c14a3b6d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_halo_AcceleratedShareRepurchaseAgreementMember_e9a28929-f7ae-4740-a722-5962dd4b3705" xlink:href="halo-20220630.xsd#halo_AcceleratedShareRepurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_50d23fe5-3d99-4ac6-a82f-d36c14a3b6d3" xlink:to="loc_halo_AcceleratedShareRepurchaseAgreementMember_e9a28929-f7ae-4740-a722-5962dd4b3705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5ada5f1-4746-446f-bc31-8ae7dbfd0f08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_847c8a69-b863-4e04-962a-8a9e123f3534" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5ada5f1-4746-446f-bc31-8ae7dbfd0f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_6ba19e6b-1e38-4036-b3ae-9393360b11f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a5ada5f1-4746-446f-bc31-8ae7dbfd0f08" xlink:to="loc_us-gaap_StockholdersEquityAbstract_6ba19e6b-1e38-4036-b3ae-9393360b11f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2f937788-8589-438e-bb99-ec9a03e19b25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6ba19e6b-1e38-4036-b3ae-9393360b11f9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2f937788-8589-438e-bb99-ec9a03e19b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_cb9aea08-0a0e-49a1-a52a-3f63b930206d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6ba19e6b-1e38-4036-b3ae-9393360b11f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_cb9aea08-0a0e-49a1-a52a-3f63b930206d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_78cfcf2f-7c5f-48bc-b116-c60fd92c4800" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6ba19e6b-1e38-4036-b3ae-9393360b11f9" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_78cfcf2f-7c5f-48bc-b116-c60fd92c4800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_500a82c5-74df-410e-932f-b6a708b31d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6ba19e6b-1e38-4036-b3ae-9393360b11f9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_500a82c5-74df-410e-932f-b6a708b31d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_e772ff6f-bd70-4cc8-9a60-de59ed515357" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6ba19e6b-1e38-4036-b3ae-9393360b11f9" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_e772ff6f-bd70-4cc8-9a60-de59ed515357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_436c7278-cd16-4a86-8eab-fb7e3aef39cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6ba19e6b-1e38-4036-b3ae-9393360b11f9" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_436c7278-cd16-4a86-8eab-fb7e3aef39cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6caa2ebb-2efa-4caf-85e4-cabd6b74bf0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6ba19e6b-1e38-4036-b3ae-9393360b11f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6caa2ebb-2efa-4caf-85e4-cabd6b74bf0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_2cf29cd9-3897-4e54-bf6e-888daa627cde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6ba19e6b-1e38-4036-b3ae-9393360b11f9" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_2cf29cd9-3897-4e54-bf6e-888daa627cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramPeriodInForce1_75f99f75-2387-45ab-a3a0-8e7c797eb0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramPeriodInForce1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6ba19e6b-1e38-4036-b3ae-9393360b11f9" xlink:to="loc_us-gaap_StockRepurchaseProgramPeriodInForce1_75f99f75-2387-45ab-a3a0-8e7c797eb0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_09bf15c1-2d4e-4ecb-84f1-9a88ab0bfe97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6ba19e6b-1e38-4036-b3ae-9393360b11f9" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_09bf15c1-2d4e-4ecb-84f1-9a88ab0bfe97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_82ba8d32-2da6-4d41-bd4f-c298c009fe6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6ba19e6b-1e38-4036-b3ae-9393360b11f9" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_82ba8d32-2da6-4d41-bd4f-c298c009fe6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_2e57ab53-282e-4a58-a747-f625f9b0df83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6ba19e6b-1e38-4036-b3ae-9393360b11f9" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_2e57ab53-282e-4a58-a747-f625f9b0df83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_e8e0be08-7158-4ea5-85fd-4198636b88db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6ba19e6b-1e38-4036-b3ae-9393360b11f9" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_e8e0be08-7158-4ea5-85fd-4198636b88db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/NetIncomelosspershare" xlink:type="simple" xlink:href="halo-20220630.xsd#NetIncomelosspershare"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/NetIncomelosspershare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6041696c-1474-4142-8621-988743711f98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_5e9f17c1-5471-4d87-8b25-a88c7cd4fe31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6041696c-1474-4142-8621-988743711f98" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_5e9f17c1-5471-4d87-8b25-a88c7cd4fe31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/NetIncomelosspershareTables" xlink:type="simple" xlink:href="halo-20220630.xsd#NetIncomelosspershareTables"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/NetIncomelosspershareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_45b0a225-3388-4f14-9f4f-7c473c4b28ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_e67b03ce-2838-413f-9f03-88e73b550de5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_45b0a225-3388-4f14-9f4f-7c473c4b28ae" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_e67b03ce-2838-413f-9f03-88e73b550de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1a4580b6-0d7c-4f90-937a-f366abf58980" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_45b0a225-3388-4f14-9f4f-7c473c4b28ae" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1a4580b6-0d7c-4f90-937a-f366abf58980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/NetIncomelosspershareSummaryDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#NetIncomelosspershareSummaryDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/NetIncomelosspershareSummaryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_fcd1c2eb-80cb-4048-890e-fe5e6fabf341" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_924445c9-c129-41c9-a182-b56401e2b877" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fcd1c2eb-80cb-4048-890e-fe5e6fabf341" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_924445c9-c129-41c9-a182-b56401e2b877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ea11ff1f-4414-45d1-aaac-44d0e904bf05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_924445c9-c129-41c9-a182-b56401e2b877" xlink:to="loc_us-gaap_AwardTypeAxis_ea11ff1f-4414-45d1-aaac-44d0e904bf05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4fbad283-8faa-4608-a2d1-1d3fd238570c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ea11ff1f-4414-45d1-aaac-44d0e904bf05" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4fbad283-8faa-4608-a2d1-1d3fd238570c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c4f1caaa-0d62-410a-ab49-99f9321a23e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4fbad283-8faa-4608-a2d1-1d3fd238570c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c4f1caaa-0d62-410a-ab49-99f9321a23e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_44893f6c-c9a6-4d88-a68b-e4d94303d9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4fbad283-8faa-4608-a2d1-1d3fd238570c" xlink:to="loc_us-gaap_RestrictedStockMember_44893f6c-c9a6-4d88-a68b-e4d94303d9b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c5ef76c9-a65b-4ced-8ec7-76bc6cc8343b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_924445c9-c129-41c9-a182-b56401e2b877" xlink:to="loc_us-gaap_DebtInstrumentAxis_c5ef76c9-a65b-4ced-8ec7-76bc6cc8343b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bec256c1-f3f6-4e06-9f0d-c964d6803129" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_c5ef76c9-a65b-4ced-8ec7-76bc6cc8343b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bec256c1-f3f6-4e06-9f0d-c964d6803129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_a891332d-239a-48b5-a39a-a817b187a8df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bec256c1-f3f6-4e06-9f0d-c964d6803129" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_a891332d-239a-48b5-a39a-a817b187a8df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_8832c113-2e5c-4ff2-946b-65dae88ea7d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_924445c9-c129-41c9-a182-b56401e2b877" xlink:to="loc_us-gaap_EarningsPerShareDilutedLineItems_8832c113-2e5c-4ff2-946b-65dae88ea7d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bd7db1dd-8ce0-4015-aabf-3259021fa614" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_8832c113-2e5c-4ff2-946b-65dae88ea7d1" xlink:to="loc_us-gaap_NetIncomeLoss_bd7db1dd-8ce0-4015-aabf-3259021fa614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fa748220-1145-4211-86f6-0b3ea3f31cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_8832c113-2e5c-4ff2-946b-65dae88ea7d1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fa748220-1145-4211-86f6-0b3ea3f31cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_cf9c3fa2-178f-4a6a-9b43-664672be225c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_8832c113-2e5c-4ff2-946b-65dae88ea7d1" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_cf9c3fa2-178f-4a6a-9b43-664672be225c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_89a06b50-4f01-4eff-ad7e-f2e3813d942d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_8832c113-2e5c-4ff2-946b-65dae88ea7d1" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_89a06b50-4f01-4eff-ad7e-f2e3813d942d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_1acde423-5a44-49ac-a0de-8b79c6670f66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_8832c113-2e5c-4ff2-946b-65dae88ea7d1" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_1acde423-5a44-49ac-a0de-8b79c6670f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_b52bf557-a253-4ae4-88ed-67eb63251f78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_1acde423-5a44-49ac-a0de-8b79c6670f66" xlink:to="loc_us-gaap_EarningsPerShareBasic_b52bf557-a253-4ae4-88ed-67eb63251f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_7bc3ba1c-9e30-4024-80c0-76157c246241" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_1acde423-5a44-49ac-a0de-8b79c6670f66" xlink:to="loc_us-gaap_EarningsPerShareDiluted_7bc3ba1c-9e30-4024-80c0-76157c246241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/NetIncomelosspershareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="halo-20220630.xsd#NetIncomelosspershareAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/NetIncomelosspershareAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_46388052-88df-4910-837f-69a1ad684c24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4cdad37a-404a-4ddb-a517-47ae9f3bf918" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_46388052-88df-4910-837f-69a1ad684c24" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4cdad37a-404a-4ddb-a517-47ae9f3bf918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.halozyme.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="halo-20220630.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.halozyme.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6a9374a3-e25f-4182-8cf0-efc862eaf92c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0f89f994-6693-47ef-9699-78fad9e10131" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6a9374a3-e25f-4182-8cf0-efc862eaf92c" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0f89f994-6693-47ef-9699-78fad9e10131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>halo-20220630_g1.jpg
<TEXT>
begin 644 halo-20220630_g1.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#Z17AI9@  34T *@    @ ! $[  (
M   0   (2H=I  0    !   (6IR=  $    @   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $=E=&%S97<@
M665S96=A=   !9 #  (    4   0J) $  (    4   0O)*1  (    #.#D
M )*2  (    #.#D  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" 1$ PL# 2(  A$! Q$!_\0
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MU[711_:N)[K[@_L;"=G]YXI_PI77/^@CI_YO_P#$T?\ "E=<_P"@CI_YO_\
M$U[711_:N)[K[@_L;"=G]YXI_P *5US_ *".G_F__P 31_PI77/^@CI_YO\
M_$U[711_:N)[K[@_L;"=G]YXI_PI77/^@CI_YO\ _$T?\*5US_H(Z?\ F_\
M\37M=%']JXGNON#^QL)V?WGBG_"E=<_Z".G_ )O_ /$T?\*5US_H(Z?^;_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO?E1P,9<KBKZ+9]3YF-?,914U)VLWNMEN:__  N?Q%_SZ:;_ -^G_P#BZ/\
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MAOY$<_\ :.+_ .?C/0O^%S^(O^?33?\ OT__ ,71_P +G\1?\^FF_P#?I_\
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MX@BMHK6*=HA#'&Q*@-@DG)Y/>MK6].L=$_M*^TO1;74)!J;VICDC:2.U0*I
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M>2S%G;10R$?9U#[]V>K-GJ>.:Z*+1;72_'5Y;S:1:RV=U8/>V\5PF\0E4+;
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M<8)R5W8W!?;-;(    P!T HHJI3E+<B,(QV"BBBI+"BBB@ KQWXW?\A72?\
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MTVWUC4K.[DNK34+J&XE_UDL<S*S_ %(.37N?_"M/!?\ SY#_ ,"G_P#BJ/\
MA6G@O_GR'_@4_P#\52_M3"_RO[E_F']C8S^=?>_\CPNSU;4=.FDFL+^YMI9?
M]8\,K*7[\D'FF/?WDB3I)=3.MPP>8-(2)".A;U(S7N__  K3P7_SY#_P*?\
M^*H_X5IX+_Y\A_X%/_\ %4_[5PU[\K^Y?YA_8N,M;F7WO_(\,L=8U/3(W33M
M0NK1)/OK!,R!OK@U%)>W4HA\VYF?R"3%N<GRR3DD>G/->\?\*T\%_P#/D/\
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MJ4:[JRV*62ZG>"U3&V 3ML7!R,#..#S7N'_"M/!?_/D/_ I__BJ/^%:>"_\
MGR'_ (%/_P#%4?VKA7O%_<O\P638Q;37WO\ R/";[4;W4YA-J-W/=RA=H>>0
MN0/3)JM7O_\ PK3P7_SY#_P*?_XJC_A6G@O_ )\A_P"!3_\ Q54LVPZ5DG]R
M_P R7D>*;NY+[W_D> 45[_\ \*T\%_\ /D/_  *?_P"*H_X5IX+_ .?(?^!3
M_P#Q5']KX?L_P_S%_86)[Q^]_P"1X!17O_\ PK3P7_SY#_P*?_XJC_A6G@O_
M )\A_P"!3_\ Q5']KX?L_P /\P_L+$]X_>_\CP"BO?\ _A6G@O\ Y\A_X%/_
M /%4?\*T\%_\^0_\"G_^*H_M?#]G^'^8?V%B>\?O?^1X!17O_P#PK3P7_P ^
M0_\  I__ (JC_A6G@O\ Y\A_X%/_ /%4?VOA^S_#_,/["Q/>/WO_ "/&?#FM
MP:#/=W4EH+J>2W:&%78A%W<,3@@_=R!CUK;B\>1V^K'5K6R-M?-I_P!E81G*
M!PPV-R22-H .>:]+_P"%:>"_^?(?^!3_ /Q5'_"M/!?_ #Y#_P "G_\ BJPG
MF&#F^:47_7S.FGEF.IQ48RCI_78\W'C33Q8:C;0G6+,7=Z]VK6MPJM\RX*,3
MU7.?PQ4(\:6']G?V4VCK]@^P?9/,WGSO[V[&=G^L^;IGWKT[_A6G@O\ Y\A_
MX%/_ /%4?\*T\%_\^0_\"G_^*J?KN#[2_KYE_P!GX_\ FC_7R/ **]__ .%:
M>"_^?(?^!3__ !5'_"M/!?\ SY#_ ,"G_P#BJZ?[7P_9_A_F<?\ 86)[Q^]_
MY'@%%>__ /"M/!?_ #Y#_P "G_\ BJ/^%:>"_P#GR'_@4_\ \51_:^'[/\/\
MP_L+$]X_>_\ (\ HKW__ (5IX+_Y\A_X%/\ _%4?\*T\%_\ /D/_  *?_P"*
MH_M?#]G^'^8?V%B>\?O?^1X!17O_ /PK3P7_ ,^0_P# I_\ XJC_ (5IX+_Y
M\A_X%/\ _%4?VOA^S_#_ ##^PL3WC][_ ,CP"BO?_P#A6G@O_GR'_@4__P 5
M1_PK3P7_ ,^0_P# I_\ XJC^U\/V?X?YA_86)[Q^]_Y'@%%>_P#_  K3P7_S
MY#_P*?\ ^*H_X5IX+_Y\A_X%/_\ %4?VOA^S_#_,/["Q/>/WO_(\ HKW_P#X
M5IX+_P"?(?\ @4__ ,51_P *T\%_\^0_\"G_ /BJ/[7P_9_A_F']A8GO'[W_
M )'@%%>__P#"M/!?_/D/_ I__BJ/^%:>"_\ GR'_ (%/_P#%4?VOA^S_  _S
M#^PL3WC][_R/ **]_P#^%:>"_P#GR'_@4_\ \51_PK3P7_SY#_P*?_XJC^U\
M/V?X?YA_86)[Q^]_Y'@%%>__ /"M/!?_ #Y#_P "G_\ BJ/^%:>"_P#GR'_@
M4_\ \51_:^'[/\/\P_L+$]X_>_\ (\ HKW__ (5IX+_Y\A_X%/\ _%4?\*T\
M%_\ /D/_  *?_P"*H_M?#]G^'^8?V%B>\?O?^1X!17O_ /PK3P7_ ,^0_P#
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M48'H*6B@!,#T%&!Z"EHH 3 ]!1@>@I:* $P/048'H*6B@!,#T%&!Z"EHH 3
M]!1@>@I:* $P/048'H*6B@!,#T%&!Z"EHH 3 ]!1@>@I:* $P/048'H*6B@!
M,#T%,G ^S2\#[A_E4E1S_P#'M+_N'^5 #E VC@=*7 ]!0OW1]*6@!,#T%&!Z
M"EHH B('VL<#_5G^8J3 ]!49_P"/P?\ 7,_S%2T )@>@HP/04M% "8'H*CM@
M/LL7 ^X/Y5+4=M_QZQ?[@_E0 _ ]!1@>@I:* $P/05'(!]HBX'?^52U%)_Q\
M1?C_ "H DP/048'H*6B@!,#T%&!Z"EHH BMP/*/ ^^W_ *$:DP/04RW_ -4?
M]]O_ $(U)0 F!Z"C ]!2T4 13 ;HN/\ EH/Y&I:BF^]%_P!=!_(U+0 4444
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M#WEO'?16;RJMQ,C/'&>K*N-Q'TW#\ZGH **** "BBB@ HHHH **** "BBB@
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M#_KF?YBI:B/_ !^#_KF?YBI: "BBB@ J.V_X]8O]P?RJ2H[;_CUB_P!P?RH
MDHHHH *BD_X^(OQ_E4M12?\ 'Q%^/\J ):*** "BBB@".W_U1_WV_P#0C4E1
MV_\ JC_OM_Z$:DH **** (IOO1?]=!_(U+44WWHO^N@_D:EH **** "BBB@
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M^6!R&1LA03QGIS6KI&H27XO5G55DM;N2 [!P0,%3]=K+GWS0!H4444 %%%%
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MJA8JR+CY?O'D5BCP9<3:%<:9<V6BQAK=85N(HF+SD,IWN"./NYQEN3G/K$?
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MO&8SP>![U@-::HV@ZI?P6U[:SB*_>2\>_9Q(N) D:KDE2#MP0H"[>">_IE%
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M1110 444V1BD;.$9RH)"KU;V&: '45D:=XDL[[3C>W"2:;#YIA4WQ2/<P)!
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M[H1Y/E)OVS'$;??QAFXZY!Z@5N6&H1:@LWE*Z-!*89$D&"K  _R(H M5'/\
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MZGJ?1J* /.[+3M8L[$Q:KYZ+->6BVT4[%F\U9-S.#Y\QQM']X=#\H[^B444
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M'_7,_P Q4M'/(.2)E-ID:2)&^JWJO)G8IN<%L<G QS3_ .QO^HCJ'_?_ /\
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M!R&1"H8Y_P"!"K32QI]]U7ZG% #J*C%Q"4=A+&50X8[AA?KZ5$-0MFOH[1)
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MO!'RMC8N=W;MJ* .-N?!<EZD,AM]+L9X[.Y@1;:(E8FD=&7!(!(&TY^[G<<
M5#>^";S6]2EU/6$L!</'*J0HS2I$YA$:,&*C)^\>@QD8SUKN** .+F\"^0D"
MZ7#8+;PP0+)9.I6*Z>/=_K, Y&&SN()RHR#5CPOX5NM&UBYOITL;=)WF<6UE
MNV1;Q  !D#./);)P.HX'2NLHH Y&'P/!;>%WL[6*U34)%7S9BI*SXD#E&[[&
MQ@X['H:J2^$)T@N+N6"ULU5994LM.5G6%PJ[&C^4;GW(&/RCG P>2>YHH XK
M_A&-9:P\U39F^U.SDAU,RLRA'DP2R8!W;1E0IQP%^;CF)?AX8+9UM&M4ED:=
MYF*'_22\J.JR8Y*[4VGTSQGI7=44 <YX9T"?2=3U2\GM=/LEOO)V6U@2538I
M!))5<DY[*/ZGHZ** "BBB@ HHHH **** "BBB@ HHHH **** "HKM2]G,H9D
M)C8;EQD<>]2U'/\ \>TO^X?Y4 45TJ?:/^)Q?]/^F7_Q%+_94_\ T&+_ /\
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M1OI<_GQ?\3>_[_\ /+T_W*RKGQ7/97M[#'8S7D=KYL\\KRH@AB0@$* ,L>I
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M+^\?]BI/[*G_ .@Q?_\ D+_XBKMO_JC_ +[?^A&I*.=AR(SO[*G_ .@Q?_\
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M0 4444 %1S_\>TO^X?Y5)4<__'M+_N'^5 #U^Z/I2TB_='TI: "BBB@"(_\
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M/&XY/;O_ +':_:FN?LT/VAEV-+Y8WE?0GKBB*SMH(UC@MXHT12JJB !03D@
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MF--0%O:PR371/%SO)^XQ*XP!C<0<GL*L2>,K^2*=]VGB-[FXLXX()2;F,H7
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MQG:,=!@?I0!YWI=_K-EY7]GW1NP+*ZN9O[1N)),F.?: .ISM&,]!R<'-3O\
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M\^%E_P"!K?\ QJCS]8_Y\++_ ,#6_P#C5:%%',NWYAROO^7^1E&?5_M0_P!
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M_,.5]_R_R/&O%'B+QU;^/!;VT<T2K*HMK:%-\4H_WMHW9YR>,>U>QQEC&ID
M#X&X#L:9-]Z+_?'\C4M:U:JJ1BE%*QE1HRIRDW)N_?H%%%%8'0%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5'/
M_P >TO\ N'^525'/_P >TO\ N'^5 #U^Z/I2TB_='TI: "BBB@"(_P#'X/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5'/_ ,>TG^X?Y5)2/Q&V/2@ 7[H^E+3(B3"A/)VB
MGT %%%% $1_X_!_US/\ ,5+4;$_:4&>-IX_*I* "BBB@ J.V_P"/6+_<'\JD
MJ.W):!23D\\GZT 24444 %12?\?$7X_RJ6HY"1-$ >"3GWXH DHHHH ****
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MT(;6SMK&#R;*WBMHLD^7"@1<GO@5-114WN-)+1##!$TZSM$AE52JR%1N /4
M^G%1M8VC0RPM:PF*9BTB&,;78]21W/%3T4[L+(K_ &"S$GF"T@W[F;=Y8SEA
MACGU..?6ECLK6(J8K:%"D?E+MC VI_='H/:IZ*+L.5%(Z-IAEAD.G6A>W $+
M>0N8P#D;3CC!]*FAL;2WD#P6L,3JI4,D8! )R1QVR<_6IZ*.9OJ+EBNA ;*T
M,!A-M"8B_F&/RQM+9W;L>N><^M'V*U^S-;_9H?(8DM%Y8VDDY.1TZ\U/11=C
MLB*:UM[C;]H@BEV@A=Z!L C! SZC@U#+I.G3^3Y]A:R?9QB'?"I\O_=R..G:
MK=%%V@<4]T1R6\,TD;S0QR/$VZ-F4$H>F1Z&J[Z1ILETUS)I]JUPX(:5H%+,
M",$$XSTXJY10FUL#BGNBO9Z?9Z?&R6%I!:HQW,L,00$^IP*>+6W6*6(01".8
MDR($&')ZY'?/>I:*+L+):%;^SK+RI8_L=OY<RA95\I<. , $8Y ''--.DZ<;
M$61T^U-J#D0>2NP'UVXQ5NBCF?<7+'L56TNP>Q%D]C;-:KT@,*F,?\!QBEN=
M-L;RW2"[LK>>&/[D<L2LJ]N 1@59HHYGW#ECV(?L=MN1OL\6Y$*(=@RJGJH]
M![46ME:V,/E6-M#;1YW;(8PBY]<"IJ*+L=EN%%%%(84444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4U_P#5M]#3J1_]6WT- #8?]1'_ +H_E3Z9#_J(_P#=
M'\J?0 4444 1-_Q]1_[K?TJ6HF_X^H_]UOZ5+0 4444 %16W_'NOX_SJ6HK;
M_CW7\?YT 2T444 %12?ZZ'ZG^52U%)_KH?J?Y4 2T444 %%%% $4'W7_ -]O
MYU+44'W7_P!]OYU+0 4444 13_=3_?7^=2U%/]U/]]?YU+0 4444 %%%% !1
M110!S?Q$@GN?ASKD-G'))/):,J)$I9B?8#D_A7F^EW7BCPMX7@L8$NM-!O+H
MW+6VERWBV\@V^5%$A)/EN,MOR1G(XKV#5M3AT?37O;H'RHV16P0,;G"YYXP-
MV3[52_X2S1A<7:27]ND-HD3R7!F3R\R%@JYSU^0\>XH XNW\3>,I?$MA!JT-
MQIGF+;?Z%!I+W$4X8 RLTX.(RI)&,\8'WJQM-U+QWX=\.-%I]O)>+)9W,\$$
MEBP:T9;K'7JY*,6"GK@8!'7U0^)-$#QH=6L@TD/VA%\]<M%S\_7[O!YZ<4T^
M)M#&GB^.K6?V4OY8F\]=I;^[G/7VH Q_A[J>N:KH,T_B!O,83E8)FM7MY)$P
M/O1NBX(.1D#!%=969+XDT2"XB@FU:R2:8*8T:=<L&^Z1ST/;UJC%XTTJ34+F
MW\U4CM)Y(+BXDFC5(F0(><MGDN ..H.<<9 .AHKD=<^(VDZ0EF]HDFK)=2;=
M]E+%MC ZDEG4'Z#)_2M:Z\0QPZEI]G;VDURU['YJLA5=J9 W88@G&X$@9('-
M &Q16)#XC>YN ;72;V:P,WDB]0(5)W;2P3.\KG^+'OTYI^O>);/P]!++>*[)
M#:37<A4CY4CQQR1R2P ]Z -BBL@>*]!,,DAUBR"PA#+F=?W>X94'G@FB3Q5H
M:6[3)JMG*!$\P$<ZDLJ9W$<]L'\J ->BLVP\0:;J.CPZE#=Q+;RI&Y+2#Y-X
M!53SP3N'YTNG^(-(U:1H],U.UNW4D%89@Q& #T'L1^= &C162WBK0%E\MM:L
M ^SS-OVA<[=NX'K_ '3GZ4^;Q+H=M;P3W&KV445RN^%WG4"1?4'/3WH TZ*Q
MK+Q9HU]?/9I?0)<B8Q)$\J[I< '*C/((/%7M,U"/5-/2ZB1XPS,I1\94JQ4@
MX]P: +=%%% !1110 4444 %%%% !1110 450U755TR.$);RW=Q<2>7!;PXW.
MV"3R2   "22?Z53B\56$4<O]LLNCSPL%DAO)47J"5*L"0P(!Z'L?2@#;HK.F
M\0Z-;K;-/JEG&+M0T!:91YH/0CGD>],N?$>E6\MU +Z"6[M8GEDM4E4R849/
MRYZXH U**SK;7]+NKM+.._M_MC1B3[,95\P#&>5SZ&F6WB;0[RX\BUUBQFF+
M;1&EPI8G('3/J0/QH U**CBN(9]_D2I)Y;E'VMG:PZ@^]24 %%%% !1110 4
M444 %%<SIOCK2KR.YDO'33HK<KF6XGCVG<S*H)#':Q*GY3@UKPZ[I5S>2VD&
MI6LEQ"NZ2)9E+(!U)&?>@"_160GBWP]+%))'K=@R1XWD7"_+D@#//<D"EL/$
MFG:BVJ^1,NW2IS#</N! PBN3QVPV/J#0!K45C6&OS7DL9GT>]L[692\5S-LV
MD 9RP#$ID<_,!Z<'BG+XM\//%)(NMZ>4BY=OM*87G SSZ\4 :]%9DOB31(;.
M"ZEU:S2WN"1#*TZA9".N#GG'?TJ1]=TJ/4!8OJ5JMTR;Q"9EW%<9SC/H,T 7
MZ*K6&HV6JVBW6F7<-W;L2%E@D#J?H1Q5F@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *:_^K;Z&G4U_]6WT- "0_P"HC_W1_*GTR'_41_[H_E3Z "BB
MB@")O^/J/_=;^E2U$W_'U'_NM_2I: "BBB@ J*V_X]U_'^=2U%;?\>Z_C_.@
M"6BBB@ J*3_70_4_RJ6HI/\ 70_4_P J ):*** "BBB@"*#[K_[[?SJ6HH/N
MO_OM_.I: "BBB@"*?[J?[Z_SJ6JFI7MK86JSWUQ%;0K(N9)7"J.?4U/;W$-U
M D]K*DT3C*O&P96'L13L[7%=7L24444AA1110 4444 4=9TM-9TN2QD?8CO&
MQ)7<"%=6QCWVX_&L+5O EM?W[7EG.+&53$T2Q(R*K() 2?+=&.1*>C#&!R>E
M;?B"XEL_#.IW-OGS8;261,?W@A(KE)QI$%[<0^);^[A:%(UTT_:)$+QB-?FB
MVGYY-^<]6^[ZC(!=M? 4-M;W(%Z?/GBB'F^66VNDSS;OG9BREGY4D].N>:EU
M+PE>ZL;>YN]607]O([1R00R0QA64*1MCE5R>!R9/7MQ56R\3:E;PQ:=JICCU
MAS:+%"\9WRJZIYK8!YVGS,D<+MYK ;6M7L_#\6G7MXMT+JUN\@1NDS,&EQR'
M#*N%&&7..AV_*2 ;=OX(O8EU'3X;Z.#3[NVBMI6:W$CRJ%(<JQ;*'+'[VX#L
M*OWO@J*]FE:2[.R2Z,Y1H@PQF$[3D\_ZG_Q[VK#U'Q)J+WD$(NX1<QZD$&CQ
MQ.)_+1CM8OGHX"G)&WY\9)ZZ7@KQ/JFN7LL6H)"RK )7,80&"0G'E$+(Y]?O
M;6^4Y'H ;+>%]-N;Z[N-3M;>_P#/G6>-+B!7\DA%3C.>NW-)K6@S:O=VKK?"
M&"&1)&B, =@R.&#1OD%&/*D\@@XQWKDK%_$2:BQAU-2\:ZK(6GMV92$NE"+M
MW_7!SP#@5/:^-=9NO$EO;-:10Q321*MJVSS'C9 3*,R;\#)Z(1\I!.<X .CM
M="U"QD6WL]7$>F+*9%@^S RJ"V[RQ)NQLSQ]S..,]Z9KNAS:M?S1J2D%YI5Q
M8R3#!\DOMP=N>>_Y5D^*+^2VEURQ%S)%=WUK"NG1AF#2OEE(CQW!(SCD#!/%
M+KFJ6<WBG39H+F2<PS?9S:AI8MS^9M9HR,!V4CYE.1L.<CN :)\)-#,;NPO4
MAO5O7O$DDM]Z$O&(R&4,"WRC@A@?PX-6T\$3VUVL[:L"6:=IO+M?+,IEWG!P
MV-H+Y ()R.&&6SH6E_'>^+(Y;&=I;::PD##D*&CFV@X/0Y+C/?;6]0!RZ>$+
MB$10PZFHM +9IHWMLL\D 4*P;<-H)1,C!Z<$9IMMX7UBW6&9=:M#?1/(WVC^
MSVQ)Y@^?>IER3D+@@@ #&"*ZJB@#F+7P1:V=K#;PW!*0WMO=@O&"S>3$D:J3
MW^YG/;/2HY?!MPBWXT_5(X3J*SI<F:T$OR22R2#9\PP1YK#G<#@';75T4 <C
M:>";BUA>S.J1R:=)<QW,D7V,+*739@"3=@#,:]5)Z@$<8W- M)[/2%2[C\N>
M266:2/<#L+R,^,CCC=6E10 4444 %%%% !1110 4444 %%%% &?JVF27_P!G
MFM+G[)>6LADAE,>]>0059<C*D'D @]"",50@\,NVJ0:GJ5XMW>QS>:S+!L0
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M]TVPL PZY(4X&/?I44G@N%]/L[9+R2-K,2-$XC7AVE64,0>#AE''>H/^$-U
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M*:?<V5D=H\J,>7U"#EOFXX[.B@#B+[4/$$DFH6$,\T,FGJ)GN((1(91*04C
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MUVGKLX51C((W9)(JI+X.U#P\WB76Y-14I=V[Y,;/O8$8);)P-HR>,\]-HR"
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M&P& &<!_4#@GCK=TC6=5N-?A@GGDDD::6.[L6LRBVB*&V.),?-DA!U(;?D
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MVC.<5)'X7L7NH+O[7>SA'$VU[DNDK!BR,<_W=W&,<!0<X% %V+46?Q%<Z:Z
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FO_ *MOH:=37_U;?0T
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M,,<M@Y6@#JTOX'O)[8%A) JLY9"%PV<88C!/!R >._6K&]>?F'R]>>E<1;^
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M+_\ %46CW"\NQ<;_ (^H_P#=;^E2UD_V1;-<*%NKXX# XOI>#Q_M5+_8EO\
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M8^NW%Q'=:9;VLK1>?<-O*]6"Q.P7\6"_@#61HOB 3S:5)<ZG$T!T9);EFD4
M2LR*"Q[$G</KD4 =?17)>&M8C&H7T5_JQN&=DDBE:=3"ZO(RH$& 4?(V%#W4
M8SDUL>&KB>YT4-=2&62.>>'S#U8)*Z GWPH_&@#5HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "FO_ *MOH:=37_U;?0T )#_J(_\
M='\J?3(?]1'_ +H_E3Z "BBB@")O^/J/_=;^E2U$W_'U'_NM_2I: "BBB@ J
M*V_X]U_'^=2U%;?\>Z_C_.@"6BBB@#C])N[J">WEN+/4B-/LI(+A#;O\\C2I
MC;G_ %G"DY7(P>M+H,WV+4+G.FZ@@GNE#22Q2;O,8ON# DJ0N!F1?E(91VKK
MZBD_UT/U/\J ):*** "BBB@"*#[K_P"^W\ZEJ*#[K_[[?SJ6@ HHHH BG^ZG
M^^O\ZEJ*?[J?[Z_SJ6@ HHHH **** "BBB@#F/B1J]]H'PYUG5-)F\B\MH-T
M,FQ6VG<!G#<'KWKBM&^*FIV>C6]G?VG]K:S]INTD%S/#9F.&':<NPS&9-LB'
M"<')Y&#7IVM+IKZ1-'KD,4]C+MCEBFB\Q'W,% *X.>2*Q9]&\%Q_9O#L^B:9
MY,,BR06C6"F&)WWD,/EVJ3L?ZX]Q0!@6/Q<2[U32;)]'\I]4T]-2C87BML@*
M,SY&W)D&W 4#YN3D8-8\_P 7M4U..UAL-)33YKE+6\@D%]%<>;!)<QQ;& 4A
M&8/SUV^]=CN\%V<<!M=(MW+E+F)+33&D<"/Y4EVHA( Z*W3'2IM-TCP1YL\^
MEZ3I$;>6EU)-%9HH92V]7W!>?FCS[%?44 <!HWQEU>T\'6D^KZ.FH7Z64^H7
M<C7T5N/(6:2-2HVX9LH1M '0'.3BO8;*X^V6%O<A=GG1+)MSG&1G'ZUR]S:>
M!+KP\E[?:3ICZ;II(3[18#;;E\,=JLN1G>"<#O6E<>*]"TS6[70I+@QW4J@1
M1QV[M&HQP"X78O&, D=10!N455U#4;?2[59[LN$:1(EV1L[%G8*H 4$]2*?:
M7D%]:QW-J^^*3.UL$9P<=#]* )Z*,CUHSGI0 449HS0 45D7OBG2K"ZE@GEF
M8P$"=XK>22.#(S^\=5*IP0>2..:OVM_;7IF%M*'\B7RI.",-@-CWX8<CUH L
M45!!>07,L\<+[GMY/*D&"-K;0V/?AAT]:+R\@L+4W%T^R)652=I/+,%' ]R*
M )Z*AL[N*^LX;JW+>5,@=-Z%&P?56 (^A%-COK>:\N+6.3,UL%,JX(VA@2.>
MG8T 6**JC4;8ZLVFJS&Y6$3LH1L*A)4$MC )*M@9SP:DN[J*QLYKJXW>5#&T
MC[$+MM R<* 23[ 9H FHI%<.H*]",C/'%+G/2@ HK(?Q/IB6\TIDG;R;HVC1
MK;2&0R@ [50+N;@YR 1CGI5*Z\?>'[4(S3W,J.NX/;V4TJCY=VTE5(#8(.T\
MC(XH Z2BD1P\:N 0& (##!'U!Z4M !1110 45&]Q#'/%#)(JR39\M">6P,G'
MX5)0 4444 %%%1I<PO<R6Z2*TT2JSH#RH;."?K@_E0!)1110 4444 %%%% !
M1110 45G:;X@TK5YGBTV]CN)(QN95STSC(SU&>XJW:7EO?VPN+.9)H2S*'0Y
M!*L5(_ @C\* )J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ IK_ZMOH:=37_ -6WT- "0_ZB/_='\J?3(?\ 41_[H_E3Z "B
MBB@")O\ CZC_ -UOZ5+43?\ 'U'_ +K?TJ6@ HHHH *BMO\ CW7\?YU+45M_
MQ[K^/\Z ):*** "HI/\ 70_4_P JEJ*3_70_4_RH EHHHH **** (H/NO_OM
M_.I:B@^Z_P#OM_.I: "BBB@"*?[J?[Z_SJ6HI_NI_OK_ #J6@ HHHH ****
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M%'M?YCG E)S\I)7[HKKM"O[J\2]AOS"UQ97)MWD@0HC_ "JX(4DD<.!C)Z4
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MQGD2$H H]P3@\&CF7;\PY7W_ "_R-YM0O?M"'^QKK[IX\V'V_P!NI/[1O?\
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M@*?W<>,Y/)WN1^6:.9=OS#E??\O\C2_M&]_Z MW_ -_8?_BZ/[1O?^@+=_\
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M1]/-K"S^3(DDCJB@\A27"G!Z9Z4 =I+;Z/IT-M&UG;11[UMH52!<+E@0H '
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M)$F!R"#U()R!D$<4H\'7D;17 LM(N &F/]ES,PM8-^W#1G8?F&S^X,[SC;W
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MUWQKY:QE5;&0" >_<UDZ?\/[;38F^S7C).FS[-,D" Q;"=N1_%UP>@] #S0
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MV,D#<<?KFA_"=LZ:DOVB4'4$='( R@9V?C\6H V9_NI_OK_.I:BG^ZG^^O\
M.I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(UG4M:T2X;7$@%[:7T]G(]O&R1R^6Y4.JL20",<9- '1T444 %%%% !1110
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MN[*VO+W^T)&CAAAC"R;E5F8,'*[<!#U-/M?$]O>7UC;P6=XT=]$98;C8OEX
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M.UL,?D% 'JU%9^AP74.E1MJ#,;N<F:968D(S'.P>@7[H^E:% !1110 4444
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M@G<>I(!&/FZUW<4@EA20# =0P'UJ"2"&.)$CB15W*NU5 &,]*L].E !1110
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M:N,L[;4;"2T:?2I\:5#+$"KHWVEGD7;Y>#G&%R2P7'O79CIS0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %17%K#=>7]HC#^5()4S_"PZ&I:* "BBB@
M HHHH **** "BBB@"*2UAFN(9Y8PTD!)B8_P$C!(_#BAK6%[R.Z:,&>-&C1^
MX5B"1^)4?E4M% !1110!%#:PV\DSPQA&G?S)2/XFP!D_@ /PJ6BB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IK_P"K;Z&G4U_]
M6WT- "0_ZB/_ '1_*GTR'_41_P"Z/Y4^@ QGK1CFBB@")O\ CZC_ -UOZ5+4
M3?\ 'U'_ +K?TJ6@ JMJ-R;/3+FX0KOBA=T#="0I/]*LU4U'2K#5H4AU.TAN
MHT;>JRH& .,9_(D?C0!S\GC"YA@2Z;2UDLC(8#,+D*_F*A+?NR/NY4@?-GOC
M'-%KXLNDL8/M6E+%/=QQR6<278<2"1@H#MM^0@L,XW#T)Z5JWOAC1[Z>6YEL
M+<7<B%?M(C&]25V[@?7'&:CTWPQHUII+VL6FVWE3H$F'E#]X!TS_ #H RSXS
MOUGFMCHB>?:F<W/^F@QHL*PL2&"Y8D3# P.ASBM:]UN=3:QZ39+>37,!N LT
M_DJL8QSG#<Y8<8]<D58M= TFQA:&TTZVAC975E2(#<'V[\^N=BY]=HIU]HFF
M:G;16]_8P7$,/^K21 0G&./3CB@#"L_&LEUY=P^EM#8'RE>=K@,RO)&' " '
M<!D G(]LTZQUW4+_ ,3:;%/9QVEI=6DMU%MG61I!\FTL, J<-T&X<]3BMZ+2
MK"")8H;.".-&5U18P "H 4@>P  ^E5;;0-)TW4ENK#3K:WGD+!I(XP&(/)&?
M3/:@#-M-4U>[MTU3[;IL5E),T8M70AU 8KCS-V/,R/N[>O'O5&+QC>QZ7:2:
MI9R03- MRHBF1C.GEN2&!7"DE.@/<?-U%=)_8&DC4SJ/]G6WVPG<9O+&[.,9
M^N._6I9-(TZ54$EE XCC\M 8P=JX(VCVP3^= &+#XJO9=EJVDI'J<WE-%;-=
M_)LD5V!>3;P0(GR &Y P3G(U=#U1]8TO[5+;?9I!-+"\7F!]K1R,A^8<$$KG
M\:?=:+IE[&Z7=C!,LBHK!HP<A,E1^&XX],FI[*QM=-M%M=/MXK:!"2L42A5!
M))/ ]22?QH =!]U_]]OYU+44'W7_ -]OYU+0 4444 13_=3_ 'U_G4M13_=3
M_?7^=2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %-?_ %;?0TZFO_JV^AH 2'_41_[H_E3Z9#_J(_\
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MQVD&N:3=-MMM3LYCO"8CN$;YCG X/4X/'M3KG6=,LU9KS4;2!5?RV,LZJ ^
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MW_'TG^ZW]*EJ)O\ CZ3_ '6_I4M !1110 5%;_ZG_@3?^A&I:BM_]3_P)O\
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M<EI0F02L?3#=L=Z .XHJO8SRW-FDES"D,V2KQI*)%4@D'# #(X] ?4 \58H
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M/6+_ '!_*I*CMO\ CUB_W!_*I* "BBB@")O^/I/]UOZ5+4;?\?2?[K?TJ2@
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M'4XYP#7&W.M:EJUQIUK;:M8W4 U6!9+W3T=8IT,<C&+Y93R"BD_,00RY'4$
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MXRQX/(JW<ZOJ">)/ML5O?-H5JWV)YEEC\DITDE.7\PE7"KNP>%8]R:AMK]]
MC,4-\EI%<W]RCW^K3RW$4(C;Y$^>08+ G'S ?*>IQ0!JV'A2ZTEQ#87ML;.3
MR3.MS:F60F-%4;&+\#" @,&P22*BD\%2"1)X+^,3PSRSP^9;[DW/<M, R[N0
M-V.H.0&!&*Q+#QG?QZ:&:_T^-@)9HOM2R,=1)F<". [@1@* .'/S+QCK/>^/
M-3M_MJ)':%X;Q8BX"E+2-@Y!D+3*I;Y-N"T9!/0C:6 -NT\([+V6^O9X)KJ>
M*X5S';[45I=@)0$D@8C&1DDDDD\U/+X?NX['1Q87L27FE1>6LD\)>.4&/8V5
M# CH#P?SK*O-3O\ 7? =M<*@@N;B\CB'EW!C61?."YWQ,Q56 S\K'KC)JCJ6
MMZUX-AM+!VA<2K+.9[B02(OS#; KS31L3@YR2Q]%] #3_P"$)G!M(QJ49AMH
M60,;4"4%T*N P(_=L3N*D'D<$<8NW/AZ+3_#EM::/90J]O<6LSI!$L?F^7(A
M8XX&=JGK63)X@\07=N\H%I9P374=BD(1FFC:2-?F,F[:-K/C 4Y ZBJ?AS2/
M$7AS^S8]9U"6<SZF4$9O);CY#%(22S\XX7 Z#;GC- #;GPOJ.K7D.C36TD&E
M075S,;@P(K@2)*I(E$A+$F7^XIQU/'.G8> FAN(9KZ\2X,$\$B*?.<;8MY48
MEE?!RP((P!CI79T4 <3J/P_DN[R>YM]2*-<><DB,9E41R2%\ 1RIDY8YSD'C
MBI6^'T)M)(([P)OGFG+^3DLSLA7=D_,!Y8!S]X<<5V-% &=86-T(;G^V7L[E
M[@X<6]L8U*XQ@@LQ;\37/3^ 7:WMWBU25KVVG9XYY&D3,>W8B$QNK?*F #NY
M.XD?,:[*B@#BHOA\;:PNH[6\A%S/' JSO"[&,Q[SD-YF_JY(^;CH<@FIQX-O
M+:2>2RU&U9[J.2&X-U9^8"C'/R@, #R<]5/''%==10!S5MX/BLX88[>YVF+4
M4O3(8\O(%0(%8YY.!][]*Z6BB@ HHHH S]2TF/4[FR>?:T5N[EXG3<)5:-D*
MGV^;WKEYOATR7!N+'5IO,$DGE^?)+\D;I&NS,<B,V!$ "2<C@YZUW%% '(#P
M3/#!]AMM1C33I! TT;PLTA>)%4;7+\ [$R"">O// /!,UK8166G7=I' VG1:
M?<K+9[\H@(W1X8!2=S'!W#.#]>OHH Y!_!-Q$UY]BU"#9?Q/;W N;;S2(R[L
M-IW##?O#G.02 <<5G7.@ZD=532[:S=M..J1WSSSP(V=I5B?,\S)SMP!LW=LX
MKT"B@# \*Z/-IMO<2WA<RRR&.%9,;HK=&(B0X)Z D_\  JWZ** "BBB@ HHH
MH **** ./7P;=',,EQ#]ENFGDO8P&/FNSNT6/IYG/KL4=*Y^_P##MWH]JL5[
MIT6M2S6LD:@VTLT<3L2=R;4;#'(SNV X'SC!KU"B@#SW2?A[-I^E1.]KIUW=
MFX$T]M<Y$<Z^4J!7;:V"F"1PPS[G(DTSX>21/"-3CT][9;MKAK6)6,8!DF<*
M 1R!YJ]>.#P.!7?44 >=W_P[OYI/]'N8#%B:**+<J+:1M/(Z&/="Y!"NHPI3
M&P8;ICI/#^A7.DZQJEQ+]G$-TX9"AW2.W.6<E01G(^4EL<X(' Z"B@ HHHH
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MXX)'.*S[W6?#]IK,EA<-?(;:Y2&20W<Y&6B9Q@;LGIC S1:/?^OO"\^WX_\
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MI>RYE+WNQA&I6]MR./NVW.GHHHKG.H**** "BBB@ I H P  /84M% !1110
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M##_^ Z?X4?8-1_Z##_\ @.G^%/E7?\PYGV_+_,TJBM_]3_P)O_0C5+[!J/\
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M.Z7&KN/G_P"?=/0>U2?8-1_Z##_^ Z?X4<J[_F',^WY?YFE16;]@U'_H,/\
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MA([ C+$ >O6M>B@"&SMQ9V,%LI++#&L8)[X&/Z5-110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 1
MVW_'K%_N#^525';?\>L7^X/Y5)0 4444 1-_Q])_NM_2I:B;_CZ3_=;^E2T
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M4 %%%% $4/WI?^NG]!4M10_>E_ZZ?T%2T %%%% $=Q_JA_OK_P"A"I*CN/\
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MR)JMB;>2*26)Q',)%,H42(BG SN4G&0#D$8[TN9_TD'(OZ;-?[!J/_08D_\
M >/_  H^P:C_ -!B3_P'C_PK"C\?1BZN5NM-N(H+<2AI%1V.^)27'W N/E8
M[B3@9 S5RPUC5+C7[ZTU*U2S6&PCG1(IEEY9I!G=M!SA1P1CT)I\[_I(.1?T
MV:/V#4?^@Q)_X#Q_X5'+8Z@&BSJ\A^?_ )]X_0^U9VD>*9[R2V26Q=;21TMQ
M=RS*7DE,0DSL50,8X)XYZ+CFJ=[KVNQ^*I+*WLX)XEO8XH$,^W<IMV<ECLRH
M! /&X]J7,_Z2#D7]-G0_8-1_Z#$G_@/'_A1]@U'_ *#$G_@/'_A6$OC^&2]M
MXHM.N&B983.X1V,;2=%&U"K8R,DLOMFM'5M;N;%M36!8B;6"&2,,#R79E.>?
M84^=_P!)!R+^FRY]@U'_ *#$G_@/'_A1]@U'_H,2?^ \?^%5M2U2YMM>LH8;
MBV2T8JLX:,N^YFVH"0PV9((!(()&.*V@P894@CU%'._Z2#D7]-F5%8Z@6EQJ
M\@^?_GWC]![5)]@U'_H,2?\ @/'_ (5=A^]+_P!=/Z"I:.=_TD'(OZ;,W[!J
M/_08D_\  >/_  H^P:C_ -!B3_P'C_PK2HHYW_20<B_IL\^^(^E>*)]"B71[
MVXNT\W]_%"JHY'\.-N"1GM]*U?AQ::Y9>%5B\1F3SO-)A29LND>!@'\<UU%Q
M_JA_OK_Z$*DK5UVZ7L[(Q6'2K>UN_0****YSI"BBB@ HHHH Q/&6L77A_P %
MZKJVG6XN+FTMFECC()&1W(') ZGV%>7^(O&/B+PUI=W_ &/XO@\4RW.BW-[O
M2*%#8-&%(F78I!0[B K@DD 9ZU[/<30VUK+/=.L<,:%Y'<X55 R2?;%<GIY\
M'16U];V'AV*U2]B:2:W&C^5]N3^+Y-@\WKR.>M '$6WQ;\0Z0^I1Z[HR7-U)
MJHM+.!;L".$"VCE=6=8B<#.0=I)+D<!<UVO@[QW=>+M5GMUT*2PMK>UAFEEG
MG^<22#(C\O;TX;YL\C''/#)M5\&:I8K%>Z(L]IJ 2]D6XT@F-@<(DT@9,#@
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MC(.#W'(HM+^"]MDGB+JKLRJ)4,;$JQ4_*P!ZC\>M %BBF/-''NWNHVKN89Y
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M[>"/.R.-<*N3DX'U)J:B@"*'[TO_ %T_H*EJ*'[TO_73^@J6@ HHHH CN/\
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MVB@#AU\ N+*Y9S:/J)AA2TN""?LI1BV$)!*@9 !'. ,UW%%% !1110 4444
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M%#8(4Y WGYVY;H?0J* /,-/T74'>]U'2--CTB6[O8H;=(+>1%CC,>R9L,B,
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M@_=!R37;X?/=W;7-Q::;:J+>Z6WLK<LT-M+(L:JZ_*O/R,2=HP2, G)KO:*
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MQ)*H"R$$@[<$G@CHV#T.,&B\>P<LNY#%JSAI?^)7?_?_ .>:^@_VJD_M=_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH CMO\ CUB_W!_*I*CMO^/6+_<'\JDH **** (F_P"/I/\ =;^E
M2U$W_'TG^ZW]*EH **** "HK?_4_\";_ -"-2U%;_P"I_P"!-_Z$: ):***
M"HIOO0_]=/Z&I:BF^]#_ -=/Z&@"6BBB@ HHHH BA^]+_P!=/Z"I:BA^]+_U
MT_H*EH **** ([C_ %0_WU_]"%25'<?ZH?[Z_P#H0J2@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH CMO^/6+_<'\JDJ.V_X]8O]P?RJ2@ HHHH B;_CZ3_=;^E2U$W_ !])_NM_
M2I: "BBB@ J*W_U/_ F_]"-2U%;_ .I_X$W_ *$: ):*** "HIOO0_\ 73^A
MJ6HIOO0_]=/Z&@"6BBB@ HHHH BA^]+_ -=/Z"I:BA^]+_UT_H*EH **** (
M[C_5#_?7_P!"%25'<?ZH?[Z_^A"I* "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@".V_X]8O]P?RJ
M2H[;_CUB_P!P?RJ2@ HHHH B;_CZ3_=;^E2U$W_'TG^ZW]*EH **** "HK?_
M %/_  )O_0C4M16_^I_X$W_H1H EHHHH *BF^]#_ -=/Z&I:BF^]#_UT_H:
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M+45O_J?^!-_Z$: ):*** "HIOO0_]=/Z&I:BF^]#_P!=/Z&@"6BBB@ HHHH
MBA^]+_UT_H*EJ*'[TO\ UT_H*EH **** ([C_5#_ 'U_]"%25'<?ZH?[Z_\
MH0J2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH CMO\ CUB_W!_*I*CMO^/6+_<'\JDH **** (F
M_P"/I/\ =;^E2U$W_'TG^ZW]*EH **** "HK?_4_\";_ -"-2U%;_P"I_P"!
M-_Z$: ):*** "HIOO0_]=/Z&I:BF^]#_ -=/Z&@"6BBB@ HHHH BA^]+_P!=
M/Z"I:BA^]+_UT_H*EH **** ([C_ %0_WU_]"%25'<?ZH?[Z_P#H0J2@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH A-OD\2R*/0'I1]G/\ SVE_.IJ* (?LY_Y[2_G1]G/_ #VE
M_.IJ* (/LQ_Y[2_G2_9S_P ]I?SJ:B@"'[.?^>TOYT?9S_SVE_.IJ* (?LY_
MY[2_G2?9C_SVD_.IZ* (?LY_Y[2_G1]G/_/:7\ZFHH A^SG_ )[2_G2?9C_S
MVE_.IZ* (?LY_P">TOYT?9S_ ,]I?SJ:B@"'[.?^>TOYT?9S_P ]I?SJ:B@"
M#[,?^>TOYTOV<_\ /:7\ZFHH A^SG_GM+^='V<_\]I?SJ:B@"$6^",RR'V)J
M:BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
:BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>halo-20220630_g2.jpg
<TEXT>
begin 644 halo-20220630_g2.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#Z17AI9@  34T *@    @ ! $[  (
M   0   (2H=I  0    !   (6IR=  $    @   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $=E=&%S97<@
M665S96=A=   !9 #  (    4   0J) $  (    4   0O)*1  (    #,38
M )*2  (    #,38  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                         #(P,C(Z,#@Z,#@@,3,Z-#DZ,#< ,C R,CHP
M.#HP." Q,SHT.3HP-P   $< 90!T &$ <P!E '< ( !9 &4 <P!E &< 80!T
M    _^$+(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T
M(&)E9VEN/2?ON[\G(&ED/2=7-4TP37!#96AI2'IR95-Z3E1C>FMC.60G/SX-
M"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B/CQR9&8Z4D1&
M('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M
M<WEN=&%X+6YS(R(^/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](G5U:60Z
M9F%F-6)D9#4M8F$S9"TQ,61A+6%D,S$M9#,S9#<U,3@R9C%B(B!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B+SX\<F1F.D1E
M<V-R:7!T:6]N(')D9CIA8F]U=#TB=75I9#IF868U8F1D-2UB83-D+3$Q9&$M
M860S,2UD,S-D-S4Q.#)F,6(B('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(^/'AM<#I#<F5A=&5$871E/C(P,C(M,#@M,#A4,3,Z
M-#DZ,#<N,38P/"]X;7 Z0W)E871E1&%T93X\+W)D9CI$97-C<FEP=&EO;CX\
M<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB=75I9#IF868U8F1D-2UB83-D
M+3$Q9&$M860S,2UD,S-D-S4Q.#)F,6(B('AM;&YS.F1C/2)H='1P.B\O<'5R
M;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^/&1C.F-R96%T;W(^/')D9CI397$@
M>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS
M>6YT87@M;G,C(CX\<F1F.FQI/D=E=&%S97<@665S96=A=#PO<F1F.FQI/CPO
M<F1F.E-E<3X-"@D)"3PO9&,Z8W)E871O<CX\+W)D9CI$97-C<FEP=&EO;CX\
M+W)D9CI21$8^/"]X.GAM<&UE=&$^#0H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(#P_>'!A8VME="!E;F0])W<G/S[_VP!#  <%!08%! <&!08(!P<("A$+"@D)
M"A4/$ P1&!4:&1@5&!<;'B<A&QTE'1<8(BXB)2@I*RPK&B O,R\J,B<J*RK_
MVP!# 0<(" H)"A0+"Q0J'!@<*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" 0= O8# 2(  A$! Q$!_\0
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M*/[&I_S,/[>J_P B/IS_ (2OP[_T'M+_ / R/_&C_A*_#O\ T'M+_P# R/\
MQKYCHH_L:G_,P_MZK_(CZ<_X2OP[_P!![2__  ,C_P :/^$K\._]![2__ R/
M_&OF.BC^QJ?\S#^WJO\ (CZ<_P"$K\._]![2_P#P,C_QH_X2OP[_ -![2_\
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M(_\ &C_A*_#O_0>TO_P,C_QKYCHH_L:G_,P_MZK_ "(^G/\ A*_#O_0>TO\
M\#(_\:/^$K\._P#0>TO_ ,#(_P#&OF.BC^QJ?\S#^WJO\B/IS_A*_#O_ $'M
M+_\  R/_ !H_X2OP[_T'M+_\#(_\:^8Z*/[&I_S,/[>J_P B/IS_ (2OP[_T
M'M+_ / R/_&C_A*_#O\ T'M+_P# R/\ QKYCHH_L:G_,P_MZK_(CZ<_X2OP[
M_P!![2__  ,C_P :/^$K\._]![2__ R/_&OF.BC^QJ?\S#^WJO\ (CZ<_P"$
MK\._]![2_P#P,C_QH_X2OP[_ -![2_\ P,C_ ,:^8Z*/[&I_S,/[>J_R(^G/
M^$K\._\ 0>TO_P #(_\ &C_A*_#O_0>TO_P,C_QKYCHH_L:G_,P_MZK_ "(^
MG/\ A*_#O_0>TO\ \#(_\:/^$K\._P#0>TO_ ,#(_P#&OF.BC^QJ?\S#^WJO
M\B/IS_A*_#O_ $'M+_\  R/_ !H_X2OP[_T'M+_\#(_\:^8Z*/[&I_S,/[>J
M_P B/IS_ (2OP[_T'M+_ / R/_&C_A*_#O\ T'M+_P# R/\ QKYCHH_L:G_,
MP_MZK_(CZ<_X2OP[_P!![2__  ,C_P :/^$K\._]![2__ R/_&OF.BC^QJ?\
MS#^WJO\ (CZ<_P"$K\._]![2_P#P,C_QH_X2OP[_ -![2_\ P,C_ ,:^8Z*/
M[&I_S,/[>J_R(^G/^$K\._\ 0>TO_P #(_\ &C_A*_#O_0>TO_P,C_QKYCHH
M_L:G_,P_MZK_ "(^G/\ A*_#O_0>TO\ \#(_\:/^$K\._P#0>TO_ ,#(_P#&
MOF.BC^QJ?\S#^WJO\B/IS_A*_#O_ $'M+_\  R/_ !H_X2OP[_T'M+_\#(_\
M:^8Z*/[&I_S,/[>J_P B/IS_ (2OP[_T'M+_ / R/_&C_A*_#O\ T'M+_P#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8%%%4]4U:RT6P:]U2<6]NA :0J3@DX' !--)R=D*4E%7;LBY17+?\+*\(_\
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MO_(_N8?6\/\ \_%]Z.IHKEO^%E>$?^@S'_WZD_\ B:/^%E>$?^@S'_WZD_\
MB:/JU?\ D?W,/K>'_P"?B^]'4T5RW_"RO"/_ $&8_P#OU)_\31_PLKPC_P!!
MF/\ []2?_$T?5J_\C^YA];P__/Q?>CJ:*Y;_ (65X1_Z#,?_ 'ZD_P#B:/\
MA97A'_H,Q_\ ?J3_ .)H^K5_Y']S#ZWA_P#GXOO1U-%<M_PLKPC_ -!F/_OU
M)_\ $T?\+*\(_P#09C_[]2?_ !-'U:O_ "/[F'UO#_\ /Q?>CJ:*Y;_A97A'
M_H,Q_P#?J3_XFC_A97A'_H,Q_P#?J3_XFCZM7_D?W,/K>'_Y^+[T=317+?\
M"RO"/_09C_[]2?\ Q-'_  LKPC_T&8_^_4G_ ,31]6K_ ,C^YA];P_\ S\7W
MHZFBN6_X65X1_P"@S'_WZD_^)H_X65X1_P"@S'_WZD_^)H^K5_Y']S#ZWA_^
M?B^]'4T5RW_"RO"/_09C_P"_4G_Q-'_"RO"/_09C_P"_4G_Q-'U:O_(_N8?6
M\/\ \_%]Z.IHKEO^%E>$?^@S'_WZD_\ B:/^%E>$?^@S'_WZD_\ B:/JU?\
MD?W,/K>'_P"?B^]'4T5RW_"RO"/_ $&8_P#OU)_\31_PLKPC_P!!F/\ []2?
M_$T?5J_\C^YA];P__/Q?>CJ:*Y;_ (65X1_Z#,?_ 'ZD_P#B:/\ A97A'_H,
MQ_\ ?J3_ .)H^K5_Y']S#ZWA_P#GXOO1U-%<M_PLKPC_ -!F/_OU)_\ $T?\
M+*\(_P#09C_[]2?_ !-'U:O_ "/[F'UO#_\ /Q?>CJ:*Y;_A97A'_H,Q_P#?
MJ3_XFC_A97A'_H,Q_P#?J3_XFCZM7_D?W,/K>'_Y^+[T=317+?\ "RO"/_09
MC_[]2?\ Q-'_  LKPC_T&8_^_4G_ ,31]6K_ ,C^YA];P_\ S\7WHZFBN6_X
M65X1_P"@S'_WZD_^)H_X65X1_P"@S'_WZD_^)H^K5_Y']S#ZWA_^?B^]'4T5
MRW_"RO"/_09C_P"_4G_Q-'_"RO"/_09C_P"_4G_Q-'U:O_(_N8?6\/\ \_%]
MZ.IHKEO^%E>$?^@S'_WZD_\ B:/^%E>$?^@S'_WZD_\ B:/JU?\ D?W,/K>'
M_P"?B^]'4T5RW_"RO"/_ $&8_P#OU)_\31_PLKPC_P!!F/\ []2?_$T?5J_\
MC^YA];P__/Q?>CJ:*Y;_ (65X1_Z#,?_ 'ZD_P#B:/\ A97A'_H,Q_\ ?J3_
M .)H^K5_Y']S#ZWA_P#GXOO1U-%<M_PLKPC_ -!F/_OU)_\ $T?\+*\(_P#0
M9C_[]2?_ !-'U:O_ "/[F'UO#_\ /Q?>CJ:*Y;_A97A'_H,Q_P#?J3_XFC_A
M97A'_H,Q_P#?J3_XFCZM7_D?W,/K>'_Y^+[T=317+?\ "RO"/_09C_[]2?\
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M_C_\37NU%']K8GR^X/[$PGG]YX3_ ,*=\3?W['_O\?\ XFC_ (4[XF_OV/\
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M>[44?VMB?+[@_L3">?WGA/\ PIWQ-_?L?^_Q_P#B:/\ A3OB;^_8_P#?X_\
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MZ7;V4<LDJP($#R8R?R  ^@&!5J@ HHHH **** "BBB@ HHHH **** "BBB@
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M"*WOKB**7R9;N"V9X8WS@@L.3@]< @5/I/B2#6-2O+*&SO89+,[96GB"J#V
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MG0!+1110 4V3_5M]*=39/]6WTH 2'_41_P"Z/Y4^F0_ZB/\ W1_*GT %%%%
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MZ#)Y.!QD\G%:-%%8R;D[LZ(Q44D@HHHI#"BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'-:6AZW!K]@;VSAN(X-Y1&GCV>9C@LHZXSD9[XXXYH T:*** "BBB@ HHHH
M**** "HH?O2_[_\ 05+6:UW>Q7$RP::\R!^'$R#/ [$TTKB;L:5%9OV_4?\
MH#R?^!$?^-'V_4?^@/)_X$1_XU7(_P"FB>=?TF:517'^I_X$/YBJ7V_4?^@/
M)_X$1_XU'/?:B8N=(D'(_P"7B/U^M'(_Z:#G7])FM16;]OU'_H#R?^!$?^-'
MV_4?^@/)_P"!$?\ C1R/^F@YU_29I45F_;]1_P"@/)_X$1_XT?;]1_Z \G_@
M1'_C1R/^F@YU_29=3_CXE^BU+62E]J/GR?\ $HDZ#_EXC_QJ3[?J/_0'D_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M CG+;@ K!E#H#M?D<G )'I5/_A#MY?\ XF2EYSFZQ;CGY]_[H9_=<GW]>O-
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M@#H;S7M/LF@5YTD>=E")&ZD[3C]X1G[@R"6["K,]_9VL1DN;N"&-4\PO)(%
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M&>*MS^"+ORS9V]Q8M:/<6]PTUS;M)<!HBG 8MSQ& "<D9[T =I1110 4444
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M:VQ^W,+7(N[CS%V@[AME!.\[N0 W)%>D44 <9X%TZZT.>[TN338X(HP"UQ'
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M!(MQ=R3;D1I0@^=CC:$7_)KM:KR6$$M[;W3IF6W#^7SP"V 3CUQQGW/K5B@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "HH?O2_P"__05+44/WI?\ ?_H* ):*** "HKC_ %/_  (?
MS%2U%<?ZG_@0_F* ):*** "BBB@")/\ CXE^BU+42?\ 'Q+]%J6@ HHHH CN
M/^/:3_=-2#I4=Q_Q[2?[IJ0=* "BBB@ J(?\?9_W!_.I:B'_ !]G_<'\Z ):
M*** "FR?ZMOI3J;)_JV^E "0_P"HC_W1_*GTR'_41_[H_E3Z "BBB@ HHHH
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M2OY#28\U2H&%/& >0,U0ATNYN/#7B>&WM[J**]1C;!HA!*Q\K;M"    @ '
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ% ^H6JS3;?*C,ZAI-V=N!GG.#C'7%-U#54T^2.+[/-<S2(\BQ0[<E4QGEB
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MW/\ J%>509?]T9YZ]JIP^)=(E2]=K^WACL;C[-.\LJJJO@'&<^_?T- &J
M , = **JOJEA%<1027ULDTV/*C:90TF>F!GG\*HV/BC3=1FF6VES' 9A+.67
MRXS$X5@3GCKD>W/% &Q16?%KNG7%U;0VES'=&YW;'@=74;1DY(-1P^)-)E6^
M9KZ")+"X^SSO+*JJCX!QG/'7'/<&@#4HJF-7TTD :A:DE&< 3KRHZGKT&#DT
MT:YI)LVNQJEF;92 TWVA-@)Z?-G% %ZBLR3Q'I4.IFQFO8(Y%M1=EGE4*(R<
M!LY_^M5FUU&"[NKFWA)+VY3<>,,&7<K ]Q_@: +5%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !4<7WI?]_P#H*DJ.'[TO^_\
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M^H:J-.MYK>W6[OD2Y7RU?RQ;X/F-SSD,-O\ P-..M '94444 %%%% !1110
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MC]<U9TO1I+'4;J^NM0FO;BYCCB8R(JJJH6(P% _OG- &K1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*XI=$O\ SM0M?L\@MM=NY_M;Y \E58J&_P"!QJ%_(^M=K7,#Q5/Y.N9M4\^R
MF:.S0,?](_A7/OYF0<=L'O0!G:?_ &_#H]MI4UK=+.?LY$@4&-(A"@D0MV.Y
M7&.OS"LS^Q]4TFPN;Y(IXI(X(7#.581%+)E)7.=I#X''\JZVS\4VUSH$=^P(
M=O*C90IQYDD:N /;YQS61;^-I9]WV^R6&UC6)IF*%O,5[9I6" $\@CN.GO0,
MA6WUB[CA%HFHRQ*]O*YU(@GSED!++C^'&2<?+TV]ZN^$1X@%\PUEIRGD?O\
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M D/^HC_W1_*GTR'_ %$?^Z/Y4^@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *PEM=!\U[T2H3I%Q/)*_FG$,CC?)N_!LX/3
MC%;M<D/#5Z;J=&$?V74[J9]0&_DQAR8R/4LN%/M]* +MKX9T5(;>YM6F^R+$
MCI&)V\I@J;4<KW(7'/L/2J4^F>'KRQ:RL;E5FN8TB@)=F^8VS*G_ )"R?_KU
M7L=%UZWTZ#2YHP4W02O=+<<($B16CV]>63MQAJH3>%M1TS2[VYA412FWC\QH
M92&;9:-&>G^V1C\Z .E/AW2;..-M0EFF)>*)&N9V?!# JBY[%L<=^,U;TOP_
M9:/,TEH9ON>6BO*66-?[JC\ORKFX/#NIRI&;2U_LV-3 SJ]T9O,D5PQEY] #
MUP6SR!BK7A'0]7TN^9]1=]@@\N0EP1<29'[S@DGH>3@_-T] "\MKX>1)-0\Y
M-FDR7/G2&4XB9LM+N^FX]>F>*+/PMIWGS3;$FM)K".RBC))'D@<YSU)&T9]%
M%9P\+WS^?;N(Q::E-/)?C?D_?8QX'?*E WLN*JP:-K4T,VDPW9MC;6*RK,KL
M=EV\6S;GNH(9_JX]* -P^'-&M?*ANVEF-Q-MC6XE+;V\J1=N.GW&D_R!5BW\
M,V$$B2.US<21NC))/.SLH3)503VY/U[US-IX8UT18B<V96;=$'=3Y;>1,GF
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M1RX8C+LH ("G/![8SFI;?5]3N]+UUBL-I>6MS]GMTED4HK&*(@;NARSG!/J
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M** "FR?ZMOI3J;)_JV^E "0_ZB/_ '1_*GTR'_41_P"Z/Y4^@ HHHH ****
M.8UWPU/J?B!-14[XXK=(_LYG=$GPY+(X7@K@C&<\CIC-8M_X;U%-9LY)[6+4
M(IKIBT#3,%=0+IP'.,8_>)@'(R,>E>@T4 <=;>&M5AC:6)X8)HH]]G!YS-'
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M1110 4444 %%%% !1110 4444 %%%% !1110 5'#]Z7_ '_Z"I*CA^]+_O\
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MC(R!F@#=HK(G\2V,:N8',S12Q1S+@J4$C*N>1SC<,@<COBM>@ HHHH ****
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MU.#[5W-%%.I5G5?--W)I4H4H\L%9!11169J11_Z^;ZC^52U%'_KYOJ/Y5+0
M4444 1W/_'K+_N'^52#H*CN?^/67_</\JD'04 %%%% !47_+Y_VS_K4M1?\
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M9Q)&Q(# =P<']0: ):*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "HXO\ 63?[_P#[**DJ.+_63?[_ /[** )**** "HKG_4'Z
MK_,5+45S_J#]5_F* ):*** "BBB@"*/_ %\WU'\JEJ*/_7S?4?RJ6@ HHHH
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M_F*EJ*Y_U!^J_P Q0!+1110 4444 11_Z^;ZC^52U%'_ *^;ZC^52T %%%%
M$=S_ ,>LO^X?Y5(.@J.Y_P"/67_</\JD'04 %%%% !47_+Y_VS_K4M1?\OG_
M &S_ *T 2T444 %(?NFEI#]TT ,MO^/6+_<'\JDJ.V_X]8O]P?RJ2@ HHHH
M**** .#^('C^[\)7R6UK'IJ 6,MX9-2N&B6<H<>3%@'=(>N/2LD_$_63I;7K
M6FD6L$FH+8Q7-W<ND,)\KS&>9L?*.0JXZD\XKOM?U"TTVSCGO+0W9,@5(UC#
MMZLP![!0S'V%<WXFOM+U&_'AZ=)8HF>!]]EJ'V>5S(<*51<%P.I]N>U SE[C
MXS:FEGIDD6F:<'NDED9IKORXYMDQC$<3-C+$+GGU'%;#_$36$UUX9K+3;33F
MO9M/CN)YVWQRI;&<-(!\NP8(.#GTK;T7[)IVFV=GI/A^271K>0QPW#2*\A.[
MF4*WS,"V26SD]<8K3AU&UOM3;36T]6GC9VN4=01$.BN3CG>.GMGT- &9X!\8
M7'C#2[J]N[:"S:*146U5V,BC8#O;('RMG*\<K@]\"G;W,T7]F:K/<7URYTJZ
MO9+=+EPLKHT14; <<"1AT].N!73K>QQ^)3IPM C26OGBX4CY@K!=I'7C<,5D
M6NLQZ9X6CNK?3F5(99HF66X4+ $=@Q,AX RN /<"@10OO$.JW&GR16MYIS3!
M[647-F6:-5>95,;<]??/(SP*-1\7WJ+\DEA&MQ<36BV_F,+F':K_ #GMGY,X
MP, CD]^B^W6=MI%I=6]EM6^DBV0B,(2TA&"1Z@<GZ55O_$6@6EMJ5^&@GFL8
M'EFV)EW"<$ XYP<#C..] $=WKES:66DPQ3VD$MW;&1KJ_8^6"JJ=O!&6.[/4
M< GFHO#^I7VK>)KFYG<1VO\ 9MO)'; L=C.\F6ZX.=G!QG&.G-77U_0YD@M=
M1GM5DD$?[B3YE5F VKDC&3D8'!YZ4]_%7A^&602:G:QLBG<S-M!"]<'H0.<X
MZ4 4/#6O3:IK%VER%_?)YT*QS[Q#&K;-CK@;')R>^>?[M4+3QO=M8PWLR6%T
M)XI7%I9R,98=BLV7)SP=N#P,%A]ZM*R\5Z5/JLT%A$FWS4\ZXR(U(:(R!SG!
M;@8]>_2F6&M^'K&.WM]'D@F(VQR-O"ND6"0[%L%EX_'MTH HWVOZK<0BWM;S
M3VE6YLF^U6A9HRDDP4QGYNO'7/(/05&WCR_#WC#3H]L8N/+A=@K(8@V"YW$G
M.WH%&,CK6[:>(O#3*D5E>68621=JQK@%C]UNG0G&&Z'UJ>/5-"DU&YBCN+3[
M4JMYQ( )"_>RW?'?GCO0!@ZCK&MBZM[%YK6"XCOK0RO K[7BEW_)R<Y!0\]^
M.!51/&-Y9>'Q.DMF!:6\!:._F8SW)=5.X,,>N <'<0>E;C^+])DO"EJ!<A1"
MSR*,;0\OEJ<'GJ<Y],XK=:SMG='>WB9D&$)0$J/0>E '+7-_J1\&P3VEV$N6
MU,1&64%LI]K*;>".V!]*J:IXYO;"$7,8TUE>>:%;)Y&%Q'Y:2-EO<F/I@8#=
M3W[CRTV[=B[<YQCC.<_SJ,V=LTS2M;Q&1AAG*#)^IH X^]\7:M86=S+<_P!D
MQ36<<1D@=W!G+J&_=\YVC=M!P=Q4_=H3QAJ%YJ%U:1VJ0*QN(8M^ \31JV';
MY\D$K]T*" 1R:Z"_\.66I7R7-T]P0NW,(D^1L=!CL..0" >^:T1;0"=IA!&)
M7&&DV#<P]": .%3Q)J1T-K6XN8?M":.MW'-"Q\QW5%8YY..H&#C.<@G.!WRG
M<H/J,U5N],M+V!XIHE"R*JL4&TE000N1VXZ5;H **** "BBB@ HHK%/B2)?$
M4NG/$1!&A'VK=D&95WM'M]0A#9^H[&@#:HKG]:\7V>EZ;%<P)+=M-]G=(XXG
M),<TJQAN%/\ >SC\.])?>,+"&"[%HQ>>%)3$TT<D<$KQ@ED$NT@D;3G&3P>#
MB@#H:*YX>-]&,S1![IY SH!'93,)&0X=4(7YBO?'H:5_&^AI<>4+B:0DH \=
MK*Z%G7<B;@N-S C ZG.* .@HK)B\3:7+97%TL[K';0&>8/$ZM&H+ Y4C((*,
M,=>*HW?C;3EM[K[ QDFA\Q5,\4L4+M&V'42;""1SP,]* .DHKG],\765ZM\;
ME);,V<MPI\Z)U#)"P#."0,]1P,UO1R"6))%W!74,-P(//J#TH =1110 4444
M %%%9>M:[!HDFG+<1NXOKL6P9,?N\HS;VS_#\N/Q% &I16-#XFLI?%%UH;9C
MGMTB(=B-LK.'.U?<!,GZTMUXMT"Q_P"/O5;>(88EBW"A6*DL>BC((R>N#B@#
M8HK!OO&6DV<ENB3B=IKU;(B/)V.0QYXZ?*1_^JETWQCHNHZ:;M+Z&,1PK-*K
M-_JPW'7H>>.,\\=: -VBL>7Q9H4%O#--J4*+.6$8.=S%<;AMQG(R">. <TT^
M*M-B\]KR>."))A%"XD$GGCRU?< N2!A^_P!>A% &U167<>(+1=)@OK _VBMV
MXCM5MF!\]CG !Z <$DG@ $U7'B9+&*1O$EN-(*R)&CO,)(Y6;.U48=6X/RD
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M1110 5%<_P"H/U7^8J6HKG_4'ZK_ #% $M%%% !1110!%'_KYOJ/Y5+44?\
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M66V5VCYR520\JO7MD D CC%O_A&H&NI+F:9WEN-PNR,KYZG[J\'(V8&W'O\
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MQ][>FS.>V 3^=:-<OXOGU"TN+2XTH,9XX+C82A= QV ;@.O>@""^\&S)I?\
MH-]-+J?DI$+M]JMYGG>9YY[9!9C@=02.]37_ (*\ZSN[+3-2>PL[ZV6WN8Q
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M??\ $+0_E_ 3_A']-_YXO_W^?_&C_A']-_YXO_W^?_&E\S6_^?6P_P# E_\
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M5O\ \]XO^^Q4']CZ9_T#K3_OPO\ A1_8^F?] ZT_[\+_ (4>Z'OD_P!JM_\
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M_P"7S_MG_6I:B_Y?/^V?]: ):*** "D/W32TA^Z: &6W_'K%_N#^525';?\
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M.P4$\XH QX/#.I:=8PVWV*_N;8-=,L-IJ1B:*5YV9)&8N,KL([G:<_*<TO\
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M:ID]UK45O)(FFV<C(A8(MXY+$#H/W5/D?],.=?TF7H_]?-]1_*I:\C\$>/\
MQ)K'C<6-_$LL$Q;S8UAVFWP#SGK[<UZY5UJ,J,N61E0Q$*\>: 4445B=!'<_
M\>LO^X?Y5(.@J.Y_X]9?]P_RJ0=!0 4444 %1?\ +Y_VS_K4M1?\OG_;/^M
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M@[^ W49&T CDFLM_%>M:QX?U*-6AMIUM/.WQ!2UJ^]1Y9"3,V<$\D(1M/'8
M'I-%9&D/-_:NKPRR-(L<\94G. 3$FX#).!GG'O6O0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7%G:1S?N+99V,T3PM\S, -CJ#CY<@]#527P7:WC&75+Z[O;ALAIG*(2-C(
MB@#&XD8&<U<T[0&L[^>\NM3O-0GG@6 M.(P%122,!%49^8Y- &=X7\:1>((X
M&G.GQ-<HC116MVT[ LI;:^8U"D 'N<X-:,?BO1I9XXHKIG\S;B18)#&NXX4,
M^W:A/8,1G(QU%9D_A"Z'AI-(BU>ZN$C\F."281HULB$ LI1 2VW(YI]S\/\
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M9*@@9ZT ;M%8EMX@SH-C>7,#RW-X=D=O;+EG;DX&X@ 84G)(''6H;;Q)+?\
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M F!D'- &Y%X6T=K614226VG@>%$-P[)'&X^81C.%!'IVZ5)>>%],OKAY9UG
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MR-IZDGCDFC6O"%XS7*V-UJ,\<UC=R3?Z4$^TW+(B1!P-H.%4@# 7CF@#H/\
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MJI=!_?4'(]0".]<;I'B_Q%-86D]M?7%].\NC[()+CRQ-YOG;U+8.-VU<\=J
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M1DD@M]\<C'<8[T >AT5D:!<3S?VFEQ*9?(U"6.,DYPO# ?AN(_"M>@ HHHH
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M-G8Q+#;PKMC1>BBIZ**3;;NQI)*R"BBBD,BC_P!?-]1_*I:BC_U\WU'\JEH
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MY43!8?Y%:%%%2VWN4HJ*LD%%%%(84444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %1Q?ZR;_?\ _914E1Q?ZR;_ '__ &44 24444 %17/^H/U7^8J6
MHKG_ %!^J_S% $M%%% !1110!%'_ *^;ZC^52U%'_KYOJ/Y5+0 4444 1W/_
M !ZR_P"X?Y5(.@J.Y_X]9?\ </\ *I!T% !1110 5%_R^?\ ;/\ K4M1?\OG
M_;/^M $M%%% !2'[II:0_=- #+;_ (]8O]P?RJ2H[;_CUB_W!_*I* "BBB@
MHHHH X[Q;>ZU:>+_  Y!INK_ &.RO99$N8?LJ2%A&AD.&/(R!MX^M96G?%V/
M4;.XO4\/7Z64<0N4N"05>#>%9SQ\I .[;W //%=AJEUI,&K:<NHP/)=^8WV-
MUM))=KE2#AE4A3M!SDC@$]*++PKH.G37DMAH]E;27P*W+10*IF!SD-@<@Y-
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M:5M=07MK'<6DJ30R#<DB'(8>QH EHHHH **** "BBB@ HHHH **** "BBB@
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MP=NXC). 20,^PJROAZU74KF]$DWF7*2HXR, 2",'''_3)?S-:U% '/P^$;>
M)#'?78LPT;O:939(Z 88G;N'W5) (!(Z<FDA\(6\"B&&^NUM&V&>VRA6<H
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M:U:BN?\ 4'ZK_,4<S_I!R+^FRIY&L?\ 00LO_ )O_CM'D:Q_T$++_P  F_\
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M/DHJL4EW_P 6<*?0[\#!KKM,6Y33+<7\XN+G8#)((]@8GGA>P[5:HH ****
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M #9)QD'%5K>POH_B%J.HO$@B^W.+9UA82RN+9,1-(6P(SDD?+]Y3R#C/HE%
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MGM21R)-&LD3JZ,,JRG((]0:\GCA\=11>'Q<2ZW>/<Q2-J$;1V_E(6R-KY&0
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MNBV=G-9RP*P:SMFM8<L3B-BA(/J<QKS6A0 4444 %%%% !1110 5'%_K)O\
M?_\ 914E9\FF6]W=32RM<!MP'[NZD0?='96 IJW43OT-"BL[^P[/^_>?^!TW
M_P 71_8=G_?O/_ Z;_XNG:/?^OO)O/M^/_ -&HKG_4'ZK_,53_L.S_OWG_@=
M-_\ %U'<:)9B$X>\ZC_E^F]1_MT6CW_K[PO/M^/_  #5HK._L.S_ +]Y_P"!
MTW_Q=']AV?\ ?O/_  .F_P#BZ+1[_P!?>%Y]OQ_X!HT5G?V'9_W[S_P.F_\
MBZ/[#L_[]Y_X'3?_ !=%H]_Z^\+S[?C_ , N1_Z^;ZC^52UE)HEF9I1NO."/
M^7Z;T_WZD_L.S_OWG_@=-_\ %T6CW_K[PO/M^/\ P#1HK._L.S_OWG_@=-_\
M71_8=G_?O/\ P.F_^+HM'O\ U]X7GV_'_@$?B+7=/\/Z/)=:I/Y4;910!EF8
MCH!WJ30]>T_Q%IJWNE3^=#G:<C!4CL0>AKG_ !EX"MO$.BB."ZG@G@8R1O--
M),O3D$,QQ]15SP/X17P?HTEJ;G[3-/)YDKA<+G&  *W<:/L;I^\8*5?VW*XK
MDMN=+1117,=05%_R^?\ ;/\ K4M1?\OG_;/^M $M%%% !2'[II:0_=- #+;_
M (]8O]P?RJ2H[;_CUB_W!_*I* "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *CB_P!9-_O_ /LHJ2JS-<132>7;
M^8K$$-Y@'8#^E %FBJOGW?\ SY?^111Y]W_SY?\ D44 6JBN?]0?JO\ ,5%Y
M]W_SY?\ D44R62[DC*BSYR#_ *T>M %VBJOGW?\ SY?^111Y]W_SY?\ D44
M6J*J^?=_\^7_ )%%'GW?_/E_Y%% $L?^OF^H_E4M4EENUD=OL?WL8_>CTI_G
MW?\ SY?^110!:HJKY]W_ ,^7_D44>?=_\^7_ )%% $US_P >LO\ N'^52#H*
MI2RW;PN@L^64@?O1Z4_S[O\ Y\O_ "** +5%5?/N_P#GR_\ (HH\^[_Y\O\
MR** +51?\OG_ &S_ *U%Y]W_ ,^7_D44SS+OS]_V/C;C_6CUH NT55\^[_Y\
MO_(HH\^[_P"?+_R** +5(?NFJWGW?_/E_P"1109[LC_CR_\ (HH FMO^/6+_
M '!_*I*9"I2"-6ZJH!_*GT %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
/!1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381107117504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Aug. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-32335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">HALOZYME THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">88-0488686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11388 Sorrento Valley Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">794-8889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HALO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,779,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001159036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381106731344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 90,932,000<span></span>
</td>
<td class="nump">$ 118,719,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">118,428,000<span></span>
</td>
<td class="nump">622,203,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net and contract assets</a></td>
<td class="nump">189,368,000<span></span>
</td>
<td class="nump">90,975,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">97,615,000<span></span>
</td>
<td class="nump">53,908,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">45,595,000<span></span>
</td>
<td class="nump">40,482,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">541,938,000<span></span>
</td>
<td class="nump">926,287,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">37,091,000<span></span>
</td>
<td class="nump">8,794,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Prepaid expenses and other assets</a></td>
<td class="nump">26,283,000<span></span>
</td>
<td class="nump">13,414,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">199,481,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">976,097,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">155,434,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,781,390,000<span></span>
</td>
<td class="nump">1,104,429,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">12,232,000<span></span>
</td>
<td class="nump">1,541,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">84,101,000<span></span>
</td>
<td class="nump">24,441,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, current portion</a></td>
<td class="nump">4,131,000<span></span>
</td>
<td class="nump">1,746,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt, net</a></td>
<td class="nump">99,048,000<span></span>
</td>
<td class="nump">89,419,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">199,512,000<span></span>
</td>
<td class="nump">117,147,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">2,739,000<span></span>
</td>
<td class="nump">2,530,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net</a></td>
<td class="nump">1,147,129,000<span></span>
</td>
<td class="nump">787,255,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">5,551,000<span></span>
</td>
<td class="nump">544,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred Income Tax Liabilities, Net</a></td>
<td class="nump">3,288,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent liability</a></td>
<td class="nump">130,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock - $0.001 par value; 20,000 shares authorized; no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, Value, Issued</a></td>
<td class="nump">138,000<span></span>
</td>
<td class="nump">138,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">271,169,000<span></span>
</td>
<td class="nump">256,347,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(2,017,000)<span></span>
</td>
<td class="num">(620,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings (accumulated deficit)</a></td>
<td class="nump">23,881,000<span></span>
</td>
<td class="num">(58,912,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">293,171,000<span></span>
</td>
<td class="nump">196,953,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,781,390,000<span></span>
</td>
<td class="nump">$ 1,104,429,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property, Plant, and Equipment and Operating Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381106707680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">137,681,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">137,681,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381112549408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 152,365<span></span>
</td>
<td class="nump">$ 136,455<span></span>
</td>
<td class="nump">$ 269,644<span></span>
</td>
<td class="nump">$ 225,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">33,943<span></span>
</td>
<td class="nump">23,018<span></span>
</td>
<td class="nump">49,865<span></span>
</td>
<td class="nump">41,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangibles</a></td>
<td class="nump">11,403<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,403<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">15,483<span></span>
</td>
<td class="nump">8,069<span></span>
</td>
<td class="nump">27,336<span></span>
</td>
<td class="nump">17,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">57,476<span></span>
</td>
<td class="nump">12,321<span></span>
</td>
<td class="nump">71,310<span></span>
</td>
<td class="nump">23,380<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">118,305<span></span>
</td>
<td class="nump">43,408<span></span>
</td>
<td class="nump">159,914<span></span>
</td>
<td class="nump">81,695<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">34,060<span></span>
</td>
<td class="nump">93,047<span></span>
</td>
<td class="nump">109,730<span></span>
</td>
<td class="nump">143,782<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Investment and other (expense) income, net</a></td>
<td class="num">(945)<span></span>
</td>
<td class="nump">221<span></span>
</td>
<td class="num">(447)<span></span>
</td>
<td class="nump">497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InducedConversionOfConvertibleDebtExpense', window );">Inducement expense related to convertible notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(20,960)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(3,104)<span></span>
</td>
<td class="num">(1,752)<span></span>
</td>
<td class="num">(4,863)<span></span>
</td>
<td class="num">(3,717)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net income before income taxes</a></td>
<td class="nump">30,011<span></span>
</td>
<td class="nump">91,516<span></span>
</td>
<td class="nump">104,420<span></span>
</td>
<td class="nump">119,602<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">7,326<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="nump">21,627<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 22,685<span></span>
</td>
<td class="nump">$ 91,458<span></span>
</td>
<td class="nump">$ 82,793<span></span>
</td>
<td class="nump">$ 119,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (USD per share)</a></td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="nump">$ 0.64<span></span>
</td>
<td class="nump">$ 0.60<span></span>
</td>
<td class="nump">$ 0.85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (USD per share)</a></td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="nump">$ 0.62<span></span>
</td>
<td class="nump">$ 0.58<span></span>
</td>
<td class="nump">$ 0.81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Shares used in computing net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (shares)</a></td>
<td class="nump">137,937<span></span>
</td>
<td class="nump">142,487<span></span>
</td>
<td class="nump">137,798<span></span>
</td>
<td class="nump">140,201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (shares)</a></td>
<td class="nump">142,216<span></span>
</td>
<td class="nump">147,624<span></span>
</td>
<td class="nump">141,795<span></span>
</td>
<td class="nump">148,096<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 85,340<span></span>
</td>
<td class="nump">$ 45,778<span></span>
</td>
<td class="nump">$ 154,945<span></span>
</td>
<td class="nump">$ 82,701<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">46,300<span></span>
</td>
<td class="nump">30,360<span></span>
</td>
<td class="nump">68,440<span></span>
</td>
<td class="nump">52,126<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=halo_CollaborativeAgreementsMember', window );">Revenues under collaborative agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 20,725<span></span>
</td>
<td class="nump">$ 60,317<span></span>
</td>
<td class="nump">$ 46,259<span></span>
</td>
<td class="nump">$ 90,650<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InducedConversionOfConvertibleDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 40<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123467568&amp;loc=d3e6835-112609<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InducedConversionOfConvertibleDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=halo_CollaborativeAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=halo_CollaborativeAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381113263120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 22,685<span></span>
</td>
<td class="nump">$ 91,458<span></span>
</td>
<td class="nump">$ 82,793<span></span>
</td>
<td class="nump">$ 119,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">732<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1,439)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized gain on foreign currency</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive income</a></td>
<td class="nump">$ 23,459<span></span>
</td>
<td class="nump">$ 91,443<span></span>
</td>
<td class="nump">$ 81,396<span></span>
</td>
<td class="nump">$ 119,307<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32262-110900<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30755-110894<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381112518512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 82,793<span></span>
</td>
<td class="nump">$ 119,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">10,377<span></span>
</td>
<td class="nump">10,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,921<span></span>
</td>
<td class="nump">1,473<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangibles</a></td>
<td class="nump">11,403<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">2,082<span></span>
</td>
<td class="nump">1,706<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Accretion of discounts on marketable securities, net</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">945<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Realized loss on marketable securities</a></td>
<td class="nump">1,727<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of equipment</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Recognition of deferred revenue</a></td>
<td class="num">(1,122)<span></span>
</td>
<td class="num">(499)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_DeferredRentPayments', window );">Lease payments deferred</a></td>
<td class="num">(394)<span></span>
</td>
<td class="num">(385)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InducedConversionOfConvertibleDebtExpense', window );">Induced conversion expense related to convertible notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,960<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred income taxes</a></td>
<td class="num">(372)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net and other contract assets</a></td>
<td class="num">(32,252)<span></span>
</td>
<td class="num">(55,466)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(9,025)<span></span>
</td>
<td class="nump">2,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(9,319)<span></span>
</td>
<td class="num">(5,831)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">29,323<span></span>
</td>
<td class="nump">207<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">88,022<span></span>
</td>
<td class="nump">95,185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(225,689)<span></span>
</td>
<td class="num">(241,926)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">725,995<span></span>
</td>
<td class="nump">152,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions of business, net of cash acquired</a></td>
<td class="num">(999,120)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,458)<span></span>
</td>
<td class="num">(803)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from the sale of assets</a></td>
<td class="nump">16,021<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(484,251)<span></span>
</td>
<td class="num">(89,866)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from term loan</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Proceeds from revolving credit facilities</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from issuance of 2027 Convertible Notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">784,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSecuredDebt', window );">Repayment of 2024 Convertible Notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(369,064)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance cost</a></td>
<td class="num">(6,003)<span></span>
</td>
<td class="num">(424)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(125,021)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised', window );">Proceeds from issuance of common stock under equity incentive plans, net of taxes paid related to net share settlement</a></td>
<td class="nump">4,445<span></span>
</td>
<td class="nump">3,578<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">368,442<span></span>
</td>
<td class="nump">293,944<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents and restricted cash</a></td>
<td class="num">(27,787)<span></span>
</td>
<td class="nump">299,263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">119,219<span></span>
</td>
<td class="nump">148,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">91,432<span></span>
</td>
<td class="nump">447,466<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Amounts accrued for purchases of property and equipment</a></td>
<td class="nump">336<span></span>
</td>
<td class="nump">242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligation</a></td>
<td class="nump">217<span></span>
</td>
<td class="nump">318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Common stock issued for induced conversion related to convertible notes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 7,865<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_DeferredRentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Rent Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_DeferredRentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From (Payments) for Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InducedConversionOfConvertibleDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 40<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123467568&amp;loc=d3e6835-112609<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InducedConversionOfConvertibleDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381108761856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income/(Loss)</div></th>
<th class="th"><div>Retained Earnings (Accumulated Deficit)</div></th>
<th class="th">
<div>Retained Earnings (Accumulated Deficit) </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 151,047<span></span>
</td>
<td class="num">$ (52,562)<span></span>
</td>
<td class="nump">$ 135<span></span>
</td>
<td class="nump">$ 625,483<span></span>
</td>
<td class="num">$ (65,535)<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="num">$ (474,593)<span></span>
</td>
<td class="nump">$ 12,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">10,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock for the induced conversion related to convertible notes</a></td>
<td class="nump">13,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">13,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock for the induced conversion related to convertible notes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units, net and shares issued under the ESPP plan</a></td>
<td class="nump">3,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">3,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchase of common stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,813)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchase of common stock</a></td>
<td class="num">(125,021)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
<td class="num">(125,018)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(46)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(46)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">119,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, ending balance at Jun. 30, 2021</a></td>
<td class="nump">119,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142<span></span>
</td>
<td class="nump">461,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="num">(342,267)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, beginning balance at Mar. 31, 2021</a></td>
<td class="nump">67,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 143<span></span>
</td>
<td class="nump">501,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(433,725)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">5,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units, net and shares issued under the ESPP plan</a></td>
<td class="nump">4,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">4,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchase of common stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,517)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchase of common stock</a></td>
<td class="num">(48,842)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">(48,840)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">91,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, ending balance at Jun. 30, 2021</a></td>
<td class="nump">119,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142<span></span>
</td>
<td class="nump">461,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="num">(342,267)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, beginning balance at Dec. 31, 2021</a></td>
<td class="nump">196,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
<td class="nump">256,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(620)<span></span>
</td>
<td class="num">(58,912)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">10,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units, net and shares issued under the ESPP plan</a></td>
<td class="nump">4,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">4,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchase of common stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(433)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchase of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(1,397)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,397)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">82,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, ending balance at Jun. 30, 2022</a></td>
<td class="nump">293,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
<td class="nump">271,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,017)<span></span>
</td>
<td class="nump">23,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, beginning balance at Mar. 31, 2022</a></td>
<td class="nump">260,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
<td class="nump">261,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,791)<span></span>
</td>
<td class="nump">1,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">5,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units, net and shares issued under the ESPP plan</a></td>
<td class="nump">3,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchase of common stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(433)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchase of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">22,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, ending balance at Jun. 30, 2022</a></td>
<td class="nump">$ 293,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
<td class="nump">$ 271,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,017)<span></span>
</td>
<td class="nump">$ 23,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33775-111570<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381113581456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Business<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Business</a></td>
<td class="text">Organization and Business <div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Halozyme Therapeutics, Inc. is a biopharma technology platform company that provides innovative and disruptive solutions with the goal of improving patient experience and outcomes. Our proprietary enzyme, rHuPH20, is used to facilitate the delivery of injected drugs and fluids. We license our technology to biopharmaceutical companies to collaboratively develop products that combine our ENHANZE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> drug delivery</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">technology with the partners&#8217; proprietary compounds.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our first commercially approved product, Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> recombinant, (&#8220;Hylenex&#8221;), and our partners&#8217; approved products and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 is the active ingredient in Hylenex and it works by breaking down hyaluronan (or &#8220;HA&#8221;), a naturally occurring carbohydrate that is a major component of the extracellular matrix of the subcutaneous (SC) space. This temporarily increases dispersion and absorption allowing for improved SC delivery of injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as our ENHANZE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> drug delivery technology (&#8220;ENHANZE&#8221;). We license the ENHANZE technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the SC route of administration. In the development of proprietary intravenous (IV) drugs combined with our ENHANZE technology, data have been generated supporting the potential for ENHANZE to reduce patient treatment burden, as a result of shorter duration of SC administration. ENHANZE may enable fixed-dose SC dosing compared to weight-based dosing required for IV administration, and potentially allow for lower rates of infusion related reactions.&#160;ENHANZE may enable more flexible treatment options such as home administration by a healthcare professional or potentially the patient. Lastly, certain proprietary drugs co-formulated with ENHANZE have been granted additional exclusivity, extending the patent life of the product beyond the patent expiry of the proprietary IV drug.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have ENHANZE collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (&#8220;Roche&#8221;), Baxalta US Inc. and Baxalta GmbH (members of the Takeda group of companies) (&#8220;Baxalta&#8221;), Pfizer Inc. (&#8220;Pfizer&#8221;), Janssen Biotech, Inc. (&#8220;Janssen&#8221;), AbbVie, Inc. (&#8220;AbbVie&#8221;), Eli Lilly and Company (&#8220;Lilly&#8221;), Bristol-Myers Squibb Company (&#8220;BMS&#8221;), Alexion Pharma International Operations Unlimited Company (an indirect wholly owned subsidiary of AstraZeneca PLC (&#8220;Alexion&#8221;), argenx BVBA (&#8220;argenx&#8221;), Horizon Therapeutics plc. (&#8220;Horizon&#8221;), ViiV Healthcare (the global specialist HIV Company majority owned by GlaxoSmithKline) (&#8220;ViiV&#8221;) and Chugai Pharmaceutical Co., Ltd (&#8220;Chugai&#8221;). In addition to receiving upfront licensing fees from our ENHANZE collaborations, we are entitled to receive event and sales attainment milestone payments, revenues from the sale of bulk rHuPH20 and royalties from commercial sales of approved partner products co-formulated with ENHANZE.  We currently receive royalties from three of these collaborations, including royalties from sales of one product from the Baxalta collaboration, three products from the Roche collaboration and one product from the Janssen collaboration. Future potential revenues from ENHANZE collaborations and from the sales and/or royalties of our approved products will depend on the ability of Halozyme and our partners to develop, manufacture, secure and maintain regulatory approvals for approved products and product candidates and commercialize product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our recent acquisition of Antares Pharma, Inc. (&#8220;Antares&#8221;), we also develop, manufacture and commercialize, for ourselves or with our partners, drug-device combination products using our advanced auto-injector technologies that are designed to provide commercial or functional advantages such as convenience, improved tolerability, and enhanced patient comfort and adherence. Also, as a result of our acquisition of Antares, our commercial portfolio of proprietary products includes XYOSTED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, TLANDO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and NOCDURNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and partnered commercial products and ongoing product development programs with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (&#8220;Teva&#8221;), Covis Group S.a.r.l. (&#8220;Covis&#8221;), Pfizer and Idorsia Pharmaceuticals Ltd. (&#8220;Idorsia&#8221;).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except where specifically noted or the context otherwise requires, references to &#8220;Halozyme,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; and &#8220;us&#8221; in these notes to the condensed consolidated financial statements refer to Halozyme Therapeutics, Inc. and its wholly owned subsidiaries, Halozyme, Inc. and Antares Pharma, Inc., Halozyme, Inc.&#8217;s wholly owned subsidiary, Halozyme Switzerland Holdings GmbH and Antares Pharma, Inc.&#8217;s wholly owned subsidiaries Antares Pharma IPL AG and Antares Pharma AG.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381113786320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and with the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) related to a quarterly report on Form 10-Q. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for a complete set of financial statements. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC on February&#160;22, 2022. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operations for the periods presented, with such adjustments consisting only of normal recurring adjustments. Operating results for interim periods are not necessarily indicative of the operating results for an entire fiscal year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim unaudited condensed consolidated financial statements include the accounts of Halozyme Therapeutics, Inc. and our wholly owned subsidiaries, Halozyme, Inc. and Antares Pharma, Inc., Halozyme, Inc.&#8217;s wholly owned subsidiary Halozyme Switzerland Holdings GmbH and Antares Pharma, Inc.&#8217;s wholly-owned Swiss subsidiaries, Antares Pharma IPL AG and Antares Pharma AG. All intercompany accounts and transactions have been eliminated. </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of interim unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our interim unaudited condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management&#8217;s estimates.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents and Marketable Securities </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of highly liquid investments, readily convertible to cash, that mature within ninety days or less from the date of purchase. As of June&#160;30, 2022, our cash and cash equivalents consisted of money market funds, bank certificate of deposits and demands deposits at commercial banks.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities are investments with original maturities of more than ninety days from the date of purchase that are specifically identified to fund current operations. Marketable securities are considered available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management&#8217;s intention to use the proceeds from the sale of these investments to fund our operations, as necessary. Such available-for-sale investments are carried at fair value with unrealized gains and losses recorded in other comprehensive income (loss) and included as a separate component of stockholders&#8217; equity. The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in the interim unaudited condensed consolidated statements of income. We use the specific identification method for calculating realized gains and losses on marketable securities sold. None of the realized gains and losses and declines in value that were judged to be as a result of credit loss on marketable securities, if any, are included in investment and other income, net in the interim unaudited condensed consolidated statements of operations.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the leases of our facilities, we are required to maintain letters of credit as security deposits during the terms of such leases. As of June&#160;30, 2022 and December&#160;31, 2021, restricted cash of $0.5 million was pledged as collateral for the letters of credit.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authoritative guidance for fair value measurements establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments include cash equivalents, available-for-sale marketable securities, accounts receivable, prepaid expenses and other assets, accounts payable, accrued expenses, long-term debt and contingent liability. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities consist of asset-backed securities, corporate debt securities, U.S. Treasury securities and commercial paper, and are measured at fair value using Level 1 and Level 2 inputs. Level 2 financial instruments are valued using market prices on less active markets and proprietary pricing valuation models with observable inputs, including interest rates, yield curves, maturity dates, issue dates, settlement dates, reported trades, broker-dealer quotes, issue spreads, benchmark securities or other market related data. We obtain the fair value of Level 2 investments from our investment manager, who obtains these fair values from a third-party pricing source. We validate the fair values of Level 2 financial instruments provided by our investment manager by comparing these fair values to a third-party pricing source.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Inventories are reviewed periodically for potential excess, dated or obsolete status. We evaluate the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price we expect to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into operating leases primarily for real estate and automobiles. These leases have contractual terms which range from 3 years to 12 years. We determine if an arrangement contains a lease at inception. Right of use (&#8220;ROU&#8221;) assets and liabilities resulting from operating leases are included in property and equipment, accrued expenses and other long-term liabilities on our condensed consolidated balance sheets. Operating lease ROU assets and liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the discount rate to calculate the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Our leases often include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that we will exercise that option. Short-term leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as automobiles, we account for the lease and non-lease components as a single lease component.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, we entered into an agreement for assignment and assumption of lease with Seismic Software, Inc. pursuant to which effective January 1, 2023, we will assume Seismic&#8217;s office lease, as amended with Kilroy Realty L.P. for approximately 72,534 square feet of space in office and research facilities which is expected to commence on January 1, 2023. The premises are intended to serve as our new headquarters.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. Costs that we incur to complete the business combination, such as legal and other professional fees, are expensed as they are incurred.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the initial accounting for a business combination is incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date. We record these adjustments to the provisional amounts with a corresponding offset to goodwill. Any adjustments identified after the measurement period are recorded in the consolidated statements of income.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill, Intangible Assets and Other Long-Lived Asset</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets acquired, including intangible assets and in-process research and development (IPR&amp;D), and liabilities assumed are measured at fair value as of the acquisition date. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of the net assets acquired. Intangible assets acquired in a business combination that are used for IPR&amp;D activities are considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon reaching the end of the relevant research and development project (i.e., upon commercialization), the IPR&amp;D asset is amortized over its estimated useful life. If the relevant research and development project is abandoned, the IPR&amp;D asset is expensed in the period of abandonment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and IPR&amp;D are not amortized; however, they are reviewed for impairment at least annually during the second quarter, or more frequently if an event occurs indicating the potential for impairment. Goodwill and IPR&amp;D are considered to be impaired if the carrying value of the reporting unit or IPR&amp;D asset exceeds its respective fair value.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform our goodwill impairment analysis at the reporting unit level, which aligns with our reporting structure and availability of discrete financial information. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair values of our reporting units are less than the carrying amounts, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and our overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair values of our reporting units are less than the carrying amounts, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair values of the reporting units with the carrying values, including goodwill. If the carrying amounts of the reporting units exceed the fair values, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill impairment test.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our identifiable intangible assets with a finite life are typically comprised of acquired device technologies and product rights. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#8217; respective estimated useful lives.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform regular reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant changes in the ability of a particular asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate revenues from payments received (i) as royalties from licensing our ENHANZE technology and other royalty arrangements, (ii) under collaborative agreements and (iii) from sales of our proprietary and partnered products. We recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers we perform the following five steps: (i) identify the promised goods or services in the contract; (ii) identify the performance obligations in the contract, including whether they are distinct in the context of the contract; (iii) determine the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ENHANZE and Device Royalties</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our ENHANZE collaboration and license agreements, our partners will pay us royalties at an on average mid-single digit percent rate of their sales if products under the collaboration are commercialized. All amounts owed to us are noncancelable after the underlying triggering event occurs, and nonrefundable once paid. Unless terminated earlier in accordance with its terms, collaborations generally continue in effect until the last to expire royalty payment term, as determined on a product by product and on a country by country basis, with each royalty term starting on the first commercial sale of that product and ending the later of: (i) a specified period or term set forth in the agreement or (ii) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration. When there are no valid claims during the applicable royalty term in a given country, the royalty rate is reduced for those sales. Partners may terminate the agreement prior to expiration for any reason in its entirety or on a target-by-target basis generally upon 90 days prior written notice to us.&#160;Upon any such termination, the license granted to partners (in total or with respect to the terminated target, as applicable) will terminate provided, however, that in the event of expiration of the agreement (as opposed to a termination), the on-going licenses granted will become perpetual, non-exclusive and fully paid. Sales-based milestones and royalties are recognized in the period the underlying sales or milestones occur. We do not receive final royalty reports from our ENHANZE partners until after we complete our financial statements for a prior quarter. Therefore, we recognize revenue based on estimates of the royalty earned, which are based on internal estimates and available preliminary reports provided by our partners. We will record adjustments in the following quarter, if necessary, when final royalty reports are received. To date, we have not recorded any material adjustments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the royalties received from licensing our ENHANZE technology, we also earn royalties in connection with licenses granted under license and development arrangements with our device partners as a result of our acquisition of Antares. These royalties are based upon a percentage of commercial sales of partnered products with rates ranging from mid-single digits to low double digits and are tiered based on levels of net sales. These sales-based royalties, for which the license was deemed the predominant element to which the royalties relate, are estimated and recognized in the period in which the partners&#8217; commercial sales occur. The royalties are generally reported and payable to us within 45 to 60 days of the end of the period in which the commercial sales are made. We base our estimates of royalties earned on actual sales information from our partners when available or estimated, prescription sales from external sources and estimated net selling price. We will record adjustments in the following quarter, if necessary, when final royalty reports are received. To date, we have not recorded any material adjustments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue under ENHANZE and Device Collaborative Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ENHANZE Collaboration and License Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our ENHANZE collaboration agreements, we grant the partner a worldwide license to develop and commercialize products using our ENHANZE technology to combine our patented rHuPH20 enzyme with their proprietary biologics directed at up to a specified number of targets. Targets are usually licensed on an exclusive, global basis. Targets selected subsequent to inception of the arrangement generally require payment of an additional license fee. The partner is responsible for all development, manufacturing, clinical, regulatory, sales and marketing costs for any products developed under the agreement. We are responsible for supply of bulk rHuPH20 based on the partner&#8217;s purchase orders and may also be separately engaged to perform research and development services. While these collaboration agreements are similar in that they originate from the same framework, each one is the result of an arms-length negotiation and thus may vary from one to the other.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, in general, collect an upfront license payment from partners and are also entitled to receive event-based payments subject to partners&#8217; achievement of specified development, regulatory and sales-based milestones. In several agreements, partners pay us annual fees to maintain their exclusive license rights if they are unable to advance product development to specified stages. We earn separate fees for bulk rHuPH20 supplies and research and development services. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although these agreements are in form identified as collaborative agreements, we concluded for accounting purposes they represent contracts with customers and are not subject to accounting literature on collaborative arrangements. This is because we grant to partners licenses to our intellectual property and provide supply of bulk rHuPH20 and research and development services which are all outputs of our ongoing activities, in exchange for consideration. Under these collaborative agreements, we do not develop assets jointly with partners, and do not share in significant risks of their development or commercialization activities. Accordingly, we concluded our collaborative agreements are appropriately accounted for pursuant to ASC Topic 606, Revenue from Contracts with Customers. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under all of our collaborative agreements, we have identified licenses to use functional intellectual property as the only performance obligation. The intellectual property underlying the license is our proprietary ENHANZE technology which represents application of rHuPH20 to facilitate delivery of drugs or fluids. Each of the licenses grants the partners rights to use </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our intellectual property as it exists and is identified on the effective date of the license, because there is no ongoing development of the ENHANZE technology required. Therefore, we recognize revenue from licenses at the point when the license becomes effective and the partner has received access to our intellectual property, usually at the inception of the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When partners can select additional targets to add to the licenses granted, we consider these rights to be options. We evaluate whether such options contain material rights, i.e. have exercise prices that are discounted compared to what we would charge for a similar license to a new partner. The exercise price of these options includes a combination of the target selection fees, event-based milestone payments and royalties. When these amounts in aggregate are not offered at a discount that exceeds discounts available to other customers, we conclude the option does not contain a material right, and we consider grants of additional licensing rights upon option exercises to be separate contracts (target selection contracts).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide customary indemnification and protection of licensed intellectual property for our customers. These provisions are part of assurance that the licenses meet the agreements&#8217; representations and are not obligations to provide goods or services.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also fulfill purchase orders for supply of bulk rHuPH20 and perform research and development services pursuant to projects authorization forms for our partners, which represent separate contracts. Additionally, we price our supply of bulk rHuPH20 and research and development services at our regular selling prices, called standalone selling price or (&#8220;SSP&#8221;). Therefore, our partners do not have material rights to order these items at prices not reflective of SSP. Refer to the discussion below regarding recognition of revenue for these separate contracts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction price for a contract represents the amount to which we are entitled in exchange for providing goods and services to the customer. Transaction price does not include amounts subject to uncertainties unless it is probable that there will be no significant reversal of revenue when the uncertainty is resolved. Apart from the upfront license payment (or target selection fees in the target selection contracts), all other fees we may earn under our collaborative agreements are subject to significant uncertainties of product development. Achievement of many of the event-based development and regulatory milestones may not be probable until such milestones are actually achieved. This generally relates to milestones such as obtaining marketing authorization approvals. With respect to other development milestones, e.g. dosing of a first patient in a clinical trial, achievement could be considered probable prior to its actual occurrence, based on the progress towards commencement of the trial. In order to evaluate progress towards commencement of a trial, we assess the status of activities leading up to our partner&#8217;s initiation of a trial such as feedback received from the applicable regulatory authorities, completion of IND or equivalent filings, readiness and availability of drug, readiness of study sites and our partner&#8217;s commitment of resources to the program. We do not include any amounts subject to uncertainties into the transaction price until it is probable that the amount will not result in a significant reversal of revenue in the future. At the end of each reporting period, we re-evaluate the probability of achievement of such milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When target exchange rights are held by partners, and the amounts attributed to these rights are not refundable, they are included in the transaction price. However, they are recorded as deferred revenues because we have a potential performance obligation to provide a new target upon an exchange right being exercised. These amounts are recognized in revenue when the right of exchange expires or is exercised.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our agreements have one type of performance obligation (licenses) which are typically all transferred at the same time at agreement inception, allocation of transaction price often is not required. However, allocation is required when licenses for some of the individual targets are subject to rights of exchange, because revenue associated with these targets cannot be recognized. When allocation is needed, we perform an allocation of the upfront amount based on relative SSP of licenses for individual targets. We determine license SSP using income-based valuation approach utilizing risk-adjusted discounted cash flow projections of the estimated return a licensor would receive. When amounts subject to uncertainties, such as milestones and royalties, are included in the transaction price, we attribute them to the specific individual target licenses which generate such milestone or royalty amounts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also estimate SSP of bulk rHuPH20 and research and development services, to determine that our partners do not have material rights to order them at discounted prices. For supplies of bulk rHuPH20, because we effectively act as a contract manufacturer to our partners, we estimate and charge SSP based on the typical contract manufacturer margins consistently with all of our partners. We determine SSP of research and development services based on a fully-burdened labor rate. Our rates are comparable to those we observe in other collaborative agreements. We also have a history of charging similar rates to all of our partners. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront amounts allocated to licenses to individual targets are recognized as revenue when the license is transferred to the partner, as discussed above, if the license is not subject to exchange rights, or when the exchange right expires or is exercised. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development milestones and other fees are recognized in revenue when they are included in the transaction price, because by that time we have already transferred the related license to the partner. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In contracts to provide research and development services, such services represent the only performance obligation. The fees are charged based on hours worked by our employees and the fixed contractual rate per hour, plus third-party pass-through costs, on a monthly basis. We recognize revenues as the related services are performed based on the amounts billed, as the partner consumes the benefit of research and development work simultaneously as we perform these services, and the amounts billed reflect the value of these services to the customer. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Device License, Development and Supply Arrangements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have several license, development and supply arrangements with pharmaceutical partners as a result of our acquisition of Antares, under which we grant a license to our device technology and know-how and provide research and development services that often involve multiple performance obligations and highly customized deliverables. For such arrangements, we identify each of the promised goods and services within the contract and the distinct performance obligations at inception and allocate consideration to each performance obligation based on relative standalone selling price, which is generally determined based on the expected cost plus mark-up. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the contract includes an enforceable right to payment for performance completed to date and performance obligations are satisfied over time, we recognize revenue over the development period using either the input or output method depending on which is most appropriate given the nature of the distinct deliverable. For other contracts that do not contain an enforceable right to payment for performance completed to date, revenue is recognized when control of the product is transferred to the customer. Factors that may indicate that the transfer of control has occurred include the transfer of legal title, transfer of physical possession, the customer has obtained the significant risks and rewards of ownership of the assets and we have a present right to payment. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our typical payment terms for development contracts may include an upfront payment equal to a percentage of the total contract value with the remaining portion to be billed upon completion and transfer of the individual deliverables or satisfaction of the individual performance obligations. We record a contract liability for cash received in advance of performance, which is presented within deferred revenue and deferred revenue, long-term in the Condensed Consolidated Balance Sheets and recognized as revenue in the Consolidated Statements of income when the associated performance obligations have been satisfied. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License fees and milestones received in exchange for the grant of a license to our functional intellectual property such as patented technology and know-how in connection with a partnered development arrangement are generally recognized at inception of the arrangement, or over the development period depending on the facts and circumstances, as the license is generally not distinct from the non-licensed goods or services to be provided under the contract. Milestone payments that are contingent upon the occurrence of future events are evaluated and recorded at the most likely amount, and to the extent that it is probable that a significant reversal will not occur when the associated uncertainty is resolved.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion on our collaborative arrangements.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Proprietary Product Sales</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recombinant</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell Hylenex recombinant in the U.S. to wholesale pharmaceutical distributors, who sell the product to hospitals and other end-user customers. Sales to wholesalers are made pursuant to purchase orders subject to the terms of a master agreement, and delivery of individual packages of Hylenex recombinant represent performance obligations under each purchase order. We use a contract manufacturer to produce Hylenex recombinant and a third-party logistics (3PL) vendor to process and fulfill orders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We concluded we are the principal in the sales to wholesalers because we control access to services rendered by both vendors and direct their activities. We have no significant obligations to wholesalers to generate pull-through sales.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling prices initially billed to wholesalers are subject to discounts for prompt payment and subsequent chargebacks when wholesalers sell Hylenex recombinant at negotiated discounted prices to members of certain group purchasing organizations (&#8220;GPOs&#8221;) and government programs. We also pay quarterly distribution fees to certain wholesalers for inventory reporting and chargeback processing, and to GPOs as administrative fees for services and for access to GPO members. We concluded the benefits received in exchange for these fees are not distinct from our sales of Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recombinant, and accordingly we apply these amounts to reduce revenues. Wholesalers also have rights to return unsold product nearing or past the expiration date. Because of the shelf life of Hylenex recombinant and our lengthy return period, there may be a significant period of time between when the product is shipped and when we issue credits on returned product. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the transaction price when we receive each purchase order taking into account the expected reductions of the selling price initially billed to the wholesaler arising from all of the above factors. We have compiled historical experience and data to estimate future returns and chargebacks of Hylenex recombinant and the impact of the other discounts and fees we pay. When estimating these adjustments to the transaction price, we reduce it sufficiently to be able to assert that it is probable that there will be no significant reversal of revenue when the ultimate adjustment amounts are known.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each purchase order contains only one type of product, and is usually shipped to the wholesaler in a single shipment. Therefore, allocation of the transaction price to individual packages is not required.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue from Hylenex recombinant product sales and related cost of sales upon product delivery to the wholesaler location. At that time, the wholesalers take control of the product as they take title, bear the risk of loss of ownership, and have an enforceable obligation to pay us. They also have the ability to direct sales of product to their customers on terms and at prices they negotiate. Although wholesalers have product return rights, we do not believe they have a significant incentive to return the product to us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon recognition of revenue from product sales of Hylenex recombinant, the estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, and GPO fees are included in accrued liabilities and net of accounts receivable. We monitor actual product returns, chargebacks, discounts and fees subsequent to the sale. If these amounts differ from our estimates, we make adjustments to these allowances, which are applied to increase or reduce product sales revenue and earnings in the period of adjustment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the orders placed by wholesalers, we incur costs such as commissions to our sales representatives. However, as revenue from product sales is recognized upon delivery to the wholesaler, which occurs shortly after we receive a purchase order, we do not capitalize these commissions and other costs, based on application of the practical expedient allowed within the applicable guidance. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Proprietary Product Sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Antares, our commercial portfolio of proprietary products includes XYOSTED, TLANDO and NOCDURNA, which we sell primarily to wholesale and specialty distributors. Revenue is recognized when control has transferred to the customer, which is typically upon delivery, at the net selling price, which reflects the variable consideration for which reserves and sales allowances are established for estimated returns, wholesale distribution fees, prompt payment discounts, government rebates and chargebacks, plan rebate arrangements and patient discount and support programs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of certain reserves and sales allowances requires us to make a number of judgements and estimates to reflect our best estimate of the transaction price and the amount of consideration to which we believe we would be ultimately entitled to receive. The expected value is determined based on unit sales data, contractual terms with customers and third-party payers, historical and estimated future percentage of rebates incurred on sales, historical and future insurance plan billings, any new or anticipated changes in programs or regulations that would impact the amount of the actual rebates, customer purchasing patterns, product expiration dates and levels of inventory in the distribution channel. The estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, rebates and customer co-pay support programs are included in accrued liabilities and net of accounts receivable.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Partnered Product Sales</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bulk rHuPH20</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell bulk rHuPH20 to partners for use in research and development and, subsequent to receiving marketing approval, we sell it for use in collaboration commercial products. Sales are made pursuant to purchase orders subject to the terms of the collaborative agreement or a supply agreement, and delivery of units of bulk rHuPH20 represent performance obligations under each purchase order. We provide a standard warranty that the product conforms to specifications. We use contract manufacturers to produce bulk rHuPH20 and have concluded we are the principal in the sales to partners. The transaction price for each purchase order of bulk rHuPH20 is fixed based on the cost of production plus a contractual markup, and is not subject to adjustments. Allocation of the transaction price to individual quantities of the product is usually not required because each order contains only one type of product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue from the sale of bulk rHuPH20 as product sales and related cost of sales upon transfer of title to our partners. At that time, the partners take control of the product, bear the risk of loss of ownership, and have an enforceable obligation to pay us. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Devices</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Antares, we are party to several license, development, supply and distribution arrangements with pharmaceutical partners, under which we produce and are the exclusive supplier of certain products, devices and/or components. Revenue is recognized when or as control of the goods transfers to the customer as discussed below.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the exclusive supplier of the Makena</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> subcutaneous auto-injector product to Covis and the exclusive supplier of OTREXUP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to Otter Pharmaceuticals, LLC (&#8220;Otter&#8221;). Because these products are custom manufactured for each customer with no alternative use and we have a contractual right to payment for performance completed to date, control is continuously transferred to the customer as the product is produced pursuant to firm purchase orders. Revenue is recognized over time using the output method based on the contractual selling price and number of units produced. The amount of revenue recognized in excess of the amount shipped/billed to the customer, if any, is recorded as contract assets in the Condensed Consolidated Balance Sheets due to the short-term nature in which the amount is ultimately expected to be billed and collected from the customer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other device partnered product sales are recognized at the point in time in which control is transferred to the customer, which is typically upon shipment. Sales terms and pricing are governed by the respective supply and distribution agreements, and there is generally no right of return. Revenue is recognized at the transaction price, which includes the contractual per unit selling price and estimated variable consideration, such as volume-based pricing arrangements or profit sharing arrangements, if any. We recognize revenue, including the estimated variable consideration we expect to receive for contract margin on future commercial sales, upon shipment of the goods to our partner. The estimated variable consideration is recognized at an amount we believe is not subject to significant reversal based on historical experience and is adjusted at each reporting period if the most likely amount of expected consideration changes or becomes fixed.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our statements of income, we report as revenues under collaborative agreements the upfront payments, event-based development and regulatory milestones and sales milestones. We also include in this category revenues from separate research and development contracts pursuant to project authorization forms. We report royalties received from partners as a separate line in our statements of income.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from sales of our proprietary and partnered products are included in product sales, net.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the footnotes to our condensed consolidated financial statements, we provide disaggregated revenue information by type of arrangement (product sales, net, collaborative agreements and research and device licensing and development revenues), and additionally, by type of payment stream received under collaborative agreements (upfront license and target nomination fees, event-based development and regulatory milestones and other fees, sales milestones and royalties).</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal costs and manufacturing overhead associated with the production of proprietary and partnered products. Cost of sales also consists of the write-down of excess, dated and obsolete inventories and the write-off of inventories that do not meet certain product specifications, if any.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include salaries and benefits, facilities and other overhead expenses, research related manufacturing services, contract services and other outside expenses. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to our research and development efforts and have no alternative future uses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed or such time when we do not expect the goods to be delivered or services to be performed.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record compensation expense associated with stock options, restricted stock awards (&#8220;RSAs&#8221;), restricted stock units (&#8220;RSUs&#8221;), performance stock units (&#8220;PSUs&#8221;) and shares issued under our employee stock purchase plan (&#8220;ESPP&#8221;) in accordance with the authoritative guidance for stock-based compensation. The cost of employee services received in exchange for an award of an equity instrument is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period of the award. Share-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed. Forfeitures are recognized as a reduction of share-based compensation expense as they occur.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases at each reporting period. We measure deferred tax assets and liabilities using enacted tax rates for the year in which the differences are expected to reverse. Significant judgment is required by management to determine our provision for income taxes, our deferred tax assets and liabilities, and any associated valuation allowances recorded against our net deferred tax assets, which are based on complex and evolving tax regulations. Deferred tax assets (&#8220;DTA&#8221;) and other tax benefits are recorded when they are more likely than not to be realized. On a quarterly basis, we assess the need for valuation allowance on our DTAs, weighing all positive and negative evidence, to assess if it is more-likely-than-not that some or all of our DTAs will be realized. We recorded a provision for income taxes of $7.3&#160;million and $21.6&#160;million using an effective tax rate of 8.1% and  20.7% the three and six months ended June&#160;30, 2022 respectively. The difference between our effective tax rate and the U.S. federal statutory rate of 21% is primarily due to tax benefits on Foreign Derived Intangible Income Deduction (FDII), and tax detriments on 162(m), other share-based compensation and non-deductible transaction costs related to Antares acquisition.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:3pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the acquisition of Antares, we assessed the organization of our business and concluded that we continue to operate our business in one segment, which includes all activities related to the research, development and commercialization of our proprietary enzymes and devices. This segment also includes revenues and expenses related to (i)&#160;research and development and manufacturing activities conducted under our collaborative agreements with third parties (ii)&#160;product sales of proprietary and partnered  products. The chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations as a single operating segment.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adoption and Pending Adoption of Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a brief description of recently issued accounting standards, those adopted in the current period and those not yet adopted:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.046%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.647%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect on the Financial <br/>Statements or Other Significant Matters</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from contracts with customers</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The new guidance requires an acquirer to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with topic 606 as if it had originated the contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2023</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Early adoption is permitted, including adoption in an interim period)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We early adopted ASU 2021-08 on April 1, 2022. The adoption did not have a material impact on our condensed consolidated financial position or results of operations.</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381116395984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combination</a></td>
<td class="text">Business Combination<div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 24, 2022, we acquired all outstanding equity interests of Antares Pharma, Inc. ("Antares") according to the terms and conditions of the Agreement and Plan of Merger, dated as of April 12, 2022 (the &#8220;Merger Agreement&#8221;). Antares is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. We acquired Antares as a part of our strategy to expand as a drug delivery company and include specialty products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total purchase consideration of Antares was $1,045.7&#160;million. Each share of Antares common stock issued and outstanding was converted into the right to receive $5.60 in cash without interest, less any applicable withholding taxes (&#8220;Merger Consideration&#8221;). Additionally, in connection with the transaction, each Antares equity award granted and outstanding as of May 24, 2022 under the Antares&#8217; equity compensation plans was converted into the right to receive Merger Consideration. Other components of purchase consideration include cash paid at closing to settle Antares existing debt of $19.7&#160;million and seller transaction costs paid by us on behalf of Antares of $22.9&#160;million. </span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of Antares was funded by cash on hand and borrowings under the new credit agreement with Bank of America, N.A. (&#8220;BofA&#8221;) and other lenders that provides for (i) a $350&#160;million revolving credit facility (the &#8220;Revolving Credit Facility&#8221;) and (ii) a $250&#160;million term loan facility (the &#8220;Term Facility&#8221;, collectively with the Revolving Credit Facility, the &#8220;2022 Facility&#8221;) as described in Note 8. We recognized transaction costs of $18.6&#160;million and $20.1&#160;million in the three and six months ended June 30, 2022, respectively. These costs are reported in the selling, general and administrative expenses line of our consolidated statements of income. Transaction costs include, but are not limited to, investment banker, advisory, legal, and other professional fees.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Consideration</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total purchase consideration was comprised of the following (in thousands):</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"/><td style="width:87.539%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.514%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash consideration for Antares shares outstanding as of May 24, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956,886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration for Antares equity compensation awards </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration for seller transaction costs paid by Halozyme</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,906&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration related to Antares closing indebtedness settled by Halozyme</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash consideration related to cash bonus awards paid by Halozyme</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total purchase consideration</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,045,668</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%">(a) Consideration for Antares equity compensation awards consists of $32.2&#160;million paid for vested equity awards as well as $13.6&#160;million paid for the pre-combination portion of unvested equity awards that were accelerated as part of the Merger Agreement. The fair value of the unvested equity awards attributable to the post-combination period of $8.7&#160;million is included in Statement of Income in Q2 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Fair Value of Assets Acquired and Liabilities Assumed</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of Antares has been accounted for using the acquisition method of accounting in accordance with ASC 805, Business Combinations, with Halozyme treated as the accounting acquirer, which requires, among other things, that the assets acquired and liabilities assumed be recognized at their fair value on the acquisition date. Acquisition accounting is dependent upon certain valuations and other studies that have yet to commence or progress to a stage where there is sufficient information for a definitive measurement. The process for estimating the fair values of identifiable intangible assets and certain tangible assets and assumed liabilities requires the use of judgment in determining the appropriate assumptions and estimates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the preliminary estimated fair values of assets acquired and liabilities assumed on the acquisition date based on preliminary valuations and management estimates that are subject to change when formal valuations and other studies are finalized. Fair value estimates are based on a complex series of judgments about future events and uncertainties and rely heavily on estimates and assumptions. The judgments used to determine the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact our results of operations. These preliminary estimates may be revised during the measurement period as third-party valuations are finalized, additional information becomes available, and as additional analyses are performed, and these differences could change the value of the intangible assets acquired, the contingent liability assumed, and the tax impacts related to the acquisition and could have a material impact on our results of operations and financial position.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:84.593%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.618%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Total purchase consideration, net of $46,548 cash acquired</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999,120&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts Payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,094&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net assets acquired, excluding goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799,639&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,481&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is the excess of the consideration transferred over the net assets recognized and represents the expected revenue and cost synergies of the combined company and assembled workforce. Goodwill will be allocated entirely to the single reportable segment. Goodwill recognized as a result of the acquisition is not deductible for tax purposes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Identifiable Intangible Assets</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The estimated fair values of identifiable intangible assets were prepared using the excess earnings method which calculates the present value of the incremental after-tax cash flows attributable solely to each intangible asset. The estimated useful lives are based on forecasted periods of benefit for each intangible asset which consider commercialization dates, the estimated revenue cycle based on the products&#8217; competitiveness in the market, and the loss of exclusivity timing with subsequent trending down of revenue. For the ATRS-1902 IPR&amp;D, the useful life is considered indefinite as the asset has not been placed into service. As such, the ATRS-1902 IPR&amp;D will be tested annually for impairment and will not be amortized. Useful lives and preliminary values are presented in the table below.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"/><td style="width:76.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.421%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount (in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful life (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auto Injector technology platform</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XYOSTED proprietary product</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TLANDO product rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ATRS-1902 (IPR&amp;D)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated fair value of intangible assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">987,500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A contingent liability with a preliminary value of $130.0&#160;million was assumed related to TLANDO. We assumed an obligation to pay development milestone payments as well as commercial milestone payments and minimum tiered royalty payments based on TLANDO net sales which are contingent upon future events. The acquisition date fair value was measured using the income approach, specifically the probability weighted expected return method for the development milestone payments and the option pricing methodology using the Monte Carlo simulation for commercial milestone payments and royalty payments. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Pro Forma Results</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements include Antares' results of operations from the date of acquisition on May 24, 2022 through June 30, 2022. Total revenues and net loss before taxes attributable to Antares during this period and included in our consolidated financial statements for both the three and six months ended June 30, 2022 total $18.7&#160;million and $39.8&#160;million, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma financial information summarizes combined results of operations of Halozyme and Antares as if the companies had been combined as of the beginning of our fiscal year 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"><tr><td style="width:1.0%"/><td style="width:58.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.179%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,376&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,839&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,212&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312,538&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The unaudited pro forma financial information for all periods presented includes the business combination accounting effects resulting from this acquisition. The unaudited pro forma results include adjustments to reflect the amortization of the inventory step-up and the incremental intangible asset amortization to be incurred based on preliminary valuations of assets as well as certain material non-recurring transaction adjustments related to the acquisition. Adjustments to interest expense, financing costs and investment income were made to reflect the capital structure of the combined entity. Adjustments to income tax expense also were made to reflect the anticipated effective tax rate of the combined entity. The unaudited pro forma financial information as presented is for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved if the acquisition had taken place at the beginning of fiscal 2021, nor is it necessarily an indication of trends in future results for a number of reasons, including, but not limited to, differences between the assumptions used to prepare the pro forma information, cost savings from operating efficiencies, potential synergies, and the impact of incremental costs incurred in integrating the businesses.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381116395984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurement</a></td>
<td class="text">Fair Value Measurement<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities consisted of the following (in thousands):</span></div><div style="margin-top:11pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:52.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.779%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,032)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-US Government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,460&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,032)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,428&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:52.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.779%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,745&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,692&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non- U.S Government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622,823&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(620)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622,203&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, 6 available-for-sale marketable securities with a fair market value of $118.4 million were in a gross unrealized loss position of $2.0 million. Based on our review of these marketable securities, we believe none of the unrealized loss is as a result of a credit loss as of&#160;June&#160;30, 2022, because we do not intend to sell these securities and it is not more-likely-than-not that we will be required to sell these securities before the recovery of their amortized cost basis.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of our contractual maturities of available-for-sale debt securities are as follows (in thousands):</span></div><div style="margin-top:11pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:67.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.063%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,428&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,965&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one but within five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,428&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622,203&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"/><td style="width:29.421%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.967%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.337%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total estimated fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total estimated fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:20pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale marketable <br/>&#160;&#160;&#160;securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-US Government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,271&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,271&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,468&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391,442&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740,910&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had no available for sale securities that were classified within Level 3 as of June&#160;30, 2022 and December&#160;31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381113254576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text">Revenue<div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our disaggregated revenues were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"><tr><td style="width:1.0%"/><td style="width:58.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.179%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,340&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,778&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,945&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,701&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Sales of bulk rHuPH20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,057&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of proprietary products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of device partnered products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,360&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,440&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues under collaborative agreements:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Upfront license and target nomination fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Event-based development and regulatory milestones and other fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Sales-based milestones</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Device Licensing and development revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,259&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues under collaborative agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,725&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,317&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,259&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,650&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,365&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,455&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269,644&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,477&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June&#160;30, 2022 we recognized revenue related to licenses granted to partners in prior periods in the amount of $100.3 million. This amount represents royalties earned in the current period in addition to $15.0 million of variable consideration in the contracts where uncertainties have been resolved and the development milestones were expected to be achieved or were achieved. We also recognized revenue of $0.5 million during the three months ended June&#160;30, 2022 that had been included in deferred revenues at December&#160;31, 2021. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2022 we recognized revenue related to licenses granted to partners in prior periods in the amount of $169.9 million. This amount represents royalties earned in the current period in addition to $15.0 million of variable consideration.in the contracts where uncertainties have been resolved and the development milestones were expected to be achieved or were achieved. We also recognized revenue of $1.0 million during the six months ended June&#160;30, 2022 that had been included in deferred revenues at December&#160;31, 2021. We did not recognize any adjustments to reduce sales reserves and allowances liability related to Hylenex recombinant sales in prior periods</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net, and deferred revenues (contract liabilities) from contracts with customers, including partners, consisted of the following (in thousands): </span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"/><td style="width:76.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.176%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.065%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,526&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,975&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the amounts included in the transaction price of our contracts with customers and allocated to goods and services not yet provided were $68.1 million, of which $61.2 million relates to unfulfilled purchase commitments and $6.9 million has been collected and is reported as deferred revenues. The unfulfilled purchase commitments are estimated to be delivered by the end of 2023. Of the total deferred revenues of $6.9 million, $4.1 million is expected to be used by our customers within the next 12 months. </span></div>We recognized contract assets of $19.8&#160;million at June&#160;30, 2022, which related to development milestones deemed probable of receipt for intellectual property licenses granted to partners in prior periods<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381107084880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Balance Sheet Items<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Certain Balance Sheet Items</a></td>
<td class="text">Certain Balance Sheet Items<div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:68.485%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from product sales to partners</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,570&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,504&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from revenues under collaborative agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from royalty payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from other product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,768&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,115&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for distribution fees and discounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,400)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,140)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,368&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,975&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:68.485%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,194&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,672&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,451&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,615&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,908&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:68.485%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid manufacturing expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,848&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,991&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,096&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,878&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,896&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less long-term portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,283)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,414)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total prepaid expenses and other assets, current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,595&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,482&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid manufacturing expenses include raw materials, slot reservation fees and other amounts paid to contract manufacturing organizations.&#160;Such amounts are reclassified to work-in-process inventory as materials are used or the contract manufacturing organization services are complete.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:68.485%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,046&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,174&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer and office equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,891&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,749)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,368&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,791&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use of assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,003&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,091&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,794&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">                            </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense was approximately $1.1 million and $0.8 million, inclusive of ROU asset amortization of $0.6 million and $0.4 million for the three months ended June&#160;30, 2022 and 2021 respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense was approximately $1.9 million and $1.5 million, inclusive of ROU asset amortization of $1.0 million and $0.8 million for the six months ended June&#160;30, 2022 and 2021 respectively.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:68.485%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and payroll taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,858&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,858&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued outsourced manufacturing expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product returns and sales allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,788&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,652&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,985&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less long-term portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,551)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(544)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total accrued expenses, current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,101&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,441&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense associated with the accretion of the lease liabilities was approximately $0.1 million and $0.1 million for the three months ended June&#160;30, 2022 and 2021 respectively and $0.2 million and $0.2 million for the six months ended June&#160;30, 2022 and 2021 respectively. Total lease expense for the three months ended June&#160;30, 2022 and 2021 was $0.6 million and $0.5 million respectively and  $1.1 million and $1.0 million for the six months ended June&#160;30, 2022 and 2021, respectively. .  </span></div>Cash paid for amounts related to leases for the three months ended June&#160;30, 2022 and 2021 was $0.9 million and $0.7 million, and $1.6 million and $1.4 million for the six months ended June&#160;30, 2022 and 2021 respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381114715440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">Goodwill and Intangible Assets<div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 24, 2022, we acquired all outstanding equity interests of Antares Pharma, Inc. A Goodwill balance of $199.5&#160;million is recognized for the the excess of the consideration transferred over the net assets acquired and represents the expected revenue and cost synergies of the combined company and assembled workforce.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the activity impacting goodwill is presented below (in thousands):</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"><tr><td style="width:1.0%"/><td style="width:84.592%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,481&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our acquired intangible assets are amortized using the straight-line method over their estimated useful lives of seven to ten years. The following table shows the cost, accumulated amortization and weighted average life in years for our acquired intangible assets at June&#160;30, 2022 (in thousands).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"/><td style="width:47.650%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.118%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.993%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.893%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.993%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.893%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.998%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average remaining life (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auto Injector technology platform</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,585&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,315&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XYOSTED proprietary product</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TLANDO product rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total definite-lived intangibles, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">927,900&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,403&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916,497&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ATRS-1902 (IPR&amp;D)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,600&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Intangibles, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">976,097&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future annual amortization of finite-lived intangible assets is shown in the following table. Actual amortization expense to be reported in future periods could differ from these estimates as a result of acquisitions, divestitures, and asset impairments, among other factors.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"/><td style="width:82.561%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.010%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Year:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,387&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,771&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,771&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916,497&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381114630320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt, Net<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Long-Term Debt, Net</a></td>
<td class="text">Long-Term Debt, Net<div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">0.25% Convertible Notes due 2027</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we completed the sale of $805.0&#160;million in aggregate principal amount of 0.25% Convertible Senior Notes due 2027 (the &#8220;2027 Convertible Notes&#8221; and collectively with the 2024 Convertible Notes the &#8220;Convertible Notes&#8221;). The net proceeds in connection with the issuance of the 2027 Convertible Notes, after deducting the initial purchasers&#8217; fee of $20.1&#160;million, was approximately $784.9&#160;million. We also incurred additional debt issuance costs totaling $0.4&#160;million. Debt issuance costs and the initial purchasers&#8217; fee are presented as a debt discount.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2027 Convertible Notes pay interest semi-annually in arrears on March 1st and September 1st of each year at an annual rate of 0.25%. The 2027 Convertible Notes are general unsecured obligations and will rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the 2027 Convertible Notes, will rank equally in right of payment with all existing and future liabilities that are not so subordinated, will be effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness and will be structurally subordinated to all indebtedness and other liabilities (including trade payables) of our current or future subsidiaries. The 2027 Convertible Notes have a maturity date of March 1, 2027.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their 2027 Convertible Notes at their option only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on June 30, 2021, if the last reported sale price per share of  common stock exceeds 130% of the conversion price for each of at least 20 trading days during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the five consecutive business days immediately after any five consecutive trading day period (such five consecutive trading day period, the &#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on our common stock, as described in the offering memorandum for the 2027 Convertible Notes; (4) if we call such notes for redemption; and (5) at any time from, and including, September 1, 2026 until the close of business on the scheduled trading day immediately before the maturity date. The Notes will be convertible, regardless of the foregoing circumstances, at any time from, and including, September 1, 2026 until the close of business on the scheduled trading day immediately preceding the maturity date. As of June&#160;30, 2022, the 2027 Convertible Notes are not convertible.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, we will pay cash for the settlement of principal and for the premium, if applicable, we will pay cash, deliver shares of common stock or a combination of cash and shares of common stock, at our election. The initial conversion rate for the 2027 Convertible Notes will be 12.9576 shares of common stock per $1,000 in principal amount of 2027 Convertible Notes, equivalent to a conversion price of approximately $77.17 per share of our common stock. The conversion rate is subject to adjustment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, we were in compliance with all covenants and there was no material adverse change in our business, operations or financial condition. </span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">1.25% Convertible Notes due 2024</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we completed the sale of $460.0 million in aggregate principal amount of 1.25% Convertible Senior Notes due 2024 (&#8220;2024 Convertible Notes&#8221;). The net proceeds in connection with the 2024 Convertible Notes, after deducting  the initial purchasers&#8217; fee of $12.7&#160;million, was approximately $447.3 million. We also incurred debt issuance cost totaling $0.3&#160;million. Debt issuance costs and the initial purchasers&#8217; fee are presented as a debt discount.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Convertible Notes pay interest semi-annually in arrears on June 1st and December 1st of each year, beginning on June 1, 2020, at an annual rate of 1.25%. The 2024 Convertible Notes are general unsecured obligations and will rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the 2024 Convertible Notes, will rank equally in right of payment with all existing and future liabilities that are not so subordinated, will be effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness and will be structurally subordinated to all indebtedness and other liabilities (including trade payables) of the our current or future subsidiaries. The 2024 Convertible Notes have a maturity date of December 1, 2024.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their 2024 Convertible Notes at their option only in the following circumstances: (1)&#160;during any calendar quarter commencing after the calendar quarter ending on March&#160;31, 2020, if the last reported sale price per share of common stock exceeds 130% of the conversion price for each of at least 20 trading days during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2)&#160;during the five consecutive business days immediately after any five consecutive trading day period (such five consecutive trading day period, the </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day; (3)&#160;upon the occurrence of certain corporate events or distributions on our common stock, as described in the offering memorandum for the 2024 Convertible Notes; (4)&#160;if we call such notes for redemption; and (5)&#160;at any time from, and including, June&#160;1, 2024 until the close of business on the scheduled trading day immediately before the maturity date. As of June&#160;30, 2022, the 2024 Convertible Notes are convertible and are classified as a current liability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021 we notified the note holders of our irrevocable election to settle the principal of the 2024 Convertible Notes in cash and for the premium, if applicable, to deliver shares of common stock. The conversion rate for the 2024 Convertible Notes will be 41.9208 shares of common stock per $1,000 in principal amount of 2024 Convertible Notes, equivalent to a conversion price of approximately $23.85 per share of our common stock. The conversion rate is subject to adjustment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we completed a privately negotiated induced conversion of $369.1&#160;million principal amount of the 2024 Convertible Notes (&#8220;Note Repurchases&#8221; or the &#8220;Induced Conversion&#8221;). In connection with the Induced Conversion, we paid approximately $370.2&#160;million in cash, which includes principal and accrued interest, and issued approximately 9.08&#160;million shares of our common stock representing the intrinsic value based on the contractual conversion rate and incremental shares as an inducement for conversion. As a result of the Induced Conversion, we recorded $21.0 million in induced conversion expense which is included in Other income (expense) of the Condensed Consolidated Statements of Income in 2021. The induced conversion expense represents the fair value of the common stock issued upon conversion in excess of the common stock issuable under the original terms of the 2024 Convertible Notes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, we were in compliance with all covenants and there was no material adverse change in our business, operations or financial condition. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Carrying Amounts of the Convertible Notes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount and fair value of our Convertible Notes were as follows as of the dates indicated (in thousands). </span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"><tr><td style="width:1.0%"/><td style="width:69.570%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.474%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Principal Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">895,936&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">895,936&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,263)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,517)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,055)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,745)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total unamortized debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,318)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,262)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amount:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,419&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878,618&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876,674&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value based on trading levels (Level 2):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,678&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">711,660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718,889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of outstanding notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">884,403&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878,567&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization per period of debt discount (in years):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of interest expense and the effective interest rates for each of our Convertible Notes for the periods shown (in thousands).</span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.058%"><tr><td style="width:1.0%"/><td style="width:38.997%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.023%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.023%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.023%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.026%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coupon Interest:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,006&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Coupon Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,574&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,008&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt discount:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortization of debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">973&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,944&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,706&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,760&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,752&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,518&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,714&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective interest rates:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revolving Credit Facility (December 2021)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, we terminated that certain credit agreement entered into on December 23, 2021 with Bank of America and the other lenders party thereto (the &#8220;2021 Credit Agreement&#8221;) evidencing a revolving credit facility (the &#8220;2021 Facility&#8221;) that provided for secured revolving loans and letters of credit in an aggregate amount of up to $75.0&#160;million.  No proceeds from the 2021 Facility were drawn down as of the date the 2021 Credit Agreement was terminated.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revolving Credit and Term Loan Facilities (May 2022)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, in connection with the closing of Antares acquisition, we entered into a credit agreement with Bank of America, N.A., as Administrative Agent, Swing Line Lender and an L/C Issuer, and the other lenders and L/C Issuers party thereto (the &#8220;2022 Credit Agreement), evidencing a credit facility (the &#8220;2022 Facility&#8221;) that provides for (i) a $350&#160;million revolving credit facility (the &#8220;Revolving Credit Facility&#8221;) and (ii) a $250&#160;million term loan facility (the &#8220;Term Facility&#8221;). The proceeds from a $120&#160;million draw on the Revolving Credit Facility and the $250&#160;million Term Facility were used to fund a portion of the Antares acquisition, pay off Antares&#8217; existing debt and pay fees and expenses in connection with the acquisition. The 2022 Credit Agreement contains an expansion feature, which allows us, subject to certain conditions, to increase the aggregate principal amount of the 2022 Facility, provided we remain in compliance with underlying financial covenants on a pro forma basis including the consolidated interest coverage ratio and the consolidated net leverage ratio covenants set forth in the 2022 Credit Agreement. The 2022 Facility will mature on November 30, 2026 unless either the Revolving Credit Facility or the Term Facility is extended prior to such date in accordance with the 2022 Credit Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Facility requires quarterly scheduled repayments of the term loans in each of the first, second, third and fourth years following the Closing in annual amounts equal to 2.50%, 5.00%, 7.50% and 10.00% of the initial principal amount of the term loans, respectively. The term loans are also subject to mandatory prepayments from the proceeds of certain asset sales, subject to our right to reinvest the proceeds thereof.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2022 Facility bear interest, at our option, at a rate equal to an applicable margin plus: (a) the applicable Term Secured Overnight Financing Rate (SOFR) (which includes a SOFR adjustment of 0.10%), or (b) a base rate determined by reference to the highest of (1) the federal funds effective rate plus 0.50%, (2) the Bank of America prime rate, (3) the Term SOFR rate for an interest period of one month plus 1.10%, and (4) 1.00%. The margin for the 2022 Facility ranges, based on our consolidated total net leverage ratio, from 0.25% to 1.25% in the case of base rate loans and from 1.25% to 2.25% </span></div>in the case of Term SOFR rate loans. In addition to paying interest on the outstanding principal under the Facility, we will pay (i) a commitment fee in respect of the unutilized commitments thereunder and (ii) customary letter of credit fees and agency fees. The commitment fees range from 0.15% to 0.35% per annum based on our consolidated net leverage ratio. As of June&#160;30, 2022, we had $120.0&#160;million and $250&#160;million in principal amount of outstanding borrowings under the 2022 Revolving Credit Facility and the 2022 Term Facility, respectively. We incurred a total of $6.0&#160;million in third party costs related to the 2022 credit agreement and recorded $3.5&#160;million as the revolving credit facility debt issuance cost and $2.5&#160;million as the term loan debt issuance cost.  As of June&#160;30, 2022, the unamortized debt issuance cost related to the revolving credit facility and the term loan is $3.4 million and $2.4 million, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381114346848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Payment Arrangement, Noncash Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Compensation</a></td>
<td class="text">Share-based Compensation<div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense related to share-based awards excluding the acceleration of Antares unvested equity awards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was comprised of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.959%"><tr><td style="width:1.0%"/><td style="width:57.246%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.912%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,456&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,764&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,179&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,608&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,904&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,883&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,635&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,372&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,377&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,295&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense by type of share-based award (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:57.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.473%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,503&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,637&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSAs, RSUs, PSUs and ESPP</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,132&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,735&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,254&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,176&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,635&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,372&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,377&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,295&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We granted stock options to purchase approximately 0.2 million and 36.3 thousand shares of common stock during the three months ended June&#160;30, 2022 and 2021, respectively and 1.5 million and 0.7 million shares of common stock during the six months ended June&#160;30, 2022 and 2021, respectively. The exercise price of stock options granted is equal to the closing price of the common stock on the date of grant. The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model (&#8220;Black-Scholes model&#8221;). Expected volatility is based on historical volatility of our common stock. The expected term of options granted is based on analyses of historical employee termination rates and option exercises. The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The dividend yield assumption is based on the expectation of no future dividend payments. The assumptions used in the Black-Scholes model were as follows:</span></div><div style="margin-top:5pt;text-align:center;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:42.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.817%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.665%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.665%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.952%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.05-41.29%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.91-44.91%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.05-41.29%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.91%-46.45%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.56-3.01%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.81-0.81%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.37-3.01%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.36%-0.81%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, our Board of Directors approved our 2021 ESPP and our stockholders approved the plan in May 2021. The ESPP enables eligible employees to purchase shares of our common stock at the end of each offering period at a price equal to 85% of the fair market value of the shares on the first business day or the last business day of the offering period, whichever is lower. Share purchases are funded through payroll deduction of at least 1% and up to 15% of an employee&#8217;s compensation for each payroll period, and no employee may purchase shares under the ESPP that exceeds $25,000 worth of our common stock for a calendar year. As of June&#160;30, 2022, 2,665,369 shares were available for future purchase. The offering period is generally for a six-months period and the first offering period commenced on June 16, 2021. Offering periods shall commence on or about the sixteenth day of June and December of each year and end on or about the fifteenth day of the next December and June respectively, occurring thereafter. During the three months ended June&#160;30, 2022, 16,858  shares were issued pursuant to the ESPP.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unrecognized estimated compensation cost by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):</span></div><div style="margin-top:5pt;text-align:center;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"/><td style="width:70.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.243%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.246%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrecognized<br/>Expense</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining<br/>Weighted-Average<br/>Recognition Period<br/>(years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.81</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.82</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.41</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.46</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381113254576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity <div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2022 and 2021, we issued an aggregate of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">350,216</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 591,891 shares of common stock, respectively, in connection with the exercises of stock options at a weighted average exercise price of $17.94 and $13.64 per share, respectively, for net proceeds of approximately $6.3 million and $8.1 million, respectively. For the six months ended June&#160;30, 2022 and 2021, we issued 248,343 and 290,149 shares of common stock, respectively, upon vesting of certain RSUs and PSUs for which 68,425 and 91,383 RSUs were withheld from the RSU holders, respectively, to pay for minimum withholding taxes totaling approximately $4.3 million and $8.0 million, respectively. Stock options and unvested restricted units totaling approximately 6.8 million shares and 5.9 million shares of our common stock were outstanding as of June&#160;30, 2022 and December&#160;31, 2021, respectively. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we announced that the Board of Directors has authorized the initiation of a capital return program to repurchase up to $550.0 million of outstanding common stock over a three-year period. During 2020, we repurchased 6.5&#160;million shares of common stock for $150.0&#160;million at an average price of $23.05. During 2021, we repurchased 4.6&#160;million shares of common stock for $200.0&#160;million at an average price of $43.02 under the program. The shares were purchased through open market transactions and through an ASR agreement. The $550.0&#160;million share repurchase program was completed in October 2021 having repurchased a total of 22.3&#160;million shares at an average price of $24.72.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2021, the Board of Directors authorized a second capital return program to repurchase up to $750.0&#160;million of outstanding stock over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMTUzMw_f787b3d2-f4a4-40e0-98f4-002839096391">three</span>-year period. Also in December 2021, as part of the second capital return program, we entered into an ASR agreement to repurchase $150.0&#160;million of common stock. At inception pursuant to the agreement, we paid $150.0&#160;million to Bank of America and took initial delivery of 3.5&#160;million shares. In June 2022, we finalized the transaction and received an additional 0.4&#160;million shares. We retired the repurchased shares and they resumed the status of authorized and unissued shares.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381113254576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (loss) per share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income (loss) per share</a></td>
<td class="text">Net Income per share<div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income per common share is computed by dividing net income for the period by the weighted average number of common shares outstanding during the period, without consideration for common stock equivalents. Outstanding stock options, unvested RSAs, unvested RSUs, unvested PSUs, common shares expected to be issued under our ESPP and the Convertible Notes are considered common stock equivalents and are only included in the calculation of diluted earnings per common share when net income is reported and their effect is dilutive. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive common shares issuable upon vesting of stock options, RSAs, RSUs and PSUs are determined using the average share price for each period under the treasury stock method. Potentially dilutive common shares issuable upon conversion of our Convertible Notes are determined using the if-converted method. Since we have committed to settle the principal amount of the Convertible Notes in cash upon conversion only, the number of shares for the conversion spread will be included as a dilutive common stock equivalent. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerators and the denominators of the basic and diluted net income per common share computations is as follows (in thousands, except per share amounts):</span></div><div style="margin-top:11pt;text-align:center;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"/><td style="width:58.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.266%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,685&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,458&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,793&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,353&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding for basic net income per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive potential common stock outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSAs, RSUs, PSUs and ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding for diluted net income per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,096&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:11pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares which have been excluded from the calculation of diluted net income per common share because their effect was anti-dilutive, include the following (shares in millions):</span></div><div style="margin-top:11pt;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"><tr><td style="width:1.0%"/><td style="width:57.531%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.702%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;June 30,</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1). The anti-dilutive securities include outstanding stock options, unvested RSAs, unvested RSUs, unvested PSUs, common shares expected to be issued under our ESPP and Convertible Notes<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381113544304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and ContingenciesFrom time to time, we may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of our business. Any of these claims could subject us to costly legal expenses and, while we generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on our consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage our reputation and business. We currently are not a party to any legal proceedings, the adverse outcome of which, in management&#8217;s opinion, individually or in the aggregate, would have a material adverse effect on our consolidated results of operations or financial position.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381110618560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and with the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) related to a quarterly report on Form 10-Q. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for a complete set of financial statements. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC on February&#160;22, 2022. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operations for the periods presented, with such adjustments consisting only of normal recurring adjustments. Operating results for interim periods are not necessarily indicative of the operating results for an entire fiscal year.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text">The accompanying interim unaudited condensed consolidated financial statements include the accounts of Halozyme Therapeutics, Inc. and our wholly owned subsidiaries, Halozyme, Inc. and Antares Pharma, Inc., Halozyme, Inc.&#8217;s wholly owned subsidiary Halozyme Switzerland Holdings GmbH and Antares Pharma, Inc.&#8217;s wholly-owned Swiss subsidiaries, Antares Pharma IPL AG and Antares Pharma AG. All intercompany accounts and transactions have been eliminated.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">Use of EstimatesThe preparation of interim unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our interim unaudited condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management&#8217;s estimates<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash Equivalents and Marketable Securities and Restricted Cash</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents and Marketable Securities </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of highly liquid investments, readily convertible to cash, that mature within ninety days or less from the date of purchase. As of June&#160;30, 2022, our cash and cash equivalents consisted of money market funds, bank certificate of deposits and demands deposits at commercial banks.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities are investments with original maturities of more than ninety days from the date of purchase that are specifically identified to fund current operations. Marketable securities are considered available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management&#8217;s intention to use the proceeds from the sale of these investments to fund our operations, as necessary. Such available-for-sale investments are carried at fair value with unrealized gains and losses recorded in other comprehensive income (loss) and included as a separate component of stockholders&#8217; equity. The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in the interim unaudited condensed consolidated statements of income. We use the specific identification method for calculating realized gains and losses on marketable securities sold. None of the realized gains and losses and declines in value that were judged to be as a result of credit loss on marketable securities, if any, are included in investment and other income, net in the interim unaudited condensed consolidated statements of operations.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the leases of our facilities, we are required to maintain letters of credit as security deposits during the terms of such leases. As of June&#160;30, 2022 and December&#160;31, 2021, restricted cash of $0.5 million was pledged as collateral for the letters of credit.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authoritative guidance for fair value measurements establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments include cash equivalents, available-for-sale marketable securities, accounts receivable, prepaid expenses and other assets, accounts payable, accrued expenses, long-term debt and contingent liability. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities consist of asset-backed securities, corporate debt securities, U.S. Treasury securities and commercial paper, and are measured at fair value using Level 1 and Level 2 inputs. Level 2 financial instruments are valued using market prices on less active markets and proprietary pricing valuation models with observable inputs, including interest rates, yield curves, maturity dates, issue dates, settlement dates, reported trades, broker-dealer quotes, issue spreads, benchmark securities or other market related data. We obtain the fair value of Level 2 investments from our investment manager, who obtains these fair values from a third-party pricing source. We validate the fair values of Level 2 financial instruments provided by our investment manager by comparing these fair values to a third-party pricing source.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Inventories are reviewed periodically for potential excess, dated or obsolete status. We evaluate the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price we expect to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into operating leases primarily for real estate and automobiles. These leases have contractual terms which range from 3 years to 12 years. We determine if an arrangement contains a lease at inception. Right of use (&#8220;ROU&#8221;) assets and liabilities resulting from operating leases are included in property and equipment, accrued expenses and other long-term liabilities on our condensed consolidated balance sheets. Operating lease ROU assets and liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the discount rate to calculate the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Our leases often include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that we will exercise that option. Short-term leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as automobiles, we account for the lease and non-lease components as a single lease component.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, we entered into an agreement for assignment and assumption of lease with Seismic Software, Inc. pursuant to which effective January 1, 2023, we will assume Seismic&#8217;s office lease, as amended with Kilroy Realty L.P. for approximately 72,534 square feet of space in office and research facilities which is expected to commence on January 1, 2023. The premises are intended to serve as our new headquarters.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. Costs that we incur to complete the business combination, such as legal and other professional fees, are expensed as they are incurred.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the initial accounting for a business combination is incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date. We record these adjustments to the provisional amounts with a corresponding offset to goodwill. Any adjustments identified after the measurement period are recorded in the consolidated statements of income.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock', window );">Goodwill and Intangible Assets and Other Long-Lived Assets</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill, Intangible Assets and Other Long-Lived Asset</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets acquired, including intangible assets and in-process research and development (IPR&amp;D), and liabilities assumed are measured at fair value as of the acquisition date. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of the net assets acquired. Intangible assets acquired in a business combination that are used for IPR&amp;D activities are considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon reaching the end of the relevant research and development project (i.e., upon commercialization), the IPR&amp;D asset is amortized over its estimated useful life. If the relevant research and development project is abandoned, the IPR&amp;D asset is expensed in the period of abandonment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and IPR&amp;D are not amortized; however, they are reviewed for impairment at least annually during the second quarter, or more frequently if an event occurs indicating the potential for impairment. Goodwill and IPR&amp;D are considered to be impaired if the carrying value of the reporting unit or IPR&amp;D asset exceeds its respective fair value.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform our goodwill impairment analysis at the reporting unit level, which aligns with our reporting structure and availability of discrete financial information. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair values of our reporting units are less than the carrying amounts, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and our overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair values of our reporting units are less than the carrying amounts, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair values of the reporting units with the carrying values, including goodwill. If the carrying amounts of the reporting units exceed the fair values, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill impairment test.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our identifiable intangible assets with a finite life are typically comprised of acquired device technologies and product rights. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#8217; respective estimated useful lives.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform regular reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant changes in the ability of a particular asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue and Cost of Product Sales</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate revenues from payments received (i) as royalties from licensing our ENHANZE technology and other royalty arrangements, (ii) under collaborative agreements and (iii) from sales of our proprietary and partnered products. We recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers we perform the following five steps: (i) identify the promised goods or services in the contract; (ii) identify the performance obligations in the contract, including whether they are distinct in the context of the contract; (iii) determine the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ENHANZE and Device Royalties</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our ENHANZE collaboration and license agreements, our partners will pay us royalties at an on average mid-single digit percent rate of their sales if products under the collaboration are commercialized. All amounts owed to us are noncancelable after the underlying triggering event occurs, and nonrefundable once paid. Unless terminated earlier in accordance with its terms, collaborations generally continue in effect until the last to expire royalty payment term, as determined on a product by product and on a country by country basis, with each royalty term starting on the first commercial sale of that product and ending the later of: (i) a specified period or term set forth in the agreement or (ii) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration. When there are no valid claims during the applicable royalty term in a given country, the royalty rate is reduced for those sales. Partners may terminate the agreement prior to expiration for any reason in its entirety or on a target-by-target basis generally upon 90 days prior written notice to us.&#160;Upon any such termination, the license granted to partners (in total or with respect to the terminated target, as applicable) will terminate provided, however, that in the event of expiration of the agreement (as opposed to a termination), the on-going licenses granted will become perpetual, non-exclusive and fully paid. Sales-based milestones and royalties are recognized in the period the underlying sales or milestones occur. We do not receive final royalty reports from our ENHANZE partners until after we complete our financial statements for a prior quarter. Therefore, we recognize revenue based on estimates of the royalty earned, which are based on internal estimates and available preliminary reports provided by our partners. We will record adjustments in the following quarter, if necessary, when final royalty reports are received. To date, we have not recorded any material adjustments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the royalties received from licensing our ENHANZE technology, we also earn royalties in connection with licenses granted under license and development arrangements with our device partners as a result of our acquisition of Antares. These royalties are based upon a percentage of commercial sales of partnered products with rates ranging from mid-single digits to low double digits and are tiered based on levels of net sales. These sales-based royalties, for which the license was deemed the predominant element to which the royalties relate, are estimated and recognized in the period in which the partners&#8217; commercial sales occur. The royalties are generally reported and payable to us within 45 to 60 days of the end of the period in which the commercial sales are made. We base our estimates of royalties earned on actual sales information from our partners when available or estimated, prescription sales from external sources and estimated net selling price. We will record adjustments in the following quarter, if necessary, when final royalty reports are received. To date, we have not recorded any material adjustments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue under ENHANZE and Device Collaborative Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ENHANZE Collaboration and License Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our ENHANZE collaboration agreements, we grant the partner a worldwide license to develop and commercialize products using our ENHANZE technology to combine our patented rHuPH20 enzyme with their proprietary biologics directed at up to a specified number of targets. Targets are usually licensed on an exclusive, global basis. Targets selected subsequent to inception of the arrangement generally require payment of an additional license fee. The partner is responsible for all development, manufacturing, clinical, regulatory, sales and marketing costs for any products developed under the agreement. We are responsible for supply of bulk rHuPH20 based on the partner&#8217;s purchase orders and may also be separately engaged to perform research and development services. While these collaboration agreements are similar in that they originate from the same framework, each one is the result of an arms-length negotiation and thus may vary from one to the other.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, in general, collect an upfront license payment from partners and are also entitled to receive event-based payments subject to partners&#8217; achievement of specified development, regulatory and sales-based milestones. In several agreements, partners pay us annual fees to maintain their exclusive license rights if they are unable to advance product development to specified stages. We earn separate fees for bulk rHuPH20 supplies and research and development services. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although these agreements are in form identified as collaborative agreements, we concluded for accounting purposes they represent contracts with customers and are not subject to accounting literature on collaborative arrangements. This is because we grant to partners licenses to our intellectual property and provide supply of bulk rHuPH20 and research and development services which are all outputs of our ongoing activities, in exchange for consideration. Under these collaborative agreements, we do not develop assets jointly with partners, and do not share in significant risks of their development or commercialization activities. Accordingly, we concluded our collaborative agreements are appropriately accounted for pursuant to ASC Topic 606, Revenue from Contracts with Customers. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under all of our collaborative agreements, we have identified licenses to use functional intellectual property as the only performance obligation. The intellectual property underlying the license is our proprietary ENHANZE technology which represents application of rHuPH20 to facilitate delivery of drugs or fluids. Each of the licenses grants the partners rights to use </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our intellectual property as it exists and is identified on the effective date of the license, because there is no ongoing development of the ENHANZE technology required. Therefore, we recognize revenue from licenses at the point when the license becomes effective and the partner has received access to our intellectual property, usually at the inception of the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When partners can select additional targets to add to the licenses granted, we consider these rights to be options. We evaluate whether such options contain material rights, i.e. have exercise prices that are discounted compared to what we would charge for a similar license to a new partner. The exercise price of these options includes a combination of the target selection fees, event-based milestone payments and royalties. When these amounts in aggregate are not offered at a discount that exceeds discounts available to other customers, we conclude the option does not contain a material right, and we consider grants of additional licensing rights upon option exercises to be separate contracts (target selection contracts).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide customary indemnification and protection of licensed intellectual property for our customers. These provisions are part of assurance that the licenses meet the agreements&#8217; representations and are not obligations to provide goods or services.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also fulfill purchase orders for supply of bulk rHuPH20 and perform research and development services pursuant to projects authorization forms for our partners, which represent separate contracts. Additionally, we price our supply of bulk rHuPH20 and research and development services at our regular selling prices, called standalone selling price or (&#8220;SSP&#8221;). Therefore, our partners do not have material rights to order these items at prices not reflective of SSP. Refer to the discussion below regarding recognition of revenue for these separate contracts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction price for a contract represents the amount to which we are entitled in exchange for providing goods and services to the customer. Transaction price does not include amounts subject to uncertainties unless it is probable that there will be no significant reversal of revenue when the uncertainty is resolved. Apart from the upfront license payment (or target selection fees in the target selection contracts), all other fees we may earn under our collaborative agreements are subject to significant uncertainties of product development. Achievement of many of the event-based development and regulatory milestones may not be probable until such milestones are actually achieved. This generally relates to milestones such as obtaining marketing authorization approvals. With respect to other development milestones, e.g. dosing of a first patient in a clinical trial, achievement could be considered probable prior to its actual occurrence, based on the progress towards commencement of the trial. In order to evaluate progress towards commencement of a trial, we assess the status of activities leading up to our partner&#8217;s initiation of a trial such as feedback received from the applicable regulatory authorities, completion of IND or equivalent filings, readiness and availability of drug, readiness of study sites and our partner&#8217;s commitment of resources to the program. We do not include any amounts subject to uncertainties into the transaction price until it is probable that the amount will not result in a significant reversal of revenue in the future. At the end of each reporting period, we re-evaluate the probability of achievement of such milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When target exchange rights are held by partners, and the amounts attributed to these rights are not refundable, they are included in the transaction price. However, they are recorded as deferred revenues because we have a potential performance obligation to provide a new target upon an exchange right being exercised. These amounts are recognized in revenue when the right of exchange expires or is exercised.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our agreements have one type of performance obligation (licenses) which are typically all transferred at the same time at agreement inception, allocation of transaction price often is not required. However, allocation is required when licenses for some of the individual targets are subject to rights of exchange, because revenue associated with these targets cannot be recognized. When allocation is needed, we perform an allocation of the upfront amount based on relative SSP of licenses for individual targets. We determine license SSP using income-based valuation approach utilizing risk-adjusted discounted cash flow projections of the estimated return a licensor would receive. When amounts subject to uncertainties, such as milestones and royalties, are included in the transaction price, we attribute them to the specific individual target licenses which generate such milestone or royalty amounts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also estimate SSP of bulk rHuPH20 and research and development services, to determine that our partners do not have material rights to order them at discounted prices. For supplies of bulk rHuPH20, because we effectively act as a contract manufacturer to our partners, we estimate and charge SSP based on the typical contract manufacturer margins consistently with all of our partners. We determine SSP of research and development services based on a fully-burdened labor rate. Our rates are comparable to those we observe in other collaborative agreements. We also have a history of charging similar rates to all of our partners. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront amounts allocated to licenses to individual targets are recognized as revenue when the license is transferred to the partner, as discussed above, if the license is not subject to exchange rights, or when the exchange right expires or is exercised. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development milestones and other fees are recognized in revenue when they are included in the transaction price, because by that time we have already transferred the related license to the partner. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In contracts to provide research and development services, such services represent the only performance obligation. The fees are charged based on hours worked by our employees and the fixed contractual rate per hour, plus third-party pass-through costs, on a monthly basis. We recognize revenues as the related services are performed based on the amounts billed, as the partner consumes the benefit of research and development work simultaneously as we perform these services, and the amounts billed reflect the value of these services to the customer. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Device License, Development and Supply Arrangements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have several license, development and supply arrangements with pharmaceutical partners as a result of our acquisition of Antares, under which we grant a license to our device technology and know-how and provide research and development services that often involve multiple performance obligations and highly customized deliverables. For such arrangements, we identify each of the promised goods and services within the contract and the distinct performance obligations at inception and allocate consideration to each performance obligation based on relative standalone selling price, which is generally determined based on the expected cost plus mark-up. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the contract includes an enforceable right to payment for performance completed to date and performance obligations are satisfied over time, we recognize revenue over the development period using either the input or output method depending on which is most appropriate given the nature of the distinct deliverable. For other contracts that do not contain an enforceable right to payment for performance completed to date, revenue is recognized when control of the product is transferred to the customer. Factors that may indicate that the transfer of control has occurred include the transfer of legal title, transfer of physical possession, the customer has obtained the significant risks and rewards of ownership of the assets and we have a present right to payment. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our typical payment terms for development contracts may include an upfront payment equal to a percentage of the total contract value with the remaining portion to be billed upon completion and transfer of the individual deliverables or satisfaction of the individual performance obligations. We record a contract liability for cash received in advance of performance, which is presented within deferred revenue and deferred revenue, long-term in the Condensed Consolidated Balance Sheets and recognized as revenue in the Consolidated Statements of income when the associated performance obligations have been satisfied. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License fees and milestones received in exchange for the grant of a license to our functional intellectual property such as patented technology and know-how in connection with a partnered development arrangement are generally recognized at inception of the arrangement, or over the development period depending on the facts and circumstances, as the license is generally not distinct from the non-licensed goods or services to be provided under the contract. Milestone payments that are contingent upon the occurrence of future events are evaluated and recorded at the most likely amount, and to the extent that it is probable that a significant reversal will not occur when the associated uncertainty is resolved.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion on our collaborative arrangements.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Proprietary Product Sales</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recombinant</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell Hylenex recombinant in the U.S. to wholesale pharmaceutical distributors, who sell the product to hospitals and other end-user customers. Sales to wholesalers are made pursuant to purchase orders subject to the terms of a master agreement, and delivery of individual packages of Hylenex recombinant represent performance obligations under each purchase order. We use a contract manufacturer to produce Hylenex recombinant and a third-party logistics (3PL) vendor to process and fulfill orders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We concluded we are the principal in the sales to wholesalers because we control access to services rendered by both vendors and direct their activities. We have no significant obligations to wholesalers to generate pull-through sales.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling prices initially billed to wholesalers are subject to discounts for prompt payment and subsequent chargebacks when wholesalers sell Hylenex recombinant at negotiated discounted prices to members of certain group purchasing organizations (&#8220;GPOs&#8221;) and government programs. We also pay quarterly distribution fees to certain wholesalers for inventory reporting and chargeback processing, and to GPOs as administrative fees for services and for access to GPO members. We concluded the benefits received in exchange for these fees are not distinct from our sales of Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recombinant, and accordingly we apply these amounts to reduce revenues. Wholesalers also have rights to return unsold product nearing or past the expiration date. Because of the shelf life of Hylenex recombinant and our lengthy return period, there may be a significant period of time between when the product is shipped and when we issue credits on returned product. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the transaction price when we receive each purchase order taking into account the expected reductions of the selling price initially billed to the wholesaler arising from all of the above factors. We have compiled historical experience and data to estimate future returns and chargebacks of Hylenex recombinant and the impact of the other discounts and fees we pay. When estimating these adjustments to the transaction price, we reduce it sufficiently to be able to assert that it is probable that there will be no significant reversal of revenue when the ultimate adjustment amounts are known.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each purchase order contains only one type of product, and is usually shipped to the wholesaler in a single shipment. Therefore, allocation of the transaction price to individual packages is not required.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue from Hylenex recombinant product sales and related cost of sales upon product delivery to the wholesaler location. At that time, the wholesalers take control of the product as they take title, bear the risk of loss of ownership, and have an enforceable obligation to pay us. They also have the ability to direct sales of product to their customers on terms and at prices they negotiate. Although wholesalers have product return rights, we do not believe they have a significant incentive to return the product to us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon recognition of revenue from product sales of Hylenex recombinant, the estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, and GPO fees are included in accrued liabilities and net of accounts receivable. We monitor actual product returns, chargebacks, discounts and fees subsequent to the sale. If these amounts differ from our estimates, we make adjustments to these allowances, which are applied to increase or reduce product sales revenue and earnings in the period of adjustment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the orders placed by wholesalers, we incur costs such as commissions to our sales representatives. However, as revenue from product sales is recognized upon delivery to the wholesaler, which occurs shortly after we receive a purchase order, we do not capitalize these commissions and other costs, based on application of the practical expedient allowed within the applicable guidance. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Proprietary Product Sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Antares, our commercial portfolio of proprietary products includes XYOSTED, TLANDO and NOCDURNA, which we sell primarily to wholesale and specialty distributors. Revenue is recognized when control has transferred to the customer, which is typically upon delivery, at the net selling price, which reflects the variable consideration for which reserves and sales allowances are established for estimated returns, wholesale distribution fees, prompt payment discounts, government rebates and chargebacks, plan rebate arrangements and patient discount and support programs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of certain reserves and sales allowances requires us to make a number of judgements and estimates to reflect our best estimate of the transaction price and the amount of consideration to which we believe we would be ultimately entitled to receive. The expected value is determined based on unit sales data, contractual terms with customers and third-party payers, historical and estimated future percentage of rebates incurred on sales, historical and future insurance plan billings, any new or anticipated changes in programs or regulations that would impact the amount of the actual rebates, customer purchasing patterns, product expiration dates and levels of inventory in the distribution channel. The estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, rebates and customer co-pay support programs are included in accrued liabilities and net of accounts receivable.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Partnered Product Sales</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bulk rHuPH20</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell bulk rHuPH20 to partners for use in research and development and, subsequent to receiving marketing approval, we sell it for use in collaboration commercial products. Sales are made pursuant to purchase orders subject to the terms of the collaborative agreement or a supply agreement, and delivery of units of bulk rHuPH20 represent performance obligations under each purchase order. We provide a standard warranty that the product conforms to specifications. We use contract manufacturers to produce bulk rHuPH20 and have concluded we are the principal in the sales to partners. The transaction price for each purchase order of bulk rHuPH20 is fixed based on the cost of production plus a contractual markup, and is not subject to adjustments. Allocation of the transaction price to individual quantities of the product is usually not required because each order contains only one type of product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue from the sale of bulk rHuPH20 as product sales and related cost of sales upon transfer of title to our partners. At that time, the partners take control of the product, bear the risk of loss of ownership, and have an enforceable obligation to pay us. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Devices</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Antares, we are party to several license, development, supply and distribution arrangements with pharmaceutical partners, under which we produce and are the exclusive supplier of certain products, devices and/or components. Revenue is recognized when or as control of the goods transfers to the customer as discussed below.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the exclusive supplier of the Makena</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> subcutaneous auto-injector product to Covis and the exclusive supplier of OTREXUP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to Otter Pharmaceuticals, LLC (&#8220;Otter&#8221;). Because these products are custom manufactured for each customer with no alternative use and we have a contractual right to payment for performance completed to date, control is continuously transferred to the customer as the product is produced pursuant to firm purchase orders. Revenue is recognized over time using the output method based on the contractual selling price and number of units produced. The amount of revenue recognized in excess of the amount shipped/billed to the customer, if any, is recorded as contract assets in the Condensed Consolidated Balance Sheets due to the short-term nature in which the amount is ultimately expected to be billed and collected from the customer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other device partnered product sales are recognized at the point in time in which control is transferred to the customer, which is typically upon shipment. Sales terms and pricing are governed by the respective supply and distribution agreements, and there is generally no right of return. Revenue is recognized at the transaction price, which includes the contractual per unit selling price and estimated variable consideration, such as volume-based pricing arrangements or profit sharing arrangements, if any. We recognize revenue, including the estimated variable consideration we expect to receive for contract margin on future commercial sales, upon shipment of the goods to our partner. The estimated variable consideration is recognized at an amount we believe is not subject to significant reversal based on historical experience and is adjusted at each reporting period if the most likely amount of expected consideration changes or becomes fixed.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our statements of income, we report as revenues under collaborative agreements the upfront payments, event-based development and regulatory milestones and sales milestones. We also include in this category revenues from separate research and development contracts pursuant to project authorization forms. We report royalties received from partners as a separate line in our statements of income.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from sales of our proprietary and partnered products are included in product sales, net.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the footnotes to our condensed consolidated financial statements, we provide disaggregated revenue information by type of arrangement (product sales, net, collaborative agreements and research and device licensing and development revenues), and additionally, by type of payment stream received under collaborative agreements (upfront license and target nomination fees, event-based development and regulatory milestones and other fees, sales milestones and royalties).</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal costs and manufacturing overhead associated with the production of proprietary and partnered products. Cost of sales also consists of the write-down of excess, dated and obsolete inventories and the write-off of inventories that do not meet certain product specifications, if any.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include salaries and benefits, facilities and other overhead expenses, research related manufacturing services, contract services and other outside expenses. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to our research and development efforts and have no alternative future uses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed or such time when we do not expect the goods to be delivered or services to be performed.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record compensation expense associated with stock options, restricted stock awards (&#8220;RSAs&#8221;), restricted stock units (&#8220;RSUs&#8221;), performance stock units (&#8220;PSUs&#8221;) and shares issued under our employee stock purchase plan (&#8220;ESPP&#8221;) in accordance with the authoritative guidance for stock-based compensation. The cost of employee services received in exchange for an award of an equity instrument is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period of the award. Share-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed. Forfeitures are recognized as a reduction of share-based compensation expense as they occur.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases at each reporting period. We measure deferred tax assets and liabilities using enacted tax rates for the year in which the differences are expected to reverse. Significant judgment is required by management to determine our provision for income taxes, our deferred tax assets and liabilities, and any associated valuation allowances recorded against our net deferred tax assets, which are based on complex and evolving tax regulations. Deferred tax assets (&#8220;DTA&#8221;) and other tax benefits are recorded when they are more likely than not to be realized. On a quarterly basis, we assess the need for valuation allowance on our DTAs, weighing all positive and negative evidence, to assess if it is more-likely-than-not that some or all of our DTAs will be realized. We recorded a provision for income taxes of $7.3&#160;million and $21.6&#160;million using an effective tax rate of 8.1% and  20.7% the three and six months ended June&#160;30, 2022 respectively. The difference between our effective tax rate and the U.S. federal statutory rate of 21% is primarily due to tax benefits on Foreign Derived Intangible Income Deduction (FDII), and tax detriments on 162(m), other share-based compensation and non-deductible transaction costs related to Antares acquisition.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:3pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the acquisition of Antares, we assessed the organization of our business and concluded that we continue to operate our business in one segment, which includes all activities related to the research, development and commercialization of our proprietary enzymes and devices. This segment also includes revenues and expenses related to (i)&#160;research and development and manufacturing activities conducted under our collaborative agreements with third parties (ii)&#160;product sales of proprietary and partnered  products. The chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations as a single operating segment.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Adoption and Pending Adoption of Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adoption and Pending Adoption of Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a brief description of recently issued accounting standards, those adopted in the current period and those not yet adopted:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.046%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.647%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect on the Financial <br/>Statements or Other Significant Matters</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from contracts with customers</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The new guidance requires an acquirer to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with topic 606 as if it had originated the contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2023</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Early adoption is permitted, including adoption in an interim period)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We early adopted ASU 2021-08 on April 1, 2022. The adoption did not have a material impact on our condensed consolidated financial position or results of operations.</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill and Intangible Assets and Other Long-Lived Assets Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381113517552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of reconciliation of numerators and denominators of basic and diluted computations</a></td>
<td class="text">A reconciliation of the numerators and the denominators of the basic and diluted net income per common share computations is as follows (in thousands, except per share amounts):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"/><td style="width:58.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.266%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,685&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,458&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,793&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,353&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding for basic net income per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive potential common stock outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSAs, RSUs, PSUs and ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding for diluted net income per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,096&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Schedule of adoption and pending adoption of recent accounting pronouncements</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e765-108305<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e725-108305<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381112358976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Business Acquisitions, by Acquisition</a></td>
<td class="text"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total purchase consideration was comprised of the following (in thousands):</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"/><td style="width:87.539%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.514%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash consideration for Antares shares outstanding as of May 24, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956,886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration for Antares equity compensation awards </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration for seller transaction costs paid by Halozyme</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,906&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration related to Antares closing indebtedness settled by Halozyme</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash consideration related to cash bonus awards paid by Halozyme</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total purchase consideration</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,045,668</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%">(a) Consideration for Antares equity compensation awards consists of $32.2&#160;million paid for vested equity awards as well as $13.6&#160;million paid for the pre-combination portion of unvested equity awards that were accelerated as part of the Merger Agreement. The fair value of the unvested equity awards attributable to the post-combination period of $8.7&#160;million is included in Statement of Income in Q2 2022.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text">These preliminary estimates may be revised during the measurement period as third-party valuations are finalized, additional information becomes available, and as additional analyses are performed, and these differences could change the value of the intangible assets acquired, the contingent liability assumed, and the tax impacts related to the acquisition and could have a material impact on our results of operations and financial position.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:84.593%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.618%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Total purchase consideration, net of $46,548 cash acquired</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999,120&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts Payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,094&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net assets acquired, excluding goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799,639&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,481&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock', window );">Schedule of Acquired Finite-Lived Intangible Assets by Major Class</a></td>
<td class="text">preliminary values are presented in the table below.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"/><td style="width:76.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.421%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount (in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful life (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auto Injector technology platform</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XYOSTED proprietary product</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TLANDO product rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ATRS-1902 (IPR&amp;D)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated fair value of intangible assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">987,500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock', window );">Schedule of Acquired Indefinite-lived Intangible Assets by Major Class</a></td>
<td class="text">preliminary values are presented in the table below.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"/><td style="width:76.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.421%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount (in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful life (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auto Injector technology platform</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XYOSTED proprietary product</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TLANDO product rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ATRS-1902 (IPR&amp;D)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated fair value of intangible assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">987,500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Business Acquisition, Pro Forma Information</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma financial information summarizes combined results of operations of Halozyme and Antares as if the companies had been combined as of the beginning of our fiscal year 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"><tr><td style="width:1.0%"/><td style="width:58.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.179%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,376&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,839&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,212&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312,538&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of acquired indefinite-lived intangible assets. Indefinite-lived intangible assets are assets that have no physical form, but have expected future economic benefit. Indefinite-lived assets are assets that are not subject to amortization. Acquired indefinite-lived intangible assets are disclosed by major class (assets that can be grouped together because they are similar, either by their nature or by their use in operations of the entity) and in total.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1486-128463<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381113876160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of available-for-sale marketable securities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities consisted of the following (in thousands):</span></div><div style="margin-top:11pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:52.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.779%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,032)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-US Government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,460&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,032)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,428&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:52.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.779%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,745&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,692&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non- U.S Government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622,823&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(620)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622,203&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of contractual maturities of available-for-sale debt securities</a></td>
<td class="text">ontractual maturities of available-for-sale debt securities are as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:67.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.063%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,428&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,965&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one but within five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,428&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622,203&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of assets measured at fair value on a recurring basis</a></td>
<td class="text">The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"/><td style="width:29.421%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.967%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.337%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total estimated fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total estimated fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:20pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale marketable <br/>&#160;&#160;&#160;securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-US Government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,271&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,271&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,468&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391,442&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740,910&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381113708928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of disaggregation of revenues</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our disaggregated revenues were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"><tr><td style="width:1.0%"/><td style="width:58.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.173%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.179%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,340&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,778&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,945&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,701&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Sales of bulk rHuPH20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,057&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of proprietary products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of device partnered products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,360&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,440&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues under collaborative agreements:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Upfront license and target nomination fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Event-based development and regulatory milestones and other fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Sales-based milestones</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Device Licensing and development revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,259&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues under collaborative agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,725&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,317&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,259&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,650&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,365&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,455&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269,644&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,477&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of accounts receivable, deferred revenues from contracts with customers, and amounts under collaborative agreements included in transaction price</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net, and deferred revenues (contract liabilities) from contracts with customers, including partners, consisted of the following (in thousands): </span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"/><td style="width:76.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.176%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.065%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,526&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,975&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381114626400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Balance Sheet Items (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of accounts receivable</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:68.485%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from product sales to partners</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,570&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,504&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from revenues under collaborative agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from royalty payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from other product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,768&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,115&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for distribution fees and discounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,400)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,140)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,368&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,975&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventories</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:68.485%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,194&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,672&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,451&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,615&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,908&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock', window );">Schedule of prepaid expenses and other assets</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:68.485%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid manufacturing expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,848&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,991&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,096&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,878&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,896&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less long-term portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,283)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,414)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total prepaid expenses and other assets, current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,595&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,482&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment, net</a></td>
<td class="text">Property and equipment, net consisted of the following (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:68.485%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,046&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,174&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer and office equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,891&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,749)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,368&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,791&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use of assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,003&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,091&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,794&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:68.485%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and payroll taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,858&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,858&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued outsourced manufacturing expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product returns and sales allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,788&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,652&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,985&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less long-term portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,551)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(544)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total accrued expenses, current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,101&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,441&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381108728144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text">The following table shows the cost, accumulated amortization and weighted average life in years for our acquired intangible assets at June&#160;30, 2022 (in thousands).<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"/><td style="width:47.650%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.118%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.993%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.893%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.993%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.893%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.998%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average remaining life (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auto Injector technology platform</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,585&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,315&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XYOSTED proprietary product</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TLANDO product rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total definite-lived intangibles, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">927,900&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,403&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916,497&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ATRS-1902 (IPR&amp;D)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,600&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Intangibles, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">976,097&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the activity impacting goodwill is presented below (in thousands):</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"><tr><td style="width:1.0%"/><td style="width:84.592%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,481&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future annual amortization of finite-lived intangible assets is shown in the following table. Actual amortization expense to be reported in future periods could differ from these estimates as a result of acquisitions, divestitures, and asset impairments, among other factors.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"/><td style="width:82.561%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.010%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Year:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,387&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,771&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,771&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916,497&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381106693984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Carrying Amounts of the Convertible Notes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount and fair value of our Convertible Notes were as follows as of the dates indicated (in thousands). </span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"><tr><td style="width:1.0%"/><td style="width:69.570%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.474%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Principal Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">895,936&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">895,936&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,263)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,517)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,055)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,745)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total unamortized debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,318)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,262)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying amount:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,419&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878,618&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876,674&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value based on trading levels (Level 2):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,678&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">711,660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718,889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of outstanding notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">884,403&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878,567&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization per period of debt discount (in years):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Interest Income and Interest Expense Disclosure</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of interest expense and the effective interest rates for each of our Convertible Notes for the periods shown (in thousands).</span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.058%"><tr><td style="width:1.0%"/><td style="width:38.997%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.023%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.023%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.023%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.026%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coupon Interest:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,006&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Coupon Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,574&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,008&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt discount:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortization of debt discount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">973&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,944&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,706&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,760&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,752&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,518&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,714&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective interest rates:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381114723088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Payment Arrangement, Noncash Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of share-based compensation expense</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense related to share-based awards excluding the acceleration of Antares unvested equity awards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was comprised of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.959%"><tr><td style="width:1.0%"/><td style="width:57.246%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.912%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,456&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,764&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,179&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,608&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,904&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,883&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,635&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,372&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,377&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,295&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of share-based compensation expense by type</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense by type of share-based award (in thousands):</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:57.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.473%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,503&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,637&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSAs, RSUs, PSUs and ESPP</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,132&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,735&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,254&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,176&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,635&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,372&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,377&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,295&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used in Black-Scholes model</a></td>
<td class="text">The assumptions used in the Black-Scholes model were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:42.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.817%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.665%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.665%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.952%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.05-41.29%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.91-44.91%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.05-41.29%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.91%-46.45%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.56-3.01%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.81-0.81%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.37-3.01%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.36%-0.81%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock', window );">Schedule of unrecognized estimated compensation cost by type</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unrecognized estimated compensation cost by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):</span></div><div style="margin-top:5pt;text-align:center;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"/><td style="width:70.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.243%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.246%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrecognized<br/>Expense</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining<br/>Weighted-Average<br/>Recognition Period<br/>(years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.81</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.82</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.41</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.46</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381113532208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (loss) per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of reconciliation of numerators and denominators of basic and diluted computations</a></td>
<td class="text">A reconciliation of the numerators and the denominators of the basic and diluted net income per common share computations is as follows (in thousands, except per share amounts):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"/><td style="width:58.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.266%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,685&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,458&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,793&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,353&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding for basic net income per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive potential common stock outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSAs, RSUs, PSUs and ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding for diluted net income per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,096&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="margin-top:11pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares which have been excluded from the calculation of diluted net income per common share because their effect was anti-dilutive, include the following (shares in millions):</span></div><div style="margin-top:11pt;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"><tr><td style="width:1.0%"/><td style="width:57.531%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.702%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>&#160;June 30,</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1). The anti-dilutive securities include outstanding stock options, unvested RSAs, unvested RSUs, unvested PSUs, common shares expected to be issued under our ESPP and Convertible Notes<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381113405888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Business (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>collaborator </div>
<div>product</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_RoyaltiesReceivedNumberOfCollaborators', window );">Royalties Received, Number of Collaborators | collaborator</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=halo_BaxaltaMember', window );">Baxalta</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_RoyaltiesReceivedNumberOfProductsSold', window );">Royalties Received, Number of Products Sold</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=halo_RocheMember', window );">Roche</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_RoyaltiesReceivedNumberOfProductsSold', window );">Royalties Received, Number of Products Sold</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=halo_JanssenMember', window );">Janssen</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_RoyaltiesReceivedNumberOfProductsSold', window );">Royalties Received, Number of Products Sold</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_RoyaltiesReceivedNumberOfCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalties Received, Number of Collaborators</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_RoyaltiesReceivedNumberOfCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_RoyaltiesReceivedNumberOfProductsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalties Received, Number of Products Sold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_RoyaltiesReceivedNumberOfProductsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=halo_BaxaltaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=halo_BaxaltaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=halo_RocheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=halo_RocheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=halo_JanssenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=halo_JanssenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381113532336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381114595696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Leases (Details)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of leases</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of leases</a></td>
<td class="text">12 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381112456864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Revenue and Cost of Product Sales (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice', window );">Period of contract termination by written notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales previously expensed as R&amp;D</a></td>
<td class="nump">$ 33,943<span></span>
</td>
<td class="nump">$ 23,018<span></span>
</td>
<td class="nump">$ 49,865<span></span>
</td>
<td class="nump">$ 41,237<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Period Of Termination By Written Notice</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381113292000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 7,326<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
<td class="nump">$ 21,627<span></span>
</td>
<td class="nump">$ 249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate, percent</a></td>
<td class="nump">8.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381114346848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Segment Information (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381033112032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 24, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Consideration related to Antares closing indebtedness settled by Halozyme</a></td>
<td class="nump">$ 19,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember', window );">Antares Pharma, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="nump">$ 1,045,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare', window );">Consideration transferred, cash paid per acquiree share (in usd per share)</a></td>
<td class="nump">$ 5.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Consideration related to Antares closing indebtedness settled by Halozyme</a></td>
<td class="nump">$ 19,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredOther1', window );">Consideration for seller transaction costs paid by Halozyme</a></td>
<td class="nump">22,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,600<span></span>
</td>
<td class="nump">$ 20,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration, liability</a></td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual', window );">Pro forma revenue of acquiree since acquisition date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,700<span></span>
</td>
<td class="nump">18,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual', window );">Proforma earnings loss of acquiree since acquisition date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,800<span></span>
</td>
<td class="num">$ (39,800)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember', window );">Antares Pharma, Inc | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, maximum borrowing capacity</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember', window );">Antares Pharma, Inc | Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, maximum borrowing capacity</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Cash Paid Per Acquiree Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredOther1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tangible or intangible assets, including a business or subsidiary of the acquirer transferred by the entity to the former owners of the acquiree. Excludes cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredOther1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=halo_TermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=halo_TermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381106820128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination -Purchase Consideration (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 24, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Consideration related to Antares closing indebtedness settled by Halozyme</a></td>
<td class="nump">$ 19,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationIntegrationRelatedCosts', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember', window );">Antares Pharma, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Cash consideration for Antares shares outstanding as of May 24, 2022</a></td>
<td class="nump">956,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards', window );">Consideration for Antares equity compensation awards</a></td>
<td class="nump">45,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredOther1', window );">Consideration for seller transaction costs paid by Halozyme</a></td>
<td class="nump">22,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Consideration related to Antares closing indebtedness settled by Halozyme</a></td>
<td class="nump">19,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_BusinessCombinationConsiderationTransferredBonusAwards', window );">Cash consideration related to cash bonus awards paid by Halozyme</a></td>
<td class="nump">365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="nump">1,045,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember', window );">Antares Pharma, Inc | Equity Compensation Awards, Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards', window );">Consideration for Antares equity compensation awards</a></td>
<td class="nump">32,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember', window );">Antares Pharma, Inc | Equity Compensation Award, Unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards', window );">Consideration for Antares equity compensation awards</a></td>
<td class="nump">$ 13,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_BusinessCombinationConsiderationTransferredBonusAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Bonus Awards</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_BusinessCombinationConsiderationTransferredBonusAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Equity Interests Issuable, Equity Compensation Awards</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredOther1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tangible or intangible assets, including a business or subsidiary of the acquirer transferred by the entity to the former owners of the acquiree. Excludes cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredOther1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationIntegrationRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationIntegrationRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=halo_ShareBasedCompensationAwardsVestedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=halo_ShareBasedCompensationAwardsVestedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=halo_ShareBasedCompensationAwardUnvestedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=halo_ShareBasedCompensationAwardUnvestedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381112566032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination - Schedule of Assets Acquired and Liabilities Assumed (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 24, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Total purchase consideration, net of $46,548 cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 999,120,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 199,481,000<span></span>
</td>
<td class="nump">$ 199,481,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember', window );">Antares Pharma, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Total purchase consideration, net of $46,548 cash acquired</a></td>
<td class="nump">999,120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash acquired</a></td>
<td class="nump">46,548,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">498,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable, net</a></td>
<td class="nump">82,160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventories, net</a></td>
<td class="nump">34,379,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">5,241,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="nump">28,661,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangibles, net</a></td>
<td class="nump">987,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts Payable</a></td>
<td class="nump">7,197,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses', window );">Accrued expenses</a></td>
<td class="nump">33,705,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability', window );">Deferred revenue, current portion</a></td>
<td class="nump">2,509,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">1,207,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities, net</a></td>
<td class="nump">159,094,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther', window );">Other long-term liabilities</a></td>
<td class="nump">135,088,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net assets acquired, excluding goodwill</a></td>
<td class="nump">799,639,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 199,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Short-Term Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Contract with Customer Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Contract with Customer Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381113317456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combination - Intangible Assets Acquired (Details) - Antares Pharma, Inc<br> $ in Thousands</strong></div></th>
<th class="th">
<div>May 24, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Estimated fair value of intangible assets acquired</a></td>
<td class="nump">$ 987,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember', window );">ATRS-1902 (IPR&amp;D)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefinitelivedIntangibleAssetsAcquired', window );">Indefinite-lived intangible assets acquired</a></td>
<td class="nump">59,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember', window );">Auto Injector technology platform</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-lived intangible assets acquired</a></td>
<td class="nump">$ 372,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (years)</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember', window );">XYOSTED proprietary product</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-lived intangible assets acquired</a></td>
<td class="nump">$ 277,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (years)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember', window );">TLANDO product rights</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-lived intangible assets acquired</a></td>
<td class="nump">$ 277,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (years)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefinitelivedIntangibleAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefinitelivedIntangibleAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_AutoInjectorTechnologyPlatformMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_AutoInjectorTechnologyPlatformMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_XYOSTEDProprietaryProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_XYOSTEDProprietaryProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_TLANDOProductRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_TLANDOProductRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381110637328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination - Summary of Proforma Financial Information (Details) - Antares Pharma, Inc - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Total Revenues</a></td>
<td class="nump">$ 168,839<span></span>
</td>
<td class="nump">$ 163,376<span></span>
</td>
<td class="nump">$ 312,538<span></span>
</td>
<td class="nump">$ 322,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 70,259<span></span>
</td>
<td class="nump">$ 60,461<span></span>
</td>
<td class="nump">$ 18,615<span></span>
</td>
<td class="nump">$ 96,752<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381112592016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Components of Available-for-sale Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 120,460<span></span>
</td>
<td class="nump">$ 622,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2,032)<span></span>
</td>
<td class="num">(620)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">118,428<span></span>
</td>
<td class="nump">622,203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">32,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">32,692<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">58,885<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(86)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">58,799<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">120,460<span></span>
</td>
<td class="nump">231,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2,032)<span></span>
</td>
<td class="num">(469)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">118,428<span></span>
</td>
<td class="nump">230,761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_NonUsMember', window );">Non-US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">282,731<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 282,731<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381033118400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>security</div>
</th>
<th class="th">
<div>May 24, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of loss positions | security</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair market value of gross unrealized loss position</a></td>
<td class="nump">$ 118,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized loss position of debt securities</a></td>
<td class="nump">2,032,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 620,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Credit losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">118,428,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">622,203,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember', window );">Antares Pharma, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=halo_AntaresPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381114591760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Contractual Maturities of Available for Sale Debt Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due within one year</a></td>
<td class="nump">$ 118,428<span></span>
</td>
<td class="nump">$ 500,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">After one but within five years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">121,238<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 118,428<span></span>
</td>
<td class="nump">$ 622,203<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381108412880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Assets Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 118,428,000<span></span>
</td>
<td class="nump">$ 622,203,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets measured on a recurring basis</a></td>
<td class="nump">189,271,000<span></span>
</td>
<td class="nump">740,910,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">32,692,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">58,799,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">118,428,000<span></span>
</td>
<td class="nump">230,761,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Non-US Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,220,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">282,731,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">70,843,000<span></span>
</td>
<td class="nump">118,707,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets measured on a recurring basis</a></td>
<td class="nump">189,271,000<span></span>
</td>
<td class="nump">349,468,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">118,428,000<span></span>
</td>
<td class="nump">230,761,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Non-US Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">70,843,000<span></span>
</td>
<td class="nump">118,707,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets measured on a recurring basis</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">391,442,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">32,692,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">58,799,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Non-US Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,220,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">282,731,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381138144464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Disaggregated Revenues (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 152,365<span></span>
</td>
<td class="nump">$ 136,455<span></span>
</td>
<td class="nump">$ 269,644<span></span>
</td>
<td class="nump">$ 225,477<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">85,340<span></span>
</td>
<td class="nump">45,778<span></span>
</td>
<td class="nump">154,945<span></span>
</td>
<td class="nump">82,701<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">46,300<span></span>
</td>
<td class="nump">30,360<span></span>
</td>
<td class="nump">68,440<span></span>
</td>
<td class="nump">52,126<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=halo_BulkrHuPH20Member', window );">bulk rHuPH20</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">25,057<span></span>
</td>
<td class="nump">24,087<span></span>
</td>
<td class="nump">41,505<span></span>
</td>
<td class="nump">40,857<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=halo_ProprietaryProductsSalesMember', window );">Proprietary Products Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">14,687<span></span>
</td>
<td class="nump">6,273<span></span>
</td>
<td class="nump">20,379<span></span>
</td>
<td class="nump">11,269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=halo_DevicePartneredProductsMember', window );">Device Partnered Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">6,556<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,556<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=halo_CollaborativeAgreementsMember', window );">Collaborative Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">20,725<span></span>
</td>
<td class="nump">60,317<span></span>
</td>
<td class="nump">46,259<span></span>
</td>
<td class="nump">90,650<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=halo_UpfrontfeesMember', window );">Upfront License Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=halo_DevelopmentFeesMember', window );">Event-Based Development Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=halo_SalesbasedmilestoneMember', window );">Sales-based milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=halo_DeviceLicensingAndDevelopmentMember', window );">Device Licensing and development revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 725<span></span>
</td>
<td class="nump">$ 317<span></span>
</td>
<td class="nump">$ 1,259<span></span>
</td>
<td class="nump">$ 650<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=halo_BulkrHuPH20Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=halo_BulkrHuPH20Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=halo_ProprietaryProductsSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=halo_ProprietaryProductsSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=halo_DevicePartneredProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=halo_DevicePartneredProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=halo_CollaborativeAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=halo_CollaborativeAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=halo_UpfrontfeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=halo_UpfrontfeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=halo_DevelopmentFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=halo_DevelopmentFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=halo_SalesbasedmilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=halo_SalesbasedmilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=halo_DeviceLicensingAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=halo_DeviceLicensingAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381110544688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 152,365<span></span>
</td>
<td class="nump">$ 136,455<span></span>
</td>
<td class="nump">$ 269,644<span></span>
</td>
<td class="nump">$ 225,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="num">(500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenues</a></td>
<td class="nump">6,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCreditsAndOtherLiabilities', window );">Deferred revenues</a></td>
<td class="nump">6,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="nump">19,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=halo_OthercollaboratorsMember', window );">Other collaborators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenues</a></td>
<td class="nump">68,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=halo_LicenseFeesAndEventBasedMember', window );">License Fees And Event-Based</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">100,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">46,300<span></span>
</td>
<td class="nump">$ 30,360<span></span>
</td>
<td class="nump">68,440<span></span>
</td>
<td class="nump">$ 52,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent', window );">Deferred revenue, current portion</a></td>
<td class="nump">$ 61,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCreditsAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income in future periods and obligations not separately disclosed in the balance sheet (other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCreditsAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income during the current period and current obligations not separately disclosed in the balance sheet (other liabilities, current).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=halo_OthercollaboratorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=halo_OthercollaboratorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=halo_LicenseFeesAndEventBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=halo_LicenseFeesAndEventBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381113719520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue - Accounts Receivable, net and Deferred Revenues from Contracts (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets', window );">Accounts receivable, net</a></td>
<td class="nump">$ 169,526<span></span>
</td>
<td class="nump">$ 90,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenues</a></td>
<td class="nump">$ 6,870<span></span>
</td>
<td class="nump">$ 4,276<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, after Allowance for Credit Loss, Current, excluding Other Contract Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381113708800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue - Additional Revenue Information (Details) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-04-01<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Deferred revenue, remaining performance obligation, expected timing</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Deferred revenue, remaining performance obligation</a></td>
<td class="nump">$ 4.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-04-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-04-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381112538240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Certain Balance Sheet Items - Accounts Receivable, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_Accountsreceivablefromproductsalestocollaborators', window );">Accounts receivable from product sales to partners</a></td>
<td class="nump">$ 56,570<span></span>
</td>
<td class="nump">$ 18,504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_Accountsreceivablefromcollaborators', window );">Accounts receivable from revenues under collaborative agreements</a></td>
<td class="nump">11,478<span></span>
</td>
<td class="nump">5,422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_Accountsreceivablefromroyalties', window );">Accounts receivable from royalty payments</a></td>
<td class="nump">87,634<span></span>
</td>
<td class="nump">63,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_Accountsreceivablefromproductsales', window );">Accounts receivable from other product sales</a></td>
<td class="nump">6,259<span></span>
</td>
<td class="nump">4,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other receivable</a></td>
<td class="nump">9,985<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="nump">19,842<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Subtotal</a></td>
<td class="nump">191,768<span></span>
</td>
<td class="nump">92,115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_AllowanceforDistributionFeesandDiscounts', window );">Allowance for distribution fees and discounts</a></td>
<td class="num">(2,400)<span></span>
</td>
<td class="num">(1,140)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Total accounts receivable, net</a></td>
<td class="nump">$ 189,368<span></span>
</td>
<td class="nump">$ 90,975<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_Accountsreceivablefromcollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due from collaborators, within one year of the balance sheet date (or the normal operating cycle, whichever is longer) for goods or services (including trade receivables) that have been delivered or sold in the normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_Accountsreceivablefromcollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_Accountsreceivablefromproductsales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable from product sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_Accountsreceivablefromproductsales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_Accountsreceivablefromproductsalestocollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable from product sales to collaborators</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_Accountsreceivablefromproductsalestocollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_Accountsreceivablefromroyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due from royalties, within one year of the balance sheet date (or the normal operating cycle, whichever is longer) for goods or services (including trade receivables) that have been delivered or sold in the normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_Accountsreceivablefromroyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AllowanceforDistributionFeesandDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allowance for Discount and Distribution Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_AllowanceforDistributionFeesandDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381107092704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Certain Balance Sheet Items - Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 10,194<span></span>
</td>
<td class="nump">$ 10,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">44,165<span></span>
</td>
<td class="nump">17,451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">43,256<span></span>
</td>
<td class="nump">25,785<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 97,615<span></span>
</td>
<td class="nump">$ 53,908<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381110637040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Certain Balance Sheet Items - Prepaid Expenses and Other Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid manufacturing expenses</a></td>
<td class="nump">$ 50,848<span></span>
</td>
<td class="nump">$ 47,991<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses</a></td>
<td class="nump">14,180<span></span>
</td>
<td class="nump">3,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">6,850<span></span>
</td>
<td class="nump">2,096<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Total prepaid expenses and other assets</a></td>
<td class="nump">71,878<span></span>
</td>
<td class="nump">53,896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Less long-term portion</a></td>
<td class="num">(26,283)<span></span>
</td>
<td class="num">(13,414)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other assets, current</a></td>
<td class="nump">$ 45,595<span></span>
</td>
<td class="nump">$ 40,482<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381033236848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Balance Sheet Items - Property and Equipment, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 45,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(13,749)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,749)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,100)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Subtotal</a></td>
<td class="nump">31,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use of assets</a></td>
<td class="nump">5,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,003<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">37,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">1,921<span></span>
</td>
<td class="nump">$ 1,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Right-of-use asset amortization</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=halo_ResearchEquipmentMember', window );">Research equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">7,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=halo_ManufacturingEquipmentMember', window );">Manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">22,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,719<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=halo_ComputerAndOfficeEquipmentMember', window );">Computer and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">6,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,370<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 8,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,628<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property, Plant, and Equipment and Operating Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=halo_ResearchEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=halo_ResearchEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=halo_ManufacturingEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=halo_ManufacturingEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=halo_ComputerAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=halo_ComputerAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381113346816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Balance Sheet Items - Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and payroll taxes</a></td>
<td class="nump">$ 15,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_Accruedmanufacturingexpenses', window );">Accrued outsourced manufacturing expenses</a></td>
<td class="nump">6,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income taxes payable</a></td>
<td class="nump">23,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerRefundLiabilityCurrent', window );">Product returns and sales allowance</a></td>
<td class="nump">21,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">706<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">15,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,648<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">7,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,820<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued expenses</a></td>
<td class="nump">89,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_AccruedLiabilitiesNoncurrent', window );">Less long-term portion</a></td>
<td class="num">(5,551)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,551)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(544)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses, current</a></td>
<td class="nump">84,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_OperatingLeaseAccretionOfLiability', window );">Expense associated with accretion of lease liabilities</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Total operating lease cost</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts related to leases</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_AccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_Accruedmanufacturingexpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued manufacturing expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_Accruedmanufacturingexpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_OperatingLeaseAccretionOfLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Accretion Of Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_OperatingLeaseAccretionOfLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 55<br> -Paragraph 27<br> -URI http://asc.fasb.org/extlink&amp;oid=123410239&amp;loc=SL49130611-203046-203046<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381116100864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Additional (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>May 24, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 199,481<span></span>
</td>
<td class="nump">$ 199,481<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381113572528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Goodwill and Other -Goodwill Rollforward (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, Beginning Balance</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired</a></td>
<td class="nump">199,481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, Ending Balance</a></td>
<td class="nump">$ 199,481<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381108614048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">$ 927,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">11,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Value</a></td>
<td class="nump">916,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">ATRS-1902 (IPR&amp;D)</a></td>
<td class="nump">59,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total Intangibles, net</a></td>
<td class="nump">$ 976,097<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_AutoInjectorTechnologyPlatformMember', window );">Auto Injector technology platform</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average remaining life (in years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">$ 372,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">5,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Value</a></td>
<td class="nump">$ 367,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_XYOSTEDProprietaryProductMember', window );">XYOSTED proprietary product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average remaining life (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">$ 277,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">2,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Value</a></td>
<td class="nump">$ 274,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_TLANDOProductRightsMember', window );">TLANDO product rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average remaining life (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">$ 277,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">2,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Value</a></td>
<td class="nump">$ 274,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_AutoInjectorTechnologyPlatformMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_AutoInjectorTechnologyPlatformMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_XYOSTEDProprietaryProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_XYOSTEDProprietaryProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_TLANDOProductRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=halo_TLANDOProductRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381114212320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets -Future Amortization (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Remainder of 2022</a></td>
<td class="nump">$ 54,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">108,771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">108,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">108,771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">108,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour', window );">Thereafter</a></td>
<td class="nump">427,026<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 916,497<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, Yea, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381030123088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt, Net - Narrative (Details)<br> $ / shares in Units, shares in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 24, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>trading_day </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2019 </div>
<div>USD ($) </div>
<div>trading_day </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 895,936,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 895,936,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 895,936,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 447,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of Debt Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,003,000<span></span>
</td>
<td class="nump">$ 424,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayments of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 369,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Amount paid for conversion of debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 370,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Stock issued for conversion of debt instrument (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InducedConversionOfConvertibleDebtExpense', window );">Induced conversion expense related to convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,960,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Proceeds from revolving credit facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_DebtInstrumentThirdPartyCosts', window );">Third-party costs</a></td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A1.25ConvertibleSeniorNotesdue2024Member', window );">1.25% Convertible Senior Notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,936,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,936,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,936,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A025ConvertibleSeniorNotesDue2027Member', window );">0.25% Convertible Senior Notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">805,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">805,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 805,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 784,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A2021CreditAgreementMember', window );">2021 Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember', window );">Credit Agreement | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, maximum borrowing capacity</a></td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Proceeds from revolving credit facilities</a></td>
<td class="nump">120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Outstanding principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember', window );">SOFR | Credit Agreement | Revolving Credit Facility | Variable Rate Component One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember', window );">Fed Funds Rate | Credit Agreement | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Credit Agreement | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | SOFR | Credit Agreement | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | SOFR | Credit Agreement | Revolving Credit Facility | Variable Rate Component Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Base Rate | Credit Agreement | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Credit Agreement | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | SOFR | Credit Agreement | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | SOFR | Credit Agreement | Revolving Credit Facility | Variable Rate Component Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Base Rate | Credit Agreement | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | 1.25% Convertible Senior Notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 460,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Lenders fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of Debt Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt Instrument, Convertible, Conversion Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.9208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt, convertible, conversion price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | 0.25% Convertible Senior Notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 805,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Lenders fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of Debt Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt Instrument, Convertible, Conversion Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.9576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt, convertible, conversion price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=halo_A025ConvertibleSeniorNotesDue2027Member', window );">0.25% Convertible Senior Notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCovenantCompliance', window );">Debt Instrument, Covenant Compliance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">in compliance<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=halo_TermLoanFacilityMember', window );">Term Loan Facility | Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, maximum borrowing capacity</a></td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Proceeds from revolving credit facilities</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Outstanding principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=halo_TermLoanFacilityMember', window );">Term Loan Facility | Credit Agreement | Year one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=halo_TermLoanFacilityMember', window );">Term Loan Facility | Credit Agreement | Year two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=halo_TermLoanFacilityMember', window );">Term Loan Facility | Credit Agreement | Year three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=halo_TermLoanFacilityMember', window );">Term Loan Facility | Credit Agreement | Year four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember', window );">Period One | Convertible Debt | 1.25% Convertible Senior Notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Debt Instrument, Convertible, Threshold Trading Days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Debt Instrument, Convertible, Threshold Consecutive Trading Days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember', window );">Period One | Convertible Debt | 0.25% Convertible Senior Notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Debt Instrument, Convertible, Threshold Trading Days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Debt Instrument, Convertible, Threshold Consecutive Trading Days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember', window );">Period Two | Convertible Debt | 1.25% Convertible Senior Notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Debt Instrument, Convertible, Threshold Trading Days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Debt Instrument, Convertible, Threshold Consecutive Trading Days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember', window );">Period Two | Convertible Debt | 0.25% Convertible Senior Notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Debt Instrument, Convertible, Threshold Trading Days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Debt Instrument, Convertible, Threshold Consecutive Trading Days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_DebtInstrumentThirdPartyCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Third-Party Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_DebtInstrumentThirdPartyCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCovenantCompliance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>States whether the entity was in compliance with the debt covenants throughout the reporting period, and describes facts and circumstances of any compliance failure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCovenantCompliance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InducedConversionOfConvertibleDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 40<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123467568&amp;loc=d3e6835-112609<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InducedConversionOfConvertibleDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=halo_A1.25ConvertibleSeniorNotesdue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=halo_A1.25ConvertibleSeniorNotesdue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=halo_A025ConvertibleSeniorNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=halo_A025ConvertibleSeniorNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=halo_A2021CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=halo_A2021CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=halo_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_VariableRateComponentAxis=halo_VariableRateComponentOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_VariableRateComponentAxis=halo_VariableRateComponentOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_VariableRateComponentAxis=halo_VariableRateComponentTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_VariableRateComponentAxis=halo_VariableRateComponentTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=halo_A025ConvertibleSeniorNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=halo_A025ConvertibleSeniorNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=halo_TermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=halo_TermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AnnualInterestPaymentPeriodAxis=halo_DebtInstrumentInterestPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_AnnualInterestPaymentPeriodAxis=halo_DebtInstrumentInterestPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AnnualInterestPaymentPeriodAxis=halo_DebtInstrumentInterestPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_AnnualInterestPaymentPeriodAxis=halo_DebtInstrumentInterestPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AnnualInterestPaymentPeriodAxis=halo_DebtInstrumentInterestPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_AnnualInterestPaymentPeriodAxis=halo_DebtInstrumentInterestPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_AnnualInterestPaymentPeriodAxis=halo_DebtInstrumentInterestPeriodFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_AnnualInterestPaymentPeriodAxis=halo_DebtInstrumentInterestPeriodFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381108410528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt, Net - Carrying Amount of Convertible Notes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Total loan balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 895,936<span></span>
</td>
<td class="nump">$ 895,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,318<span></span>
</td>
<td class="nump">19,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,048<span></span>
</td>
<td class="nump">89,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,147,129<span></span>
</td>
<td class="nump">787,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">878,618<span></span>
</td>
<td class="nump">876,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt Instrument, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">884,403<span></span>
</td>
<td class="nump">878,567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A1.25ConvertibleSeniorNotesdue2024Member', window );">1.25% Convertible Senior Notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Total loan balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,936<span></span>
</td>
<td class="nump">90,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,263<span></span>
</td>
<td class="nump">1,517<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,673<span></span>
</td>
<td class="nump">89,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt Instrument, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 172,743<span></span>
</td>
<td class="nump">159,678<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1', window );">Debt Instrument, Convertible, Remaining Discount Amortization Period</a></td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A025ConvertibleSeniorNotesDue2027Member', window );">0.25% Convertible Senior Notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Total loan balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 805,000<span></span>
</td>
<td class="nump">805,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,055<span></span>
</td>
<td class="nump">17,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">788,945<span></span>
</td>
<td class="nump">787,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt Instrument, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 711,660<span></span>
</td>
<td class="nump">$ 718,889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1', window );">Debt Instrument, Convertible, Remaining Discount Amortization Period</a></td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=halo_A1.25ConvertibleSeniorNotesdue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=halo_A1.25ConvertibleSeniorNotesdue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=halo_A025ConvertibleSeniorNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=halo_A025ConvertibleSeniorNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381108419024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt, Net - Components of Interest Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of Debt Discount (Premium)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,082<span></span>
</td>
<td class="nump">$ 1,706<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentInterest', window );">Debt Instrument, Periodic Payment, Interest</a></td>
<td class="nump">$ 787<span></span>
</td>
<td class="nump">$ 787<span></span>
</td>
<td class="nump">1,574<span></span>
</td>
<td class="nump">2,008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of Debt Discount (Premium)</a></td>
<td class="nump">973<span></span>
</td>
<td class="nump">965<span></span>
</td>
<td class="nump">1,944<span></span>
</td>
<td class="nump">1,706<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense recognized</a></td>
<td class="nump">1,760<span></span>
</td>
<td class="nump">1,752<span></span>
</td>
<td class="nump">3,518<span></span>
</td>
<td class="nump">3,714<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A1.25ConvertibleSeniorNotesdue2024Member', window );">1.25% Convertible Senior Notes due 2024 | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentInterest', window );">Debt Instrument, Periodic Payment, Interest</a></td>
<td class="nump">284<span></span>
</td>
<td class="nump">284<span></span>
</td>
<td class="nump">568<span></span>
</td>
<td class="nump">1,337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of Debt Discount (Premium)</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="nump">254<span></span>
</td>
<td class="nump">586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense recognized</a></td>
<td class="nump">$ 411<span></span>
</td>
<td class="nump">$ 409<span></span>
</td>
<td class="nump">$ 822<span></span>
</td>
<td class="nump">$ 1,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective rate at end of period</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=halo_A025ConvertibleSeniorNotesDue2027Member', window );">0.25% Convertible Senior Notes due 2027 | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentInterest', window );">Debt Instrument, Periodic Payment, Interest</a></td>
<td class="nump">$ 503<span></span>
</td>
<td class="nump">$ 503<span></span>
</td>
<td class="nump">$ 1,006<span></span>
</td>
<td class="nump">$ 671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of Debt Discount (Premium)</a></td>
<td class="nump">846<span></span>
</td>
<td class="nump">840<span></span>
</td>
<td class="nump">1,690<span></span>
</td>
<td class="nump">1,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense recognized</a></td>
<td class="nump">$ 1,349<span></span>
</td>
<td class="nump">$ 1,343<span></span>
</td>
<td class="nump">$ 2,696<span></span>
</td>
<td class="nump">$ 1,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective rate at end of period</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=halo_A1.25ConvertibleSeniorNotesdue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=halo_A1.25ConvertibleSeniorNotesdue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=halo_A025ConvertibleSeniorNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=halo_A025ConvertibleSeniorNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381108324448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Share-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">36,300<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 5,635<span></span>
</td>
<td class="nump">$ 5,372<span></span>
</td>
<td class="nump">$ 10,377<span></span>
</td>
<td class="nump">$ 10,295<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">2,503<span></span>
</td>
<td class="nump">2,637<span></span>
</td>
<td class="nump">5,123<span></span>
</td>
<td class="nump">5,119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=halo_RSURSAandPRSUawardsMember', window );">RSAs, RSUs, PSUs and ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">3,132<span></span>
</td>
<td class="nump">2,735<span></span>
</td>
<td class="nump">5,254<span></span>
</td>
<td class="nump">5,176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">2,456<span></span>
</td>
<td class="nump">1,764<span></span>
</td>
<td class="nump">4,473<span></span>
</td>
<td class="nump">3,412<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 3,179<span></span>
</td>
<td class="nump">$ 3,608<span></span>
</td>
<td class="nump">$ 5,904<span></span>
</td>
<td class="nump">$ 6,883<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=halo_RSURSAandPRSUawardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=halo_RSURSAandPRSUawardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381033269840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,635<span></span>
</td>
<td class="nump">$ 5,372<span></span>
</td>
<td class="nump">$ 10,377<span></span>
</td>
<td class="nump">$ 10,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">36,300<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=halo_A2021ESPPPlanMember', window );">2021 ESPP Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,665,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,665,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,503<span></span>
</td>
<td class="nump">$ 2,637<span></span>
</td>
<td class="nump">$ 5,123<span></span>
</td>
<td class="nump">$ 5,119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=halo_RSURSAandPRSUawardsMember', window );">RSAs, RSUs, PSUs and ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,132<span></span>
</td>
<td class="nump">$ 2,735<span></span>
</td>
<td class="nump">$ 5,254<span></span>
</td>
<td class="nump">$ 5,176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock | 2021 ESPP Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">ESPP purchase price of common stock, percent of market price</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount', window );">Maximum contribution amount</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate', window );">Minimum employee subscription rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum employee subscription rate</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod', window );">Purchase period (in months)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Minimum Employee Subscription Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=halo_A2021ESPPPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=halo_A2021ESPPPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=halo_RSURSAandPRSUawardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=halo_RSURSAandPRSUawardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381108360672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Assumptions Used in the Black-Scholes Model (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems', window );"><strong>Schedule of Share-based Compensation Arrangements Valuation Inputs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Average expected term (in years)</a></td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">2.56%<span></span>
</td>
<td class="nump">0.81%<span></span>
</td>
<td class="nump">1.37%<span></span>
</td>
<td class="nump">0.36%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">3.01%<span></span>
</td>
<td class="nump">0.81%<span></span>
</td>
<td class="nump">3.01%<span></span>
</td>
<td class="nump">0.81%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems', window );"><strong>Schedule of Share-based Compensation Arrangements Valuation Inputs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">41.05%<span></span>
</td>
<td class="nump">44.91%<span></span>
</td>
<td class="nump">41.05%<span></span>
</td>
<td class="nump">44.91%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems', window );"><strong>Schedule of Share-based Compensation Arrangements Valuation Inputs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">41.29%<span></span>
</td>
<td class="nump">44.91%<span></span>
</td>
<td class="nump">41.29%<span></span>
</td>
<td class="nump">46.45%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Schedule of Share-based Compensation Arrangements Valuation Inputs [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>halo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381033227392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation - Unrecognized Estimated Compensation Cost (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized Expense</a></td>
<td class="nump">$ 28,109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Remaining Weighted-Average Recognition Period (years)</a></td>
<td class="text">2 years 9 months 21 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized Expense</a></td>
<td class="nump">$ 33,922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Remaining Weighted-Average Recognition Period (years)</a></td>
<td class="text">2 years 9 months 25 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized Expense</a></td>
<td class="nump">$ 5,073<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Remaining Weighted-Average Recognition Period (years)</a></td>
<td class="text">2 years 4 months 28 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized Expense</a></td>
<td class="nump">$ 172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Remaining Weighted-Average Recognition Period (years)</a></td>
<td class="text">5 months 15 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381108283248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit) (textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="nump">$ 550,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramPeriodInForce1', window );">Stock Repurchase Program, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Stock repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Weighted-average price paid per share (USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43.02<span></span>
</td>
<td class="nump">$ 23.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Stock repurchased (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="nump">6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 125,021,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=halo_AcceleratedShareRepurchaseAgreementMember', window );">Accelerated share repurchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit) (textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Stock repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Stock repurchased (shares)</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit) (textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares of common stock issued as a result of stock option exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,216<span></span>
</td>
<td class="nump">591,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Stock options weighted average exercise price (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.94<span></span>
</td>
<td class="nump">$ 13.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Net proceeds from stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300,000<span></span>
</td>
<td class="nump">$ 8,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit) (textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Stock issued during period, shares, restricted stock award, net of forfeitures (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">248,343<span></span>
</td>
<td class="nump">290,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Number of RSUs withheld to pay for minimum withholding taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,425<span></span>
</td>
<td class="nump">91,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments for tax withholding for restricted stock units vested, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,300,000<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=halo_StockOptionsAndRestrictedStockUnitsMember', window );">Stock options and restricted units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit) (textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding stock options and restricted stock units (in shares)</a></td>
<td class="nump">6,800,000<span></span>
</td>
<td class="nump">5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramPeriodInForce1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which shares may be purchased under a stock repurchase plan authorized by an entity's Board of Directors, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramPeriodInForce1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=halo_AcceleratedShareRepurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=halo_AcceleratedShareRepurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=halo_StockOptionsAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=halo_StockOptionsAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381108581664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (loss) per share - Summary (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 22,685<span></span>
</td>
<td class="nump">$ 91,458<span></span>
</td>
<td class="nump">$ 82,793<span></span>
</td>
<td class="nump">$ 119,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding for basic net income (loss) per share (shares)</a></td>
<td class="nump">137,937<span></span>
</td>
<td class="nump">142,487<span></span>
</td>
<td class="nump">137,798<span></span>
</td>
<td class="nump">140,201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding for diluted net income (loss) per share (shares)</a></td>
<td class="nump">142,216<span></span>
</td>
<td class="nump">147,624<span></span>
</td>
<td class="nump">141,795<span></span>
</td>
<td class="nump">148,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (USD per share)</a></td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="nump">$ 0.64<span></span>
</td>
<td class="nump">$ 0.60<span></span>
</td>
<td class="nump">$ 0.85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (USD per share)</a></td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="nump">$ 0.62<span></span>
</td>
<td class="nump">$ 0.58<span></span>
</td>
<td class="nump">$ 0.81<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive potential common stock outstanding (shares)</a></td>
<td class="nump">1,709<span></span>
</td>
<td class="nump">1,758<span></span>
</td>
<td class="nump">1,484<span></span>
</td>
<td class="nump">4,210<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive potential common stock outstanding (shares)</a></td>
<td class="nump">2,274<span></span>
</td>
<td class="nump">2,932<span></span>
</td>
<td class="nump">2,182<span></span>
</td>
<td class="nump">3,076<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive potential common stock outstanding (shares)</a></td>
<td class="nump">296<span></span>
</td>
<td class="nump">447<span></span>
</td>
<td class="nump">331<span></span>
</td>
<td class="nump">609<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140381113605600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (loss) per share - Antidilutive Securities (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from per share calculation (in shares)</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">13,500<span></span>
</td>
<td class="nump">15,300<span></span>
</td>
<td class="nump">13,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>halo-20220630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:halo="http://www.halozyme.com/20220630"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="halo-20220630.xsd" xlink:type="simple"/>
    <context id="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i73af0220bff74c0b84c26e30e7814735_I20220802">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <instant>2022-08-02</instant>
        </period>
    </context>
    <context id="ia8f041b537984ded88384fd5745e75e2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibbcde496e999416f83088ace845dbf65_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2302c2baba3a4084b1cd7169564a4517_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ifecd7d767a3c48d6a094b68ee21e3340_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i488611ceda1e4bf3a1df6ada966c72ff_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie448ea4ebc7a4047b9528cc3d06dac35_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iefbbc65edf2e4319adad4df5fa76e1f3_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9220796b173a4a9298008c86f02bacf1_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id5cfeb9eb65745ed9779cd8409a1de20_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0d0fdcb3db8c45fdb97bc693b3691d65_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5331ecfa85164578966f7ba36c8377ac_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:CollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i88e4277b0c454a79a9c899981c6d0ade_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:CollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if13d9aa4327240bcaf9417558eeae8c3_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:CollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic72a2d641a084db2bfd8a448fdafa5bb_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:CollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i07515ff25e39495196802eb714e47e89_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if3b15a6a41d2423d9142e3d2a1b50b32_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaed74cb4c1b045a48ff8547f85ae3d8e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia62abf9a289242aaacca39406bc0f1e4_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie9f7dc1cc92f4c1690a144db55ad717c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia5e07277da1a43438f0f8d84d2f7bc96_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0c9b3b22251847568c83ac3f79ea4436_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i678f6fef80154c5b8c01dadcd09593ac_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9b633a2efd834d73bd14291c139ac728_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i64fb6378ac874aa599802032078bb7e5_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6a959347106f415cb34e9be834baba86_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5c00abe406104a5fa545c8d934524371_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i09401d5b007348c08fa5bd1cce5097ce_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id807b2395d514e89a6ed524bc67e0ed3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i01b7804e8c8443c18f2bf4001bc7328d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id2a2ebb74994496290986a6cbda39dc8_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i57063aa70d174824a4db07d8773b05bf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i39034bfa63bd4a90ac54d7016591ef9d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iac6ced6cc2b3433c8b37d84dc56b068e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6a77403a19ee410d81160e0a394e0979_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic61e51e1f5f94cd39c6967eae2703020_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ieb6ff5498b9346a8b865a91ca3bb935c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i37c4cbbc8ea6440cb197130f93f66a30_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0c794de6a0af4c0a9af7f772745e791c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id6b066604d9e4d658947efe4930f28f6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie27fff43f3db4d7d8d49ecaaf23b1d61_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7e4238b1c16a4fd28a06ed5e284bb84a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i727d5a62b3f847b797bca56701f39cf9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if67373bdd7be4012b17710d463c192a1_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i380920b6a9284e80ae55f918a1ae24cb_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i12326da779a8483f93c5e05dd4d6d7c4_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6f15b7f19dfa4b62bc91d2ad4477ae61_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4c838a1fe9a644b6956ff4487ba688eb_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i14d6ff976f1c46d0bae0a1ff38eae093_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iac7f0b69fa364a3e83aa58d5f386c6ca_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i26444fd86b024585b6b74771eb48128a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7985573ca9a44f7ea10f5ecb82f97c91_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie2bb1215be014cfeae503eb2306453b0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie6ca52ba2c1e43a7b6a8fd1d47849366_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2ca0a460bc7a457a905e2205ba207797_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i256c983ac3a44d07b5c0bbac2a5206ef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if563dcd8d731444e986d351aa923f779_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id3449ce3d1a2440f9631288531d75f21_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i715d67b1e934443c87c14fc6a9baf147_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3b21a0a518454ebb9f2099e2057850ed_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6dbcbf35901d41ee95e2479d1b0cc0e8_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i322f16862e9a44f9ad3ca6a551d79a4f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8939fd0a8f934008b17b41bf8467d682_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">halo:BaxaltaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie69bf9190a574ccbbe399d8da056c46e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">halo:RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6aeb602d0b6f4c559f18892fc21aa407_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">halo:JanssenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i03b0b3511b2544be8e14af45977bfbce_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iecce61f93caa4b668869678174aa5845_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4bc0e55590f348ac92553d587cadfd3d_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="i475bb2a82ae54a4286363422e755c916_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="i86ae6c3b418d4a88aa081e1790735e1b_I20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-24</instant>
        </period>
    </context>
    <context id="i5c984de515d647a5b30035159dcaec53_I20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-24</instant>
        </period>
    </context>
    <context id="i00acc9b249264652bb496012352851f4_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if15049277def4dcdb9cbdffbe5d753f1_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i615a905f496c4c0d9f797e929cacf41f_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">halo:ShareBasedCompensationAwardsVestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="i82c9562114b64891bb65718130793579_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">halo:ShareBasedCompensationAwardUnvestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="i1e07b7230a7b4293910918c1158913a7_I20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-24</instant>
        </period>
    </context>
    <context id="i77c93c8b4e414609a78dfb4f6f64ed57_I20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <instant>2022-05-24</instant>
        </period>
    </context>
    <context id="i36b527310aeb4abebd94653011e3f9db_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:AutoInjectorTechnologyPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="i079a89cb03c6429c974b822df12e4303_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:XYOSTEDProprietaryProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="i827e16b84dc24a16a310f235506fdd09_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:TLANDOProductRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="i89ede30c1fb341e6b5c377169cbac030_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="i5a3a21a6a5d44d869b7b90d70c8531c7_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id9372d0e89f64744be923e43620998cc_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">halo:AntaresPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4fc34bcf05bf42a1ad015e84425c8d0d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i919614e2dc9744fea40ea36e3bad8795_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i02b96f8f266746e5bef1a7a56d0020d7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4c5035736b1a4598ae99008fbf3463ef_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i729eff0e2b1b45abacd1da9f077ac641_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3327c7ae03814e5b98e511ab356d1e06_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie6a49dbb96ea4e068ffae31a73e0450d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifbbf1f4395c847e88fbb88a23315b862_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibadaba53276e46a791964bbdd74a640d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4820381fb1924e4b8f10130527b2a041_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7582cec4a13c42d3948f9997e4a05ea2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i524d67132d7a47e18cfb74ff6a106bd6_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4d8fc069e3434518b16ab9ff92f7ac83_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib35f4ff4fd844014ad607bcd93940767_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i08ee73d0afc54dd4af894979a2e3d955_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i70626fa06a394bfb9bd482b2edc20c84_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i394b8f9cfd4246c9ad0423ab43c011ee_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i8b150997591648f4bb1e80dcf1a1016c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i8b00c3afda9e45bb8cd0405f8b5f14a0_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib42d2c1ec2894fec8370868a75e097f5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4b3fe709b3f74022a916820d6a66f819_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i30d3e114033048b4bf56fe57daa86654_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaff254b4c0d8405ba942acab54575f2f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib8485788d2894891ac3dbdffaa1a04f6_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i35bedd3b896a45e6bef76a745aea55b8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie6f16378a34f47e5bc64f9f37e501985_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8679bef0769643ff80b9deb03b454f3e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibf47bb6ce3e3440e8d32edd5fa5d2a77_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1ce27062172c4df39f203c5fbbcda25d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0355f361557b4963951d67530b3f33a4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if0a3288eab784be19fb61c3da624b2ce_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i46f6abf3fb844711ba56aa80aa191fde_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4fb4248efc9c4394903dd84bafe5032c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icf3f9180d2d54718b7d17a4b462cd60f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i797d735ce11e40a3a597d7b067205876_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0c825fe74c2e4db9a79927b3f36b3b4b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie3ddca14e94e4ee7bc84deba437d724a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ied28f46dba994350bcda53f1634bf3dd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie1965c9e97674996b395dc7e83265e6e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i41ce1d46c93d4d23a5dcc7490d03b394_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9d7cfdf4a9444c87946ea6f8f8104d55_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ifbee317a1c93450289e3face1229333c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i35a6d850025546848755145a7abf15b7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8114c060d9e745e0ad9ea5a8ccb12e9b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i73361786868247609ad6e713642b4441_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i18df9e45de3648af8edb0ce21a72898c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib6fcbc87cdee4fccae17a9f9a6e02d05_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i41ae64b0863d43efb250b560920603c1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic37ed5614087440da569f079f0f651bd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia715fa809717495ca3ea42208886f693_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i30cb808ae8294ad2963b8d25bd8ddd70_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:BulkrHuPH20Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib5ac7dbc74fd416bba2eecdc24f27658_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:BulkrHuPH20Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i61902b5268704612925502d224a5f0dc_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:BulkrHuPH20Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia1581eb1b56a4683bd3a80a5ce16e03c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:BulkrHuPH20Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5576b7ccca364865ba7aae184bb4cf37_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:ProprietaryProductsSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5b180128f3634ec092ab2d598df56185_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:ProprietaryProductsSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i727ff9da39cc4faab1ee412cb6667251_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:ProprietaryProductsSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6c83d19f90094700a1790868f713787d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:ProprietaryProductsSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5b1f6429290349caa513971198a9d7f3_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DevicePartneredProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iccc79e0e6fcd45f7baf4dc4675fdb639_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DevicePartneredProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic38072713d2a499bb6a5b530797ec390_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DevicePartneredProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="idff30f1d38214c3cbaa6aa448432d11c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DevicePartneredProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6c4e1c2852834e3db83be2ab724c4ec7_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:UpfrontfeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9b169ddfeec745d1be5c150f76f1b9ce_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:UpfrontfeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id99a3d7ca0084d3c8ad32c30e53803ca_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:UpfrontfeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i29bf66c271ba4ae7987ec7bd8ff4520f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:UpfrontfeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i68f176f459d54d48893f0655ba31ec14_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DevelopmentFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i044be8133aeb4fe6a48b3663a56504bc_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DevelopmentFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i120c080d9b5a4f57b9e656994552257c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DevelopmentFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ifaf7a7f2b9314cabb0bba3ca0238fc37_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DevelopmentFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i667bd7d9d0494b2f898d65a0be893385_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:SalesbasedmilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id4f91bfe396b4e2fabebbdcc9ab97e9a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:SalesbasedmilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0177b2094d7a422a923115b1b3b4755d_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:SalesbasedmilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1b98cb4091434500999a3bd53a43e318_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:SalesbasedmilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id036393f1ef94ab59c494be346f81453_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DeviceLicensingAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if2c6a315d3c94850a81a0adb2158a25b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DeviceLicensingAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i889d129efa02476986931ae8af732baa_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DeviceLicensingAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8770b425828c4e6cadb0c28e912fc453_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:DeviceLicensingAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iffcd168ae7a94e5db1b32f7feb3a8b62_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:LicenseFeesAndEventBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ice04128a0ca3439cae58ae72f295f29f_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">halo:LicenseFeesAndEventBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1ce4ecc3d70b49ab961fee2475a6ee4e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">halo:OthercollaboratorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i065c6dc939e647029141b2829def68d5_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i70ed32619a3c450b95acdcb7833975bf_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic9bf3392f031425891062f5e0f545ba6_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ResearchEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i91ce62cbf8364228b4b121202d34470e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ResearchEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i51bfe79b4f7f4ddea8ca6aecd47c6748_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5e78480ba6bd4f1d9d17749c899a126b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib8be187f821b4c40912a67590b98722f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if48f37b3f1b94e6bb28d9642c03cb051_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">halo:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifef082b6dbf1487f9b03c2077818edec_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia927806080fd413c87442beab744f69b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifb0dbd53c41e477d9ab6a6f8b2df947a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:AutoInjectorTechnologyPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3e8b070a3aa646febf62fbbd0ae3ce5e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:AutoInjectorTechnologyPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie6cf0130a2b443be99ea94b47e536125_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:XYOSTEDProprietaryProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="icd6500afde964db6843f15bf9ff223c9_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:XYOSTEDProprietaryProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="idab608f91ce0499fb31e66934a3d01cd_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:TLANDOProductRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib9cf38a8f67047f4b770a4b2f6f4c0c4_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">halo:TLANDOProductRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i930ea774bf7d4904b46c5d6ce72d032d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic0d782f4478a4d7ea80f060e128b6b7a_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="idd66a9946d9840eba7c66b86f6e2fe5a_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ifd4cd55303894cb1aa89a03028006576_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9bc3be2ae627408894cf317b830d625e_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i79862e9f8f4240af943f624cdae37039_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i92d9886e9d374222a3d3959bf913fd55_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="iae83682afbfd42498583c6364b173a85_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="i9dffca0ebc3943fe8411a72b02312868_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="i564c0f73ae6841618d8d0305f3c128f2_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="ibc9e7ea69dc54bc580f0327b080e6620_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="i522b480a4e0c413cbd63f8e8b3903d03_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7db32790c0274f1b85142a533eef25ea_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie4bc8fa5f8b24012aff99c9e405c3c38_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia71fa90d90d249b2826bd60cb35507b5_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ifb771b640f1343b39c99c088eeaa56cc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0b4b3f5b65f748fea9d3a16a4370a81e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9dac37b234cb4e39aa59635df2320abd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3f9a5cd5449946e383c3e70f8ef08350_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iac94068bcee94ca094f560cb73997234_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i50e1360e4c7b4de39282c845c5d73c43_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i765e5eeb91e54b43b5f00f6ebddec276_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i421730450b74464b90e09befbd503cfc_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9858e2352550465683b249270d6735a6_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5021845805034e388a208b835a6c92c0_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9ec81c8774a34665930c2c67a277cbbf_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i00e19a2b430241ed99f4d4d16ef7f9d0_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ifd0b274a39124464a2f81ffe163b7216_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib06303cf7360468aad8efb6d193ac2e0_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="idf400d7ec4c1409c979f5a18ed50eed6_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4c76ed9108314a75b3e7842e7f8460ec_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0d86d5b0f18546fa82fc1f13b48c7daa_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i78253359e5ad475094259801bb6c9cca_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i87582d2ecc124f6db85794fe5ea82eb5_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A1.25ConvertibleSeniorNotesdue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i904690f836a44521b7c1da764f701566_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia588495e94d64915826033625b6cae2d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A025ConvertibleSeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i09b74f6ef1644d8e930a5c4759e82823_I20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:A2021CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="ib607a4df5a844d5ebe887a6e5e01a915_I20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-24</instant>
        </period>
    </context>
    <context id="i5bbab44d4d5c4f71b7e66b61049265a3_I20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-24</instant>
        </period>
    </context>
    <context id="ie899756b47294e60987e6e1a4eefdc3e_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="ibb0fc522997c467cbcef1d255211f031_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="i02f9ba7cd53c4aa2923afca3b66da448_I20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="halo:AnnualInterestPaymentPeriodAxis">halo:DebtInstrumentInterestPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-24</instant>
        </period>
    </context>
    <context id="ib893c55155b64b2d9ba4c8642f2c3120_I20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="halo:AnnualInterestPaymentPeriodAxis">halo:DebtInstrumentInterestPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-24</instant>
        </period>
    </context>
    <context id="i2d84d81913354102bacd27bce79cae8a_I20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="halo:AnnualInterestPaymentPeriodAxis">halo:DebtInstrumentInterestPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-24</instant>
        </period>
    </context>
    <context id="ib5959be9d203461f9800ee2d21d52824_I20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="halo:AnnualInterestPaymentPeriodAxis">halo:DebtInstrumentInterestPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-24</instant>
        </period>
    </context>
    <context id="icd07e3cd9dc54a55ac0339e3aa933aa6_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="halo:VariableRateComponentAxis">halo:VariableRateComponentOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="i39c021912c0a4737966b6fc9307a0131_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="i3b5fd9edb8e049a19ff19cafcd90c13b_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="ia986ec6d3c6d41d2a6808a4f5cfcff5c_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="i1dce68f7e11a4d3a8fa7baa2b614c2aa_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="i3809e60efe0d46cab0ef2132238b94c8_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="i64eaeaec62e1494894adad24d117aef9_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="halo:VariableRateComponentAxis">halo:VariableRateComponentTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="i71fba559ee5e40e6895e295b7e58d09a_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="halo:VariableRateComponentAxis">halo:VariableRateComponentTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="i10a6ebe671434acfac51d92f04f6b880_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="ia1a876b10c4244179ee15979f3e64628_D20220524-20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="i79fb023f35cc4ee996ea4cb525c92c5f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="icac5073a8dfa4150a03fa81e7c9db6f9_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">halo:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">halo:TermLoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0b599c875f4f40e294c8d28f8eb1e582_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7cfceed396a74b66a22f992517fbad65_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i59eefa49da754fc4a678bcfece8e4fa5_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5b377684337249a79d005226a445c9d3_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie13a988e22704be5a5271b3555ac5742_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibc0b6f8877784e66b28f844b0f81f44c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibbf1cd99aace4cbfa194e2f7dedc5157_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i57f7d92fa5174c7a9550dfc6b218d957_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1c0e86c5373e4602b110c2747e91ff9a_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibb8fed0bdf764dd2bd8a75a83eba117c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i46d36ab336df48ad98a01cfdfc1a2696_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if8257a7f99e248c4b487a6942b94aec0_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i03beebbe6fad4ae4a59c0a56d53de652_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:RSURSAandPRSUawardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ifa122ca61ec54b1c824632d4d8f8bd63_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:RSURSAandPRSUawardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8786b34524304c2c89d022706441552b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:RSURSAandPRSUawardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib3dfae04892c4acfbec9d00a8bc5641d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:RSURSAandPRSUawardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2b9b85bf65324a6796a32c109822a4ae_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic7177752d30b457e85b8d0e18806711a_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia075a8f22ebb4c19bcb72e7ad3ead56a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia02f509257fd46da8f0a5f3e5e678761_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i132fba3a55ea459d84aa0bb90100bdd7_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ifa39c538bf934a02b5928070f514abbb_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i543c949f5482411dabdc5d1d89631950_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib0f607a6eb8841f78c2d102cf0eab6aa_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i21d64138ff854e21be215de2a288c045_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">halo:A2021ESPPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i96a1543f8d6e4bfbb485a55166a6038c_I20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">halo:A2021ESPPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="i49fcdbfe0faf49d1a3e26def4e7b572f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">halo:A2021ESPPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib6ded8ac2e08484aa08a3116e39e8ed6_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">halo:A2021ESPPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i039a8cae3d874e6fb7155efc49a70811_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i90338c7e90e04fbb88f9eaebe6f9c0a4_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i846c45d299c548bd93d9ca4e31ef2c27_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="icd47428a7d224a1cb5358f0397539915_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ife8e3a854f8d4e9a9d92bcbe808224ee_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8d6e73a624be47fea5d20e683c6bea8e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="idc726257139b49b6a58fe70d504a57d9_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i68a4a2f139194eaf961414023ef77512_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iea8e1a13442143e58800a7fa395d7502_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0c6331a6ec0e49a3ba11830898b654f5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">halo:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ida58a610325c429a94dfe3fb62450540_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="if2cda56e59c543bdb0c8c9ac8c626f34_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6eddd51f62374e059ee58a39542c4f58_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if429dbd362794e36ab10ac51992df878_D20191101-20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="i02c1d101b0e4433cb0667cb17eedd9ca_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic73a9ae57f1f4045a6e76817123e3ac0_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">halo:AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia44d229bf8fa4a2cbef0e366dafed174_D20220601-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">halo:AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie55dcf742b2e4dffa0c703e02b2973d4_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i589ea088db504147b0ffc55414faf533_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1a8ca59aa7d8490c970c1e0dae5c4eae_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i472657a1189640ed803ebfce1b25d59f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7fd2c85ec0bb4267bea086d8a0cd4161_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic7f900d934cc4dfca248ded4a6faaf36_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i24cfdda4dd3d45168530f3505f70dc4d_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibfecde32e655413b98a5b79476a9c15f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001159036</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="collaborator">
        <measure>halo:collaborator</measure>
    </unit>
    <unit id="product">
        <measure>halo:product</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>halo:segment</measure>
    </unit>
    <unit id="security">
        <measure>halo:security</measure>
    </unit>
    <unit id="trading_day">
        <measure>halo:trading_day</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180L2ZyYWc6YTgwOWFiNmNiNTY3NDI1NTk2ZDdjOTgxMzFjYjEyMzAvdGFibGU6M2Y0Yjk0Zjk5YzgwNGZjMjhiYzAwNDNjN2U3NjM2ZDUvdGFibGVyYW5nZTozZjRiOTRmOTljODA0ZmMyOGJjMDA0M2M3ZTc2MzZkNV8xLTEtMS0xLTQ3ODAx_fc33a280-c0dc-448c-8f0a-58aad57a998a">0001159036</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180L2ZyYWc6YTgwOWFiNmNiNTY3NDI1NTk2ZDdjOTgxMzFjYjEyMzAvdGFibGU6M2Y0Yjk0Zjk5YzgwNGZjMjhiYzAwNDNjN2U3NjM2ZDUvdGFibGVyYW5nZTozZjRiOTRmOTljODA0ZmMyOGJjMDA0M2M3ZTc2MzZkNV8yLTEtMS0xLTQ3ODAx_218ed7ec-e5a3-45fa-8cfe-de7fa9b66473">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180L2ZyYWc6YTgwOWFiNmNiNTY3NDI1NTk2ZDdjOTgxMzFjYjEyMzAvdGFibGU6M2Y0Yjk0Zjk5YzgwNGZjMjhiYzAwNDNjN2U3NjM2ZDUvdGFibGVyYW5nZTozZjRiOTRmOTljODA0ZmMyOGJjMDA0M2M3ZTc2MzZkNV8zLTEtMS0xLTQ3ODAx_c15c1158-47d6-4fb3-99e5-6a4e6e9d6b51">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180L2ZyYWc6YTgwOWFiNmNiNTY3NDI1NTk2ZDdjOTgxMzFjYjEyMzAvdGFibGU6M2Y0Yjk0Zjk5YzgwNGZjMjhiYzAwNDNjN2U3NjM2ZDUvdGFibGVyYW5nZTozZjRiOTRmOTljODA0ZmMyOGJjMDA0M2M3ZTc2MzZkNV80LTEtMS0xLTQ3ODAx_9b3579af-cd1f-49f9-9466-e9f5a4188501">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180L2ZyYWc6YTgwOWFiNmNiNTY3NDI1NTk2ZDdjOTgxMzFjYjEyMzAvdGFibGU6M2Y0Yjk0Zjk5YzgwNGZjMjhiYzAwNDNjN2U3NjM2ZDUvdGFibGVyYW5nZTozZjRiOTRmOTljODA0ZmMyOGJjMDA0M2M3ZTc2MzZkNV81LTEtMS0xLTQ3ODAx_73a865cb-f8b5-4e81-9ec2-e962d0175ccc">--06-30</dei:CurrentFiscalYearEndDate>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i70ed32619a3c450b95acdcb7833975bf_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181OC9mcmFnOmRiMTk5MTNjMzE2YjRlMzE4YzRhOTdlOGEyMDE5MjlhL3RhYmxlOjc3ODljNDgzY2IzZjQ5MzZhZTlkYTg3ZmNjNjE0MzUxL3RhYmxlcmFuZ2U6Nzc4OWM0ODNjYjNmNDkzNmFlOWRhODdmY2M2MTQzNTFfMS0xLTEtMS00NzgwMQ_a958d286-9d61-4224-ad66-7007d509228e">P12M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:StockRepurchaseProgramPeriodInForce1
      contextRef="i02c1d101b0e4433cb0667cb17eedd9ca_D20211201-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMTUzMw_f787b3d2-f4a4-40e0-98f4-002839096391">P3Y</us-gaap:StockRepurchaseProgramPeriodInForce1>
    <dei:DocumentType
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGV4dHJlZ2lvbjoxOTVlODlhNTRlYmQ0NjUzODdiOGYxNDk5Njg5OWJmOV8xODA0_3c294a08-26c0-4afb-a8d5-a965f01943ec">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGFibGU6ZTE2OTA0ODFlOTliNGRiY2JmZjRkYjU4NzRmZThlOTIvdGFibGVyYW5nZTplMTY5MDQ4MWU5OWI0ZGJjYmZmNGRiNTg3NGZlOGU5Ml8wLTAtMS0xLTQ3ODAx_b9320bd8-d064-4221-bb05-df1cdc5c4bd3">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGV4dHJlZ2lvbjoxOTVlODlhNTRlYmQ0NjUzODdiOGYxNDk5Njg5OWJmOV8xMzQ_9b9b3d80-3220-4f18-81d5-49604edcecb9">2022-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGFibGU6YzQ0MjJmYmRjMDc5NGFjZmIyMGY3NTcxMzlkMmQyNzQvdGFibGVyYW5nZTpjNDQyMmZiZGMwNzk0YWNmYjIwZjc1NzEzOWQyZDI3NF8wLTAtMS0xLTQ3ODAx_7259ae3e-2b4f-4b9b-9fd0-2b8e76bf2d23">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGV4dHJlZ2lvbjoxOTVlODlhNTRlYmQ0NjUzODdiOGYxNDk5Njg5OWJmOV8xODAx_e02706c4-1ed2-4cda-ab78-96a3c6ef0f4f">001-32335</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGV4dHJlZ2lvbjoxOTVlODlhNTRlYmQ0NjUzODdiOGYxNDk5Njg5OWJmOV8xNzk3_3a6fcb1b-9ba2-4833-81a7-700e7d709e35">HALOZYME THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGFibGU6OTYxOGZhYzU4OTA3NGZkYTlmNDNhY2YzNDQzNGMyMjUvdGFibGVyYW5nZTo5NjE4ZmFjNTg5MDc0ZmRhOWY0M2FjZjM0NDM0YzIyNV8wLTAtMS0xLTQ3ODAx_6cfcdd40-2028-4276-a491-f08b90ca6243">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGFibGU6OTYxOGZhYzU4OTA3NGZkYTlmNDNhY2YzNDQzNGMyMjUvdGFibGVyYW5nZTo5NjE4ZmFjNTg5MDc0ZmRhOWY0M2FjZjM0NDM0YzIyNV8wLTItMS0xLTQ3ODAx_ac295ef2-d5df-43f9-a91a-01bde10255fb">88-0488686</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGFibGU6OTYxOGZhYzU4OTA3NGZkYTlmNDNhY2YzNDQzNGMyMjUvdGFibGVyYW5nZTo5NjE4ZmFjNTg5MDc0ZmRhOWY0M2FjZjM0NDM0YzIyNV8zLTAtMS0xLTQ3ODAx_a7ae3d3a-b659-4cf6-a722-833e86f187c4">11388 Sorrento Valley Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGFibGU6OTYxOGZhYzU4OTA3NGZkYTlmNDNhY2YzNDQzNGMyMjUvdGFibGVyYW5nZTo5NjE4ZmFjNTg5MDc0ZmRhOWY0M2FjZjM0NDM0YzIyNV8zLTItMS0xLTQ3ODAx_91a5b43d-7ee4-4a28-b89c-64a6197e3d9f">92121</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGFibGU6OTYxOGZhYzU4OTA3NGZkYTlmNDNhY2YzNDQzNGMyMjUvdGFibGVyYW5nZTo5NjE4ZmFjNTg5MDc0ZmRhOWY0M2FjZjM0NDM0YzIyNV80LTAtMS0xLTQ3ODAx_5fb7f4c6-0138-4ad6-8e37-df6d20973d1f">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGFibGU6OTYxOGZhYzU4OTA3NGZkYTlmNDNhY2YzNDQzNGMyMjUvdGFibGVyYW5nZTo5NjE4ZmFjNTg5MDc0ZmRhOWY0M2FjZjM0NDM0YzIyNV81LTAtMS0xLTQ3ODAx_ec60de9d-ab4f-4f4a-b029-f8635545a392">CA</dei:EntityAddressStateOrProvince>
    <dei:CityAreaCode
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGV4dHJlZ2lvbjoxOTVlODlhNTRlYmQ0NjUzODdiOGYxNDk5Njg5OWJmOV8xNzk4_206fe21a-7adb-4dfc-b198-e0b574573489">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGV4dHJlZ2lvbjoxOTVlODlhNTRlYmQ0NjUzODdiOGYxNDk5Njg5OWJmOV8xODAy_5f642421-6248-4c71-a739-90681c4c889d">794-8889</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGFibGU6NmQyNmRiOTU2NjAyNDljYzlkN2RkYjEwZTMzMGNjZGQvdGFibGVyYW5nZTo2ZDI2ZGI5NTY2MDI0OWNjOWQ3ZGRiMTBlMzMwY2NkZF8xLTAtMS0xLTQ3ODAx_17ce1eea-18bd-42a3-a4b4-a90b97a409a2">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGFibGU6NmQyNmRiOTU2NjAyNDljYzlkN2RkYjEwZTMzMGNjZGQvdGFibGVyYW5nZTo2ZDI2ZGI5NTY2MDI0OWNjOWQ3ZGRiMTBlMzMwY2NkZF8xLTEtMS0xLTQ3ODAx_d7efc617-bdb5-4eaa-b144-f6a3e7efd7fc">HALO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGFibGU6NmQyNmRiOTU2NjAyNDljYzlkN2RkYjEwZTMzMGNjZGQvdGFibGVyYW5nZTo2ZDI2ZGI5NTY2MDI0OWNjOWQ3ZGRiMTBlMzMwY2NkZF8xLTItMS0xLTQ3ODAx_ae3b6731-00c2-4837-9de2-0b312a8cbe83">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGV4dHJlZ2lvbjoxOTVlODlhNTRlYmQ0NjUzODdiOGYxNDk5Njg5OWJmOV8xODAz_aa725dcb-3676-4651-96b7-7e71b0df2735">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGV4dHJlZ2lvbjoxOTVlODlhNTRlYmQ0NjUzODdiOGYxNDk5Njg5OWJmOV8xNzk5_2a939cc9-f8c3-4fd9-b2d1-987b41896c2a">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGFibGU6ZjMzNzBiYTkxODA3NDllNzk5Mjk1MWUwZWE1ZTliOTkvdGFibGVyYW5nZTpmMzM3MGJhOTE4MDc0OWU3OTkyOTUxZTBlYTVlOWI5OV8wLTAtMS0xLTQ3ODAx_9cf3d7c5-058d-4317-a1c6-f39aaa08f61b">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGFibGU6ZjMzNzBiYTkxODA3NDllNzk5Mjk1MWUwZWE1ZTliOTkvdGFibGVyYW5nZTpmMzM3MGJhOTE4MDc0OWU3OTkyOTUxZTBlYTVlOWI5OV8xLTMtMS0xLTQ3ODAx_dd63f45c-5a40-47d5-b863-0e6e7b35a4a6">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGFibGU6ZjMzNzBiYTkxODA3NDllNzk5Mjk1MWUwZWE1ZTliOTkvdGFibGVyYW5nZTpmMzM3MGJhOTE4MDc0OWU3OTkyOTUxZTBlYTVlOWI5OV8yLTMtMS0xLTQ3ODAx_c6d2bf7f-2abb-4b5f-a124-d0b606f5d411">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGV4dHJlZ2lvbjoxOTVlODlhNTRlYmQ0NjUzODdiOGYxNDk5Njg5OWJmOV8xODAw_4200c5a9-93d8-456d-b1db-0196f1e1ba0c">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i73af0220bff74c0b84c26e30e7814735_I20220802"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xL2ZyYWc6MTk1ZTg5YTU0ZWJkNDY1Mzg3YjhmMTQ5OTY4OTliZjkvdGV4dHJlZ2lvbjoxOTVlODlhNTRlYmQ0NjUzODdiOGYxNDk5Njg5OWJmOV8xNzgy_fd525d12-c39a-4747-8db1-da798cffb6c9"
      unitRef="shares">137779370</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMy0yLTEtMS00NzgwMQ_ad3c84b6-4b33-4d44-91bd-4952795f3e37"
      unitRef="usd">90932000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMy00LTEtMS00NzgwMQ_02a03b13-585d-4977-991d-005e4adcff99"
      unitRef="usd">118719000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfNC0yLTEtMS00NzgwMQ_0aa28eda-6ab2-4349-b184-242b559d78cc"
      unitRef="usd">118428000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfNC00LTEtMS00NzgwMQ_5cf2c69f-d01c-412f-adf4-31bae1b745ec"
      unitRef="usd">622203000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfNS0yLTEtMS00NzgwMQ_e7aca5e2-35c8-4e1a-8406-33b8612e43c6"
      unitRef="usd">189368000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfNS00LTEtMS00NzgwMQ_c17c6176-a72d-4e18-bd76-fc7cb8b0d5a5"
      unitRef="usd">90975000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfNi0yLTEtMS00NzgwMQ_a8929514-b043-4c6d-a50f-8bc174365051"
      unitRef="usd">97615000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfNi00LTEtMS00NzgwMQ_83dd31a4-da74-4c4c-b169-bb497ecd0f3c"
      unitRef="usd">53908000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfNy0yLTEtMS00NzgwMQ_0071273d-7d87-4fcb-8ca1-dfccbf2b2635"
      unitRef="usd">45595000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfNy00LTEtMS00NzgwMQ_a9710c0b-369c-4623-834d-bfaf9fe12a63"
      unitRef="usd">40482000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfOC0yLTEtMS00NzgwMQ_a7c3d446-5dab-4b3b-a883-85c34ede2045"
      unitRef="usd">541938000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfOC00LTEtMS00NzgwMQ_f03fd4eb-199e-41d1-960c-ad1ac5b05f96"
      unitRef="usd">926287000</us-gaap:AssetsCurrent>
    <halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfOS0yLTEtMS00NzgwMQ_5c1d2be8-d56c-4146-90d2-1f4a46a74078"
      unitRef="usd">37091000</halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfOS00LTEtMS00NzgwMQ_c88397a7-21e6-4f72-bda8-15df3e7f5618"
      unitRef="usd">8794000</halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMTAtMi0xLTEtNDc4MDE_354035b5-8c41-4032-b1cb-99b0b2ce5019"
      unitRef="usd">26283000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMTAtNC0xLTEtNDc4MDE_c502011c-57cd-4885-b612-63bc87339af2"
      unitRef="usd">13414000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:Goodwill
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMTEtMi0xLTEtNTAxMjA_1e8a0ec9-d736-4a17-9f7d-958942a80e86"
      unitRef="usd">199481000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMTEtNC0xLTEtNTAxMjc_0c1aa864-22ad-4c49-aecc-1d734beb9ce9"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMTItMi0xLTEtNTAxMjA_add42e21-b609-4af3-9267-61d8992497d1"
      unitRef="usd">976097000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMTItNC0xLTEtNTAxMjc_aa76334a-acfb-4441-8b7b-94b6c879d96d"
      unitRef="usd">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMTEtMi0xLTEtNDc4MDE_4a191d78-dc64-4719-b1a4-dc8cfb278fa8"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMTEtNC0xLTEtNDc4MDE_125f81a9-ec20-45f0-bd7f-8080fa10d3f5"
      unitRef="usd">155434000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMTItMi0xLTEtNDc4MDE_c47694da-816f-4a29-b2fc-8af45f3a5d29"
      unitRef="usd">500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMTItNC0xLTEtNDc4MDE_55084aa2-405f-44e1-b068-7c1766cc5a62"
      unitRef="usd">500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:Assets
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMTMtMi0xLTEtNDc4MDE_cad02db4-0658-478c-a7d1-48ecd9f670f6"
      unitRef="usd">1781390000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMTMtNC0xLTEtNDc4MDE_f8efb009-b7be-4cf2-b9c4-72149f256ec0"
      unitRef="usd">1104429000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMTctMi0xLTEtNDc4MDE_a8c358e4-0fa4-4496-ac86-2a5c62de6d76"
      unitRef="usd">12232000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMTctNC0xLTEtNDc4MDE_4b348b15-576f-4aa8-baf0-82b0143a0de5"
      unitRef="usd">1541000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMTgtMi0xLTEtNDc4MDE_61d40961-d433-4c46-b30e-2baff0140e58"
      unitRef="usd">84101000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMTgtNC0xLTEtNDc4MDE_809e3d7e-eb64-479c-bd8d-16b961b0c8ef"
      unitRef="usd">24441000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMTktMi0xLTEtNDc4MDE_9f9ae700-8b19-4059-ba73-ae19379ca721"
      unitRef="usd">4131000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMTktNC0xLTEtNDc4MDE_25a3b981-e140-4697-a787-1d5fef7cbc61"
      unitRef="usd">1746000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjAtMi0xLTEtNDc4MDE_82e006a9-47ff-4051-a6fa-06fe7b1fd0d6"
      unitRef="usd">99048000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjAtNC0xLTEtNDc4MDE_14afe1dc-b4ae-4184-899e-e0182fdd50e4"
      unitRef="usd">89419000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjEtMi0xLTEtNDc4MDE_a89e2a61-6e59-4801-8932-a2eae8abcb5a"
      unitRef="usd">199512000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjEtNC0xLTEtNDc4MDE_1c9a00fa-f375-4e21-9a54-8c8923c5f594"
      unitRef="usd">117147000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjItMi0xLTEtNDc4MDE_23c79696-f31e-4ab2-8729-5dafcdf0bf75"
      unitRef="usd">2739000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjItNC0xLTEtNDc4MDE_fc2a3485-46ce-482b-a7c0-8e1090f2baad"
      unitRef="usd">2530000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:LongTermDebt
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjMtMi0xLTEtNDc4MDE_5e4c09cf-5b3d-450d-bd03-0da484893045"
      unitRef="usd">1147129000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjMtNC0xLTEtNDc4MDE_3c276ce1-f719-4639-a48a-9483d78e7a31"
      unitRef="usd">787255000</us-gaap:LongTermDebt>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjQtMi0xLTEtNDc4MDE_0a63b4d4-6a48-4d4d-9361-3b130bdc019c"
      unitRef="usd">5551000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjQtNC0xLTEtNDc4MDE_334f83b7-82eb-4e89-ad9d-d7d0698a6cbe"
      unitRef="usd">544000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjctMi0xLTEtNjEyMTA_294c269e-95f0-475b-a236-053dfda1a767"
      unitRef="usd">3288000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjctNC0xLTEtNjEyMjQ_201dbe58-11c8-4d0b-a33e-b1e76aa69f03"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjctMi0xLTEtNTQ4ODU_a8dae0bd-f427-4836-8f1a-378a5f4dc00d"
      unitRef="usd">130000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjctNC0xLTEtNTQ4OTM_f3cab9fa-6a66-4df6-b6ed-f077671721f9"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjUtMi0xLTEtNDc4MDE_d2c5e1c6-eb9e-4b58-9b93-513f9d15288b"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjUtNC0xLTEtNDc4MDE_303e4ccb-7af4-4a89-b69f-ab73fdfa8bc4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjctMC0xLTEtNDc4MDEvdGV4dHJlZ2lvbjo2NzZhM2VhNDk4MzE0ZTY3ODkxNmU4ZTkwYWRmMDhjNl8yMg_e07f430c-9df7-46aa-b0f3-3b9ddddcaed2"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjctMC0xLTEtNDc4MDEvdGV4dHJlZ2lvbjo2NzZhM2VhNDk4MzE0ZTY3ODkxNmU4ZTkwYWRmMDhjNl8yMg_fd66dfaf-ce20-489e-aeed-7cb195dfe1c0"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjctMC0xLTEtNDc4MDEvdGV4dHJlZ2lvbjo2NzZhM2VhNDk4MzE0ZTY3ODkxNmU4ZTkwYWRmMDhjNl8zNg_9966d590-95fe-4c43-b83c-eb9795985f53"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjctMC0xLTEtNDc4MDEvdGV4dHJlZ2lvbjo2NzZhM2VhNDk4MzE0ZTY3ODkxNmU4ZTkwYWRmMDhjNl8zNg_ab47fd08-6912-40a8-b419-052a95965df2"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjctMC0xLTEtNDc4MDEvdGV4dHJlZ2lvbjo2NzZhM2VhNDk4MzE0ZTY3ODkxNmU4ZTkwYWRmMDhjNl81OA_1e5c20b1-a161-46b9-aeea-5eb445f14ce0"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjctMC0xLTEtNDc4MDEvdGV4dHJlZ2lvbjo2NzZhM2VhNDk4MzE0ZTY3ODkxNmU4ZTkwYWRmMDhjNl81OA_572cc325-a4ee-45ad-856e-2f81bbac5adc"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjctMC0xLTEtNDc4MDEvdGV4dHJlZ2lvbjo2NzZhM2VhNDk4MzE0ZTY3ODkxNmU4ZTkwYWRmMDhjNl81OA_7a2db87b-537f-49ed-a2f8-29e39b3b5f49"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjctMC0xLTEtNDc4MDEvdGV4dHJlZ2lvbjo2NzZhM2VhNDk4MzE0ZTY3ODkxNmU4ZTkwYWRmMDhjNl81OA_e9696133-15df-47bd-9224-35f2935263c5"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjctMi0xLTEtNDc4MDE_efca8b59-47a7-4020-a096-83dc6b1f6b36"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjctNC0xLTEtNDc4MDE_8673db7b-9bd6-4953-85f7-4a8a6b261836"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjgtMC0xLTEtNDc4MDEvdGV4dHJlZ2lvbjo2ZWNjNTFjMjFmMjQ0YjBkODE2OTk1MmE2ZDcxMjkwYl8xOQ_1e505b16-98b8-4e26-b126-d3cbb5c827a7"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjgtMC0xLTEtNDc4MDEvdGV4dHJlZ2lvbjo2ZWNjNTFjMjFmMjQ0YjBkODE2OTk1MmE2ZDcxMjkwYl8xOQ_a50c7eec-930e-4f80-9bf9-57b10e2f92be"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjgtMC0xLTEtNDc4MDEvdGV4dHJlZ2lvbjo2ZWNjNTFjMjFmMjQ0YjBkODE2OTk1MmE2ZDcxMjkwYl8zMw_4e585c26-e225-423b-bb68-94ec6d694ddc"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjgtMC0xLTEtNDc4MDEvdGV4dHJlZ2lvbjo2ZWNjNTFjMjFmMjQ0YjBkODE2OTk1MmE2ZDcxMjkwYl8zMw_dd4e6a3e-adc7-4e60-9b48-74c24904a55e"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjgtMC0xLTEtNDc4MDEvdGV4dHJlZ2lvbjo2ZWNjNTFjMjFmMjQ0YjBkODE2OTk1MmE2ZDcxMjkwYl81NQ_0c18b088-b750-430e-ab83-709b398eb577"
      unitRef="shares">137681000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjgtMC0xLTEtNDc4MDEvdGV4dHJlZ2lvbjo2ZWNjNTFjMjFmMjQ0YjBkODE2OTk1MmE2ZDcxMjkwYl81NQ_153aa585-5bbc-4bef-b39b-d803feac14d2"
      unitRef="shares">137681000</us-gaap:CommonStockSharesIssued>
    <us-gaap:SharesOutstanding
      contextRef="ibbcde496e999416f83088ace845dbf65_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjgtMC0xLTEtNDc4MDEvdGV4dHJlZ2lvbjo2ZWNjNTFjMjFmMjQ0YjBkODE2OTk1MmE2ZDcxMjkwYl82Mg_ba9a13cd-2260-4684-ab8a-174fd7304c72"
      unitRef="shares">137498000</us-gaap:SharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjgtMi0xLTEtNDc4MDE_50f33a50-76a9-4309-91ad-7cfeafae458a"
      unitRef="usd">138000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjgtNC0xLTEtNDc4MDE_39024a37-2671-439c-abb1-b07f4c9639af"
      unitRef="usd">138000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjktMi0xLTEtNDc4MDE_4095f9df-d6bc-471e-8f1d-a7df140d75e3"
      unitRef="usd">271169000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMjktNC0xLTEtNDc4MDE_3fff563b-a53f-4f07-bb3c-d7e17ed9857d"
      unitRef="usd">256347000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMzAtMi0xLTEtNDc4MDE_6f219974-683a-4775-acb2-daaf873facf5"
      unitRef="usd">-2017000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMzAtNC0xLTEtNDc4MDE_20c3583f-e510-4998-9975-14dd247042aa"
      unitRef="usd">-620000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMzEtMi0xLTEtNDc4MDE_b73119dd-be7b-4687-b387-70d112dabfff"
      unitRef="usd">23881000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMzEtNC0xLTEtNDc4MDE_5aee779a-021a-4946-99cb-a9b2ed2d3f1f"
      unitRef="usd">-58912000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMzItMi0xLTEtNDc4MDE_00cbbdef-1378-48fe-b8fd-0d31247f19b0"
      unitRef="usd">293171000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMzItNC0xLTEtNDc4MDE_5e9cf375-38b6-4604-b5a0-9de75e78fc2c"
      unitRef="usd">196953000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMzMtMi0xLTEtNDc4MDE_c98f5c41-8bf0-40a7-8260-5fedd36374af"
      unitRef="usd">1781390000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xOS9mcmFnOjFjM2JlMDdjNDhlYTRkZjQ4YTJhNzJkNjllZTdiYTgxL3RhYmxlOmM2NzM4ODk2M2YyZjQ3ZTJiZGZhODYzNzcxNjg3OTBlL3RhYmxlcmFuZ2U6YzY3Mzg4OTYzZjJmNDdlMmJkZmE4NjM3NzE2ODc5MGVfMzMtNC0xLTEtNDc4MDE_3f6a4744-b4a3-4c94-874e-2e4def9372f7"
      unitRef="usd">1104429000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2302c2baba3a4084b1cd7169564a4517_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMy0yLTEtMS00NzgwMQ_c2f396aa-bdcd-4e53-9649-3a6a710b2773"
      unitRef="usd">85340000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifecd7d767a3c48d6a094b68ee21e3340_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMy00LTEtMS00NzgwMQ_71b7807b-b1af-4548-bd89-e059d6e3e2eb"
      unitRef="usd">45778000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i488611ceda1e4bf3a1df6ada966c72ff_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMy02LTEtMS00NzgwMQ_7888c8c4-0ef0-4624-baf7-05b5e6e78c1d"
      unitRef="usd">154945000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie448ea4ebc7a4047b9528cc3d06dac35_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMy04LTEtMS00NzgwMQ_4f48cdd4-b6e7-48ce-bfdf-3ed4049c5e71"
      unitRef="usd">82701000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iefbbc65edf2e4319adad4df5fa76e1f3_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfNC0yLTEtMS00NzgwMQ_a826e5dd-a4f2-4395-bd6b-59a3b293243b"
      unitRef="usd">46300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9220796b173a4a9298008c86f02bacf1_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfNC00LTEtMS00NzgwMQ_76729442-4a74-46ac-ad81-ee0af370af6e"
      unitRef="usd">30360000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id5cfeb9eb65745ed9779cd8409a1de20_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfNC02LTEtMS00NzgwMQ_389384c6-1224-4708-b5e6-0362089eb059"
      unitRef="usd">68440000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0d0fdcb3db8c45fdb97bc693b3691d65_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfNC04LTEtMS00NzgwMQ_da092fce-2379-49cb-ae55-49c88eec6ded"
      unitRef="usd">52126000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5331ecfa85164578966f7ba36c8377ac_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfNS0yLTEtMS00NzgwMQ_0a974d9c-302c-499d-860e-32ab262f8def"
      unitRef="usd">20725000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i88e4277b0c454a79a9c899981c6d0ade_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfNS00LTEtMS00NzgwMQ_7aa646fa-6be8-4474-aecc-5ff86be08e4a"
      unitRef="usd">60317000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if13d9aa4327240bcaf9417558eeae8c3_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfNS02LTEtMS00NzgwMQ_d0d4d3ed-0578-407f-b65b-0d5c3c99fd60"
      unitRef="usd">46259000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic72a2d641a084db2bfd8a448fdafa5bb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfNS04LTEtMS00NzgwMQ_87f7687c-51ae-4c4b-a971-c76a07dc0950"
      unitRef="usd">90650000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfNi0yLTEtMS00NzgwMQ_5001e0b7-578c-4358-a707-db5986f44847"
      unitRef="usd">152365000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfNi00LTEtMS00NzgwMQ_bfe89e09-7222-478c-8eab-cb0c569c691d"
      unitRef="usd">136455000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfNi02LTEtMS00NzgwMQ_8c43bbed-c334-4d79-b27e-a9d021dd79aa"
      unitRef="usd">269644000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfNi04LTEtMS00NzgwMQ_7712a555-19a8-4d6a-bcf6-ae5ee4b6a41a"
      unitRef="usd">225477000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfOC0yLTEtMS00NzgwMQ_e3c59560-5f13-42ce-b1f3-7352ccab8ce0"
      unitRef="usd">33943000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfOC00LTEtMS00NzgwMQ_f85b1a7e-c042-43df-a6a8-ba17130436e3"
      unitRef="usd">23018000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfOC02LTEtMS00NzgwMQ_9bd694db-4a23-432e-93c4-7807099e0d9b"
      unitRef="usd">49865000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfOC04LTEtMS00NzgwMQ_0951ea85-de43-4614-af1c-4bd5b00fce5f"
      unitRef="usd">41237000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfOS0yLTEtMS01ODcyNQ_67a6926d-b60a-4784-a1ac-4cc78d5e0ef7"
      unitRef="usd">11403000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfOS00LTEtMS01ODczMg_55df2673-7d44-42b0-911b-e904076776c8"
      unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfOS02LTEtMS01ODczOQ_5cc4db4e-dbdd-4b63-986f-b08e43bec53b"
      unitRef="usd">11403000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfOS04LTEtMS01ODc0Ng_29daae19-74ad-46d6-bf0a-6e38c750fad1"
      unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfOS0yLTEtMS00NzgwMQ_39076623-9065-4b02-8897-f76f3176bf11"
      unitRef="usd">15483000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfOS00LTEtMS00NzgwMQ_43f9dc87-7d55-4730-b094-9385653ebcf0"
      unitRef="usd">8069000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfOS02LTEtMS00NzgwMQ_2f99143f-a388-4e57-b840-b9c2d9994da8"
      unitRef="usd">27336000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfOS04LTEtMS00NzgwMQ_ac384f87-f318-4e5b-8862-419e024c48d1"
      unitRef="usd">17078000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTAtMi0xLTEtNDc4MDE_ca504eb2-47e7-4937-9d1a-d7816dd09c58"
      unitRef="usd">57476000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTAtNC0xLTEtNDc4MDE_cb931620-7b12-40c0-9e8d-1ec1c98f5780"
      unitRef="usd">12321000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTAtNi0xLTEtNDc4MDE_95d9749c-82cc-49f7-b2b6-30e3894feec7"
      unitRef="usd">71310000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTAtOC0xLTEtNDc4MDE_c9346d05-6281-41d0-a855-8b59be8445b2"
      unitRef="usd">23380000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTEtMi0xLTEtNDc4MDE_3aec1171-1cca-45ca-91e9-d26597d6af05"
      unitRef="usd">118305000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTEtNC0xLTEtNDc4MDE_6269cda7-9bbd-4af9-bbc4-af944563577c"
      unitRef="usd">43408000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTEtNi0xLTEtNDc4MDE_f6911c7b-52e9-4447-a95e-9ef441c228de"
      unitRef="usd">159914000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTEtOC0xLTEtNDc4MDE_033cd66f-26e4-484f-8d80-7b6a3cae50f5"
      unitRef="usd">81695000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTItMi0xLTEtNDc4MDE_49c27242-2312-471c-b381-f0d1e2625282"
      unitRef="usd">34060000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTItNC0xLTEtNDc4MDE_ed485071-0e6d-4945-9f0a-7c2896af91cb"
      unitRef="usd">93047000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTItNi0xLTEtNDc4MDE_b86aee11-7740-4c94-bb3c-4b345ed83f82"
      unitRef="usd">109730000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTItOC0xLTEtNDc4MDE_f74872a4-f2f7-4a0c-bcdd-5b9154470023"
      unitRef="usd">143782000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTQtMi0xLTEtNDc4MDE_d8a8fd67-c063-480f-a326-3b06bb3cbd4b"
      unitRef="usd">-945000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTQtNC0xLTEtNDc4MDE_541e44f7-53fe-4e77-95b6-b7ae8a768f19"
      unitRef="usd">221000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTQtNi0xLTEtNDc4MDE_8ac3ec6b-3c0b-4b73-a69f-5e34f57c88e1"
      unitRef="usd">-447000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTQtOC0xLTEtNDc4MDE_000ae063-2a5c-4f73-b837-dbcecb539955"
      unitRef="usd">497000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InducedConversionOfConvertibleDebtExpense
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTUtMi0xLTEtNDc4MDE_d852fb40-626f-4f7d-bf77-063a5db575d2"
      unitRef="usd">0</us-gaap:InducedConversionOfConvertibleDebtExpense>
    <us-gaap:InducedConversionOfConvertibleDebtExpense
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTUtNC0xLTEtNDc4MDE_7ba65d53-695c-4f9e-ae26-f219df868043"
      unitRef="usd">0</us-gaap:InducedConversionOfConvertibleDebtExpense>
    <us-gaap:InducedConversionOfConvertibleDebtExpense
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTUtNi0xLTEtNDc4MDE_942331eb-bcf8-4802-9649-9cef298d2d17"
      unitRef="usd">0</us-gaap:InducedConversionOfConvertibleDebtExpense>
    <us-gaap:InducedConversionOfConvertibleDebtExpense
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTUtOC0xLTEtNDc4MDE_9b451ca6-df15-40eb-a070-d8bec119d070"
      unitRef="usd">20960000</us-gaap:InducedConversionOfConvertibleDebtExpense>
    <us-gaap:InterestExpense
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTYtMi0xLTEtNDc4MDE_30ae56ec-3ba9-41bb-99b4-7fe76d8a0e7d"
      unitRef="usd">3104000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTYtNC0xLTEtNDc4MDE_0a64a006-33ac-401e-be59-f45b8964248a"
      unitRef="usd">1752000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTYtNi0xLTEtNDc4MDE_0a47a69e-bbd6-4353-8d07-7edca669af4a"
      unitRef="usd">4863000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTYtOC0xLTEtNDc4MDE_25b35e4d-ee9f-4f5e-a7a6-2060847c1ce1"
      unitRef="usd">3717000</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTctMi0xLTEtNDc4MDE_4721deb4-fe4e-47ad-9d73-c23eecb7f0ae"
      unitRef="usd">30011000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTctNC0xLTEtNDc4MDE_24a4bf4e-d508-4d31-b240-efb559493ae9"
      unitRef="usd">91516000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTctNi0xLTEtNDc4MDE_9a3d46b6-a230-4031-8901-1c3880df16dd"
      unitRef="usd">104420000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTctOC0xLTEtNDc4MDE_8c3e5f8c-568e-4eb4-85fb-00b026877fd5"
      unitRef="usd">119602000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTgtMi0xLTEtNDc4MDE_ba48ff0c-95d8-4747-b836-534f3ab47456"
      unitRef="usd">7326000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTgtNC0xLTEtNDc4MDE_eb5da88a-5ab1-4dca-8efd-2ddb4603ede6"
      unitRef="usd">58000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTgtNi0xLTEtNDc4MDE_9a6a9410-62e0-411a-95a9-22a3f8e1a473"
      unitRef="usd">21627000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTgtOC0xLTEtNDc4MDE_103c59db-3f2e-411f-83f5-7ca2703deedf"
      unitRef="usd">249000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTktMi0xLTEtNDc4MDE_b854388d-e3fd-4fa3-8855-20458af28a5b"
      unitRef="usd">22685000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTktNC0xLTEtNDc4MDE_176fce60-02a9-4dee-a93b-41d148685c09"
      unitRef="usd">91458000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTktNi0xLTEtNDc4MDE_a0754598-91f1-4937-8bb8-d82427c9b01c"
      unitRef="usd">82793000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMTktOC0xLTEtNDc4MDE_786b2ab9-7142-411f-83c4-d7eb6d91474d"
      unitRef="usd">119353000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMjItMi0xLTEtNDc4MDE_1d2092c9-27ac-4a6f-8b38-09f855b78a38"
      unitRef="usdPerShare">0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMjItNC0xLTEtNDc4MDE_7552e1b1-c3ee-47ef-89dc-4c0246a1290f"
      unitRef="usdPerShare">0.64</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMjItNi0xLTEtNDc4MDE_523b7e11-a8e2-409e-aedc-aa4e8791e748"
      unitRef="usdPerShare">0.60</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMjItOC0xLTEtNDc4MDE_9f546968-24d4-4837-bde9-41718f13d2b8"
      unitRef="usdPerShare">0.85</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMjMtMi0xLTEtNDc4MDE_8995a73b-5ccb-4438-a3c6-eff5ea978e53"
      unitRef="usdPerShare">0.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMjMtNC0xLTEtNDc4MDE_aee1a367-b89e-4924-8293-c2bd74fca42b"
      unitRef="usdPerShare">0.62</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMjMtNi0xLTEtNDc4MDE_bf0eb8de-d3f7-431d-b291-a424d5f94f1b"
      unitRef="usdPerShare">0.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMjMtOC0xLTEtNDc4MDE_e93a9c21-20fc-45f2-8de4-1115bfea56fe"
      unitRef="usdPerShare">0.81</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMjYtMi0xLTEtNDc4MDE_cff2ced6-d891-420c-8900-b6d609a9b7ef"
      unitRef="shares">137937000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMjYtNC0xLTEtNDc4MDE_ee6523cf-b967-4eb8-adeb-fa4211cd1a61"
      unitRef="shares">142487000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMjYtNi0xLTEtNDc4MDE_36eebfc3-0083-49ce-9127-3bda4721a6fc"
      unitRef="shares">137798000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMjYtOC0xLTEtNDc4MDE_89e6a812-a2d3-4534-93c2-9653f10161c6"
      unitRef="shares">140201000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMjctMi0xLTEtNDc4MDE_22cd4c1b-79bc-4da8-976c-d4a8d8094bf7"
      unitRef="shares">142216000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMjctNC0xLTEtNDc4MDE_25f7537f-48e6-40f9-9b09-a8242b15f633"
      unitRef="shares">147624000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMjctNi0xLTEtNDc4MDE_bca66a71-04cb-4465-8896-c65ab56a3800"
      unitRef="shares">141795000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yNS9mcmFnOmUwODA3NDhiNzQzZjRiMjFhNDcwMDljNDk1NjZiZTkxL3RhYmxlOjhhYTk1MWE4OTNmYTRmYmRhYTg0OTUyNDI2MzViYjA0L3RhYmxlcmFuZ2U6OGFhOTUxYTg5M2ZhNGZiZGFhODQ5NTI0MjYzNWJiMDRfMjctOC0xLTEtNDc4MDE_4d518a34-00c9-4da5-a89c-e1969cdb4823"
      unitRef="shares">148096000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yOC9mcmFnOmRkNGQ3ZTA1NGZkZDQzYWE5MWIyOWY1OGRlNTk5NTc2L3RhYmxlOjhhOWI1M2Y4ZDhjODQzNWNhMTBjZTVkN2NmZTY4ZGFlL3RhYmxlcmFuZ2U6OGE5YjUzZjhkOGM4NDM1Y2ExMGNlNWQ3Y2ZlNjhkYWVfMi0yLTEtMS00NzgwMQ_85b363d4-a679-442b-baa8-ad436f7b43ee"
      unitRef="usd">22685000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yOC9mcmFnOmRkNGQ3ZTA1NGZkZDQzYWE5MWIyOWY1OGRlNTk5NTc2L3RhYmxlOjhhOWI1M2Y4ZDhjODQzNWNhMTBjZTVkN2NmZTY4ZGFlL3RhYmxlcmFuZ2U6OGE5YjUzZjhkOGM4NDM1Y2ExMGNlNWQ3Y2ZlNjhkYWVfMi00LTEtMS00NzgwMQ_c154d82d-6939-45b0-940a-bc0ef625135c"
      unitRef="usd">91458000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yOC9mcmFnOmRkNGQ3ZTA1NGZkZDQzYWE5MWIyOWY1OGRlNTk5NTc2L3RhYmxlOjhhOWI1M2Y4ZDhjODQzNWNhMTBjZTVkN2NmZTY4ZGFlL3RhYmxlcmFuZ2U6OGE5YjUzZjhkOGM4NDM1Y2ExMGNlNWQ3Y2ZlNjhkYWVfMi02LTEtMS00NzgwMQ_a0754598-91f1-4937-8bb8-d82427c9b01c"
      unitRef="usd">82793000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yOC9mcmFnOmRkNGQ3ZTA1NGZkZDQzYWE5MWIyOWY1OGRlNTk5NTc2L3RhYmxlOjhhOWI1M2Y4ZDhjODQzNWNhMTBjZTVkN2NmZTY4ZGFlL3RhYmxlcmFuZ2U6OGE5YjUzZjhkOGM4NDM1Y2ExMGNlNWQ3Y2ZlNjhkYWVfMi04LTEtMS00NzgwMQ_786b2ab9-7142-411f-83c4-d7eb6d91474d"
      unitRef="usd">119353000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yOC9mcmFnOmRkNGQ3ZTA1NGZkZDQzYWE5MWIyOWY1OGRlNTk5NTc2L3RhYmxlOjhhOWI1M2Y4ZDhjODQzNWNhMTBjZTVkN2NmZTY4ZGFlL3RhYmxlcmFuZ2U6OGE5YjUzZjhkOGM4NDM1Y2ExMGNlNWQ3Y2ZlNjhkYWVfNC0yLTEtMS00NzgwMQ_31c3175d-30d5-4fa8-a1f7-f2ecf84fccdc"
      unitRef="usd">732000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yOC9mcmFnOmRkNGQ3ZTA1NGZkZDQzYWE5MWIyOWY1OGRlNTk5NTc2L3RhYmxlOjhhOWI1M2Y4ZDhjODQzNWNhMTBjZTVkN2NmZTY4ZGFlL3RhYmxlcmFuZ2U6OGE5YjUzZjhkOGM4NDM1Y2ExMGNlNWQ3Y2ZlNjhkYWVfNC00LTEtMS00NzgwMQ_170e2384-ac7d-4ad0-991b-27da34771a55"
      unitRef="usd">-1000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yOC9mcmFnOmRkNGQ3ZTA1NGZkZDQzYWE5MWIyOWY1OGRlNTk5NTc2L3RhYmxlOjhhOWI1M2Y4ZDhjODQzNWNhMTBjZTVkN2NmZTY4ZGFlL3RhYmxlcmFuZ2U6OGE5YjUzZjhkOGM4NDM1Y2ExMGNlNWQ3Y2ZlNjhkYWVfNC02LTEtMS00NzgwMQ_d1fab9fd-1a94-4fdb-a5ca-d82e97ce56a7"
      unitRef="usd">-1439000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yOC9mcmFnOmRkNGQ3ZTA1NGZkZDQzYWE5MWIyOWY1OGRlNTk5NTc2L3RhYmxlOjhhOWI1M2Y4ZDhjODQzNWNhMTBjZTVkN2NmZTY4ZGFlL3RhYmxlcmFuZ2U6OGE5YjUzZjhkOGM4NDM1Y2ExMGNlNWQ3Y2ZlNjhkYWVfNC04LTEtMS00NzgwMQ_9bf040b3-d5b9-449e-8aab-89f645ad47ac"
      unitRef="usd">-84000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yOC9mcmFnOmRkNGQ3ZTA1NGZkZDQzYWE5MWIyOWY1OGRlNTk5NTc2L3RhYmxlOjhhOWI1M2Y4ZDhjODQzNWNhMTBjZTVkN2NmZTY4ZGFlL3RhYmxlcmFuZ2U6OGE5YjUzZjhkOGM4NDM1Y2ExMGNlNWQ3Y2ZlNjhkYWVfNS0yLTEtMS00NzgwMQ_aef0f93e-14bb-4c50-bf49-2e6b56bd5a76"
      unitRef="usd">-2000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yOC9mcmFnOmRkNGQ3ZTA1NGZkZDQzYWE5MWIyOWY1OGRlNTk5NTc2L3RhYmxlOjhhOWI1M2Y4ZDhjODQzNWNhMTBjZTVkN2NmZTY4ZGFlL3RhYmxlcmFuZ2U6OGE5YjUzZjhkOGM4NDM1Y2ExMGNlNWQ3Y2ZlNjhkYWVfNS00LTEtMS00NzgwMQ_137ce8be-ac48-468a-a4be-7a6aa89db555"
      unitRef="usd">20000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yOC9mcmFnOmRkNGQ3ZTA1NGZkZDQzYWE5MWIyOWY1OGRlNTk5NTc2L3RhYmxlOjhhOWI1M2Y4ZDhjODQzNWNhMTBjZTVkN2NmZTY4ZGFlL3RhYmxlcmFuZ2U6OGE5YjUzZjhkOGM4NDM1Y2ExMGNlNWQ3Y2ZlNjhkYWVfNS02LTEtMS00NzgwMQ_6946d03a-e15c-419d-b2de-54bc6f9ac363"
      unitRef="usd">-2000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yOC9mcmFnOmRkNGQ3ZTA1NGZkZDQzYWE5MWIyOWY1OGRlNTk5NTc2L3RhYmxlOjhhOWI1M2Y4ZDhjODQzNWNhMTBjZTVkN2NmZTY4ZGFlL3RhYmxlcmFuZ2U6OGE5YjUzZjhkOGM4NDM1Y2ExMGNlNWQ3Y2ZlNjhkYWVfNS04LTEtMS00NzgwMQ_d065bf49-7ca3-4a58-9e63-e7f2ac5420d9"
      unitRef="usd">-15000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yOC9mcmFnOmRkNGQ3ZTA1NGZkZDQzYWE5MWIyOWY1OGRlNTk5NTc2L3RhYmxlOjhhOWI1M2Y4ZDhjODQzNWNhMTBjZTVkN2NmZTY4ZGFlL3RhYmxlcmFuZ2U6OGE5YjUzZjhkOGM4NDM1Y2ExMGNlNWQ3Y2ZlNjhkYWVfNi0yLTEtMS00NzgwMQ_3c53ed3c-330d-4269-a9dd-376dc8038e60"
      unitRef="usd">40000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yOC9mcmFnOmRkNGQ3ZTA1NGZkZDQzYWE5MWIyOWY1OGRlNTk5NTc2L3RhYmxlOjhhOWI1M2Y4ZDhjODQzNWNhMTBjZTVkN2NmZTY4ZGFlL3RhYmxlcmFuZ2U6OGE5YjUzZjhkOGM4NDM1Y2ExMGNlNWQ3Y2ZlNjhkYWVfNi00LTEtMS00NzgwMQ_26891dc0-1c14-41c6-bccd-bdf4e2b9ec6d"
      unitRef="usd">6000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yOC9mcmFnOmRkNGQ3ZTA1NGZkZDQzYWE5MWIyOWY1OGRlNTk5NTc2L3RhYmxlOjhhOWI1M2Y4ZDhjODQzNWNhMTBjZTVkN2NmZTY4ZGFlL3RhYmxlcmFuZ2U6OGE5YjUzZjhkOGM4NDM1Y2ExMGNlNWQ3Y2ZlNjhkYWVfNi02LTEtMS00NzgwMQ_abd83111-dc00-4c56-bda3-7c5ef0a658cd"
      unitRef="usd">40000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yOC9mcmFnOmRkNGQ3ZTA1NGZkZDQzYWE5MWIyOWY1OGRlNTk5NTc2L3RhYmxlOjhhOWI1M2Y4ZDhjODQzNWNhMTBjZTVkN2NmZTY4ZGFlL3RhYmxlcmFuZ2U6OGE5YjUzZjhkOGM4NDM1Y2ExMGNlNWQ3Y2ZlNjhkYWVfNi04LTEtMS00NzgwMQ_08500d53-254b-4726-8cf5-d314f833cfaa"
      unitRef="usd">23000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yOC9mcmFnOmRkNGQ3ZTA1NGZkZDQzYWE5MWIyOWY1OGRlNTk5NTc2L3RhYmxlOjhhOWI1M2Y4ZDhjODQzNWNhMTBjZTVkN2NmZTY4ZGFlL3RhYmxlcmFuZ2U6OGE5YjUzZjhkOGM4NDM1Y2ExMGNlNWQ3Y2ZlNjhkYWVfNy0yLTEtMS00NzgwMQ_39b18530-89d2-4ab1-bcc3-86745caab9a5"
      unitRef="usd">23459000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yOC9mcmFnOmRkNGQ3ZTA1NGZkZDQzYWE5MWIyOWY1OGRlNTk5NTc2L3RhYmxlOjhhOWI1M2Y4ZDhjODQzNWNhMTBjZTVkN2NmZTY4ZGFlL3RhYmxlcmFuZ2U6OGE5YjUzZjhkOGM4NDM1Y2ExMGNlNWQ3Y2ZlNjhkYWVfNy00LTEtMS00NzgwMQ_ddbd5cdd-d036-4fba-9a1a-a5789693d798"
      unitRef="usd">91443000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yOC9mcmFnOmRkNGQ3ZTA1NGZkZDQzYWE5MWIyOWY1OGRlNTk5NTc2L3RhYmxlOjhhOWI1M2Y4ZDhjODQzNWNhMTBjZTVkN2NmZTY4ZGFlL3RhYmxlcmFuZ2U6OGE5YjUzZjhkOGM4NDM1Y2ExMGNlNWQ3Y2ZlNjhkYWVfNy02LTEtMS00NzgwMQ_4bdc0de4-ea64-4716-9cf0-1f6de8186518"
      unitRef="usd">81396000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18yOC9mcmFnOmRkNGQ3ZTA1NGZkZDQzYWE5MWIyOWY1OGRlNTk5NTc2L3RhYmxlOjhhOWI1M2Y4ZDhjODQzNWNhMTBjZTVkN2NmZTY4ZGFlL3RhYmxlcmFuZ2U6OGE5YjUzZjhkOGM4NDM1Y2ExMGNlNWQ3Y2ZlNjhkYWVfNy04LTEtMS00NzgwMQ_5e140ab4-ddb0-40e2-83f5-cbbbc849a5ea"
      unitRef="usd">119307000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfNC0yLTEtMS00NzgwMQ_4d4fb5e7-4a25-43af-bbf2-5e67ac5b4555"
      unitRef="usd">82793000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfNC00LTEtMS00NzgwMQ_286b5831-7102-4eeb-b73f-b2d7be78ede4"
      unitRef="usd">119353000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfNi0yLTEtMS00NzgwMQ_6d174f9b-31e1-4b47-9aa2-eaae2eee588a"
      unitRef="usd">10377000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfNi00LTEtMS00NzgwMQ_735a0e9f-763c-41dc-b6de-1c6b3036f57e"
      unitRef="usd">10295000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfNy0yLTEtMS00NzgwMQ_8a4c8e6b-50dd-4f2c-9b8d-4612e6c753bb"
      unitRef="usd">1921000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfNy00LTEtMS00NzgwMQ_69282028-24c8-4e3d-aabb-7c78618f696c"
      unitRef="usd">1473000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfOC0yLTEtMS01NjMwNg_90071ad2-84b9-400c-abb2-a6a2595a874c"
      unitRef="usd">11403000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfOC00LTEtMS01NjMxNQ_86d6769e-4f7c-4d95-9d80-33bfef7c60c3"
      unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfOC0yLTEtMS00NzgwMQ_4478e3ac-f315-4164-ab61-563112339a21"
      unitRef="usd">2082000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfOC00LTEtMS00NzgwMQ_d23ece6f-7a64-492e-8437-022dae907feb"
      unitRef="usd">1706000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMTAtMi0xLTEtNDc4MDE_489c8eaa-bb61-4c09-9d96-dce49e5acb1c"
      unitRef="usd">-800000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMTAtNC0xLTEtNDc4MDE_7d6af0c6-0fea-4390-ae10-501db6227110"
      unitRef="usd">-945000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMTEtMi0xLTEtNDc4MDE_3cfcf1db-af00-4a74-b070-66f4ebfea841"
      unitRef="usd">-1727000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMTEtNC0xLTEtNDc4MDE_9109d0d6-861f-435f-b22f-e2148b49f9da"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMTItMi0xLTEtNDc4MDE_0b51d171-25b9-4f28-9507-f73f7d066eed"
      unitRef="usd">-80000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMTItNC0xLTEtNDc4MDE_232c16a1-ba6c-4970-9e60-7c67678b4cef"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMTQtMi0xLTEtNDc4MDE_10d6bebc-a05e-4ddf-af15-1975593c76e7"
      unitRef="usd">-1122000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMTQtNC0xLTEtNDc4MDE_0c889080-862f-4cc7-ab7d-56a2e3559849"
      unitRef="usd">-499000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <halo:DeferredRentPayments
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMTUtMi0xLTEtNDc4MDE_1eb74232-851a-43ae-af4c-a6432f80ffc6"
      unitRef="usd">394000</halo:DeferredRentPayments>
    <halo:DeferredRentPayments
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMTUtNC0xLTEtNDc4MDE_dd1bf5ee-d2b1-4d12-b426-20838ec2901a"
      unitRef="usd">385000</halo:DeferredRentPayments>
    <us-gaap:InducedConversionOfConvertibleDebtExpense
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMTgtMi0xLTEtNDc4MDE_7e1eff4c-d20d-4d0e-8247-f4c059e7eca5"
      unitRef="usd">0</us-gaap:InducedConversionOfConvertibleDebtExpense>
    <us-gaap:InducedConversionOfConvertibleDebtExpense
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMTgtNC0xLTEtNDc4MDE_83b7ac1a-de37-44f6-91f7-4ab16b1edc7a"
      unitRef="usd">20960000</us-gaap:InducedConversionOfConvertibleDebtExpense>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMTktMi0xLTEtNDc4MDE_f8bca400-9b51-48b1-b463-b21c92f2ede0"
      unitRef="usd">372000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMTktNC0xLTEtNDc4MDE_95df51ba-b9af-4a0f-aa49-56229b9edca3"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMjItMi0xLTEtNDc4MDE_ffb7417b-7f9c-4719-b80f-7d3c6c9592f4"
      unitRef="usd">32252000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMjItNC0xLTEtNDc4MDE_54a4da76-14e4-4363-8d1c-e05882a451a8"
      unitRef="usd">55466000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMjMtMi0xLTEtNDc4MDE_d434ae42-27de-4f21-bf85-a1105c2962bd"
      unitRef="usd">9025000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMjMtNC0xLTEtNDc4MDE_47355bf9-8bbd-4277-81a5-2087d6d5e457"
      unitRef="usd">-2427000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMjQtMi0xLTEtNDc4MDE_482ffbf6-3617-4a39-b099-57a25af68a3a"
      unitRef="usd">9319000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMjQtNC0xLTEtNDc4MDE_043811d0-6bb7-4f4d-862b-99ff3e8de76e"
      unitRef="usd">5831000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMjUtMi0xLTEtNDc4MDE_119a5821-bb01-4395-a672-587e120db470"
      unitRef="usd">29323000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMjUtNC0xLTEtNDc4MDE_fcf0bc60-33af-4170-be6c-734d44811b4b"
      unitRef="usd">207000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMjYtMi0xLTEtNDc4MDE_d7bca708-5c73-4291-970c-16928ebc587b"
      unitRef="usd">88022000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMjYtNC0xLTEtNDc4MDE_5e33ec54-b74b-4bbb-b4dd-667618e5e171"
      unitRef="usd">95185000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMjgtMi0xLTEtNDc4MDE_57ee1d09-f6e2-4b17-919e-c2c281ca4157"
      unitRef="usd">225689000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMjgtNC0xLTEtNDc4MDE_0a23b9bd-f041-46fe-b729-5022d78b85a1"
      unitRef="usd">241926000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMjktMi0xLTEtNDc4MDE_a2bc11d3-bd83-41ce-b44e-e6c58be25ad4"
      unitRef="usd">725995000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMjktNC0xLTEtNDc4MDE_29cbc73d-72f1-43b1-810d-6a54ae5a7924"
      unitRef="usd">152863000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMzAtMi0xLTEtNTAxNDA_586bc0a5-03cb-4f43-94c8-b9c0c1720797"
      unitRef="usd">999120000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMzAtNC0xLTEtNTAxNTY_7065eb27-ac55-47e6-b082-ddbab050209e"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMzAtMi0xLTEtNDc4MDE_857aae5e-4ad9-4614-9df5-f33ab9b893b7"
      unitRef="usd">1458000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMzAtNC0xLTEtNDc4MDE_16fc35fb-5589-4c82-b15e-f2d960061a9c"
      unitRef="usd">803000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMzEtMi0xLTEtNDc4MDE_bfcf2047-fc52-4bc8-b1d4-4ece99b0a77f"
      unitRef="usd">16021000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMzEtNC0xLTEtNDc4MDE_1d7f5a97-4e3a-4c75-b83d-7fc1da40e75c"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMzItMi0xLTEtNDc4MDE_866e3151-62c5-40aa-82e7-6f839c09e93a"
      unitRef="usd">-484251000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMzItNC0xLTEtNDc4MDE_cea4df63-37b6-48be-b895-dd7534991c7f"
      unitRef="usd">-89866000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMzYtMi0xLTEtNTAxNzM_c7cfa007-6dbd-465c-8a91-3f7606f4a1d1"
      unitRef="usd">250000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMzYtNC0xLTEtNTAxODU_fbc96c53-c3b3-474b-885f-348845a7bf16"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMzctMi0xLTEtNTAxNzM_33a078c0-62cf-4ee0-9487-29ac1c2eded2"
      unitRef="usd">120000000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMzctNC0xLTEtNTAxODU_6a523714-79a6-4be9-af85-31bc0cdc3aa3"
      unitRef="usd">0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMzUtMi0xLTEtNDc4MDE_afe2dc99-fee7-44a4-9e59-98b704a6f25c"
      unitRef="usd">0</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMzUtNC0xLTEtNDc4MDE_90b0d147-e82c-409d-b911-b593f173136b"
      unitRef="usd">784875000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:RepaymentsOfSecuredDebt
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMzYtMi0xLTEtNDc4MDE_ce726d27-10ac-4ab5-9672-a086ab455f78"
      unitRef="usd">0</us-gaap:RepaymentsOfSecuredDebt>
    <us-gaap:RepaymentsOfSecuredDebt
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMzYtNC0xLTEtNDc4MDE_83d99f7a-7b06-4167-a123-f12e373616e2"
      unitRef="usd">369064000</us-gaap:RepaymentsOfSecuredDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMzctMi0xLTEtNDc4MDE_3d0df2f4-812c-4ed6-b355-b7cdedc20e93"
      unitRef="usd">6003000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMzctNC0xLTEtNDc4MDE_94cbf44a-9ba9-4de6-b69b-1cf3885ce5e3"
      unitRef="usd">424000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMzgtMi0xLTEtNDc4MDE_763ec87b-e75f-461a-9eaa-3fce7a523d4c"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMzgtNC0xLTEtNDc4MDE_850aab96-30a0-4023-9528-45cd1f1417a9"
      unitRef="usd">125021000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <halo:ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMzktMi0xLTEtNDc4MDE_bcb56f61-8a80-433a-9ebe-74cad5d69845"
      unitRef="usd">4445000</halo:ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised>
    <halo:ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfMzktNC0xLTEtNDc4MDE_7eb79d1b-2bb2-42db-9ec9-2e95123c5089"
      unitRef="usd">3578000</halo:ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfNDAtMi0xLTEtNDc4MDE_e2fe13cd-f001-43a7-b36f-ab6301a361b0"
      unitRef="usd">368442000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfNDAtNC0xLTEtNDc4MDE_cc129ab8-ef29-4bf8-8564-d0470e61c3c9"
      unitRef="usd">293944000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfNDEtMi0xLTEtNDc4MDE_45b57cee-d444-4cc2-86df-129b7e8b3c19"
      unitRef="usd">-27787000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfNDEtNC0xLTEtNDc4MDE_d59e4535-8f51-40e9-81b7-181e23cf9849"
      unitRef="usd">299263000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfNDItMi0xLTEtNDc4MDE_7d9c4056-4b55-4a55-aa6b-fb5c0bbf548a"
      unitRef="usd">119219000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if3b15a6a41d2423d9142e3d2a1b50b32_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfNDItNC0xLTEtNDc4MDE_772c08d9-1fa4-4a90-99d3-3a3a5fafad11"
      unitRef="usd">148203000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfNDMtMi0xLTEtNDc4MDE_9a676689-8ce8-4878-9f94-f1659efde375"
      unitRef="usd">91432000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iaed74cb4c1b045a48ff8547f85ae3d8e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfNDMtNC0xLTEtNDc4MDE_6309e9c1-7e5a-49ed-a2ed-bda10ff3ea8c"
      unitRef="usd">447466000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfNDYtMi0xLTEtNDc4MDE_d0ae9a17-05a6-473f-992a-8f090813b56d"
      unitRef="usd">336000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfNDYtNC0xLTEtNDc4MDE_18fc141e-dd63-4c65-84fb-0167e404b7e5"
      unitRef="usd">242000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfNDctMi0xLTEtNDc4MDE_c6d745f5-ea88-455b-9314-05c8c4adeb65"
      unitRef="usd">217000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfNDctNC0xLTEtNDc4MDE_e084bb03-a7f0-4455-afb1-7f820738304a"
      unitRef="usd">318000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:StockIssued1
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfNTAtMi0xLTEtNDc4MDE_109b6ea6-ee57-4639-8e2e-557ecff71cdf"
      unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zMS9mcmFnOjM5MDUzYTY0MDlhMjQ2NDA4NDQ5MTY0MGMyYzkwNDNmL3RhYmxlOjk3NGJjZTE3NmIxNzQzODBiNzZjZGVkZTUyYTFkYjZiL3RhYmxlcmFuZ2U6OTc0YmNlMTc2YjE3NDM4MGI3NmNkZWRlNTJhMWRiNmJfNTAtNC0xLTEtNDc4MDE_ac565517-23a7-4e5b-a6c5-72b78a8e3123"
      unitRef="usd">7865000</us-gaap:StockIssued1>
    <us-gaap:SharesOutstanding
      contextRef="ia62abf9a289242aaacca39406bc0f1e4_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMy0yLTEtMS00NzgwMQ_1d46b0ea-a8c4-46b0-ae37-dac71e822396"
      unitRef="shares">137888000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ia62abf9a289242aaacca39406bc0f1e4_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMy00LTEtMS00NzgwMQ_da9ebcf3-45df-401c-981b-9cdc6789f457"
      unitRef="usd">138000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie9f7dc1cc92f4c1690a144db55ad717c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMy02LTEtMS00NzgwMQ_fde2c027-64c7-426f-b1be-66b0479c695d"
      unitRef="usd">261713000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia5e07277da1a43438f0f8d84d2f7bc96_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMy04LTEtMS00NzgwMQ_88076fe4-7d60-442a-97af-8a20d20a5e82"
      unitRef="usd">-2791000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0c9b3b22251847568c83ac3f79ea4436_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMy0xMC0xLTEtNDc4MDE_7259b076-d74e-48a7-8eb0-9255a024bc82"
      unitRef="usd">1196000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i678f6fef80154c5b8c01dadcd09593ac_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMy0xMi0xLTEtNDc4MDE_c6bffbfc-810f-49c1-aa32-ea7da4f111ca"
      unitRef="usd">260256000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9b633a2efd834d73bd14291c139ac728_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNS02LTEtMS00NzgwMQ_ac6065fa-fd73-417d-b1ee-b72c8d63f727"
      unitRef="usd">5635000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNS0xMi0xLTEtNDc4MDE_77412365-5bca-490a-af88-0e79cccff3ff"
      unitRef="usd">5635000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i64fb6378ac874aa599802032078bb7e5_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNy0yLTEtMS00NzgwMQ_065d804d-5ddb-4d3e-82d8-7e0b110b491e"
      unitRef="shares">226000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i64fb6378ac874aa599802032078bb7e5_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNy00LTEtMS00NzgwMQ_0d551fd6-008b-4285-960b-4b538518f5b1"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i9b633a2efd834d73bd14291c139ac728_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNy02LTEtMS00NzgwMQ_8ae70ad9-c3ed-412a-8861-3f35e20b14f9"
      unitRef="usd">3821000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNy0xMi0xLTEtNDc4MDE_667d7249-9ac0-4b85-9050-18413955d7a1"
      unitRef="usd">3821000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i64fb6378ac874aa599802032078bb7e5_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfOS0yLTEtMS00NzgwMQ_ed6ebbac-31fb-483a-9415-3d4c53ee1825"
      unitRef="shares">433000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i64fb6378ac874aa599802032078bb7e5_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfOS00LTEtMS00NzgwMQ_6c1308c2-611c-4a50-81b4-a3767e7a86f1"
      unitRef="usd">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i9b633a2efd834d73bd14291c139ac728_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfOS02LTEtMS00NzgwMQ_c95cd40b-dd62-4707-9f4c-f431a359708c"
      unitRef="usd">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfOS0xMi0xLTEtNDc4MDE_c713bdf0-d348-4cf4-a6a6-9af77a21c505"
      unitRef="usd">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="i6a959347106f415cb34e9be834baba86_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMTAtOC0xLTEtNDc4MDE_5c35db40-c1a4-428e-ba43-1b7c2468cb9d"
      unitRef="usd">774000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMTAtMTItMS0xLTQ3ODAx_6ce3a70c-d082-401d-8cf9-5c9b7d84ccb0"
      unitRef="usd">774000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:NetIncomeLoss
      contextRef="i5c00abe406104a5fa545c8d934524371_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMTEtMTAtMS0xLTQ3ODAx_28496c7a-3c8c-4cda-87ba-89d99fa358f9"
      unitRef="usd">22685000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMTEtMTItMS0xLTQ3ODAx_796c988a-28bf-4da2-b499-3fdb52bc7fff"
      unitRef="usd">22685000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i09401d5b007348c08fa5bd1cce5097ce_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMTItMi0xLTEtNDc4MDE_98c3ee96-d73e-404a-a730-adec243175c4"
      unitRef="shares">137681000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i09401d5b007348c08fa5bd1cce5097ce_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMTItNC0xLTEtNDc4MDE_6905059c-cc53-4bdd-a8db-bff39bb88374"
      unitRef="usd">138000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id807b2395d514e89a6ed524bc67e0ed3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMTItNi0xLTEtNDc4MDE_489b2230-3dfe-4ea0-af1c-eaf4ae09d24b"
      unitRef="usd">271169000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i01b7804e8c8443c18f2bf4001bc7328d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMTItOC0xLTEtNDc4MDE_0c2cdf87-4f26-4cb4-bd5c-2b96960131b9"
      unitRef="usd">-2017000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id2a2ebb74994496290986a6cbda39dc8_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMTItMTAtMS0xLTQ3ODAx_a31570b5-b241-403e-8908-e5d90955cf22"
      unitRef="usd">23881000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMTItMTItMS0xLTQ3ODAx_17f42f89-3876-4df7-a951-1b08eea53897"
      unitRef="usd">293171000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ibbcde496e999416f83088ace845dbf65_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMTctMi0xLTEtNDc4MDE_ba9a13cd-2260-4684-ab8a-174fd7304c72"
      unitRef="shares">137498000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ibbcde496e999416f83088ace845dbf65_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMTctNC0xLTEtNDc4MDE_9ea23412-bf0c-4df6-a1c9-2bebeccf8145"
      unitRef="usd">138000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i57063aa70d174824a4db07d8773b05bf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMTctNi0xLTEtNDc4MDE_15154dba-214a-4ac7-a692-9808e4b174b7"
      unitRef="usd">256347000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i39034bfa63bd4a90ac54d7016591ef9d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMTctOC0xLTEtNDc4MDE_eca830a8-7ae5-413a-bea3-6a31ccb9808b"
      unitRef="usd">-620000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iac6ced6cc2b3433c8b37d84dc56b068e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMTctMTAtMS0xLTQ3ODAx_95dd9269-077d-4c5f-afd8-709d72843d1c"
      unitRef="usd">-58912000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMTctMTItMS0xLTQ3ODAx_b2568fa7-c9c5-45ea-ad94-5bf9daaa01d7"
      unitRef="usd">196953000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6a77403a19ee410d81160e0a394e0979_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMTktNi0xLTEtNDc4MDE_b3cbb0b2-7f2d-4635-9fd0-41feb1fac69b"
      unitRef="usd">10377000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMTktMTItMS0xLTQ3ODAx_ef32dec2-8c68-4f6a-b4c9-067ff6aa6e2d"
      unitRef="usd">10377000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ic61e51e1f5f94cd39c6967eae2703020_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMjEtMi0xLTEtNDc4MDE_66c744b1-2fa6-4349-992d-0e4d3f1e5a7e"
      unitRef="shares">616000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic61e51e1f5f94cd39c6967eae2703020_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMjEtNC0xLTEtNDc4MDE_28b28b68-2c6f-49ab-b870-3515fe0558ad"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6a77403a19ee410d81160e0a394e0979_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMjEtNi0xLTEtNDc4MDE_7fd2e74f-ff4c-4c5d-a4d4-0ec456facb72"
      unitRef="usd">4445000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMjEtMTItMS0xLTQ3ODAx_84eabb14-c644-485d-8ab9-b051d988fc26"
      unitRef="usd">4445000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="ic61e51e1f5f94cd39c6967eae2703020_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMjMtMi0xLTEtNDc4MDE_273fe946-d8aa-48b8-ad58-3c216618c91b"
      unitRef="shares">433000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="ic61e51e1f5f94cd39c6967eae2703020_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMjMtNC0xLTEtNDc4MDE_ee6879f5-c5fb-4e03-8fc4-399f4be0575b"
      unitRef="usd">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i6a77403a19ee410d81160e0a394e0979_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMjMtNi0xLTEtNDc4MDE_5ef96f60-c707-4844-bf28-0a252202cf82"
      unitRef="usd">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMjMtMTItMS0xLTQ3ODAx_1eac0dae-fb1e-4f1e-8b9d-3a267a03e376"
      unitRef="usd">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="ieb6ff5498b9346a8b865a91ca3bb935c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMjUtOC0xLTEtNDc4MDE_37b61223-f547-454a-ba28-6da04f5c460a"
      unitRef="usd">-1397000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMjUtMTItMS0xLTQ3ODAx_d93eb640-aa2d-4a75-8a89-d8d4718d4469"
      unitRef="usd">-1397000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:NetIncomeLoss
      contextRef="i37c4cbbc8ea6440cb197130f93f66a30_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMjYtMTAtMS0xLTQ3ODAx_b357c4e9-630c-47b0-94a8-f7de715e2690"
      unitRef="usd">82793000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMjYtMTItMS0xLTQ3ODAx_59851858-975f-4004-8aea-0709e214d398"
      unitRef="usd">82793000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i09401d5b007348c08fa5bd1cce5097ce_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMjctMi0xLTEtNDc4MDE_fb12a84c-84a0-4add-bc02-0b1e267a9b80"
      unitRef="shares">137681000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i09401d5b007348c08fa5bd1cce5097ce_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMjctNC0xLTEtNDc4MDE_60f2b6d1-8135-49de-bf9d-d6b9f05e3c1a"
      unitRef="usd">138000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id807b2395d514e89a6ed524bc67e0ed3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMjctNi0xLTEtNDc4MDE_4766f106-f275-4fed-bff3-e7c93ef1c61f"
      unitRef="usd">271169000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i01b7804e8c8443c18f2bf4001bc7328d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMjctOC0xLTEtNDc4MDE_ea1dc012-bdab-4ea2-bfc0-abb5e9821acb"
      unitRef="usd">-2017000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id2a2ebb74994496290986a6cbda39dc8_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMjctMTAtMS0xLTQ3ODAx_db2d9317-94be-4afc-bbcf-64cc304aa271"
      unitRef="usd">23881000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMjctMTItMS0xLTQ3ODAx_43028c73-23b6-48c9-9e44-fe7650ace428"
      unitRef="usd">293171000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i0c794de6a0af4c0a9af7f772745e791c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMzItMi0xLTEtNDc4MDE_a9eefdd2-194b-410d-a33c-df6713e0de42"
      unitRef="shares">143380000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i0c794de6a0af4c0a9af7f772745e791c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMzItNC0xLTEtNDc4MDE_d7bfd71a-419f-48ec-975e-37e116caa48a"
      unitRef="usd">143000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id6b066604d9e4d658947efe4930f28f6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMzItNi0xLTEtNDc4MDE_bc3ce288-e147-4824-8b69-28217991ed27"
      unitRef="usd">501186000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie27fff43f3db4d7d8d49ecaaf23b1d61_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMzItOC0xLTEtNDc4MDE_bb69e29b-0dce-47f7-a047-c15a306b0928"
      unitRef="usd">-9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7e4238b1c16a4fd28a06ed5e284bb84a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMzItMTAtMS0xLTQ3ODAx_409855c1-ad3e-4f69-8011-54e89011efba"
      unitRef="usd">-433725000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i727d5a62b3f847b797bca56701f39cf9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMzItMTItMS0xLTQ3ODAx_7d21b333-c0e2-4611-ac23-b26340a060b7"
      unitRef="usd">67595000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if67373bdd7be4012b17710d463c192a1_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMzQtNi0xLTEtNDc4MDE_868235c4-89ce-4665-80f4-f110fd0ca753"
      unitRef="usd">5372000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMzQtMTItMS0xLTQ3ODAx_ff0b9602-73b1-45d5-af70-b43c0f3d8fe9"
      unitRef="usd">5372000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i380920b6a9284e80ae55f918a1ae24cb_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMzYtMi0xLTEtNDc4MDE_2259db90-ae9d-447b-a167-a4198dabf025"
      unitRef="shares">318000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i380920b6a9284e80ae55f918a1ae24cb_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMzYtNC0xLTEtNDc4MDE_8c3dbdb1-93b5-4b0a-b071-7dafb68360ae"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if67373bdd7be4012b17710d463c192a1_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMzYtNi0xLTEtNDc4MDE_4a02b012-7e9f-4baf-92a4-cc4dfe8ff60c"
      unitRef="usd">4179000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMzYtMTItMS0xLTQ3ODAx_d13bfc67-075f-4f4b-a80e-7e0ec55962b0"
      unitRef="usd">4180000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i380920b6a9284e80ae55f918a1ae24cb_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMzgtMi0xLTEtNDc4MDE_63c0f7a7-37bc-4bf3-a82a-2fa3dd37e38c"
      unitRef="shares">1517000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i380920b6a9284e80ae55f918a1ae24cb_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMzgtNC0xLTEtNDc4MDE_c983962b-2c9a-40db-b6f6-cb3075ae666d"
      unitRef="usd">2000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="if67373bdd7be4012b17710d463c192a1_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMzgtNi0xLTEtNDc4MDE_10ffe1e5-8551-4a05-b3ce-f8fee4ba7c8b"
      unitRef="usd">48840000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfMzgtMTItMS0xLTQ3ODAx_a7c99358-9050-41cb-b497-775c6fa1c4bc"
      unitRef="usd">48842000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="i12326da779a8483f93c5e05dd4d6d7c4_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNDAtOC0xLTEtNDc4MDE_28a36620-1ccb-47e4-8dfb-4859fe7c59ed"
      unitRef="usd">-15000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNDAtMTItMS0xLTQ3ODAx_c83c579b-cd90-404e-8480-4f7839cb7fce"
      unitRef="usd">-15000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:NetIncomeLoss
      contextRef="i6f15b7f19dfa4b62bc91d2ad4477ae61_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNDEtMTAtMS0xLTQ3ODAx_e9cd62e4-c780-474a-8236-8cffe9aef199"
      unitRef="usd">91458000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNDEtMTItMS0xLTQ3ODAx_cf3f3c47-0218-48b1-a77e-e2393d232b65"
      unitRef="usd">91458000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i4c838a1fe9a644b6956ff4487ba688eb_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNDItMi0xLTEtNDc4MDE_24f6a8c4-91ac-45bd-8353-48ce4062bce6"
      unitRef="shares">142181000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i4c838a1fe9a644b6956ff4487ba688eb_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNDItNC0xLTEtNDc4MDE_7f9cf7c6-ee0b-4302-ac12-77010fcb0a82"
      unitRef="usd">142000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i14d6ff976f1c46d0bae0a1ff38eae093_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNDItNi0xLTEtNDc4MDE_5c24511c-2b23-4e3a-83e5-cb6aa0d3e667"
      unitRef="usd">461897000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iac7f0b69fa364a3e83aa58d5f386c6ca_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNDItOC0xLTEtNDc4MDE_985a1132-4ac6-4e49-b620-0709827f4133"
      unitRef="usd">-24000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i26444fd86b024585b6b74771eb48128a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNDItMTAtMS0xLTQ3ODAx_6c2cbe41-c9e1-44f2-bc99-5e5b5c48a8fa"
      unitRef="usd">-342267000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iaed74cb4c1b045a48ff8547f85ae3d8e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNDItMTItMS0xLTQ3ODAx_94c1dd31-af1e-4b84-9dbb-0c673f87c897"
      unitRef="usd">119748000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i7985573ca9a44f7ea10f5ecb82f97c91_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNDctMi0xLTEtNDc4MDE_800b220b-2820-4047-8ee1-ac1a031644cd"
      unitRef="shares">135030000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i7985573ca9a44f7ea10f5ecb82f97c91_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNDctNC0xLTEtNDc4MDE_3d148657-528c-4993-bb2a-623330f62cc5"
      unitRef="usd">135000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie2bb1215be014cfeae503eb2306453b0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNDctNi0xLTEtNDc4MDE_2e340f88-1f0c-44a8-afe7-b63d893fb10a"
      unitRef="usd">625483000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie6ca52ba2c1e43a7b6a8fd1d47849366_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNDctOC0xLTEtNDc4MDE_2a6cc8e3-f9af-49e5-aedd-6167d359dead"
      unitRef="usd">22000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2ca0a460bc7a457a905e2205ba207797_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNDctMTAtMS0xLTQ3ODAx_8d8f975b-b22a-4c02-b494-f1fb792ea132"
      unitRef="usd">-474593000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if3b15a6a41d2423d9142e3d2a1b50b32_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNDctMTItMS0xLTQ3ODAx_a857057c-c98b-45ff-8fb9-00b73aa053bb"
      unitRef="usd">151047000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i256c983ac3a44d07b5c0bbac2a5206ef_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNDgtNi0xLTEtNDk0OTE_d741dd1f-f0eb-4b90-bf11-1be2a2da9ae3"
      unitRef="usd">-65535000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if563dcd8d731444e986d351aa923f779_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNDgtMTAtMS0xLTQ3ODAx_1d068ef2-66f9-464c-8195-701da3423019"
      unitRef="usd">12973000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id3449ce3d1a2440f9631288531d75f21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNDgtMTItMS0xLTYwMjY2_0d24b7b5-290d-4eb3-8b59-cc6e931da043"
      unitRef="usd">-52562000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i715d67b1e934443c87c14fc6a9baf147_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNDktNi0xLTEtNDc4MDE_6ac3fa98-6a25-4609-8ba7-87a1f2e0a0cb"
      unitRef="usd">10295000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNDktMTItMS0xLTQ3ODAx_0cc3c85c-fbda-4038-9368-2934c53523b1"
      unitRef="usd">10295000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i3b21a0a518454ebb9f2099e2057850ed_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNTAtMi0xLTEtNDk0Njc_2fb54e7b-aeff-4443-bb2f-da3e6bb02b6a"
      unitRef="shares">9083000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i3b21a0a518454ebb9f2099e2057850ed_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNTAtNC0xLTEtNDk0NzQ_1cd7237b-c4f6-4924-9196-14f62edb995d"
      unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i715d67b1e934443c87c14fc6a9baf147_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNTAtNi0xLTEtNDk0ODE_4f66e3b8-879f-4846-a3aa-fbfb2eacdabd"
      unitRef="usd">13095000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNTAtMTItMS0xLTYwMjYx_d23da5ad-86ac-4f89-b906-0a8651905030"
      unitRef="usd">13104000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i3b21a0a518454ebb9f2099e2057850ed_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNTAtMi0xLTEtNDc4MDE_c849b193-5334-430f-9ecf-d1699f6419fa"
      unitRef="shares">881000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i3b21a0a518454ebb9f2099e2057850ed_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNTAtNC0xLTEtNDc4MDE_c9cdb605-2cea-4e75-a38e-dce55c4b769f"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i715d67b1e934443c87c14fc6a9baf147_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNTAtNi0xLTEtNDc4MDE_9bb7f63f-a061-40e9-8ef0-71127568d116"
      unitRef="usd">3577000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNTAtMTItMS0xLTQ3ODAx_1c8dc64c-2d04-4bc0-b3a8-e9e47244c5f7"
      unitRef="usd">3578000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i3b21a0a518454ebb9f2099e2057850ed_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNTItMi0xLTEtNDc4MDE_dfc9ac15-04b2-487b-9fe7-f774b4cdec41"
      unitRef="shares">2813000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i3b21a0a518454ebb9f2099e2057850ed_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNTItNC0xLTEtNDc4MDE_dbbcfa93-1519-427a-a1bf-8a9351efea8f"
      unitRef="usd">3000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i715d67b1e934443c87c14fc6a9baf147_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNTItNi0xLTEtNDc4MDE_3bc783ce-c800-4a0e-a6c6-3647386f49d3"
      unitRef="usd">125018000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNTItMTItMS0xLTQ3ODAx_21215848-723e-48d0-95f9-040047fdda0a"
      unitRef="usd">125021000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="i6dbcbf35901d41ee95e2479d1b0cc0e8_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNTQtOC0xLTEtNDc4MDE_e83105cf-3dea-453f-b2f1-338b4ebbc43e"
      unitRef="usd">-46000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNTQtMTItMS0xLTQ3ODAx_93b83c1f-f789-45e3-85f2-315dc9ba04da"
      unitRef="usd">-46000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:NetIncomeLoss
      contextRef="i322f16862e9a44f9ad3ca6a551d79a4f_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNTUtMTAtMS0xLTQ3ODAx_054b224e-bb18-49a6-9e07-318868b89c1c"
      unitRef="usd">119353000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNTUtMTItMS0xLTQ3ODAx_cfc316bf-1a92-45f2-8ae7-52bbb8d5ed53"
      unitRef="usd">119353000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i4c838a1fe9a644b6956ff4487ba688eb_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNTYtMi0xLTEtNDc4MDE_54bf529a-158a-4325-adfb-1a9e307d2dfd"
      unitRef="shares">142181000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i4c838a1fe9a644b6956ff4487ba688eb_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNTYtNC0xLTEtNDc4MDE_86c75e27-ff0b-436f-a754-df2d19cc71b8"
      unitRef="usd">142000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i14d6ff976f1c46d0bae0a1ff38eae093_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNTYtNi0xLTEtNDc4MDE_f92a4213-1964-4f6f-b414-b1673a200ef2"
      unitRef="usd">461897000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iac7f0b69fa364a3e83aa58d5f386c6ca_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNTYtOC0xLTEtNDc4MDE_71fa99aa-8a49-4676-8ad9-3992bd01df28"
      unitRef="usd">-24000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i26444fd86b024585b6b74771eb48128a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNTYtMTAtMS0xLTQ3ODAx_256293e4-8ade-40e6-8632-2436e8997b8d"
      unitRef="usd">-342267000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iaed74cb4c1b045a48ff8547f85ae3d8e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18zNC9mcmFnOjEwOTM0MzA5MWFhYzRkMGQ5OGYyOGQ2MzllMTMzNzczL3RhYmxlOmNlYmU0M2NlY2NiMTQ1NDA4MjZhZWU3MzhlY2IwMjU3L3RhYmxlcmFuZ2U6Y2ViZTQzY2VjY2IxNDU0MDgyNmFlZTczOGVjYjAyNTdfNTYtMTItMS0xLTQ3ODAx_b4a241ff-6333-4b61-8933-41917d58e468"
      unitRef="usd">119748000</us-gaap:StockholdersEquity>
    <us-gaap:NatureOfOperations
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180MC9mcmFnOjgzZjVhMzdlNDE3NTQ3ZmViNjcxZWRlMjA5YjQxYTA4L3RleHRyZWdpb246ODNmNWEzN2U0MTc1NDdmZWI2NzFlZGUyMDliNDFhMDhfNDA0NA_dffd928e-abea-489b-a7ae-4276c2ba0d20">Organization and Business &lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Halozyme Therapeutics, Inc. is a biopharma technology platform company that provides innovative and disruptive solutions with the goal of improving patient experience and outcomes. Our proprietary enzyme, rHuPH20, is used to facilitate the delivery of injected drugs and fluids. We license our technology to biopharmaceutical companies to collaboratively develop products that combine our ENHANZE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; drug delivery&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;technology with the partners&#x2019; proprietary compounds.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our first commercially approved product, Hylenex&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; recombinant, (&#x201c;Hylenex&#x201d;), and our partners&#x2019; approved products and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 is the active ingredient in Hylenex and it works by breaking down hyaluronan (or &#x201c;HA&#x201d;), a naturally occurring carbohydrate that is a major component of the extracellular matrix of the subcutaneous (SC) space. This temporarily increases dispersion and absorption allowing for improved SC delivery of injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as our ENHANZE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; drug delivery technology (&#x201c;ENHANZE&#x201d;). We license the ENHANZE technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the SC route of administration. In the development of proprietary intravenous (IV) drugs combined with our ENHANZE technology, data have been generated supporting the potential for ENHANZE to reduce patient treatment burden, as a result of shorter duration of SC administration. ENHANZE may enable fixed-dose SC dosing compared to weight-based dosing required for IV administration, and potentially allow for lower rates of infusion related reactions.&#160;ENHANZE may enable more flexible treatment options such as home administration by a healthcare professional or potentially the patient. Lastly, certain proprietary drugs co-formulated with ENHANZE have been granted additional exclusivity, extending the patent life of the product beyond the patent expiry of the proprietary IV drug.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We currently have ENHANZE collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (&#x201c;Roche&#x201d;), Baxalta US Inc. and Baxalta GmbH (members of the Takeda group of companies) (&#x201c;Baxalta&#x201d;), Pfizer Inc. (&#x201c;Pfizer&#x201d;), Janssen Biotech, Inc. (&#x201c;Janssen&#x201d;), AbbVie, Inc. (&#x201c;AbbVie&#x201d;), Eli Lilly and Company (&#x201c;Lilly&#x201d;), Bristol-Myers Squibb Company (&#x201c;BMS&#x201d;), Alexion Pharma International Operations Unlimited Company (an indirect wholly owned subsidiary of AstraZeneca PLC (&#x201c;Alexion&#x201d;), argenx BVBA (&#x201c;argenx&#x201d;), Horizon Therapeutics plc. (&#x201c;Horizon&#x201d;), ViiV Healthcare (the global specialist HIV Company majority owned by GlaxoSmithKline) (&#x201c;ViiV&#x201d;) and Chugai Pharmaceutical Co., Ltd (&#x201c;Chugai&#x201d;). In addition to receiving upfront licensing fees from our ENHANZE collaborations, we are entitled to receive event and sales attainment milestone payments, revenues from the sale of bulk rHuPH20 and royalties from commercial sales of approved partner products co-formulated with ENHANZE.  We currently receive royalties from three of these collaborations, including royalties from sales of one product from the Baxalta collaboration, three products from the Roche collaboration and one product from the Janssen collaboration. Future potential revenues from ENHANZE collaborations and from the sales and/or royalties of our approved products will depend on the ability of Halozyme and our partners to develop, manufacture, secure and maintain regulatory approvals for approved products and product candidates and commercialize product candidates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Through our recent acquisition of Antares Pharma, Inc. (&#x201c;Antares&#x201d;), we also develop, manufacture and commercialize, for ourselves or with our partners, drug-device combination products using our advanced auto-injector technologies that are designed to provide commercial or functional advantages such as convenience, improved tolerability, and enhanced patient comfort and adherence. Also, as a result of our acquisition of Antares, our commercial portfolio of proprietary products includes XYOSTED&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, TLANDO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#x2122;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and NOCDURNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and partnered commercial products and ongoing product development programs with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (&#x201c;Teva&#x201d;), Covis Group S.a.r.l. (&#x201c;Covis&#x201d;), Pfizer and Idorsia Pharmaceuticals Ltd. (&#x201c;Idorsia&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Except where specifically noted or the context otherwise requires, references to &#x201c;Halozyme,&#x201d; &#x201c;the Company,&#x201d; &#x201c;we,&#x201d; &#x201c;our,&#x201d; and &#x201c;us&#x201d; in these notes to the condensed consolidated financial statements refer to Halozyme Therapeutics, Inc. and its wholly owned subsidiaries, Halozyme, Inc. and Antares Pharma, Inc., Halozyme, Inc.&#x2019;s wholly owned subsidiary, Halozyme Switzerland Holdings GmbH and Antares Pharma, Inc.&#x2019;s wholly owned subsidiaries Antares Pharma IPL AG and Antares Pharma AG.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <halo:RoyaltiesReceivedNumberOfCollaborators
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180MC9mcmFnOjgzZjVhMzdlNDE3NTQ3ZmViNjcxZWRlMjA5YjQxYTA4L3RleHRyZWdpb246ODNmNWEzN2U0MTc1NDdmZWI2NzFlZGUyMDliNDFhMDhfMzExMQ_7d232ba7-12e9-4b5b-b77a-6bba07afb509"
      unitRef="collaborator">3</halo:RoyaltiesReceivedNumberOfCollaborators>
    <halo:RoyaltiesReceivedNumberOfProductsSold
      contextRef="i8939fd0a8f934008b17b41bf8467d682_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180MC9mcmFnOjgzZjVhMzdlNDE3NTQ3ZmViNjcxZWRlMjA5YjQxYTA4L3RleHRyZWdpb246ODNmNWEzN2U0MTc1NDdmZWI2NzFlZGUyMDliNDFhMDhfMzE3Mw_8829b4ab-a021-433f-a531-e8b0ce57a300"
      unitRef="product">1</halo:RoyaltiesReceivedNumberOfProductsSold>
    <halo:RoyaltiesReceivedNumberOfProductsSold
      contextRef="ie69bf9190a574ccbbe399d8da056c46e_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180MC9mcmFnOjgzZjVhMzdlNDE3NTQ3ZmViNjcxZWRlMjA5YjQxYTA4L3RleHRyZWdpb246ODNmNWEzN2U0MTc1NDdmZWI2NzFlZGUyMDliNDFhMDhfMzIxNg_94a7420e-dff9-4475-a1c0-ccd1432c09a5"
      unitRef="product">3</halo:RoyaltiesReceivedNumberOfProductsSold>
    <halo:RoyaltiesReceivedNumberOfProductsSold
      contextRef="i6aeb602d0b6f4c559f18892fc21aa407_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180MC9mcmFnOjgzZjVhMzdlNDE3NTQ3ZmViNjcxZWRlMjA5YjQxYTA4L3RleHRyZWdpb246ODNmNWEzN2U0MTc1NDdmZWI2NzFlZGUyMDliNDFhMDhfMzI2MQ_6a8f535e-a562-42b5-8de7-350af7cceebe"
      unitRef="product">1</halo:RoyaltiesReceivedNumberOfProductsSold>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMzI3ODc_40e21d5f-af3b-45b4-b4e5-f70077e43996">Summary of Significant Accounting Policies&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) and with the rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) related to a quarterly report on Form 10-Q. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for a complete set of financial statements. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC on February&#160;22, 2022. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operations for the periods presented, with such adjustments consisting only of normal recurring adjustments. Operating results for interim periods are not necessarily indicative of the operating results for an entire fiscal year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim unaudited condensed consolidated financial statements include the accounts of Halozyme Therapeutics, Inc. and our wholly owned subsidiaries, Halozyme, Inc. and Antares Pharma, Inc., Halozyme, Inc.&#x2019;s wholly owned subsidiary Halozyme Switzerland Holdings GmbH and Antares Pharma, Inc.&#x2019;s wholly-owned Swiss subsidiaries, Antares Pharma IPL AG and Antares Pharma AG. All intercompany accounts and transactions have been eliminated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of interim unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our interim unaudited condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management&#x2019;s estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash Equivalents and Marketable Securities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents consist of highly liquid investments, readily convertible to cash, that mature within ninety days or less from the date of purchase. As of June&#160;30, 2022, our cash and cash equivalents consisted of money market funds, bank certificate of deposits and demands deposits at commercial banks.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities are investments with original maturities of more than ninety days from the date of purchase that are specifically identified to fund current operations. Marketable securities are considered available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management&#x2019;s intention to use the proceeds from the sale of these investments to fund our operations, as necessary. Such available-for-sale investments are carried at fair value with unrealized gains and losses recorded in other comprehensive income (loss) and included as a separate component of stockholders&#x2019; equity. The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in the interim unaudited condensed consolidated statements of income. We use the specific identification method for calculating realized gains and losses on marketable securities sold. None of the realized gains and losses and declines in value that were judged to be as a result of credit loss on marketable securities, if any, are included in investment and other income, net in the interim unaudited condensed consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the leases of our facilities, we are required to maintain letters of credit as security deposits during the terms of such leases. As of June&#160;30, 2022 and December&#160;31, 2021, restricted cash of $0.5 million was pledged as collateral for the letters of credit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The authoritative guidance for fair value measurements establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments include cash equivalents, available-for-sale marketable securities, accounts receivable, prepaid expenses and other assets, accounts payable, accrued expenses, long-term debt and contingent liability. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale marketable securities consist of asset-backed securities, corporate debt securities, U.S. Treasury securities and commercial paper, and are measured at fair value using Level 1 and Level 2 inputs. Level 2 financial instruments are valued using market prices on less active markets and proprietary pricing valuation models with observable inputs, including interest rates, yield curves, maturity dates, issue dates, settlement dates, reported trades, broker-dealer quotes, issue spreads, benchmark securities or other market related data. We obtain the fair value of Level 2 investments from our investment manager, who obtains these fair values from a third-party pricing source. We validate the fair values of Level 2 financial instruments provided by our investment manager by comparing these fair values to a third-party pricing source.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Inventories are reviewed periodically for potential excess, dated or obsolete status. We evaluate the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price we expect to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into operating leases primarily for real estate and automobiles. These leases have contractual terms which range from 3 years to 12 years. We determine if an arrangement contains a lease at inception. Right of use (&#x201c;ROU&#x201d;) assets and liabilities resulting from operating leases are included in property and equipment, accrued expenses and other long-term liabilities on our condensed consolidated balance sheets. Operating lease ROU assets and liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the discount rate to calculate the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Our leases often include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that we will exercise that option. Short-term leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as automobiles, we account for the lease and non-lease components as a single lease component.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, we entered into an agreement for assignment and assumption of lease with Seismic Software, Inc. pursuant to which effective January 1, 2023, we will assume Seismic&#x2019;s office lease, as amended with Kilroy Realty L.P. for approximately 72,534 square feet of space in office and research facilities which is expected to commence on January 1, 2023. The premises are intended to serve as our new headquarters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. Costs that we incur to complete the business combination, such as legal and other professional fees, are expensed as they are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the initial accounting for a business combination is incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date. We record these adjustments to the provisional amounts with a corresponding offset to goodwill. Any adjustments identified after the measurement period are recorded in the consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill, Intangible Assets and Other Long-Lived Asset&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets acquired, including intangible assets and in-process research and development (IPR&amp;amp;D), and liabilities assumed are measured at fair value as of the acquisition date. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of the net assets acquired. Intangible assets acquired in a business combination that are used for IPR&amp;amp;D activities are considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon reaching the end of the relevant research and development project (i.e., upon commercialization), the IPR&amp;amp;D asset is amortized over its estimated useful life. If the relevant research and development project is abandoned, the IPR&amp;amp;D asset is expensed in the period of abandonment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill and IPR&amp;amp;D are not amortized; however, they are reviewed for impairment at least annually during the second quarter, or more frequently if an event occurs indicating the potential for impairment. Goodwill and IPR&amp;amp;D are considered to be impaired if the carrying value of the reporting unit or IPR&amp;amp;D asset exceeds its respective fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform our goodwill impairment analysis at the reporting unit level, which aligns with our reporting structure and availability of discrete financial information. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair values of our reporting units are less than the carrying amounts, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and our overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair values of our reporting units are less than the carrying amounts, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair values of the reporting units with the carrying values, including goodwill. If the carrying amounts of the reporting units exceed the fair values, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill impairment test.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our identifiable intangible assets with a finite life are typically comprised of acquired device technologies and product rights. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#x2019; respective estimated useful lives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform regular reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant changes in the ability of a particular asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generate revenues from payments received (i) as royalties from licensing our ENHANZE technology and other royalty arrangements, (ii) under collaborative agreements and (iii) from sales of our proprietary and partnered products. We recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers we perform the following five steps: (i) identify the promised goods or services in the contract; (ii) identify the performance obligations in the contract, including whether they are distinct in the context of the contract; (iii) determine the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ENHANZE and Device Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of our ENHANZE collaboration and license agreements, our partners will pay us royalties at an on average mid-single digit percent rate of their sales if products under the collaboration are commercialized. All amounts owed to us are noncancelable after the underlying triggering event occurs, and nonrefundable once paid. Unless terminated earlier in accordance with its terms, collaborations generally continue in effect until the last to expire royalty payment term, as determined on a product by product and on a country by country basis, with each royalty term starting on the first commercial sale of that product and ending the later of: (i) a specified period or term set forth in the agreement or (ii) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration. When there are no valid claims during the applicable royalty term in a given country, the royalty rate is reduced for those sales. Partners may terminate the agreement prior to expiration for any reason in its entirety or on a target-by-target basis generally upon 90 days prior written notice to us.&#160;Upon any such termination, the license granted to partners (in total or with respect to the terminated target, as applicable) will terminate provided, however, that in the event of expiration of the agreement (as opposed to a termination), the on-going licenses granted will become perpetual, non-exclusive and fully paid. Sales-based milestones and royalties are recognized in the period the underlying sales or milestones occur. We do not receive final royalty reports from our ENHANZE partners until after we complete our financial statements for a prior quarter. Therefore, we recognize revenue based on estimates of the royalty earned, which are based on internal estimates and available preliminary reports provided by our partners. We will record adjustments in the following quarter, if necessary, when final royalty reports are received. To date, we have not recorded any material adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the royalties received from licensing our ENHANZE technology, we also earn royalties in connection with licenses granted under license and development arrangements with our device partners as a result of our acquisition of Antares. These royalties are based upon a percentage of commercial sales of partnered products with rates ranging from mid-single digits to low double digits and are tiered based on levels of net sales. These sales-based royalties, for which the license was deemed the predominant element to which the royalties relate, are estimated and recognized in the period in which the partners&#x2019; commercial sales occur. The royalties are generally reported and payable to us within 45 to 60 days of the end of the period in which the commercial sales are made. We base our estimates of royalties earned on actual sales information from our partners when available or estimated, prescription sales from external sources and estimated net selling price. We will record adjustments in the following quarter, if necessary, when final royalty reports are received. To date, we have not recorded any material adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue under ENHANZE and Device Collaborative Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ENHANZE Collaboration and License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of our ENHANZE collaboration agreements, we grant the partner a worldwide license to develop and commercialize products using our ENHANZE technology to combine our patented rHuPH20 enzyme with their proprietary biologics directed at up to a specified number of targets. Targets are usually licensed on an exclusive, global basis. Targets selected subsequent to inception of the arrangement generally require payment of an additional license fee. The partner is responsible for all development, manufacturing, clinical, regulatory, sales and marketing costs for any products developed under the agreement. We are responsible for supply of bulk rHuPH20 based on the partner&#x2019;s purchase orders and may also be separately engaged to perform research and development services. While these collaboration agreements are similar in that they originate from the same framework, each one is the result of an arms-length negotiation and thus may vary from one to the other.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We, in general, collect an upfront license payment from partners and are also entitled to receive event-based payments subject to partners&#x2019; achievement of specified development, regulatory and sales-based milestones. In several agreements, partners pay us annual fees to maintain their exclusive license rights if they are unable to advance product development to specified stages. We earn separate fees for bulk rHuPH20 supplies and research and development services. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although these agreements are in form identified as collaborative agreements, we concluded for accounting purposes they represent contracts with customers and are not subject to accounting literature on collaborative arrangements. This is because we grant to partners licenses to our intellectual property and provide supply of bulk rHuPH20 and research and development services which are all outputs of our ongoing activities, in exchange for consideration. Under these collaborative agreements, we do not develop assets jointly with partners, and do not share in significant risks of their development or commercialization activities. Accordingly, we concluded our collaborative agreements are appropriately accounted for pursuant to ASC Topic 606, Revenue from Contracts with Customers. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under all of our collaborative agreements, we have identified licenses to use functional intellectual property as the only performance obligation. The intellectual property underlying the license is our proprietary ENHANZE technology which represents application of rHuPH20 to facilitate delivery of drugs or fluids. Each of the licenses grants the partners rights to use &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;our intellectual property as it exists and is identified on the effective date of the license, because there is no ongoing development of the ENHANZE technology required. Therefore, we recognize revenue from licenses at the point when the license becomes effective and the partner has received access to our intellectual property, usually at the inception of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When partners can select additional targets to add to the licenses granted, we consider these rights to be options. We evaluate whether such options contain material rights, i.e. have exercise prices that are discounted compared to what we would charge for a similar license to a new partner. The exercise price of these options includes a combination of the target selection fees, event-based milestone payments and royalties. When these amounts in aggregate are not offered at a discount that exceeds discounts available to other customers, we conclude the option does not contain a material right, and we consider grants of additional licensing rights upon option exercises to be separate contracts (target selection contracts).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We provide customary indemnification and protection of licensed intellectual property for our customers. These provisions are part of assurance that the licenses meet the agreements&#x2019; representations and are not obligations to provide goods or services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also fulfill purchase orders for supply of bulk rHuPH20 and perform research and development services pursuant to projects authorization forms for our partners, which represent separate contracts. Additionally, we price our supply of bulk rHuPH20 and research and development services at our regular selling prices, called standalone selling price or (&#x201c;SSP&#x201d;). Therefore, our partners do not have material rights to order these items at prices not reflective of SSP. Refer to the discussion below regarding recognition of revenue for these separate contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transaction price for a contract represents the amount to which we are entitled in exchange for providing goods and services to the customer. Transaction price does not include amounts subject to uncertainties unless it is probable that there will be no significant reversal of revenue when the uncertainty is resolved. Apart from the upfront license payment (or target selection fees in the target selection contracts), all other fees we may earn under our collaborative agreements are subject to significant uncertainties of product development. Achievement of many of the event-based development and regulatory milestones may not be probable until such milestones are actually achieved. This generally relates to milestones such as obtaining marketing authorization approvals. With respect to other development milestones, e.g. dosing of a first patient in a clinical trial, achievement could be considered probable prior to its actual occurrence, based on the progress towards commencement of the trial. In order to evaluate progress towards commencement of a trial, we assess the status of activities leading up to our partner&#x2019;s initiation of a trial such as feedback received from the applicable regulatory authorities, completion of IND or equivalent filings, readiness and availability of drug, readiness of study sites and our partner&#x2019;s commitment of resources to the program. We do not include any amounts subject to uncertainties into the transaction price until it is probable that the amount will not result in a significant reversal of revenue in the future. At the end of each reporting period, we re-evaluate the probability of achievement of such milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When target exchange rights are held by partners, and the amounts attributed to these rights are not refundable, they are included in the transaction price. However, they are recorded as deferred revenues because we have a potential performance obligation to provide a new target upon an exchange right being exercised. These amounts are recognized in revenue when the right of exchange expires or is exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because our agreements have one type of performance obligation (licenses) which are typically all transferred at the same time at agreement inception, allocation of transaction price often is not required. However, allocation is required when licenses for some of the individual targets are subject to rights of exchange, because revenue associated with these targets cannot be recognized. When allocation is needed, we perform an allocation of the upfront amount based on relative SSP of licenses for individual targets. We determine license SSP using income-based valuation approach utilizing risk-adjusted discounted cash flow projections of the estimated return a licensor would receive. When amounts subject to uncertainties, such as milestones and royalties, are included in the transaction price, we attribute them to the specific individual target licenses which generate such milestone or royalty amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also estimate SSP of bulk rHuPH20 and research and development services, to determine that our partners do not have material rights to order them at discounted prices. For supplies of bulk rHuPH20, because we effectively act as a contract manufacturer to our partners, we estimate and charge SSP based on the typical contract manufacturer margins consistently with all of our partners. We determine SSP of research and development services based on a fully-burdened labor rate. Our rates are comparable to those we observe in other collaborative agreements. We also have a history of charging similar rates to all of our partners. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upfront amounts allocated to licenses to individual targets are recognized as revenue when the license is transferred to the partner, as discussed above, if the license is not subject to exchange rights, or when the exchange right expires or is exercised. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Development milestones and other fees are recognized in revenue when they are included in the transaction price, because by that time we have already transferred the related license to the partner. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In contracts to provide research and development services, such services represent the only performance obligation. The fees are charged based on hours worked by our employees and the fixed contractual rate per hour, plus third-party pass-through costs, on a monthly basis. We recognize revenues as the related services are performed based on the amounts billed, as the partner consumes the benefit of research and development work simultaneously as we perform these services, and the amounts billed reflect the value of these services to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Device License, Development and Supply Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have several license, development and supply arrangements with pharmaceutical partners as a result of our acquisition of Antares, under which we grant a license to our device technology and know-how and provide research and development services that often involve multiple performance obligations and highly customized deliverables. For such arrangements, we identify each of the promised goods and services within the contract and the distinct performance obligations at inception and allocate consideration to each performance obligation based on relative standalone selling price, which is generally determined based on the expected cost plus mark-up. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the contract includes an enforceable right to payment for performance completed to date and performance obligations are satisfied over time, we recognize revenue over the development period using either the input or output method depending on which is most appropriate given the nature of the distinct deliverable. For other contracts that do not contain an enforceable right to payment for performance completed to date, revenue is recognized when control of the product is transferred to the customer. Factors that may indicate that the transfer of control has occurred include the transfer of legal title, transfer of physical possession, the customer has obtained the significant risks and rewards of ownership of the assets and we have a present right to payment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our typical payment terms for development contracts may include an upfront payment equal to a percentage of the total contract value with the remaining portion to be billed upon completion and transfer of the individual deliverables or satisfaction of the individual performance obligations. We record a contract liability for cash received in advance of performance, which is presented within deferred revenue and deferred revenue, long-term in the Condensed Consolidated Balance Sheets and recognized as revenue in the Consolidated Statements of income when the associated performance obligations have been satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License fees and milestones received in exchange for the grant of a license to our functional intellectual property such as patented technology and know-how in connection with a partnered development arrangement are generally recognized at inception of the arrangement, or over the development period depending on the facts and circumstances, as the license is generally not distinct from the non-licensed goods or services to be provided under the contract. Milestone payments that are contingent upon the occurrence of future events are evaluated and recorded at the most likely amount, and to the extent that it is probable that a significant reversal will not occur when the associated uncertainty is resolved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further discussion on our collaborative arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Sales,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Proprietary Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Hylenex&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recombinant&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sell Hylenex recombinant in the U.S. to wholesale pharmaceutical distributors, who sell the product to hospitals and other end-user customers. Sales to wholesalers are made pursuant to purchase orders subject to the terms of a master agreement, and delivery of individual packages of Hylenex recombinant represent performance obligations under each purchase order. We use a contract manufacturer to produce Hylenex recombinant and a third-party logistics (3PL) vendor to process and fulfill orders&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We concluded we are the principal in the sales to wholesalers because we control access to services rendered by both vendors and direct their activities. We have no significant obligations to wholesalers to generate pull-through sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling prices initially billed to wholesalers are subject to discounts for prompt payment and subsequent chargebacks when wholesalers sell Hylenex recombinant at negotiated discounted prices to members of certain group purchasing organizations (&#x201c;GPOs&#x201d;) and government programs. We also pay quarterly distribution fees to certain wholesalers for inventory reporting and chargeback processing, and to GPOs as administrative fees for services and for access to GPO members. We concluded the benefits received in exchange for these fees are not distinct from our sales of Hylenex&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;recombinant, and accordingly we apply these amounts to reduce revenues. Wholesalers also have rights to return unsold product nearing or past the expiration date. Because of the shelf life of Hylenex recombinant and our lengthy return period, there may be a significant period of time between when the product is shipped and when we issue credits on returned product. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the transaction price when we receive each purchase order taking into account the expected reductions of the selling price initially billed to the wholesaler arising from all of the above factors. We have compiled historical experience and data to estimate future returns and chargebacks of Hylenex recombinant and the impact of the other discounts and fees we pay. When estimating these adjustments to the transaction price, we reduce it sufficiently to be able to assert that it is probable that there will be no significant reversal of revenue when the ultimate adjustment amounts are known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each purchase order contains only one type of product, and is usually shipped to the wholesaler in a single shipment. Therefore, allocation of the transaction price to individual packages is not required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenue from Hylenex recombinant product sales and related cost of sales upon product delivery to the wholesaler location. At that time, the wholesalers take control of the product as they take title, bear the risk of loss of ownership, and have an enforceable obligation to pay us. They also have the ability to direct sales of product to their customers on terms and at prices they negotiate. Although wholesalers have product return rights, we do not believe they have a significant incentive to return the product to us.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon recognition of revenue from product sales of Hylenex recombinant, the estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, and GPO fees are included in accrued liabilities and net of accounts receivable. We monitor actual product returns, chargebacks, discounts and fees subsequent to the sale. If these amounts differ from our estimates, we make adjustments to these allowances, which are applied to increase or reduce product sales revenue and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the orders placed by wholesalers, we incur costs such as commissions to our sales representatives. However, as revenue from product sales is recognized upon delivery to the wholesaler, which occurs shortly after we receive a purchase order, we do not capitalize these commissions and other costs, based on application of the practical expedient allowed within the applicable guidance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Proprietary Product Sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of our acquisition of Antares, our commercial portfolio of proprietary products includes XYOSTED, TLANDO and NOCDURNA, which we sell primarily to wholesale and specialty distributors. Revenue is recognized when control has transferred to the customer, which is typically upon delivery, at the net selling price, which reflects the variable consideration for which reserves and sales allowances are established for estimated returns, wholesale distribution fees, prompt payment discounts, government rebates and chargebacks, plan rebate arrangements and patient discount and support programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The determination of certain reserves and sales allowances requires us to make a number of judgements and estimates to reflect our best estimate of the transaction price and the amount of consideration to which we believe we would be ultimately entitled to receive. The expected value is determined based on unit sales data, contractual terms with customers and third-party payers, historical and estimated future percentage of rebates incurred on sales, historical and future insurance plan billings, any new or anticipated changes in programs or regulations that would impact the amount of the actual rebates, customer purchasing patterns, product expiration dates and levels of inventory in the distribution channel. The estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, rebates and customer co-pay support programs are included in accrued liabilities and net of accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Partnered Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Bulk rHuPH20&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sell bulk rHuPH20 to partners for use in research and development and, subsequent to receiving marketing approval, we sell it for use in collaboration commercial products. Sales are made pursuant to purchase orders subject to the terms of the collaborative agreement or a supply agreement, and delivery of units of bulk rHuPH20 represent performance obligations under each purchase order. We provide a standard warranty that the product conforms to specifications. We use contract manufacturers to produce bulk rHuPH20 and have concluded we are the principal in the sales to partners. The transaction price for each purchase order of bulk rHuPH20 is fixed based on the cost of production plus a contractual markup, and is not subject to adjustments. Allocation of the transaction price to individual quantities of the product is usually not required because each order contains only one type of product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenue from the sale of bulk rHuPH20 as product sales and related cost of sales upon transfer of title to our partners. At that time, the partners take control of the product, bear the risk of loss of ownership, and have an enforceable obligation to pay us. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Devices&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of our acquisition of Antares, we are party to several license, development, supply and distribution arrangements with pharmaceutical partners, under which we produce and are the exclusive supplier of certain products, devices and/or components. Revenue is recognized when or as control of the goods transfers to the customer as discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are the exclusive supplier of the Makena&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; subcutaneous auto-injector product to Covis and the exclusive supplier of OTREXUP&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to Otter Pharmaceuticals, LLC (&#x201c;Otter&#x201d;). Because these products are custom manufactured for each customer with no alternative use and we have a contractual right to payment for performance completed to date, control is continuously transferred to the customer as the product is produced pursuant to firm purchase orders. Revenue is recognized over time using the output method based on the contractual selling price and number of units produced. The amount of revenue recognized in excess of the amount shipped/billed to the customer, if any, is recorded as contract assets in the Condensed Consolidated Balance Sheets due to the short-term nature in which the amount is ultimately expected to be billed and collected from the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All other device partnered product sales are recognized at the point in time in which control is transferred to the customer, which is typically upon shipment. Sales terms and pricing are governed by the respective supply and distribution agreements, and there is generally no right of return. Revenue is recognized at the transaction price, which includes the contractual per unit selling price and estimated variable consideration, such as volume-based pricing arrangements or profit sharing arrangements, if any. We recognize revenue, including the estimated variable consideration we expect to receive for contract margin on future commercial sales, upon shipment of the goods to our partner. The estimated variable consideration is recognized at an amount we believe is not subject to significant reversal based on historical experience and is adjusted at each reporting period if the most likely amount of expected consideration changes or becomes fixed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our statements of income, we report as revenues under collaborative agreements the upfront payments, event-based development and regulatory milestones and sales milestones. We also include in this category revenues from separate research and development contracts pursuant to project authorization forms. We report royalties received from partners as a separate line in our statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from sales of our proprietary and partnered products are included in product sales, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the footnotes to our condensed consolidated financial statements, we provide disaggregated revenue information by type of arrangement (product sales, net, collaborative agreements and research and device licensing and development revenues), and additionally, by type of payment stream received under collaborative agreements (upfront license and target nomination fees, event-based development and regulatory milestones and other fees, sales milestones and royalties).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal costs and manufacturing overhead associated with the production of proprietary and partnered products. Cost of sales also consists of the write-down of excess, dated and obsolete inventories and the write-off of inventories that do not meet certain product specifications, if any.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses include salaries and benefits, facilities and other overhead expenses, research related manufacturing services, contract services and other outside expenses. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to our research and development efforts and have no alternative future uses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed or such time when we do not expect the goods to be delivered or services to be performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record compensation expense associated with stock options, restricted stock awards (&#x201c;RSAs&#x201d;), restricted stock units (&#x201c;RSUs&#x201d;), performance stock units (&#x201c;PSUs&#x201d;) and shares issued under our employee stock purchase plan (&#x201c;ESPP&#x201d;) in accordance with the authoritative guidance for stock-based compensation. The cost of employee services received in exchange for an award of an equity instrument is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period of the award. Share-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed. Forfeitures are recognized as a reduction of share-based compensation expense as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We provide for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases at each reporting period. We measure deferred tax assets and liabilities using enacted tax rates for the year in which the differences are expected to reverse. Significant judgment is required by management to determine our provision for income taxes, our deferred tax assets and liabilities, and any associated valuation allowances recorded against our net deferred tax assets, which are based on complex and evolving tax regulations. Deferred tax assets (&#x201c;DTA&#x201d;) and other tax benefits are recorded when they are more likely than not to be realized. On a quarterly basis, we assess the need for valuation allowance on our DTAs, weighing all positive and negative evidence, to assess if it is more-likely-than-not that some or all of our DTAs will be realized. We recorded a provision for income taxes of $7.3&#160;million and $21.6&#160;million using an effective tax rate of 8.1% and  20.7% the three and six months ended June&#160;30, 2022 respectively. The difference between our effective tax rate and the U.S. federal statutory rate of 21% is primarily due to tax benefits on Foreign Derived Intangible Income Deduction (FDII), and tax detriments on 162(m), other share-based compensation and non-deductible transaction costs related to Antares acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the acquisition of Antares, we assessed the organization of our business and concluded that we continue to operate our business in one segment, which includes all activities related to the research, development and commercialization of our proprietary enzymes and devices. This segment also includes revenues and expenses related to (i)&#160;research and development and manufacturing activities conducted under our collaborative agreements with third parties (ii)&#160;product sales of proprietary and partnered  products. The chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations as a single operating segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Adoption and Pending Adoption of Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a brief description of recently issued accounting standards, those adopted in the current period and those not yet adopted:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Standard&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effective Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect on the Financial &lt;br/&gt;Statements or Other Significant Matters&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from contracts with customers&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The new guidance requires an acquirer to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with topic 606 as if it had originated the contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;January 1, 2023&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(Early adoption is permitted, including adoption in an interim period)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We early adopted ASU 2021-08 on April 1, 2022. The adoption did not have a material impact on our condensed consolidated financial position or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMzI5MjI_92a1fab3-eff3-40ab-bcb7-2d4a4658f6eb">&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) and with the rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) related to a quarterly report on Form 10-Q. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for a complete set of financial statements. These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC on February&#160;22, 2022. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operations for the periods presented, with such adjustments consisting only of normal recurring adjustments. Operating results for interim periods are not necessarily indicative of the operating results for an entire fiscal year.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMzI4NTY_1caf1409-4e99-407f-99a2-928b0fc98910">The accompanying interim unaudited condensed consolidated financial statements include the accounts of Halozyme Therapeutics, Inc. and our wholly owned subsidiaries, Halozyme, Inc. and Antares Pharma, Inc., Halozyme, Inc.&#x2019;s wholly owned subsidiary Halozyme Switzerland Holdings GmbH and Antares Pharma, Inc.&#x2019;s wholly-owned Swiss subsidiaries, Antares Pharma IPL AG and Antares Pharma AG. All intercompany accounts and transactions have been eliminated.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMzI4ODI_caff0e20-69ab-4473-9be1-ee1bd81b52fc">Use of EstimatesThe preparation of interim unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our interim unaudited condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management&#x2019;s estimates</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMzI4MDA_1de9c2e1-c428-4b4d-ae08-cec16050bd23">&lt;div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash Equivalents and Marketable Securities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents consist of highly liquid investments, readily convertible to cash, that mature within ninety days or less from the date of purchase. As of June&#160;30, 2022, our cash and cash equivalents consisted of money market funds, bank certificate of deposits and demands deposits at commercial banks.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities are investments with original maturities of more than ninety days from the date of purchase that are specifically identified to fund current operations. Marketable securities are considered available-for-sale. These investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date which reflects management&#x2019;s intention to use the proceeds from the sale of these investments to fund our operations, as necessary. Such available-for-sale investments are carried at fair value with unrealized gains and losses recorded in other comprehensive income (loss) and included as a separate component of stockholders&#x2019; equity. The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in the interim unaudited condensed consolidated statements of income. We use the specific identification method for calculating realized gains and losses on marketable securities sold. None of the realized gains and losses and declines in value that were judged to be as a result of credit loss on marketable securities, if any, are included in investment and other income, net in the interim unaudited condensed consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the leases of our facilities, we are required to maintain letters of credit as security deposits during the terms of such leases. As of June&#160;30, 2022 and December&#160;31, 2021, restricted cash of $0.5 million was pledged as collateral for the letters of credit.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfNDE4MQ_c47694da-816f-4a29-b2fc-8af45f3a5d29"
      unitRef="usd">500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMzI4NDQ_5ff96427-3c3f-4ee3-a941-276a70792805">&lt;div style="margin-top:6pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The authoritative guidance for fair value measurements establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments include cash equivalents, available-for-sale marketable securities, accounts receivable, prepaid expenses and other assets, accounts payable, accrued expenses, long-term debt and contingent liability. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale marketable securities consist of asset-backed securities, corporate debt securities, U.S. Treasury securities and commercial paper, and are measured at fair value using Level 1 and Level 2 inputs. Level 2 financial instruments are valued using market prices on less active markets and proprietary pricing valuation models with observable inputs, including interest rates, yield curves, maturity dates, issue dates, settlement dates, reported trades, broker-dealer quotes, issue spreads, benchmark securities or other market related data. We obtain the fair value of Level 2 investments from our investment manager, who obtains these fair values from a third-party pricing source. We validate the fair values of Level 2 financial instruments provided by our investment manager by comparing these fair values to a third-party pricing source.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMzI3Njg_a94f1344-5de2-4936-8147-0a4c30a39659">&lt;div style="margin-top:9pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Inventories are reviewed periodically for potential excess, dated or obsolete status. We evaluate the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the price we expect to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on hand.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMzI4MDI_2feda62f-e147-427f-ba31-5e3fbbc75b02">&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into operating leases primarily for real estate and automobiles. These leases have contractual terms which range from 3 years to 12 years. We determine if an arrangement contains a lease at inception. Right of use (&#x201c;ROU&#x201d;) assets and liabilities resulting from operating leases are included in property and equipment, accrued expenses and other long-term liabilities on our condensed consolidated balance sheets. Operating lease ROU assets and liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the discount rate to calculate the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Our leases often include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that we will exercise that option. Short-term leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as automobiles, we account for the lease and non-lease components as a single lease component.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, we entered into an agreement for assignment and assumption of lease with Seismic Software, Inc. pursuant to which effective January 1, 2023, we will assume Seismic&#x2019;s office lease, as amended with Kilroy Realty L.P. for approximately 72,534 square feet of space in office and research facilities which is expected to commence on January 1, 2023. The premises are intended to serve as our new headquarters.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i03b0b3511b2544be8e14af45977bfbce_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfNzM5Mw_fb6c6124-0da4-4f58-95a9-dbfff0ea66a0">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="iecce61f93caa4b668869678174aa5845_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfNzM5OQ_ba8999e5-08c5-45c6-8d0e-0a36f6aaf917">P12Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMTkyNDE0NTM1NjQ1NzU_af1dd1bb-1dad-49f2-b127-c92cc5ab5824">&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition. These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. Costs that we incur to complete the business combination, such as legal and other professional fees, are expensed as they are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the initial accounting for a business combination is incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date. We record these adjustments to the provisional amounts with a corresponding offset to goodwill. Any adjustments identified after the measurement period are recorded in the consolidated statements of income.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <halo:GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMTkyNDE0NTM1NjQ1NzY_ef15ce84-3552-4a12-8530-ecf5f7ceffad">&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill, Intangible Assets and Other Long-Lived Asset&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets acquired, including intangible assets and in-process research and development (IPR&amp;amp;D), and liabilities assumed are measured at fair value as of the acquisition date. Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of the net assets acquired. Intangible assets acquired in a business combination that are used for IPR&amp;amp;D activities are considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon reaching the end of the relevant research and development project (i.e., upon commercialization), the IPR&amp;amp;D asset is amortized over its estimated useful life. If the relevant research and development project is abandoned, the IPR&amp;amp;D asset is expensed in the period of abandonment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill and IPR&amp;amp;D are not amortized; however, they are reviewed for impairment at least annually during the second quarter, or more frequently if an event occurs indicating the potential for impairment. Goodwill and IPR&amp;amp;D are considered to be impaired if the carrying value of the reporting unit or IPR&amp;amp;D asset exceeds its respective fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform our goodwill impairment analysis at the reporting unit level, which aligns with our reporting structure and availability of discrete financial information. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair values of our reporting units are less than the carrying amounts, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and our overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair values of our reporting units are less than the carrying amounts, then no additional assessment is deemed necessary. Otherwise, we proceed to compare the estimated fair values of the reporting units with the carrying values, including goodwill. If the carrying amounts of the reporting units exceed the fair values, we record an impairment loss based on the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill impairment test.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our identifiable intangible assets with a finite life are typically comprised of acquired device technologies and product rights. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#x2019; respective estimated useful lives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform regular reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant changes in the ability of a particular asset to generate positive cash flows for our strategic business objectives, and the pattern of utilization of a particular asset.&lt;/span&gt;&lt;/div&gt;</halo:GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMzI4MTI_f098c36d-e795-44d2-a8e0-4604abc9ab10">&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generate revenues from payments received (i) as royalties from licensing our ENHANZE technology and other royalty arrangements, (ii) under collaborative agreements and (iii) from sales of our proprietary and partnered products. We recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers we perform the following five steps: (i) identify the promised goods or services in the contract; (ii) identify the performance obligations in the contract, including whether they are distinct in the context of the contract; (iii) determine the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ENHANZE and Device Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of our ENHANZE collaboration and license agreements, our partners will pay us royalties at an on average mid-single digit percent rate of their sales if products under the collaboration are commercialized. All amounts owed to us are noncancelable after the underlying triggering event occurs, and nonrefundable once paid. Unless terminated earlier in accordance with its terms, collaborations generally continue in effect until the last to expire royalty payment term, as determined on a product by product and on a country by country basis, with each royalty term starting on the first commercial sale of that product and ending the later of: (i) a specified period or term set forth in the agreement or (ii) expiration of the last to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration which valid claim covers a product developed under the collaboration. When there are no valid claims during the applicable royalty term in a given country, the royalty rate is reduced for those sales. Partners may terminate the agreement prior to expiration for any reason in its entirety or on a target-by-target basis generally upon 90 days prior written notice to us.&#160;Upon any such termination, the license granted to partners (in total or with respect to the terminated target, as applicable) will terminate provided, however, that in the event of expiration of the agreement (as opposed to a termination), the on-going licenses granted will become perpetual, non-exclusive and fully paid. Sales-based milestones and royalties are recognized in the period the underlying sales or milestones occur. We do not receive final royalty reports from our ENHANZE partners until after we complete our financial statements for a prior quarter. Therefore, we recognize revenue based on estimates of the royalty earned, which are based on internal estimates and available preliminary reports provided by our partners. We will record adjustments in the following quarter, if necessary, when final royalty reports are received. To date, we have not recorded any material adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the royalties received from licensing our ENHANZE technology, we also earn royalties in connection with licenses granted under license and development arrangements with our device partners as a result of our acquisition of Antares. These royalties are based upon a percentage of commercial sales of partnered products with rates ranging from mid-single digits to low double digits and are tiered based on levels of net sales. These sales-based royalties, for which the license was deemed the predominant element to which the royalties relate, are estimated and recognized in the period in which the partners&#x2019; commercial sales occur. The royalties are generally reported and payable to us within 45 to 60 days of the end of the period in which the commercial sales are made. We base our estimates of royalties earned on actual sales information from our partners when available or estimated, prescription sales from external sources and estimated net selling price. We will record adjustments in the following quarter, if necessary, when final royalty reports are received. To date, we have not recorded any material adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue under ENHANZE and Device Collaborative Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ENHANZE Collaboration and License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of our ENHANZE collaboration agreements, we grant the partner a worldwide license to develop and commercialize products using our ENHANZE technology to combine our patented rHuPH20 enzyme with their proprietary biologics directed at up to a specified number of targets. Targets are usually licensed on an exclusive, global basis. Targets selected subsequent to inception of the arrangement generally require payment of an additional license fee. The partner is responsible for all development, manufacturing, clinical, regulatory, sales and marketing costs for any products developed under the agreement. We are responsible for supply of bulk rHuPH20 based on the partner&#x2019;s purchase orders and may also be separately engaged to perform research and development services. While these collaboration agreements are similar in that they originate from the same framework, each one is the result of an arms-length negotiation and thus may vary from one to the other.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We, in general, collect an upfront license payment from partners and are also entitled to receive event-based payments subject to partners&#x2019; achievement of specified development, regulatory and sales-based milestones. In several agreements, partners pay us annual fees to maintain their exclusive license rights if they are unable to advance product development to specified stages. We earn separate fees for bulk rHuPH20 supplies and research and development services. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although these agreements are in form identified as collaborative agreements, we concluded for accounting purposes they represent contracts with customers and are not subject to accounting literature on collaborative arrangements. This is because we grant to partners licenses to our intellectual property and provide supply of bulk rHuPH20 and research and development services which are all outputs of our ongoing activities, in exchange for consideration. Under these collaborative agreements, we do not develop assets jointly with partners, and do not share in significant risks of their development or commercialization activities. Accordingly, we concluded our collaborative agreements are appropriately accounted for pursuant to ASC Topic 606, Revenue from Contracts with Customers. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under all of our collaborative agreements, we have identified licenses to use functional intellectual property as the only performance obligation. The intellectual property underlying the license is our proprietary ENHANZE technology which represents application of rHuPH20 to facilitate delivery of drugs or fluids. Each of the licenses grants the partners rights to use &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;our intellectual property as it exists and is identified on the effective date of the license, because there is no ongoing development of the ENHANZE technology required. Therefore, we recognize revenue from licenses at the point when the license becomes effective and the partner has received access to our intellectual property, usually at the inception of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When partners can select additional targets to add to the licenses granted, we consider these rights to be options. We evaluate whether such options contain material rights, i.e. have exercise prices that are discounted compared to what we would charge for a similar license to a new partner. The exercise price of these options includes a combination of the target selection fees, event-based milestone payments and royalties. When these amounts in aggregate are not offered at a discount that exceeds discounts available to other customers, we conclude the option does not contain a material right, and we consider grants of additional licensing rights upon option exercises to be separate contracts (target selection contracts).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We provide customary indemnification and protection of licensed intellectual property for our customers. These provisions are part of assurance that the licenses meet the agreements&#x2019; representations and are not obligations to provide goods or services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also fulfill purchase orders for supply of bulk rHuPH20 and perform research and development services pursuant to projects authorization forms for our partners, which represent separate contracts. Additionally, we price our supply of bulk rHuPH20 and research and development services at our regular selling prices, called standalone selling price or (&#x201c;SSP&#x201d;). Therefore, our partners do not have material rights to order these items at prices not reflective of SSP. Refer to the discussion below regarding recognition of revenue for these separate contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transaction price for a contract represents the amount to which we are entitled in exchange for providing goods and services to the customer. Transaction price does not include amounts subject to uncertainties unless it is probable that there will be no significant reversal of revenue when the uncertainty is resolved. Apart from the upfront license payment (or target selection fees in the target selection contracts), all other fees we may earn under our collaborative agreements are subject to significant uncertainties of product development. Achievement of many of the event-based development and regulatory milestones may not be probable until such milestones are actually achieved. This generally relates to milestones such as obtaining marketing authorization approvals. With respect to other development milestones, e.g. dosing of a first patient in a clinical trial, achievement could be considered probable prior to its actual occurrence, based on the progress towards commencement of the trial. In order to evaluate progress towards commencement of a trial, we assess the status of activities leading up to our partner&#x2019;s initiation of a trial such as feedback received from the applicable regulatory authorities, completion of IND or equivalent filings, readiness and availability of drug, readiness of study sites and our partner&#x2019;s commitment of resources to the program. We do not include any amounts subject to uncertainties into the transaction price until it is probable that the amount will not result in a significant reversal of revenue in the future. At the end of each reporting period, we re-evaluate the probability of achievement of such milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When target exchange rights are held by partners, and the amounts attributed to these rights are not refundable, they are included in the transaction price. However, they are recorded as deferred revenues because we have a potential performance obligation to provide a new target upon an exchange right being exercised. These amounts are recognized in revenue when the right of exchange expires or is exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because our agreements have one type of performance obligation (licenses) which are typically all transferred at the same time at agreement inception, allocation of transaction price often is not required. However, allocation is required when licenses for some of the individual targets are subject to rights of exchange, because revenue associated with these targets cannot be recognized. When allocation is needed, we perform an allocation of the upfront amount based on relative SSP of licenses for individual targets. We determine license SSP using income-based valuation approach utilizing risk-adjusted discounted cash flow projections of the estimated return a licensor would receive. When amounts subject to uncertainties, such as milestones and royalties, are included in the transaction price, we attribute them to the specific individual target licenses which generate such milestone or royalty amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also estimate SSP of bulk rHuPH20 and research and development services, to determine that our partners do not have material rights to order them at discounted prices. For supplies of bulk rHuPH20, because we effectively act as a contract manufacturer to our partners, we estimate and charge SSP based on the typical contract manufacturer margins consistently with all of our partners. We determine SSP of research and development services based on a fully-burdened labor rate. Our rates are comparable to those we observe in other collaborative agreements. We also have a history of charging similar rates to all of our partners. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upfront amounts allocated to licenses to individual targets are recognized as revenue when the license is transferred to the partner, as discussed above, if the license is not subject to exchange rights, or when the exchange right expires or is exercised. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Development milestones and other fees are recognized in revenue when they are included in the transaction price, because by that time we have already transferred the related license to the partner. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In contracts to provide research and development services, such services represent the only performance obligation. The fees are charged based on hours worked by our employees and the fixed contractual rate per hour, plus third-party pass-through costs, on a monthly basis. We recognize revenues as the related services are performed based on the amounts billed, as the partner consumes the benefit of research and development work simultaneously as we perform these services, and the amounts billed reflect the value of these services to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Device License, Development and Supply Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have several license, development and supply arrangements with pharmaceutical partners as a result of our acquisition of Antares, under which we grant a license to our device technology and know-how and provide research and development services that often involve multiple performance obligations and highly customized deliverables. For such arrangements, we identify each of the promised goods and services within the contract and the distinct performance obligations at inception and allocate consideration to each performance obligation based on relative standalone selling price, which is generally determined based on the expected cost plus mark-up. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the contract includes an enforceable right to payment for performance completed to date and performance obligations are satisfied over time, we recognize revenue over the development period using either the input or output method depending on which is most appropriate given the nature of the distinct deliverable. For other contracts that do not contain an enforceable right to payment for performance completed to date, revenue is recognized when control of the product is transferred to the customer. Factors that may indicate that the transfer of control has occurred include the transfer of legal title, transfer of physical possession, the customer has obtained the significant risks and rewards of ownership of the assets and we have a present right to payment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our typical payment terms for development contracts may include an upfront payment equal to a percentage of the total contract value with the remaining portion to be billed upon completion and transfer of the individual deliverables or satisfaction of the individual performance obligations. We record a contract liability for cash received in advance of performance, which is presented within deferred revenue and deferred revenue, long-term in the Condensed Consolidated Balance Sheets and recognized as revenue in the Consolidated Statements of income when the associated performance obligations have been satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License fees and milestones received in exchange for the grant of a license to our functional intellectual property such as patented technology and know-how in connection with a partnered development arrangement are generally recognized at inception of the arrangement, or over the development period depending on the facts and circumstances, as the license is generally not distinct from the non-licensed goods or services to be provided under the contract. Milestone payments that are contingent upon the occurrence of future events are evaluated and recorded at the most likely amount, and to the extent that it is probable that a significant reversal will not occur when the associated uncertainty is resolved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further discussion on our collaborative arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Sales,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Proprietary Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Hylenex&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recombinant&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sell Hylenex recombinant in the U.S. to wholesale pharmaceutical distributors, who sell the product to hospitals and other end-user customers. Sales to wholesalers are made pursuant to purchase orders subject to the terms of a master agreement, and delivery of individual packages of Hylenex recombinant represent performance obligations under each purchase order. We use a contract manufacturer to produce Hylenex recombinant and a third-party logistics (3PL) vendor to process and fulfill orders&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We concluded we are the principal in the sales to wholesalers because we control access to services rendered by both vendors and direct their activities. We have no significant obligations to wholesalers to generate pull-through sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling prices initially billed to wholesalers are subject to discounts for prompt payment and subsequent chargebacks when wholesalers sell Hylenex recombinant at negotiated discounted prices to members of certain group purchasing organizations (&#x201c;GPOs&#x201d;) and government programs. We also pay quarterly distribution fees to certain wholesalers for inventory reporting and chargeback processing, and to GPOs as administrative fees for services and for access to GPO members. We concluded the benefits received in exchange for these fees are not distinct from our sales of Hylenex&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;recombinant, and accordingly we apply these amounts to reduce revenues. Wholesalers also have rights to return unsold product nearing or past the expiration date. Because of the shelf life of Hylenex recombinant and our lengthy return period, there may be a significant period of time between when the product is shipped and when we issue credits on returned product. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the transaction price when we receive each purchase order taking into account the expected reductions of the selling price initially billed to the wholesaler arising from all of the above factors. We have compiled historical experience and data to estimate future returns and chargebacks of Hylenex recombinant and the impact of the other discounts and fees we pay. When estimating these adjustments to the transaction price, we reduce it sufficiently to be able to assert that it is probable that there will be no significant reversal of revenue when the ultimate adjustment amounts are known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each purchase order contains only one type of product, and is usually shipped to the wholesaler in a single shipment. Therefore, allocation of the transaction price to individual packages is not required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenue from Hylenex recombinant product sales and related cost of sales upon product delivery to the wholesaler location. At that time, the wholesalers take control of the product as they take title, bear the risk of loss of ownership, and have an enforceable obligation to pay us. They also have the ability to direct sales of product to their customers on terms and at prices they negotiate. Although wholesalers have product return rights, we do not believe they have a significant incentive to return the product to us.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon recognition of revenue from product sales of Hylenex recombinant, the estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, and GPO fees are included in accrued liabilities and net of accounts receivable. We monitor actual product returns, chargebacks, discounts and fees subsequent to the sale. If these amounts differ from our estimates, we make adjustments to these allowances, which are applied to increase or reduce product sales revenue and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the orders placed by wholesalers, we incur costs such as commissions to our sales representatives. However, as revenue from product sales is recognized upon delivery to the wholesaler, which occurs shortly after we receive a purchase order, we do not capitalize these commissions and other costs, based on application of the practical expedient allowed within the applicable guidance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Proprietary Product Sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of our acquisition of Antares, our commercial portfolio of proprietary products includes XYOSTED, TLANDO and NOCDURNA, which we sell primarily to wholesale and specialty distributors. Revenue is recognized when control has transferred to the customer, which is typically upon delivery, at the net selling price, which reflects the variable consideration for which reserves and sales allowances are established for estimated returns, wholesale distribution fees, prompt payment discounts, government rebates and chargebacks, plan rebate arrangements and patient discount and support programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The determination of certain reserves and sales allowances requires us to make a number of judgements and estimates to reflect our best estimate of the transaction price and the amount of consideration to which we believe we would be ultimately entitled to receive. The expected value is determined based on unit sales data, contractual terms with customers and third-party payers, historical and estimated future percentage of rebates incurred on sales, historical and future insurance plan billings, any new or anticipated changes in programs or regulations that would impact the amount of the actual rebates, customer purchasing patterns, product expiration dates and levels of inventory in the distribution channel. The estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, rebates and customer co-pay support programs are included in accrued liabilities and net of accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Partnered Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Bulk rHuPH20&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sell bulk rHuPH20 to partners for use in research and development and, subsequent to receiving marketing approval, we sell it for use in collaboration commercial products. Sales are made pursuant to purchase orders subject to the terms of the collaborative agreement or a supply agreement, and delivery of units of bulk rHuPH20 represent performance obligations under each purchase order. We provide a standard warranty that the product conforms to specifications. We use contract manufacturers to produce bulk rHuPH20 and have concluded we are the principal in the sales to partners. The transaction price for each purchase order of bulk rHuPH20 is fixed based on the cost of production plus a contractual markup, and is not subject to adjustments. Allocation of the transaction price to individual quantities of the product is usually not required because each order contains only one type of product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenue from the sale of bulk rHuPH20 as product sales and related cost of sales upon transfer of title to our partners. At that time, the partners take control of the product, bear the risk of loss of ownership, and have an enforceable obligation to pay us. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Devices&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of our acquisition of Antares, we are party to several license, development, supply and distribution arrangements with pharmaceutical partners, under which we produce and are the exclusive supplier of certain products, devices and/or components. Revenue is recognized when or as control of the goods transfers to the customer as discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are the exclusive supplier of the Makena&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; subcutaneous auto-injector product to Covis and the exclusive supplier of OTREXUP&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to Otter Pharmaceuticals, LLC (&#x201c;Otter&#x201d;). Because these products are custom manufactured for each customer with no alternative use and we have a contractual right to payment for performance completed to date, control is continuously transferred to the customer as the product is produced pursuant to firm purchase orders. Revenue is recognized over time using the output method based on the contractual selling price and number of units produced. The amount of revenue recognized in excess of the amount shipped/billed to the customer, if any, is recorded as contract assets in the Condensed Consolidated Balance Sheets due to the short-term nature in which the amount is ultimately expected to be billed and collected from the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All other device partnered product sales are recognized at the point in time in which control is transferred to the customer, which is typically upon shipment. Sales terms and pricing are governed by the respective supply and distribution agreements, and there is generally no right of return. Revenue is recognized at the transaction price, which includes the contractual per unit selling price and estimated variable consideration, such as volume-based pricing arrangements or profit sharing arrangements, if any. We recognize revenue, including the estimated variable consideration we expect to receive for contract margin on future commercial sales, upon shipment of the goods to our partner. The estimated variable consideration is recognized at an amount we believe is not subject to significant reversal based on historical experience and is adjusted at each reporting period if the most likely amount of expected consideration changes or becomes fixed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our statements of income, we report as revenues under collaborative agreements the upfront payments, event-based development and regulatory milestones and sales milestones. We also include in this category revenues from separate research and development contracts pursuant to project authorization forms. We report royalties received from partners as a separate line in our statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from sales of our proprietary and partnered products are included in product sales, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the footnotes to our condensed consolidated financial statements, we provide disaggregated revenue information by type of arrangement (product sales, net, collaborative agreements and research and device licensing and development revenues), and additionally, by type of payment stream received under collaborative agreements (upfront license and target nomination fees, event-based development and regulatory milestones and other fees, sales milestones and royalties).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs, internal costs and manufacturing overhead associated with the production of proprietary and partnered products. Cost of sales also consists of the write-down of excess, dated and obsolete inventories and the write-off of inventories that do not meet certain product specifications, if any.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <halo:RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMTI3ODU_b5ced0df-453b-43f0-a9fc-39ab90cc3892">P90D</halo:RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMzI4OTI_1e9b5196-c4b5-4e0a-ad2a-24342c75fd61">&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses include salaries and benefits, facilities and other overhead expenses, research related manufacturing services, contract services and other outside expenses. Research and development expenses are charged to operating expenses as incurred when these expenditures relate to our research and development efforts and have no alternative future uses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed or such time when we do not expect the goods to be delivered or services to be performed.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMzI4NDg_75083d03-412d-4e7d-8d0e-00691b6e8535">&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record compensation expense associated with stock options, restricted stock awards (&#x201c;RSAs&#x201d;), restricted stock units (&#x201c;RSUs&#x201d;), performance stock units (&#x201c;PSUs&#x201d;) and shares issued under our employee stock purchase plan (&#x201c;ESPP&#x201d;) in accordance with the authoritative guidance for stock-based compensation. The cost of employee services received in exchange for an award of an equity instrument is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period of the award. Share-based compensation expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized and any previously recognized compensation expense is reversed. Forfeitures are recognized as a reduction of share-based compensation expense as they occur.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMzI4NzA_860a8e51-c163-40da-b6dc-707c32420460">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We provide for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are determined based on the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases at each reporting period. We measure deferred tax assets and liabilities using enacted tax rates for the year in which the differences are expected to reverse. Significant judgment is required by management to determine our provision for income taxes, our deferred tax assets and liabilities, and any associated valuation allowances recorded against our net deferred tax assets, which are based on complex and evolving tax regulations. Deferred tax assets (&#x201c;DTA&#x201d;) and other tax benefits are recorded when they are more likely than not to be realized. On a quarterly basis, we assess the need for valuation allowance on our DTAs, weighing all positive and negative evidence, to assess if it is more-likely-than-not that some or all of our DTAs will be realized. We recorded a provision for income taxes of $7.3&#160;million and $21.6&#160;million using an effective tax rate of 8.1% and  20.7% the three and six months ended June&#160;30, 2022 respectively. The difference between our effective tax rate and the U.S. federal statutory rate of 21% is primarily due to tax benefits on Foreign Derived Intangible Income Deduction (FDII), and tax detriments on 162(m), other share-based compensation and non-deductible transaction costs related to Antares acquisition.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMTkyNDE0NTM1ODY0NzA_3f3b1f8e-7e4a-4edd-aeeb-7e0dbd4256e6"
      unitRef="usd">7300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMTkyNDE0NTM1ODY1MjY_2a8196ef-c7a4-4664-a85d-3f728600a2a1"
      unitRef="usd">21600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMzE2ODY_935bfac5-32c0-4828-8a00-704f8164a9b4"
      unitRef="number">0.081</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMTA5OTUxMTY2MDc2Nw_5e99b9c3-29f0-4146-96af-453c6c644f8f"
      unitRef="number">0.207</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMzI3NjA_5c673233-4558-438a-9a65-90b9f2991cb7">&lt;div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the acquisition of Antares, we assessed the organization of our business and concluded that we continue to operate our business in one segment, which includes all activities related to the research, development and commercialization of our proprietary enzymes and devices. This segment also includes revenues and expenses related to (i)&#160;research and development and manufacturing activities conducted under our collaborative agreements with third parties (ii)&#160;product sales of proprietary and partnered  products. The chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations as a single operating segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMzIwMDM_e76f0d31-1b9a-49aa-8f2c-c673f153d1ca"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMzI3OTA_60b2a329-dd18-45e8-b00c-6324b516330d">&lt;div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Adoption and Pending Adoption of Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a brief description of recently issued accounting standards, those adopted in the current period and those not yet adopted:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Standard&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effective Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect on the Financial &lt;br/&gt;Statements or Other Significant Matters&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from contracts with customers&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The new guidance requires an acquirer to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with topic 606 as if it had originated the contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;January 1, 2023&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(Early adoption is permitted, including adoption in an interim period)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We early adopted ASU 2021-08 on April 1, 2022. The adoption did not have a material impact on our condensed consolidated financial position or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180My9mcmFnOjhiYmYxMmYwNTQ4MjRkZDZiNDU3YThhYWM1MDc1OWE4L3RleHRyZWdpb246OGJiZjEyZjA1NDgyNGRkNmI0NTdhOGFhYzUwNzU5YThfMzI5MjE_7c059d42-8dca-4546-a45a-e0783f1ca8da"
      xsi:nil="true"/>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGV4dHJlZ2lvbjo2NTU5OTViOThjYTk0NThkYmM3NTFmODA1N2FlNDliM18xOTI0MTQ1MzUyNjA1Mg_5392483c-db92-4fb8-8303-2de2e6a6e54e">Business Combination&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 24, 2022, we acquired all outstanding equity interests of Antares Pharma, Inc. ("Antares") according to the terms and conditions of the Agreement and Plan of Merger, dated as of April 12, 2022 (the &#x201c;Merger Agreement&#x201d;). Antares is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. We acquired Antares as a part of our strategy to expand as a drug delivery company and include specialty products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total purchase consideration of Antares was $1,045.7&#160;million. Each share of Antares common stock issued and outstanding was converted into the right to receive $5.60 in cash without interest, less any applicable withholding taxes (&#x201c;Merger Consideration&#x201d;). Additionally, in connection with the transaction, each Antares equity award granted and outstanding as of May 24, 2022 under the Antares&#x2019; equity compensation plans was converted into the right to receive Merger Consideration. Other components of purchase consideration include cash paid at closing to settle Antares existing debt of $19.7&#160;million and seller transaction costs paid by us on behalf of Antares of $22.9&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition of Antares was funded by cash on hand and borrowings under the new credit agreement with Bank of America, N.A. (&#x201c;BofA&#x201d;) and other lenders that provides for (i) a $350&#160;million revolving credit facility (the &#x201c;Revolving Credit Facility&#x201d;) and (ii) a $250&#160;million term loan facility (the &#x201c;Term Facility&#x201d;, collectively with the Revolving Credit Facility, the &#x201c;2022 Facility&#x201d;) as described in Note 8. We recognized transaction costs of $18.6&#160;million and $20.1&#160;million in the three and six months ended June 30, 2022, respectively. These costs are reported in the selling, general and administrative expenses line of our consolidated statements of income. Transaction costs include, but are not limited to, investment banker, advisory, legal, and other professional fees.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Purchase Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total purchase consideration was comprised of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash consideration for Antares shares outstanding as of May 24, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;956,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consideration for Antares equity compensation awards &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consideration for seller transaction costs paid by Halozyme&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consideration related to Antares closing indebtedness settled by Halozyme&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash consideration related to cash bonus awards paid by Halozyme&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total purchase consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,045,668&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%"&gt;(a) Consideration for Antares equity compensation awards consists of $32.2&#160;million paid for vested equity awards as well as $13.6&#160;million paid for the pre-combination portion of unvested equity awards that were accelerated as part of the Merger Agreement. The fair value of the unvested equity awards attributable to the post-combination period of $8.7&#160;million is included in Statement of Income in Q2 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Fair Value of Assets Acquired and Liabilities Assumed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition of Antares has been accounted for using the acquisition method of accounting in accordance with ASC 805, Business Combinations, with Halozyme treated as the accounting acquirer, which requires, among other things, that the assets acquired and liabilities assumed be recognized at their fair value on the acquisition date. Acquisition accounting is dependent upon certain valuations and other studies that have yet to commence or progress to a stage where there is sufficient information for a definitive measurement. The process for estimating the fair values of identifiable intangible assets and certain tangible assets and assumed liabilities requires the use of judgment in determining the appropriate assumptions and estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the preliminary estimated fair values of assets acquired and liabilities assumed on the acquisition date based on preliminary valuations and management estimates that are subject to change when formal valuations and other studies are finalized. Fair value estimates are based on a complex series of judgments about future events and uncertainties and rely heavily on estimates and assumptions. The judgments used to determine the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact our results of operations. These preliminary estimates may be revised during the measurement period as third-party valuations are finalized, additional information becomes available, and as additional analyses are performed, and these differences could change the value of the intangible assets acquired, the contingent liability assumed, and the tax impacts related to the acquisition and could have a material impact on our results of operations and financial position.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Total purchase consideration, net of $46,548 cash acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;987,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts Payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net assets acquired, excluding goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;799,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is the excess of the consideration transferred over the net assets recognized and represents the expected revenue and cost synergies of the combined company and assembled workforce. Goodwill will be allocated entirely to the single reportable segment. Goodwill recognized as a result of the acquisition is not deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Identifiable Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The estimated fair values of identifiable intangible assets were prepared using the excess earnings method which calculates the present value of the incremental after-tax cash flows attributable solely to each intangible asset. The estimated useful lives are based on forecasted periods of benefit for each intangible asset which consider commercialization dates, the estimated revenue cycle based on the products&#x2019; competitiveness in the market, and the loss of exclusivity timing with subsequent trending down of revenue. For the ATRS-1902 IPR&amp;amp;D, the useful life is considered indefinite as the asset has not been placed into service. As such, the ATRS-1902 IPR&amp;amp;D will be tested annually for impairment and will not be amortized. Useful lives and preliminary values are presented in the table below.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.418%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Useful life (years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Auto Injector technology platform&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;XYOSTED proprietary product&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;TLANDO product rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ATRS-1902 (IPR&amp;amp;D)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated fair value of intangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;987,500&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;A contingent liability with a preliminary value of $130.0&#160;million was assumed related to TLANDO. We assumed an obligation to pay development milestone payments as well as commercial milestone payments and minimum tiered royalty payments based on TLANDO net sales which are contingent upon future events. The acquisition date fair value was measured using the income approach, specifically the probability weighted expected return method for the development milestone payments and the option pricing methodology using the Monte Carlo simulation for commercial milestone payments and royalty payments. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Pro Forma Results&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our consolidated financial statements include Antares' results of operations from the date of acquisition on May 24, 2022 through June 30, 2022. Total revenues and net loss before taxes attributable to Antares during this period and included in our consolidated financial statements for both the three and six months ended June 30, 2022 total $18.7&#160;million and $39.8&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following unaudited pro forma financial information summarizes combined results of operations of Halozyme and Antares as if the companies had been combined as of the beginning of our fiscal year 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.179%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;&#160;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The unaudited pro forma financial information for all periods presented includes the business combination accounting effects resulting from this acquisition. The unaudited pro forma results include adjustments to reflect the amortization of the inventory step-up and the incremental intangible asset amortization to be incurred based on preliminary valuations of assets as well as certain material non-recurring transaction adjustments related to the acquisition. Adjustments to interest expense, financing costs and investment income were made to reflect the capital structure of the combined entity. Adjustments to income tax expense also were made to reflect the anticipated effective tax rate of the combined entity. The unaudited pro forma financial information as presented is for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved if the acquisition had taken place at the beginning of fiscal 2021, nor is it necessarily an indication of trends in future results for a number of reasons, including, but not limited to, differences between the assumptions used to prepare the pro forma information, cost savings from operating efficiencies, potential synergies, and the impact of incremental costs incurred in integrating the businesses.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i4bc0e55590f348ac92553d587cadfd3d_D20220524-20220524"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGV4dHJlZ2lvbjo2NTU5OTViOThjYTk0NThkYmM3NTFmODA1N2FlNDliM18xOTI0MTQ1MzUyNjEzNw_140b1ff0-5b3c-4655-99b7-19bd78efbc5f"
      unitRef="usd">1045700000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <halo:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare
      contextRef="i4bc0e55590f348ac92553d587cadfd3d_D20220524-20220524"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGV4dHJlZ2lvbjo2NTU5OTViOThjYTk0NThkYmM3NTFmODA1N2FlNDliM18xOTI0MTQ1MzUyNjE1Nw_b9dd2e5a-827e-453d-b1fb-7999f4806341"
      unitRef="usdPerShare">5.60</halo:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="i475bb2a82ae54a4286363422e755c916_D20220524-20220524"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGV4dHJlZ2lvbjo2NTU5OTViOThjYTk0NThkYmM3NTFmODA1N2FlNDliM18xOTI0MTQ1MzUyNjA5MA_313be68c-5251-4cc5-94d9-48ac1776e240"
      unitRef="usd">19700000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferredOther1
      contextRef="i4bc0e55590f348ac92553d587cadfd3d_D20220524-20220524"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGV4dHJlZ2lvbjo2NTU5OTViOThjYTk0NThkYmM3NTFmODA1N2FlNDliM18xOTI0MTQ1MzUyNjE2NQ_2fbd2e5c-c0d8-4437-84a6-ffea0463abcd"
      unitRef="usd">22900000</us-gaap:BusinessCombinationConsiderationTransferredOther1>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i86ae6c3b418d4a88aa081e1790735e1b_I20220524"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGV4dHJlZ2lvbjo2NTU5OTViOThjYTk0NThkYmM3NTFmODA1N2FlNDliM18xOTI0MTQ1MzUyNjE5NA_a7e578d4-8934-46ac-8d41-e3825e80062e"
      unitRef="usd">350000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i5c984de515d647a5b30035159dcaec53_I20220524"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGV4dHJlZ2lvbjo2NTU5OTViOThjYTk0NThkYmM3NTFmODA1N2FlNDliM18xOTI0MTQ1MzUyNjE4MA_6f46283c-212f-4e31-bb75-68d57e94938e"
      unitRef="usd">250000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i00acc9b249264652bb496012352851f4_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGV4dHJlZ2lvbjo2NTU5OTViOThjYTk0NThkYmM3NTFmODA1N2FlNDliM18xOTI0MTQ1MzUyNjEwNg_4b7b5cb1-bfea-486e-a012-faf1da508c5a"
      unitRef="usd">18600000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="if15049277def4dcdb9cbdffbe5d753f1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGV4dHJlZ2lvbjo2NTU5OTViOThjYTk0NThkYmM3NTFmODA1N2FlNDliM18xOTI0MTQ1MzUyNjEyMQ_daaea80a-3849-4b8b-90bf-8dfb561b7d27"
      unitRef="usd">20100000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGV4dHJlZ2lvbjo2NTU5OTViOThjYTk0NThkYmM3NTFmODA1N2FlNDliM18xOTI0MTQ1MzUyNjA1Mw_59ff7158-6626-4b04-92aa-fe6d858a9a2f">&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total purchase consideration was comprised of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash consideration for Antares shares outstanding as of May 24, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;956,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consideration for Antares equity compensation awards &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consideration for seller transaction costs paid by Halozyme&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consideration related to Antares closing indebtedness settled by Halozyme&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash consideration related to cash bonus awards paid by Halozyme&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total purchase consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,045,668&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%"&gt;(a) Consideration for Antares equity compensation awards consists of $32.2&#160;million paid for vested equity awards as well as $13.6&#160;million paid for the pre-combination portion of unvested equity awards that were accelerated as part of the Merger Agreement. The fair value of the unvested equity awards attributable to the post-combination period of $8.7&#160;million is included in Statement of Income in Q2 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="i4bc0e55590f348ac92553d587cadfd3d_D20220524-20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6ZjRiZDU1ZTlkMGQ2NGY4ZWJkZjg0NzM4NDIxMjRkYzEvdGFibGVyYW5nZTpmNGJkNTVlOWQwZDY0ZjhlYmRmODQ3Mzg0MjEyNGRjMV8wLTItMS0xLTYwMjk0_9023feee-6eeb-4174-9905-8a7915a74045"
      unitRef="usd">956886000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <halo:BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards
      contextRef="i4bc0e55590f348ac92553d587cadfd3d_D20220524-20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6ZjRiZDU1ZTlkMGQ2NGY4ZWJkZjg0NzM4NDIxMjRkYzEvdGFibGVyYW5nZTpmNGJkNTVlOWQwZDY0ZjhlYmRmODQ3Mzg0MjEyNGRjMV8xLTItMS0xLTYwMjk0_e840ab42-8a49-44de-a579-9976f018ac45"
      unitRef="usd">45828000</halo:BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards>
    <us-gaap:BusinessCombinationConsiderationTransferredOther1
      contextRef="i4bc0e55590f348ac92553d587cadfd3d_D20220524-20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6ZjRiZDU1ZTlkMGQ2NGY4ZWJkZjg0NzM4NDIxMjRkYzEvdGFibGVyYW5nZTpmNGJkNTVlOWQwZDY0ZjhlYmRmODQ3Mzg0MjEyNGRjMV8yLTItMS0xLTYwMjk0_e380158e-208d-478f-bf42-a2eb7fe783ef"
      unitRef="usd">22906000</us-gaap:BusinessCombinationConsiderationTransferredOther1>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="i4bc0e55590f348ac92553d587cadfd3d_D20220524-20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6ZjRiZDU1ZTlkMGQ2NGY4ZWJkZjg0NzM4NDIxMjRkYzEvdGFibGVyYW5nZTpmNGJkNTVlOWQwZDY0ZjhlYmRmODQ3Mzg0MjEyNGRjMV8zLTItMS0xLTYwMjk0_e3b3f421-1053-47c3-98de-77185dc40248"
      unitRef="usd">19683000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <halo:BusinessCombinationConsiderationTransferredBonusAwards
      contextRef="i4bc0e55590f348ac92553d587cadfd3d_D20220524-20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6ZjRiZDU1ZTlkMGQ2NGY4ZWJkZjg0NzM4NDIxMjRkYzEvdGFibGVyYW5nZTpmNGJkNTVlOWQwZDY0ZjhlYmRmODQ3Mzg0MjEyNGRjMV80LTItMS0xLTU3Mjg5_bc9212a1-b34d-49a4-8bc9-d123aca4f17f"
      unitRef="usd">365000</halo:BusinessCombinationConsiderationTransferredBonusAwards>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i4bc0e55590f348ac92553d587cadfd3d_D20220524-20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6ZjRiZDU1ZTlkMGQ2NGY4ZWJkZjg0NzM4NDIxMjRkYzEvdGFibGVyYW5nZTpmNGJkNTVlOWQwZDY0ZjhlYmRmODQ3Mzg0MjEyNGRjMV81LTItMS0xLTYwMjk0_185888ba-924b-4267-a40d-79e81ce4fdcb"
      unitRef="usd">1045668000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <halo:BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards
      contextRef="i615a905f496c4c0d9f797e929cacf41f_D20220524-20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGV4dHJlZ2lvbjo2NTU5OTViOThjYTk0NThkYmM3NTFmODA1N2FlNDliM18xOTI0MTQ1MzUyNjA3NA_db6da482-f657-43c9-8bbf-81c0f35d6976"
      unitRef="usd">32200000</halo:BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards>
    <halo:BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards
      contextRef="i82c9562114b64891bb65718130793579_D20220524-20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGV4dHJlZ2lvbjo2NTU5OTViOThjYTk0NThkYmM3NTFmODA1N2FlNDliM18xOTI0MTQ1MzUyNjA1OQ_cff0da33-27c7-4486-9e8f-991ee6a4f1d0"
      unitRef="usd">13600000</halo:BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGV4dHJlZ2lvbjo2NTU5OTViOThjYTk0NThkYmM3NTFmODA1N2FlNDliM18xOTI0MTQ1MzUyNjIwOQ_54eef4ec-e40c-470b-836b-14ef8216c361"
      unitRef="usd">8700000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGV4dHJlZ2lvbjo2NTU5OTViOThjYTk0NThkYmM3NTFmODA1N2FlNDliM18xOTI0MTQ1MzUyNjA1NA_928ff590-0029-4cd0-81ef-753f06cb30ff">These preliminary estimates may be revised during the measurement period as third-party valuations are finalized, additional information becomes available, and as additional analyses are performed, and these differences could change the value of the intangible assets acquired, the contingent liability assumed, and the tax impacts related to the acquisition and could have a material impact on our results of operations and financial position.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Total purchase consideration, net of $46,548 cash acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;987,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts Payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net assets acquired, excluding goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;799,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="i4bc0e55590f348ac92553d587cadfd3d_D20220524-20220524"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NzA5NGVkY2MyOTRiNDA2ZDk5ZTA0NTk0YmYwZWY0OTQvdGFibGVyYW5nZTo3MDk0ZWRjYzI5NGI0MDZkOTllMDQ1OTRiZjBlZjQ5NF8xLTAtMS0xLTU4MjIzL3RleHRyZWdpb246MjNhZTIyNTBhMGI2NGMwY2FjOTIzNWYwZDc3MmM5YWJfMTA5OTUxMTYyNzk4MA_29ac8fd0-3e42-4433-a3e7-8d9b39123f0a"
      unitRef="usd">46548000</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i4bc0e55590f348ac92553d587cadfd3d_D20220524-20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NzA5NGVkY2MyOTRiNDA2ZDk5ZTA0NTk0YmYwZWY0OTQvdGFibGVyYW5nZTo3MDk0ZWRjYzI5NGI0MDZkOTllMDQ1OTRiZjBlZjQ5NF8xLTItMS0xLTYwMzQx_c35bbe12-f213-40df-99ee-ee2a59c7b52c"
      unitRef="usd">999120000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <halo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments
      contextRef="i1e07b7230a7b4293910918c1158913a7_I20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NzA5NGVkY2MyOTRiNDA2ZDk5ZTA0NTk0YmYwZWY0OTQvdGFibGVyYW5nZTo3MDk0ZWRjYzI5NGI0MDZkOTllMDQ1OTRiZjBlZjQ5NF8zLTItMS0xLTYwMzUw_29ac4565-cd9a-4b4f-a0da-7ff3a6bc629c"
      unitRef="usd">498000</halo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="i1e07b7230a7b4293910918c1158913a7_I20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NzA5NGVkY2MyOTRiNDA2ZDk5ZTA0NTk0YmYwZWY0OTQvdGFibGVyYW5nZTo3MDk0ZWRjYzI5NGI0MDZkOTllMDQ1OTRiZjBlZjQ5NF80LTItMS0xLTYwMzUw_e88d75a4-bca5-48d2-970b-133f0363c920"
      unitRef="usd">82160000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="i1e07b7230a7b4293910918c1158913a7_I20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NzA5NGVkY2MyOTRiNDA2ZDk5ZTA0NTk0YmYwZWY0OTQvdGFibGVyYW5nZTo3MDk0ZWRjYzI5NGI0MDZkOTllMDQ1OTRiZjBlZjQ5NF81LTItMS0xLTYwMzUw_0270e239-109d-4f14-9bca-ff480260dac8"
      unitRef="usd">34379000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="i1e07b7230a7b4293910918c1158913a7_I20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NzA5NGVkY2MyOTRiNDA2ZDk5ZTA0NTk0YmYwZWY0OTQvdGFibGVyYW5nZTo3MDk0ZWRjYzI5NGI0MDZkOTllMDQ1OTRiZjBlZjQ5NF82LTItMS0xLTYwMzUw_f4778dba-f985-4f97-a7bc-db362c054e93"
      unitRef="usd">5241000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="i1e07b7230a7b4293910918c1158913a7_I20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NzA5NGVkY2MyOTRiNDA2ZDk5ZTA0NTk0YmYwZWY0OTQvdGFibGVyYW5nZTo3MDk0ZWRjYzI5NGI0MDZkOTllMDQ1OTRiZjBlZjQ5NF83LTItMS0xLTYwMzQz_540ab2da-b0c1-4761-ada8-cad443a195e5"
      unitRef="usd">28661000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i1e07b7230a7b4293910918c1158913a7_I20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NzA5NGVkY2MyOTRiNDA2ZDk5ZTA0NTk0YmYwZWY0OTQvdGFibGVyYW5nZTo3MDk0ZWRjYzI5NGI0MDZkOTllMDQ1OTRiZjBlZjQ5NF84LTItMS0xLTYwMzQ1_5d23ad3f-6236-47d0-9e82-5a5dfb6ba5ee"
      unitRef="usd">987500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="i1e07b7230a7b4293910918c1158913a7_I20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NzA5NGVkY2MyOTRiNDA2ZDk5ZTA0NTk0YmYwZWY0OTQvdGFibGVyYW5nZTo3MDk0ZWRjYzI5NGI0MDZkOTllMDQ1OTRiZjBlZjQ5NF8xMC0yLTEtMS02MDM0Nw_fdc542a3-5311-4332-b2dd-fd28a10c90a8"
      unitRef="usd">7197000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <halo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses
      contextRef="i1e07b7230a7b4293910918c1158913a7_I20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NzA5NGVkY2MyOTRiNDA2ZDk5ZTA0NTk0YmYwZWY0OTQvdGFibGVyYW5nZTo3MDk0ZWRjYzI5NGI0MDZkOTllMDQ1OTRiZjBlZjQ5NF8xMS0yLTEtMS02MDM0Nw_2a83257c-7a44-4f9b-b9c2-fb7be3e72c1a"
      unitRef="usd">33705000</halo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses>
    <halo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability
      contextRef="i1e07b7230a7b4293910918c1158913a7_I20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NzA5NGVkY2MyOTRiNDA2ZDk5ZTA0NTk0YmYwZWY0OTQvdGFibGVyYW5nZTo3MDk0ZWRjYzI5NGI0MDZkOTllMDQ1OTRiZjBlZjQ5NF8xMi0yLTEtMS02MDM0Nw_e4abb3c5-9e92-4a38-b767-27043e38cd51"
      unitRef="usd">2509000</halo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability>
    <halo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability
      contextRef="i1e07b7230a7b4293910918c1158913a7_I20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NzA5NGVkY2MyOTRiNDA2ZDk5ZTA0NTk0YmYwZWY0OTQvdGFibGVyYW5nZTo3MDk0ZWRjYzI5NGI0MDZkOTllMDQ1OTRiZjBlZjQ5NF8xMy0yLTEtMS02MDM0Nw_9901993d-2a34-4ba5-8897-ac2e03610df3"
      unitRef="usd">1207000</halo:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i1e07b7230a7b4293910918c1158913a7_I20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NzA5NGVkY2MyOTRiNDA2ZDk5ZTA0NTk0YmYwZWY0OTQvdGFibGVyYW5nZTo3MDk0ZWRjYzI5NGI0MDZkOTllMDQ1OTRiZjBlZjQ5NF8xNC0yLTEtMS02MDM0Nw_64a705e3-8f83-41db-a8c4-93d6d22d2153"
      unitRef="usd">159094000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther
      contextRef="i1e07b7230a7b4293910918c1158913a7_I20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NzA5NGVkY2MyOTRiNDA2ZDk5ZTA0NTk0YmYwZWY0OTQvdGFibGVyYW5nZTo3MDk0ZWRjYzI5NGI0MDZkOTllMDQ1OTRiZjBlZjQ5NF8xNS0yLTEtMS02MDM0Nw_e35ee853-7545-4e11-ac18-e8cc712a9d5e"
      unitRef="usd">135088000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i1e07b7230a7b4293910918c1158913a7_I20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NzA5NGVkY2MyOTRiNDA2ZDk5ZTA0NTk0YmYwZWY0OTQvdGFibGVyYW5nZTo3MDk0ZWRjYzI5NGI0MDZkOTllMDQ1OTRiZjBlZjQ5NF8xNi0yLTEtMS02MDM0Nw_3767c71d-fb72-4fa0-962a-7fc130c75297"
      unitRef="usd">799639000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill
      contextRef="i77c93c8b4e414609a78dfb4f6f64ed57_I20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NzA5NGVkY2MyOTRiNDA2ZDk5ZTA0NTk0YmYwZWY0OTQvdGFibGVyYW5nZTo3MDk0ZWRjYzI5NGI0MDZkOTllMDQ1OTRiZjBlZjQ5NF8xNy0yLTEtMS01Njk2NA_1d648f11-0977-4b60-82da-61988288f894"
      unitRef="usd">199481000</us-gaap:Goodwill>
    <us-gaap:ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGV4dHJlZ2lvbjo2NTU5OTViOThjYTk0NThkYmM3NTFmODA1N2FlNDliM18xOTI0MTQ1MzUyNjA1NQ_271c7a75-c1f4-429b-8be1-fb8d9d067941">preliminary values are presented in the table below.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.418%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Useful life (years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Auto Injector technology platform&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;XYOSTED proprietary product&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;TLANDO product rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ATRS-1902 (IPR&amp;amp;D)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated fair value of intangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;987,500&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock>
    <us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGV4dHJlZ2lvbjo2NTU5OTViOThjYTk0NThkYmM3NTFmODA1N2FlNDliM18xOTI0MTQ1MzUyNjA1NQ_c4d8f763-d96c-431f-850e-1685aa363363">preliminary values are presented in the table below.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.418%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Useful life (years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Auto Injector technology platform&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;XYOSTED proprietary product&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;TLANDO product rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ATRS-1902 (IPR&amp;amp;D)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated fair value of intangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;987,500&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="i36b527310aeb4abebd94653011e3f9db_D20220524-20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6ZTc3YzAzYWUzZTYyNDE3MWFkYmE1N2ZjYmQzOGUyMDAvdGFibGVyYW5nZTplNzdjMDNhZTNlNjI0MTcxYWRiYTU3ZmNiZDM4ZTIwMF8xLTItMS0xLTYwNDIw_855554c2-7061-4429-b7f5-65b39076d11e"
      unitRef="usd">372900000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i36b527310aeb4abebd94653011e3f9db_D20220524-20220524"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6ZTc3YzAzYWUzZTYyNDE3MWFkYmE1N2ZjYmQzOGUyMDAvdGFibGVyYW5nZTplNzdjMDNhZTNlNjI0MTcxYWRiYTU3ZmNiZDM4ZTIwMF8xLTQtMS0xLTYwNDI4_24f9e192-5932-4e84-bdf3-41e659e6b9fd">P7Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="i079a89cb03c6429c974b822df12e4303_D20220524-20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6ZTc3YzAzYWUzZTYyNDE3MWFkYmE1N2ZjYmQzOGUyMDAvdGFibGVyYW5nZTplNzdjMDNhZTNlNjI0MTcxYWRiYTU3ZmNiZDM4ZTIwMF8yLTItMS0xLTYwNDIw_9b35b12a-6c41-4650-8f00-f26794a957f7"
      unitRef="usd">277400000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i079a89cb03c6429c974b822df12e4303_D20220524-20220524"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6ZTc3YzAzYWUzZTYyNDE3MWFkYmE1N2ZjYmQzOGUyMDAvdGFibGVyYW5nZTplNzdjMDNhZTNlNjI0MTcxYWRiYTU3ZmNiZDM4ZTIwMF8yLTQtMS0xLTYwNDI4_cb526134-a555-4e31-93fd-7d447c67d840">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="i827e16b84dc24a16a310f235506fdd09_D20220524-20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6ZTc3YzAzYWUzZTYyNDE3MWFkYmE1N2ZjYmQzOGUyMDAvdGFibGVyYW5nZTplNzdjMDNhZTNlNjI0MTcxYWRiYTU3ZmNiZDM4ZTIwMF8zLTItMS0xLTYwNDIw_cd975507-aaba-4425-adfe-b729fe2bf328"
      unitRef="usd">277600000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i827e16b84dc24a16a310f235506fdd09_D20220524-20220524"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6ZTc3YzAzYWUzZTYyNDE3MWFkYmE1N2ZjYmQzOGUyMDAvdGFibGVyYW5nZTplNzdjMDNhZTNlNjI0MTcxYWRiYTU3ZmNiZDM4ZTIwMF8zLTQtMS0xLTYwNDI4_102887a3-0903-47ba-be76-e376a9feb05e">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:IndefinitelivedIntangibleAssetsAcquired
      contextRef="i89ede30c1fb341e6b5c377169cbac030_D20220524-20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6ZTc3YzAzYWUzZTYyNDE3MWFkYmE1N2ZjYmQzOGUyMDAvdGFibGVyYW5nZTplNzdjMDNhZTNlNjI0MTcxYWRiYTU3ZmNiZDM4ZTIwMF80LTItMS0xLTYwNDIw_a6fb999f-3c9f-4600-b0ef-dccc5f42913e"
      unitRef="usd">59600000</us-gaap:IndefinitelivedIntangibleAssetsAcquired>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i1e07b7230a7b4293910918c1158913a7_I20220524"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6ZTc3YzAzYWUzZTYyNDE3MWFkYmE1N2ZjYmQzOGUyMDAvdGFibGVyYW5nZTplNzdjMDNhZTNlNjI0MTcxYWRiYTU3ZmNiZDM4ZTIwMF81LTItMS0xLTYwNDIw_1e0cf02f-6d27-4820-81f2-f5258da407ba"
      unitRef="usd">987500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i1e07b7230a7b4293910918c1158913a7_I20220524"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGV4dHJlZ2lvbjo2NTU5OTViOThjYTk0NThkYmM3NTFmODA1N2FlNDliM18xOTI0MTQ1MzUzNDU5Mg_5d0d1c3c-ecb5-47d2-ab1d-e277d0218235"
      unitRef="usd">130000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
      contextRef="if15049277def4dcdb9cbdffbe5d753f1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGV4dHJlZ2lvbjo2NTU5OTViOThjYTk0NThkYmM3NTFmODA1N2FlNDliM18xOTI0MTQ1MzUyNjIyMw_6c4ab53d-c413-4998-8312-9fab94c506e0"
      unitRef="usd">18700000</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
      contextRef="i00acc9b249264652bb496012352851f4_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGV4dHJlZ2lvbjo2NTU5OTViOThjYTk0NThkYmM3NTFmODA1N2FlNDliM18xOTI0MTQ1MzUyNjIyMw_c516787b-4b87-4a3e-8cb0-81315a408841"
      unitRef="usd">18700000</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual
      contextRef="if15049277def4dcdb9cbdffbe5d753f1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGV4dHJlZ2lvbjo2NTU5OTViOThjYTk0NThkYmM3NTFmODA1N2FlNDliM18xOTI0MTQ1MzUyNjI0MQ_91fd9aeb-8d55-4564-a81b-c9fe9cac1019"
      unitRef="usd">39800000</us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual
      contextRef="i00acc9b249264652bb496012352851f4_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGV4dHJlZ2lvbjo2NTU5OTViOThjYTk0NThkYmM3NTFmODA1N2FlNDliM18xOTI0MTQ1MzUyNjI0MQ_ab146ce7-6cc7-4046-ae12-82a0b1460ac6"
      unitRef="usd">-39800000</us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGV4dHJlZ2lvbjo2NTU5OTViOThjYTk0NThkYmM3NTFmODA1N2FlNDliM18xOTI0MTQ1MzUyNjA1Ng_deb7006a-e604-4d64-b861-d6c16613eac8">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following unaudited pro forma financial information summarizes combined results of operations of Halozyme and Antares as if the companies had been combined as of the beginning of our fiscal year 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.179%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;&#160;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i5a3a21a6a5d44d869b7b90d70c8531c7_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NjBjZGU0OTAwNzhlNGUwMGI2ZjAxOTBjZGFhYjViZGMvdGFibGVyYW5nZTo2MGNkZTQ5MDA3OGU0ZTAwYjZmMDE5MGNkYWFiNWJkY18yLTItMS0xLTYwNDk2_8a9f49d6-0189-468f-a409-a592aa559aa1"
      unitRef="usd">163376000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i00acc9b249264652bb496012352851f4_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NjBjZGU0OTAwNzhlNGUwMGI2ZjAxOTBjZGFhYjViZGMvdGFibGVyYW5nZTo2MGNkZTQ5MDA3OGU0ZTAwYjZmMDE5MGNkYWFiNWJkY18yLTQtMS0xLTYwNDk4_dbdfa059-7cc7-4a4e-b300-4f39f075dafc"
      unitRef="usd">168839000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="id9372d0e89f64744be923e43620998cc_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NjBjZGU0OTAwNzhlNGUwMGI2ZjAxOTBjZGFhYjViZGMvdGFibGVyYW5nZTo2MGNkZTQ5MDA3OGU0ZTAwYjZmMDE5MGNkYWFiNWJkY18yLTYtMS0xLTYwNTAw_9c2e95ac-284e-4c76-bd95-968fcff94b7c"
      unitRef="usd">322212000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="if15049277def4dcdb9cbdffbe5d753f1_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NjBjZGU0OTAwNzhlNGUwMGI2ZjAxOTBjZGFhYjViZGMvdGFibGVyYW5nZTo2MGNkZTQ5MDA3OGU0ZTAwYjZmMDE5MGNkYWFiNWJkY18yLTgtMS0xLTYwNTAy_7d82d80f-87f6-4a83-9835-00c35bb97b63"
      unitRef="usd">312538000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i5a3a21a6a5d44d869b7b90d70c8531c7_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NjBjZGU0OTAwNzhlNGUwMGI2ZjAxOTBjZGFhYjViZGMvdGFibGVyYW5nZTo2MGNkZTQ5MDA3OGU0ZTAwYjZmMDE5MGNkYWFiNWJkY18zLTItMS0xLTYwNDk2_2ff33072-17df-4cde-83df-12b09e38e960"
      unitRef="usd">60461000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i00acc9b249264652bb496012352851f4_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NjBjZGU0OTAwNzhlNGUwMGI2ZjAxOTBjZGFhYjViZGMvdGFibGVyYW5nZTo2MGNkZTQ5MDA3OGU0ZTAwYjZmMDE5MGNkYWFiNWJkY18zLTQtMS0xLTYwNDk4_7a84eac8-9c6f-4ad0-aae9-e35a54d44b59"
      unitRef="usd">70259000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="id9372d0e89f64744be923e43620998cc_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NjBjZGU0OTAwNzhlNGUwMGI2ZjAxOTBjZGFhYjViZGMvdGFibGVyYW5nZTo2MGNkZTQ5MDA3OGU0ZTAwYjZmMDE5MGNkYWFiNWJkY18zLTYtMS0xLTYwNTAw_5ec3ad48-284d-4d94-b33b-6a8217deb35e"
      unitRef="usd">96752000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="if15049277def4dcdb9cbdffbe5d753f1_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTE0L2ZyYWc6NjU1OTk1Yjk4Y2E5NDU4ZGJjNzUxZjgwNTdhZTQ5YjMvdGFibGU6NjBjZGU0OTAwNzhlNGUwMGI2ZjAxOTBjZGFhYjViZGMvdGFibGVyYW5nZTo2MGNkZTQ5MDA3OGU0ZTAwYjZmMDE5MGNkYWFiNWJkY18zLTgtMS0xLTYwNTAy_cb852c7e-e3ce-4969-b1e5-4b6edcd90373"
      unitRef="usd">18615000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RleHRyZWdpb246MmY1MTI5Mjc5OGYzNGYzNzhmZGQ5NjI5NTBiMDIyMTVfMTAyOQ_2519ca22-2dc6-47c1-9add-7eb95781bbef">Fair Value Measurement&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale marketable securities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,032)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-US Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,032)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non- U.S Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;622,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(620)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;622,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, 6 available-for-sale marketable securities with a fair market value of $118.4 million were in a gross unrealized loss position of $2.0 million. Based on our review of these marketable securities, we believe none of the unrealized loss is as a result of a credit loss as of&#160;June&#160;30, 2022, because we do not intend to sell these securities and it is not more-likely-than-not that we will be required to sell these securities before the recovery of their amortized cost basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of our contractual maturities of available-for-sale debt securities are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After one but within five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;622,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.967%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.337%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale marketable &lt;br/&gt;&#160;&#160;&#160;securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-US Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;740,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had no available for sale securities that were classified within Level 3 as of June&#160;30, 2022 and December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RleHRyZWdpb246MmY1MTI5Mjc5OGYzNGYzNzhmZGQ5NjI5NTBiMDIyMTVfMTAyMg_6412e797-2b51-4669-94ad-5aa1b0a99f48">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale marketable securities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,032)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-US Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,032)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non- U.S Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;622,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(620)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;622,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4fc34bcf05bf42a1ad015e84425c8d0d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfMi0yLTEtMS00NzgwMQ_5c9c44bf-4d8f-4fca-a6d1-1342bae7bf22"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4fc34bcf05bf42a1ad015e84425c8d0d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfMi00LTEtMS00NzgwMQ_ea69c792-d02f-4c51-99e8-cf59737505aa"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4fc34bcf05bf42a1ad015e84425c8d0d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfMi02LTEtMS00NzgwMQ_05f445d7-c1d6-4d33-bca7-9862113b2aef"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4fc34bcf05bf42a1ad015e84425c8d0d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfMi04LTEtMS00NzgwMQ_05fba5a4-d6f0-4ebe-8a42-cab9dff402d1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i919614e2dc9744fea40ea36e3bad8795_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfMy0yLTEtMS00NzgwMQ_d745ddcf-3f16-4647-9be9-a5745d1759ba"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i919614e2dc9744fea40ea36e3bad8795_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfMy00LTEtMS00NzgwMQ_27a4d922-a3c5-4e19-becb-b9ef37222e53"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i919614e2dc9744fea40ea36e3bad8795_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfMy02LTEtMS00NzgwMQ_1f6ff51b-67da-47fa-841b-8f1fe341018e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i919614e2dc9744fea40ea36e3bad8795_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfMy04LTEtMS00NzgwMQ_e5e59471-c05d-4be2-916c-94c578300e13"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i02b96f8f266746e5bef1a7a56d0020d7_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfNC0yLTEtMS00NzgwMQ_50427455-e5fd-4d62-88d6-d1d06f4a4aa9"
      unitRef="usd">120460000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i02b96f8f266746e5bef1a7a56d0020d7_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfNC00LTEtMS00NzgwMQ_55afe951-bb12-402e-a63d-26f395abc4ca"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i02b96f8f266746e5bef1a7a56d0020d7_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfNC02LTEtMS00NzgwMQ_e2b5ab2a-d77f-4fb0-b116-55aa7a17baaa"
      unitRef="usd">2032000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i02b96f8f266746e5bef1a7a56d0020d7_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfNC04LTEtMS00NzgwMQ_0e0878ff-de01-4208-ba2b-70967df4fd45"
      unitRef="usd">118428000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4c5035736b1a4598ae99008fbf3463ef_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfNS0yLTEtMS00NzgwMQ_abdd6344-a555-4532-9eed-377d73c6bac3"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4c5035736b1a4598ae99008fbf3463ef_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfNS00LTEtMS00NzgwMQ_d95dba17-5447-47f1-a90a-0fa42155e7a1"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4c5035736b1a4598ae99008fbf3463ef_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfNS02LTEtMS00NzgwMQ_73933991-779d-4114-99ec-110bbd591f85"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4c5035736b1a4598ae99008fbf3463ef_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfNS04LTEtMS00NzgwMQ_c691d6a2-29a3-4bdb-b421-e12e1e51591c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i729eff0e2b1b45abacd1da9f077ac641_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfNi0yLTEtMS00NzgwMQ_0afb7b10-bcb0-4cd5-b2e7-fcde0d72ecc6"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i729eff0e2b1b45abacd1da9f077ac641_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfNi00LTEtMS00NzgwMQ_73698b16-dc10-466d-a0f8-c33ea4ce2810"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i729eff0e2b1b45abacd1da9f077ac641_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfNi02LTEtMS00NzgwMQ_d73b7a03-7fde-44db-beb3-66315ac50506"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i729eff0e2b1b45abacd1da9f077ac641_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfNi04LTEtMS00NzgwMQ_7b837b03-02b2-4fdb-a2b8-4e309b271420"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfNy0yLTEtMS00NzgwMQ_d6445524-a668-4d06-85d9-92cdd17dd163"
      unitRef="usd">120460000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfNy00LTEtMS00NzgwMQ_0642aa78-5cc3-4738-8fe0-53d64d3c567d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfNy02LTEtMS00NzgwMQ_392b0d67-cd5a-436c-b18f-fb48702d1e53"
      unitRef="usd">2032000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjViMmM2ZDAwOTU3OTQ4ODc4MWJhNDBlNGIxMTc5ZTE1L3RhYmxlcmFuZ2U6NWIyYzZkMDA5NTc5NDg4NzgxYmE0MGU0YjExNzllMTVfNy04LTEtMS00NzgwMQ_253c3caa-7c09-459e-b3f8-1e9645dfc704"
      unitRef="usd">118428000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3327c7ae03814e5b98e511ab356d1e06_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfMi0yLTEtMS00NzgwMQ_e23d0cb5-8306-465b-9cbb-5b0e7b04f1e1"
      unitRef="usd">32745000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3327c7ae03814e5b98e511ab356d1e06_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfMi00LTEtMS00NzgwMQ_f530ce7a-9546-4f94-9233-1a6fb48bf008"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3327c7ae03814e5b98e511ab356d1e06_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfMi02LTEtMS00NzgwMQ_ee9412c1-8b7c-479b-93d8-54bfd8684267"
      unitRef="usd">53000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3327c7ae03814e5b98e511ab356d1e06_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfMi04LTEtMS00NzgwMQ_2df4d7f1-4365-4b01-8f70-5025f056bcd6"
      unitRef="usd">32692000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie6a49dbb96ea4e068ffae31a73e0450d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfMy0yLTEtMS00NzgwMQ_d136a713-d561-4fa1-94a9-8c486ec34bb2"
      unitRef="usd">58885000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie6a49dbb96ea4e068ffae31a73e0450d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfMy00LTEtMS00NzgwMQ_eb1eecc4-751e-4b15-b367-46fad0a6703e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie6a49dbb96ea4e068ffae31a73e0450d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfMy02LTEtMS00NzgwMQ_b7b90c57-6cfc-4cab-9a97-85da85945384"
      unitRef="usd">86000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie6a49dbb96ea4e068ffae31a73e0450d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfMy04LTEtMS00NzgwMQ_4b7b49d8-ad40-44a8-869b-bb86ce2ddac3"
      unitRef="usd">58799000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ifbbf1f4395c847e88fbb88a23315b862_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfNC0yLTEtMS00NzgwMQ_3c9b22a4-2d49-4d57-b112-ab477e59b61d"
      unitRef="usd">231230000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifbbf1f4395c847e88fbb88a23315b862_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfNC00LTEtMS00NzgwMQ_f3942ca8-d991-40a4-a950-6692ff753dcd"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ifbbf1f4395c847e88fbb88a23315b862_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfNC02LTEtMS00NzgwMQ_dcd87cff-e9ba-4bd3-8824-2d2bea7d4724"
      unitRef="usd">469000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifbbf1f4395c847e88fbb88a23315b862_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfNC04LTEtMS00NzgwMQ_66f58a5a-9054-4dc5-bda1-904130147eb8"
      unitRef="usd">230761000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibadaba53276e46a791964bbdd74a640d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfNS0yLTEtMS00NzgwMQ_02515649-3cf0-4bcb-b1ac-10b2c00b6781"
      unitRef="usd">17232000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibadaba53276e46a791964bbdd74a640d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfNS00LTEtMS00NzgwMQ_589e5a9d-0640-49c7-a78b-16ef89062185"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibadaba53276e46a791964bbdd74a640d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfNS02LTEtMS00NzgwMQ_28c46523-2bd5-4cc6-98bd-683f9a215ab1"
      unitRef="usd">12000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibadaba53276e46a791964bbdd74a640d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfNS04LTEtMS00NzgwMQ_86ea875e-a8f5-48e4-9ebf-693ac30299d2"
      unitRef="usd">17220000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4820381fb1924e4b8f10130527b2a041_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfNi0yLTEtMS00NzgwMQ_e6c8db08-683e-4eff-9849-7781519ca0ff"
      unitRef="usd">282731000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4820381fb1924e4b8f10130527b2a041_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfNi00LTEtMS00NzgwMQ_708489d0-7f39-48c6-86db-0ad1598e457b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4820381fb1924e4b8f10130527b2a041_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfNi02LTEtMS00NzgwMQ_e207ed1e-bea6-428d-a345-22114f7d428f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4820381fb1924e4b8f10130527b2a041_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfNi04LTEtMS00NzgwMQ_568d146a-1575-4eec-be7c-f7b5f40e8ab7"
      unitRef="usd">282731000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfNy0yLTEtMS00NzgwMQ_f418baec-9612-4188-be1d-40f351b99517"
      unitRef="usd">622823000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfNy00LTEtMS00NzgwMQ_c38e0246-9a8b-4c88-88cc-f4194c44c2d7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfNy02LTEtMS00NzgwMQ_c937fdc3-9bb7-4e68-8db1-c8a3f780dc04"
      unitRef="usd">620000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjhlN2Y5ZmUzZGFmYjQ3OWNiNTc1ODZkZjlhMzdjZmYwL3RhYmxlcmFuZ2U6OGU3ZjlmZTNkYWZiNDc5Y2I1NzU4NmRmOWEzN2NmZjBfNy04LTEtMS00NzgwMQ_4b81bff2-1e69-4cd1-9c9d-f851da9ad0bd"
      unitRef="usd">622203000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RleHRyZWdpb246MmY1MTI5Mjc5OGYzNGYzNzhmZGQ5NjI5NTBiMDIyMTVfMTI5_90e50ecc-3762-490b-a018-030b742e6927"
      unitRef="security">6</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RleHRyZWdpb246MmY1MTI5Mjc5OGYzNGYzNzhmZGQ5NjI5NTBiMDIyMTVfMjAx_2be437e3-8246-4a00-b4d4-e6aa8ab7adf1"
      unitRef="usd">118400000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RleHRyZWdpb246MmY1MTI5Mjc5OGYzNGYzNzhmZGQ5NjI5NTBiMDIyMTVfMjQ4_78861cce-7d03-40d4-b060-c59f1a3bbd64"
      unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RleHRyZWdpb246MmY1MTI5Mjc5OGYzNGYzNzhmZGQ5NjI5NTBiMDIyMTVfMzE1_e1a16560-c982-4920-ae3d-e3fb5a54924a"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RleHRyZWdpb246MmY1MTI5Mjc5OGYzNGYzNzhmZGQ5NjI5NTBiMDIyMTVfMTAyNw_0617675f-c1d5-423c-8464-6ffaa9c61b1f">ontractual maturities of available-for-sale debt securities are as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After one but within five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;622,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjkxZTEwNThiNGIwMDRiNzY5MDJmMGI4NDM2OTY3ZjIxL3RhYmxlcmFuZ2U6OTFlMTA1OGI0YjAwNGI3NjkwMmYwYjg0MzY5NjdmMjFfMi0yLTEtMS00NzgwMQ_1ebddc84-9026-4287-8101-f0ef3941b268"
      unitRef="usd">118428000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjkxZTEwNThiNGIwMDRiNzY5MDJmMGI4NDM2OTY3ZjIxL3RhYmxlcmFuZ2U6OTFlMTA1OGI0YjAwNGI3NjkwMmYwYjg0MzY5NjdmMjFfMi00LTEtMS00NzgwMQ_ccc74c9e-6142-4a71-a1e0-b9e80fafaa8e"
      unitRef="usd">500965000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjkxZTEwNThiNGIwMDRiNzY5MDJmMGI4NDM2OTY3ZjIxL3RhYmxlcmFuZ2U6OTFlMTA1OGI0YjAwNGI3NjkwMmYwYjg0MzY5NjdmMjFfMy0yLTEtMS00NzgwMQ_5a24aecb-7593-4af9-929e-0c0ef309aab4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjkxZTEwNThiNGIwMDRiNzY5MDJmMGI4NDM2OTY3ZjIxL3RhYmxlcmFuZ2U6OTFlMTA1OGI0YjAwNGI3NjkwMmYwYjg0MzY5NjdmMjFfMy00LTEtMS00NzgwMQ_4bdfcecc-f345-45f5-9a0e-6832c4cc1d9e"
      unitRef="usd">121238000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjkxZTEwNThiNGIwMDRiNzY5MDJmMGI4NDM2OTY3ZjIxL3RhYmxlcmFuZ2U6OTFlMTA1OGI0YjAwNGI3NjkwMmYwYjg0MzY5NjdmMjFfNC0yLTEtMS00NzgwMQ_961b6e4e-ca40-4ccd-9298-90362ce66a0a"
      unitRef="usd">118428000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOjkxZTEwNThiNGIwMDRiNzY5MDJmMGI4NDM2OTY3ZjIxL3RhYmxlcmFuZ2U6OTFlMTA1OGI0YjAwNGI3NjkwMmYwYjg0MzY5NjdmMjFfNC00LTEtMS00NzgwMQ_c359452f-c277-465f-b806-064afea99a7f"
      unitRef="usd">622203000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RleHRyZWdpb246MmY1MTI5Mjc5OGYzNGYzNzhmZGQ5NjI5NTBiMDIyMTVfMTA0NQ_f3ae2225-2767-4faa-8e2c-7b727da54b32">The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.967%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.337%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale marketable &lt;br/&gt;&#160;&#160;&#160;securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-US Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;740,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7582cec4a13c42d3948f9997e4a05ea2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMy0yLTEtMS00NzgwMQ_4d5eb49c-f5e6-4001-87c8-aadc9c2a42c8"
      unitRef="usd">70843000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i524d67132d7a47e18cfb74ff6a106bd6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMy00LTEtMS00NzgwMQ_daa98bd3-0d10-4156-95e1-1258fbc6c03c"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4d8fc069e3434518b16ab9ff92f7ac83_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMy02LTEtMS00NzgwMQ_56c59dd8-3aa0-4393-a85d-5f9e12e19867"
      unitRef="usd">70843000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib35f4ff4fd844014ad607bcd93940767_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMy04LTEtMS00NzgwMQ_7f1ae9b9-d3d6-4f60-b314-5e9a75d59fe1"
      unitRef="usd">118707000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i08ee73d0afc54dd4af894979a2e3d955_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMy0xMC0xLTEtNDc4MDE_3896b370-239c-4943-af95-2612dae4ab37"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i70626fa06a394bfb9bd482b2edc20c84_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMy0xMi0xLTEtNDc4MDE_2dfb58de-a769-4603-96f3-05c99dd1758c"
      unitRef="usd">118707000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i394b8f9cfd4246c9ad0423ab43c011ee_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfNC0yLTEtMS00NzgwMQ_52fd60eb-0c60-492f-ab42-8d6584f8512a"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8b150997591648f4bb1e80dcf1a1016c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfNC00LTEtMS00NzgwMQ_f6c53fbe-90ff-4945-805e-7e8606dee674"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8b00c3afda9e45bb8cd0405f8b5f14a0_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfNC02LTEtMS00NzgwMQ_94ab7971-d6ab-4409-acdd-7820ce464156"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib42d2c1ec2894fec8370868a75e097f5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfNC04LTEtMS00NzgwMQ_c7db4b04-bb2b-402d-bc0c-597ce41a7dcd"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4b3fe709b3f74022a916820d6a66f819_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfNC0xMC0xLTEtNDc4MDE_5a473f42-005d-48d0-8e26-f8f20c9688a0"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i30d3e114033048b4bf56fe57daa86654_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfNC0xMi0xLTEtNDc4MDE_e5868000-e66a-4cac-b031-48c6c665393a"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaff254b4c0d8405ba942acab54575f2f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfNy0yLTEtMS00NzgwMQ_f1b80947-de07-4d30-9bae-fff86b63b35e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib8485788d2894891ac3dbdffaa1a04f6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfNy00LTEtMS00NzgwMQ_693a00a2-9c60-4063-bf82-42a1f8d2d6c3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4fc34bcf05bf42a1ad015e84425c8d0d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfNy02LTEtMS00NzgwMQ_22a3b83b-b923-49cd-b00f-a3a623543ac6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i35bedd3b896a45e6bef76a745aea55b8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfNy04LTEtMS00NzgwMQ_74fc0c85-9dfc-4025-ba19-e92670cab1bf"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie6f16378a34f47e5bc64f9f37e501985_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfNy0xMC0xLTEtNDc4MDE_73a16cd4-ed3a-4820-aa12-5d70bc6cd4da"
      unitRef="usd">32692000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3327c7ae03814e5b98e511ab356d1e06_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfNy0xMi0xLTEtNDc4MDE_db6047f4-27e6-4acd-8109-be7a411cdae2"
      unitRef="usd">32692000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8679bef0769643ff80b9deb03b454f3e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfOC0yLTEtMS00NzgwMQ_ddb9546a-1c6e-432c-b08f-78f2681d570c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibf47bb6ce3e3440e8d32edd5fa5d2a77_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfOC00LTEtMS00NzgwMQ_e918c689-27fc-43ed-acc8-871ac92a9ac0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i919614e2dc9744fea40ea36e3bad8795_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfOC02LTEtMS00NzgwMQ_a738eba0-7b5d-41dc-8d51-d1ca02863d0f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1ce27062172c4df39f203c5fbbcda25d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfOC04LTEtMS00NzgwMQ_e028cefe-1372-4c32-b884-98cf2987d5f4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0355f361557b4963951d67530b3f33a4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfOC0xMC0xLTEtNDc4MDE_b06636f4-11e6-4837-b7f1-d2f747687e87"
      unitRef="usd">58799000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie6a49dbb96ea4e068ffae31a73e0450d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfOC0xMi0xLTEtNDc4MDE_03a28906-2f52-494c-ba21-913a6c86336e"
      unitRef="usd">58799000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if0a3288eab784be19fb61c3da624b2ce_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfOS0yLTEtMS00NzgwMQ_6f2eb51b-3930-4f54-bfe1-61bc04d6e510"
      unitRef="usd">118428000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i46f6abf3fb844711ba56aa80aa191fde_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfOS00LTEtMS00NzgwMQ_d85571db-0795-49aa-9b87-e9024bc7703a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i02b96f8f266746e5bef1a7a56d0020d7_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfOS02LTEtMS00NzgwMQ_dd686fec-e548-494d-8449-903e7c85755e"
      unitRef="usd">118428000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4fb4248efc9c4394903dd84bafe5032c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfOS04LTEtMS00NzgwMQ_d1d2bd28-cf19-4e15-9186-f653bb3158ae"
      unitRef="usd">230761000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icf3f9180d2d54718b7d17a4b462cd60f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfOS0xMC0xLTEtNDc4MDE_1c2b7073-083c-4dc3-bc4a-776d97e4d909"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifbbf1f4395c847e88fbb88a23315b862_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfOS0xMi0xLTEtNDc4MDE_dcab0701-ada6-4aeb-842c-09cd63b101e4"
      unitRef="usd">230761000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i797d735ce11e40a3a597d7b067205876_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMTAtMi0xLTEtNDc4MDE_e3956dcc-82f2-44c1-a784-3584be54751f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0c825fe74c2e4db9a79927b3f36b3b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMTAtNC0xLTEtNDc4MDE_52939578-5c1b-4850-a6f4-98047ab26d46"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie3ddca14e94e4ee7bc84deba437d724a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMTAtNi0xLTEtNDc4MDE_e4bd090d-3c67-400d-a078-f31c490a15bb"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ied28f46dba994350bcda53f1634bf3dd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMTAtOC0xLTEtNDc4MDE_188d16a6-105f-49b0-a88c-a76b8fd44870"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie1965c9e97674996b395dc7e83265e6e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMTAtMTAtMS0xLTQ3ODAx_1f31c94a-8098-4ae6-af78-cc7ff00b18e2"
      unitRef="usd">17220000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i41ce1d46c93d4d23a5dcc7490d03b394_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMTAtMTItMS0xLTQ3ODAx_276e9cc2-1bec-4659-9355-a38c137f58b6"
      unitRef="usd">17220000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9d7cfdf4a9444c87946ea6f8f8104d55_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMTEtMi0xLTEtNDc4MDE_7f09869e-6592-4712-890d-414c347974f3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifbee317a1c93450289e3face1229333c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMTEtNC0xLTEtNDc4MDE_9e0b8525-5ed0-407c-bf8f-02ec3b94a6d9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i729eff0e2b1b45abacd1da9f077ac641_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMTEtNi0xLTEtNDc4MDE_45e47f50-6710-4d1c-bf7b-bc1c418de7ee"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i35a6d850025546848755145a7abf15b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMTEtOC0xLTEtNDc4MDE_bd9d4ae0-1c51-49d4-befc-a11d44e22aba"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8114c060d9e745e0ad9ea5a8ccb12e9b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMTEtMTAtMS0xLTQ3ODAx_dac8b604-ae03-4382-929f-8331123cd0ca"
      unitRef="usd">282731000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4820381fb1924e4b8f10130527b2a041_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMTEtMTItMS0xLTQ3ODAx_b0c9d618-73da-40da-a464-76d44018f02f"
      unitRef="usd">282731000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i73361786868247609ad6e713642b4441_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMTItMi0xLTEtNDc4MDE_c5450450-68b8-4a6e-a5a3-185aa8383a80"
      unitRef="usd">189271000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i18df9e45de3648af8edb0ce21a72898c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMTItNC0xLTEtNDc4MDE_06a45108-fb42-40dd-a0c2-baa93fd1713c"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMTItNi0xLTEtNDc4MDE_f668b883-88d1-4249-81e4-4a0cf995f738"
      unitRef="usd">189271000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib6fcbc87cdee4fccae17a9f9a6e02d05_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMTItOC0xLTEtNDc4MDE_6f10b4ab-3d2c-4d93-8f55-687797063337"
      unitRef="usd">349468000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i41ae64b0863d43efb250b560920603c1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMTItMTAtMS0xLTQ3ODAx_80bede3d-0af6-4907-9563-3fca89e1bdcf"
      unitRef="usd">391442000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RhYmxlOmI1ZDY0ZjAwMDVhMzRlYzhhYzlhZGM3OTRmMmUxYjRjL3RhYmxlcmFuZ2U6YjVkNjRmMDAwNWEzNGVjOGFjOWFkYzc5NGYyZTFiNGNfMTItMTItMS0xLTQ3ODAx_3e6d29dc-6c73-4ed5-b477-5d9173cdcb30"
      unitRef="usd">740910000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic37ed5614087440da569f079f0f651bd_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RleHRyZWdpb246MmY1MTI5Mjc5OGYzNGYzNzhmZGQ5NjI5NTBiMDIyMTVfOTQ5_8f9b3722-99a7-4d8f-99ba-eb1051f835f5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia715fa809717495ca3ea42208886f693_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RleHRyZWdpb246MmY1MTI5Mjc5OGYzNGYzNzhmZGQ5NjI5NTBiMDIyMTVfOTQ5_aa29295a-fb8a-4030-9fc8-684a44b316d1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i1e07b7230a7b4293910918c1158913a7_I20220524"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN180OS9mcmFnOjJmNTEyOTI3OThmMzRmMzc4ZmRkOTYyOTUwYjAyMjE1L3RleHRyZWdpb246MmY1MTI5Mjc5OGYzNGYzNzhmZGQ5NjI5NTBiMDIyMTVfMTkyNDE0NTM0OTM3OTY_3147a3b8-d61d-48f2-ba95-ba0c35bd5a5e"
      unitRef="usd">130000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RleHRyZWdpb246OTQzNTc4NTJkNzlkNGViYTg5YTU4YjM2Y2MyMWJhZjZfMTY1Mw_3f4e9a67-3f08-4f5f-9a2b-6632e7e4fdb8">Revenue&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our disaggregated revenues were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.179%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;&#160;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product sales, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Sales of bulk rHuPH20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales of proprietary products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales of device partnered products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product sales, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues under collaborative agreements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Upfront license and target nomination fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Event-based development and regulatory milestones and other fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Sales-based milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Device Licensing and development revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues under collaborative agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended June&#160;30, 2022 we recognized revenue related to licenses granted to partners in prior periods in the amount of $100.3 million. This amount represents royalties earned in the current period in addition to $15.0 million of variable consideration in the contracts where uncertainties have been resolved and the development milestones were expected to be achieved or were achieved. We also recognized revenue of $0.5 million during the three months ended June&#160;30, 2022 that had been included in deferred revenues at December&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June&#160;30, 2022 we recognized revenue related to licenses granted to partners in prior periods in the amount of $169.9 million. This amount represents royalties earned in the current period in addition to $15.0 million of variable consideration.in the contracts where uncertainties have been resolved and the development milestones were expected to be achieved or were achieved. We also recognized revenue of $1.0 million during the six months ended June&#160;30, 2022 that had been included in deferred revenues at December&#160;31, 2021. We did not recognize any adjustments to reduce sales reserves and allowances liability related to Hylenex recombinant sales in prior periods&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable, net, and deferred revenues (contract liabilities) from contracts with customers, including partners, consisted of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.176%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.065%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, the amounts included in the transaction price of our contracts with customers and allocated to goods and services not yet provided were $68.1 million, of which $61.2 million relates to unfulfilled purchase commitments and $6.9 million has been collected and is reported as deferred revenues. The unfulfilled purchase commitments are estimated to be delivered by the end of 2023. Of the total deferred revenues of $6.9 million, $4.1 million is expected to be used by our customers within the next 12 months. &lt;/span&gt;&lt;/div&gt;We recognized contract assets of $19.8&#160;million at June&#160;30, 2022, which related to development milestones deemed probable of receipt for intellectual property licenses granted to partners in prior periods</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RleHRyZWdpb246OTQzNTc4NTJkNzlkNGViYTg5YTU4YjM2Y2MyMWJhZjZfMTYzNg_12d6913b-f22d-4e19-acb0-07a634bd7333">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our disaggregated revenues were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.179%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;&#160;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product sales, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Sales of bulk rHuPH20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales of proprietary products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales of device partnered products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product sales, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues under collaborative agreements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Upfront license and target nomination fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Event-based development and regulatory milestones and other fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Sales-based milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Device Licensing and development revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues under collaborative agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2302c2baba3a4084b1cd7169564a4517_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMi0yLTEtMS00NzgwMQ_6b6d87a8-114d-4579-b9a5-bf4dead29f84"
      unitRef="usd">85340000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifecd7d767a3c48d6a094b68ee21e3340_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMi00LTEtMS00NzgwMQ_c4a726bc-5b94-4901-9ea1-089fae425b9e"
      unitRef="usd">45778000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i488611ceda1e4bf3a1df6ada966c72ff_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMi02LTEtMS00NzgwMQ_e1be3e19-2395-4fef-bf1b-a438e198fac0"
      unitRef="usd">154945000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie448ea4ebc7a4047b9528cc3d06dac35_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMi04LTEtMS00NzgwMQ_9ee2d6bc-59cc-4143-b19c-6b55af7abd5d"
      unitRef="usd">82701000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i30cb808ae8294ad2963b8d25bd8ddd70_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfNS0yLTEtMS00NzgwMQ_9c44a031-e9c2-4ff4-a997-c83cad11cccb"
      unitRef="usd">25057000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib5ac7dbc74fd416bba2eecdc24f27658_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfNS00LTEtMS00NzgwMQ_9c3b4371-275e-411a-a007-7280f483f51f"
      unitRef="usd">24087000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i61902b5268704612925502d224a5f0dc_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfNS02LTEtMS00NzgwMQ_e3f0b061-ccf5-44c3-9f90-30c024270b16"
      unitRef="usd">41505000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia1581eb1b56a4683bd3a80a5ce16e03c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfNS04LTEtMS00NzgwMQ_9c52c362-23ae-4eab-bfaf-2314c2b890d1"
      unitRef="usd">40857000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5576b7ccca364865ba7aae184bb4cf37_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfNy0yLTEtMS01MDQwMQ_f9693459-85db-46d0-9107-1667e66cc330"
      unitRef="usd">14687000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b180128f3634ec092ab2d598df56185_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfNy00LTEtMS01MDQxMA_17b737bf-c5a4-4569-9451-8b96721477ba"
      unitRef="usd">6273000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i727ff9da39cc4faab1ee412cb6667251_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfNy02LTEtMS01MDQxNw_b17c9e38-7a41-457e-9431-dd8edf542cf5"
      unitRef="usd">20379000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c83d19f90094700a1790868f713787d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfNy04LTEtMS01MDQyNA_c8e917d8-c2e2-4e92-b549-0b2fff9e8bf2"
      unitRef="usd">11269000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b1f6429290349caa513971198a9d7f3_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfOC0yLTEtMS01MDQwMQ_04ed64f6-46ab-4ce6-9eb8-d420c261f9fb"
      unitRef="usd">6556000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iccc79e0e6fcd45f7baf4dc4675fdb639_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfOC00LTEtMS01MDQxMA_95052b07-f219-4aff-8a5d-56f7481ad2f2"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic38072713d2a499bb6a5b530797ec390_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfOC02LTEtMS01MDQxNw_6812a8b1-c73d-4cfd-acda-9d1562b9bf8d"
      unitRef="usd">6556000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idff30f1d38214c3cbaa6aa448432d11c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfOC04LTEtMS01MDQyNA_b80761bd-fca9-402c-ae5b-1d99461ff5a5"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iefbbc65edf2e4319adad4df5fa76e1f3_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfOC0yLTEtMS00NzgwMQ_3b06f73c-e305-46e6-ab36-c01ec6c0e968"
      unitRef="usd">46300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9220796b173a4a9298008c86f02bacf1_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfOC00LTEtMS00NzgwMQ_91c8bede-e58d-4a23-84c6-b8d85969ceeb"
      unitRef="usd">30360000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id5cfeb9eb65745ed9779cd8409a1de20_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfOC02LTEtMS00NzgwMQ_6747d499-7b27-493b-9302-806f039a1e1c"
      unitRef="usd">68440000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0d0fdcb3db8c45fdb97bc693b3691d65_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfOC04LTEtMS00NzgwMQ_4b89caf7-98b0-4673-b4bf-678c563e9890"
      unitRef="usd">52126000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c4e1c2852834e3db83be2ab724c4ec7_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTEtMi0xLTEtNDc4MDE_f9fbb4a9-3533-4810-9076-83c25807d2fb"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b169ddfeec745d1be5c150f76f1b9ce_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTEtNC0xLTEtNDc4MDE_c9c679de-0023-40aa-a3e4-b1ca97897b52"
      unitRef="usd">40000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id99a3d7ca0084d3c8ad32c30e53803ca_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTEtNi0xLTEtNDc4MDE_2ce4f1c3-7adf-4408-ba59-cfbcdf95361e"
      unitRef="usd">30000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i29bf66c271ba4ae7987ec7bd8ff4520f_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTEtOC0xLTEtNDc4MDE_69d5fa85-b1c9-4919-83df-5f55dff88dde"
      unitRef="usd">40000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i68f176f459d54d48893f0655ba31ec14_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTItMi0xLTEtNDc4MDE_6ebd0a4c-8f2c-4a9c-a060-852aa3d091c8"
      unitRef="usd">15000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i044be8133aeb4fe6a48b3663a56504bc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTItNC0xLTEtNDc4MDE_2676ee92-d7b0-47d2-9c99-bcef5c705df8"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i120c080d9b5a4f57b9e656994552257c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTItNi0xLTEtNDc4MDE_b84f1571-af10-4409-a5ec-5dd2eeb37c8a"
      unitRef="usd">15000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifaf7a7f2b9314cabb0bba3ca0238fc37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTItOC0xLTEtNDc4MDE_2aaeb3f2-db34-44ee-bbc0-57066dfb5ef5"
      unitRef="usd">30000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i667bd7d9d0494b2f898d65a0be893385_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTMtMi0xLTEtNDc4MDE_dc193bce-edd9-4984-b7f4-590b8ae7b317"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id4f91bfe396b4e2fabebbdcc9ab97e9a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTMtNC0xLTEtNDc4MDE_aabd0cbc-b993-4dbf-98ac-78705dcc00e5"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0177b2094d7a422a923115b1b3b4755d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTMtNi0xLTEtNDc4MDE_dadb2e6e-cee8-4e23-b98f-b9506214a220"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b98cb4091434500999a3bd53a43e318_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTMtOC0xLTEtNDc4MDE_27ab215c-10e7-4ba1-ad5a-6baf4150e735"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id036393f1ef94ab59c494be346f81453_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTQtMi0xLTEtNDc4MDE_89778ddb-0ba5-4e57-ad1b-75018e2b9e14"
      unitRef="usd">725000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if2c6a315d3c94850a81a0adb2158a25b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTQtNC0xLTEtNDc4MDE_453ce1f9-d79a-47a1-9823-f846ecab2204"
      unitRef="usd">317000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i889d129efa02476986931ae8af732baa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTQtNi0xLTEtNDc4MDE_5b1820cb-3d80-4d3b-be14-63e7c4a60557"
      unitRef="usd">1259000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8770b425828c4e6cadb0c28e912fc453_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTQtOC0xLTEtNDc4MDE_20bca2fb-630a-494f-8ac7-72811ba85227"
      unitRef="usd">650000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5331ecfa85164578966f7ba36c8377ac_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTUtMi0xLTEtNDc4MDE_c943e45b-811a-4688-9daa-c2826c0c6a22"
      unitRef="usd">20725000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i88e4277b0c454a79a9c899981c6d0ade_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTUtNC0xLTEtNDc4MDE_9517dc92-197a-44d3-ada5-1a2fdbfeda62"
      unitRef="usd">60317000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if13d9aa4327240bcaf9417558eeae8c3_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTUtNi0xLTEtNDc4MDE_3b98206c-8bf8-4231-82f6-d57283650ccc"
      unitRef="usd">46259000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic72a2d641a084db2bfd8a448fdafa5bb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTUtOC0xLTEtNDc4MDE_c983fe36-355a-42aa-a64b-33c64fc573ab"
      unitRef="usd">90650000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTctMi0xLTEtNDc4MDE_c1741f49-12e0-4adf-a9f4-6c9440fff173"
      unitRef="usd">152365000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTctNC0xLTEtNDc4MDE_fddcd0a2-a55f-4169-9cde-cbc72d4835d7"
      unitRef="usd">136455000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTctNi0xLTEtNDc4MDE_e1be95a9-e03b-4168-9189-13a8751a3555"
      unitRef="usd">269644000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOjA0ZDllMmM5ZGQ5NDRiYWM5YmY0MzUxYjIwMTA2NThmL3RhYmxlcmFuZ2U6MDRkOWUyYzlkZDk0NGJhYzliZjQzNTFiMjAxMDY1OGZfMTctOC0xLTEtNDc4MDE_170941de-996b-4dec-bf99-c1020128131a"
      unitRef="usd">225477000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iffcd168ae7a94e5db1b32f7feb3a8b62_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RleHRyZWdpb246OTQzNTc4NTJkNzlkNGViYTg5YTU4YjM2Y2MyMWJhZjZfMjE3_957cfccc-3f15-4022-bd76-89628a748aa4"
      unitRef="usd">100300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i68f176f459d54d48893f0655ba31ec14_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RleHRyZWdpb246OTQzNTc4NTJkNzlkNGViYTg5YTU4YjM2Y2MyMWJhZjZfMTA5OTUxMTYyOTk0Ng_6ebd0a4c-8f2c-4a9c-a060-852aa3d091c8"
      unitRef="usd">15000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RleHRyZWdpb246OTQzNTc4NTJkNzlkNGViYTg5YTU4YjM2Y2MyMWJhZjZfMzE0_2a8be76b-3164-40d4-be1e-d06a9b1b7294"
      unitRef="usd">500000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice04128a0ca3439cae58ae72f295f29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RleHRyZWdpb246OTQzNTc4NTJkNzlkNGViYTg5YTU4YjM2Y2MyMWJhZjZfMTA5OTUxMTYyOTkxMA_7438bf71-b4eb-4b45-86c3-df05739fda18"
      unitRef="usd">169900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i120c080d9b5a4f57b9e656994552257c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RleHRyZWdpb246OTQzNTc4NTJkNzlkNGViYTg5YTU4YjM2Y2MyMWJhZjZfMTA5OTUxMTYzMTg0OA_b84f1571-af10-4409-a5ec-5dd2eeb37c8a"
      unitRef="usd">15000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RleHRyZWdpb246OTQzNTc4NTJkNzlkNGViYTg5YTU4YjM2Y2MyMWJhZjZfMTA5OTUxMTYzMTg1Ng_7c445da8-1357-49bc-b925-7b510e04b352"
      unitRef="usd">1000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RleHRyZWdpb246OTQzNTc4NTJkNzlkNGViYTg5YTU4YjM2Y2MyMWJhZjZfMTY0Mw_44d3c292-0764-4998-a15b-0a5a0d5c336c">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable, net, and deferred revenues (contract liabilities) from contracts with customers, including partners, consisted of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.176%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.065%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <halo:AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOmFjZTc1MGQ4NDI2MjQyY2ZiNDA0ZWJmODIzNTA5M2NmL3RhYmxlcmFuZ2U6YWNlNzUwZDg0MjYyNDJjZmI0MDRlYmY4MjM1MDkzY2ZfMS0yLTEtMS00NzgwMQ_9d775e62-0303-4a27-8129-097f4ed01800"
      unitRef="usd">169526000</halo:AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets>
    <halo:AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOmFjZTc1MGQ4NDI2MjQyY2ZiNDA0ZWJmODIzNTA5M2NmL3RhYmxlcmFuZ2U6YWNlNzUwZDg0MjYyNDJjZmI0MDRlYmY4MjM1MDkzY2ZfMS00LTEtMS00NzgwMQ_cdc20857-4c70-4315-9d3e-0abcf6f04fa3"
      unitRef="usd">90975000</halo:AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOmFjZTc1MGQ4NDI2MjQyY2ZiNDA0ZWJmODIzNTA5M2NmL3RhYmxlcmFuZ2U6YWNlNzUwZDg0MjYyNDJjZmI0MDRlYmY4MjM1MDkzY2ZfMi0yLTEtMS00NzgwMQ_ce3388fd-ae8f-41e3-8821-2e4a33671586"
      unitRef="usd">19842000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOmFjZTc1MGQ4NDI2MjQyY2ZiNDA0ZWJmODIzNTA5M2NmL3RhYmxlcmFuZ2U6YWNlNzUwZDg0MjYyNDJjZmI0MDRlYmY4MjM1MDkzY2ZfMi00LTEtMS00NzgwMQ_32a0ba7c-6b25-4d85-81c9-7c41202f90f0"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:DeferredRevenue
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOmFjZTc1MGQ4NDI2MjQyY2ZiNDA0ZWJmODIzNTA5M2NmL3RhYmxlcmFuZ2U6YWNlNzUwZDg0MjYyNDJjZmI0MDRlYmY4MjM1MDkzY2ZfMy0yLTEtMS00NzgwMQ_68f17dda-3d26-4a93-80e7-387d9912acff"
      unitRef="usd">6870000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RhYmxlOmFjZTc1MGQ4NDI2MjQyY2ZiNDA0ZWJmODIzNTA5M2NmL3RhYmxlcmFuZ2U6YWNlNzUwZDg0MjYyNDJjZmI0MDRlYmY4MjM1MDkzY2ZfMy00LTEtMS00NzgwMQ_50a40147-33e8-4f38-a400-d352f311d528"
      unitRef="usd">4276000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="i1ce4ecc3d70b49ab961fee2475a6ee4e_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RleHRyZWdpb246OTQzNTc4NTJkNzlkNGViYTg5YTU4YjM2Y2MyMWJhZjZfOTAz_ba5f40fd-c602-473a-82d1-4be9e2b6187f"
      unitRef="usd">68100000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent
      contextRef="i065c6dc939e647029141b2829def68d5_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RleHRyZWdpb246OTQzNTc4NTJkNzlkNGViYTg5YTU4YjM2Y2MyMWJhZjZfOTE2_83e19b2f-77ed-4a79-8cc0-852dabcbbe70"
      unitRef="usd">61200000</us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent>
    <us-gaap:DeferredCreditsAndOtherLiabilities
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RleHRyZWdpb246OTQzNTc4NTJkNzlkNGViYTg5YTU4YjM2Y2MyMWJhZjZfOTY3_a0f2291f-b344-4526-bdac-a8e4ed22105f"
      unitRef="usd">6900000</us-gaap:DeferredCreditsAndOtherLiabilities>
    <us-gaap:DeferredCreditsAndOtherLiabilities
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RleHRyZWdpb246OTQzNTc4NTJkNzlkNGViYTg5YTU4YjM2Y2MyMWJhZjZfMTE0OA_a0f2291f-b344-4526-bdac-a8e4ed22105f"
      unitRef="usd">6900000</us-gaap:DeferredCreditsAndOtherLiabilities>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i70ed32619a3c450b95acdcb7833975bf_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RleHRyZWdpb246OTQzNTc4NTJkNzlkNGViYTg5YTU4YjM2Y2MyMWJhZjZfMTE1Mg_27b897ad-cc21-41d8-ae16-ae253972ac7c"
      unitRef="usd">4100000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN181NS9mcmFnOjk0MzU3ODUyZDc5ZDRlYmE4OWE1OGIzNmNjMjFiYWY2L3RleHRyZWdpb246OTQzNTc4NTJkNzlkNGViYTg5YTU4YjM2Y2MyMWJhZjZfMTIzNA_f6359586-0d70-4799-8efd-3fd940b55d18"
      unitRef="usd">19800000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfMTE4Nw_846d0b9a-07cb-4a08-859d-e5dff5acf84c">Certain Balance Sheet Items&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable from product sales to partners&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable from revenues under collaborative agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable from royalty payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable from other product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for distribution fees and discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other assets consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid manufacturing expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total prepaid expenses and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less long-term portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,283)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,414)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total prepaid expenses and other assets, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid manufacturing expenses include raw materials, slot reservation fees and other amounts paid to contract manufacturing organizations.&#160;Such amounts are reclassified to work-in-process inventory as materials are used or the contract manufacturing organization services are complete.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,749)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;                            &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense was approximately $1.1 million and $0.8 million, inclusive of ROU asset amortization of $0.6 million and $0.4 million for the three months ended June&#160;30, 2022 and 2021 respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense was approximately $1.9 million and $1.5 million, inclusive of ROU asset amortization of $1.0 million and $0.8 million for the six months ended June&#160;30, 2022 and 2021 respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and payroll taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued outsourced manufacturing expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product returns and sales allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less long-term portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,551)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(544)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total accrued expenses, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expense associated with the accretion of the lease liabilities was approximately $0.1 million and $0.1 million for the three months ended June&#160;30, 2022 and 2021 respectively and $0.2 million and $0.2 million for the six months ended June&#160;30, 2022 and 2021 respectively. Total lease expense for the three months ended June&#160;30, 2022 and 2021 was $0.6 million and $0.5 million respectively and  $1.1 million and $1.0 million for the six months ended June&#160;30, 2022 and 2021, respectively. .  &lt;/span&gt;&lt;/div&gt;Cash paid for amounts related to leases for the three months ended June&#160;30, 2022 and 2021 was $0.9 million and $0.7 million, and $1.6 million and $1.4 million for the six months ended June&#160;30, 2022 and 2021 respectively.</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfMTIwOQ_fb37e134-15fb-4c02-952f-c83ba2390a80">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable from product sales to partners&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable from revenues under collaborative agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable from royalty payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable from other product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for distribution fees and discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <halo:Accountsreceivablefromproductsalestocollaborators
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjVlODhmZGFiOTdiNjQ0Y2E4ZTk4OTc2OGNjNTRjMGRkL3RhYmxlcmFuZ2U6NWU4OGZkYWI5N2I2NDRjYThlOTg5NzY4Y2M1NGMwZGRfMS0yLTEtMS00NzgwMQ_3af4c21b-0543-4b80-a6f3-c078d36b50d9"
      unitRef="usd">56570000</halo:Accountsreceivablefromproductsalestocollaborators>
    <halo:Accountsreceivablefromproductsalestocollaborators
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjVlODhmZGFiOTdiNjQ0Y2E4ZTk4OTc2OGNjNTRjMGRkL3RhYmxlcmFuZ2U6NWU4OGZkYWI5N2I2NDRjYThlOTg5NzY4Y2M1NGMwZGRfMS00LTEtMS00NzgwMQ_97fa564f-c953-4201-ab75-7035076fd092"
      unitRef="usd">18504000</halo:Accountsreceivablefromproductsalestocollaborators>
    <halo:Accountsreceivablefromcollaborators
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjVlODhmZGFiOTdiNjQ0Y2E4ZTk4OTc2OGNjNTRjMGRkL3RhYmxlcmFuZ2U6NWU4OGZkYWI5N2I2NDRjYThlOTg5NzY4Y2M1NGMwZGRfMi0yLTEtMS00NzgwMQ_f091618d-9a40-4f38-940c-9cc1c96cb141"
      unitRef="usd">11478000</halo:Accountsreceivablefromcollaborators>
    <halo:Accountsreceivablefromcollaborators
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjVlODhmZGFiOTdiNjQ0Y2E4ZTk4OTc2OGNjNTRjMGRkL3RhYmxlcmFuZ2U6NWU4OGZkYWI5N2I2NDRjYThlOTg5NzY4Y2M1NGMwZGRfMi00LTEtMS00NzgwMQ_afdedcdd-18d9-4021-b751-5efbd91bfeb9"
      unitRef="usd">5422000</halo:Accountsreceivablefromcollaborators>
    <halo:Accountsreceivablefromroyalties
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjVlODhmZGFiOTdiNjQ0Y2E4ZTk4OTc2OGNjNTRjMGRkL3RhYmxlcmFuZ2U6NWU4OGZkYWI5N2I2NDRjYThlOTg5NzY4Y2M1NGMwZGRfMy0yLTEtMS00NzgwMQ_2e7ad72b-4e0b-4c2d-9ea9-ac4cb4c8506f"
      unitRef="usd">87634000</halo:Accountsreceivablefromroyalties>
    <halo:Accountsreceivablefromroyalties
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjVlODhmZGFiOTdiNjQ0Y2E4ZTk4OTc2OGNjNTRjMGRkL3RhYmxlcmFuZ2U6NWU4OGZkYWI5N2I2NDRjYThlOTg5NzY4Y2M1NGMwZGRfMy00LTEtMS00NzgwMQ_eb4b7405-5499-4c0c-9e43-bbbb100b2da4"
      unitRef="usd">63555000</halo:Accountsreceivablefromroyalties>
    <halo:Accountsreceivablefromproductsales
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjVlODhmZGFiOTdiNjQ0Y2E4ZTk4OTc2OGNjNTRjMGRkL3RhYmxlcmFuZ2U6NWU4OGZkYWI5N2I2NDRjYThlOTg5NzY4Y2M1NGMwZGRfNC0yLTEtMS00NzgwMQ_bb303a1f-7630-4923-a6f8-a1e43d54bb47"
      unitRef="usd">6259000</halo:Accountsreceivablefromproductsales>
    <halo:Accountsreceivablefromproductsales
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjVlODhmZGFiOTdiNjQ0Y2E4ZTk4OTc2OGNjNTRjMGRkL3RhYmxlcmFuZ2U6NWU4OGZkYWI5N2I2NDRjYThlOTg5NzY4Y2M1NGMwZGRfNC00LTEtMS00NzgwMQ_bdbf7aac-65a4-49f8-9ae3-9e2bb8b5dea4"
      unitRef="usd">4634000</halo:Accountsreceivablefromproductsales>
    <us-gaap:OtherReceivables
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjVlODhmZGFiOTdiNjQ0Y2E4ZTk4OTc2OGNjNTRjMGRkL3RhYmxlcmFuZ2U6NWU4OGZkYWI5N2I2NDRjYThlOTg5NzY4Y2M1NGMwZGRfNS0yLTEtMS01ODY4Mw_05e7a4ba-bedc-464b-8c5e-5903c48fc735"
      unitRef="usd">9985000</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjVlODhmZGFiOTdiNjQ0Y2E4ZTk4OTc2OGNjNTRjMGRkL3RhYmxlcmFuZ2U6NWU4OGZkYWI5N2I2NDRjYThlOTg5NzY4Y2M1NGMwZGRfNS00LTEtMS01ODY5MA_7df1c677-68c5-4c33-a7a8-e75bcdbd2f80"
      unitRef="usd">0</us-gaap:OtherReceivables>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjVlODhmZGFiOTdiNjQ0Y2E4ZTk4OTc2OGNjNTRjMGRkL3RhYmxlcmFuZ2U6NWU4OGZkYWI5N2I2NDRjYThlOTg5NzY4Y2M1NGMwZGRfNS0yLTEtMS00NzgwMQ_ce3388fd-ae8f-41e3-8821-2e4a33671586"
      unitRef="usd">19842000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjVlODhmZGFiOTdiNjQ0Y2E4ZTk4OTc2OGNjNTRjMGRkL3RhYmxlcmFuZ2U6NWU4OGZkYWI5N2I2NDRjYThlOTg5NzY4Y2M1NGMwZGRfNS00LTEtMS00NzgwMQ_32a0ba7c-6b25-4d85-81c9-7c41202f90f0"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjVlODhmZGFiOTdiNjQ0Y2E4ZTk4OTc2OGNjNTRjMGRkL3RhYmxlcmFuZ2U6NWU4OGZkYWI5N2I2NDRjYThlOTg5NzY4Y2M1NGMwZGRfNi0yLTEtMS00NzgwMQ_a44d7637-4da0-498c-b218-17a06e48457a"
      unitRef="usd">191768000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjVlODhmZGFiOTdiNjQ0Y2E4ZTk4OTc2OGNjNTRjMGRkL3RhYmxlcmFuZ2U6NWU4OGZkYWI5N2I2NDRjYThlOTg5NzY4Y2M1NGMwZGRfNi00LTEtMS00NzgwMQ_952df24b-bc5f-4ee4-a27b-ec2ace313829"
      unitRef="usd">92115000</us-gaap:AccountsReceivableGrossCurrent>
    <halo:AllowanceforDistributionFeesandDiscounts
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjVlODhmZGFiOTdiNjQ0Y2E4ZTk4OTc2OGNjNTRjMGRkL3RhYmxlcmFuZ2U6NWU4OGZkYWI5N2I2NDRjYThlOTg5NzY4Y2M1NGMwZGRfNy0yLTEtMS00NzgwMQ_c1ec1d16-fdaa-49f0-b99f-8221c5c0782f"
      unitRef="usd">2400000</halo:AllowanceforDistributionFeesandDiscounts>
    <halo:AllowanceforDistributionFeesandDiscounts
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjVlODhmZGFiOTdiNjQ0Y2E4ZTk4OTc2OGNjNTRjMGRkL3RhYmxlcmFuZ2U6NWU4OGZkYWI5N2I2NDRjYThlOTg5NzY4Y2M1NGMwZGRfNy00LTEtMS00NzgwMQ_d86ec0e6-1b20-439b-a816-91bc34ee0f9b"
      unitRef="usd">1140000</halo:AllowanceforDistributionFeesandDiscounts>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjVlODhmZGFiOTdiNjQ0Y2E4ZTk4OTc2OGNjNTRjMGRkL3RhYmxlcmFuZ2U6NWU4OGZkYWI5N2I2NDRjYThlOTg5NzY4Y2M1NGMwZGRfOC0yLTEtMS00NzgwMQ_129e0234-fa6d-40e9-9eaa-ee9cc4ea7902"
      unitRef="usd">189368000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjVlODhmZGFiOTdiNjQ0Y2E4ZTk4OTc2OGNjNTRjMGRkL3RhYmxlcmFuZ2U6NWU4OGZkYWI5N2I2NDRjYThlOTg5NzY4Y2M1NGMwZGRfOC00LTEtMS00NzgwMQ_3a826a02-5b95-4208-834d-9cd18eb07d7f"
      unitRef="usd">90975000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfMTE5MA_2b258bf0-1100-4bab-99d9-f1e6ab565200">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmM4YzFlYzhmNDVkNjQ2NTQ4ZDE4ZTM1ZGJlMTQxM2I0L3RhYmxlcmFuZ2U6YzhjMWVjOGY0NWQ2NDY1NDhkMThlMzVkYmUxNDEzYjRfMS0yLTEtMS00NzgwMQ_f9027114-f5db-478d-a341-9f29cb745caf"
      unitRef="usd">10194000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmM4YzFlYzhmNDVkNjQ2NTQ4ZDE4ZTM1ZGJlMTQxM2I0L3RhYmxlcmFuZ2U6YzhjMWVjOGY0NWQ2NDY1NDhkMThlMzVkYmUxNDEzYjRfMS00LTEtMS00NzgwMQ_bec0ee16-22cd-464f-b4df-0a8f90bee447"
      unitRef="usd">10672000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmM4YzFlYzhmNDVkNjQ2NTQ4ZDE4ZTM1ZGJlMTQxM2I0L3RhYmxlcmFuZ2U6YzhjMWVjOGY0NWQ2NDY1NDhkMThlMzVkYmUxNDEzYjRfMi0yLTEtMS00NzgwMQ_6a5755db-e3d1-4039-b3b0-8085673506ee"
      unitRef="usd">44165000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmM4YzFlYzhmNDVkNjQ2NTQ4ZDE4ZTM1ZGJlMTQxM2I0L3RhYmxlcmFuZ2U6YzhjMWVjOGY0NWQ2NDY1NDhkMThlMzVkYmUxNDEzYjRfMi00LTEtMS00NzgwMQ_d37dad60-7ed5-48d6-bced-200e4e68b928"
      unitRef="usd">17451000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmM4YzFlYzhmNDVkNjQ2NTQ4ZDE4ZTM1ZGJlMTQxM2I0L3RhYmxlcmFuZ2U6YzhjMWVjOGY0NWQ2NDY1NDhkMThlMzVkYmUxNDEzYjRfMy0yLTEtMS00NzgwMQ_71823a67-4632-4bda-9ccc-ca11d0dd90d5"
      unitRef="usd">43256000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmM4YzFlYzhmNDVkNjQ2NTQ4ZDE4ZTM1ZGJlMTQxM2I0L3RhYmxlcmFuZ2U6YzhjMWVjOGY0NWQ2NDY1NDhkMThlMzVkYmUxNDEzYjRfMy00LTEtMS00NzgwMQ_a7aa23af-dac5-457a-9161-68b71f344f0f"
      unitRef="usd">25785000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmM4YzFlYzhmNDVkNjQ2NTQ4ZDE4ZTM1ZGJlMTQxM2I0L3RhYmxlcmFuZ2U6YzhjMWVjOGY0NWQ2NDY1NDhkMThlMzVkYmUxNDEzYjRfNC0yLTEtMS00NzgwMQ_aaba38a7-ee56-420c-8bfc-280c27698ffa"
      unitRef="usd">97615000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmM4YzFlYzhmNDVkNjQ2NTQ4ZDE4ZTM1ZGJlMTQxM2I0L3RhYmxlcmFuZ2U6YzhjMWVjOGY0NWQ2NDY1NDhkMThlMzVkYmUxNDEzYjRfNC00LTEtMS00NzgwMQ_b89ef4d8-509e-43cd-a8fa-2a7deb819612"
      unitRef="usd">53908000</us-gaap:InventoryNet>
    <us-gaap:ScheduleOfOtherAssetsTableTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfMTIyMQ_ad03e946-08d0-4a9c-b016-c16d1c544099">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other assets consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid manufacturing expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total prepaid expenses and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less long-term portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,283)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,414)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total prepaid expenses and other assets, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherAssetsTableTextBlock>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjBjNzE3MDFlYTllZDQ2M2RiMmMyNjcxNWQxOWM5ODY4L3RhYmxlcmFuZ2U6MGM3MTcwMWVhOWVkNDYzZGIyYzI2NzE1ZDE5Yzk4NjhfMS0yLTEtMS00NzgwMQ_e0bd5b68-d14a-4b19-973f-da8283f6a105"
      unitRef="usd">50848000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjBjNzE3MDFlYTllZDQ2M2RiMmMyNjcxNWQxOWM5ODY4L3RhYmxlcmFuZ2U6MGM3MTcwMWVhOWVkNDYzZGIyYzI2NzE1ZDE5Yzk4NjhfMS00LTEtMS00NzgwMQ_80f8f307-cfcf-4a70-8b72-a70762228e43"
      unitRef="usd">47991000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjBjNzE3MDFlYTllZDQ2M2RiMmMyNjcxNWQxOWM5ODY4L3RhYmxlcmFuZ2U6MGM3MTcwMWVhOWVkNDYzZGIyYzI2NzE1ZDE5Yzk4NjhfMy0yLTEtMS00NzgwMQ_141d6b9f-237d-42fc-ad2d-539cb8b51085"
      unitRef="usd">14180000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjBjNzE3MDFlYTllZDQ2M2RiMmMyNjcxNWQxOWM5ODY4L3RhYmxlcmFuZ2U6MGM3MTcwMWVhOWVkNDYzZGIyYzI2NzE1ZDE5Yzk4NjhfMy00LTEtMS00NzgwMQ_c3d97db6-17c4-4648-a6f2-e411c335a15d"
      unitRef="usd">3809000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherAssets
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjBjNzE3MDFlYTllZDQ2M2RiMmMyNjcxNWQxOWM5ODY4L3RhYmxlcmFuZ2U6MGM3MTcwMWVhOWVkNDYzZGIyYzI2NzE1ZDE5Yzk4NjhfNC0yLTEtMS00NzgwMQ_aae3a854-4902-4362-94f3-2eddf93c50a8"
      unitRef="usd">6850000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjBjNzE3MDFlYTllZDQ2M2RiMmMyNjcxNWQxOWM5ODY4L3RhYmxlcmFuZ2U6MGM3MTcwMWVhOWVkNDYzZGIyYzI2NzE1ZDE5Yzk4NjhfNC00LTEtMS00NzgwMQ_43e48f08-3d98-49d6-ad55-f4f2e3533296"
      unitRef="usd">2096000</us-gaap:OtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjBjNzE3MDFlYTllZDQ2M2RiMmMyNjcxNWQxOWM5ODY4L3RhYmxlcmFuZ2U6MGM3MTcwMWVhOWVkNDYzZGIyYzI2NzE1ZDE5Yzk4NjhfNS0yLTEtMS00NzgwMQ_325a8318-4850-4f5f-a1e1-ef45c47467c1"
      unitRef="usd">71878000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjBjNzE3MDFlYTllZDQ2M2RiMmMyNjcxNWQxOWM5ODY4L3RhYmxlcmFuZ2U6MGM3MTcwMWVhOWVkNDYzZGIyYzI2NzE1ZDE5Yzk4NjhfNS00LTEtMS00NzgwMQ_d08bbdd9-f040-4930-b4f9-c4efa601000a"
      unitRef="usd">53896000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjBjNzE3MDFlYTllZDQ2M2RiMmMyNjcxNWQxOWM5ODY4L3RhYmxlcmFuZ2U6MGM3MTcwMWVhOWVkNDYzZGIyYzI2NzE1ZDE5Yzk4NjhfNi0yLTEtMS00NzgwMQ_0f5b3c47-0a18-442f-b8fc-ad7c3073d4d3"
      unitRef="usd">26283000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjBjNzE3MDFlYTllZDQ2M2RiMmMyNjcxNWQxOWM5ODY4L3RhYmxlcmFuZ2U6MGM3MTcwMWVhOWVkNDYzZGIyYzI2NzE1ZDE5Yzk4NjhfNi00LTEtMS00NzgwMQ_3ae77e25-8609-4a5d-8f4c-9a177bed6bf8"
      unitRef="usd">13414000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjBjNzE3MDFlYTllZDQ2M2RiMmMyNjcxNWQxOWM5ODY4L3RhYmxlcmFuZ2U6MGM3MTcwMWVhOWVkNDYzZGIyYzI2NzE1ZDE5Yzk4NjhfNy0yLTEtMS00NzgwMQ_d884f219-c4a3-4ba3-bb89-835c7c03d586"
      unitRef="usd">45595000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjBjNzE3MDFlYTllZDQ2M2RiMmMyNjcxNWQxOWM5ODY4L3RhYmxlcmFuZ2U6MGM3MTcwMWVhOWVkNDYzZGIyYzI2NzE1ZDE5Yzk4NjhfNy00LTEtMS00NzgwMQ_76fbc849-c149-4124-a482-7d6583f04214"
      unitRef="usd">40482000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfMTIzNA_84265cb1-bbf1-413f-ac36-c2627b3c2027">Property and equipment, net consisted of the following (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,749)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic9bf3392f031425891062f5e0f545ba6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjNjN2I3MWJjM2U2ODQ0ZTdhOTFjZjUwOGQ0YjFhOWEzL3RhYmxlcmFuZ2U6M2M3YjcxYmMzZTY4NDRlN2E5MWNmNTA4ZDRiMWE5YTNfMS0yLTEtMS00NzgwMQ_08e6b377-480b-4529-8dbb-5b230870cee7"
      unitRef="usd">7046000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i91ce62cbf8364228b4b121202d34470e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjNjN2I3MWJjM2U2ODQ0ZTdhOTFjZjUwOGQ0YjFhOWEzL3RhYmxlcmFuZ2U6M2M3YjcxYmMzZTY4NDRlN2E5MWNmNTA4ZDRiMWE5YTNfMS00LTEtMS00NzgwMQ_30643fa0-307c-4ce2-bd2f-3c68b75f2814"
      unitRef="usd">7174000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i51bfe79b4f7f4ddea8ca6aecd47c6748_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjNjN2I3MWJjM2U2ODQ0ZTdhOTFjZjUwOGQ0YjFhOWEzL3RhYmxlcmFuZ2U6M2M3YjcxYmMzZTY4NDRlN2E5MWNmNTA4ZDRiMWE5YTNfMi0yLTEtMS00NzgwMQ_9e5cd419-e847-4762-9e9f-093501b24e4b"
      unitRef="usd">22758000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5e78480ba6bd4f1d9d17749c899a126b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjNjN2I3MWJjM2U2ODQ0ZTdhOTFjZjUwOGQ0YjFhOWEzL3RhYmxlcmFuZ2U6M2M3YjcxYmMzZTY4NDRlN2E5MWNmNTA4ZDRiMWE5YTNfMi00LTEtMS00NzgwMQ_cc7d6e4f-b97b-4e63-b1c9-b536c6990e81"
      unitRef="usd">5719000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib8be187f821b4c40912a67590b98722f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjNjN2I3MWJjM2U2ODQ0ZTdhOTFjZjUwOGQ0YjFhOWEzL3RhYmxlcmFuZ2U6M2M3YjcxYmMzZTY4NDRlN2E5MWNmNTA4ZDRiMWE5YTNfMy0yLTEtMS00NzgwMQ_4394b75e-8ee1-4032-ac4e-27df6ac33da7"
      unitRef="usd">6497000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if48f37b3f1b94e6bb28d9642c03cb051_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjNjN2I3MWJjM2U2ODQ0ZTdhOTFjZjUwOGQ0YjFhOWEzL3RhYmxlcmFuZ2U6M2M3YjcxYmMzZTY4NDRlN2E5MWNmNTA4ZDRiMWE5YTNfMy00LTEtMS00NzgwMQ_3e5ba674-4d05-428a-a3f8-36903cbdcc0d"
      unitRef="usd">5370000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ifef082b6dbf1487f9b03c2077818edec_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjNjN2I3MWJjM2U2ODQ0ZTdhOTFjZjUwOGQ0YjFhOWEzL3RhYmxlcmFuZ2U6M2M3YjcxYmMzZTY4NDRlN2E5MWNmNTA4ZDRiMWE5YTNfNC0yLTEtMS00NzgwMQ_a5ef604e-1098-4cf6-9165-02e0ecb2310a"
      unitRef="usd">8816000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia927806080fd413c87442beab744f69b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjNjN2I3MWJjM2U2ODQ0ZTdhOTFjZjUwOGQ0YjFhOWEzL3RhYmxlcmFuZ2U6M2M3YjcxYmMzZTY4NDRlN2E5MWNmNTA4ZDRiMWE5YTNfNC00LTEtMS00NzgwMQ_14202db2-4005-4325-9da2-dcb62790549e"
      unitRef="usd">1628000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjNjN2I3MWJjM2U2ODQ0ZTdhOTFjZjUwOGQ0YjFhOWEzL3RhYmxlcmFuZ2U6M2M3YjcxYmMzZTY4NDRlN2E5MWNmNTA4ZDRiMWE5YTNfNS0yLTEtMS00NzgwMQ_b4b8e3ce-c23f-4d91-b0a3-1116333c67a3"
      unitRef="usd">45117000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjNjN2I3MWJjM2U2ODQ0ZTdhOTFjZjUwOGQ0YjFhOWEzL3RhYmxlcmFuZ2U6M2M3YjcxYmMzZTY4NDRlN2E5MWNmNTA4ZDRiMWE5YTNfNS00LTEtMS00NzgwMQ_cb7db1db-b454-4c32-8c9b-8dd97bbae858"
      unitRef="usd">19891000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjNjN2I3MWJjM2U2ODQ0ZTdhOTFjZjUwOGQ0YjFhOWEzL3RhYmxlcmFuZ2U6M2M3YjcxYmMzZTY4NDRlN2E5MWNmNTA4ZDRiMWE5YTNfNi0yLTEtMS00NzgwMQ_01ff37d4-e9a7-4910-9e7d-95bb3bccc2f4"
      unitRef="usd">13749000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjNjN2I3MWJjM2U2ODQ0ZTdhOTFjZjUwOGQ0YjFhOWEzL3RhYmxlcmFuZ2U6M2M3YjcxYmMzZTY4NDRlN2E5MWNmNTA4ZDRiMWE5YTNfNi00LTEtMS00NzgwMQ_69b80f3a-9b26-4eb3-a55d-f93b821981c9"
      unitRef="usd">13100000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjNjN2I3MWJjM2U2ODQ0ZTdhOTFjZjUwOGQ0YjFhOWEzL3RhYmxlcmFuZ2U6M2M3YjcxYmMzZTY4NDRlN2E5MWNmNTA4ZDRiMWE5YTNfNy0yLTEtMS00NzgwMQ_54b3558e-3823-47bd-bed8-927a5ae4be1d"
      unitRef="usd">31368000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjNjN2I3MWJjM2U2ODQ0ZTdhOTFjZjUwOGQ0YjFhOWEzL3RhYmxlcmFuZ2U6M2M3YjcxYmMzZTY4NDRlN2E5MWNmNTA4ZDRiMWE5YTNfNy00LTEtMS00NzgwMQ_54c751d9-429b-4d54-9f6b-790b8706bc4e"
      unitRef="usd">6791000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjNjN2I3MWJjM2U2ODQ0ZTdhOTFjZjUwOGQ0YjFhOWEzL3RhYmxlcmFuZ2U6M2M3YjcxYmMzZTY4NDRlN2E5MWNmNTA4ZDRiMWE5YTNfOC0yLTEtMS00NzgwMQ_51c0f714-2122-4504-b670-fa72857f7d86"
      unitRef="usd">5723000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjNjN2I3MWJjM2U2ODQ0ZTdhOTFjZjUwOGQ0YjFhOWEzL3RhYmxlcmFuZ2U6M2M3YjcxYmMzZTY4NDRlN2E5MWNmNTA4ZDRiMWE5YTNfOC00LTEtMS00NzgwMQ_6c2789b4-8783-461b-9fef-130ce55bbe7e"
      unitRef="usd">2003000</us-gaap:OperatingLeaseRightOfUseAsset>
    <halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjNjN2I3MWJjM2U2ODQ0ZTdhOTFjZjUwOGQ0YjFhOWEzL3RhYmxlcmFuZ2U6M2M3YjcxYmMzZTY4NDRlN2E5MWNmNTA4ZDRiMWE5YTNfOS0yLTEtMS00NzgwMQ_b7c43fe0-b894-401c-b2f1-5074b761685a"
      unitRef="usd">37091000</halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOjNjN2I3MWJjM2U2ODQ0ZTdhOTFjZjUwOGQ0YjFhOWEzL3RhYmxlcmFuZ2U6M2M3YjcxYmMzZTY4NDRlN2E5MWNmNTA4ZDRiMWE5YTNfOS00LTEtMS00NzgwMQ_5cb3f2c2-db87-46aa-9549-b89ce3799da5"
      unitRef="usd">8794000</halo:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfNjg2_3d49ae50-fa6f-458a-b4cf-fef27536e1a2"
      unitRef="usd">1100000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfNjkz_1077b454-3e39-487f-bb93-9552766f069f"
      unitRef="usd">800000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfNzM2_8730b509-c4ba-472b-83bf-cbc13dffa6fb"
      unitRef="usd">600000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfNzQz_6ef3b479-ef5c-4f23-a8b3-ebfcb6f05b9a"
      unitRef="usd">400000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfMTA5OTUxMTYyOTIwMw_a7616433-bd08-4022-b508-be1d8193e71f"
      unitRef="usd">1900000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfMTA5OTUxMTYyOTIxMQ_d8fc2c46-95a5-448f-a75e-3bec3b0a5293"
      unitRef="usd">1500000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfMTA5OTUxMTYyOTIxOQ_ac5b6132-12f2-44c8-a548-2315751146d7"
      unitRef="usd">1000000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfMTA5OTUxMTYyOTIyNw_791ba9a3-08f1-41f6-b4d7-6426b5a90d8a"
      unitRef="usd">800000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfMTIwMQ_4bc8c31f-c6d0-43f4-835a-282bad9c815e">&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and payroll taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued outsourced manufacturing expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product returns and sales allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less long-term portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,551)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(544)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total accrued expenses, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmE5MjEwMTIxM2U2NjRjOTZiNTRhYWE3OTZiZGFhMjIzL3RhYmxlcmFuZ2U6YTkyMTAxMjEzZTY2NGM5NmI1NGFhYTc5NmJkYWEyMjNfMi0yLTEtMS00NzgwMQ_1951e6f5-7e08-4f1f-a011-11baec51b5b2"
      unitRef="usd">15858000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmE5MjEwMTIxM2U2NjRjOTZiNTRhYWE3OTZiZGFhMjIzL3RhYmxlcmFuZ2U6YTkyMTAxMjEzZTY2NGM5NmI1NGFhYTc5NmJkYWEyMjNfMi00LTEtMS00NzgwMQ_fc9ee8f6-4d1e-41b2-ac2e-24474dd2ffdd"
      unitRef="usd">9858000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <halo:Accruedmanufacturingexpenses
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmE5MjEwMTIxM2U2NjRjOTZiNTRhYWE3OTZiZGFhMjIzL3RhYmxlcmFuZ2U6YTkyMTAxMjEzZTY2NGM5NmI1NGFhYTc5NmJkYWEyMjNfMy0yLTEtMS00NzgwMQ_e067e4b8-f56b-4541-beab-904e8a5a268f"
      unitRef="usd">6242000</halo:Accruedmanufacturingexpenses>
    <halo:Accruedmanufacturingexpenses
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmE5MjEwMTIxM2U2NjRjOTZiNTRhYWE3OTZiZGFhMjIzL3RhYmxlcmFuZ2U6YTkyMTAxMjEzZTY2NGM5NmI1NGFhYTc5NmJkYWEyMjNfMy00LTEtMS00NzgwMQ_04a63b30-e3fb-4015-9df7-e4d6688eeaad"
      unitRef="usd">6514000</halo:Accruedmanufacturingexpenses>
    <us-gaap:TaxesPayableCurrent
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmE5MjEwMTIxM2U2NjRjOTZiNTRhYWE3OTZiZGFhMjIzL3RhYmxlcmFuZ2U6YTkyMTAxMjEzZTY2NGM5NmI1NGFhYTc5NmJkYWEyMjNfNC0yLTEtMS01ODM4Mg_061668e1-8519-4720-9eb2-f6dcb9e8ad89"
      unitRef="usd">23036000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmE5MjEwMTIxM2U2NjRjOTZiNTRhYWE3OTZiZGFhMjIzL3RhYmxlcmFuZ2U6YTkyMTAxMjEzZTY2NGM5NmI1NGFhYTc5NmJkYWEyMjNfNC00LTEtMS01ODM4OQ_60d0128c-b9e9-470c-a805-b007fa0ee97d"
      unitRef="usd">1439000</us-gaap:TaxesPayableCurrent>
    <us-gaap:ContractWithCustomerRefundLiabilityCurrent
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmE5MjEwMTIxM2U2NjRjOTZiNTRhYWE3OTZiZGFhMjIzL3RhYmxlcmFuZ2U6YTkyMTAxMjEzZTY2NGM5NmI1NGFhYTc5NmJkYWEyMjNfNS0yLTEtMS01ODM4Mg_d56564c2-e932-4bbe-98dd-325b3f5e4b9d"
      unitRef="usd">21222000</us-gaap:ContractWithCustomerRefundLiabilityCurrent>
    <us-gaap:ContractWithCustomerRefundLiabilityCurrent
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmE5MjEwMTIxM2U2NjRjOTZiNTRhYWE3OTZiZGFhMjIzL3RhYmxlcmFuZ2U6YTkyMTAxMjEzZTY2NGM5NmI1NGFhYTc5NmJkYWEyMjNfNS00LTEtMS01ODM4OQ_f7b1db0e-9337-4488-bcf6-8dbc5b1f0079"
      unitRef="usd">706000</us-gaap:ContractWithCustomerRefundLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmE5MjEwMTIxM2U2NjRjOTZiNTRhYWE3OTZiZGFhMjIzL3RhYmxlcmFuZ2U6YTkyMTAxMjEzZTY2NGM5NmI1NGFhYTc5NmJkYWEyMjNfNC0yLTEtMS00NzgwMQ_634d1026-80d8-4178-b1ad-a57a6ec1568e"
      unitRef="usd">15506000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmE5MjEwMTIxM2U2NjRjOTZiNTRhYWE3OTZiZGFhMjIzL3RhYmxlcmFuZ2U6YTkyMTAxMjEzZTY2NGM5NmI1NGFhYTc5NmJkYWEyMjNfNC00LTEtMS00NzgwMQ_22aa9213-eb47-4721-b45c-d2299354dbd8"
      unitRef="usd">3648000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmE5MjEwMTIxM2U2NjRjOTZiNTRhYWE3OTZiZGFhMjIzL3RhYmxlcmFuZ2U6YTkyMTAxMjEzZTY2NGM5NmI1NGFhYTc5NmJkYWEyMjNfNS0yLTEtMS00NzgwMQ_f17554fc-2fd9-4136-a8f0-d8b196a3f184"
      unitRef="usd">7788000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmE5MjEwMTIxM2U2NjRjOTZiNTRhYWE3OTZiZGFhMjIzL3RhYmxlcmFuZ2U6YTkyMTAxMjEzZTY2NGM5NmI1NGFhYTc5NmJkYWEyMjNfNS00LTEtMS00NzgwMQ_8df2d951-46d3-47f0-b8d4-c65007896e70"
      unitRef="usd">2820000</us-gaap:OperatingLeaseLiability>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmE5MjEwMTIxM2U2NjRjOTZiNTRhYWE3OTZiZGFhMjIzL3RhYmxlcmFuZ2U6YTkyMTAxMjEzZTY2NGM5NmI1NGFhYTc5NmJkYWEyMjNfNi0yLTEtMS00NzgwMQ_9f5ee6c9-f9d9-41ee-b329-61c5e1b2efda"
      unitRef="usd">89652000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmE5MjEwMTIxM2U2NjRjOTZiNTRhYWE3OTZiZGFhMjIzL3RhYmxlcmFuZ2U6YTkyMTAxMjEzZTY2NGM5NmI1NGFhYTc5NmJkYWEyMjNfNi00LTEtMS00NzgwMQ_5148193a-b8b1-473e-a1f3-3fd402b6974d"
      unitRef="usd">24985000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <halo:AccruedLiabilitiesNoncurrent
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmE5MjEwMTIxM2U2NjRjOTZiNTRhYWE3OTZiZGFhMjIzL3RhYmxlcmFuZ2U6YTkyMTAxMjEzZTY2NGM5NmI1NGFhYTc5NmJkYWEyMjNfNy0yLTEtMS00NzgwMQ_013081f9-e35a-413a-aaba-78570fba3e63"
      unitRef="usd">5551000</halo:AccruedLiabilitiesNoncurrent>
    <halo:AccruedLiabilitiesNoncurrent
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmE5MjEwMTIxM2U2NjRjOTZiNTRhYWE3OTZiZGFhMjIzL3RhYmxlcmFuZ2U6YTkyMTAxMjEzZTY2NGM5NmI1NGFhYTc5NmJkYWEyMjNfNy00LTEtMS00NzgwMQ_f84d0996-3e7e-4461-9b13-32c9b2b09676"
      unitRef="usd">544000</halo:AccruedLiabilitiesNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmE5MjEwMTIxM2U2NjRjOTZiNTRhYWE3OTZiZGFhMjIzL3RhYmxlcmFuZ2U6YTkyMTAxMjEzZTY2NGM5NmI1NGFhYTc5NmJkYWEyMjNfOC0yLTEtMS00NzgwMQ_ab555280-f128-4a2e-a2a9-bd0a9767a9f7"
      unitRef="usd">84101000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RhYmxlOmE5MjEwMTIxM2U2NjRjOTZiNTRhYWE3OTZiZGFhMjIzL3RhYmxlcmFuZ2U6YTkyMTAxMjEzZTY2NGM5NmI1NGFhYTc5NmJkYWEyMjNfOC00LTEtMS00NzgwMQ_aa17db5a-08bd-482b-8a48-873f8ef070be"
      unitRef="usd">24441000</us-gaap:AccruedLiabilitiesCurrent>
    <halo:OperatingLeaseAccretionOfLiability
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfOTM4_c74e36bd-7a3a-4ed8-bc7b-653e8ab94595"
      unitRef="usd">100000</halo:OperatingLeaseAccretionOfLiability>
    <halo:OperatingLeaseAccretionOfLiability
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfOTQ1_ef514d56-9c06-4c3b-add6-02014294d9c2"
      unitRef="usd">100000</halo:OperatingLeaseAccretionOfLiability>
    <halo:OperatingLeaseAccretionOfLiability
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfMTY0OTI2NzQ0MzUxOQ_0ec52906-9f23-4950-b8a1-1cf8ab13e0e3"
      unitRef="usd">200000</halo:OperatingLeaseAccretionOfLiability>
    <halo:OperatingLeaseAccretionOfLiability
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfMTY0OTI2NzQ0MzUyNw_827d9ed3-7721-46c5-9123-08e7b10b42f6"
      unitRef="usd">200000</halo:OperatingLeaseAccretionOfLiability>
    <us-gaap:OperatingLeaseCost
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfMTA1NA_b4e8cdad-b3bc-4aad-aeea-561a4a57b51a"
      unitRef="usd">600000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfMTA2MQ_923b6f81-649e-46e5-9de3-4499b71a6aad"
      unitRef="usd">500000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfMTY0OTI2NzQ0MzU5NA_f9061add-81b3-4e7d-bfac-24f886cccf33"
      unitRef="usd">1100000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfMTY0OTI2NzQ0MzYwMg_164a7524-c612-4486-be50-526bcbf307bb"
      unitRef="usd">1000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfMTE1OA_b19d1d5f-290a-42d2-a5e5-5f2417d23746"
      unitRef="usd">900000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfMTE2NQ_ae5988a7-a412-4be4-bc20-3020dc1d07fe"
      unitRef="usd">700000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfMTA5OTUxMTYyOTUxNA_8df62f8e-1403-44fc-bff7-7aecfc7c986b"
      unitRef="usd">1600000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182MS9mcmFnOjA5M2FkMTA1NGJjZTQ2NGI5ZjUzZWI0MTc5MjI3NTYxL3RleHRyZWdpb246MDkzYWQxMDU0YmNlNDY0YjlmNTNlYjQxNzkyMjc1NjFfMTA5OTUxMTYyOTUyNg_cf6fcaa6-b74c-4a96-8e37-6ccc112c07a4"
      unitRef="usd">1400000</us-gaap:OperatingLeasePayments>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGV4dHJlZ2lvbjpmNGE2NmUyYTFjMTM0ODRkYWZiMjY1ZjFmODg5NWRiN18xOTI0MTQ1MzQ4NzcyMQ_7c8b0599-f6d7-4204-b36b-d543bdcea7c0">Goodwill and Intangible Assets&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 24, 2022, we acquired all outstanding equity interests of Antares Pharma, Inc. A Goodwill balance of $199.5&#160;million is recognized for the the excess of the consideration transferred over the net assets acquired and represents the expected revenue and cost synergies of the combined company and assembled workforce.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the activity impacting goodwill is presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our acquired intangible assets are amortized using the straight-line method over their estimated useful lives of seven to ten years. The following table shows the cost, accumulated amortization and weighted average life in years for our acquired intangible assets at June&#160;30, 2022 (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.118%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.993%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.993%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.998%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average remaining life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Auto Injector technology platform&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;XYOSTED proprietary product&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;TLANDO product rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total definite-lived intangibles, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;927,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;916,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ATRS-1902 (IPR&amp;amp;D)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Intangibles, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;976,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated future annual amortization of finite-lived intangible assets is shown in the following table. Actual amortization expense to be reported in future periods could differ from these estimates as a result of acquisitions, divestitures, and asset impairments, among other factors.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.010%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.029%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortization (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;916,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:Goodwill
      contextRef="i1e07b7230a7b4293910918c1158913a7_I20220524"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGV4dHJlZ2lvbjpmNGE2NmUyYTFjMTM0ODRkYWZiMjY1ZjFmODg5NWRiN18xOTI0MTQ1MzQ4ODc4NA_db6a7b9a-250f-46d3-8977-7c5943a81c2f"
      unitRef="usd">199500000</us-gaap:Goodwill>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGV4dHJlZ2lvbjpmNGE2NmUyYTFjMTM0ODRkYWZiMjY1ZjFmODg5NWRiN18xOTI0MTQ1MzQ4ODc5OQ_523e7c1d-584f-4d63-bba5-fc6dbb7e9dc3">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the activity impacting goodwill is presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6YjNiZTM4Y2E5ZTBmNDNiODliYjExNjJhOGIxMDc2NWMvdGFibGVyYW5nZTpiM2JlMzhjYTllMGY0M2I4OWJiMTE2MmE4YjEwNzY1Y18wLTItMS0xLTYwNTUy_9438fee0-6bdb-49e0-9065-e66208bac497"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6YjNiZTM4Y2E5ZTBmNDNiODliYjExNjJhOGIxMDc2NWMvdGFibGVyYW5nZTpiM2JlMzhjYTllMGY0M2I4OWJiMTE2MmE4YjEwNzY1Y18xLTItMS0xLTU2OTgz_c21b7a4b-d517-4f26-a8f6-1433e5409cb2"
      unitRef="usd">199481000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:Goodwill
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6YjNiZTM4Y2E5ZTBmNDNiODliYjExNjJhOGIxMDc2NWMvdGFibGVyYW5nZTpiM2JlMzhjYTllMGY0M2I4OWJiMTE2MmE4YjEwNzY1Y18yLTItMS0xLTYwNTU2_9e873ba6-14e8-49d6-a7ca-b1123f6eda3f"
      unitRef="usd">199481000</us-gaap:Goodwill>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGV4dHJlZ2lvbjpmNGE2NmUyYTFjMTM0ODRkYWZiMjY1ZjFmODg5NWRiN18xOTI0MTQ1MzQ4NzczMw_becd017a-04ff-4dac-98ef-8b16c2638504">The following table shows the cost, accumulated amortization and weighted average life in years for our acquired intangible assets at June&#160;30, 2022 (in thousands).&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.118%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.993%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.993%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.998%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average remaining life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Auto Injector technology platform&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;XYOSTED proprietary product&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;TLANDO product rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total definite-lived intangibles, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;927,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;916,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ATRS-1902 (IPR&amp;amp;D)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Intangibles, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;976,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ifb0dbd53c41e477d9ab6a6f8b2df947a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6OTJhZmRlNzJjMDMyNDJiZGJmYzIxNjJiNjhmMjZmMWEvdGFibGVyYW5nZTo5MmFmZGU3MmMwMzI0MmJkYmZjMjE2MmI2OGYyNmYxYV8xLTItMS0xLTYwNjAy_afb7d490-f97a-4a9d-b183-903cb26f8bba">P7Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i3e8b070a3aa646febf62fbbd0ae3ce5e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6OTJhZmRlNzJjMDMyNDJiZGJmYzIxNjJiNjhmMjZmMWEvdGFibGVyYW5nZTo5MmFmZGU3MmMwMzI0MmJkYmZjMjE2MmI2OGYyNmYxYV8xLTQtMS0xLTYwNTU5_5f4c4e96-ed18-4195-932c-19e361c68e43"
      unitRef="usd">372900000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i3e8b070a3aa646febf62fbbd0ae3ce5e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6OTJhZmRlNzJjMDMyNDJiZGJmYzIxNjJiNjhmMjZmMWEvdGFibGVyYW5nZTo5MmFmZGU3MmMwMzI0MmJkYmZjMjE2MmI2OGYyNmYxYV8xLTYtMS0xLTYwNTYw_6ea618d7-e2ef-40b8-8178-9d58009c6da1"
      unitRef="usd">5585000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i3e8b070a3aa646febf62fbbd0ae3ce5e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6OTJhZmRlNzJjMDMyNDJiZGJmYzIxNjJiNjhmMjZmMWEvdGFibGVyYW5nZTo5MmFmZGU3MmMwMzI0MmJkYmZjMjE2MmI2OGYyNmYxYV8xLTgtMS0xLTYwNTc3_599c5fab-4a25-4b33-8ec3-e3d23dfa16f8"
      unitRef="usd">367315000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ie6cf0130a2b443be99ea94b47e536125_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6OTJhZmRlNzJjMDMyNDJiZGJmYzIxNjJiNjhmMjZmMWEvdGFibGVyYW5nZTo5MmFmZGU3MmMwMzI0MmJkYmZjMjE2MmI2OGYyNmYxYV8yLTItMS0xLTYwNjAy_223292b7-2100-4213-8932-fb4b0e7d88ae">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="icd6500afde964db6843f15bf9ff223c9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6OTJhZmRlNzJjMDMyNDJiZGJmYzIxNjJiNjhmMjZmMWEvdGFibGVyYW5nZTo5MmFmZGU3MmMwMzI0MmJkYmZjMjE2MmI2OGYyNmYxYV8yLTQtMS0xLTYwNTU5_ea84ddc2-9536-4570-94f8-b4f4f6028307"
      unitRef="usd">277400000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="icd6500afde964db6843f15bf9ff223c9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6OTJhZmRlNzJjMDMyNDJiZGJmYzIxNjJiNjhmMjZmMWEvdGFibGVyYW5nZTo5MmFmZGU3MmMwMzI0MmJkYmZjMjE2MmI2OGYyNmYxYV8yLTYtMS0xLTYwNTYw_e266fc7d-3776-4299-b4ae-969f8871e5b7"
      unitRef="usd">2908000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="icd6500afde964db6843f15bf9ff223c9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6OTJhZmRlNzJjMDMyNDJiZGJmYzIxNjJiNjhmMjZmMWEvdGFibGVyYW5nZTo5MmFmZGU3MmMwMzI0MmJkYmZjMjE2MmI2OGYyNmYxYV8yLTgtMS0xLTYwNTc3_ab703757-b0f3-4acc-88db-f1eb264f4bb0"
      unitRef="usd">274492000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="idab608f91ce0499fb31e66934a3d01cd_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6OTJhZmRlNzJjMDMyNDJiZGJmYzIxNjJiNjhmMjZmMWEvdGFibGVyYW5nZTo5MmFmZGU3MmMwMzI0MmJkYmZjMjE2MmI2OGYyNmYxYV8zLTItMS0xLTYwNjAy_85227d31-03c8-4edc-b315-a886b968c5d8">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ib9cf38a8f67047f4b770a4b2f6f4c0c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6OTJhZmRlNzJjMDMyNDJiZGJmYzIxNjJiNjhmMjZmMWEvdGFibGVyYW5nZTo5MmFmZGU3MmMwMzI0MmJkYmZjMjE2MmI2OGYyNmYxYV8zLTQtMS0xLTYwNTU5_a83ab2fc-f058-4db8-a20d-e773c8fbb4c5"
      unitRef="usd">277600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib9cf38a8f67047f4b770a4b2f6f4c0c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6OTJhZmRlNzJjMDMyNDJiZGJmYzIxNjJiNjhmMjZmMWEvdGFibGVyYW5nZTo5MmFmZGU3MmMwMzI0MmJkYmZjMjE2MmI2OGYyNmYxYV8zLTYtMS0xLTYwNTYw_ea562b2d-68af-4aa7-83f3-be780bc00417"
      unitRef="usd">2910000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib9cf38a8f67047f4b770a4b2f6f4c0c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6OTJhZmRlNzJjMDMyNDJiZGJmYzIxNjJiNjhmMjZmMWEvdGFibGVyYW5nZTo5MmFmZGU3MmMwMzI0MmJkYmZjMjE2MmI2OGYyNmYxYV8zLTgtMS0xLTYwNTc3_afcbc8bd-8e4a-4136-afb9-cd5b0e694f7b"
      unitRef="usd">274690000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6OTJhZmRlNzJjMDMyNDJiZGJmYzIxNjJiNjhmMjZmMWEvdGFibGVyYW5nZTo5MmFmZGU3MmMwMzI0MmJkYmZjMjE2MmI2OGYyNmYxYV80LTQtMS0xLTYwNTU5_883d4461-af46-42b2-9514-f27caac08b32"
      unitRef="usd">927900000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6OTJhZmRlNzJjMDMyNDJiZGJmYzIxNjJiNjhmMjZmMWEvdGFibGVyYW5nZTo5MmFmZGU3MmMwMzI0MmJkYmZjMjE2MmI2OGYyNmYxYV80LTYtMS0xLTYwNTYw_316a0e5a-0861-4aba-bd84-1aded77beb28"
      unitRef="usd">11403000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6OTJhZmRlNzJjMDMyNDJiZGJmYzIxNjJiNjhmMjZmMWEvdGFibGVyYW5nZTo5MmFmZGU3MmMwMzI0MmJkYmZjMjE2MmI2OGYyNmYxYV80LTgtMS0xLTYwNTc3_3fe4f3e6-a030-4035-8bcd-220b7f37a383"
      unitRef="usd">916497000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6OTJhZmRlNzJjMDMyNDJiZGJmYzIxNjJiNjhmMjZmMWEvdGFibGVyYW5nZTo5MmFmZGU3MmMwMzI0MmJkYmZjMjE2MmI2OGYyNmYxYV81LTgtMS0xLTYwNTgy_e85fb20c-9899-4a05-886e-d42a9dd82aa3"
      unitRef="usd">59600000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6OTJhZmRlNzJjMDMyNDJiZGJmYzIxNjJiNjhmMjZmMWEvdGFibGVyYW5nZTo5MmFmZGU3MmMwMzI0MmJkYmZjMjE2MmI2OGYyNmYxYV82LTgtMS0xLTYwNTgy_bbb9e3a5-3bd8-45d9-b016-36b06f4b51d3"
      unitRef="usd">976097000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGV4dHJlZ2lvbjpmNGE2NmUyYTFjMTM0ODRkYWZiMjY1ZjFmODg5NWRiN18xOTI0MTQ1MzQ4NzczNA_e5db5c22-64db-422b-9100-dfbd926c3d8b">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated future annual amortization of finite-lived intangible assets is shown in the following table. Actual amortization expense to be reported in future periods could differ from these estimates as a result of acquisitions, divestitures, and asset impairments, among other factors.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.010%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.029%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortization (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;916,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6MDlmNjQ0ODk1MDEwNGY4NDk1MTgzMTNhNTNiYWE0YjEvdGFibGVyYW5nZTowOWY2NDQ4OTUwMTA0Zjg0OTUxODMxM2E1M2JhYTRiMV8xLTItMS0xLTYwNjA4_b2e626de-f58f-45ff-84c7-fe44cd7e81a1"
      unitRef="usd">54387000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6MDlmNjQ0ODk1MDEwNGY4NDk1MTgzMTNhNTNiYWE0YjEvdGFibGVyYW5nZTowOWY2NDQ4OTUwMTA0Zjg0OTUxODMxM2E1M2JhYTRiMV8yLTItMS0xLTYwNjA4_d8d3bd49-0aa5-4209-9069-24f3f6b8d3e0"
      unitRef="usd">108771000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6MDlmNjQ0ODk1MDEwNGY4NDk1MTgzMTNhNTNiYWE0YjEvdGFibGVyYW5nZTowOWY2NDQ4OTUwMTA0Zjg0OTUxODMxM2E1M2JhYTRiMV8zLTItMS0xLTYwNjA4_5dce2fda-fab4-449f-b8cd-7381272ce9db"
      unitRef="usd">108771000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6MDlmNjQ0ODk1MDEwNGY4NDk1MTgzMTNhNTNiYWE0YjEvdGFibGVyYW5nZTowOWY2NDQ4OTUwMTA0Zjg0OTUxODMxM2E1M2JhYTRiMV80LTItMS0xLTYwNjA4_7f456d6d-f53b-41d4-a9be-b6e7b109e803"
      unitRef="usd">108771000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6MDlmNjQ0ODk1MDEwNGY4NDk1MTgzMTNhNTNiYWE0YjEvdGFibGVyYW5nZTowOWY2NDQ4OTUwMTA0Zjg0OTUxODMxM2E1M2JhYTRiMV81LTItMS0xLTYwNjA4_4d5672e9-8799-404d-85d5-575eb2c6f2c9"
      unitRef="usd">108771000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <halo:FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6MDlmNjQ0ODk1MDEwNGY4NDk1MTgzMTNhNTNiYWE0YjEvdGFibGVyYW5nZTowOWY2NDQ4OTUwMTA0Zjg0OTUxODMxM2E1M2JhYTRiMV82LTItMS0xLTYwNjA4_9c9f8d08-ab82-4759-a44b-9776d6e3b671"
      unitRef="usd">427026000</halo:FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN18xMTgxL2ZyYWc6ZjRhNjZlMmExYzEzNDg0ZGFmYjI2NWYxZjg4OTVkYjcvdGFibGU6MDlmNjQ0ODk1MDEwNGY4NDk1MTgzMTNhNTNiYWE0YjEvdGFibGVyYW5nZTowOWY2NDQ4OTUwMTA0Zjg0OTUxODMxM2E1M2JhYTRiMV83LTItMS0xLTYwNjA4_d0b16955-94a7-4bea-975b-0911e171db8a"
      unitRef="usd">916497000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:LongTermDebtTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTkyNDE0NTM1MjE2MDU_9a87d1f3-dd35-49a4-8937-913d1ebaf3a6">Long-Term Debt, Net&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;0.25% Convertible Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021, we completed the sale of $805.0&#160;million in aggregate principal amount of 0.25% Convertible Senior Notes due 2027 (the &#x201c;2027 Convertible Notes&#x201d; and collectively with the 2024 Convertible Notes the &#x201c;Convertible Notes&#x201d;). The net proceeds in connection with the issuance of the 2027 Convertible Notes, after deducting the initial purchasers&#x2019; fee of $20.1&#160;million, was approximately $784.9&#160;million. We also incurred additional debt issuance costs totaling $0.4&#160;million. Debt issuance costs and the initial purchasers&#x2019; fee are presented as a debt discount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2027 Convertible Notes pay interest semi-annually in arrears on March 1st and September 1st of each year at an annual rate of 0.25%. The 2027 Convertible Notes are general unsecured obligations and will rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the 2027 Convertible Notes, will rank equally in right of payment with all existing and future liabilities that are not so subordinated, will be effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness and will be structurally subordinated to all indebtedness and other liabilities (including trade payables) of our current or future subsidiaries. The 2027 Convertible Notes have a maturity date of March 1, 2027.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders may convert their 2027 Convertible Notes at their option only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on June 30, 2021, if the last reported sale price per share of  common stock exceeds 130% of the conversion price for each of at least 20 trading days during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the five consecutive business days immediately after any five consecutive trading day period (such five consecutive trading day period, the &#x201c;measurement period&#x201d;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on our common stock, as described in the offering memorandum for the 2027 Convertible Notes; (4) if we call such notes for redemption; and (5) at any time from, and including, September 1, 2026 until the close of business on the scheduled trading day immediately before the maturity date. The Notes will be convertible, regardless of the foregoing circumstances, at any time from, and including, September 1, 2026 until the close of business on the scheduled trading day immediately preceding the maturity date. As of June&#160;30, 2022, the 2027 Convertible Notes are not convertible.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon conversion, we will pay cash for the settlement of principal and for the premium, if applicable, we will pay cash, deliver shares of common stock or a combination of cash and shares of common stock, at our election. The initial conversion rate for the 2027 Convertible Notes will be 12.9576 shares of common stock per $1,000 in principal amount of 2027 Convertible Notes, equivalent to a conversion price of approximately $77.17 per share of our common stock. The conversion rate is subject to adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, we were in compliance with all covenants and there was no material adverse change in our business, operations or financial condition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;1.25% Convertible Notes due 2024&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, we completed the sale of $460.0 million in aggregate principal amount of 1.25% Convertible Senior Notes due 2024 (&#x201c;2024 Convertible Notes&#x201d;). The net proceeds in connection with the 2024 Convertible Notes, after deducting  the initial purchasers&#x2019; fee of $12.7&#160;million, was approximately $447.3 million. We also incurred debt issuance cost totaling $0.3&#160;million. Debt issuance costs and the initial purchasers&#x2019; fee are presented as a debt discount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2024 Convertible Notes pay interest semi-annually in arrears on June 1st and December 1st of each year, beginning on June 1, 2020, at an annual rate of 1.25%. The 2024 Convertible Notes are general unsecured obligations and will rank senior in right of payment to all indebtedness that is expressly subordinated in right of payment to the 2024 Convertible Notes, will rank equally in right of payment with all existing and future liabilities that are not so subordinated, will be effectively junior to any secured indebtedness to the extent of the value of the assets securing such indebtedness and will be structurally subordinated to all indebtedness and other liabilities (including trade payables) of the our current or future subsidiaries. The 2024 Convertible Notes have a maturity date of December 1, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders may convert their 2024 Convertible Notes at their option only in the following circumstances: (1)&#160;during any calendar quarter commencing after the calendar quarter ending on March&#160;31, 2020, if the last reported sale price per share of common stock exceeds 130% of the conversion price for each of at least 20 trading days during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2)&#160;during the five consecutive business days immediately after any five consecutive trading day period (such five consecutive trading day period, the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;measurement period&#x201d;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day; (3)&#160;upon the occurrence of certain corporate events or distributions on our common stock, as described in the offering memorandum for the 2024 Convertible Notes; (4)&#160;if we call such notes for redemption; and (5)&#160;at any time from, and including, June&#160;1, 2024 until the close of business on the scheduled trading day immediately before the maturity date. As of June&#160;30, 2022, the 2024 Convertible Notes are convertible and are classified as a current liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021 we notified the note holders of our irrevocable election to settle the principal of the 2024 Convertible Notes in cash and for the premium, if applicable, to deliver shares of common stock. The conversion rate for the 2024 Convertible Notes will be 41.9208 shares of common stock per $1,000 in principal amount of 2024 Convertible Notes, equivalent to a conversion price of approximately $23.85 per share of our common stock. The conversion rate is subject to adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021, we completed a privately negotiated induced conversion of $369.1&#160;million principal amount of the 2024 Convertible Notes (&#x201c;Note Repurchases&#x201d; or the &#x201c;Induced Conversion&#x201d;). In connection with the Induced Conversion, we paid approximately $370.2&#160;million in cash, which includes principal and accrued interest, and issued approximately 9.08&#160;million shares of our common stock representing the intrinsic value based on the contractual conversion rate and incremental shares as an inducement for conversion. As a result of the Induced Conversion, we recorded $21.0 million in induced conversion expense which is included in Other income (expense) of the Condensed Consolidated Statements of Income in 2021. The induced conversion expense represents the fair value of the common stock issued upon conversion in excess of the common stock issuable under the original terms of the 2024 Convertible Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, we were in compliance with all covenants and there was no material adverse change in our business, operations or financial condition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Carrying Amounts of the Convertible Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount and fair value of our Convertible Notes were as follows as of the dates indicated (in thousands). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;895,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;895,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,517)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,055)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,745)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total unamortized debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,318)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,262)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying amount:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;788,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;787,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value based on trading levels (Level 2):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;711,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;718,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of outstanding notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;884,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining amortization per period of debt discount (in years):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of interest expense and the effective interest rates for each of our Convertible Notes for the periods shown (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.058%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.026%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;&#160;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Coupon Interest:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Coupon Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of debt discount:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amortization of debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective interest rates:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revolving Credit Facility (December 2021)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, we terminated that certain credit agreement entered into on December 23, 2021 with Bank of America and the other lenders party thereto (the &#x201c;2021 Credit Agreement&#x201d;) evidencing a revolving credit facility (the &#x201c;2021 Facility&#x201d;) that provided for secured revolving loans and letters of credit in an aggregate amount of up to $75.0&#160;million.  No proceeds from the 2021 Facility were drawn down as of the date the 2021 Credit Agreement was terminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revolving Credit and Term Loan Facilities (May 2022)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, in connection with the closing of Antares acquisition, we entered into a credit agreement with Bank of America, N.A., as Administrative Agent, Swing Line Lender and an L/C Issuer, and the other lenders and L/C Issuers party thereto (the &#x201c;2022 Credit Agreement), evidencing a credit facility (the &#x201c;2022 Facility&#x201d;) that provides for (i) a $350&#160;million revolving credit facility (the &#x201c;Revolving Credit Facility&#x201d;) and (ii) a $250&#160;million term loan facility (the &#x201c;Term Facility&#x201d;). The proceeds from a $120&#160;million draw on the Revolving Credit Facility and the $250&#160;million Term Facility were used to fund a portion of the Antares acquisition, pay off Antares&#x2019; existing debt and pay fees and expenses in connection with the acquisition. The 2022 Credit Agreement contains an expansion feature, which allows us, subject to certain conditions, to increase the aggregate principal amount of the 2022 Facility, provided we remain in compliance with underlying financial covenants on a pro forma basis including the consolidated interest coverage ratio and the consolidated net leverage ratio covenants set forth in the 2022 Credit Agreement. The 2022 Facility will mature on November 30, 2026 unless either the Revolving Credit Facility or the Term Facility is extended prior to such date in accordance with the 2022 Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Term Facility requires quarterly scheduled repayments of the term loans in each of the first, second, third and fourth years following the Closing in annual amounts equal to 2.50%, 5.00%, 7.50% and 10.00% of the initial principal amount of the term loans, respectively. The term loans are also subject to mandatory prepayments from the proceeds of certain asset sales, subject to our right to reinvest the proceeds thereof.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the 2022 Facility bear interest, at our option, at a rate equal to an applicable margin plus: (a) the applicable Term Secured Overnight Financing Rate (SOFR) (which includes a SOFR adjustment of 0.10%), or (b) a base rate determined by reference to the highest of (1) the federal funds effective rate plus 0.50%, (2) the Bank of America prime rate, (3) the Term SOFR rate for an interest period of one month plus 1.10%, and (4) 1.00%. The margin for the 2022 Facility ranges, based on our consolidated total net leverage ratio, from 0.25% to 1.25% in the case of base rate loans and from 1.25% to 2.25% &lt;/span&gt;&lt;/div&gt;in the case of Term SOFR rate loans. In addition to paying interest on the outstanding principal under the Facility, we will pay (i) a commitment fee in respect of the unutilized commitments thereunder and (ii) customary letter of credit fees and agency fees. The commitment fees range from 0.15% to 0.35% per annum based on our consolidated net leverage ratio. As of June&#160;30, 2022, we had $120.0&#160;million and $250&#160;million in principal amount of outstanding borrowings under the 2022 Revolving Credit Facility and the 2022 Term Facility, respectively. We incurred a total of $6.0&#160;million in third party costs related to the 2022 credit agreement and recorded $3.5&#160;million as the revolving credit facility debt issuance cost and $2.5&#160;million as the term loan debt issuance cost.  As of June&#160;30, 2022, the unamortized debt issuance cost related to the revolving credit facility and the term loan is $3.4 million and $2.4 million, respectively.</us-gaap:LongTermDebtTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i930ea774bf7d4904b46c5d6ce72d032d_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMjg_ebad1dd9-c335-4820-8647-83e56a1a14f0"
      unitRef="number">0.0025</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i930ea774bf7d4904b46c5d6ce72d032d_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfOTg_96b96655-0626-47c6-9309-81baa531945e"
      unitRef="usd">805000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i930ea774bf7d4904b46c5d6ce72d032d_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTM0_4c4e627a-9d51-4ed6-98da-7d98d2680561"
      unitRef="number">0.0025</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="i930ea774bf7d4904b46c5d6ce72d032d_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfNDAz_383c3094-ac67-4a8f-81b6-6cbfc5d15e9d"
      unitRef="usd">20100000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="ic0d782f4478a4d7ea80f060e128b6b7a_D20210301-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfNDI1_c5448208-2738-44cd-beac-c226dd161863"
      unitRef="usd">784900000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="idd66a9946d9840eba7c66b86f6e2fe5a_D20210301-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfNDg2_6a14f941-f4f7-461b-ae6c-7351d4b63db8"
      unitRef="usd">400000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i930ea774bf7d4904b46c5d6ce72d032d_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfNzA2_d3b719c5-5090-4bb0-a960-77dd1d7169bd"
      unitRef="number">0.0025</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="ifd4cd55303894cb1aa89a03028006576_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTYyMg_11e6129f-c649-46da-bdb6-0ce0cf69d87c"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="ifd4cd55303894cb1aa89a03028006576_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTY3MA_32f55a85-d76e-45c8-9b25-dc51d0613c06"
      unitRef="trading_day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="ifd4cd55303894cb1aa89a03028006576_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTY5Nw_0de4e68b-d0b3-4d66-a306-b47d8d289374"
      unitRef="trading_day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i9bc3be2ae627408894cf317b830d625e_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTgzNA_040e5b7a-b0f2-41bf-a1d9-3350e9cb0a4d"
      unitRef="trading_day">5</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i9bc3be2ae627408894cf317b830d625e_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTg4NQ_90983067-b5aa-4181-8ab8-ad67dbb7e2da"
      unitRef="trading_day">5</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i9bc3be2ae627408894cf317b830d625e_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTkyNQ_9c2b510c-8fe7-42de-9320-cc616ecf8066"
      unitRef="trading_day">5</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i9bc3be2ae627408894cf317b830d625e_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMjExMQ_7976c97a-3068-4bfd-afd6-49db6768a633"
      unitRef="number">0.98</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="idd66a9946d9840eba7c66b86f6e2fe5a_D20210301-20210331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMzE4Mw_1882bdbf-ca81-4ca8-8db0-0ec0070cc517"
      unitRef="number">12.9576</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i930ea774bf7d4904b46c5d6ce72d032d_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMzMxNw_de6da82c-ebaa-4343-ae04-b633572d84ec"
      unitRef="usdPerShare">77.17</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentCovenantCompliance
      contextRef="i79862e9f8f4240af943f624cdae37039_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMzQxNQ_4e8ccb92-810a-4ebc-8b04-6b3ef0356bfe">in compliance</us-gaap:DebtInstrumentCovenantCompliance>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i92d9886e9d374222a3d3959bf913fd55_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMzUzMQ_2833304e-0406-424b-9685-63f5c995b43c"
      unitRef="number">0.0125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i92d9886e9d374222a3d3959bf913fd55_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMzYwNA_4f45f50b-dd11-48bd-aae8-752bf2229a32"
      unitRef="usd">460000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i92d9886e9d374222a3d3959bf913fd55_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMzY0MA_e624539a-9553-40b4-8cb1-33e0bc564f2d"
      unitRef="number">0.0125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="i92d9886e9d374222a3d3959bf913fd55_I20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMzgxNw_691e920c-d886-439a-b519-f2882fa0763e"
      unitRef="usd">12700000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="iae83682afbfd42498583c6364b173a85_D20191101-20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMzgzOQ_ed256c8f-5399-4820-a965-735fda2ac31a"
      unitRef="usd">447300000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i9dffca0ebc3943fe8411a72b02312868_D20191101-20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMzg4OA_13858194-e305-4620-8c0e-52f97809b6b6"
      unitRef="usd">300000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i92d9886e9d374222a3d3959bf913fd55_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfNDEzNA_75c6aa7d-e6cf-44de-941e-6768079753dd"
      unitRef="number">0.0125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i564c0f73ae6841618d8d0305f3c128f2_D20191101-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfNTA1Nw_cde2ee08-f101-4b41-bc9f-5e987aec8d11"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i564c0f73ae6841618d8d0305f3c128f2_D20191101-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfNTEwNQ_4be6c316-520d-4854-bc9a-20fd4027a88d"
      unitRef="trading_day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i564c0f73ae6841618d8d0305f3c128f2_D20191101-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfNTEzMg_ac022122-205a-4098-bc02-228f07b04255"
      unitRef="trading_day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="ibc9e7ea69dc54bc580f0327b080e6620_D20191101-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfNTI2OQ_a46ea2df-d8f8-46e9-abea-a5d81d8db758"
      unitRef="trading_day">5</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="ibc9e7ea69dc54bc580f0327b080e6620_D20191101-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfNTMyMA_beb75265-b7ab-4df5-84d0-d00416ca9a66"
      unitRef="trading_day">5</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="ibc9e7ea69dc54bc580f0327b080e6620_D20191101-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfNTM2MA_7fcd8cdd-b780-4119-be35-d0aa159747d5"
      unitRef="trading_day">5</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="ibc9e7ea69dc54bc580f0327b080e6620_D20191101-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfNTU0Ng_34ebb931-d8e8-4ca2-afe8-952b3ac18fec"
      unitRef="number">0.98</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i9dffca0ebc3943fe8411a72b02312868_D20191101-20191130"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfNjQwNQ_285e2111-cef2-44e7-8f09-79133dc1ef9c"
      unitRef="number">41.9208</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i92d9886e9d374222a3d3959bf913fd55_I20191130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfNjUzOQ_fb49103c-ada5-43d8-9bf7-b2ecf81033b0"
      unitRef="usdPerShare">23.85</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="i522b480a4e0c413cbd63f8e8b3903d03_D20210301-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfNjY5Mg_208da09e-9bde-4206-8635-5b763ed839d8"
      unitRef="usd">369100000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i522b480a4e0c413cbd63f8e8b3903d03_D20210301-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfNjg1Nw_9a18b78c-2dcb-4e71-a72b-ec498b03387a"
      unitRef="usd">370200000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i522b480a4e0c413cbd63f8e8b3903d03_D20210301-20210331"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfNjk0MQ_eae5039b-354e-4b02-bca4-a240bd5efcf5"
      unitRef="shares">9080000.00</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:InducedConversionOfConvertibleDebtExpense
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfNzE1Mg_d78736b9-9362-4b9c-804e-22718cee8f73"
      unitRef="usd">21000000</us-gaap:InducedConversionOfConvertibleDebtExpense>
    <us-gaap:InducedConversionOfConvertibleDebtExpense
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfNzE1Mg_dc8c860a-b215-41bd-9cbf-e42959636509"
      unitRef="usd">21000000</us-gaap:InducedConversionOfConvertibleDebtExpense>
    <us-gaap:DebtInstrumentCovenantCompliance
      contextRef="i79862e9f8f4240af943f624cdae37039_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfOTY5Mg_4e8ccb92-810a-4ebc-8b04-6b3ef0356bfe">in compliance</us-gaap:DebtInstrumentCovenantCompliance>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfOTY5OQ_a491ce9a-65c8-49c2-a731-af9db19325b7">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Carrying Amounts of the Convertible Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount and fair value of our Convertible Notes were as follows as of the dates indicated (in thousands). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;895,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;895,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,517)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,055)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,745)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total unamortized debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,318)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,262)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying amount:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;788,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;787,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value based on trading levels (Level 2):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;711,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;718,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of outstanding notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;884,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining amortization per period of debt discount (in years):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i7db32790c0274f1b85142a533eef25ea_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfMi0yLTEtMS00NzgwMQ_f954abf4-c775-461b-adee-eb3003e8ad1d"
      unitRef="usd">90936000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ie4bc8fa5f8b24012aff99c9e405c3c38_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfMi00LTEtMS00NzgwMQ_90206761-6e26-4a42-a4fc-5bc39615ecbb"
      unitRef="usd">90936000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ia71fa90d90d249b2826bd60cb35507b5_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfMy0yLTEtMS00NzgwMQ_4e6d3060-846a-48a7-b3ad-81d9e879b45f"
      unitRef="usd">805000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ifb771b640f1343b39c99c088eeaa56cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfMy00LTEtMS00NzgwMQ_f09ba1bd-1477-4104-8348-d66ffb329f45"
      unitRef="usd">805000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfNC0yLTEtMS00NzgwMQ_c932a86c-ec32-4c7a-bbff-dcfd48ab9faf"
      unitRef="usd">895936000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfNC00LTEtMS00NzgwMQ_ba532d80-464f-4c67-8960-77c5c83ad095"
      unitRef="usd">895936000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i7db32790c0274f1b85142a533eef25ea_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfNy0yLTEtMS00NzgwMQ_1758ca9d-3b7d-4696-a8f3-74fd445ff33e"
      unitRef="usd">1263000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="ie4bc8fa5f8b24012aff99c9e405c3c38_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfNy00LTEtMS00NzgwMQ_af014d4b-72c2-4e5e-b811-b1a3baf3f187"
      unitRef="usd">1517000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="ia71fa90d90d249b2826bd60cb35507b5_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfOC0yLTEtMS00NzgwMQ_02880d70-55f2-4017-8e08-1c4676024bd4"
      unitRef="usd">16055000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="ifb771b640f1343b39c99c088eeaa56cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfOC00LTEtMS00NzgwMQ_4147560b-dcc5-4450-b0d2-28a77c1a887c"
      unitRef="usd">17745000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfOS0yLTEtMS00NzgwMQ_6d1e1edf-ac80-43ac-a79f-abeed7f04c8d"
      unitRef="usd">17318000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfOS00LTEtMS00NzgwMQ_ec8ce63d-40f1-442c-807b-1251733ad072"
      unitRef="usd">19262000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebtCurrent
      contextRef="i7db32790c0274f1b85142a533eef25ea_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfMTItMi0xLTEtNDc4MDE_99c29c6b-1302-4725-b02f-df71e74c18ee"
      unitRef="usd">89673000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ie4bc8fa5f8b24012aff99c9e405c3c38_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfMTItNC0xLTEtNDc4MDE_cd0c7e9e-f7f7-4dc1-8c22-18df519208fe"
      unitRef="usd">89419000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebt
      contextRef="ia71fa90d90d249b2826bd60cb35507b5_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfMTMtMi0xLTEtNDc4MDE_e46ccf8c-2b42-4786-8e59-530c4ee0d296"
      unitRef="usd">788945000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ifb771b640f1343b39c99c088eeaa56cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfMTMtNC0xLTEtNDc4MDE_6f35b905-bb6a-48d0-9617-ae3887efdcdc"
      unitRef="usd">787255000</us-gaap:LongTermDebt>
    <us-gaap:ConvertibleNotesPayable
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfMTQtMi0xLTEtNDc4MDE_89aabfa8-72e6-468c-ab70-261937fa5268"
      unitRef="usd">878618000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfMTQtNC0xLTEtNDc4MDE_2674653a-d215-41ed-9f7d-46f49d5ffcea"
      unitRef="usd">876674000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i7db32790c0274f1b85142a533eef25ea_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfMTctMi0xLTEtNDc4MDE_2f982da6-6fbe-4f10-8e95-9b9a8d69458a"
      unitRef="usd">172743000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ie4bc8fa5f8b24012aff99c9e405c3c38_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfMTctNC0xLTEtNDc4MDE_7a471da7-1921-4cb0-8241-3a150339ef7e"
      unitRef="usd">159678000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ia71fa90d90d249b2826bd60cb35507b5_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfMTgtMi0xLTEtNDc4MDE_badae77e-abdd-4e0e-a258-5e3d6c30e7e3"
      unitRef="usd">711660000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ifb771b640f1343b39c99c088eeaa56cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfMTgtNC0xLTEtNDc4MDE_55426922-88ea-458a-8b03-f3d8fa3fc10d"
      unitRef="usd">718889000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ia8f041b537984ded88384fd5745e75e2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfMTktMi0xLTEtNDc4MDE_bd5343ff-61d8-475d-8423-d5d4677e4718"
      unitRef="usd">884403000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfMTktNC0xLTEtNDc4MDE_787617e3-434b-4f19-9e82-cc7c78f446af"
      unitRef="usd">878567000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="i0b4b3f5b65f748fea9d3a16a4370a81e_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfMjItMi0xLTEtNDc4MDE_9deb6103-c923-404c-ad5b-1edd532359fb">P2Y4M24D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="i9dac37b234cb4e39aa59635df2320abd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfMjItNC0xLTEtNDc4MDE_edc7fef6-998e-4d3c-b39d-be71e49fe0fb">P2Y10M24D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="i3f9a5cd5449946e383c3e70f8ef08350_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfMjMtMi0xLTEtNDc4MDE_132d61e1-04a5-46f6-a5a6-f3d599ee384f">P4Y8M12D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="iac94068bcee94ca094f560cb73997234_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOmM4OGY5MTk1ZWFhMzRiNjBhMGExOWQwZDJmYTFjZDgzL3RhYmxlcmFuZ2U6Yzg4ZjkxOTVlYWEzNGI2MGEwYTE5ZDBkMmZhMWNkODNfMjMtNC0xLTEtNDc4MDE_e3a2cc0a-9e3a-4691-af4c-877d7ee384aa">P5Y2M12D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfOTcwMA_83be3301-bb5d-402b-b26d-aebf8ab41563">&lt;div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of interest expense and the effective interest rates for each of our Convertible Notes for the periods shown (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.058%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.026%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;&#160;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Coupon Interest:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Coupon Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of debt discount:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total amortization of debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective interest rates:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest
      contextRef="i50e1360e4c7b4de39282c845c5d73c43_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMy0yLTEtMS00NzgwMQ_d9cc934b-a828-4704-925a-e336e92b004f"
      unitRef="usd">284000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest
      contextRef="i765e5eeb91e54b43b5f00f6ebddec276_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMy00LTEtMS00NzgwMQ_c09d3d23-df8f-42cf-a28e-df0e07cfa44c"
      unitRef="usd">284000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest
      contextRef="i421730450b74464b90e09befbd503cfc_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMy02LTEtMS00NzgwMQ_45e64819-71f6-4c82-94b9-5d78e11e2ffd"
      unitRef="usd">568000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest
      contextRef="i9858e2352550465683b249270d6735a6_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMy04LTEtMS00NzgwMQ_54c5490e-ccca-4c78-9895-a9c81b85cf45"
      unitRef="usd">1337000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest
      contextRef="i5021845805034e388a208b835a6c92c0_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfNC0yLTEtMS00NzgwMQ_22e13ad6-42e8-49df-8449-fea3ec2dc0c2"
      unitRef="usd">503000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest
      contextRef="i9ec81c8774a34665930c2c67a277cbbf_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfNC00LTEtMS00NzgwMQ_228d8fc8-23c6-4877-ace6-668b738251b3"
      unitRef="usd">503000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest
      contextRef="i00e19a2b430241ed99f4d4d16ef7f9d0_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfNC02LTEtMS00NzgwMQ_4f095f85-8d0c-4e72-acaa-ddbe0c159ca9"
      unitRef="usd">1006000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest
      contextRef="ifd0b274a39124464a2f81ffe163b7216_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfNC04LTEtMS00NzgwMQ_e7670bf6-223d-42f4-b555-4b7b9cdcc85d"
      unitRef="usd">671000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest
      contextRef="ib06303cf7360468aad8efb6d193ac2e0_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfNS0yLTEtMS00NzgwMQ_d68fee5d-3d9f-4223-9cfd-ccb9cdb12d72"
      unitRef="usd">787000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest
      contextRef="idf400d7ec4c1409c979f5a18ed50eed6_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfNS00LTEtMS00NzgwMQ_ee78461c-de74-4023-8334-8d9fca792528"
      unitRef="usd">787000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest
      contextRef="i4c76ed9108314a75b3e7842e7f8460ec_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfNS02LTEtMS00NzgwMQ_8d7a1c53-97ba-4926-98fe-f011096c2a56"
      unitRef="usd">1574000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest
      contextRef="i0d86d5b0f18546fa82fc1f13b48c7daa_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfNS04LTEtMS00NzgwMQ_c7462e19-25be-42b7-96f3-e9bae86aa477"
      unitRef="usd">2008000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i50e1360e4c7b4de39282c845c5d73c43_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfOC0yLTEtMS00NzgwMQ_8b5f7cb8-13a3-4b8a-8516-c5dddc9762fa"
      unitRef="usd">127000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i765e5eeb91e54b43b5f00f6ebddec276_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfOC00LTEtMS00NzgwMQ_ca06170a-1863-4f68-ba4b-03c1dc5529aa"
      unitRef="usd">125000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i421730450b74464b90e09befbd503cfc_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfOC02LTEtMS00NzgwMQ_c4e79744-4afe-4598-8439-170c5b9a91a1"
      unitRef="usd">254000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i9858e2352550465683b249270d6735a6_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfOC04LTEtMS00NzgwMQ_8f3dec83-edd7-496d-8b6b-9e80c22cf191"
      unitRef="usd">586000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i5021845805034e388a208b835a6c92c0_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfOS0yLTEtMS00NzgwMQ_b2461e60-934d-47ce-ac51-f97e878aa5b7"
      unitRef="usd">846000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i9ec81c8774a34665930c2c67a277cbbf_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfOS00LTEtMS00NzgwMQ_0cd2278c-7141-4190-96bd-74adda88d90d"
      unitRef="usd">840000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i00e19a2b430241ed99f4d4d16ef7f9d0_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfOS02LTEtMS00NzgwMQ_4c634fb2-20e6-422c-924e-fdc5f721570e"
      unitRef="usd">1690000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="ifd0b274a39124464a2f81ffe163b7216_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfOS04LTEtMS00NzgwMQ_8b25fcc7-9dcc-4f92-92bf-e8bdb3c1f865"
      unitRef="usd">1120000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="ib06303cf7360468aad8efb6d193ac2e0_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTAtMi0xLTEtNDc4MDE_cce10154-cf2c-42ef-9c75-eea5531edfbc"
      unitRef="usd">973000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="idf400d7ec4c1409c979f5a18ed50eed6_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTAtNC0xLTEtNDc4MDE_e428c37d-53a1-4c09-86f4-5c3582443d2b"
      unitRef="usd">965000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i4c76ed9108314a75b3e7842e7f8460ec_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTAtNi0xLTEtNDc4MDE_48b6b49f-1a66-4b94-8e31-b47f0f9a41b4"
      unitRef="usd">1944000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i0d86d5b0f18546fa82fc1f13b48c7daa_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTAtOC0xLTEtNDc4MDE_836e9144-e16b-47f9-9dba-ffd93d115e58"
      unitRef="usd">1706000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestExpenseDebt
      contextRef="i50e1360e4c7b4de39282c845c5d73c43_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTMtMi0xLTEtNDc4MDE_38578a75-1525-40f3-a5a1-50aa66e6afeb"
      unitRef="usd">411000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i765e5eeb91e54b43b5f00f6ebddec276_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTMtNC0xLTEtNDc4MDE_98003f57-7440-4456-9665-37c782909cfc"
      unitRef="usd">409000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i421730450b74464b90e09befbd503cfc_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTMtNi0xLTEtNDc4MDE_d4ffce28-1b71-4fc2-a483-e7c439b8a40b"
      unitRef="usd">822000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i9858e2352550465683b249270d6735a6_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTMtOC0xLTEtNDc4MDE_4eba4186-a9ce-4485-a71e-7e2babcfcc83"
      unitRef="usd">1923000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i5021845805034e388a208b835a6c92c0_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTQtMi0xLTEtNDc4MDE_4cef0b1e-5d46-4cf7-82fc-bda55260fc82"
      unitRef="usd">1349000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i9ec81c8774a34665930c2c67a277cbbf_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTQtNC0xLTEtNDc4MDE_b018843f-a36d-4f31-b9b6-efbd07a84ca9"
      unitRef="usd">1343000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i00e19a2b430241ed99f4d4d16ef7f9d0_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTQtNi0xLTEtNDc4MDE_653dc124-ee63-4920-bf1c-ad7a170fe421"
      unitRef="usd">2696000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ifd0b274a39124464a2f81ffe163b7216_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTQtOC0xLTEtNDc4MDE_1cb68d67-07c4-4475-9800-e7b1182a721a"
      unitRef="usd">1791000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ib06303cf7360468aad8efb6d193ac2e0_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTUtMi0xLTEtNDc4MDE_feb3f70c-790d-45c1-ad25-c205884d81c2"
      unitRef="usd">1760000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="idf400d7ec4c1409c979f5a18ed50eed6_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTUtNC0xLTEtNDc4MDE_f9ff79a5-4222-4bd7-ab66-2eca66c2a897"
      unitRef="usd">1752000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i4c76ed9108314a75b3e7842e7f8460ec_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTUtNi0xLTEtNDc4MDE_3c008a13-e2ed-44f6-a864-9195eff2fec2"
      unitRef="usd">3518000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i0d86d5b0f18546fa82fc1f13b48c7daa_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTUtOC0xLTEtNDc4MDE_2916924b-8fb0-4f84-b353-03723397afe7"
      unitRef="usd">3714000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i78253359e5ad475094259801bb6c9cca_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTgtMi0xLTEtNDc4MDE_db68cccb-f132-4cc2-b6ba-016382382f81"
      unitRef="number">0.018</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i87582d2ecc124f6db85794fe5ea82eb5_I20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTgtNC0xLTEtNDc4MDE_84ffcb5a-8319-4cdb-bf54-f7b89a386139"
      unitRef="number">0.018</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i78253359e5ad475094259801bb6c9cca_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTgtNi0xLTEtNDc4MDE_b0d0cad6-6285-4ade-99a9-cbb7e95c0533"
      unitRef="number">0.018</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i87582d2ecc124f6db85794fe5ea82eb5_I20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTgtOC0xLTEtNDc4MDE_f42a66ef-d3f1-4ab6-97dc-6c08431615be"
      unitRef="number">0.018</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i904690f836a44521b7c1da764f701566_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTktMi0xLTEtNDc4MDE_089aab27-026d-412e-bb50-2939c0725f81"
      unitRef="number">0.007</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ia588495e94d64915826033625b6cae2d_I20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTktNC0xLTEtNDc4MDE_5d7923ed-ea9c-4f4e-9ceb-f14b6221b2b7"
      unitRef="number">0.007</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i904690f836a44521b7c1da764f701566_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTktNi0xLTEtNDc4MDE_3f4963f3-f5ca-4e1d-98f7-d98e1e8f5be4"
      unitRef="number">0.007</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ia588495e94d64915826033625b6cae2d_I20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RhYmxlOjA0OWM5YTE5NzQ4ODRjN2VhNmFjZWI0ZTg5YTljNjc5L3RhYmxlcmFuZ2U6MDQ5YzlhMTk3NDg4NGM3ZWE2YWNlYjRlODlhOWM2NzlfMTktOC0xLTEtNjI1NjI_1808250e-9014-4f61-9cb1-0fda51e43d1d"
      unitRef="number">0.007</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i09b74f6ef1644d8e930a5c4759e82823_I20220531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1Nzc4Mw_8f80be4d-b5b8-414f-a0bd-1156ffff7fdd"
      unitRef="usd">75000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ib607a4df5a844d5ebe887a6e5e01a915_I20220524"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1Nzc5OA_68427f7e-decd-4a1d-a39c-036190203c71"
      unitRef="usd">350000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i5bbab44d4d5c4f71b7e66b61049265a3_I20220524"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1NzgxMg_4975ae03-3c21-4ed6-857b-d093d797b5c1"
      unitRef="usd">250000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="ie899756b47294e60987e6e1a4eefdc3e_D20220524-20220524"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1NzgyNg_8667bf6b-955e-427f-a369-9cf3899d0541"
      unitRef="usd">120000000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="ibb0fc522997c467cbcef1d255211f031_D20220524-20220524"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1Nzg0MA_1bda7534-84e7-471a-bcbb-5f3d65765c4c"
      unitRef="usd">250000000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i02f9ba7cd53c4aa2923afca3b66da448_I20220524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1Nzg1NA_d0ef17e7-bda9-4a71-9e82-3622ddc1b474"
      unitRef="number">0.0250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib893c55155b64b2d9ba4c8642f2c3120_I20220524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1Nzg2MQ_4969d246-d589-4c57-9aaf-0829bd46e4a8"
      unitRef="number">0.0500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2d84d81913354102bacd27bce79cae8a_I20220524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1Nzg2OA_c30fcc06-9df0-41c6-bcbd-3ef37c116614"
      unitRef="number">0.0750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib5959be9d203461f9800ee2d21d52824_I20220524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1Nzg3NQ_116c2953-dcec-4798-94f1-8a543f46df37"
      unitRef="number">0.1000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="icd07e3cd9dc54a55ac0339e3aa933aa6_D20220524-20220524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1Nzg4Mw_5352f057-50a7-4486-92c4-ef0716f029be"
      unitRef="number">0.0010</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i39c021912c0a4737966b6fc9307a0131_D20220524-20220524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1Nzg5Nw_d1a820e3-e49c-444c-a49f-0c1c2f0cf69b"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i3b5fd9edb8e049a19ff19cafcd90c13b_D20220524-20220524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1Nzg5MA_d368326b-ae53-496a-ac0d-4650f7c214e6"
      unitRef="number">0.0110</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ia986ec6d3c6d41d2a6808a4f5cfcff5c_D20220524-20220524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1NzkwNA_3517e304-8c55-4d2d-b781-d0957d61abf0"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i1dce68f7e11a4d3a8fa7baa2b614c2aa_D20220524-20220524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1NzkxMQ_48141653-bfbc-4232-a66f-a782acd5093c"
      unitRef="number">0.0025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i3809e60efe0d46cab0ef2132238b94c8_D20220524-20220524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1NzkxOA_826751a4-3cd1-402b-b1e5-905e76858a0d"
      unitRef="number">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i64eaeaec62e1494894adad24d117aef9_D20220524-20220524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1NzkyNQ_0b1361aa-55b1-405d-a8d1-b4a8b580d1c4"
      unitRef="number">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i71fba559ee5e40e6895e295b7e58d09a_D20220524-20220524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1NzkzMg_5dd21d7c-daab-4e05-9e27-db807892295c"
      unitRef="number">0.0225</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i10a6ebe671434acfac51d92f04f6b880_D20220524-20220524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1NzkzOQ_46cd527d-9d03-4840-accf-d934e50b8e0b"
      unitRef="number">0.0015</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="ia1a876b10c4244179ee15979f3e64628_D20220524-20220524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1Nzk0Ng_083a1de4-12d4-4b09-b804-a351fe3a733f"
      unitRef="number">0.0035</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i79fb023f35cc4ee996ea4cb525c92c5f_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1NzEyNw_92cfb4de-21b0-424e-b51a-b111dbb469c1"
      unitRef="usd">120000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="icac5073a8dfa4150a03fa81e7c9db6f9_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1NzE0Mw_1e542eda-54bd-42a4-9a32-a9c31e8d60af"
      unitRef="usd">250000000</us-gaap:DebtInstrumentCarryingAmount>
    <halo:DebtInstrumentThirdPartyCosts
      contextRef="i475bb2a82ae54a4286363422e755c916_D20220524-20220524"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1NzYzMA_ddd7c029-25d5-424c-b307-3c904b2c4dc3"
      unitRef="usd">6000000</halo:DebtInstrumentThirdPartyCosts>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="ib607a4df5a844d5ebe887a6e5e01a915_I20220524"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1NzY1MQ_432f10af-2d31-4646-9a5c-6a3f9428bf88"
      unitRef="usd">3500000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i5bbab44d4d5c4f71b7e66b61049265a3_I20220524"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1NzY2OQ_3038becc-251d-4ae4-abe3-4ddd84752ff8"
      unitRef="usd">2500000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i79fb023f35cc4ee996ea4cb525c92c5f_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1NzY4Nw_29f0c9f3-e29b-4312-a79a-1f861ea30416"
      unitRef="usd">3400000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="icac5073a8dfa4150a03fa81e7c9db6f9_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182NC9mcmFnOjViYzllZDkxYjhlZTQ5ZTI5ZGJmOWY0OTRjYzg3MWFiL3RleHRyZWdpb246NWJjOWVkOTFiOGVlNDllMjlkYmY5ZjQ5NGNjODcxYWJfMTA5OTUxMTY1NzcwMg_59757ebc-a9a3-4fd6-aae4-53877008c00f"
      unitRef="usd">2400000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RleHRyZWdpb246YTk0M2RlMDBjM2NhNDYzNGJmNGNkYTc3YjUyMzkzZThfMjM5MA_fa301b3a-733c-4da6-b3ed-7a72eb251d25">Share-based Compensation&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total share-based compensation expense related to share-based awards excluding the acceleration of Antares unvested equity awards&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was comprised of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.959%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.912%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;&#160;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation expense by type of share-based award (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;&#160;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSAs, RSUs, PSUs and ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We granted stock options to purchase approximately 0.2 million and 36.3 thousand shares of common stock during the three months ended June&#160;30, 2022 and 2021, respectively and 1.5 million and 0.7 million shares of common stock during the six months ended June&#160;30, 2022 and 2021, respectively. The exercise price of stock options granted is equal to the closing price of the common stock on the date of grant. The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model (&#x201c;Black-Scholes model&#x201d;). Expected volatility is based on historical volatility of our common stock. The expected term of options granted is based on analyses of historical employee termination rates and option exercises. The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The dividend yield assumption is based on the expectation of no future dividend payments. The assumptions used in the Black-Scholes model were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.817%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;&#160;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.05-41.29%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.91-44.91%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.05-41.29%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.91%-46.45%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.56-3.01%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.81-0.81%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.37-3.01%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.36%-0.81%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, our Board of Directors approved our 2021 ESPP and our stockholders approved the plan in May 2021. The ESPP enables eligible employees to purchase shares of our common stock at the end of each offering period at a price equal to 85% of the fair market value of the shares on the first business day or the last business day of the offering period, whichever is lower. Share purchases are funded through payroll deduction of at least 1% and up to 15% of an employee&#x2019;s compensation for each payroll period, and no employee may purchase shares under the ESPP that exceeds $25,000 worth of our common stock for a calendar year. As of June&#160;30, 2022, 2,665,369 shares were available for future purchase. The offering period is generally for a six-months period and the first offering period commenced on June 16, 2021. Offering periods shall commence on or about the sixteenth day of June and December of each year and end on or about the fifteenth day of the next December and June respectively, occurring thereafter. During the three months ended June&#160;30, 2022, 16,858  shares were issued pursuant to the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total unrecognized estimated compensation cost by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrecognized&lt;br/&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remaining&lt;br/&gt;Weighted-Average&lt;br/&gt;Recognition Period&lt;br/&gt;(years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.81&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.82&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.41&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.46&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RleHRyZWdpb246YTk0M2RlMDBjM2NhNDYzNGJmNGNkYTc3YjUyMzkzZThfMjQwMQ_334abf7a-3f58-40a2-976e-80e833f8e55c">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total share-based compensation expense related to share-based awards excluding the acceleration of Antares unvested equity awards&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was comprised of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.959%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.912%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;&#160;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0b599c875f4f40e294c8d28f8eb1e582_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjQyNDY3NDM2NTI0ZTQ1MTg4NzFiMzAzNjY3ZTIyMjZmL3RhYmxlcmFuZ2U6NDI0Njc0MzY1MjRlNDUxODg3MWIzMDM2NjdlMjIyNmZfMi0yLTEtMS00NzgwMQ_0b79707f-2bba-4d3a-863c-139e3a163433"
      unitRef="usd">2456000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7cfceed396a74b66a22f992517fbad65_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjQyNDY3NDM2NTI0ZTQ1MTg4NzFiMzAzNjY3ZTIyMjZmL3RhYmxlcmFuZ2U6NDI0Njc0MzY1MjRlNDUxODg3MWIzMDM2NjdlMjIyNmZfMi00LTEtMS00NzgwMQ_9185d10b-03fb-4a08-965a-c32f56c8f22b"
      unitRef="usd">1764000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i59eefa49da754fc4a678bcfece8e4fa5_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjQyNDY3NDM2NTI0ZTQ1MTg4NzFiMzAzNjY3ZTIyMjZmL3RhYmxlcmFuZ2U6NDI0Njc0MzY1MjRlNDUxODg3MWIzMDM2NjdlMjIyNmZfMi02LTEtMS00NzgwMQ_b5c222a4-1c04-4e5a-9268-89c6402d3def"
      unitRef="usd">4473000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5b377684337249a79d005226a445c9d3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjQyNDY3NDM2NTI0ZTQ1MTg4NzFiMzAzNjY3ZTIyMjZmL3RhYmxlcmFuZ2U6NDI0Njc0MzY1MjRlNDUxODg3MWIzMDM2NjdlMjIyNmZfMi04LTEtMS00NzgwMQ_6309ea46-7362-437b-acf5-fe8c9526de7d"
      unitRef="usd">3412000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie13a988e22704be5a5271b3555ac5742_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjQyNDY3NDM2NTI0ZTQ1MTg4NzFiMzAzNjY3ZTIyMjZmL3RhYmxlcmFuZ2U6NDI0Njc0MzY1MjRlNDUxODg3MWIzMDM2NjdlMjIyNmZfMy0yLTEtMS00NzgwMQ_7e01b0de-1e77-464d-b9ea-46d0c6c39b74"
      unitRef="usd">3179000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibc0b6f8877784e66b28f844b0f81f44c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjQyNDY3NDM2NTI0ZTQ1MTg4NzFiMzAzNjY3ZTIyMjZmL3RhYmxlcmFuZ2U6NDI0Njc0MzY1MjRlNDUxODg3MWIzMDM2NjdlMjIyNmZfMy00LTEtMS00NzgwMQ_4b355e4f-e269-4532-84f1-8ee4ed2b3338"
      unitRef="usd">3608000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibbf1cd99aace4cbfa194e2f7dedc5157_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjQyNDY3NDM2NTI0ZTQ1MTg4NzFiMzAzNjY3ZTIyMjZmL3RhYmxlcmFuZ2U6NDI0Njc0MzY1MjRlNDUxODg3MWIzMDM2NjdlMjIyNmZfMy02LTEtMS00NzgwMQ_ac19370b-2e35-4efa-a412-ea0d22a77e91"
      unitRef="usd">5904000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i57f7d92fa5174c7a9550dfc6b218d957_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjQyNDY3NDM2NTI0ZTQ1MTg4NzFiMzAzNjY3ZTIyMjZmL3RhYmxlcmFuZ2U6NDI0Njc0MzY1MjRlNDUxODg3MWIzMDM2NjdlMjIyNmZfMy04LTEtMS00NzgwMQ_508ecba5-4536-4c39-a114-3a612a2250d0"
      unitRef="usd">6883000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjQyNDY3NDM2NTI0ZTQ1MTg4NzFiMzAzNjY3ZTIyMjZmL3RhYmxlcmFuZ2U6NDI0Njc0MzY1MjRlNDUxODg3MWIzMDM2NjdlMjIyNmZfNC0yLTEtMS00NzgwMQ_fbbfeac0-f578-4991-aed8-c353fa31a3ee"
      unitRef="usd">5635000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjQyNDY3NDM2NTI0ZTQ1MTg4NzFiMzAzNjY3ZTIyMjZmL3RhYmxlcmFuZ2U6NDI0Njc0MzY1MjRlNDUxODg3MWIzMDM2NjdlMjIyNmZfNC00LTEtMS00NzgwMQ_828854db-6884-4970-9561-2ea2efdd2f6c"
      unitRef="usd">5372000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjQyNDY3NDM2NTI0ZTQ1MTg4NzFiMzAzNjY3ZTIyMjZmL3RhYmxlcmFuZ2U6NDI0Njc0MzY1MjRlNDUxODg3MWIzMDM2NjdlMjIyNmZfNC02LTEtMS00NzgwMQ_362d1624-bfbf-4398-a60c-ddd31a75976f"
      unitRef="usd">10377000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjQyNDY3NDM2NTI0ZTQ1MTg4NzFiMzAzNjY3ZTIyMjZmL3RhYmxlcmFuZ2U6NDI0Njc0MzY1MjRlNDUxODg3MWIzMDM2NjdlMjIyNmZfNC04LTEtMS00NzgwMQ_b42c45da-70ca-42f1-9905-f81e13e0ce74"
      unitRef="usd">10295000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RleHRyZWdpb246YTk0M2RlMDBjM2NhNDYzNGJmNGNkYTc3YjUyMzkzZThfMjQwOQ_90131b2c-3fa1-48be-9bfc-7d51d1d8fc91">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation expense by type of share-based award (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;&#160;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSAs, RSUs, PSUs and ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1c0e86c5373e4602b110c2747e91ff9a_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjgzZTIyNTM0YTEzZDRmN2RiZTdlYTAyZDk2ZWJhOGU0L3RhYmxlcmFuZ2U6ODNlMjI1MzRhMTNkNGY3ZGJlN2VhMDJkOTZlYmE4ZTRfMi0yLTEtMS00NzgwMQ_3511b9a0-f661-4cba-aeab-473785328e83"
      unitRef="usd">2503000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibb8fed0bdf764dd2bd8a75a83eba117c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjgzZTIyNTM0YTEzZDRmN2RiZTdlYTAyZDk2ZWJhOGU0L3RhYmxlcmFuZ2U6ODNlMjI1MzRhMTNkNGY3ZGJlN2VhMDJkOTZlYmE4ZTRfMi00LTEtMS00NzgwMQ_0de3312f-9547-48c1-8709-4c7af069fb5d"
      unitRef="usd">2637000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i46d36ab336df48ad98a01cfdfc1a2696_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjgzZTIyNTM0YTEzZDRmN2RiZTdlYTAyZDk2ZWJhOGU0L3RhYmxlcmFuZ2U6ODNlMjI1MzRhMTNkNGY3ZGJlN2VhMDJkOTZlYmE4ZTRfMi02LTEtMS00NzgwMQ_3feab985-9392-467b-8436-c5121140a162"
      unitRef="usd">5123000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if8257a7f99e248c4b487a6942b94aec0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjgzZTIyNTM0YTEzZDRmN2RiZTdlYTAyZDk2ZWJhOGU0L3RhYmxlcmFuZ2U6ODNlMjI1MzRhMTNkNGY3ZGJlN2VhMDJkOTZlYmE4ZTRfMi04LTEtMS00NzgwMQ_bd0a94fe-7e21-4750-99e9-d054764718dd"
      unitRef="usd">5119000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i03beebbe6fad4ae4a59c0a56d53de652_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjgzZTIyNTM0YTEzZDRmN2RiZTdlYTAyZDk2ZWJhOGU0L3RhYmxlcmFuZ2U6ODNlMjI1MzRhMTNkNGY3ZGJlN2VhMDJkOTZlYmE4ZTRfMy0yLTEtMS00NzgwMQ_92398c8a-4051-47de-a1bc-c873051b4343"
      unitRef="usd">3132000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifa122ca61ec54b1c824632d4d8f8bd63_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjgzZTIyNTM0YTEzZDRmN2RiZTdlYTAyZDk2ZWJhOGU0L3RhYmxlcmFuZ2U6ODNlMjI1MzRhMTNkNGY3ZGJlN2VhMDJkOTZlYmE4ZTRfMy00LTEtMS00NzgwMQ_562b7ac6-a9c2-48c4-a435-260c95e3ea27"
      unitRef="usd">2735000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8786b34524304c2c89d022706441552b_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjgzZTIyNTM0YTEzZDRmN2RiZTdlYTAyZDk2ZWJhOGU0L3RhYmxlcmFuZ2U6ODNlMjI1MzRhMTNkNGY3ZGJlN2VhMDJkOTZlYmE4ZTRfMy02LTEtMS00NzgwMQ_ba6fc98c-0104-4cf6-9b57-a5e209ce3a45"
      unitRef="usd">5254000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib3dfae04892c4acfbec9d00a8bc5641d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjgzZTIyNTM0YTEzZDRmN2RiZTdlYTAyZDk2ZWJhOGU0L3RhYmxlcmFuZ2U6ODNlMjI1MzRhMTNkNGY3ZGJlN2VhMDJkOTZlYmE4ZTRfMy04LTEtMS00NzgwMQ_d6ea8808-d084-47df-857a-883be7be8230"
      unitRef="usd">5176000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjgzZTIyNTM0YTEzZDRmN2RiZTdlYTAyZDk2ZWJhOGU0L3RhYmxlcmFuZ2U6ODNlMjI1MzRhMTNkNGY3ZGJlN2VhMDJkOTZlYmE4ZTRfNC0yLTEtMS00NzgwMQ_9b33e0b3-5de5-43aa-8074-6d23bd2e7359"
      unitRef="usd">5635000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjgzZTIyNTM0YTEzZDRmN2RiZTdlYTAyZDk2ZWJhOGU0L3RhYmxlcmFuZ2U6ODNlMjI1MzRhMTNkNGY3ZGJlN2VhMDJkOTZlYmE4ZTRfNC00LTEtMS00NzgwMQ_cebc9fc0-4196-41f3-bf84-921586bf483b"
      unitRef="usd">5372000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjgzZTIyNTM0YTEzZDRmN2RiZTdlYTAyZDk2ZWJhOGU0L3RhYmxlcmFuZ2U6ODNlMjI1MzRhMTNkNGY3ZGJlN2VhMDJkOTZlYmE4ZTRfNC02LTEtMS00NzgwMQ_23a2a184-fb49-46f8-8f38-331f853da236"
      unitRef="usd">10377000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjgzZTIyNTM0YTEzZDRmN2RiZTdlYTAyZDk2ZWJhOGU0L3RhYmxlcmFuZ2U6ODNlMjI1MzRhMTNkNGY3ZGJlN2VhMDJkOTZlYmE4ZTRfNC04LTEtMS00NzgwMQ_7e993628-2ba6-45c5-bc9c-e3dfad267497"
      unitRef="usd">10295000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RleHRyZWdpb246YTk0M2RlMDBjM2NhNDYzNGJmNGNkYTc3YjUyMzkzZThfMjgy_d3adf6eb-6129-4694-aa82-5b7eb7f3afd0"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RleHRyZWdpb246YTk0M2RlMDBjM2NhNDYzNGJmNGNkYTc3YjUyMzkzZThfMjg5_1d950f5d-293a-473a-8f47-c774e9e38f0d"
      unitRef="shares">36300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RleHRyZWdpb246YTk0M2RlMDBjM2NhNDYzNGJmNGNkYTc3YjUyMzkzZThfMTA5OTUxMTYzMDMzMQ_518c8c1b-e298-4b64-a820-9d9d2a7f260e"
      unitRef="shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RleHRyZWdpb246YTk0M2RlMDBjM2NhNDYzNGJmNGNkYTc3YjUyMzkzZThfMTA5OTUxMTYzMDM0OQ_1493b505-6c5c-4e24-9f06-fcfe4524cbe9"
      unitRef="shares">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RleHRyZWdpb246YTk0M2RlMDBjM2NhNDYzNGJmNGNkYTc3YjUyMzkzZThfMjM4MA_f8839f39-5dc0-4d75-ba05-88d5050efd36">The assumptions used in the Black-Scholes model were as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.817%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;&#160;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.05-41.29%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.91-44.91%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.05-41.29%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.91%-46.45%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.56-3.01%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.81-0.81%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.37-3.01%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.36%-0.81%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i2b9b85bf65324a6796a32c109822a4ae_D20220401-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfMi0yLTEtMS00NzgwMS90ZXh0cmVnaW9uOmZiYmE1MDNmMmUxZTQ3ZWNiMTcyMTlkYjEyNDZlNjYwXzQ_8f132a95-5a14-4517-a8de-c79ba2c1976d"
      unitRef="number">0.4105</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="ic7177752d30b457e85b8d0e18806711a_D20220401-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfMi0yLTEtMS00NzgwMS90ZXh0cmVnaW9uOmZiYmE1MDNmMmUxZTQ3ZWNiMTcyMTlkYjEyNDZlNjYwXzc_08fad020-7665-464b-b6ca-b8af6efab09e"
      unitRef="number">0.4129</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="ia075a8f22ebb4c19bcb72e7ad3ead56a_D20210401-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfMi00LTEtMS00NzgwMS90ZXh0cmVnaW9uOjI5ZjJlMjRlM2UxMTQwNTY5OTY0Mjg2NWZjMzdmZjMyXzQ_b1984ea3-1dbd-41eb-9950-69c361cf1b44"
      unitRef="number">0.4491</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="ia02f509257fd46da8f0a5f3e5e678761_D20210401-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfMi00LTEtMS00NzgwMS90ZXh0cmVnaW9uOjI5ZjJlMjRlM2UxMTQwNTY5OTY0Mjg2NWZjMzdmZjMyXzc_44793256-5fbc-468f-9533-5bc89a0bbc9a"
      unitRef="number">0.4491</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i132fba3a55ea459d84aa0bb90100bdd7_D20220101-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfMi02LTEtMS00NzgwMS90ZXh0cmVnaW9uOmNkZDgwMTA3NjNkYzQwOTdiYmRhNTMzZWRhZWVkN2U5XzQ_97744a84-e104-46c0-a8bf-9770fdbb730d"
      unitRef="number">0.4105</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="ifa39c538bf934a02b5928070f514abbb_D20220101-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfMi02LTEtMS00NzgwMS90ZXh0cmVnaW9uOmNkZDgwMTA3NjNkYzQwOTdiYmRhNTMzZWRhZWVkN2U5Xzc_59b8a9a9-e680-4719-bce7-28fe047a3d0c"
      unitRef="number">0.4129</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i543c949f5482411dabdc5d1d89631950_D20210101-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfMi04LTEtMS00NzgwMS90ZXh0cmVnaW9uOmRiODMzOWY4ZWNkYzQzNDliYmI1NjZjMjRhNTk4NzY0XzQ_a2c09628-196d-4335-bb17-2f0c0f98feb8"
      unitRef="number">0.4491</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="ib0f607a6eb8841f78c2d102cf0eab6aa_D20210101-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfMi04LTEtMS00NzgwMS90ZXh0cmVnaW9uOmRiODMzOWY4ZWNkYzQzNDliYmI1NjZjMjRhNTk4NzY0Xzc_33ff6722-45a2-45f5-9f66-f29fb64a92d6"
      unitRef="number">0.4645</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfMy0yLTEtMS00NzgwMQ_e46657a1-5831-470f-bb48-a37640e55cfd">P4Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfMy00LTEtMS00NzgwMQ_7b8f8637-8da6-42e5-8da0-291109dcd620">P4Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfMy02LTEtMS00NzgwMQ_04430e64-bf98-408e-8c00-1f15a48a499c">P4Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfMy04LTEtMS00NzgwMQ_6c7cb493-f85b-4ce0-b307-d2d457cd3dcb">P4Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfNC0yLTEtMS00NzgwMS90ZXh0cmVnaW9uOjNmNTY2YWYyMzdhZTQ5MTI5MzNmOTJiNzc0MGZmOTdmXzQ_19867fda-9fc2-46d6-bb65-10a3c397e273"
      unitRef="number">0.0256</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfNC0yLTEtMS00NzgwMS90ZXh0cmVnaW9uOjNmNTY2YWYyMzdhZTQ5MTI5MzNmOTJiNzc0MGZmOTdmXzc_08698426-01c6-4dc0-aa44-0a5887174ace"
      unitRef="number">0.0301</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfNC00LTEtMS00NzgwMS90ZXh0cmVnaW9uOjkyMTQ3MjU2MDI1NjQyMTlhYmZiMjk0NDhmOTc3NjZiXzQ_d5517230-31ad-4fd5-9856-537bae283384"
      unitRef="number">0.0081</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfNC00LTEtMS00NzgwMS90ZXh0cmVnaW9uOjkyMTQ3MjU2MDI1NjQyMTlhYmZiMjk0NDhmOTc3NjZiXzc_3f8f6b19-94f8-48d0-96f8-0491420281f2"
      unitRef="number">0.0081</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfNC02LTEtMS00NzgwMS90ZXh0cmVnaW9uOjQ4MTQ1MWM0MDVjNjQ3MjNhYjgyYzQ5MDRiNDAzZDdlXzQ_79bffbf2-aad4-4e06-b0cf-384d02df8a6d"
      unitRef="number">0.0137</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfNC02LTEtMS00NzgwMS90ZXh0cmVnaW9uOjQ4MTQ1MWM0MDVjNjQ3MjNhYjgyYzQ5MDRiNDAzZDdlXzc_81d77bad-f231-4934-a58f-312454f9780e"
      unitRef="number">0.0301</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfNC04LTEtMS00NzgwMS90ZXh0cmVnaW9uOjkyNDk0YzBmN2ViNjRhNTg4MGEzYzEzYzMxZmY5OTI3XzQ_04fa95b6-84ff-41bb-86e0-1b73ecef65b6"
      unitRef="number">0.0036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfNC04LTEtMS00NzgwMS90ZXh0cmVnaW9uOjkyNDk0YzBmN2ViNjRhNTg4MGEzYzEzYzMxZmY5OTI3Xzc_828ebf6a-a6bf-4068-a0f0-f106e39fa538"
      unitRef="number">0.0081</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfNS0yLTEtMS00NzgwMQ_c8e0814e-a339-4fc8-9ad6-61c7686b6d4d"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfNS00LTEtMS00NzgwMQ_40ee8f9b-1ec3-49c0-85b1-bbe9ac48a78a"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfNS02LTEtMS00NzgwMQ_0ade22db-6e12-4766-a4a7-1f74ff1c00c1"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjhjZGI1MDk3Mzg4ODRiZThhYTM3ZTU4YzJiYTgwNDc3L3RhYmxlcmFuZ2U6OGNkYjUwOTczODg4NGJlOGFhMzdlNThjMmJhODA0NzdfNS04LTEtMS00NzgwMQ_044a9d37-57e1-4881-a71c-43663842c02a"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i21d64138ff854e21be215de2a288c045_D20210201-20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RleHRyZWdpb246YTk0M2RlMDBjM2NhNDYzNGJmNGNkYTc3YjUyMzkzZThfMTM5MA_cfd34c30-f3b4-40cf-96fc-148a7e34f59b"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate
      contextRef="i96a1543f8d6e4bfbb485a55166a6038c_I20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RleHRyZWdpb246YTk0M2RlMDBjM2NhNDYzNGJmNGNkYTc3YjUyMzkzZThfMTU5Mg_3a1564d9-ecc5-46c0-afae-a1ba4b31d95f"
      unitRef="number">0.01</halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="i96a1543f8d6e4bfbb485a55166a6038c_I20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RleHRyZWdpb246YTk0M2RlMDBjM2NhNDYzNGJmNGNkYTc3YjUyMzkzZThfMTYwNQ_902c1da3-4a12-4983-ba79-8a0376bdaf76"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount
      contextRef="i21d64138ff854e21be215de2a288c045_D20210201-20210228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RleHRyZWdpb246YTk0M2RlMDBjM2NhNDYzNGJmNGNkYTc3YjUyMzkzZThfMTcyNw_93062d15-1df4-4ad3-a3a5-df93b4d1f466"
      unitRef="usd">25000</halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i49fcdbfe0faf49d1a3e26def4e7b572f_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RleHRyZWdpb246YTk0M2RlMDBjM2NhNDYzNGJmNGNkYTc3YjUyMzkzZThfMTA5OTUxMTYzMDQyNw_4f6ad5cf-bdca-4beb-8b6a-f4462da829b3"
      unitRef="shares">2665369</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod
      contextRef="i21d64138ff854e21be215de2a288c045_D20210201-20210228"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RleHRyZWdpb246YTk0M2RlMDBjM2NhNDYzNGJmNGNkYTc3YjUyMzkzZThfMjM4OA_164f171d-7cfa-4039-8560-c4d3202ee334">P6M</halo:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="ib6ded8ac2e08484aa08a3116e39e8ed6_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RleHRyZWdpb246YTk0M2RlMDBjM2NhNDYzNGJmNGNkYTc3YjUyMzkzZThfMTkyNDE0NTM0ODk1MTY_97324c15-9443-4997-983b-0abb8a3a95bb"
      unitRef="shares">16858</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RleHRyZWdpb246YTk0M2RlMDBjM2NhNDYzNGJmNGNkYTc3YjUyMzkzZThfMjM3NA_b82bbff2-ca1b-4690-94ef-1383bcca2dd9">&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total unrecognized estimated compensation cost by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrecognized&lt;br/&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remaining&lt;br/&gt;Weighted-Average&lt;br/&gt;Recognition Period&lt;br/&gt;(years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.81&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.82&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.41&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.46&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i039a8cae3d874e6fb7155efc49a70811_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjk2MDdiZThjMWI4YzRkMDNhYWZhZTVlNWVhOGJiNGMxL3RhYmxlcmFuZ2U6OTYwN2JlOGMxYjhjNGQwM2FhZmFlNWU1ZWE4YmI0YzFfMi0yLTEtMS00NzgwMQ_05f922e5-9250-4283-b639-3536bb010e79"
      unitRef="usd">28109000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i46d36ab336df48ad98a01cfdfc1a2696_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjk2MDdiZThjMWI4YzRkMDNhYWZhZTVlNWVhOGJiNGMxL3RhYmxlcmFuZ2U6OTYwN2JlOGMxYjhjNGQwM2FhZmFlNWU1ZWE4YmI0YzFfMi00LTEtMS00NzgwMQ_f6d9e301-123b-4840-949a-df6c6120431f">P2Y9M21D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i90338c7e90e04fbb88f9eaebe6f9c0a4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjk2MDdiZThjMWI4YzRkMDNhYWZhZTVlNWVhOGJiNGMxL3RhYmxlcmFuZ2U6OTYwN2JlOGMxYjhjNGQwM2FhZmFlNWU1ZWE4YmI0YzFfNC0yLTEtMS00NzgwMQ_0472af45-b40a-428d-a976-4ce6aab7c6ed"
      unitRef="usd">33922000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i846c45d299c548bd93d9ca4e31ef2c27_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjk2MDdiZThjMWI4YzRkMDNhYWZhZTVlNWVhOGJiNGMxL3RhYmxlcmFuZ2U6OTYwN2JlOGMxYjhjNGQwM2FhZmFlNWU1ZWE4YmI0YzFfNC00LTEtMS00NzgwMQ_c498d661-c997-4c59-9b9b-48f26abb5065">P2Y9M25D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="icd47428a7d224a1cb5358f0397539915_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjk2MDdiZThjMWI4YzRkMDNhYWZhZTVlNWVhOGJiNGMxL3RhYmxlcmFuZ2U6OTYwN2JlOGMxYjhjNGQwM2FhZmFlNWU1ZWE4YmI0YzFfNS0yLTEtMS00NzgwMQ_67a08adc-0ed7-4761-ae87-dbb393cda3a2"
      unitRef="usd">5073000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ife8e3a854f8d4e9a9d92bcbe808224ee_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjk2MDdiZThjMWI4YzRkMDNhYWZhZTVlNWVhOGJiNGMxL3RhYmxlcmFuZ2U6OTYwN2JlOGMxYjhjNGQwM2FhZmFlNWU1ZWE4YmI0YzFfNS00LTEtMS00NzgwMQ_57ecfd56-52cf-45b1-a7e0-411553b48db5">P2Y4M28D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i8d6e73a624be47fea5d20e683c6bea8e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjk2MDdiZThjMWI4YzRkMDNhYWZhZTVlNWVhOGJiNGMxL3RhYmxlcmFuZ2U6OTYwN2JlOGMxYjhjNGQwM2FhZmFlNWU1ZWE4YmI0YzFfNi0yLTEtMS00NzgwMQ_86fe1f41-d32c-4d0d-83a8-0e29dc59ef1a"
      unitRef="usd">172000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="idc726257139b49b6a58fe70d504a57d9_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN182Ny9mcmFnOmE5NDNkZTAwYzNjYTQ2MzRiZjRjZGE3N2I1MjM5M2U4L3RhYmxlOjk2MDdiZThjMWI4YzRkMDNhYWZhZTVlNWVhOGJiNGMxL3RhYmxlcmFuZ2U6OTYwN2JlOGMxYjhjNGQwM2FhZmFlNWU1ZWE4YmI0YzFfNi00LTEtMS00NzgwMQ_89d5bd6b-bb37-4ef9-8e1d-a73c534a5a6e">P0Y5M15D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMjAwMw_e520d78d-c9bd-457b-83ca-857b155c8dd5">Stockholders&#x2019; Equity &lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June&#160;30, 2022 and 2021, we issued an aggregate of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;350,216&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and 591,891 shares of common stock, respectively, in connection with the exercises of stock options at a weighted average exercise price of $17.94 and $13.64 per share, respectively, for net proceeds of approximately $6.3 million and $8.1 million, respectively. For the six months ended June&#160;30, 2022 and 2021, we issued 248,343 and 290,149 shares of common stock, respectively, upon vesting of certain RSUs and PSUs for which 68,425 and 91,383 RSUs were withheld from the RSU holders, respectively, to pay for minimum withholding taxes totaling approximately $4.3 million and $8.0 million, respectively. Stock options and unvested restricted units totaling approximately 6.8 million shares and 5.9 million shares of our common stock were outstanding as of June&#160;30, 2022 and December&#160;31, 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share Repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, we announced that the Board of Directors has authorized the initiation of a capital return program to repurchase up to $550.0 million of outstanding common stock over a three-year period. During 2020, we repurchased 6.5&#160;million shares of common stock for $150.0&#160;million at an average price of $23.05. During 2021, we repurchased 4.6&#160;million shares of common stock for $200.0&#160;million at an average price of $43.02 under the program. The shares were purchased through open market transactions and through an ASR agreement. The $550.0&#160;million share repurchase program was completed in October 2021 having repurchased a total of 22.3&#160;million shares at an average price of $24.72.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In December 2021, the Board of Directors authorized a second capital return program to repurchase up to $750.0&#160;million of outstanding stock over a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMTUzMw_f787b3d2-f4a4-40e0-98f4-002839096391"&gt;three&lt;/span&gt;-year period. Also in December 2021, as part of the second capital return program, we entered into an ASR agreement to repurchase $150.0&#160;million of common stock. At inception pursuant to the agreement, we paid $150.0&#160;million to Bank of America and took initial delivery of 3.5&#160;million shares. In June 2022, we finalized the transaction and received an additional 0.4&#160;million shares. We retired the repurchased shares and they resumed the status of authorized and unissued shares.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i46d36ab336df48ad98a01cfdfc1a2696_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfOTQ_c09eb107-cf71-4760-a550-c52354f20e99"
      unitRef="shares">350216</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="if8257a7f99e248c4b487a6942b94aec0_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMTAx_d7cc20d1-4b44-43e0-858f-88f12b1f9c7f"
      unitRef="shares">591891</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i46d36ab336df48ad98a01cfdfc1a2696_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMjMy_b3ae20fb-061a-4c97-bea1-4968cefc2b49"
      unitRef="usdPerShare">17.94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="if8257a7f99e248c4b487a6942b94aec0_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMjM5_d919bbc2-e68b-4fed-ba32-b62a7ea4033d"
      unitRef="usdPerShare">13.64</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i46d36ab336df48ad98a01cfdfc1a2696_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMzAx_1ae88145-ef59-4a16-aec1-e35af5c5d636"
      unitRef="usd">6300000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="if8257a7f99e248c4b487a6942b94aec0_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMzA4_f872a8fd-2344-4a0d-ad6d-406306559c1c"
      unitRef="usd">8100000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i846c45d299c548bd93d9ca4e31ef2c27_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMzcx_3d30d8e9-ef97-482b-92e4-a868b16ec540"
      unitRef="shares">248343</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i68a4a2f139194eaf961414023ef77512_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMzc4_3b1582a8-0950-40f0-9a72-3f94b69e9bfe"
      unitRef="shares">290149</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i846c45d299c548bd93d9ca4e31ef2c27_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfNDY3_18176739-b2b7-4f1a-ac89-82b390f278ca"
      unitRef="shares">68425</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i68a4a2f139194eaf961414023ef77512_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfNDc0_8b1ad177-0d66-4598-88dc-cf1ec58d5fee"
      unitRef="shares">91383</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i846c45d299c548bd93d9ca4e31ef2c27_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfNTky_5d286895-390f-4164-8d3d-8317aa6a2f25"
      unitRef="usd">4300000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i68a4a2f139194eaf961414023ef77512_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfNTk5_8bf81e7e-a7fb-405a-9a85-16d26ae5397e"
      unitRef="usd">8000000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="iea8e1a13442143e58800a7fa395d7502_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfNjg0_0e3a24dd-07be-46fc-a34e-2c88a71d6e01"
      unitRef="shares">6800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i0c6331a6ec0e49a3ba11830898b654f5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfNjk4_e637adf6-5f74-48fc-a6af-37219f18f45c"
      unitRef="shares">5900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="ida58a610325c429a94dfe3fb62450540_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfOTMy_ece30798-fd6e-471c-ac24-27230b51a970"
      unitRef="usd">550000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramPeriodInForce1
      contextRef="iae83682afbfd42498583c6364b173a85_D20191101-20191130"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMjAwOQ_a69b7a69-ec0d-427a-a392-6a23d197a24c">P3Y</us-gaap:StockRepurchaseProgramPeriodInForce1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="if2cda56e59c543bdb0c8c9ac8c626f34_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMTAxNA_79cec606-d504-43f8-af0e-fa4580090856"
      unitRef="shares">6500000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="if2cda56e59c543bdb0c8c9ac8c626f34_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMTA0NA_b0bfcd08-b4c1-4da9-aa75-2cf6ff1465fb"
      unitRef="usd">150000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="if2cda56e59c543bdb0c8c9ac8c626f34_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMTA3MA_5ebc14a5-0106-436c-bde0-7203b0338b6d"
      unitRef="usdPerShare">23.05</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i6eddd51f62374e059ee58a39542c4f58_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMTEwMg_205ffbfb-c0e3-4bd7-a6ed-2ad8d0990a81"
      unitRef="shares">4600000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i6eddd51f62374e059ee58a39542c4f58_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMTEzMg_4002ae35-5321-4b0e-ba45-8ba9f09fd9db"
      unitRef="usd">200000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i6eddd51f62374e059ee58a39542c4f58_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMTE1OA_b02256f3-fdc3-4f0c-bd8c-330e4995508b"
      unitRef="usdPerShare">43.02</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="ida58a610325c429a94dfe3fb62450540_I20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMTI3Mw_40ebf162-d4d1-4732-a25d-ed7e0f0c4ca8"
      unitRef="usd">550000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="if429dbd362794e36ab10ac51992df878_D20191101-20211031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMTM2MQ_1a7dcada-fef0-4220-a631-9025253d94d0"
      unitRef="shares">22300000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="if429dbd362794e36ab10ac51992df878_D20191101-20211031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMTM5NA_48885ada-2cb0-4202-b602-647facdb19b5"
      unitRef="usdPerShare">24.72</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMTUwMg_845f7f1d-174e-4462-ac71-236302b2ce23"
      unitRef="usd">750000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ic73a9ae57f1f4045a6e76817123e3ac0_D20211201-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMTY2NQ_b9efd4f1-606d-4af7-90e5-028a2bb7c263"
      unitRef="usd">150000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ic73a9ae57f1f4045a6e76817123e3ac0_D20211201-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMTczMw_2339e7ac-11b5-4497-80aa-a2d6db8b97e9"
      unitRef="usd">150000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ic73a9ae57f1f4045a6e76817123e3ac0_D20211201-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMTc4NA_7cc15244-c42f-41ff-998e-3c4525335187"
      unitRef="shares">3500000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ia44d229bf8fa4a2cbef0e366dafed174_D20220601-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183My9mcmFnOjQyMmQ2ZDllYTQxMTQwY2Y4YzFhMjYwZjI4YTAyMTM2L3RleHRyZWdpb246NDIyZDZkOWVhNDExNDBjZjhjMWEyNjBmMjhhMDIxMzZfMTY0OTI2NzQ0Mzk3OA_6a8adbc4-b826-4a07-a26b-532fad34fbb1"
      unitRef="shares">400000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RleHRyZWdpb246NmExZDEyMzNiODQ2NDdiODkzN2IyMTdiNjczODczMTNfMTY0OQ_1976105a-ecb9-4a64-ab02-ecc8319d9de2">Net Income per share&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income per common share is computed by dividing net income for the period by the weighted average number of common shares outstanding during the period, without consideration for common stock equivalents. Outstanding stock options, unvested RSAs, unvested RSUs, unvested PSUs, common shares expected to be issued under our ESPP and the Convertible Notes are considered common stock equivalents and are only included in the calculation of diluted earnings per common share when net income is reported and their effect is dilutive. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive common shares issuable upon vesting of stock options, RSAs, RSUs and PSUs are determined using the average share price for each period under the treasury stock method. Potentially dilutive common shares issuable upon conversion of our Convertible Notes are determined using the if-converted method. Since we have committed to settle the principal amount of the Convertible Notes in cash upon conversion only, the number of shares for the conversion spread will be included as a dilutive common stock equivalent. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the numerators and the denominators of the basic and diluted net income per common share computations is as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:center;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.266%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;&#160;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding for basic net income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive potential common stock outstanding:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSAs, RSUs, PSUs and ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding for diluted net income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares which have been excluded from the calculation of diluted net income per common share because their effect was anti-dilutive, include the following (shares in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.702%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;&#160;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1). The anti-dilutive securities include outstanding stock options, unvested RSAs, unvested RSUs, unvested PSUs, common shares expected to be issued under our ESPP and Convertible Notes</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RleHRyZWdpb246NmExZDEyMzNiODQ2NDdiODkzN2IyMTdiNjczODczMTNfMTY1MA_943f473f-d87e-45f4-98d0-d20056574bb2">A reconciliation of the numerators and the denominators of the basic and diluted net income per common share computations is as follows (in thousands, except per share amounts):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.266%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;&#160;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding for basic net income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive potential common stock outstanding:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSAs, RSUs, PSUs and ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding for diluted net income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfMy0yLTEtMS00NzgwMQ_85b363d4-a679-442b-baa8-ad436f7b43ee"
      unitRef="usd">22685000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfMy00LTEtMS00NzgwMQ_c154d82d-6939-45b0-940a-bc0ef625135c"
      unitRef="usd">91458000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfMy02LTEtMS00NzgwMQ_a0754598-91f1-4937-8bb8-d82427c9b01c"
      unitRef="usd">82793000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfMy04LTEtMS00NzgwMQ_786b2ab9-7142-411f-83c4-d7eb6d91474d"
      unitRef="usd">119353000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfNS0yLTEtMS00NzgwMQ_57c25836-e644-4680-8ecf-c09236d1ad16"
      unitRef="shares">137937000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfNS00LTEtMS00NzgwMQ_e77992b0-4c38-4982-878f-bd76da612939"
      unitRef="shares">142487000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfNS02LTEtMS00NzgwMQ_73afdbac-a78c-436a-b096-80925455eb32"
      unitRef="shares">137798000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfNS04LTEtMS00NzgwMQ_9f7773b0-107d-45fc-92ef-5c53ffd2d040"
      unitRef="shares">140201000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i1c0e86c5373e4602b110c2747e91ff9a_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfNy0yLTEtMS00NzgwMQ_c9797492-3966-400a-9d3f-6445b2d74a91"
      unitRef="shares">2274000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ibb8fed0bdf764dd2bd8a75a83eba117c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfNy00LTEtMS00NzgwMQ_4f339c0c-532e-4c5a-b60a-70fadb1b7e87"
      unitRef="shares">2932000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i46d36ab336df48ad98a01cfdfc1a2696_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfNy02LTEtMS00NzgwMQ_9fd9d92f-becb-48c2-b772-734503090711"
      unitRef="shares">2182000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="if8257a7f99e248c4b487a6942b94aec0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfNy04LTEtMS00NzgwMQ_cde04780-ae88-4237-9287-3c2768e07493"
      unitRef="shares">3076000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ie55dcf742b2e4dffa0c703e02b2973d4_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfOC0yLTEtMS00NzgwMQ_5391f07b-36e6-4ea9-b9e9-cae1ea2dd4e8"
      unitRef="shares">296000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i589ea088db504147b0ffc55414faf533_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfOC00LTEtMS00NzgwMQ_31bb633f-87e3-40db-a4f2-935283fcefce"
      unitRef="shares">447000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i1a8ca59aa7d8490c970c1e0dae5c4eae_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfOC02LTEtMS00NzgwMQ_1d96642d-ce9b-4485-923f-98470766f304"
      unitRef="shares">331000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i472657a1189640ed803ebfce1b25d59f_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfOC04LTEtMS00NzgwMQ_67131c3e-2a40-46d3-a2a1-eefb1e11926b"
      unitRef="shares">609000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i7fd2c85ec0bb4267bea086d8a0cd4161_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfOS0yLTEtMS00NzgwMQ_03c50635-2d56-4e3d-9c2a-1cc25413a274"
      unitRef="shares">1709000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ic7f900d934cc4dfca248ded4a6faaf36_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfOS00LTEtMS00NzgwMQ_1e78adaa-7dc8-4ad8-9d11-c36ec7b550d3"
      unitRef="shares">1758000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i24cfdda4dd3d45168530f3505f70dc4d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfOS02LTEtMS00NzgwMQ_ef32702e-4017-4f31-8306-36e2c6f8bc80"
      unitRef="shares">1484000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ibfecde32e655413b98a5b79476a9c15f_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfOS04LTEtMS00NzgwMQ_c6568f58-c2e1-4a04-b12f-526aa7cd0680"
      unitRef="shares">4210000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfMTAtMi0xLTEtNDc4MDE_294c63cf-01a2-4b06-8dce-72e72a3f6ba2"
      unitRef="shares">142216000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfMTAtNC0xLTEtNDc4MDE_ffac6d27-c7d1-49f9-975e-5068b575f794"
      unitRef="shares">147624000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfMTAtNi0xLTEtNDc4MDE_78bf488c-215a-456e-b3e2-cbc101d3d1ae"
      unitRef="shares">141795000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfMTAtOC0xLTEtNDc4MDE_84eea921-ff9a-4548-9212-0363fe46ea58"
      unitRef="shares">148096000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfMTItMi0xLTEtNDc4MDE_1d2092c9-27ac-4a6f-8b38-09f855b78a38"
      unitRef="usdPerShare">0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfMTItNC0xLTEtNDc4MDE_7552e1b1-c3ee-47ef-89dc-4c0246a1290f"
      unitRef="usdPerShare">0.64</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfMTItNi0xLTEtNDc4MDE_523b7e11-a8e2-409e-aedc-aa4e8791e748"
      unitRef="usdPerShare">0.60</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfMTItOC0xLTEtNDc4MDE_9f546968-24d4-4837-bde9-41718f13d2b8"
      unitRef="usdPerShare">0.85</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfMTMtMi0xLTEtNDc4MDE_8995a73b-5ccb-4438-a3c6-eff5ea978e53"
      unitRef="usdPerShare">0.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfMTMtNC0xLTEtNDc4MDE_aee1a367-b89e-4924-8293-c2bd74fca42b"
      unitRef="usdPerShare">0.62</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfMTMtNi0xLTEtNDc4MDE_bf0eb8de-d3f7-431d-b291-a424d5f94f1b"
      unitRef="usdPerShare">0.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOmMzZmNhMWNkYmFhMTQ5YTY5NTkzYzBhODRiMDQwMWI2L3RhYmxlcmFuZ2U6YzNmY2ExY2RiYWExNDlhNjk1OTNjMGE4NGIwNDAxYjZfMTMtOC0xLTEtNDc4MDE_e93a9c21-20fc-45f2-8de4-1115bfea56fe"
      unitRef="usdPerShare">0.81</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RleHRyZWdpb246NmExZDEyMzNiODQ2NDdiODkzN2IyMTdiNjczODczMTNfMTY1MQ_8933b7cb-0556-4349-8500-ce858e4134fd">&lt;div style="margin-top:11pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares which have been excluded from the calculation of diluted net income per common share because their effect was anti-dilutive, include the following (shares in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.702%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;&#160;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1). The anti-dilutive securities include outstanding stock options, unvested RSAs, unvested RSUs, unvested PSUs, common shares expected to be issued under our ESPP and Convertible Notes</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i07515ff25e39495196802eb714e47e89_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOjk1OTZkZDdkODdkYTQ4NDhhYzRlZDA2NmJlNzVlNjExL3RhYmxlcmFuZ2U6OTU5NmRkN2Q4N2RhNDg0OGFjNGVkMDY2YmU3NWU2MTFfMi0yLTEtMS00NzgwMQ_24ecae5b-90c4-48b5-880d-bd8146596eef"
      unitRef="shares">15000000.0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iddc64e12a28740a5b0e7e35c1751aa6c_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOjk1OTZkZDdkODdkYTQ4NDhhYzRlZDA2NmJlNzVlNjExL3RhYmxlcmFuZ2U6OTU5NmRkN2Q4N2RhNDg0OGFjNGVkMDY2YmU3NWU2MTFfMi0zLTEtMS00NzgwMQ_a3bfa5f6-3c90-43c5-8329-3c56536ae0e6"
      unitRef="shares">13500000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOjk1OTZkZDdkODdkYTQ4NDhhYzRlZDA2NmJlNzVlNjExL3RhYmxlcmFuZ2U6OTU5NmRkN2Q4N2RhNDg0OGFjNGVkMDY2YmU3NWU2MTFfMi01LTEtMS00NzgwMQ_1f59b2c5-6437-4b41-92f2-fee4366b1517"
      unitRef="shares">15300000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ifca7ef64bc7846b7b89c1f7ff2e24ff3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183Ni9mcmFnOjZhMWQxMjMzYjg0NjQ3Yjg5MzdiMjE3YjY3Mzg3MzEzL3RhYmxlOjk1OTZkZDdkODdkYTQ4NDhhYzRlZDA2NmJlNzVlNjExL3RhYmxlcmFuZ2U6OTU5NmRkN2Q4N2RhNDg0OGFjNGVkMDY2YmU3NWU2MTFfMi03LTEtMS00NzgwMQ_a63e7fd1-7cac-44e4-ad46-932222de1329"
      unitRef="shares">13500000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmJkMDljNTJiZGMwMzQ1MTQ5M2RmN2ZiNzA3NzI4MGM3L3NlYzpiZDA5YzUyYmRjMDM0NTE0OTNkZjdmYjcwNzcyODBjN183OS9mcmFnOjMxOGQ3ODVmM2ZkNDRmN2U4MzA4NDk5NmVmN2U1ZWZjL3RleHRyZWdpb246MzE4ZDc4NWYzZmQ0NGY3ZTgzMDg0OTk2ZWY3ZTVlZmNfMTAwNg_5d35b51f-45bc-423b-980d-58a15917e754">Commitments and ContingenciesFrom time to time, we may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of our business. Any of these claims could subject us to costly legal expenses and, while we generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on our consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage our reputation and business. We currently are not a party to any legal proceedings, the adverse outcome of which, in management&#x2019;s opinion, individually or in the aggregate, would have a material adverse effect on our consolidated results of operations or financial position.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>80
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MJPGH%H N6JAQHD+U3&[#B)/[+)YS:0+#-2S+;CK4<3HF.#2T)ER_@.N? O?
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M_H^>>ZRW0)M3+<6A-U8C..1E]S?[UD_$F8'B@0U(;T!T S9C0'L#>ND=6&_
M+KV#WQNTKB\[W]N)2S*9K:XK\8RJ!JW8F@_M[+?6:K[RLDF4>UFI7W-E)U=K
M46Y5V/D6J4^U*/)M)M7%O51_5#[(&HE']-N15UD3UQJ]^5)FIVVN,&_1>_3E
M/D%O?GJ+ZGU6\1KE)?I]+TYU5F[K=^BGR?7U4JKA-C==;OJAW79#(S-#H^@7
M4<I]C5(UQ"U@G]CM XO]4DW3,%?D9:YNB97PYU/Y 5'O'2(>(<!XUI>;8\B=
MOW?W](?O/ID,.B0.;?GH#-\=?^+EB==74& [4P:;-K7OJCYF&WZS4,6MYM43
M7ZS^^0\<>/^"9M4E6>*2+'5$-IE_-LP_L[&O?A<R*U2I[J( !:&S#UK[IE\\
MK;!/:.!?+Y_.IQ> T8#Y&BPQ822( \:FL!2 $9^%X0";..L/SOK69.L+4+E#
M_-NQ*5=PVODNT\XE6>*2+'5$-HE$,$0BL*;=6M2R:0EU5L!9UYG[9PE :<RH
MEG0FBE /1UK.F2@61WH"IP *$SJ3<>'@9VCU\^-!5#+_7]OU&G_S4F;E+G^8
M\3HTQH Q\W2O392G>7P13VKCF7@;#=Y&5F_O5)YDU6:/5*=6,NM)Z<=CT_TA
M5R-SB#Z+=%=-5.0%L>:M"2(AI8'F+7##T LCV.-X\#BV>GROI*FJ)^_0CI>J
MMA2MY]E6*:R\EDVM>>*0\[$Q%C]DH3;BM8E2"=ETW8GW)BK$%&L9D9HH0FDT
M$V_LC;+/NZ!]"*.N@C+- [(RHI[>20 <H\S3GVJ(SH]CK+<2 !?A(/9G7#]3
MO-CJ^MA,\G(C#F"<>XI)&6->X.D>F["8>BS4/39AV(M#JL<:PC$:1F3&93*Z
M3.S]4^YYU;N+WO2Q?@OVT)[)41-URI8X94M=L4UC,NIG;)6'JT_E$Z]E4V7;
MVB/:$ VQZ8/U#I4<K,(]^7FJO(^9\42:*&+4(8B*Z3F< B@6SS19/(I8;%>Q
MG\KM:=,N-%\JD)*T1;L$E0)MA)HCU895UT6ED#/5B7VOJZZ_#TF^#TD!R'OB
MQ<%<+1[%+;8J-C4)DJL,&Z8 ]-(W;ZZ:!=,]!6 X](GN+0!C4:#K#/"F(9Z+
M^J@AL5U$_LKE2S%ZX(^BXB]7,OLV$V1 5GH>QKK[)BS&/@YT]TV8FDI&C(@#
M.*P"/E>/1W&)[>KRT^"N->:FS@LIT<4&@/*-EFMB" Z(\8P#,!;/.#MJ2VP7
MEV.T02<C8,481$8E,V%*,9B.FK"(A+&1V"9,!9;Z=,;7457BV-IHSS);J8QN
M7PQNLU9Y^NHVZY(M<<J6NF*;;MF-0I?8A>YM5N<;]*;9J1PB\A:*2,\3G7>
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MQWIA,&&Q%_CZWO?R["3:@5>[]@A@K9[W4RF[LT7#M\,QPX_MX3KM^UM\M<;
M]PF^2KM#A"-]=Z;QEZS:Y66-"OZH;N5]"%41J[IC@MV%%,?V'-R#D%(<VH][
MGJERU #4[X]"R)>+Y@;#8<W5_P%02P,$%     @ >H$)54FQZ^>I P  : T
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M8)6"6#\T'2P[E^3L+JB?W*!A.K91PD9FSK,#S!HB\>4JTKBH<Z0<.PM',H2
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M@YMR-]=2O1<JZ+E-]=Z\)1B6(<WJM<T;?&?.4<Y5/]GDSB+7^%7 N+_$H*<
M;U-"I.E+V452JATA(01V)UB1!>"96$S07X*[-TVR53LCDBZE X5IFITYH]WV
M_-PY*M4U3/CGOZYNOKY_UUX[QN+KY<GG=U=TL3Q\-3UBS3Y?G;W[]N7S24O$
M>9:"HHH-N<-,=';N^'5)DVS#L1YKF+S*9K!!0ZS1[];"*,E8\^!-I(>CK^I.
M;O>+B\1'DT=X+&J3DXC[S#Q#@(/XR'/,S41._,3TI+QY;X A>RX*AQOLMM"P
M*:DAZEO4^U6N*FKU\%7JG#,Z!D"VCA";<I*Q#S/$*J8KXE('U4[SW$IF*3$8
M.=J.W:#+N!'5KA.SIB-O;RWO$2-MNB4RL5FN6P?0:XG4%TC9T%Y^H6Q!]TR*
M??M2DZX=W?O+T+^_[&[-C[W)2Z\\P@,#$<>SL[<_L0N/M@F;ESX/L5[W].(&
MN8A8FS1+&\JRD";AAX3]#^:4L)O'Q,7UI3CYN(,A5B>[WLGN#UZUH\KF_(<"
M 4YM8WKKWJUV_UF<I%?U/7GZP^,3QD*-EF?4#$</)B]_&0F?_D1(#]%5_.(^
M<S&ZDG_B9E8H3P38GSDD0?-  KI_<H[_"U!+ P04    " !Z@0E5UJ;K\#$J
M  !ZA0  &    'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;-5];8_;5I+N7R&\
M%P,;4+?M=I*9C1T#CI.)O9O)^+HG&^!>W \4>20QIDB%AVQ9^?5;]535>:&H
MMF>S6.!^B-/=(L]+G7I]JNKHQ;$?/OB=<V/Q<=]V_IL'NW$\?/WXL:]V;E_Z
MZ_[@.OIDTP_[<J1?A^UC?QA<6>.E??OXYLF3KQ[ORZ9[\/(%_O9N>/FBG\:V
MZ=R[H?#3?E\.IV]=VQ^_>?#T@?WA?;/=C?R'QR]?',JMNW7CSX=W _WV.(Q2
M-WO7^:;OBL%MOGGPZNG7WW[!S^.!_VC<T2<_%[R3==]_X%_>UM\\>,(+<JVK
M1AZAI/_=N=>N;7D@6L9O.N:#,"6_F/YLH_\5>Z>]K$OO7O?M+TT][KYY\)<'
M1>TVY=2.[_OC&Z?[^9+'J_K6X]_B*,]^\>Q!44U^[/?Z,JU@WW3R__*CTB%Y
MX2]/+KQPHR_<8-TR$5;Y73F6+U\,_;$8^&D:C7_ 5O$V+:[I^%!NQX$^;>B]
M\>6M'$;1;XK;9MLUFZ8JN[%X557]U(U-MRW>]6U3-<Z_>#S2?/S6XTK'_E;&
MOKDP]E?%W_INW/GB^ZYV=?[^8UIG6.R-+?;;FWL'_+>INRZ>/5D5-T]N;NX9
M[UG8_#.,]^S"> N[+/[OJ[4?!V*6_[>T81GOB^7Q6("^]H>R<M\\( GQ;KAS
M#U[^Z5^>?O7D^3VK_2*L]HO[1O^#1W7OV,LK__P)BV]+WWA^\!V_W8TE1.X?
M.T=B5_7[0]F=^/FF&]W0[(NI*Z>Z&5U=5#WQ1N?E)T_#U27_>=-T95<U95MX
M&LN1%AA]L2OO7+%VKBMHC8=RH.>:#A,,-3WM2'3&7?%SAX%O^3U?;%WGAK)M
M3_R<._ G95S_86AHED-+#S[\T[_\Y>;FR?.?KV^OBQ]>O7J'WY\^?U2472TC
MC[2=8>*'^4^#VTXM]HF-\X=X]]95T]",C3[V_<=J5W9;5[SN]_O&0YG97+??
MOPZS#*[%SL>^*(O?IG(@2M&J::/],!;T$BNAXNF3J_]]C1,8:MI >UKQQ*>B
M[HNN'XD<53O51/2VM34UG6ANJ$!:3]WXJNW]1.=$@_\V-4S&]:D(^R[H>5H"
MGUKK1E=XL@PTUM*)7/,)>_<'CY5718NG]=!Z!T<$\+M^:FE51&ZR,WS(-,JO
M4R>*/)Q%,MD_/852"H/WTU"\ZKJ)WGE_1NY_!SUXNI,KA\*Q*BN^<Y7;K]U0
M/'L*943_;IK6)7Q"1XM1W'J86(9N;D1K@60)H>)RTX.R*8VP!_JWKWUQ$.FB
M]W@;#<PBVS>/$R_K7\E@R(Z/NZ;:K7AW/$Y_:#H>E\YQ7W9D;/FA54$B5'2T
M%>]YB7+NF[(9;!Y9C#)27"D?;A,8BAXE"P@9(%=A4(FP'9RM?"4T\E.URQ;,
MA]AX2&7?M5 Z'=.CI0E(H ;^('G^NOB[3$9_MA7PG'.*88LD&;;-AH9N:/E5
MR=Z [:U?'*OLZ+A'$A#:NZ]H)<P!U__=6LUD=M1AITZ(^:9L^]]/>\?S#>7!
M36-3^57QMJNN07?FVN.N9]76'SL:W4]KW]0-[='1<_9Z\L8K.E$6^W>[D@@K
M'\P?9'WT],_/_86A3W%9MW2.OY..XI'?]"VK(U_\L%^_N3C7;.PK&9O&\7ZV
M^/SMXNV['XM7/RR,2W\E;=BV<@1Z))&*_ +9\LZ7E7!EM""N;<B;XE.Y+G[V
M8(3OB?OV,!I\PF)B@@3\T3/FAUB^F_&D9BKH6]7"/A%-M@+[\H,K7%@3[Z7T
MY#L?9"OCKAR+<K,AZ1?6V<N>Q6!$Q?;'=7/&Z]"B)'PL^R2HVY[_N&;K3X)-
MZ[TKVXG>QM3YXG^=ZBT&78ER@FBR0UVSHMR1[/=#PU*&.4GNR#!C82:2<IJD
M@.5'>NF.V*6?2%I8JY]3)Z'GFL[;W;'^[]6L^+XKURVKXMJ)JJJ:H9KVM'ER
M)6B+WY[XKZ0,B4O(6J[2[=#*B6%_!>U[ID33L4*FB6JW'1S8B<R5&T8*B^C$
M:;VD;3VTWHHCD0EZ3?:U+\E^-W220[$9^GVR[" P8>KKXG7I=\7WQ#%$Z7!$
M?RN'#V[$?A+W X^ZY%'5L;RZ'44K)-YM0Q\SKQ!M1CT=MKFL)NGI.]I!PZ/2
M+BL:;66$98J CXG+.O(E:8]U>:*3& KRC[QLA(E:@QDVQ6$:R _RCL05VHU<
M>1=<^178A2? ;JH+ZV9.(0/6=^3P[+'C8D/'1TM>E]V'@LD-'U5FK$D0?*,$
MJBF49<:)?QS9P]F3TF".Y_>)M@D9?>+%#2XED(@O\>J6!*856LB#6-S FKS,
MJ7*1&BK%S$X'5V'QK'2;FNW.IA%WD/=8L ED_HHF]K[E@F#$U^SMWI5-R\]<
MD?JY\D31Z+7%/>&EEB1(9B56M0GI;XZY@J2'?8E^VHJ# R51V_9/LC5F91(O
M.B'QEH@=0)&U._4LO2QE.NZZ;.&S"_2 MT4M!)=F00Y8F750R427R8O1/ Q]
MY5R=D)EWJ:9]MD\C)_-;)"5D,SA"Y,+#.3DCW#G%2O)+F%RCN$VL_#0*F3H2
MH[;YG3[=D@X0+B2_V\/M9O==5314%RO8P>T8Z[CC:>AW5SSDQR7\"-XJK;.D
MPX9E<GB-:-U!HDE_5A_(L-*Q>R48A&@\B<M2]2+Y^T6NH>A-O"NV!.S[T+F-
MS>_!_M'R]@UI1SY2,@CD0^L''$^(Y8'-$FY88=7BXV4#I2\W/O/"(W%%O8,P
M0HH5'<YHONQG&[3$C,& \TC7Q2\N,([)7)"W2E:Y=\3G0@:2QPI1'ES#2P?*
M[RQ2E19#_L5/+ _J:5X>1-14Q9$Y' 9A)BB((TDR[*<H!)(P\($8$!Z92$JD
MP$@7%T/!P(8F.:U4H?V/43Y56>]I(K+R_!"LT\_!^M+0^Q!(MV2?1:&RH&[*
MJFEU#^1C\/)#Y JFHX71?_362*/XA"!L<H4 IZCZZPG!1#8I6%5F7;10(,Q"
MU#?$_<!JT7O_Z\GUE\6^:5O$JK0""J-Q<JQ4R>\ET@QD-RQ .EOT=?%7UB7_
M@>.GO_XU^&5O.YIL$KHB")F(3VEO$LILR9!#H_+(B3K:TZ[(6LMKM%QBBX:4
M+C/0N"-?Y8H(F[VPH]]+LD\G<]0.Y&4Q#_TN\3/QP6&BL28O[",3,$GC(&9C
M>.P@YE\7/Y(5:0NB6^W(W12:]&N&F\"L.K#H#5_\-O5,6)J^$I$0"%?9VS_7
MX6ZRX70,86)8XD\,$VVP:_!238Q5C1S[# @5[;>PSN?@!IG\63;YU)WOAB84
M,A(+CVR7R*/LS7\A>2D+]Y&<&[\2;&+3!_9&R"LQ*/$O<7K-4_:'@KF8@J?4
MXR67G"4E01,BKUB$.?>K5DLV[H+N"#$54<,UV.!*8B1R']W' VL!GZ@/<QO"
M>X?R)"^Q 9A<?&E%:JO;7K$HT@;7HH-(G;#.9974-N6:Q?^D@B%,&IWQQ,['
M+?-Q[DM&PD8VF*;H#Q2NB#IK6+>%Z&-P+44NW6C'DF QQLEQ0G5R-  0@ZU!
M@AKKN[Z]<TD 8%@@O6^R[A- U2(CB7 "$]!GC%S05+5CZH#)X%P0W:O&V^+@
MAB XDQ@0JN3\J/^;#M!"PNP,0>\(M2;NI\5;$5$*J N=)?WQH#2,NL/3&U4Y
M^6 S/6FY41A$R8P/^OS,26]_)C>G<1"V>;4NJP]LMQ*&)Q>- FGVLL"4Z4<(
MW?\Q0.V=,M<;G!NBBD-)ED]<(?"C*.*YNSAY/CK5C(EFN5$%<AU^7Y9N'AHC
MU3J4\K#JN[Z3B&RF]'@><ISI(2(/[8*?YI<E?H<7U->NM6AGKM56JE0"_$7B
M43"UZ)-3XUH$+'?\6Q8@\'NDLYS]0K0GE0C>U[\$^&(<2'PYM!OZ#VZXJLEO
M(JZ$+@^C:!Z2'G)=M>.MI:=!BE9860EB"#OK7/B!_1IN \#->![$%/$ HK^/
MX$( E> M280RL)WL=32ORBAE9[S*UK89ZBMRW<=(;D\C5N*5TL-PGV;K\>F"
MECF SO&NJ07&7UXA?P(0QSR?V0J1=+AO?6]IR(X!&GHX_1FAJT2")?N?Y*E"
M_2#6&. \BL<+WE'7X#5_VOA4K3&63+L;_'C5="O]J9]&@9;(A5X8B(=@6IEF
M9ODEKTO2.I4+V#=G2IC%28\-HE36+"@D%"L1C8 &\;[)!:M$8? FQ"^35 @)
MQ8K#'7(CRW85P45F6#45<](,[JYQ1W8^ $=K>,\.VJ%')$LGZ3Y66(JXSLRT
M:_*DD7FA82</Y@BXVICJ^\"P33(O2"G)J<&0N;'\H)+:FT(7+XM<:WK-L^]R
M#P*WF:!U6:-ZY2-1[;]-_-BHT^X <TE(S@? >.#'@X)D*FS8^]#74R6NT9D=
M, 45IH$"2A8'WE)+22^R]P].W;EV0\["!@39]@S^ZYI8@R*>8&/Y6D'B'6W9
M07/50I>8 ]#H@S:QEX0!+YJY#^[SJ"9P&OM]3YZ)"VDP?0\@,SLP@P)]$F4H
MNH%<(#3",V D$+ZG-_(SSCJ(A01LQ$AX"?+,PTK@*+.QU)$F=@?A/]14 'RD
MCRS+^/[O/\=<)JRZA)WJ5S5 )#B2A L/-3<GQ3QB9,OA!@$VX68<-*%TYA<$
M?R(Z>>G$O8#4%^+(#"/*4CZR>=K9I1V)]%4]>5F_8R3U](0[X8M$\8'&%1XG
MNC?[::\3D,^C8>R=&V)DBA,-$"*M,%@P!(][15IX9TI S<^JI@9B3#J%!$RL
M)N):>#Q0WY6$:PQ,]L/0'X$^,.-EV\@RN^;Z+*Z*C\RXRD)?PVUD8."[ G6X
M91HI?8PBXGGVEPZD*%L?DJQ\.J<Y1<4[9_;YJ _) \S-'6L"K\YT RTI89CJ
M9'J&4<1:@IX %I!&#;%.;XF GB:@#Z!9A0*V1;QGLFO/SSE]=N;''<\!ZY58
M#?7S#:PAE=6R7F<WT##>7B7T-OJRNF[H-Z009*?XC A..F$OY3,&JELN,^"'
MR@B9F*BR,Q&$[KK U(U/101V@TM?6(=<,0PEUF.)]Z&GH.=4"W'2(T'']:_(
MNG=7\EL *[,$4%:?P?RH^*-AG"V'?0S$*8F#LE'RK0):D"AD@8G4SD6@Y;XU
M*;+*-17V:/B0[3J#[32/9"O8L*6F@Y6T44#04\_Q78CI8IS.!RNC@TZWKO%[
MBDMOB7F/Y6#)V@,Y*FQ9F7N%5 Z)/K:/_U9V*"@0".K9*O ;)G$V9(#,^\V&
M;3$F!<Y=[J6& 0OX]Z8=^E/QGHP;:?,?K]]=R_H/I*D^PJNBD_GSS>K+9U\4
MGJM2B*&<%(2@7 @0MLR@M0 .=(J0G6Z ^$A\ 7$<3$4QU\UV=&WIUWT33<\H
M:^;:$*Y- FXTL7]Y+'84 FB]#&?MU+5C.[]F68=41YBQK(B!?)/BO!P%AI(@
M89VV[:MS5]Q,Q=B/4@6!(%<4,#S!C1O4,<)C9+4;BY@-8M88*GZFYJM2///,
MCN%4<P/6#(G/FT4*799E2O9J:BZ$=Z'XA\S.I[/-G/QD# 6""L91CZU *<UL
M-] .HJ3$08>'.R-8T"KEED1GRTN>43HCWWP. :99FLZ)!39G#Y#E0L(-'W0S
M;(>RH!0X084:VU21;:)J:6E];>++D'!L'$JY&,AUP,>&H'*!!*(J2XV)VJJW
M5I E>CXI0Y/*FZ4U:)+$EKH^"4$[X5J-EA'R(,"076[HF+QE9_GY! +6!\'F
M6EL&IT0W8U4$6CRP7/3U7030+XPLJ23+SIV-GEB=<CP3RUH=$DT$0LA37T<B
M"7YWS1$BAS *O:0)?"$%H%7%F3<79J+GD!OYT/5'.O0C:L]@W*2\PM5G6[6Q
M%O:C$Y7F#V:BX%U6\Z2*8HE$XA4P"L62Q@577!BUV;!O1:]%[G[%!2_)F$GN
MN"2/:+AP3,%!'A)'YS/29S_HQ&RI@DB^BC[XWR$@/[*S_R.9JUH^"T^HFIO!
M1W-E"(&_0EX7X;D:%<F0 0+'3AZ^???^3^7^\/R[1ZN+BO,>Y.TR4Z3[%/O%
MX2*<-*#]S0AW?3.UB#A7$>#TJ<8+2,A=GF'165F#S?3_=4K6N6W@U,6RE@@I
M#.1D6)T$T@CPMU@:D&RFQ5FQ.FJ5$PSR0,YV3=3MNXSUO>]),6A]SO+YD--"
M^H44QL\'8.QEM3.]H1I,0GC%WB^.0XR 4IN'S;6[7A43CQ9A5LTM/Q+D(=DW
M&(_SVI*!9O/)Y]",/C&?R2D&#?WY*^+1A3:NOCA_, LJ92J K, C72/'8;)D
M&'7ZPRZ>%[O^2&L95M'(!)P))9#[ [&:.)_B)K,7RN6M9+R3Y*=W''9;K?$J
M%&MLV#.@M[D0!0 $EW[0P5=DR'PHGM1!(HZ53WWO?L[R _(>DVAS >&2<S%K
M-Q'3%CF7@]HL=UP)TD I+^06H(_I -B:P,*9(LVH1HKXQ)&/&J?9O"TS0HAA
M6G+T#26?AN19QF>KD!32 !V)+"N;&-BD+Q8 9S9V:8ERX&)KN7J DZ6T%,VO
M&*J'E*&!212Z2F(?3(F3;IL/[-]+O5(_BAI9@)_SC3$11)<@*L7;V:&I#4N5
M?+17[-POK56#[A4IN#$P/1=I2L3 B81JZ)EE>XZ80@TRIJG)_ TGS;$![,^<
M3;\*%;.L KA6.I)=N8&=!M8 *S6;0M90*, NOQZ=V/&%/> X(L%!3:$V[^5_
MA.(CXQ,=1:2U4*=L=2/@&F#NCJUB4NP$BWULO(!06DQE#G(YN!G&/EOHN7SX
M6 2?B_$%AGB[6=S+I<%%Q.<T4W\6?I: :R8IJ(G)<#.IM72=YETXG8LF,>BB
MTZ'T8L/3 TYIR$;8?"A)HAG!3*_HVXR,:VG&@@13E#4*?O6)T% ]P6"H-U(!
M,YX.FDY \5CC71UB/M:D9*XX*A]=M>OZMM]:?E+!]V)@F,?GI6&?LY+$80""
ME  XT<Y^$DJ2$:U,+5'5"Y;YSOE,;5MN0W3@3,M)C9.:+';:8+9@::1R-93_
MFX#>N\UT$7,P6WPF<]*&Q!:RY52+!O[6&7M)_2=,@/!D->-8Y@RFK.Y7>$NU
MO$A$!2T6C0DH:K&*+FA]RB!?T_X+HA;JG_1-,Z(C&E4,)U94OTKR02@RV+3]
MT0<IGJ\BA2RQYE;4C!WS!80E"00N"_6]OL+"7E(OX*]F(<^8(CHTR7RAKRJK
MV]!J/0N648"IJ:_4$I6'9@QN:I8^LR" FU9E9:ML ND<LSQ9D9PXJ2#RVIH*
M@B"^#T>%D$5L@H.9N_2(X)_),OF1+=G0$$KT5LFBAA*.'6I5 %A.%!4DI:#G
M<W-='PD<4?^]1,)X]!<7%S3(YYH+#PBTU*(0,1XVG)LJAOY4M@A5\%Q+I.Q@
M@WGAW__TYM5/_^?[J-).B43*FZ<T64:;>=C0N%+AC]*[-5=T0*%'P)K'H.?H
M0<PI24XUP6F%!)0G;;R#WVHYS!#@(_ZW?4J>@/C<8$%^?@\=K9G) 4 F*C38
MU*+15TKE@":+8(([0SVT1>@)Z&CP<)9I73LI&6LEY'#6@"A .%?-G*V!S$"J
M1&T70W*:J(;5I*;JR+CJH\N,WX9H+5FK#1/;C^[@O\89JX4Y&>YQB281D,"$
MS^4D\[>CWT8,3&ZXXIJS5U.G(U&"$C?5Z#BKQO0E]S$$N=GT-'_JV[FTLTBD
M/IW*#HN-8#=:LXK6%21GR$/?/<H1Y[.! U#T>5N6^L2'=X\N,>9#I"@>\;%Y
M&L+?3]'K('E2! N_XGV0U(42WE1:$[G3AD&1ZE0&I?]#A<M+.H-T!$/342,P
MPM'!M6!#LN54;7VE"9NZV39 MBIG&<U08R8"W6QBV4'2\I,O#J%IQ!78>G-S
M6?!(CZ*V)[-K7<6TTKQK -LP? N3-)*7M76(Y-(@>F5I*))M>AKO]TQU+L:[
M)HJ*FV_92K*\Y= V*,H^:W=FGQB$7^6[\7D]'K'Y!$LEF:0$ZFD9'T":],#I
M %.DJJ,Q-@#U>;6..9+K4_A1V[(8MJ3Q26>B[$A_U!XQ7C,C06$BY#O]6 [:
M^RD:A N TEJZV-)1CME\K@ORAM)J>DA432C[#.4WE@)&2S-#4[M@64/VCAZ!
MJ@$ULO[7&9WTKZC:XM:9)K(^%\U(V]*=G/WP9GKWYN9)K$A+5J;/*KH$$&Z9
M.T73)_/)^#XYBD\.0M9JAS8>;B@0'LYWD,!#Y8$+%,";V5$A -HVW ZD9RO(
MEST$Z4-JF=:DD)28'4CB=?'.Y)S]KCPE'\\!->>!W+$KFIU[R;RC<V'TVJ([
MHEP;S$>LM.6:SM.5_*2Q1Q0' (C_^D1ZLV2BX]",(T+G4?7M9+@ESPCWV):*
MU! X0A79EO2UYC6##GO(G(4\(8\^RYB9LE3IEF5*<C80_9&HP4@?J_);I?A?
M&4R7ZI?- N=&JC[D@.A WJ$&%>F>%$#MNRMIZM3=^; ]K&?MT)M$ G5P7-RT
M0C8=-1SH76*1I(B)2^F@RV[YS*\D_MYS;G[L.[M (:KVO%@GQTEG*E7]LR$=
M#5I5:J=Z"S<<@!FTZ 7.!)20E'*:C0JG)EI15/DQH.#N8BY,,W?"0PJD(J26
M$NZ 2N0V.* 1\R+VL%+2]T"4%QIE46W;22U:FJP-!4"'07N;A[CC>86H;1@T
MP[E:F)5FDKJ9,Q>08C*F 4!:B4NQ3&D]6/CXXF-:L1/R:UDQ"\L9[V= <C3M
M]'_;!3S+I"?R3@@A/BMBT/2^[T'B9!CIT.Y<<L7$F0"(4@WNRRPGD$8>$0]6
M&"9PV*QQBQ])DT_T)^UPMXQ]+B7"!E!@I?D[[ M)E6IJ+,%3Y_&*ZB+P#:\W
MU/S-O2G$)73P)%+3.O[1BMFYL2<M2P HCCDYH%5-+SOPB0H(NUE!=(2_4UUZ
M+ -&*2&"JWMF9@9+VM ;']]+&:$%<R$3'U D@Q 654MHS9& 5X[(0*ES>HJ6
M^<=N?BC1LH3J=0D6I6%"/$9-QW_Q)?_^E1H?%?LD&[:TLK.56'<+Q)<).VNW
MI['B"D67%'(#UA3&R*X;,84877"6Z:A3^J3B!%TCOAH:*6B2T3 "%]I!-4G5
MN#!+/ HP1EJA_?^']C%H0Z1_(11ZG2$+KR*R8,^^/@N!?E1N3Q[^Y\*H)'0Z
MJ@.2,C$IAV,_M/61BTU-M)(&LKQ1A6U3#([NPULD*[#F"#@ZNBS6ZN"Z#E>#
M6 *@R1&4=0,@NO):S2D)^>D@KDCTB;L)79:H 6+/B#6)_* Y;DEEZKZ$M;LB
M^""K8MOV:W3UHW? WI6KX)S<9B(I3BE?TO+IX"XE]=:I:$NYE,5%O=1FQSR+
MD7GCG):PZ5DTDHODJ)]E"2X#\7QB.SBYU4V<18+[39$<"0FC^RN[9:IG5E?A
M#] B'Y04Q)IG'$YQ*1((3 .Y$^'(E^4G<C]/TB'1?@BGFA=/RZY"?6&XRH#E
M:+#EG<3(<IM<*.0D[MB6VSQ5<C'#'I&I7W9-ZS3I=DD*I ^%O!Z&)*T0%RB/
MWM,PNO1V@#W_1O_RA8$KB4:Y1;LQ?-VL,XKO]_ZJI9431W=N2^%!E.)Q-TD0
M<X?KDZ!$NP#6(-)C4N,6)F4D"=(=8E?B?'H''8[".<9:BI&:QZ 65[P6 _90
M'R5.+CQ_M:\!64VN)YD;-B[#H'>,BZ/<91P9&4]Z^1?]>/AFWB&GFBFEL'J%
M<:3^ +5R6<NV*(D8/A@I)#NE$+]@=5-GUK2L[X!_S,)><P[BACS[1MI P^Y>
MN#@!ZV".S_@<[&]YLL_@S%=MO \C+X*6PK\"+)X69/F+,/1*X@VK/-_(30GA
MGKIIX*!-RPI#L=%E0-:8AFU<>E--'+)MN ]=NBF[^;(25Y9U68-,GW5E1H.3
MQ+O!6>9.&KUV"(S.QYZUBU@/Q 5E\UFT3P(C7'4WC=+T+3;3KB6*E4^K,R \
M V&OH_7-E<SY$6F &0RII)E^Y;YB*XTUF@C*IR_XG?)$FM\9&O_!1Z0RW2F6
M."MQ2C8TNP,PXQUIJ+F4[1B<5'>351:MG-?=IZ7GKVY?D]=T:"KR5[]:!4<(
MZNEUSGFOC?.,E'H#X7UKB9Y8(B(I'S&S;?36O[*]Q%)>80N&'!8!;+'&RV^G
M6&T2A33^+/VSX W9?36A]$_1&W,FC*7YTAFIAY=V8DX<R[6:]3!M 69LVJFI
M&6F'+=JDB]'XTV=!BBE(I=(]$L?%4'K#@!169B6B:M1C>T$=L7-;P"I(ON"&
MJ&<)0I8QK;RW0"J[K^/3X$@2QKM0@25]^T?%+L,Q"1CED^7'[*7X7EP!$! "
MO@'4WZ^A5L&[U)G/O</$B^+UA!,AB587,_4*U8,5LQ62OG-HP208*DG54#SA
M=6A/RGM!+9T%=-(:F+1#, 8S,@YIP&OR2R%NH3-)6\1#]6B2ZT_3U$=K:T)E
M-"G1095H&7RN),8H4;"M9!'9RR>,-52VYM@GEE6U6KN%H+CQ)F>IN$_=GN"1
M1 <H0Q@C[NU=6N,>>P_,6/:H#:KEWHC0(Z>UY%)+$&\\B@$R\Q3.(IC@3"F+
MBA(^JGLG!6%V4N7LK,1NI RA"H ]TGF\@?2"< I0(9W$*&[\DUP997K[X1E=
MPV>/I-Y&#;5LB74@%PSONWA1DIKS4=]'-T9EM:Y+VLAJ$*IH+@0C"B7P6DE3
M#G8[PS1 G8="N2 Z>^Y#RB0RJ2=*+S#-O:$T;\H.C&YR(27^B_K<FZG=(",Y
MBW3NB9A F,\-<3*;JY7%WB[W^3VD/O:QA"-Z&#,3M'#.Y"D$GE%70:5PNG?Y
MGUXV=S6B3%'*L3)HA[.1-)_XX%U=MBR;>7L^9]KL'N3;<-MR9B R2$H=*6BP
MF7*#^ U1=9)KN\?Z5,$)TH,R"KU^A&9D9(<K,U0ELU1/<CWSFJ^JYWV5<+"R
M,@@VZV:I>IMOB>K_.$OBV[W*\LB\9<!*/I*2#B"9ERHYA'&ME%)X/"TI 7"H
M8K:TFJ"&0FV3JL4D7,AOL)DD+2T5K33]6C2?"N;@+$'$WD'FY7)\Z,LVI5TP
MY>DMF0*4\-TYG'B'#@A!^Z58F4L9%@V$ 8CW:+F5>*G0VWCEJ-6@'"L*;O))
M7SJA5KKGG'+]9BE691\^B\3W#.$8))Q8MRS+T-5I:)XDP7CE>E]0.!S)9\$_
M2)-O' - ,\/]QQIJC?-2P*L%F,SA>GS76N*D"2M>-X-X*U-9B#+(56%-.LM_
M"LG3;<49R+!?;Z^)/06'W-B]( PV-J$ UP RKK# 91P))2N[/#QI,P@4"7EE
M)#/$/&F):%>E5T)I@1*=-ES&(^D"GW?6FWO"*P 0HBJHCQ[:)P<H;0.QD!\0
M%6[^D'K>T+W3\KVL7 =],!=VCL5):V&LT\/8X<B(Q6N^Z&B6,IOG^A/<1^^7
MT_N08D?0IGC[TW=("H0;IOC^<[X!6J^/15GA8M\#13SI,[BX<JI/)#V6RES:
M&=.M&8UJK"4DPQ [Z,A'VJ<IX*#6NM.G51NZN)=+KT2$+B@]T]K0?&)E@!V"
M1S^E RW#@6):4@9CF@N2$IE9>Z>&3%?9;3"RJ%@9.D/WYK+?U5I#(9<AQ1HU
M<3OSY(KV<:;9)6-[:Z0XHYCYVJ)W@\U22\VZ9\?W0W'94 :41'*RZ2;674]C
M*)/UV0!JS[5T*NF#FM_<L+"X-PO-4Y8#8MQ<>[A#P6J">DE/:%(AO(PWI&ZE
M!$-*"TG;=C.:T RH#U./O3:7.-#BK#CBS(@.=NU+&%F*E.#0H@,MC/VM7:W&
MB>=HRK U@->G@]Q0O+RUA^9^/TH@N-B*$!A"J:A2 L2=K]Q#6!6J44)LO;+Z
M1XOZSJ10+_<P5\[ A'"8R?M-\KT6H%"(&."P<_5*;YW8->G6>DK"])E)5YY+
M*!O!$#N%I!/2\E[>A0'C)7[Q#%5"\C5WI)T5"+#(H>SF=$D<(=4\Z16&XJ"0
M:YM$8O:M"/.=SFX:,K>*7Y8,H#3\J@<2;X6#56?=)$7A$G[Z#U?A\N 40[#B
M<XMJFN2[4F)>>'"D %EARB*X+  67,V44>L3.CQVZU\J,SJ_^/9"%2_;8E-
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M(F/6;QX\?9#\E9&T;QZ\>OKUJYL'C^G-^/C+%P>R07_3-$+K-O3JD^L_?_E
M>,1^&?L##\GZE>PG?N0;R=W #]#GFYY\#?V%)V ($,M[^9]02P,$%     @
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MFYHI>+7(5"UEHA89U+(Y*B=^,]2;VKU^H /*T*.C)C+5!16NANH(+-@UE"6
MO2141/2\^$G"M:XK^G9@+U$;#HJ!&7<7I$[#67G'?0*>2RH-.VAY3Q[M^%^<
M:;OM5N?<1.C:#V]BR$H:6Z#Z<.6IT$)T;>+BH)T3:5H)S]:T,=A]T((O0B22
MWFKV<2!)6>\T_1EU32U1$/7<NZCRU S1FCZT+'OT[UVQJ[P<8)S@"'B/GMB
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MF<]W:@>XN6J>=4V?EE)<^ "%'9'",1M>WW&C\+WI43+L2*I'F+WUS7%MZF=
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M#G)67C/#1N=*KHFRW*C-?CA7G30:QS,+RKU1N,M1SHP^,J[(5R9R(+? =*X
M(V[.NP9U6XYN4NJY+/30 WKZY%9F9J')AVP*TUWY+MI4&T8KPR[IBPK_R+,.
M"7V/4)_2%_2%M:.ATQ<>=_2:ZT1(ZZLF?XTGVBC,C;_W^5RHC/:KM/5RII<L
M@8L6%H0&M8+6Z.V;H.^_?\'@J#8X>DG[*Y#Y%3UDO&)<L(F -E9V6S,!F%;J
M$8RE$0U)KKCA&*%$8@5J U,B9\0L@,RDP%+FV9R\XQE29*Y9-M6G9P0Q@QHS
M,DZE,OQ?%+R2VI ;);4F#QFV#N&H-]@R]'/R)USCL1^TX5AT2&@X,,8MTYZP
MY!'I#1M/R-LW,0WH^R-?5U(MI4*M6+@3T]10<1SZ?>C<=\@7Y0*X:0H&U/>B
MOE\SOJ.>'])3$@2Q%]&8_"FS]L,]N9$K4)F+_"M.O9)I"BKA3) E6X(Z*G!2
MV]-TO[+II+;J&A)()Z@P#!Q:P?^+5DB]0=3;M;$7GA8[_2%] :A>[,5Q;QON
MN']J:8/A\#!&%+VD80.CJ#\\1:KO#?J!0\C*'L H&* LW<H&%ERD4?\Y/#1&
MQ\+@&2P5_83T*?5B&NZZWJ?^:;E'_1#C9DMMIY@\TB?L9RMVS<V",#*S2!0<
M9.4 0:TGF &="">)$'8HKD$!P2IF9.Z0S;?("KM>2LW=]+2BM.-7@AURB:,0
M6P+NY JG\\H.X*)!Z -V>7@:F8#@L *2R0RJAO+T4*X)PS_4JG&V6BY&$@53
M;HI]MB\^$TA8CD?C&5.)Z@VZ92";$B/1!B%*RQIAPJ9%4"6>9KDQ_:$M^".(
M3=LL6-:V1/PP5N,:O<83T*+O.4=+#BN= ((#SBT%B4VH3>DF@L'J&DMLC>%M
M@FO,6.2%NGX<:C5<-KC8@-V$RC'-D*<ZR8;E>48\+1>&QF"\BIZMCW3LYUWA
M.@>73BAF =L 4XTN<D)ZON\-^STRGAD4LRR3W%02,[QO.9%MHPNHK<1X1T>5
M]E]V9DN9/>ZNB"'#[)ELT/U_I*K<VQ"S68)7Q(CI!;'@8.2P?@MP?[I@',PV
M4FDQ(%'4[ "1N6Q$?F5-<[@5)Z!,@K#-I7*PYMJ9;AW92B\X**:2Q>;5T?^$
ME2)(]4O)%VDP!_;FRBM8KY[$ZLQ>W6!3M8I9CL8A+ /?BZ/=1E63+'@#?["S
M6=%>/;.>_KY\,SDT5(YI+0?+T?ER3$\Y:XZ-G"J]Z\0OU]70J2=#8PC]\C6A
M'$>'IM(Q\6HZ;:=4$ \].@AV\:UI833$*X8MW7 8>%%$;6I$V @"GWS#?&=3
M[*C;ZL.BQIIE>TK.39]$,*WYC".<9=\H<CC<U^==U3TKE,Z^ZW:W\2C">,S=
MT\]>9_/,%.^CFEJ_+L?%HVK+7CQ-;YF:V]N/@!F*^IU!KT54\=PK%D8NW1-K
M(@T^V-SG E_(H"P#[L^D--7"'E"_N4?_ 5!+ P04    " !Z@0E5'HH.Y#X&
M   _$   &0   'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6S56&UOVS80_BN$
M%Q0MH-F2+,EVF@1(F@[9L*)!TJX?AGV@I;/%52(]DK*3_?K=D9(LYPT=]J'8
MA\8DQ7M[[KDCV9.=TE]-"6#975U)<SHJK=T<3R8F+Z'F9JPV(/'+2NF:6YSJ
M]<1L-/#""=75) [#;%)S(4=G)V[M6I^=J,960L*U9J:I:Z[O+Z!2N]-1-.H6
M;L2ZM+0P.3O9\#7<@OV\N=8XF_1:"E&#-$))IF%U.CJ/CB\2VN\V_"9@9P9C
M1I$LE?I*DY^+TU%(#D$%N24-''^V\ ZJBA2A&W^U.D>]21(<CCOM/[G8,98E
M-_!.55]$8<O3T7S$"ECQIK(W:G<%;3PIZ<M59=Q?MO-[D]F(Y8VQJFZ%T8-:
M2/_+[UH<!@+S\!F!N!6(G=_>D//RDEM^=J+5CFG:C=IHX$)UTNB<D)246ZOQ
MJT Y>W8#6Y -G$PL*J.E2=X*7GC!^!G!C'U0TI:&O9<%%(?R$W2B]R3N/+F(
M7U3X2R/';!H&+ [C^ 5]TSZRJ=,W?3DRMM*J9N_05XT,0'1MR=XY7$&SW\^7
MQJW_\10 7G_RM'ZJEF.SX3F<CK <#.@MC,Y>_1!EX=L7O$]Z[Y.7M+^4EQ<%
MGW:KP^)CHUDA#%^O-:RYA0+KRGTQ; <:&#=LI2HL5,->"\ELJ1K#96'>'+-/
MI08XR#F[%7>'"Y0Y^A,-1C?JGE=6H(4C-D^#:1+B($F#V6R.@RA-@D62TK<X
MF(41N]:J:#!/AE=@ B:Q+=W2D*D56S;55Z:OFNNKF)3$:1"F,QHD03BG01(%
M:4C*DC"8XZ=><J/51@NPV'9H3!8,BY(@0[$LB&=3]#68SA8LBH(X6^P%"]B*
M'-B&:RL1H&(OG05IFK%7/\SC*'[[8/9)65YU6X>AH&=9, W)>V3Z-*-!-@\2
M!TH:!U&<L9LN(PUBJAD6>,672G/J7HQCX@![HC7'[/,&J2TMJ]!#:?";+!A&
MN$8[4F&KX*[MK<!!CU@YLXA,V-D_6'F/5NV/U. *BAJ[]8;L.*U(EJ;B5B%Z
MM<!@K)*HE+XH6Z*/SD;D3708M-/6C .TU3Y0T6V.PP/9=GKIP?_5Q2?DVED<
M^M:2E\WBE$VC&</DI0N6I6&; ?UM4!*%PH"48#8P+=',)XJ4';%%&#S2Z)@;
M8P))))IF09+2"*D39$E"(R1G,INQRT:3XX@2_J,"JGV]@*L7;'G0MSRL0%2?
MJ[44?^\+$W\K5ZA6=8DV;*VY;-=:9AJ&Y8H45YIM '\*MT!F>:T:A JY?!2%
MX7A*\%=(C#%6M##=9PVN61 8NB]8X%JBE591WFA-H'O]M,J+0CB.H1]'43H.
M.]UD;<NUX,L*Y10F#^'W=.R4M?T8^TY)C:>1.6B+=PAGN.28GR4 '?M&55MT
MPI$;!8?I'Q#)=2^XV^!9[W%98N1Y*8!D$13?W=J%,?N"D\JHI_ FH,)QVH=2
M_(L,VI);=+[PO@N95TWA <1[ F@][+>X\Q)RJ)=(S&GD%$3C(5\,=M?ORI9L
M,5Y\7[:,_Q=LB0:A%-^<O__.%72K$ 7V>KOW#"._1Z3_Q N.;VV6W,9C"/PQ
MQ-HK@>_>G(YZCF :9 M?BDK8^R&%KNXKD'#GU-=+/%%D>YH]YL]YGA,UR$ .
M8DNY=$=>T#;MAR&][G+:6\94OO&7M4&ZZ;:6M[<U/$,]3(1PQ^3 ,\:0QY@,
M M[?8&C3PSO,808>0?IL$-3DL;6G>#J[\V Q2_<W2FX,T&UB$<R3N#_"+A]%
MG 7S6<@2O&UD[-Q=+@[<"0;U9P[XX%H/UK#A_B&#P.>.>:K1SV+5YS?ODKE6
ME"=:)@8(2CI1YQ[#PYO*5I U1_RC;#Z..D8'9&A7BKS$]6@<]TSW-'$$:^2J
MJ5:X3O>C1N<E'O/H6%V+EH1D]"C;=Q/DO?&\IR/95R'M$83\1FDW-X]90UT(
MOL$<5;>QHN;[\BZ@PD.?E"WO':(@'6$0^NF8??3,L>Z,?TQ6JO*!^P$[2O8(
MD=</>DECO!V7H#XCE* VG5A4ED5QVQ_&[*D'PV3PJ$/YM7NZ&N88ZM]W_6K_
M.C[WC\+]=O^T_H"W0B&QR&&%HN%XEHZ8]L]5/[%JXYZ(2V7163<L\84/FC;@
M]Y52MIN0@?[_#,[^ 5!+ P04    " !Z@0E5LU@I+G8&  !W$0  &0   'AL
M+W=O<FMS:&5E=',O<VAE970Q,RYX;6RM6%V/VS86_2N$.R@2@+%%?2N=&2"3
MM-@L&C28M-N'Q3[0$FT3I427I,8S^^OWD)(U]F3L-IN\6!+)>W@_SKV\].5.
MFS_L1@A'[EO5V:O9QKGMZ\7"UAO1<CO76]%A9J5-RQT^S7IAMT;P)@BU:A%'
M4;YHN>QFUY=A[*.YOM2]4[(3'PVQ?=MR\W CE-Y=S=AL/W KUQOG!Q;7EUN^
M%I^$^VW[T>!K,:$TLA6=E;HC1JRN9F_8ZYO4KP\+_B7%SAZ\$V_)4NL__,?[
MYFH6>86$$K7S"!R/._%6*.6!H,:?(^9LVM(+'K[OT7\*ML.6);?BK5:_R\9M
MKF;EC#1BQ7OE;O7N'V*T)_-XM58V_)+=L#;-9J3NK=/M* P-6MD-3WX_^N%
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M,<AI% 6S68C/1;!8+!VGQ["MJ'AD'@JOB,4DF(1C)\-T-D=TH[>^G'BD?-L
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M/LG3(C\MYHN^'Z)<=WXD!(5M^*=01G#!9'\OU#QM?FUU8W]DU ZW/]7ZAE5
M1WAK3$75,+VP9N!OJG+//SE:E555[OARJR2VEP;@^W6)"L3=T +-;]!>_1M0
M2P,$%     @ >H$)5570CPR#!P  EQ(  !D   !X;"]W;W)K<VAE971S+W-H
M965T,38N>&ULK5A;;^,V&OTKA#LI.H L2[)\R>0")#-3; O,;A!WM@^+?: E
MVB(BB2Y)V?'^^IZ/E!0KR5Q:[(,EF9?SW0\_Z?*@](,IA+#LL2IK<S4JK-V]
MFTQ,5HB*FU#M1(V9C=(5M_BKMQ.STX+G;E-53I(HFD\J+NO1]:4;N]/7EZJQ
MI:S%G6:FJ2JNC[>B5(>K43SJ!N[EMK T,+F^W/&M6 G[>7>G\6_2H^2R$K61
MJF9:;*Y&-_&[VY36NP7_EN)@3IX96;)6ZH'^_))?C2)22)0BLX3 <=N+]Z(L
M"0AJ_-%BCGJ1M/'TN4/_V=D.6];<B/>J_%WFMK@:+4<L%QO>E/9>'?XA6GMF
MA)>ITK@K._BU\VC$LL985;6;H4$E:W_GCZT?3C8LO[0A:3<D3F\OR&GY@5M^
M?:G5@6E:#31Z<*:ZW5!.UA24E=68E=AGKU<%UV),=N7LO:H0:\/)79<3"W1:
M,\E:I%N/E'P!:<X^J=H6AGVL<Y$/]T^@5:]:TJEVFWP5\->F#MDT"E@2)<E7
M\*:]J5.'-_T.4^_X$9EEV8W6O-X*>@[8/U6=<5.PCX_D!L'^<[,V5B-O_ON:
M-[RP]'5A5$OOS(YGXFJ$8C%"[\7H^L<?XGET\153TMZ4]&OH?REJ?P^)_:8L
M+YDYF<Y.IT7K(RU*;C%IU6 M/W"=&ZS*RB:7]9;90J ",U2C]@!JPVYJBQV&
M-?5>& (1?S32'KO-!VZ<3"T)$>L)8Z-*\ @A_B1KC*C&\#HW;]^QWPHMQ" '
MV4H^#@<HD^@2GSS=(SI<9P4##NIY#Y[:N=QXPY(@G<UQCX/%/,4]#=+%%/=I
MD,8)6X%*H$C MJ*&5:4#X#F*5%+:$-M@9;PXQW4>+=DL.(]2-@^6RRE;?<NO
M;[!\/IVY^W21D!(1'A;^(3F??1MB?63VN!/DN1>A^;]Y;V55]L#4CB0;Y[)9
M-'7W^73AM(^3J;_'Y^Q^=6,"7#_C>H>K<]G'U=T=.6H*R& !FV=!,DMIQV+^
M'7[X7; MBICRQPR404KN&@065C.^VVGU*,'BHCRR*$S I8@>'0O08#H/I[TW
MO+,,N0UNK;#$P^:-[A+9.F=5WC?"^09D)7JR<J#DG@#U87;"G3R02\-Q.!O(
MCL)%___;D@UB\I?EAHBN0%H(G:&4& HJ\UDQ<%?G1&FH#I'.\!^)S$IE2'R_
MS0V>ZJ=J-Y;#N33O@+S,#9>:[7G9N G!465>7)N%),M8%Y;\51C6F,[TVY)G
M#^-55JA2F/$GH2VQB$<CW6A=I7)1LI]^_&&9)-'%8(>?<S/QQ=O0D7Q&8O<*
M#"9+(AZHXVL$D 6*6 $6CCA9 ;U4HP?F=]YMX:S0E5OVTJT]-J]Y>30^TB=R
M1+4KU1&911BR]M4,(A&^3EI;NS@:+QCL^##>4#Y*R$'8K=LRD$?N^QRNL %]
MFVGTD1VE*'.0J6:<[826BC@$G19H&$X_2%NX32^LHL%6#Q"(V&PPS;CU58%F
MK5MSD@.YW,L<R=K*Y ;]7XOP3$4OK3\>:L4VC6WT"<3.']NMZ4]0.$,(1]8O
M,Z7-B0-<@PWM^6'^/N&]EC=I'$:S,:[)^1E+T_ \'KOKV2LS9^-T'J:S,W:S
MQZ&Q?>YCXN4CSB/SEJ7A$K]%_[O_0J23<#8?3\,(XJ)P&8_I<@:>F2[ZT>G\
MK!WNU7\6%BJ,.+GXXOV7FOTLUKI!X]XR#-7!K:(J1JP^2 U8I8UGVCT%%?/>
M8\3O+H$QXDH&@<G%Z5J*VJ[D+JD^<2_!Q]AM%C5?4RA%*;<23WVE#$G^B3Z?
MUVB7HF1O3T1(7L>K;?YC"6])KN>_)>+4-1Y$97AO><"+4L]HCI);J3[W-E(C
M+FNB+6$,R R<H=U,R5],M/4T5"1@AT+BW0OI016";!4Z]*=];RI<AW^;QF4I
M3B/5; LJ#HWL1@^3-UE71+"J%"09L:<8-#NR*_9VP>&=)UV<%Q=FV$H003AG
M==B=B@2%^NP9JX(YS^- VGG371!M 5W0$ J!WNY-,@NB**)7-EN\&C'/3:!%
MQ(QK5Q,ANW'1'9QY ;4:<S0'\_-.L*_U/9<EI8U#:HFD4]'GUO,,@+?;5@YG
MM9>/\W;<GK==FM3Y2:"?0Y )HLX\ISD]XWG0IO._AFL-J0N7=EMH!\E<X]6Y
M.^NM -L57;(X/)+_062B6L.Y72Z3=]R,2_!G.!NY&>+08"T>[1,.;77HIVT#
M2CS+&MWU'C@Z@(,@?/C^1B@@\Y>SY2 R$K2-A8B%:>B(;_L,2I*P?>UH:M")
MVM;R?_16T'<(@]S,%-734X_K.XHN/ ?W.B[R,6]I5@OZ1$&*:WK-,!+,2:]E
M5.]M\!25G"L^9AI<ND::NI2>I!5;$UBOW:"1#J!Y2>6MR&$'ZK9JA6UHL(>-
MVN=3 ^][U5YTT\L@CL[!\,O8=<WT[C$-SNDL"I>);Z&I,X[P6I*$:<NU:(W1
M*4=A.G_M57-R\K&@$GKK/HE0W3>U]=\-^M'^J\N-_]CPM-Q_LOG$]59"T5)L
ML!6=[&R$?L1]!O%_K-JY3P]K9:VJW&,A.&B!%F!^H^"=]@\)Z+]%7?\)4$L#
M!!0    ( 'J!"57M5% 5GP0  ( +   9    >&PO=V]R:W-H965T<R]S:&5E
M=#$W+GAM;)U6VV[C-A#]%4(;;%]<63<[]JYC(-ELT2VP;1!WVX>B#XPTMHA(
MI):D;*=?WQE2EB^)@[0O-B\S9VYGJ)EME'XT)8!EV[J2YBHHK6T^#(<F+Z'F
M)E0-2+Q9*EUSBUN]&II& R^<4ET-DR@:#VLN9#"?N;,[/9^IUE9"PIUFIJUK
MKI]NH%*;JR .=@?W8E5:.AC.9PU?P0+LM^9.XV[8HQ2B!FF$DDS#\BJXCC_<
M9"3O!/X0L#$':T:1/"CU2)LOQ540D4-006X)@>/?&CY!51$0NO&]PPQZDZ1X
MN-ZA_^1BQU@>N(%/JOI3%+:\"B8!*V#)V\K>J\W/T,4S(KQ<5<;]LHV73=!B
MWAJKZDX9][60_I]ONSP<*$RB,PI)IY XO[TAY^4MMWP^TVK#-$DC&BU<J$X;
MG1.2BK*P&F\%ZMGYPJK\L515 =K\P#Y_;X5]F@TM(M/],.]0;CQ*<@9ES+XJ
M:4O#/LL"BF/](7K4NY7LW+I)7@7\I94A2Z,!2Z(D>04O[<-,'5YZ!L\'QOZZ
M?C!6(Q/^?BE&#Y&]#$'=\<$T/(>K .EO0*\AF+]_%X^CCZ\XF/4.9J^AO[D.
M;T=Y_VZ2Q)<?.RQVVVHA5\R6P(S8LMK7"ZA>#+,-?;89EP4MX@'; !/&M"C!
ML7]6*PTK;H&I)4M'T2")QTYV-(T'DVG,3,DQ+W2;JQKQF2%O!MBZI@'7?-73
M@ F)UU)V3;D1MG0^P19T+HS7=XI,-21B&+>,HRO47N3)&C2^%KT":[3(G4\7
M\64XS9Q+%W$:CC/6@/9>G3J!CQF3^.(U6N4 A3/*&]QM!38ZBK"+<9ABOU65
M>SH(<A+&NX-CN)#A^_!_$YMDDT&:I?YN&@WB;/K&1+8-WJS!6"HKR8*V^ BS
M^\4WX^#N:$&1;DJ1EVP\&63)R-U@P=))ZB4WH,&5H82J8$NM:A<*WK&.2*>&
MK6(-?W+(^"")NJV]/DH[AO$M.F^5Y15M3]*:/4]K="ZMBV,:H'0K*6!,&PI:
MK#LM6RGL67OC<-*;Z]+J*!M.3X\Q@ZK51QGWN<$OF;&HY,"=W/.JWD(.]0.R
M+8T'78E/0B$C[!Z:5N<E)YI_D>Q7M?9:211/'2FXE*J5.49E2Z0]%>)&<5V0
MU5NA$4]IPQ" \=:62HM_G"BR"9,@N&LIHC++>2,P(>B%;;4DGJ\TKZETNO<!
M&40'%Z-1M*^!S\,^XJ-\H+\:P6VI 7Y\ JZIPX0JPMWK@J%'+I"]E0)K,'HA
MV4? Q*6+^,@/ZGK9=_N^R9,TC$:'!N-G!K-P_":#.+B\P6"&!A-D&;:"2W67
MRY#]3AWOX1U1]@Y@@E2[*AF-3OBQUH_XU.!G1QJ>[[F\$T*CUXM[?%XQJ3CM
M6 ]\4A5GY[!VNXIND L865,!]0*V_V_($<^I)$:FK"E+A\GAOE4HM"0Y:,9=
M=YQ+>Q9>)B&QMN>ZS_T9CA[PDS,#^.07_XF4EZ^1\CD;7_H"#P^FHAKTRLU^
ME*U66C\@]:?]>'GMIZJ]N)]-OW*]$EBW"I:H&H67HX!I/^_YC56-F[$>E,6)
MS2U+')%!DP#>+Y6RNPT9Z(?N^;]02P,$%     @ >H$)5?8+:E\S!0  ( T
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M6H688)FQ"!3+ [MF0E@@J/&]Q1SL15K&_KY#_^!LART;JMFU%-]X;HJ+P6Q
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M+O_D,J=+(G#F'M3^/4.SW^9]EF\VP $9>W<,=A::D;G_<?F4D!M)$F! R/^
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M/""+!E8(AU+F!T"=+@.EUC/D$0M*PMY-MA\Z4%Z] Q9'$@%,)1=,I17A-TY
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M0"^5F9= R7'63AVL??Y)&$6K\H25/# XX#6/JM,11^IF(*:/#-T+&K-D^77
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MC\R-[%1Z6"B<FUZKV"13Q9PA#GW]('7=3P8.'K>[;9D3;N]?/UA"S/L4=WJ
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M'=4  D'M'6:LK2A%@A)SJ$8021(L.4S.)%Y&"N4)^P5VF'#1MXUVEXFL/<W
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M%"^Q<]<H9#:.]1N_CS1,E 9?L5)ID[WY^14%!4++-+P< KO32YMF2G><K<<
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M<$29&#2+&M7B0PHKBD>SJF9\K 9^9'E$KY[1/>[ +H@[!6R.;J0[150"<)A
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M1GO TS/B#5GCE=F<9^ _D:^D]:D;@\^#W1:IXVB4%D'58 3^@V&Z3*1LEY/
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MC2]RXJB[#MMMK&I\5[M3EGJD7^[IIP2U.T#?MXK2J]\X \-OSO(_4$L#!!0
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M[U'9'M04WNO6K2S\UE:R>FH_Q0B',-E#F.=L%/"/KGT)<42 18R-X,7#LN.
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MSI S0^ID)]5WO0$P[+&NA#Z=;(S9'L_G.M] S?5,;D'@EY54-3?XJM9SO57
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MK1NG;#\K_;3M]]+P\E5E6+ E-_C1R"-:ON4JUTB5E4TNZA4S!6!I9EBFJA6
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M^5$Y9A(]/%/ZY[6UC\B_U6,3V=8Y%1@ET]9V79#W^3Y>"J@3I6= T:.A!8:
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MLL,4VU>09@.^GPNA-Q,3H&F(HS]02P,$%     @ >H$)5?,!+L0R @  (04
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M<(']X_&5ZCV7!@DH'"H:O9MBI+N&[ *KZG"G=\JZ#@G#TKUAH'V"6R^4LL?
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MPIHG\A.5_$;Q37;&L.!*\3B[7!,,F75: 9XO.5>O-VD#Y;G6[!]02P,$%
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M]V8H(6*KZFO[8]0ES.CKW(2U8$$#5B\Z#XLP#!VU#-GVW'HXSL:XYS<]8J#
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MS?D=OOY?@2\LW\19@1*^5D,Y[R*E;7F]_;Y^(\6NVE]^)Z04:?5RR]F*YV6
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M7)=3<DD@QX*VE5Z([4?L_8PM7R8JY;ZP[6-] EFKM*A[L%%0,][]Z6.?ASU
M$+T "'M ^*^ 40\8.:.=,F=K3C5-$RFV(&VT8;,#EQN'-FX8M[>XU-+L,H/3
MZ0(WR%N$=W"39:+E6L$",V0;NJKP'+BI(\ISF&.!4F(.?;R"0HH:9H)K:6Y"
MP>D<-665.C-,]\LYG)Z<P0DP#E]+T2I#H1)/&[WV5"_KM=UVVL(7M'UN^06,
M_',(_3 \ I^]#I]C9N"!@P>'<,]D:4A5.*0J='RCOZ3JP+FY+EW"S%T42OAQ
MLU)N_><QNQU_=)S?OM=KU= ,I\0\2(5R@R1]^R:(_??'S/\GLH-4C(94C%YC
M3X=:D8>U<LQTQQ0[)MM3-FD07XW#./$V^W:>AUWY5Y/Q$'6@,QIT1J_J',I6
M]F5[3&#T[.3X<N(_D?<\* HG\1-UWMX[M#WP"Y5KQA546!B8?S$9$Y!=7^DF
M6C3N::Z$-O7CAJ5IQ2AM@-DOA-"[B7WM0W-/_P!02P,$%     @ >H$)57^G
M1BEI @  LP4  !D   !X;"]W;W)K<VAE971S+W-H965T-#@N>&ULK93+;MLP
M$$5_9< &10(DUL-.6KBR #MNT10-:L1-NPBRH*61180B59)^].]+4K*@ HY7
MV4A\S%S>,\0PV4GUHDM$ _N*"STAI3'U. AT5F)%]4#6*.Q.(55%C9VJ=:!K
MA33W214/XC"\"2K*!$D3O[90:2(WAC.!"P5Z4U54_9TAE[L)B<AAX8&M2^,6
M@C2IZ1J7:![KA;*SH%/)685",RE 83$ATV@\&[EX'_"+X4[WQN!(5E*^N,E=
M/B&A,X0<,^,4J/UM\18Y=T+6QI]6DW1'NL3^^*#^Q;-;EA75>"OY;Y:;<D(^
M$LBQH!MN'N3N*[8\UTXODUS[+^S:V)! MM%&5FVR=5 QT?SIOJU#+R&.7TF(
MVX38^VX.\B[GU- T47('RD5;-3?PJ#[;FF/"7<K2*+O+;)Y)'W"+8H-P!=,\
M9ZY0E,-A\4XTM^[*=SY'0QG7%S:TW;^T W?O3*QA@<K'B@SAQXJSM<^ZA,_[
MVM8?<_C)*A<G"UC:+5W0K E8&JH,6.\(3],]T\]CB,,XO@I'5V$$9\ $W#/.
M;:Q. F.)G>\@:^EF#5W\"MVWC1C ,+STDO"XG,/YV<7_,H$M6%>UN*M:['6'
MIZOV!@6 I^]6&^X,5OKY&&!C9'3<B&O9L:YIAA-B>U*CVB))W[^+;L)/)S"'
M'>;PE'HZQP*5LM[5@5=UO'6/5_9X\<!K/.\QI-.'1C%44IA2GP 8=0"C-P8X
MYK<Y(PK](>Z5VZ:C090$V[ZSH->#[CF[IVK-A :.A<T*!Q^N":CFB6@F1M:^
M+5?2V";WP]*^JJA<@-TOI#2'B>OT[IU._P%02P,$%     @ >H$)5;H#RU)]
M P  S@H  !D   !X;"]W;W)K<VAE971S+W-H965T-#DN>&ULK99MC]HX$,>_
MBI6K3JW4;A[(XQ8B[8).UY-.72UM[T75%R89(*H3YVP'NM_^Q@Z; C'HM.H;
MB).9\>\_ML<SW7/Q76X!%/E1LT;.G*U2[:WKRF(+-94WO(4&OZRYJ*G"H=BX
MLA5 2^-4,S?PO-BM:=4X^=2\>Q#YE'>*50T\""*[NJ;BZ1X8W\\<WWE^\5AM
MMDJ_</-I2S>P!/6Y?1 X<H<H955#(RO>$ 'KF7/GW\Y]XV LOE2PET?/1$M9
M<?Y=#SZ4,\?31,"@4#H$Q;\=S($Q'0DY_CT$=88YM>/Q\W/T/XQX%+.B$N:<
M_5.5:CMS4H>4L*8=4X]\_R<<!$4Z7L&9-+]D?[#U'%)T4O'ZX(P$==7T__3'
M(1%'#GYXP2$X. 3_UV%R<)@8H3V9D;6@BN93P?=$:&N,IA],;HPWJJD:O8Q+
M)?!KA7XJGX-0N-CDGC+:%$"69N]\4%!+\H[<%07O&B7)(Q10[>B*P5O2H,'K
M!: ;DV_0Z/-R05Z_>D->$8SS:<L[29M23EV%>'H2MSB@W/<HP064O[KFADR\
MMR3P@L#B/K_NOH "W7WC[I^ZNYB4(3/!D)G Q)M<B'>:D4=@5$%)%I4L&)>=
M $F^WJVD$K@1O]G$]M%#>W1].F]E2PN8.7C\)(@=./GOO_FQ]]XF_1<%.TG$
M9$C$Y%KT?-@$8M@$9"UX35K!RZY01%*&V5"<M%2H!H1U[?LY8C.'KBV[/(JC
MQ)NZNV.=8RL_C;QPL#H1$ X"PI<)$+"#ID/VKBE!$#Q+C*ZXH+JR$+H1 %BP
ME%5./V-T#.J'27HF9VP5A7IOV]1$@YKHA6KX$V7J"5?AZ2)V- )*DW@2GF&/
MK>))%$5V[GC@CE_&S=46DW^RF6SH\1@JB+(S\K%1>"SO!#P9P).KX!\-WT]J
M&UPRFC?+TN@,;FSDV<G2@2R]2C;GC:D_A$H)]@5/Q_LT2\/@C&QL=8$L&\BR
MJV3+;J6XHLR&E%F0_"0^/SMCLRSP_0N;T/=^WG?>]6W(L',QA1U[(%)66,&K
M56=:BC5@*<"[2[_M]ZKU$O-&8.^"T#NO9#8S+!$7\NH?W=?^5?Y/.JW8_8P.
MD[F8K<"^I:AFDU'"+7:9ER7G&7>/F@W=Z?U-Q:9J)&&P1C_O)D')HF^>^H'B
MK>D_5EQA-V,>M]AP@M &^'W-N7H>Z)9F:&'S_P!02P,$%     @ >H$)5>E*
M&'.H @  ^08  !D   !X;"]W;W)K<VAE971S+W-H965T-3 N>&ULK55M3]LP
M$/XK5H8FD 9Y3X&UD: 5@DF34 OCP[0/;G)M+1P[L]V6_?N=G1+U)53[L"^)
MS[[G\7-GW[F_ENI5+P ,>:NXT -O84Q][?NZ6$!%]86L0>#*3*J*&C35W->U
M EHZ4,7]* @ROZ),>'G?S3VJO"^7AC,!CXKH9551]><6N%P/O-![GQBS^<+8
M"3_OUW0.$S#/]:-"RV]92E:!T$P*HF V\&["ZV%F_9W##P9KO34F-I*IE*_6
M>"@'7F % 8?"6 :*OQ4,@7-+A#)^;SB]=DL+W!Z_L]^YV#&6*=4PE/R%E68Q
M\"X]4L*,+KD9R_4];.))+5\AN79?LFY\>SV/%$MM9+4!HX**B>9/WS9YV *$
MR0> : .(_A40;P"Q"[11YL(:44/SOI)KHJPWLMF!RXU#8S1,V%.<&(6K#'$F
M'X(R>-;DEG(J"B 3=W4>#%2:G),'L0)AI&*@R>D(T)/K,YQ_GHS(Z<D9.2$(
M?5K(I::BU'W?H"++ZQ>;W6^;W:,/=O^V%!<D#KZ0*(BB#OCP.'P$!<)#!P]W
MX3[FH4U&U"8C<GSQ!WR[21@#IP9*,F*ZX%(O%2;AY\U4&X5W[U=7L U[TLUN
MZ_%:U[2 @8<%IT&MP,L_?PJSX&M7Z/^);"<1<9N(^!A[/J9KO&0&%*.\\U@;
M>.;@ME&L\C (KY*^O]H.H<LKZT6MUXZVI-66'-7V@FWAG(GS6LD"=*>ZAB#=
MVC=)PBS=4W?H%?:2-.Q6E[;JTJ/J[IA@6(TEF4O971'IH;@X2K,]<8=>4=J[
M3+O%9:VX[*BX)VDHQY)MB[I+7W9P:%>]+-Q/WJ%7&E\%EWOZ_*W&9!^%[U3-
MF="$PPQQP44/ U1-HVT,(VO7JZ;28.=SPP6^3:"L Z[/I#3OAFU_[6N7_P50
M2P,$%     @ >H$)5<]&K..S @  E0<  !D   !X;"]W;W)K<VAE971S+W-H
M965T-3$N>&ULK95=;]L@%(;_"K)ZT4IM_?V1RHG4)IO6:=.BIMVNJ7T26\7@
M 6ZZ?S_ CI7&3M:+W=B W_?PG .&=,OXBR@ )'JK"!53JY"ROK%MD15087'-
M:J#JRYKQ"DO5Y1M;U!QP;DP5L3W'B>P*E]2:I69LR6<I:R0I*2PY$DU58?[G
M#@C;3BW7V@T\E)M"Z@%[EM9X RN03_62JY[=1\G+"J@H&44<UE/KUKV9QUIO
M!#]+V(J]-M*9/#/VHCOW^=1R-! 0R*2.@-7K%>9 B ZD,'YW,:U^2FW<;^^B
M?S:YJUR>L8 Y([_*7!93*[%0#FO<$/G ME^@RR?4\3)&A'FB;:=U+)0U0K*J
M,RN"JJ3M&[]U==@SN,$1@]<9O(\:_,[@FT1;,I/6 DL\2SG;(J[5*IINF-H8
MM\JFI'H55Y*KKZ7RR=D<N%1KC>XPP30#M#);YUY")= 56G*H<9FC3V]JUP@0
M"-,<_9 %<'0K!$B!SA>@_$1<*/73:H'.SR[0&5(!'PO6""47J2T5IY[-SCJF
MNY;).\+TM:'7R'<ND>=XWHA]?MJ^@$S976-WW]MM59V^1%Y?(L_$"X[$VQ6A
MPK19JVW7\))N$'0E&4NOC1>9>/HW>IV%3A(DJ?VZG\50%<23B=NKWL'Z/:Q_
M$K9=G+I#/@79Q@GWIG<#-W$.((<J/W$FXXQ!SQA\@!&;#31&%@SFC)+P$&PH
M\IQ)- X6]F#A2;!')C$9%,]L>O8/YG" $[M)?+CD0U7H)\>HHYXZ.DG]#81
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M#G6C_J74^RB&0RI&&D4?>GKH00L],$*_SV6*XSJ=R^1&*X)U? -%VW%M-^@
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M6]EVI E84[EIRVB1"RZWRO7YBJ U4WU"^FH/JO)4C<8J3]4(*DL3ZJP\E>=
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M+$R7!FD#S/Y*"+V=V'?=]_WD#U!+ P04    " !Z@0E5T%U98VT"  #)!0
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MW;0RO1:E#3#G2R'T>F$3^.Z=_0)02P,$%     @ >H$)5<^I-1JL!   *!D
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M2!/>*$H8K 22355A\>L"*&_GSLAY[%B3;:E,AYLF-=["#:B[>B5TY/8J.:F
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ML.ANUBY0O+:WV88K?3?:9JD?(Q!F@AXO.%>/@;D@^^<M_0-02P,$%     @
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MDRRG6$ZSG,&X@Z::[S45NP3@WL,Z!5T$P'()RPF6DRRG6$ZSG,$XMU/"O;4
MX;=<"^ ?O'=;H5Q\SQVL')W/#D,;=%C!<I+E%,MIEC,8=] O>XL!PF^R&, _
M:O]&81<#A.W% .-6D[!K 5!.LIQB.<UR!N,.FF1O+4#XS=<"^/>@?\.P:P'"
M]EJ =L.P2P%03K*<8CG-<@;C#AIF;RE >-12@$=/ GS-4@#_T/T[A5T*@'()
MRPF6DRRG6$ZSG,&X@Z;:6PH0PDL!0G8I ,K%+)>PG& YR7**Y33+&8P[Z)2]
MI0#AMUP*X!^\?UMU+ 5HOVJ/V6$3EA,L)UE.L9QF.8-Q!_VRMQ8@_"9K ?RC
M]F^4]EJ <:M)V*4 *"=83K*<8CG-<@;C#IID;RE ^,V7 OCWH'_#M)<"M!N&
M70F <H+E),LIEM,L9S#NKF%.JZLLJ^.T3L]>KK+R,CO/KJ^K8%'<KNO-('M?
M#<KL8M-/+WZ,3DY;7S\/7\1AQ]>3\(7H^KH,7ZCMUT_ML&<O;YHYV\]I>9FO
MJ^ ZNVAV8?!\VA1Z,VV[>OBD+FZ:%C\)/A1U7:RV'UYEZ3(K-S_0?/^B*.K[
M3S8#?"K*W[>_YMG_ U!+ P04    " !Z@0E5L9XOVR@%  #8&P  &0   'AL
M+W=O<FMS:&5E=',O<VAE970U.2YX;6RU65USHS84_2L:=]O9G<D&)#Z=VIY)
M3'>:3K*3R<?VH=,'V2@VLX!<28XW_?65, ';"-EDZ$L"^-Z#SD'<>X1&&\J^
M\R4A OS(TIR/!TLA5A>6Q>=+DF%^3E<DE[\\4Y9A(4_9PN(K1G!<)&6IA6S;
MMS*<Y(/)J+AVQR8CNA9IDI,[!O@ZRS![O2(IW8P'</!VX3Y9+(6Z8$U&*[P@
M#T0\K>Z8/+,JE#C)2,X3F@-&GL>#2W@1(4<E%!'?$K+A.\= 49E1^EV=7,?C
M@:U&1%(R%PH"RW\O9$K25"')<?Q3@@ZJ>ZK$W>,W]"\%>4EFACF9TO3/)!;+
M\2 <@)@\XW4J[NGF=U(2\A3>G*:\^ LV9:P] /,U%S0KD^4(LB3?_L<_2B%V
M$I#?DH#*!'28X+4D.&6"<Y  W98$MTQP"V6V5 H=(BSP9,3H!C 5+='402%F
MD2WI)[EZ[@^"R5\3F2<F-S1??'XD+ ,1F8DS\%5.M<]@BAE[3?(%N,SH.A>
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ME&?;;:3MB:"K8F-E1H6@67&X)#@F3 7(WY^I= [EB;I!M9DW^0]02P,$%
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MMP4:*==V1]TZJI'"8^\;=;3I_F!S^R=(=C%[H125+Z/_HK?[069B;T^"=H1
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M-Y0H22'C"<T0@_7,NG-O0]=7@M+B2P([?G*,5"@OE+ZJP7TTLQSE$1!8"87
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M SW\@FN')I(OIBDK_X-#C;4,$.\9IUEM+%:0D;QZC;[4@>@8"!ZU :H-T-#
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M?H9CKYY2?^CKF7E+U88)33BL455P^19M5?4<J@]&EJ[1KJ3!MNVV.8YN4%8
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M;N$G/!S/99G?.=%\[-_U2=)F'7Y=E^45'/MFOEI9'%ZZ/;PP?/D/4$L#!!0
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M.'Y\EIUM^K=\-OXC;O$"4$L! A0#%     @ >H$)50=!36*!    L0   !
M             ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !Z
M@0E5B@I%;^X    K @  $0              @ &O    9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    " !Z@0E5F5R<(Q &  "<)P  $P
M@ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( 'J!"56JC]C2
MV 4  -,>   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    " !Z@0E5<%IR7Z@&  !R'   &
M@($;#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ >H$)
M5=YMKC3_ @  J0H  !@              ("!^10  'AL+W=O<FMS:&5E=',O
M<VAE970S+GAM;%!+ 0(4 Q0    ( 'J!"56UM,LR5 <  +@I   8
M      " @2X8  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M" !Z@0E52;'KYZD#  !H#0  &               @(&X'P  >&PO=V]R:W-H
M965T<R]S:&5E=#4N>&UL4$L! A0#%     @ >H$)56H<;MN'"   424  !@
M             ("!ER,  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4
M Q0    ( 'J!"57L:M70:@P  +2'   8              " @50L  !X;"]W
M;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " !Z@0E533A*<$(*  #5
M&0  &               @('T.   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL
M4$L! A0#%     @ >H$)5=:FZ_ Q*@  >H4  !@              ("!;$,
M 'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( 'J!"56>\Y*H
MV@\  #@J   9              " @=-M  !X;"]W;W)K<VAE971S+W-H965T
M,3 N>&UL4$L! A0#%     @ >H$)51@?-59Z!0  ?P\  !D
M ("!Y'T  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " !Z
M@0E5'HH.Y#X&   _$   &0              @(&5@P  >&PO=V]R:W-H965T
M<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( 'J!"56S6"DN=@8  '<1   9
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M970Q-RYX;6Q02P$"% ,4    " !Z@0E5]@MJ7S,%   @#0  &0
M    @(%_L@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (
M 'J!"57KTNI/T ,  * (   9              " @>FW  !X;"]W;W)K<VAE
M971S+W-H965T,3DN>&UL4$L! A0#%     @ >H$)5<Y))/1&.0  O<(  !D
M             ("!\+L  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"
M% ,4    " !Z@0E539A 7\4#  #R"   &0              @(%M]0  >&PO
M=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( 'J!"57<>[0\4@<
M $83   9              " @6GY  !X;"]W;W)K<VAE971S+W-H965T,C(N
M>&UL4$L! A0#%     @ >H$)5>6&\U7$!   N X  !D              ("!
M\@ ! 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " !Z@0E5
MO$:GP'($  "*"@  &0              @('M!0$ >&PO=V]R:W-H965T<R]S
M:&5E=#(T+GAM;%!+ 0(4 Q0    ( 'J!"57]-R5FMP4  %P/   9
M      " @98* 0!X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%
M  @ >H$)5;PQEN*3!   ]@H  !D              ("!A! ! 'AL+W=O<FMS
M:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " !Z@0E5$1SB?<0$  !W#
M&0              @(%.%0$ >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+
M 0(4 Q0    ( 'J!"575+V-_O00  'X,   9              " @4D: 0!X
M;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ >H$)50IG X(F
M!     H  !D              ("!/1\! 'AL+W=O<FMS:&5E=',O<VAE970R
M.2YX;6Q02P$"% ,4    " !Z@0E5SL* 7M\"   <"P  &0
M@(&:(P$ >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( 'J!
M"57S 2[$,@(  "$%   9              " @; F 0!X;"]W;W)K<VAE971S
M+W-H965T,S$N>&UL4$L! A0#%     @ >H$)5:_[$9Q  @  JP8  !D
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M=#,V+GAM;%!+ 0(4 Q0    ( 'J!"57-!_#%0@0  (44   9
M  " @60Y 0!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @
M>H$)51PUT]KH!0  ]2<  !D              ("!W3T! 'AL+W=O<FMS:&5E
M=',O<VAE970S."YX;6Q02P$"% ,4    " !Z@0E5_E707GP#  #M#0  &0
M            @('\0P$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4
M Q0    ( 'J!"546Q%=F\P(  /,(   9              " @:]' 0!X;"]W
M;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ >H$)54-7>1O]!
MOQT  !D              ("!V4H! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX
M;6Q02P$"% ,4    " !Z@0E5",IV%M,#  !K$@  &0              @($-
M4 $ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( 'J!"56,
MP!31G (  )<&   9              " @1=4 0!X;"]W;W)K<VAE971S+W-H
M965T-#,N>&UL4$L! A0#%     @ >H$)55#8@>BJ!P  BDD  !D
M     ("!ZE8! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( 'J!"56Z \M2?0,  ,X*   9              "
M@7QO 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ >H$)
M5>E*&'.H @  ^08  !D              ("!,',! 'AL+W=O<FMS:&5E=',O
M<VAE970U,"YX;6Q02P$"% ,4    " !Z@0E5ST:LX[,"  "5!P  &0
M        @($/=@$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0
M   ( 'J!"54W2%H_;04  '$F   9              " @?EX 0!X;"]W;W)K
M<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ >H$)5=!F<2GZ!   <1@
M !D              ("!G7X! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q0
M2P$"% ,4    " !Z@0E5I\X%'4H"   #!@  &0              @('.@P$
M>&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( 'J!"57075EC
M;0(  ,D%   9              " @4^& 0!X;"]W;W)K<VAE971S+W-H965T
M-34N>&UL4$L! A0#%     @ >H$)5<^I-1JL!   *!D  !D
M ("!\X@! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " !Z
M@0E50R3K:H0"  #J!@  &0              @('6C0$ >&PO=V]R:W-H965T
M<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( 'J!"56<(LT68!8  &EJ 0 9
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M970V,BYX;6Q02P$"% ,4    " !Z@0E5CC"F;?4#   3%   &0
M    @(&6O $ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    (
M 'J!"54Z!S%9?0,  *P.   9              " @<+  0!X;"]W;W)K<VAE
M971S+W-H965T-C0N>&UL4$L! A0#%     @ >H$)50;A]N/B!P  E4H  !D
M             ("!=L0! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"
M% ,4    " !Z@0E5["!KA/L$  !G&P  &0              @(&/S $ >&PO
M=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( 'J!"54KTGTTMP(
M !@(   9              " @<'1 0!X;"]W;W)K<VAE971S+W-H965T-C<N
M>&UL4$L! A0#%     @ >H$)54[T>[=# P  +!0   T              ( !
MK]0! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !Z@0E5EXJ[',     3 @
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8;6Q02P4&     $L 2P"$%   P>(!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>294</ContextCount>
  <ElementCount>340</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>77</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/OrganizationandBusiness</Role>
      <ShortName>Organization and Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2111103 - Disclosure - Business Combination</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/BusinessCombination</Role>
      <ShortName>Business Combination</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2118104 - Disclosure - Fair Value Measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/FairValueMeasurement</Role>
      <ShortName>Fair Value Measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2124105 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2130106 - Disclosure - Certain Balance Sheet Items</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CertainBalanceSheetItems</Role>
      <ShortName>Certain Balance Sheet Items</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2137107 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/GoodwillandIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2143108 - Disclosure - Long-Term Debt, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/LongTermDebtNet</Role>
      <ShortName>Long-Term Debt, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2148109 - Disclosure - Share-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SharebasedCompensation</Role>
      <ShortName>Share-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2154110 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2156111 - Disclosure - Net Income (loss) per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/NetIncomelosspershare</Role>
      <ShortName>Net Income (loss) per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2160112 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2312302 - Disclosure - Business Combination (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/BusinessCombinationTables</Role>
      <ShortName>Business Combination (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/BusinessCombination</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2319303 - Disclosure - Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/FairValueMeasurementTables</Role>
      <ShortName>Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/FairValueMeasurement</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2325304 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/Revenue</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2331305 - Disclosure - Certain Balance Sheet Items (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CertainBalanceSheetItemsTables</Role>
      <ShortName>Certain Balance Sheet Items (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/CertainBalanceSheetItems</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2338306 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/GoodwillandIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/GoodwillandIntangibleAssets</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2344307 - Disclosure - Long-Term Debt, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/LongTermDebtNetTables</Role>
      <ShortName>Long-Term Debt, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/LongTermDebtNet</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2349308 - Disclosure - Share-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SharebasedCompensationTables</Role>
      <ShortName>Share-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/SharebasedCompensation</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2357309 - Disclosure - Net Income (loss) per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/NetIncomelosspershareTables</Role>
      <ShortName>Net Income (loss) per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/NetIncomelosspershare</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Organization and Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/OrganizationandBusinessDetails</Role>
      <ShortName>Organization and Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/OrganizationandBusiness</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies - Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Summary of Significant Accounting Policies - Revenue and Cost of Product Sales (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesRevenueandCostofProductSalesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Revenue and Cost of Product Sales (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Summary of Significant Accounting Policies - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - Business Combination - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/BusinessCombinationNarrativeDetails</Role>
      <ShortName>Business Combination - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2414408 - Disclosure - Business Combination -Purchase Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails</Role>
      <ShortName>Business Combination -Purchase Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2415409 - Disclosure - Business Combination - Schedule of Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>Business Combination - Schedule of Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2416410 - Disclosure - Business Combination - Intangible Assets Acquired (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails</Role>
      <ShortName>Business Combination - Intangible Assets Acquired (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2417411 - Disclosure - Business Combination - Summary of Proforma Financial Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/BusinessCombinationSummaryofProformaFinancialInformationDetails</Role>
      <ShortName>Business Combination - Summary of Proforma Financial Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2420412 - Disclosure - Fair Value Measurement - Components of Available-for-sale Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails</Role>
      <ShortName>Fair Value Measurement - Components of Available-for-sale Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2421413 - Disclosure - Fair Value Measurement - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails</Role>
      <ShortName>Fair Value Measurement - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2422414 - Disclosure - Fair Value Measurement - Contractual Maturities of Available for Sale Debt Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/FairValueMeasurementContractualMaturitiesofAvailableforSaleDebtSecuritiesDetails</Role>
      <ShortName>Fair Value Measurement - Contractual Maturities of Available for Sale Debt Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2423415 - Disclosure - Fair Value Measurement - Assets Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurement - Assets Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2426416 - Disclosure - Revenue - Disaggregated Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails</Role>
      <ShortName>Revenue - Disaggregated Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2427417 - Disclosure - Revenue - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/RevenueNarrativeDetails</Role>
      <ShortName>Revenue - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2428418 - Disclosure - Revenue - Accounts Receivable, net and Deferred Revenues from Contracts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/RevenueAccountsReceivablenetandDeferredRevenuesfromContractsDetails</Role>
      <ShortName>Revenue - Accounts Receivable, net and Deferred Revenues from Contracts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2429419 - Disclosure - Revenue - Additional Revenue Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/RevenueAdditionalRevenueInformationDetails</Role>
      <ShortName>Revenue - Additional Revenue Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2432420 - Disclosure - Certain Balance Sheet Items - Accounts Receivable, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails</Role>
      <ShortName>Certain Balance Sheet Items - Accounts Receivable, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2433421 - Disclosure - Certain Balance Sheet Items - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails</Role>
      <ShortName>Certain Balance Sheet Items - Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2434422 - Disclosure - Certain Balance Sheet Items - Prepaid Expenses and Other Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails</Role>
      <ShortName>Certain Balance Sheet Items - Prepaid Expenses and Other Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2435423 - Disclosure - Certain Balance Sheet Items - Property and Equipment, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails</Role>
      <ShortName>Certain Balance Sheet Items - Property and Equipment, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2436424 - Disclosure - Certain Balance Sheet Items - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails</Role>
      <ShortName>Certain Balance Sheet Items - Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2439425 - Disclosure - Goodwill and Intangible Assets - Additional (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Additional (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2440426 - Disclosure - Intangible Assets, Goodwill and Other -Goodwill Rollforward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/IntangibleAssetsGoodwillandOtherGoodwillRollforwardDetails</Role>
      <ShortName>Intangible Assets, Goodwill and Other -Goodwill Rollforward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2441427 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2442428 - Disclosure - Goodwill and Intangible Assets -Future Amortization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails</Role>
      <ShortName>Goodwill and Intangible Assets -Future Amortization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2445429 - Disclosure - Long-Term Debt, Net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails</Role>
      <ShortName>Long-Term Debt, Net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2446430 - Disclosure - Long-Term Debt, Net - Carrying Amount of Convertible Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails</Role>
      <ShortName>Long-Term Debt, Net - Carrying Amount of Convertible Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2447431 - Disclosure - Long-Term Debt, Net - Components of Interest Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails</Role>
      <ShortName>Long-Term Debt, Net - Components of Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2450432 - Disclosure - Share-based Compensation - Share-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails</Role>
      <ShortName>Share-based Compensation - Share-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2451433 - Disclosure - Share-based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails</Role>
      <ShortName>Share-based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2452434 - Disclosure - Share-based Compensation - Assumptions Used in the Black-Scholes Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails</Role>
      <ShortName>Share-based Compensation - Assumptions Used in the Black-Scholes Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2453435 - Disclosure - Share-based Compensation - Unrecognized Estimated Compensation Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails</Role>
      <ShortName>Share-based Compensation - Unrecognized Estimated Compensation Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2455436 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2458437 - Disclosure - Net Income (loss) per share - Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/NetIncomelosspershareSummaryDetails</Role>
      <ShortName>Net Income (loss) per share - Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/NetIncomelosspershareTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="halo-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2459438 - Disclosure - Net Income (loss) per share - Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.halozyme.com/role/NetIncomelosspershareAntidilutiveSecuritiesDetails</Role>
      <ShortName>Net Income (loss) per share - Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.halozyme.com/role/NetIncomelosspershareTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="halo-20220630.htm">halo-20220630.htm</File>
    <File>ex31110qq22022.htm</File>
    <File>ex31210qq22022.htm</File>
    <File>ex3210qq22022.htm</File>
    <File>halo-20220630.xsd</File>
    <File>halo-20220630_cal.xml</File>
    <File>halo-20220630_def.xml</File>
    <File>halo-20220630_lab.xml</File>
    <File>halo-20220630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>halo-20220630_g1.jpg</File>
    <File>halo-20220630_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1000">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>86
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "halo-20220630.htm": {
   "axisCustom": 2,
   "axisStandard": 24,
   "contextCount": 294,
   "dts": {
    "calculationLink": {
     "local": [
      "halo-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "halo-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "halo-20220630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "halo-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "halo-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "halo-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd"
     ]
    }
   },
   "elementCount": 533,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 2,
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 7
   },
   "keyCustom": 28,
   "keyStandard": 312,
   "memberCustom": 37,
   "memberStandard": 37,
   "nsprefix": "halo",
   "nsuri": "http://www.halozyme.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.halozyme.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111103 - Disclosure - Business Combination",
     "role": "http://www.halozyme.com/role/BusinessCombination",
     "shortName": "Business Combination",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118104 - Disclosure - Fair Value Measurement",
     "role": "http://www.halozyme.com/role/FairValueMeasurement",
     "shortName": "Fair Value Measurement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124105 - Disclosure - Revenue",
     "role": "http://www.halozyme.com/role/Revenue",
     "shortName": "Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130106 - Disclosure - Certain Balance Sheet Items",
     "role": "http://www.halozyme.com/role/CertainBalanceSheetItems",
     "shortName": "Certain Balance Sheet Items",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137107 - Disclosure - Goodwill and Intangible Assets",
     "role": "http://www.halozyme.com/role/GoodwillandIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143108 - Disclosure - Long-Term Debt, Net",
     "role": "http://www.halozyme.com/role/LongTermDebtNet",
     "shortName": "Long-Term Debt, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2148109 - Disclosure - Share-based Compensation",
     "role": "http://www.halozyme.com/role/SharebasedCompensation",
     "shortName": "Share-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2154110 - Disclosure - Stockholders' Equity",
     "role": "http://www.halozyme.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2156111 - Disclosure - Net Income (loss) per share",
     "role": "http://www.halozyme.com/role/NetIncomelosspershare",
     "shortName": "Net Income (loss) per share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2160112 - Disclosure - Commitments and Contingencies",
     "role": "http://www.halozyme.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ia8f041b537984ded88384fd5745e75e2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "role": "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ia8f041b537984ded88384fd5745e75e2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312302 - Disclosure - Business Combination (Tables)",
     "role": "http://www.halozyme.com/role/BusinessCombinationTables",
     "shortName": "Business Combination (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319303 - Disclosure - Fair Value Measurement (Tables)",
     "role": "http://www.halozyme.com/role/FairValueMeasurementTables",
     "shortName": "Fair Value Measurement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325304 - Disclosure - Revenue (Tables)",
     "role": "http://www.halozyme.com/role/RevenueTables",
     "shortName": "Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331305 - Disclosure - Certain Balance Sheet Items (Tables)",
     "role": "http://www.halozyme.com/role/CertainBalanceSheetItemsTables",
     "shortName": "Certain Balance Sheet Items (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2338306 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "role": "http://www.halozyme.com/role/GoodwillandIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2344307 - Disclosure - Long-Term Debt, Net (Tables)",
     "role": "http://www.halozyme.com/role/LongTermDebtNetTables",
     "shortName": "Long-Term Debt, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2349308 - Disclosure - Share-based Compensation (Tables)",
     "role": "http://www.halozyme.com/role/SharebasedCompensationTables",
     "shortName": "Share-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2357309 - Disclosure - Net Income (loss) per share (Tables)",
     "role": "http://www.halozyme.com/role/NetIncomelosspershareTables",
     "shortName": "Net Income (loss) per share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ia8f041b537984ded88384fd5745e75e2_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "role": "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ia8f041b537984ded88384fd5745e75e2_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "halo:RoyaltiesReceivedNumberOfCollaborators",
      "reportCount": 1,
      "unique": true,
      "unitRef": "collaborator",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Organization and Business (Details)",
     "role": "http://www.halozyme.com/role/OrganizationandBusinessDetails",
     "shortName": "Organization and Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "halo:RoyaltiesReceivedNumberOfCollaborators",
      "reportCount": 1,
      "unique": true,
      "unitRef": "collaborator",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ia8f041b537984ded88384fd5745e75e2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalentsNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Restricted Cash (Details)",
     "role": "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails",
     "shortName": "Summary of Significant Accounting Policies - Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:LesseeLeasesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "i03b0b3511b2544be8e14af45977bfbce_I20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies - Leases (Details)",
     "role": "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails",
     "shortName": "Summary of Significant Accounting Policies - Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:LesseeLeasesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "i03b0b3511b2544be8e14af45977bfbce_I20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "halo:RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Summary of Significant Accounting Policies - Revenue and Cost of Product Sales (Details)",
     "role": "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesRevenueandCostofProductSalesDetails",
     "shortName": "Summary of Significant Accounting Policies - Revenue and Cost of Product Sales (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "halo:RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "i07515ff25e39495196802eb714e47e89_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Summary of Significant Accounting Policies - Income Taxes (Details)",
     "role": "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails",
     "shortName": "Summary of Significant Accounting Policies - Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:IncomeTaxPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "i07515ff25e39495196802eb714e47e89_D20220401-20220630",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410406 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details)",
     "role": "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Segment Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "i475bb2a82ae54a4286363422e755c916_D20220524-20220524",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - Business Combination - Narrative (Details)",
     "role": "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
     "shortName": "Business Combination - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "i4bc0e55590f348ac92553d587cadfd3d_D20220524-20220524",
      "decimals": "2",
      "lang": "en-US",
      "name": "halo:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "i475bb2a82ae54a4286363422e755c916_D20220524-20220524",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414408 - Disclosure - Business Combination -Purchase Consideration (Details)",
     "role": "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails",
     "shortName": "Business Combination -Purchase Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "i07515ff25e39495196802eb714e47e89_D20220401-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationIntegrationRelatedCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415409 - Disclosure - Business Combination - Schedule of Assets Acquired and Liabilities Assumed (Details)",
     "role": "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails",
     "shortName": "Business Combination - Schedule of Assets Acquired and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "i4bc0e55590f348ac92553d587cadfd3d_D20220524-20220524",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "i1e07b7230a7b4293910918c1158913a7_I20220524",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416410 - Disclosure - Business Combination - Intangible Assets Acquired (Details)",
     "role": "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails",
     "shortName": "Business Combination - Intangible Assets Acquired (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "i89ede30c1fb341e6b5c377169cbac030_D20220524-20220524",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:IndefinitelivedIntangibleAssetsAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "i07515ff25e39495196802eb714e47e89_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)",
     "role": "http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "i07515ff25e39495196802eb714e47e89_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "i00acc9b249264652bb496012352851f4_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417411 - Disclosure - Business Combination - Summary of Proforma Financial Information (Details)",
     "role": "http://www.halozyme.com/role/BusinessCombinationSummaryofProformaFinancialInformationDetails",
     "shortName": "Business Combination - Summary of Proforma Financial Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "i00acc9b249264652bb496012352851f4_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ia8f041b537984ded88384fd5745e75e2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420412 - Disclosure - Fair Value Measurement - Components of Available-for-sale Marketable Securities (Details)",
     "role": "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails",
     "shortName": "Fair Value Measurement - Components of Available-for-sale Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ia8f041b537984ded88384fd5745e75e2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ia8f041b537984ded88384fd5745e75e2_I20220630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "security",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421413 - Disclosure - Fair Value Measurement - Narrative (Details)",
     "role": "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails",
     "shortName": "Fair Value Measurement - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ia8f041b537984ded88384fd5745e75e2_I20220630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "security",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ia8f041b537984ded88384fd5745e75e2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422414 - Disclosure - Fair Value Measurement - Contractual Maturities of Available for Sale Debt Securities (Details)",
     "role": "http://www.halozyme.com/role/FairValueMeasurementContractualMaturitiesofAvailableforSaleDebtSecuritiesDetails",
     "shortName": "Fair Value Measurement - Contractual Maturities of Available for Sale Debt Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ia8f041b537984ded88384fd5745e75e2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ia8f041b537984ded88384fd5745e75e2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423415 - Disclosure - Fair Value Measurement - Assets Measured at Fair Value on a Recurring Basis (Details)",
     "role": "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails",
     "shortName": "Fair Value Measurement - Assets Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ia8f041b537984ded88384fd5745e75e2_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "i07515ff25e39495196802eb714e47e89_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426416 - Disclosure - Revenue - Disaggregated Revenues (Details)",
     "role": "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails",
     "shortName": "Revenue - Disaggregated Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "i30cb808ae8294ad2963b8d25bd8ddd70_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "i07515ff25e39495196802eb714e47e89_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427417 - Disclosure - Revenue - Narrative (Details)",
     "role": "http://www.halozyme.com/role/RevenueNarrativeDetails",
     "shortName": "Revenue - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "i07515ff25e39495196802eb714e47e89_D20220401-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ia8f041b537984ded88384fd5745e75e2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "halo:AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428418 - Disclosure - Revenue - Accounts Receivable, net and Deferred Revenues from Contracts (Details)",
     "role": "http://www.halozyme.com/role/RevenueAccountsReceivablenetandDeferredRevenuesfromContractsDetails",
     "shortName": "Revenue - Accounts Receivable, net and Deferred Revenues from Contracts (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ia8f041b537984ded88384fd5745e75e2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "halo:AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "i70ed32619a3c450b95acdcb7833975bf_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429419 - Disclosure - Revenue - Additional Revenue Information (Details)",
     "role": "http://www.halozyme.com/role/RevenueAdditionalRevenueInformationDetails",
     "shortName": "Revenue - Additional Revenue Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "i70ed32619a3c450b95acdcb7833975bf_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ia8f041b537984ded88384fd5745e75e2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "halo:Accountsreceivablefromproductsalestocollaborators",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432420 - Disclosure - Certain Balance Sheet Items - Accounts Receivable, net (Details)",
     "role": "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails",
     "shortName": "Certain Balance Sheet Items - Accounts Receivable, net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ia8f041b537984ded88384fd5745e75e2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "halo:Accountsreceivablefromproductsalestocollaborators",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "i07515ff25e39495196802eb714e47e89_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)",
     "role": "http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "i07515ff25e39495196802eb714e47e89_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ia8f041b537984ded88384fd5745e75e2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433421 - Disclosure - Certain Balance Sheet Items - Inventories (Details)",
     "role": "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails",
     "shortName": "Certain Balance Sheet Items - Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ia8f041b537984ded88384fd5745e75e2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ia8f041b537984ded88384fd5745e75e2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434422 - Disclosure - Certain Balance Sheet Items - Prepaid Expenses and Other Assets (Details)",
     "role": "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails",
     "shortName": "Certain Balance Sheet Items - Prepaid Expenses and Other Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ia8f041b537984ded88384fd5745e75e2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ia8f041b537984ded88384fd5745e75e2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435423 - Disclosure - Certain Balance Sheet Items - Property and Equipment, net (Details)",
     "role": "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails",
     "shortName": "Certain Balance Sheet Items - Property and Equipment, net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ia8f041b537984ded88384fd5745e75e2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436424 - Disclosure - Certain Balance Sheet Items - Accrued Expenses (Details)",
     "role": "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails",
     "shortName": "Certain Balance Sheet Items - Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ia8f041b537984ded88384fd5745e75e2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439425 - Disclosure - Goodwill and Intangible Assets - Additional (Details)",
     "role": "http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalDetails",
     "shortName": "Goodwill and Intangible Assets - Additional (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440426 - Disclosure - Intangible Assets, Goodwill and Other -Goodwill Rollforward (Details)",
     "role": "http://www.halozyme.com/role/IntangibleAssetsGoodwillandOtherGoodwillRollforwardDetails",
     "shortName": "Intangible Assets, Goodwill and Other -Goodwill Rollforward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ia8f041b537984ded88384fd5745e75e2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441427 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details)",
     "role": "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ia8f041b537984ded88384fd5745e75e2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ia8f041b537984ded88384fd5745e75e2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442428 - Disclosure - Goodwill and Intangible Assets -Future Amortization (Details)",
     "role": "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails",
     "shortName": "Goodwill and Intangible Assets -Future Amortization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ia8f041b537984ded88384fd5745e75e2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ia8f041b537984ded88384fd5745e75e2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445429 - Disclosure - Long-Term Debt, Net - Narrative (Details)",
     "role": "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails",
     "shortName": "Long-Term Debt, Net - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "iae83682afbfd42498583c6364b173a85_D20191101-20191130",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromConvertibleDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ia8f041b537984ded88384fd5745e75e2_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446430 - Disclosure - Long-Term Debt, Net - Carrying Amount of Convertible Notes (Details)",
     "role": "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails",
     "shortName": "Long-Term Debt, Net - Carrying Amount of Convertible Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ia8f041b537984ded88384fd5745e75e2_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfDebtDiscountPremium",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447431 - Disclosure - Long-Term Debt, Net - Components of Interest Expense (Details)",
     "role": "http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails",
     "shortName": "Long-Term Debt, Net - Components of Interest Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ib06303cf7360468aad8efb6d193ac2e0_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentPeriodicPaymentInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "i07515ff25e39495196802eb714e47e89_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450432 - Disclosure - Share-based Compensation - Share-based Compensation Expense (Details)",
     "role": "http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails",
     "shortName": "Share-based Compensation - Share-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "i0b599c875f4f40e294c8d28f8eb1e582_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "i07515ff25e39495196802eb714e47e89_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451433 - Disclosure - Share-based Compensation - Narrative (Details)",
     "role": "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails",
     "shortName": "Share-based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ib6ded8ac2e08484aa08a3116e39e8ed6_D20220401-20220630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "i07515ff25e39495196802eb714e47e89_D20220401-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452434 - Disclosure - Share-based Compensation - Assumptions Used in the Black-Scholes Model (Details)",
     "role": "http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails",
     "shortName": "Share-based Compensation - Assumptions Used in the Black-Scholes Model (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "i07515ff25e39495196802eb714e47e89_D20220401-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "i039a8cae3d874e6fb7155efc49a70811_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453435 - Disclosure - Share-based Compensation - Unrecognized Estimated Compensation Cost (Details)",
     "role": "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails",
     "shortName": "Share-based Compensation - Unrecognized Estimated Compensation Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "i039a8cae3d874e6fb7155efc49a70811_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455436 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "role": "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "iaeb1fbdd2531417fa64e83bfcd95c8a5_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "i07515ff25e39495196802eb714e47e89_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458437 - Disclosure - Net Income (loss) per share - Summary (Details)",
     "role": "http://www.halozyme.com/role/NetIncomelosspershareSummaryDetails",
     "shortName": "Net Income (loss) per share - Summary (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "i7fd2c85ec0bb4267bea086d8a0cd4161_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "i07515ff25e39495196802eb714e47e89_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459438 - Disclosure - Net Income (loss) per share - Antidilutive Securities (Details)",
     "role": "http://www.halozyme.com/role/NetIncomelosspershareAntidilutiveSecuritiesDetails",
     "shortName": "Net Income (loss) per share - Antidilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "i07515ff25e39495196802eb714e47e89_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "i7985573ca9a44f7ea10f5ecb82f97c91_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)",
     "role": "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "i7985573ca9a44f7ea10f5ecb82f97c91_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Business",
     "role": "http://www.halozyme.com/role/OrganizationandBusiness",
     "shortName": "Organization and Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.halozyme.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "halo-20220630.htm",
      "contextRef": "ie1f5ae8571374e8092178723cb4ad29f_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 77,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.halozyme.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "halo_A025ConvertibleSeniorNotesDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.25% Convertible Senior Notes due 2027",
        "label": "0.25% Convertible Senior Notes due 2027 [Member]",
        "terseLabel": "0.25% Convertible Senior Notes due 2027"
       }
      }
     },
     "localname": "A025ConvertibleSeniorNotesDue2027Member",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails",
      "http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_A1.25ConvertibleSeniorNotesdue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.25% Convertible Senior Notes due 2024 [Member]",
        "label": "1.25% Convertible Senior Notes due 2024 [Member]",
        "terseLabel": "1.25% Convertible Senior Notes due 2024"
       }
      }
     },
     "localname": "A1.25ConvertibleSeniorNotesdue2024Member",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails",
      "http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_A2021CreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Credit Agreement",
        "label": "2021 Credit Agreement [Member]",
        "terseLabel": "2021 Credit Agreement"
       }
      }
     },
     "localname": "A2021CreditAgreementMember",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_A2021ESPPPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 ESPP Plan",
        "label": "2021 ESPP Plan [Member]",
        "terseLabel": "2021 ESPP Plan"
       }
      }
     },
     "localname": "A2021ESPPPlanMember",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_AcceleratedShareRepurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accelerated share repurchase agreement",
        "label": "Accelerated share repurchase agreement [Member]",
        "terseLabel": "Accelerated share repurchase agreement"
       }
      }
     },
     "localname": "AcceleratedShareRepurchaseAgreementMember",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, after Allowance for Credit Loss, Current, excluding Other Contract Assets",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current, excluding Other Contract Assets",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/RevenueAccountsReceivablenetandDeferredRevenuesfromContractsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_Accountsreceivablefromcollaborators": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsReceivableGrossCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due from collaborators, within one year of the balance sheet date (or the normal operating cycle, whichever is longer) for goods or services (including trade receivables) that have been delivered or sold in the normal course of business.",
        "label": "Accounts receivable from collaborators",
        "terseLabel": "Accounts receivable from revenues under collaborative agreements"
       }
      }
     },
     "localname": "Accountsreceivablefromcollaborators",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_Accountsreceivablefromproductsales": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsReceivableGrossCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts receivable from product sales",
        "label": "Accounts receivable from product sales",
        "terseLabel": "Accounts receivable from other product sales"
       }
      }
     },
     "localname": "Accountsreceivablefromproductsales",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_Accountsreceivablefromproductsalestocollaborators": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableGrossCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts receivable from product sales to collaborators",
        "label": "Accounts receivable from product sales to collaborators",
        "terseLabel": "Accounts receivable from product sales to partners"
       }
      }
     },
     "localname": "Accountsreceivablefromproductsalestocollaborators",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_Accountsreceivablefromroyalties": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsReceivableGrossCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due from royalties, within one year of the balance sheet date (or the normal operating cycle, whichever is longer) for goods or services (including trade receivables) that have been delivered or sold in the normal course of business.",
        "label": "Accounts receivable from royalties",
        "terseLabel": "Accounts receivable from royalty payments"
       }
      }
     },
     "localname": "Accountsreceivablefromroyalties",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_AccruedLiabilitiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Liabilities, Noncurrent",
        "label": "Accrued Liabilities, Noncurrent",
        "negatedTerseLabel": "Less long-term portion"
       }
      }
     },
     "localname": "AccruedLiabilitiesNoncurrent",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_Accruedmanufacturingexpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued manufacturing expenses",
        "label": "Accrued manufacturing expenses",
        "terseLabel": "Accrued outsourced manufacturing expenses"
       }
      }
     },
     "localname": "Accruedmanufacturingexpenses",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_AllowanceforDistributionFeesandDiscounts": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance for Discount and Distribution Fees",
        "label": "Allowance for Distribution Fees and Discounts",
        "negatedTerseLabel": "Allowance for distribution fees and discounts"
       }
      }
     },
     "localname": "AllowanceforDistributionFeesandDiscounts",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_AnnualInterestPaymentPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Interest Payment Period",
        "label": "Annual Interest Payment Period [Axis]",
        "terseLabel": "Annual Interest Payment Period [Axis]"
       }
      }
     },
     "localname": "AnnualInterestPaymentPeriodAxis",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "halo_AnnualInterestPaymentPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Interest Payment Period [Domain]",
        "label": "Annual Interest Payment Period [Domain]",
        "terseLabel": "Annual Interest Payment Period [Domain]"
       }
      }
     },
     "localname": "AnnualInterestPaymentPeriodDomain",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_AntaresPharmaIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Antares Pharma, Inc",
        "label": "Antares Pharma, Inc [Member]",
        "terseLabel": "Antares Pharma, Inc"
       }
      }
     },
     "localname": "AntaresPharmaIncMember",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails",
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails",
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.halozyme.com/role/BusinessCombinationSummaryofProformaFinancialInformationDetails",
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails",
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_AutoInjectorTechnologyPlatformMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Auto Injector Technology Platform",
        "label": "Auto Injector Technology Platform [Member]",
        "terseLabel": "Auto Injector technology platform"
       }
      }
     },
     "localname": "AutoInjectorTechnologyPlatformMember",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails",
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_BaxaltaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Baxalta [Member]",
        "label": "Baxalta [Member]",
        "terseLabel": "Baxalta"
       }
      }
     },
     "localname": "BaxaltaMember",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/OrganizationandBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_BulkrHuPH20Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "bulk rHuPH20 for use in collaboration products",
        "label": "bulk rHuPH20 [Member]",
        "terseLabel": "bulk rHuPH20"
       }
      }
     },
     "localname": "BulkrHuPH20Member",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_BusinessCombinationConsiderationTransferredBonusAwards": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Bonus Awards",
        "label": "Business Combination, Consideration Transferred, Bonus Awards",
        "terseLabel": "Cash consideration related to cash bonus awards paid by Halozyme"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredBonusAwards",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Equity Interests Issuable, Equity Compensation Awards",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issuable, Equity Compensation Awards",
        "terseLabel": "Consideration for Antares equity compensation awards"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuableEquityCompensationAwards",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Cash Paid Per Acquiree Share",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Cash Paid Per Acquiree Share",
        "terseLabel": "Consideration transferred, cash paid per acquiree share (in usd per share)"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Short-Term Investments",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Short-Term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsShortTermInvestments",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Contract with Customer Liability",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Contract with Customer Liability",
        "terseLabel": "Deferred revenue, current portion"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContractWithCustomerLiability",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Accrued Expenses",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Accrued Expenses",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccruedExpenses",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Contract with Customer Liability",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Contract with Customer Liability",
        "terseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesContractWithCustomerLiability",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_CollaborativeAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreements [Member]",
        "label": "Collaborative Agreements [Member]",
        "terseLabel": "Revenues under collaborative agreements",
        "verboseLabel": "Collaborative Agreements"
       }
      }
     },
     "localname": "CollaborativeAgreementsMember",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_ComputerAndOfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer and office equipment.",
        "label": "Computer and Office Equipment [Member]",
        "terseLabel": "Computer and office equipment"
       }
      }
     },
     "localname": "ComputerAndOfficeEquipmentMember",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails",
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_CreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Agreement",
        "label": "Credit Agreement [Member]",
        "terseLabel": "Credit Agreement"
       }
      }
     },
     "localname": "CreditAgreementMember",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_DebtInstrumentInterestPeriodFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Interest, Period Four",
        "label": "Debt Instrument, Interest, Period Four [Member]",
        "terseLabel": "Year four"
       }
      }
     },
     "localname": "DebtInstrumentInterestPeriodFourMember",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_DebtInstrumentInterestPeriodOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Interest, Period One",
        "label": "Debt Instrument, Interest, Period One [Member]",
        "terseLabel": "Year one"
       }
      }
     },
     "localname": "DebtInstrumentInterestPeriodOneMember",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_DebtInstrumentInterestPeriodThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Interest, Period Three",
        "label": "Debt Instrument, Interest, Period Three [Member]",
        "terseLabel": "Year three"
       }
      }
     },
     "localname": "DebtInstrumentInterestPeriodThreeMember",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_DebtInstrumentInterestPeriodTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Interest, Period two",
        "label": "Debt Instrument, Interest, Period two [Member]",
        "terseLabel": "Year two"
       }
      }
     },
     "localname": "DebtInstrumentInterestPeriodTwoMember",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_DebtInstrumentThirdPartyCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Third-Party Costs",
        "label": "Debt Instrument, Third-Party Costs",
        "terseLabel": "Third-party costs"
       }
      }
     },
     "localname": "DebtInstrumentThirdPartyCosts",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_DeferredRentPayments": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Rent Payments",
        "label": "Deferred Rent Payments",
        "negatedTerseLabel": "Lease payments deferred"
       }
      }
     },
     "localname": "DeferredRentPayments",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_DevelopmentFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development Fees [Member]",
        "label": "Development Fees [Member]",
        "terseLabel": "Event-Based Development Fees"
       }
      }
     },
     "localname": "DevelopmentFeesMember",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_DeviceLicensingAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Device Licensing and Development",
        "label": "Device Licensing and Development [Member]",
        "terseLabel": "Device Licensing and development revenue"
       }
      }
     },
     "localname": "DeviceLicensingAndDevelopmentMember",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_DevicePartneredProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Device Partnered Products",
        "label": "Device Partnered Products [Member]",
        "terseLabel": "Device Partnered Products"
       }
      }
     },
     "localname": "DevicePartneredProductsMember",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, Yea, After Year Four",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Yea, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationYeaAfterYearFour",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill and Intangible Assets and Other Long-Lived Assets Policy",
        "label": "Goodwill and Intangible Assets and Other Long-Lived Assets Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Intangible Assets and Other Long-Lived Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsAndOtherLongLivedAssetsPolicyPolicyTextBlock",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "halo_JanssenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen Collaboration [Member]",
        "label": "Janssen [Member]",
        "terseLabel": "Janssen"
       }
      }
     },
     "localname": "JanssenMember",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/OrganizationandBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_LicenseFeesAndEventBasedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Fees And Event-Based [Member]",
        "label": "License Fees And Event-Based [Member]",
        "terseLabel": "License Fees And Event-Based"
       }
      }
     },
     "localname": "LicenseFeesAndEventBasedMember",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_ManufacturingEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing Equipment [Member]",
        "label": "Manufacturing Equipment [Member]",
        "terseLabel": "Manufacturing equipment"
       }
      }
     },
     "localname": "ManufacturingEquipmentMember",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_OperatingLeaseAccretionOfLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Accretion Of Liability",
        "label": "Operating Lease, Accretion Of Liability",
        "terseLabel": "Expense associated with accretion of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseAccretionOfLiability",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_OthercollaboratorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other collaborators [Member]",
        "label": "Other collaborators [Member]",
        "terseLabel": "Other collaborators"
       }
      }
     },
     "localname": "OthercollaboratorsMember",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From (Payments) for Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "label": "Proceeds From (Payments) for Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from issuance of common stock under equity incentive plans, net of taxes paid related to net share settlement"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property, Plant, and Equipment and Operating Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "label": "Property, Plant, and Equipment and Operating Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "totalLabel": "Property and equipment, net",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails",
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_ProprietaryProductsSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proprietary Products Sales",
        "label": "Proprietary Products Sales [Member]",
        "terseLabel": "Proprietary Products Sales"
       }
      }
     },
     "localname": "ProprietaryProductsSalesMember",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_RSURSAandPRSUawardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock Unit, Restricted Stock Awards, and Performance Restricted Stock Unit awards [Member]",
        "label": "RSU, RSA, and PRSU awards [Member]",
        "verboseLabel": "RSAs, RSUs, PSUs and ESPP"
       }
      }
     },
     "localname": "RSURSAandPRSUawardsMember",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_ResearchEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research equipment.",
        "label": "Research Equipment [Member]",
        "terseLabel": "Research equipment"
       }
      }
     },
     "localname": "ResearchEquipmentMember",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Remaining Performance Obligation, Period Of Termination By Written Notice",
        "label": "Revenue, Remaining Performance Obligation, Period Of Termination By Written Notice",
        "terseLabel": "Period of contract termination by written notice"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesRevenueandCostofProductSalesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "halo_RocheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Roche",
        "label": "Roche [Member]",
        "terseLabel": "Roche"
       }
      }
     },
     "localname": "RocheMember",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/OrganizationandBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_RoyaltiesReceivedNumberOfCollaborators": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties Received, Number of Collaborators",
        "label": "Royalties Received, Number of Collaborators",
        "terseLabel": "Royalties Received, Number of Collaborators"
       }
      }
     },
     "localname": "RoyaltiesReceivedNumberOfCollaborators",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/OrganizationandBusinessDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "halo_RoyaltiesReceivedNumberOfProductsSold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties Received, Number of Products Sold",
        "label": "Royalties Received, Number of Products Sold",
        "terseLabel": "Royalties Received, Number of Products Sold"
       }
      }
     },
     "localname": "RoyaltiesReceivedNumberOfProductsSold",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/OrganizationandBusinessDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "halo_SalesbasedmilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-based milestone [Member]",
        "label": "Sales-based milestone [Member]",
        "terseLabel": "Sales-based milestone"
       }
      }
     },
     "localname": "SalesbasedmilestoneMember",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Schedule of Share-based Compensation Arrangements Valuation Inputs [Table]",
        "label": "Schedule of Share-based Compensation Arrangements Valuation Inputs [Line Items]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements Valuation Inputs [Line Items]"
       }
      }
     },
     "localname": "ScheduleofSharebasedCompensationArrangementsValuationInputsLineItems",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "halo_ScheduleofSharebasedCompensationArrangementsValuationInputsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Share-based Compensation Arrangements Valuation Inputs [Table]",
        "label": "Schedule of Share-based Compensation Arrangements Valuation Inputs [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements Valuation Inputs [Table]"
       }
      }
     },
     "localname": "ScheduleofSharebasedCompensationArrangementsValuationInputsTable",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount",
        "terseLabel": "Maximum contribution amount"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Minimum Employee Subscription Rate",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Minimum Employee Subscription Rate",
        "terseLabel": "Minimum employee subscription rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "halo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period",
        "terseLabel": "Purchase period (in months)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "halo_ShareBasedCompensationAwardUnvestedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Award, Unvested",
        "label": "Share-based Compensation Award, Unvested [Member]",
        "terseLabel": "Equity Compensation Award, Unvested"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardUnvestedMember",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_ShareBasedCompensationAwardsVestedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Awards, Vested",
        "label": "Share-based Compensation Awards, Vested [Member]",
        "terseLabel": "Equity Compensation Awards, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardsVestedMember",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_StockOptionsAndRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Options And Restricted Stock Units [Member]",
        "label": "Stock Options And Restricted Stock Units [Member]",
        "terseLabel": "Stock options and restricted units"
       }
      }
     },
     "localname": "StockOptionsAndRestrictedStockUnitsMember",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_TLANDOProductRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TLANDO, Product Rights",
        "label": "TLANDO, Product Rights [Member]",
        "terseLabel": "TLANDO product rights"
       }
      }
     },
     "localname": "TLANDOProductRightsMember",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails",
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_TermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan Facility",
        "label": "Term Loan Facility [Member]",
        "terseLabel": "Term Loan Facility"
       }
      }
     },
     "localname": "TermLoanFacilityMember",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_UpfrontfeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront fees [Member]",
        "label": "Upfront fees [Member]",
        "terseLabel": "Upfront License Fees"
       }
      }
     },
     "localname": "UpfrontfeesMember",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_VariableRateComponentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Rate Component",
        "label": "Variable Rate Component [Axis]",
        "terseLabel": "Variable Rate Component [Axis]"
       }
      }
     },
     "localname": "VariableRateComponentAxis",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "halo_VariableRateComponentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Rate Component [Domain]",
        "label": "Variable Rate Component [Domain]",
        "terseLabel": "Variable Rate Component [Domain]"
       }
      }
     },
     "localname": "VariableRateComponentDomain",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_VariableRateComponentOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Rate Component One",
        "label": "Variable Rate Component One [Member]",
        "terseLabel": "Variable Rate Component One"
       }
      }
     },
     "localname": "VariableRateComponentOneMember",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_VariableRateComponentTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Rate Component Two",
        "label": "Variable Rate Component Two [Member]",
        "terseLabel": "Variable Rate Component Two"
       }
      }
     },
     "localname": "VariableRateComponentTwoMember",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "halo_XYOSTEDProprietaryProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "XYOSTED Proprietary Product",
        "label": "XYOSTED Proprietary Product [Member]",
        "terseLabel": "XYOSTED proprietary product"
       }
      }
     },
     "localname": "XYOSTEDProprietaryProductMember",
     "nsuri": "http://www.halozyme.com/20220630",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails",
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r60",
      "r62",
      "r123",
      "r124",
      "r299",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/OrganizationandBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r0",
      "r130",
      "r136",
      "r142",
      "r229",
      "r415",
      "r416",
      "r417",
      "r435",
      "r436",
      "r470",
      "r471",
      "r472",
      "r473",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r0",
      "r130",
      "r136",
      "r142",
      "r229",
      "r415",
      "r416",
      "r417",
      "r435",
      "r436",
      "r470",
      "r471",
      "r472",
      "r473",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r0",
      "r130",
      "r136",
      "r142",
      "r229",
      "r415",
      "r416",
      "r417",
      "r435",
      "r436",
      "r470",
      "r471",
      "r472",
      "r473",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r298",
      "r327",
      "r394",
      "r396",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r547",
      "r597",
      "r599",
      "r610",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails",
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r298",
      "r327",
      "r394",
      "r396",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r547",
      "r597",
      "r599",
      "r610",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "verboseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails",
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r195",
      "r371",
      "r376",
      "r551",
      "r596",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails",
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r195",
      "r371",
      "r376",
      "r551",
      "r596",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails",
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r298",
      "r327",
      "r384",
      "r394",
      "r396",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r547",
      "r597",
      "r599",
      "r610",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails",
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r298",
      "r327",
      "r384",
      "r394",
      "r396",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r547",
      "r597",
      "r599",
      "r610",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails",
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r61",
      "r62",
      "r123",
      "r124",
      "r299",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/OrganizationandBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r42",
      "r516"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "auth_ref": [
      "r198",
      "r199"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, before Allowance for Credit Loss, Current",
        "totalLabel": "Subtotal"
       }
      }
     },
     "localname": "AccountsReceivableGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r23",
      "r198",
      "r199"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "totalLabel": "Total accounts receivable, net",
        "verboseLabel": "Accounts receivable, net and contract assets"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails",
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Accretion of discounts on marketable securities, net"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities and Other Liabilities",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      },
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Total accrued expenses, current",
        "verboseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails",
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r41",
      "r271"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r26",
      "r67",
      "r69",
      "r70",
      "r585",
      "r604",
      "r605"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r66",
      "r70",
      "r77",
      "r78",
      "r79",
      "r127",
      "r128",
      "r129",
      "r465",
      "r600",
      "r601",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income/(Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted average remaining life (in years)"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r415",
      "r416",
      "r417",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r397",
      "r399",
      "r421",
      "r422"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net income to net cash provided by in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r399",
      "r411",
      "r420"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r89",
      "r106",
      "r311",
      "r497"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of Debt Discount (Premium)",
        "verboseLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r106",
      "r256",
      "r265"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangibles"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive shares excluded from per share calculation (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/NetIncomelosspershareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r214",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r120",
      "r179",
      "r188",
      "r193",
      "r228",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r462",
      "r466",
      "r483",
      "r514",
      "r516",
      "r558",
      "r582"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r8",
      "r59",
      "r120",
      "r228",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r462",
      "r466",
      "r483",
      "r514",
      "r516"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r475"
     ],
     "calculation": {
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Fair value of assets measured on a recurring basis"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r207"
     ],
     "calculation": {
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r208"
     ],
     "calculation": {
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses",
        "terseLabel": "Unrealized loss position of debt securities"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails",
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r204",
      "r235"
     ],
     "calculation": {
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r209",
      "r212",
      "r575"
     ],
     "calculation": {
      "http://www.halozyme.com/role/FairValueMeasurementContractualMaturitiesofAvailableforSaleDebtSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "After one but within five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementContractualMaturitiesofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r209",
      "r211",
      "r574"
     ],
     "calculation": {
      "http://www.halozyme.com/role/FairValueMeasurementContractualMaturitiesofAvailableforSaleDebtSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementContractualMaturitiesofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r201",
      "r205",
      "r235",
      "r562"
     ],
     "calculation": {
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.halozyme.com/role/FairValueMeasurementContractualMaturitiesofAvailableforSaleDebtSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Estimated Fair Value",
        "totalLabel": "Estimated Fair Value",
        "verboseLabel": "Debt securities, available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails",
      "http://www.halozyme.com/role/FairValueMeasurementContractualMaturitiesofAvailableforSaleDebtSecuritiesDetails",
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r203",
      "r235"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Marketable securities, available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r400",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/NetIncomelosspershareSummaryDetails",
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails",
      "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails",
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]",
        "terseLabel": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]",
        "terseLabel": "Base Rate"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r393",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails",
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails",
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.halozyme.com/role/BusinessCombinationSummaryofProformaFinancialInformationDetails",
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails",
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r393",
      "r395",
      "r444",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails",
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails",
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.halozyme.com/role/BusinessCombinationSummaryofProformaFinancialInformationDetails",
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails",
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails",
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails",
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.halozyme.com/role/BusinessCombinationSummaryofProformaFinancialInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r442",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "terseLabel": "Business Acquisition, Pro Forma Information"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r442",
      "r443"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "terseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationSummaryofProformaFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r442",
      "r443"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Total Revenues"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationSummaryofProformaFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r440"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r451",
      "r452",
      "r455"
     ],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Consideration transferred",
        "totalLabel": "Consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r451",
      "r452"
     ],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Cash consideration for Antares shares outstanding as of May 24, 2022"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "auth_ref": [
      "r449",
      "r451",
      "r452",
      "r457"
     ],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "terseLabel": "Consideration related to Antares closing indebtedness settled by Halozyme"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredOther1": {
     "auth_ref": [
      "r456"
     ],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tangible or intangible assets, including a business or subsidiary of the acquirer transferred by the entity to the former owners of the acquiree. Excludes cash.",
        "label": "Business Combination, Consideration Transferred, Other",
        "terseLabel": "Consideration for seller transaction costs paid by Halozyme"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredOther1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r450",
      "r453",
      "r459"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration, liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r450",
      "r454"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Business Combination"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombination"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationIntegrationRelatedCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.",
        "label": "Business Combination, Integration Related Costs",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "BusinessCombinationIntegrationRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": {
     "auth_ref": [
      "r441"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.",
        "label": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual",
        "negatedLabel": "Proforma earnings loss of acquiree since acquisition date"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": {
     "auth_ref": [
      "r441"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.",
        "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual",
        "terseLabel": "Pro forma revenue of acquiree since acquisition date"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r447"
     ],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r447"
     ],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r447"
     ],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "terseLabel": "Accounts Payable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r447"
     ],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "terseLabel": "Deferred tax liabilities, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r447"
     ],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Intangibles, net",
        "verboseLabel": "Estimated fair value of intangible assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails",
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "auth_ref": [
      "r446",
      "r447"
     ],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of inventory recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "terseLabel": "Inventories, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r446",
      "r447"
     ],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "totalLabel": "Net assets acquired, excluding goodwill"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": {
     "auth_ref": [
      "r447"
     ],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r446",
      "r447"
     ],
     "calculation": {
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r110",
      "r111",
      "r112"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Amounts accrued for purchases of property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "auth_ref": [
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).",
        "label": "Cash Acquired from Acquisition",
        "terseLabel": "Cash acquired"
       }
      }
     },
     "localname": "CashAcquiredFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r39",
      "r108"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r14",
      "r109",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash Equivalents and Marketable Securities and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r103",
      "r108",
      "r113"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r103",
      "r487"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/OrganizationandBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r52",
      "r278",
      "r563",
      "r589"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 12)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r275",
      "r276",
      "r277",
      "r279",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r127",
      "r128",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, par value (usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r22",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "verboseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r22",
      "r516"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common Stock, Value, Issued"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r72",
      "r74",
      "r75",
      "r84",
      "r567",
      "r592"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r115",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of accounts receivable, deferred revenues from contracts with customers, and amounts under collaborative agreements included in transaction price"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r350",
      "r351",
      "r372"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsReceivableGrossCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "terseLabel": "Contract assets",
        "verboseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails",
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r373"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "negatedLabel": "Revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerRefundLiabilityCurrent": {
     "auth_ref": [
      "r375"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current.",
        "label": "Contract with Customer, Refund Liability, Current",
        "terseLabel": "Product returns and sales allowance"
       }
      }
     },
     "localname": "ContractWithCustomerRefundLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r293",
      "r295",
      "r296",
      "r298",
      "r302",
      "r303",
      "r304",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r320",
      "r321",
      "r322",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.",
        "label": "Convertible Debt Securities [Member]",
        "terseLabel": "Convertible Debt Securities"
       }
      }
     },
     "localname": "ConvertibleDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/NetIncomelosspershareSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleNotesPayable": {
     "auth_ref": [
      "r20",
      "r560",
      "r583",
      "r607"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable",
        "terseLabel": "Convertible Notes Payable"
       }
      }
     },
     "localname": "ConvertibleNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r385",
      "r392",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r87",
      "r551"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales previously expensed as R&amp;D",
        "verboseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesRevenueandCostofProductSalesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "verboseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r110",
      "r112"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "verboseLabel": "Amount paid for conversion of debt instrument"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r110",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Stock issued for conversion of debt instrument (shares)"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r119",
      "r125",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r320",
      "r321",
      "r322",
      "r323",
      "r500",
      "r559",
      "r560",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails",
      "http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails",
      "http://www.halozyme.com/role/NetIncomelosspershareSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r20",
      "r313",
      "r560",
      "r580"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Outstanding principal"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r297",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Debt, convertible, conversion price (in usd per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r48",
      "r297",
      "r342",
      "r343",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Debt Instrument, Convertible, Conversion Ratio"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Convertible, Remaining Discount Amortization Period",
        "terseLabel": "Debt Instrument, Convertible, Remaining Discount Amortization Period"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Debt Instrument, Convertible, Threshold Consecutive Trading Days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "terseLabel": "Debt Instrument, Convertible, Threshold Trading Days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentCovenantCompliance": {
     "auth_ref": [
      "r20",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "States whether the entity was in compliance with the debt covenants throughout the reporting period, and describes facts and circumstances of any compliance failure.",
        "label": "Debt Instrument, Covenant Compliance",
        "terseLabel": "Debt Instrument, Covenant Compliance"
       }
      }
     },
     "localname": "DebtInstrumentCovenantCompliance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r295",
      "r320",
      "r321",
      "r498",
      "r500",
      "r501"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Total loan balance",
        "verboseLabel": "Aggregate principal"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r304",
      "r320",
      "r321",
      "r480"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Debt Instrument, Fair Value Disclosure"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "auth_ref": [
      "r49"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.",
        "label": "Debt Instrument, Fee Amount",
        "terseLabel": "Lenders fee"
       }
      }
     },
     "localname": "DebtInstrumentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r47",
      "r318",
      "r498",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective rate at end of period"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r47",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate, stated percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails",
      "http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r50",
      "r119",
      "r125",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r320",
      "r321",
      "r322",
      "r323",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails",
      "http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails",
      "http://www.halozyme.com/role/NetIncomelosspershareSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPaymentInterest": {
     "auth_ref": [
      "r50"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments applied to interest.",
        "label": "Debt Instrument, Periodic Payment, Interest",
        "terseLabel": "Debt Instrument, Periodic Payment, Interest"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Period One"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "Period Two"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r50",
      "r119",
      "r125",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r320",
      "r321",
      "r322",
      "r323",
      "r342",
      "r344",
      "r345",
      "r346",
      "r497",
      "r498",
      "r500",
      "r501",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails",
      "http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r302",
      "r497",
      "r501"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "terseLabel": "Unamortized discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r302",
      "r314",
      "r320",
      "r321",
      "r499"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "terseLabel": "Unamortized debt issuance cost"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r206",
      "r235",
      "r240",
      "r241"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss",
        "terseLabel": "Credit losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {
     "auth_ref": [
      "r221"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Gain (Loss)",
        "negatedLabel": "Realized loss on marketable securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Schedule of available-for-sale marketable securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r216",
      "r236",
      "r243"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position",
        "terseLabel": "Fair market value of gross unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r217",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of loss positions"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredCreditsAndOtherLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income in future periods and obligations not separately disclosed in the balance sheet (other liabilities).",
        "label": "Deferred Credits and Other Liabilities",
        "terseLabel": "Deferred revenues"
       }
      }
     },
     "localname": "DeferredCreditsAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income during the current period and current obligations not separately disclosed in the balance sheet (other liabilities, current).",
        "label": "Deferred Credits and Other Liabilities, Current",
        "verboseLabel": "Deferred revenue, current portion"
       }
      }
     },
     "localname": "DeferredCreditsAndOtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r499"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r427",
      "r428"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r427",
      "r428"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred Income Tax Liabilities, Net"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenue": {
     "auth_ref": [
      "r30"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred Revenue",
        "terseLabel": "Deferred revenues"
       }
      }
     },
     "localname": "DeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueAccountsReceivablenetandDeferredRevenuesfromContractsDetails",
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Revenue, Current",
        "terseLabel": "Deferred revenue, current portion"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred Revenue, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "DeferredRevenueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r106",
      "r177"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails",
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails",
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r371",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails",
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of disaggregation of revenues"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Share-based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net income per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r85",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r143",
      "r145",
      "r151",
      "r152",
      "r153",
      "r157",
      "r158",
      "r473",
      "r474",
      "r568",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.halozyme.com/role/NetIncomelosspershareSummaryDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r85",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r145",
      "r151",
      "r152",
      "r153",
      "r157",
      "r158",
      "r473",
      "r474",
      "r568",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.halozyme.com/role/NetIncomelosspershareSummaryDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]",
        "terseLabel": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareDilutedLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/NetIncomelosspershareSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Reconciliation [Abstract]",
        "terseLabel": "Net income per share:"
       }
      }
     },
     "localname": "EarningsPerShareReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/NetIncomelosspershareSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Income (loss) per share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/NetIncomelosspershare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate, percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and payroll taxes"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r412"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized Expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Remaining Weighted-Average Recognition Period (years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options",
        "verboseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/NetIncomelosspershareSummaryDetails",
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails",
      "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails",
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r77",
      "r78",
      "r79",
      "r127",
      "r128",
      "r129",
      "r132",
      "r139",
      "r141",
      "r163",
      "r229",
      "r341",
      "r347",
      "r415",
      "r416",
      "r417",
      "r435",
      "r436",
      "r472",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r495",
      "r600",
      "r601",
      "r602",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityInterestIssuedOrIssuableByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of equity interests that are issued or issuable in a business combination.",
        "label": "Equity Interest Type [Axis]",
        "terseLabel": "Equity Interest Type [Axis]"
       }
      }
     },
     "localname": "EquityInterestIssuedOrIssuableByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityInterestIssuedOrIssuableTypeDomain": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of equity interest issued or issuable to acquire an entity in a business combination.",
        "label": "Equity Interest Issued or Issuable, Type [Domain]",
        "terseLabel": "Equity Interest Issued or Issuable, Type [Domain]"
       }
      }
     },
     "localname": "EquityInterestIssuedOrIssuableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r475",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of assets measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r475",
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r304",
      "r320",
      "r321",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r476",
      "r520",
      "r521",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r304",
      "r385",
      "r386",
      "r391",
      "r392",
      "r476",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r304",
      "r320",
      "r321",
      "r385",
      "r386",
      "r391",
      "r392",
      "r476",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r304",
      "r320",
      "r321",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r476",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r304",
      "r320",
      "r321",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r520",
      "r521",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r478",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "verboseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FederalFundsEffectiveSwapRateMember": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg.",
        "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]",
        "terseLabel": "Fed Funds Rate"
       }
      }
     },
     "localname": "FederalFundsEffectiveSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r504",
      "r509",
      "r513"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Right-of-use asset amortization"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r214",
      "r215",
      "r224",
      "r225",
      "r226",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r238",
      "r239",
      "r242",
      "r243",
      "r312",
      "r339",
      "r469",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Useful life (years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r264"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r266"
     ],
     "calculation": {
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r266"
     ],
     "calculation": {
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r266"
     ],
     "calculation": {
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r266"
     ],
     "calculation": {
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r257",
      "r261",
      "r264",
      "r268",
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails",
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r264",
      "r553"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Value"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r257",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails",
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r264",
      "r552"
     ],
     "calculation": {
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Net Carrying Value",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsFutureAmortizationDetails",
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r258"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finite-lived Intangible Assets Acquired",
        "terseLabel": "Finite-lived intangible assets acquired"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r107",
      "r484",
      "r486"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "terseLabel": "Unrealized gain on foreign currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r385",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt security issued by government not domiciled in United States of America (US).",
        "label": "Debt Security, Government, Non-US [Member]",
        "terseLabel": "Non-US Government securities"
       }
      }
     },
     "localname": "ForeignGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Loss on disposal of equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r250",
      "r251",
      "r516",
      "r556"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill, Ending Balance",
        "periodStartLabel": "Goodwill, Beginning Balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsAdditionalDetails",
      "http://www.halozyme.com/role/IntangibleAssetsGoodwillandOtherGoodwillRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r252"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill acquired"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IntangibleAssetsGoodwillandOtherGoodwillRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/IntangibleAssetsGoodwillandOtherGoodwillRollforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "ATRS-1902 (IPR&amp;D)"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r81",
      "r179",
      "r187",
      "r189",
      "r192",
      "r194",
      "r554",
      "r564",
      "r570",
      "r594"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r273",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r121",
      "r140",
      "r141",
      "r178",
      "r429",
      "r437",
      "r438",
      "r595"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r76",
      "r425",
      "r426",
      "r431",
      "r432",
      "r433",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable, net and other contract assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r105",
      "r548"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Recognition of deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedTerseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Dilutive potential common stock outstanding (shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/NetIncomelosspershareSummaryDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r260",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r267"
     ],
     "calculation": {
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "ATRS-1902 (IPR&amp;D)"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r260",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IndefinitelivedIntangibleAssetsAcquired": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition.",
        "label": "Indefinite-lived Intangible Assets Acquired",
        "terseLabel": "Indefinite-lived intangible assets acquired"
       }
      }
     },
     "localname": "IndefinitelivedIntangibleAssetsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InducedConversionOfConvertibleDebtExpense": {
     "auth_ref": [
      "r294"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms.",
        "label": "Induced Conversion of Convertible Debt Expense",
        "negatedTerseLabel": "Inducement expense related to convertible notes",
        "terseLabel": "Induced conversion expense related to convertible notes"
       }
      }
     },
     "localname": "InducedConversionOfConvertibleDebtExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r255",
      "r262"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Total Intangibles, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r80",
      "r176",
      "r496",
      "r499",
      "r569"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r89",
      "r309",
      "r319",
      "r322",
      "r323"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense recognized"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.",
        "label": "Interest Income and Interest Expense Disclosure [Table Text Block]",
        "terseLabel": "Interest Income and Interest Expense Disclosure"
       }
      }
     },
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r31",
      "r246"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r56",
      "r516"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Total inventories",
        "verboseLabel": "Inventories, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails",
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r13",
      "r57",
      "r116",
      "r162",
      "r244",
      "r245",
      "r247",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r33",
      "r246"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r32",
      "r246"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Schedule of contractual maturities of available-for-sale debt securities"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Term of leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r29",
      "r120",
      "r228",
      "r483",
      "r516",
      "r561",
      "r587"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r46",
      "r120",
      "r228",
      "r282",
      "r283",
      "r284",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r463",
      "r466",
      "r467",
      "r483",
      "r514",
      "r515",
      "r516"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Commitment fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r43"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Credit facility, maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r20",
      "r303",
      "r315",
      "r320",
      "r321",
      "r560",
      "r584"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Long-term debt, net"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "terseLabel": "Current portion of long-term debt, net"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.halozyme.com/role/LongTermDebtNetCarryingAmountofConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long-term Debt [Text Block]",
        "terseLabel": "Long-Term Debt, Net"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r50",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetComponentsofInterestExpenseDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "verboseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r164",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "verboseLabel": "Organization and Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/OrganizationandBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r103",
      "r104",
      "r107"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r71",
      "r73",
      "r79",
      "r82",
      "r107",
      "r120",
      "r131",
      "r134",
      "r135",
      "r136",
      "r137",
      "r140",
      "r141",
      "r150",
      "r179",
      "r187",
      "r189",
      "r192",
      "r194",
      "r228",
      "r282",
      "r283",
      "r284",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r474",
      "r483",
      "r565",
      "r590"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited",
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited",
      "http://www.halozyme.com/role/NetIncomelosspershareSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "Adoption and Pending Adoption of Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Non-US"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r179",
      "r187",
      "r189",
      "r192",
      "r194"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r510",
      "r513"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Total operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r503"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "verboseLabel": "Lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r505",
      "r511"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts related to leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r502"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails": {
       "order": 2.0,
       "parentTag": "halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Right of use of assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r45"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssets": {
     "auth_ref": [
      "r17",
      "r557",
      "r581"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets classified as other.",
        "label": "Other Assets",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTax": {
     "auth_ref": [
      "r77",
      "r78",
      "r83",
      "r227",
      "r488",
      "r493",
      "r495",
      "r566",
      "r591"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax, after reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Tax",
        "terseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "auth_ref": [
      "r64",
      "r68",
      "r485",
      "r494"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "negatedTerseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r65",
      "r67"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain (loss) on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "verboseLabel": "Investment and other (expense) income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r5",
      "r7",
      "r249"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other prepaid expenses"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivables": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccountsReceivableGrossCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from parties in nontrade transactions, classified as other.",
        "label": "Other Receivables",
        "terseLabel": "Other receivable"
       }
      }
     },
     "localname": "OtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccountsReceivablenetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of common stock",
        "terseLabel": "Payments for repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedTerseLabel": "Payment of debt issuance cost",
        "terseLabel": "Payments of Debt Issuance Costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "terseLabel": "Payments for tax withholding for restricted stock units vested, net"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r91",
      "r95",
      "r202"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisitions of business, net of cash acquired",
        "terseLabel": "Total purchase consideration, net of $46,548 cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Shares [Member]"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r400",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r21",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r21",
      "r516"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock - $0.001 par value; 20,000 shares authorized; no shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid Expense and Other Assets",
        "totalLabel": "Total prepaid expenses and other assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r6",
      "r37",
      "r38"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets",
       "weight": 1.0
      },
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Total prepaid expenses and other assets, current",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails",
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent": {
     "auth_ref": [
      "r17",
      "r557",
      "r581"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets",
       "weight": 1.0
      },
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Noncurrent",
        "negatedTerseLabel": "Less long-term portion",
        "verboseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails",
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r5",
      "r7",
      "r248",
      "r249"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid manufacturing expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r99"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from Convertible Debt"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "terseLabel": "Proceeds from issuance of 2027 Convertible Notes"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from term loan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLongTermLinesOfCredit": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Proceeds from Long-term Lines of Credit",
        "terseLabel": "Proceeds from revolving credit facilities"
       }
      }
     },
     "localname": "ProceedsFromLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r91",
      "r92",
      "r202"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from sales and maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from the sale of assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r98",
      "r414"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "verboseLabel": "Net proceeds from stock options exercised"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales, net"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails",
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r41",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails",
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r40",
      "r270"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r15",
      "r16",
      "r272",
      "r516",
      "r576",
      "r588"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails": {
       "order": 1.0,
       "parentTag": "halo_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Subtotal"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r15",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r15",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails",
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "auth_ref": [
      "r101"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Repayments of Convertible Debt",
        "terseLabel": "Repayments of convertible debt"
       }
      }
     },
     "localname": "RepaymentsOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfSecuredDebt": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.",
        "label": "Repayments of Secured Debt",
        "negatedLabel": "Repayment of 2024 Convertible Notes"
       }
      }
     },
     "localname": "RepaymentsOfSecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r424",
      "r550",
      "r612"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "verboseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r9",
      "r17",
      "r108",
      "r113",
      "r608"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted stock",
        "verboseLabel": "RSAs"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/NetIncomelosspershareSummaryDetails",
      "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units",
        "verboseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails",
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r25",
      "r347",
      "r418",
      "r516",
      "r586",
      "r603",
      "r605"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings (accumulated deficit)"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r127",
      "r128",
      "r129",
      "r132",
      "r139",
      "r141",
      "r229",
      "r415",
      "r416",
      "r417",
      "r435",
      "r436",
      "r472",
      "r600",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings (Accumulated Deficit)"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r174",
      "r175",
      "r186",
      "r190",
      "r191",
      "r195",
      "r196",
      "r197",
      "r370",
      "r371",
      "r551"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "verboseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails",
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r117",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "verboseLabel": "Revenue and Cost of Product Sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r360",
      "r361",
      "r374",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/Revenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r358"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Deferred revenue, remaining performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueAdditionalRevenueInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueAdditionalRevenueInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Deferred revenue, remaining performance obligation, expected timing"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueAdditionalRevenueInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueAdditionalRevenueInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueAdditionalRevenueInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r512",
      "r513"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligation"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalties"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.halozyme.com/role/RevenueDisaggregatedRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Schedule of accounts receivable"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.",
        "label": "Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]",
        "terseLabel": "Schedule of Acquired Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of acquired indefinite-lived intangible assets. Indefinite-lived intangible assets are assets that have no physical form, but have expected future economic benefit. Indefinite-lived assets are assets that are not subject to amortization. Acquired indefinite-lived intangible assets are disclosed by major class (assets that can be grouped together because they are similar, either by their nature or by their use in operations of the entity) and in total.",
        "label": "Schedule of Acquired Indefinite-lived Intangible Assets by Major Class [Table Text Block]",
        "terseLabel": "Schedule of Acquired Indefinite-lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/NetIncomelosspershareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Schedule of Available-for-sale Securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r210",
      "r213",
      "r218",
      "r219",
      "r220",
      "r222",
      "r572",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r444",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationIntangibleAssetsAcquiredDetails",
      "http://www.halozyme.com/role/BusinessCombinationNarrativeDetails",
      "http://www.halozyme.com/role/BusinessCombinationPurchaseConsiderationDetails",
      "http://www.halozyme.com/role/BusinessCombinationScheduleofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.halozyme.com/role/BusinessCombinationSummaryofProformaFinancialInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r444",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments"
       }
      }
     },
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/OrganizationandBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Schedule of share-based compensation expense by type"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of numerators and denominators of basic and diluted computations"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/NetIncomelosspershareTables",
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable": {
     "auth_ref": [
      "r145",
      "r149",
      "r151",
      "r153",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Complete disclosure pertaining to an entity's diluted earnings per share.",
        "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]",
        "terseLabel": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/NetIncomelosspershareSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r399",
      "r410",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r399",
      "r410",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of share-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r257",
      "r263",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r257",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r253",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r13",
      "r34",
      "r35",
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Schedule of inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r133",
      "r136",
      "r160",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table Text Block]",
        "terseLabel": "Schedule of adoption and pending adoption of recent accounting pronouncements"
       }
      }
     },
     "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.",
        "label": "Schedule of Other Assets [Table Text Block]",
        "terseLabel": "Schedule of prepaid expenses and other assets"
       }
      }
     },
     "localname": "ScheduleOfOtherAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r41",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule of Property and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/BusinessCombinationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r400",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails",
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of assumptions used in Black-Scholes model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost [Table Text Block]",
        "terseLabel": "Schedule of unrecognized estimated compensation cost by type"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg.",
        "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]",
        "terseLabel": "SOFR"
       }
      }
     },
     "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Noncash Expense [Abstract]",
        "terseLabel": "Share-based Payment Arrangement, Noncash Expense [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails",
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Maximum employee subscription rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Stock options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r403",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "verboseLabel": "Outstanding stock options and restricted stock units (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r398",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/NetIncomelosspershareSummaryDetails",
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.halozyme.com/role/SharebasedCompensationSharebasedCompensationExpenseDetails",
      "http://www.halozyme.com/role/SharebasedCompensationUnrecognizedEstimatedCompensationCostDetails",
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Stock options weighted average exercise price (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r400",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "verboseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r406",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Average expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationAssumptionsUsedintheBlackScholesModelDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "ESPP purchase price of common stock, percent of market price"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Equity, ending balance (in shares)",
        "periodStartLabel": "Equity, beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "verboseLabel": "Number of RSUs withheld to pay for minimum withholding taxes (in shares)"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r114",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "verboseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r54",
      "r77",
      "r78",
      "r79",
      "r127",
      "r128",
      "r129",
      "r132",
      "r139",
      "r141",
      "r163",
      "r229",
      "r341",
      "r347",
      "r415",
      "r416",
      "r417",
      "r435",
      "r436",
      "r472",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r495",
      "r600",
      "r601",
      "r602",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails",
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r163",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsPrepaidExpensesandOtherAssetsDetails",
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r110",
      "r111",
      "r112"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Common stock issued for induced conversion related to convertible notes"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r53",
      "r306",
      "r341",
      "r342",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock for the induced conversion related to convertible notes (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r21",
      "r22",
      "r341",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "verboseLabel": "Stock issued during period, shares, restricted stock award, net of forfeitures (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r21",
      "r22",
      "r341",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r21",
      "r22",
      "r341",
      "r347",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "verboseLabel": "Number of shares of common stock issued as a result of stock option exercises (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r54",
      "r341",
      "r347"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock for the induced conversion related to convertible notes"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r54",
      "r341",
      "r347"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units, net and shares issued under the ESPP plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock Repurchase Program, Authorized Amount (shares)"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramPeriodInForce1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period which shares may be purchased under a stock repurchase plan authorized by an entity's Board of Directors, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Stock Repurchase Program, Period in Force",
        "terseLabel": "Stock Repurchase Program, period"
       }
      }
     },
     "localname": "StockRepurchaseProgramPeriodInForce1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r21",
      "r22",
      "r341",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "negatedTerseLabel": "Repurchase of common stock (shares)"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "auth_ref": [
      "r21",
      "r22",
      "r341",
      "r347"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).",
        "label": "Stock Repurchased and Retired During Period, Value",
        "negatedTerseLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r22",
      "r27",
      "r28",
      "r120",
      "r200",
      "r228",
      "r483",
      "r516"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Equity, ending balance",
        "periodStartLabel": "Equity, beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity (deficit) (textual)",
        "verboseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r118",
      "r326",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r340",
      "r347",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Certain Balance Sheet Items"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItems"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CertainBalanceSheetItemsAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r214",
      "r215",
      "r224",
      "r225",
      "r226",
      "r312",
      "r339",
      "r469",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.",
        "label": "Treasury Stock Acquired, Average Cost Per Share",
        "terseLabel": "Weighted-average price paid per share (USD per share)"
       }
      }
     },
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r22",
      "r341",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "terseLabel": "Stock repurchased (shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r341",
      "r347",
      "r348"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "terseLabel": "Stock repurchased"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r122",
      "r385",
      "r392",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/FairValueMeasurementAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.halozyme.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/LongTermDebtNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r144",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (shares)",
        "verboseLabel": "Weighted average common shares outstanding for diluted net income (loss) per share (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.halozyme.com/role/NetIncomelosspershareSummaryDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r143",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (shares)",
        "verboseLabel": "Weighted average common shares outstanding for basic net income (loss) per share (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.halozyme.com/role/NetIncomelosspershareSummaryDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Shares used in computing net income per share:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.halozyme.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e725-108305"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e765-108305"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27340-111563"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33775-111570"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467568&loc=d3e6835-112609"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130611-203046-203046"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30755-110894"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(g)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r613": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r614": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r615": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r616": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r617": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r618": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r619": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r620": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r621": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r622": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r623": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r624": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r625": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>87
<FILENAME>0001159036-22-000050-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001159036-22-000050-xbrl.zip
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MR@].G!QQ%8WG/I:4RV>AKU+X.JTC^GG.(JI.5$)%ZTZ"[!,LH0A,>]\[N,Z
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MK)6&Y+NE?HUF:>9#Q*NDE<N[*:O'&1:E$])*7F6]AX7EBY $KW/%W)UV6#/
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MMD*<BR_D@D7F6/)!@\K:!H]&&^^5UD)HNP1KCS.WQ-G[PPS9@LTB>$GQ(83
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MTBPBOL[?9"%ZQ8P+$=&K",RKK NCL=)[2X:\%"9;*<%.R6(U0RX-0Q5M4(G
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M$F <<Z"RCCEF^GME-/=2D%;W'@JR,L<E,1J>(AJ7+7(.*DEP&6P $,%P%05
MA8SF\ZKV!PQPFKJS/.:YLH(QWW+,HV&8D25E(@3Z47 IA'3!J^A65K  S&Y%
MH![8"HQ"H/^B$<B55\XK2)"$2IQ;P.PK9 7+@] _$8'ZZJV_?[+QZZN"E;18
MRW, K3VB1L6(R'F-PNM@4;O$?)78VVJ>8#GM:N5C;\=;# P&-)8KJ2!FB)HG
M+S)3V03GV,IB5U'0W";0.#AK F=1":6X);="6F-]EFB4$56*@E:QR9+I)FEA
M:5Z6I8Y1(7IO$%0,6NA24$SGQ=^W5WV5_.&TB2GMR8KD-%EI_Y<R**X9,)E+
MW7L;?0J&XM25+BQNZLRT]N4%[7UT5F>5*?(1998N"9<=!D[!CZA0I9SM;NQU
M<'](R%B^^:(7H33@^MAB!PC]>+Q!$(KGV.Z=EG.W+D[I:C-8 I]#O>28(V*2
MWH!5P1@0(GLO-+<4\B:C*U0^9^$%/)>:.F76@O#;)[!:Y:C 6!=BQH@.509=
MH9HZ"R_@N13:T4%::YR2T@KEP?K$*&00H\(+Y*EEA0KM++R YU)]![D$[QP*
M89D*J$$+RTLK+TT$S:JE\\'[V&X39WZ.W9*-1F+>2)U6MT4T#DI"VD32@V7T
MQB$R8M;.66N=*ONK"]52*K!2[5*IN&S>>#%$/1>_'$+F,7D/$)$B[ S<*Q39
M)DQ1<VV7S2\OAJCGXZ$MB=4+(EO<JFC!:\U2CF3=W"4_$?42>>C%$/5<?#6/
M#)V)6EJ)RC 1.&=16&71\YS?KQ16P5=OO(-^^K3"T5;GM-V[1-*!7GR[.^IA
MO92>.+B,B864K5$IB9 <!5#@) ;@W%;)$R^,(.=34]8D:2!(:5)6#I)WP'C,
MA+\<A/&F0GYV800YGQ+P3F@+-GN/0KFH@BJUJ+P2P2O 2;.3:GC1A1'D7'PD
MDP$Q!#09$DE.@?:1@39)RX1&5RF>_4B0HYG^O?W7>_L;T$TOZ2<H)RQEJ$H!
MBQ 1#,>H5>#1"66D2"I1Q!J2D=5UD'.2XER\H[/.!*FT4)*I**+SB95Y)J,4
MUUJ$ZGK'^=GB[%UCD"D#,N6\B"7;*6 LL\#@0M1&\51=US@_6YR]7R0B$YP.
MV6@IRC*--R!%Y,P[(8 <907\XG?GD%72!4;+K;5:),F"TA9)>"XQY,XQ8SFO
M0K _S^RFV0L,6 GALQ!$/U7D/L1@!5I($B%I Q7@+'.SL+G0$V B:^8I\,N)
M GF2'04*6:)&8YTUO*("FXF%S45@7(H<0(+6"$K[Y!0 "\$3]V AI2JL:LS3
MA\UA5@6DCUJZD+U49&Y!>^&895ES!2%4(0"8IP^;PV*2DM$KG[6BB)OS!"%%
MG7ARWDCN=16FP>;IP^;1;#"7,OH&@W.*9^NB2)R)F!E",)5HA#5/'S:'.(PG
M"IJER]EIA8('^J,3"A#.1::N4R+%M<"$<(LFL.MH^F4;N@WHW RF1^THMO9?
MOBS'II7X?)\)[8=7%7%_51%UX::@*A2B<P+D[))!%3)%%4X3]^'&@&'2Q4D[
MFY6&S$E#;O>JN2GT'\B))^<;4\C(,F3E$P>)PB3,"FW05E1@C\P/"OW'!#&]
MS0F!1CVY4<=>IT:1A@/)N4'IT5VW?EWL^9?Y263^LS%,>G 14"9G%9H<+*>P
M,<>2Q,P<YXMO1_-<QWT0BZ(!(J]ET3-DBMR9<]DCE(W4N:S1JLJ*9 \'PWXK
M#C&-A/*ZVQH.]O9?5T0L3IFH=!*>0G7E0O(R^0@*)<<LHJC"K,JBR&?^ 7Q,
MRBKAP"8A%/ 8M-0N$QA:+?V'IFK5D^%+[.=>OP/=B/O'T'^(!,\'L:Y,9$$"
MQ7I$XQ5Z\,F+$ ,ZYDA"B-6WKAE(9OYV56(P*\$(%5#9C$" 66KUR&@"@L/*
MVM7L8J3IV52*5ABA+9<^*!\,$,2A94DS!=HF7WV;FN7<QESLR3A0(#))L.Q,
M@>P-5UPQ(3%;J[FHP+SE0I*.^>PA) #DP*52@BN)VCG&P);%'YVL9J)RX#@*
MD6\$6(.-;KI+GA7!2Q:-E!P,1H84_\JRR<!)YKP+AHC)F!1R+A:W__$BRH?7
MN9A.)^1$#@P,9U+HJ 1Q1)4RRAR(;6BFU:C?&_></[S]?-,(<%_G?$HL640:
M!(.ZQ* RI,"BBQ[H+R-,ENIC=R ?7E4?%GGE#<WY$3>**27-LQ'2*F2C(I*N
MX*X2D0S;?<R$%G#<OHU^3&G<,IE9"DD:88E^E"T\G)4J?MZ+E)T=C5NQN(F^
MD<(MVKB-C>^^^L;9=,:-B<@3C4H@1Z*DC(&9TF>76R1%]'&RW,RO5R]GX5*^
MW4[Y_9?R;B'\#R5S2O" VF:>%5.:?+$UCEL:()1PO;UHIN/VO:YX%./OX>E9
M/Q[# %_V>T=]Z-Q<6H@1V]B'XHEOGWO?DE@_3H+G(&)0*@GA0W:YA#8Q8&:$
M+"9!QL2MFD"QJ4!06@$1C\CQK(-6U#K%;)4( HFB96#1,HF,?O=6)E6A)<'[
M!:W+N#"HG4=@SJ6@F>+*!I9SU)I^S)"UK/#6LOD(<3Z9P&5M5WL FYSR+'K+
M(D>6R,7&T@"A^C. ,[?$V<\!*BN,MF4NPAO%,#G"TI C\B!TTCXOW1S@,L[]
MV9Q$=!HC"T$)8T,!5Y,<^<:DN.$5\HEW%71]7XBWUSW'_K 5VEA.&[47: U;
MRUDH+-KL&4M>JAB)YT00RB5,"DP&R-)4R$4NHDSGXC&%BCDE4"D14=7<."U9
MEIKI;%DB*5?(8RZB3.>S,SMC3"@%FL)?9? .=+!>60,^<ETE![J(,GUX?_JH
M=?&XCX,>!<\X&/]ZC)!&#Y]:YT]^I[\FHD[,1RU"BDR2^2HO4[8Y6&:M<!2&
M_EWFBSY\9S"\;),,.ZUN_1A+EYO'PIX.?WO72L/CQYRQ_[4V.N_)[X-3Z#[Y
M/?0?T;?'/X\O\NFEH']$5QOV3A]KNE)Y_CJT6T?=QY$&%/MTP6'I+'-]?NCU
MZ3WJL==NP^D 'U__\%MJ#4[;</FXU6VWNE@??>FWR=5#;SCL=48W&$D\0GMR
MD]']QH<_O,4Z&[_)D,9KF*[O/#F\/CKT:)@^/>;=NF>?/\S6^?MCCT;7[E^?
M,!E,>3I<&WV/WJJ,VC_7Y-I'+SYY%7XZK UZ[5:J_3<;_>^WR?$RD.*3@Z>0
M4JM[])C5^.@6'Y[AT6B@OBP8^1G!E$>\/IV>N-=_?'V_3)I8S]!IM2\?_^\F
MF>6@UL!WM;U>![K_^]<!= ?U >EN'I\X:%WA8TY/-O[UW7@P+%UG),K)X'!1
MAO9U8[NYM5G;;VXTM_9OZ]:-AU^4I]W?>OIZ;[NYO;5?VVALUK;^_?1?&XWG
M6[6GNSL[V_O[V[N-A7^%-S X)M49]KJ_UC;7GZ[7!-/*?_:Q;ZB-F8G:J'N]
MQ;/=O9W:[X2#W5ZW0;Z HJ?:!"[W,(_J%6<-Z$KRCU7HF!?<.BMD# J2F 2-
M'_&86A>*1TO8>KS9BR,/4V*UM<GJJ_SK,FSVSE^(O?,#N7.63K;.#Y_[D]W.
MGV]W-MLGC>:?K</G.^]VKE[QG>8KO2/V.@UQV&I<;<C&U;;:>;XC7\A&^^#J
MM'6XN:$/KEY?'G3V3G8V=UBCN<5VFXVWAR>I<W 2WS6NXN7NYA\G#>XN7HC#
MRX,WT>PTW_+#YI$^:+YFAV_^?-O8/. [5T?RX.2X4^ZWVSQ0N\UVZ_#D[7EZ
M_I=*__JS?2C:Y^&D=[';_*N]N]D^;C3WV@>=5ZQQ\OIJ=S.U=I\?7#0VW^K&
MR9'>??-G9_<O=[&[N<'^EE%X11%:79C(Z@IRJ(-+N@[>Z,RX5Q+CVA/.ZJ]&
MWNB#%-[[A^EJA;F75M0^4>,I/X?[Z#'4G8_QRP[TW]9VN_B/^YB5'CN)F3I%
MK]:=X=_C$]6ZU>9>+O&;/*U<9TI]BZ?]G%N]]HSB]*+XQIN U<;\Z=#T3M?N
M$LP'MWSM:^OEZX_%NM W/NN/.=/XPQNW.CD;$-.]O#\X;O1;T*Z][K9B+V%M
M9_]S=B"^IH!COO+PP/CJC%@N]MN7>WC:ZP_7:J/<WB'=@ :! H''H==K!VBW
M>\/0NZ@DA#YKA>>OS6%S2^PV-]CNYK-V.=9XOM<Z$']V#D_VWAZ<O%:-J[W.
M8?.8CFU/OO,7W4MW#YNG[9WF@=[9?*5VWKPF>-UFA\__/#GH'';*-1K-(]EX
M?MC>??Y:[[3=NQ?-C>'./KMXT7PE"8(O_@Y>"A:2JR=F5%T)"AY"8+J>2LGN
MJ*,*2:X]^9__]E:9WSZ'PA.6/C&J:=G+=+&=?0W;1SK]ZO7&7G-K[\5!;6_K
MY>Y>L_;R]=[^ZXU&L];<K1$O:Q+YJG%9V]VK<?U+^D=M]UFM^:^MV@W*]IZN
M;3QMEL/<2_5^H!:007]U8,94J->O#8^Q]I]KBZR-P\@:19>89D&27H[NMS4.
M9F\AP>-$G]0[=,_C\K5Z@LOZ)4*_CMU*0L+WLRIZ_K]]\$$FQ^J2QK*N,G=U
MQXE4*6^8PA0Q!K_VY,^S+O[/?W/#?I/LUUH9]R\;]^)KZ.[>B@>M>-!R\J!F
MGYZO59*+EYT('5R]8CLG?W;&]XFZ\?S9R6%G^W+G^8%L-",A7/OM3N?59>/J
MU<=$Z*2Q^>IRIW,X>J?&U5MV\*9!S[;][O D\L;5UM7NFU>7AYO;LO'L#B)D
MA?: $NLBJ%Q7!*)UGQ.C7QU:$[)(XIH(J4H3H:].X(R4NKFWT=C?'M&=>3&A
M!W<L_IN8S_"]#5Y3G]SO=<8^]/O^K@U[M1_Y_LV_%\9;WV]0G_8ZG=:@K+K4
MGK7(%9,AE;68!X32K=%"2[G9^%Z5Q,@?FF^[^!M9J7<=59UC$G45$]0A6%<O
MY7>CP<RRRF5-C1-WE%)_C'*?3GPM."7\^_/_6YQ7N=]4](-;QAX>C=H6=8>E
M.,M/9AW$%N3?$DR.@9/?#T#6X:2DP ELG02"-EGF4>JU)__:>+%[>+"S59S=
MWL;+K=?-[:?[O]:V&T_79S-)_?'L\'TGJ6>W1/2Q<7YF_OI!AN>]^QE=\'%K
M2&\:[_$T6Q<0AR.CJ/5RK?_>&&HPJ U.,9:,@E1K=6NMX: 6CT>3( \CW_N-
MWN<G_9<$?"L6J+MU+>5W1>I?.B;6M?N^;W[Q8<VZ<O>;5OC^^'^L>S,(:+Y*
M.!\Z2!_[S](NL$^Q^:A)X*AKX-/>67?8OWS:2_AIO#XH9YSV>^?E.A6=IQQ'
M[/39Q>[SPV.Z%QW;*,L-;P^:[4YCLW%\( ZN*"J_:CS?N=PY>?U1Q-XC'[RE
M#CO/Z+V.-$7[[+"S=[S[YH#M"(KZ3^B9Z;D/KK8O&W_=$;&;F&-*BA6AN+H2
MUM1!>5[/S 7/8BF/0A'[)K9+'PW\;,@^M6!]#"4/K=YWST%]% 1^USO];!;;
MA(OM2;+@N+5GA0/#69OB]FU3A"B\QBSJ2:=<5S+[.G@.=<9#0LZ$UCFL/7&N
MSI1SQIDO&F,%?([[=I8YTNE?1HZAUNO7>L-C[-=.SOJM06K%T:P2\<[632<R
M.JU_!-W6U>CW?U0%LKZ:OU(]R/IN@6^O[ZWOK]<F)93ZM=N(4VOTUO]QE_)_
M0XKGG5F:-T\U7SZU N:V( YC(Z4^#@:3?U[0 _"5L_B:L[CZA+>!+85P)=2#
MT;ZN8B;>9H6H.RG1F<R=C6KM">?2N=I^K]\G+>O5_H)V&R])2R!5E<DM(2PN
MEF&^[%%4U3YLG8Y#KI5E?M4R/Z)Q1-ET4#+5+:*J*Z"P*C@?ZT:!X=Z2U?J\
M]H1$)'C5&=QB:>Y3^G&WW^R]6TT$?%5MV2<.A8(+FU4L)3BD([5-INY0VGK*
M)@E6BF%P4MM]TI[-%A[U?L!_?)9C+99R?S=;)>RL%?"\DY,N\ALOECF/HKS=
M_LM^[YPBNM7LWX\;/?_$Z#$:EM"G.HSR=;(B/LF$KV=GI-9*@_1B[<E3TC@:
M_&X+9F/U58NLOALI)II>)BU.^Z3DK5-HU_ "X]FP=5[6T"C$Q<'//F6QR#LG
M[[>*]\L#8F9A/1M]A,K2]1]*.%!_TX!D%!SJ%E*HE]H6]<"]JR,+VBIMI7)^
M[8G3[F/L^L=#)DJ]Z)&QO3SN=7_:1*E+8I1&"25XW0A%C#):7@<K?=TSXWA4
MT3F?UIY8K^J.?KQ_GM3LLN^^,?WAEP_I/__SWXX4YK=!;8AM/"UZ4.N.%.'7
M,CW=/BO 5@,RVUJ\Q10_ VB3]?>RM7+6NWR_NG0VWFW]OH+#).T#^YAJIV?]
MP5G)_QCV:G3&:+*6BU_"/XK'*^F@&W'X^/K=9YNE8/6ZL/9[LA2D7-?W7/C_
MELMROTYH,OTT!;7.V?VV*=SMA:\'G$P3O_W,K["WB9A'^Q2^6%?ATX/?3/SF
MN;+<; W;HYPHA'A<BVT8#.Y!@'Z:T>G#" _W+SNAU_[E7H3W7F,SWNNRS$/7
MF.3:C?0*+^)QZ;I;(YA]=]RB3SY@\3V&=!:6?F<-E=]^%D5_0,(Y<<"77(01
MV%22<(YG0QIE9U)GK[7;?"T:)QN7#7K.@ZOVVX8HV[BWWATV=ZYVGC=.#I]_
MO'NI)PXWM\7A\VW=:!Z(G<UMMONF<;+[YI4\?+[7VFG^T:9OOCL0],S/Z!D_
MG@WA-B)'A#IW(=65 %D'%50=/ O>@F(>Q'C7!1G8J/SCK[7_OY0LXK53Z-?.
MH7WV/1E2*]-X6-.8N)>Q=UG9Q3WL8NNV722+.1INZR$%75<(0"&V4O5L0"(=
M2S;'<4[_7+1_^;W\#/S&UH0[C/>M?#S57IA%Y6?99V<_'R?VH0S&2EYG+([V
MQ-BZ3RCJ+$@NP)76D9)8,,7##1@D^,_8M]1*:2(<UEZ\>/H=9O6@9.['+C[?
M,U>OMC@/O'JUU:LMU .O7NTG>+7[K!Y^-+7^S<51ICFWOMU-)=,9:^&R%H^1
MF$&G%"U\=XRC]/<RC_YAJ^7CVB_\'^,EUF,8U'*KC:D&[3:=4FJ>E.GY_YRU
MRN3\L%<+.#F!KCR9GQ]_E<N2-S\N23&9JK\QPW_-%<OT?3E<2E+4$AWM'HU.
M/>UCQ-&,'A>U446I0>T7NAZQRMK@+![7!L>]LO7SN@3$\!B&'[U&[1W<?M3R
MG.,O3U[D'[_6H)MJOX@;;QN(H-))X83>I7QI=#Y]LSS*Y&*E$,Q@]"2C)X7!
ML.99+<'E8/VS52$>.N'EZ=DH/W=<E:9$JD,8G@TJR;1_:,GPZF\ *W2*H2Z-
M-75E-*][$VS=HN6!I2QLV3U^@(./&?'MI()[&ND;&NNBIH,?,L^+A]V"_<5[
M?TYE&[V[RIK,=%C*K=V]*JI4%FMK!7,(;CJMX9!0"ML$._U>MTP:M"]K>([]
MR]IVF4N .,KGV80AC"NU? 3"'ZYQ<\5T[XS.5$P7B-W#H[/V>+?+?KU9^Z6,
MKOU-2+$^.6%XW!IMJ3^EV_WCH<%X_+SOX14'_Y@?>-X8X#*^$RS]R<"S<?56
M_RW 2Q]CR=Z+LJYR\O4@$B&HLT&5CDQ1P!? <P6A*PB=/802:D&M36^"-?C0
M@G*$*OW"\.[\M$;*6[_SP*!3MCCU)R2QH%[L=6@,+@N?I:L1_RN#=E0[ZO?>
M#8^OCZX3O<71HR7,K>ZH0-DH+;/D\0AZR\\\X.@P_^WZM*^>\-G'FYPWYK23
MDS_SK->7;'7''H*+4!?7+/TF-5]_7#75J54N%XBO>Z&GGPNDU@7_OD(H7WQ:
MN^Z$G_[3\G5SS[(MTZV$NJ1+,A^*[/6?$I0<]?J7=ZS(C$X:@4R<G%3IQ9G#
MDYVKQM4?K8/FVQ(*RL9FNUU8S<[)6[[SYO6[PS=;=,UV:[?Y]N.2I9V=JQVY
M\_S/X]WFEBI;(';?O)9TWN5N\_7%8?./]D%A4F^V]>Y=!5!\S#+9J.M,NU17
MDMLZ\&CJ67H 8"X;'M:>O+C; <QP%VUE"O[>M];*I!C^30^UE,,V3=39^%0!
MEW[\IJ]VZBZU>R#7=*_Q6TA=:]S%L3]?+7>E>]^O>\LV;--4P_W/A4P_P3A.
M5?T>G+&.)/7'V8#N/!@L;W']&3%58J@['Z7A)2.STK&N0;&ZLDG7@S.RSM"@
M#9(^!?,MQ?7OZ?&^=^/NLAGC-$%MZ^ZIG16D+1BD7<OI^4A,3\=26D';#T+;
MY2?0%DT2(=M<%Q!"706=*0@7JIY8,,QDG13GWPQMG^1YS'%]83X3F]ZM*RN^
M9V*3VW7-[4-,;!K_?7LGOW)+\P#SFG;=:#?URPJ^KLST]X_299W_@7Y4W$W#
MN\S%FV[G+RSME W7=RY(M?)=R_FC17R*=KN]T1K\V6"\+$0C,.[1=T<#FUY_
M=*_V9;GYNQ;=NJPW=>G5>B5L.6\-1M%S%[JQ^#Z*J4M-ZW+R8 C=!/TTJ)4R
M-JWTN2W3\A?XQYTK/+59KTNRSZU+_E!QCJJM5PZ.L=U^O[+X"ZG-:-EPW-O@
MRXMRG\^4.,#!#ZPXW[<;V_T:(SQ\K%A&<(GYU _EP;W[6PG&H@9?]S*YNM(F
MU0-/H<ZX-YDC#\#B5_G0*IGBSAR3JN!2V0\TKAE2<*1W-AQYBY';.(8^#J[1
MI?]IT9$XWJ(Z&&]1?;\W]?UF5;KDZ!J_CC*[YMF!90(TST897/3(9]W6&&;&
M[[AV&WJLA%P@)>1L563!J2@,2H;6<66E_GM[A#B.B35"Y-CJ0'OPS[7MQK,[
M<FY'0S3::+4_NM7NAP&^W1>79%!/O6%]<D%B241]Z%KL)P.FQM71Y=\Y::$3
M%_4H/=255;;N4N#U!-:[F',PT:\](<_PJ[7^5VG9-3A=2WB>Z%3:$)'1;)P=
MD5V/H4A<M^V=GPFLWZLCW$?S+N]K_<PVH"3^1PC"OB>BI%C4L_O5M_GV\NU?
MVD3,;F\%%I_="OP-=>8^5W7IR>^A_^C)9^4Y>1-;6N*>]L9AQ.,^EL3><_PP
MQ/_K]DS=Y*W8AZ] H#<X&W[ZE<\_Q<V_R[5'T!42\U&+D"*32G-%;"/;'"RS
M5C@6[=]V[?H[Q_T/T>$1UD,?X6T=,KWZ8VB_@\O!VJ/;JDN:-7E=553K6Y]T
M 7MQ?;%IW=<MV"]00<+MQN;6OS]YZ#E2QCEE_GFS;N1W9?[Y=2:G/XECU;I6
MX@'FQ[B9?@<TO<[9]SWKEZ^J]?WF\JJ03#B[=@65?Z>'* L^FP&XJT[V^-DH
M9ICT(7I\UB4H*V>M/7E)'O2'ZM].=='VF[JH?\E+Y/PP+/DKH_D[+,RSU([[
M)4[][Z\3*\[6GNR?=<AE78ZV=[4&;VO/*$+J]0>_/X*[EK3F)N\[:-AH-?CS
M5K52A&]3!/GC(K][24<\A/"_1ERG-.+?"JH/*?UO?)9OD+XD;["QUQP[R^W1
MSA\N?JL]VVYL-)YN;[R@Z.+9[M[.1G-[M_% 6O*#"#'C*9/Q@M\0.Y-"!>O3
M9TTK3S=5%3=K3YZ]7_P<-?48U6!X:#?WP/TF5@1KP=7.ETJ=],5N67VGGT9S
M?J-$]C^@3=J(M?UCQ.&@]LOK+IRE%AWY1ZU>^_.LBS7)QM/"H]V8FQAQM HC
M^>A3OB $[:ZDOA5'>RA=,C/SOBMD66QM$/JSR/+!NY6@KC2S[^!'^-*D^V!M
MI$Q5??D"BONMB]I.;U1,9&N4%_4I;JZ@\B<UCA54KK1AH@WNGE!9,L'Z>$SG
ME3I)7P#.%?:LM.U+VF97V+/2AI$V2'Y?[('!<>U9N_?NXU!PA3,KS?J<9KD5
MSJRT8:P-ZIXX,\HU/>ZUZ1:#2:9N;>L_9ZWAY8KIK'3NFW7.KQ!HI0UC;;"E
M6,N0GFG8JWT&BNY:@;D).RL(^<F41K&U)YRMEI0_75(6JR7E!===I]>>[$ 7
MCD8X]G[7TV9K$,\&@[*-J#"CC2ZT+P>M$??Z '\%'\?;=\LY>S@X:X_IV>XI
MCA]I41*P5E@X2WV2L^-3%<)"N<+"!===SN3:DU>E8D!K.-I&-,(U^J!]_7N!
MQ79O<%:VC&Z$WMGPNK%<23I=8=W/J"]V=M-7%0([M0*[A5=>,YIL&_9),".@
M>]GO14P%VU9(]C,JPQ21[/J<Z^?4G^PWOB.??JI9IJM\_87/UV?^5L+^AXS]
MW;(I>)6MO\K6KSBH$@8]>8%'T!Z[UE'GL)5O_2G5P*ZF1.["L(T5B"V\]NJU
M)PNXI7:%7S/5@!5^K9:WJJF\;NW)Z^ZXKA^6EJO[T![7^YOD"]WHQ5TF05X/
ML!R<$+85VOV4"K-"N]4"5B655_"U)YN88;00__JT=+C&;JO7OX%R*T3[&95B
MA6BK5:IJ*J]:>[)#WR'>EI'HVHT5^!62_8S*L$*RNY!,KY!LX977KCW9';7!
MV.Z.:Z+3I588]C.JP0K#[L(PL\*P15=>R=:>;%T<MT+KX8N.K:!K$:7O9K?/
M9;57;M'U0:X]V=]^WMAHOM[;VE_AP<\H?S>%'=-?[@]RL_/%@S3Z^(X\OP=M
M8B,^&LWOZC92:B'/O]W(C98=YK;I/E [L'OV[/ALN?";;_,M[S'^J%7V"P\?
M"[$^3GB=A_;LGO5K8=(XOG18')R%$XRC'IAPHP=:GUY[O.)YUHV$H-#JEM6!
MTN$SML]&K=&&Q[T!UA(.8K\5QOT82X^TP:239AL"MNGCDK4IV&\WQW'T$?^M
M?&-R]"7TA[7M7VN%[=?$K[4'W')X??-12S?Z_JLSNC>!VR6=?MKK#]=KS6.D
M%QN/P/AUQXU)<Z_=[KTK\/3]BC GA=X;O<Q>04422?/_L?>N36TDR]KH7U%P
M=IQ8*T+E7??+S/L2P1@\PQP#'IM9$_871UU!MI!8NMC&O_YD=4L@)#S#11(M
MJ!UK>P!)K>JN?)YZ,BLKL]_*9O#+Q QNVZWO6M-R=@M#1T2OP,[IK>R\FF9Y
MU_Z'2X3:]<=%V(OJ6?QR";V\@@S&YY5-M@:5I694I4'_K+*VET?_V=]%Q.1V
MA!4GYQ:WPPZ,TPY:YV/7[?C6:;3=W'X7;#7F5H3C+JRJ-C?2M:W0&4XN/^U>
M&.*7V.V?9U35;0X'%4KR?\\! [TJ_^%\T ]CX .?^_/E@@8U"^0VAW&0,=;Y
M;J<7K:YPGOOIP@=_>*E,&F?G$4!4O=]UNCFO OAF.#X_!]BY<?=S:_#;^,UO
M%.<_YW?M'?ZV<_AA;R6S)S/[WF+Z%K1$Q@%B+V[H=N3L,-9*[?_]?XCBCVAU
M6]O3"1AF>X$I\.-!?5!QF!OI5C,TZ)\/.G&45[CI'-73E\./7SO9? +<(7S@
M(D\=D';UN<ME([]W<,6M_4MNO55SKD(ERZ&2_32'M_Z-4SN+Y-"OFFT/HH_3
MXZMG>66'_\^]3<=@Z'WX9(UIVP7DPC4[Z>H/+0O&E"_1=_E#]:IO6R.X5[ 5
MN$T821N [4];R7:ZV?3@"@$0=-'Z6M$3Z(W<^W,$3#*QKLY@GAA.8B];5.ZW
M^B7VQK'8U3KM:I+B=AO;JJG@!D.KER(')C8<]F'5R*JC:M<^[, Z$%.*^<-P
MT0G1M/)$CZ:455T-C!1,I$S](U!*;@2<>\AF0(\3_  XKM<3F*4  KZB@7&O
MZA\(?P6=#V_.M)#1._.A>MVIEWEX93R\OMC#1ZLEIS6P7^%C((@Z%>F VCG)
MYM"N^K[W>U/3  '3\7$X]33^6Q_%OZB^Y;_5,?P+^.Q_QYULL>XB?U]_,&O(
MP]QMN)7UT>02$V.;Z)G?8 )Z\=O5N&9-OG^3M/F!_;=O$E>7E>BF[[^FQP8W
M2"S "3@D,VBJB+1&XW \/(]5H;KIUUPNSS<NS9=O\[FQH^M/_WQY[5,[.(MA
MT^!V.TW4-+CQ.@#P5U[A !K];(R=0:@LI5,7%X.)R[O &4T7K1XLV,-AMD+X
M]AH#:6K94TN\<LPOWS.8^'MPN4K_Y][E'3?.$Y\=^2_]CH?W9[RY&:$_P;X-
M9YU>U>V\?K_OHW-;,?_)P)XMO#RT9^?=Z]]176_A?: P -W5:[F3^C#[W-<\
MBND=O6@!'<'=PZ.I&K%7ACKQ).!V.M<DPUF,H\E?,XXZH[KL6N7A^^DG%X3L
MY"'G%B6;9OB;OLY\K5:.;-S9Z"_J^-/G>'&=GUKV9!"K.%"E)Z\#HUXO0(K"
MHY^P616GKO7GY2<O1>S?7;Z=8V%P03#6"C)I,CA8BH;9;*^936U00YCP3@(O
ML#<"# _'(&H&Q8K6:$73Y?I'Z^PDB/"/8O6*@^.E-(F][Q=GL5U3&-C!5*?.
MKMG@,=E!Q;C33_D?N#A92N7X3F9(FTUJRG53DYJ-JX+#/LB7KT;;'\7J0I<W
M<WWYA@$. 4K@V-MA#:;K(CU3=9'0ZS3*:_'U:MF+)Q>7)CKY0\<#P?AQ%8"?
M3#=82K=SUIDLU_T>_&Y;"<:9.K$;:E\)=#303<UT$P,:17_:@]N%[_AZV@':
M.X,U&FPI&UD=M<YQ[(K.KFRI%T_J>E43VZQBCC=8."S!K\:5CH_?X/$.9Q;I
M^1O)]!WJT#M\P3^,-(]QHM.K(8YKCW/F B!AX3,^5LY 5K-9L$]O*^3AY,*K
M]?X$X"JO!=WZNMD+ 34+2T"63&G<W33KWVA%>W3'@-1TQJ81J9N"4/DRM;*;
M)=_\R1F/J%JO6U]L_JYJWZY>N*\1ZXSW-.Y=&4C+P[WE8"[HT:G_>3F*B9F>
M35W089UF#BK9QT&OUJBUE+GN9D[$2ATFJQ3(J?TR&6[EP-:O3.3W#3<]%2 _
M<BZO5HYTN?OEK^U^W>P&3I[;5#UU+V9BO;:*RQ0G<.V0N?+^+JYL*,=88 [/
M8=8Z.="2:CA]Z=0JH=Z4O0:PRQ *7-".J@N A4Q(?S:4,A_=^\=PQE0&38.Z
M5[LWHVJS].J;:PE41WSG-YUNWDB:1CE2C7.XVJT'EO_\OSDP9,^R3[D8WGC1
M.IJ%97XB,,C^PG.]<EOAT<X/L][LS@1TM:-UXP.9,DKWXMKGX]RG)\_H;R!8
MW4D)?C^F9WHCG6<,P215D>P?+1(3[9,M*WNK(*WZTPA)=[KE,@V09LOJIZL]
MU"O[FET33B+0^V2Q'-G/<!$_<5Z! (:C29@3;.RL/1&!-SFH.;YW;>4H=K5&
MNWKU Y[(:0 GU5Y7)LN='O!X',XL[C"QEQMIZ<;WS,9$ZGF_<?-VF%NB@(%U
M?&V$J1;VU_9TRT;NH]C&7['6P;'V_0:VWH&_=(:\/>^,X+^3/8O)S%4!U%-8
M)?-ZF"5=KY]WV\:#JN%R)0" R;YVNMUJ'V["1[7LG.S0CGOA;V9Z,NYJ4I]%
M8B7[<6)E,W(D"^"6!KBKJ$OEE\TLE:!872U5<Y2ASHP$'S+OYUU!,K_G16M*
MZO56([P/.#UU)EDVBV'I#-X9=5!_SS0 72_O=?)6%;:)Y_:BWAJ<N5 .L\#J
MT:W2(PI)K]%FCF%.+OWKVM?.JVS682G:T<P"_;)Z953Y%E6OH';>?0#WXN0D
M^S3M:J)O5/P_\N0GZW(.--<^?9GY-<[\RZN9GCC."S-<36GHY%6N,H'^U^PV
MG';.ZS3/.*P2+N,W\#*KO<R9]G19X>5/7^7>A7@^J'1=E9^0]5I_FI9Q=M;O
MU9_>- O8Z! -.(7_E ER+2@QB%<N7:KF-S>!R#/OQJ-I$EYVWB:O5)Q^/JJ$
MVU4F,+Q\%468W:H&/=?M?YU(O,K?^VJ'D]7J,NKZJ?IE;N,R&UK9J'R4/:&9
M7 40 -7NQ4RB<T7S=7K3U4;))!/D6B0"R"'V\G90[0M\@7D(G3KB7;]O5 <A
MIMF\UPRW.MQ6%H]U3OUN'?ZLXOS7XSYU)&A*#.<Y/&-]'%=IY5>APDP?IV/X
MY"1K[4N_^P5&/*M7IPS4[4QMK#ZZDC\ZH8?:P:R4;J>7":#C.UE:YE]J?]$#
M6>6\G&(<CY;!?9F>;?UI!\SFBL5G@^CMR^VJ*C@T$R<\Z>?X^R1(D#.RT\#F
M&ZC/BF2EV>OU\VFN<)G@6.F-Z<+1KC[XPX,>-P3EY_;@P**K? 0[6<3:"X&G
M2B;%? .3U(J)90(J8JMKOP['G=$D;:T*NO?K0,7D(X6YUAJQG(29_'_'G3J2
M<[FY4Y\L6CP3<AEBOL&1*7.W9L%1)]GG3?61_=:J0LP5U+H W3'\=@V =8!C
M-M*0>00^]PD6JV'H^,L_QF\Y>%WM6G@_&&?8GP&K_)VL^.$IR)OB7[?YW..?
MGKST[_+1TLHCK%RSJN]X,?3U&OKL G/]0/.L2@+A!):=Y5%AHO6O(E6FMYVP
MR-=JUP*8I][IF&YOU'L@=6;:];C8S R7R5OCY.WT1AV4=YRS<U#GG@RGZT 5
MD#JMCLZ#;O7CL_K 3I:0^]4#K9I@YB5F%WCS:XZ)=*M3/CE-)>]A]V:E1>;1
M,0C*_B ?(<C^">C'>ZPH:UP9B%A8&4;UN7JX?QC4X**8ZGH7@NM9&]<<%7B(
M?Y=C"%Y,ZM?)J!?3[=1AOQO:TUR@<W"NLYM<97YD&X?9B+UAOMQ)!D=OFA">
MKUQ#9#C)4IT>M,T>69;#P_'9E?M_,9/>6F=+Y;RI?!@L?UVW>\T#^]']59DE
M5:;CZ/(X6QU7[H=J^=O(+?V-CAC_$NN=O&'_+/Z@UL+\<< ?Y[@-:KOIA&K2
M@62RSST8G_SO)& (]NGRL95L*E<91)/=QMJ^Z[,$0YC%Z5^NY2Q-LP4F.047
MD]S#R4G*N<2G"3XJKJ[^'K]MFFUM--5-TD6J)/=*ZK9AR01RRYO9^:13;_I;
M.\]<3HGNYX.W@[X-K13!B";V,!QEG[ N(>(GZ_-E0O/, =_+Z;]*8\Y1JLL\
M1^#&'#RJCW?G<$V^3CM?I X75,$=W_G2Z;9SI9)\PJJ[<#0PA[LBO% 7&:KS
M.>$'<*KJT'7*489\H\.3_N!D<F0+++I.X02GM#NN]V+S48;J&*7OG->0 &H]
MB.#"PBVU)S]UPDR$?/I,9I[$].1,^_(XY#AO^D]'-8CGX_K,8OZ8'9SE@57W
M<EJS<NI,X#S)U8EVD%.])R<LQSESMSL]]IMW!P?CF6S BNHO,[':59HI_'DV
ML^_&W>.9'8;ZXT4L/PXL9XD3C&*4RQ_4Q]=3S&8_2=OL5JT?SZ]:/\Z>U\W[
MQMU\K'Y<OP<F=#3=P&G/'/6YD@\SI\ZFYV/:$STQR9*NSA#_J"#0WQ;YN3R2
MNV$&M=$:XJ_9T-QL*.-JHZ>36IU1EIHAUF=7L_%,U_*:QW+V<>:5P73[I\XK
ML,/1Y-7J(W%:B*V?$JHJMTW+I$W.9F6]46O*BD"[TUH,[>M["9>7O-SUS@'"
M^?3FNFA,72TFWU\6-\.\<7FEKU_M[EQ6?IN5*L4"UVB!KRK2J,^9S#%!>RH7
M\Q_S$ZR*4< ,3A?,_J!>KNMC%=5O.:VEJA4XF!R@@)<KGKH\['*SX/Q1IOT,
M75;?VN_F>H,3'JQL<[+]F5/R9L\;5O08.M.DK9F\OLI)J^+B^3,+:7\37AW6
M94XFA9-FW,.I4S>-02X<C+S4.-7N;*_?N_KP]=S]3J^JHMV:/:8VS\X%"VO$
MPILJLR+;_VA2X')R'FL4X4F[ZEAJID%[7NWAWU!8K>4Z_9E#L)U>+GDTC15<
M*\-Y,H@VYZ'FX@9II@#G10T;8/TZSZ-2VI.S'W6F&4#LJIC&[)O\J>V=Q/8T
MC^P\CCH9E%/),A7Z$T6PH ;BU?W4M]JO(X" X"ISH/-WF[//+I&<;W B^?T8
M8"<?9+NWK*]"J8^+>QC"#W,T9D]G#F+GS(W!][H2S<"??0#*Y<IW523/?@$_
M+T.KO5!W\<?5,F=/L==Y@5>U=2?I@LO-$=RT962CO<3CNB)#=8*W7Z<%S\0=
MZF/;M:JY.2.LV@7+GSZ%Z>Q.Q<^PUEVP1IS5BU0<5BW0IM5DP7[1]'3Q126W
MKJJ&U"M#I<FGD9!I,MAD/+,6?][O=ORT&>YY-O>JTE1E9[/U9\?#A7AGM2,[
M4X-TLCS" M7_6FTOU?Y$M<+5Y]9LI7VF.9#_%#]M7\=%MRZ%5IVAK8O/%4-?
M;SBD"OQE69*37:>BX[(Z@3WOA)E<UVSCM2G.&M/\[LBU L97DF22/C]S[OWR
MZ[Y,-FVJDGE D+G;Z32I=HZ/;ZQ</%?NO#[),S.0)YSV\FM5AK5;E<#_<9'P
MHB-NI2..*C]Y)D9K1Y5::+=..Y?,7_F3N4K9V67]^SI47Z7KYOA/7N.'_5XO
M=B<(N3ECXI_/>!>.6]*F\TQIE?SV+-LN:[O794BK$T&^/G%8G^:QK5X^,I;#
M:)VAS9WGKVJ.>CN"OP U@6JKR^*625SI\:X+EV=P9/UGX/MAW0@;G&+PS/QI
MK(O^7 QS7XK*60O]K[WI>:^K--BY.JN7B; +)_<F0)_N'Q6G^=(\Q%+:VK!E
MM+6I'OH#/.WU/]*;%_ W.V^/6_M5:)_0GUNO]@]W#E_N[[QN[1^^.GI[L'.\
M?W2X:("W?-)RZY\(2?!Y,<#-6CK?W/PTJMXRY$6K[B:Y^.]5%YEW>6>\BC'?
M^^F8FYY.4^SBMYW71Q_>'^RUCG_;>[OS9N_/X_V7[]I@%2]OI68?=>POCPYW
M]P[?[>VVX*=W1Z_W=W>.X9=?=EZ#;>^UWOVVMW?\KO%W\:\_>Q;<"A (_WZ\
ML9K;#74_.U_],5PBP *9\_]AT3O/979/JYA%G?[_X_N8<:YK\%>=W*Y6K %X
M5*@JVW4^C#]-?_@Y;PYU[<5/G5XUINI#/T^N-5GF;NC$4CVT^N4K!G^!:Q:?
M])2<?//DY1?52].>=-=>4^0%D?2'+^,7Y)ZO"6KN]<F_&RPA+R3^\<OW'2QY
MP;%8S6#YK2Z[_&Z@#VLJ66/QAVTEEXI0_4\(K2;\]W$OMAAN5]*$8GK5(/#Y
M/8O=Z&/5PXZ1R^=!KCV/?[ G!W[ R0 H+:#)D%/U?S_?^3&LHV?VS0]AY]V[
MV47PQU/[CS=["_/XX34FS)YY'RZ2\ZD[H36]^65\P>,,\L[VXWV,?V\_S>JX
M_G):?WPXC*/A3_<RH[E[OM<,;<(UED0FK>J_IM%688>G]7YG_B$GTWRQW6LN
MTA(1?)?'AUMW[?S\&(_O?^8?TYUN<?;6JAS01MW;_^E\^ZG7[[T:3.J2CGN=
MT=O<)'H\#%O5QB2,OOI#Q^J$.7&"*:-YB$%KIGD*0G$1E8CTXW[6+U@RO)5/
M_7?.;'?X?[<0F%+/GL5\171B[?E/V1IW>B'_9^_*%'=&+^U@< &/[3^V.XY;
MK6HW? 3?^VWT4V]\AD*_ZFJ=+PO&"8\O5F9:^?2!_>?"[?:_O*9OO[QG!^/P
M:>_+AU_-IZ.SWS\?['8_'1[_WOGPZ\'7@^]_D(/C/\0!?7MV2#]T#K_OL,/O
M^_S@UP/VFAUVWW\_[WS8W1'OO_]Y\?[L[:>#W0-\>+R'CXX//W_X%,[>?_)?
M#[_[BZ/=7SX=$OWMZ)TY\V>O>D>?7GTZH+]W#W;#I\/=T^[[X[?P_C_X^^/?
M3P^___[Y\%.W^^$X=-X?GWQ[S=Z>OC_[UCTZ.Z"'WP_XT>YG>D#?7\#[V8=J
MG!].CW;??X?O^7;XZ80='?_2G7X&OFO\@?XIWW^'N_Q^PH^.WW__\.GWL\/=
MT#V >_UPML<//QW />W1HUTO#G[]3SJXP!>OC_=&!^\P/OQ^\O7@CX\V,*^Y
MDX@[QA /G"-#7$#<"*J,2"PRM;5M<-LPT*/7+62[#K@\!!)3TKP#- I!%8+Z
M9X**CB07 A6,<**2E3QJYI(/1GAM1450A%!&"D$UBZ#P'$%A:C%SA"&A1:8E
MI9 Q)"",1>0V^)2,V=HF1+<5,0UBJ"7Y%QL@*0^J;+8Z&%AONU6'ORZSYA"@
M ^6SK2MU0>C='NV-;+[9E+<D3;8SG;=7_<$[F+5WEW.Z&]WHZK>)?UG(;UGD
M=_AR09UA:ZF.P2)I'46<<8,<T1Q13IT0)BCM?4U^G.J'DM_?$-"JY%D!]YKU
M3 'WXX%[7MD(GZB7)J& B4><T(1L2!PQXFPD+O,V@%M2VJ:8-0C<SR=8MN-]
MM2DZJ3E2'P'HQ>DIVVF'W2K NM(P_=_QWVU=U<WFOV6)F\F,OKV<T,,X*F2W
M;+)[MZ!DHK+>PD0A!NL5XI%8I#F6B#&G):&1,R]!R6C39O+!2J9Y@::"Y*4K
MF8+D]2!Y7K9XHKPD2B*K:,A(UL@%^#5YY9UV. @KZHBQ$@T"\O.)Q^Q7)Y+[
M@RH* VJEA%TV09E,9^T":*SPU]+XJ[.XXZ4--8)PY#!GB'L9D!4X(>V V3B3
M @L"_*7:DCR8OTI(I<' 79(0*<!=$7#GA8=F(3!B.0I6<0 N]\@1:9!SW*CH
M T[,;VT+UC:X2;'0YQ,N>9.;W77"57F=JYHI_EHR6HF5;((BF4SG7CV;.[UP
ME*=RIYK!XF@MF^\64W,P5H0J%I *6B&>O$/:6X)"\MXEZJADX&AQT1:F28Y6
MP7-#A4K!\WKQ/*]?K%$$>^P0D\8C+BE#FO& 7++)I$BHE0SPC-M<-RG5;IF!
M$X9?4-%D"7/<SRTLEJ!6ENB&W>ILPQ.EOF5M^Q226P7)'2UFK%CE6>!<(A&L
MRTG%#EF8-:2%9SR&2#$'T2(X:1NV+"_MU@#9H-C+<P;]LG:("NA7!/IY99,P
M2X%'AX@Q$7$2"#(2>V0#L5XX+)*16]N&RC;5:E- OX(#ILW2.F^FY>ASF":?
M!)LT)KWOEE%QZ-:D:DYMM__3=/;>=&UO!,[<WG0"LV,W+5?T.MIA?)M'>93^
M!)\O,^).KIVSX_WX;%Q5J-S-?>I]IZIC!)_=.>O#0ZTK4Q?27!II+F;$"$\"
M=5&C(&1._P/-9'"@B"1NN;2*8Z6WMIEJ8T,:Y X6-FB8W"ELL(ELL)!5 XN
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MM0E_<(')-9]W>;J)\8N;1[TXRD&:9>PA%?_N<?>02D.255#?8@49H#=EI)%
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M,D&5&JE/1,9/Y_SMY927<,72-,&GQ0,2*3G%B7)()>,15\0@IT$8J,"\]$:
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MZDG._4?K*7Y]M?M<*'!Y%'C#T4IBK- Y>.-@'CDS EFI*!):14)Q<%QA\/=
MZ] F]2$M8&]>,&<Y8"]XOA.>YR5-\@D[+W,WOIQ31A1&+DJ/%..!<U [CKN<
M[OX$HS?-%3.'<=3R=GC:.A_TOW0"*!AW,9MU!1/PY?[UT9?HU+G^(,0!@B?U
M4Y[,8;_;":WI\WG:!+ATM0.3_A+F_,UDRG^Y^'.8TVJ/IM.^<SGK1>$LCQ'?
M+VY4*0=K&]9(>,40IX8@H[!')'=@C\Z#T@%&U+J-;RA>=;\DVUO#:(/B/<^8
M&I:NC0HU/ XU+&3E1,:B%QPYQ1WBSCGD> A(2B6)CB(21;:VC6B3&\I6-)0:
MEA0B:JZ8JILJ7==-CYZA?JMI?>ST];L/<IG[JLT^#O%F//"G-F^H]M,2>Q>5
M#9='T]_3RD['_1W_WW%G$.=;FEPU.\F'\<M*N[R5=K',AE QDH -2C)26&F)
M0H:8B#SU5!-O.:G22JAH2UWV5)\HQ)>NHPO$'Q'B"YNIEC)G7$ )<X*X3!%D
M-35(Y*[:2CLM+(AIRDG;T">8X]YP>3/HP]##L)4&_;/6$ R]SAP#-$P LES=
M4_9='DWV3&;Z%4QTW0ZED.*Z2'&Q8H>ESA,2&')!,\2)!U+D/*(HO= N4F$#
MW]I6H'N,>7"(H>RO-A?GR]<^!>>/B/.%'DC&P\RR@!1-.8W"$:0)#DA:P6T4
M5AD*.">"MK5L4A[%\PGP5!["L&H45&D=-Q[">X;#NH(!_*':H+6U'U%J[F]Z
ML.>7R?3&X6$<':6\W3)Y)10F7!H3?M^Y4CS'.]]@7!^%ELYC*Q"&V<PYM0P9
M[C5RQF-/%,7*J*UM8TR;T,6"BR72TUA\-RK0<VMXEW)E]T;VI<;)R#Y^_U%A
M*:*C"EDO!.(J2N2PIB@$9QT6F&(3-[!<V5.*\LQN8IU/NJ!6<9Z']:=^WEY>
MLX3-M>:V.[WP@_ZV1=8L2=9,RT@+9<&1BPCFT2 N"4<F)($28]896."8JSH@
M<J%+N8.GB>W5JYJ_P7:![_VTR_28BTR>B>20$!K@ZT&V. )H3C08B;$DUOC<
M=WXQ-K/Q/0\;+EFN;4R-3F.U.97U2REG\"1VGXI>60/A[2WH%9=\HC@WLO$B
M)]SD" P)'/'HHS$.6Z42Z!79AI6J0;Y:07CC0S'W17B)Q-P;W MJ)BC@;:,
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MLAXW/:MG#=O@PZ7VU<UUV9R,NYU!G)1+FQ,)L[JI,'5QU)F<Q<[^R6^_=4
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M2M@V"'(KA(T((D!4%E'"+>+6*V2EH<AHK"-W($R7-]&%[#*^GA)9@:X"W6,
MNMOD@#.#&7?)2N8"MP9;#PJD,)'"D)A,N![I;I$#7E'M5JBVFN8=O04B;352
M-@K$";/(1<N0M(QX[S*XN9U=27%-\JY@]I3!S'KI8Y#>4\<X8UX[EHMW!B^D
MPU+'C8!9Y6\;#+BMIGL;$8*ATB"L5$#<BX1L"H!\V 1%-6>!^)U=H;N&T(IV
M%>T>&]K=!NRB(\F%0 4CG"B@<#QJYI(/1GAM[Q1KJQBW28Q;R?1VX'_J9!7R
MQ@.=$]$B&PQ'P@'?MM9B$L!))49VC5AO'KNE3FIMK%ZOO.&53Z)N>=FI12ZW
MOBM-ON)@; NBQX_Y]UK-O%;UK7*J<GHH9%-:I3AFEI@8.<%!$Y!MQ)89'K%1
ML[JMY,9U6_?"N^EX<AX'D_'I<)%6GC/*#P9M+GG!T *ASY<0]%4$DCKN3>))
M'+WO^=AT$GT5_?#MH-SEBJ:BE</>A</^M;;/XIAW#CN*5*+@IDLFD$D!(TY2
M]DJLE\8!A<5=INZ\S5)QH>+W'>6T+?=XI.OE%G8DDB1LU$(1IGC4V%"BM*(
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M,N2H9!R#S<(.?%2INL*L8]R6NJBU5UB]\H97/HGR[F6?%KG<<[%T#(N#L2V
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MD&C=%+[39 ;84_O^'YWF>PJ:OP5>U5?@GBJV\]N,HO?5LH%]M_IV:BJOE=D
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M^@ 78*85?#=G/_GW_/V_<5 AVW@KL]?:;*A.&K=3IS'^O.>9^T^]H[CR)LJ
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M.XO=@_\4N\IXW?_P%<=ASBG&" N>()+R$.7*O$2I9'F<9B%CLMBP\(1S*;;
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MI3 P\UR9QK'7QO?6I<WB+1GQ1N.I=%GI<B6.L"M=WB-=+H1CAJ AV$04 T[
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MF$V+3VGK6%=HK-^,L-VVZL="E^N\/LA8Q<U6ZQ[#H9E<SSC@I<=#K^M$_%1
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M"5++S//=]D"H9LV/F36+2<"9>4,M:!(3U02BH,1ZA]MVSD9Y);R0Z1''759
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M' 2HS).7S!-A!260)1"?$R.*^4 AJB09G98W!6Y6Z+BSHGK9P<,J*^>SR-X
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MG)CB;  &08"V&G(M)[X)B,X^)<&T0PU6@*3<V"2R0T6&<RN$"!71*XKH^1,
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M& IFKTC"&0(+,3<Y0<BAZ+@Q_CL>M Y^>[JWN[_=.CA*+1?^-^F.NHW@1/Q
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MYT(9QIWQC 0M(F[F.1(7HB,V,JFXMSZ;6#?S1X_SF+.@F46!C Y!!.^<<@[
M@. E;OO^'1=U,_]1B,_[+#Q2N&(^DAP<;N:4!^*2](1%:P'5]2R=7,7-?!-2
M$ \&8]>[<$S<<2+B#R<U/^I NML]_*,A_)2]#TJFF'D"P:R++D+,,CNM$JM>
MFK5C_?E4+.$I&FLBD"2H)*"2(LX+10)E*:A DU5F:P=46] [KR&X2H=5E04K
M"UZRH$5FTU9YIH4#9[DUE)I@5*8<YRBS&H"S9BRXD-C%@O$I)I*D0?/6<4$,
M!$6\B49:95'L_=:.H&VA*@M6%MQ,%HPRY.1M\DIJ0)70:FU#-$"M8S'QZN1;
M-Q:<3Q-3&G0$:XGV7!.PPA,K*"<&540J<)43"UL[RK3A[NM)5Q:L++B2+$@C
MS3%X$;T)4,XPK48+&;$BE&51U3J!Z\:"\TEGX(T-+FMBC:=H$6M!//A,E#9!
M*I&LL71K1_(VXS]]UG$O+%B+!-9KU"*!=[R#O+IH HJ/D4KC[5[/(:R;;MDM
M]VZ8IIVWG]32@?4:M73@5TH'_GF:A_B%5J\;4G^$N.G'UM@-WZ5QJS\XZ?:G
MW:-S^L$66K5.Q&;6B5 !T'+E1G(C(!7-7?C$G=<<\)U0$Z772F7O%'6]2S\6
MM7UO-T!G]]G;$DOLP5DBI! $#*/$4JV($8%+0W7D)=98MNG/'V*M7GA2Y:U'
MREO6,V5CQ/TN:)"1^20#DS1KE9FW(=5CIW7CK;U?ON2M8(/2-B9"*4?>HLX1
M)Q(0SX*SVECM)6\*W%3BJL2U/L05K74BZN H-1!%,"X*'@1-4A@J@JLG16M'
M7',*%P\),@N":!<S :"&>"<M"=F'F*T4BJ7FP+P25R6N]2$N;GU6*G#-O .7
MM#4:=2\?3<X@.<WU<&?=B&M_3N-"A5IF9V11L2P!RRP:B4AA,DL9<S8FQK2"
M&M<FN-"O>@*?(6S&N*4@)$J"?NH-3HO_O/$(#M.[2<^-!\/S%HXB(9+Z.(CR
MSF!\E(8_[A^L]4MNZE SF:$1"A+!!!&,L2)3):5W@J7 H#K4UHLF7RXXU%3R
MD3H(Q&0>"#@;B*.*$B.Y0]6>EH#)TCQT&319*Q6M+M(I@$^&">&2AYR4 ^.%
M4L)))2GX4+/WUPCD\]XGKK1*I391U"7214=.;+"6^)"R#)JB0F26EO%74;ZZ
M*&><!FIHM%XZR%)[FY14UH*4G$M=&T"L']3G]G-O(#.I&7&9T>*OL<3)%(B,
MD:?DA0[&U?W\\2,]ET['.G-O2PE]YSWUJ+0'1[DP.<QJAE<'QQHA?=[!@?HY
MXCGCINX%(-)3(MX'2J2F2L7L92HU1I?CF5V]TH-KX^!HR@_.'!R?O1BUY."=
MNBV4]E%'&RE8\#P;:Z*2CJ*%8X68U5&_5[=%-69^D/<Z"QZ+&)@5:+F0%&-Q
M[!H@7F<@TE)O7-)>,+V*Y4LJRI=]^ S9,I^3L,I#XMGYY'T,P3IO=;*N1LVL
M&]3G_1;.^4B##\1;*PA$GXDU+A!MBL\B!$K3M(SZ:IWA5*0OVSG)M/:<6HC:
M >?.<L&8],P+#UK*>/]NB[J?_SC(Y_=S%SU/*A&T,0Q!(A<(=Y/QAZ2*,W"X
MH'4_WP"4,USVX(%:!@(DI;8$E_DHA0.1!#/59;%N4%]P66CG.9.!,)HT >\8
M<5$ZHDJM:";Q1;&*^_FFQ63L3ALE_-8D9^$#-"$75X,SAE-@U=B+.S5OJ%#"
MBLQ2MN"\M*$X,Y( E0T#>4\5^2KCW8+Q?E]P5ABKM8G1$^J=1.5&:F0\YHF6
ME)G$O4T,MG8T_^ENW/4L9G61G'E03C 91;!@)'6&.5JT7B:-X]+?CZ.B(OE6
M2)[W12#CAL2R)5%;1T"C[F(-VBK9@$H!]1JDXJT=P6J#UD>,9&-L9-RF["@'
MK:Q15C"7C,M:<.]JOLOZP7QNPRXM>#D-GHAH*($H//&X1Q,ED@[@%)52;^VP
M-I>KU,^M GW90->:>N#2<!,@J8"[-0V\-/OC.5PHWW?NBZA8OA66%]P-U ?'
MLT?P4MRR+92N14$3S0UCWAG).6)9R1H>\1!-#H8W*Z3T$ 5@OEJF[;&7>KSU
M\S\:PI>B9+24A#&F0&ICE2HM[$3IX*NU"S739;UV@S\77#%H>XL$TA,D?]P-
ME#'$1N<(;NM<!8HF.N>-\WD)WIC;XFC%TYPK'VX<'QJ3@&N-6B](<-HZ&XRU
MUK"@(G6QEJ19.SZ<=VA9R70,EA-F-?(AFKK$12<)0Y4Y^IRB4\B'BK:7X-.J
M?%CY<+WY,#,1K7,@N.90[,IL@6DI34HNF2"JYV_M^'!./Q3>&ERW0(S/A@ 7
MC!B>%8E2<R.4I"&$ID'6$EQ_E0\K'ZXW'P;-'8\*F"N5OSSW.9K2'S9'EYWT
MO@9KK1L?SGM/@S4B)Z&(D!+U0UY*%BKP1(B@( >IA?-;.Y:VE^! O2\^_$J'
M!+A5AX1U*"A>K[&:U_B.>_\Z&6=VQ;?++]SY-W#7?T_+F)+ ])&>")R%.)CX
M7KHD@DW1-I8W#X]&ZZ!:,IDSETE8L))992A/7C-(H).QU4N_7EI'6/32,PTL
M@R6,)TJ@%!UU-@-1P0)05!*8%J5^!6^C279+M6-I@%JN.5;YL/+AC\:(1]3%
M$T-3S&B@:'?1I).0""+)G%,/4+6K\N'/\>&\ES[C$D?J.'%29@),66)#3"1X
MM, C&"%CB4<3J@VR\F'EP\WFP\2R=,E(S82&9*CE3!O-1?"H27";JY=^[?AP
M3C],S"<KG26)"E_XT!#+#*J+PIFRZ0DI2PJALFT%4/FP\N%&\V$.3J>L )4%
M \KKTO&698T6=.*0\SV%,5<^7!X?SGOIF:86&"J$UBKD0YQ6XK.U)#"*^QPW
M3#"'?,AE&_1MPS@>G \;;^D_Q@YOBO_&[H>=BR?8FZ"T=</.O_#%B_&>N.&[
M;K\9COJ2PXY1/+OY?/I2MQ]3?_R$\^UI8^1[AC O$-Z=#$M>]?@HX7_#E%HG
M^)6C42OAV&+KUTD_35=&T':K*"JML]0:IC!XU\>;Q M?*_[;<V/\>SRXZ*0Y
M:KT;NO[LM5,W'/?3<-3J]ENGP^Y@V#K%X0YB\T*YMSL93/KCUB"W_N\VI))#
MQ'W7)>TL)!E+'1:.I)(\[L%>\>\YX>2]D8I:3U+II?^\.G_S.IYZ#FK_H!!!
M !SC^STDB;T7?W4/#][)PX,_X?"XPP]YY[SS^M>C-\=($,?/Q%LK=<@A!"(R
MDP1P!8B/I46B5=PX#<8Y0(N1TFVQP >E0F$/?]EN'1QU1Q?R,4RGPS0JP?BM
MX>#<]<9=E+/DAGT4LYDDA<EP6"H#3 6LO%K@WT@2"N)MI&M]6@YLG'0=/)7[
M!W]^[!P<GN\?X%;U[L;= [873X@O1*VPSP<W[!:2+Y(PZN*>,NW_>R%;LU4;
MM<Z.TC"A\ 3<-%RWW\CAD?N06CZE/HHI[D ?4":;;L+XQ:LE*ZXT$#DK%TD?
M3U.8\:1')@Q'W52^BR39O'_QPG;K-?[1&PVNX]];$N?/GEXL$.=U\OP;SF2W
MUQV?S^3^U>6PJU1?*]6?GM&W'#>NI%&!$DP!<F:$DO692*3*6=S?-+?(F71[
MT<-V*<;QMEOZ^,B-47KC5'B[_4)#4T*-*2>DT_@Y10H_N9M".O%I.+L*:Z["
MMEN7RENC'JV].C3J?EPK92@D"JAF.QJ< &&#2[)H1CQS*_-*>9PV#MA?;E<?
M.T_?:A#&9\V(AX3&D@=)C J"Q$RE%C9'Q\IVI>SV8H3G"JA&Z].]88-E[5/G
MX!W=?WKC1@P_I!IM/S;5Z&<=]U4UNGNI9JCPZP @HS.$":D)V*8V+Y=$>\DH
M;H5>E#[6[%M"'6^WV2])34)1C=W8Z@_&GZ45T7".9%S4H2;5O @\7F\2<&2E
M:G^!31I^F/4<=+W>X,PAP$:H7\P$Z:K2\1]4F?KI8W/Y$]_MH^8QN\R\QO&E
MRO:%0VL)J/@^#@J=CY_VXR4>#@K#'.!M_]T;A/<;)^6'M'/VMB3 !6XYH;J8
M -8:XICTA#KI:)1!"!6V6@FIX!2G=SR<I*UU5;>?AE"4ER+?(74_E,5OM_II
MW)X5>IR'U=\NMIE+P<?=Y>^MC&K#U1T()0R5G:F(C=HSJ!:H7ZC>[>DF-BJ
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M^-&HE5 %BJU2[W^JL@K:;A5D-S)3%K>TYSE->*D/J'5LSZE<BQKB%25LIN9
M::EQ.AAURP>>#!/:-'BM62>-F6EVY5LSY9=^_HKSJ.=.QE__RD+[@ =2Y;B>
MFYTK/X^&GYL?O$OD_[/WIDUM)-NZ\%]1<,^YX8X@V3D/[O,2P39V'W<THNVF
MVR_^0N0(PD)B:S#&O_ZNK)(8)#%+("#O/=L-2%65E;G6D\]:N0;7B_8;LMG2
M>VO;)_:TO_*ORPP6Z.O%"9Q\]_H-UZN&!+.>.K.12E(41^()#YQP&HR)(4II
M2$H$1V'M9$^9A V+A.0Z.8RGH"VVGH-5#%N$UC;PE4*ZKP;1>_5'*HQK,6V5
M-L3VSM\_MG9V3[=W/IYLG>S9[%?EC"$7L$8<%@#!)JM1#E#4!,1>D90I^'0N
MQKUWU>2MBDERYY7FTJGL1R!) =N*E*?$1KLJ*13\L07B1]7H-7GJN00&;@7B
M7"=D<^DXYJ)G#D@0-2P+Q'27UX42\KFC2*%B<Y2;[4][U@LG":.(T$1!;KQ&
M5G"-*","Z#+A,J@L-],Y'LL#)$4FYB<3I\V3/66(L\8RA'75OR])Y'A02'(J
MG; & Y6ZWK@_(^O]UH][4O7+K'"QC1S_\@<Q#-MQ.VUXWP/Z^$?+NE8;^'OL
M[V1G\BMNZ%@5(G5>>T; :)<!(\X2SPW$+:*:.AN,UT1,-6A\'AU"1^M]WNGU
M+KTC;_;>BYG=X6;:$:4%9&D!65I EA:0R]@"<HPZL 7'Z^=E^;[YXL-,QUM8
M;M0->]BY4^C8GO9@WV@,[(]XOV28T@&N=(![FJR@]T?'[>YIC)]C%4-T@8^_
M&_9ZKZ/VP]%[^-O[DZWLX*%_T^;AY\/M'1C3#GS^Y3W+/W_][<,!7#<5.K2[
M QQ^9^,'7)]#A^!96Z)Y]!&>_>%@%Y[5A/>&>P#/G]D8B1A!HDP"J9B]BPF8
MO\6$( )V8?0"UM?E WZQJA_>&.F9I4$7S"N8MZ $JH)YCXEYD^&2R9L8=9*(
M!Q(1[&&YV0J-B'*N."QN2B&LK)OG!'DO/N][3'V[PT&_.^QY^/'H<B_,D5NG
MI((O,^FKXLU':WEI_<;+5X!O;L W7?,F8JDB=QHE(7.'<TY0+N*/#(9MS I+
MI4ZYX 7E=(FR1XL2+QF+*4K\F$H\R5XPMY(YAE%DR>4<O-S((2D4>9!2ZQBM
M#5F)!7EPLD=) ;^]_GWL^.Y1K#UPV1^7CVN>NC[?"X>Q.3F@=O*2_5FO6#&_
MY@Q@%WI*D>W-+;ZUOX<E :"*!&E!3 X3S_6%P09+,GAG@(@$;5;6*5O%[,%-
MI4JSRR76WSDY4XK^+E9_\47]W?ZT)W' A&J/0%FS_F*/K,8".8QA$7&,1H7<
M28JS!S?@+ATN;Z]Y?_:Z8>@'C5X$,M[I5^>"?9!S^"F'M>2PN>(;>0Y\Y!W<
M-#_N2VMP\&[8AW>//7@"3.?83WQ:8&[>,/?7%$T)0@K)/471,(JX<Q$9'0)B
M5#B61.3. ,Q1LDII\9:\9+6>$TVYBUH7S;V+YDX2E*1RHR<,^LJ8R@D2&KG<
MN58'YP4L)O 4,# 47J:6M2_>/[(].(B]AIT(PBT>DN? 2*JUFXZ7+RQD<<Z2
MLX*?C >"*8 7#AK!_@-81FQ 5B@KHR="ZEC%YXB'PUEQEBRQ*L^K=&]1Y<?V
MFXQ5F5)K#26Y$@)7V>])<B]*CP*EQC#!@PMZ99VM2CZOL)/B-[F%$E:YA(WV
MF(,7'\FS8"27RA*>&5 %OQ;@$#D+FR-*")X\HBGW3"%,HKR<*&A'C+0L$<W!
MK%I5^L'X5?PA2ZS""VDB4%1XD9Z1L0KKD"@L$T%<AMST+.5*SH$C+P7&2AL9
M%<[M S2=+@)0?"-/U#Y@)[=Z7#K/R6MN_#:_;M@39E@NN)P-M M_*G@X-SR<
MSGXR2<0HO4')5)0F1N08-4@2+R)Q-*9@5]:U697BP6<\SRS[J6#!8S?*+ECP
MJ%@P542=\%Q.S0(C<D"0%(O(DL002X%CZJ11/)_W\E6CIRMK+2D6O +G3;_?
M:'<[^V@0>T>-XUP"JMLI/IP[3^2;)TH"NH!NS6['%S?TG'%N.@D($X8U20;%
M7->)$T \:YU%2@N%D[,L2I9[00HQ7=3]E^+!>1$*/,<$H"L4N.CH771T*D,9
M<!4;(Q&+*B+.)4'&$> BU!M''392Y7ZM?#K#YTDTM#AH9CAH5ALC92@]'I>W
M>$5I)O8H?JT27C#G/6-&CV_KA!!48Y0(U8A;"O8KM2:7#;=&265-4BOKFJ\2
M7'HS%C@M</I\78,%3N</IY,4W%JB@@,+&6L7$->YF9'E&FG%DHX)*^QBY0[D
M_.7 Z>6FBF>-<\[K<3_7-BKO1XU2;+_?S7TH@*>?M 8'5=GG3-SCN.-!_D/[
M4D08Z-NR-#6L[.[+<1,;X\%OISN&4+RVZO?;.UM\SRL>F02%5I99Q('C(N>5
M0U*PJ*TS7!B1Z]TO8S_#LOH/6OU/9"\F07@0$AF/)>*>.02@*1&FF'!J>#">
MWK#Z<VA-=F<)FEMGE2)!#VJ0L MC^4B;/S_AK9]_YXXJ.'I!#8B2R5WN -IS
M.)4EB/@$8$)8Q)%E>9J.'7CZCBI%%N8G"[F3BJ8JF!@84CFPGTLOD %N#_0Q
M*D>PXS3)&V3AX9U4&K4KLB8PX^9P]X2LS'F>M"'K9>%\U^W?TN!Y?<((]]_8
M<[ U^& #<LQYQ&U.$HO1(B&)Y58H!W1CV;NOEB6_]9+3'+Y&F9-)$R2YB8 Y
M,9>"B[ 3<6- \:RL2L'A:SK!31.3I^WY5@3@7AN0 /U/0$0(T%FDB0,1B J0
M(%F/@!9H+;WWB;$YMVJ?>WNWLOSW6?[=DZW]/2*Y58+F6'Z2N_MIB5P$0BJH
M=-XEAI5S-W3WNP__6)T@(&N-NS1>?D8>I"OZ%-_8=_B=[1\TCFTK5--KC[K#
MSJ#?Z-6%WQN#;DW6^B^$I?UI3X]@J6X9J?KZU/8]V0:F1DP@020$MJ-%G :*
MK("]6R3*B0H4]M+*5)AC1]\%,[6R[#<L.VU^VK-1&  %A2S/".TB1\Y3C!BF
M.'@2L$HQ+[NZIF_OD[F.RKH_M-_JWS^ I.F0)$TZ(L)QYNG) TE+"BD;??+*
M&RVK77J.1MJ"25H1@3N(P&ES?\\G"4MB@9XIGNUT(Y&.3*%,T0FA'BO+LPA,
MQ_;-M>7N)"V;H&VW;>EZD9*M5QT'K[S/+;NCWN).(V+&<__3XVZ_E5_@;46I
MX.U&;4]'Q_47KAJ=J^+S2ZSK=]O#P=673 WYB<@GU1.D^L*_>;B53KF C1?4
M!6"C7!!N6  U=PHK137V:H\035;&EQWTSAM<[D?D>M%^0S;!.[ZU[1-[VE_Y
MUV4I !&X..^34W;UPMTD4 N?TZE6F=6<JK7&@GM-_];MAA-0V8U.^-@9V,Y^
MR[7K7N7]S5;?M[O]86]9^DT#0NW_^(-^/=W]XN77P\\'S<.O[:VC]S]V?[[_
MV=S<QU]_^P#7@,GY9??'U\-]OKWSSS>XQ_?PVS\\_._O[:^T_=T='A\U?P.R
M<P3/W/EPN+6SA;<W/W_;_?*UM76X2[X>?CC:WMP7S2^?6_F98,("TL)[_/S$
M\UBV/NTIKQT6QN1JX JX,0:2Q*1#07 &DAVM\KC>X "Y8MC(^XW+@8K"I C+
ME9O8.\L#<\X1PBU/T_VJQ^M28>/YRC3JI9F*>)CL3CYM!=XX@.4W>F?KR'BF
M;K,W+,^[S,;0[4YCRYXV**\WQM7&20[]^,^PU8.-TX(TY-92( NAZB8%?Q^<
M-EH9\V,?#/9N:FR I, OC3\/+!"=59 <O];8:)Q)D[/M7&0Y?_4N_(Q$K!P
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M? =%I''A*FI;$\<KY"OKUW[LQ!X(P[#3CP#JH&==!XI2.<)J/<VU:D!6.M]
M!"MJ#+)7G0UDV3FNL3471@"Y;&2%<K!VG=C/Q-9FQ<_%$V!E^R"U_6$^CVAU
M[*AXPJS;7$=:SX<2_W.F!U,WJ;AP'DW\T>I7Y#:_QJA00[ME7:L-J!-' \R3
MT.GFHY%+PQL]S,5&3.F,RQ\.JQG(;]N!UQG-V.6WKE\!]"76EF/^[;MM#\\H
M^:@0175U'EU_".IYZ1YGT^YRC88>4/1AKWK=2Q,X:\[SE75EB(LO^@8V[+KX
M4&/0LR'FJ<J'-OU?\IBZPUZCVL_S>'OCB8)']5NA97MP@VNEZ,!^AW=JP"X*
MKS,X;801K(Q :;6Z;EY0S>23 ?7_=ML!-BAXT=.,B'D6\G*V>E>JU_CS[G%=
MFZ13"^SEJB.^U?/#H_X@[X[]MXTWY!>P.GNUU,*# /<Z 9 ;Y+V7+3;?/0(A
M]]7GE0F7[S;U+?@M?P,>^ONP$QL,KXX\7JU:!-L6=H:S,B:5U^NXU_)5'9-&
M_R#K!*Q@];!NGNBN!Y7[41N>=]LN4@#"*03#3!ON'<E^\5SKE&J,I5#R!C9W
MX[YQ8=ISP'K_ %;I?.?83G_EL?^9WVT'@&(_C^^U;B9;.[NG6_M[A$1)J$G(
M2VZ V(5<>AO,0^PC]DF:H)5?62=LVF7VWV,$J\6_GU>_%AM@T37+R!5M!HUV
MS/)UI:!D# +QW OV= FD9:<>S68^+!W+!GY]HL&V-O8834)8+5!0,B(NO$;&
M4?C5 ^?'DC"/9?8<3$E&8[2D /ZG_3%^94EY)C( ?\O;<=[E+X@#><WR()HG
M>SA$'J5V*&#'$ ?#'%F&)7)<!1UH/KGE*^LSD"*OZ'A"+\O&V<Y4E[<Z(R:K
MY_O2A>^/ :<%FQYPD<H%!632Q^H+D]O>KXTW])<'2I]QGKE(;78F<ZRS""9&
ME-,,!TE%7#@"3;8^AEWU!#@?<.]7+(W[N60=YC@*IVQNR$X1)RXA2X)!C D<
MC7?8<K"#$HC<]?+HAOU6198K@;PH6C6CRKSKF4C.E;A5I&B6%/'FISV##:R(
M5,@)FQL :H*TS3U[@U3!.15IL+>1HHLH55?_:[RI++DB.B]0=+Z=9M'QU F"
M/=(I*L1IB,@PBI'WDLCHD\92WD]T5B^> AX!>P8+O/)EU!^/CP&S]7ART/+U
M4=_X-N>6VW^15;"!9YY?=RJ3](RGS]ACIQ];G?^T1ZZ<SEW]A$\@T\7PNR(H
MZ/V/K4][RBCI#>R? '\:<9<"LBE(Q V8?TIJ*UFNB*ROMON.>]U\7CS^]79>
MA,J]=-&1D'\83LC@^$#@@F59NZ>GOPLLC_W2&!YW:T]*U]>^J_K(VX-(V.IH
MO'?<K>X0O^>SG^S8"BV0G98;UJ[-[)"9&-EJ/F,(L>_A6[6#LGI KN6:GWT4
MC^"6G3 \JO3H:D<EC)#_DETM)Y5KIEV_PKD&]F*(1Y5/J X7>"-^J3WSIXU!
MZRA6=6.GZ/$%KW[ES)&@?X-6NYZU=K=?O?X9M1E-3G]4-SE<FNR+E,=%&%&L
M >"B!Z]V^=6.K+$KTI^_Z&HCQ\KT0H4.(W'(-]KO3OFT5I_LW<XMA1FOMU&-
M.[O'ZO.JD8^,KEZSL&?.X@LS\0(\FW]G73K7O"HNKEKS? #E;?_@3-[[<3!H
MUUM$=KB?[S/9P3[Z#LSZ46MX5/D:[?%QN^5M)3"3-UT%5<M%FD=042W'99P
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MHC2 *UA(-E"3;L%:/F8YB7W 6=\]BAN=,/[#^Q_'L=./&6';W?ZP%W>RTN[
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M7!(/YKKB.06;(<T8!VO3)&^5H8+J@FL%UUXOKG&O9 R&8,T(MTHXEE6&1I5
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MH/'!^E:[-3AMO-F,/F8,:&2=_N5L@JKI6-K7OVJ5:=V1I;%E3_/[T-7&26P
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MBB!M+EE,^/>@[JM.@N6Z3.-HXXLINZ@GOQD,4T';AN2N+F'['LE/Q,+X'!1
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M OS%*[Z6R<NJ1S;NPH?DWO-$A&MU%L*^3\DG']0W^"TD7#&5/R02ACSW+DI
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M5P0UD15;G%5<R_6M[6J/IJ8L@+\5#]V;CXA]E[#5R^(X0!#L']11[&GOPSA
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MXLF=5^0A\'^09'JDP__<]7O_G-[]Q0N2LNM/KMQX=78Z_?J+K$!D0DM!(ZV
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MH(<NG2$JVQFE8; F9Z=;HIXU0LG1X>%+T<]# :>J][<WYO*HU*MI>><,,OM
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MDMA(]+@DRN4X1/NJX70$I9"QC$(;FMP0F7L\TP[[WH(A=3U9-,RH\=]PUK3
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MMID8;:JUI@=U@WJ;;-:S8U:,?)!),B6@<=V";LMF<W"N.4)?TM&A#]Q@-&/
M+TQD^M[[8("N!Z[^;U$R0FMI[\.[]W_;;]8LU3I&]"'O:814_-5__<X:@%[=
M8:G4-^BKTQ.?OZ\WQI8);JSNKJA7U'IE6LTU/51D9):X]]H$)'63.)>YQ6']
M<IV7D8F,OW+3W_587%TKME41\:,^!F*U$T8&1JA5;+Z.%O7QP_5%QYFJ\$M"
M3;7A&"LUG$CI4@2OG>8MB9O:J1@3-]4)AC>_O;WA',F'-Y^I)<T;Q-*4&Q)
M_"##KCY8W3W\%%"[Q+P<A(4P/X@8D99+\K$T 9092+AJDN5%HQ+_T"RNNQ8?
MC7VS$J?\?ELJHEIL9'59I8&/? >^18X>,F:[T(4+\WA:XE$E\226I!3&,=,J
M3**,'(SVS\?I.![$I;J2#ANX[4I<%\5*I^5Q,HWO8QJGZ5R1D=I#[X\X_D-0
M*:=PN I#&>R-(I9"%[SMU .1F0<'28;*+R0=B-L067QY\>N;C[__<>%F498T
M/"Z!&@9YW'5U_86N;CF!L9XYZ8O!X(]X.X%D%3;2J4Y'RV:_-1LMC_G^R6AY
MT:*YZ!2Y;]5<M#H;_:GH$:'_^>-;+TBFX\"7GE#2 24="W9-Z9)J.U%'J$ V
MEL(J8 GKR4GO8^Q*WT9&L@T*PTR\WV_E)7[*]V<E?L^?4M5AMJ2UN"ED:O^2
M+AZW6 [>,XD/&D]WNH?/?'G;?/L)E?E]!(1UIZQOJ_JW82C+\6T#3_[ZX78K
M.;(#!PNWNPI#,BL.HA !V*(1-D5Q3M,VU_$]3M<=O&P<#+\SW^);],?M2AIF
MU AA%]+E637+R51N<!=OJM!S6^R4"U>X'V1IR,4ZBJ--0E<&<$Q(Z06P^KZW
M=_WZH+^O:QO;\)N.V]";P&FV7:63GN<U>J9QL7,9GP)X22P5,3S\Z_W%;P?'
MVLUK=Y73^#Y+JGF0AD[6MM^UE&.SE,<?V1*>ZT"I /<FR#F7)5-J\)]A /25
M4H0EH43B';Z',&PXXE((;!,!VO!1_70$[L31X?G!J[_^O0OAQ'5A:Y-9<=_S
MFM:WQ[RY2**O2""..-T6#]RV<(PX55O^9G]!GO,G. S\)AV70R2A$=!OQE&S
M3C%*=2WU.NR 1QOI*+<2LAMRYTO2-VXN_;J=Y-V&[@^WSSONAC%<$KNP#M#!
M'<<\[2J-0+MAS\S;D&+54QQ$^S:\T<UY>N0HK^I_XVSR8$@-4268)'=!#M9K
M/$$8I8N;W_Y^T.\?[_O+0B+.U6;2EPCG(P=CRW7N<UL.>031MWCW/ N,SY3R
M'M[E4:,9W1[W%<+&8NH,E,V>-8*L9J:N;F"D^IF(BCZD14QJ$"BH_P'MF!&"
MIWD?,ES#1ZNCZ,.'CUO3J:?:N\U-#ED7V^W&!%6):0/!ZFG$-JT*8'O,9F.J
MICUJ<SA+84\A)0$[:78N$=9B][+^/$)!KE*%#(H)]&[P^63BKF7]L<D#G,W-
MZQ.X"OQED,PH>!,0QW)!G]6Q[%0 <J_S$?<W*XN:@[5)LWKB4*]VKAVH#F(9
M,U"(&;00*$#$0L<N2H1!O_I\34+ ,^1.2 ]XL<PN!GUMF &180D07#3\-\UR
MQ#F;M91 /<TVT(Z,)M-Q#+ZZ=U\E=U@J3M>""CD((^S5O/X#U^_E02O;\G6'
M <WUG@98,IEX QK4F?/X0R1,1.#G-H 0,Y<3N)$\(*S4VF"7N7O;U:Q8-2MG
MNYJ5)8[K&[E[P3[81O^KB+AO9=+)#-S*,<D3\-WOL5#PPV\L55R.9,DB^(63
MJL"FW.(+V!LTGG3&]97(JY3QOKK[C;XOCK:""ZCEVH0=W0&T3LU90Y/\\=]_
M_'9Q\WGS"H0^?WA>E*'62@(X?BPY1MSG%DI07[GZHX8<XLQ'P#A RT6"Z#8*
MFO]N_#(AU8O7%]>?#VXOFUU'\#OWWD%D'$[NG%\>H/^WTL;V[H#&%3"WC#VN
MM;00I5.;.Y(RV -5:.J/U*UZM$E0+N<XH7R2I5R^P5-I2U!49%#9S368Y 6#
M5:C8VW,V&22CX& 48L$!'+E=@P.,"DNV^AO<,$R+6I-1O!>O7]^\N;WU[;-]
M8[_304: UPRJ)$$]*LH[BY\.P/ZD=[8N$!:'\[U [0)BB)5 /UJ@TYG[X<['
M\=0,KHRDOL:P CV <6KE97<,TT:S>"3Q3R\2_Q&_+6.5VT< ,<5C3*+%R1,D
M&#TBDR,<1?S5N(%ZJ=%7I%$L,\#Q([1NC7'B;'9C:DV6C'J\P\+">E1O0[;Z
M&+G72HV$WM6.:T$]!%,A3^EQZ$$2[7= IX5YF Y]F*!9!]W.*S.<Z+E13*I(
MF5>_O3WHW_3TJPA-9"@C#B+S%BLZ4T=71DSJ-]=O_O&/"VF.WBLC,"^D(/"@
MS </^_YC\'I@>.4@#+UHIOT3GP(C!!_C<^X#MDZ' .<&:@;>?8!L"@_E(J%V
M-P>^FR'L<TRP[L4875WZ_!"'2-:PXK'/S&=UA!]AC!K"FIAB22D) V1N;$>C
MI.IHQ!W3EJ0889340M8)L_0>WHBUEXY]ZFIY,-?4'<AL=TSSL%E @80::K-3
MX]1Y(PR2S2$'JIKT"'_;MU&$])-KP0?U-3N -M2*CE_3085U&FD8-&JKKFE:
M'VJO%L8+470C6W-)_='A].LE7):4HU3:]LX0XS;*4[=^?77Y2187'AC3OOH
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M&/^S EL,1UO$PSC#EJ$XM![*"=G&.O((KC*,T6X#,55D>1P4,3J058YMT'.
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MP/:*:D %;:0=.QXSCU_,4L /40?6> BQ':Y&YV9P&Y+92^)@@'Y=',D"\1!
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MDIC O)^.R8+/P6E.;6M8$-GH2TBFA7,7.48CN+L30[!Q/I2H8(7$,:,4M,E
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MMU',YH*-GQLJ7$ ^? M&/)@X!W_%CXF[=PWVF7=UY7M7930!2P@<_Q2X4@7
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M\.Z2;$#J7:0Y6T;"H*7U'%];*K9=0^6;9GQ34]L;O6D$F[$JAN :S<A6< T
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M&FB%*_M(L2"VB!4FYB*R(FK9%SG5)F;<H"BW]YIZ^1R^U,&/?T;9% .[_^8
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M$:>WY@Y-#K^CR4.B@+,S0.1#3\D".A)UX;IW+G,$PH/'#2.6)I0:<H<%=C[
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M/%;(Y:0#9KM>>60XY0X^5\M'KXMB45A[X18ID))2_HQ #/#,\\C9?W=V9S5
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M/4HLJ"W]&I8]C9-/6[%JNZC2F^0X/#&!QJR<AL<0M?:AJ_,%4"Z\2&S9KJ>
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M$6=L422A80B6"+.-79O8;UY>,GW,>N)U$?_ CH++%!$S;B#.:] /= N\K]Q
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MW_M/A/A^Q#*(\T-/(2=;X0<F/VF;F7,Q4VBI<T_C0@ZWK-(<<Q#(SD!4K-I
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MT I@2Q!C9Q5[BS]35M!#;NFC'!T1@#H$U0I,%M1_W,,-H&5U"PO<%B]C$;<
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M5ND^.3QL=]2!_KLYKX@=:8#A>PQZ@Q0]\ZQC/12:^X=&.52; #Y8WO@0=L*
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M_M?!>S+6#@#BL\8P=>"*MVP=)E\]0#KD@Q-CJ@:X-4+TSNW%YB%!4RBH EN
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M3/P;RF[RV.5WG1FOKYIR@-) T7>1S>J17T\9JX83F^H2.$ZAAL97UFS?R-
MA3ULFKZFINQDGE7!6.//HVB>EV52(Q.NV\T,MO'J*]0DS8)DK&F!XG1NGIIS
M9](^BU("<IZV!=0MV)RQ"24DI-\[.))EW;6?ZP>?5>A8_P?E_/(LA3PZ*-I7
MU<IP V"1)';V$#T,+<+8866TB J!B<D<)'#&HX9N,O 5"I.82 A.\<SC\&1R
M^;@"IA"HVI>H#M\I]@P^)\>"Z1=@>NV01BC^M>W%9N;A)3P;.A6P$5_L?BI(
M5?OF]IR1.Y/,_9!%ZR_LL%QF.2D4&"$POZ*[1D*L'Y?/QI$7:H!3C*1WS:WH
ME!X*4-6P8/USX)C>RD/K9#6%$6WBV>?:<V9'D"V=G=,B8&H]3* FY67!:8KA
MG4L8VFIA?X_U8*INDO>^; ELNA5'V=\'B$C@/#(UY@!(7,/ZAV@!3RMF@$'G
M'H 7$/A06S>DC<+F_*S ^(](W'PVB4G,J89%7V#<)/T* 947I<P#EX",7+(@
M/G"S $ #\6CCR*Z-,-'3UEW<N@G8"$E'CJ<\"'2?T:,QUAB(J*%,#^ ]*D33
M8DG#<_+?_L?DV?Y/4%&ZK,KB#,C"D;S-F;HY"HCFV92^5CN_H>%. /1?B2ED
M16Q^G84M03&RK5/;BGJ\\GWZ20YWDQTS-O.F\S%4(-9]Y3V FEH/ U,_$NIB
M&W7,N^$N!*0XC6;@H6;OSA3$9>)/=0H,X7*%7A+0"F>'[\BJ4"@\#YG3&1ZF
M-8N;603P@&+IJ*L"[HVWN<G( GZ"WYOX'""P(VXS0JH /@W<<\SBFEHY%,\4
MR&I1(-1Y+R O8U07C"#E$# >'PGO:D8'M5"O:>=[1U/6R]\9,,B5="WA\287
M&JTQG>NP[1:F#,2'R(TKPG,J=B.+B[<"GG.P!Z$4B7!K;<TWQ@&/_,JXCS7H
M[^+13#@;^!4M-B,D245IRRTGP2WU%UUH'IK<,8HE[:*%:R-$$"3[_-DS&MP<
M))6,=LI]UQ]>C!"2QPO"9'PQL' Z(-X',@]NZ-L0U7A!YD]LIO?X#&Y3/0]Y
M$M48IEP&8LY1AS+F=]LC,L4&3%)<ZY.;4&3(="R<<[6D[1LK&3#8Q3]F#(=P
M)NN,@MWVZD&A%JEP+\%$XH2":IM<?JVS!<BDI28T0?^[$8J1$$1ELG-^4T'Z
MK2)Y!#Z,KME5HZ$M]2V\E*$Z<K? _A7?^_$0 ,_7(P#@<;/D?_\IFR;[+V=/
M#Z;);/_PZ.GDZ.5A,G\^GS[??_[\X,7^[/G_G>P?_NE^X08F!]U XNF1+#%>
M%WM'+[^)V[N&IA1B@L/QMZGI#CU".#H3-Q8',!A_:Z&.T5#P"!OY;UB5H)]?
MJ2M41\=38)0C @,LQ=U:'^31^/GW)L,VF/;2VT>#W@:[*/RNB"!.VDIP[>Z@
MKAJ4#077_#_:(B4W_'!_!*0(![=F$+_K0!WC*=M_._8,XOH<#Z,+YV466J^"
M 2/1 SI#Z60F@?6$FA/ ^Q+!*A3V7<E @RJI.W$0</BI0E]K92XTHN-N;^K\
M&.@/,7_P&J-).FV")@PZG#TI;^R..($6V(?!R@E)0?0E<BFZE ^'] M8P9L3
MR ^2:<X'Y^0L=-FK7#;A8QM,MGH? [[&V2UIOV76!+D9X06=K[% AC6,F;&=
M?-Y]*J.6F[&+FH(SB-\NH+4SAT=VD\/]#74,_1*@E;>(OV2+[%^RP $7OL#<
M('?C*,%DETQ+&\U@DP"U.K5+(%F!"5]<;-(:B<W+U'CAZJ:8A(#9><S4X5QO
MR>;%@BEF^'N<Y1)48>:4"$ HZ8B]021DT>J3!<]31O.\A4BL2;N,&5A1$YXO
MR+^)7T@OX;N"<(TX=SS[DB;A<RA=V;H'C7+L# 1A6E97-H\*:J1R3^S%=5[G
MU&VO%2ION!T[CGZV CI2Q V6:M7,W7(M(5^Z9C_[@IADA?'6[(?V4?=<Y#*>
MI2G\0@D'F%<6P""!G0HT6>X*D_W_28TQ=J)NK[W^NUK+O_NB8IDC42&I8R,U
M*G65C<P/:)+*A*,J78T:,0]O'K ,8&Y:[K:&A &"GML*.B-]&#4TIV*U1S>Q
MW025-GEGV))$Z#2/,?/N7C3/,W<Q>!D,MM&($IT&*YIS&D&6JI67&#*O+I#)
M:DDJQ<CD[R:)#1X,+QA1=RNT9::6\55OJ!IX1 8-I0)B,8 W'5%]I(!/:+<'
MN_YP&MD21LAI&;X2$]EJR&ST\2AF,YX'VSXT ^/H&*F ;WKD$E\@G&&80G5Q
MLJ=UI@OW-]VFD<"S/VV#9WYT_SSS$R&&0.XC4"=,P!'?Q#S>Z6#>L&+RFFBM
M.'OJ(XKH#[S?0S#_*C=D\LDS^\I+?66/4+6T)RDVC(HQ\>E7VXTV3>7R5,E'
M1.X7/F*! I7:V] #% ,PHCO7R%5:MPLWKE0\H2P.=<,9W1SP"'/L]!/75AGV
M/AH3X[ZM=T;N,+3H"LL&4C5-.PM%A1=8MR\(NC"S68MJ,\HK(?KK7/S <$R@
M3%TBNY/S+)V[IQ$*SO>(BJ!Z+OWMC9ZG_#=J%M3D()1,2F':@O=?*;.1Z=O5
MF?!3C$E3FD7I"&)>-Z/J?LUR&%F4%LR:N]:_F&0L(NF:-=^CX!4<2*"@0C9M
M75&8T:::$="1 <89Q'+E&#,E?G^0 5IAY@;L0A_>7:U*$Z7DT?A#2+)A>. K
M"/@RUU0M!KUX\):BW9J![FQ<!VL\1J0&-&NKIAQB 8)1!4C5GC""4 +/N1/G
MV1*;"*65>\W ;4> _CN6&AG< DG_6G*S"BY#U40D]3'EL/7[R,>)GLZV-'O)
M_]W[IZ7LITLB[F^9#D\GS-]XDYV +(S E^T<QPA=2&@Z9F6GZ ,P-4X.X[W)
MTT?I8Z1\:/,S-!*MCH8Q4H%IA CDY>$1[?P%)F],_(0.JW_FT48#$GZF-R@H
M!P9-$(F/J#8X'3 5H6T+'+@A%5R1R#])$MLR*.(+_(U24V[_?$#+#F_V!GBZ
M)_M[?]MHV4\.[I$OX86ZG)E%V' N;D3T'BI-WJY_D-[Z#?VE^[VWWQ?1VW@5
M'1R9&)TX AK1_YPYB\F*=6Y-'#O? RQ;1%;AS,5C?(BKDHR'5WY\?3(B'8]"
MHH4E!&H-G[9$21+<0V4<@,8#\G!U[?E&>&;TD+@((EC/>F!RJ"1D"20D!)$+
MWH>R5,)])5_!3U3<[>N.13QZV>2(!0N-#NX9V4=8@-:LV8:/C //PY'((#,'
M7'@[5>&AC;DV-XQ4:YZBGUTS&4=Y7[D3:I#Z&NV-AGNC[7[O=X(SX>FR 2/H
MHF<X6:;N?<<P=MTT_AHYXQO--]MI@A\G-TGZF[YTDQ6C-AQPP*#27!FW:T72
MNRM*=W:^,+K94U^10_OQ"IXO;J?@^?(^%CR__2"OT:\__O I.CU%5>+)Y*?H
M_:=?7G^(3M^]>?_A[?&GT_?OOCJ]-#G8BO32Y/ZEEY".E/(N*690MP%<^@:=
M$BAA(1W\(C5,1I!_+?,+REXXMWOIS%?82J$@N%% $$4M8LY<DT86U+W"^@>?
MW05D,+#QJ/)0?-_"<!SPC] U69*&$\!M+=)9<!S@_"AEN8L)1NP(N3<ZHY98
M9(@V)9I+/@(5/69@]0+&0F)J+W$+(*>:*,V4GD2.&_DN@/6S5/NM,0/A>:0Q
MZ*$**')P>!F5PJ+8"+I6NR&KYRM,8S#$"76B"3F=-@VK.6!O(X8PTL)V'B^7
M*>NW&W8[Q8[Q96Y"*#53GL]T#:%4!T4HQU^/^U\>@J85)BIE#2E,\G.'JAL"
M(8+G=Z>:FB"G(N(-E@4#0$6JX($C()*US 7,L#E:)4N_BVF Y'T-91U6IT=4
M49" 7[-SY3(K&)TF5-#YRBAS(9OS&>;%+F]W@,MJ:'R__KQXNAWGQ?'].3 .
MQH<P& CY><.-+%<#\>YA[# Y<$/[(9T#REJ"0V:^'(Z<F66$R$5&:EF5WH_I
M2"^)#'=)2SP8(^DT2X46TYEJ]QG8<P?[/]F/XJ\F )!',0H*)$[=K=U2H!]<
MQ,_?>]O?O*^T?DI$*<XHK>H,-YK/AYP$:,T/?B^^U[W(CX&&QQ\K:7W->TH&
MV70J&-B8SY9;UCR$4%T2?1PA6LY3JEV[)T*0K=PR1)@,/ !D!;&4*;B+0H;J
M?^D+O2<\KPB&R)/ T^F*6)]$&0U%E_0D]7"81^$F)68(10SGKGN1!M(H0$5H
M!X!0+Z"BFD'7,5-2FL2@+CH!HD'_,*_>XZ)H-=T54>(!TWO_.8X&MNFF9O3%
M5IC1@_MC1<7M_KVH@+"UP33M1U%^>>W6G3O4._6TW\F-9!_]9@[Z]S:XJC=&
M8 02O =T.BS0)BSXV8J:X*LT-X?(&'CR<O;9)F":\RH%2I^B.:_79F'^LE&*
M>S(42J\91L962%X$Z)OWW'#F\;)._R+_^ G"BSQ>_24K<%#P2S_Q+3F9,D
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MR?JJW9-IF:S<?\Z;1?[O_S]02P,$%     @ >H$)541H5?O@$@  9,\  !$
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M<@Y&<H'('8=)1 E9/V=:@Z,9V;[=RZPDFY%-B3B F5+]HZ0SPMQ/;S/\\#T
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M].2?&1=_/BGSV?&3?\[F?XX_ 6-_7_W1B]G'K_/QAZ/E$\FEO/[;^4].<1N
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MCN<.!RY^^4+KE;@UGL+\ZRNBQ,HEI;\DMM3E3<+".3FQHURK*S+YHRD;02I
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M&L&]KE?BO"DOYDC+=B1*EE:YP!!+9)J&SD*QDF54B2?D7.0^9\T/0AN2=W
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M,INT5.1#9LL@>^*KDBE#;>R?^LSH8]/R#MQL<;A\OR4-K@<)#E%;9S$415/
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M,)],O9N1%*&WTC#!N<#H#8=.]SUO &Y(X<'V9&DDE/9L>3F>CA='F&OGHFO
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M5.,\TSN=.RMTK)<LL8RF$#!PC-1<9D*B"E(YZ7I9'_?B&ECOA-Y&2#L9=77
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MCIY? -FCRIN+@J8FGV8%F3SPD%A4.3.5P5H7?.:-\IHW /E=N!^M2&NPA?
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M-Z&V1:A;DTZ?0?HGYF^+R7QC/]DB9';(K%.<:<EKJPQ,S$FOP<<LP+4IN7T
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MV*&).]P%N('GFP^)"X]P'5";G-]LPO]=./L]@.F&J;NT=V3FO6F G/:B;*&
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M"9UKEUAH4[NV/L;]NX9=Z.1N:7833AJD0=U&^ALD/+L<7@TF/<F5D\&9VF"
M!FT*9U$49 *#=4'5MW@?6OF&Z!25L:6]&VP^+N'"!2R75;&A]M-)](>F^(>%
M&&DQ1I&3*YX,T>9:H7L G:0*MK)VDYLYA@DQCW\C(SP?#C[C:%+CI(JV9TF=
MD<?,4.C:)$X#\V" @2M:>(W<J#9"> #4:8BA*ZNWN)L#ODZK(-Z4Z<#'XZO:
M-.+Y<#P9]RQ*\L4E9\%IQ;2CL!E<CDS$[&RRF(MK5']Z/Z@3$41'5F_2!NCF
M<&^H]0-1/*[%,]]<FS?E_628_OEVU$_X8=0_/Z>XK&C)C0BJMF=+3&=7&P
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M/[\:C0AE3_E@P6D*KU42]68NP[P&0U1FKV.L%Y"VJ0!; >8T9+"KE1NU2EU
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MZKNR6#M0_T;@I;&#H3W(UA%D8TWYX[.^@8V3HS"5DQ/(2,!$WX3;P,B(F\5
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M"1BQ#XGR>2I.P.M.X\I@LR"(>^[=*?W-2]&3"=&#=+TG7KZT>!2S,(HI^5#
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M"OQ^8$$N1!3YSD%T0+FBN!Z9N?YC\^P!%'C:^ )RQ_;S440][.C ]AH*-,M
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M-^9#WCQM=4!T;1RFS,%1Z$0Y(F!$$8# [R5\HZQ[TEE05:%E=EDS%4Q^(NY
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M5:F%#;D8#<D3-BO+)"$IS>'GSX,)K3WQJO;&GN?EY=H(P-U,D9RM*0OU^5$
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ML4LY#XQ%F&?(%^71I['6^?POFB$Q*Q;^A+)[3(JH7S+40)3:6$T"L7_TV43
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MJ M9?$P%)S8J%Q0QQW;GJS#M(L/#P-S;W*P]=&IC\25GBP(?)QP)L>+W9=_
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MG>IF<6J3L7XB$H3[/AB"=IQ@"G8%VCN)K[65+_<SJ+E-+Z:Z)-OLR_*/<M>
MHTH(X?QC2EPK,&PWP@#?BRHY)EW239C,3)L:7U^M]AP7M 4BI@FPVO$/W(OP
MCXG"N6X$CCG/K2O.<I8*2O>=R8CZ,G:CS3$^Z'_$(("[ES@AV"%O]P5@;85M
M,0I(;J%MUS<\<!T?EYJT*1@NP%-M28UYXFY*"B)VG,PY'1.W/<[FU[G-<P]2
MY<W3.N^%G$RCY=PCZ#L$/ />#G;N3*#D*6KCK5'-U^--G3HGDZUM?G:P9&L+
M)Z>2T ?"^1%U^BKPT$3!G"/-/C;.;P9X[$ E4M3/3C1'<I:H@A>V/G@O4J(H
M 3^) !10#/X\H?KN)0ZXZM2K,PV:UDE .R:JF#X5&VI1AZ&WUO"=4=T@SG"+
M$MW^HO+HH.\Y+=-G3*H\%=]USE39=UL&<& (%$AJI?;J$1=^OT^9MH N1W.:
M!$WKU'4WB7%UJV3O<EDE$+7=(<IH_"*VU>%H^!GP6D]XF3+*BV)G1<3:$)/I
M5 R4D!QUEDDK[(R=;-_?B.(F;M^0P=KQ@CBXMBE6(YM/"?G! /US*&0U@@3A
MUB&8G%6 0'3;YMWI0(?U%/.&UINV9@*']F,7#1!6").C6 N9_2>]9EJ$MIPB
M<]BTI::A[DA8J'WOA@*JD*(PI?4M".6BW[+COWP!8I>/^4N]E06FIL]N_6[O
MSH7XPW&Q+11^FJ\ZAF!(:,4 S_]RKAP676\VPY03)QNFC#L>SL%:-K@;&- I
M/?;.YG"W@AOSU0K"A'DE;]/%XX^RZ7ZRTJSU?M(2;<[>9A;URSMCBN$ >S0$
MS[C#":ZU4(]2&>PPDZNY(_6S\86MRT57W]SW79],!4R:]9WBU@$(I3F-5J3R
M,G7U6JO,ZNVSG.\;H!IEH],#4U5B4E!0+!9P4BV#Q5,%I2^E],A!W6+^)UG>
M51E8UHXDU8#YS10A"F_G/A'B+<:<GR!\V)9>[_SD"F?^ZDU"(<3V,B\IR8$E
M;#/6#X/X/M"B"W'WZT^$,7H=]UOE0-W$1>O3'L7FG&^CA-"/M,!1G:F0Y7%Y
MVO/"/90L%%]QDSO+LV> POEJY%F9S=.L"_R'8>N(HM3XE[D.X&U!7^F9_X<I
M=AJYVM.;BB1Q,0< @]WJKE]%OP%#X(=G0&;<,^#3^B^Z)NJ%*'<WCJ*R]3LI
MCO'[>^';TV? M^A_3C+!+2AU(8['?X>MK:CK']E/43]-_Z)YTNB U4-^8VOD
MY&> ,,W38\>=XB!3URGERE1.K>\FQ;3P_LXS8!WVAX_RWV:\U N">?PI'__.
M'4KZ!28V^_4K\^'F&;"IN'S\4]]?M.G',R#1[O@Z%ZH3N/2NJ5S<]#<QH@6^
MXX//@ Z[)SS??TX<9:J\I-PX2OXC:E[\SX?X)"E/7TV^/!9F"U^./@K%_[66
M\W_%<Q3$%=L":R\!/_7?F?OO6&U!6?6]7?ZMH^.P.@J0K%>> 41_$5[\W_*L
MHFKW3V8E_VWREZA/_E;V\QC;V*&J0N2_P2KCTD\+K!LBUL\*/E([*<?./DJD
M5A+U,^7O4"N,L+*;HRV+%=.H"JESJ3B+QVQQ/'-.\10U@'\?0GQ.';EEB6GJ
MCG:FJG>1O2];'$4($>(&2>F)?AE9P][N@99[BFDR,2]X&M606<**X%#<OO+O
M[!BU<_W (.0$OFEH7MTED.37(BE%)GE44;49#[HNE][SVK\B/?.S8^.5ZOIF
M8P+*)M-\*>D@@K=U4<98K*,E8^0>_?*SN-V-Z]6.&RXNUW6GRIA3E.=^6/!V
M3P;1W 7IM;*_;<T@&/KM F@?E'!+AGX9(8@EE.#@#31_ ]VM?P'YGAX;=*R-
MS<H5#,#B\@^AB&P4=,BPI/V%DU.+FI^X=PJRB*@:=VAEEVULLMVF' ?X3T<A
M Q@./H$F;4^?1@W%H9TEN&CQXI^%G8NN>4#S49;IXQ$<AZ>V!BU3G)*?I1C-
M)&H'5C8 (1E.C?:"EGO)FR_H9350$FYR=NUM0>]J;1W\\# O/?I\9#]&=^&\
MIT K/[H+4$UA,8G87.8UBM^Y]!"X$GEI+D17BZ/MD].G19#RY%Z^]3)]_@5)
M,'N4W/X]&H4SX.<K+8+F25_LU2-NQ1+.Y#3I,/?':99'L?V+HHY-O.E&_@IN
M!JC,*X^T;C"4(^+XH*>!_;!?S+'* B@@Z)2O,T[4V*X5'%,I9@R&PNWX-Z(#
M2KPA;@3I+APWU6CE>W6AL>K;;/=>'<PL3Q]-?]L6#1<Z!6D@6-2<^RV:&0/F
MZ)7)2__((0"_/ -:_SM%[A ;@6.K-NFS]_'W;]R5;*JT90B'JI7'D9RZB);8
MTU1B[W1[S[):'G1.-DEDZ\]D\LH(:UC';]T<(NSQ2#84D!;J"7QQM \K_%!/
M<QLER7N(TJ6$Q3++3;7OMB%UU(5:O;!5JOR)!B.\8 XW^_)U>*X;GFU.IP^3
MFMW*B9O['C.:O3:O9"@]T(M-J1=^@&&'&E?NS-(SAD0MK=#!UO[@129?QPQ#
M/E8%?AR0/J[(.&$6!MKV"]X-YIVULKRLL-73KS(L]M()NGDORSSZ6)S"JK.L
M])8=UJ4HW)'J)V%H5/B?<" KV.\20=,18<RMW":^CK8:^\'[UI9QW6_FH@VL
M\9\![0LD.R_MQ65S#\[-)^1)<%?DYE\1[29NR9Z=B2#NPU9),.$6X$2(\11E
MU21,/YI0RQ$B3#Q,(!05/4VB))*/11O8^,,P;<=8,[4OHC4K+<H.4P+QJV9L
MF#2D$-_QM:.-\9$;W1,#FL0EDEX.[((2N0W22JK ^AM/K2KQ ,7I_-]VOM@2
M?HM7-G'H*J(-C6,6%&4:_-O4_T^#'B!"$<"&K2B%1PLG G &..?G^+W,23/Y
MC::V\X%J#C:Y- $.,N( UBT(?B#M?7PQ*$!RKL;@O"$57;OX067=_$OG*><,
ME"7BASAX5_1[5'VM.("J2!S=C\[?#["!KOGO6@,1M32]!%E.#@E.A54_U^'(
M8?#W=L#=+"4N)K1!PL+?\(/B(Z:4 MJ1R+&(N%YSEE,&$B,>( B__3)PS ,/
M3VDY+'*ASV&4\?^^LD99[X_D4KZ_M)0Y'.7?P>/#_\R6^C.8KWJY1\]IE1JR
MB,G*W^()%ZB1V[ND='CCQLTLV+(:LF@]P?^!B,>%UB^M^/A0M3Z2[H4)56W;
ML!;K*H,ZDBD@L+KV%V^74&.O$7>@;$8UYAI9BPW=HI*J^<9[NJ@G=1Y5)99E
M-I\^KQ3 ]&\M6/G^P5"+\;(U J<FMH4JA$AL#'GVQ3+8-%>/Z  ;-9'_\8*(
MB+N,Z:-K>EE/4*>".],G!5&BC5D,7Q09TM45WR7V_L(/AJK^KK",HC T0S4Z
M" K/D2#=M+NLZA(MPP_Z5!5UV=9E?+04MM[JH?3"/5O)<H"Y3.6A_;N]42_B
M-_>O: 2-QB[NC"ZV2<75PGM2M#VMW; %OGI@&@K7#IBL\(*&EUOUG::S4?+5
M6L]UD[RHKR![<![PW;L[>-&V0B:(+OR@,:?TP'7.NG%DR4*-OB67JR5=--+1
M'M4+IG=(2-(V?2SAX]I1;47PN["PD_WSQ\1:4#=2^H";!3A^4_$=:6<0[Z;3
M<L15WXO8+7HT9YDVN=F=%/KWIBZ7Z7I!JY'Y;HXLDB2!L2IFY[T19/B!<JWM
MF2=SB@.:>THM7TST1_H)GZ@\/PZWV/ -,4KO_;QGS)X1RQWD" OK>-,5X+5A
MZD=O\8E]FI,^L[:6L[5_F*X&!'C74X,)S7K;_1)!/STOK,6D7/VHEGGA#9LU
M_Q?S1>ZW*)@M?BN%*)ALV.5*0N33X!KSC),ZI@OMZK76DO?54;[-8C]N.=6Z
M/P&GG%](2UT_?'V3CF-H++6E&B: F]T \/@AZ" ")"!>;<^FSGE'4F);CK1D
MB_ 9C$GF^>M;$F3V&5 ?U,V8=W.,6< R%7]_+D6#WA,E*=%%EB Q_NW4N(QR
MMJ)+'8IANDRF'ZK.U77Y:[$/C9?G=B_3;'.QK"#%O-ZK(%$#)URJR(W*=BFR
M?_2VR:Y5K&@<#\Y(>_ZUN(SUTJ#C+1OA)*[4-*%2#_0D-^M'0?<6AD<B9C<=
MQ[R>";IK>F55AX)4'XIB2HCJ^>+L]0.J+3,D911V/Z753_-U&1VJZ*_K*$]*
M6W\^M&R),V97X Z*&]>R^5)$O5CU&P<8"3,YQ(D 7_K,_>DG@/R[G\"IG>[\
M4]Q60@-?GJ-'3#NN5*:5?H;H37D+/;\/7Q^0GZ='0<0?)+J [ORW:3';--@K
MWH:#GH:7-C4;A*>HH/YW1DWJ%COM>46)S3-@'H.WP>AA&8L^"I:ID/JQ199*
M5O%7>)%A%0[^ _&[G9X>X0:B:(%+KIO*=Q0L%!&!72AM;+2&_J[=Q!+M7[*P
MOCZ)8'_S$YA3_^4 ADWFW3JL\,;P]R6+*ST#*,/=!E )#[")5M@USRV60D+J
M2Y<7)(J]K.?M[[,&]P6JPWU:_ 3M[\9XMY=:+&D1QA:]WW%N@AYL@96UHV C
MX28WQSX.X6\MRH!G0)VD /%DK$NYEV;09+TLMS341$V.,@8I^,-^,:"%!E2L
M)WURD(6%3.^++UJP!&%8BIC2T<A+^8(D,) FE9I(.:EE)"S7XG1;G2)L.INI
M';6W18[+E8P7!Y;C>LPV,M_<CLZT<+&[:=P/NQZB10@/Z_\X>])#G+,27%N;
MEMM.(.DA4Z8!BCQ^O0:*'%?A>*3O(?Z4Z+V<KK[<=S,!=-]1IM(*=UXS.M,:
MW4C;!YS>7O/1(HP[SUY@6$Z4=2P'#WXWD0KJIJOI-(K&/!%$]48FVJ\XTGGS
MPO?]^6A4'&E[UM1PP9(XP@Y/0SPN-=9ZMY_:,@)"ON<+/+C.PR2^\O+#CDMO
M4>JJ5BHMF02F0:Q^%3ILQJ1N$C(XLA"Z9M\P)@JOXDH76B:\I2_9DK+9&OWI
ML0&$03S[V=IA?[1')MXBM5W:6%YMKV=*?S74<*G1:+%XB?Y:4'JC"O'B\6PV
MJ5#+'4J[Z_7E1]YL@139:S*]F"G4&.'4*+X +"^?-:OIW_]!JE*S'$6\)/]R
MQ69PX^G(IN,>#[NOR)P UL!'$'6I9?4:NQ#HY& G&*\8#T_S;O?D(W- MT!U
MY_;Z1&\K%:<HIA<^C.[T-ZP:N!WGI 8X+"'5Q1S?V# P(DZ+^]A?"''G.:[0
M4U@["US_&,]WY5AG1 P6"6_URZ\>)$O^)<OW_VTEK=4SH-0NN_ O]04 _\O[
MQ_:O*HF_VFS_JR+B/SV"?V;DEA?U.G E.^%'!- GA2;2T "U2(BW?A]!+,O7
M:HKTFI::KBF:S'QO.55=8XKB'(::*' 52'#2G/'7_Y4+C(7]\?RIR2D?8B68
MOGI=;FU0;UY/_M9F;(\HCH';1/HJA(:0PD60H-C,@:S<HH@I^;&4A.L4.Z;,
M?\M0="U[0#F&Q0.E@'W4;E*$Y.T$IY45?WR@K 1Q9-W<%JJI0J+6CBD@+J((
M$[*$A26":%C/D8JQK/=J[/+PHLNVJS^S"3C""Y3&N0*H> ^MV"+8>G!.J_R_
MY+E$LI%4:)BJ:RD7>Y)G6II[DV+6Q:\H >G<.:=[ZY**:LMQ1^:P9_D^7 $O
MDQU5^U%(<2VUTN+2LIET-.)#F!D<8;L#S'YU>IES3/>.[>?I%ZV#38*KS"J^
MLU5$9%XX\N^F'^P]J9Q2 $<5+AA6')(9"OB[ZBI1GUQY$*+24DI+K&Y29)88
MOVD/WS0)%$6VM0QAN'318?&@5&97<!UW<M^R]S/PV0::4H6!S0T]T+7CD\'4
M3Z(10:!<,@\&GO)P<O15409VU),R11>\EH<7N:\PI:MK2 LM=[]6T>PJWEV*
M\&G1'_N(S3+9@->!D9VQ@='9.RK?WM,1\L5XOO2<QQ#N7O2MR895I:R-N39D
MT#=M$5H,-_,%2*=5#G6G;7 CU+-U;_Y&C>;!.J+ELP86NK2Q"7-HQ"RE5(AA
MU"NH-&=1(KPT*8#C'Y%N\A/.@W8_B,*Z7K_8S97:^8FD !%T1ZA7D\>S@)JS
M'%U V)?E/AHJ(MR7C4YZM]JNGH;MG3Z12[IX >8XVNB 4F5K:\HFX "9$&I6
M$&EIX&7&R2>C*S(KUX=NA][-K]>1Q%.SY=L@KELE'JSV*<R:*A[**BG0)2!C
MOY?8I47B:TN*Y)</1@%3$&(.0:).[<I/V +$+6]*S<@R7]RFD:TY$89.$*RW
M^C7V5X@;+![J4DRI#ULQ1F5SCN P#NM(7>#0,:UN!-ET1F_R[)@)S(Y:+AU>
MG[*[/WRHTEUNW:,=6 V&^\K, TC;3C/T8URU2N1R\S5KBIV\PCV[7+9@$^H%
M5D?L.+)W=@E\?.PTBAV7L_I<>^=$FI^?WQ&GK\1<(Y"5;7,IS@\!7?(R  &9
MA?!EW$&<&J>;M8U<0N)YCMUV++'#5;$S]T&ND17^CBS]C($)65CES!M>@Z?^
M!F#TLMV8H&XS0D,6>10*,OX?I<#YS*_>;1Z'VN(=?ND_9,QF<8?.IM9,7"%P
M3D(+^WJL781,'SHS<BDRI:.8 ?(V!1J]MM8]D\N(K2BNR_.XN4$QV]3V94V\
M?2?Z$6& DYT91L/F@-5=>,ALBK#8:Z+]K(=O\;J=+@C&A/=;E%RKA4AH?:('
M'N1%/RKPO3&\4ZH[G@8GB%^Q0QZ_&ON"$7!I])B)AN)N64\SK(Q$)VTY5DVG
M>"6'+8SX:JDRWWZ8#E&/R<B&QR?K<1ZC12CYC^\=_M<!GY%?HGG(-<RY+3RV
MQ3/%,]P:Y4E7$@#9N+Y^DUIH19"2QB: >3#1L&B8P8X7FV:VI]I%1!*M&:)>
MU=R8.'8E:_YIUH32)<I13*HL7P,"2. 1X,)BG=B9$VA_E:H^FSTC(/HBOJ/]
M!75.'-@R'%@2D0 <TXZ+01&-8A/ARZ5ZT60";/\N:,D?7F1CLY=BAA[39QQ'
M$I-EG.92P46.O*YU@JMYR <M,Z4-VM1GF)$!O8U $NX\8N'RZ;HR(M1H)?)B
MG'E0EI>PH(E[D&+W*7")54?- [HK-F*>@5!9<JM0S/ NQKY,-E).\$7="6*]
M_?;>4,0$3$)"]J.'.= NV^ERL9^*?XA3'0/8AR2% U#!Q-SP7O@6'4\F09T1
MS0%36M,X4%072B]@Z[NYB0/).H(CM\%\;XV^CCFT!//^OEM^?-C/Q\_,^;TD
M7Y*T2[4Y)ME6VY>DS+'_,,[_!%"._F]%(D.^N(>L!S#-4ATX,PM0+T<J<,?8
MIHPUX@?^I[,S(#VO;86>M4*QFSZ[']\Y?9P09K./8)FNN]"H8&O!II!1^V8@
MDL'3&#E-NZ+/0>-Y0[F#\0TV]5<_&<%OLFVWM0-E7 G+?@B\]S6.@ T%%$F[
M<@V=M?KRUJA+>JF(]S;U&EQG2-5^GQRB=1TF9B[UM'H%ZQAIQAU'8O6-6='5
M+_GL7SCP]0?21"T=GE+4.SBX7A(JL5^%@C__ZA(9@.<:KRY]+831UA)E!UX\
MQ'AK+6K8D^<1-&W/K\8@@_DKUW]E L7TJB]&H-<_$J\69PQP_#'U8ZVL$/\T
M\QF8-4@?3;B54BTJESK(T-VK6TU3)S&79!3/]! >K,CW=1H0N0Y6C$B[NMSW
M'RQ;ED?2[;>Q((\K6&BKL\\=-!V1G1L$&8XG$%)(.*3WTQ01#:#8$\F\1 6[
M *[SKEZ9/A[#Y@74"-LQV[A.T1^#I\0#I%+.D)VH#PU93 D1G??WC*#VDFZP
MSQ7)$<-&^>+D*5'.\:X/#(VJ2B.NV%_/4,YP+K$*8^!FEW5%76M2W5:H8G.<
M EBZRV7VWHP^S-O=UO8Z<:T1M41_@WDZ/(!QQYUM$14264ZO$#PDLY=$Z.SY
M7O5;AOYBMS]&#(1,)O+DN?+INS[PGWV$&_9P7^%*\_YZ'_W)'*&,*9=(G[US
MOQPX4ZW0;;\3<:7-6>@'CO[0HC'5?5IN/;DXX!^VS N51((0:=OI2@HSZOR&
MIYHG]2M>#$907V'B&H('O>\(^D9V0#>XVR_?SE$( 4<]7U1BCD1X:#BR S&+
M$;W4T(PVT#[_A@9+&)9SY^,DD=9$FMP+%0CXZKE$P\P*GH[R^!-W6A*9[Z?W
M8.F,VZI?ZRS@5NOM^1IF!\<\(WXF"DP@K_ZOBD-K,'NV,U3^6=[T(XD@'"X(
M>\GNZ> 9D'3H>U?B>T/=\>O7^C-@P[GCU\>/N2OAP]6YXF:^AEK/@/'19\ 3
MBLPSH%?Q,=3N&2#,_0RX(V5^!N"+YZXP,_7V/0.BBYX!JW:'2G/R-^*UVK1:
MI=M^G5L_=;')3U4Z%A*? 5=7OL\ _ZEGP(6*IN"WRQ/S28WU__+[?]W*_!;C
M-PF*6K[]S4_"8\7/@']__E&JK&ZG-D7#!9@O8WU_XH(&"$=P6+URZ$+)F/ES
M"UM%#0<+KKAOT&X/[XOF8%6M0RE]3YPKY8YJFTN4I<H:3VS8?^Z3KPAY:B8O
M?OHH8L$5PM/:QN\A?'AY\9LO+V6L6.M+\9JS^^!M*'.^8,=:SN39ZR0CW;"A
MP \US3#(::6=29AH$RGS+F5($7\)=^TT51/!I:4;&B\1#E<^A:%0:NV?4NH;
MQ4_A\#+L%5^] $&1KEM]MV?^6\EH_UT5-BA+M6@8N]/<_E'5$-(>#X![!G@&
M3U]?U[]F+M)A0'J'IJ48PX3]+GWA+X(TPX9EF8;>J\DL]ZGI''4KQ >TY^X=
M2J68A(\8RAPWQ*JPBA9)2:%D]YW%_[D/O_H\1QMH0$?N"4,UMJ^+?@/&F1=5
M(U$)1)8@4E6.D2SW@$4^$8Y66MKK'BY%==>)4^GR#_IG9*5E/-*W3-3E3W(
M!3E-+(+JQ(19FV%M5CQ**M,1%3]SB9W*CJ39(Z&+20<Y89V'?UOC;X]?%\I.
M?*_T&VR 0?4%78N%IZHVD[1F*IBVH]6"!^LF8ED>^#K2*2.U6_9SO!?@[-T%
MKOO&FJC3/%\<SNQ<EA,C0]+>&N('8R/$S34=%[=2NQG@[U5\FJ:NHW[CUI!@
M;"+;TCK0N:*VAX*)"E<[D0)H*;AK8J[S;1#,S2W5 E$8!$PS&.O_Q&:_+GM_
MT9 G(-!A6_? N#-WRY1$-W10%K&!A (W@ %M0LG>3[/Y?MY[W:WE'#U2+[4P
M#+8C$H%<#E,BK"-&\2L_ VJ]63TX:WQ2T$A;#W*BK5P9]TR\]&LQ,U*KU_QH
M]>[:CVBSFP,&X^0>W!;S6LV4U$$U@P_M62:$"(.'O=KG\Q$&%Z3=8HG0Y3C4
M##:Y#64*[WX O2//_D(:L43=>4129"G?(A&H[5+3\!E IWV&%F%F[KUA1L3;
M[]EB8I9C/O\Z>(QG(Y$P<'R8G$E("H%WJ>/MAD._-&#O5$"OXA%FO62X@D0<
MR*$X$HB!]"TGO9_D%&S4M!.KEG47:.123IU>7S:.(!V3?#_@"HA.(G>V!:3]
MO/!/F8K])6S$P$@1_*8Y2BS$XAZJ@==T@WF2%W?\D0DEB.,XKR46I%&^2W 0
M"X[Z$)8+9Z3]W43;$0Y$*L$#D'72;J^&76!HL:%4UX?)>!?8CP K*RE4EM;R
MO<PJ%^AT4#DN/YJ]Q1UX5VOP/I _ 8B(3 JLQ-?]^0SXYAGT(V%UR*=F,\E9
M%K^NYB7^3QYQGJ75-'NGB;T*\;P[QUWD4OSR)O5\J)TP(N!AT'&MT5Y>$'44
MH#G!7- Q37KVE:-:>QR!A7!U=V@PS8>@[CBC>H[#!@BI>U'$,:DCR;BE@ZI>
M%N8$:J)#U<V[TN*ZO9E7'GW1.@R.L;G"\\7:C+T/ U3__]D\[*]*TZ._P&D6
MXM]-- K>/>4(WTI>%D[ *:P-"G"Q0RQ0EFA4WO# D-86-HS/>8N+LK Y6B<Y
MU[&U[N6=YXN+5D7!WPOCK&A23$5I1HQIV-[V(TD.1R?QEBHM6QHIU<%2YC6A
MD[E-B?2$];*U?5F=> -/^JO!;#A7:<BDGB^87]ZEG'7WS$TN:HUR1GY=+8:0
M\,^^,PI8O$=_>X7=@.(9U&KA1KRB77-8*U*CW4OR<NS#D"&6&XQPR=6IGPCE
MC1]5]+OY7/\S3@U.^EL/(XW34TX$(O,Y:O*6^QCF[VQ:"32D#I>I,8>?J,@-
MPT]?,;S*>E"&.&K*^#*&4R#Z;'665).ZQHU9(E[85MRJ<BGTY^NLZ Z3?[?9
M,R)AK7/D12EF_#+&9[M?0"?C2[@F(&P!!;[-MK)KJ-$:&J5NI8SG&Q!NQP\E
M95,,ID7@_S#EK8%?/K0^Z,%"%^ ,\88UZ6\TA8Y\KZ5OR?KBR*.;,YKH[^6P
M48FSF,K?"%1(E*@/WCH7R/?.4TQ&('$L#.B/VH->]<.J5L0F+ [FIMXS*0[R
M)A(X%@?&X"7H+/*2LY#]H'*/NME6G]J$G&0WI"I!5Y;1HI?LP]^X,7_ S=J&
MD:0 9!YI]-A7)0T><Y*(XB4];GY],Z#]QJ'"'$O!_\FP:8"Q)4TUOS\DW^Y$
MW2!E_Q$)_.8(,@(M3>@T''%<Y!TX$.V7SOK95VQ5:1G[F#/A 1NVLYYGVJ+%
MU]? DG!H/#N-N#I TCY_!GSY06J[]6,TO49SJ2?5NTFFM88->=N/RY-L(PH)
M8-*_F?Y)@SF/6U+>(RM="H8C55,K3U]TWT5AH^_E<^):+HS9Y578HKYV.-TI
M,,YJB]%GY+M:U-F=."9ZE)MOUE^^4A%)EO\,0.-06AFW 4?J&T1;6[^L5@'8
M*7W6_\[ PXL@8-U;EK=&60][,'Z!F9AAZ'=\!6E!0>F8\F.[/GVM$ZQ>:5O8
MZI7?#%,&KB5&B%"*OEULL:"&_1@<&"BJU\%6;+Y@*KC0E#-J#K=6^E(>H7'I
M^FNL?U37_5[R1ZE:\TT^<IN/64&7[3>"1(AQ4_( !@D+%[ZDF/<6/US$58IM
M6X5.R\%XX:B;W8O3VK%AZYNA_4?=E>0^%FXR% XX7PALACI3N1TZ>7U801E&
M:)0>NX"G>A_U38)MK:U%%8^8J=[!,1;U-Q1TE4H\W9MU2R:1SE]DV2FB(S2V
MV3C/J;\^==PZ5JRJYU9LC11<6GG/]1TU0FP'Z^N]Q_=,S])B]_:SH?N;%\(G
MAZXV0N/@'FU<O/2[P\ (_\<5DILL=+=FN:HYIV7.AD(/^/ OY03SBI>+:$[5
M>:;VVC843BV$O,HI,TU39[C#[[TBV1_D^(%V3%84 U(Q)?Y4(92$%82.DEA2
MUQRGK1]+P&@O=OB\7[N)$1G%#*Q]H*>-V1S<B=U]B=I)'>\@-_WC8?\\\L=U
MDNLHW1&;B&U,LH&_P&I0_X>2B#2R]#$X#CCT0\WT5'DWJYS&L$,F4+A\F'E7
MPQ6B.V,B.AQM;T!<P(I9BOJUUS)]:HQSLIA/^*!5JH8"!&0CKOPJ@N\5#!-[
MB"L 6[O=Q_+X0[N6NTM7B=:9_UYCK.&J-;'[1+#YK)H5/1<;&U=<W"+VEPIR
ME2\-%2#8ZW'",'!$LO*(BFXN0]-0^F<6\*M8$=+/*V#?/VO:WSX=^;9WC/V7
M[R94OK*H.28#ME;!>* NZ%B7F3UH]R$4&R[X?@+47OCEO:WJL9'E.U1[5L%0
MF4"JK,BT!CD1G<+,S>U _VFKI.C".R_%UI!'D[:RFLI9E=A?I<&SWJ(5C.DG
M]M)5D8*V-IMI'V2T!5Q31Z!,Z\HQ<$?LTV& ^1D.4E6)E*DU5&-81\ 2;P&[
M#0MA].CE]M[ 8=2CI6*N%4%S1G;)(G7'4CV8]>OB.6/#!3 PRI'78.7T.H<<
M7Q8_-'C[I.")/]S*ID )X3ZVK^^#2^?*>D"FYW!F7U(MQ^O$N4T=A+Z&2(=Z
M$T,CA=/+N*JS(9P9IW4 O.JYX G&B]CF:*7I7>C*2GX/A$R@D)P+S[LWB6+_
MH513-8-DAO&U5K!,?G/PT:3-28:8=Z]"!?R 5XP>L#EV/BU.HU6K9-$G1U;B
MV^QF;9.51E!9Q#CH2VNGHM1/)FS>O5H7>:"EO6 9XQMHP19/!52*66[VG<#;
M^D&]YO<A>Z0.4WZ<IP(D#;"&R.2"SQ;0)6WJT9/:@-'=#5I7'G)ZYWY+!F=9
M>?'I.LBIS69K2VWU ^<*,]?4V3+1CAK%;G@QC;"7H/L.W^/CCK*%<6=*H(ZX
M=1*!G*Y@&7<+9A21 C>*P.F/$CZWT!^I5H099VO HCWH]T$J5;:J8-4!$.&@
MB#V*/=QQ#)SA+62VHC[51F+[ \,'S&C\J&+JCGB9'5LZM9'M2NLGYW>YQTG$
M& =LG8DOZWN"OJN:Q-?)T@O!X\P$X 4NI*0^X1Z'+W^9E]%"A*4;IZP=G3D6
M<TA]A&AC.?;$>-H KE*R-RN!@T4Z=;!33!:='IIH=OA8'$0F12T$BN]&F=83
MR'W)F\D485J"<DYN=B11-Y> (@<:IB 5(\ ^63]IJ9KLY*ES^3/ 9.V#'SU[
MPY8(@^1N8W06_N#"W;IJA[A=U<)2V>U;&\2XL05,?8VO'</]*.:DD.MB8)]G
MKK@3!Y?J&U*AF975P9M@@S>+8 D< P]$"2F:P^\BI/7XG8-;+0?.+=?U*8NR
M9=ROF;GR7:K3O0<!J&+;&+5$H(BB_7(^;.+U[@(M;9XJ<R4K*XCJUD[>V:6'
M?CMK]/8 :>>8.4)K3B/RG7\1(>-6M/SG-=[XD=?>H2]%0LR&>.W6L$3IH[PV
MK'6/B1.6W%U]J#C"9$5J!;AQ#50\&-99%9P"4.3JX*8GM8-@49A+WI>#=NC:
M$I08V*E/U1FJH0T74 3*_G+5\#[BDZJ\S,6?GJ$G^VU?B%9.HUZC=[7K:L"*
M"3><TFX!9[053'; 57T=T1<!2SX50&7,6R1;M)C"$636R4L4>_:4 #M\RROS
M-UM[0"^(V?18OC5COAFED?ME9 S<"JDD69[7!(J;N-$Q[#7.JD7B34V=KD^W
M'?UL0,_)ZPO]#C_.V)P[/WFN!.JQPE<BSL:)NRGB .F1, RRGO3NX]]7B@_^
MH+N5>H3EZTF]H[[-=*A4OL7,MZ-+MBQ1/\5++CS!&2->SNK-TM S9X5Y)2+C
M*(_-*VQ5-/HLFG5T86+ [/_@2_L_&G_E&;O\A;8GX/\VY*;_%2@_@(\J+],X
M2 QU*N('V]'UH!<;Q:TC5 &J!?W YV^AQS\_\)4<UAP1''KVT/HUKD+9X*YI
M8.6B9>ZFP[JM4;):(QFH.<91J\;FG8S=K'2BO'I)I*R9FD.UYP79I+TCKXZ\
MRL")N$,3;Z$FD7C,XYE)"0 H&L_ DIPY_,6%9 AF$A:G%@X>:^U*4ZR8?TQ>
MW,0-<E:8'5J>&U>LCD89='E@JE$??)G*U.VF#7"*^E9[^@OHYE*HL7C,/604
MA!:&"-/N<RM].8)%XN#?>3PFSUDCP+6^1)G7BEU8/KQ:7OS9]DK/U?%^]Y,I
M3Y]'GT,O0(;Z&1!2Q[EPI:%IT!T#'Z 1OUG%'X,ME("<N_4"0=3L_E1\=%JB
MC[8A)-4+296FW6F]TG(L=?.7Q!!BPPSU:Q8(B.'JNW4N(!NK_]UE24Y@YN8.
MR<S4'6-OY8*U"[N=$4CDZOW<,:CE_4M,5I Y%2>B_L\(!:261R/)P!ZTPO5>
M:[*A^=,,[RX1F,ZRQ,HMV/4:KX&X,(2)F5%W;>^;S'%GWQN==NML.>P.4NQ\
MV>(#<KLVZ!E_08 1G@S1 B&HG]+%D/_27K+0WJ/D)TW(I][BAG('MYO4IASG
MA,^B>(GVCLARR'B8QM>#;_R ;UH*5@4F]"RXX2?WW3]-"J!.#%/A-FY >97@
M].$Z2:6**P4DC0I$K7CJ&MTK<JZ&NXF?SECP;+UC[!&PD.7KQ038W2BA:_LJ
M:M,INV>JJXP-3:8Q PB\1C&$^W[L_N/:DVWGXG/Y9F;(V46+<G,.=:Q22[;2
ME.@(3,;\QD!'DD\J<)]DU60"E9O,G3T*=-9D5W\1E"B0!:GO.\%U\F"B>.MO
MC:87Q#J1IO=FI%M_@0HG/$5EY<*+@J)X24NH)YC+]]Q/.$,93TQCAL$2+R^#
M:1AKQ#XI](-WU7\+@)#!N5Q&+@55+A\S,=S^K*BA1<]@S361070WA(<$VQ/@
MLM=B8>4CH'@(<\N0?.VT+$)J,(#R8H#!]11,:Q3A,)4IV!?M:X>]5+;5&&K;
M/DR8B*1?.>WGB<4WS<0AL^GE\":IM#[^=129^VAC;*#^6_.%V*H8%(5N@>T*
MJ\'--DFV\O9R=,F;ROI.<"W3P/W@BG=7H\L)+8+<S3%D4GUMK;X^=^2]J:H"
M\0<L9,\T.)7M.0%6CQ+171V+Z;65OH(W2F5GD>F-0B$H9(T\Q=_K2H?CS)R0
M?ME;$A0-F'(];-MWVMYSP_,J2([VMYFINS/1DW)H/M;O&,Y%3-U;EJV]#Q"=
MCOX:P'.800LOQ;F*^PQ0)V:06+N!S.FQJM#3E5GS4/P@LG-05C].-+/&L4@B
M:!BUM\F.Z2>,4AU&J*/'11GR]/]XG?E"WJQX<052[#&WY*RLM;0<;I]'G_ P
M'M?HYV</$.RST/KV4M06"+&RXG\&U*<6MG#Y1Q0ZD0BA)S[LMP&T6C(E)W*X
M;G'4%]4'(J82WQ(;)VCC?X=VFAWPSW OM0<6NCLR&E.W)JKFH9)Q$$8D8OQ?
MS'UE6%Q;TF[C[B2X)(TD6'!W@H7@3J-I'!IWET""0Q,:E^ $=T]P=W=W:%R#
MY&9FSIF9\^/[[CSWN\]S[X_=?WKO7;5JKUV[:E6M]ST_.[\JJJ4"6,?/*[HZ
M7BS:LM:))0P,4J9C\.\(NQ]*W?J"WK56W2L$NCO-HER?)SO,T20 I.TWTAE5
M.'L28WM9:R8PP)Z 5Y5]&I67E!9[TE;[/Q,RBNTL)LO #9]Y)_J<@_=\!6-&
M*ER-4/4.R+T6%(5*(,[.S$<J6&3S8?W7R[<;Y;?NXD\=X9M##?=O9W')EM"0
M @-0;]P>YIZ($:K_+1%&UN8]6UY0@/ O$_>!'0_0VPO7)DN_ULIA*[S27-"3
M1LG<7I#GWXJ;G2D9%W^6.\EBW@ **RG=2@9SL$01PM"=$T:XHI6I=S)FW(89
MDV;&$A=('",MD&*Y]M55Q0GN".P8!][#5I3&;YHL#D\T)V4G7UX(MPJ."T^\
M3S56;<F0%W8>TQQXA5CZ/1ELM>T+&T%'?O%1\E7'Q^6;"K3W&YFL7SA!->^"
M6(I1/-JP4ZNAWS^E9(0#<KE]A>Y%5WH4^.GKZC3Q>UE,.B"DR!8_6@4AS$H-
M 1*.)C8L$L'H*\_,^DC1D%V1PNNE 1(\47E#A%*.-MB5[]SE*>-"M86=) ['
M_#2*K6PK/17L\6,&"6S1.2I<]+V<)_*S YA&\^8,/(VL*NM2^S^,W\46VS)"
M96110R>.R+?9R'OF1L()S-C+ME7'D"(#F*:)$>0O(9P*$C8,Z98S!T_&(5EJ
M@8UW=9MD6Q<G6D.6NAC2]*+[O<OPWCS!<$#) B1"$7O8S,XL()XH*='%<PO.
MORDZ35M;#T! -D9YA=K>D9&SY\!?9)F%69JO(S*PU!I5K?0W>45F?Y.WD>J9
MI[<*HB/LK>-A#B3%.B]&77S:9^(4"F^4!F@U5X:?@W3I6:AG[ 4Y?\>U$RT_
M@TC#B=Y71BINSX/*,^YW%@EC.*K3ZBG3;GC,PP%E3;Y0[A!66G66(%WT, EW
MRE!A)]E2ADSP\U239WG?-^)B6G99NM)@C(UT4-]AW?]/FP28_M@C-%7[1S?T
M'J+>[_/Y'QF.#S#@VPW54Y\GCW*#UG&:'\ZYBZ(:?P%T.^(3^MH/%;*&KUDE
M=P7MLH*\\W#H*N6;AS[<!R.^BVT@B_-3(Y.U/CSXHQTZ@/[/BM\_P5 +_\00
M^X=R?P(Z_(DA9OGO\0E2TFU<\:HE#:YKNKI\:E]+7; +IZW6@CM"&A]:N==&
MC7UX2GI&E+V%O]5C:<EC/IR.A*O3'!Q*5<#6R9',V_<)H[U_RWBVP$8A_WL<
MM]<6AS*8;6X[W+*ERW>(&+%!8"N\.U/F5-_?_/3H)T/R5N?+?I0<G=>AC+Y;
M['=N14(TAS&.XJ3/Q4@(3S0F;#-ESS,U)B?5HD(VZOHPN41EEI)1EU"0=K:V
MC&>$?P%(:A65A'1LN;],[C0J@/KH2,;U/2ODG2E!I"@OR((O9NU;W81:2"PH
M46?EZIVVV3XH*'+D.@#OU P*/P8(_LY@WJ4J3@@3[(R*)N;N$]3#$M44GZ6\
M,F-M-7(P]+.\.-*>4D%#R/$QFX8+4UF)EN?D?_6#J1^0./%<:FWVZ>9&O8MJ
M,!\@J$$8H]S:: T=V(3#GM^\</,<9TEU3C.UH"EUNN'-0&XZ/3=<M1($[S=9
MO1 =-^9=3.RD^C88E[Z6AGN5Y[C1BO5^!N[RF@W;7:V00):JN<::HXV-Y,-9
M)**LJCC%%TT#*=7Z";B6=]4Z^=LP-YF1[O2@0@0)$;F"!4,)7QNJX>*3\/=P
M6X(T2A>Q=X",<$X1RQ&OW_Z2+(<;H*I+\OWU1 E;7I"G.1@!T3U\11X8#!1K
M<54K:D>#\N^4+ZPN&B:'U'Q]"/,IX@?B!,S=K'\"S@2PJ*I(>*(,5?=B'7M[
M"A>AHB\L2H%70ZE$+%M:@CJFE@Q$^Q(2Y!>46=IED9;"?PL-'3EF/N2W*QWT
M5*=U60FA0)O6013]J [^7I]ROC$CP,53H<ZT%O4U$)B1'@70R?X6)3-W,)Q?
MS-&H\_;H*P7FQP3D.G8,ICFR4=3<YJ;PGA&;XJ@5#8Z:F$JLNC%.ARQ"Y0JR
M+(S"7&W<K'))3JY>XL;1=X!7)9_.1)-@%^],TUM2<RS'2VM"I5X!X!I8C0T"
M?<C@C(1WA[TK-+7HPR)#A8<-(JU?)@KOW"'T&@%SM'#AR.A72+G9<93"UFOX
MI(A(V 17:'G_:&0AUK!WQ';NQH8R]?/ZU##"VOI[U]7^^ 8](]?ON.$$Y89/
MOOTV$G#^M3K([Y]8^7\Y+*R^TT[4>F:P\EX+A0$IDK5%N"(CK\B.F9;SMEL?
M*QJJDQD^5K]R$4 N?@8\I8WI"&#XOYL^_/W=9_A7D6U*\1> 1O6W=UJ=^&-%
M)?MOX/6N#_[I"G_6R_[A-/X%/PC[ VRY\._NZ>]>X\]"TS_!EO]!.?KG6DWA
M/[&6_^(Q.1]D\WCKORH:A\BFG,4WA@<5OZPDHXQ&*!%:1?I:/PNY/*-TM-:*
MDR:%65&6?-8_IMN*:6GHS7,1O)J"B5).E:V-IJ+D5C&(:&+0##0,#L+])A5F
MH#,ZV[6U+:$O7%DWP\8\'>PZCFBWH'ZG(YOB%#]AB24@0_VE6]L%U*;Z:,+J
MQIA^RXO:Q"UC;6P)?;P/3-!;O2=?H')4GH)-T#E#+L*&3J[3.1.8?Q"A7@2)
M^@KE)-H.-D$_J3;PV]6OE)PV9RX)CL2]<L#5%AHU;-A(\U$OG5<06S2I;E(
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MG;TN+L$L_OCI%">B?KN/\4D/[UV)C[/[\V@>YG3.*2EAM7[;RE4[NAY/0L*
M5S?(:Z>6_R*$XTM5:;V7I#FR*6_RN#"Y_@6PRWT:;_T%R&)=?7S\] L04>9W
MV-T4E5'Y+/*G9O-2=DU\TANL;$D2OS4W1"-,F2'<;\[!*57"!B)5=RFE"37L
MGS<:/(V;+[1>T=&[5RX(4EI0&D/Q4/^=,/!>YN8IH-[_YIKFB2T&3K'Z$W'Y
M%V!USO^V:3>QU[DNAU)L;O*S,TG2.OV'Y^KG^%J< 7 F.7-]0O$1@4K(!I7,
MC=&$2K>]/=C+PK)#_U/<-$G4@09$X)(1+5CVMP$__9W(L?JO%E-=/"#)1J&9
MFY4M?ZC]-/OXL[-FMC9DJA;+GVEA0[LYK:W:P-.Q%_DEN\Q;SR6%X&A9];A(
MS2B\;J?5O:;H(H;TK?UK53*@"=N^68=G)"\8*T#\P,GY7](J_RI-]CKJY!'!
M[G=H?B3V8/ A\[DUAU&ZZ*92Y;U^&!;H3GL[1]3*@:^N3?N86ER@#_';_A-[
M2SB.52WI"Z@-@3MGKC:@X-@-CX5W?*I>C9,KZ-_8^P25_V*O:$7)F^&()[I9
M ^7?PYI\_+G3&^;:[*MV5**R GJ;B/+2"O/[=M,K?@VZ$*/W\=$?9Z+K-\A*
M%N4;JNOO-1*M[ANDV^3FFF6R8 O*%!<90F>C:/\<4OE_-R057Z_U&C*V#/[2
M8^-6!=TOHI=H(QH?2 /C0@_$\T5K'692%B*:09[K33;>#%\""FX<-P6$TX]E
MMU,$$NV'!(S\!Q^BWOQE(&)_>27V4WASX_<=*8J[H>M.59[AE?PO!O ', #!
MYU!<C/TI+=[B;X<$MRG'%&*UOK 9Y-C/QF$Y_=A*U^8X<[YC_S:U>5],O9&L
M?Y OBQGQWRX1_7$RE;G ]^,2I?D7X$?%+\"9J^S;Z?R6[^?+.1[?VW'ZYP16
MCNX>T V9.94IC+J)"7_[#Y!<8MV3;PK]S4CG4!3 07U;K)6LG1;_7T2@LE+_
MG9U,\8@.\(1T94TLKF_?YZ_)>ZCA%^)#RZOI-J0/ *0"(EP%Z][SM33H^WSU
MRCO*CF;$56(T7)R(RI2N(@W_(F/<$ 7>+AJ.9?0(83%4R'/"60Z@]K2/XT'B
M3Z[+'EY/NQJGVU%7ES06#0TAAG)GD41/(O[D]>[$SC(1W%8O[\(=#M /3]1G
MJHLPU%55JPW>?WWG6/2ZT4 T/2C\50ENP)\K5-&U[C86.:,,6277PW6OGWE_
M,L[(B4G)JIRJ&?=Q 7E**=@CV_+QV[/CMQGOLHA+97;DS7+GS5QZVM*9:<1M
MLK;R!3V;_@QL$'*\G4$M73M#6M*_=>(OL;,C7WYYSXU%&E#,[XG+D0F5H6[!
M;5%!/4H9^63O4,R64]#-T[;TM4!\ N 8-RH<[AI=;N)O=EVX)3?&-T1GAOW)
M437#8X3_JH3B!$6!OG8Y.M7=QM[$XP,GW8R?[6>PALJS>H1(V@-<##I5O& V
MR/S7"+6(HT0\HF4@"'H$CFV86ZQH7*,,G@02(U0U[7[*B:(W4'^OD6+P>6.#
MG5H)%V&4M6^S_&5VRY2+CBM?VK($;XZ%_6N0W#'1,',G+W[%[A828T'A3E76
MZ=L%OU0;JWR#^2P# 9?[&,%!KZ8@>5>$T!GZI%@G/+)]-84UCY$O,UHW'SAG
M0[?S.,S2/,W927?C@P2NLW"$,@FMGI\0J^M+VNVRE\\C?S9'E-544Q=H8^/T
M:[4&EUOZF>ZY&HCY4$0.7G\9\KA?;-RDNM!1NV6#;RIP3[&&!'P/OPO6W?'=
M&^C"X#.VL$/H$><?09%B#"QG"!W L#_2PQ&=A\/%*\T^X"Z1F,7BR[0YI7KN
M!J$ 7-&T)T*FGN^J5!,MTUH"+V9=!N<*1W1<]^7S5SJ_S??3UGJXR9T*JZ/0
M$7_(]<F-=#S4KW]@GH\:$&XJ?E_%0F.]9"X%?(N*KI&@GI[U,# G(%#VJ;-B
M]%G4H/YBO]W$BC)3+P,?Q H#>2VN;R> .ZJ%@3ZRDTQ: %/#V(]XD]A<]84T
MYZLV)P&:*,%P@&+$X_@DE9"Z3]+'#.,HODV*NLC-0^7L *(/FQ0R7!E?ID/I
MS9D)$7OI0B@S]7R) :G: @M<:;O$$/6TP%%#P8EQ<6S\'JHDF=34$ZH<QD.E
MA1_+5,Z3K:S$@.X@.KI<N;QH>4Q4Y5)A %=@Y+GE?[J2G"O Y.#@V'Z9A>W+
M="$S!3?S%I*.7N&5:@(9L5+B-1S((7RB))A\Y@FO>1"21REC0YUEB;@?\Z;1
MGZ5R74O7.^^QS&VH"?&;IFJKJ0=O*0U0<N'O;8AL3]>A&),A;$&MQCR8?LZ@
M^_1Q+ZOCM_B;__@ KF4%\NX-] 9W L3?CHP'M;Y"*FF9Y"X^G;FYUG(7.H53
MCC,?]P+6HAV'Y5A+R 6(I6Q5(&R(;*A+D-%)).JD,N-;R9-[S;SY@O19R2UK
M&O;&2("84P[:]B;9<E0!A?S63,3ZO:X5KUN3ET[WUIP43A<(/?I<9QY$:&Q:
MU(F=EN%%+0'8@P/'I*^SKF%UCJ.Q]?$L3-_-UQOL;'WFT58RJ8.SI&VO':WT
MK"5$^=KJSD+B*2/+V&T2/[7S5:Z,>BWXA??3]Z8T:>W>LU.KY;O;WK<5T1[U
M#GF@I119K G4L(JI3>FMC!BH@F4GATM8GMZ'T4479IT3)V(Z>%GD =R@BWL_
M77C':]-K5$] EIJT^FPZ^%D(;0/!^[$X3%9Z+Y<5'*E",QC3*UF*,>WBJM,X
M>N3[T#+?C:9VQHM]*K6%ZCR-Q4=$A(&>].2<],\.AFQ8_:@7)>RT9E9Z& T$
M25^:Q5 P2LHG%JQL^:QZ!0A*Y.W%+2V-L+A<99A$A E_P5[+W.3O'VU5=,^W
MJC_K2[SFK7_-_#K./$1?@(HKKI^J."6B[;D-3TV\GDZ?1+,-='QWA//[%FO<
M!>1F?R'I.]'T4T^32[R>2!%,*+&!4RQUA\ZZV0W>CO*%:AX-C?1$G(IP7\]]
M\6NS,JMT>O-B-SE$(Q"$4@%8B_TF>/G,#L'&PH+8[4E#:^\K$%-<10A!W_L6
MHW2M/N9]= __A[HZ^5+==[UN9QQT\H%]M%>T:8&QLL0Y[;-Q-=J(@W(-"/EB
M\\Y<6#I\\$X9-YHDVZ>UD8NHUC;!11&9F9\+K^';* PCPZNO;2FI\42^Y6=N
M4. H'5BR8@]O)2.]&ZN(O+.OK-@R7@^D\B:::&CPHSA0Z;=*[:,P=00*LAM5
M'WWP=VUBL*5N$72>2AFC1LX@U0%AX>1;Y=NX25;JVS=9!8FB*>8B.CAH.,@B
M(Y4]C=7?6R\B=J<0L<>^X( C(UT\+EU,"ARJ)V^@4PX$@G+L2'FZK$716Z=*
M)7M8N)?>/'C-TRQ3RI57P"31A3R%.)[ZCYO\?T>W*6C3F[6-.E^;- +/7KX]
M3W*#=UDV(#(P8K;4(Q5EX<[O1/,NC/ 95XC[?1#YI*ZJ9R3A;8-\]ES5D32.
M4//5O=PHDR?:7/BVK0^COY4SA;Y$WFK?V_<+(3V;PO2J&MDX+9%%M,?Z=@)H
M:;NZ#R)3$%=F@91K 61_"U;>*QR:+Y_SB#VEPZ&?<B,Z*8-'Q(6*FV]9CC(.
M%,]E/B)M?8VKDJ,BH3OWQTPWE?WP[6"H55PX?)M%F-D3LL[<2O<(184YG+&\
M39#&+D"I*P*?9\B-OH<))]<HHY>%>1<L@>AK%(GY,-S&V<C=XJ:_Q$>F&5_]
MK2I]Y,=4 95WQ-GH)LXG<I@I>\E&=]Z'$^WGQ_QNY6GEX.!XY3DK?5H$95L1
MA4YVP\^'$N;83[_G -:5@@BO0%X#;(-YW1$H%.^XR]3B#4#*HN/87VFBPE-N
MJHE7:9YZB^7L[\#@L>;F$LEB18KP&?DT>01-#S#S7R]8EQP^VA\EADY,*K=,
M66@0RL':T6 %M(0&7TS7UA"5J9AE_BRHF:_NW1 9\>PD%\D7C+Y$W^E2>-F'
MZN!6+T,F_-,5#0E W/N96]=E$092N^X=X)(Q46W,C\TG4W9H"T6[*GD4'>TL
MS==?P!$H4;.2CFN&OOJ8J-@2@,6FK!K)CU;PS/L)?T]-;@9K?V+N\],D$5-E
M@VEL'VD=)X8YW6:YK<:U*$UC10MLG4<WSRI/Z@64?E"FN2(WNK0/991?160/
M,?Q CS=N@WB2E=NL-OKU1P:/#R% >3--(":%/VTA'9N($D)WJM O &9G_DIK
MI)O# L=P1Z]-A6)S@!O\<<TN(,!YD<?TUEM9<'KZ:.9,P=$#U\QRUL=FN\1,
MLS(6'>V'LZZ@?^<]A)?AGF>3;K_Z:)(.'1N$L1CW8.#@A2>.QPVH.'RBFCK9
MFF*LK1*;WX8*-8*'!K2-.XH,.I,1-P5&27>2?P$P:(*/>'1.C$-'7K,AGXC\
M7#BRC#0FN:"PD^AT;@BOI G&'*2?2JGM2CR&,RV1QMHZ@06P(HT]C8VO&=,N
ME.Q16;M;!GV+E!U9X,SR+Z)(&*2E:0'L ()(?SV Z<_>D!,6S2L=6[-ZJ#F,
MWL:9UP&!L^K+0!H!5 955GAZWS6*3SI*<0I6-S/Y)FD"]2X]N:.,&"]5 $E@
MQ('=63&QTRGO<C;%KHCGRPUNCSD!,%1]!&#2CL8ONDM[IJ:<U5VH;.'*,H%:
MQR3>=E?71Y,AHA7 Q7;B0Y&[%_^>I>:JOBEDRT-M"($IWWD'\.,5&FTB &DF
M&>?FXZ1BC0U<3+%..G;0'A,4Y@-%A-YBG!/$P?;X=TKU;R72V4*BBQW-9X/,
M&LRB**ODCF\I/B&34:"MQO[^="HI8/,F%"M;'O&^6U$3O8)/.<C^3:$QQ-6#
MC&<7VY,G6B/:B4[<BI!6,W RIH45=B]*W;GW1C'H-E6Z9?*H%JOP:SA.91+1
M@$6< L.#IPDG1X#'*(":J?^T'_;S-7@Z_YZ8#^+&JHD?_'JY^4WDIC-1C.'M
M1O8OP$?EHQC;GVXY/*U3[RIS>WA\F+KP@PJ"8[,>+1'W9EJ$'!U<NC-FS%M4
M3@A[&^D(L8.Z<'ZP[V=\O\)YG UQB6%6_A[>LPR4#".9#XRFC]VTZH"+]T92
MVNT/R]NOVX!LP-CJP\'<7,_YE]Z;4GL<RRC/1JKS^&-_+^ 9C2\:MD+9&:WI
MBLOQ#'&,)!35#T"XW@\>!HBG) 8O>LG8@D'(]DE2E4 =$,NS"@3T3CI$!]F7
M4 -0^ZQVW4)47Z7W)&<[\J3>T[T?UBN#P>9\.6 TQI%UZJV42J9$0UWC#T^*
M1WHXI$V\4CA?G,*/TZ$*'V$_PSE\P@@3XXKTI!9T9U^&SXD(UFF/S"E;>O/H
M DX!<"LJ=ZK<C>_C6"&D;.[@=VYC&(1A+J.N.09TTOZ<H._]6'KU\D.PLD)Q
M&#I4#BZC&[RY:]QB-AO4"^4?YL3#])QQQU\Y<"=!Z^>M.[?5L''!)I-KVP[4
M%!!;IG0MM/.CV:]> 0W%5()#^4VUH_0'"N4I,SYN;:WM<B.P[N2LMTKIU8_O
M5-?\R+!)'!BT(]-Z*ZD;:-;)OEBS!A6D3K!^0[!WK<Z03G<],\%<HRJ!J\/$
M;(N\+BZ1(;!&S:58?SH5:PVK_@6P?G_MYM3/VIH<!5 [: N:ZT=R[#U,H>EP
M&TF!/F:KN"*[. $&4-W\Q)YGX23_]Y6T_R^._VG_PZ:/P8<;:H:)'>]7Q\;1
M&!HU3:"5;P(>?6U:%+@(=]'6RKB=;@L)X8H05_S)]:9HBP1TV3=,7Q;\(T(8
M@04^U,QE?S*HB5-J?67\+%:SI"=:P?8P'_RM*W_\P_GJ )/<UN[@GG/:;CC,
MLK:8]&G8T;EX](-P,D-CH-32<S-(N[A1$RF#9&3D3PNJ4F*$'ET=:[2V2BG6
MUD,B3[IZ=KFW[D3BYN:T<%H[VB!Q(!#8JG'/43_UHG7L,F*0E8$,[ G10B*+
MZW':QT,V4>8'U).B/5O])TZ"H]:U.\TBN=E4D^+DP&0_"X2)4I9B8,A)XG$2
MA7;M<<UM$QA]\#]IS@!D%QTLU&9\RALN/%#CUJK F1#L&:VQ*",F"C_]!;C5
M-:0_W0TN:0FCC?&-FKZJ2<G+ZSHIK&SXDFNI$=6L;G+7S'E).8;V7=506:R+
MYOFB=2*GL*#5Y/=95PM,7QCX98W6BE-?M_S [G:;_D_R@GP?[3.4Z9Z /):R
MIY7JL!?!RNF&ZW%IKR-A3"1;E-N?A-=4T*I4#1ES?#3/8*79RR.P%)-&(MVN
MQOHXZ9)XI<H:-;9SD.4'=S,EB8'9W%N@[E1M*>%Z;5> X8*1L@5PL:>?\CLH
M ?=;5RQZ+QDWPOCX_R,N^/\4L>J?9'[6_U9=_P?2Q9]U]+Q_SL^_,Z#^.3,4
M_M@OJO$/NM2_\9_^": A_0>B8,T_Z%+_-_C<Q%<&[UB!BK!KCZTX(!/O6P1S
MEG9Q,EHGN1/-(]=[F_J&\ V**-&-!3%>'7MB9O2[NW;D(D,\VC1PFGJ+1('B
MM[UX/;U^2F<NF;V)(.U7![?\NVAVS"]/.KTR:LP@'\[1(\\B+!1H!^MP%M-0
M&8620L@VD?BW=@+8^")L4Q4KFJOJ6EJ?QN)R0DG!6 S;6N;8E&5+R"**HK-=
MUS>),[RGNBO<[N-D)@USWPT!_:/##6!:EQXYLIW*\B=JB4(YV V?LFO!8]8R
MM[O%2.R[#QXWB!['44&"15?%%?ODEWP3[^/WPW&@BY+]1.6QX@),K>P@-.IP
M-&O F#+A?A7]HBRP?NY8:T8%__':."M&L[]'E@QGSS+5<+Y$H4 B?]5 ^ 5V
M54?ED6);7/H(GEW;#.5W%.C "L\X#UDRC'_3Y4="G@Q!'Y67BP#.;\N2QWK8
MJ/H3\E:Z6GS5UY>K?#J7T\T@3+Z/E/$.7DP!K$Q>-2LJV;.->L,_RP,A&YSR
M%!3CMP)4E:.VLY5G="0IP@NY=>YN;JK=NQAVS_P]DD8TF(DF*P$7BN/<KUU
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M/')]WKQJOW4D!,9'[0=ND\Y/*]B)X+(F[,..0:U,WET&0HJ>QU@'^>OTC;I
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M4Q3-<===B*=.R729;*,XQHH<YO../==B[]%UKCDB(SN\FR0?F(9#E^%?+<$
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MVF$>C"^2%?C2G0IXV)@48\KH$'=L%GX<NBSS5]:9?9>!]_)<D4VH;U$E'9A
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M?!"4/C4%WA4<G9I980G?#<W)RV'-LLM3L+/'3[>.3MN2L]!U>7I\NUZR7H8
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M2W*"R+1Z7JF]$"I"",6SD2&5F8E=ME[CQ4JY>XPS5!YT_KR,]>9 W/F5=]8
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MEU(=9A%>:!<_X@$"2=3DW&*MEX5H2YQR$9 ;7,'2H75E_N[SLY$WX#SDV.$
M01NF@&_3/)XA.[)%(]2GBN2S3VK:U?*X&/F2!\%8G%H?OG2L:4?L-$$2'<S=
M4N("IOEP0W'JAA"M%$KMX/C,@T]^FF!YCR(;23MYM HWCU<0+*F/?5+A:7$1
M;P I\0-/4'[H,ON$T5&'F/80-RMB1[-5S/$SG]':9B2V=*Y8!CZ57M^T]@QN
M\!V+C7/&<IH*$+QFBE0)CQ_RE&Y-<J-)Y7;J8X]1EVIBPGC+F29SWL>*;8@
M,1N_M2@VGN]\HX(S;Z,*_580E<*TWO.-QEE?]0MBF1_[0O5B@% $X[>HD_G9
M_!3V?"[S4DC"1WPY:A)V!*I8<3]Q8:V(?W*YLJQG-D-Y6S5*6*LN3"C 3LGQ
MC/UV(3S<#AG= $&&BC?WSXBG[@=%72I&QY:H# AG,^A"%.W<,)KC!^ "NV)M
M (=%%;ABX1?/#"2/MI[5I0"Q9W'F=).FY/&1+CR3)(@[.E-(';W?G;5RM$D
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MK4I<-C\=]6D?#*'>M/!#/3&+K+PMBY!D8/FK07UTEFKSW")F3A2S893]^,4
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M\^\4R7L$,KS3]W=H8[E9PLV1LUW5GQ;)QT7'@V]XH<0JMS5D/^ANJ>;$[A"
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M ;$N[HLQWQ?XFGP35GNY&#VD;CI;U@,5IUX 0>$1S\I6PG:#?E))P51JD]_
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M[9-7K/;5&0[FX0$XM+R]V%0"3["\B,/:'-3^BDO^HTW'+_FV10=B/[ OIA\
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MR]G1EMCV8ZIN"+^1X[-8:N;<TVUSB9C#<WPO+G*MUJ<KHV?I=:L!6<72;KS
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MA\B>T!38WM3XL[?6.X85FI=N:>N5V;OG6'*]B)%@ME^?L_>4__Q:]AL"T:Y
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M%AX?0UL6T92^\T/83O;WKGT:>VOF']6.\BAPCBHWA#T8H\%X NFG-K[%0!9
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M)9*BRB\Y?;H0<\>;L2:G291I8:].8O[!4I2HX%!![5\0V8:X(6!Z>_<%W9Y
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M):K*GL,?XYP)1LY1A0$-Q!6YLE]T@U;5-IH6AQ;F:^OC^]<<LG,$=:R*E/@
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MZ". K+"_.7[P]K-DR%_%\AD*58\ T6G1*\1'P)U;;@:9<=_63<]OM4"\YX^
MBEJGBM7?;LC'S]S8HSB]-WX$^"L^ GHL3ERCKQ^>;FU[6@_K?XX*^7=&2=3^
M(<.GM=^5^>9\.MLC7?$;2'T$',_']TV+0F]Z'@& S$< :*R_.8P3=OT23]WO
M[^^0^Q\-(F3]4\1KH![C*!)H7]GPQ OTHWU+F].IEHX Y4+M.&?PS5?3>\)9
MA7A@:Y_XOB<1'#JP4],)0C-:.74$*)HNDB29L+V6!A)NS@09&7(:AV/^^_K?
M6A(D[J).G4W-5VC\1$ZH58Y1N>3?\C3'1-9*[I%>3RHA?+ 8)(Z5PPB.)&"8
M.*"J'#5*EP  X$:-LFY)*>R\AW[^\ AF=G+H1Z7$G@CL.>46Q@,L,PJG\K N
M'ZQ'ZI4&OGGC=2PG :#**8)3!0@ &%!*TTN0%!20/S[]D8C\:V1D$$JV5!91
M?HX_KD7W&W:@2]Y)[ER#$>RL!V^7 ?Y930A;QA';809W>+WB<U1*.$B<GZ)L
MQG^<=8'+QP([E6BZV#B]GB7/.%,60\>6Q"N2>+XHR<?E:=E@-P4!&I/^-GUS
M*VW:BJ+8LG'=CLU /(BND!!Y[B:U,*.</%U_MVK<- 5S#SPD:T%:>G(#($JN
MZ(-V5EK[KYY1D]VCX)GM6WE)KIJZZC0Q$XX#WZX+!A,$)G "$W#CS<YX0VDZ
M.4F]=U]%X>16YD <!V]U)H,4XU!5*K%0P&4CX'B&"\YIN>LE]V J=:O2VRIC
M*@[$>8[^+O_G;6@)?)3.0%7S+FUG3U$S9TK/:?JE<FP@1PWR*W]!AS#D[/.U
MG,Q?\[ZPK[%#7-&(,YQZ5>H((C8VP?""AGW(LVJ>0ORF1=*%:E,9#QJ,D3+O
M%U(I4$,0BMQLSM?'_9FCB2P5/3>9.]^SS+LEC,5OHI7P!,(9=(&9TLZ("^36
M; FEQ]?EI-3<M"1:<ZF[!WMY.6(T7E\&T(8!H/D:+4<VO$5(524C+J4X[8 $
M:J5@@>JT9]>I#*T>(@FTE8$VY7$?/BR9Q SAUCK2&$2\A7?(+4)A/^>">Z*_
M&_G!K6<MXHQ(."9OWIL2FRY)+@3T$0\C>:FF^(5S#:EL0^9T";]);5W;DV2_
M3D."\^^/'P6AF^MY6"MF2E@;BR;CX0X)VL4P)EHL$FOY7XOAD'L!/PH)%UCE
M:OLJ:B1\>Z%L_[PVO#,*\L4G$MEPQ,\*H"5D:4\1YBK_<3\.MW"$F0K0X0(A
M*C+P)4&\1;M1+[6>-]+.[TR*S?LPG/UMQ12.Y=K@$1"O-;0J^.P$1RZY:F/
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MT-Z\?C=WZT_J"_7_C[FWCHJCV]K$F^ >'(([08.[!^D0-'AC08.[$QP"C4.
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M,@<BJ(NR<OHV7@@PP([GG027.M4&'T#0U49+>E"6EK_?HR8X$*%DDA))JR+
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M &$_TA9.Q@Y,D93A%STJ7=.5 W<JN2]K_!#=<#_^'HYXW298:B+$.7#"8I\
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MOMP7E*#;;O]-4.[!AKA)?E]!SQP-O8:MMZ\'VMV<Y/^X2*BW9>:W65'$7AU
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MDR/,M<4&15"4AKX1_$D3J6X%5?T\TRCZ%G!QF Q8RJY*Z8.\TN5N.:@_9$R
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M IK(@%V]KX\1CNK>F,FZ*GS<BVM&P6.:UA1@:)I_8OBQ3O%WB#)['"5<>-6
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M):SI0(_T3!M-_\H Z_ '2R\I_27#W W$PG@*[_1!*L&3+[5F+8@_LOZ<%&#
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M*SIUYW)R>_[V\ZF4CB,>B*=%,^Z*7F;(4^^<8#.RHSE8D;MZD'5!6_J+G[?
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M1$ECUE?JKGZ:ZLYA0ZFZHC %;&YX_X%$I]^J#3&.K8[VBNK@7[@(*OF.-)\
MK^]HYEA+2ELF'<H%,IS&;=G&PNDM6_-LIL$':"?=K<DCK99I3$:Y3H-C--:
MWDE1:)XU2=]YW\P$E[%VCE.2OFA5\ )QN<(([F"ZHPZ[Z+LL VM-/<-WA8:O
MPL\YXK?H2KF5$7Q1)$<\HX3/- QA.HMW+""8\@#4I%XA1A?!G-L?S12U5>/7
ME,X*9I41)WAY5+1*++N=M_W1TOO1)$%P9&,K0\T:D'1O].UV[- AZMC1:5;I
MZ@2@-Y3$U1C@C_H!RXEG(J_\C*\TK]!0?T%>X)@MWHWGU6G=T!!@;A]'W#!@
M;%KQPW,;6(^1YJ_CJ_5*<DOF3Q'AOH!00,^&'(JS+N\10O');G/CU D?^JZ?
M,9M@.+(L,!Q)F^P6K@*PA+WKB8;Y"Y([?^N:98X@TJF#BCP; -OL\&%(HC:,
M8%OU;GPGU]\,!7WUX;$#Z@&Y2C<#L>[<LL0"\%/#78F3)#ZQ!P?%*H3I-M8K
MW">NQ9B0\U6^ %1^D52&]NUD.)\^ >3J9T@>S!1NPYO?609VDK9A!IFS-K.$
MOZ1B?G;T6%8H7SQLE@>)OS9=66:*&G0S?;\TPI\_UY81=4F?_VN*W#+\YX.T
MA?R0N..[JG">"@J\F!M#^: H#B8R^M^GX8K]##RLJKQH]/:\_:N?<1QTAHY,
MJ^*WC9:Z':7]I<U_*IZVNUC]1HU(7:D23=<$%:T@HML=(+VV%M$6Y83#_.SP
M+6@\+P@2N,BJ_O7A7(8._;G@,ID%M7$_@*COM[W*">L1!LY*O <G!;9%FUE1
M3YA'8S[K=/J"+(?B) DPCNTK7J0))I?U[V-;CCI$1^Q%XFHF-1Z087G61?Q6
M+W4S=6IT[5/RWG'I9<I=6 ACD&[T#/YCD8CT.LK(=UW4,M%DP$SE&4I*_G**
ME]#\ZLY"SW.M6$BGK=.S%ERCW(WJHN3Q#YAY5L+EWRNTJ0TJ.VGFU]^Q"KQ+
MI77[>9LXJ_R?\@3UARU<V:8[NPO5GB60OH)SHPZ(:25##%46LW)D+7TL5WW&
MWN\^WG?_ 6A]R/@=C$FE1-Y=/'\"$*K%N=_W[WBW<ESP6L-+"O3V:@<6 K=(
M"H^?)>5BUF^Y#//<B3\!'@,(GP"KB:TWR1<GGQ^19ET'!Y4'*:(_TJN]S/E2
M;,'M"?>]W&TEKB%W2#T2TB>=+=+$<_K$/JHAKX\GS&EA$M6VA:^L]T@X8<?+
M@3$'J8M%_UH7B=.V91[C(!;D>*/3;0;\DJRZ<P;MYB_^4P7O?Z+M7/?E1AEI
MW:=+A>%[C2? ^V$ST6@%A!4[>H1/WHX7[(Z]&GHRO=3T IJ0%IU45W._R'G9
MYOH+V4*5*K<G@$Z/%>($<ZENQR.G.&AJUPMM\W'0?P2=7!/G0C3 0[6^HY1G
ME;$(0@V<N0S#!FG(31Z5U(@TZ @F+R_'$Z^HQU\ EJ3-S_R:%J-P1D*W+VG(
M<LFIEH_2(@8YJ^)W^O-DT5WPG:,OS'&"L:NC^X;!&=T.8%3+\A;8N@M\0V]3
M1\_<NU[FPCRZWCR?UK($8#>N%[]".Q)@YN&,..@,<Y.WMVVPM%-%V0"0:CHI
M4+KF0YL5V9X GP\/H6SFRN[^E@T0=;N0<?]#"0DDPBD4U'#'88 +KXZPS8I[
M&$HTDE2V M56AKLBT;<^U ^H2!D.8I"0C93WC2XVRGU'FPTV.LVPJ5= 5-*[
MQ8IT 3.R35Z$.EGGYX_<>B[@HD$Q\1]]M27.D%VZPF7F1X;;2@ 2)?]D0%N!
M;L\OM:O,R6UGR@[9(.D)^7,E21&,XR4U6O-G#2>25,3$_<LWZS[EN2WED_:B
MG1B&X%Z'SRTNMOMYOJL] C@XN/3^+%-O6>820 QIW5NU)R"E6D?<I:Y*X9?0
MX<$/P8'](HJ(1 CC&H:3-]GO3[]6%!LL>O0,ZQ]M]F"6?2D5,(\\<1Z5>M._
MT?="<]3DP[@\G8SH>$\>75SM??!.?\]Z#(+&@23%E*X0=%/$9I"WOF:2[Z7V
M!L\A/K,)WN80;?E:E /JD(,#U^NZL\<09W<L?*75[^>SSJ(V-5OJ X'*=J-#
MS8&TEK$SOL+6H/B)>WW'0H-.^RNYFJE2V=[8G>QJF^V^OCS?#QE-(RMIIV@E
M'!@'*ALTF'/[,5TOXF%/ "_RU$_1BKJ 7W8HOGP__EL5)/[.^<*B]$]@ R#F
M#ZN:W? $4/]8]*<4R]_:#O]!1//L'W_,_U<S'@@A&VD2G0OP#-MT%OZ-!<S<
M^D]+*MM^+$[-6Y:M5#T0Z+U(MG()+MY"#[ I+KS((98'1$@:26M)XRKY=5]]
M:1$6M*H5VJ$BS5!GQ?^J#Q@8,K*-)4D+QQ5:<RUN.A!3\;7Z.3C'MH+*N;!7
M%X8>Y'2HW"?#+(2L=@9P=_ <0YGQR_KQ"[MDNC00R:&;82IVY/-VJ^<-6VJZ
MB..<::&5.*4*JGSHQ-4Z8]WDMW@;(;27VW+=GW5V4:U,>28!.B@IN3?^2YSQ
MV(I\Z S^LHUWUHDH!%Q,B7XMIDKE0CI,%53%:1S@1O^-E0V1)X"P CM]4]R)
MA+-C@T+XJZP65;?S9\;FE&,H6V])QA=F9%_%@"%K, WLSDIYBLA$.9Y )$^W
M/<VWL'>O6^H]+/7;HF<4Z>'K$T)4CC5)4NT2+(_2#5\F1%5L?"PI"998\>5M
MH];#<I4*LR5OTV0HC[=R3N5POVH_]!3D*Q+#([T_+E1'.+ S!&B\H< N\Z\X
M$7^+;FCQ!I6L/Q-7*D&J(D'%?] \NMMN<=UJVP*VF"Z#&#T5F467@I.2]^-<
M1ESG.: M1H5KL!J.CE1QFY2(Z[ESJ<)A$*J856GTUD-'KZ77F22KEO<S\1(0
M:ZW*^SZ&-#4<?P&JK'R&U<^K(0J/KXRLY$RU2^2Q8[T54S>1\_[]/L*_\5((
MUB7/%7:M=F\3O)C@)*O#TXL1CH5_2V^I41WMB(]:5G9T.A\9=6<8"Q]X5']O
M*L6U"Z$7<USD<Y>J3%$;LSTZWJE/7S=])ZP<\AH^&IG"=CFJ*@:2]N7*.?T:
M1\G=N3UTIH@I21^S/F\:T5CX[*-&V]X/,1:=TTN_*?$YI+[M^YX()M>(5=(E
M=4K"R0SKJ6Q?[M7.9//X,^E30DK^CFG4Q"4YC"CA7]D7LZ'PW8X%HT$1HG1Z
M]K.70>N;W$45[W46Y.3TX2+F&[7,F5@_JJG$J1@W5> $;';JN07?&Y"?N8[(
M#P#RV9O9OAHM\5;FKHF&@;H2<"J:2CF[_SK W^MP++5/4T:QJ\E?CR]T8M?-
MM[S_PC_2R;+I<&4_FMQ@N:XBW+5(^N&2_X!TH8H[-SR4B(=6D G@=@BR#@5T
M)W2Z5?12)G\TJZ^]H)Y3IJ]6IB<12>*Y,&[ZZ"H05*U]>A)T6)V7. +-Z1R0
MPX*KZE<LLBK>VVC^'UX9H+_XJ?21HKEH.4\" GX%:,ZBM6 TG]M9>@==TGW6
M%TA?-'%-EG^/F GD#K\4$U9'M;3TL?_(R%]J* .2WC5!]$SE1(([P/KZ1JR[
M/;JO_5R)ZD)833]W7H4UO)WAEVS:^E*I?/&,^WFDQN)W&P.8CT: ;I"1W(B8
MIK'I?($B3&--6YW, 47M120 9?G"+!FPQ\87AGD7@)S7%B\9]!I9PD5(VCGR
MY"5-H%&9>$"[05"&>108W';U65G9-#9Q8HTBY!U$<'/;13S8#I?8PD7L8\]T
M1$2U;1V>(3@OJXE6'Q3W,HA^!S-HS679KRT39SF1+MXL4"/&&T2"2_I#E^3\
M=4+XYRB*\&%[H,4F(L,8M_\:SD%ZSI0V%:I4ZV19C:,P1ZQ#*'W<UY4)?C2F
MS(Z?;4+TT:DZSC^2'_/6#["%O9AM:51J%F(Q2XZ Z8KAR&VWNC&*HC\WQQ ;
MD?#0?EB5"3>=!C7P"F!\SEX\.A(Q2(J7<2&E20K#_H8EA1#D(,1D/;%\(V\0
MJW3.SC:IE5;\(0S"V,*5@BYNGTBL\;!U^\7NEFL4Q5>,(/2B*!+-IA*\+$\]
M%?$M5)]P%,>>OPA%4\_,3@F/E*91SC&T*1=FKU<US>L5%KC"UA5&K^A *D/&
MJDVL+2^:OQGNX.QKA5C_IV 6[SBPG[ O#)C$'.C+!J^G.E,K9G-6:)RZ+&%1
M]@H+TROI6C&_&O)+<%!''<*1:C]:\.4CU*R(,2%RKSUZ8>I'H@TL!^*'7]Z"
M'V_%OR20IT6D\@RZ>]ACN<U=K"A*?Z[J6U)3S2DK<6S4#:Q15C9Z)=S0(,\S
M/\R3PQO#-C3Q4G!S1U?=TV%+5_;;WK7&C=V:D1Q*EF>EBC *JBU<?,<3+P<#
MUZ$A$UL$=& D-\Y>?9=H5[)U%].Q/MW0B^1@[;G&SDM#R);6.;]L].H .96K
MC1U=@SS_HH.E<;U_TVU;U$'.61EJML%04_LX%:G=6*63\D ]L]M7+ZWD89$X
MTOW%5+62.H?VS!?G4 4_+8O@19P6CQRI'6 7*5(5=UNM3*3BM*?Q\?5UC#67
MD1IRKH!FA.3)0I50E#D_3WFIDJ^'X"Z?'12SJUQO]"'."U87I%R?Y952Q0($
M"L0H5>$IB'PTN_!,!AQ#TC^\LSH7[;JH/3F_QEYT#M^<%#L(F.1]A[^4:-Q2
M/U5R^'$N@N7VB#(/2?/X]O[V'<2,M,VDKP^Q!/+#@#$+-81NB@_?X;6;YD)P
MS%X&K2%7)+TCTJV7Z@;/OK,DE07Q[O6"3\C;M8=T,?#1JG5<;J/R)?C]I^#S
M:3..=D"/^ \A,N!U%7]DZ3PT=$5%];BOW>Y:YFAK%.2_H0X?XJ>T!;[4:&]'
M\16^O<0$@3V.V>W60BGL+\]%_738$6Y#]J9<+[^"]Q=<5]*OK^JN)O5[2+]W
M.8/DLCY>Z5%BN9<JL6&^J3^%-UBSE;%M-S<3@!FZ.Q2Y>^_*T3^4]RUXQL"V
MDOG*T-[R&)9$S.2(.NLM]PO\4E>K7JJD>T6)G;FNY<OY'&Z%F/D$^-3:^5$A
MX<[G]?E\+>J=@7&J)=FH(;[!?OL7[BBM<']<@PVV:C;Y-TU5=Z]_7>9JR',K
M,DS%KY@LX2%3(&)_0UVE:Q(!6Q4?KM?4&D5UDO>2[PJJ<Z)N_5-F[C\BSJK*
MG2ZV/?X:NK-M%NL@HNH))9JP-^&/WXD@3GL"H*/$/0$D*AZK?3JD\GQ&#WU*
MQ!7=F!9D&G+^X3T5/ '^_.WGNZ12^YX5B9HQ7MC69)=['8]B#5$%1OU6[".Q
M0XY0ORP=DT$JW393MH@!*.F4(ZQUG7.<>E_9T5Z4VT.S,+5 $ G_AGROT!)=
M6I5[^;EJKK6LJ@CG'^4HNK^C?OX>/_U-W.N?W(]:_Y+P_RMW\E]K'J"\^E:R
MLK?"@/\Y'LHO(AN_Q1(+]' 2;=_/H83_CA[;^VO. H>N9IS21NT(!9X[LA"M
MO@!A; JU]PFI^P1G#KM]?/4.(D!M<-O-3\;5;[A+]K._T&>.7&WA1<J=\)SB
MLZ.03\:VE*<2/+?)@*[6Z9-)V?$3Y).H"+NZY\-$5B//K=.V*8J-8YOLT/K:
MUV9U]5^N&V$(QO!-E-3*K8\KF;^DSE@WF *\T6&>GI\FXG$U%N+=_\]S(Y82
M3'8G-_/']!G7I2\,\,;O0"SH%!&'Z:#J*"ACOEN7>R=&R[)78(?B;+2K\D[L
M "1+T<?WOJ*_:)[;"-M"B2H8MKN[I[=6( 2\$"+-0WQ?8>KT-N<1&Z?>;EV#
MN(5F11.(=02!(O%VS_R@0F&G'3?7A:]$L]2>$79/BID[1K>[A;VH]:-I;@4(
ML+K23N4A>C?Q/3 U(7JY'X*XU-5DEI2#/.:)LH_*=)&)@ZAX)EZ&\/F=&M&L
M+D6V7(QF[5FL,W>0'4\JX_BH!/-F"51F4TZV'OSCR,S+RRN!&[C:E+0.BOH$
MEQ\==9"BW.2;Z#>Q9.4@JHT2=6*?E0O'ZQ1JI^I1A<1 ##[4GDJQ!19UVDD%
M\0<J=<E+YU!^)$((R[F![[Y)T?3?889NU7U6),B)A^92*_8(!_2JRZ&56BO?
M_GP"8$&N^9,OMZ>[']/-&P)+7\%S^EDMI*7F9(Q=>H=0A'6S92%0K"IE[&:-
M?B$4W5> /D^+2)^>K-KQGX,,4?I[,_$;&B%(ZBPGU,&(R8 MIK/EGT*URLQO
M]TH7B.9;9.&<>0'\XQ<DF#V3!ZE0(?UF#\]?AM?Q5S/\JV:5=X9[W@YF%QZ.
MG_M0(Z/N>Z>P=-_^4DUC:!Y3-+$>&WDTKZAFT9%_O,!R@NU#WD_\O/,#I/<L
M:-AWO5A_L^W3%-TK->$KN-?L[4$@'$;Z%L($%R3AGD#2T1%9M=JR(#6F/%[;
M+#&<N+=P]LG?&U.QP6[695183AK9I*O"8B9C03.\GSL6#MU33?A6[=PSP]_-
MSK7[,M"17=B.=/<L+U*U,G =5GPT7C*6RUK!S%6P_QR.6IZ)R?M'N3RX9'^V
MT:TJK]/2DF_?$+VYCY8K2$0ZRNDP!U'\^X%3CA?,/%UHA0]BBB2WY=1P$%F*
M#'#X91G*YQ78V-S$1L3_YGGZ<H[T(.X"8X0?*#I.^TV[T)SG3IUI<_-4LT3!
MNW;8U5F?47%N"%Y<! HB=IL_:8&=U'H02$>,O0>?,W2"B-"?H0,WE6#(^2!F
MR(=0,Z\:?X&MV)&N+9]>+\XARS&B_F<O$4*WS*97&G?GX/?J^E:KK%J4HWFI
M9(\>[6=RJ0A+FW[A*'Q9D$V*"-GLFO()_1H4 MYH-9 ,>2$Q4A$WBNUM6&24
M^PC7R,&/7\Z+@XCZDJ9)VD"5 "PB$_DU84]M]].6$(8O;I%YBZ1T3C]2A+GV
MG6?3'ZL1AL&PS3?UC0+X$&6&XJNK5LNZ.Z5@@D%0CSM>?=MB/]*I("J?M1JU
M6%SJ;/+7F%-PFV7(T)L0O4$<=V1#K((%AR4:;>)QF>R]^'YR\!RXJP()OU .
M(/FITF_/7Y$ZJ0 GP507981 H#F1F:OAHOE!5=7;69)R2ER@H?Z\9'W<W&;/
MCH0H(FTS#)LRLKXYNF!S4 A!32-\.H*I2^!764AVP.%9M_D,^SE'2D.,>6)/
MVX?F\(+=W\&'P8P!2MPWLT,=/&D=-5YB51DH*/4)T-CEC5Z$!YEQJ[RMO1J7
M921SI_-U&-*+[ Z1>"-)8O5_(V8?C54)VM^' ./WP ZDH?L*O<M4<;Y?2Z94
M'_X2)%E]]%KU67-9O=>FF:M] ER<_:&(,O$$.-/Z4Q$E F-'U-UQO>\G7UBW
MA6@(D-I@+8%5.&YQ5/6R["$,]?[^]V+;UGMMIX_"-QZ_;1QQ27.\[KF\HYT"
MC77<MHX._50,R)HEH]IP D(ZZRJ6LAUJ7S$!TUE]%=!YZM/!37^'E&1A#CP6
MZV=*?; Q+6^F6:\Y_19,-_GJT2L( HPE18XTQ%5:+M[7'YY?FHF;YG.UG/O]
MA$-C_R/YOW38H.%L=22-@6(N;P(_?^/K!(%&3Z=)^9W"!*F'2U3ZJ6<BLQ2Y
ML-:N-WH&:E!O1V^1P9Q#?^5(5I6=V\6I6AP!J.'9@J_83.B&**ADO^I&M\O]
M5^&7YNJ6)DR$E&&\0_57)N7<J!,Y"=K3U<,2^G''%LU5_LB1,++XY<>1B!U_
M(0M6)R]X3O@:8E-V\]5=MX!?:9TJG>QG673XYG7T%^:WBH24*".(YF=PE/W9
M[]-9XAR57-907AS-%\C?>_AY[&Y#?T:K<JII@R[;4'5E+6[L/$I%)>QFN7DK
M7\*&PIW>V53Z?\Q$-/C/]D-X/*27;&!ZD6T':9',X.=^?<DVOU7/(9J5X"@*
M**QO>V!&'&,NXX3:&(ZQ?29D!C<MSK\]MQIW&GRI%;;K2ID_2ADE2$F^4GU&
M]=!3AF40N$1N.&2*_O5[D<)%D+K^="4.MYX#9Q/.\4^$N?&W9E_WR4OC"/I=
MW=R%*U7RU0CCZF1<.9?>N*VT68;;D0D2%[=P-U;70#AV K.LV$E&#J4'ZF*R
MWG%8C9[9T2)<U\8TJZ,ZRCHU4M?D6S_W["[Y^7D"+(>1RX5'UR?QTG;7G0KM
MM_>^TR"8.]FZ_KSJMP=I![%LAHH^ 2"]6.?<<>>J'SIP!^[.PO%6O:A^($[G
MEPDUG,&KD AS[='U3A;([+JL*Q89T;67CE$V?X< >+#V@<G2>[-BQKBKD&-H
M=4-,[VB=(IO!NR-T<;OGJ ]QM[I,NZ.OS1''F<N$,WH,EAR,/#YJ!3*%F,>9
M8L0[5E8PA)535&::5$2TG:,5+<B'UB@/OY$//<K2*YW1J!2\YFU2-E6E0'!
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M),=Q(_N\,OLP/_#QT,R3[YI%W ,#^T4!$CX_WEH*E1B&O7;6XZB3G-\S^=!
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MC7@- ]2G!=\(!<S>9BC42;C6@NZFGKZAZL;C7PKL [KI'Z6Z:(%OM*R!1Q)
ME[5/QK:Y(9>/3%#ZZTY24RV)1TE&"9@N3 :\M;,:$W8W>[?790N8=X;$(T>O
M<U<Q$12B.QK>>81S"HW& 7%O$T>$E9)0<&IG_'RX1KB& :R1Z^$LSN9RVO;9
MN!V6_F74'*$Y2(\&TQW1##/=**HK=<X:6-)2IYW;2DE'YF#&@W@ALUE45ZD]
M3=-!_WY,BF5_OM[2D@(SS/&9(V5C P3EKUDU0-?8H]?G&1?D?/< (NDS\HSS
M Y'#EPYWK'_C*?G=5ZOTUW^K+%HEF. %-^V*;%TYJ-PM$4;[[AU@C-9NW ,
M4]F5K5]^W -:O>X!_A.^1ZZ^QG/W@/<G]P#$_'O ^K<J[WO &T]#GU;*"^1(
M@K3;8,O;Z]$;[)1[0'C.7]N0_*47'2?PBWM &^OO)H'Y\U +BSC[IM7HR_<I
M$[=7L?_>$]Q6I0<_0"('R[\F#3&@G'7W76EZN/^]]:*!A>(>,+-,E.'0>X=
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M4<*#( V@^AI$:@5'.21(^4-)0@0E.$PE2>S>Z[WCS>\]7P'4$3_;4N@_2'4
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M,&%/8+/'#\C. ,L2!PYFTDPMIYJ8B<HE:&O @3F')946H)VOUBK0,0OL[5H
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M3Y,8(>B)%$.4<"5KGF3J/TKN$L]3VH9LNM)/"]]*'R=J>_^*-[A_T(>?U=]
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MZ!OU2B#WXM=2R.WJ?2;%,L4T]CR40!8QM4Y+HA325.C_4!1%*8XH\JS6:5>
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M%M9%"PXVL2Y_>J1$I'/Q\G>/^H/EW7[]\F%;?9LQT_5+= 43B2.(>*";P;(
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M4U<NN:0QBK&$D5H(0N1S JD0"?12REE(J2>PD?=B,>;<A&.'&K2P%V#_>!Q
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M%P]55'$=9;QO#>W["4N(6M?$'HLA0KZ$:2 I]&(>BCC"D0RM5IB&X\Y-$IJ
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MQ:2 6&?"4AGSB$M.*3(J@M WR.P<H5TKVQW0ILG @*:^SPGM]TY<T32RYS"
MH6&=?\]0<%T7X.<WG;XC\!FS3G8'/O?9@<GOI!2?R$8TATV)AZ7G,0(IQ@RB
M6*VE2!0+*)+8][B,66IW<'=X^[D]V!H=T/ L$Z8/.3/;'1K.Q-A>?TO"""=P
MIXUVF[E\.,2TN<DGS3O*/C[]J2$%/S4'KY5WD&UNV@J5S9>0<<$)]5(8AHF
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M4>&WS*:X1+^9)KDD=60]>O^,R;?]K-EG7QA2X38CX]*@TV9I&%)PE+EA>MW
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MD(>Z;SQ1_TF%\EIQ1"6/<!IZ@ME%UAF//;_0.D?M>.QGP4SS1F%V9*W;4=J
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M$VUW7T NT#[W520&][PO7SW=_O=5#X[VPJ]_VB\$,]U8/JG>%DW+BE)QD5.
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M8-7AQ8NG*Q"\9O]1+=_5#WN65]!R8SHURM<_]W_]WZ7<Z!M]__E!_M#>FZH
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MY(.YD=\[P,LN*Z8A#=/TK1N/<&IKHX.YD;'761PQR)S%<8ZEGB! 8P8!A(0
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MM("T0CC0VM )H\$EH-V=IEOI.7EVM*!SN_)V 8RWZT=:KA9$,2P8*@#5*S0
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MD).RF)W[SUG)\BK_+B$'%;PWZQ]R1<V?CT_+TN2C+/*"Q4('\""&K#!]D@J
M45* (H.8IC%*)7)::EX;<&Z+QQ.9QL[DZ&"S>P^00<CM&"8DD"-SS$T8>K7T
ML $F>!./P4$G;]MA \&Y1AU6UWE&P:;=T1?YU&[["[V4^B*WY4:*M[M-DP=7
MKD4MD%PM6"Z3E.4%X++( >18 E9(J+'G!6<JP7&6>YR<N-@PTV.3@_4F8-7O
M@D<=NE;&K^A551M^^95]^[Q8QJ"A89Y(,[U&L6=WO;1L+8\:TUMYWKNHL3Y@
M#.F!6=@(T<6 :>,_#VA.HCN?>]Q =.^K:B=%LE"<BI04,8 8ZQ54QA1@&4U!
MFL1Y)F%!L'+;K.O=?&ZKI3=],BIK&TVAG0[&Q([7O1I, EQE]MHVLE$DV:[;
MGS;)B2N3$>=!7QW:#O3D@>$D]-/8%9A7GCD;GC>Z :;GA6>NG7WNGW\F4/;'
M1664A8F94"P4$!@G #+( 98Q!"E-H?8TC3,"W?HIV@_NL6X9F1>.,CV>SBJ8
MW9CJ<7DF[!@A,+HOE^ Q+!TU8F['5<#&3>NX//S+9G1<A>5J,L?U.WCDBI^I
M:GVS7E6EJ#>9UJOZ"+21/F@ZTW8=$BI#I>8@I?EQOXG-O6E;6RU22D@"]90I
M0O2JIQ ,, P30 O]+58Y3#.<6:>/CV?G_-9./;?J5=/]:FL6HS5':KKL-[J*
M:.V#0SKRB!,^S+ SFL:1Z?B\0,'QO/8<O>L:>^]]C3IG][_J^QO=SVC.';+2
MYS'W$R6JO_!WP"V;??R9&4QP'W'XZ7+>Q\?P* U^@N'<5A/59KOXC?Y5/NX>
MN[8G*N%"&DEO#!& *$4 ,].D(&99S"7-J+)L2WER[_F=0K?FV9'R*5;#K\Z;
M_!_Y9=?:%; QR45OAP('?5$O:-#_>AXPG-YU$FZXZ$SW-%_^@*_DX0_]=EMO
M?GZA?_ZF0_I-29?51[G]I+[(2FY^R&I!5,QCGE( 3>T^1'$!6)HPD",I(,GR
MF"16[<WMAYS;&EL;&CUVEKK*&E[%UVZG(2QJ(S_E>V/O(H/=WMZ[2%ML-G,Z
MFT.J&=KB$UC*\.JP$^L8VL)P*F)H?:4OU=2[^6_VF_F?5*^RW1PB=\E2J4)<
MD9B#)%<2P$)*0$D6:]K)BCC!-(44>BFL6AHPTQ/<QOXZ=:W-5PMX'&(_.P0A
MQ+B @#(E ,Q@## LC!(N%80J7L 4N;T/0D[+A*^%]Z?'4R\Y+[;OD1'0'OUU
MT@!],-J\0_KB)'6N4/".Y,Y8!7ZUV(X^\1O&$933%XWK#6ZMGKGG?+.3XD-)
M6;FLZQGKG/Y#A42A@TP99YK2,J-AR'(=>Z:L "DF"D%&1)H*O\J8:T//C=..
MJEX:VSM2\RYBN0J_Y>G[**".?3;?P[,U.^K9/5%UB2U@(U6.7!W^A:I";&&Y
M7/%A?0?/FFFSQ6;:&]1:FY#Q5+*8@H0CJ)=;G &"(-*DQ0F/$4>,. EV']U]
M;D14&]>VUO"0.3U&SHY@O/$8F4/LH7"O&S[G<MBJX*,1IJWY/>?<247OV0]Y
M'(T?9T%W^^=->N W#:EL]VX)%T62Z*")0!H#*'*BPR<BC,Q!09B(8YI:;:>Y
M##JWA_N_)#6%\=H^AV-)6X MSI5'@&UD#C@IANB,OFL3BZ/:;A_=2UM<'<YN
M1\!WHH-82YP#G:0ZXC1X+&I[K^G..!V].SJP=+W6;WWUKER56UF+?YVH@_6Z
MS+7QZ$>]JOOVIUS^D+^M5]OOU2+%2::77<B(7:9&!)\"PGBN%V0Y5 KF$ ON
MLB"[S9RYD;S^BF9NB[8;I\-NE3<=R"._$AI'6M7"Y^*&/;WYOE=W4?WJ_;0*
MN$L6!M"@B\X;39ITE1H&ON?+VD!W]:/5CW)K^LM_WJQ_E$**US]_KXP9VB:Z
MXN7JX9YORQ]UM'S/-,53OEVD*B&4\PSDB#'-IXD 5"@.>)H)F,"4Q2QU$R9P
M-V)^:2)[8R.ZM_8_W3C58R[L>'1<?$?F3G,,;:R/.O,C]C-Z93R(RM7?H@/N
M!R]T[-WZ$3#^]@<Q*%]ZF#$I1_K#])P7;[C3#45]W]=+?475Y- M,IYGD+("
MQ'5]']53@@5F@$B82PA9@B1>;-=;NK0\;3@9PFDIN!]HO,?MFQFCJ>]K[?P?
M_P].$_2_VB1UC\J]8TA)RG#!% 5IQO1R/$X8H$8P5RHE$Y05$LIX\=24:IHN
M*%, ^WRX\>!M;+N+F'PH5W43(D:7[A(39W!-8B5AC!A@F="OY;0@@"19 I L
MBAQE1''(6EQ_65E6I(5 M1ML?$Q;L;=0@%H>==T$T=A'6CWC_F>7;7Z_W6Y*
MMFN4F+?KZ#/=!*T;NXQ(^)K4XV&FKTP]Z^;9^M3SG_1L,-M\P[]^EW+[I4E?
M>5M6?+FN=IO>XI +EF59JGE FFS0I-#<D"L",@[S-):)9G6WKK%6P\YM;Z.U
M.JK-CEJ[HY[A-JO%6Z;!CD?"@SLRMP3!U;WSJA-,8=NIV@T];8]4)SA.&I^Z
M7>U'5HUB1,V!C?1&4ZF_@)D0#"<<Y#D5 ,HDTTMKPH!,-67)% DA+8M(KHPT
MO[V"OHC&7=0H^G1B&J_*5>2E\7,)9SOZ"8#=R'S3@O:U :TQ\BZXE,85'((2
MRJ6Q)F60*PX_IXQK'_>4W="PUA5MIU]?0E"&,26@H"+7-)%*'2Y*!GBL8*9R
M6%!FU:KL^E!S6[CL+0U,% -@VW%%& A'IHL#>D>,$9PPKH,15A7C\G#3JF!<
M=?M$]>+Z%;[%*GPC:27?RN;/O6IS]9G^-$'N_4J<)O\M]%HC00)RD&0) 5#I
MP CSQ&3L"20H2Y'BPFW]X6?(_)8GG=714V-V+3!S6X:QYQS9\='XN(_,59T#
MT:O.A;_U-.ZKZ'-O'LYD)H>LHK@%R< E%5ZF3%Q?<0M<I\46-]W-<ROI5&W@
MB^3KAU7Y+RG>"[G:EJJDAP/I1K#(2"OV;-"_VSU*\6:W,3N);6^^C7RBI6A/
MK;L&?LWO%BB."XQR!%*9:NZ5* 4X41E0*<YRHB1"J=.B[D6\F.%ZT=BZ9^B>
M:#YUZ$O[LM\,R\VRN<_WV'MO9S5H#A!$?0RZ-JD="O7WHE_8T@)Q%[50M!?<
M1=TWJH6CUX3U2J-C]VV]EYS0L+N$+^+)M)N.+SE9)WN8+VJ,1_%!'?F\-OK$
MIPH]?Y?55HJNJV)&("FP?C\FIH9(TA10LP="<P*Q3%@62ZNNBDZCSNVE=EDA
MZRYJ['9(G[>&?O@M-!J@8Y\&&Y,!JU7/!P#U*4RP1M:A,F$,A"<J3;!$.E!I
M@BM0@[4)UC>;KCC!U;^CZ@3GB_WBJ('FY8<C-<<C8:=[SHAG.KOK]>+S;/>J
M=T0\R@FQ%VI!EX!N%DRZ=/,"Y_F2R^\F_NVK#O(3K?B$20/MZHWN'\T62;)0
M68'2(E6 9B;9A:D$D(0EI@>UP%A0R9%CNSS;H6>X@5L;%M6QFY$9YD=B+,+4
MS95[+]Q[6UG-AQW%C8'QR.Q6EQT>;+Z+]E8?%2,VAH=M>N6"5/#F5U:#3]X$
MRP62<\VPG*[WB/;N=]OU^]7_D5S/[C?)OZ_6R_6#$7K?Z@>STP@M.$%*" P2
MRC"  L4 <YZ A$@)>8)C+JV*$ZU'G%N49VR..J.C[=[JZ*DUVR$4L4+<(L +
MC>/(M'0,X<'@J+/8)ZRSPM(AI N-Z43AW%5L P5R+O ,!G%6-YHN@'/QZRAX
M<[KPMHX_[]:;0^LP(W.VSW-:(%RHC*4"J!P;&1"2 8H*! 031*I<95)BOTX_
MEP>U>@HF[?!SN2FA7V.? < 94H2G4("$F9RO#*> 0"7UZQ$J_3[DO"B@4\Y7
M&+BG/,OK^OZ8Y?MF.N3M5NUA\1SYQ7@$Y?&7N)]2&KYOTG5T1NF7-##LB_1)
MN@[#I?Y(%E?Z;BHTF6AO]/_*;=6=[?0SCW *\UC$FG@0KM-.C0B4$"#.BXSS
M+*>02K>NV->&G!L%=19K^ODA5SO7C"\+C&VW"$(B-_KF0 M::VWOR'R4A"U[
M< +O!UP==N*= %L83O< K*\,552^/P5 ,".8TQP0%F< 4H( H2D&"M,80E'(
MC#E6P%P>;'Z;E'U;CTO,'64S!A!611$3<WHN!2,:81D#EF,!*"X2PAGC&6+.
MG7EOQG<2<>"CRM^VO]PK(57)R^W?HE=;^==V1Y<^?<3/0VU'YF$ '/N<W+YJ
M>I03K.L@C5Q(_3)G4]?=OEY8'4H)Y/RA<?==CZEBA<HP2-,8:5K1RT3&TP+D
M$.,$(:F06TW2\'"SHY9><D.[5(_N-QO]$=D<?7S4\VT$>[JT0=_ZZBNS8,DX
MP; =FW5&@-6=>JS0"DL_PT-.2T%6[I_0D-U50:GH\,5X_?/PD?9[4V>WO*/E
MYN]TN9-U<N.3N:KZ4E;_?+>1LA/I_$*W\K=R95J4+:BII<RS'.2JX "FL  T
M5P(065 8<PPQ4@%(+;CA<Z-'8RI01N"W;(V--MK:N^BQL3<(!X:?_IO8]$4G
M=4)>/L[E.WAM).G.\K=Q_2XRSD>U]U'/_;O( ! 9!/;2Q=&7^JORVY6O2BA>
M'VW>IGA#A#=^#N^:T:;$\JTUWOC^"6"'C(QW^AEMLC(6*L$,BRP!@E(*8($Y
MP%DA0<HQ30N94I(ZUN]>&FI^>R?W#P^;^M O>MJ4*UX^T:5[&M=95 7+DC1-
M%9!Z!6#$77- "YR"--<H(X(PR6.W?>_;,9WBK=W('B[7=.6G'W<14-M-[MMA
M&GUK^YG<OK%RE#2W(2""I[6='6SR-+8AE\^EK0U^WE=&H:'N?>](QK*<R0P4
MV,CF"R.6+W($DIRK-,Z* D+NU=GS:!B//(=I^G>VZS%YI5&A%91V'."#S%3Z
M!"T:([1M/.MS8"6!XS$FE@@XZ^!I[?_YCX58,_779+\H)8ULLOPL]7=CM:4/
M<J$$PGFL4I"P3  (=>#/B,CU0BI)B.#ZRY$X!?Y.H\]M'; WL0[:([HUJK(F
M5Z01L[UE47!M'GQ6"@'1G7KY\"SD/0!_,'^L984E:B.N-:Y9\((+$$MPAE<E
MMC?QJ9^F2UG5VRR/I?[;=KWJNEY!S.($YQC F.8 JI0"K! !G%.9<*$@2JRZ
M70\/,S?&J@UM]YWVIKJ4[E[$<YB0PJ$T]@;>.8"\BIPO(N52U1P"L:G*F/V0
M<ZQ>O@;(<+GRQ:LGK$^^YL%Q0?+53[N1HI#EXHTY^MY(^F8MY$*OVB36\1I(
M*#9I11(!PA(&TC3/*,LU$Y+,A@:?WWANQ/>F3LO0QD7&.KOG^ 2L88Z[!8*1
M6<W2>^MG\9*K9Q9!E>3_\;#^\?_I2YKUC_Y+O>RI'\N3&TWR(%XROWOT+O[>
M+\+Z(K>T7$GQ"]V8)A[5/=>$O&L4M)L<JT5>MS/1SYW^P[0=-"WK,:4@(10*
M+ DF.'/;G[X^Z/QVJCN;(]D:';VB![.C+B'-+:ZR0-\NF J+Z,A/_![*7_90
M]NR-WEZ#TCEHLD<G:*1D,>RDX9$]#,]C(H<K/0*A,\I7;]:KJM27U__XMJ&K
MJLEN?KU>[:I&\V0A:,P9CU,-.U< BC0#)($"",3RC!,L2&JU/+C!AMFM)$Q:
M%>_;'6W:?A;;=50G73%C?41K\QMA!?8S^M\:@G_]?'2)MCPGS2(4&W\J1N:W
M\Z*&1SY$/2?NHMJ-5E)I_"EPB/'&GXJ) L!QIL0M/KP-S,'@T?/6TT66M_E^
M%';>>"N_9?('/:"4GY[J,58/'XRL\3>Y>33%?*NV"(9S@;F.46$J$QVM,@)(
MEA8@45F,<@0ARYU.'ZX/.;>WC['.G# LC:F.5786 -NMA,/"-O*;HC'V+MJ;
M&]7VWD4=E)W-X=;"]O@$70M;##OI6M@>AN=K88<K/=;"YDX?UG3UCG)3MO>S
MW9<EBA/)$ ,$DA3 HL" Y44.Z@-/E><,*GMAG?-CS))-C)E19Z?#TN@"C!:K
MS]O!&9DS3G'Q.0*X )##VO!VH"9:^SE\D=P6=,,(#"[8+EPZW8)LV/:C!=>5
MC_KN.U;;3<FW;1>=WU?EMOKR]?=.,3K&--:0@4+%.8!89 !#%(,\2Q%!J1"D
MD*Y;C@/CS7"W\>OOC@NH84 Q3%!>( GRQ/2IR+(,$"YBC:HP)RPISV7ALC@-
M!N<DA2Q[8QNQF6AGS T)K^TF;2#01M^?W>-5&QK5ED:OS)?R;P%/39UP";PS
M.S3BQ)NR%LZ?[L?:7.2K\T"W==G$)S50)<]X*BF4 A2L4'I!FFN&3J4$*DN0
MDDHE,7%2MK(:=6[$LC?:A&IGB^V]*X:M)L&.=H)#.S+]!$'50ZO  :7 L@4V
M(T^L8.  QJF8@<O%GB3%OTNQ6\I/ZK1'BA06'5*^&?F+;_*O[>NED8N#5.$<
M%QG@G%$ 8:+71SG"0%%%>,P$S HGE:S ]LV.^%KWS!-ZIEF3_JMEJR9'5@P\
MZY;\^7)S.3;3AIK&Z(_:Q\@X&=5>AF3F<? /R^&!;9R6[<<!^.2],-(PM_6+
MK$>L2K,%]4'_X+U^=56+@A0X)0P"(H@$,$<4,);D(,$()@0I#MW"Y:'!YL;M
M^Z/2GK'1'\;<J+;7<24[B+,= 8=";ZIC?V?@O+L,#B$R2C/ LP.^2,^^(=<O
MM=8;O.8&59N#N.OGS?IA0Q_O_RJK!>6,*68DM90J $1Y"JBHJ].*/,DH3!6W
MRD^Z/M3<**2VM"]1W-JJ S=MK8]XUGF$+==O07 ;>RGF"9F?@,H@&N$E3\X/
M-[U(R:#;9V5%AJ\(US3SNEC)Y\Z.NGQS(5!",LD(4((G +)<!ZPR1T H)!A,
M<2XYOK6GIJM1<Z.ASKJVY#5Z5:ZBQ_5J^[VR3-,..F,69\\O, ]3T!IX/:PY
M]7I0<VH_BY\="I?#/FLWM_H<<P8G[00ZR4P&:1KJ"[E/3U'GL5Z\Y:@O.C8=
M2;WO[;<"__WKMXVDU6[S\ZODNTV]8= >R\9)3#EE"B"8FI1,G "&: S2#",&
M,P19XJ0!=7FHN;WZ?O^/K_\1=<9&U=Y:MZ7W +1V2^\P@(W\COK]ZP&I@YDC
MG'-?1R/HTGM@N$F7WM?=?K[TMKC"5QJ*KQ_E_H!J?Y#*8T55$@O 66XDHA@$
MF"@*,DF*3!0D)\KI-/O".'-CB<;,Z'#@ZGM<?0E7.Y8(@-;(%.$#E(>$U" ,
M@:6DSH\UL:34H,.GTE+#'W=7&[C7]Q&U]MR2/BR@B*7(: ZRF$( B= D$&<4
ML)01G.54Y)E5CXV3.\_ML=\;%QGK[/4&CN$:?K9O F'DI]G2?R?%@;.^>DD.
M'-]I,LV!LP[T10?.?\"S5^5&FM+35B2NZU74' $NH")(JB(&C.OW,*1" 4HS
M_5C"(L60I[S(\&)K9$[M7L9#@SD]FOLAQ_MJ-NJM3XW%G69CTWQK73??HK79
MCNT2A]"V>T6'PG#D)[LU<]]9XM"T['X8-_?>B!: A.V*.#3@M/T0+5P_Z81H
M<\UM!_F]>M#3_ *3.6"18?!FMS'-D)I/ZKO(\H>YLEK$:2&+.$M!8C2D(::I
MYB11 )J(O"B$(DQX)02,:?3LEAV<&W7?*MKL;;R+5O)R;>/+3;<=*<YM$D<F
MU_,U]&?RQNI4,,O,L;NH];R]H+YAYWSXA(DIIFJ4Q(M1#7^1!(XIIN)2(L@D
M8WN<#FN*E$M36"S%L^/G^X>-K,/>=O\U13I*C6,%8E/+I5](!<")PB!/2$&+
M6(A4V(O?6 \[PU=*9WA4U1D4O1;CM+/=X<C0?@(LCG-'@77LV-@*49^*8WMH
M'<Y;1X%XHA/5&[^\;J>DSD -GH/:WVVZDTYG#X_.,MVO#J%H_V:]^B$WVU*_
M-[[(1UH:<;6W956OD^\?U_HW_ZJ_A,U!:;* $.'<%-PIJ22 '"- &5.:]9.4
M9RIF%!)_A7M':^;V,C@19N_Y8Y:5K4=1YU+4]\DINR3,9-H%&9--T<@OEE%G
MYT89?4]41Y35=[7H!67V/<$;EMWWO:GO=O2:2RFJ=]K5NF3Q4],,[I>_Y(:7
ME10+21F"&<0 <X0!)#$'#*L"("PY-:G<F;Z=DR#%U3%=GMUI1"D^RFWTU)H=
MF:]%*Z>P;BR/9&>ZZ_;T-?1M]Z@#(CKZ1G4?QD9EH34W^N4JC!Z[U9;0!-ZR
MOC;JQ/O6EB"<;E[;7NB;E6+4HU?E5GXH?TCQ7D<>JX=ROPOQRU]\N1.: ']=
MK\6?Y7*Y2$B<21%G@"B4 BAR!7"<)T!QF10DQD)"I\H25P/FMO*[__;E*]"@
MI-&K]Y^__ _Z^/2_WCHJ<3O/@1TGC8GLR!1U,!TLC>W1P?AN<_?5WOZH<R"@
M:K<O=H$391R-F#B#Q@^BT]0:S_OX$=Z[RT.]_OD;_3_KS9LEK:JZQJL04@>V
MDFF&@PG0\:\$-,^IV>T419'3 A/APG4.8\^-YAK3P8<+3R/[&=7V1[4#7K5V
M+A-C1X CP3TR]P5%VIGX/# +RGDNXT]*=Q[ /&<ZGUO<DFO\C?[5)CV\EBO-
ML=L%)P5+%(T!31 %,!%"<UE1 !%3IBB"5##JGFM\,L[<R*M-H=W2OWQ;T9Z'
MTW8==C-(HR^W:GRTB?OLI5>ME4'75(,XC)!C?#K6"^087W3X?([QY8_[44&7
M^7(X)?XHM^WY\2++!6&DR(#(!#-\8%1'D *"*D4I5C3ERFUK:6BX^>TJ74H+
MJC-&>"NI[97W. A[G&%6Y$Q_<7F: T@*"4A&<I 5T/2/,=75Q"7+-!3HTV69
MTB#Y6(,@VY%S*.C&/QIO\/K2PXNJK<DN72[7?U)-2)$RJ\*-%.4V^K"NJGUZ
M4S@*MT$K*(\/#C@IF=NX_IS1K:ZY42FUD38T1;#KE?YG$Q^Q.%,BBS' .2F,
M0H..69DB(!:)4(RH-(.)ET+JN='FMMIKA3H/1OI)OPP";$<NP6 ;F5V<$?-7
M.!U"8AQET[,COHRBZ9#S%Y5,!R_RW .CY>;O=+F3YEASN:YV^LNTKYM4.:%0
MI3&(BTP F',=+5*5 I(DBC$A4JF<\CR&!IL;=1A;H]K8J&>M=VGJ(,Z6>UB!
MT!M[T\H;./<=*@M$PFY)#0TX[1Z4A>LGFTXVUWB&EG5<U*VW<YPSF)@^V9+I
MH*9(8L ($2"A:4R0Q 5"PBFHZ=]]GE$,;\L'O +$(_ L@Q5?2,:.3MKRB?#Q
MQCF'PP881R-,&U&<<^XDA#C[(<_\S[*B#P\;^5"G+QDIW!]RM9.UM.VB@!P6
M<9H!F!%HVMY00$2*S6L_8RR1!91.6\-#@\WMM7]L:Z-(75O;:DL[OO8'<;9[
MTD.A-_*#[P^<>]:D!2)ADR*'!IPVY]'"]9.41IMK_&CD'[)\^+Z5XOZ'W- '
M^7%G4M,_J3IUO?JTVU9;NA)USN1R9YIT[]<=M>;M?OT;%U@@F>GH N=ZO:!0
M#I@B,5"8RHQG(H;2*<X(8];<J*DQ/]H92;MR%7$=!N[J9IUFE[ILSFV>Y*8I
MXOA/-YX*-)%VC#;]](S,?9U#4>M1U+A4-XYI)JWG55VJNC(][!JF'",P"HMP
M4"X-9-JDK!L6SN?\'/CNOFD"^J6@OU0_/TK-QX1)##$#J3![QFFA (6XEAD0
M69KD69$ZG@7V;S^_L[_.NE)6'D=/1]!!D3..4@T=E0K 7&+]4B,<Y$0'O3%D
MD.=.JC&^P$T7^98'\&[ S>[-X8O&R/R_-^LN^CCP[?%(DSAU-W!N1&^ B1,B
M3ET[S8(X\QEW>;5?5MMR^_-=N6RI=9')+%%8YJ! 6"\W]7,)""MB@+.$()A1
MCI2R55A[?O.Y+1H;^R)C8+LJL1=:.P%N^"&]%8ZQ3[;LD7"27+ODLI?JVLG-
M)A->N^1&7WOMXF=N:%IR(MS<5+7<K\1[;;,>\(?\K.>Q^KQ>EOSGHI DUL^J
M! *:]ZM@ C!2I$!F-(9)G&2L2-R6)AY6S&\%<TD6W:/'B>.$V+VX1P9Y9.HX
M*R;?TYO_H[%XI+YS_M"%;Z'B:,?TO57\@#K;=,7S5C>W.WY7KNB*EW3Y>=TT
MB=IOKY",0:I$ G1L ?7"A>0 YTD,<F2:'2=9IMP*[FP&G=N"YJ@M[][JJ#,[
M1*OCRQ-@27:!81V;W6Y'])8VQU<A&JO+\>6!7ZK)\54H!GH<7[\VF*[EF_7*
M[#LW^@A5*8Q>3=W+KM$F^_E1.]X>9LN,L)BE&#!FEFLR1H 6,@8RACG5B[4\
M(^A&P4I[:^9&90?+HV5G[<TJE Z38\=FDT$^,LV=UXWLS<&1+W=[E4BSJ;/W
M9U0I2'=8Q]9X=+#HI<4;W<&S4&7TN*D?RWY8KQZ^R<VCD9_95^2PG,2)47<1
MIB(G(YI%BR(''&=4ID3*(G$J.3XSQNP8L<VB>C+2.DT6P5);#?38CY'0=GML
MSY^#UH[Y;@1L9#[[L ?F;0U,A]UO='NMRY(S60T@$92"SHTS*;$,./J<+H8^
MZD8"U69KQ%W$CF\_;;[*S8^2RT9T@"'%&8>@P'$&(#&;786 ()6%(C0CBE*K
M?D"7!IC;X]_:6)?<M68Z%6Q<!'+X>0\!S\@/NP<RU@_Y-?>'GG!];>_IUO]Z
M_F1?O/DDC_4UU[IG^NKGO 7=GN1F^]-L$VWO5\+4;SR9<.V;OM_;M1&46Q"*
M,<R-D!M#!$":I0 +F0.!4L20X*EPJ\^R&'-NCWW])FM$+KX=25Q$?S0&.V[E
MV,!NMP((#.84*P(_''VDW&R1"2WF=G7<J>7<;($X(^AF?>F-U5VO?[ZF2U,9
M_/6[E-M?-^O=DXYKVG1OA1(:(PAR$:< HI@ R@76-)1G M%,8>G4GM1FT+E1
MT*%HZ<[(ZK1V1[7A46>Y7PJXU1S8T5%H9$?FHS"@^E>%6: T3G78T, O4R5F
M <7%:C&;:WVS<HS0R49'^_6V2KV;_<:4R6]^OED+N<C33."88*!4G#?MC@BE
M E!,<ZQ4SC"SBG\LQYL;*;49*T<VWS7=/R.C[]!8'AG379-ZAG$?9J,1T!R9
MB$( Z9$39 7/#6E"P_>?.'/(RMG39"*[RWSIY>LC72Z[?=V%DIB)1%"@(ZU"
MTXF, <%,@AA3'JM<9819;:A>N/],Z:.V,>J,="6*8P1MB<$;EVF(P!(2CT?^
MK.,W/.+']YOXD3[KS.DC?/YCGFDP_+L4NZ7\I+JF5U<T8?MJB2;]JLZ^6B@L
M,EXP!A*1$@ 3CG1(HW*@2)+&3"80QT['SF',FAM!=%Z98Y9]@SP+O>5CW5''
M-)LP$VP7+TT_;2/S5Y@9:T.ND=(5@V(>-O<GC&G39@<%A?,D?RCLW;V[<"NY
MT6/730T^T\VG3;T0%'7T^5ENZFS,A1*02\WJ.OHK$KUZ8YK38Y&"G"-LE!)5
M 9G;1KG-L'/C[+W53=.3N^B);J(?M=K.JUTE#@7 CHT'+"?!=ML\-+2C'Z]U
MJ'YM4-4VF\BPL;I5,])V-^6\0=MW.P 5NI&WS=!3M_1V@.-,<V^7JSWZHKY9
M+_7?ZV#UQZ$A7]7VBZ1I7(A$(9 5F28H@A@@A4Q 6F N2$QH:M><^_I0<R.E
M5E&BBG;Z[;&)>-_V0PM)RY6B!=*(I2@1B(.\@!+ %)OB#)R"5$A:I 7/DI3;
M%0&%Q7J:6I\C<Z/[\/ .DWQ8R$8F]DM8^72.'0;-H5ML,/ FZA#K#Z);<U@K
M7 8;P@[?8;HFL%:>'#5^M;O";X']3#:TS8"(52%CS H D21Z/1TK0&)*3&M!
M%F>Q(E0Z[9&<'65N;ZKG\K:>&2;G$;5;'-^,T]A[I,X0.2][!R$(NLH]/]*D
MB]I!9Y^O88<_[/?X?]I^EYN#[GBUX+& J="+)DC-.0@E.I+.8@IRFJ4)+6"1
MYT[Z?L\'F-M#7]O7:R_@]JR?P&?WF-\"RLA/>(-'S[9P3_8EKX,^U">#3/H\
M7W+Q^:-\\7.^!<(ZJ'U?53LIWNXVY>JAZ3G<J$2=KU=>Q'$2%XD.C%0F4@ E
M2@'EF &A7_FF@D0AG+K5"SO;,#<N,-;764AK913T'M>KMGOPTVYC?K.-MNM]
M!V'SH>/>PB;_^H>L:MD]_4MMV793\FVW':<#X'+;:$A%K\I5LQ-7.6[%^<RT
MY7G(N/,W]N%'(Z77V'_7*NNU?UX69^AZH[Q;;Y0LM[N0VW<WX!FXJ-G=CHEK
MG+V!.BUY]K]52)F:WE?L]<_#1]IOX/V?=-/:U-CZONT1OT@$H[&"!!"58<W)
M@@.60 8DA2E#7!&(W#0<0EHW-[;N/]M]]X[45]C/\QQ@G.QHHF4-HYO:>!I"
M&,?W*V!)UB\UL5/0^+1S&DASYT;L)U#C\;5P!CH]-X)KI^!SZR">8OOMN50C
MT2'?K*MM]>MF754+"6$A&2$Z]"X(@$110%/*=3A>8(VLP!FT.C*Z.M+<B-T4
MS49EMQ;GQDY'8?V+F-JQ:Q"D1F;*&J1]P%*;>!?51@;4TK^&0U@A_8NC3:NB
M?\WI$PG]JQ>$%-<Y"$U\TW15-4,W.X/O5_KIU$%G2U!&B\Q\/TP)$><REB:G
MV33G E E#+ "8Y#$J20BI@BQ %([7K;-C7W>T.J[Z>EZ<*9NF'F_VM;KBB9J
MC]8]S79:F7#_-_HS2N%=9 Z>0@CU^$VT'<&]T/2-3(D717QZ4]GS["YJ3S/V
MSG6+1K.1T_DWMJC/3:!/(/'C9]\,!']N M9._N>V(3R;J3T:^9M_M>U:S"K
M:/Z;LIC/&_E8[AX7<98@EL@4($6A28!1@*), BE(JM>.&4ESXMBL^]J8\\N#
MZ9MLV-GH T6BM=JQ ]M5Q'&:B%1?"T224P!AKM^N&4Q! 6&<$(P83YV*I(/B
M/<4[\SG:]>*TLSEZU5KMN-5]'7>[EUU0-$=^A=T*I'OG/%MPPG;3NSKJM!WV
M;$$XZ;IG?>&-PK\?]-NG[NBR(# F!8T)($(OYV%LRIX)%X!(@1A36<(S["7S
MNQ]B;N1RD*#]P]@8U4;Z"O@>@+0]%;L%GK%W2]V0\1?B/7%^'-G=PS O([)[
MXN9%2=W33]ZJP7)&16&OVKL?]@UMCII[=)#$DJA<K^YXDNC%'I* */TWB@LE
M".4%@4ZG^+<:-#?RZ,N,G-<8N>O)6A\>J,ZQ&SCGYKFU8Z@I9VQD/IMFLF[0
MC+D-X9'T9#R->B&MF=L@O*Q#<^-]?1OC\8VDE7PKFS_?UZ+ 1EC]'^7V^YM=
MM5T_RLU>$7B1<$PY*A3(J,FMAH@!G @&>)XBQ"07,'$J4W0<?V[D;)I=/JS*
M0XS>UMEMFI(AUXYQ;G-AQZXC(CPRF7:61Z\ZV_]F3L,[\Z,_M?U1YT!/T3QD
MASHO[ (WL7.S8>(^=UX G;;"\[N-'^>U]7Q?I,D^;U*LU'KS:-CW$UN6#VUV
M*84BD5" C%#3B@MQP& > ZX*G(HL%Y(YI9%;C3HW?GO[C-#N]%]:^TTM=N=
MM-Y[X$9Y=E-A1W3! 1Z9WKYTD.XMCGHF1P>;[Z+[Q\%-7V=><X(J*)O9C3PI
MASF!\9RYW"Z^536HG^QC3NG?K3>G:3Z')*#J?EE_%^J]O?,I0_59_^M:H[56
M33EHT!0T3YE,,Y 4>KD':48T_\$8("(+HI2D*78Z$G@1+^;&IWV%FZJ7 <C[
MF8+R+_-W:;($C06^"D13?EDLMR+G_A48>[?S6BZ_<<),N_%B(AFC%YB)D52/
MIO3DA4227F"R+FLJO80QGAD'/VBY-#<T)M*E_"IYVT/&''@=_K5@N4C2),Y
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M<8 =F<]."ICV('^I06Y,CSY?!_G&ZB4;O$8L71H<_@7KEFQ@&2Y:LKK#K5G
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M\OM@;\3[!M]%R\YD-_;RF1<[*AL9[9%Y;2\5T#/_+NK!_^88_@]7X7<FN1L
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MTDF^OUTO=*)_,Y"73_9OO[4G@Y=Z3%5RJD/E)KE +WGK_H!E/[D:"L525.2
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M/($T2?,\#2#J>&;HN<539T4=56=W:%''<W-AN3$^"L)C[YL/BSKNC9]2U'$
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M.BEI68/PG)?L+[R->D(<RWS>F%9.VY^?EZ;YZTK\HC_[9 X[%P6,82YCHP[
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M/-8L1!#F.$8D25Q613Z-F]J<;6MIM&?J0&%#KYUHQVFOU37A][>'](HS 8:
MSRMA>C5P5((- >U+0@[2QNLK.K9I[X?UMO;SXF>04Y4D<0PPQ@Q D2-0%$0!
M@?,B36(N,+5:6[^*]5,; EZ*/KR>K./ECK<;%2;;G8&'C4 RCRT$1W48[;XU
MKZKV:-U[DU5]O.S!:P?HA>^<D"J0]D8,W2^IUG?*U+G>C=*R^K9<B!F7$D.5
M4@ 13 &$3  6<PDRS(E(8(XX=M1<.=_8%/=*JKH\5D47[OJ/9S&-<9J16!
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M>NT70;FDO7[^ :/JJ%_TXZ4F^N4;ALWL/VMV,.1@$OJWY_XP+Q236 )4L!1
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M7POC^<3]JY_L0ZGQ+:WFU;?'E:3BKOQWNJKWXHS8?3*#,>.<*0945D@C2L\
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M9X])#L&[Q6^*1#ASQTVP" [[47I&^!8'B@OOCDQ::<.9RI0J)&: 08P E.8
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M%%N)75YJ:&I4=B!_'6V-=<S#O@BO!<EY BTPV8V$EP/[><)M)!8<C)\;+UJ
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M9V0\:/[B_X#, 3*_-<8LVAVWKI@]$$>UQ!QNO;(*]W<3ISXC!18L(1AD"N4
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MF-V6Q8YSE$M((9!,KPHASS @*BT R2E3:2HR_8+:1O(?/'EJ+V)MG$VYZPN
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M\DPOTX@$E+,<$,ZE(GE*X\*I.FWWX*FQ;6>7&R=L84JSA,100*!83/34&0I
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MLW_/N/R5OD.QM"DF2<*LPT"!4HP* K<<1"ZL1).8+>H@_3^R\'9(Z#B!.81
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MI)0NXH&'^'FU6IT2+X)H3D4Q$(5G4#K9VAS,@$DI\NJ4,-G&J7N<IK$S:R.
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M8901NLVD[#V('1=NA^'C8; U4U47>'RQ6&V._XLQ2->2BUI&I3A""IOB.VG
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M C.+FH789J#GTW1U\OYC(!0-IX(.G.X--[\MYHO;>^/R]&72)YE1 .V$^I#
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ML]HS\W\O9M5=^3-.YU4,;^;O<SQ=G@\764Y7U:>BO\X_GLOE:M:6)X>&.1;
MBIA(#;R %]*"P1*D11;(]3DJW@_EJ(.RK2,B<\N-<528=+Q=-G?MBR5% /,7
MFQGD\>S#$N>KV3E TG^<KM;GC0R^3EP1WLKD@2=?NRB54AM4*# J<<$\:I[:
M^!X#$-]!&5E_FZ"5\ONI)GJ(.Y(F<7>YWZ\-P81BF"0D';OH*7Q6H39@P9A!
M:Z8EDH!#;G-1O@N5'92OC0?D9NKLP$(_(-6KPT;[9+2- @P+)#.L#:-<"* 3
M4ZYV%9.N63/VQXCJY)'*$9SKH33S70VDNY4/PM6G7V>+/UIGO^XO<Z1\US?X
M&S[#=;7B]7L\[FS,A$W-E*Y3O3Q@\!F"2Z9DHV)JY%P]1=4 N:OZF6^7BR]3
MDM_SL]])"Z_F5T_"GI'M_G+N:E_*066?'-.ECIU%4,4H0&X$.==1JBB,-*I-
M6F]W6KO)@AV&I@=27BV5UD5>['9:+S)ABD<'4F:LHX*(_"#()6%9YZ@8:U5^
MTE%2M;76G\RK[J* +O!S'1NM/BS>Y;B8Q^DLWV+JPV)7>;I@,-7792()"K'0
M94#4!JP2B81C.#9Z1]J"FW$#[B.C>70X=+$I+NL2\\83)X]KH^Z)9QQ]C P<
MT@FD2K: Y(I#SMQ'H3RSC68O/DS/N&9V?*3<;0ARN-*Z -_+3&O'Z89Z^GJ6
M-QJ=IYO=FB9*!FN2<9!XG3PI66UKDB34IDS(F8C:MX'B-M2-:S&[ ^;@"NT"
MIM]H'I:"=UB\ >T8'4)>D<""CJ"UP*A52"ZT:<$^0!>W9KF>[J YH!([2#S>
MYJ8^/*]%9HO3^?KM,I],3T\F*LCLB^>@:'W:93R!KV7H6A0?."=V69OJTV^2
M-FZ/D\Z!>:@J^S"8,2[/3?]MWB[XJFVH+GA;O9I_R1?JF"B;:GFM Y2N,BL=
M^* M./J!S,9FUNBI]W[TCON*NS\<MU?ZH7>4 SFM87VCW. +3F=U8,"OB^5[
MK!G\\YNLR[NM298H+<\.7*P%X]D4"#D4\%&+;(1+J=&KE=WH'/=)>'=@;JCD
M+D!\HW*&^'E32*XDR?79VQG.U[_\Y^ETT\ITH@H*7QSYYJ(V'/2;=O/(0$=3
M4*:H#;:Y7=^.OG'?IW<'V@9*[0*L=\L27LT?FE_P>HIA.INNSR9HB#-3,].<
MT6XT4@'Y\"3(6+0NJN@BVKB^.Q(Z[E/Y[N#;4LUCC^5Z>;'F.Q+W6SP[=WV8
M<-$@)R1AL'1J*$M.4(F06!*&*^VMNMN^].%I7 ]]^KC/3;L!US#2[Z<X;OL.
M='4> J]FWN1(VR,Y#X%K#?7AN)4^6.*XD14<LDT@9S\\1MOJMH-LU7W+?KDC
M;S0%FYC,5<C"0 G:D^AR!E^T )V4TM%B4(T*YK8B;SNP_O>Y@QI>IST9V;N\
M74GQ!7Z>KG%V)4*;/(5[(8%T/()R,D P00%+3'.5;?"Z31G*]C1NA]S_/I=4
MC;3;1>;U/F_/XGGZC22?IU\VHRV++8%%%4&KF$'QPH ^R8+,/'.F4\GQ6(;V
M/G7C7O6WPL8W(7B@FCJ-TVNB=T[_$6W=B2#:F2 FO/3D;W,Z%+R2!82A3V(J
MQI*.A;H;9(U[@3\:W/953*<X>[O,GW&:+CV0"S?YV3QMWKY<7/$ZQ1-MG0)<
M).(S> '..@W$NU3<>Z5MJ[[I^] [[OW]:,@<7)6=0O;2X+_%LVKM:Y%,C,M3
M6N\BP56W9FU$:K(K@#S6WJ2F#GZ5$8R,+IE@=<IM!MSL1^^X-_NCG]V#J;(+
M5W+[<MR)<\QJ9D+MAU5O%** D*HW[DKQ";T)H<T=Y_8TCFM-CU^HWT)U'?1!
M?H2S\X*"AP49$N?,)@.&UU>$Q2+XX&HK3FL3+TF2 (X)SB=H[:;WR5$>)PVE
MM"ZLY>6UPH?%L_B?I]-EOELS<%U-4!.YDQ0T"4YR"%E*.H&P'@PL@LA1%R.2
MT+9-H[T=">WR@=-@R%D<3XG]9#=)FC'GM!G7<5XH\ TVR9G.B"1(RV4&59T8
M9Q0#1QP+FQ3/J4W@M"NE7;Y?:@;6EFKLX-+HWF9\?KJ:SC,%@.==*ZJL+WZ2
M)B5QH[SSH+FI<Y.PMK?,%J*,=;QI<K%1B[U=J.S2!SV:+1U*?5W$\_>XNU5K
M5:>$795;^6B-C4$#A7P>5!(1G%06<E$64_9,\C:]^+:G<=RX?6Q@#J.Z/F!Y
M[TQXG+EH;/)&:I!8K]!<G;*E>:T%](FAER:'-DT;=B!RW!+[T0_T8937P5F^
MO20GB@E3^P< L4!R*RX">L?!&.%"%EY'U<9<;D_CN+7R1T9E(]7UFTOZ=3K'
M>7Q8D+X$&T0T("1+H()UX##5SE$&+0_(=6P3">U.:S>MOHZ22QI*:7WDDFX<
M!*]6JU/B+)^_#)QP+$H7M;DV\'7_UGJJ0@Y*H> NHN=.W.WI-?RA?9NF+C-$
M@^'AB3/Z -5T<"3?Y.3U8O[Q0UZ>O*X!&NU8HF:ZGLBDG)&>@K(B5*T+L"0G
MGFC7.I,CDT9@F\3Y-TGK,L]S#,@=KJC.D%=WSB8=<+F97BQ6]5&HJ2/,! .M
M1 !E&4(P)+ZH4A;.NQ)E>S/W,&U=)G&.@;T!5-4!^-[ESQ?Q_YNRR8_FM+'>
M@J$K7&C0AK:/$F3"72'?52C)E$I69=_F[?DC!'69DFD%LR&4TD?^Y8J-2O_M
MC5)BD4RK4F43::,D 6@]"4A&D0@;,:I&-NUQHKK,KS0S9@,IIZ.;O N.?ETL
M:0N=+N,G7.7Z:.CD9#%_OU[$OTUBX)R\ PXV,C+/60?PFX(2U!*]CYF'-E6W
MWZ:MRS1*:_ -I*I1K=WF3>5-U^ &<]=!T?D,NNM6=1>_]&RYQ/G'36[@U3S.
M3NL<CS>?J]9_^9J7<4J_.4'F,NIZ-8EU3D>* 8(J!7BV+@E3M!9W<X //XQM
M2.2XO0>.A-ZN--V!][B]V"<H60B8$%#6/:Q)TDX@6<K"6##%%9/;=(7;GL9Q
M^P\<V0 W4ET'>>S*5OU?O1WZ@K.\>45$$IM&,O2;:_9YNOV-&[_Y\."/J_WZ
MRU<ZJ&@3OZ-#XY=2<AUH;H30/ABP) ]0)3$(UBIP3"HN=>3!MWGQ>%P^QPW
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M'U2PRB39&$(/D=4)HO;0]V/0.5CX'2#I#@\O%R?D34XR5T*[VG36)%4[R&M
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M;LZ9S<_.NZ:LKMNF%,6L-(&!*S4;7).TCO%8?27OA! \AE8ISAU)'?=U8P=
M'4B+O<#TNGE5VCQ!7M?Y'?<WYD0&J7,R$H*JS:QBRN!XM$!,<:TY'1BE55'^
M]E2.VP#GZ.!LH;M^FN%MQ^)YF%DD_9^/&4B@D429./A0-$BF,"EC5+0-[>=V
M1&X%3O_?!YR[:ZX?;#Y6X/9ZL5H]SV6QS!_PZ\1H51M9>9"RMM*MHY <)P9U
MTHFXC4F+-C,!MR)ONPL"]B, <GAU=7!\_Y;7UUQ,"L>L0ZA=U)0"I2B>\X+8
MD"X7Q;- LUWIS\Y8NT7&=ICZ(6Z=]A=_%S,I[E^:.6>D5,5 B*S.;.,!G"H2
MZI#KI$A0LE7&9[^KRQ_CLND@-732Z^>!&S,ZR%&94"!'7D#1GX#!D6EE.IBZ
M5SPV?+V_^\TE_R&N<PY4Q*!P&OCU_IOE1YQ/_VOS.;13+H=/WB9]NX?YCWW4
M(&_NMZ)SH.?T-]>Z?N)?@3U/;V]P\*9<M(O V?7K_ZMGU=84PA=JB&%3 IL5
M!$%N3W%")Q=\9*)-FG00\@_VHK!V!7I3+EJH$!D3Q,)$( OLI*J/[!R=Y8R<
M04,:8YIE+VT;@=RG9=PBGN/CZYZ3=9AV!O2TCF/.7M9'+[,AK=KE)[8T;@]2
MW96-*QJ9Y)E!\+4,P10-+B,#$UV2/FLK&STU[<+&O8^?<CJ=;<83S.CGB^6F
M@/Q&/_<5D5.[##WRXP_TU8H(J1OPHO:X%.VX$2"4K@+-!7Q*"8PP/*)))?LV
MJ8WA>?D1;.PN^+[G-(Z+CK&?O2Q.Y_1)I*SUV6]XDC>O@@0ZKR+WP&.A:)X9
M"TXX 9H[+4M&E[:KN]SN:<L#%(Q<!#XR(A8#JF=D>%UGP9]]7.:-<.ZR=/$@
M*#)FM/$"?$%/$JI^33(*C,M""J8,#UM%S%MA;FNR1GQ'=;#F%ZW5,"*V-H-<
MGN-7G*WQLI6#85ZG0D0+%4%%IB%8=%!;TM#2%GFZ>R0_/&3GUL>.!X!&.EL,
M(L"Q5?]N03;Z@FX>1:9=$2"*.@T\$P?.Z5J=:+PQ):M2[IY6#RO^QH>.4^Y_
M)+7O*[RQE?Y_Z%0E/5Q0[J72*D4+6A0)2L4((9 T"*W,),T<WW*HUJV/':?V
M_4B*WU^ '=SW#>"+O;YZU,>3"DKP D'E6!NZ.G!6,Y#!69X-ESPT:EH^(!<C
MMZKHPTL>'1YC6\5WBS,ZQ*=Y]2['3,REWT[K]KZIEL5R-0G):J^"@&A< L69
M!(P\0>'.<!%%"?=BNL=.R6W6&[GI_FA@6+353+=@>[M<I-.X7KU?S-+$8D$K
M;(9(OP5*U^+ZH@W$9(P57#F>[6%8N[G<R,WQ^X;:WGKIM8WY^].3$UR>+<K[
MZ<?YM$PCSM?/8JR>4BVM6\RFL;Z#V>,&8<M/'N0F81\N!KI1N+_,=1HU\9*S
MM:!"KND%E2&@]X 9BQ7&!HEMO*+':3HX]_^4?#^02)_/ZJQBZYECB9/G4;BN
M+K4'BHIHXY54)P9)EF.;[AC;T3?N:3H08NXEWH=73;\7GMMM^/;F:PPS-I8Y
M,\I[2>=:+2 +H))G@(4I<-)::[(U3C1JL-O,G#W'U73UIMQ9X.S\S^L](V5T
M(M@ $NN8TD"A/0J!()7-68>DF#1-.-^.OF[-V2Z(N6O.&JBFBTK96[>R=[E!
M9X1.*4(R0=4).[YVL?7DOVH>"GFK5NDF0'N*JG$#@D;P&DP-':3R?E_E-^67
MU7IZ@NN\FFAK2M8V0A01JQ,1 *6*X 0=[DZ@2J8-B&[3,6[;DT:P.4#4'0#E
M8C+LMR;'WAWKO=D=$U8"2D[,F4W7HDS>(RH70=@83*8_N1!M;-,!5(_;C:25
M[3J6&CN [*\X76Z>]MVH6'HU)TY/3VXP)94($34'.N\+[<.@P6MI(20L@GF!
M@K=Y3KP5>>-V$6D$PN$5TX5[5J<BSNE7[CF:#K633CM@H;Y\"*9>[\D"V::D
MN8W&N*WZ$^\,L<<H&K?'1R-4#2+^+H#T.J]6.6\FJ*[N!2T!L5AF(4E3![!;
MDI7,H@Z \CRI2/]N8ZZ>(&K<3AR-X#24$CHX""^KXU\L3@+9V\U-QX61Y1%=
M"IZ#D:8^RI()0DRT51AW64KK8J.'X8_3-&[KC%8IB6%4,/:EXY\7B_3'=#8C
M%_$5*67^L?;RVDR#KI=LF\?MKQ?SCZ_KO=?YMQ].O7AA3>!THLM2!VBZ;,%E
M\B0MXRGEPAR3VU4,#430N!TQ!L;<:)KJP-2]R^0$G.9?2<8O%O.-#/\Z77]Z
M<;I:+T[R\BYWAHY_;=%0'*/J6&H6R#7(&JQ3WDD4PC=JS+8;G2,WR&AD$QOJ
MJ@LWCJ+J3"34>/HEL3I;?-X,\_Q:N\GE"^.OI2Z(FU:>PH(J*0)J+^D/I9U-
MR%KUU=Z"N)%;:#1#W;!:Z0)J#W<K/&\+MSD!(O%(IO[M#*_\CF0<$XYV$1K:
M1<K6\1U:>BA"AN2S3E8U'!"P&[$C]^%H!,766NL"FN>M:3[@U[OV7.>BN?,>
M>!:*/(M2!QAC+;LC_T*X[*-I<_8^1M'([3F:I44&D'\'GMW[_+$:ZG?Y\V+Y
M^)VNLLBB8@*XBV2Y17T_4?_@&D72/"OR6ML8M6W(VPYAW]N=PO":Z0!NO^4_
M;HAKN9C3ES'?R$_?Y8\A^0F:,] Z4:#$L@)DP56\2),$DQ';7)WN2NEV(/S>
M[A2:ZNM[+V;;O.EH6,IV\?E'+&1[B*/V96PQ<<]LR."1D**B=>#K' ;DRCEN
MZ^B%-L5<#:MRK]X.78XW?IN7EX[I--8H:3H[K2U+J\2OMX]0S.64"R16GZB:
M@H )-9ESD5'FR'1NU.=V/X*[+73;!5./-\QHI[P.SN)K-I^P\K5JX5-]T[%Z
M-;_Y.]-YG)*ANU'&+'FTQ4GBWM;Q*<E)")@$Y.**-HREV*@D<U@^NJVM&P;1
M1U?U]_W,YG8)SP'=NPY9[H@.P!;\MO<''(4RZ)0B?(?Z2K;"RZ0$!8-DC'%;
M]%UY]^X/?*L4K#ZD.UU6"S$IL414-@&SEH&J;T]<% QB"+[0AF,I-,M=;TEC
MMZ?^+LAY((/=0D7?M_T[+]1H;O=N+W-$>_<$?^WM'!=H)3<&.)>$5EL[0=.7
MX JG2#VA9]CF35X[.W>CO.=E7L7E=)-U/V]^8&/-H_,,S-3R'L48^(@<HM>H
M'"\LJC;U>D\0U:TEVP4;3]18':2$L5NK55]TTQ6,G$V!QFF(B6(JI<BL.R3R
M,X_29^NU-%LA9[O6:9?+CHN-P92X.%2B/<#@LH.71".C2V#KM".EDX8@K0 *
M@&00P2BGMDJ/; ^$T9ND[:>RNTK?0WXCJ_TOT_GTY/3D@G!#S'&E!.A<'3M!
M/ET@>8"PWA6TWF@_7,/.6TN/K/I]%+<80HJCWG)O2,>O-T@7T<2< P=GM 'E
M:VUPEG5^ G,J2>Z=V*JL8CL W%QZQ$YY0P!@;REV4>;P\"GX^JJ?3+#)!9T=
MU%8,H)#'.@,O X5D7$93M"QM\N7?(&S<+.+0OD,+;720 #]GYV+TP/SCAJ\/
M>7FR&:E\<7?J/,7TR8(-=3!M]AS0UYRGRY9;BY(U*B3\-FT]NJ=[0N%!F VF
ME^\[ W-1SHOS]&*Q6B\N^UV]Q]D1\C+;+'[4[/2.LFB?P_$<M2NURL'K5*<Y
MR7KGQR&+HI1UI4C;QD ,G\,Y[[-V+N)WN39B/1_E61;+$YS'_";,IA_/NS-L
MQD&]*7537CR[>7[VU^5T3=+^;;&>QMKI4BO)&$(VRM+^-Y'DXG7M]J9XYL78
M>Q5CCW3(&X:@;A,]NP#H=D>\$335P:%==_Z;4M_AU O+]WGYA9@X[_['A=!8
MB@<C%*NBS+7DR8&.W%GD3AC1)I_Z.$W=WB;O [N!5?!]G\M7!<!'.(8?6.N(
MI^ZW.&U_R.HDDW8) 64M*M0V0[ F0"+[E()06F*;-Q7M+DJNA'KQ1.9YGN<R
M74^R<BX429%9#O0'+QDPJ$3;5$GI&4IA[W:6';A\_S9!W9Z;NV#BT>+] X3?
MP5'X2RDYKJ^&71,_[W"=:XPTG9^2S&X,U=-<B8 I@BR.#GDGZG6241"E+\PI
M&7-I ZOM:>SVJ#P$:8U4]'T?G1<O&U[--_YJ7;/Y"?KXDD<\2+?DN_UY*FPP
M/KA49\AY4#X0MDLMTL\:>8ZH<;MD>D?GZ64[\*NLT86P-_-$T9><(*;:$SQ(
M8AN3 YN=(V:)9]TF0G^4I&[/U%UP<>^ER" *Z-6P/=!H9!]C]=#'#&* ODG?
M0$;E@74H!-QTNG@6__-TNIINOG7]](@+KY4"8QW2F281?!$&7&#($'UTKLW>
MVXW.!IV 7DY7<;98G2YOO _0&*6J0SP+T[67N',08JVB+I%%Z0P6T\8)VXZ^
M<<U20V1MT37H4'5]1W9K_U=KCW]8*QO6\#W:CGCC)DE3!U-*G<@[-S4<P/K
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M=0=Q]FEPKN,MET5,IDB2" 7C*C*2C349K"JL>*=]U)T62/13NSKPH;:?<CH
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MS;N(LT^#<R,X4QFE<K19 G&@2"3@+7,01; 8C'5:M<DD_D#32 <^U/933I]
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M,:!;D]BQ[[D+=AXOUAA213V<X=?E7"2FTVH,-C?"&<G9\%Z##,Z1^?<(090
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M#JEDFWRVW/$VM0J#D-])^' 4Q.W4_:&%^K]3S$\H+(M6LCIUK,ZR0)' :\;
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M^ZBM P2^/)TIRQ!-G1)6GYV1D'B$H".YMR%JF8Q%;G=+4_Y[L-:I4#B>ZCK
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MON7'Q3K3749 4Z.E;.M3 LE!)LWKG9TS?ICK,&"Q:5Y6-+8;HTJX@_NI9[(
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M<N+G!D/??)X^WFAL0O=51P=E,G\0)Z27Q>>-H_MA_OG+Y1_E;VO<)$UGW/%
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MPB"SQ&6.O"3?YG@Y31G<KX20Y7?$[0KWYES=OJ]3) +A#)14'Y13?$8!&==
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M,,]UJ76+MIU'^S)MTR/J*/6_"*>C==$]NK:OUNFPC2EEBH5-8G4L:8&HR W
M$G4(4KBDV_A10ZCK"6''(V(OP!V@GNXA]\?BYBVS$<P9:PQH+RTH1<Z@UY&B
M%!D<+RHJTS!.'T!@S\ [!!E[0>\P-76/OD__6&[9$EEK67P"6Y]#J6(Y>),B
MA,)E#CHS4Z:P>;<$3A\J3HB^P]34 ?IJ:'5Y<_5,?V=S0.008F)&0Z! #Q3W
M 7Q@""I1V,=T(3&V:2?]%#4]X>IXA^UH>7>(F>WNTK9PE[D [I0@Y(L,4<<
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MX+?;\&PWTD>,T:M00'I9DVZ&@:OCUXOQ(4F=?&*MGJ@\2]0P;)U5/F$L%72
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M\@JD*J@](OU[BC3$\Q0.0]L9IQU&4DX'H'O*8)./\'5^N:W<NE=$FIA")V.
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MP2$3@(D+'T325OUW;]Q#>N/N!:Y3],;=1],=H/WY!JM)E5PHD@7C?005M8"
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MUDY=7:"1=M)J$UAO!LW5^L[K<N)+BGKCU>6FOF'Y..*^%Y#/4O%)EB" 6U=
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M,3$Q,'%Q,C(P,C(N:'1M4$L! A0#%     @ >H$)533KY'66"   4C(  !(
M             ( !U@@  &5X,S$R,3!Q<3(R,#(R+FAT;5!+ 0(4 Q0    (
M 'J!"55,(AJ#\P4  .DU   1              "  9P1  !E>#,R,3!Q<3(R
M,#(R+FAT;5!+ 0(4 Q0    ( 'J!"55BI-JX^1X# !\9'P 1
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M              "  9II!P!H86QO+3(P,C(P-C,P7W!R92YX;6Q02P4&
/  L "P#- @  [ <(

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
